

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:55:01 ; Search time 40.0222 Seconds
(without alignments)
1315.434 Million cell updates/sec

Title: US-09-674-752-38

Perfect score: 664

Sequence: 1 EVOLVKSGLVKPGSLRL.....ATWRAFDIWRGTMVTSSG 126

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Published Applications AA_Main:*
- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
 - 2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
 - 3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
 - 4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
 - 5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
 - 6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	483.5	72.8	252	3	US-09-880-748-1362 Sequence 1362, Ap
2	483.5	72.8	252	4	US-10-293-418-1362 Sequence 1362, Ap
3	483	72.7	240	4	US-10-062-188-9 Sequence 9, Appli
4	483	72.7	257	4	US-10-062-188-7 Sequence 7, Appli
5	478	72.0	248	3	US-09-880-748-913 Sequence 913, App
6	478	72.0	248	4	US-10-293-418-913 Sequence 913, App
7	476.5	71.8	471	6	US-11-031-485-64 Sequence 64, Appl
8	476.5	71.8	472	6	US-11-031-485-30 Sequence 30, Appl
9	475.5	71.6	116	4	US-10-091-300-24 Sequence 24, Appl
10	475.5	71.6	116	5	US-10-482-630-76 Sequence 76, Appl
11	475.5	71.6	116	5	US-10-506-997-24 Sequence 24, Appl
12	474.5	71.5	250	3	US-09-880-748-883 Sequence 883, App
13	474.5	71.5	250	4	US-10-293-418-883 Sequence 883, App
14	474.5	71.5	256	3	US-09-880-748-1318 Sequence 1318, Ap
15	474.5	71.5	256	4	US-10-293-418-1318 Sequence 1318, Ap
16	473.5	71.3	245	5	US-10-778-394-76 Sequence 76, Appl
17	473.5	71.3	247	3	US-09-880-748-1764 Sequence 1764, Ap
18	473.5	71.3	247	4	US-10-293-418-1764 Sequence 1764, Ap
19	472.5	71.2	114	6	US-11-136-538-1 Sequence 1, Appli
20	472.5	71.2	250	6	US-11-090-847-136 Sequence 136, App
21	472.5	71.2	444	4	US-10-150-475A-6 Sequence 6, Appli
22	472.5	71.2	444	4	US-10-704-522-6 Sequence 6, Appli
23	472.5	71.2	444	4	US-10-645-215-6 Sequence 6, Appli
24	472.5	71.2	444	6	US-11-136-538-7 Sequence 7, Appli
25	471.5	71.0	125	5	US-10-725-962-18 Sequence 18, Appl
26	471.5	71.0	126	4	US-10-041-860-13 Sequence 13, Appl
27	471.5	71.0	126	4	US-10-041-860-208 Sequence 208, App

28	471.5	71.0	126	4	US-10-565-383-6 Sequence 6, Appli
29	471.5	71.0	129	5	US-10-516-758-24 Sequence 24, Appl
30	471	70.9	250	3	US-09-880-748-1179 Sequence 1179, Ap
31	471	70.9	250	4	US-10-293-418-1179 Sequence 1179, Ap
32	470.5	70.9	116	4	US-10-091-300-31 Sequence 31, Appl
33	470.5	70.9	116	5	US-10-482-630-83 Sequence 83, Appl
34	470.5	70.9	116	5	US-10-506-997-31 Sequence 31, Appl
35	470	70.8	123	5	US-10-727-155-158 Sequence 158, App
36	470	70.8	123	6	US-11-021-715-56 Sequence 56, Appl
37	469	70.6	241	3	US-09-880-748-1937 Sequence 1937, Ap
38	469	70.6	241	4	US-10-293-418-1937 Sequence 1937, Ap
39	468.5	70.6	237	3	US-09-880-748-2019 Sequence 2019, Ap
40	468.5	70.6	237	3	US-09-880-748-2040 Sequence 2040, Ap
41	468.5	70.6	237	4	US-10-293-418-2019 Sequence 2019, Ap
42	468.5	70.6	237	4	US-10-293-418-2040 Sequence 2040, Ap
43	468.5	70.6	240	3	US-09-880-748-2007 Sequence 2007, Ap
44	468.5	70.6	240	4	US-10-293-418-2007 Sequence 2007, Ap
45	468.5	70.6	248	3	US-09-880-748-1974 Sequence 1974, Ap

ALIGNMENTS

RESULT 1

US-09-880-748-1362
; Sequence 1362, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,916
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1362
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1362

Query Match 72.8%; Score 483.5; DB 3; Length 252;
Best Local Similarity 74.2%; Pred. No. 1.1e-37;
Matches 98; Conservative 6; Mismatches 15; Indels 13; Gaps 2;

Qy	1	EVOLVKSGLVKPGSLRLSCAASGFTTRDYIHVROTPGKGLVWSISSSGNVYD 60	: : : : : : : : :
Db	1	EVOLVSSGGLVPGGSLRLSCAASGFTFNPYTNWVRQAPGKGLVWSISSSNIIYY 60	: : : : : : : :
Qy	61	ADSVKGRFTISRDNNKVVYLNNSLAEDMAYVFCAR-----DGTIFGSAATWRAFDI 114	: : : : : : : :
Db	61	ADSVKGRFTISRDNAKNSLYLNNSLRADETAVYVCARGHYDILTGYVFG-----FDY 113	: : : : : : : :
Qy	115	WGRGTMVTSSG 126	:
Db	114	WGRGTMVTSSG 125	:

RESULT 2

US-10-293-418-1362
; Sequence 1362, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:

```
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1362
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1362

Query Match          72.8%; Score 483.5; DB 4; Length 252;
Best Local Similarity 74.2%; Pred. No. 1.1e-37;
Matches 98; Conservative 6; Mismatches 15; Indels 13; Gaps 2;

QY 1 EVOLVKSGLVKPGSLRLSCAASGFTFRYYDIHWVROTPGKLEWVSSISSGNYIDY 60
Db 1 EVOLVESGGLVKPGSLRLSCAASGFTFNPTMNMVVRQAPGKLEWVSSISSNYIY 60

QY 61 ADSVKGRFTISRDNANNVYLOMNSLRAEDMAVYFCARDG-TIFGSAATWRAFDI 114
Db 61 ADSVKGRFTISRDNAKNSLYLOMNSLRAEDTAVYYCARHYDILTGYFG-----FDY 113

QY 115 WGRGTMVTVSSG 126
Db 114 WRGTLTVTSSG 125

RESULT 3
US-10-062-188-9
; Sequence 9, Application US/10062188
; Publication No. US20040096826A1
; GENERAL INFORMATION:
; APPLICANT: Evans, Glen A.
; TITLE OF INVENTION: Methods For Creating Recombination
; FILE REFERENCE: P-EA 5008
; CURRENT APPLICATION NUMBER: US/10/062,188
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 231
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct
US-10-062-188-9

Query Match          72.7%; Score 483; DB 4; Length 240;
Best Local Similarity 75.8%; Pred. No. 1.1e-37;
Matches 96; Conservative 8; Mismatches 17; Indels 6; Gaps 2;

QY 1 EVOLVKSGLVKPGSLRLSCAASGFTFRYYDIHWVROTPGKLEWVSSISSGNYIDY 60
Db 1 EVOLVESGGLVKPGSLRLSCAASGFTFNPTMNMVVRQAPGKLEWVSSISSNYIY 60

QY 61 ADSVKGRFTISRDNANNVYLOMNSLRAEDMAVYFCARDG-TIFGSAATWRAFDI 119
Db 61 ADSVKGRFTISRDNAKNSLYLOMNSLRAEDTAVYYCARSSITIFGG-----GMDVWGRGT 115

QY 120 MVTVSSG 126
Db 116 LVTVSSG 122

RESULT 5
US-09-880-748-913
; Sequence 913, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 913
; LENGTH: 248
; TYPE: PRT
```



```
; ORGANISM: Homo sapiens
US-09-880-748-913

Query Match      72.0%; Score 478; DB 3; Length 248;
Best Local Similarity 72.2%; Pred. No. 3.5e-37;
Matches 91; Conservative 14; Mismatches 21; Indels 0; Gaps 0;

QY 1 EVOLVKSGLVKPGGSLRLSCAASGFTFRYDIHWVROTPGKLEWVSSISGGNYIDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVOLVESGGGLVPGGSLRLSCAAGFTFSSYSNMWVRQAPGKLEWVSSISNRGSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNANNVYLNQNSLRAEDMAYFCARDGTIFGSAATWRAFDWGRGT 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNANNVYLNQNSLRAEDMAYFCARDGTIFGSAATWRAFDWGRGT 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 VTVSSG 126
    |||||
Db 121 VTVSSG 126
    |||||

RESULT 6
US-10-293-418-913
; Sequence 913, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 913
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-913

Query Match      72.0%; Score 478; DB 4; Length 248;
Best Local Similarity 72.2%; Pred. No. 3.5e-37;
Matches 91; Conservative 14; Mismatches 21; Indels 0; Gaps 0;

QY 1 EVOLVKSGLVKPGGSLRLSCAASGFTFRYDIHWVROTPGKLEWVSSISGGNYIDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVOLVESGGGLVPGGSLRLSCAAGFTFSSYSNMWVRQAPGKLEWVSSISNRGSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNANNVYLNQNSLRAEDMAYFCARDGTIFGSAATWRAFDWGRGT 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNANNVYLNQNSLRAEDMAYFCARDGTIFGSAATWRAFDWGRGT 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 VTVSSG 126
    |||||
Db 121 VTVSSG 126
    |||||

RESULT 7
US-11-031-485-64
; Sequence 64, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
; APPLICANT: PULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.
; TITLE OF INVENTION: ANTIBODIES TO MADCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 30
; LENGTH: 472
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-64

Query Match      71.8%; Score 476.5; DB 6; Length 472;
Best Local Similarity 75.4%; Pred. No. 9.6e-37;
Matches 95; Conservative 9; Mismatches 21; Indels 1; Gaps 1;

QY 1 EVOLVKSGLVKPGGSLRLSCAASGFTFRYDIHWVROTPGKLEWVSSISGGNYIDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 EVOLVESGGGLVPGGSLRLSCAASGFTFSSYSNMWVRQAPGKLEWVSSISSSSIY 79
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNANNVYLNQNSLRAEDMAYFCARDGTIFG-SAATWRAFDWGRGT 119
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 ADSVKGRFTISRDNANNVYLNQNSLRAEDTAVVYCARDGYSYSSGWSYVVYVGMVWGQGT 139
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 120 MVTVSS 125
    |||||
Db 140 TTVTSS 145
    |||||

RESULT 8
US-11-031-485-30
; Sequence 30, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
; APPLICANT: PULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.
; TITLE OF INVENTION: ANTIBODIES TO MADCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 30
; LENGTH: 472
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-30

Query Match      71.8%; Score 476.5; DB 6; Length 472;
Best Local Similarity 75.4%; Pred. No. 9.6e-37;
Matches 95; Conservative 9; Mismatches 21; Indels 1; Gaps 1;

QY 1 EVOLVKSGLVKPGGSLRLSCAASGFTFRYDIHWVROTPGKLEWVSSISGGNYIDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 EVOLVESGGGLVPGGSLRLSCAASGFTFSSYSNMWVRQAPGKLEWVSSISSSSIY 79
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNANNVYLNQNSLRAEDMAYFCARDGTIFG-SAATWRAFDWGRGT 119
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 ADSVKGRFTISRDNANNVYLNQNSLRAEDTAVVYCARDGYSYSSGWSYVVYVGMVWGQGT 139
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
```



```
; ORGANISM: Homo sapiens
US-09-880-748-883

Query Match      71.5%; Score 474.5; DB 3; Length 250;
Best Local Similarity 76.0%; Pred. No. 7.5e-37;
Matches 95; Conservative 9; Mismatches 20; Indels 1; Gaps 1;

Qy  2 VQLVKSGLVKPGGSLRLSCAASGFTFRYDIHWVQTGKGLWVSSISGGNYIDYA 61
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db  2 VQLVQSGGGLVQPGGSLRLSCAASGFTFRSYMNVVRQAPGKGLWVSSISGGN-IYYA 60

Qy  62 DSVKGRFTISRDNANVVYLQMSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTMV 121
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db  61 DSVKGRFTISRDNANVYLQMSLRAEDTAVYYCARDIGSFYDILTALRLNLYGMDVW 120

Qy  122 TVSSG 126
    |||||
Db  121 TVSSG 125

RESULT 13
US-10-293-418-883
; Sequence 883, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523p2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 883
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-883

Query Match      71.5%; Score 474.5; DB 4; Length 250;
Best Local Similarity 76.0%; Pred. No. 7.5e-37;
Matches 95; Conservative 9; Mismatches 20; Indels 1; Gaps 1;

Qy  2 VQLVKSGLVKPGGSLRLSCAASGFTFRYDIHWVQTGKGLWVSSISGGNYIDYA 61
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db  2 VQLVQSGGGLVQPGGSLRLSCAASGFTFRSYMNVVRQAPGKGLWVSSISGGN-IYYA 60

Qy  62 DSVKGRFTISRDNANVVYLQMSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTMV 121
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db  61 DSVKGRFTISRDNANVYLQMSLRAEDTAVYYCARDIGSFYDILTALRLNLYGMDVW 120

Qy  122 TVSSG 126
    |||||
Db  121 TVSSG 125

RESULT 14
US-09-880-748-1318
; Sequence 1318, Application US/09880748
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523p2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 883
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-883

Query Match      71.5%; Score 474.5; DB 3; Length 256;
Best Local Similarity 71.8%; Pred. No. 7.7e-37;
Matches 94; Conservative 11; Mismatches 21; Indels 5; Gaps 2;

Qy  1 EVOLVKSGGLVKPGGSLRLSCAASGFTFRYDIHWVQTGKGLWVSSISGGNYIDY 60
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db  1 EVOLVQSGGGLVKPGGSLRLSCAASGFTFSSYMNVRQAPGKGLWVSSISSSSIYY 60

Qy  61 ADSVKGRFTISRDNANVVYLQMSLRAEDMAVYFCARDGTIFGSAATWR---APDIW 115
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db  61 ADSVKGRFTISRDNANVYLQMSLRAEDTAVYYCARDIGSFYDILTALRLNLYGMDVW 120

Qy  116 GRGTMVTVSSG 126
    ||||| ||||| |||||
Db  121 GKGLTVTVSPG 131

RESULT 15
US-10-293-418-1318
; Sequence 1318, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523p2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1318
; LENGTH: 256
; TYPE: PRT
; ORGANISM: Homo sapiens
```

US-10-293-418-1318

Query Match	71.5%;	Score	474.5;	DB	4;	Length	256;
Best Local Similarity	71.8%;	Pred. No.	7.7e-37;				
Matches	94;	Conservative	11;	Mismatches	21;	Indels	5;
		Gaps	2;				
Qy	1	EVOLVKGGLVKPGGSLRLSCAASGFTPRRYDIHWVROTPGKGLEWVSSISSGGNYIDY	60				
Db	1	EVOLVQGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKLEWVSSISSSSIIYY	60				
Qy	61	ADSVKGRFTISRDNANNVYLOMNSLRAEDMAYFCARD-GTIFGSAATWR----	115				
Db	61	ADSVKGRFTISRDNAKNSLYLOMNSLRAEDTAVYYCARDLGSPYDILTALRLLENYGMVW	120				
Qy	116	GRGTMVTVSSG	126				
Db	121	GKGLVTVSPG	131				

Search completed: May 5, 2006, 09:02:17
Job time : 40.0222 secs


```
Db      1  EVOLVESGGGLVKPGGSLRLSCAASGFTFNPTMNVWRQAPGKLEWVSSISSSNVIYY 60
QY      61  ADSVKGRFTISRDNANNVYLVQNSLRADMAVYFCAR-----DGTIFGSAATWRAFDI 114
          |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      61  ADSVKGRFTISRDNANKSLYLQNSLRAEDTAVYVCARGHYDILTGYVFG-----FDY 113
QY      115  WGRGTWTVVSSG 126
Db      114  WGRGTLTVTVSSG 125

RESULT 2
US-11-266-444-1362
; Sequence 1362, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1362
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1362

Query Match      72.8%; Score 483.5; DB 11; Length 252;
Best Local Similarity 74.2%; Pred. No. 1.5e-34;
Matches 98; Conservative 6; Mismatches 15; Indels 13; Gaps 2;

QY      1  EVOLVKSGEGLVKPGGSLRLSCAASGFTFRFYDIHWVRQTPGKLEWVSSISGGNYIDY 60
          |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      1  EVOLVESGGGLVKPGGSLRLSCAASGFTFNPTMNVWRQAPGKLEWVSSISSSNVIYY 60
QY      61  ADSVKGRFTISRDNANNVYLVQNSLRAEDMAVYFCAR-----DGTIFGSAATWRAFDI 114
          |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      61  ADSVKGRFTISRDNANKSLYLQNSLRAEDTAVYVCARGHYDILTGYVFG-----FDY 113
QY      115  WGRGTWTVVSSG 126
Db      114  WGRGTLTVTVSSG 125

RESULT 3
US-11-054-515-913
; Sequence 913, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
```

```
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 913
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-913

Query Match      72.0%; Score 478; DB 11; Length 248;
Best Local Similarity 72.2%; Pred. No. 4.4e-34;
Matches 91; Conservative 14; Mismatches 21; Indels 0; Gaps 0;

QY      1  EVOLVKSGEGLVKPGGSLRLSCAASGFTFRFYDIHWVRQTPGKLEWVSSISGGNYIDY 60
          |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      1  EVOLVESGGGLVKPGGSLRLSCAAGFTFSSYSMNVWRQAPGKLEWVSSISNRGSYIYY 60
QY      61  ADSVKGRFTISRDNANNVYLVQNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGCTM 120
          |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      61  ADSVKGRFTISRDNANKNTLYLQNSLRAEDTAVYVCAREGRDILTGVYVYGLDVMGQGTL 120
QY      121  VTVSSG 126
Db      121  VTVSSG 126

RESULT 4
US-11-266-444-913
; Sequence 913, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 913
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-913

Query Match      72.0%; Score 478; DB 11; Length 248;
Best Local Similarity 72.2%; Pred. No. 4.4e-34;
Matches 91; Conservative 14; Mismatches 21; Indels 0; Gaps 0;
```

```
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 883
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-266-444-883

Query Match      71.5%; Score 474.5; DB 11; Length 250;
Best Local Similarity 76.0%; Pred. No. 8.9e-34;
Matches 95; Conservative 9; Mismatches 20; Indels 1; Gaps 1;

Qy  2  VOLVKSGEGLVKPGSLRLSCAASGFTFRYDIHWVRQTPEKGLWVSSISGGNYIDYA 61
Db  2  VOLVQSGGGLVQPGSLRLSCAASGFTFRSYSMNVWRQAPGKLEWVSSISGGN-IYYA 60

Qy  62  DSVKGRFTISRDNANVVYLQMSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTMV 121
Db  61  DSVRGRFTISRDNAKNSVYLQMSLRAEDTAVYICARDSDYDILTYGRGYFDYWGKGLV 120

Qy  122  TVSSG 126
Db  121  TVSSG 125

RESULT 7
US-11-054-515-1318
; Sequence 1318, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 883
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-883

Query Match      71.5%; Score 474.5; DB 11; Length 250;
Best Local Similarity 76.0%; Pred. No. 8.9e-34;
Matches 95; Conservative 9; Mismatches 20; Indels 1; Gaps 1;

Qy  2  VOLVKSGEGLVKPGSLRLSCAASGFTFRYDIHWVRQTPEKGLWVSSISGGNYIDYA 61
Db  2  VOLVQSGGGLVQPGSLRLSCAASGFTFRSYSMNVWRQAPGKLEWVSSISGGN-IYYA 60

Qy  62  DSVKGRFTISRDNANVVYLQMSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTMV 121
Db  61  DSVRGRFTISRDNAKNSVYLQMSLRAEDTAVYICARDSDYDILTYGRGYFDYWGKGLV 120

Qy  122  TVSSG 126
Db  121  TVSSG 125

RESULT 6
US-11-266-444-883
; Sequence 883, Application US/11266444
; Publication No. US20060062789A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 883
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-883

Query Match      71.5%; Score 474.5; DB 11; Length 250;
Best Local Similarity 76.0%; Pred. No. 8.9e-34;
Matches 95; Conservative 9; Mismatches 20; Indels 1; Gaps 1;

Qy  2  VOLVKSGEGLVKPGSLRLSCAASGFTFRYDIHWVRQTPEKGLWVSSISGGNYIDYA 61
Db  2  VOLVQSGGGLVQPGSLRLSCAASGFTFRSYSMNVWRQAPGKLEWVSSISGGN-IYYA 60

Qy  62  DSVKGRFTISRDNANVVYLQMSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTMV 121
Db  61  DSVRGRFTISRDNAKNSVYLQMSLRAEDTAVYICARDSDYDILTYGRGYFDYWGKGLV 120

Qy  122  TVSSG 126
Db  121  TVSSG 125

RESULT 5
US-11-054-515-883
; Sequence 883, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 883
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-883

Query Match      71.5%; Score 474.5; DB 11; Length 250;
Best Local Similarity 76.0%; Pred. No. 8.9e-34;
Matches 95; Conservative 9; Mismatches 20; Indels 1; Gaps 1;

Qy  2  VOLVKSGEGLVKPGSLRLSCAASGFTFRYDIHWVRQTPEKGLWVSSISGGNYIDYA 61
Db  2  VOLVQSGGGLVQPGSLRLSCAASGFTFRSYSMNVWRQAPGKLEWVSSISGGN-IYYA 60

Qy  62  DSVKGRFTISRDNANVVYLQMSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTMV 121
Db  61  DSVRGRFTISRDNAKNSVYLQMSLRAEDTAVYICARDSDYDILTYGRGYFDYWGKGLV 120

Qy  122  TVSSG 126
Db  121  TVSSG 125

RESULT 6
US-11-266-444-883
; Sequence 883, Application US/11266444
; Publication No. US20060062789A1
```

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1318
; LENGTH: 256
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1318

Query Match      71.5%; Score 474.5; DB 11; Length 256;
Best Local Similarity 71.8%; Pred. No. 9.1e-34;
Matches 94; Conservative 11; Mismatches 21; Indels 5; Gaps 2;

QY 1 EVQLVKGEGLVKPGGSLRLSCAASGFTFRDYDIHWVROTPGKLEWVSSISSGGNYIDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVSGGGLVPGGSLRLSCAASGFTFSYSNMNVVRQAPGKLEWVSSISSSSYIY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNANNVVYLNQNSLRADTMVYFCARD-GTIFGSAATWR---AFDIW 115
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNANVYLNQNSLRADTMVYFCARDLGSFYDILTALRLENYGMDVW 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 116 GRGTMVTVSSG 126
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 KGKTLTVSPG 131
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 8
US-11-266-444-1318
; Sequence 1318, Application US/11266444
; Publication No. US2006062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulatc
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 1318
; LENGTH: 256
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1318

Query Match      71.5%; Score 474.5; DB 11; Length 256;
Best Local Similarity 71.8%; Pred. No. 9.1e-34;
Matches 94; Conservative 11; Mismatches 21; Indels 5; Gaps 2;

QY 1 EVQLVKGEGLVKPGGSLRLSCAASGFTFRDYDIHWVROTPGKLEWVSSISSGGNYIDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVSGGGLVPGGSLRLSCAASGFTFSYSNMNVVRQAPGKLEWVSSISSSSYIY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNANNVVYLNQNSLRADTMVYFCARD-GTIFGSAATWR---AFDIW 115
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNANVYLNQNSLRADTMVYFCARDLGSFYDILTALRLENYGMDVW 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 116 GRGTMVTVSSG 126
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 KGKTLTVSPG 131
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 9
```

```
US-10-771-257-14
; Sequence 14, Application US/10771257
; Publication No. US2005028864A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: SISSA - Scuola Superiore Internazionale di Studi Avanzati
; APPLICANT: Cattaneo, Antonino
; APPLICANT: Maritan, Amos
; APPLICANT: Visintin, Michela
; APPLICANT: Rabbitts, Terrence H
; APPLICANT: Settanni, Giovanni
; TITLE OF INVENTION: Intracellular antibodies
; FILE REFERENCE: 18396/2272
; CURRENT APPLICATION NUMBER: US/10/771,257
; CURRENT FILING DATE: 2004-02-03
; PRIOR APPLICATION NUMBER: PCT/GB02/03512
; PRIOR FILING DATE: 2002-08-01
; PRIOR APPLICATION NUMBER: GB 0119004.0
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: GB 0121577.1
; PRIOR FILING DATE: 2001-09-06
; PRIOR APPLICATION NUMBER: GB 0200928.0
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: GB 0203569.9
; PRIOR FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: IT RM2001A000633
; PRIOR FILING DATE: 2001-10-25
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-771-257-14

Query Match      71.4%; Score 474; DB 9; Length 119;
Best Local Similarity 72.0%; Pred. No. 4.9e-34;
Matches 90; Conservative 13; Mismatches 16; Indels 6; Gaps 1;

QY 1 EVQLVKGEGLVKPGGSLRLSCAASGFTFRDYDIHWVROTPGKLEWVSSISSGGNYIDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGLVQPGGSLRLSCASGFTFSYSMNVVRQAPGKLEWVSSISSSSYIY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNANNVVYLNQNSLRADTMVYFCARDGTIFGSAATWRADFWGRGTM 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNANVYLNQNSLRADTMVYFCAREG-----PNWAHFDWMQQTGL 114
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 121 VTVSS 125
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 115 VTVSS 119
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 10
US-11-127-677-14
; Sequence 14, Application US/11127677
; Publication No. US20050272107A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: Rabbitts, Terrence H
; APPLICANT: Tanaka, Tomoyuki
; TITLE OF INVENTION: Intracellular antibodies
; FILE REFERENCE: 18396/2462
; CURRENT APPLICATION NUMBER: US/11/127,677
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: PCT/GB03/04942
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: GB 0226729.2
; PRIOR FILING DATE: 2002-11-15
; NUMBER OF SEQ ID NOS: 150
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 119
; TYPE: PRT
```


GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:05 ; Search time 8.0277 Seconds
(without alignments)
1510.185 Million cell updates/sec

Title: US-09-674-752-38
Perfect score: 664
Sequence: 1 EVQLVKSGEGLVPGGSLRL.....ATWRAFDINGRGTMTVTSSG 126

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_80.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	475.5	71.6	141	2 S31669	Ig heavy chain V r
2	467.5	70.4	128	2 S26790	Ig heavy chain V r
3	454	68.4	143	2 S23624	Ig heavy chain V r
4	452.5	68.1	145	2 S11239	Ig heavy chain V r
5	452	68.1	117	2 S34012	Ig heavy chain V r
6	451	67.9	125	2 S30531	Ig heavy chain V r
7	449.5	67.7	118	2 S31105	Ig heavy chain (su
8	449	67.6	121	2 S31104	Ig heavy chain (su
9	448.5	67.5	128	2 S31595	Ig heavy chain V r
10	448	67.5	119	2 S31108	Ig heavy chain - h
11	447.5	67.4	118	2 S31116	Ig heavy chain - h
12	447.5	67.4	140	2 S70442	Ig heavy chain pre
13	447	67.3	123	2 S30532	Ig heavy chain V r
14	446.5	67.2	128	2 S26786	Ig heavy chain V r
15	446	67.2	121	2 S36005	Ig heavy chain V r
16	445	67.0	119	2 S36005	Ig heavy chain V r
17	445	67.0	127	2 S19878	Ig heavy chain V r
18	445	67.0	130	2 S17783	Ig variable region
19	444	66.9	138	2 S31666	Ig heavy chain V r
20	442.5	66.6	136	2 S31587	Ig heavy chain V r
21	442.5	66.6	147	2 S37780	Ig variable region
22	442	66.6	121	2 S31118	Ig heavy chain - h
23	441	66.4	119	2 S31107	Ig heavy chain - h
24	440.5	66.3	114	2 S31107	Ig heavy chain - h
25	440.5	66.3	122	2 S31117	Ig heavy chain - h
26	440	66.3	119	2 S36005	Ig heavy chain V r
27	440	66.3	121	2 S19666	Ig heavy chain V r
28	438.5	66.0	122	1 M3HUM	Ig heavy chain V-I
29	438.5	66.0	124	2 S20782	Ig heavy chain V r

ALIGNMENTS

RESULT 1

S31669

Ig heavy chain V region - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C/Accession: S31669

R/Cuisinier, A.M.; Gauthier, L.; Boublil, L.; Fougereau, M.; Tonnelle, C.

submitted to the EMBL Data Library, June 1992

A/Description: Mechanisms that generate human immunoglobulin diversity operate from the

A/Reference number: S31585

A/Accession: S31669

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-141 <CUI>

A/Cross-references: UNIPARC:UPI00011647C; EMBL:Z14212; NID:g30959; PIDN:CAA78581.1; PID

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotrimer; immunoglobulin

F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 71.6%; Score 475.5; DB 2; Length 141;
Best Local Similarity 75.2%; Pred. No. 3.9e-37;
Matches 94; Conservative 9; Mismatches 19; Indels 3; Gaps 1;

Qy	1	EVQLVKS	GEGLVPGGSLRLSCAASGFTPRRYDIHWVROTPGKGLVWVSSISGGNYIDY	60
Db	20	EVQLVSG	GGGLVPGGSLRLSCAASGFTFSSYSNMNVVRQAPGKGLVWVSSISSSSTIYY	79
Qy	61	ADSVKGR	FTISRDNANNVYVYLNQNSLRAEDMAYVFCARDGTIFGSAATWRAFDIWRGTM	120
Db	80	ADSVKGR	FTISRDNANNVYVYLNQNSLRAEDTAVYVCARGRLTGEKG---YFDLWGRGTL	136
Qy	121	VTVSS	125	
Db	137	VTVSS	141	

RESULT 2

S26790

Ig heavy chain V region - human

C/Species: Homo sapiens (man)

C/Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000

C/Accession: S26790

R/Mortari, F.; Newton, J.A.; Wang, J.Y.; Schroeder Jr., H.W.

Eur. J. Immunol. 22, 241-245, 1992

A/Title: The human cord blood antibody repertoire. Frequent usage of the V(H)7 gene fami

A/Reference number: S26786; MUID:92111632; PMID:1730251

A/Accession: S26790

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-128 <MOR>

A/Cross-references: UNIPARC:UPI000115FC4; EMBL:X61013; NID:g32798; PIDN:CAA43347.1; PID

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin F;15-98/Domain: immunoglobulin homology <IMM>

	Query Match	70.4%	Score 467.5;	DB 2;	Length 128;
	Best Local Similarity	73.6%	Pred. NO. 1.9e-36;		
	Matches	95;	Conservative	9;	Mismatches 20; Indels 5; Gaps 2;
Qy	1 EVQLVKGSGEGLVKPGGSLRLSCAASGFTFRFDYDIHWVRQTPTKGLEWVSISSSGGNIYYD Y : : : :	:	: : : :	:	:
Dd	1 QVLVESGGGVLPKGGSLRLSCAASGFTFSDYINSWIRQAAPKLEWWSYISSGSITYY D : : : :	:	: : : :	:	:
Qy	61 ADS VKGRFTISRDNANNVVYLQMNSLRADMAVFPCARDGTIFG----SAATWRAFDIWG I : : : :	:	: : : :	:	:
Dd	61 ADS VKGRFTISRDNAKNLSLYLQMSLRADETAVFYCARDPFGGGLRIAVAGDW-YFDLWG I : : : :	:	: : : :	:	:
Qy	117 RGTMTVTSSS S ::: :::	S			
Dd	120 RGTLTVTSSS S ::: :::	S			

RESULT 3

S23624

Ig heavy chain V region - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999

C/Accession: S23624

R/Olee, T.; Lu, E.W.; Soto-Gil, R.W.; Defos, M.; Kozin, F.; Carson, D.A.; J. Exp. Med. 175, 831-842, 1992

A>Title: Genetic analysis of self-associating immunoglobulin G rheumatoid factors from

A/Reference number: S23623; MUID:92156804; PMID:1740665

A/Accession: S23624

A>Status: preliminary

A/Molecule type: DNA

A/Residues: 1-143 <OLE>

A/Cross-references: UNIPARC:UPI0000115F94; EMBL:X59703; NID:G32012; PIDN:CAA42224.1; PID

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F:15-98/Domain: immunoglobulin homology <IMM>

Query Match	68.4%	Score 454;	DB 2;	Length 143;
Best Local Similarity	72.0%	Pred. NO. 3.9e-35;		
Matches	90;	Conservative 10;	Mismatches 17;	Indels 8; Gaps 1;
Qy	1	EVQLVKGSGEGLAVKPGGSLRLSCAASGFTFRFDYDHWVQTPGKGLEWVSSISGGNYIDY	60	
Db	1	EVQLVESGGGLVQPGGSLRLSCAASGFTFSYNNWVRQAPGKGLEWVSYISSSSTIYY	60	
Qy	61	ADSVKGRFTISRDNANNNVYVYQMNLSRAEDMAVYFCARDGTIFGSAATWRAFDIWGRGTM	120	
Db	61	ADSVKGRFTISRDNAKNSLYLQMNLSRAEDTAVVYCARSG-----YRGDDYWGQGTLL	112	
Qy	121	VTVSS	125	
Db	113	VTVSS	117	

RESULT 4
S11239
Ig heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 21-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S11239
R:Felgenhauer, M.; Kohl, J.; Rueker, F.
Nucleic Acids Res. 18, 4927, 1990
A:Title: Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of
A:Reference number: S11239; MUID:90370490; PMID:1637678
A:Accession: S11239
A:Status: preliminary
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-145 <FEU>
A:Cross-references: UNIPARC:UPI0000113781; EMBL:X53613; NID:g23865; PIDN:CAA37675.1; PDB:
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

F;34-117/Domain: immunoglobulin homology <IMM>

Query Match	68.1%;	Score	452.5;	DB 2;	Length	145;			
Best local Similarity	71.4%;	Pred. No.	5.5e-35;						
Matches	90;	Conservative	11;	Mismatches	24;	Indels	1;	Gaps	1
Qy	1	EVOLVKSGEGLVPGGSLRLSLCAASGFTFRYYDIHWVRQTPGKGLEWVSSISGGNGNYIDY	60						
Db	20	EVQVSEGGGLVQGRSLRLSLCAASGFTFDNYAMHWVRQAPGKGLEWVSGISWDSSSTCY	79						
Qy	61	ADSVKGRFTTISRDNANNVYLQMSLRAEDNAVYFCARDGTIFGSAATWR-AFDIWRGRT	119						
Db	80	ADSVKGRFTTISRDNAKNSLYIQMSLRAEDMALYYCVKGRDYYDSGGYFTVAFDIWGGQT	139						
Qy	120	MVTVSS	125						
Db	140	MVTVSS	145						

RESULT 5

S34012

lg heavy chain V region - human

C/Species: Homo sapiens (man)

C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996

C/Accession: S34012; S30538

R/Mariette, X.; Tsapis, A.; Brouet, J.C.

Eur. J. Immunol. 23, 846-851, 1993

A/Title: Nucleotide sequence analysis of the variable domains of four human

A/Reference number: S34001; MUID:93209281; PMID:7681398

A/Accession: S34012

A>Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-117 <NAR>

A/Cross-references: UNIPARC:UPI0000176D30; EMBL:Z18324

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F:15-95/Domain: immunoglobulin homology <IMM>

Query Match	58.1%;	Score 452;	DB 2;	Length 117;
Best local Similarity	74.6%;	Pred. No. 4.8e-35;		
Matches 94;	Conservative 8;	Mismatches 14;	Indels 10;	Gaps 3
Qy	1	EVOLVKSGGELVKPGGSLRLSCAASGTFTRFYDTHWVQRTPKGKLEWVSSISSSGGNYIDY	60	
Db	1	EVVLESGGELVKPGGSLRLSCAASGTFSSYNNWVRQAPGKLEWVSSSSS---	YIF 57	
Qy	61	ADSVKGRFTISRDNANNNVYLQNNLSRAEDNAVYFCARDGTI-FGSAATWRAFDIWGRGT	119	
Db	58	ADSVKGRFTISRDNAKNSLYLQNNLSRAEDTAVYYCARAGSYGYFA-----	DWYGRGT 111	
Qy	120	MVTVSS	125	
Db	112	LVTVSS	117	

```

RESULT 6
S30531
IG heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 31-Dec-2004
C:Accession: S30531
R:Mariette, X.
submitted to the EMBL Data Library, October 1992
A:Reference number: S30520
A:Accession: S30531
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-125 <MAR>
A:Cross-references: UNIPROT:Q9UL91; UNIPARC:UPI0000176C10; EMBL:Z18317
C:Superfamily: immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

```

```
Query Match      67.9%; Score 451; DB 2; Length 125;
Best Local Similarity 71.2%; Pred. No. 6.4e-35;
Matches 89; Conservative 10; Mismatches 26; Indels 0; Gaps 0;

Qy 1 EVQLVKSQEGVLVPGGSLRLSCAASGFTFRYDIHWVROTPGKGLEWVSISSGNYIDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYSNWVRQAPGKGLEWISYSSSTIYY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 61 ADSVKGRFTISRDNANNVYLVQNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNANKSLYLQNSLRAEDTAVYICARSNYDSGYSHYFDYWGQTL 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 121 VTVSS 125
    |||||
Db 121 VTVSS 125
    |||||

RESULT 7
S31105
Ig heavy chain (subclass IgM) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 23-Jul-1999
C;Accession: S31105
R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31105
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-118 <RAA>
A;Cross-references: UNIPARC:UPI000011600C; EMBL:X63081; NID:G32648; PIDN:CAA44803.1; PID
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match      67.7%; Score 449.5; DB 2; Length 118;
Best Local Similarity 73.6%; Pred. No. 8.3e-35;
Matches 92; Conservative 9; Mismatches 17; Indels 7; Gaps 2;

Qy 1 EVQLVKSQEGVLVPGGSLRLSCAASGFTFRYDIHWVROTPGKGLEWVSISSGNYIDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGLVQPGGSLRLSCAASGFTFSYMSWIRQAPGKGLEWVSISSGSTIYY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 61 ADSVKGRFTISRDNANNVYLVQNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNANKSLYLQNSLRAEDTAVYICA--GQLGDD-----AFDIWGQGT 113
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 121 VTVSS 125
    |||||
Db 114 VTVSS 118
    |||||

RESULT 8
S31104
Ig heavy chain (subclass IgM) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 23-Jul-1999
C;Accession: S31104
R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31104
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-121 <RAA>
A;Cross-references: UNIPARC:UPI000011600B; EMBL:X63080; NID:G32646; PIDN:CAA44802.1; PID
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>
```

```
Query Match      67.6%; Score 449; DB 2; Length 121;
Best Local Similarity 72.8%; Pred. No. 9.5e-35;
Matches 91; Conservative 10; Mismatches 20; Indels 4; Gaps 3;

Qy 1 EVQLVKSQEGVLVPGGSLRLSCAASGFTFRYDIHWVROTPGKGLEWVSISSGNYIDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGSLRLSCAASGFTFDYAMHWVRQAPGKGLEWVSGISWNSGSIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 61 ADSVKGRFTISRDNANNVYLVQNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNANKSLYLQNSLRAEDTALYYCAKD--VFWGSG--W-YFDLWGRGTL 116
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 121 VTVSS 125
    |||||
Db 117 VTVSS 121
    |||||

RESULT 9
S31595
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31595
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31595
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-128 <CUI>
A;Cross-references: UNIPARC:UPI0000116458; EMBL:Z14171; NID:G31007; PIDN:CAA78540.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;23-106/Domain: immunoglobulin homology <IMM>

Query Match      67.5%; Score 448.5; DB 2; Length 128;
Best Local Similarity 72.0%; Pred. No. 1.1e-34;
Matches 90; Conservative 9; Mismatches 21; Indels 5; Gaps 1;

Qy 1 EVQLVKSQEGVLVPGGSLRLSCAASGFTFRYDIHWVROTPGKGLEWVSISSGNYIDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 9 EVQLVESGGGLVQPGSLRLSCAASGFTFDYAMHWVRQAPGKGLEWVSGISWNSGSIY 68
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 61 ADSVKGRFTISRDNANNVYLVQNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 69 ADSVKGRFTISRDNANKSLYLQNSLRAEDTALYYCAK-----APGDHDAFDIWGQGT 123
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 121 VTVSS 125
    |||||
Db 124 VTVSS 128
    |||||

RESULT 10
S31108
Ig heavy chain - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C;Accession: S31108
R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31108
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-119 <RAA>
A;Cross-references: UNIPARC:UPI0000176DC8; EMBL:X62956
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>
```



```
Matches 91; Conservative 11; Mismatches 20; Indels 9; Gaps 3;
Qy 1 EVQLVKSGEGLVKPGSRLRLSCAASGFTFRYYDIHWVQTPGKGLEWVSSISGGNYIDY 60
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QQLVSGGGGLVKPGSRLRLSCAASGFTFSYYKSWIRQAQPGKLEWVSYISSSSYTNY 60
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 61 ADSVKGRFTISRDNANNVYLQMNLSRAEDMAVYFCARDGTIFGSA-----TWRAFDI 114
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNAKNSLYLQMNLSRAEDTAVYYCAR-GLYCSSTSCYIWSNNW--FDP 117
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 115 WGRGTMTVTSS 125
   ||:|||||
Db 118 WQGTLTVTSS 128
   ||:|||||

RESULT 15
G36005
Ig heavy chain V region (M74) - human
C:Species: Homo sapiens (man)
C:Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 31-Dec-2004
C:Accession: G36005
R:Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A:Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A:Reference number: A36005; MUID:90349571; PMID:2117273
A:Accession: G36005
A:Status: Preliminary
A:Molecule type: mRNA
A:Residues: 1-121 <SCH>
A:Cross-references: UNIPROT:Q8WUK1; UNIPARC:UPI0000176C2C; GB:M34031
C:Genetics:
A:Gene: GDB:IGH@;IGHD1
A:Cross-references: GDB:118731; OMIM:146910
A:Map position: 14q32.33-14q32.33
C:Superfamily: immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 67.2%; Score 446; DB 2; Length 121;
Best Local Similarity 69.6%; Pred. No. 1.8e-34;
Matches 87; Conservative 13; Mismatches 21; Indels 4; Gaps 1;
Qy 1 EVQLVKSGEGLVKPGSRLRLSCAASGFTFRYYDIHWVQTPGKGLEWVSSISGGNYIDY 60
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QQLVSGGGVVPGRSLRLSCAASGFTFSYYAMHWVQAQPGKLEWVAVISYDGSNKYY 60
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 61 ADSVKGRFTISRDNANNVYLQMNLSRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCARDKDWG----WALFDYWGQGT 116
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 121 VTSS 125
   |||||
Db 117 VTSS 121
   |||||

Search completed: May 5, 2006, 08:51:33
Job time : 8.0277 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:58 ; Search time 49.9114 Seconds
(without alignments)
1781.089 Million cell updates/sec

Title: US-09-674-752-38

Perfect score: 664

Sequence: 1 EVOLVKSGEGLVPGGSLRL.....ATWRAFDWGRGTMTVSSG 126

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt 05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	459.5	69.2	606	2 Q6GMV2_HUMAN	Q6gm22 homo sapien
2	459	69.1	464	2 Q6MZU6_HUMAN	Q6mzu6 homo sapien
3	445.5	67.1	118	2 Q9UL91_HUMAN	Q9ul91 homo sapien
4	445	67.0	597	2 Q6BBB9_HUMAN	Q6bbb9 homo sapien
5	444.5	66.9	613	2 Q6WUK1_HUMAN	Q6wuk1 homo sapien
6	444	66.5	240	2 Q65ZC9_HUMAN	Q65zc9 homo sapien
7	441.5	66.5	494	2 Q96K68_HUMAN	Q96k68 homo sapien
8	438.5	66.0	122	1 HV3G_HUMAN	P01768 homo sapien
9	438	66.0	121	2 Q9UL71_HUMAN	Q9ul71 homo sapien
10	437	65.8	493	2 Q6GMX2_HUMAN	Q6gmx2 homo sapien
11	434.5	65.4	573	2 Q8WU38_HUMAN	Q8wu38 homo sapien
12	431	64.9	470	2 Q6PJA4_HUMAN	Q6pja4 homo sapien
13	429.5	64.7	473	2 Q6MZV7_HUMAN	Q6mzv7 homo sapien
14	429	64.6	499	2 Q8N5K4_HUMAN	Q8n5k4 homo sapien
15	425.5	64.1	475	2 Q6NZQ6_HUMAN	Q6nzq6 homo sapien
16	425.5	64.1	487	2 Q99KA4_MOUSE	Q99ka4 mus musculus
17	425	64.0	113	2 Q9UL90_HUMAN	Q9ul90 homo sapien
18	425	64.0	478	2 Q6PI81_HUMAN	Q6pi81 homo sapien
19	423	63.7	472	2 Q6N089_HUMAN	Q6n089 homo sapien
20	421.5	63.5	467	2 Q4VBH1_RAT	Q4vbh1 rattus norv
21	421.5	63.5	469	2 Q6E9F4_HUMAN	Q6e9f4 homo sapien
22	420.5	63.3	122	2 Q9UL84_HUMAN	Q9ul84 homo sapien
23	418.5	63.0	473	2 Q91Z05_MOUSE	Q91z05 mus musculus
24	418	63.0	119	2 Q920E7_MOUSE	Q920e7 mus musculus
25	418	63.0	470	2 Q7Z5W1_HUMAN	Q7z5w1 homo sapien
26	416	62.7	255	2 Q6KB05_MOUSE	Q6kb05 mus musculus
27	413.5	62.3	479	2 Q6NZV6_HUMAN	Q6nzv6 homo sapien
28	412.5	62.1	119	2 Q5F218_MOUSE	Q5f218 mus musculus
29	408.5	61.5	112	2 Q9HCC1_HUMAN	Q9hcc1 homo sapien
30	408.5	61.5	136	1 HV16_MOUSE	P01783 mus musculus
31	408.5	61.5	494	2 Q6ZW64_HUMAN	Q6zw64 homo sapien

RESULT 1					
ID	Q6GMV2_HUMAN	PRELIMINARY;	PRT;	606	AA.
AC	Q6GMV2;	2004 (TrEMBLrel. 27, Created)			
DT	05-JUL-2004	(TrEMBLrel. 27, Last sequence update)			
DT	05-JUL-2004	(TrEMBLrel. 27, Last annotation update)			
DE	IGHM protein.				
GN	Name=IGHM;				
OS	Homo sapiens (Human)				
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;				
OC	Homo.				
OX	NCBI_TaxID=9606;				
RN	[1]				
RP	NUCLEOTIDE SEQUENCE.				
RC	TISSUE=Primary B-Cells;				
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;				
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Colling F.S., Wagner L., Shenmen C.M., Schuler G.D., Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haie F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C., Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.H., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smal M.A., Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.; "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.";				
RT	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).				
RL	[2]				
RN	NUCLEOTIDE SEQUENCE.				
RP	TISSUE=Primary B-Cells;				
RC	NIH MGC Project;				
RG	Submitted (JUN-2004) to the EMBL/GenBank/DBDJ databases.				
RL	EMBL; BC073758; AAH473758.1; -; mRNA.				
DR	SMR; Q6GMV2; 20-256.				
DR	InterPro; IPR003599; Ig.				
DR	InterPro; IPR007110; Ig-like.				
DR	InterPro; IPR003597; Ig cl.				
DR	InterPro; IPR003006; Ig_MHC.				
DR	InterPro; IPR003596; Ig_v.				
DR	Pfam; PF07654; Cl-set; 4.				
DR	SMART; SM00409; IG; 2.				
DR	SMART; SM00407; IGC1; 4.				
DR	SMART; SM00406; IGV; 1.				

ALIGNMENTS

```

DR PROSITE; PS50835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 606 AA; 66185 MW; B6B38B51114E4C55 CRC64;

Query Match 69.2%; Score 459.5; DB 2; Length 606;
Best Local Similarity 67.9%; Pred. No. 1e-38;
Matches 93; Conservative 10; Mismatches 21; Indels 13; Gaps 2;

QY 1 EVLVKSGEGLVKPGGSLRLSCAASGFTFRYYDIHWVQTPGKGLWVSSISSGGNYIDY 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 20 QVQLVSGGGLVKPGGSLRLSCAASGFTFDYIMSWIRQAPGKGLWVSSISSSYTNY 79

QY 61 ADSVKGRFTISRDNANVYLVQNSLRADMAVYFCARDGTIFGSAATWR----- 110
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 80 ADSVKGRFTISRDNANVYLVQNSLRADMAVYFCARDGTIFGSAATWR----- 137

QY 111 -AFDIWGRGTMVTVSSG 126
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 138 YGNDVWGQGTIVTVSSG 154

RESULT 2
Q6MZU6_HUMAN PRELIMINARY; PRT; 464 AA.
AC Q6MZU6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE Hypothetical protein DKFp686C15213.
GN Name=DKFp686C15213;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Bloembergen H., Boecker M., Brandt P., Mewes H.W., Weil B., Amid C.,
RA Oanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640874; CAB45931.1; -; mRNA.
DR HSSP; P01861; IADQ.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IG1; 3.
DR SMART; SM00407; IG1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
KW Hypothetical protein.
SQ SEQUENCE 464 AA; 51099 MW; 2FCA72C66E8A0ABC CRC64;

Query Match 69.1%; Score 459; DB 2; Length 464;
Best Local Similarity 73.0%; Pred. No. 8.7e-39;
Matches 92; Conservative 9; Mismatches 17; Indels 8; Gaps 2;

QY 1 EVLVKSGEGLVKPGGSLRLSCAASGFTFRYYDIHWVQTPGKGLWVSSISS--GGNYID 59
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 20 EVLVSGGGLVKPGGSLRLSCAASGFTFSSYNNVVRQAPGKGLWVSSFSRGGSYEY 79

QY 60 YADSVKGRFTISRDNANVYLVQNSLRADMAVYFCARDGTIFGSAATWRADFWGRGT 119
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 80 YADSVKGRFTISRDNANVYLVQNSLRADMAVYFCARDGTIFGSAATWRADFWGRGT 132

QY 120 MVTVSS 125
:||||:
Db 133 LVTVSS 138

RESULT 3
Q9UL91_HUMAN PRELIMINARY; PRT; 118 AA.
AC Q9UL91;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berny S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528;
RA Manheimer-Lory A., Katz J.B., Fillinger M., Ghossein C., Smith A.,
RA Diamond B.;
RT "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype.";
RL J. Exp. Med. 174:1639-1652(1991).
RN [3]
RP PROTEIN SEQUENCE.
RX PubMed=1555592;
RA Makiya R., Stigbrand T.;
RT "Placental alkaline phosphatase has a binding site for the human immunoglobulin-G Fc portion.";
RL Eur. J. Biochem. 205:341-345(1992).
DR EMBL; AF035023; AAD56259.1; -; mRNA.
DR PIR; PH0875; PH0875.
DR PIR; S21205; S21205.
DR PIR; S30531; S30531.
DR HSSP; P01783; IIGC.
DR SMR; Q9UL91; 1-117.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
FT NON_TER 1
FT NON_TER 118
SQ SEQUENCE 118 AA; 12843 MW; D0633949F2AC149D CRC64;

Query Match 67.1%; Score 445.5; DB 2; Length 118;
Best Local Similarity 74.2%; Pred. No. 4.6e-38;
Matches 92; Conservative 9; Mismatches 16; Indels 7; Gaps 2;

QY 1 EVLVKSGEGLVKPGGSLRLSCAASGFTFRYYDIHWVQTPGKGLWVSSISSGGNYIDY 60
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVLVSGGGLVQPGGSLRLSCAASGFTFSSYNNVVRQAPGKGLWVSSISITIIYY 60

QY 61 ADSVKGRFTISRDNANVYLVQNSLRADMAVYFCARDGTIFGSAATWRADFWGRGT 120
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVKGRFTISRDNANVYLVQNSLRADMAVYFCARDGTIFGSAATWRADFWGRGT 113

QY 121 VTVS 124
||||:
Db 114 VTVS 117

RESULT 4
Q96BB9_HUMAN PRELIMINARY; PRT; 597 AA.
ID Q96BB9_HUMAN

```

```

Query Match      67.0%  Score 445;  DB 2;  Length 597;
Best Local Similarity 66.7%  Pred No. 3.2e-37;
Matches 84;  Conservative 18;  Mismatches 24;  Indels 0;  Gaps 0;

QY  1  EVLVKSGEGVLKPGGSLRLSCAASGFTFRYDIHWVQTPGKGLEWVSISSGNNYIDY 60
    |||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Db  20  EVQLLEGGGVLQPGGSLRLSCAASGFTFSYANNVVRQAPGKGLEWVSISSGGSTYY 79
    |||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||

QY  61  ADSVKGRTFTSRDNNANNVYLVQNSLRADMAVYFCARDGTIFGSAATWRAFDIWRGSTM 120

```

RL	Eur. J. Immunol.	22:247-251(1992).
RN	[6]	
RN	NUCLEOTIDE SEQUENCE.	
RP	PubMed=1904154;	
RX	Neale G.A., Kitchingman G.R.;	
RA	"mRNA transcripts initiating within the human immunoglobulin mu heavy	
RT	chain enhancer region contain a non-translatable exon and are	
RT	extremely heterogeneous at the 5' end.";	
RT	Nucleic Acids Res.	19:2427-2433(1991).
RL	[7]	
RN	NUCLEOTIDE SEQUENCE	
RP	PubMed=2840480; DOI=10.1084/jem.168.1.229;	
RX	Bird J., Gallil N., Link M., Stiles D., Sklar J.;	
RA	"Continuing rearrangement but absence of somatic hypermutation in	
RT	immunoglobulin genes of human B cell precursor leukemia.";	
RT	J. Exp. Med.	168:229-245(1988).
RL	[8]	
RN	NUCLEOTIDE SEQUENCE.	
RP	PubMed=2538551; DOI=10.1084/jem.169.4.1391;	
RX	Nickerson K.G., Beriman J., Glickman E., Chess L., Alt F.W.;	
RA	"Early human IGH gene assembly in Epstein-Barr virus-transformed fetal	
RT	B cell lines. Preferential utilization of the most JH-proximal D	
RT	segment (DQ52) and two unusual VH-related rearrangements.";	
RT	J. Exp. Med.	169:1391-1403(1989).
RL	[9]	
RN	NUCLEOTIDE SEQUENCE.	
RP	MEDLINE=93301610; PubMed=8315388; DOI=10.1084/jem.178.1.331;	
RX	Hillson J.L., Karr N.S., Opplinger I.R., Mannik M., Sasso E.H.;	
RA	"the structural basis of germline-encoded VH3 immunoglobulin binding	
RT	to staphylococcal protein A.";	
RT	J. Exp. Med.	178:331-336(1993).
RL	EMBL; BC020240; AAH20240.1; -, mRNA.	
DR	PIR; F36005; F36005.	
DR	PIR; G36005; G36005.	
DR	PIR; PH1642; PH1642.	
DR	PIR; PH1643; PH1643.	
DR	PIR; PH1645; PH1645.	
DR	PIR; PH1646; PH1646.	
DR	PIR; PL0098; PL0098.	
DR	PIR; PL0120; PL0120.	
DR	PIR; SI5590; SI5590.	
DR	PIR; S31116; S31116.	
DR	PIR; S31119; S31119.	
DR	PIR; S70442; S70442.	
DR	HSSP; P01861; IADQ.	
DR	SMR; Q8WUK1; 20-242.	
DR	Ensembl; ENSG0000030076; Homo sapiens.	
DR	InterPro; IPR007110; Ig-like.	
DR	InterPro; IPR003597; Ig cl.	
DR	InterPro; IPR003006; Ig MHC.	
DR	InterPro; IPR003596; Ig v.	
DR	Pfam; PF07654; Cl-set; 4.	
DR	SMART; SM00406; IGv; 1.	
DR	PROSITE; PS50835; IG LIKE; 5.	
DR	PROSITE; PS00290; IG MHC; UNKNOWN_3.	
KW	Immunoglobulin domain.	
SQ	SEQUENCE 613 AA; 67296 MW; 60C7F5950671E315 CRC64;	
Query Match		
Best Local Similarity 66.9%; Score 444.5; DB 2; Length 613;		
Matches 88; Conservative 12; Mismatches 17; Indels 13; Gaps 2;		
Qy	1 EVQLVKGEGLVKGGSLRLSCAASGFFPRFDYTHWRQTQPKGLEWVSISSGNYIDI 60	
Dd	: :: :	
Db	20 QVQLVSGGVVQPGSRSLRSLCAASGFTFSYGMHWVRQAPFKGLEWVAIVSYDGSKYY 79	
Qy	61 ADSVKGRFTTISRDNANNVVYLQMNSLRAREDMAVYPCARDGTIFGSAATW----RAFDIWG 116	
Dd	: :	
Db	80 ADSVKGRFTTISRDNASKNTLYLQMNSLRAREDIAVYCAKD-----WSGEVFEDIWG 130	
Qy	117 RGTWTVTSSG 126	
Dd	: :	
Db	131 QGTWTVTSSG 140	

OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC	Homo.
OX	NCBI_TaxID=9606;
RN	[1]
RP	PROTEIN SEQUENCE.
RP	MEDLINE=81013859; PubMed=6774332;
RA	Lehman D.W., Putnam F.W.;
RT	"Amino acid sequence of the variable region of a human mu chain:
RT	Location of a possible JH segment ";
RL	Proc. Natl. Acad. Sci. U.S.A. 77:3239-3243(1980).
CC	-I- MISCELLANEOUS: This mu chain was isolated from the plasma of a
CC	patient with macroglobulinemia.
CC	-I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC	-----
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration
CC	between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC	the European Bioinformatics Institute. There are no restrictions on its
CC	use as long as its content is in no way modified and this statement is not
CC	removed.
CC	-----
DR	PIR; A02051; M3HUAM.
DR	HSP; P01772; 2FB4.
DR	SMR; P01768; 2-122.
DR	GO; GO:0005576; C:extracellular region; NAS.
DR	GO; GO:0003823; F:antigen binding; NAS.
DR	GO; GO:0006955; P:immune response; NAS.
DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003596; Ig_v.
DR	SMART; SM00406; IGV; 1.
DR	PROSITE; PS00835; IG LIKE; 1.
KW	Direct protein sequencing; Immunoglobulin domain;
KW	Immunoglobulin V region; Pyrrolidone carboxylic acid.
FT	DOMAIN 1 112 Ig-like.
FT	MOD_RES 1 1 Pyrrolidone carboxylic acid.
FT	NON_TER 122 122
FT	SEQUENCE 122 AA; 13668 MW; A42D0F17D252F1C2 CRC64;
QY	Query Match 66.0%; Score 438.5; DB 1; Length 122;
QY	Best Local Similarity 65.6%; Pred. No. 2.5e-37;
QY	Matches 82; Conservative 21; Mismatches 19; Indels 3; Gaps 1;
QY	1 EVQLVKSGELVKPGSRLSLCAASGFTPRRYDIHWVROTQKGLWVSSISGGNYIDY 60
DB	1 QVELVESGGGVZPGRSLRLCAASGFTSNYAMHWVQPPKGLWVAIVSYBGBKYY 60
QY	61 ASVSKGRFTISRDNANNVYLVQNSLRABDMAYVCARDGTTFGSAATWRAFDIWGRGTW 120
DB	61 ASVSKGRFTISRDBSKBTLTLQVNSLRABETAVYVCARDRPLYGB---YRAFNWQGGTL 117
QY	121 VTVSS 125
DB	118 VTVSS 122
RESULT 9	
Q9UL71_HUMAN	
ID	Q9UL71_HUMAN PRELIMINARY; PRT; 121 AA.
AC	Q9UL71;
DT	01-MAY-2000 (TrEMBLrel. 13, Created)
DT	01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT	01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE	Myosin-reactive immunoglobulin heavy chain variable region
DE	(fragment).
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC	Homo.
OX	NCBI_TaxID=9606;
RN	[1]
RP	NUCLEOTIDE SEQUENCE.
RP	MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;


```
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Director MGC Project;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
RN [3]
RP PROTEIN SEQUENCE.
RX PubMed=155592;
RA Makiya R., Stigbrand T.;
RT "Placental alkaline phosphatase has a binding site for the human
RT immunoglobulin-G Fc portion.";
RL Eur. J. Biochem. 205:341-345 (1992).
DR EMBL; BC021276; AAH21276.1; -; mRNA.
DR PIR; S21205; S21205.
DR PIR; S30532; S30532.
DR HSP; P18529; I18K.
DR Ensemble; ENSG00000196122; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 1.
DR SMART; SM0047; Ig; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 573 AA; 62967 MW; PD072344033AC530 CRC64;

Query Match 65.4%; Score 434.5; DB 2; Length 573;
Best Local Similarity 69.8%; Pred. No. 3.8e-36;
Matches 88; Conservative 11; Mismatches 24; Indels 3; Gaps 2;

Qy 1 EVQLVKGEGLVKPGGSLRLSAAAGTFRRYDIHWVROTPGKLEWVSSISGNYIDY 60
Db 20 EVQLVESGGGLVQPGSLRLSCAASGTFDFDYAMHWVROAPGKLEWVSGISG 79
Qy 61 ADSVKGRTISRDNANNVYLNQNSLRAEDMAYVFCARDGTIFGS-AATRAPDWCGRGT 119
Db 80 ADSVKGRTISRDNANKSLYLNQNSLRAEDTALYICAKGGS--GSYIGYYIGMDVWGQGT 137
Qy 120 MVTVSS 125
Db 138 TVTVSS 143

RESULT 12
Q6PJA4 HUMAN
ID Q6PJA4_HUMAN PRELIMINARY; PRT; 470 AA.
AC Q6PJA4
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J.J., Hsieh F.,
RA Datschenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,

RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalak U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC018747; AAH18747.1; -; mRNA.
DR HSP; P01861; IADQ.
DR SMR; Q6PJA4; 20-470.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
SQ SEQUENCE 470 AA; 51716 MW; 7B49556A11FD7D99 CRC64;

Query Match 64.9%; Score 431; DB 2; Length 470;
Best Local Similarity 67.7%; Pred. No. 7e-36;
Matches 86; Conservative 12; Mismatches 21; Indels 8; Gaps 2;

Qy 1 EVQLVKGEGLVKPGGSLRLSAAAGTFRRYDIHWVROTPGKLEWVSSISGNYIDY 60
Db 20 EVQLVESGGGLVQPGGSLRLSCVSGTFTSSYMSWVRQAPGKLEWVANIKQDSSEKY 79
Qy 61 ADSVKGRTISRDNANNVYLNQNSLRAEDMAYVFCARDGTIFGSAATWRA--FDIWRG 118
Db 80 VDSVKGRTISRDNANKSLYLNQNSLRAEDTAVVYCARDG-----SSWRDWFDPWQGG 133
Qy 119 TMVTVSS 125
Db 134 TLTVTSS 140

RESULT 13
Q6MZV7 HUMAN
ID Q6MZV7_HUMAN PRELIMINARY; PRT; 473 AA.
AC Q6MZV7
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686C11235.
GN Name=DKFZp686C11235;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Small intestine;
RG The German cDNA Consortium;
RA Bloecker H., Boecher M., Brandt P., Mewes H.W., Weil B., Amid C.,
RA Oranger A., Fobo G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640853; CAB545920.1; -; mRNA.
DR HSP; P01861; IADQ.
```

```
DR InterPro: IPR003599; Ig.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003597; Ig_c1.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam: PF07654; Cl-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein_MHC; UNKNOWN_2.
SQ SEQUENCE 473 AA; 52121 MW; 9476EAE4C0BFC447 CRC64;

Query Match 64.7%; Score 429.5; DB 2; Length 473;
Best Local Similarity 65.4%; Pred. No. 1e-35;
Matches 83; Conservative 17; Mismatches 22; Indels 5; Gaps 2;

QY 1 EVLVKSGGLVPGGSLRLSCAASGFTFRYDIHWVROTPTGKLEWVSSISSGGNYIDY 60
Db 20 EQLVSGGGLVPGGSLRLSCAASGFTFSFEMNVRQAPGKLEWLSYITRSGNTVY 79
QY 61 ADSVKGRFTISRDNANNVYLVQNSLRADTMVYFCARDGTIFGSAATW--RAPDIWGRG 118
Db 80 ADSLQGRFTISRDNARNSLYLQNSLRADTAVYICARQNE---HTSPWTPSFDFYWGQG 136
QY 119 TMVTVSS 125
Db 137 ILTVSS 143

RESULT 14
Q8N5K4 HUMAN
ID Q8N5K4 HUMAN PRELIMINARY; PRT; 499 AA.
AC Q8N5K4.
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE MGC27165 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Blood;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Blakesley R.W., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Sapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.A., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzyzanski M.I., Skalska U., Smalls D.E.,
RA Schnurch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Blood;
RA Strauberg R.;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.

DR EMBL; BC032249; AAH32249.1; -; mRNA.
DR HSP; P01876; IOWO.
DR SMR; Q8N5K4; 269-477.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003597; Ig_c1.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 499 AA; 53376 MW; 93A5C89582054F32 CRC64;

Query Match 64.6%; Score 429; DB 2; Length 499;
Best Local Similarity 66.9%; Pred. No. 1.2e-35;
Matches 85; Conservative 13; Mismatches 27; Indels 2; Gaps 1;

QY 1 EVLVKSGGLVPGGSLRLSCAASGFTFRYDIHWVROTPTGKLEWVSSISSGGNYIDY 60
Db 20 EVLVSGGGLVPGGSLRLSCATSGFTFDDSGASWVRQAPGKLEWVSSINWNGSTNY 79
QY 61 ADSVKGRFTISRDNANNVYLVQNSLRADTMVYFCARDGTIFGSAATWRAF--DIWGRG 118
Db 80 ADSVKGRFTISRDNANNVYLVQNSLRVEDTALYYCARDFTKYCSGSGCLGYTMDVWGKG 139
QY 119 TMVTVSS 125
Db 140 TTVTVSS 146

RESULT 15
Q6MZQ6 HUMAN
ID Q6MZQ6 HUMAN PRELIMINARY; PRT; 475 AA.
AC Q6MZQ6.
DT 03-JUL-2004 (TrEMBLrel. 27, Created)
DT 03-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 03-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686G1190.
GN Name=DKFZp686G1190;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Esophagus tumor;
RG The German cDNA Consortium;
RA Bahr A., Lauber J., Mewes H.W., Weil B., Amid C., Osanger A., Fobo G.,
RA Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640347; CAE45972.1; -; mRNA.
DR HSP; P01861; IADQ.
DR SMR; Q6MZQ6; 20-475.
DR InterPro: IPR003599; Ig.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003597; Ig_c1.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 475 AA; 52043 MW; B7EAE255A26F4B8E CRC64;

Query Match 64.1%; Score 425.5; DB 2; Length 475;
Best Local Similarity 67.4%; Pred. No. 2.6e-35;
Matches 87; Conservative 15; Mismatches 20; Indels 7; Gaps 3;
```


THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:18 ; Search time 43.9015 Seconds
(without alignments)
1140.944 Million cell updates/sec

Title: US-09-674-752-51

Perfect score: 597

Sequence: 1 QVQLVQSGAEVKKPKGSSVKV.....YCELDWFYIWGGTMTVTSS 114

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

A Geneseq_21.*
1: Geneseqp1980s.*
2: Geneseqp1990s.*
3: Geneseqp2000s.*
4: Geneseqp2001s.*
5: Geneseqp2002s.*
6: Geneseqp2003as.*
7: Geneseqp2003bs.*
8: Geneseqp2004s.*
9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	597	100.0	114	3 AAY50974	Aay50974 Human FVI
2	586	98.2	116	3 AAY50971	Aay50971 Human FVI
3	522	87.4	122	6 ADA89182	Ada89182 Human ant
4	520.5	87.2	271	5 AAG66039	Aag66039 scFv 1b4
5	520	87.1	118	3 AAY99558	Aay99558 Human LH1
6	520	87.1	118	6 ABR42842	Abr42842 Tumour-sp
7	520	87.1	118	6 ABR42861	Abr42861 Tumour-sp
8	520	87.1	118	6 ABR42840	Abr42840 Tumour-sp
9	520	87.1	118	6 ABR42841	Abr42841 Tumour-sp
10	520	87.1	118	7 ABR02449	Abw02449 Human mon
11	520	87.1	118	7 ABW02451	Abw02451 Human mon
12	520	87.1	118	7 ABW02447	Abw02447 Human mon
13	520	87.1	118	7 ABW02450	Abw02450 Human mon
14	520	87.1	124	6 ABR55793	Abr55793 Heavy cha
15	517.5	86.7	121	6 ABR55777	Abr55777 Heavy cha
16	516.5	86.5	119	6 ADA89118	Ada89118 MS-Pro-21
17	516.5	86.5	119	7 ADG74369	Adg74369 MSPRO hea
18	516.5	86.5	125	6 ABR55803	Abr55803 Heavy cha
19	516	86.4	270	5 AAU97198	Aau97198 Human ant
20	515.5	86.3	481	2 AAR24442	Aar24442 Sequence
21	515	86.3	220	6 ABR01512	Abr01512 Human ant
22	514.5	86.2	123	6 ABR55771	Abr55771 Heavy cha
23	514	86.1	120	6 ABR55817	Abr55817 Heavy cha
24	512	85.8	126	9 ADZ41969	Adz41969 Ig H chai

25	511.5	85.7	121	6 ABR55787	Abr55787 Heavy cha
26	510	85.4	220	6 ABR01538	Abr01538 Human ant
27	509.5	85.3	127	9 ADZ41988	Adz41988 Ig H chai
28	509.5	85.3	245	4 AAB67617	Aab67617 Human leu
29	509	85.3	248	7 ADF18276	Adf18276 Anti-TL5
30	508.5	85.2	115	5 ABB57559	Abb57559 HLA-DR-sp
31	508.5	85.2	119	7 ADJ80430	Adj80430 Hybrid hu
32	508.5	85.2	225	6 ABR01510	Abr01510 Human ant
33	508.5	85.2	245	4 AAB67618	Aab67618 Human leu
34	508.5	85.2	247	8 ADE83874	Ade83874 Chemokine
35	508	85.1	120	2 AAW27550	Aaw27550 Human Ab
36	508	85.1	120	6 ABJ18672	Abj18672 Antibody
37	508	85.1	120	6 ABJ18718	Abj18718 Antibody
38	507.5	85.0	115	8 ADJ57855	Adj57855 Heavy var
39	507.5	85.0	489	9 ADY29671	Ady29671 Human hea
40	507.5	85.0	589	8 ADV25271	Adv25271 Anti-EpCA
41	507	84.9	128	9 ADZ41976	Adz41976 Ig H chai
42	507	84.9	253	5 ABP45498	Abp45498 Human Bly
43	507	84.9	253	7 ADG96325	Adg96325 Single ch
44	506.5	84.8	119	6 ADA89119	Ada89119 MS-Pro-24
45	506.5	84.8	119	7 ADG74370	Adg74370 MSPRO hea

ALIGNMENTS

RESULT 1	
AA550974	
ID	AA550974 standard; protein; 114 AA.
XX	
AC	AA550974;
XX	
DT	23-MAR-2000 (first entry)
XX	
DE	Human FVIII heavy chain variable region protein fragment.
XX	
KW	Human; heavy chain; antibody; factor VIII; hemostatic; variable region; hemophilia A.
XX	
OS	Homo sapiens.
XX	
PN	WO9958680-A2.
XX	
PD	18-NOV-1999.
XX	
PF	07-MAY-1999; 99WO-NL000285.
XX	
PR	08-MAY-1998; 98EP-00201543.
XX	
PA	(SANQ-) STICHTING SANQUIN BLOEDVOORZIEENING.
XX	
PI	Voorberg JJ, Van Den Brink EN, Turenhout EAM;
XX	
DR	WPI; 2000-053102/04.
DR	N-PSDB; AAZ43867.
XX	
PT	New polynucleotide, polypeptide and antibody useful for diagnosing the presence of neutralizing antibodies against factor VIII and for treatment of hemophilia A patients with these antibodies.
XX	
PS	Example 9; Fig 11B; 61pp; English.
XX	
CC	This invention describes a novel polynucleotide (I) (and complements and hybridizable polynucleotides) comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity which has hemostatic activity. (I) is useful as a primer or probe for detecting the presence of inhibitory antibodies directed against factor VIII. The polypeptides of the invention and the antibodies generated from them are useful in compositions for neutralizing factor VIII inhibiting antibodies in hemophilia A patients. This sequence represents a fragment of the human factor VIII antibody heavy chain variable region protein DP-10 which is used in the method of the invention
XX	

Best Local Similarity 86.1%; Pred. No. 6.8e-38;
Matches 105; Conservative 2; Mismatches 7; Indels 8; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSTLTSTSEDATVYCYCELD----WFY-----IWGGQTWTV 112
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSSEDTAVYYCARDSSGWLDAFDIWGGQTWTV 120

Qy 113 SS 114
Db 121 SS 122

RESULT 4
AAG66039
ID AAG66039 standard; protein; 271 AA.
XX AC AAG66039;
XX DT 27-FEB-2002 (first entry)
XX DE scFv 1b4 antibody fragment.
XX KW Ryk protein; angiogenesis; variant; receptor tyrosine kinase; cytostatic;
XX KW antidiabetic; ophthalmological; cardiant; vulnerary; antiangiogenic;
XX KW gene therapy; fusion protein.
XX OS Synthetic.
XX PN WO200185789-A2.
XX PD 15-NOV-2001.
XX PF 09-MAY-2001; 2001WO-US015043.
XX PR 10-MAY-2000; 2000US-00568783.
XX PA (FARB) BAYER CORP.
XX PI Rocznik S, Dubois-Stringfellow NA, Zolotorev A;
XX WPI; 2002-049443/06.
XX DR N-PSDB; AAI6770.
XX PT Modulating angiogenesis at a site, for treating or preventing cancer,
XX PT metastasis, diabetic retinopathy, cardiovascular disease, wound by
XX PT supplying composition comprising variant Ryk protein to the site.
XX PS Example; Page 79-80; 81pp; English.
XX CC The invention relates to modulating angiogenesis at a site by supplying a
XX CC composition comprising a variant Ryk protein (I) (a member of the
XX CC receptor tyrosine kinase family), or modulating formation of cells into
XX CC capillary-like structures by contacting the cells with a composition
XX CC comprising (I). The method is useful modulating angiogenesis at a site
XX CC (preferably, within a human) or modulating the formation of cells
XX CC (endothelial cells of human origin) into capillary-like structure. The
XX CC (I) is useful for preventing, treating or ameliorating a medical
XX CC condition e.g., cancer, metastasis, diabetic retinopathy, macular
XX CC degeneration, cardiovascular disease, wound, pregnancy, or a clinical
XX CC condition involving angiogenesis in the reproductive system, including
XX CC regulation of placental vascularization in an individual. The variant
XX CC protein is supplied to the individual as a source of polynucleotide
XX CC encoding the protein and expressing the protein in vivo. (I) is used as
XX CC an immunogen to produce an antibody against it. The antibodies are useful
XX CC for modulating angiogenesis at a site. Polynucleotides encoding (I) is
XX CC useful in gene therapy technique for treating above mentioned medical
XX CC conditions. The present sequence represents the scFv 1b4 antibody
XX CC fragment

SQ Sequence 271 AA;
Query Match 87.2%; Score 520.5; DB 5; Length 271;
Best Local Similarity 87.2%; Pred. No. 2e-37; 8; Indels 3; Gaps 1;
Matches 102; Conservative 4; Mismatches 4;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 5 EVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 64

Qy 61 AQKFGQGRVTITADESTSTAYMELSTLTSTSEDATVYCYCELD----LDWFIYWGQGTWTVSS 114
Db 65 AQKFGQGRVTITADESTSTAYMELSLRSSEDTAVYYCARSYDYDFYWGQGTWTVSS 121

RESULT 5
AAY99558
ID AAY99558 standard; protein; 118 AA.
XX AC AAY99558;
XX DT 20-SEP-2000 (first entry)
XX DE Human LH13 monoclonal antibody heavy chain variable region.
XX KW Human; LH13 monoclonal antibody; hybridoma; tumour-specific; cancer;
XX KW cytostatic; cytotoxic; heavy chain variable region.
XX OS Homo sapiens.
XX PN WO200032635-A2.
XX PD 08-JUN-2000.
XX PF 01-DEC-1999; 99WO-US028485.
XX PR 02-DEC-1998; 98US-00203768.
XX PA (IXSY-) IXSYS INC.
XX PI Watkins JD, Huse WD;
XX WPI; 2000-412293/35.
XX DR N-PSDB; AAA48411.
XX PT New tumor-specific human monoclonal antibody, useful for the treatment
XX PT and diagnosis of cancer, comprises at least one complementarity
XX PT determining region.
XX PS Claim 10; Page 82-83; 84pp; English.
XX CC The present sequence is the heavy chain variable region of a human tumour
XX CC -specific monoclonal antibody. Neoplastic cells selectively express
XX CC antigens which are not present on normal cells. Thus monoclonal
XX CC antibodies can be produced that are specifically directed against tumour-
XX CC specific antigens. The antibodies can be conjugated to cytotoxic or
XX CC cytostatic agents and used to selectively target cancer cells for the
XX CC elimination of tumours. They can also be linked to diagnostic moieties
XX CC that allow the imaging of neoplastic cells. Nucleic acids encoding human
XX CC tumour-specific monoclonal antibodies can be used to express the
XX CC antibodies and can be recombinantly engineered to produce modified
XX CC antibodies with higher affinity or higher selectivity for tumour cells.
XX CC Tumour-specific antibodies were produced by hybridoma cell cultures
XX CC generated by in vitro immunisation of human spleen cell cultures with
XX CC breast carcinoma cells. The nucleic acid encoding the monoclonal antibody
XX CC was then isolated from the hybridoma by RT-PCR. The present sequence was
XX CC produced by LH13 hybridoma cell line

SQ Sequence 118 AA;
Query Match 87.1%; Score 520; DB 3; Length 118;
Best Local Similarity 85.6%; Pred. No. 9.9e-38;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;

```
QY 1 QVOLVSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
DB 1 QVOLVSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
QY 61 AQKFGQGRVITTADESTSTAYMELSTLTSTEDTAVYYCELD---WFYIWGGQTMVTYSS 114
DB 61 AQKFGQGRVITTADESTSTAYMELSSRLSDEDTAVYYCAREDSGWHYWGQGLTLVTYSS 118

RESULT 6
ID ABR42842 standard; protein; 118 AA.
XX
AC ABR42842;
XX
DT 08-SEP-2003 (first entry)
XX
DE Tumour-specific human MAb LH13 VH variant S97N.
XX
KW Human; monoclonal antibody; antibody; LH13; breast cancer;
KW ovarian cancer; lung cancer; antitumour; therapy; diagnosis; mutant;
KW mutein.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 101
FT /note= "wild-type Ser substituted by Asn"
XX
PN WO2003044036-A1.
XX
PD 30-MAY-2003.
XX
PF 19-NOV-2002; 2002WO-US037134.
XX
PR 19-NOV-2001; 2001US-00989901.
XX
PA (MOLE-) APPLIED MOLECULAR EVOLUTION INC.
XX
PI Watkins JD;
XX
DR WPI; 2003-457585/43.
DR N-PSDB; ACC58833.
XX
PS New isolated human monoclonal antibody or its functional fragment
PT comprising a complementary determining region, useful for reducing
PT neoplastic cell proliferation, particularly for treating and diagnosing
PT cancer.
XX
PS Claim 1; Page 124; 151pp; English.
XX
CC This is the protein sequence of the heavy chain variable region (VH) of
CC tumour-specific human monoclonal antibody (MAb) LH13 variant clone S97N,
CC in which the Ser residue at position 97 (numbering system of Kabat et al)
CC of the native LH13 VH is substituted by Asn. A functional variant of LH13
CC comprises an unmodified VL and the modified VH. MAb LH13 specifically
CC binds a product produced by breast, lung and ovarian carcinoma cells, as
CC compared to normal fibroblasts and melanoma cells. The invention provides
CC tumour-specific human MAb such as LH13 and functional fragments, e.g.
CC Fv, Fab, Fab' or F(ab')2, of them that comprise a complementarity
CC determining region selected from a group including the variant VH. These
CC specifically bind to neoplastic cells compared to normal cells. They are
CC used in claimed methods of reducing neoplastic cell proliferation and of
CC detecting a neoplastic cell in a sample, where the neoplastic cell is a
CC breast cancer, lung cancer or ovarian cancer cell
XX
SQ Sequence 118 AA;
XX
Query Match 87.1%; Score 520; DB 6; Length 118;
Best Local Similarity 85.6%; Pred. No. 9.9e-38;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;

QY 1 QVOLVSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
DB 1 QVOLVSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
QY 61 AQKFGQGRVITTADESTSTAYMELSTLTSTEDTAVYYCELD---WFYIWGGQTMVTYSS 114
DB 61 AQKFGQGRVITTADESTSTAYMELSSRLSDEDTAVYYCAREDSGWHYWGQGLTLVTYSS 118

RESULT 7
ID ABR42861 standard; protein; 118 AA.
XX
AC ABR42861;
XX
DT 08-SEP-2003 (first entry)
XX
DE Tumour-specific human monoclonal antibody LH13 VH.
XX
KW Human; monoclonal antibody; antibody; LH13; breast cancer;
KW ovarian cancer; lung cancer; antitumour; therapy; diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003044036-A1.
XX
PD 30-MAY-2003.
XX
PF 19-NOV-2002; 2002WO-US037134.
XX
PR 19-NOV-2001; 2001US-00989901.
XX
PA (MOLE-) APPLIED MOLECULAR EVOLUTION INC.
XX
PI Watkins JD;
XX
DR WPI; 2003-457585/43.
DR N-PSDB; ACC58852.
XX
PS New isolated human monoclonal antibody or its functional fragment
PT comprising a complementary determining region, useful for reducing
PT neoplastic cell proliferation, particularly for treating and diagnosing
PT cancer.
XX
PS Disclosure; Page 119; 151pp; English.
XX
CC This is the protein sequence of the heavy chain variable region of tumour
CC -specific human monoclonal antibody (MAb) LH13. The hybridoma producing
CC this MAb was generated by in vitro immunization of human spleen cells
CC with breast carcinoma cells, and immortalization of the immunized
CC lymphocytes by transformation with EBV and fusion with K6H6/BS5
CC heteromelanoma cells. MAb LH13 specifically binds a product produced by
CC breast, lung and ovarian carcinoma cells, as compared to normal
CC fibroblasts and melanoma cells. The invention provides tumour-specific
CC human MAb such as LH13 and functional fragments of them. These
CC specifically bind to neoplastic cells compared to normal cells. They are
CC used in claimed methods of reducing neoplastic cell proliferation and of
CC detecting a neoplastic cell in a sample, where the neoplastic cell is a
CC breast cancer, lung cancer or ovarian cancer cell
XX
SQ Sequence 118 AA;
XX
Query Match 87.1%; Score 520; DB 6; Length 118;
Best Local Similarity 85.6%; Pred. No. 9.9e-38;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;

QY 1 QVOLVSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
DB 1 QVOLVSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
QY 61 AQKFGQGRVITTADESTSTAYMELSTLTSTEDTAVYYCELD---WFYIWGGQTMVTYSS 114
DB 61 AQKFGQGRVITTADESTSTAYMELSSRLSDEDTAVYYCAREDSGWHYWGQGLTLVTYSS 118

RESULT 8
ID ABR42861 standard; protein; 118 AA.
XX
AC ABR42861;
XX
DT 08-SEP-2003 (first entry)
XX
DE Tumour-specific human monoclonal antibody LH13 VH.
XX
KW Human; monoclonal antibody; antibody; LH13; breast cancer;
KW ovarian cancer; lung cancer; antitumour; therapy; diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003044036-A1.
XX
PD 30-MAY-2003.
XX
PF 19-NOV-2002; 2002WO-US037134.
XX
PR 19-NOV-2001; 2001US-00989901.
XX
PA (MOLE-) APPLIED MOLECULAR EVOLUTION INC.
XX
PI Watkins JD;
XX
DR WPI; 2003-457585/43.
DR N-PSDB; ACC58852.
XX
PS New isolated human monoclonal antibody or its functional fragment
PT comprising a complementary determining region, useful for reducing
PT neoplastic cell proliferation, particularly for treating and diagnosing
PT cancer.
XX
PS Disclosure; Page 119; 151pp; English.
XX
CC This is the protein sequence of the heavy chain variable region of tumour
CC -specific human monoclonal antibody (MAb) LH13. The hybridoma producing
CC this MAb was generated by in vitro immunization of human spleen cells
CC with breast carcinoma cells, and immortalization of the immunized
CC lymphocytes by transformation with EBV and fusion with K6H6/BS5
CC heteromelanoma cells. MAb LH13 specifically binds a product produced by
CC breast, lung and ovarian carcinoma cells, as compared to normal
CC fibroblasts and melanoma cells. The invention provides tumour-specific
CC human MAb such as LH13 and functional fragments of them. These
CC specifically bind to neoplastic cells compared to normal cells. They are
CC used in claimed methods of reducing neoplastic cell proliferation and of
CC detecting a neoplastic cell in a sample, where the neoplastic cell is a
CC breast cancer, lung cancer or ovarian cancer cell
XX
SQ Sequence 118 AA;
XX
Query Match 87.1%; Score 520; DB 6; Length 118;
Best Local Similarity 85.6%; Pred. No. 9.9e-38;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;
```

Db 61 A Q K F Q G R V T I T A D E S T S T A Y M E L S S L R S E D T A V Y C A R E D S S G W Y H W G Q G T L V T V S S 118

RESULT 8	
ABR42840	
ID	ABR42840 standard; protein; 118 AA.
XX	
XX	ABR42840;
XX	
XX	08-SEP-2003 (first entry)
DT	
XX	Tumour-specific human MAb LH13 VH variant S97G.
DE	
XX	
XX	Human; monoclonal antibody; antibody; LH13; breast cancer;
KW	ovarian cancer; lung cancer; antitumour; therapy; diagnosis; mutant;
KW	mutin.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	Misc-difference 101
FT	/note= "wild-type Ser substituted by Gly"
XX	
XX	WO2003044036-A1.
XX	
PD	30-MAY-2003.
XX	
XX	19-NOV-2002; 2002WO-US037134.
XX	
PR	19-NOV-2001; 2001US-00989901.
XX	
XX	(MOLE-) APPLIED MOLECULAR EVOLUTION INC.
PA	
XX	Watkins JD;
PI	
XX	
XX	WPI; 2003-457585/43.
DR	
DR	N-PSDB; ACC58831.
XX	
XX	New isolated human monoclonal antibody or its functional fragment
PT	comprising a complementary determining region, useful for reducing
PT	neoplastic cell proliferation, particularly for treating and diagnosing
PT	cancer.
XX	
XX	Claim 1; Page 122; 151pp; English.
XX	
CC	This is the protein sequence of the heavy chain variable region (VH) of
CC	tumour-specific human monoclonal antibody (MAb) LH13 variant clone S97G
CC	in which the Ser residue at position 97 (numbering system of Kabat et al
CC	of the native LH13 VH is substituted by Gly. A functional variant of LH
CC	comprises an unmodified VL and the modified VH. MAb LH13 specifically
CC	binds a product produced by breast, lung and ovarian carcinoma cells, a
CC	compared to normal fibroblasts and melanoma cells. The invention provid
CC	tumour-specific human MAbs such as LH13 and functional fragments, e.g.
CC	Fv, Fab, Fab' or Fab'/2, of them that comprise a complementarity
CC	determining region selected from a group including the variant VH. These
CC	specifically bind to neoplastic cells compared to normal cells. They ar
CC	used in claimed methods of reducing neoplastic cell proliferation and o
CC	detecting a neoplastic cell in a sample, where the neoplastic cell is a
CC	breast cancer, lung cancer or ovarian cancer cell
XX	
XX	Sequence 118 AA;
SQ	

Query Match	87.1%	Score 520;	DB 6;	Length 118;
Best Local Similarity	85.6%;	Pred. No. 9.9e-38;		
Matches 101;	Conservative 6;	Mismatches 7;	Indels 4;	Gaps 1;
Qy	1	QVQLVQSGAEVKPGSSVKYISKASGGTFFSSHAISWVRAPQGLEWMGDIIPILGTGNY	60	
Db	1	QVQLVQSGAEVKPGSSVKYISKASGGTFFSSHAISWVRAPQGLEWMGDIIPILGTGNY	60	
Qy	61	AQKPGQRTVITADESTAYMELSTLTSEDPAVYCYELD----	WFYTWGQGTWTVVSS	114

Db 61 AQFQGRVTITADESTAYMELSSLRSEDTAVYCCAREDSGWYHWGGTLTVSS 118

RESULT 9	
ABR42841	
ID	ABR42841 standard; protein; 118 AA.
XX	
AC	ABR42841;
XX	
DT	08-SEP-2003 (first entry)
XX	
DE	Tumour-specific human MAb LH13 VH variant S97T.
XX	
KW	Human; monoclonal antibody; antibody; LH13; breast cancer
KW	ovarian cancer; lung cancer; antitumour; therapy; diagnos
KW	muten.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PH	Key Location/Qualifiers
FT	Misc-difference 101
FT	/note= "wild-type Ser substituted by Thr"
XX	
XX	W02003044036-A1.
XX	
PN	30-MAY-2003.
PD	
XX	
XX	19-NOV-2002; 2002WO-US037134.
XX	
PR	19-NOV-2001; 2001US-00989901.
XX	
PA	(MOLE-) APPLIED MOLECULAR EVOLUTION INC.
XX	
PI	Watkins JD;
XX	
WP	WPI; 2003-457595/43.
DR	N-PSDB; ACC59832.
DR	
XX	
PT	New isolated human monoclonal antibody or its functional
PT	comprising a complementary determining region, useful for
PT	neoplastic cell proliferation, particularly for treating
PT	cancer.
XX	
PS	Claim 1; Page 123; 151pp; English.
XX	
CC	This is the protein sequence of the heavy chain variable
CC	tumour-specific human monoclonal antibody (Mab) LH13 vari
CC	in which the Ser residue at position 97 (numbering system
CC	of the native LH13 VH is substituted by Thr. A functional
CC	comprises an unmodified VL and the modified VH. Mab LH13
CC	binds a product produced by breast, lung and ovarian carc
CC	compared to normal fibroblasts and melanoma cells. The in
CC	tumour-specific human MAb such as LH13 and functional fr
CC	Fv, Fab, Fab' or F(ab') ₂ , of them that comprise a complem
CC	determining region selected from a group including the vari
CC	specifically bind to neoplastic cells compared to normal
CC	used in claimed methods of reducing neoplastic cell proli
CC	detecting a neoplastic cell in a sample, where the neopla
CC	breast cancer, lung cancer or ovarian cancer cell
XX	
SQ	Sequence 118 AA;

```
Query Match      87.1%; Score 520; DB 6; Length 118;
Best Local Similarity 85.6%; Pred. No. 9.9e-38;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;

Qy    1 QVQLVSGAEVKKPGSSVKVCASGQTPESSHAISWVRQAPGGGLEWMGDIIPIPLGTGY 60
      ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db     1 QVQLVSGAEVKKPGSSVKVCASGQTPESSHAISWVRQAPGGGLEWMGDIIPIFGTANY 60
      ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy    61 AOKFQGRVTITADESTSTAYMEISLTSETPAYVYCELD----WFYTWGGGTWTWTVSS 114
      : : : : : :
```

```

Db      61 AQKFGQRTITADESTSTAYMELSLRSEDATVYYCAREDTSGWHYWGQTLVTVSS 118

RESULT 10
ABW02449
ID      ABW02449 standard; protein; 118 AA.
XX
AC      ABW02449;
XX
XX      12-FEB-2004 (first entry)
XX
DE      Human monoclonal antibody VH variant (S97G) protein from LH13 clone.
XX
KW      Human; monoclonal antibody; neoplastic cell proliferation; breast cancer;
KW      lung cancer; tumour; ovarian cancer cell; heavy chain variable region;
KW      VH; cytostatic; variant.
XX
XX      Homo sapiens.
OS      Synthetic.
XX
XX      Key Location/Qualifiers
FH      Misc-difference 101
FT      /note= "Wild-type Ser substituted with Gly; This position
FT      corresponds to position 97 of HCDR3 according to the
FT      numbering system of Kabat at al"
XX
XX      US2003198638-A1.
XX
XX      23-OCT-2003.
XX
XX      19-NOV-2002; 2002US-00300675.
XX
XX      19-NOV-2001; 2001US-0421146P.
XX
XX      (WATK/) WATKINS J D.
XX
XX      Watkins JD;
XX
XX      WPI; 2003-852771/79.
XX      N-PSDB; AAD64353.
XX
XX      New tumor-specific human monoclonal antibodies is useful for detecting
XX      neoplastic cells in a biological sample, or for reducing proliferation of
XX      neoplastic cells, particularly breast cancer, lung cancer or ovarian
XX      cancer cells.
XX
XX      Claim 1; SEQ ID NO 10; Opp; English.
XX
XX      The present invention relates to novel tumour-specific human monoclonal
XX      antibodies or their functional fragments. Sequences of the invention are
XX      useful for detecting neoplastic cells in a biological sample or for
XX      reducing neoplastic cell proliferation, particularly breast cancer, lung
XX      cancer or ovarian cancer cells. The present sequence is human monoclonal
XX      antibody heavy chain variable region (VH) variant protein from LH13 clone
XX
XX      Sequence 118 AA;
XX
XX      Query Match 87.1%; Score 520; DB 7; Length 118;
XX      Best Local Similarity 85.6%; Pred. NO. 9.9e-38;
XX      Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;
XX
Qy      1 QVQLVQSGAEVKKPGSSVKVSKASGGTFTSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db      1 QVQLVQSGAEVKKPGSSVKVSKASGGTFTSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy      61 AQKFGQRTITADESTSTAYMELSLRSEDATVYYCAREDTSGWHYWGQTLVTVSS 114
Db      61 AQKFGQRTITADESTSTAYMELSLRSEDATVYYCAREDTSGWHYWGQTLVTVSS 118

RESULT 12
ABW02447
ID      ABW02447 standard; protein; 118 AA.
XX
AC      ABW02447;
XX
XX      12-FEB-2004 (first entry)
XX
DE      Human monoclonal antibody VH protein from LH13 clone.

```


XX Human; monoclonal antibody; neoplastic cell proliferation; breast cancer;
KW lung cancer; tumour; ovarian cancer cell; heavy chain variable region;
KW VH; cytotostatic.
XX
OS Homo sapiens.
XX
XX US2003198638-A1.
XX
XX 23-OCT-2003.
XX
XX 19-NOV-2002; 2002US-00300675.
XX
XX 19-NOV-2001; 2001US-0421146P.
XX
XX (WATK/) WATKINS J D.
XX
XX Watkins JD;
XX
XX WPI; 2003-852771/79.
XX
XX N-PSDB; AAD64351.
XX
XX New tumor-specific human monoclonal antibodies is useful for detecting
PT neoplastic cells in a biological sample, or for reducing proliferation of
PT neoplastic cells, particularly breast cancer, lung cancer or ovarian
PT cancer cells.
XX
XX Disclosure; SEQ ID NO 6; Opp; English.
XX
XX The present invention relates to novel tumour-specific human monoclonal
CC antibodies or their functional fragments. Sequences of the invention are
CC useful for detecting neoplastic cells in a biological sample or for
CC reducing neoplastic cell proliferation, particularly breast cancer, lung
CC cancer or ovarian cancer cells. The present sequence is human monoclonal
CC antibody heavy chain variable region (VH) protein from LH13 clone
XX
SQ Sequence 118 AA;
Query Match 87.1%; Score 520; DB 7; Length 118;
Best Local Similarity 85.6%; Pred. No. 9.9e-38;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;
Qy 1 QVQLVQSGAEVKPGSSVKVSKCKASGCTFSSHAISWVRQAPGQGLEWMGDIPIPGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKCKASGCTFSSHAISWVRQAPGQGLEWMGDIPIPGTANY 60
Qy 61 AQPQGRVTITADESTSTAYMELSTLTSEDATVYYCELD----WFIYWGQGTWTVSS 114
Db 61 AQPQGRVTITADESTSTAYMELSLRSEDATVYYCAREDSGWHYWGQGTWTVSS 118
RESULT 13
ABW02450
ID ABW02450 standard; protein; 118 AA.
XX
XX AC ABW02450;
XX
XX DT 12-FEB-2004 (first entry)
XX
XX Human monoclonal antibody VH variant (S97T) protein from LH13 clone.
XX
XX Human; monoclonal antibody; neoplastic cell proliferation; breast cancer;
KW lung cancer; tumour; ovarian cancer cell; heavy chain variable region;
KW VH; cytotostatic; variant.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FT Misc-difference 101
/note= "Wild-type Ser substituted with Thr; This position
FT corresponds to position 97 of HCDR3 according to the
FT numbering system of Kabat at al"
FT

XX US2003198638-A1.
XX
XX 23-OCT-2003.
XX
XX 19-NOV-2002; 2002US-00300675.
XX
XX 19-NOV-2001; 2001US-0421146P.
XX
XX (WATK/) WATKINS J D.
XX
XX Watkins JD;
XX
XX WPI; 2003-852771/79.
XX
XX N-PSDB; AAD64354.
XX
XX New tumor-specific human monoclonal antibodies is useful for detecting
PT neoplastic cells in a biological sample, or for reducing proliferation of
PT neoplastic cells, particularly breast cancer, lung cancer or ovarian
PT cancer cells.
XX
XX Claim 1; SEQ ID NO 12; Opp; English.
XX
XX The present invention relates to novel tumour-specific human monoclonal
CC antibodies or their functional fragments. Sequences of the invention are
CC useful for detecting neoplastic cells in a biological sample or for
CC reducing neoplastic cell proliferation, particularly breast cancer, lung
CC cancer or ovarian cancer cells. The present sequence is human monoclonal
CC antibody heavy chain variable region (VH) variant protein from LH13 clone
XX
SQ Sequence 118 AA;
Query Match 87.1%; Score 520; DB 7; Length 118;
Best Local Similarity 85.6%; Pred. No. 9.9e-38;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;
Qy 1 QVQLVQSGAEVKPGSSVKVSKCKASGCTFSSHAISWVRQAPGQGLEWMGDIPIPGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKCKASGCTFSSHAISWVRQAPGQGLEWMGDIPIPGTANY 60
Qy 61 AQPQGRVTITADESTSTAYMELSTLTSEDATVYYCELD----WFIYWGQGTWTVSS 114
Db 61 AQPQGRVTITADESTSTAYMELSLRSEDATVYYCAREDTSGWHYWGQGTWTVSS 118
RESULT 14
ABR55793
ID ABR55793 standard; protein; 124 AA.
XX
XX AC ABR55793;
XX
XX DT 02-SEP-2003 (first entry)
XX
XX Heavy chain variable region of anti-Ang-2 antibody 551 HC.
XX
XX Ang-2; angiotensin-2; anorectic; cytostatic; antiarteriosclerotic;
KW gynaecological; antiinflammatory; osteopathic; antipsoriatic; cancer;
KW angiogenesis; antibody.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FT Region 26..36
/note= "complementarity determining region (CDR) 1"
FT Region 50..66
/note= "complementarity determining region (CDR) 2"
FT Region 96..114
/note= "complementarity determining region (CDR) 3"
XX
XX WO2003030833-A2.
XX
XX 17-APR-2003.
XX

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:53:55 ; Search time 12.5227 Seconds
(without alignments)
752.634 Million cell updates/sec

Title: US-09-674-752-51

Perfect score: 597

Sequence: 1 QVOLVSGAEVKKPGSSVKV.....YCELDWFYWGQGTMTVSS 114

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA.*

- 1: /cgn2_6/ptodata/1/iaa/5_COMB.pep.*
- 2: /cgn2_6/ptodata/1/iaa/6_COMB.pep.*
- 3: /cgn2_6/ptodata/1/iaa/H_COMB.pep.*
- 4: /cgn2_6/ptodata/1/iaa/PCTRUS_COMB.pep.*
- 5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep.*
- 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	520	87.1	118	2	US-09-203-768A-6
2	516	86.4	270	2	US-09-976-118-2
3	508	85.1	120	2	US-09-025-769B-35
4	508	85.1	120	2	US-09-025-769B-57
5	508	85.1	120	2	US-09-490-070A-35
6	508	85.1	120	2	US-09-490-070A-57
7	508	85.1	120	2	US-09-490-153-35
8	508	85.1	120	2	US-09-490-153-57
9	508	85.1	120	2	US-09-490-324-35
10	508	85.1	120	2	US-09-490-324-57
11	503.5	84.3	119	2	US-09-025-769B-21
12	503.5	84.3	119	2	US-09-490-070A-21
13	503.5	84.3	119	2	US-09-490-153-21
14	503.5	84.3	119	2	US-09-490-324-21
15	492.5	82.5	123	1	US-08-652-816A-1
16	492.5	82.5	123	1	US-08-652-816A-6
17	492.5	82.5	123	1	US-08-652-816A-8
18	492.5	82.5	123	1	US-08-652-816A-9
19	476.5	79.8	121	1	US-08-232-081B-41
20	474.5	79.5	119	2	US-08-983-607-50
21	474.5	79.5	120	1	US-08-428-197-12
22	474.5	79.5	120	1	US-08-428-197-13
23	474.5	79.5	120	4	PCT-US93-10555-12
24	474.5	79.5	120	4	PCT-US93-10555-13
25	471.5	79.0	476	1	US-08-378-939-10
26	470.5	78.8	123	1	US-08-652-816A-7
27	466	78.1	126	2	US-08-844-215-7

28	462	77.4	98	2	US-10-194-975-9	Sequence 9, Appl
29	461	77.2	147	1	US-08-217-918-4	Sequence 4, Appl
30	458	76.7	98	2	US-10-194-975-10	Sequence 10, Appl
31	455	76.4	122	2	US-09-424-840B-24	Sequence 24, Appl
32	455	76.2	102	1	US-07-834-539A-55	Sequence 55, Appl
33	455	76.2	102	1	US-08-053-131-63	Sequence 63, Appl
34	455	76.2	102	1	US-08-645-641-63	Sequence 63, Appl
35	455	76.2	102	1	US-07-853-408B-63	Sequence 63, Appl
36	455	76.2	102	1	US-08-096-762-63	Sequence 63, Appl
37	455	76.2	102	1	US-08-800-353-55	Sequence 55, Appl
38	455	76.2	102	1	US-08-308-865-63	Sequence 63, Appl
39	455	76.2	102	4	PCT-US92-06185-55	Sequence 55, Appl
40	455	76.2	102	4	PCT-US92-10983-63	Sequence 63, Appl
41	455	76.2	117	2	US-09-042-353-232	Sequence 232, App
42	455	76.2	117	2	US-08-758-417A-80	Sequence 80, Appl
43	452	75.7	128	1	US-08-202-047-22	Sequence 22, Appl
44	452	75.7	128	2	US-08-964-690-22	Sequence 22, Appl
45	452	75.7	128	2	US-08-635-109-3	Sequence 3, Appl

ALIGNMENTS

RESULT 1
US-09-203-768A-6
; Sequence 6, Application US/09203768A
; Patent No. 6787638
; GENERAL INFORMATION:
; APPLICANT: Huse, William D.
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Human Monoclonal Antibodies and Methods
; TITLE OF INVENTION: of Use
; FILE REFERENCE: P-IX 2947
; CURRENT APPLICATION NUMBER: US/09/203,768A
; CURRENT FILING DATE: 1998-12-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-203-768A-6

Query Match 87.1%; Score 520; DB 2; Length 118;
Best Local Similarity 85.6%; Pred. No. 3e-46;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;
Qy 1 QVOLVSGAEVKKPGSSVKVCKASGCTFSHAISWVRQAPGQGLEWMGDIPIILGTGNY 60
Db 1 QVOLVSGAEVKKPGSSVKVCKASGCTFSYAISWVRQAPGQGLEWMGGIPIFGTANY 60
Qy 61 AQKFGQRTTITADESTSTAYMELSTLTSEDATYYCELD----WFIYWGQGTMTVSS 114
Db 61 AQKFGQRTTITADESTSTAYMELSLRSEDATYYCAREDSGWHYWGQGTMTVSS 118

RESULT 2
US-09-976-118-2
; Sequence 2, Application US/09976118
; Patent No. 6699473
; GENERAL INFORMATION:
; APPLICANT: Ralsch, Kevin Paul
; APPLICANT: Curiel, David T.
; APPLICANT: Bonner, James Allen
; TITLE OF INVENTION: Human Anti-Epidermal Growth Factor Receptor
; TITLE OF INVENTION: Single-Chain Antibodies
; FILE REFERENCE: D6355
; CURRENT APPLICATION NUMBER: US/09/976,118
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: US 60/240,353
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2

```
; LENGTH: 270
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: amino acid sequence of anti-EGFR scFV
; OTHER INFORMATION: clone pSEX91-63
US-09-976-118-2

Query Match      86.4%; Score 516; DB 2; Length 270;
Best Local Similarity 81.7%; Pred. No. 2.1e-45;
Matches 103; Conservative 3; Mismatches 8; Indels 12; Gaps 1;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
   |||||

QY 61 AQKFGQGRVTTITADESTSTAYMELSLTSTEDTAVYYCELD-----WFVWGQGT 108
   |||||
Db 61 AQKFGQGRVTTITADESTSTAYMELSLSLRSDTAVYYCARDPDYVSGSGSYYPNWFDPWGQGT 120
   |||||

QY 109 MVTVSS 114
   :|||||
Db 121 LVTVSS 126

RESULT 3
US-09-025-769B-35
; Sequence 35, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-35

Query Match      85.1%; Score 508; DB 2; Length 120;
Best Local Similarity 81.7%; Pred. No. 2.1e-45;
Matches 103; Conservative 3; Mismatches 8; Indels 12; Gaps 1;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
   |||||

QY 61 AQKFGQGRVTTITADESTSTAYMELSLTSTEDTAVYYCELD-----WFVWGQGT 114
   |||||
Db 61 AQKFGQGRVTTITADESTSTAYMELSLSLRSDTAVYYCARDPDYVSGSGSYYPNWFDPWGQGT 120
   |||||

RESULT 4
US-09-025-769B-57
; Sequence 57, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-57

Query Match      85.1%; Score 508; DB 2; Length 120;
Best Local Similarity 85.8%; Pred. No. 5.2e-45;
Matches 103; Conservative 3; Mismatches 8; Indels 6; Gaps 2;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
   |||||

QY 61 AQKFGQGRVTTITADESTSTAYMELSLTSTEDTAVYYCELD-----WFVWGQGT 114
   |||||
Db 61 AQKFGQGRVTTITADESTSTAYMELSLSLRSDTAVYYCARDPDYVSGSGSYYPNWFDPWGQGT 120
   |||||

RESULT 5
US-09-490-070A-35
```

Sequence 35, Application US/09490070A
Patent No. 6696248
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
White & McAuliffe
STREET: 1666 K Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20006
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,070A
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: Colin G. Sandercock, Esq.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 37629-0005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2000
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-490-070A-35

Query Match 85.1%; Score 508; DB 2; Length 120;
Best Local Similarity 85.8%; Pred. No. 5.2e-45;
Matches 103; Conservative 3; Mismatches 8; Indels 6; Gaps 2;
Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQRTITADESTAYMELSTLTSEDATVYICEL---DWFY---IWGGTMTVTSS 114
Db 61 AQKFGQRTITADESTAYMELSLSESDATVYICARWGGDGFYADYWGQGLTIVTSS 120

RESULT 6
US-09-490-070A-57
Sequence 57, Application US/09490070A
Patent No. 6696248
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(poly)peptide libraries
NUMBER OF SEQUENCES: 373

CORRESPONDENCE ADDRESS:
ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
White & McAuliffe
STREET: 1666 K Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20006
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,070A
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: Colin G. Sandercock, Esq.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 37629-0005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2000
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-09-490-070A-57

Query Match 85.1%; Score 508; DB 2; Length 120;
Best Local Similarity 85.8%; Pred. No. 5.2e-45;
Matches 103; Conservative 3; Mismatches 8; Indels 6; Gaps 2;
Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQRTITADESTAYMELSTLTSEDATVYICEL---DWFY---IWGGTMTVTSS 114
Db 61 AQKFGQRTITADESTAYMELSLSESDATVYICARWGGDGFYADYWGQGLTIVTSS 120

RESULT 7
US-09-490-153-35
Sequence 35, Application US/09490153
Patent No. 6708484
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)


```

; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-490-324-35

Query Match      85.1%; Score 508; DB 2; Length 120;
Best Local Similarity 85.8%; Pred. No. 5.2e-45;
Matches 103; Conservative 3; Mismatches 8; Indels 6; Gaps 2;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSTLTSEDVAVYCYCEL---DMFY---IMQGGMVTVSS 114
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCARWGGDGFYANDYMGQGLTVTVSS 120

RESULT 10
US-09-490-324-57
; Sequence 57, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-09-490-324-57

Query Match      85.1%; Score 508; DB 2; Length 120;
Best Local Similarity 85.8%; Pred. No. 5.2e-45;
Matches 103; Conservative 3; Mismatches 8; Indels 6; Gaps 2;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPFGTANY 60

; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-490-324-35

Query Match      85.1%; Score 508; DB 2; Length 120;
Best Local Similarity 85.8%; Pred. No. 5.2e-45;
Matches 103; Conservative 3; Mismatches 8; Indels 6; Gaps 2;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSTLTSEDVAVYCYCEL---DMFY---IMQGGMVTVSS 114
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCARWGGDGFYANDYMGQGLTVTVSS 120

RESULT 11
US-09-025-769B-21
; Sequence 21, Application US/09025769B
; Patent No. 630064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-21

Query Match      84.3%; Score 503.5; DB 2; Length 119;
Best Local Similarity 84.9%; Pred. No. 1.5e-44;
Matches 101; Conservative 3; Mismatches 10; Indels 5; Gaps 1;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSTLTSEDVAVYCYCEL---LDMFYIMQGGMVTVSS 114
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCARAFYCSGFDYMGQGLTVTVSS 119

RESULT 12
US-09-490-070A-21
; Sequence 21, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
;

```

Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
STREET: 1666 K Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20006
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490.070A
FILING DATE: 24-Jan-2000
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: Colin G. Sandercock, Esq.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 37629-0005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2020
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-09-490-070A-21
Query Match 84.3%; Score 503.5; DB 2; Length 119;
Best Local Similarity 84.9%; Pred. No. 1.5e-44;
Matches 101; Conservative 3; Mismatches 10; Indels 5; Gaps 1;
Qy 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISVWRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISVWRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQGVTTTADSTSTAYMELSTLTSTEDTAVYYCE-----LDWFIYWGQGTMTVTVSS 114
Db 61 AQKFGQGVTTTADSTSTAYMELSSLRSEDTAVYYCARAPGCGDFYWGQGTMTVTVSS 119
RESULT 13
US-09-490-153-21
Sequence 21, Application US/09490153
Patent No. 6706484
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York

COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490.153
FILING DATE: 24-Jan-2000
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/09/025.769B
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 119 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-09-490-153-21
Query Match 84.3%; Score 503.5; DB 2; Length 119;
Best Local Similarity 84.9%; Pred. No. 1.5e-44;
Matches 101; Conservative 3; Mismatches 10; Indels 5; Gaps 1;
Qy 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISVWRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISVWRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQGVTTTADSTSTAYMELSTLTSTEDTAVYYCE-----LDWFIYWGQGTMTVTVSS 114
Db 61 AQKFGQGVTTTADSTSTAYMELSSLRSEDTAVYYCARAPGCGDFYWGQGTMTVTVSS 119
RESULT 14
US-09-490-324-21
Sequence 21, Application US/09490324
Patent No. 6828422
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490.324
FILING DATE: 24-Jan-2000


```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-09-490-324-21

Query Match      84.3%; Score 503.5; DB 2; Length 119;
Best Local Similarity 84.9%; Pred. No. 1.5e-44;
Matches 101; Conservative 3; Mismatches 10; Indels 5; Gaps 1;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFQGRVTITADESTSTAYMELSTLTSEDYAVYCE-----LDWFYWGQGTMTVYSS 114
Db 61 AQKFQGRVTITADESTSTAYMELSLRSSEDTAVYICARAPGCGFDYWGQGTMTVYSS 119

RESULT 15
US-08-652-816A-1
; Sequence 1, Application US/08652816A
; Patent No. 5872215
; GENERAL INFORMATION:
; APPLICANT: Osbourn, JK
; APPLICANT: Allen, DJ
; APPLICANT: McCafferty, JG
; TITLE OF INVENTION: Specific binding members, materials and
; TITLE OF INVENTION: methods.
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/652,816A
; FILING DATE: 23-MAY-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9125579.4
; FILING DATE: 02-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9125579.8
; FILING DATE: 02-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9206318.9
; FILING DATE: 24-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9206372.6
; FILING DATE: 23-SEP-1992
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: GB 9525004.9
; FILING DATE: 07-DEC-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9610824.6
; FILING DATE: 23-MAY-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB92/02240
; FILING DATE: 02-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/244,597
; FILING DATE: 01-JUN-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: David W. Clough
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 28111/33308
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; US-08-652-816A-1

Query Match      82.5%; Score 492.5; DB 1; Length 123;
Best Local Similarity 79.7%; Pred. No. 2.1e-43;
Matches 98; Conservative 8; Mismatches 8; Indels 9; Gaps 2;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSNPINLWLRQAPGQGLEWMGSIIPSEGTANY 60
Qy 61 AQKFQGRVTITADESTSTAYMELSTLTSEDYAVYCE-----ELDFY--IWGGGTMTVT 111
Db 61 AQKFQGRVTITADESTSTAYMELSLRSSEDTAVYICAGRSNHYELYYIMDVWGQGTMTVT 120

Qy 112 VSS 114
Db 121 VSS 123
```

Search completed: May 5, 2006, 08:56:23
Job time : 12.5227 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 09:02:26 ; Search time 34.9773 Seconds
(without alignments)
1361.814 Million cell updates/sec

Title: US-09-674-752-51

Perfect score: 597

Sequence: 1 QVOLVSGAEVKPGSSVKV.....YCELDWFYINGQGTMTVTSS 114

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications_AA_Main:

- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
- 3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
- 4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
- 6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	522	87.4	122	4	US-10-371-942-26
2	520.5	87.2	271	4	US-10-275-589-22
3	520	87.1	118	4	US-10-300-675-6
4	520	87.1	118	4	US-10-300-675-10
5	520	87.1	118	4	US-10-300-675-12
6	520	87.1	118	4	US-10-300-675-14
7	520	87.1	118	5	US-10-910-124-6
8	520	87.1	124	4	US-10-269-805-25
9	517.5	86.7	121	4	US-10-269-805-9
10	516.5	86.5	119	5	US-10-734-661A-99
11	516.5	86.5	125	4	US-10-269-805-35
12	516	86.4	270	3	US-09-976-118-2
13	516	86.4	270	4	US-10-703-277-2
14	515	86.3	220	4	US-10-128-520-149
15	514.5	86.2	123	4	US-10-269-805-3
16	514	86.1	120	4	US-10-269-805-49
17	513.5	86.0	119	4	US-10-308-817-191
18	513.5	86.0	119	4	US-10-453-698-191
19	511.5	85.7	121	4	US-10-269-805-19
20	510	85.4	220	4	US-10-128-520-175
21	509	85.3	248	5	US-10-943-197-6
22	508.5	85.2	115	4	US-10-275-046-66
23	508.5	85.2	225	4	US-10-128-520-147
24	508	85.1	120	4	US-10-125-687-1
25	508	85.1	120	5	US-10-996-191-1
26	507.5	85.0	115	6	US-11-039-767-6
27	507.5	85.0	489	5	US-10-644-256-3

28	507	84.9	253	3	US-09-880-748-1509	Sequence 1509, Ap
29	507	84.9	253	4	US-10-293-418-1509	Sequence 1509, Ap
30	506.5	84.8	119	5	US-10-734-661A-100	Sequence 100, App
31	506.5	84.8	229	4	US-10-128-520-155	Sequence 155, App
32	506.5	84.8	248	3	US-09-880-748-1733	Sequence 1733, Ap
33	506.5	84.8	248	3	US-09-880-748-1733	Sequence 1734, Ap
34	506.5	84.8	248	4	US-10-293-418-1733	Sequence 1733, Ap
35	506.5	84.8	248	4	US-10-293-418-1733	Sequence 1734, Ap
36	506	84.8	120	4	US-10-269-805-37	Sequence 37, Appl
37	505.5	84.7	219	4	US-10-128-520-160	Sequence 160, App
38	505.5	84.7	223	4	US-10-128-520-172	Sequence 172, App
39	505.5	84.7	238	5	US-10-496-861-7	Sequence 7, Appli
40	505.5	84.7	244	3	US-09-880-748-1881	Sequence 1881, Ap
41	505.5	84.7	244	4	US-10-293-418-1881	Sequence 1881, Ap
42	505.5	84.7	248	3	US-09-880-748-1718	Sequence 1718, Ap
43	505.5	84.7	248	3	US-09-880-748-1879	Sequence 1879, Ap
44	505.5	84.7	248	4	US-10-293-418-1718	Sequence 1718, Ap
45	505.5	84.7	248	4	US-10-293-418-1879	Sequence 1879, Ap

ALIGNMENTS

RESULT 1

US-10-371-942-26
; Sequence 26, Application US/10371942
; Publication No. US20030223994A1
; GENERAL INFORMATION:
; APPLICANT: Hoogenboom, Henricus Renerus Jacobus Mattheus
; APPLICANT: Reiter, Yoram
; TITLE OF INVENTION: MHC-PEPTIDE COMPLEX BINDING LIGANDS
; FILE REFERENCE: 10280-034001
; CURRENT APPLICATION NUMBER: US/10/371,942
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,994
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-371-942-26

Query Match	87.4%	Score 522;	DB 4;	Length 122;
Best Local Similarity	86.1%	Pred. No. 4.7e-41;		
Matches	105;	Conservative	2;	Mismatches 7;
			Indels	8;
			Gaps	2;
Qy	1	QVOLVSGAEVKPGSSVKVCKASGCTFS	SHAI	SWVRQAPGQGLEWMGDIPI
				ILGTGNY 60
Db	1	QVOLVSGAEVKPGSSVKVCKASGCTFS	SHAI	SWVRQAPGQGLEWMGDIPI
				ILGTGNY 60
Qy	61	AQPKQGRVTITADESTAYMELSTLT	SED	TAVYYCELD----
				WFY-----IWGGGTMTVT 112
Db	61	AQPKQGRVTITADESTAYMELSTLT	SED	TAVYYCELD----
				WFY-----IWGGGTMTVT 120
Qy	113	SS	114	
Db	121	SS	122	

RESULT 2

US-10-275-589-22
; Sequence 22, Application US/10275589
; Publication No. US20040023864A1
; GENERAL INFORMATION:
; APPLICANT: Dubois-Stringfellow, Nathalie
; APPLICANT: Steve, Rocznik
; APPLICANT: Zolotarev, Alya
; TITLE OF INVENTION: Method of Regulating Angiogenesis Using RYK Protein
; FILE REFERENCE: MSB 7266
; CURRENT APPLICATION NUMBER: US/10/275,589
; CURRENT FILING DATE: 2002-11-06

```
; PRIOR APPLICATION NUMBER: US 09/568,783
; PRIOR FILING DATE: 2000-05-11
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 22
; LENGTH: 271
; TYPE: PRT
; ORGANISM: ARTIFICIAL
; FEATURE:
; OTHER INFORMATION: Amino acid sequence for scFv 1b4 antibody
US-10-275-589-22

Query Match      87.2%; Score 520.5; DB 4; Length 271;
Best Local Similarity 87.2%; Pred. No. 1.5e-40;
Matches 102; Conservative 4; Mismatches 8; Indels 3; Gaps 1;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 5 EVQLVSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 64
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 AQKFGQGRVTITADESTSTAYMELSTLTSEDYAVYCE---LDWFIYWGQGTMTVSS 114
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 65 AQKFGQGRVTITADESTSTAYMELSLRSSEDTAVYCARSYVDWFDYWGQGTMTVSS 121
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 3
US-10-300-675-6
; Sequence 6, Application US/10300675
; Publication No. US20030198638A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-300-675-6

Query Match      87.1%; Score 520; DB 4; Length 118;
Best Local Similarity 85.6%; Pred. No. 7e-41;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 AQKFGQGRVTITADESTSTAYMELSTLTSEDYAVYCELD---WFIYWGQGTMTVSS 114
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSSEDTAVYCARSDTSWGYHWGQGTMTVSS 118
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 4
US-10-300-675-10
; Sequence 10, Application US/10300675
; Publication No. US20030198638A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial Sequence
```

```
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Recombinant variant
US-10-300-675-10

Query Match      87.1%; Score 520; DB 4; Length 118;
Best Local Similarity 85.6%; Pred. No. 7e-41;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 AQKFGQGRVTITADESTSTAYMELSTLTSEDYAVYCELD---WFIYWGQGTMTVSS 114
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSSEDTAVYCARSDTSWGYHWGQGTMTVSS 118
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 5
US-10-300-675-12
; Sequence 12, Application US/10300675
; Publication No. US20030198638A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Recombinant variant
US-10-300-675-12

Query Match      87.1%; Score 520; DB 4; Length 118;
Best Local Similarity 85.8%; Pred. No. 7e-41;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 AQKFGQGRVTITADESTSTAYMELSTLTSEDYAVYCELD---WFIYWGQGTMTVSS 114
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSSEDTAVYCARSDTSWGYHWGQGTMTVSS 118
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 6
US-10-300-675-14
; Sequence 14, Application US/10300675
; Publication No. US20030198638A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Recombinant variant
US-10-300-675-14

Query Match      87.1%; Score 520; DB 4; Length 118;
Best Local Similarity 85.6%; Pred. No. 7e-41;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPIFGTANY 60

Qy 61 AQKFGQRTITADESTSTAYMELSTLTSEDYAVYYC-----WFIWGQGTMTVSS 114
Db 61 AQKFGQRTITADESTSTAYMELSLRSEDYAVYYCAREDSNGWYHWGQGLTVTSS 118

RESULT 7
US-10-910-124-6
; Sequence 6, Application US/10910124
; Publication No. US20050003469A1
; GENERAL INFORMATION:
; APPLICANT: Huse, William D.
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Human Monoclonal Antibodies and Methods
; FILE REFERENCE: of Use
; FILE REFERENCE: P-IX 2947
; CURRENT APPLICATION NUMBER: US/10/910,124
; CURRENT FILING DATE: 2004-08-02
; PRIOR APPLICATION NUMBER: US/09/203,768
; PRIOR FILING DATE: 1998-12-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-910-124-6

Query Match      87.1%; Score 520; DB 5; Length 118;
Best Local Similarity 85.6%; Pred. No. 7e-41;
Matches 101; Conservative 6; Mismatches 7; Indels 4; Gaps 1;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPIFGTANY 60

Qy 61 AQKFGQRTITADESTSTAYMELSTLTSEDYAVYYC-----WFIWGQGTMTVSS 114
Db 61 AQKFGQRTITADESTSTAYMELSLRSEDYAVYYCAREDSNGWYHWGQGLTVTSS 118

RESULT 8
US-10-269-805-25
; Sequence 25, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-25

Query Match      87.1%; Score 520; DB 4; Length 124;
; OTHER INFORMATION: Recombinant variant
US-10-300-675-14
```

```
Best Local Similarity 84.7%; Pred. No. 7.4e-41;
Matches 105; Conservative 2; Mismatches 7; Indels 10; Gaps 1;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPIFGTANY 60

Qy 61 AQKFGQRTITADESTSTAYMELSTLTSEDYAVYYC-----ELDWFIWGQGTMTV 110
Db 61 AQKFGQRTITADESTSTAYMELSLRSEDYAVYYCARGYDFWGSYSLDAFDIWGQGTMTV 120

Qy 111 TVSS 114
Db 121 TVSS 124

RESULT 9
US-10-269-805-9
; Sequence 9, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-9

Query Match      86.7%; Score 517.5; DB 4; Length 121;
Best Local Similarity 86.0%; Pred. No. 1.2e-40;
Matches 104; Conservative 3; Mismatches 7; Indels 7; Gaps 1;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPIFGTANY 60

Qy 61 AQKFGQRTITADESTSTAYMELSTLTSEDYAVYYC-----ELDWFIWGQGTMTVS 113
Db 61 AQKFGQRTITADKSTSTAYMELSLRSEDYAVYYCAAFSPFTTADAFDIWGQGTMTVS 120

Qy 114 S 114
Db 121 S 121

RESULT 10
US-10-734-661A-99
; Sequence 99, Application US/10734661A
; Publication No. US20050147612A1
; GENERAL INFORMATION:
; APPLICANT: ProChon Biotech, Ltd.
; APPLICANT: MorphoSys AG
; APPLICANT: Yavon, Avner
; APPLICANT: Thomassen-Wolf, Elisabeth
; APPLICANT: Rom, Eran
; APPLICANT: Borges, Eric
; TITLE OF INVENTION: ANTIBODIES THAT BLOCK RECEPTOR PROTEIN TYROSINE KINASE ACTIVATION
; FILE REFERENCE: 81408-4400
; CURRENT APPLICATION NUMBER: US/10/734,661A
; CURRENT FILING DATE: 2003-12-15
; PRIOR APPLICATION NUMBER: US 60/299,187
; PRIOR FILING DATE: 2001-06-20
; PRIOR APPLICATION NUMBER: PCT/IL02/00494
; PRIOR FILING DATE: 2002-06-20
; NUMBER OF SEQ ID NOS: 106
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 99
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: polypeptide sequence of a VH domain
US-10-734-661A-99

Query Match      86.5%; Score 516.5; DB 5; Length 119;
Best Local Similarity 86.6%; Pred. No. 1.5e-40;
Matches 103; Conservative 4; Mismatches 7; Indels 5; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSHSAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSHSAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVYCELD-WFY----IMQGQTMVTYSS 114
Db 61 AQKFGQGRVTITADESTAYMELSSLRSEDTAVYICARDNWFKPSDVWGQGLTVYSS 119

RESULT 11
US-10-269-805-35
; Sequence 35, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-35

Query Match      86.5%; Score 516.5; DB 4; Length 125;
Best Local Similarity 83.2%; Pred. No. 1.6e-40;
Matches 104; Conservative 3; Mismatches 7; Indels 11; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSHSAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSHSAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVYCELD-WFY-----LWFYIMWGQTM 109
Db 61 AQKFGQGRVTITADESTAYMELSSLRSEDTAVYICARSPYIYDILTGIDAFDIMGQTM 120
Qy 110 VTYSS 114
Db 121 VTYSS 125

RESULT 12
US-09-976-118-2
; Sequence 2, Application US/09976118
; Patent No. US20020058033A1
; GENERAL INFORMATION:
; APPLICANT: Ratsch, Kevin Paul
; APPLICANT: Curiel, David T.
; APPLICANT: Bonner, James Allen
; TITLE OF INVENTION: Human Anti-Epidermal Growth Factor Receptor
; FILE REFERENCE: D6355
; CURRENT APPLICATION NUMBER: US/09/976,118
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: US 60/240,353

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 270
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: amino acid sequence of anti-EGFR scFv
; OTHER INFORMATION: clone pSEX81-63
US-10-703-277-2

Query Match      86.4%; Score 516; DB 3; Length 270;
Best Local Similarity 81.7%; Pred. No. 3.9e-40;
Matches 103; Conservative 3; Mismatches 8; Indels 12; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSHSAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSHSAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVYCELD-----WFIYWGQGT 108
Db 61 AQKFGQGRVTITADESTAYMELSSLRSEDTAVYICARDPDYVYSGSYYPNWFDPWGQGT 120
Qy 109 MVTYSS 114
Db 121 LVTYSS 126

RESULT 13
US-10-703-277-2
; Sequence 2, Application US/10703277
; Publication No. US20040071698A1
; GENERAL INFORMATION:
; APPLICANT: Ratsch, Kevin Paul
; APPLICANT: Curiel, David T.
; APPLICANT: Bonner, James Allen
; TITLE OF INVENTION: Human Anti-Epidermal Growth Factor Receptor
; FILE REFERENCE: D6355
; CURRENT APPLICATION NUMBER: US/10/703,277
; CURRENT FILING DATE: 2003-11-06
; PRIOR APPLICATION NUMBER: US/09/976,118
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: US 60/240,353
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 270
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: amino acid sequence of anti-EGFR scFv
; OTHER INFORMATION: clone pSEX81-63
US-10-703-277-2

Query Match      86.4%; Score 516; DB 4; Length 270;
Best Local Similarity 81.7%; Pred. No. 3.9e-40;
Matches 103; Conservative 3; Mismatches 8; Indels 12; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSHSAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSHSAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVYCELD-----WFIYWGQGT 108
Db 61 AQKFGQGRVTITADESTAYMELSSLRSEDTAVYICARDPDYVYSGSYYPNWFDPWGQGT 120
Qy 109 MVTYSS 114
Db 121 LVTYSS 126

RESULT 14
```

```
US-10-128-520-149
; Sequence 149, Application US/10128520
; Publication No. US20040105862A1
; GENERAL INFORMATION:
; APPLICANT: PAN et al.
; TITLE OF INVENTION: Human TIMP-1 Antibodies
; FILE REFERENCE: 02973.00073
; CURRENT APPLICATION NUMBER: US/10/128,520
; PRIOR FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: US 60/285,683
; PRIOR FILING DATE: 2001-04-24
; NUMBER OF SEQ ID NOS: 381
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 149
; LENGTH: 220
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-128-520-149

Query Match      86.3%; Score 515; DB 4; Length 220;
Best Local Similarity 87.1%; Pred. No. 4e-40;
Matches 101; Conservative 5; Mismatches 8; Indels 2; Gaps 1;

QY      1 QVQLVSGAEVKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db      1 QVQLVSGAEVKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
QY      61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVVYCELDWFYI--WGQGTMTVTVSS 114
Db      61 AQKFGQGRVTITADESTAYMELSSLRSEDTAVYVCARTYYFDSWGQGLTVTVSS 116

RESULT 15
US-10-269-805-3
; Sequence 3, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-3

Query Match      86.2%; Score 514.5; DB 4; Length 123;
Best Local Similarity 83.7%; Pred. No. 2.4e-40;
Matches 103; Conservative 4; Mismatches 7; Indels 9; Gaps 2;

QY      1 QVQLVSGAEVKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db      1 QVQLVSGAEVKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
QY      61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVVYCELDWFYI--WGQGTMTVTVSS 111
Db      61 AQKFGQGRVTITADESTAYMELSSLRSEDTAVYVCARGVVGDFDMLSPFDYWGQGLTVT 120
QY      112 VSS 114
Db      121 VSS 123
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:52 ; Search time 8.63636 Seconds
(without alignments)
610.959 Million cell updates/sec

Title: US-09-674-752-51

Perfect score: 597

Sequence: 1 QVOLVQSGAEVKKPGSSVKV.....YCELDWFYIWGQGTMTVTS 114

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Published Applications AA New:*
- 1: /SIDSS5/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
 - 2: /SIDSS5/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
 - 3: /SIDSS5/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
 - 4: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
 - 5: /SIDSS5/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
 - 6: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
 - 7: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
 - 8: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
 - 9: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
 - 10: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
 - 11: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
 - 12: /SIDSS5/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	520	87.1	124	9	US-10-982-440-25
2	517.5	86.7	121	9	US-10-982-440-9
3	516.5	86.5	125	9	US-10-982-440-35
4	514.5	86.2	123	9	US-10-982-440-3
5	514	86.1	120	9	US-10-982-440-49
6	511.5	85.7	121	9	US-10-982-440-19
7	508	85.1	120	9	US-10-834-397-35
8	508	85.1	120	9	US-10-834-397-57
9	507.5	85.0	589	11	US-11-271-090-3
10	507	84.9	253	11	US-11-054-515-1509
11	507	84.9	253	11	US-11-266-444-1509
12	506.5	84.8	248	11	US-11-054-515-1733
13	506.5	84.8	248	11	US-11-054-515-1734
14	506.5	84.8	248	11	US-11-266-444-1733
15	506.5	84.8	248	11	US-11-266-444-1734
16	506	84.8	120	9	US-10-982-440-37
17	505.5	84.7	244	11	US-11-054-515-1881
18	505.5	84.7	244	11	US-11-266-444-1881
19	505.5	84.7	248	11	US-11-054-515-1718
20	505.5	84.7	248	11	US-11-054-515-1879
21	505.5	84.7	248	11	US-11-266-444-1718

22	505.5	84.7	248	11	US-11-266-444-1879	Sequence 1879, Ap
23	504.5	84.5	627	9	US-10-493-909-47	Sequence 47, Appl
24	504	84.4	254	11	US-11-054-515-1866	Sequence 1866, Ap
25	504	84.4	254	11	US-11-266-444-1866	Sequence 1866, Ap
26	503.5	84.3	119	9	US-10-834-397-21	Sequence 21, Appl
27	502.5	84.2	248	11	US-11-054-515-1719	Sequence 1719, Ap
28	502.5	84.2	248	11	US-11-054-515-1732	Sequence 1732, Ap
29	502.5	84.2	248	11	US-11-054-515-1737	Sequence 1737, Ap
30	502.5	84.2	248	11	US-11-266-444-1719	Sequence 1719, Ap
31	502.5	84.2	248	11	US-11-266-444-1732	Sequence 1732, Ap
32	502.5	84.2	248	11	US-11-266-444-1737	Sequence 1737, Ap
33	502	84.1	120	9	US-10-982-440-15	Sequence 15, Appl
34	501.5	84.0	248	11	US-11-054-515-1741	Sequence 1741, Ap
35	501.5	84.0	248	11	US-11-266-444-1741	Sequence 1741, Ap
36	500.5	83.8	253	11	US-11-054-515-1880	Sequence 1880, Ap
37	500.5	83.8	253	11	US-11-266-444-1880	Sequence 1880, Ap
38	500	83.8	124	11	US-11-040-159-6	Sequence 6, Appl
39	499.5	83.7	248	11	US-11-054-515-1727	Sequence 1727, Ap
40	499.5	83.7	248	11	US-11-054-515-1728	Sequence 1728, Ap
41	499.5	83.7	248	11	US-11-266-444-1727	Sequence 1727, Ap
42	499.5	83.7	248	11	US-11-266-444-1728	Sequence 1728, Ap
43	499	83.6	257	11	US-11-054-515-1553	Sequence 1553, Ap
44	499	83.6	257	11	US-11-266-444-1553	Sequence 1553, Ap
45	496	83.1	120	9	US-10-982-440-5	Sequence 5, Appl

ALIGNMENTS

RESULT 1

US-10-982-440-25

; Sequence 25, Application US/10982440

; Publication No. US20060018909A1

; GENERAL INFORMATION:

; APPLICANT: Oliner, John

; APPLICANT: Graham, Kevin

; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents

; FILE REFERENCE: 04-881-A

; CURRENT APPLICATION NUMBER: US/10/982,440

; CURRENT FILING DATE: 2004-11-04

; PRIOR APPLICATION NUMBER: 60/620,161

; PRIOR FILING DATE: 2004-10-19

; NUMBER OF SEQ ID NOS: 215

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 25

; TYPE: PRT

; LENGTH: 124

; ORGANISM: Homo sapiens

; US-10-982-440-25

Query Match 87.1%; Score 520; DB 9; Length 124;

Best Local Similarity 84.7%; Pred. No. 2.5e-34;

Matches 105; Conservative 2; Mismatches 7; Indels 10; Gaps 1;

Qy 1 QVOLVQSGAEVKKPGSSVKVSKASGTFSSHAISWVRQAPGQGLEWMGDIPIILGTGNY 60

Db 1 QVOLVQSGAEVKKPGSSVKVSKASGTFSSHAISWVRQAPGQGLEWMGDIPIIFGTANY 60

Qy 61 AQKFGQGVTTTADSTSTAYMELSTLTSEDATVYVC-----ELDPFYIWGQGTMTV 110

Db 61 AQKFGQGVTTTADSTSTAYMELSLRSEDATVYVCARGYDFWMSGYSLDAFDIWGQGTMTV 120

Qy 111 TVSS 114

Db 121 TVSS 124

RESULT 2

US-10-982-440-9

; Sequence 9, Application US/10982440

; Publication No. US20060018909A1

; GENERAL INFORMATION:

; APPLICANT: Oliner, John

```

; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; PRIOR FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 9
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-982-440-9

```

```

Query Match      86.7%; Score 517.5; DB 9; Length 121;
Best Local Similarity 86.0%; Pred. No. 3.8e-34;
Matches 104; Conservative 3; Mismatches 7; Indels 7; Gaps 1;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGGLEWMGDIIPILGTGNY 60
   |||||
Db 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGGLEWMGDIIPILGTGNY 60
   |||||
QY 61 AQKFGQVRVITADESTSTAYMELSTLTSEDYAVYIC-----ELDWFIWGQGTWTVSS 113
   |||||
Db 61 AQKFGQVRVITADESTSTAYMELSSLRSEDTAVYICAFSPFTTDAFDIWGQGTWTVSS 120
   |||||
QY 114 S 114
   ||
Db 121 S 121

```

```

RESULT 3
US-10-982-440-35
; Sequence 35, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 35
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-982-440-35

```

```

Query Match      86.5%; Score 516.5; DB 9; Length 125;
Best Local Similarity 83.2%; Pred. No. 4.6e-34;
Matches 104; Conservative 3; Mismatches 7; Indels 11; Gaps 1;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGGLEWMGDIIPILGTGNY 60
   |||||
Db 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGGLEWMGDIIPILGTGNY 60
   |||||
QY 61 AQKFGQVRVITADESTSTAYMELSTLTSEDYAVYIC-----LDWFIWGQGTW 109
   |||||
Db 61 AQKFGQVRVITADESTSTAYMELSSLRSEDTAVYICARSPYYDILTGDAPDIWGQGTW 120
   |||||
QY 110 VTVSS 114
   |||||
Db 121 VTVSS 125

```

```

RESULT 4
US-10-982-440-3
; Sequence 3, Application US/10982440

```

```

; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-982-440-3

```

```

Query Match      86.2%; Score 514.5; DB 9; Length 123;
Best Local Similarity 83.7%; Pred. No. 6.6e-34;
Matches 103; Conservative 4; Mismatches 7; Indels 9; Gaps 2;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGGLEWMGDIIPILGTGNY 60
   |||||
Db 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGGLEWMGDIIPILGTGNY 60
   |||||
QY 61 AQKFGQVRVITADESTSTAYMELSTLTSEDYAVYIC-----ELDW---FYIWGQGTWTVT 111
   |||||
Db 61 AQKFGQVRVITADESTSTAYMELSSLRSEDTAVYICARGVGVGDFWLSFFDYWGQGTTLVT 120
   |||||
QY 112 VSS 114
   |||
Db 121 VSS 123

```

```

RESULT 5
US-10-982-440-49
; Sequence 49, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 49
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-982-440-49

```

```

Query Match      86.1%; Score 514; DB 9; Length 120;
Best Local Similarity 86.7%; Pred. No. 7e-34;
Matches 104; Conservative 4; Mismatches 6; Indels 6; Gaps 3;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGGLEWMGDIIPILGTGNY 60
   |||||
Db 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSHAISWVRQAPGGLEWMGDIIPILGTGNY 60
   |||||
QY 61 AQKFGQVRVITADESTSTAYMELSTLTSEDYAVYIC---ELDW-FYI--WGQGTWTVSS 114
   |||||
Db 61 AQKFGQVRVITADESTSTAYMELSSLRSEDTAVYICATSRLEWLLYLDYWGQGTTLVTSS 120
   |||||

```

```

RESULT 6
US-10-982-440-19
; Sequence 19, Application US/10982440
; Publication No. US20060018909A1

```

```

; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; PRIOR FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 19
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-19

Query Match      85.7%; Score 511.5; DB 9; Length 121;
Best Local Similarity 85.1%; Pred. No. 1.1e-33;
Matches 103; Conservative 3; Mismatches 8; Indels 7; Gaps 1;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGCTFSSHAISWVRQAPGQGLEWMGGIIPIFGTANY 60
QY 61 AQKFGQGVITADESTSTAYMELSTLTSEDYAVYCYCEL-----DWFYIWGQGTWVTVS 113
Db 61 AQKFGQGVITADESTSTAYMELSSLRSEDTAVYCYCARPESGYWGDAFDIWGQGTWTVS 120
QY 114 S 114
Db 121 S 121

RESULT 7
US-10-834-397-35
; Sequence 35, Application US/10834397
; Publication No. US20060003334A1
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/834,397
; FILING DATE: 29-Apr-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-10-834-397-35

Query Match      85.1%; Score 508; DB 9; Length 120;
Best Local Similarity 85.8%; Pred. No. 2.1e-33;
Matches 103; Conservative 3; Mismatches 8; Indels 6; Gaps 2;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY 60
QY 61 AQKFGQGVITADESTSTAYMELSTLTSEDYAVYCYCEL---DWFY---INGQGTWTVSS 114
Db 61 AQKFGQGVITADESTSTAYMELSSLRSEDTAVYCYCARMGDGFYANDYWGQGTWTVSS 120

RESULT 8
US-10-834-397-57
; Sequence 57, Application US/10834397
; Publication No. US20060003334A1
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/834,397
; FILING DATE: 29-Apr-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
```

```
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-10-834-397-57

Query Match      85.1%; Score 508; DB 9; Length 120;
Best Local Similarity 85.0%; Pred. No. 2.1e-33;
Matches 103; Conservative 3; Mismatches 8; Indels 6; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSSHAIISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSSHAIISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVYCEL---DMFY---IWGQGTMTVTSS 114
Db 61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVYCARWGGDGFYANDYWGQGTILVTVSS 120

RESULT 9
US-11-271-090-3
; Sequence 3, Application US/11271090
; Publication No. US20060063234A1
; GENERAL INFORMATION:
; APPLICANT: CRUCCELL HOLLAND B.V.
; APPLICANT: Jones, David H.A.
; TITLE OF INVENTION: Efficient production of IgM in recombinant mammalian cells
; FILE REFERENCE: 0088 WO P00 PRI
; CURRENT APPLICATION NUMBER: US/11/271,090
; CURRENT FILING DATE: 2005-11-09
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 3
; LENGTH: 589
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: amino acid sequence anti-EpCAM IgM heavy chain
US-11-271-090-3

Query Match      85.0%; Score 507.5; DB 11; Length 589;
Best Local Similarity 87.0%; Pred. No. 8.7e-33;
Matches 100; Conservative 6; Mismatches 8; Indels 1; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSSHAIISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 22 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSSHAIISWVRQAPGQGLEWMGDIIPILGTGNY 81
Qy 61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVYCELDWF-YIWGQGTMTVTSS 114
Db 82 AQKFGQGRVTITADESTAYMELSLRSEDYAVYCARDPFLHWGQGTILVTYST 136

RESULT 10
US-11-054-515-1509
; Sequence 1509, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunosepecifically Bind Blys
; FILE REFERENCE: PF523p3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 05/880,748
; PRIOR FILING DATE: 2001-06-15
```

```
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1509
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1509

Query Match      84.9%; Score 507; DB 11; Length 253;
Best Local Similarity 79.7%; Pred. No. 4.7e-33;
Matches 102; Conservative 4; Mismatches 8; Indels 14; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSSHAIISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSSHAIISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVYCYC-----ELDWFYIWGQ 106
Db 61 AQKFGQGRVTITADKSTSTAYMELSLRSEDYAVYCYCQGYDILTYPEGGWFDPMCK 120
Qy 107 GTMTVTSS 114
Db 121 GTMTVTSS 128

RESULT 11
US-11-266-444-1509
; Sequence 1509, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunosepecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523PID1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1509
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1509

Query Match      84.9%; Score 507; DB 11; Length 253;
Best Local Similarity 79.7%; Pred. No. 4.7e-33;
Matches 102; Conservative 4; Mismatches 8; Indels 14; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSSHAIISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSSHAIISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVYCYC-----ELDWFYIWGQ 106
Db 61 AQKFGQGRVTITADESTAYMELSTLTSEDYAVYCYC-----ELDWFYIWGQ 106
```

Db 61 A QKQGRVTITADKSTSTAYMELSLRSEDNAVYTCAREQGYDILTGYYPEGWFDPMCK 120

Qy 107 GTMTVTS 114
|||||

Db 121 GTMTVTS 128

RESULT 12
US-11-054-515-1733
; Sequence 1733, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1733
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1733

Query Match 84.8%; Score 506.5; DB 11; Length 248;
Best Local Similarity 82.4%; Pred. No. Se-33; 7; Indels 11; Gaps 2;
Matches 103; Conservative 4; Mismatches

Qy 1 QVQLVQSGAEYVKPGSSVKVSKASGGTFFSSHAISWVRQAPQGLEWMGDIPIILGTGNY 60
Db 1 QVQLVQSGAEYVKPGSSVKVSKASGGTFFSSVAISWVRQAPQGLEWMGDIPIIFGTANY 60

Qy 61 A QKQGRVTITADKSTSTAYMELSLRSEDNAVYTCAREQGYDILTGYYPEGWFDPMCK 109
Db 61 A QKQGRVTITADKSTSTAYMELSLRSEDNAVYTCAREQGYDILTGYYPEGWFDPMCK 120

Qy 110 VTSVSS 114
|||||

Db 121 VTSVSS 125

RESULT 13
US-11-054-515-1734
; Sequence 1734, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:51:41 ; Search time 7.48485 Seconds
(without alignments)
1465.455 Million cell updates/sec

Title: US-09-674-752-51
Perfect score: 597
Sequence: 1 QVOLVSGAEVKPGSSVKV.....YCSLDWFYWGQGTMTVTVSS 114
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_80.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	516	86.4	116	2 PH0959	Ig heavy chain V r
2	513.5	86.0	119	2 PH0961	Ig heavy chain V r
3	510.5	85.5	125	2 PH0957	Ig heavy chain V r
4	508.5	85.2	129	2 A33548	Ig heavy chain V-1
5	507	84.9	128	2 PH0952	Ig heavy chain V r
6	504.5	84.5	133	2 C33548	Ig heavy chain V-1
7	504.5	84.5	627	2 S14683	Ig mu chain precu
8	503.5	84.3	135	2 PH0953	Ig heavy chain V r
9	502	84.1	132	2 S46394	Ig heavy chain V r
10	501	83.9	120	2 PH0962	Ig heavy chain V r
11	501	83.9	132	2 PH0954	Ig heavy chain V r
12	498	83.4	122	2 PH0958	Ig heavy chain V r
13	495.5	83.0	127	2 PH0955	Ig heavy chain V r
14	493	82.6	126	2 B33548	Ig heavy chain V-1
15	493	82.6	136	2 PH0960	Ig heavy chain V r
16	472	79.1	135	2 B32274	Ig heavy chain pre
17	465	77.9	116	2 S36261	Ig heavy chain V r
18	462	77.4	98	2 S26915	Ig heavy chain V r
19	462	77.4	115	2 S31698	Ig heavy chain pre
20	462	77.4	123	2 S44108	Ig heavy chain V-D
21	458	76.7	98	2 S24680	Ig heavy chain V1
22	457.5	76.6	113	2 PH1663	Ig heavy chain V r
23	456.5	76.5	109	2 PH1671	Ig heavy chain V r
24	454	76.0	108	2 PH1664	Ig heavy chain V r
25	453	75.9	119	2 S44106	Ig heavy chain V-D
26	451	75.5	98	2 S46463	Ig heavy chain V1
27	443	74.2	97	2 PH0870	Ig heavy chain V r
28	438.5	73.5	121	2 A49590	Ig heavy chain V r
29	436	73.0	171	2 S23623	Ig heavy chain V r

Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V-I
Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V-1
Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V-I
anti-Sm antibody V
Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V r
anti-PR2 erythrocy

ALIGNMENTS

RESULT 1

PH0959
Ig heavy chain V region (G6+ T-L26) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C;Accession: PH0959
R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0959
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-116 <MAR>

A;Cross-references: UNIPARC:UPI0000176CE3
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;1-30/Region: framework 1
F;15-98/Domain: immunoglobulin homology <IMM>
F;31-35/Region: complementarity-determining 1
F;36-50/Region: framework 2
F;51-67/Region: complementarity-determining 2
F;68-98/Region: framework 3
F;99-104/Region: complementarity-determining 3

Query Match 86.4%; Score 516; DB 2; Length 116;
Best Local Similarity 87.9%; Pred. No. 9.8e-40;
Matches 102; Conservative 4; Mismatches 8; Indels 2; Gaps 1;

Qy 1 QVOLVSGAEVKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIPIILGTGNY 60
Db 1 QVOLVSGAEVKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIPIILGTGNY 60
Qy 61 AQFQGRVTITADESTAYMELSTLTSEDTAVYYCELDWFIWGQGTMTVTVSS 114
Db 61 AQFQGRVTITADESTAYMELSLRSEDTAVYYCARGDNWFDPNQGGTLTVTVSS 116

RESULT 2

PH0961
Ig heavy chain V region (G6+ T-L33) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C;Accession: PH0961
R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0961
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-119 <MAR>


```
Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPFGTANY 60
Qy 61 AQKFGQGRVTITADESTSTAYMELSTLTSTEDTAVYYC-----ELDWFYIWGQ 106
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCARGGNYDIWGSYRNDAPDIWQ 120
Qy 107 GTMTVTSS 114
Db 121 GTMTVTSS 128

RESULT 6
C33548
Ig heavy chain V-1 region (783) - human
C;Species: Homo sapiens (man)
C;Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996
C;Accession: C33548
R;Kipps, T.J.; Tomhave, E.; Pratt, L.F.; Duffy, S.; Chen, P.P.; Carson, D.A.
Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989
A;Title: Developmentally restricted immunoglobulin heavy chain variable region gene expression
A;Reference number: A33548; MUID:89345575; PMID:2503826
A;Accession: C33548
A;Status: preliminary; nucleic acid sequence not shown; not compared with conceptual translation
A;Molecule type: DNA
A;Residues: 1-133 <KIP>
A;Cross-references: UNIPARC:UPI0000176D2B
A;Experimental source: the sequence was determined from the differentiated gene
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 84.5%; Score 504.5; DB 2; Length 133;
Best Local Similarity 76.7%; Pred. No. 1.2e-38;
Matches 102; Conservative 5; Mismatches 7; Indels 19; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPFGTANY 60
Qy 61 AQKFGQGRVTITADESTSTAYMELSTLTSTEDTAVYYC-----ELDWFY--- 102
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAKTLGILPYSSGWYPNSDYIYGM 120
Qy 103 -IWGQGTMTVTSS 114
Db 121 DVWGQGTMTVTSS 133

RESULT 7
S14683
Ig mu chain precursor, membrane-bound (clone 201) - human
C;Species: Homo sapiens (man)
C;Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 23-Jul-1999
C;Accession: S14683; S08047
R;Friedlander, R.M.; Nusenzweig, M.C.; Leder, P.
Nucleic Acids Res. 18, 4278, 1990
A;Title: Complete nucleotide sequence of the membrane form of the human IgM heavy chain.
A;Reference number: S14683; MUID:90332450; PMID:21115996
A;Accession: S14683
A;Molecule type: mRNA
A;Residues: 1-627 <FRI>
A;Cross-references: UNIPARC:UPI000016AB02; EMBL:X17115; NID:g33450; PIDN:CAA34971.1; PID
C;Superfamily: immunoglobulin C region; immunoglobulin homology
C;Keywords: immunoglobulin; membrane protein
F;1-15/Domain: signal sequence #status predicted <SIG>
F;16-627/Product: Ig mu chain #status predicted <MAT>
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 84.5%; Score 504.5; DB 2; Length 627;
Best Local Similarity 76.7%; Pred. No. 6e-38;
Matches 102; Conservative 5; Mismatches 7; Indels 19; Gaps 2;
```

```
Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 20 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPFGTANY 79
Qy 61 AQKFGQGRVTITADESTSTAYMELSTLTSTEDTAVYYC-----ELDWFY--- 102
Db 80 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAKTLGILPYSSGWYPNSDYIYGM 139
Qy 103 -IWGQGTMTVTSS 114
Db 140 DVWGQGTMTVTSS 152

RESULT 8
PH0953
Ig heavy chain V region (G6+ CLL-SIC) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C;Accession: PH0953
R;Martin, T.; Duffy, S.P.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0953
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-135 <MAR>
A;Cross-references: UNIPARC:UPI0000176CDD
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;1-30/Region: framework 1
F;15-98/Domain: immunoglobulin homology <IMM>
F;31-35/Region: complementarity-determining 1
F;36-50/Region: framework 2
F;51-67/Region: complementarity-determining 2
F;68-98/Region: framework 3
F;99-123/Region: complementarity-determining 3

Query Match 84.1%; Score 503.5; DB 2; Length 135;
Best Local Similarity 77.8%; Pred. No. 1.5e-38;
Matches 105; Conservative 2; Mismatches 7; Indels 21; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSHAISWVRQAPGQGLEWMGGIIPFGTANY 60
Qy 61 AQKFGQGRVTITADESTSTAYMELSTLTSTEDTAVYYC-----EL-----D 99
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCARNGYCGDGCYSRWELLRFDFSED 120
Qy 100 WFIWGQGTMTVTSS 114
Db 121 AFDIWGQGTMTVTSS 135

RESULT 9
S46394
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 27-Jan-1995 #sequence_revision 27-Jan-1995 #text_change 20-Jun-2000
C;Accession: S46394
R;Figini, M.; Marks, J.D.; Winter, G.; Griffiths, A.D.
J. Mol. Biol. 239, 68-78, 1994
A;Title: In vitro assembly of repertoires of antibody chains on the surface of phage by
A;Reference number: S46390; MUID:94254092; PMID:8196048
A;Accession: S46394
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-132 <FIG>
A;Cross-references: UNIPARC:UPI000011663B; EMBL:Z31681; NID:g509788; PIDN:CAA83486.1; PI
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
```



```
C;Accession: PH0955
R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kippes, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0955
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-127 <MAR>
A;Cross-references: UNIPARC:UPI0000176CDF
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-30/Region: framework 1
F;15-98/Domain: immunoglobulin homology <IMM>
F;31-35/Region: complementarity-determining 1
F;36-50/Region: framework 2
F;51-67/Region: complementarity-determining 2
F;68-98/Region: framework 3
F;99-115/Region: complementarity-determining 3

Query Match      83.0%; Score 495.5; DB 2; Length 127;
Best Local Similarity 78.7%; Pred. No. 7.6e-38;
Matches 100; Conservative 6; Mismatches 8; Indels 13; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIPIILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQRTVITADESTSTAYMELSTLTSEDATVYYC-----ELDWFY---IWGQGT 107
Db 61 AQKFGQRTVITADESTSTAYMELSLRSEDATVYYCARVSIFGVVQVHHYVMDVWGKG 120

Qy 108 TMTVSS 114
Db 121 TTVTVSS 127

RESULT 14
B33548
Ig heavy chain V-1 region (AND) - human
C;Species: Homo sapiens (man)
C;Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996
C;Accession: B33548
R;Kippes, T.J.; Tomhave, E.; Pratt, L.F.; Duffy, S.; Chen, P.P.; Carson, D.A.
Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989
A;Title: Developmentally restricted immunoglobulin heavy chain variable region gene exp
A;Reference number: A33548; MUID:89345575; PMID:2503826
A;Accession: B33548
A;Status: preliminary; nucleic acid sequence not shown; not compared with conceptual tra
A;Molecule type: DNA
A;Residues: 1-126 <KIP>
A;Cross-references: UNIPARC:UPI0000176D2A
A;Experimental source: the sequence was determined from the differentiated gene
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match      82.6%; Score 493; DB 2; Length 126;
Best Local Similarity 79.4%; Pred. No. 1.3e-37;
Matches 100; Conservative 5; Mismatches 9; Indels 12; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIPIILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQRTVITADESTSTAYMELSTLTSEDATVYYC-----ELDWFY---IWGQGT 108
Db 61 AQKFGQRTVITADESTSTAYMELSLRSEDATVYYCARVSIFGVVQVHHYVMDVWGGLGT 120

Qy 109 TMTVSS 114
Db 121 TTVTVSS 126
```

```
RESULT 15
PH0960
Ig heavy chain V region (G6+ T-L30) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C;Accession: PH0960
R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kippes, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0960
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-136 <MAR>
A;Cross-references: UNIPARC:UPI0000176CE4
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-30/Region: framework 1
F;15-98/Domain: immunoglobulin homology <IMM>
F;31-35/Region: complementarity-determining 1
F;36-50/Region: framework 2
F;51-67/Region: complementarity-determining 2
F;68-98/Region: framework 3
F;99-124/Region: complementarity-determining 3

Query Match      82.6%; Score 493; DB 2; Length 136;
Best Local Similarity 73.5%; Pred. No. 1.4e-37;
Matches 100; Conservative 6; Mismatches 8; Indels 22; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGDIPIILGTGNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQRTVITADESTSTAYMELSTLTSEDATVYYC-----ELDWF 101
Db 61 AQKFGQRTVITADKSTSTAYMELSLRSEDATVYYCARGRTRVSVSTLYDSSGYDFSGY 120

Qy 102 Y---IWGQGTMTVTVSS 114
Db 121 YGMDVWGQGTITVTVSS 136

Search completed: May 5, 2006, 08:54:47
Job time : 7.48485 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 09:04:30 ; Search time 42.8939 Seconds
(without alignments)
1875.095 Million cell updates/sec

Title: US-09-674-752-51

Perfect score: 597

Sequence: 1 QVQLVSGAEVKKPGSSVKV.....YCELDWFYINGQGTMTVTSS 114

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	482	80.7	116	2	Q9UL89 HUMAN
2	453	75.9	120	2	G6NSA4 HUMAN
3	444.5	74.5	208	2	Q6ZP87 HUMAN
4	430.5	72.1	117	1	HV1A_HUMAN
5	424.5	71.1	500	2	G6N091 HUMAN
6	422	70.7	124	2	Q9UL92 HUMAN
7	416.5	69.8	119	2	Q9UL94 HUMAN
8	416.5	69.8	119	2	Q6PJF1 HUMAN
9	410.5	68.8	125	2	Q9UL95 HUMAN
10	408	68.3	496	2	Q96DK0 HUMAN
11	404	67.7	159	2	Q96Q80 HUMAN
12	402.5	67.4	244	2	Q65ZC8 HUMAN
13	399.5	66.9	473	2	Q9D814 MOUSE
14	393	65.8	518	2	G6N030 HUMAN
15	390	65.3	498	2	G6N041 HUMAN
16	390	65.3	613	2	Q8VCX7 MOUSE
17	389.5	65.2	150	2	Q9Y298 HUMAN
18	385.5	64.6	458	2	Q5BJZ2 RAT
19	385	64.5	117	1	HV1B_HUMAN
20	385	64.5	143	2	Q924Q0 MOUSE
21	383	64.2	475	2	G6N095 HUMAN
22	380.5	63.7	168	2	Q8VDC9 MOUSE
23	380.5	63.7	480	2	Q6P089 HUMAN
24	378	63.3	500	2	Q9BRV0 HUMAN
25	376	63.0	463	2	Q99LC4 MOUSE
26	375.5	62.9	134	2	Q65Z86 MOUSE
27	375.5	62.9	616	2	Q504M7 MOUSE
28	373.5	62.6	138	1	HV4H_MOUSE
29	373.5	62.6	497	2	Q8WY24 HUMAN
30	373.5	62.6	614	2	Q7TMT6 MOUSE
31	373	62.5	469	2	Q7Z7P5_HUMAN

32	373	62.5	617	2	Q4KML5 MOUSE
33	372.5	62.4	119	2	Q9GYZ2 MOUSE
34	372.5	62.4	519	2	Q5EBM2_HUMAN
35	372	62.3	143	2	Q91V67_MOUSE
36	371	62.1	117	1	HV1G_HUMAN
37	371	62.1	147	1	HV1C_HUMAN
38	370	62.0	591	2	Q4QQW0 RAT
39	369	61.8	114	1	HV00_MOUSE
40	368.5	61.7	598	2	Q568Y0 RAT
41	368	61.6	143	2	Q924P9_MOUSE
42	367.5	61.6	117	1	HV12_MOUSE
43	367.5	61.6	120	2	Q5F3I1_MOUSE
44	366	61.3	465	2	Q6PUB2_MOUSE
45	365.5	61.2	117	2	Q9QXE9_MOUSE

ALIGNMENTS

RESULT 1

Q9UL89_HUMAN
ID Q9UL89_HUMAN PRELIMINARY; PRT; 116 AA.
AC Q9UL89; 2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531; Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berney S.M., Young D.C.;
RA "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528; Manheimer-Lory A., Katz J.B., Pillinger M., Grossein C., Smith A., Diamond B.;
RA "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype";
RL J. Exp. Med. 174:1639-1652(1991).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=93301610; PubMed=8315388; DOI=10.1084/jem.178.1.331; Hillson J.L., Karr N.S., Oppiger I.R., Mannik M., Sasso E.H.;
RA "The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A.";
RL J. Exp. Med. 178:331-336(1993).
DR EMBL: AF035025; AAD56261.1; -; mRNA.
DR PIR; PH0870; PH0870.
DR PIR; PH1671; PH1671.
DR HSSP; P01751; INQB.
DR SMR; Q9UL89; 1-115.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1_v.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 116
SQ SEQUENCE 116 AA; 13605 MW; C8F9131DE13EA898 CRC64;

Query Match 80.7%; Score 482; DB 2; Length 116;
Best Local Similarity 81.9%; Pred. No. 2.2e-41;
Matches 95; Conservative 8; Mismatches 7; Indels 6; Gaps 2;

```
QY 5 VQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNYAQKF 64
Db 1 VQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGRIIPILGTGNYAQKF 60
QY 65 QGRVTITADSTSTAYMELSTLTSEDYAVYYCELD-----WFY-IMGOGTMTVTS 114
Db 61 QGRVTITADSTSTAYMELSSLSRSEDYAVYYCASSNWGPYWFYFDLWGRGLTIVTS 116

RESULT 2
Q6NSA4 HUMAN
ID Q6NSA4_HUMAN PRELIMINARY; PRT; 120 AA.
AC Q6NSA4;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE IGHV1-69 protein.
GN Name=IGHV1-69;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Pooled;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heien F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting M., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Pooled;
RG NIH MGC Project;
RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC070333; AAH70333.1; -; mRNA.
DR HSSP; P01751; 1A6W
DR SMR; Q6NSA4; 21-116.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 120 AA; 13035 MW; 64620FAC874585D4 CRC64;

Query Match 75.9%; Score 453; DB 2; Length 120;
Best Local Similarity 88.9%; Pred. No. 2.2e-38;
Matches 88; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 20 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGGIIPVFGTNY 79
QY 61 AQKFGQGVITADESTSTAYMELSTLTSEDYAVYYCELD 99
Db 80 TQKFGQGVITADESTSTAYMELSSLSRSEDYAVYYCARD 118

Query Match 74.5%; Score 444.5; DB 2; Length 208;
Best Local Similarity 70.2%; Pred. No. 2.9e-37;
Matches 85; Conservative 12; Mismatches 17; Indels 7; Gaps 1;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 20 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGGIIPVFGTNY 79
QY 61 AQKFGQGVITADESTSTAYMELSTLTSEDYAVYYCELD-----WFY-IMGOGTMTVTS 113
Db 80 AQKFGQGVITADESTSTAYMELSSLSRSEDYAVYYCAREYVSGPNWFDPMGQGLTIVTS 139

114 S 114
140 S 140

RESULT 4
HVIA_HUMAN
ID HVIA_HUMAN STANDARD; PRT; 117 AA.
AC P01742;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region EU.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=71064024; PubMed=5489771; Gall W.E., Gottlieb P.D.,
RA Cunningham B.A., Rutishauser U., Gall W.E., Gottlieb P.D.,
RA Waddal M.J., Edelman G.M.;
RT "The covalent structure of a human gamma G-immunoglobulin. VII. Amino
acid sequence of heavy-chain cyanogen bromide fragments H1-H4."
RL Biochemistry 9:3161-3170(1970).
```

```

[2]
RN DISULFIDE BOND.
RP MEDLINE=71064027; PubMed=4923144;
RX Gall W.E., Edelman G.M.;
RA "The covalent structure of a human gamma G-immunoglobulin. X.
RT Intrachain disulfide bonds.";
RL Biochemistry 9:3188-3196(1970).
CC -1- MISCELLANEOUS: The sequence of the gamma-1 C region of this
CC myeloma protein has also been determined.
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR PIR; A90563; GIHUEU.
DR HSSP; P01751; 1A6W.
DR SMR; P01742; 1-102.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Pyrrolidone carboxylic acid.
FT DOMAIN 1 112
FT MOD RES 1 1 Ig-like.
FT DISULFID 22 96 Pyrrolidone carboxylic acid.
FT NON TER 117 117
FT SEQUENCE 117 AA; 12472 MW; 99D60ADAEBD52818 CRC64;

Query Match 72.1%; Score 430.5; DB 1; Length 117;
Best Local Similarity 75.4%; Pred. No. 4.3e-36;
Matches 89; Conservative 8; Mismatches 16; Indels 5; Gaps 2;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Qy 61 AQKFGQGVTTITADESTAYMELSTLTSEDYAVYICELDFWFIWG----QGTMTVTS 114
Db 61 AQKFGQGVTTITADESTAYMELSTLTSEDYAVYICELDFWFIWG----QGTMTVTS 114
Qy 61 AQKFGQGVTTITADESTAYMELSTLTSEDYAVYICELDFWFIWG----QGTMTVTS 114
Db 61 AQKFGQGVTTITADESTAYMELSTLTSEDYAVYICELDFWFIWG----QGTMTVTS 114

RESULT 5
Q6N091_HUMAN PRELIMINARY; PRT; 500 AA.
AC Q6N091;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686C02220 (Fragment).
GN Name=DKFZp686C02220;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;
RG The German Human cDNA Consortium;
RA Wambutt R., Heubner D., Mewes H.W., Well B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640625; CA645779.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q6N091; 270-478.
DR InterPro; IPR003599; Ig.

```

```

DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON TER 1
FT SEQUENCE 500 AA; 54160 MW; 3C423A17D65A41B4 CRC64;

Query Match 71.1%; Score 424.5; DB 2; Length 500;
Best Local Similarity 69.9%; Pred. No. 8.7e-35;
Matches 86; Conservative 9; Mismatches 19; Indels 9; Gaps 1;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 38 QVQLVQSGAEVKPGASVKVSKASGYTFSDHSITLRLQAPGQGLEWIGWISAYSGQTY 97
Qy 61 AQKFGQGVTTITADESTAYMELSTLTSEDYAVYICELDW-----FYINQGGTMTV 111
Db 98 AQNLQGRVTMTDTSTSTAYMELSLRSDDTAVYVYCAKQDSYTTIPNDAPHINQGGTMTV 157
Qy 112 VSS 114
Db 158 VSS 160

RESULT 6
Q9UL92_HUMAN PRELIMINARY; PRT; 124 AA.
AC Q9UL92;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035022; AAD56258.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
FT NON TER 1
FT NON TER 124 124
FT SEQUENCE 124 AA; 13580 MW; 1BAACBD96ACD2A2 CRC64;

Query Match 70.7%; Score 422; DB 2; Length 124;
Best Local Similarity 68.5%; Pred. No. 3.4e-35;
Matches 85; Conservative 12; Mismatches 17; Indels 10; Gaps 1;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
Db 1 EVQLVESGAEVKPGASVKVSKASGYTFSSYMHVWVRQAPGQGLEWGINFSGGSTY 60
Qy 61 AQKFGQGVTTITADESTAYMELSTLTSEDYAVYICELDFWFI-----WGQGTMTV 110

```



```

RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
EL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035019; AAD56295.1; -; mRNA.
DR HSSP; P01751; INOB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 125
SQ SEQUENCE 125 AA; 13516 MW; 0D3CD5C232488EAC CRC64;

Query Match 68.8%; Score 410.5; DB 2; Length 125;
Best Local Similarity 68.0%; Pred. No. 5.1e-34;
Matches 85; Conservative 9; Mismatches 20; Indels 11; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPQGQLEWMGDIIPILGTGNY 60
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 EVQLVESGAEVKKPGASVKVSKASGYFTFTGYVHWVRQAPQGQLEWMGWINPNSGGTNY 60

Qy 61 AQKFQGRVTITADESTSTAYMELSTLTSEDVAVYCE-----DWFIWGQGTM 109
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 AQKQGRVTMTDRTTISTAYMELSLRLSDDTAVVYCARSGQGGRIAAGDAFDIWGQGTM 120

Qy 110 VTSS 114
Db :|||||
121 VTSS 125

RESULT 10
Q96DK0_HUMAN
ID Q96DK0 HUMAN PRELIMINARY; PRT; 496 AA.
AC Q96DK0;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein FLJ25298.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Stomach mucosa;
RA Ishibashi T., Kanehori K., Yosida M., Watanabe S., Ishida S., Ono Y.,
RA Hokuta T., Hiraoka S., Murakawa K., Takiguchi S., Kusano J., Chiba Y.,
RA Watanabe M., Fujimori K., Tanai H., Ishida M., Yamashita H., Chiba Y.,
RA Suzuki Y., Hata H., Nakagawa K., Mizuno S., Morinaga M., Kawamura M.,
RA Sugiyama T., Irie R., Otsuki T., Sato H., Nishikawa T., Sugiyama A.,
RA Kawakami B., Nagai K., Isogai T., Sugano S.;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK058027; BAB71633.1; -; mRNA.
DR HSSP; P01876; 10W0.
DR SMR; Q96DK0; 266-474.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 2.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 496 AA; 53533 MW; C72EE1E247C86FED CRC64;

Query Match 68.3%; Score 408; DB 2; Length 496;
Best Local Similarity 65.3%; Pred. No. 4.2e-33;
Matches 82; Conservative 16; Mismatches 14; Indels 16; Gaps 3;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPQGQLEWMGDIIPILGTGNY 60
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 QVQLVQSGAEVKKPGASVKVSKASGYTFSNYNMVVRQAPQGQPEWGVNPSGGSARY 79

Qy 61 AQKFQGRVTITADESTSTAYMELSTLTSEDVAVYCE-----WFIW---IW 104
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 SQKFGGLTWRDTSVTVMDSLSLRSDDTAVYFCAREMEITPGGAVSGYFYIGMDVW 139

Qy 105 GQGTMTVTSS 114
Db :|||||
140 GQGTMTVTSS 149

RESULT 12
Q65ZC8_HUMAN
ID Q65ZC8 HUMAN PRELIMINARY; PRT; 244 AA.
AC Q65ZC8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]

```

```

Matches 81; Conservative 13; Mismatches 20; Indels 10; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPQGQLEWMGDIIPILGTGNY 60
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 QVHLVQSGAEVKKPGSSVKVSKASANMFRSYATVWRQAPQGQLEWMGGIIPNFGAPNY 79

Qy 61 AQKFQGRVTITADESTSTAYMELSTLTSEDVAVYCE-----ELDWFYI--WGQGTMV 110
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 AQNFQDRVTISADSDTTTVMYVLMELTSLTFTDFAFYCGRLTYVSGSYVYLQHNQGQGLV 139

Qy 111 TVSS 114
Db :|||||
140 TVSS 143

RESULT 11
Q96QS0_HUMAN
ID Q96QS0 HUMAN PRELIMINARY; PRT; 159 AA.
AC Q96QS0;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Putative matrix cell adhesion molecule-3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Tilson M.D.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY039025; AAK82649.1; -; mRNA.
DR HSSP; P01869; 1AE6.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 159 AA; 17497 MW; 5D29537E881FAF02 CRC64;

Query Match 67.7%; Score 404; DB 2; Length 159;
Best Local Similarity 63.1%; Pred. No. 3.1e-33;
Matches 82; Conservative 16; Mismatches 14; Indels 16; Gaps 3;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSHAISWVRQAPQGQLEWMGDIIPILGTGNY 60
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 QVQLVQSGAEVKKPGASVKVSKASGYTFSNYNMVVRQAPQGQPEWGVNPSGGSARY 79

Qy 61 AQKFQGRVTITADESTSTAYMELSTLTSEDVAVYCE-----WFIW---IW 104
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 SQKFGGLTWRDTSVTVMDSLSLRSDDTAVYFCAREMEITPGGAVSGYFYIGMDVW 139

Qy 105 GQGTMTVTSS 114
Db :|||||
140 GQGTMTVTSS 149

RESULT 12
Q65ZC8_HUMAN
ID Q65ZC8 HUMAN PRELIMINARY; PRT; 244 AA.
AC Q65ZC8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]

```

```

RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR EMBL: Y13057; CAA73500.1; -; mRNA.
DR InterPro: IPR003599; Ig.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003596; Ig_v.
DR SMART: SM00409; IGV; 2.
DR SMART: SM00406; IGV; 2.
DR PROSITE: PS0835; IG_LIKE; 2.
FT NON_TER 1 244
FT NON_TER 244 AA; 26127 MW; 481F17868338F2BF CRC64;
SQ SEQUENCE 244 AA; 26127 MW; 481F17868338F2BF CRC64;

Query Match 67.4%; Score 402.5; DB 2; Length 244;
Best Local Similarity 67.8%; Pred. No. 7.1e-33;
Matches 82; Conservative 9; Mismatches 23; Indels 7; Gaps 1;

QY 1 QVQLVSGAERVKPKGSSVKVSKASGCTFSSHAISVWRQAPGQGLEWMGDIIPILGTGNY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVSGAERVKPKGSSVKVSKASGCTFSDHYMHVWRQAPGQGLEWMGIDPNNGDTRF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 AQKFGQGVTTADESTAYMELSTLTSETAYVYCELD-----WFIYWGQGTWVTVS 113
   ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGVTTDRDTSIAAYMEVSRUSDPTAVVYCAREGTGSAIYGMQVWGQGLTVTVS 120
   ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 114 S 114
Db 121 S 121

RESULT 13
Q9DBL4 MOUSE
ID Q9DBL4_MOUSE PRELIMINARY; PRT; 473 AA.
AC Q9DBL4
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Mus musculus 10 day old male pancreas cDNA, RIKEN full-length enriched
DE library, clone:1810060009 product:immunoglobulin heavy chain 6 (heavy
DE chain of IgM), full insert sequence.
DE Name:igh-1a;
GN Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C57BL/6J; TISSUE=Pancreas;
RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RA Carninci P., Hayashizaki Y.;
RT "High-efficiency full-length cDNA cloning.";
RL Meth. Enzymol. 303:19-44(1999).
[2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C57BL/6J; TISSUE=Pancreas;
RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
RA Kawai J., Shingawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavani T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,
RA Schirni L.M., Staabli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai M., Okido T., Furuno M., Aono H., Baldarelli R., Barch G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,

```

```

RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohseki S.,
RA Hayashizaki Y.;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
[3]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C57BL/6J; TISSUE=Pancreas;
RA The FANTOM Consortium,
RT the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573(2002).
[4]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C57BL/6J; TISSUE=Pancreas;
RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RT "Normalization and subtraction of cap-trapper-selected cDNAs to
RT prepare full-length cDNA libraries for rapid discovery of new genes.";
RL Genome Res. 10:1617-1630(2000).
[5]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C57BL/6J; TISSUE=Pancreas;
RX MEDLINE=20350913; PubMed=11076861; DOI=10.1101/gr.152600;
RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,
RA Konno H., Akiyama J., Nishi K., Kitsuai T., Tashiro H., Itoh M.,
RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
RA Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Wataniki M.,
RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsura S., Kawai J.,
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RT "RIKEN integrated sequence analysis (RISA) system-384-Format
RT sequencing pipeline with 384 multicapillary sequencer.";
RL Genome Res. 10:1757-1771(2000).
[6]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C57BL/6J; TISSUE=Pancreas;
RX Adachi J., Aizawa K., Akahira S., Akimura T., Azai A., Aono H.,
RA Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,
RA Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Hori F.,
RA Imotani K., Ishii Y., Itoh M., Izawa M., Kaya S., Kurihara C.,
RA Kawai J., Kojima Y., Konno H., Kouda M., Koya S., Numazaki R., Ohno M.,
RA Matsuyama T., Miyazaki A., Nishi K., Nomura K., Nomura K., Sakai K.,
RA Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Shiraki T.,
RA Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,
RA Sogabe Y., Suzuki H., Tagami M., Tagawa A., Takahashi F., Tanaka T.,
RA Tejima Y., Toya T., Yamamura T., Yasunishi A., Yoshida K., Yoshino M.,
RA Muramatsu M., Hayashizaki Y.;
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
EMBL: AK007918; BAB25349.1; -; mRNA.
DR PIR: PH1165; PH1165.
DR PIR: S19966; S19966.
DR PIR: S26746; S26746.
DR HSSP: P01864; 1BOG.
DR SNR: Q9DBL4; 20-469.
DR Ensembl: ENSMUSG0000054328; Mus musculus.
DR MGI: MGI:96443; Igh-1a.
DR GO: GO:0042571; C:immunoglobulin complex, circulating; IDA.
DR GO: GO:0005771; C:multivesicular body; IDA.
DR GO: GO:0003823; F:antigen binding; IDA.
DR GO: GO:0003788; F:antibody-dependent cellular cytotoxicity; IDA.
DR GO: GO:0030333; P:antigen processing; IDA.
DR GO: GO:0006958; P:complement activation, classical pathway; IDA.
DR GO: GO:0045022; P:early endosome to late endosome transport; IDA.
DR GO: GO:0008333; P:endosome to lysosome transport; IDA.
DR GO: GO:0006911; P:phagocytosis, engulfment; IDA.
DR GO: GO:0006910; P:phagocytosis, recognition; IDA.
DR GO: GO:0050871; P:positive regulation of B cell activation; IDA.
DR GO: GO:0050778; P:positive regulation of immune response; IDA.

```

```

Db      20  QVHLVGSAGAEVKKPGASVKVCSCTASGYPFTNHFNVRQAPGQSLWMGMWINTGNGNTKY 79
Qy      61  AQKQFGRVITADESTSTAYMELSTLTSETDAYVYCELD-----WFIYWGQGTMTVTV 112
      :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      80  SQKFGQGVITRTDTWTTTATYMDLSSLRSEDTAVYWCARDAPQGVTTTTFDYWGQGTLTVT 139
Qy      113  SS 114
      ||
Db      140  SS 141

RESULT 15
Q6N041_HUMAN
ID   Q6N041_HUMAN PRELIMINARY;          PRT;   498 AA.
AC   Q6N041;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DI   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DB   Hypothetical protein DKFp686O16217 (Fragment).
GN   Name=DKFp686O16217;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RS   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Human rectum tumor;
RG   The German Human cDNA Consortium;
RA   Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA   Mewes H.W., Weil B., Anid C., Oeinger A., Fobo G., Han M., Wiemann S.;
RL   Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR   EMBL; BX640710; CA645829.1; -; mRNA.
DR   HSSP; P01751; 1A6W.
DR   SMR; Q6N041; 268-476.
DR   InterPro; IPR003599; Ig.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR003597; Ig_c1.
DR   InterPro; IPR003006; Ig_MHC.
DR   InterPro; IPR003596; Ig_v.
DR   Pfam; PF07654; Cl-set; 2.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00407; IGC1; 3.
DR   SMART; SM00406; IGV; 1.
DR   PROSITE; PS50835; IG_LIKE; 4.
DR   PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW   Hypothetical protein.
FT   NON_TER 1
SQ   SEQUENCE 498 AA; 54125 MW; 40B3208A84E03B46 CRC64;

Query Match          65.3%; Score 390; DB 2; Length 498;
Best Local Similarity 63.7%; Pred. No. 3e-31;
Matches 79; Conservative 15; Mismatches 20; Indels 10; Gaps 1;

Qy      1  QVQLVQSGAEVKKPGSSVKVCSKASGTFSSHAISWVRQAPGQGLEWMGDIIPILGTGNY 60
      :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      35  QVQLVQSGADVKKPGASVKVCSKASGYTFNTYFFHWVRQAPGQGPENMGMINPRDGS TKY 94
Qy      61  AQKQFGRVITADESTSTAYMELSTLTSETDAYVYCELD-----WFIYWGQGTMTV 110
      :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      95  AQKFGQGVSMTRDTSTSTIYMELSSLRSEDTAMFFCARAGPGYGTYSASYFDYWGQGTLV 154
Qy      111  TVSS 114
      |||
Db      155  TVSS 158

Search completed: May 5, 2006, 09:14:32
Job time : 43.8939 secs

```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:25 ; Search time 11.3112 Seconds
(without alignments)
716.302 Million cell updates/sec

Title: US-09-674-752-52

Perfect score: 506

Sequence: 1 EVOLLESGGLVQPGGSLRL.....LYLQMSLRAEDTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued_Patents_AA.*

1: /cgn2_6/ptodata/1/iaa/5_COMB.pep.*

2: /cgn2_6/ptodata/1/iaa/6_COMB.pep.*

3: /cgn2_6/ptodata/1/iaa/H_COMB.pep.*

4: /cgn2_6/ptodata/1/iaa/PCUS_COMB.pep.*

5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep.*

6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	506	100.0	98	2	US-10-194-975-22
2	506	100.0	98	2	US-09-534-717-619
3	506	100.0	98	2	US-08-896-535-74
4	506	100.0	117	2	US-08-545-809A-109
5	506	100.0	117	2	US-09-515-697-109
6	506	100.0	128	2	US-09-840-459-77
7	506	100.0	128	2	US-09-840-459-79
8	506	100.0	128	2	US-09-497-625A-77
9	506	100.0	128	2	US-09-497-625A-79
10	506	100.0	240	2	US-09-192-854-2
11	506	100.0	240	2	US-09-511-939-2
12	503	99.4	116	2	US-09-840-459-80
13	503	99.4	116	2	US-09-497-625A-80
14	503	99.4	120	2	US-09-840-459-85
15	503	99.4	120	2	US-09-497-625A-85
16	503	99.4	121	2	US-09-840-459-92
17	503	99.4	121	2	US-09-497-625A-92
18	503	99.4	125	2	US-09-840-459-76
19	503	99.4	125	2	US-09-840-459-84
20	503	99.4	125	2	US-09-497-625A-76
21	503	99.4	125	2	US-09-497-625A-84
22	502	99.2	98	2	US-09-534-717-623
23	502	99.2	125	1	US-08-428-197-1
24	502	99.2	125	4	PCT-US93-10555-1
25	500	98.8	120	2	US-09-025-769B-38
26	500	98.8	120	2	US-09-025-769B-63
27	500	98.8	120	2	US-09-490-070A-38

28	500	98.8	120	2	US-09-490-070A-63	Sequence 63, Appl
29	500	98.8	120	2	US-09-490-153-38	Sequence 38, Appl
30	500	98.8	120	2	US-09-490-153-63	Sequence 63, Appl
31	500	98.8	120	2	US-09-490-324-38	Sequence 38, Appl
32	500	98.8	120	2	US-09-490-324-63	Sequence 63, Appl
33	500	98.8	131	2	US-08-983-607-28	Sequence 28, Appl
34	500	98.8	281	2	US-09-025-769B-178	Sequence 178, App
35	500	98.8	281	2	US-09-490-070A-178	Sequence 178, App
36	500	98.8	281	2	US-09-490-153-178	Sequence 178, App
37	500	98.8	281	2	US-09-490-324-178	Sequence 178, App
38	497	98.2	124	2	US-08-983-607-51	Sequence 51, Appl
39	496	98.0	127	2	US-09-840-459-87	Sequence 87, Appl
40	496	98.0	127	2	US-09-497-625A-87	Sequence 87, Appl
41	494	97.6	123	2	US-09-840-459-82	Sequence 82, Appl
42	494	97.6	123	2	US-09-497-625A-82	Sequence 82, Appl
43	494	97.6	288	2	US-09-818-247-22	Sequence 22, Appl
44	493	97.4	98	1	US-08-428-197-48	Sequence 48, Appl
45	493	97.4	98	4	PCT-US93-10555-48	Sequence 48, Appl

ALIGNMENTS

RESULT 1

US-10-194-975-22
; Sequence 22, Application US/10194975
; Patent No. 6881557
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 22
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-194-975-22

Query Match	100.0%;	Score 506;	DB 2;	Length 98;
Best Local Similarity	100.0%;	Pred. No. 4.5e-45;		
Matches	98;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	1	EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGSGSTYY	60	
Db	1	EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGSGSTYY	60	
Qy	61	ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK	98	
Db	61	ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK	98	

RESULT 2

US-09-534-717-619
; Sequence 619, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER FILING DATE: 2000-03-24
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 619
; LENGTH: 98
; TYPE: PRT

```
; ORGANISM: Homo sapiens
US-09-534-717-619

Query Match      100.0%; Score 506; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.5e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||
Db 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||

RESULT 3
US-08-896-535-74
; Sequence 74, Application US/08896535
; Patent No. 6936464
; GENERAL INFORMATION:
; APPLICANT: Zhu, Delin
; APPLICANT: Hawkins, Robert Edward
; APPLICANT: Russell, Stephen James
; APPLICANT: Stevenson, Freda Katherine
; APPLICANT: Winter, Gregory Paul
; TITLE OF INVENTION: Improvements in or Relating to
; NUMBER OF SEQUENCES: 79
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pillsbury Madison & Sutro, L.L.P.
; STREET: 1100 New York Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3918
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/896,535
; FILING DATE: 18-JUL-1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/411,622
; FILING DATE: 14-JUN-1995
; PRIOR APPLICATION DATA: PCT/GB93/02054
; APPLICATION NUMBER: PCT/GB93/02054
; FILING DATE: 04-OCT-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9220808.1
; FILING DATE: 02-OCT-1992
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 98 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-896-535-74

Query Match      100.0%; Score 506; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.5e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||
Db 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||

; ORGANISM: Homo sapiens
US-09-534-717-619

Query Match      100.0%; Score 506; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.5e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||
Db 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||

RESULT 4
US-08-545-809A-109
; Sequence 109, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 109:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-545-809A-109

Query Match      100.0%; Score 506; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 5.6e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||
Db 20 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 79
   |||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||
Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 117
   |||

RESULT 5
US-09-515-697-109
; Sequence 109, Application US/09515697
; Patent No. 6936705
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasaku
; APPLICANT: Matsuda, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
```

```
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/515.697
; FILING DATE: 29-Feb-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/545.809
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 109:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 109:
US-09-515-697-109

Query Match 100.0%; Score 506; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 5.6e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 20 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 79
QY 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 80 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 117

RESULT 6
US-09-840-459-77
; Sequence 77, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-840-459-79

Query Match 100.0%; Score 506; DB 2; Length 128;
Best Local Similarity 100.0%; Pred. No. 6.2e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
QY 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 7
US-09-840-459-79
; Sequence 79, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-840-459-79

Query Match 100.0%; Score 506; DB 2; Length 128;
Best Local Similarity 100.0%; Pred. No. 6.2e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
QY 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 8
```

```

US-09-497-625A-77
; Sequence 77, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-497-625A-77

Query Match      100.0%; Score 506; DB 2; Length 128;
Best Local Similarity 100.0%; Pred. No. 6.2e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 9
US-09-497-625A-79
; Sequence 79, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-497-625A-79

Query Match      100.0%; Score 506; DB 2; Length 128;
Best Local Similarity 100.0%; Pred. No. 6.2e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 9
US-09-497-625A-79
; Sequence 79, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-497-625A-79

```

```

; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-497-625A-79

Query Match      100.0%; Score 506; DB 2; Length 128;
Best Local Similarity 100.0%; Pred. No. 6.2e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 10
US-09-192-854-2
; Sequence 2, Application US/09192854
; Patent No. 6696245
; GENERAL INFORMATION:
; APPLICANT: Winter, Greg
; APPLICANT: Tomlinson, Ian
; TITLE OF INVENTION: Methods for Selecting Functional Peptides
; FILE REFERENCE: 3789/72916
; CURRENT APPLICATION NUMBER: US/09/192,854
; CURRENT FILING DATE: 1998-11-17
; EARLIER APPLICATION NUMBER: 60/066,729
; EARLIER FILING DATE: 1997-11-21
; NUMBER OF SEQ ID NOS: 212
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-192-854-2

Query Match      100.0%; Score 506; DB 2; Length 240;
Best Local Similarity 100.0%; Pred. No. 1.3e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 11
US-09-511-939-2
; Sequence 2, Application US/09511939
; Patent No. 6846634
; GENERAL INFORMATION:
; APPLICANT: Tomlinson, Ian M
; APPLICANT: Winter, Gregory
; TITLE OF INVENTION: Method to Screen Phage Display Libraries with Different Ligands
; FILE REFERENCE: 8039/1070
; CURRENT APPLICATION NUMBER: US/09/511,939
; CURRENT FILING DATE: 2002-04-10
; PRIOR APPLICATION NUMBER: GB 9722131.1
; PRIOR FILING DATE: 1997-10-20
; PRIOR APPLICATION NUMBER: US 60/065,248
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: US 60/066,729
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: PCT/GB98/03135
; PRIOR FILING DATE: 1998-10-20
; NUMBER OF SEQ ID NOS: 350
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 240

```



```
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-511-939-2

Query Match      100.0%; Score 506; DB 2; Length 240;
Best Local Similarity 100.0%; Pred. No. 1.3e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
Db 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 12
US-09-840-459-80
; Sequence 80, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1998-07-23
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 80
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-80

Query Match      99.4%; Score 503; DB 2; Length 116;
Best Local Similarity 99.0%; Pred. No. 1.1e-44;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
Db 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 14
US-09-840-459-85
; Sequence 85, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 85
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-85

Query Match      99.4%; Score 503; DB 2; Length 120;
Best Local Similarity 99.0%; Pred. No. 1.2e-44;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
Db 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

US-09-497-625A-80
; Sequence 80, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 80
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-80

Query Match      99.4%; Score 503; DB 2; Length 116;
Best Local Similarity 99.0%; Pred. No. 1.1e-44;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
Db 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
```

```
RESULT 15
US-09-497-625A-85
; Sequence 85, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 85
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-497-625A-85

Query Match          99.4%; Score 503; DB 2; Length 120;
Best Local Similarity 99.0%; Pred. No. 1.2e-44;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGGTTY 60
      |||:|||||
Db       1 EVQLVEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGGTTY 60
      |||:|||||

QY      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
      |||:|||||
Db       61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
      |||:|||||
```

Search completed: May 5, 2006, 08:53:49
Job time : 11.3112 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:56:13 ; Search time 7.32964 Seconds
(without alignments)
618.844 Million cell updates/sec

Title: US-09-674-752-52

Perfect score: 506

Sequence: 1 EVQLLESGGGLVPGGSLRL.....LYLQNSLRAEDTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications AA_New:
1: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
2: /SIDSS5/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
3: /SIDSS5/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
4: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
5: /SIDSS5/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
6: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
7: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
8: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
9: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
10: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
11: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
12: /SIDSS5/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	506	100.0	98	9	US-10-789-273-10
2	506	100.0	98	11	US-11-144-248-32
3	506	100.0	98	11	US-11-054-669-22
4	506	100.0	98	11	US-11-084-554-33
5	506	100.0	98	11	US-11-144-222-32
6	506	100.0	98	11	US-11-004-590-23
7	506	100.0	98	11	US-11-136-250-33
8	506	100.0	98	11	US-11-182-343-32
9	506	100.0	98	11	US-11-049-536-721
10	506	100.0	116	9	US-10-925-366A-1
11	506	100.0	116	11	US-11-102-512-1
12	506	100.0	116	11	US-11-098-758-1
13	506	100.0	116	11	US-11-166-496-8
14	506	100.0	120	9	US-10-925-366A-235
15	506	100.0	120	11	US-11-098-758-235
16	506	100.0	123	9	US-10-982-440-59
17	506	100.0	240	9	US-10-925-366A-219
18	506	100.0	240	11	US-11-098-758-219
19	506	100.0	313	11	US-11-000-463-427
20	506	100.0	470	11	US-11-144-248-46
21	506	100.0	470	11	US-11-144-222-46

22	506	100.0	470	11	US-11-182-343-46	Sequence 46, Appl
23	503	99.4	118	11	US-11-112-240-22	Sequence 22, Appl
24	503	99.4	118	11	US-11-112-304A-22	Sequence 22, Appl
25	503	99.4	120	11	US-11-112-240-2	Sequence 2, Appl
26	503	99.4	120	11	US-11-112-304A-2	Sequence 2, Appl
27	503	99.4	122	9	US-10-515-241-11	Sequence 11, Appl
28	503	99.4	122	11	US-11-112-240-6	Sequence 6, Appl
29	503	99.4	123	11	US-11-112-304A-6	Sequence 6, Appl
30	503	99.4	123	11	US-11-112-240-30	Sequence 30, Appl
31	503	99.4	123	11	US-11-112-304A-30	Sequence 30, Appl
32	503	99.4	130	11	US-11-109-264-54	Sequence 54, Appl
33	501	99.0	97	11	US-11-093-274-34	Sequence 34, Appl
34	500	98.8	120	9	US-10-834-397-38	Sequence 38, Appl
35	500	98.8	120	9	US-10-834-397-63	Sequence 63, Appl
36	500	98.8	123	9	US-10-982-440-23	Sequence 23, Appl
37	500	98.8	125	11	US-11-144-248-16	Sequence 16, Appl
38	500	98.8	125	11	US-11-144-222-16	Sequence 16, Appl
39	500	98.8	125	11	US-11-182-343-16	Sequence 16, Appl
40	500	98.8	239	11	US-11-054-515-1922	Sequence 1922, Ap
41	500	98.8	239	11	US-11-054-515-2018	Sequence 2018, Ap
42	500	98.8	239	11	US-11-054-515-2035	Sequence 2035, Ap
43	500	98.8	239	11	US-11-266-444-1922	Sequence 1922, Ap
44	500	98.8	239	11	US-11-266-444-2018	Sequence 2018, Ap
45	500	98.8	239	11	US-11-266-444-2035	Sequence 2035, Ap

ALIGNMENTS

RESULT 1

US-10-789-273-10
; Sequence 10, Application US/10789273
; Publication No. US20050249725A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Gurik
; APPLICANT: Saldanha, Jose
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
; FILE REFERENCE: ELN-002CP
; CURRENT APPLICATION NUMBER: US/10789, 273
; CURRENT FILING DATE: 2004-02-27
; PRIOR APPLICATION NUMBER: US/10/388,389
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/010,942
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: US 60/251,892
; PRIOR FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-789-273-10

Query Match	100.0%;	Score	506;	DB	98;	Length	98;
Best Local Similarity	100.0%;	Pred. No.	1.4e-37;				
Matches	98;	Conservative	0;	Mismatches	0;	Indels	0;
Gaps	0;						

QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSATISGGSGTYY 60
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSATISGGSGTYY 60
QY 61 ADSVKGRTTISRDNKNTLYLQNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRTTISRDNKNTLYLQNSLRAEDTAVYYCAK 98

RESULT 2

US-11-144-248-32
; Sequence 32, Application US/11144248
; Publication No. US20050244408A1

```

; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Beebe, Jean
; APPLICANT: Miller, Penelope E.
; APPLICANT: Moyer, James D.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; FILE REFERENCE: ABX-PF2
; CURRENT APPLICATION NUMBER: US/11/144,248
; CURRENT FILING DATE: 2005-06-02
; PRIOR APPLICATION NUMBER: US/10/038,591
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,927
; PRIOR FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-144-248-32

```

```

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98

```

```

RESULT 3
US-11-054-669-22
; Sequence 22, Application US/11054669
; Publication No. US20050261480A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES
; FILE REFERENCE: 30219/US/3
; CURRENT APPLICATION NUMBER: US/11/054,669
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: US 10/194,975
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-669-22

```

```

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98

```

```

RESULT 4
US-11-084-554-33

```

```

; Sequence 33, Application US/11084554
; Publication No. US20050260679A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; FILE REFERENCE: ABGENIX.100A
; CURRENT APPLICATION NUMBER: US/11/084,554
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-084-554-33

```

```

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98

```

```

RESULT 5
US-11-144-222-32
; Sequence 32, Application US/11144222
; Publication No. US20050281812A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Beebe, Jean
; APPLICANT: Miller, Penelope E.
; APPLICANT: Moyer, James D.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; FILE REFERENCE: ABX-PF2
; CURRENT APPLICATION NUMBER: US/11/144,222
; CURRENT FILING DATE: 2005-06-02
; PRIOR APPLICATION NUMBER: US/10/038,591
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,927
; PRIOR FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-144-222-32

```

```

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98

```

```

Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
RESULT 6
US-11-004-590-23
; Sequence 23, Application US/11004590
; Publication No. US2006000883A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hammond, Phillip W.
; TITLE OF INVENTION: METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING
; FILE REFERENCE: 185832/US/5
; CURRENT APPLICATION NUMBER: US/11/004,590
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: US 60/527,167
; PRIOR FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: US 60/581,613
; PRIOR FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US 60/601,665
; PRIOR FILING DATE: 2004-08-13
; PRIOR APPLICATION NUMBER: US 60/619,483
; PRIOR FILING DATE: 2004-10-14
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-004-590-23

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Qy      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 7
US-11-136-250-33
; Sequence 33, Application US/11136250
; Publication No. US20060021074A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korvet, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ARGENTX.100A2
; CURRENT APPLICATION NUMBER: US/11/136,250
; CURRENT FILING DATE: 2005-05-23
; PRIOR APPLICATION NUMBER: 11/084,554
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: PCT/US2005/009306
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-136-250-33

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Qy      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 8
US-11-182-343-32
; Sequence 32, Application US/11182343
; Publication No. US20060018910A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce
; APPLICANT: Gualberto, Antonio
; APPLICANT: Melvin, Carrie M.
; APPLICANT: Roberts, Luisa M.
; TITLE OF INVENTION: COMBINATION TREATMENT FOR BREAST CANCER
; FILE REFERENCE: PC32226A
; CURRENT APPLICATION NUMBER: US/11/182,343
; CURRENT FILING DATE: 2005-07-15
; PRIOR APPLICATION NUMBER: 60/588,721
; PRIOR FILING DATE: 2004-07-16
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 32
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-182-343-32

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Qy      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 9
US-11-049-536-721
; Sequence 721, Application US/11049536
; Publication No. US20060024297A1
; GENERAL INFORMATION:
; APPLICANT: Wood, Clive R.
; APPLICANT: Dransfield, Daniel T.
; APPLICANT: Pieters, Henk
; APPLICANT: Hoet, Rene
; APPLICANT: Hufton, Simon E.
; TITLE OF INVENTION: TIE COMPLEX BINDING PROTEINS
; FILE REFERENCE: 10280-128001
; CURRENT APPLICATION NUMBER: US/11/049,536
; CURRENT FILING DATE: 2005-02-02
; PRIOR APPLICATION NUMBER: US 10/916,840
; PRIOR FILING DATE: 2004-08-12
; PRIOR APPLICATION NUMBER: US 60/494,713
; PRIOR FILING DATE: 2003-08-12
; NUMBER OF SEQ ID NOS: 721
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 721
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-049-536-721

```

```

Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
RESULT 6
US-11-004-590-23
; Sequence 23, Application US/11004590
; Publication No. US2006000883A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hammond, Phillip W.
; TITLE OF INVENTION: METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING
; FILE REFERENCE: 185832/US/5
; CURRENT APPLICATION NUMBER: US/11/004,590
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: US 60/527,167
; PRIOR FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: US 60/581,613
; PRIOR FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US 60/601,665
; PRIOR FILING DATE: 2004-08-13
; PRIOR APPLICATION NUMBER: US 60/619,483
; PRIOR FILING DATE: 2004-10-14
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-004-590-23

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Qy      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 7
US-11-136-250-33
; Sequence 33, Application US/11136250
; Publication No. US20060021074A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korvet, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ARGENTX.100A2
; CURRENT APPLICATION NUMBER: US/11/136,250
; CURRENT FILING DATE: 2005-05-23
; PRIOR APPLICATION NUMBER: 11/084,554
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: PCT/US2005/009306
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-136-250-33

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Qy      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 8
US-11-182-343-32
; Sequence 32, Application US/11182343
; Publication No. US20060018910A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce
; APPLICANT: Gualberto, Antonio
; APPLICANT: Melvin, Carrie M.
; APPLICANT: Roberts, Luisa M.
; TITLE OF INVENTION: COMBINATION TREATMENT FOR BREAST CANCER
; FILE REFERENCE: PC32226A
; CURRENT APPLICATION NUMBER: US/11/182,343
; CURRENT FILING DATE: 2005-07-15
; PRIOR APPLICATION NUMBER: 60/588,721
; PRIOR FILING DATE: 2004-07-16
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 32
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-182-343-32

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db      1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Qy      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 9
US-11-049-536-721
; Sequence 721, Application US/11049536
; Publication No. US20060024297A1
; GENERAL INFORMATION:
; APPLICANT: Wood, Clive R.
; APPLICANT: Dransfield, Daniel T.
; APPLICANT: Pieters, Henk
; APPLICANT: Hoet, Rene
; APPLICANT: Hufton, Simon E.
; TITLE OF INVENTION: TIE COMPLEX BINDING PROTEINS
; FILE REFERENCE: 10280-128001
; CURRENT APPLICATION NUMBER: US/11/049,536
; CURRENT FILING DATE: 2005-02-02
; PRIOR APPLICATION NUMBER: US 10/916,840
; PRIOR FILING DATE: 2004-08-12
; PRIOR APPLICATION NUMBER: US 60/494,713
; PRIOR FILING DATE: 2003-08-12
; NUMBER OF SEQ ID NOS: 721
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 721
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-049-536-721

```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated peptide
US-11-049-536-721

Query Match      100.0%; Score 506; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||

RESULT 10
US-10-925-366A-1
; Sequence 1, Application US/10925366A
; Publication No. US20050271663A1
; GENERAL INFORMATION:
; APPLICANT: Ignatovich, Olga
; APPLICANT: Dewildt, Rudolph M.T.
; APPLICANT: Benjamin, Woolven
; APPLICANT: Grant, Steven
; APPLICANT: Jones, Philip
; APPLICANT: Baaran, Amrik
; APPLICANT: Brewis, Neil
; TITLE OF INVENTION: Compositions and Methods for Treating Inflammatory Disorders
; FILE REFERENCE: 8039/2105
; CURRENT APPLICATION NUMBER: US/10/925,366A
; CURRENT FILING DATE: 2004-08-24
; PRIOR FILING DATE: US 10/744,774
; PRIOR APPLICATION NUMBER: PCT/GB2003/002804
; PRIOR FILING DATE: 2003-06-30
; PRIOR APPLICATION NUMBER: PCT/GB2002/03014
; PRIOR FILING DATE: 2002-06-28
; PRIOR APPLICATION NUMBER: GB 0230202.4
; PRIOR FILING DATE: 2002-12-27
; PRIOR APPLICATION NUMBER: GB 115841.9
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: PCT/GB2004/002829
; PRIOR FILING DATE: 2004-01-08
; PRIOR APPLICATION NUMBER: US 60/535,076
; PRIOR FILING DATE: 2003-11-28
; PRIOR APPLICATION NUMBER: US 60/509,613
; PRIOR FILING DATE: 2003-10-08
; NUMBER OF SEQ ID NOS: 368
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-925-366A-1

Query Match      100.0%; Score 506; DB 9; Length 116;
Best Local Similarity 100.0%; Pred. No. 1.7e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||

RESULT 11
US-11-102-512-1
; Sequence 1, Application US/11102512
; Publication No. US20060062784A1
; GENERAL INFORMATION:
; APPLICANT: Grant et al., S.
; TITLE OF INVENTION: Compositions monovalent for CD40L binding and methods of use
; FILE REFERENCE: 8039/2132B
; CURRENT APPLICATION NUMBER: US/11/102,512
; CURRENT FILING DATE: 2005-04-08
; PRIOR APPLICATION NUMBER: 60/610,819
; PRIOR FILING DATE: 2004-09-17
; NUMBER OF SEQ ID NOS: 247
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-102-512-1

Query Match      100.0%; Score 506; DB 11; Length 116;
Best Local Similarity 100.0%; Pred. No. 1.7e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||

RESULT 12
US-11-098-758-1
; Sequence 1, Application US/11098758
; Publication No. US20060073141A1
; GENERAL INFORMATION:
; APPLICANT: Ignatovich, Olga
; APPLICANT: Dewildt, Rudolph M.T.
; APPLICANT: Benjamin, Woolven
; APPLICANT: Grant, Steven
; APPLICANT: Jones, Philip
; APPLICANT: Baaran, Amrik
; APPLICANT: Brewis, Neil
; TITLE OF INVENTION: Compositions and Methods for Treating Inflammatory Disorders
; FILE REFERENCE: 8039/2105B
; CURRENT APPLICATION NUMBER: US/11/098,758
; CURRENT FILING DATE: 2005-04-04
; PRIOR APPLICATION NUMBER: 10/925,366
; PRIOR FILING DATE: 2004-10-08
; PRIOR APPLICATION NUMBER: US 10/744,774
; PRIOR FILING DATE: 2003-12-23
; PRIOR APPLICATION NUMBER: PCT/GB2003/002804
; PRIOR FILING DATE: 2003-06-30
; PRIOR APPLICATION NUMBER: PCT/GB2002/03014
; PRIOR FILING DATE: 2002-06-28
; PRIOR APPLICATION NUMBER: GB 0230202.4
; PRIOR FILING DATE: 2002-12-27
; PRIOR APPLICATION NUMBER: GB 115841.9
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: PCT/GB2004/002829
; PRIOR FILING DATE: 2004-06-30
; PRIOR APPLICATION NUMBER: US 60/535,076
; PRIOR FILING DATE: 2004-01-08
; PRIOR APPLICATION NUMBER: PCT/GB2003/005646
; PRIOR FILING DATE: 2003-12-24
; PRIOR APPLICATION NUMBER: GB 0327706.8
; PRIOR FILING DATE: 2003-11-28
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 368
```

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-11-098-758-1

Query Match      100.0%; Score 506; DB 11; Length 116;
Best Local Similarity 100.0%; Pred. No. 1.7e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 13
US-11-166-496-8
; Sequence 8, Application US/11166496
; Publication No. US20060083747A1
; GENERAL INFORMATION:
; APPLICANT: Domantis Limited
; APPLICANT: Winter, Greg
; APPLICANT: Tomlinson, Ian
; APPLICANT: Ignatovich, Olga
; APPLICANT: Brewis, Neil
; TITLE OF INVENTION: FC Fusion
; FILE REFERENCE: 8039/2172
; CURRENT FILING DATE: 2005-06-24
; PRIOR APPLICATION NUMBER: US/11/166,496
; PRIOR FILING DATE: 2005-06-24
; PRIOR APPLICATION NUMBER: PCT/GB03/05597
; PRIOR FILING DATE: 2003-12-24
; PRIOR APPLICATION NUMBER: GB 0230203.2
; PRIOR FILING DATE: 2002-12-27
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: VH dummy
US-11-166-496-8

Query Match      100.0%; Score 506; DB 11; Length 116;
Best Local Similarity 100.0%; Pred. No. 1.7e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 14
US-10-925-366A-235
; Sequence 235, Application US/10925366A
; Publication No. US20050271663A1
; GENERAL INFORMATION:
; APPLICANT: Ignatovich, Olga
; APPLICANT: Dewildt, Rudolph M.T.
; APPLICANT: Benjamin, Woolven
; APPLICANT: Grant, Steven
; APPLICANT: Jones, Philip
; APPLICANT: Baaran, Amrik
; APPLICANT: Brewis, Neil
```

```
; TITLE OF INVENTION: Compositions and Methods for Treating Inflammatory Disorders
; FILE REFERENCE: 8039/2105
; CURRENT APPLICATION NUMBER: US/10/925,366A
; CURRENT FILING DATE: 2004-08-24
; PRIOR APPLICATION NUMBER: US 10/744,774
; PRIOR FILING DATE: 2003-12-23
; PRIOR APPLICATION NUMBER: PCT/GB2003/002804
; PRIOR FILING DATE: 2003-06-30
; PRIOR APPLICATION NUMBER: PCT/GB2002/03014
; PRIOR FILING DATE: 2002-06-28
; PRIOR APPLICATION NUMBER: GB 0230202.4
; PRIOR FILING DATE: 2002-12-27
; PRIOR APPLICATION NUMBER: GB 115841.9
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: PCT/GB2004/002829
; PRIOR FILING DATE: 2004-06-30
; PRIOR APPLICATION NUMBER: US 60/535,076
; PRIOR FILING DATE: 2004-01-08
; PRIOR APPLICATION NUMBER: PCT/GB2003/005646
; PRIOR FILING DATE: 2003-12-24
; PRIOR APPLICATION NUMBER: GB 0327706.8
; PRIOR FILING DATE: 2003-11-28
; PRIOR APPLICATION NUMBER: US 60/509,613
; PRIOR FILING DATE: 2003-10-08
; NUMBER OF SEQ ID NOS: 368
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 235
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Dummy VH for Library
; NAME/KEY: MISC FEATURE
; LOCATION: (103)..(106)
; OTHER INFORMATION: Xaa at position 103-106 is an amino acid encoded by the NNK
US-10-925-366A-235

Query Match      100.0%; Score 506; DB 9; Length 120;
Best Local Similarity 100.0%; Pred. No. 1.7e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 15
US-11-098-758-235
; Sequence 235, Application US/11098758
; Publication No. US20060073141A1
; GENERAL INFORMATION:
; APPLICANT: Ignatovich, Olga
; APPLICANT: Dewildt, Rudolph M.T.
; APPLICANT: Benjamin, Woolven
; APPLICANT: Grant, Steven
; APPLICANT: Jones, Philip
; APPLICANT: Baaran, Amrik
; APPLICANT: Brewis, Neil
; TITLE OF INVENTION: Compositions and Methods for Treating Inflammatory Disorders
; FILE REFERENCE: 8039/2105B
; CURRENT APPLICATION NUMBER: US/11/098,758
; CURRENT FILING DATE: 2005-04-04
; PRIOR APPLICATION NUMBER: 10/925,366
; PRIOR FILING DATE: 2004-10-08
; PRIOR APPLICATION NUMBER: US 10/744,774
; PRIOR FILING DATE: 2003-12-23
; PRIOR APPLICATION NUMBER: PCT/GB2003/002804
```

```

; PRIOR FILING DATE: 2003-06-30
; PRIOR APPLICATION NUMBER: PCT/GB2002/03014
; PRIOR FILING DATE: 2002-06-28
; PRIOR APPLICATION NUMBER: GB 0230202.4
; PRIOR FILING DATE: 2002-12-27
; PRIOR APPLICATION NUMBER: GB 115841.9
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: PCT/GB2004/002829
; PRIOR FILING DATE: 2004-06-30
; PRIOR APPLICATION NUMBER: US 60/535,076
; PRIOR FILING DATE: 2004-01-08
; PRIOR APPLICATION NUMBER: PCT/GB2003/005646
; PRIOR FILING DATE: 2003-12-24
; PRIOR APPLICATION NUMBER: GB 0327706.8
; PRIOR FILING DATE: 2003-11-28
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 368
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 235
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Dummy VH for Library
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (103)..(106)
; OTHER INFORMATION: Xaa at position 103-106 is an amino acid encoded by the NNK
; OTHER INFORMATION: codon, where N is any of G, A, T or C.
US-11-098-758-235

```

```

Query Match      100.0%; Score 506; DB 11; Length 120;
Best Local Similarity 100.0%; Pred. No. 1.7e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLLESGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATISGGGTTY 60
Db      1 EVQLLESGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATISGGGTTY 60

Qy      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

```

Search completed: May 5, 2006, 08:57:44
Job time : 7.32964 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:05 ; Search time 6.24377 Seconds
(without alignments)
1510.185 Million cell updates/sec

Title: US-09-674-752-52
Perfect score: 506
Sequence: 1 EVQLLESGGGLVQPGGSLRL.....LYLQMNSLRAEDTAVYYCAK 98

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_80.*
1: PIR1.*
2: PIR2.*
3: PIR3.*
4: PIR4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	506	100.0	98	2 S26889	Ig heavy chain V r
2	506	100.0	117	2 A45953	Ig heavy chain pre
3	506	100.0	119	2 D36005	Ig heavy chain V r
4	506	100.0	119	2 C36005	Ig heavy chain V r
5	506	100.0	119	2 S31108	Ig heavy chain - h
6	506	100.0	120	2 S48798	Ig heavy chain V r
7	506	100.0	123	2 S31114	Ig heavy chain - h
8	506	100.0	138	2 S31666	Ig heavy chain V r
9	503	99.4	118	2 S31121	Ig heavy chain - h
10	503	99.4	119	2 S31107	Ig heavy chain - h
11	503	99.4	140	2 S31686	Ig heavy chain V r
12	503	99.4	160	2 S05271	Ig heavy chain pre
13	502	99.2	117	1 H3H026	Ig heavy chain pre
14	501	99.0	121	2 S31113	Ig heavy chain - h
15	501	99.0	140	2 S31588	Ig heavy chain V r
16	494	97.6	127	2 S38489	Ig heavy chain - h
17	490	96.8	121	2 S55673	Ig heavy chain - h
18	489	96.6	134	2 S31699	Ig heavy chain V r
19	488	96.4	124	2 S20782	Ig heavy chain V r
20	487	96.2	117	2 A34964	Ig heavy chain pre
21	482	95.3	117	2 B34964	Ig heavy chain pre
22	478	94.5	113	2 S25571	Ig heavy chain V r
23	467	92.3	98	2 S54856	Ig heavy chain V r
24	466	92.1	108	2 PH1648	Ig heavy chain V r
25	466	92.1	109	2 PH1649	Ig heavy chain V r
26	466	92.1	112	2 PH1647	Ig heavy chain V r
27	463	91.5	120	2 E49590	Ig heavy chain V r
28	462	91.3	140	2 A30532	Ig heavy chain pre
29	458	90.5	98	2 S26891	Ig heavy chain V r

ALIGNMENTS

RESULT 1

S26889
Ig heavy chain V region (DP-47) - human
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26889
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V regions
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26889
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-98 <TOM>
A;Cross-references: UNIPARC:UPI0000031F42; EMBL:Z12347; NID:g32914; PIDN:CAA78217.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 506; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVVRQAPGKLEWVAISGSGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVVRQAPGKLEWVAISGSGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98

RESULT 2

A45953
Ig heavy chain precursor V-III region (VH26) - human
C;Species: Homo sapiens (man)
C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 07-May-1999
C;Accession: A45953
R;Chen, P.P.; Liu, M.F.; Sinha, S.; Carson, D.A.
Arthritis Rheum. 31, 1429-1431, 1988
A;Title: A 16/6 idiotype-positive anti-DNA antibody is encoded by a conserved V-H gene w
A;Reference number: A45953; MUID:89050363; PMID:3263866
A;Accession: A45953
A;Status: preliminary; not compared with conceptual translation
A;Molecule type: DNA
A;Residues: 1-117 <CHE>
A;Cross-references: UNIPARC:UPI0000113BD6
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 506; DB 2; Length 117;

Best Local Similarity 100.0%; Pred. No. 5.8e-40; Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||
Db 20 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 79
|||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDATVYYCAK 98
|||||
Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRAREDATVYYCAK 117
|||||

RESULT 3

D36005

Ig heavy chain V region (M43) - human

C;Species: Homo sapiens (man)

C;Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998

C;Accession: D36005

R;Schroeder Jr., H.W.; Wang, J.Y.

Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990

A;Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene

A;Reference number: A36005; MUID:90349571; PMID:2117273

A;Accession: D36005

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-119 <SCH>

A;Cross-references: UNIPARC:UPI0000176C2A; GB:M34024

C;Genetics:

A;Gene: IGH@; IGHDI1

A;Cross-references: GDB:118731; OMIM:146910

A;Map position: 14q32.33-14q32.33

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotrimer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 506; DB 2; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDATVYYCAK 98
|||||

Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDATVYYCAK 98
|||||

RESULT 4

C36005

Ig heavy chain V region (30p1) - human

C;Species: Homo sapiens (man)

C;Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Aug-1996

C;Accession: C36005

R;Schroeder Jr., H.W.; Wang, J.Y.

Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990

A;Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene

A;Reference number: A36005; MUID:90349571; PMID:2117273

A;Accession: C36005

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-119 <SCH>

A;Cross-references: UNIPARC:UPI0000176C27; GB:M18513

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotrimer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 506; DB 2; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||

Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDATVYYCAK 98
|||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDATVYYCAK 98
|||||

RESULT 5

S31108

Ig heavy chain - human

C;Species: Homo sapiens (man)

C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999

C;Accession: S31108

R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman, Eur. J. Immunol. 22, 247-251, 1992

A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple

A;Reference number: S31104; MUID:92111633; PMID:1730252

A;Accession: S31108

A;Status: preliminary; nucleic acid sequence not shown; translation not shown

A;Molecule type: mRNA

A;Residues: 1-119 <RAA>

A;Cross-references: UNIPARC:UPI0000176DC8; EMBL:X62956

A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotrimer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 506; DB 2; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDATVYYCAK 98
|||||

Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDATVYYCAK 98
|||||

RESULT 6

S48798

Ig heavy chain V region (anti-Sm, VH3/DXP4/JH4b) - human

C;Species: Homo sapiens (man)

C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999

C;Accession: S48798

R;Mahmoudi, M.; Edwards, J.; Cairns, E.; Bell, D.

submitted to the EMBL Data Library, October 1994

A;Description: Molecular characterization of natural human anti-Sm autoantibodies.

A;Reference number: S48797

A;Accession: S48798

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-120 <NAH>

A;Cross-references: UNIPARC:UPI0000116701; EMBL:Z46382; NID:G562324; PIDN:CAA86521.1; PII

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotrimer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 506; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 6e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDATVYYCAK 98
|||||

Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDATVYYCAK 98
|||||

RESULT 7

```
S31114
Ig heavy chain - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C;Accession: S31114
E;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31114
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-123 <R>AA>
A;Cross-references: UNIPARC:UPI0000176C8A; EMBL:X62963
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match          100.0%; Score 506; DB 2; Length 123;
Best Local Similarity 100.0%; Pred. No. 6.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 8
S31666
Ig heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31666
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31666
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-138 <CUI>
A;Cross-references: UNIPARC:UPI0000116474; EMBL:Z14202; NID:g30963; PIDN:CAA78571.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match          100.0%; Score 506; DB 2; Length 138;
Best Local Similarity 100.0%; Pred. No. 6.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 20 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 79

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 117

RESULT 9
S31121
Ig heavy chain - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C;Accession: S31121
R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
```

```
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31121
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-118 <R>AA>
A;Cross-references: UNIPARC:UPI0000176E3B; EMBL:X62971
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>
```

```
Query Match          99.4%; Score 503; DB 2; Length 118;
Best Local Similarity 99.0%; Pred. No. 1.1e-39;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
```

```
RESULT 10
S31107
Ig heavy chain - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C;Accession: S31107
R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31107
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-119 <R>AA>
A;Cross-references: UNIPARC:UPI0000176DC7; EMBL:X62955
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>
```

```
Query Match          99.4%; Score 503; DB 2; Length 119;
Best Local Similarity 99.0%; Pred. No. 1.1e-39;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
```

```
RESULT 11
S31686
Ig heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31686
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31686
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-140 <CUI>
A;Cross-references: UNIPARC:UPI0000116477; EMBL:Z14205; NID:g30969; PIDN:CAA78574.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
```

C;Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 99.4%; Score 503; DB 2; Length 140;
Best Local Similarity 99.0%; Pred. No. 1.3e-39;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||
DB 20 EVOLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 79
|||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
:|||||
DB 80 SDSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 117
:|||||

RESULT 12
S05271
IG heavy chain precursor - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 31-Dec-2004
C;Accession: S05271; S04602
R;Kishimoto, T.
submitted to the EMBL Data Library, March 1989
A;Reference number: S05270
A;Accession: S05271
A;Molecule type: mRNA
A;Residues: 1-160 <KIS1>
A;Cross-references: UNIPROT:Q96BB9; UNIPARC:UPI0000176B50; EMBL:X14584
R;Kishimoto, T.; Okajima, H.; Okumoto, T.; Taniguchi, M.
Nucleic Acids Res. 17, 4385, 1989
A;Title: Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of
A;Reference number: S04601; MUID:89296497; PMID:2500644
A;Accession: S04602
A;Molecule type: mRNA
A;Residues: 1-144 <KIS2>
A;Cross-references: UNIPARC:UPI0000176B51; EMBL:X14584
C;Superfamily: immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-19/Domain: signal sequence #status predicted <SIG>
F;20-160/Product: IG heavy chain (fragment) #status predicted <MAT>
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 99.4%; Score 503; DB 2; Length 160;
Best Local Similarity 99.0%; Pred. No. 1.5e-39;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||
DB 20 EVOLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 79
|||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
|||||
DB 80 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 117
|||||

RESULT 13
H3HU26
IG heavy chain precursor V-III region (VH26) - human
C;Species: Homo sapiens (man)
C;Date: 31-Mar-1981 #sequence_revision 31-Mar-1981 #text_change 09-Jul-2004
C;Accession: A02047; S34011
R;Matthysens, G.; Rabbitts, T.H.
Proc. Natl. Acad. Sci. U.S.A. 77, 6561-6565, 1980
A;Title: Structure and multiplicity of genes for the human immunoglobulin heavy chain va
A;Reference number: A02047; MUID:81101090; PMID:6450418
A;Accession: A02047
A;Molecule type: DNA
A;Residues: 1-117 <RF1>
A;Cross-references: UNIPROT:P01764; UNIPARC:UPI000012CEF4
A;Note: the sequence was determined from the germline gene
R;Marette, X.; Tsapis, A.; Brouet, J.C.
Eur. J. Immunol. 23, 846-851, 1993

A;Title: Nucleotide sequence analysis of the variable domains of four human monoclonal
A;Reference number: S34001; MUID:93209281; PMID:7681398
A;Accession: S34011
A;Molecule type: mRNA
A;Residues: 20-117 <MAR>
A;Cross-references: UNIPARC:UPI000017372F
C;Genetics:
A;Gene: GDB:IGHV@
A;Cross-references: GDB:128528; OMIM:147070
A;Map position: 14q32.33-14q32.33
A;Introns: 16/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-19/Domain: signal sequence #status predicted <SIG>
F;20-117/Product: IG heavy chain V-III region (VH26) #status predicted <MAT>
F;34-117/Domain: immunoglobulin homology <IMM>
F;41-115/Diulfide bonds: #status predicted

Query Match 99.2%; Score 502; DB 1; Length 117;
Best Local Similarity 99.0%; Pred. No. 1.4e-39;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVOLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||
DB 20 EVOLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 79
|||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
|||||
DB 80 GDSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 117
|||||

RESULT 14
S31113
IG heavy chain - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C;Accession: S31113
R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman,
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31113
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-121 <RAA>
A;Cross-references: UNIPARC:UPI0000176C89; EMBL:X62962
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 99.0%; Score 501; DB 2; Length 121;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||
DB 1 EVOLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
|||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCA 97
|||||
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCA 97
|||||

RESULT 15
S31588
IG heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31588
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the

A;Reference number: S31585
A;Accession: S31588
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-140 <CUI>
A;Cross-references: UNIPARC:UPI0000116472; EMBL:Z14200; NID:G30957; PIDN:CAA78569.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 99.0%; Score 501; DB 2; Length 140;
Best Local Similarity 99.0%; Pred. No. 2e-39;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
|||
Db 20 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 79
|||

Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
|||
Db 80 ADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCAK 117
|||

Search completed: May 5, 2006, 08:51:34
Job time : 6.24377 secs

THIS PAGE BLANK (USP10)

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 02:23:11 ; Search time 70.5 Seconds
(without alignments)
610.768 Million cell updates/sec

Title: US-09-674-752-52

Perfect score: 506

Sequence: 1 EVQLLESGGGLVPGGSLRL.....LYIQMNSLRAEDTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 81

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Listing first 500 summaries

Database :

A_Geneseq_21.*

1: Geneseqp1980s.*

2: Geneseqp1990s.*

3: Geneseqp2000s.*

4: Geneseqp2001s.*

5: Geneseqp2002s.*

6: Geneseqp2003as.*

7: Geneseqp2003bs.*

8: Geneseqp2004s.*

9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	506	100.0	98	3	AAY50972 Human FVI
2	506	100.0	98	3	AAB40093 Anti-hIL1
3	506	100.0	98	4	AAE12710 Antibody
4	506	100.0	98	5	ABG78202 Human Fv
5	506	100.0	98	5	ABG76930 Humanised
6	506	100.0	98	5	ABG77150 Germaline
7	506	100.0	98	5	ABG91893 Human ant
8	506	100.0	98	6	ABU58802 Mucin 1 (
9	506	100.0	98	6	ABP58503 Human ant
10	506	100.0	98	6	ABJ18690 Antibody
11	506	100.0	98	6	ABO27089 Human ger
12	506	100.0	98	7	ADD28053 Lymphoma
13	506	100.0	98	7	ADF10128 Antibody
14	506	100.0	98	7	ADF10026 VEGF anti
15	506	100.0	98	7	ADF09918 Antibody
16	506	100.0	98	7	ADJ80302 VH gene 1
17	506	100.0	98	7	ADM41877 Human ant
18	506	100.0	98	8	ADO25804 Anti-TNF-
19	506	100.0	98	8	ADO25802 Anti-TNF-
20	506	100.0	98	8	ADR28566 Human ant
21	506	100.0	98	8	ADR88414 Human pro
22	506	100.0	98	8	ADU17936 Humanised
23	506	100.0	98	9	ADY54702 Human VH
24	506	100.0	98	9	ADY75307 Protein e

RESULT 1

AAY50972

ID AAY50972 standard; protein; 98 AA.

XX

AC AAY50972;

XX

DT 23-MAR-2000 (first entry)

XX

DE Human FVIII antibody A2 scFv heavy chain protein DP-47 #1.

XX

KW Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

ALIGNMENTS

Ady93870 Anti-SARS
Adc60990 Human ant
Adp22373 Human ant
Adg09392 Human c-M
Adel2518 Human Vh3
Adw96622 Human ger
Adw80194 Human ant
Abg69320 Antibody
Abp95999 HSA antib
Abp95999 HSA antib
Adl92382 Anti-HSA
Adq14599 Single-do
Adq77187 Dummy VH
Adq77171 VH dummy
Adq90914 VH chain
Adg78329 DP47-JH4b
Adt88238 Human ant
Adu86514 Immunoglo
Adz41141 Dummy VH
Aar66315 Human imm
Adl92384 Anti-HSA
Adq77189 Dummy VH
Adz41143 Dummy VH
Aea41074 Germline
Adp56507 Human ant
Abp56504 Human ant
Abp56506 Human ant
Adp22356 Human ant
Adr55827 Heavy cha
Adp46964 Murine he
Adel12493 Human IGF
Aae07014 Human hea
Adq89299 Human imm
Adg89301 Human imm
Abo09574 Human hea
Adi45736 Single st
Abj36939 Synthetic
Aay02472 A single
Abp95997 Human ser
Adl92369 Human pha
Adq77165 HSA Heavy
Aea62548 Her-2/neu
Aea62549 Her-2/neu
Adi58088 Reg IV-sp
Adi58093 Reg IV-sp
Adg09246 Human c-M
Adi58052 Reg IV-sp
Ado58062 S2 cell d
Adel12378 Human IGF
Ado25153 Melanoma
Aau14320 Human nov
Abp55467 MALI3 pr
Abg77158 Germline
Adr28580 Human ant
Adu02382 Novel hum

KW scFv; A2.
 XX Homo sapiens.
 OS WO9558680-A2.
 PN
 XX
 XX 18-NOV-1999.
 PD
 XX 07-MAY-1999; 99WO-NI000285.
 PF
 XX 08-MAY-1998; 98EP-00201543.
 PR
 XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
 PA
 XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 PI WPI; 2000-053102/04.
 XX
 XX New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 PS
 XX Example 9; Fig 11A; 61pp; English.
 XX
 CC This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has
 CC hemostatic activity. (I) is useful a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents a human factor VIII
 CC antibody A2 specific scFv protein DP-47 which is used in the method of
 CC the invention
 XX
 SQ Sequence 98 AA;
 Query Match 100.0%; Score 506; DB 3; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
 DB 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQMSLRRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQMSLRRAEDTAVYYCAK 98
 RESULT 2
 AAB40093
 ID AAB40093 standard; protein; 98 AA.
 AC AAB40093;
 XX
 XX 05-FEB-2001 (first entry)
 DT
 XX Anti-hIL12 antibody H chain V region amino acid sequence SEQ ID 619.
 DE
 XX Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
 KW complementarity determining region; CDR; antirheumatic; antiarthritic;
 KW antisclerotic; neuroprotective; antipsoriatic; antidiabetic; cardiac;
 KW antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
 KW multiple sclerosis; rheumatoid arthritis.
 XX
 XX Homo sapiens.
 OS
 XX WO200056772-A1.
 PN
 XX 28-SEP-2000.
 PD
 XX 24-MAR-2000; 2000WO-US007946.

XX 25-MAR-1999; 99US-0126603P.
 PR (BADI) BASF AG.
 XX (GEMY) GENETICS INST INC.
 PA
 XX
 XX Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DE, White M;
 PI Kaymakalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;
 PI Veidman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
 PI Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL;
 XX WPI; 2000-638250/61.
 DR
 XX New human antibody specific for human interleukin-12 (IL-12) used to
 PT treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
 PT disease and multiple sclerosis.
 PT
 XX Claim 75; Page 121; 377pp; English.
 PS
 XX This invention relates to a new human antibody specific for human
 CC interleukin-12 (IL-12). The invention also includes antigen binding
 CC portions that bind to IL-12. Sequences AAB39485-B39516 represent human
 CC anti-IL-12 antibody heavy and light chain complementarity determining
 CC region (CDR) amino acid sequences, and also includes variable region
 CC amino acid sequences. Other variable region amino acid sequences are
 CC given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
 CC represent other CDR sequences. Light chain CDR3 consensus sequences are
 CC given in AAB40064-B40067. Primers used in the identification and
 CC construction of the antibodies of the invention are given in AAC61062-
 CC C61071. The antibody of the invention is a neutralising antibody and has
 CC antirheumatic; antiarthritic; antisclerotic; antidiabetic; antiparasitic;
 CC neuroprotective; antipsoriatic; antidiabetic; cardiac; antiparasitic;
 CC antibacterial and immunosuppressive activity. The antibodies or antigen-
 CC binding fragments are useful in the treatment of disorders associated
 CC with detrimental release of human IL-12, especially Crohn's disease,
 CC multiple sclerosis and rheumatoid arthritis. They can also be used in the
 CC manufacture of a pharmaceutical composition to treat human IL-12
 CC disorders
 XX
 SQ Sequence 98 AA;
 Query Match 100.0%; Score 506; DB 3; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
 DB 1 EVOLLEGGGLVOPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQMSLRRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQMSLRRAEDTAVYYCAK 98
 RESULT 3
 AAE12710
 ID AAE12710 standard; peptide; 98 AA.
 XX
 XX AAE12710;
 AC
 XX 04-JAN-2002 (first entry)
 DT
 XX Antibody variable heavy chain region (VH) from DP47 germ line.
 DE
 XX Tumour-associated antigen mucin-1; MUC-1; adenocarcinoma; VH;
 KW variable heavy chain region; cancer; breast; ovary; lung; bladder;
 KW cyostatic; therapy.
 XX
 XX Unidentified.
 OS
 XX WO200175110-A2.
 PN

PD 11-OCT-2001.
 XX 30-MAR-2001; 2001WO-US010589.
 PF 30-MAR-2000; 2000US-00538913.
 XX (DYAX-) DYAX CORP.
 XX Hoogenboom HRJM, Henderikx MPG;
 XX WPI; 2001-626437/72.
 XX Novel isolated tumor-associated antigen mucin-1-specific binding member
 PT for diagnosing and treating cancer, comprises mucin-1 binding domain or
 PT its portion for binding to an epitope of the protein core of mucin-1.
 XX Example 1; Page 35; 126pp; English.
 PS
 CC The invention relates to an isolated tumour-associated antigen mucin-1
 CC (MUC-1)-specific binding member comprising an antigen binding domain
 CC region having an antibody variable light (VL) or heavy (VH) region, or a
 CC complementarity determining region (CDR) of VL or VH. MUC1-specific
 CC binding member is useful for diagnosing cancer, preferably adenocarcinoma
 CC The binding of MUC1-specific binding member to MUC1 is detected by a
 CC detection method selected from enzyme-linked immunosorbent assay,
 CC magnetic resonance imaging, scintillation counting, and X-ray film. MUC1-
 CC specific binding member is useful for treating cancer, preferably
 CC adenocarcinoma, in an individual, where the cancer is present in tissue
 CC of the breast, ovary, lung, or bladder of the individual. MUC1-specific
 CC binding member is useful for diagnosing and imaging MUC1-expressing
 CC cancer cells and tissues, for purifying or isolating non-glycosylated,
 CC underglycosylated or cancer-associated forms of MUC1 or MUC1 epitope-
 CC containing molecules, and for therapeutically or prophylactically
 CC treating cancer. The present sequence is antibody variable heavy chain
 CC region (VH) from DP47 germ line
 XX
 SQ Sequence 98 AA;
 Query Match 100.0%; Score 506; DB 4; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATISGSGSTYY 60
 DB 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATISGSGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 RESULT 4
 ABG78202
 ID ABG78202 standard; protein; 98 AA.
 XX
 AC ABG78202;
 XX
 DT 15-NOV-2002 (first entry)
 XX Human Fv molecule hypervariable region related peptide #77.
 DE
 DE Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
 KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
 KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.
 XX
 OS Homo sapiens.
 XX
 PN WO200259264-A2.
 XX
 PD 01-AUG-2002.
 XX
 PF 31-DEC-2001; 2001WO-US049440.
 XX

PR 29-DEC-2000; 2000US-00751181.
 XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
 PA
 XX Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;
 PI Plaksin D, Peretz T;
 XX WPI; 2002-619166/66.
 DR
 XX Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
 PT or fragment, or construct of fragment with enhanced binding
 PT characteristics so as to selectively bind target cell in favor of other
 PT cells.
 XX
 PS Claim 13; Page 187; 232pp; English.
 XX
 CC The invention relates to a peptide or polypeptide comprising an Fv
 CC molecule, a construct or fragments or a construct of a fragment with
 CC enhanced binding characteristics which selectively and/or specifically
 CC binds to a target cell in favour of other cells, where binding is
 CC primarily determined by a first hypervariable region and Fv is a single
 CC chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
 CC association with or attached, coupled, combined, linked or fused to a
 CC pharmaceutical agent, is useful in the manufacture of a medicament, where
 CC the medicament has activity against a diseased cell, preferably a cancer
 CC cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
 CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
 CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
 CC composition for use in inhibiting the growth of a diseased or cancer
 CC cell. This sequence represents a human Fv molecule hypervariable region
 CC related peptide of the invention
 XX
 SQ Sequence 98 AA;
 Query Match 100.0%; Score 506; DB 5; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATISGSGSTYY 60
 DB 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATISGSGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 RESULT 5
 ABG76930
 ID ABG76930 standard; protein; 98 AA.
 XX
 AC ABG76930;
 XX
 DT 05-NOV-2002 (first entry)
 XX Humanised antibody associated protein #4.
 DE
 DE Humanized; immunoglobulin; Ig; light chain; LC; heavy chain; HC;
 KW variable region complementarity determining region; 3D6; 10D5;
 KW variable framework region; amyloidogenic disease; Alzheimer's disease;
 KW amyloid deposit; variable light chain; VL; variable heavy chain; VH;
 KW neurotropic; neuroprotective; inhibitor of beta amyloid accumulation;
 KW Abeta; antibody.
 XX
 OS Homo sapiens.
 XX
 PN WO200246237-A2.
 XX
 PD 13-JUN-2002.
 XX
 PF 06-DEC-2001; 2001WO-US046587.
 XX
 PF 06-DEC-2000; 2000US-0251892P.
 XX

PI Szanthon E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
 XX WPI; 2002-674776/72.
 XX
 XX Novel isolated epitope present on cancer cells and important in
 PT physiological phenomena such as cell rolling, metastasis and
 PT inflammation, for treating autoimmune, inflammatory or cardiovascular
 PT diseases, and cancer.
 XX
 XX Disclosure; Page 263-264; Opp; English.
 XX
 XX The invention relates to an isolated epitope present on cancer cells and
 CC important in physiological phenomena such as cell rolling, metastasis and
 CC inflammation, where the epitope is capable of being bound by an antibody,
 CC its antigen-binding fragment or its complex comprising at least one
 CC antibody or its binding fragment having a first hypervariable region. The
 CC epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
 CC disease, thrombosis, restenosis, metastasis, growth and/or replication of
 CC tumour or leukaemia cells, increase in number of tumour or leukaemia
 CC cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
 CC platelet and/or cell-platelet adhesion or aggregation, for increasing
 CC mortality of tumour or leukaemia cells, for increasing the susceptibility
 CC of diseased cells to damage by anti-disease, anti-cancer or anti-
 CC leukaemia agents, or for decreasing the number of tumour or leukaemia
 CC cells in a patient, or in the manufacture of a medicament for the above
 CC mentioned purposes. The epitopes are useful for diagnosing and treating
 CC diseases such as cancer, leukaemia, autoimmune diseases, inflammatory
 CC diseases, cardiovascular diseases such as myocardial infarction,
 CC reinnopathic diseases and other diseases mediated by abnormal platelet
 CC function and diseases caused by sulphated tyrosine-dependent protein-
 CC protein interactions. This sequence represents a human antibody fragment
 CC of the invention
 XX
 XX SQ Sequence 98 AA;
 XX
 XX Query Match 100.0%; Score 506; DB 5; Length 98;
 XX Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 RESULT 8
 ID ABUS8802 standard; protein; 98 AA.
 XX
 XX AC ABUS8802;
 XX
 XX 15-APR-2003 (first entry)
 XX
 XX Mucin 1 (MUC-1) binding antibody light chain variable region #2.
 XX
 XX Mucin-1-specific binding member; human; cancer; adenocarcinoma;
 KW breast cancer; ovarian cancer; bladder cancer; lung cancer;
 KW anti-cancer regimen; anti-cancer drug; radiation treatment.
 XX
 XX Homo sapiens.
 OS
 XX US2002146750-A1.
 PN
 XX 10-OCT-2002.
 PD
 XX 30-MAR-2001; 2001US-00822698.
 PF
 XX 30-MAR-2000; 2000US-00538913.
 PR
 XX (HOOG/) HOOGENBOOM H R J M.
 PA

PA (HEND/) HENDERIKX M P G.
 XX
 XX Hoogenboom HRJM, Henderikx MPG;
 XX
 XX WPI; 2003-198057/19.
 XX
 XX Isolated mucin-1-specific binding member for diagnosing and/or treating
 PT cancer, e.g. breast cancer, comprises antigen binding domain having
 PT region that contains specific amino acid sequence.
 XX
 XX Disclosure; Page 16; 70pp; English.
 XX
 XX The invention describes an isolated mucin-1-specific binding member
 CC having an antigen binding domain including a region that comprises a
 CC specific amino acid sequence. The inventive MUC1-specific binding member
 CC is used in the diagnosis and/or treatment of cancer, e.g. adenocarcinoma,
 CC found in various tissues, e.g. breast, ovary, bladder, and lung. It can
 CC be used alone or as a component in a more complex anti-cancer regimen
 CC which may contain anti-cancer drug(s) and/or radiation treatment (e). The
 CC inventive binding member recognizes tumour-associated MUC1 on
 CC adenocarcinoma. Its affinity is high enough to bind to tumour cells. This
 CC is the amino acid sequence of a mucin 1 (MUC-1) specific antibody region
 CC used to isolate MUC-1 antigen binding domains for use in the treatment of
 CC cancer
 XX
 XX SQ Sequence 98 AA;
 XX
 XX Query Match 100.0%; Score 506; DB 6; Length 98;
 XX Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 RESULT 9
 ID ABP56503 standard; protein; 98 AA.
 XX
 XX AC ABP56503;
 XX
 XX 20-MAR-2003 (first entry)
 XX
 XX Human anti-Fc-epsilon-R1 alpha autoantibody heavy chain DP-47.
 XX
 XX Autoantibody; Fc-epsilon-R1 receptor alpha-chain; immunosuppressive;
 KW allergic disease; urticaria; late phase allergic reaction; malignancy;
 KW intrinsic asthma; drug intolerance; food intolerance; immunoglobulin E;
 KW conditional autoimmunity; IGE mediated disease.
 XX
 XX Homo sapiens.
 OS
 XX Synthetic.
 XX
 XX WO2002028085-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-EP003660.
 PF
 XX 04-APR-2001; 2001US-0281024P.
 PR
 XX (ZLBB-) ZLB BIOPLASMA AG.
 PA
 XX Miescher S;
 PI
 XX WPI; 2003-103348/09.
 XX
 XX Identifying and obtaining inhibitor of a pathological process for
 PT

PT treating e.g. autoimmunity comprises determining if a compound is capable
PT of modulating the binding of the Fc-epsilon-R1 receptor and an
PT autoantibody against its alpha-chain.
XX
XX
XX Claim 20; Page 22; 29pp; English.
XX
XX The present invention describes a method for identifying and obtaining an
XX inhibitor of a pathological process. The method comprises determining if
XX a compound is capable of modulating the binding of the Fc-epsilon-R1
XX receptor alpha-chain and an autoantibody against its alpha-chain. Also
XX described: (1) use of the autoantibody against the Fc-epsilon-R1 receptor
XX alpha-chain for identifying and obtaining an inhibitor of a pathological
XX process; (2) use of the identified inhibitor for inhibiting activity of
XX the autoantibody against the Fc-epsilon-R1 receptor alpha-chain; and (3)
XX a compound identified by the method, which binds but does not activate
XX the receptor; and (4) a polypeptide capable of specific binding to the Fc
XX -epsilon-R1 receptor alpha-chain. The method is useful for obtaining an
XX inhibitor of a pathological process e.g. imbalance between cell-bound and
XX free IgE e.g. allergic disease (urticaria, late phase allergic reactions,
XX intrinsic asthma, drug intolerance and food intolerance), IgE mediated
XX disease or malignancy. The compound is useful for treating a pathological
XX process, particularly conditional autoimmunity. The present sequence
XX represents a human recombinant anti-Fc-epsilon-R1 alpha autoantibody
XX heavy chain protein sequence from the present invention
XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 506; DB 6; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVOLLESGGLVPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWWSAISGGSTYY 60
DB 1 EVOLLESGGLVPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWWSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 10
ABJ18690
ID ABJ18690 standard; protein; 98 AA.
AC
XX
XX ABJ18690;
XX
XX 06-MAR-2003 (first entry)
XX
XX Antibody library related human protein sequence SEQ ID No 19.
XX
XX Library; recombinant antibody; clustering variable region; in silico;
XX immunogenecity; antibody therapeutic; human.
XX
XX Homo sapiens.
XX
XX WO200284277-A1.
XX
XX 24-OCT-2002.
XX
XX 17-APR-2002; 2002WO-US012202.
XX
XX 17-APR-2001; 2001US-0284407P.
XX
XX (ABMA-) ABMAXIS INC.
XX
XX Luo P;
XX
XX WPI; 2003-093043/08.
XX
XX Constructing a library of recombinant antibodies useful as source of
XX antibody candidates for screening antigens comprises clustering variable
XX regions of antibodies having known 3-dimensional structures into
XX structural ensembles.

XX
PS Disclosure; Page 111; 119pp; English.
XX
XX The invention relates to a novel method for the construction of a library
XX of recombinant antibodies. The novel method comprises clustering variable
XX regions of a collection of antibodies having known 3D structures into at
XX least two families of structural ensembles, each comprising at least two
XX different antibody sequences but with substantially identical main chain
XX conformations. The method is useful for constructing a library of
XX artificial antibodies in silico which provides a structurally diverse and
XX yet functionally more relevant source of antibody candidates which can
XX then be screened for binding a wide variety of target molecules,
XX including small molecules, and biomacromolecules such as proteins,
XX peptides and nucleic acids. The libraries constructed are useful as a
XX source of antibody candidates for further screening for novel antibodies
XX with high affinity against a wide range of antigens and having no or
XX minimum immunogenicity to human subjects treated with antibody
XX therapeutics. This sequence represents a human peptide region of an
XX antibody relating to the novel antibody library construction method of
XX the invention
XX

SQ Sequence 98 AA;
Query Match 100.0%; Score 506; DB 6; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVOLLESGGLVPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWWSAISGGSTYY 60
DB 1 EVOLLESGGLVPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWWSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 11
ABO27089
ID ABO27089 standard; protein; 98 AA.
XX
XX ABO27089;
XX
XX 10-SEP-2003 (first entry)
XX
XX Human germline heavy chain variable region gene segment #22.
XX
XX Human; heavy chain variable region; VH; humanised antibody;
XX chimeric antibody; complementarity determining region; CDR;
XX canonical CDR structure type.
XX
XX Homo sapiens.
XX
XX US2003039649-A1.
XX
XX 27-FEB-2003.
XX
XX 12-JUL-2002; 2002US-00194975.
XX
XX 12-JUL-2001; 2001US-0305111P.
XX
XX (FOOTE/) FOOTE J.
XX
XX Foote J;
XX
XX WPI; 2003-492151/46.
XX
XX Making humanized antibody for converting antibody, by making chimeric
XX antibodies containing complementarity determining region from non-human
XX antibody and appropriate framework sequences of human antibodies.
XX
XX Example 1; Fig 1; 31pp; English.
XX
XX The invention describes a method of making a humanised antibody,
XX

CC comprising making chimeric antibodies containing a complementarity
CC determining region (CDR) from a non-human antibody and appropriate
CC framework sequences (I) of human antibodies. (I) is selected by using
CC canonical CDR structure types of non-human antibody in comparison to
CC germline canonical CDR structure types of human antibodies as the basis
CC for selection, for humanisation. The method is useful for making a
CC humanised antibody or a converted antibody. The method is applicable for
CC converting a subject antibody sequence of any subject species to a less
CC immunogenic form suitable for use in an object species. The method is
CC reliable for identifying suitable human framework sequences to support
CC non-human CDR regions and to provide humanised antibodies that retain
CC high antigen binding with low immunogenicity in humans, without the need
CC for direct comparison of framework sequences, without the need for
CC determining critically important amino acid residues in the framework,
CC and without the need for multiple iteration and construction to obtain
CC humanised antibodies with suitable therapeutic properties. The antibody
CC has high affinity and low immunogenicity without need for comparing
CC framework sequences between non-human and human antibodies. This sequence
CC represents a human heavy chain variable region gene segment used in the
CC creation of humanised antibodies
XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 506; DB 6; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGGSTYY 60
DB 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGGSTYY 60
QY 61 ADSVKGRTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
DB 61 ADSVKGRTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 12
ADD28053
ID ADD28053 standard; protein; 98 AA.
AC ADD28053;
XX
XX
DT 15-JAN-2004 (first entry)
DE Lymphoma related immunoglobulin variable region V3-23.
DE
DE B-cell; malignant; immunoglobulin; immunoglobulin variable region;
KW Ig variable region; glycosylation site; lymphoma; B cell receptor;
KW cytosolic; gene therapy; glycosylation inhibitor;
KW non-Hodgkin's lymphoma.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO2003074059-A2.
XX
XX 12-SEP-2003.
XX
XX 24-FEB-2003; 2003WO-GB000783.
XX
XX 07-MAR-2002; 2002GB-00005395.
XX
XX (CANC-) CANCER RES TECHNOLOGY LTD.
XX
XX Zhu D, Stevenson F;
XX WPI; 2003-902720/82.
XX
XX Classifying a B-cell as malignant or normal by isolating a sequence
PT representing an Ig variable region from the B cell, detecting the
PT presence of a glycosylation site and classifying the cell as malignant or
PT normal.
XX

PS Disclosure; Fig 3; 61pp; English.
XX
XX The present invention describes a method for classifying a B-cell as
CC malignant or normal comprising: (a) isolating a sequence representing an
CC immunoglobulin (Ig) variable region from the B cell; (b) detecting the
CC presence of a glycosylation site; and (c) classifying the cell as
CC malignant or normal on the basis of the presence or absence of a
CC glycosylation site. Also described: (1) treating a patient suffering from
CC or at risk of having lymphoma; (2) screening for substances capable of
CC inhibiting glycosylation of the Ig variable region of the B cell receptor
CC ; and (3) screening for substances (S) capable of inhibiting the
CC interaction between lectins of the type found in the germinal centre and
CC N-glycans found on the surface of Ig of lymphoma cells. (S) has
CC cytosolic activity, and can be used in gene therapy, and as a
CC glycosylation inhibitor. The method is useful in classifying a B-cell as
CC malignant or normal. The glycosylation inhibitor is useful in preparing a
CC medicament for treating non-Hodgkin's lymphoma. The present sequence
CC represents an Ig variable region sequence which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 506; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGGSTYY 60
DB 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGGSTYY 60
QY 61 ADSVKGRTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
DB 61 ADSVKGRTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 13
ADF10128
ID ADF10128 standard; protein; 98 AA.
AC ADF10128;
XX
XX
DT 12-FEB-2004 (first entry)
DE Antibody heavy chain variable region VH_3-23.
DE
DE Antibody; stability; solubility; antigen binding affinity;
KW variable region; human.
XX
OS Homo sapiens.
XX
XX WO2003074679-A2.
XX
XX 12-SEP-2003.
XX
XX 03-MAR-2003; 2003WO-US006598.
XX
XX 01-MAR-2002; 2002US-0360843P.
XX 29-MAY-2002; 2002US-0384197P.
XX
XX (XENC-) XENCOR.
XX
XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
XX WPI; 2003-722066/68.
XX
XX Computer optimization of physicochemical properties of antibodies
PT comprises analyzing the interactions of amino acids at variable
PT positions.
XX
XX Example 16; Fig 40a; 135pp; English.
XX
XX The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC

CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.

XX Sequence 98 AA;
 SQ

Query Match 100.0%; Score 506; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVOPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
 DB 1 EVOLLESGGLVOPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 14
 ADF10026
 ID ADF10026 standard; protein; 98 AA.
 XX
 AC ADF10026;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE VEGF antibody heavy chain variable region VH_3-23.
 XX
 KW Antibody; stability; solubility; antigen binding affinity;
 KW variable region; human; VEGF.
 XX
 OS Homo sapiens.
 XX
 PN W02003074679-A2.
 XX
 PD 12-SEP-2003.
 XX
 PF 03-MAR-2003; 2003WO-US006598.
 XX
 PR 01-MAR-2002; 2002US-0360843P.
 XX
 PR 29-MAY-2002; 2002US-0384197P.
 XX
 PA (XENC-) XENCOR.
 XX
 PI Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
 XX
 DR WPI; 2003-722066/68.
 XX
 CC Computer optimization of physicochemical properties of antibodies
 CC comprises analyzing the interactions of amino acids at variable
 CC positions.
 XX
 PS Example 6; Fig 16a; 135pp; English.
 XX
 CC The present invention relates to a method for optimizing at least one
 CC physico-chemical property of an antibody by a computational screening
 CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.

CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.

XX Sequence 98 AA;
 SQ

Query Match 100.0%; Score 506; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVOPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
 DB 1 EVOLLESGGLVOPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 15
 ADF09918
 ID ADF09918 standard; protein; 98 AA.
 XX
 AC ADF09918;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Antibody heavy chain variable region VH_3-23.
 XX
 KW Antibody; stability; solubility; antigen binding affinity;
 KW variable region; human.
 XX
 OS Homo sapiens.
 XX
 PN W02003074679-A2.
 XX
 PD 12-SEP-2003.
 XX
 PF 03-MAR-2003; 2003WO-US006598.
 XX
 PR 01-MAR-2002; 2002US-0360843P.
 XX
 PR 29-MAY-2002; 2002US-0384197P.
 XX
 PA (XENC-) XENCOR.
 XX
 PI Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
 XX
 DR WPI; 2003-722066/68.
 XX
 CC Computer optimization of physicochemical properties of antibodies
 CC comprises analyzing the interactions of amino acids at variable
 CC positions.
 XX
 PS Disclosure; Fig 2a; 135pp; English.
 XX
 CC The present invention relates to a method for optimizing at least one
 CC physico-chemical property of an antibody by a computational screening
 CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.

XX Sequence 98 AA;
 SQ

Query Match 100.0%; Score 506; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 60
 DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 16
 ADJ80302
 ID ADJ80302 standard; protein; 98 AA.
 AC ADJ80302;
 XX
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE VH gene locus amino acid sequence #22.
 XX
 XX hybrid antibody; antibody; framework region; homology; immunogenicity.
 XX
 XX Homo sapiens.
 XX
 XX WO2003048321-A2.
 PN
 XX
 PD 12-JUN-2003.
 XX
 XX
 XX 03-DEC-2002; 2002WO-US038450.
 PF
 XX
 XX 03-DEC-2001; 2001US-0336591P.
 PR
 XX
 XX (ALEX-) ALEXION PHARM INC.
 PA
 XX
 XX Rother R, Wu D;
 PI
 XX
 XX WPI; 2003-513753/48.
 DR
 XX
 XX Producing a hybrid antibody or hybrid antibody fragment by operatively
 PT linking the selected framework sequences to one or more complementarity
 PT determining regions of the initial antibody.
 XX
 XX Disclosure; SEQ ID NO 62; 77pp; English.

The invention relates to a method of producing a hybrid antibody or
 hybrid antibody fragment by: (i) providing an initial antibody having
 specificity for a target; (ii) determining the sequence of a variable
 region of the initial antibody; (iii) selecting a first component of the
 variable region consisting of FR1, FR2, FR3 and FR4; (iv) comparing the
 sequence of the first component to sequences contained in a reference
 database of antibody sequences or antibody fragment sequences from a
 target species; (v) selecting a sequence from an antibody in the database
 which demonstrates a high degree of homology to the first component; (vi)
 selecting a second component of the variable region which is different
 than the first component, the second component selected from the group
 consisting of FR1, FR2, FR3 and FR4; (vii) comparing the sequence of the
 second component to sequences contained in a reference database of
 antibody sequences or antibody fragment sequences from the target species
 ; (viii) selecting a sequence from the database which demonstrates a high
 degree of homology to the second component and which is from a different
 antibody than the selected antibody; and (ix) operatively linking the
 selected framework sequences to one or more complementarity determining
 regions (CDRs) of the initial antibody to produce a hybrid antibody or
 hybrid antibody fragment. The method is useful for producing a hybrid
 antibody or hybrid antibody fragment (claimed). The antibody and
 fragments are useful for therapeutic and diagnostic purposes. The method
 uses entire framework regions from a single antibody variable heavy or
 variable light chain to receive the CDRs. This produces antibodies that
 are highly homologous and exhibit reduced immunogenicity while

CC maintaining an optimum binding profile. This sequence represents the
 CC amino acid sequence of an antibody from the VH gene locus.

XX
 SQ Sequence 98 AA;
 Query Match 100.0%; Score 506; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 60
 DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 17
 ADM41877
 ID ADM41877 standard; protein; 98 AA.
 AC ADM41877;
 XX
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Human anti-beat-lactamase antibody protein #56.
 XX
 XX antiaesthetic; antiallergic; immunosuppressive; antiinflammatory;
 KW gene therapy.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO2003035694-A2.
 PN
 XX
 PD 01-MAY-2003.
 XX
 XX 12-JUL-2002; 2002WO-EP007804.
 PF
 XX
 XX 24-OCT-2001; 2001EP-00204037.
 PR
 XX 24-OCT-2001; 2001US-0335054P.
 PR
 XX 11-JAN-2002; 2002JP-00004184.
 XX
 XX (VLAA-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
 PA
 XX
 XX Muyldermans S;
 PI
 XX
 XX WPI; 2003-482033/45.
 DR
 XX
 XX New functional heavy chain antibody, a functional single domain heavy
 PT chain antibody, or its functional VH domain or fragment, useful for
 PT preparing a medicament for the treating a disease related to asthma or
 PT acute allograft rejection.
 XX
 XX Disclosure; SEQ ID NO 101; 98pp; English.

The invention relates to a new functional heavy chain antibody, a
 functional single domain heavy chain antibody, or its functional VH
 domain or fragment comprises an amino acid which is neither a charged
 amino acid nor a Cys at position 45, and comprising an amino acid
 sequence selected from a group of fully defined sequences. The heavy
 chain antibody, a functional single domain heavy chain antibody, a
 functional VH domain, or its fragment, the nucleic acid and polypeptide
 CC are useful for preparing a medicament for the treating a disease related
 CC to asthma, rhinoconjunctivitis, allergic disorders, acute allograft
 CC rejection, Crohn's disease and ulcerative colitis.

XX
 SQ Sequence 98 AA;
 Query Match 100.0%; Score 506; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 EVOLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
DB 1 EVOLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDVAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDVAVYYCAK 98

RESULT 18
AD025804
ID AD025804 standard; protein; 98 AA.
XX
AC AD025804;
XX
DT 12-AUG-2004 (first entry)
XX
DE Anti-TNF-alpha protein-related human protein #2.
XX
KW anti-Tumour Necrosis Factor-alpha; anti-TNF-alpha;
KW single domain antibody; antiinflammatory; antirheumatic;
KW neuroprotective; anabolic; hypertensive; hepatotropic; immunosuppressive;
KW antidiabetic; nephrotropic; antithyroid; CNS-gen; thyromimetic;
KW antianaemic; dermatological; antiinfertility; muscular-gen;
KW antipsoriatic; antipyretic; vasotropic; gene therapy; inflammation;
KW rheumatoid arthritis; Crohn's disease; ulcerative colitis;
KW inflammatory bowel syndrome; multiple sclerosis; Addison's disease;
KW autoimmune hepatitis; autoimmune parotitis; diabetes type I;
KW Guillain-Barre syndrome; Hashimoto's disease; haemolytic anaemia;
KW systemic lupus erythematosus; male infertility; myaesthesia gravis;
KW pemphigus; psoriasis; rheumatic fever; sarcoidosis; scleroderma;
KW Sjogren's syndrome; spondyloarthropathy; thyroiditis; vasculitis; human.
XX
OS Homo sapiens.
XX
PN WO2004041862-A2.
XX
PD 21-MAY-2004.
XX
PF 07-NOV-2003; 2003WO-BE000192.
XX
PR 08-NOV-2002; 2002US-0425063P.
PR 08-NOV-2002; 2002US-0425073P.
PR 10-JAN-2003; 2003EP-00447005.
PR 23-JUN-2003; 2003WO-EP006581.
PR 08-JUL-2003; 2003WO-EP007313.
XX
PA (ABLY-) ABLYNX NV.
XX
PI Silence K, Lauwereys M, De Haard H;
XX WPI; 2004-400645/37.
XX
PT New polypeptides derived from single domain heavy chain antibodies
PT directed to Tumor Necrosis Factor-alpha, useful for preventing, treating
PT or alleviating disorders such as inflammation, diabetes or Grave's
PT disease.
XX
XX Example 2; Page 53; 92pp; English.
XX
CC This invention relates to novel anti-Tumour Necrosis Factor-alpha (anti-
CC TNF-alpha) polypeptides comprising at least one anti-TNF-alpha single
CC domain antibody. The invention may be useful for the development of
CC compounds with an antiinflammatory, antirheumatic, antipsoriatic,
CC neuroprotective, anabolic, hypertensive, hepatotropic, immunosuppressive,
CC antidiabetic, nephrotropic, antithyroid, CNS-gen., thyromimetic,
CC antianaemic, dermatological, antiinfertility, muscular-gen.,
CC antipsoriatic, antipyretic or vasotropic activity. In addition, the
CC disclosed sequences may be useful for gene therapy. The invention may be
CC useful for preparing a medicament for treating, preventing and/or
CC alleviating the disorders such as inflammation, rheumatoid arthritis,
CC Crohn's disease, ulcerative colitis, inflammatory bowel syndrome,
```

```
CC multiple sclerosis, Addison's disease, autoimmune hepatitis, autoimmune
CC parotitis, diabetes type I, epididymitis, glomerulonephritis, Grave's
CC disease, Guillain-Barre syndrome, Hashimoto's disease, haemolytic
CC anaemia, systemic lupus erythematosus, male infertility, myaesthesia
CC gravis, pemphigus, psoriasis, rheumatic fever, sarcoidosis, scleroderma,
CC Sjogren's syndrome, spondyloarthropathies, thyroiditis or vasculitis. The
CC anti-TNF-alpha polypeptide is also used for purifying TNF-alpha or for
CC inhibiting the interaction between the TNF-alpha and TNF-alpha receptors.
CC The present sequence is that of an human protein which was used in the
CC exemplification of the invention.
XX
SQ Sequence 98 AA;
```

Query Match 100.0%; Score 506; DB 8; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 EVOLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
DB 1 EVOLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDVAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAREDVAVYYCAK 98
```

RESULT 19

```
AD025802
ID AD025802 standard; protein; 98 AA.
XX
AC AD025802;
XX
DT 12-AUG-2004 (first entry)
XX
DE Anti-TNF-alpha protein-related human protein #1.
XX
```

```
KW anti-Tumour Necrosis Factor-alpha; anti-TNF-alpha;
KW single domain antibody; antiinflammatory; antirheumatic; antineumatic;
KW neuroprotective; anabolic; hypertensive; hepatotropic; immunosuppressive;
KW antidiabetic; nephrotropic; antithyroid; CNS-gen; thyromimetic;
KW antianaemic; dermatological; antiinfertility; muscular-gen;
KW antipsoriatic; antipyretic; vasotropic; gene therapy; inflammation;
KW rheumatoid arthritis; Crohn's disease; ulcerative colitis;
KW inflammatory bowel syndrome; multiple sclerosis; Addison's disease;
KW autoimmune hepatitis; autoimmune parotitis; diabetes type I;
KW epididymitis; glomerulonephritis; Grave's disease;
KW Guillain-Barre syndrome; Hashimoto's disease; haemolytic anaemia;
KW systemic lupus erythematosus; male infertility; myaesthesia gravis;
KW pemphigus; psoriasis; rheumatic fever; sarcoidosis; scleroderma;
KW Sjogren's syndrome; spondyloarthropathy; thyroiditis; vasculitis; human.
XX
```

Homo sapiens.

WO2004041862-A2.

21-MAY-2004.

07-NOV-2003; 2003WO-BE000192.

08-NOV-2002; 2002US-0425063P.

08-NOV-2002; 2002US-0425073P.

10-JAN-2003; 2003EP-00447005.

23-JUN-2003; 2003WO-EP006581.

08-JUL-2003; 2003WO-EP007313.

(ABLY-) ABLYNX NV.

Silence K, Lauwereys M, De Haard H;

WPI; 2004-400645/37.

New polypeptides derived from single domain heavy chain antibodies
directed to Tumor Necrosis Factor-alpha, useful for preventing, treating

PT or alleviating disorders such as inflammation, diabetes or Grave's
 XX disease.
 XX
 XX Example 2; Page 53; 92pp; English.
 XX
 CC This invention relates to novel anti-Tumour Necrosis Factor-alpha (anti-
 CC TNF-alpha) polypeptides comprising at least one anti-TNF-alpha single
 CC domain antibody. The invention may be useful for the development of
 CC compounds with an anti-inflammatory, anti-rheumatic, anti-heumatic,
 CC neuroprotective, anabolic, hypertensive, hepatotropic, immunosuppressive,
 CC antidiabetic, nephrotropic, antithyroid, CNS-gen., thyromimetic,
 CC antianaemic, dermatological, antifertility, muscular-gen.,
 CC antiparotitic, antipyretic or vasotropic activity. In addition, the
 CC disclosed sequences may be useful for gene therapy. The invention may be
 CC useful for preparing a medicament for treating, preventing and/or
 CC alleviating the disorders such as inflammation, rheumatoid arthritis,
 CC Crohn's disease, ulcerative colitis, inflammatory bowel syndrome,
 CC multiple sclerosis, Addison's disease, autoimmune hepatitis, autoimmune
 CC parotitis, diabetes type I, epidiymitis, glomerulonephritis, Grave's
 CC disease, Guillain-Barre syndrome, Hashimoto's disease, haemolytic
 CC anaemia, systemic lupus erythematosus, male infertility, myasthenia
 CC gravis, pemphigus, psoriasis, rheumatic fever, sarcoidosis, scleroderma,
 CC Sjogren's syndrome, spondyloarthropathies, thyroiditis or vasculitis. The
 CC anti-TNF-alpha polypeptide is also used for purifying TNF-alpha or for
 CC inhibiting the interaction between the TNF-alpha and TNF-alpha receptors.
 CC The present sequence is that of an human protein which was used in the
 CC exemplification of the invention.
 XX
 XX Sequence 98 AA;

Query Match 100.0%; Score 506; DB 8; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
 DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYCAK 98

RESULT 20
 ADR28566
 ID ADR28566 standard; protein; 98 AA.
 XX
 XX ADR28566;
 XX
 XX 18-NOV-2004 (first entry)
 XX
 XX Human anti-IGF-IR antibody heavy chain DP-47 SEQ ID NO:32.
 XX
 XX aging; multiple myeloma; liquid tumour; liver cancer; thymus disorder;
 XX T-cell-mediated autoimmune disease; endocrinological disorder; ischaemia;
 XX neurodegenerative disorder; human;
 XX anti-insulin-like growth factor I receptor antibody;
 XX anti-IGF-IR antibody; cytostatic; immunosuppressive; endocrine;
 XX vasotropic; neuroprotective; nootropic; antithyroid; vaccine;
 XX gene therapy.
 XX
 XX Homo sapiens.
 XX
 XX WO2004071529-A2.
 XX
 XX 26-AUG-2004.
 XX
 XX 03-FEB-2004; 2004WO-IB000366.
 XX
 XX 13-FEB-2003; 2003US-0447353P.
 XX
 XX (PFIZ) PFIZER PROD INC.
 XX

PI Cohen BD, Bedian V, Wang HF, Obrocea M, Gomez-Navarro J;
 PI Cusmano JD, Guyot DJ, Page KL;
 XX
 XX WPI: 2004-625776/60.
 XX N-PSDB; ADR28565.
 XX
 XX Treating or preventing aging or a disorder (e.g. multiple myeloma,
 XX autoimmune disease or neurodegenerative disorder) in humans comprises
 XX administering an amount of a human anti-insulin-like growth factor I
 XX receptor antibody.

XX Disclosure; SEQ ID NO 32; 105pp; English.
 XX
 XX The present invention describes a method for treating or preventing aging
 XX or a disorder (e.g. multiple myeloma, liquid tumour, liver cancer, thymus
 XX disorder, T-cell-mediated autoimmune disease, endocrinological disorder,
 XX ischaemia or neurodegenerative disorder) in a mammal. The method
 XX comprises administering to the mammal an amount of a human anti-insulin-
 XX like growth factor I receptor (IGF-IR) antibody. Also described is a
 XX pharmaceutical composition for treating or preventing the above-mentioned
 XX disorder in a mammal, comprising an amount of the human anti-IGF-IR
 XX antibody and a pharmaceutical carrier. The composition has cytostatic,
 XX immunosuppressive, endocrine, vasotropic, neuroprotective, nootropic and
 XX antithyroid activities, and can be used in vaccines and in gene therapy.
 XX The method and composition are useful for preventing or treating aging or
 XX a disorder (e.g. multiple myeloma, liquid tumour, liver cancer, thymus
 XX disorder, T-cell-mediated autoimmune disease, endocrinological disorder,
 XX ischaemia or neurodegenerative disorder) in mammals, such as humans. The
 XX human IGF-IR antibody is used in preparing a composition for the
 XX treatment or prevention of the above-mentioned disorders. The present
 XX sequence represents a human anti-IGF-IR antibody heavy chain amino acid
 XX sequence, which is used in the exemplification of the present invention.
 XX
 XX Sequence 98 AA;

Query Match 100.0%; Score 506; DB 8; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
 DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYCAK 98

RESULT 21
 ADR88414
 ID ADR88414 standard; protein; 98 AA.
 XX
 XX ADR88414;
 XX
 XX 16-DEC-2004 (first entry)
 XX
 XX Human protein relating to the invention SEQ ID NO:10.
 XX
 XX 3D6; immunoglobulin; complementarity determining region; CDR; 10D5;
 XX variable framework region; neuroprotective; nootropic; gene therapy;
 XX amyloidogenic disease; Alzheimer's disease.
 XX
 XX Homo sapiens.
 XX
 XX WO2004080419-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007503.
 XX
 XX 12-MAR-2003; 2003US-00388389.
 XX
 XX (NEUR-) NEURALAB LTD.

```
PA (AMHP ) WYETH.
XX
XX Basi G, Saldanha JW, Yednock T;
XX
XX WPI; 2004-668880/65.
XX
XX New humanized antibodies that recognize beta amyloid peptides, useful for
XX preventing or treating amyloidogenic diseases, such as Alzheimer's
XX disease.
XX
XX Disclosure; SEQ ID NO 10; 176pp; English.
XX
XX The invention relates to a novel humanised immunoglobulin light or heavy
XX chain. The humanised immunoglobulin light or heavy chain comprises:
XX variable region complementarity determining regions (CDR's) from the 3D6
XX immunoglobulin light chain variable region sequence of 132 amino acids
XX fully defined in the specification (ADR88406), or heavy chain variable
XX region sequence of 138 amino acids fully defined in the specification
XX (ADR88408); or from the 10D5 immunoglobulin light chain variable region
XX sequence of 131 amino acids given in the specification (ADR88418) or
XX heavy chain variable region sequence of 142 amino acids fully defined in
XX the specification (ADR88420); and a variable framework region from a
XX human acceptor immunoglobulin light or heavy chain sequence, provided
XX that at least one framework residue is substituted with the corresponding
XX amino acid residue from the mouse 3D6 or 10D5 light or heavy chain
XX variable region sequence, where the framework residue is a residue that
XX non-covalently binds antigen directly, a residue adjacent to a CDR, a CDR
XX -interacting residue or a residue participating in the VL-VH interface.
XX An antibody of the invention has neuroprotective and neurotrophic activity,
XX and may have a use in gene therapy. The composition and methods are
XX useful for preventing or treating an amyloidogenic disease, such as
XX Alzheimer's disease. The variable region sequence is useful in producing
XX a three-dimensional image of a 3D6 or 10D5 immunoglobulin, immunoglobulin
XX chain, or its domain. The present sequence represents a human protein
XX relating to the invention.
XX
XX Sequence 98 AA;
SQ
Query Match 100.0%; Score 506; DB 8; Length 98;
Best Local Similarity 100.0%; Pred. NO. 3.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSATSGSGSTYY 60
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSATSGSGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
RESULT 22
ADU17936
ID ADU17936 standard; protein; 98 AA.
XX
XX ADU17936;
XX
XX 27-JAN-2005 (first entry)
XX
XX Humanised IFN-alpha receptor-1 Ab-related human DP47 protein SeqID48.
XX
XX humanised antibody; interferon-alpha receptor-1; IFN-alpha receptor-1;
XX immunosuppressive; antiinflammatory; dermatological; antidiabetic;
XX gene therapy; autoimmune disorder; inflammatory bowel disease; SLE; IDDM;
XX transplant rejection; graft-versus-host disease;
XX insulin dependent diabetes mellitus; systemic lupus erythematosus; human.
XX
XX Homo sapiens.
XX
XX WO2004094473-A2.
XX
XX 04-NOV-2004.
XX
```

```
23-APR-2004; 2004WO-US012649.
XX
XX 23-APR-2003; 2003US-0465058P.
XX
XX (MEDA-) MEDAREX INC.
XX
XX Cardarelli JM, Chen TT, King D, Bebbington CR, Pogue SL, Carr FJ;
XX Williams S;
XX
XX WPI; 2004-795531/78.
XX
XX New humanized antibodies that specifically bind interferon (IFN)-alpha
XX receptor-1, useful for diagnosing, preventing or treating disorders
XX associated with type I IFN, such as autoimmune disorders or transplant
XX rejection.
XX
XX Example 1; SEQ ID NO 48; 79pp; English.
XX
XX This invention relates to a novel humanised antibody or humanised
XX antibody fragment that specifically binds interferon (IFN)-alpha receptor
XX -1. The invention may be useful for the production of compounds with an
XX immunosuppressive, antiinflammatory, dermatological or antidiabetic
XX activity. In addition, the disclosed sequences may be useful for gene
XX therapy. The invention or compounds developed are useful for diagnosing,
XX preventing or treating disorders associated with type I IFN, such as an
XX autoimmune disorder (for example inflammatory bowel disease, systemic
XX lupus erythematosus or insulin dependent diabetes mellitus), transplant
XX rejection or graft-versus-host disease. The present sequence is that of a
XX protein which was used during the development of the novel humanised IFN-
XX alpha receptor-1 antibodies of the invention.
XX
XX Sequence 98 AA;
SQ
Query Match 100.0%; Score 506; DB 8; Length 98;
Best Local Similarity 100.0%; Pred. NO. 3.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSATSGSGSTYY 60
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSATSGSGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
RESULT 23
ADV54702
ID ADV54702 standard; protein; 98 AA.
XX
XX ADV54702;
XX
XX 19-MAY-2005 (first entry)
XX
XX Human VH allotype protein fragment, Hu_VH_3_23.
XX
XX Screening; monoclonal antibody; antibody production; cytostatic;
XX neoplasm; heavy chain variable region; cancer; antibody engineering.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Region 28..35
XX /note= "CDR1"
XX Region 50..66
XX /note= "CDR2"
XX
XX US2005048578-A1.
XX
XX 03-MAR-2005.
XX
XX 15-JUN-2004; 2004US-00869355.
XX
```

PR 26-JUN-2003; 2003US-0483391P.
 PR 30-JUN-2003; 2003US-0484185P.
 PA (EPIT-) EPITOMICS INC.
 XX Zhang D;
 XX
 DR WPI; 2005-212284/22.
 XX
 XX Screening for monoclonal antibodies with a desirable activity, comprises
 PT producing a library of mammalian cells expressing variants of a parental
 PT antibody, and identifying cells expressing antibodies with the desired
 PT activity.
 XX
 XX Example 2; SEQ ID NO 12; 37pp; English.
 XX
 CC The present invention relates to a method of screening for monoclonal
 CC antibodies with a desirable activity. The method involves altering a
 CC nucleic acid encoding a selected parental humanized monoclonal antibody
 CC to make a library of nucleic acids, introducing the library into
 CC mammalian cells such that a library of monoclonal antibodies are produced
 CC on the surfaces of the mammalian cells and sorting the cells to isolate a
 CC cell producing a humanized monoclonal antibody with desirable activity,
 CC e.g., increased affinity for an binding partner as compared to the
 CC parental antibody. Antibodies produced by the methods of the invention
 CC are useful in the diagnosis and treatment of diseases such as cancer. The
 CC present sequence is the human VH1 allotype protein fragment. This
 CC sequence is used in humanization of rabbit monoclonal antibody B1-CDR
 CC grafting.
 XX
 SQ Sequence 98 AA;
 Query Match 100.0%; Score 506; DB 9; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
 Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
 Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 RESULT 24
 ADY75307
 ID ADY75307 standard; protein; 98 AA.
 XX
 AC ADY75307;
 XX
 DT 02-JUN-2005 (first entry)
 XX
 DE Protein encoded by human germline heavy chain V minigene VH3 3-23.
 XX
 XX Antibody engineering; antibody; antibody production; gene library;
 KW DNA recombination; gene amplification; primer extension;
 KW heavy chain variable region.
 XX
 OS Homo sapiens.
 XX
 XX WO2005023993-A2.
 PN
 XX 17-MAR-2005.
 PD
 XX 09-SEP-2004; 2004WO-US029617.
 XX
 XX 09-SEP-2003; 2003US-0501073P.
 PR
 XX (INTE-) INTEGRIGEN INC.
 PA
 XX Sharma V, Leonard L, Smider V;
 PI
 XX

DR WPI; 2005-223364/23.
 XX
 XX Producing polynucleotide encoding human germline antibody V-region for
 PT generating full-length antibody germline V-region genes, by obtaining V
 PT or J minigene and joining V minigene with J minigene, or joining J
 PT minigene with V minigene.
 XX
 XX Disclosure; Fig 10; 52pp; English.
 XX
 XX The present invention relates to producing germline antibody genes by a
 CC completely in vitro approach that mimics the natural process of V(D)J
 CC recombination. The antibody genes are completely human and native in
 CC their sequence, and libraries of such antibody genes can be constructed
 CC which represent an unselected population representing the entire antibody
 CC repertoire. The method uses gene amplification to produce a V minigene,
 CC and a hybrid primer capable of hybridizing to a V minigene and either a D
 CC or V minigene. The hybrid primer facilitates recombination of a V
 CC minigene to a D or J minigene to produce a full length V-region gene.
 CC Also disclosed is a library comprising member polynucleotides encoding a
 CC exogenously rearranged human germline antibody V-regions. In producing a
 CC polynucleotide encoding a human germline antibody V-region, a D minigene
 CC is further joined to the 3' end of the V minigene and the 5' end of the J
 CC minigene. The V minigene or the J minigene in is obtained by chemical
 CC synthesis or by amplification from a germline DNA library. Joining the V
 CC minigene with at least one J minigene is performed by primer extension
 CC using at least two or three oligonucleotide primers. The V minigene is
 CC derived from human immunoglobulin kappa locus, human immunoglobulin
 CC lambda locus, or human immunoglobulin heavy chain locus. The V-region
 CC also comprises a serine protease triad. The human germline antibodies can
 CC be used as precursors to more high affinity antibodies, and are useful in
 CC the generation of efficiently pairing libraries of heavy and light
 CC chains. The present sequence is a polypeptide encoded by human germline
 CC heavy chain V minigene, family VH3 locus 3-23.
 XX
 SQ Sequence 98 AA;
 Query Match 100.0%; Score 506; DB 9; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.1e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
 Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
 Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 RESULT 25
 ADY93870
 ID ADY93870 standard; protein; 98 AA.
 XX
 AC ADY93870;
 XX
 DT 16-JUN-2005 (first entry)
 XX
 DE Anti-SARS 3-23 germline antibody VH region EQ ID NO:20.
 XX
 KW glycoprotein; respiratory-gen.; virucide; sars coronavirus infection;
 KW antibody; heavy chain variable region.
 XX
 OS SARS coronavirus.
 XX
 XX US2005069869-A1.
 PN
 XX 31-MAR-2005.
 PD
 XX 04-AUG-2004; 2004US-00911838.
 PF
 XX 04-AUG-2003; 2003US-0492529P.
 PR
 XX 09-OCT-2003; 2003US-0510251P.
 PR
 XX 18-FEB-2004; 2004US-0545670P.
 PR

26-APR-2004; 2004US-0565595P.

(AMBR/) AMBROSINO D.
(HERN/) HERNANDEZ H.
(GREE/) GREENOUGH T.
(LUZU/) LUZURIAGA K.
(SOMA/) SOMASUNDARAN M.
(BABC/) BABCOCK G J.
(THOM/) THOMAS W D.
(SULL/) SULLIVAN J.

Ambrosino D, Hernandez H, Greenough T, Luzuriaga K;
Somasundaran M, Babcock GJ, Thomas WD, Sullivan J;
WPI; 2005-252952/26.

New isolated nucleic acid encoding a SARS-CoV spike glycoprotein
PT polypeptide, and optimized for expression in a human host, useful for
PT diagnosing, preventing and/or treating SARS-CoV infection.

Example 17; SEQ ID NO 20; 138pp; English.

The invention relates to an isolated nucleic acid comprising a sequence
CC encoding a SARS coronavirus (SARS-CoV) spike glycoprotein (S protein), or
CC its fragment, where the sequence has been optimized for expression in a
CC human host. Also described: (1) a nucleic acid expression vector
CC comprising the above nucleic acid; (2) an isolated cell comprising the
CC expression vector of (1); (3) a polypeptide encoded by the above nucleic
CC acid; (4) an isolated polypeptide comprising an extracellular portion of
CC the SARS-CoV S polypeptide located between amino acids 15-1190 of
CC ADY93852, or its fragment; (5) an isolated antibody, or its antigen
CC binding fragment, that specifically binds to the polypeptide of (3); (6)
CC an isolated antibody, or its antigen binding fragment, that specifically
CC binds to an antigen binding fragment of an anti-S protein antibody; (7) a
CC composition comprising a polypeptide of (4) or an antibody, or its
CC antigen binding fragment, and a pharmaceutical carrier; (8) making an S
CC protein, or its fragment, of SARS-CoV; (9) making an antibody, or its
CC antigen binding fragment, that specifically binds to an S protein of SARS
CC -CoV; (10) evaluating a biological sample for the presence of SARS-CoV;
CC (11) evaluating an antibody, or its antigen binding fragment, for
CC inhibition of infection by SARS-CoV; (12) treating a subject at risk for,
CC or exposed to SARS-CoV; (13) an immunoconjugate comprising the antibody
CC of (5) linked to a therapeutic agent; (14) an isolated nucleic acid
CC molecule encoding the antibody, its antigen-binding portion, variable
CC heavy chain or variable light chain of (5); (15) an expression vector
CC comprising the nucleic acid molecule of (14); (16) a host cell comprising
CC the expression vector of (15); (17) a transgenic mammal comprising human
CC immunoglobulin heavy and light chain transgenes, where the mouse
CC expresses the antibody of (5); (18) a hybridoma prepared from the mammal
CC of (17), where the hybridoma produces the antibody; and (19) preparing an
CC anti-S protein antibody. The methods and compositions of the present
CC invention are useful for the diagnosis, prevention and/or treatment of
CC SARS-CoV infection. The present sequence represents an anti-SARS antibody
CC heavy chain variable region from the present invention.

XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 506; DB 9; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60

QY 61 ADSVKGKFTISRDNKNTLYLQMSLRADTAVYYCAK 98
Db 61 ADSVKGKFTISRDNKNTLYLQMSLRADTAVYYCAK 98

RESULT 26
AD60990
ID ADC60990 standard; protein; 109 AA.

ADC60990;

18-DEC-2003 (first entry)

Human anti-CD45RB monoclonal antibody, SEQ ID NO 17.

monoclonal antibody; CD45RB; antigen; cell proliferation;
immunosuppressive; neuroprotective; tissue rejection; organ rejection;
autoimmune disease; multiple sclerosis; human; anti-CD45RB.

Homo sapiens.

WO2003048327-A2.

12-JUN-2003.

02-DEC-2002; 2002WO-US038540.

03-DEC-2001; 2001US-0337276P.

(ABGE-) ABGENIX INC.

Foltz I, Babcock J, Palathumpat V, Yang X, King CT;
WPI; 2003-558954/52.

New anti-CD45RB monoclonal antibody, useful for treating an autoimmune
disease e.g. multiple sclerosis.

Disclosure; SEQ ID NO 17; 121pp; English.

The invention relates to a novel isolated monoclonal antibody comprising
a heavy chain having a sequence chosen from one of 22 fully defined
sequences comprising 135-147 amino acids, given in the specification, and
is specific for CD45RB antigen. The invention further relates to:
inhibiting cell proliferation associated with the expression of CD45RB
antigen; and treating a disease associated with the expression of a
CD45RB antigen in a patient. The monoclonal antibody has the activities
of immunosuppressive and neuroprotective. The monoclonal antibody is
useful for treating the rejection of a mammalian cell, tissue or organ,
especially an autoimmune disease in a mammal, especially a human e.g.
multiple sclerosis. This sequence represents a human protein of the anti-
CD45RB monoclonal antibody of the invention.

XX
SQ Sequence 109 AA;

Query Match 100.0%; Score 506; DB 7; Length 109;
Best Local Similarity 100.0%; Pred. No. 3.5e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60

QY 61 ADSVKGKFTISRDNKNTLYLQMSLRADTAVYYCAK 98
Db 61 ADSVKGKFTISRDNKNTLYLQMSLRADTAVYYCAK 98

RESULT 27
ADP22373
ID ADP22373 standard; protein; 109 AA.

XX
AC ADP22373;
XX
DT 09-SEP-2004 (first entry)
XX
DE Human anti-TNFa antibody heavy chain variable region SEQ ID NO:279.
XX human; monoclonal antibody; tumour necrosis factor-alpha; TNFa;
KW anti-TNFa antibody; anabolic; antiarteriosclerotic; antiarthritic;
KW antibacterial; antiinflammatory; antipsoriatic; antirheumatic;

KW eating-disorder; immunomodulator; immunosuppressive; nephrotropic;
 KW neuroprotective; vasotropic; antiapoptotic; TNFa antagonist;
 KW TNF induced apoptosis; neoplastic disease; breast cancer; ovarian cancer;
 KW bladder cancer; lung cancer; glioblastoma; stomach cancer;
 KW endometrial cancer; kidney cancer; colon cancer; pancreatic cancer;
 KW prostate cancer; immuno-mediated inflammatory disease;
 KW rheumatoid arthritis; glomerulonephritis; atherosclerosis; psoriasis;
 KW restenosis; autoimmune disease; Crohn's disease; graft-host reaction;
 KW septic shock; cachexia; anorexia; multiple sclerosis.
 XX
 OS Homo sapiens.
 XX
 FN WO2004050683-A2.
 XX
 XX 17-JUN-2004.
 XX
 XX 02-DEC-2003; 2003WO-US038281.
 XX
 XX 02-DEC-2002; 2002US-0430729P.
 XX (ABGE-) ABGENIX INC.
 XX
 FI Babcock JS, Kang JS, Foord O, Green L, Feng X, Klakamp S;
 PI Haak-Frendscho M, Rathanaswami P, Pigott C, Liang ML, Lee R;
 PI Manchulenko K, Faggioni R, Senaldi G, Qiaojuan JS;
 XX
 XX WPI; 2004-480601/45.

XX New recombinant human monoclonal antibody that specifically binds to
 PT Tumor Necrosis Factor-alpha, useful for treating neoplastic disease such
 PT as cancers, or immuno-mediated inflammatory diseases such as rheumatoid
 PT arthritis.

XX Example 10; SEQ ID NO 279; 213pp; English.

XX The present invention describes a human monoclonal antibody (I) that
 CC specifically binds to tumour necrosis factor-alpha (TNFa) and comprises:
 CC (a) a heavy chain complementarity determining region 1 (CDRI) having the
 CC two fully defined 5 amino acid sequence (S1, ADP22417) or (S2, ADP22421);
 CC and (b) a light chain CDRI having the two fully defined 11 amino acid
 CC sequence (S3, ADP22418) or (S4, ADP22424). Also described: (1) assaying
 CC (M1) the level of TNFa in a patient sample, comprising contacting with
 CC (I), and detecting the level of binding between the antibody and TNFa in
 CC the sample; (2) a composition comprising the antibody or its functional
 CC fragment and a carrier; (3) treating (M2) an animal suffering from a
 CC neoplastic, or an immuno-mediated inflammatory disease by selecting an
 CC animal in need of treatment for the disease by administering the human
 CC monoclonal antibody of (I); and (4) inhibiting (M3) TNFa induced
 CC apoptosis in an animal by selecting an animal in need of treatment for
 CC TNFa induced apoptosis by administering the human monoclonal antibody of
 CC (I). (I) has anabolic, antiarteriosclerotic, antiarthritic,
 CC antibacterial, antiinflammatory, antipsoaritic, antirheumatic, eating-
 CC disorders, immunomodulator, immunosuppressive, nephrotropic,
 CC neuroprotective, vasotropic and antiapoptotic activities, and can be used
 CC as a TNFa antagonist. The antibody (I) is useful in the preparation of
 CC medicament for treating TNF induced apoptosis, neoplastic disease such as
 CC breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma,
 CC stomach cancer, endometrial cancer, kidney cancer, colon cancer,
 CC pancreatic cancer, and prostate cancer; or immuno-mediated inflammatory
 CC diseases such as rheumatoid arthritis, glomerulonephritis,
 CC atherosclerosis, psoriasis, restenosis, autoimmune disease, Crohn's
 CC disease, graft-host reactions, septic shock, cachexia, anorexia, and
 CC multiple sclerosis. The present sequence represents a human anti-TNFA
 CC antibody heavy chain variable region, which is used in the
 CC exemplification of the present invention.

XX SQ Sequence 109 AA;

Query Match 100.0%; Score 506; DB 8; Length 109;
 Best Local Similarity 100.0%; Pred. No. 3.5e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWVSATISGGSGTYY 60

Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWVSATISGGSGTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAATVYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAATVYCAK 98
 RESULT 28
 ADS09392
 ID ADS09392 standard; protein; 109 AA.
 XX AC
 XX ADS09392;
 XX 18-NOV-2004 (first entry)
 DT
 XX Human c-Met protein tyrosine kinase germline antibody, VH3_DP-47_3-23.
 DE
 XX c-Met; tyrosine kinase antibody; antigen binding; cytostatic;
 KW ophthalmological; antiinflammatory; analgesic; vasotropic; antipsoriatic;
 KW osteopathic; cancer; tumour; ophthalmic disease; glaucoma; retinitis;
 KW retinopathy; uveitis; ocular photophobia; macular degeneration; pain;
 KW acute injury; eye; hyperproliferative disorder; restenosis; angioplasty;
 KW psoriasis; HGF; osteoporosis; cancer.
 XX
 OS Homo sapiens.
 XX
 PN WO2004072117-A2.
 XX
 XX 26-AUG-2004.
 XX
 XX 11-FEB-2004; 2004WO-IB000503.
 XX
 XX 13-FEB-2003; 2003US-0447073P.
 XX
 XX (PHAA) PHARMACIA CORP.
 XX Morton PA, Arbuckle JA, Evans ML, Joy WD, Kahn LE, Shieh JJ;
 XX WPI; 2004-616044/59.
 XX
 XX Novel c-Met protein tyrosine kinase antibody or its antigen-binding
 PT portion specifically binding to c-Met, useful for manufacture of
 PT medicament for treating cancer or tumor and for treatment of ophthalmic
 PT diseases such as glaucoma.
 XX
 XX Disclosure; SEQ ID NO 154; 303pp; English.
 XX
 XX The invention relates to a novel c-Met protein tyrosine kinase antibody
 CC or its antigen binding portion that specifically binds to c-Met. The c-
 CC Met antibody comprises any one of 1-60 fully defined sequence of 238,
 CC 244, 240, 250, 251, 242, 245, 247, 246, 253, 249, 243, 241, etc., amino
 CC acids as given in the specification, or its fragment. The invention
 CC further comprises a pharmaceutical composition comprising the c-Met
 CC protein tyrosine kinase antibody and a carrier; an isolated cell that
 CC produces the c-Met protein tyrosine kinase antibody; and an isolated
 CC nucleic acid molecule that comprises a nucleic acid sequence that encodes
 CC a heavy chain or its antigen-binding portion or light chain or its
 CC antigen-binding portion of the c-Met protein tyrosine kinase antibody.
 CC The c-Met protein tyrosine kinase antibody has cytostatic,
 CC ophthalmological, antiinflammatory, analgesic, vasotropic, antipsoriatic,
 CC and osteopathic activities. The c-Met protein tyrosine kinase antibody is
 CC useful for the manufacture of medicament for the treatment of cancer or
 CC tumour. The c-Met protein tyrosine kinase antibody is useful for
 CC diagnosing the presence or ligand of c-Met expressing tissue. The c-Met
 CC protein tyrosine kinase antibody is useful for detecting c-Met in a
 CC biological sample in vitro or in vivo. The c-Met protein tyrosine kinase
 CC antibody is also useful in the treatment or prevention of ophthalmic
 CC diseases such as glaucoma, retinitis, retinopathies (e.g., diabetic
 CC retinopathy), uveitis, ocular photophobia, macular degeneration and pain
 CC associated with acute injury to the eye. The pharmaceutical composition
 CC is useful for the treatment of hyperproliferative disorders such as
 CC restenosis after angioplasty, and psoriasis, and for the treatment of

CC indicating the reaction of the antibody with the antigen, if present), a
 CC purified protein variant of EGFRvIII, selecting variants of antibodies to
 CC EGFRvIII, making antibody variants to EGFRvIII and killing a targeted
 CC cell. The composition and methods are useful for diagnosing, preventing
 CC or treating diseases associated with the expression of EGFRvIII, such as
 CC cancer, gliomas, tumors and carcinomas. The present sequence is a human
 CC germline antibody heavy chain protein, used to compare to the VH regions
 CC of the anti-EGFRvIII antibodies of the invention.
 XX
 SQ Sequence 109 AA;

Query Match 100.0%; Score 506; DB 9; Length 109;
 Best Local Similarity 100.0%; Pred. No. 3.5e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATSGGGSTYY 60
 Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATSGGGSTYY 60
 Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 31
 ADW80194
 ID ADW80194 standard; protein; 109 AA.

AC ADW80194;

DT 21-APR-2005 (first entry)

DE Human anti-EGFRvIII antibody 250/139 VH-related germline protein.

KW cell death; antibody; toxin; cytostatic; cancer; neoplasm; lung tumor;
 KW colon tumor; stomach tumor; renal tumor; prostatic cancer; breast tumor;
 KW ovary tumor; epidermal growth factor receptor; EGFRvIII;
 KW heavy chain variable region.

OS Homo sapiens.

PN WO2005010151-A2.

PD 03-FEB-2005.

PF 25-JUN-2004; 2004WO-US020295.

PR 27-JUN-2003; 2003US-0483145P.

PR 26-NOV-2003; 2003US-0525570P.

PR 15-APR-2004; 2004US-0562453P.

PA (ABGE-) ABGENIX INC.

PI Weber R, Feng X, Foord O, Green L, Gudas J, Keyt B, Liu Y;
 PI Rathanaswami P, Raya R, Yang XD, Corvalan J, Foltz I, Jia X;
 PI Kang J, King CT, Klakamp SL, Su QJ;

DR WPI; 2005-123139/13.

XX New isolated antibody that binds to epidermal growth factor receptor type
 PT III mutant EGFRvIII and being conjugated to therapeutic agent such as
 PT toxin, useful for inhibiting cell proliferation associated with
 PT expression of EGFRvIII.

PS Example 3; SEQ ID NO 8; 233pp; English.

XX The invention relates to a novel method for killing a target cell. The
 CC method comprises contacting the cell with an isolated antibody or its
 CC fragment that binds to epidermal growth factor receptor type III deletion
 CC mutant (EGFRvIII), the antibody being conjugated to a therapeutic agent,
 CC which is a toxin chosen from AEPF, MMAE, AURISTATIN E, DM-1 and ZAP, and
 CC where the antibody comprises a heavy chain amino acid sequence chosen
 CC from antibodies 13.1.2, 131, 170, 150, 095, 250. EGFR variants are caused

CC by gene rearrangement accompanied by gene amplification. Eight major
 CC variants of EGFR are known. EGFRvIII, which is the most commonly
 CC occurring variant of EGFR in human cancers, comprises a 267 aa in-frame
 CC deletion in the extracellular domain. The method of the invention
 CC demonstrates cytostatic activity and may be useful for inhibiting cell
 CC proliferation associated with the expression of EGFRvIII or for
 CC inhibiting cell proliferation of cells expressing EGFRvIII. As such the
 CC method may be utilized, in vivo, on a mammal e.g. human, suffering from
 CC an epithelial cell cancer such as lung, colon, gastric, renal, prostate,
 CC breast, glioblastoma or ovarian carcinoma. The current sequence is that
 CC of the human anti-EGFRvIII antibody 250/139 VH-related germline protein
 CC of the invention.
 XX

SQ Sequence 109 AA;

Query Match 100.0%; Score 506; DB 9; Length 109;

Best Local Similarity 100.0%; Pred. No. 3.5e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATSGGGSTYY 60
 Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATSGGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 32

ABG69320

ID ABG69320 standard; protein; 116 AA.

AC ABG69320;

DT 21-OCT-2002 (first entry)

DE Antibody DP47 heavy chain variable region.

KW Sequence arrayed library; SAL; antibody library; protein identification;
 KW DP47; DPK22.

OS Homo sapiens.

PN JP2002174635-A.

PD 21-JUN-2002.

PF 07-DEC-2000; 2000JP-00373259.

PR 07-DEC-2000; 2000JP-00373259.

PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.

PA (KOKU-) KOKURITSU SEISHIN SHINKEI CENT SOCHO.

DR WPI; 2002-579732/62.

DR N-PSDB; ABK99213.

XX Screening of an antibody used for the identification of an objective
 PT protein in high efficiency.

PS Example 8; Fig 1; 43pp; Japanese.

XX The invention relates to screening an antibody against a specific protein
 CC in an objective structure sample containing a protein group in high
 CC efficiency, comprising reacting an objective structure sample containing
 CC a protein group or a portion containing an objective protein in the
 CC sample with an antibody library, recovering the antibody combined with
 CC the protein, replicating the recovered antibody and reacting it with the
 CC objective protein at least once. The method is used for the
 CC identification of an objective protein. The present sequence is an
 CC antibody chain (derived from the DP47 heavy chain, the DPK22 light chain)
 CC used in the method of the invention
 XX

SQ Sequence 116 AA;
 Query Match 100.0%; Score 506; DB 5; Length 116;
 Best Local Similarity 100.0%; Pred. No. 3.7e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
 DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 33
 ID AAO21548 standard; protein; 116 AA.
 XX AAO21548;
 AC AAO21548;
 XX 02-SEP-2002 (first entry)
 DT DT
 DE Antibody screening method related protein VH (DP-47).
 XX Screening antibody; 2-D electrophoresis; plural protein; protein spot;
 KW antibody library; proteomics.
 XX Unidentified.
 XX W0200242774-A1.
 XX 30-MAY-2002.
 XX 05-JUN-2001; 2001WO-JP004732.
 XX 24-NOV-2000; 2000JP-00358539.
 XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 PA (NINA-) JAPAN NAT CENT NEUROLOGY & PSYCHIATRY.
 XX Kaneko K;
 XX WPI; 2002-471742/50.
 DR N-PSDB; AAL39119.
 XX Screening an antibody using 2-D electrophoresis on plural proteins in
 PT samples for separating individual protein spots to react with an antibody
 PT library useful in proteomics and other biological sciences.
 XX Disclosure; Fig 1; 78pp; Japanese.

XX The invention relates to a novel method for screening an antibody,
 CC comprising performing 2-D electrophoresis on plural proteins in a sample.
 CC Individual protein spots are separated by reacting them with an antibody
 CC library and then replicating the bound antibodies before reacting them
 CC with the spot proteins again. The method is useful for screening an
 CC antibody specific for a target protein, e.g. from a phage antibody
 CC library, which is useful in proteomics for studying various protein and
 CC complementary deoxyribonucleic acid (cDNA) expression libraries as well
 CC as gene functions, and in other biological and medical sciences. This
 CC sequence is a protein relating to the antibody screening method of the
 CC invention

SQ Sequence 116 AA;
 Query Match 100.0%; Score 506; DB 5; Length 116;
 Best Local Similarity 100.0%; Pred. No. 3.7e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
 DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 34
 ID ABP95999 standard; protein; 116 AA.
 XX ABP95999;
 AC ABP95999;
 XX 01-MAY-2003 (first entry)
 DT DT
 DE HSA antibody related VH chain VH dummy.
 XX Ligand; human serum albumin; HSA; antibody; cytostatic; anti-HIV;
 KW antiinflammatory; antianaemic; immunosuppressive; neuroprotective;
 KW dual-specific ligand; cancer; HIV infection; hepatitis; rubella; anaemia;
 KW inflammation; autoimmune disorder; multiple sclerosis; Crohn's disease;
 KW myasthenia gravis.
 XX Homo sapiens.
 OS Synthetic.
 XX W02003002609-A2.
 XX 09-JAN-2003.
 XX 28-JUN-2002; 2002WO-GB003014.
 XX 28-JUN-2001; 2001GB-00015841.
 XX (MEDI-) MEDICAL RES COUNCIL.
 PA Winter G, Ignatovich O, Tomlinson I;
 XX WPI; 2003-210246/20.
 DR Dual-specific ligand having immunoglobulins with binding specificity to
 PT different antigens or epitopes, useful for treating, preventing or
 PT diagnosing diseases, e.g. cancer, HIV infection, inflammations, or
 PT myasthenia gravis.
 XX Example 1; Fig 3; 84pp; English.

XX The present invention describes a dual-specific ligand (I) comprising:
 CC (a) a first single immunoglobulin variable domain with a binding
 CC specificity to a first antigen or epitope; and (b) a second complementary
 CC immunoglobulin single variable domain with a binding activity to a second
 CC antigen or epitope. The binding domains are mutually complementary, and
 CC share the same specificity. (I) has cytostatic, anti-HIV, antianaemic,
 CC antiinflammatory, immunosuppressive and neuroprotective activities. The
 CC dual-specific ligand is useful for treating, preventing or diagnosing
 CC diseases, e.g. cancer, HIV infection, hepatitis, rubella, anaemia,
 CC inflammations or autoimmune disorders (e.g. multiple sclerosis, Crohn's
 CC disease or myasthenia gravis). The dual-specific ligand may be used to
 CC recruit cytotoxic T-cells to a cancer cell. The dual-specific ligand is
 CC also useful for monitoring the efficacy of drugs, as well as for
 CC monitoring toxicity. The present sequence represents a human serum
 CC albumin (HSA) related antibody VH sequence, which is used in an example
 CC from the present invention

SQ Sequence 116 AA;
 Query Match 100.0%; Score 506; DB 6; Length 116;
 Best Local Similarity 100.0%; Pred. No. 3.7e-42;
 Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60


```
Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 37
ADQ77187
ID      ADQ77187 standard; protein; 116 AA.
XX
XX
AC      ADQ77187;
XX
XX      07-OCT-2004 (first entry)
XX
XX      Dummy VH protein #1.
XX
XX      Antiinflammatory; Antiallergic; Cytostatic; Antibacterial; Virucide;
XX      Immunosuppressive; Immunotherapy; single domain antibody; dab; TNF alpha;
XX      TNF receptor 1; p55; inflammation; allergic hypersensitivity; cancer;
XX      bacterial infection; viral infection; autoimmune disorder.
XX
XX      Synthetic.
XX
XX      WO2004058821-A2.
XX
XX      15-JUL-2004.
XX
XX      24-DEC-2003; 2003WO-GB005646.
XX
XX      27-DEC-2002; 2002GB-00030202.
XX
XX      30-JUN-2003; 2003WO-GB002804.
XX
XX      28-NOV-2003; 2003GB-00027706.
XX
XX      (DOMA-) DOMANTIS LTD.
XX
XX      Winter G, Tomlinson I, Ignatovich O, Woolven B;
XX      WPI; 2004-534127/51.
XX
XX      New dual specific ligand comprising a first dab specific for a target
XX      ligand, and a second dab specific for a receptor for the target ligand,
XX      useful for treating inflammation, cancer, allergy or autoimmune diseases.
XX
XX      Example 9; Fig 13; 196pp; English.
XX
XX      The present invention relates to a dual specific ligand comprising a
XX      first single domain antibody (dab) specific for a target ligand (e.g. TNF
XX      alpha), and a second dab specific for a receptor for the target ligand
XX      (e.g. TNF receptor 1 (p55)). The dab specific for TNFalpha comprises the
XX      amino acid sequence of TAR1-5-19, TAR1-5 or TAR1-27 and the dab specific
XX      for TNF receptor 1 (p55) comprises the amino acid sequence of TAR2h-10,
XX      TAR2h-5 or TAR2h-10-27. The dual specific ligands are useful for
XX      targeting cytokines and other molecules that cooperate synergistically in
XX      therapeutic situations in the body of an organism. They are useful for
XX      preventing, suppressing or treating inflammatory states, allergic
XX      hypersensitivity, cancer, bacterial or viral infection, and autoimmune
XX      disorders. The present sequence is a heavy chain variable domain sequence
XX      used to illustrate the invention.
XX
XX      Sequence 116 AA;

Query Match      100.0%; Score 506; DB 8; Length 116;
Best Local Similarity 100.0%; Pred. No. 3.7e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSATISGSGSTYY 60
Db      1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSATISGSGSTYY 60
QY      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
Db      61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 39
ADQ90914
ID      ADQ90914 standard; protein; 116 AA.
XX
XX
AC      ADQ90914;
XX
```

```

DT 07-OCT-2004 (first entry)
DE Vh chain protein from immunoglobulin clone Vh dummy.
XX
XX immunoglobulin molecule; epitope binding specificity; antibody;
XX light chain variable domain; inflammatory state;
XX allergic hypersensitivity; cancer; bacterial infection; viral infection;
XX autoimmune disorder.
OS Synthetic.
XX
XX WO2004058822-A2.
XX
XX 15-JUL-2004.
XX
XX 24-DEC-2003; 2003WO-GB005657.
XX
XX 27-DEC-2002; 2002GB-00030201.
XX
XX (DOMA-) DOMANTIS LTD.
XX
XX Winter G, Tomlinson I, Ignatovich O;
XX
XX WPI; 2004-525864/50.
XX
XX Generating an immunoglobulin molecule of predetermined epitope binding
XX specificity, useful in cancer treatments, comprises selecting an antibody
XX light chain variable domain comprising an epitope binding specificity.
XX
XX Example 3; Fig 10; 70pp; English.
XX
XX The invention involves the generation of an immunoglobulin molecule of
XX predetermined epitope binding specificity by selecting an antibody light
XX chain variable domain comprising an epitope binding specificity, and
XX operably linking the antibody single light chain variable domain to an
XX immunoglobulin skeleton. The method is useful for generating an
XX immunoglobulin molecule of predetermined epitope binding specificity. The
XX immunoglobulin molecules are useful for preventing, suppressing or
XX treating inflammatory states, allergic hypersensitivity, cancer,
XX bacterial or viral infection, and autoimmune disorders. This sequence
XX represents the protein from a dummy immunoglobulin Vh clone from the
XX method to generate the immunoglobulin molecules of the invention.
XX
XX Sequence 116 AA;
XX
XX Query Match 100.0%; Score 506; DB 8; Length 116;
XX Best Local Similarity 100.0%; Pred. No. 3.7e-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 60
XX |||||
XX 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 60
XX
XX 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
XX |||||
XX 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
XX
XX RESULT 40
XX ADS78329
XX ID ADS78329 standard; protein; 116 AA.
XX
XX AC ADS78329;
XX
XX 16-DEC-2004 (first entry)
XX
XX DP47-JH4b Vh framework sequence, SEQ ID 2.
XX
XX Antibacterial; Antinflammatory; Immunosuppressive; Cytostatic;
XX Antidiabetic; Antiarthritic; Antirheumatic; Respiratory; Virucide;
XX Hepatotropic; antibody single variable domain; antibody; variable domain;
XX TNFalpha; sepsis; inflammation; cancer; autoimmune disorder; diabetes;
XX rheumatoid arthritis; transplantation rejection; pulmonary disorder;

```

```

KW hepatitis; heavy chain variable domain; heavy chain; variable domain; VH;
KW DP47-JH4b.
OS Synthetic.
XX
XX Key Location/Qualifiers
XX Region 31..35 /label= HCDR1
XX Region 50..66 /label= HCDR2
XX Region 99..105 /label= HCDR3
XX
XX WO2004081026-A2.
XX
XX 23-SEP-2004.
XX
XX 30-JUN-2004; 2004WO-GB002829.
XX
XX 30-JUN-2003; 2003WO-GB002804.
XX 08-OCT-2003; 2003US-0509613P.
XX 08-JAN-2004; 2004US-0535076P.
XX
XX (DOMA-) DOMANTIS LTD.
XX
XX Basran A;
XX
XX WPI; 2004-737199/72.
XX N-PSDB; ADS78328.
XX
XX Novel polymer-linked antibody single variable domain, in which polymer is
XX linked to cysteine or lysine residue, useful for treating inflammation,
XX cancer, autoimmune disorders, transplantation rejection, pulmonary
XX disorder or hepatitis.
XX
XX Disclosure; SEQ ID NO 2; 171pp; English.
XX
XX The present invention relates to polymer-linked antibody single variable
XX domain proteins (dAB) (I) which have a half-life of 1.3 or more hours,
XX where the polymer is linked to dAB at a cysteine or lysine of the dAB.
XX One such polymer which can be linked to the dAB is PEG. (I) preferably
XX has specificity for TNFalpha. The PEG-linked dAB comprise a heavy chain
XX variable domain (VH) framework selected from the group consisting of
XX DP47, DP45 and DP38; and/ or the light chain variable domain (VL)
XX framework is DPK9. (I) is useful for treating sepsis, inflammation,
XX cancer, autoimmune disorders (e.g., diabetes or rheumatoid arthritis),
XX transplantation rejection, pulmonary disorder or hepatitis, or for
XX diagnosing above disorders. The present sequence is the VH framework
XX sequence based on germline sequence DP47-JH4b.
XX
XX Sequence 116 AA;
XX
XX Query Match 100.0%; Score 506; DB 8; Length 116;
XX Best Local Similarity 100.0%; Pred. No. 3.7e-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 60
XX |||||
XX 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 60
XX
XX 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
XX |||||
XX 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
XX
XX RESULT 41
XX ADT88238
XX ID ADT88238 standard; protein; 116 AA.
XX
XX AC ADT88238;
XX
XX 30-DEC-2004 (first entry)
XX

```

DE Human antibody VH DUMMY protein.
 XX
 KW Antiinflammatory; antiallergic; dermatological; immunosuppressive;
 KW antiasthmatic; antibacterial; antidiabetic; antiarthritic; antirheumatic;
 KW cyostatic; neuroprotective; muscular; virucide; immunoglobulin; Ig;
 KW inflammatory disease; allergic hypersensitivity; asthma; cancer;
 KW bacterial infection; viral infection; autoimmune disease;
 KW type I diabetes; multiple sclerosis; rheumatoid arthritis;
 KW systemic lupus erythematosus; Crohn's disease; myasthenia gravis; human;
 KW VH; heavy chain variable domain; antibody.
 XX
 OS Homo sapiens.
 XX
 PN US2004202995-A1.
 XX
 XX 14-OCT-2004.
 XX
 XX 09-APR-2003; 2003US-00409814.
 XX
 XX 09-APR-2003; 2003US-00409814.
 XX
 XX (DOMA-) DOMANTIS.
 XX
 XX De Wildt RMT, Jespers L, Tomlinson IM;
 XX
 DR WPI; 2004-728000/71.
 DR N-PSDB; ADT88237.
 XX
 XX Novel immunoglobulin (Ig) variable region fusion polypeptide having
 PT signal peptide of bacteriophage protein linked to amino acid sequence
 PT with tag and to Ig variable region polypeptide, useful in selecting Ig
 PT polypeptide binding to target.
 XX
 XX Example; SEQ ID NO 2; 32pp; English.
 PS
 CC The invention relates to a novel immunoglobulin (Ig) variable region
 CC fusion polypeptide which comprises a signal peptide of a bacteriophage
 CC protein, an amino acid sequence tag and an Ig variable region
 CC polypeptide. The invention also provides nucleic acid molecules encoding
 CC such fusion polypeptides. Sequences of the invention are useful in
 CC producing nucleic acid library and peptide library that are useful in
 CC selecting a population of Ig variable region polypeptides that bind a
 CC target ligand, from repertoire of polypeptides. They are also useful in
 CC preventing, suppressing or treating inflammatory diseases, allergic
 CC hypersensitivity, asthma, cancer, bacterial or viral infection and
 CC autoimmune diseases including Type I diabetes, multiple sclerosis,
 CC rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease and
 CC myasthenia gravis. The present sequence is human antibody VH (heavy chain
 CC variable domain) DUMMY protein.
 XX
 XX Sequence 116 AA;
 PS
 CC Query Match 100.0%; Score 506; DB 8; Length 116;
 CC Best Local Similarity 100.0%; Pred. No. 3.7e-42;
 CC Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSISGSGSTYY 60
 DB 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSISGSGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQNMNSLRADTAIVYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQNMNSLRADTAIVYCAK 98
 RESULT 42
 ADU86514
 ID ADU86514 standard; protein; 116 AA.
 XX
 AC ADU86514;
 XX
 DT 10-FEB-2005 (first entry)
 XX

DE Immunoglobulin heavy chain variable region DP47dummy seqid 3.
 XX
 KW antiinflammatory; antibacterial; virucide; cytostatic; antiporiatic;
 KW antidiabetic; vasotropic; vaccine; protein purification; protein folding;
 KW diagnosis; inflammation; immune disorder; allergic hypersensitivity;
 KW infection; autoimmune disease; asthma; psoriasis;
 KW insulin dependent diabetes; multiple sclerosis; rheumatoid arthritis;
 KW systemic lupus erythematosus; myasthenia gravis; hematological disease;
 KW neoplasm; immunoglobulin; heavy chain variable region; DP47dummy; DP47d.
 XX
 OS Homo sapiens.
 XX
 PN WO2004101790-A1.
 XX
 XX 25-NOV-2004.
 XX
 XX 14-MAY-2004; 2004WO-GB002102.
 XX
 XX 14-MAY-2003; 2003US-0470340P.
 PR 17-MAR-2004; 2004US-0554021P.
 XX
 XX (DOMA-) DOMANTIS LTD.
 XX
 XX Jespers LS, Jones PC, Famm KHJ, Winter GP;
 XX
 DR WPI; 2004-821888/81.
 DR N-PSDB; ADU86512.
 XX
 XX Recovering a polypeptide that unfolds reversibly from a repertoire of
 PT polypeptides for treating e.g., cancer, by unfolding a portion of the
 PT displayed polypeptides and refolding a portion of the unfolded
 PT polypeptides.
 XX
 XX Disclosure; SEQ ID NO 3; 222pp; English.
 PS
 CC The invention describes a method of recovering a polypeptide that unfolds
 CC reversibly from a repertoire of polypeptides that unfolds reversibly and
 CC has a common selectable characteristic that distinguishes folded
 CC polypeptides from unfolded or misfolded polypeptides. The method
 CC comprises providing a polypeptide display system comprising the
 CC repertoire of displayed polypeptides; unfolding at least a portion of the
 CC displayed polypeptides; refolding at least a portion of the unfolded
 CC polypeptides; and recovering at least one polypeptide that unfolds
 CC reversibly and has the selectable characteristic from the refolded
 CC portion. The method is useful in recovering a polypeptide that unfolds
 CC reversibly from a repertoire of polypeptides that unfolds reversibly. The
 CC library or repertoire is useful for selecting a polypeptide comprising an
 CC antibody variable domain that unfolds reversibly or a polypeptide that
 CC refolds reversibly and comprising an antibody format. The polypeptide is
 CC useful in the manufacture of a medicament for diagnosing, treating or
 CC preventing a disease or medical condition mediated by a cytokine,
 CC cytokine receptor, enzyme, enzyme co-factor or DNA binding protein, such
 CC as an inflammatory state, allergic hypersensitivity, cancer, bacterial or
 CC viral infection or an autoimmune disorder, e.g., asthma, psoriasis, Type
 CC I diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus
 CC erythematosus, Crohn's disease, myasthenia gravis, leukemia or solid
 CC tumor. This is the amino acid sequence of human immunoglobulin heavy
 CC chain variable region DP47dummy (DP47d) that can be used in the screening
 CC and detection of reversibly unfolded proteins.
 XX
 XX Sequence 116 AA;
 PS
 CC Query Match 100.0%; Score 506; DB 8; Length 116;
 CC Best Local Similarity 100.0%; Pred. No. 3.7e-42;
 CC Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSISGSGSTYY 60
 DB 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSISGSGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQNMNSLRADTAIVYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQNMNSLRADTAIVYCAK 98

```

RESULT 43
ID ADZ41141 standard; protein; 116 AA.
XX
AC ADZ41141;
XX
DT 30-JUN-2005 (first entry)
XX
DE Dummy VH chain based on antibodies V3-23/DP47 and JH4b, SEQ ID 2.
XX
KW Single chain antibody; antibody engineering; inflammation;
KW antiinflammatory; sepsis; antibacterial; immunosuppressive; infection;
KW hypersensitivity; antiallergic; immunosuppressive; immune disorder;
KW cancer; cytostatic; neoplasm; autoimmune disease; diabetes; antidiabetic;
KW endocrine disease; gastrointestinal disease; metabolic disorder;
KW rheumatoid arthritis; antiarthritic; antirheumatic;
KW musculoskeletal disease; multiple sclerosis; neuroprotective;
KW neurological disease; Crohn's disease; gastrointestinal-gen.;
KW gastrointestinal disease; ulcerative colitis; antiulcer; aplastic anemia;
KW antianemic; hematological disease; hashimoto's disease; antithyroid;
KW graves disease; reiter's syndrome; ophthalmological; uropathic;
KW transplant rejection; graft versus host disease; pulmonary disease;
KW respiratory-gen.; respiratory disease; pulmonary fibrosis;
KW myocardial ischemia; cardiac; vasotropic; cardiovascular disease;
KW bone disease; osteopathic; hepatitis; hepatotropic; reperfusion injury;
KW injury; fever; antipyretic; temperature disorder.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2005035572-A2.
XX
XX
PD 21-APR-2005.
XX
XX
PF 08-OCT-2004; 2004WO-GB004253.
XX
XX
PR 08-OCT-2003; 2003US-0509613P.
PR 08-JAN-2004; 2004US-0535076P.
PR 30-JUN-2004; 2004WO-GB002829.
XX
XX
PA (DOMA-) DOMANTIS LTD.
XX
XX
PI Tomlinson I, Baaran A, Jones P;
XX
XX
DR WPI; 2005-306343/31.
DR N-PSDB; ADZ41140.
XX
XX
PT Composition useful for treating or preventing sepsis, autoimmune
PT disorders and pulmonary disorders, comprises polypeptide having single
PT human immunoglobulin variable domain that binds polypeptide antigen, e.g.
PT human cytokine.
XX
XX
PS Example 1; SEQ ID NO 2; 169pp; English.
XX
XX
CC The invention relates to a composition comprising a polypeptide having a
CC single human immunoglobulin variable domain that binds a polypeptide
CC antigen with kd less than or equal to 100 nM, where the polypeptide is
CC present at a concentration of at least 400 microm as determined by
CC absorbance of light at 280 nm wavelength. The polypeptides are termed
CC domain antibodies (dab) and may occur as homodimers or heterodimers
CC (where the second polypeptide is a partner dab which does not bind to the
CC target protein) linked via (Gly4Ser)n linkers. The dab polypeptides
CC contain human framework regions, synthetic/modified complementarity
CC domains (CDR) or contain mutations at positions defined in the
CC specification. dab antibodies were created which bind to TNFalpha, TNF
CC receptor (p55), mouse serum albumin (MSA) and human serum albumin (HSA).
CC The polypeptide is useful for treating or preventing a disease or
CC disorder in an individual in need of treatment, which involves
CC administering the polypeptide to the individual. The polypeptide (or an
CC extended release dosage formulation containing it) is useful for
CC preventing or treating diseases or disorders related to target antigens,

```

```

CC such as inflammation, sepsis, allergic hypersensitivity, cancer,
CC autoimmune disorders (e.g., diabetes, rheumatoid arthritis, multiple
CC sclerosis, Crohn's disease, ulcerative colitis, aplastic anemia,
CC Hashimoto's disease, Graves disease, Reiter's syndrome), transplant
CC rejection, graft versus host disease, pulmonary disorder (e.g., pulmonary
CC fibrosis, pulmonary sarcoidosis), cardiac disorders (e.g., ischemia of
CC heart), inflammatory bone disorders, hepatitis, reperfusion injury and
CC pyrexia. The polypeptide comprises single immunoglobulin variable domain
CC polypeptides that bind target antigen with high affinity and are soluble
CC at high concentration, without aggregation or precipitation. The present
CC sequence represents a dummy or library variable domain used to create the
CC dab antibodies of the invention.
XX
SQ Sequence 116 AA;
Query Match 100.0%; Score 506; DB 9; Length 116;
Best Local Similarity 100.0%; Pred. No. 3.7e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSATISGSGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSATISGSGSTYY 60
Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
RESULT 44
AAR66315
ID AAR66315 standard; protein; 117 AA.
XX
AC AAR66315;
XX
DT 25-MAR-2003 (revised)
DT 03-AUG-1995 (first entry)
XX
XX
DE Human immunoglobulin variable heavy chain #21.
XX
KW Primer; PCR; amplify; human; immunoglobulin; variable; heavy chain;
KW cosmid; placenta; vector; pJB81; E.coli; mammalian.
XX
OS Homo sapiens.
XX
XX
PN WO9426895-A1.
XX
XX
PD 24-NOV-1994.
XX
XX
PF 10-MAY-1993; 93WO-JP000603.
XX
XX
PR 10-MAY-1993; 93WO-JP000603.
XX
XX
PA (NIBS) JAPAN TOBACCO INC.
XX
XX
PI Honjo T, Matsuda F;
XX
XX
DR WPI; 1995-006791/01.
DR N-PSDB; AAR66315.
XX
XX
PT DNA fragment comprising human immunoglobulin Vh genes - for the
PT production of human immunoglobulin in mammalian hosts.
XX
XX
PS Claim 32; Page 60-61; 130pp; Japanese.
XX
XX
CC Protein sequences (AAR6295-51) are novel human immunoglobulin heavy
CC chain sequences encoded by novel isolated genes. The genes (AAQ78939-
CC 79002) were isolated and cloned from a series of cosmid constructs; Y202;
CC Y103; Y21; Y6; Y24; 3-31; M84; M18 and M131, by PCR amplification using
CC primers AAQ78917-38. The genes are subdivided into 5 families of Vh
CC genes. The fragments cover a region of 800 kb. The DNA fragments were
CC isolated from high molecular weight DNA from human placenta. The DNA was
CC partially digested with Taqi restriction enzyme. The fragments were
CC separated by gel electrophoresis and 35-45 kb fractions were collected.

```

CC The fragments were ligated with ClaI-digested cosmid vector pJ881. The
CC ligation products were in vitro packed and infected into E.coli 490A. The
CC fragments were then subcloned by colony hybridisation. The Vh genes and
CC the DNA fragments encoding them are useful in producing human
CC immunoglobulin in mammalian hosts. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 117 AA;
Query Match 100.0%; Score 506; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 3.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVVRQAPGKLEWVSAISGSGSTYY 60
Db 20 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVVRQAPGKLEWVSAISGSGSTYY 79
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 98
Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 117
RESULT 45
ADL92384
ID ADL92384 standard; protein; 120 AA.
XX
AC ADL92384;
XX
DT 20-MAY-2004 (first entry)
XX
DE Anti-HSA human framework dummy VH protein for library 2.
XX
KW immunoglobulin single variable domain; cystostatic; antiinflammatory;
KW antirheumatic; antiarthritic; antiaesthatic; antiallergic; antibacterial;
KW virucide; immunosuppressive; antidiabetic; neuroprotective; muscular;
KW dermatological; gene therapy; inflammatory; rheumatoid arthritis; asthma;
KW Crohn's disease; allergic hypersensitivity; bacterial; viral infection;
KW autoimmune disorder; type I diabetes; multiple sclerosis;
KW myasthenia gravis; systemic lupus erythematosus; cancer; HSA;
KW human serum albumin; human; antibody heavy chain variable region;
KW framework dummy VH.
XX
OS Homo sapiens.
XX
PN WO2004003019-A2.
XX
PD 08-JAN-2004.
XX
PF 30-JUN-2003; 2003WO-GB002804.
XX
PR 28-JUN-2002; 2002WO-GB003014.
PR 27-DEC-2002; 2002GB-00030202.
XX
PA (DOMA-) DOMANTIS LTD.
XX
PI Winter G, Tomlinson I, Ignatovich O, Holt L, De Angelis E;
XX WPI; 2004-142855/14.
DR N-PSDB; ADL92383.
DR
XX
PT New dual-specific ligands, useful in drug discovery and development, or
PT for diagnosing, preventing or treating a disease, such as cancer,
PT autoimmune disease, or inflammatory disease, including rheumatoid
PT arthritis or asthma.
XX
PS Disclosure; Fig 14; 174pp; English.
XX
CC The invention relates to a novel dual-specific ligand comprising a first
CC immunoglobulin single variable domain having a binding specificity to a
CC first epitope or antigen and a second complementary immunoglobulin single
CC variable domain having a binding activity to a second epitope or antigen.
CC The ligand of the invention demonstrates cytostatic, antiinflammatory,
CC antirheumatic, antiarthritic, antiaesthatic, antiallergic, antibacterial,

CC virucide, immunosuppressive, antidiabetic, neuroprotective, muscular and
CC dermatological activities and may be useful in gene therapy, ligand
CC binding assays or for diagnosing, preventing or treating a disease
CC selected from an inflammatory disease such as rheumatoid arthritis,
CC asthma or Crohn's disease, an allergic hypersensitivity, a bacterial or
CC viral infection, an autoimmune disorder such as type I diabetes, multiple
CC sclerosis, myasthenia gravis or systemic lupus erythematosus or cancer.
CC The current sequence is that of the anti-HSA (human serum albumin) human
CC framework dummy VH protein for library 2 of the invention.
XX
SQ Sequence 120 AA;
Query Match 100.0%; Score 506; DB 8; Length 120;
Best Local Similarity 100.0%; Pred. No. 3.9e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVVRQAPGKLEWVSAISGSGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVVRQAPGKLEWVSAISGSGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 98
RESULT 46
ADQ77189
ID ADQ77189 standard; protein; 120 AA.
XX
AC ADQ77189;
XX
DT 07-OCT-2004 (first entry)
XX
DE Dummy VH protein #2.
XX
KW Antiinflammatory; Antiallergic; Cytostatic; Antibacterial; Virucide;
KW Immunosuppressive; Immunotherapy; single domain antibody; dab; TNF alpha;
KW TNF receptor 1; p55; inflammation; allergic hypersensitivity; cancer;
KW bacterial infection; viral infection; autoimmune disorder.
XX
OS Synthetic.
XX
PN WO2004058821-A2.
XX
PD 15-JUL-2004.
XX
PF 24-DEC-2003; 2003WO-GB005646.
XX
PR 27-DEC-2002; 2002GB-00030202.
PR 30-JUN-2003; 2003WO-GB002804.
PR 28-NOV-2003; 2003GB-00027706.
XX
PA (DOMA-) DOMANTIS LTD.
XX
PI Winter G, Tomlinson I, Ignatovich O, Woolven B;
XX WPI; 2004-534127/51.
DR N-PSDB; ADQ77190.
DR
XX
PT New dual specific ligand comprising a first dab specific for a target
PT ligand, and a second dab specific for a receptor for the target ligand,
PT useful for treating inflammation, cancer, allergy or autoimmune diseases.
XX
PS Disclosure; Fig 14; 196pp; English.
XX
CC The present invention relates to a dual specific ligand comprising a
CC first single domain antibody (dab) specific for a target ligand (e.g. TNF
CC alpha), and a second dab specific for a receptor for the target ligand
CC (e.g. TNF receptor 1 (p55)). The dab specific for TNFalpha comprises the
CC amino acid sequence of TAR1-5-19, TAR1-5 or TAR1-27 and the dab specific
CC for TNF receptor 1 (p55) comprises the amino acid sequence of TAR2h-10,
CC TAR2h-5 or TAR2h-10-27. The dual specific ligands are useful for
CC targeting cytokines and other molecules that cooperate synergistically in

CC therapeutic situations in the body of an organism. They are useful for
 CC preventing, suppressing or treating inflammatory states, allergic
 CC hypersensitivity, cancer, bacterial or viral infection, and autoimmune
 CC disorders. The present sequence is a heavy chain variable domain sequence
 CC used to illustrate the invention.

XX
 SQ Sequence 120 AA;

Query Match 100.0%; Score 506; DB 8; Length 120;
 Best Local Similarity 100.0%; Pred. No. 3.9e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
 Db 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60

Qy 61 ADSVKGRTISRDNKNTLYLQNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRTISRDNKNTLYLQNSLRAEDTAVYYCAK 98

RESULT 47
 ADZ41143
 ID ADZ41143 standard; protein; 120 AA.
 XX
 AC ADZ41143;
 XX
 DT 30-JUN-2005 (first entry)
 XX
 DE Dummy VH chain based on antibodies V3-23/DP47 and JH4b, SEQ ID 4.
 XX
 KW Single chain antibody; antibody engineering; inflammation;
 KW antiinflammatory; sepsis; antibacterial; immunosuppressive; infection;
 KW hypersensitivity; antiallergic; immunosuppressive; immune disorder;
 KW cancer; cytostatic; neoplasm; autoimmune disease; diabetes; antidiabetic;
 KW endocrine disease; gastrointestinal disease; metabolic disorder;
 KW rheumatoid arthritis; antiarthritic; antirheumatic;
 KW musculoskeletal disease; multiple sclerosis; neuroprotective;
 KW neurological disease; Crohns disease; gastrointestinal-gen.;
 KW gastrointestinal disease; ulcerative colitis; antiulcer; aplastic anemia;
 KW anemic; hematological disease; hashimoto disease; antithyroid;
 KW graves disease; reiter's syndrome; ophthalmological; uropathic;
 KW transplant rejection; graft versus host disease; pulmonary disease;
 KW respiratory-gen.; respiratory disease; pulmonary fibrosis;
 KW myocardial ischemia; cardiac; vasotropic; cardiovascular disease;
 KW bone disease; osteopathic; hepatitis; hepatotropic; reperfusion injury;
 KW injury; fever; antipyretic; temperature disorder.

XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2005035572-A2.
 XX
 XX 21-APR-2005.
 XX
 XX 08-OCT-2004; 2004WO-GB004253.
 XX
 PR 08-OCT-2003; 2003US-0509613P.
 PR 08-JAN-2004; 2004US-0535076P.
 PR 30-JUN-2004; 2004WO-GB002829.
 XX
 XX (DOMA-) DOMANTIS LTD.
 XX
 PI Tomlinson I, Basran A, Jones P;
 XX
 XX WPI; 2005-306343/31.
 XX N-PSDB; ADZ41142.
 DR
 DR
 DR
 XX Composition useful for treating or preventing sepsis, autoimmune
 PT disorders and pulmonary disorders, comprises polypeptide having single
 PT human immunoglobulin variable domain that binds polypeptide antigen, e.g.
 PT human cytokine.

PS Example 1; SEQ ID NO 4; 169pp; English.
 XX
 CC The invention relates to a composition comprising a polypeptide having a
 CC single human immunoglobulin variable domain that binds a polypeptide
 CC antigen with Kd less than or equal to 100 nM, where the polypeptide is
 CC present at a concentration of at least 400 microm as determined by
 CC absorbance of light at 280 nm wavelength. The polypeptides are termed
 CC domain antibodies (dAb) and may occur as homodimers or heterodimers
 CC (where the second polypeptide is a partner dAb which does not bind to the
 CC target protein linked via (Gly4Ser)n linkers. The dAb polypeptides
 CC contain human framework regions, synthetic/modified complementarity
 CC domains (CDR) or contain mutations at positions defined in the
 CC specification. dAb antibodies were created which bind to TNFalpha, TNF
 CC receptor (p55), mouse serum albumin (MSA) and human serum albumin (HSA).
 CC The polypeptide is useful for treating or preventing a disease or
 CC disorder in an individual in need of treatment, which involves
 CC administering the polypeptide to the individual. The polypeptide (or an
 CC extended release dosage formulation containing it) is useful for
 CC preventing or treating diseases or disorders related to target antigens,
 CC such as inflammation, sepsis, allergic hypersensitivity, cancer,
 CC autoimmune disorders (e.g., diabetes, rheumatoid arthritis, multiple
 CC sclerosis, Crohn's disease, ulcerative colitis, aplastic anemia, multiple
 CC Hashimoto's disease, Graves disease, Reiter's syndrome), transplant
 CC rejection, graft versus host disease, pulmonary disorder (e.g., pulmonary
 CC fibrosis, pulmonary sarcoidosis), cardiac disorders (e.g., ischemia of
 CC heart), inflammatory bone disorders, hepatitis, reperfusion injury and
 CC pyrexia. The polypeptide comprises single immunoglobulin variable domain
 CC polypeptides that bind target antigen with high affinity and are soluble
 CC at high concentration, without aggregation or precipitation. The present
 CC sequence represents a dummy or library variable domain used to create the
 CC dAb antibodies of the invention.

XX
 SQ Sequence 120 AA;

Query Match 100.0%; Score 506; DB 9; Length 120;
 Best Local Similarity 100.0%; Pred. No. 3.9e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
 Db 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60

Qy 61 ADSVKGRTISRDNKNTLYLQNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRTISRDNKNTLYLQNSLRAEDTAVYYCAK 98

RESULT 48
 AEA41074
 ID AEA41074 standard; protein; 120 AA.
 XX
 AC AEA41074;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Germline VH3-23, DH1-26, JH4 amino acid sequence SEQ ID NO:104.
 XX
 KW monoclonal antibody; macrophage colony stimulating factor inhibition;
 KW heavy chain.
 XX
 OS Unidentified.
 XX
 PN GB2405873-A.
 XX
 XX 16-MAR-2005.
 XX
 XX 09-SEP-2004; 2004GB-00020044.
 XX
 XX 10-SEP-2003; 2003US-0502163P.
 PR
 XX (WARN) WARNER LAMBERT CO LLC.
 PA (ABGE-) ABGENIX INC.
 PA
 XX


```

XX 04-APR-2001; 2001US-0281024P.
XX (ZLBB-) ZLB BIOPLASMA AG.
XX Miescher S;
XX WPI; 2003-103348/09.
XX Identifying and obtaining inhibitor of a pathological process for
XX treating e.g. autoimmunity comprises determining if a compound is capable
XX of modulating the binding of the Fc-epsilon-R1 receptor and an
XX autoantibody against its alpha-chain.
XX Claim 20; Page 22; 29pp; English.
XX The present invention describes a method for identifying and obtaining an
XX inhibitor of a pathological process. The method comprises determining if
XX a compound is capable of modulating the binding of the Fc-epsilon-R1
XX receptor alpha-chain and an autoantibody against its alpha-chain. Also
XX described: (1) use of the autoantibody against the Fc-epsilon-R1 receptor
XX alpha-chain for identifying and obtaining an inhibitor of a pathological
XX process; (2) use of the identified inhibitor for inhibiting activity of
XX the autoantibody against the Fc-epsilon-R1 receptor alpha-chain; and (3)
XX a compound identified by the method, which binds but does not activate
XX the epsilon-R1 receptor alpha-chain. The method is useful for obtaining an
XX inhibitor of a pathological process e.g. imbalance between cell-bound and
XX free IgE e.g. allergic disease (urticaria, late phase allergic reactions,
XX intrinsic asthma, drug intolerance and food intolerance), IgE mediated
XX disease or malignancy. The compound is useful for treating a pathological
XX process, particularly conditional autoimmunity. The present sequence
XX represents a human recombinant anti-Fc-epsilon-R1 alpha autoantibody
XX heavy chain protein sequence from the present invention
XX
SQ Sequence 121 AA;
      Query Match      100.0%; Score 506; DB 6; Length 121;
      Best Local Similarity 100.0%; Pred. No. 3.9e-42;
      Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPKGLEWVSAISGGSGTTY 60
Db 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPKGLEWVSAISGGSGTTY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRADTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRADTAVYYCAK 98

RESULT 51
ABP56506
ID ABP56506 standard; protein; 121 AA.
XX
XX AC ABP56506;
XX
XX DT 20-MAR-2003 (first entry)
XX
XX DE Human anti-Fc-epsilon-R1 alpha autoantibody heavy chain UM-alpha-16.
XX
XX KW Autoantibody; Fc-epsilon-R1 receptor alpha-chain; immunosuppressive;
XX allergic disease; urticaria; late phase allergic reaction; malignancy;
XX intrinsic asthma; drug intolerance; food intolerance; immunoglobulin E;
XX conditional autoimmunity; IgE mediated disease.
XX
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX PN WO200282085-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-EP003660.

```

```

XX 04-APR-2001; 2001US-0281024P.
XX (ZLBB-) ZLB BIOPLASMA AG.
XX Miescher S;
XX WPI; 2003-103348/09.
XX Identifying and obtaining inhibitor of a pathological process for
XX treating e.g. autoimmunity comprises determining if a compound is capable
XX of modulating the binding of the Fc-epsilon-R1 receptor and an
XX autoantibody against its alpha-chain.
XX Claim 20; Page 22; 29pp; English.
XX The present invention describes a method for identifying and obtaining an
XX inhibitor of a pathological process. The method comprises determining if
XX a compound is capable of modulating the binding of the Fc-epsilon-R1
XX receptor alpha-chain and an autoantibody against its alpha-chain. Also
XX described: (1) use of the autoantibody against the Fc-epsilon-R1 receptor
XX alpha-chain for identifying and obtaining an inhibitor of a pathological
XX process; (2) use of the identified inhibitor for inhibiting activity of
XX the autoantibody against the Fc-epsilon-R1 receptor alpha-chain; and (3)
XX a compound identified by the method, which binds but does not activate
XX the epsilon-R1 receptor alpha-chain. The method is useful for obtaining an
XX inhibitor of a pathological process e.g. imbalance between cell-bound and
XX free IgE e.g. allergic disease (urticaria, late phase allergic reactions,
XX intrinsic asthma, drug intolerance and food intolerance), IgE mediated
XX disease or malignancy. The compound is useful for treating a pathological
XX process, particularly conditional autoimmunity. The present sequence
XX represents a human recombinant anti-Fc-epsilon-R1 alpha autoantibody
XX heavy chain protein sequence from the present invention
XX
SQ Sequence 121 AA;
      Query Match      100.0%; Score 506; DB 6; Length 121;
      Best Local Similarity 100.0%; Pred. No. 3.9e-42;
      Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPKGLEWVSAISGGSGTTY 60
Db 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPKGLEWVSAISGGSGTTY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRADTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRADTAVYYCAK 98

RESULT 52
ADP22356
ID ADP22356 standard; protein; 122 AA.
XX
XX AC ADP22356;
XX
XX DT 09-SEP-2004 (first entry)
XX
XX DE Human anti-TNFA antibody heavy chain variable region SEQ ID NO:262.
XX
XX KW human; monoclonal antibody; tumour necrosis factor-alpha; TNFA;
XX anti-TNFA antibody; anabolic; antiarteriosclerotic; antiarthritic;
XX antibacterial; antiinflammatory; antipapillary; antirheumatic;
XX eating-disorder; immunomodulator; immunosuppressive; nephrotropic;
XX neuroprotective; vasotropic; antiapoptotic; TNFA antagonist;
XX TNF induced apoptosis; neoplastic disease; breast cancer; ovarian cancer;
XX bladder cancer; lung cancer; glioblastoma; stomach cancer;
XX endometrial cancer; kidney cancer; colon cancer; pancreatic cancer;
XX prostate cancer; immuno-mediated inflammatory disease;
XX rheumatoid arthritis; glomerulonephritis; atherosclerosis; psoriasis;
XX restenosis; autoimmune disease; Crohn's disease; graft-host reaction;
XX septic shock; cachexia; anorexia; multiple sclerosis.
XX

```

```

OS Homo sapiens.
XX WO2004050693-A2.
XX 17-JUN-2004.
XX 02-DEC-2003; 2003WO-US038281.
XX 02-DEC-2002; 2002US-0430729P.
XX (ABGE-) ABGENIX INC.
XX Babcock JS, Kang JS, Foord O, Green L, Feng X, Klokamp S;
XX Haak-Frendscho M, Rathanaswami P, Pigott C, Liang ML, Lee R;
XX Manchulenchko K, Faggioni R, Senaldi G, Qiaojuan JS;
XX WPI; 2004-480601/45.
XX N-PSDB; ADP22355.
XX New recombinant human monoclonal antibody that specifically binds to
XX Tumor Necrosis Factor-alpha, useful for treating neoplastic disease such
XX as cancers, or immuno-mediated inflammatory diseases such as rheumatoid
XX arthritis.
XX Example 10; SEQ ID NO 262; 213pp; English.
XX The present invention describes a human monoclonal antibody (I) that
XX specifically binds to tumour necrosis factor-alpha (TNFa) and comprises:
XX (a) a heavy chain complementarity determining region 1 (CDR1) having the
XX two fully defined 5 amino acid sequence (S1, ADP22417) or (S2, ADP22421);
XX and (b) a light chain CDR1 having the two fully defined 11 amino acid
XX sequence (S3, ADP22418) or (S4, ADP22424). Also described: (1) assaying
XX (M1) the level of TNFa in a patient sample, comprising contacting with
XX (I), and detecting the level of binding between the antibody and TNFa in
XX the sample; (2) a composition comprising the antibody or its functional
XX fragment and a carrier; (3) treating (M2) an animal suffering from a
XX neoplastic, or an immuno-mediated inflammatory disease by selecting an
XX animal in need of treatment for the disease by administering the human
XX monoclonal antibody of (I); and (4) inhibiting (M3) TNFa induced
XX apoptosis in an animal by selecting an animal in need of treatment for
XX TNFa induced apoptosis by administering the human monoclonal antibody of
XX (I). (I) has anabolic, antiarteriosclerotic, antiarthritic,
XX antibacterial, antiinflammatory, antiposoriatic, antirheumatic, eating-
XX disorders, immunomodulator, immunosuppressive, nephrotropic,
XX neuroprotective, vasotropic and antiapoptotic activities, and can be used
XX as a TNFa antagonist. The antibody (I) is useful in the preparation of
XX medicament for treating TNF induced apoptosis, neoplastic disease such as
XX breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma,
XX stomach cancer, endometrial cancer, kidney cancer, colon cancer,
XX pancreatic cancer, and prostate cancer; or immuno-mediated inflammatory
XX diseases such as rheumatoid arthritis, glomerulonephritis,
XX atherosclerosis, psoriasis, restenosis, autoimmune disease, Crohn's
XX disease, graft-host reactions, septic shock, cachexia, anorexia, and
XX multiple sclerosis. The present sequence represents a human anti-TNPa
XX antibody heavy chain variable region, which is used in the
XX exemplification of the present invention.
XX
SQ Sequence 122 AA;
Query Match 100.0%; Score 506; DB 8; Length 122;
Best Local Similarity 100.0%; Pred. No. 4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

```

```
RESULT 54
ADP46964
ID ADP46964 standard; protein; 126 AA.
XX
XX
AC ADP46964;
XX
XX
DT 09-SEP-2004 (first entry)
XX
XX Murine heavy chain variable anti-amphetamine antibody protein SeqID 20.
XX
XX murine; mouse; antibody; amphetamine; methamphetamine; phencyclidine;
XX PCP; drug addiction; antiaddictive; antibody therapy.
XX
XX Mus musculus.
XX
XX Key Location/Qualifiers
XX FT Misc-difference 99..105
XX FT /label=Xaa
XX FT /note="Xaa can be any amino acid"
XX
XX WO2004050032-A2.
XX
XX 17-JUN-2004.
XX
XX 02-DEC-2003; 2003WO-US038384.
XX
XX 02-DEC-2002; 2002US-0430717P.
XX
XX (ABGE-) ABGENIX INC.
XX
XX Owens SM, Carroll FI, Abraham P, Gunnell MG, Haak-Frendscho M;
XX Feng X;
XX
XX WPI; 2004-460981/43.
XX
XX New isolated antibody or its binding fragment that binds specifically to
XX a drug of abuse, useful for treating a patient suffering from addiction
XX to a drug of abuse, e.g. amphetamine, methamphetamine, or phencyclidine.
XX
XX Example 1; SEQ ID NO 20; 88pp; English.
XX
XX This invention relates to novel antibodies, or binding fragments thereof,
XX that bind directly to various drugs of abuse. Specifically, it refers to
XX human or chimeric monoclonal antibodies that are capable of binding to
XX amphetamine, methamphetamine or phencyclidine (PCP). The present
XX invention describes generating hybridoma cell lines that produce such
XX antibodies and transforming a cell with a gene encoding the antibody,
XX which when conjugated to a therapeutic agent, toxin or radioisotope can
XX be used to treat a patient suffering from a drug addiction. Accordingly,
XX these compositions exhibit antiaddictive activities and can be used for
XX antibody therapy to treat patients suffering from a drug addiction. This
XX polypeptide sequence is a murine heavy chain variable anti-amphetamine
XX antibody of the invention.
XX
XX Sequence 126 AA;
XX
XX Query Match 100.0%; Score 506; DB 8; Length 126;
XX Best Local Similarity 100.0%; Pred. No. 4.1e-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
XX |||||
XX Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
XX |||||
XX Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRADTAVYYCAK 98
XX |||||
XX Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRADTAVYYCAK 98
XX |||||
XX
XX RESULT 55
XX ADS12493
XX ID ADS12493 standard; protein; 127 AA.
XX
XX
XX
XX ADS12493;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human IGF-1R 11A2 VH antibody protein Seq 124.
XX
XX human; antibody; insulin-like growth factor I receptor; IGF-IR;
XX somatomedin-C; cancer; inflammation; pathological liver condition;
XX cytostatic; antiinflammatory; hepatotropic; gene therapy.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX WO2004083248-A1.
XX
XX 30-SEP-2004.
XX
XX 04-MAR-2004; 2004WO-IB000646.
XX
XX 14-MAR-2003; 2003US-0455094P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Morton PA, Arbuckle JA, Bailey KJ, Nicaastro PJ, Runnels HA;
XX WPI; 2004-691024/67.
XX
XX New antibody that specifically binds to insulin-like growth factor I
XX receptor for diagnosing or treating cancer, inflammation or pathological
XX liver conditions.
XX
XX Disclosure; SEQ ID NO 124; 258pp; English.
XX
XX This invention relates to a novel antibody or its antigen binding portion
XX that binds to the insulin-like growth factor I receptor (IGF-IR), also
XX known as somatomedin-C, in order to inhibit binding of IGF-I and IGF-II
XX to the receptor (IGF-IR). Specifically, it refers to an IGF-IR antibody
XX selected from PINT-6A1, PINT-7A2, PINT-7A4, PINT-7A5, PINT-7A6, PINT-8A1,
XX PINT-9A2, PINT-11A1, PINT-11A2, PINT-11A3, PINT-11A4, PINT-11A5, PINT-
XX 11A7, PINT-11A12, PINT-12A1, PINT-12A2, PINT-12A3, PINT-12A4, and PINT-
XX 12A5 or fragments derived thereof. The present invention describes an
XX isolated cell line (and non-human transgenic animals) useful for
XX expressing nucleic acid molecules that encode at least one variable light
XX (VL) and at least one variable heavy (VH) chain antibody regions, as well
XX as the pharmaceutical compositions derived thereof. Accordingly, it
XX provides a method of diagnosing the presence or location of an IGF-IR-
XX expressing tissue, a method for treating diseases such as cancer, as well
XX as diagnosing or treating inflammation and other pathological liver
XX conditions. As such, these compositions exhibit cytostatic,
XX antiinflammatory and hepatotropic activities and can be used for gene
XX therapy purposes. This polypeptide sequence is a human IGF-IR variable
XX heavy chain antibody protein of the invention.
XX
XX Sequence 127 AA;
XX
XX Query Match 100.0%; Score 506; DB 8; Length 127;
XX Best Local Similarity 100.0%; Pred. No. 4.1e-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
XX |||||
XX Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
XX |||||
XX Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRADTAVYYCAK 98
XX |||||
XX Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRADTAVYYCAK 98
XX |||||
XX
XX RESULT 56
XX AAE07014
XX ID AAE07014 standard; protein; 128 AA.
XX
XX
XX
XX AAE07014;
```

XX
DT 16-OCT-2001 (first entry)
XX Human heavy chain variable (VH) region, 038062.
XX
XX Human, humanised antibody; CC-chemokine receptor 2; CCR2; nephrotropic;
KW neuroprotective; immunosuppressive; human immunodeficiency virus;
KW HIV infection; cytostatic; vasotropic; leukocyte trafficking; allergy;
KW inflammatory disorder; autoimmune disorder; rheumatoid arthritis; shock;
KW multiple sclerosis; atherogenesis; atherosclerosis; restenosis; asthma;
KW anaphylaxis; malignancy; inflammation; stenosis; allograft rejection;
KW fibrotic disease; angioptasty; acquired immune deficiency syndrome; AIDS;
KW inflammatory glomerulopathy; vascular intervention; LD9 antibody;
KW neonatal hyperplasia; VH; heavy chain variable region.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Region 31..35
XX /label= CDR1
XX /note= "Complementarity determining region 1"
XX Region 50..66
XX /label= CDR2
XX /note= "Complementarity determining region 2"
XX Region 99..117
XX /label= CDR3
XX /note= "Complementarity determining region 3"
XX Misc-difference 109
XX /label= Unknown
XX
XX WO200157226-A1.
XX
XX 09-AUG-2001.
XX
XX 02-FEB-2001; 2001WO-US003537.
XX
XX 03-FEB-2000; 2000US-00497625.
XX (MILL-) MILLENNIUM PHARM INC.
XX Larosa GJ, Horvath C, Newman W, Jones ST, O'brien S, O'keefe T;
XX WPI; 2001-48888/53.
XX
XX Humanized immunoglobulin for treating a CC-chemokine receptor 2-mediated
XX disorder in a patient, comprises a binding specificity for CCR2, and a
XX non-human antigen binding region and human immunoglobulin.
XX
XX Disclosure; Page 168; 183pp; English.
XX
XX The patent discloses a humanised antibody or its antigen-binding
XX fragment, having binding specificity for CC-chemokine receptor 2 (CCR2),
XX comprising an antigen binding region of non-human origin and at least a
XX portion of an immunoglobulin of human origin. The humanised antibodies
XX are useful for inhibiting the interaction of a cell expressing CCR2. They
XX are useful for inhibiting or treating HIV infection. The proteins of the
XX invention are useful for inhibiting leukocyte trafficking, for treating
XX CCR2-mediated disorders such as inflammatory disorder, autoimmune
XX disorders such as rheumatoid arthritis and multiple sclerosis,
XX atherogenesis and atherosclerosis, and for inhibiting restenosis. They
XX are useful in therapy or diagnosis, and in the manufacture of a
XX medicament for treating CCR-2 mediated disease. They are also useful for
XX treating allergy, anaphylaxis, malignancy, chronic reaction and acute
XX inflammation, histamine and IgE- mediated allergic reaction, shock,
XX stenosis, allograft rejection, fibrotic disease, asthma, inflammatory
XX glomerulopathies, acquired immune deficiency syndrome (AIDS), restenosis
XX associated with vascular intervention, including angioptasty and/or stent
XX placement in a mammal. Humanised antibodies are also useful for
XX inhibiting narrowing of the lumen of a vessel in a mammal, and inhibiting
XX neointimal hyperplasia of a vessel in a mammal, preferably associated
XX with vascular intervention. The present sequence is human heavy chain
XX variable (VH) region, 038062

SQ Sequence 128 AA;
Query Match 100.0%; Score 506; DB 4; Length 128;
Best Local Similarity 100.0%; Pred. No. 4.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVOLLESGGLVOPGGSLRLSCAASGFTFSSVAMSVWRQAPGKLEWVSAISGGSTYY 60
DB 1 EVOLLESGGLVOPGGSLRLSCAASGFTFSSVAMSVWRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
RESULT 57
ADQ89299
ID ADQ89299 standard; protein; 128 AA.
XX
AC ADQ89299;
XX
DT 21-OCT-2004 (first entry)
XX
DE Human immunoglobulin protein #26.
XX
KW Human; immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2;
KW CCR2; inflammatory disease; autoimmune disorder; graft rejection;
KW HIV infection; atherosclerosis; antiinflammatory; immunosuppressive;
KW anti-HIV; virucide; antiarteriosclerotic.
XX
OS Homo sapiens.
XX
PN US2004151721-A1.
XX
PD 05-AUG-2004.
XX
PF 10-DEC-2003; 2003US-00733563.
XX
PR 19-OCT-2001; 2001US-0350166P.
PR 26-JUN-2002; 2002US-0392364P.
PR 17-OCT-2002; 2002US-00272899.
XX
XX (OKEE/) O'KEEFE T.
XX (PONA/) PONA P.
XX O'keefe T, Ponath P;
XX
XX WPI; 2004-580175/56.
XX
XX New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
XX useful for diagnosing and/or treating inflammatory or autoimmune
XX diseases, and HIV infection.
XX
XX Disclosure; SEQ ID NO 77; 128pp; English.
XX
XX The invention relates to humanised immunoglobulin heavy and light chains
XX which have specificity for the CC-chemokine receptor 2 (CCR2) and an
XX immunoglobulin or its antigen binding fragment comprising the chains. The
XX humanised immunoglobulin or its antigen binding fragment preferably
XX comprises two heavy chains and two light chains. The humanised
XX immunoglobulin and its heavy and light chains are useful for the
XX diagnosis, prevention and/or treatment of diseases or conditions
XX associated with aberrant expression or activity of the CCR2 polypeptide,
XX such as inflammatory diseases, autoimmune disorders, graft rejection, HIV
XX infection and atherosclerosis. This sequence represents a human
XX immunoglobulin protein of the invention.
XX
SQ Sequence 128 AA;
Query Match 100.0%; Score 506; DB 8; Length 128;
Best Local Similarity 100.0%; Pred. No. 4.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSQAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
 |||||
 Db 1 EVQLLESGGGLVQPGGSLRLSQAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
 |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 |||||
 Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 |||||

RESULT 58
 ADQ89301
 ID ADQ89301 standard; protein; 128 AA.
 XX
 AC ADQ89301;
 XX
 AC
 DT 21-OCT-2004 (first entry)
 XX
 DE Human immunoglobulin protein #28.
 XX
 KW Human; immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2;
 KW CCR2; inflammatory disease; autoimmune disorder; graft rejection;
 KW HIV infection; atherosclerosis; antiinflammatory; immunosuppressive;
 KW anti-HIV; virucide; antiarteriosclerotic.
 XX
 OS Homo sapiens.
 XX
 OS
 XX US2004151721-A1.
 PN
 XX
 XX 05-AUG-2004.
 PD
 XX 10-DEC-2003; 2003US-00733563.
 PF
 XX 19-OCT-2001; 2001US-0350166P.
 PR
 XX 26-JUN-2002; 2002US-0392364P.
 PR
 XX 17-OCT-2002; 2002US-00272899.
 XX
 PA (OKEE/) O'KEEFE T.
 PA (PONA/) PONATH P.
 XX
 XX O'keefe T, Ponath P;
 XX
 XX WPI; 2004-580175/56.
 DR
 XX
 XX New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
 PT useful for diagnosing and/or treating inflammatory or autoimmune
 PT diseases, and HIV infection.
 XX
 XX Disclosure; SEQ ID NO 79; 128pp; English.
 PS
 XX The invention relates to humanised immunoglobulin heavy and light chains
 CC which have specificity for the CC-chemokine receptor 2 (CCR2) and an
 CC immunoglobulin or its antigen binding fragment comprising the chains. The
 CC humanised immunoglobulin or its antigen binding fragment preferably
 CC comprises two heavy chains and two light chains. The humanised
 CC immunoglobulin and its heavy and light chains are useful for the
 CC diagnosis, prevention and/or treatment of diseases or conditions
 CC associated with aberrant expression or activity of the CCR2 polypeptide,
 CC such as inflammatory diseases, autoimmune disorders, graft rejection, HIV
 CC infection and atherosclerosis. This sequence represents a human
 CC immunoglobulin protein of the invention.
 XX
 SQ Sequence 128 AA;

Query Match 100.0%; Score 506; DB 8; Length 128;
 Best Local Similarity 100.0%; Pred. No. 4.2e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSQAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
 |||||
 Db 1 EVQLLESGGGLVQPGGSLRLSQAASGFTFSYAMSWVRQAPGKGLEWVSAISGGSTYY 60
 |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 |||||

Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
 |||||

RESULT 59
 AEB09572
 ID AEB09572 standard; protein; 128 AA.
 XX
 AC AEB09572;
 XX
 AC
 DT 08-SEP-2005 (first entry)
 XX
 DE Human heavy chain variable region SEQ ID NO 77.
 XX
 KW antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
 KW antibody engineering; therapeutic; diagnosis; inflammation;
 KW autoimmune disease; immune disorder; graft rejection; HIV infection;
 KW infection; atherosclerosis; cardiovascular disease; metabolic disorder;
 KW heavy chain variable region.
 XX
 OS Homo sapiens.
 XX
 OS
 XX WO2005060368-A2.
 PN
 XX 07-JUL-2005.
 PD
 XX 10-DEC-2003; 2003WO-US039599.
 PF
 XX 10-DEC-2003; 2003WO-US039599.
 PR
 XX (MILL-) MILLENNIUM PHARM INC.
 PA
 XX Okeefe T, Ponath P;
 PI
 XX WPI; 2005-488561/49.
 DR
 XX
 XX New humanized immunoglobulin or its antigen binding portion having
 PT binding specificity for CC-chemokine receptor 2 and having a heavy chain
 PT and light chain, for treating inflammatory diseases, HIV, and autoimmune
 PT diseases.
 XX
 XX Disclosure; SEQ ID NO 77; 192pp; English.
 PS
 XX The invention describes a humanized immunoglobulin (I) or its antigen
 CC binding portion having binding specificity for CC-chemokine receptor 2
 CC (CCR2) and having a heavy chain and a light chain, where the heavy chain
 CC comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)
 CC sequence, given in specification or its portion, and the light chain
 CC comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given
 CC in specification. Also described are: a humanized immunoglobulin heavy
 CC chain, or its antigen binding fragment, having binding specificity for
 CC CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the
 CC amino acid of (SEQ ID NO: 110), or its portion; and a humanized
 CC immunoglobulin light chain, or its antigen binding fragment, having
 CC binding specificity for CCR2 and comprising the amino acid sequence of
 CC (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)
 CC sequence, given in specification. The following are disclosed: isolated
 CC nucleic acid molecules comprising nucleic acid sequence encoding (I); a
 CC construct comprising nucleic acid molecule encoding (I); and host cell
 CC comprising the nucleic acid molecule. (I) is useful as a therapeutic
 CC agent for controlling lymphocyte homing the mucosal lymphoid tissue thus
 CC reducing inflammatory response, for use in the treatment of diseases
 CC associated with leukocyte infiltration of tissue, e.g. in the treatment
 CC of inflammatory diseases, autoimmune diseases, graft rejection, HIV
 CC infection and monocyte-mediated disorders such as atherosclerosis. (I) is
 CC useful for detecting and/or measuring the level of CCR2 in a sample (e.g.
 CC tissues or body fluids such as inflammatory exudates, blood, serum, bowel
 CC fluid), and for modulating binding function and/or leukocyte trafficking
 CC modulated by CCR2. This sequence represents a human heavy chain variable
 CC region used in a comparison with a murine 1D9 antibody heavy chain
 CC variable region fragment in the creation of a humanized anti-CCR2-
 CC antibody.
 XX
 SQ Sequence 128 AA;

Query Match 100.0%; Score 506; DB 9; Length 128;
 Best Local Similarity 100.0%; Pred. No. 4.2e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
 |||||
 DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
 |||||

QY 61 ADSVKGRTISRDNKNTLYLQMSLRADDTAVYYCAK 98
 |||||
 DB 61 ADSVKGRTISRDNKNTLYLQMSLRADDTAVYYCAK 98
 |||||

RESULT 60
 AEB09574
 ID AEB09574 standard; protein; 128 AA.
 AC AEB09574;
 DT 08-SEP-2005 (first entry)
 DE Human heavy chain variable region SEQ ID NO 79.
 XX
 KW antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
 KW antibody engineering; therapeutic; diagnosis; inflammation;
 KW autoimmune disease; immune disorder; graft rejection; HIV infection;
 KW infection; atherosclerosis; cardiovascular disease; metabolic disorder;
 KW heavy chain variable region.
 XX
 OS Homo sapiens.
 XX
 PN WO2005060368-A2.
 XX
 PD 07-JUL-2005.
 XX
 PF 10-DEC-2003; 2003WO-US039599.
 XX
 PR 10-DEC-2003; 2003WO-US039599.
 XX
 PA (MILL-) MILLENNIUM PHARM INC.
 XX
 PI Okeefe T, Ponath P;
 XX
 DR WPI; 2005-488561/49.
 XX
 PT New humanized immunoglobulin or its antigen binding portion having
 PT binding specificity for CC-chemokine receptor 2 and having a heavy chain
 PT and light chain, for treating inflammatory diseases, HIV, and autoimmune
 PT diseases.
 XX
 PS Disclosure; SEQ ID NO 79; 192pp; English.
 XX
 CC The invention describes a humanized immunoglobulin (I) or its antigen
 CC binding portion having binding specificity for CC-chemokine receptor 2
 CC (CCR2) and having a heavy chain and a light chain, where the heavy chain
 CC comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)
 CC sequence, given in specification or its portion, and the light chain
 CC comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given
 CC in specification. Also described are: a humanized immunoglobulin heavy
 CC chain, or its antigen binding fragment, having binding specificity for
 CC CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the
 CC amino acid of (SEQ ID NO: 110), or its portion; and a humanized
 CC immunoglobulin light chain, or its antigen binding fragment, having
 CC binding specificity for CCR2 and comprising the amino acid sequence of
 CC (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)
 CC sequence, given in specification. The following are disclosed: isolated
 CC nucleic acid molecules comprising nucleic acid sequence encoding (i); a
 CC construct comprising nucleic acid molecule encoding (i); and host cell
 CC comprising the nucleic acid molecule. (i) Is useful as a therapeutic
 CC agent for controlling lymphocyte homing the mucosal lymphoid tissue thus
 CC reducing inflammatory response, for use in the treatment of diseases
 CC associated with leukocyte infiltration of tissue, e.g. in the treatment

CC of inflammatory diseases, autoimmune diseases, graft rejection, HIV
 CC infection and monocyte-mediated disorders such as atherosclerosis. (i) Is
 CC useful for detecting and/or measuring the level of CCR2 in a sample (e.g.
 CC tissues or body fluids such as inflammatory exudates, blood, serum, bowel
 CC fluid), and for modulating binding function and/or leukocyte trafficking
 CC modulated by CCR2. This sequence represents a human heavy chain variable
 CC region used in a comparison with a murine 1D9 antibody heavy chain
 CC variable region fragment in the creation of a humanized anti-CCR2-
 CC antibody.
 XX
 SQ Sequence 128 AA;
 Query Match 100.0%; Score 506; DB 9; Length 128;
 Best Local Similarity 100.0%; Pred. No. 4.2e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
 |||||
 DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
 |||||

QY 61 ADSVKGRTISRDNKNTLYLQMSLRADDTAVYYCAK 98
 |||||
 DB 61 ADSVKGRTISRDNKNTLYLQMSLRADDTAVYYCAK 98
 |||||

RESULT 61
 ADI45736
 ID ADI45736 standard; protein; 136 AA.
 XX
 AC ADI45736;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE Single stranded nucleic acid cleavage method related protein #1.
 XX
 KW single-stranded nucleic acid cleavage; restriction endonuclease;
 KW complementation; genetic package; bacteriophage display library;
 KW antibody fragment.
 XX
 OS Unidentified.
 XX
 PN WO200179481-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012454.
 XX
 PR 17-APR-2000; 2000US-0198069P.
 XX
 PA (DYAX-) DYAX CORP.
 XX
 PI Ladner RC, Cohen EH, Nastri HG, Rookey KL, Hoet R;
 XX
 DR WPI; 2002-011131/01.
 XX
 PT Selective cleavage of single-stranded nucleic acid, useful for preparing
 PT display libraries of proteins and peptides, by hybridization with
 PT oligonucleotide and enzymatic restriction.
 XX
 PS Disclosure; SEQ ID NO 187; 190pp; English.
 XX
 CC The invention relates to a method of cleaving single-stranded (ss)
 CC nucleic acid (I) at a selected location, using an oligonucleotide (ON)
 CC that is complementary to (I) in the target region and a restriction
 CC endonuclease (RE). The ON forms, with its complement in (I), an RE
 CC recognition site that ensures cleavage only at the selected location.
 CC Contact between (I) and ON, and treatment with RE, are done at a
 CC temperature at which (i) (I) is maintained in substantially ss form and
 CC (ii) RE is active. ON is (i) single stranded, and includes a sequence
 CC that forms, with its complement in (I), the RE site or (ii) has a double-
 CC stranded (ds) region that includes a recognition site for a type IIS RE
 CC that cleaves at a remote site formed by complementation of (I) and the ss
 CC region of ON. The method is used to construct libraries of genetic

CC packages (phages) that display diverse families of (poly)peptides and
 CC proteins (A), especially human Fab or other antibody fragments. The
 CC libraries are screened to identify (A) for possible therapeutic use. The
 CC method is not biased to DNAs containing native sequences complementary to
 CC amplification primers and allows any sequences that may be deleterious to
 CC expression to be removed before cloning and display. DNAs are cut only at
 CC a single (constant) site, without the need to build an RE site into the
 CC primers used for reverse transcription or amplification, and any natural
 CC or synthetic site can be used for cleavage. The use of a partially ds ON
 CC allows cleavage at sites where no restriction sites occur naturally or
 CC can be created. Both methods allow use of 5' and 3' primers for maximum
 CC diversity. This sequence represents a protein sequence used in the
 CC invention.

XX SQ Sequence 136 AA;

Query Match 100.0%; Score 506; DB 5; Length 136;
 Best Local Similarity 100.0%; Pred. No. 4.5e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSGSTYY 60
 Db 7 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSGSTYY 66

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
 Db 67 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 104

RESULT 62
 ABP55473
 ID ABP55473 standard; protein; 136 AA.
 AC ABP55473;
 XX
 DT 18-FEB-2003 (first entry)
 DE Synthetic 3-23 VH protein sequence SEQ ID NO:487.
 XX Library; cleavage; display; diverse family.
 XX Synthetic.
 XX WO200283872-A2.
 XX 24-OCT-2002.
 XX 17-APR-2002; 2002WO-US012405.
 XX 17-APR-2001; 2001US-00837306.
 PR 24-OCT-2001; 2001US-00000516.
 PR 25-OCT-2001; 2001US-00045674.
 XX (LADN/) LADNER R C.
 PA (COHE/) COHEN E H.
 PA (NAST/) NASTRI H G.
 PA (ROOK/) ROOKEY K L.
 PA (HOET/) HOET R.
 PA (HOOG/) HOOGENBOOM H R J M.
 XX Ladner RC, Cohen EH, Nastri HG, Rookey KL, Hoet R;
 PI Hoogenboom HRJM;
 PI
 XX WPI; 2003-093015/08.
 DR N-PSDB; AB237388.
 XX
 PT Cleaving single-stranded nucleic acid sequences at a desired location by
 PT contacting the nucleic acid with an single strand oligonucleotide
 PT complementary to a nucleic acid region where cleavage is desired.
 XX Example 3; Page 414; 485pp; English.
 PS
 XX The present invention describes a method for cleaving single-stranded

CC nucleic acid sequences at a desired location. Also described: (1) methods
 CC for displaying or expressing a member of a diverse family of peptides,
 CC polypeptides or proteins on the surface of a genetic package and
 CC collectively displaying at least a part of the diversity of the family,
 CC where the displayed or expressed peptide, polypeptide or protein is
 CC encoded at least in part by a nucleic acid that has been cleaved at a
 CC desired location; (2) a method for preparing single-stranded nucleic
 CC acids; (3) a method for preparing a library comprising a collection of
 CC genetic packages that display a member of a diverse family of peptides,
 CC polypeptides or proteins and that collectively display at least a portion
 CC of the family; (4) a vector comprising a DNA sequence encoding an
 CC antibody variable region linked to a version of PIII anchor which does
 CC not mediate infection of phage particles, and wild-type gene III; (5) a
 CC method for producing a population or a library of immunoglobulin genes;
 CC and (6) a library of immunoglobulins that comprise members having at
 CC least one variable domain in which at least one of CDR1 and CDR2 contain
 CC synthetic diversity and CDR3 diversity is captured from B cells. The
 CC method is useful for cleaving single-stranded nucleic acid sequences at a
 CC desired location, which can be subsequently used to produce libraries or
 CC genetic packages that display and/or express a diverse family of
 CC peptides, polypeptides or proteins. AB236912 to AB237510 and ABP55464 to
 CC ABP55499 represent sequences used in the exemplification of the present
 CC invention

XX SQ Sequence 136 AA;

Query Match 100.0%; Score 506; DB 6; Length 136;
 Best Local Similarity 100.0%; Pred. No. 4.5e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSGSTYY 60
 Db 7 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSGSTYY 66

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
 Db 67 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 104

RESULT 63
 ABJ36939
 ID ABJ36939 standard; protein; 177 AA.
 AC ABJ36939;
 XX
 DT 01-MAY-2003 (first entry)
 DE Anti-CD40 monoclonal antibody related protein SEQ ID No 64.
 XX Antiallergic; haemostatic; immunomodulator; cytostatic; antibody;
 KW human CD40; IL-12; LPS; lipopolysaccharide; IFNgamma; interferon gamma;
 KW dendritic cell; high G28-5; CD95 expression; high G28-5; B cell line;
 KW immunoactivator; anti-tumour agent; immunosuppressant; allergy;
 KW autoimmune disease; coagulation factor VIII inhibitor; anti-CD40.
 XX Unidentified.
 OS
 XX WO200288186-A1.
 PN
 XX 07-NOV-2002.
 PD
 XX 26-APR-2002; 2002WO-JF004292.
 PF
 XX 27-APR-2001; 2001WO-US013672.
 PR 11-MAY-2001; 2001JP-00142482.
 PR 05-OCT-2001; 2001JP-00310535.
 PR 26-OCT-2001; 2001US-00040244.
 XX (KIRI) KIRIN BEER KK.
 PA
 XX Mikayama T, Yoshida H, Force WR, Chen X, Takahashi N;
 PI WPI; 2003-120463/11.
 XX
 DR

```

DR N-PSDB; ABT31881.
XX
PT Anti-CD40 monoclonal antibody with antagonist/agonist activity to CD40,
PT or functional fragment, is useful in the treatment of e.g. autoimmune
PT diseases or cancer.
XX
PS Claim 15; Page 59; 94pp; Japanese.
XX
CC The invention relates to an antibody to human CD40, or its functional
CC fragment, has at least one of the following properties: acting on
CC dendritic cells to produce IL-12 in the presence of LPS
CC (lipopolysaccharide) and IFNgamma (interferon gamma); acting on dendritic
CC cells to activate maturity of the dendritic cells with high G28-5
CC antibody; and activating CD95 expression with high G28-5 antibody against
CC B cell line. Such antibodies or functional fragments can be used as
CC immunoadjuvants, anti-tumour agents, immunosuppressants, and as remedies
CC for autoimmune diseases, allergy or coagulation factor VIII inhibitors
CC syndrome. This sequence represents a protein relating to the anti-CD40
CC monoclonal antibody of the invention
XX
SQ Sequence 177 AA;
Query Match 100.0%; Score 506; DB 6; Length 177;
Best Local Similarity 100.0%; Pred. No. 6e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
DB 20 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 79
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
DB 80 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 117

RESULT 64
AAV02472
ID AAY02472 standard; protein; 240 AA.
XX
AC AAY02472;
XX
DT 15-JUL-1999 (first entry)
XX
DE A single chain antibody (ScFv).
XX
KW Screening; functional polypeptide; ligand; non-functional; enrichment;
KW single chain antibody; ScFv.
XX
OS Unidentified.
XX
PN WO9920749-A1.
XX
PD 29-APR-1999.
XX
PF 20-OCT-1998; 98WO-GB003135.
XX
PR 20-OCT-1997; 97GB-00022131.
PR 13-NOV-1997; 97US-0065428P.
PR 21-NOV-1997; 97US-0066729P.
XX
PA (MEDI-) MEDICAL RES COUNCIL.
XX
PI Tomlinson I, Winter G;
XX
WPI; 1999-288302/24.
DR N-PSDB; AAX36070.
XX
PT Screening for functional polypeptides which bind a ligand.
XX
PS Disclosure; Fig 2; 67pp; English.
XX
CC The specification describes a method for screening for functional
CC polypeptides which bind a ligand. The method comprises contacting a

```

```

CC repertoire of polypeptides with a generic ligand, and then screening
CC selected functional polypeptides with a target ligand. The method permits
CC the removal from a chosen repertoire of polypeptides, those which are non
CC -functional, e.g. as a result of the introduction of frame-shift
CC mutations, stop codons, folding mutants or expression mutants which would
CC be or are incapable of binding to any target ligand. The method also
CC permits the enrichment of a chosen repertoire of polypeptides for those
CC polypeptides which are functional, well folded and highly expressed. The
CC polypeptides obtained can be used in diagnostic, prophylactic and
CC therapeutic procedures. The present sequence represents the single chain
CC antibody (ScFv) that forms the basis of a library according to the
CC invention
XX
SQ Sequence 240 AA;
Query Match 100.0%; Score 506; DB 2; Length 240;
Best Local Similarity 100.0%; Pred. No. 8.5e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
DB 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 65
ABP95997
ID ABP95997 standard; protein; 240 AA.
XX
AC ABP95997;
XX
DT 01-MAY-2003 (first entry)
XX
DE Human serum albumin antibody related protein #1.
XX
KW Ligand; human serum albumin; HSA; antibody; cytostatic; anti-HIV;
KW antiinflammatory; antianaemic; immunosuppressive; neuroprotective;
KW dual-specific ligand; cancer; HIV infection; hepatitis; rubella; anaemia;
KW inflammation; autoimmune disorder; multiple sclerosis; Crohn's disease;
KW myasthenia gravis.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2003002609-A2.
XX
PD 09-JAN-2003.
XX
PF 28-JUN-2002; 2002WO-GB003014.
XX
PR 28-JUN-2001; 2001GB-00015841.
XX
PA (MEDI-) MEDICAL RES COUNCIL.
XX
PI Winter G, Ignatovich O, Tomlinson I;
XX
WPI; 2003-210246/20.
DR N-PSDB; AB276706.
XX
PT Dual-specific ligand having immunoglobulins with binding specificity to
PT different antigens or epitopes, useful for treating, preventing or
PT diagnosing diseases, e.g. cancer, HIV infection, inflammations, or
PT myasthenia gravis.
XX
XX Example 1; Fig 1; 84pp; English.
XX
CC The present invention describes a dual-specific ligand (I) comprising:
CC (a) a first single immunoglobulin variable domain with a binding
CC specificity to a first antigen or epitope; and (b) a second complementary
CC immunoglobulin single variable domain with a binding activity to a second

```


CC antigen or epitope. The binding domains are mutually complementary, and
 CC the first and second domains lack mutually complementary domains that
 CC share the same specificity. (I) has cytostatic, anti-HIV, antianaemic,
 CC antiinflammatory, immunosuppressive and neuroprotective activities. The
 CC dual-specific ligand is useful for treating, preventing or diagnosing
 CC diseases, e.g. cancer, HIV infection, hepatitis, rubella, anaemia,
 CC inflammations or autoimmune disorders (e.g. multiple sclerosis, Crohn's
 CC disease or myasthenia gravis). The dual-specific ligand may be used to
 CC recruit cytotoxic T-cells to a cancer cell. The dual-specific ligand is
 CC also useful for monitoring the efficacy of drugs, as well as for
 CC monitoring toxicity. The present sequence represents a human serum
 CC albumin (HSA) related antibody sequence, which is used in an example from
 CC the present invention
 XX
 SQ Sequence 240 AA;

Query Match 100.0%; Score 506; DB 6; Length 240;
 Best Local Similarity 100.0%; Pred. No. 8.5e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
 DB 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98

RESULT 66
 ID ADL92369
 AC ADL92369 standard; protein; 240 AA.

XX AC ADL92369;
 XX DT 20-MAY-2004 (first entry)
 XX DE Human phage single domain antibody (dab) library-related protein.
 XX DE immunoglobulin single variable domain; cytostatic; antiinflammatory;
 KW antirheumatic; antiarthritic; antiaethmatic; antiallergic; antibacterial;
 KW virucide; immunosuppressive; antidiabetic; neuroprotective; muscular;
 KW dermatological; gene therapy; inflammatory; rheumatoid arthritis; asthma;
 KW Crohn's disease; allergic hypersensitivity; bacterial; viral infection;
 KW autoimmune disorder; type I diabetes; multiple sclerosis;
 KW myasthenia gravis; systemic lupus erythematosus; cancer; domain antibody;
 KW dab; human; phage library.
 XX OS Homo sapiens.
 XX PN WO2004003019-A2.
 XX PD 08-JAN-2004.
 XX XX 30-JUN-2003; 2003WO-GB002804.
 XX PF 28-JUN-2002; 2002WO-GB003014.
 XX PR 27-DEC-2002; 2002GB-00030202.
 XX (DOMA-) DOMANTIS LTD.
 XX PA Winter G, Tomlinson I, Ignatovich O, Holt L, De Angelis E;
 XX PI WPI; 2004-142855/14.
 XX DR N-PSDB; ADL92368.
 XX XX New dual-specific ligands, useful in drug discovery and development, or
 PT for diagnosing, preventing or treating a disease, such as cancer,
 PT autoimmune disease, or inflammatory disease, including rheumatoid
 PT arthritis or asthma.
 XX Example 1; Fig 1; 174pp; English.

CC The invention relates to a novel dual-specific ligand comprising a first
 CC immunoglobulin single variable domain having a binding specificity to a
 CC first epitope or antigen and a second complementary immunoglobulin single
 CC variable domain having a binding activity to a second epitope or antigen.
 CC The ligand of the invention demonstrates cytostatic, antiinflammatory,
 CC antirheumatic, antiarthritic, antiaethmatic, antiallergic, antibacterial,
 CC virucide, immunosuppressive, antidiabetic, neuroprotective, muscular and
 CC dermatological activities and may be useful in gene therapy, ligand
 CC binding assays or for diagnosing, preventing or treating a disease
 CC selected from an inflammatory disease such as rheumatoid arthritis,
 CC asthma or Crohn's disease, an allergic hypersensitivity, a bacterial or
 CC viral infection, an autoimmune disorder such as type I diabetes, multiple
 CC sclerosis, myasthenia gravis or systemic lupus erythematosus or cancer.
 CC The current sequence is that of the human phage single domain antibody
 CC (dab) library-related protein of the invention.
 XX
 SQ Sequence 240 AA;

Query Match 100.0%; Score 506; DB 8; Length 240;
 Best Local Similarity 100.0%; Pred. No. 8.5e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
 DB 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98

RESULT 67
 ADQ77165
 ID ADQ77165 standard; protein; 240 AA.

XX AC ADQ77165;
 XX DT 07-OCT-2004 (first entry)
 XX DE HSA Heavy chain variable domain protein.
 XX Antiinflammatory; Antiallergic; Cytostatic; Antibacterial; Virucide;
 KW immunosuppressive; Immunotherapy; single domain antibody; dab; TNF alpha;
 KW TNF receptor 1; p55; inflammation; allergic hypersensitivity; cancer;
 KW bacterial infection; viral infection; autoimmune disorder.
 XX OS Synthetic.
 XX WO2004058821-A2.
 XX PN 15-JUL-2004.
 XX PD 24-DEC-2003; 2003WO-GB005646.
 XX XX 27-DEC-2002; 2002GB-00030202.
 XX PR 30-JUN-2003; 2003WO-GB002804.
 XX PR 28-NOV-2003; 2003GB-00027706.
 XX (DOMA-) DOMANTIS LTD.
 XX PA Winter G, Tomlinson I, Ignatovich O, Woolven B;
 XX PI WPI; 2004-534127/51.
 XX DR New dual specific ligand comprising a first dab specific for a target
 XX ligand, and a second dab specific for a receptor for the target ligand,
 PT useful for treating inflammation, cancer, allergy or autoimmune diseases.
 PT Example 1; Fig 1; 196pp; English.
 XX The present invention relates to a dual specific ligand comprising a
 CC first single domain antibody (dab) specific for a target ligand (e.g. TNF
 CC alpha), and a second dab specific for a receptor for the target ligand

CC (e.g. TNF receptor 1 (p55)). The dab specific for TNFalpha comprises the
CC amino acid sequence of TAR1-5-19, TAR1-5 or TAR1-27 and the dab specific
CC for TNF receptor 1 (p55) comprises the amino acid sequence of TAR2h-10,
CC TAR2h-5 or TAR2h-10-27. The dual specific ligands are useful for
CC targeting cytokines and other molecules that cooperate synergistically in
CC therapeutic situations in the body of an organism. They are useful for
CC preventing, suppressing or treating inflammatory states, allergic
CC hypersensitivity, cancer, bacterial or viral infection, and autoimmune
CC disorders. The present sequence is a heavy chain variable domain sequence
CC used to illustrate the invention.

XX SQ Sequence 240 AA;

Query Match 100.0%; Score 506; DB 8; Length 240;
Best Local Similarity 100.0%; Pred. No. 8.5e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLVWSAISGGSTYY 60
Db 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLVWSAISGGSTYY 60

QY 61 ADSVKGRTISRDNKNTLYLQNSLRADTAVYYCAK 98
AEA62548
Db 61 ADSVKGRTISRDNKNTLYLQNSLRADTAVYYCAK 98

RESULT 68
AEA62548
ID AEA62548 standard; protein; 241 AA.
AC AEA62548;

XX DT 25-AUG-2005 (first entry)

XX DE Her-2/neu tumor associated antigen related scFv40, SEQ ID 1.

XX KW Cytostatic; Vaccine; Cell-therapy; antibody; single chain antibody;
XX KW tumor-associated antigen; tumor.

XX OS Homo sapiens.

PH Key Location/Qualifiers
FT Region 1..30 /label= Framework_region_FR1
FT Region 31..35 /label= Complementarity_determining_region_CDR1
FT Region 36..53 /label= Framework_region_FR2
FT Region 54..66 /label= Framework_region_FR2
FT Region 67..98 /label= Complementarity_determining_region_CDR2
FT Region 99..104 /label= Framework_region_FR3
FT Region 105..118 /label= Complementarity_determining_region_CDR3
FT Region 119..133 /label= Framework_region_FR4
FT Region 134..154 /label= Linker
FT Region 155..165 /label= Framework_region_FR1
FT Region 166..180 /label= Complementarity_determining_region_CDR1
FT Region 181..187 /label= Framework_region_FR2
FT Region 188..219 /label= Complementarity_determining_region_CDR2
FT Region 220..228 /label= Framework_region_FR3
FT Region 229..241 /label= Complementarity_determining_region_CDR3
FT Region /label= Framework_region_FR4

PN EP1544215-A1.
XX 22-JUN-2005.
PD 17-DEC-2003; 2003EP-00293196.
XX 17-DEC-2003; 2003EP-00293196.
XX 17-DEC-2003; 2003EP-00293196.
XX (INRM) INERM INST NAT SANTE & RECH MEDICALE.
PA Gauthier P, Pelegriin A, Coelho M, Teulon I;
XX WPI; 2005-428165/44.
XX

XX New human anti-idiotypic antibody Fab or scFv fragment having the ability
FT to mimic Her-2/neu tumor associated antigen, useful for preventing or
FT treating breast cancer, ovary cancer, uterus cancer, stomach cancer, or
FT lung cancer.

XX Claim 5; SEQ ID NO 1; 33pp; English.

XX The present invention relates to novel human anti-idiotypic antibody Fab
CC or single chain (sc) Fv fragments (AEA62548 and AEA62549), which mimic
CC Her-2/neu tumor associated antigen. The fragment comprises AEA62550 or
CC AEA62552, which are heavy chain variable domain (VH) complementarity
CC determining region (CDR)3 regions, and AEA62551 or AEA62553, which are
CC light chain variable domain (VL) CDR3 regions. The antibody fragment is
CC useful for the preparation of a medicament for the prevention or
CC treatment of a tumor, where Her-2/neu is overexpressed. The tumor is
CC adenocarcinoma. The tumor is selected from breast cancer, ovary cancer,
CC uterus cancer, stomach cancer, or lung cancer.

XX SQ Sequence 241 AA;

Query Match 100.0%; Score 506; DB 9; Length 241;
Best Local Similarity 100.0%; Pred. No. 8.5e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLVWSAISGGSTYY 60
Db 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLVWSAISGGSTYY 60

QY 61 ADSVKGRTISRDNKNTLYLQNSLRADTAVYYCAK 98
Db 61 ADSVKGRTISRDNKNTLYLQNSLRADTAVYYCAK 98

RESULT 69
AEA62549
ID AEA62549 standard; protein; 241 AA.
XX AC AEA62549;

XX DT 25-AUG-2005 (first entry)

XX DE Her-2/neu tumor associated antigen related scFv69, SEQ ID 2.

XX KW Cytostatic; Vaccine; Cell-therapy; antibody; single chain antibody;
XX KW tumor-associated antigen; tumor.

XX OS Homo sapiens.

XX Key Location/Qualifiers
FT Region 1..30 /label= Framework_region_FR1
FT Region 31..35 /label= Complementarity_determining_region_CDR1
FT Region 36..53 /label= Framework_region_FR2
FT Region 54..66 /label= Complementarity_determining_region_CDR2
FT Region 67..98 /label= Framework_region_FR3

```

FT Region 99. .104
FT /label= Complementarity_determining_region_CDR3
FT Region 105. .118
FT /label= Framework_region_FR4
FT Region 119. .133
FT /label= Linker
FT Region 134. .154
FT /label= Framework_region_FR1
FT Region 155. .165
FT /label= Complementarity_determining_region_CDR1
FT Region 166. .180
FT /label= Framework_region_FR2
FT Region 181. .187
FT /label= Complementarity_determining_region_CDR2
FT Region 188. .219
FT /label= Framework_region_FR3
FT Region 220. .228
FT /label= Complementarity_determining_region_CDR3
FT Region 229. .241
FT /label= Framework_region_FR4
XX EPI544215-A1.
XX
XX 22-JUN-2005.
XX
XX 17-DEC-2003; 2003EP-00293196.
XX
XX 17-DEC-2003; 2003EP-00293196.
XX
XX (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX
XX Gauthier P, Pelegrin A, Coelho M, Teulon I;
XX
XX WPI; 2005-420165/44.
XX
XX New human anti-idiotypic antibody Fab or scFv fragment having the ability
XX to mimic Her-2/neu tumor associated antigen, useful for preventing or
XX treating breast cancer, ovary cancer, uterus cancer, stomach cancer, or
XX lung cancer.
XX
XX Claim 6; SEQ ID NO 2; 33pp; English.
XX
XX The present invention relates to novel human anti-idiotypic antibody Fab
XX or single chain (sc) Fv fragments (AEA62548 and AEA62549), which mimic
XX Her-2/neu tumor associated antigen. The fragment comprises AEA62550 or
XX AEA62552, which are heavy chain variable domain (VH) complementarity
XX determining region (CDR)3 regions, and AEA62551 or AEA62553, which are
XX light chain variable domain (VL) CDR3 regions. The antibody fragment is
XX useful for the preparation of a medicament for the prevention or
XX treatment of a tumor, where Her-2/neu is overexpressed. The tumor is
XX adenocarcinoma. The tumor is selected from breast cancer, ovary cancer,
XX uterus cancer, stomach cancer, or lung cancer.
XX
XX Sequence 241 AA;
XX
XX Query Match 100.0%; Score 506; DB 9; Length 241;
XX Best Local Similarity 100.0%; Pred. No. 8.5e-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATISGGSTYY 60
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATISGGSTYY 60
Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
XX
XX RESULT 70
XX ADI58088
XX ID ADI58088 standard; protein; 245 AA.
XX
XX AC ADI58088;
XX
XX 22-APR-2004 (first entry)
XX
XX Reg IV-specific single chain antibody fragment (scFv) #47.
XX
XX antibody; regeneration IV; Reg IV; single chain antibody fragment; scFv;
XX inflammatory bowel disorder; ulcerative colitis; Crohn's disease;
XX diabetes; non-insulin dependent diabetes; insulin dependent diabetes;
XX cancer; human.
XX
XX Homo sapiens.
XX
XX WO2004003144-A2.
XX
XX 08-JAN-2004.
XX
XX 26-JUN-2003; 2003WO-US019908.
XX
XX 01-JUL-2002; 2002US-0392382P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA;
XX
XX WPI; 2004-071976/07.
XX
XX N-PSDB; ADI58154.
XX
XX Novel antibody, useful for treating, preventing or ameliorating
XX inflammatory bowel disorder, cancer of the gastrointestinal tract or
XX diabetes (non-insulin dependent diabetes or insulin dependent diabetes).
XX
XX Claim 2; SEQ ID NO 48; 324pp; English.
XX
XX The invention comprises an antibody that specifically binds a
XX regeneration IV (Reg IV) protein. The invention specifically comprises
XX the amino acid and coding sequences of single chain antibody fragments
XX (scFv's) that bind Reg IV protein. The antibody of the invention is
XX useful for treating, preventing and ameliorating: inflammatory bowel
XX disorders (e.g. ulcerative colitis or Crohn's disease), diabetes (e.g.
XX non-insulin dependent diabetes or insulin dependent diabetes), and cancer
XX of the gastrointestinal tract. The antibody of the invention is also
XX useful for detecting the expression of a Reg IV protein. The present
XX amino acid sequence represents an scFv of the invention.
XX
XX Sequence 245 AA;
XX
XX Query Match 100.0%; Score 506; DB 8; Length 245;
XX Best Local Similarity 100.0%; Pred. No. 8.7e-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATISGGSTYY 60
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVSATISGGSTYY 60
Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
XX
XX RESULT 71
XX ADI58093
XX ID ADI58093 standard; protein; 245 AA.
XX
XX AC ADI58093;
XX
XX 22-APR-2004 (first entry)
XX
XX Reg IV-specific single chain antibody fragment (scFv) #52.
XX
XX antibody; regeneration IV; Reg IV; single chain antibody fragment; scFv;
XX inflammatory bowel disorder; ulcerative colitis; Crohn's disease;
XX diabetes; non-insulin dependent diabetes; insulin dependent diabetes;
XX cancer; human.

```

XX OS Homo sapiens.
 XX PN WO2004003144-A2.
 XX PD 08-JAN-2004.
 XX XX 26-JUN-2003; 2003WO-US019908.
 XX PR 01-JUL-2002; 2002US-03922382P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX PA Rosen CA;
 XX PI WPI; 2004-071976/07.
 XX DR N-PSDB; ADI58159.
 XX XX Novel antibody, useful for treating, preventing or ameliorating
 PT inflammatory bowel disorder, cancer of the gastrointestinal tract or
 PT diabetes (non-insulin dependent diabetes or insulin dependent diabetes).
 XX PS Claim 2; SEQ ID NO 53; 324pp; English.
 XX CC The invention comprises an antibody that specifically binds a
 CC regeneration IV (Reg IV) protein. The invention specifically comprises
 CC the amino acid and coding sequences of single chain antibody fragments
 CC (scFv's) that bind Reg IV protein. The antibody of the invention is
 CC useful for treating, preventing and ameliorating: inflammatory bowel
 CC disorders (e.g. ulcerative colitis or Crohn's disease), diabetes (e.g.
 CC non-insulin dependent diabetes or insulin dependent diabetes), and cancer
 CC of the gastrointestinal tract. The antibody of the invention is also
 CC useful for detecting the expression of a Reg IV protein. The present
 CC amino acid sequence represents an scFv of the invention.
 XX SQ Sequence 245 AA;
 Query Match 100.0%; Score 506; DB 8; Length 245;
 Best Local Similarity 100.0%; Pred. No. 8.7e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGGSTYY 60
 DB 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
 RESULT 72
 ADS09246
 ID ADS09246 standard; protein; 250 AA.
 XX AC ADS09246;
 XX DT 18-NOV-2004 (first entry)
 XX DE Human c-Met protein tyrosine kinase antibody, PGIA-1-A8.
 XX KW c-Met; tyrosine kinase antibody; antigen binding; cytostatic;
 KW ophthalmological; antiinflammatory; analgesic; vasotropic; antipsoriatic;
 KW osteopathic; cancer; tumour; ophthalmic disease; glaucoma; retinitis;
 KW retinopathy; uveitis; ocular photophobia; macular degeneration; pain;
 KW acute injury; eye; hyperproliferative disorder; restenosis; angioplasty;
 KW psoriasis; HGF; osteoporosis; cancer.
 XX OS Homo sapiens.
 XX PN WO2004072117-A2.
 XX PD 26-AUG-2004.

PF 11-FEB-2004; 2004WO-IB000503.
 XX PR 13-FEB-2003; 2003US-0447073P.
 XX PA (PHAA) PHARMACIA CORP.
 XX PI Morton PA, Arbuckle JA, Evans ML, Joy WD, Kahn LE, Shieh JJ;
 XX DR WPI; 2004-616044/59.
 XX DR N-PSDB; ADS09306.
 XX PT Novel c-Met protein tyrosine kinase antibody or its antigen-binding
 PT portion specifically binding to c-Met, useful for manufacture of
 PT medicament for treating cancer or tumor and for treatment of ophthalmic
 PT diseases such as glaucoma.
 XX PS Claim 1; SEQ ID NO 8; 303pp; English.
 XX CC The invention relates to a novel c-Met protein tyrosine kinase antibody
 CC or its antigen binding portion that specifically binds to c-Met. The c-
 CC Met antibody comprises any one of 1-60 fully defined sequence of 238,
 CC 244, 240, 250, 251, 242, 245, 247, 246, 253, 243, 241, etc., amino
 CC acids as given in the specification, or its fragment. The invention
 CC further comprises: a pharmaceutical composition comprising the c-Met
 CC protein tyrosine kinase antibody and a carrier; an isolated cell that
 CC produces the c-Met protein tyrosine kinase antibody; and an isolated
 CC nucleic acid molecule that comprises a nucleic acid sequence that encodes
 CC a heavy chain or its antigen-binding portion or light chain or its
 CC antigen-binding portion of the c-Met protein tyrosine kinase antibody.
 CC The c-Met protein tyrosine kinase antibody has cytostatic,
 CC ophthalmological, antiinflammatory, analgesic, vasotropic, antipsoriatic,
 CC and osteopathic activities. The c-Met protein tyrosine kinase antibody is
 CC useful for the manufacture of medicament for the treatment of cancer or
 CC tumour. The c-Met protein tyrosine kinase antibody is useful for
 CC diagnosing the presence or ligation of c-Met expressing tissue. The c-Met
 CC protein tyrosine kinase antibody is useful for detecting c-Met in a
 CC biological sample in vitro or in vivo. The c-Met protein tyrosine kinase
 CC antibody is also useful in the treatment or prevention of ophthalmic
 CC diseases such as glaucoma, retinitis, retinopathies (e.g., diabetic
 CC retinopathy), uveitis, ocular photophobia, macular degeneration and pain
 CC associated with acute injury to the eye. The pharmaceutical composition
 CC is useful for the treatment of hyperproliferative disorders such as
 CC restenosis after angioplasty, and psoriasis, and for the treatment of
 CC animals that lack sufficient HGF, e.g. osteoporosis and cancer. This
 CC sequence represents the protein of a phage display generated human c-Met
 CC antibody of the invention.
 XX SQ Sequence 250 AA;
 Query Match 100.0%; Score 506; DB 8; Length 250;
 Best Local Similarity 100.0%; Pred. No. 8.9e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGGSTYY 60
 DB 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGGSTYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
 RESULT 73
 ADI58052
 ID ADI58052 standard; protein; 252 AA.
 XX AC ADI58052;
 XX DT 22-APR-2004 (first entry)
 XX DE Reg IV-specific single chain antibody fragment (scFv) #11.
 XX KW antibody; regeneration IV; Reg IV; single chain antibody fragment; scFv;

KW inflammatory bowel disorder; ulcerative colitis; Crohn's disease;
KW diabetes; non-insulin dependent diabetes; insulin dependent diabetes;
KW cancer; human.
XX Homo sapiens.
XX WO2004003144-A2.
XX PD 08-JAN-2004.
XX XX
XX 26-JUN-2003; 2003WO-US019908.
XX XX
XX 01-JUL-2002; 2002US-0392382P.
XX XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX XX
XX Rosen CA;
XX WPI; 2004-071976/07.
XX DR N-PSDB; ADI58118.
XX XX
XX Novel antibody, useful for treating, preventing or ameliorating
PT inflammatory bowel disorder, cancer of the gastrointestinal tract or
PT diabetes (non-insulin dependent diabetes or insulin dependent diabetes).
XX
XX Claim 2; SEQ ID NO 12; 324pp; English.
XX
XX The invention comprises an antibody that specifically binds a
CC regeneration IV (Reg IV) protein. The invention specifically comprises
CC the amino acid and coding sequences of single chain antibody fragments
CC (scFv's) that bind Reg IV protein. The antibody of the invention is
CC useful for treating, preventing and ameliorating: inflammatory bowel
CC disorders (e.g. ulcerative colitis or Crohn's disease), diabetes (e.g.
CC non-insulin dependent diabetes or insulin dependent diabetes), and cancer
CC of the gastrointestinal tract. The antibody of the invention is also
CC useful for detecting the expression of a Reg IV protein. The present
CC amino acid sequence represents an scFv of the invention.
XX
XX Sequence 252 AA;
SQ
Query Match 100.0%; Score 506; DB 8; Length 252;
Best Local Similarity 100.0%; Pred. No. 9e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
Qy 61 ADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAK 98
RESULT 74
AD058062
ID AD058062 standard; protein; 252 AA.
XX AC AD058062;
XX 12-AUG-2004 (first entry)
XX DT
XX S2 cell derived human scFvVL-VH protein.
XX
XX B cell; surface immunoglobulin; Ig; binding site; antigen; human CD28;
KW closed system; detection laser-beam; catcher tube;
KW electrochemical device; fluorescence activated cell sorter; FACS;
KW antibody variable region; human.
XX
XX Homo sapiens.
OS
XX WO2004044584-A1.
XX FN
XX 27-MAY-2004.
PD

XX 12-NOV-2003; 2003WO-EP012664.
XX
XX 13-NOV-2002; 2002EP-00025335.
XX
XX (MICR-) MICROMET AG.
XX
XX Baeuerle P, Hoffmann P, Weinberger S, Kischel R;
PI
XX WPI; 2004-449579/42.
XX DR N-PSDB; ADO58063.
XX
XX Identifying a B cell carrying a surface immunoglobulin molecule having a
PT binding site for an antigen of interest, useful for constructing
PT therapeutic antibodies, comprises contacting a sample with the antigen
PT and a receptor.
XX
XX Example 6; SEQ ID NO 62; 156pp; English.
XX
XX The invention relates to a novel method for identifying a B cell carrying
CC a surface immunoglobulin (Ig) molecule having a binding site for an
CC antigen of interest. The method comprises contacting a sample putatively
CC containing the B cell with the antigen of interest and with a receptor
CC specifically binding to the Ig molecule, and assessing the presence of
CC the detectable signal. The invention further comprises: an antibody
CC generated by the method above which is specific for human CD28 or
CC comprising an amino acid(s) sequence(s) given in the specification,
CC and/or are encoded by a nucleic acid sequence(s) also given in the
CC specification; and a device for assessing the presence of a detectable
CC signal defined above, where the device comprises a closed system for the
CC detection laser-beam and a catcher tube, and where the B cell of interest
CC can be collected as a single cell by means of an electrochemical device,
CC which is triggered by an electric signal generated by the fluorescence
CC activated cell sorter (FACS) device, where the electrochemical device
CC moves the nozzle of the steady catcher tube liquid stream for a
CC programmed time over a collecting tube, microtiter plate or other
CC container after a B cell is sorted. The method is useful for identifying
CC a B cell carrying a surface Ig molecule having a binding site for an
CC antigen of interest. The method is also useful for cloning of antibody
CC variable regions from the identified B cells, which may subsequently be
CC employed in the construction of proteins such as antibodies or its
CC fragments or derivatives useful in therapeutic approaches. The method is
CC useful as an alternative to phage display for the gain of antibodies or
CC its fragments. This sequence represents an S2 cell derived human
CC polypeptide of the invention.
XX
XX Sequence 252 AA;
SQ
Query Match 100.0%; Score 506; DB 8; Length 252;
Best Local Similarity 100.0%; Pred. No. 9e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 60
Db 129 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWVAISGGSTYY 188
Qy 61 ADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAK 98
Db 189 ADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAK 226
RESULT 75
AD512378
ID AD512378 standard; protein; 253 AA.
XX AC AD512378;
XX
XX 16-DEC-2004 (first entry)
XX DT
XX Human IGF-1R antibody identified as PINT-11A2 Seq 9.
XX DE
XX human; antibody; insulin-like growth factor I receptor; IGF-IR;
KW somatomedin-C; cancer; inflammation; pathological liver condition;
KW

```

KW cytostatic; antiinflammatory; hepatotropic; gene therapy.
XX Homo sapiens.
OS Synthetic.
XX WO2004083248-A1.
XX 30-SEP-2004.
XX 04-MAR-2004; 2004WO-IB000646.
XX 14-MAR-2003; 2003US-0455094P.
XX (PHAA ) PHARMACIA CORP.
XX Morton PA, Arbuckle JA, Bailey KJ, Nicastro PJ, Runnels HA;
XX WPI; 2004-691024/67.
XX N-PSDB; ADS12397.
XX New antibody that specifically binds to insulin-like growth factor I
XX receptor for diagnosing or treating cancer, inflammation or pathological
XX liver conditions.
XX Claim 1; SEQ ID NO 9; 258pp; English.
XX This invention relates to a novel antibody or its antigen binding portion
XX that binds to the insulin-like growth factor I receptor (IGF-IR), also
XX known as somatomedin-C, in order to inhibit binding of IGF-I and IGF-II
XX to the receptor (IGF-IR). Specifically, it refers to an IGF-IR antibody
XX selected from PINT-6A1, PINT-7A5, PINT-7A4, PINT-7A5, PINT-7A6, PINT-8A1,
XX PINT-9A2, PINT-11A1, PINT-11A2, PINT-11A3, PINT-11A4, PINT-11A5, PINT-
XX 11A7, PINT-11A12, PINT-12A1, PINT-12A2, PINT-12A3, PINT-12A4, and PINT-
XX 12A5 or fragments derived thereof. The present invention describes an
XX isolated cell line (and non-human transgenic animals) useful for
XX expressing nucleic acid molecules that encode at least one variable light
XX (VL) and at least one variable heavy (VH) chain antibody regions, as well
XX as the pharmaceutical compositions derived thereof. Accordingly, it
XX provides a method of diagnosing the presence or location of an IGF-IR-
XX expressing tissue, a method for treating diseases such as cancer, as well
XX as diagnosing or treating inflammation and other pathological liver
XX conditions. As such, these compositions exhibit cytostatic,
XX antiinflammatory and hepatotropic activities and can be used for gene
XX therapy purposes. This polypeptide sequence is a human IGF-IR antibody
XX (scFv) protein of the invention.
XX Sequence 253 AA;
XX
XX Query Match 100.0%; Score 506; DB 8; Length 253;
XX Best Local Similarity 100.0%; Pred. No. 9e-42;
XX Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 EVQLLESGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVAISGGSGTYY 60
XX |||||
XX Db 1 EVQLLESGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVAISGGSGTYY 60
XX |||||
XX QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
XX |||||
XX Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
XX |||||
XX
XX RESULT 76
XX ADO25153
XX ID ADO25153 standard; protein; 274 AA.
XX
XX AC ADO25153;
XX
XX XX 01-JUL-2004 (first entry)
XX
XX DE Melanoma cell adhesion molecule binding protein, scFv5.
XX
XX KW melanoma cell adhesion molecule; MCAM; invasion; metastasis; cancer;
XX metastatic; sarcoma; cytostatic; anti-idiotypic.
XX

```

```

XX OS Unidentified.
XX PN EP1382615-A1.
XX XX 21-JAN-2004.
XX PD 15-JUL-2002; 2002EP-00015591.
XX PF 15-JUL-2002; 2002EP-00015591.
XX PR (XERI-) XERION PHARM AG.
XX PA Unger CM, Zehetmeier C;
XX PI WPI; 2004-101663/11.
XX DR N-PSDB; ADO25162.
XX DR Novel polypeptide useful for detecting melanoma cell adhesion molecules,
XX for treating or preventing metastasis in patient.
XX PT Claim 1; SEQ ID NO 5; 63pp; English.
XX PS The invention relates to a novel polypeptide e.g. an antibody fragment,
XX CC that binds to melanoma cell adhesion molecules (MCAM), comprising a
XX CC sequence chosen from fully defined sequences of 276, 277, 278, 279, 280, 281
XX CC and 273 amino acids as given in the specification. The invention
XX CC further comprises: a bioconjugate comprising the melanoma cell adhesion
XX CC molecule binding protein; a diagnostic kit comprising the protein and/or
XX CC the bioconjugate and a container; a pharmaceutical composition comprising
XX CC the protein and/or bioconjugate and a carrier; an isolated nucleic acid
XX CC molecule encoding the protein; a vector comprising the nucleic acid; a
XX CC host cell comprising the nucleic acid and vector; use of a molecule
XX CC inhibiting MCAM function in the manufacture of a medicament for the
XX CC treatment or prevention of invasion and/or metastasis of naturally
XX CC occurring cancer cells, where invasiveness and/or metastatic potential of
XX CC the cancer cells depends on melanoma cell adhesion molecule (MCAM)
XX CC function; and a method for identifying a protein which binds specifically
XX CC to the extracellular region of MCAM, where the protein is capable of
XX CC inhibiting invasiveness of sarcoma cells. The novel protein and
XX CC compositions have cytostatic activity. The MCAM binding protein and
XX CC bioconjugate are useful for the detection of MCAM, or for identifying a
XX CC MCAM inhibiting molecule that specifically binds to human MCAM. The MCAM
XX CC binding protein and bioconjugate are useful for treating or preventing
XX CC metastasis in a patient, involves administering the MCAM binding protein
XX CC and bioconjugate to inhibit MCAM mediated invasiveness and/or metastatic
XX CC potential. The MCAM inhibiting molecule is useful for inhibiting MCAM
XX CC function in the manufacture of a medicament for treating or preventing
XX CC invasion and/or metastasis of naturally occurring cancer cells. The MCAM
XX CC inhibiting molecule inhibits gene expression of MCAM, where the molecule
XX CC is an antisense oligonucleotide, an siRNA or siRNA-like hairpin RNA, or a
XX CC vector leading to the cellular presence of an siRNA or siRNA-like hairpin
XX CC RNA. The MCAM inhibiting molecule inhibits gene expression of MCAM, where
XX CC the molecule binds to the extracellular region of MCAM, more particularly
XX CC the molecule is chosen from a small chemical compound, an antibody, an
XX CC antibody fragment, an anti-idiotypic antibody, the MCAM binding protein or
XX CC or its bioconjugate. This sequence represents an MCAM binding protein of
XX CC the invention.
XX
XX SQ Sequence 274 AA;
XX
XX Query Match 100.0%; Score 506; DB 8; Length 274;
XX Best Local Similarity 100.0%; Pred. No. 9.8e-42;
XX Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 EVQLLESGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVAISGGSGTYY 60
XX |||||
XX Db 1 EVQLLESGGGLVOPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVAISGGSGTYY 60
XX |||||
XX QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
XX |||||
XX Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
XX |||||
XX

```


CC ABP5499 represent sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 367 AA;

Query Match 100.0%; Score 506; DB 6; Length 367;
Best Local Similarity 100.0%; Pred. No. 1.4e-41; Indels 0; Gaps 0;
Matches 98; Conservative 0; Mismatches 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
|||
Db 23 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 82
|||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
|||
Db 83 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 120
|||

RESULT 79
ABG77158
ID ABG77158 standard; protein; 470 AA.
XX
AC ABG77158;
XX
DT 24-OCT-2002 (first entry)
XX
DE Germline protein sequence of anti-IGF-IR antibody DP-47(3-23)/D6-19/JH6.
XX
KW Insulin-like growth factor I receptor; antibody; human; cytostatic;
KW osteopathic; antiatherosclerotic; antipsoriatic; IGF-IR; tumour;
KW anti-neoplastic; anti-tumour; anti-angiogenic; neuropathy; osteoporosis;
KW acromegaly; gigantism; psoriasis; atherosclerosis.
XX
OS Homo sapiens.
XX
PN WO200253596-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-US051113.
XX
PR 05-JAN-2001; 2001US-0259927P.
XX
PA (PFIZ) PFIZER INC.
PA (ABGE-) ABGENIX INC.
XX
PI Cohen BD, Beebe J, Miller PE, Moyer JD, Corvalan JR, Gallo M;
XX WPI; 2002-575410/61.
XX
DR Novel humanized, chimeric monoclonal antibody that specifically binds to
XX insulin-like growth factor I (IGF-I) receptor useful for inhibiting
XX binding of IGF-I or IGF-II to receptor and for treating cancer in humans.
XX
PS Disclosure; Fig 19B; 172pp; English.

CC This invention relates to a novel humanised, chimeric or human monoclonal
XX antibody or its antigen binding portion that specifically binds to
CC insulin-like growth factor I receptor (IGF-IR). The antibodies of the
CC invention can act as an inhibitor of binding of IGF-I or IGF-II with IGF-
CC IR and can inhibit in vivo tumour growth and IGF-IR tyrosine
CC phosphorylation. The antibodies of the invention are useful for
CC diagnosing the presence or location of an IGF-IR-expressing tumour in a
CC subject. The antibody or its antigen-binding portion is also useful for
CC treating cancer in a human. The method for this further involves an anti
CC neoplastic, anti-tumour, anti-angiogenic or chemotherapeutic agent. The
CC antibodies may also be useful for increasing IGF-IR activity and thus
CC restoring IGF-IR activity in a condition characterised by low IGF-IR
CC levels e.g. neuropathy, or osteoporosis. An antibody of the invention is
CC also useful for inducing apoptosis of specific cells in a patient, and to
CC treat non-cancerous states or disease, e.g. acromegaly, gigantism,
CC psoriasis and atherosclerosis. Fully human anti-IGF-IR antibodies
CC minimise the immunogenic and allergic responses intrinsic to mouse or

CC mouse-derivatised monoclonal antibodies and thus increase the efficacy
CC and safety of the administered antibodies. The present sequence
CC represents an anti-insulin-like growth factor I receptor antibody of the
CC invention
XX
SQ Sequence 470 AA;

Query Match 100.0%; Score 506; DB 5; Length 470;
Best Local Similarity 100.0%; Pred. No. 1.8e-41; Indels 0; Gaps 0;
Matches 98; Conservative 0; Mismatches 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
|||
Db 20 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 79
|||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
|||
Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 117
|||

RESULT 80
ADR28580
ID ADR28580 standard; protein; 470 AA.
XX
AC ADR28580;
XX
DT 18-NOV-2004 (first entry)
XX
DE Human anti-IGF-IR antibody DP-47(3-23)/D6-19/JH6 protein SEQ ID NO:46.
XX
KW aging; multiple myeloma; liquid tumour; liver cancer; thymus disorder;
KW T-cell-mediated autoimmune disease; endocrinological disorder; ischaemia;
KW neurodegenerative disorder; human;
KW anti-IGF-IR antibody; cytostatic; immunosuppressive; endocrine;
KW vasotropic; neuroprotective; nootropic; antithyroid; vaccine;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN WO2004071529-A2.
XX
PD 26-AUG-2004.
XX
PF 03-FEB-2004; 2004WO-IB000366.
XX
PR 13-FEB-2003; 2003US-0447353P.
XX
PA (PFIZ) PFIZER PROD INC.
XX
PI Cohen BD, Bedian V, Wang HF, Obrocea M, Gomez-Navarro J;
PI Cusmano JD, Guyot DJ, Page KL;
XX
DR WPI; 2004-625776/60.
XX
PS Treating or preventing aging or a disorder (e.g. multiple myeloma,
XX autoimmune disease or neurodegenerative disorder) in humans comprises
XX administering an amount of a human anti-insulin-like growth factor I
XX receptor antibody.
XX
PS Disclosure; SEQ ID NO 46; 105pp; English.

CC The present invention describes a method for treating or preventing aging
XX or a disorder (e.g. multiple myeloma, liquid tumour, liver cancer, thymus
CC disorder, T-cell-mediated autoimmune disease, endocrinological disorder,
CC ischaemia or neurodegenerative disorder) in a mammal. The method
CC comprises administering to the mammal an amount of a human anti-insulin-
CC like growth factor I receptor (IGF-IR) antibody. Also described is a
CC pharmaceutical composition for treating or preventing the above-mentioned
CC disorder in a mammal, comprising an amount of the human anti-IGF-IR
CC antibody and a pharmaceutical carrier. The composition has cytostatic,
CC immunosuppressive, endocrine, vasotropic, neuroprotective, nootropic and
CC antithyroid activities, and can be used in vaccines and in gene therapy.

CC The method and composition are useful for preventing or treating aging or
 CC a disorder (e.g. multiple myeloma, liquid tumour, liver cancer, thymus
 CC disorder, T-cell-mediated autoimmune disease, endocrinological disorder,
 CC ischaemia or neurodegenerative disorder) in mammals, such as humans. The
 CC human IGF-IR antibody is used in preparing a composition for the
 CC treatment or prevention of the above-mentioned disorders. The present
 CC sequence represents a human anti-IGF-IR antibody heavy chain amino acid
 CC sequence, which is used in the exemplification of the present invention.
 XX
 SQ Sequence 470 AA;

Query Match 100.0%; Score 506; DB 8; Length 470;
 Best Local Similarity 100.0%; Pred. No. 1.8e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSGSTYY 60
 DB 20 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSGSTYY 79
 QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
 DB 80 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 117

RESULT 81
 ADU02382
 ID ADU02382 standard; protein; 782 AA.

XX AC ADU02382;
 XX DT 27-JAN-2005 (first entry)
 XX DE Novel human polypeptide seqid 849.
 XX KW cytostatic; antipsoriatic; antiinflammatory; gene therapy; Nanodisc;
 KW proliferative disorder; inflammatory disorder; immune disorder;
 KW metabolic disorder; bone disorder; CNS disorder; cancer; psoriasis;
 KW ulcerative colitis; human.

OS Homo sapiens.
 XX WO2004093804-A2.
 XX PD 04-NOV-2004.
 XX PF 19-APR-2004; 2004WO-US012047.

XX PR 18-APR-2003; 2003US-0463708P.
 PR 18-APR-2003; 2003US-0463732P.
 PR 02-MAY-2003; 2003US-0467199P.
 PR 19-MAY-2003; 2003US-0467230P.
 PR 19-MAY-2003; 2003US-0471306P.
 PR 19-MAY-2003; 2003US-0471336P.
 PR 08-JUL-2003; 2003US-0485223P.
 PR 08-JUL-2003; 2003US-0485224P.
 PR 14-JUL-2003; 2003US-0486446P.
 PR 14-JUL-2003; 2003US-0486480P.
 PR 08-AUG-2003; 2003US-0493573P.
 PR 08-AUG-2003; 2003US-0493577P.
 PR 08-SEP-2003; 2003US-0505059P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX PI Lee E, Hestir K, Chu K, Masuoka L, Williams LT;

XX WPI; 2004-775861/76.
 XX N-PSDB; ADU01650.

XX New first nucleic acid molecule comprising a polynucleotide sequence
 PT given in the specification, useful in preparing a composition for
 PT diagnosing or treating e.g., cancer, psoriasis or ulcerative colitis.
 XX Claim 14; SEQ ID NO 849; 291pp; English.

XX The invention describes a new first nucleic acid molecule comprising a
 CC polynucleotide sequence given in the specification. Also described are:
 CC an animal injected with the nucleic acid molecule; a second nucleic acid
 CC molecule comprising a second polynucleotide sequence that is at least
 CC about 70, 80, 90 or 95% homologous to the first nucleic acid molecule or
 CC that hybridises to the first polynucleotide sequence under high
 CC stringency conditions; a vector comprising the nucleic acid molecule; a
 CC promoter that drives the expression of the nucleic acid molecule; a
 CC host cell transformed, transfected, transduced or infected with the
 CC nucleic acid molecule; a nucleic acid composition comprising a carrier or
 CC a buffer and one or more compositions comprising the nucleic acid
 CC molecule, vector or host cell; a substantially purified polypeptide; an
 CC animal injected with the polypeptide; a polypeptide composition
 CC comprising the polypeptide molecule and a carrier or buffer; a cell
 CC culture medium comprising the polypeptide or transfected cells
 CC transfected with the polynucleotide; making a transformed, transfected,
 CC transduced, or infected host cell; synthesising Nanodiscs simultaneously
 CC and for synthesising a series of simultaneously-synthesised Nanodiscs
 CC sequentially utilising a dynamic system; preparing a hydrophobic protein
 CC for determination of crystal structure; immunising a non-human animal;
 CC screening for modulators of hydrophobic protein activity; a diagnostic
 CC kit; determining the presence of the nucleic acid molecule or its
 CC complement; determining the presence of an antibody to the polypeptide in
 CC a sample; an antibody specifically recognising, binding to or modulating
 CC the biological activity of at least one polypeptide encoded by a nucleic
 CC acid molecule or its biologically active fragment; an antibody
 CC composition comprising the antibody and a carrier; a bacteriophage, where
 CC the antibody is displayed on the bacteriophage; a bacterial cell
 CC comprising the bacteriophage; a non-human animal injected with the
 CC antibody composition; a host cell that secretes the antibody; making an
 CC antibody; diagnosing a disease, disorder, syndrome, or condition
 CC comprising cancer, or proliferative, inflammatory, immune, metabolic,
 CC conditions in a patient; a modulator composition comprising a modulator
 CC and a carrier; gene therapy; prophylactic or therapeutic treatment of a
 CC subject; an isolated modified cell comprising at least one first
 CC heterologous nucleic acid molecule, where the first heterologous nucleic
 CC acid molecule comprises a first polynucleotide sequence that encodes a
 CC first polypeptide; a non-human animal deficient in the polypeptide or
 CC that over-expresses the polypeptide; isolated tissues derived from the
 CC non-human animal; and one or more cells derived from the non-human
 CC animal. The nucleic acid is useful in preparing a composition for
 CC diagnosing or treating e.g., cancer, psoriasis or ulcerative colitis.
 CC This is the amino acid sequence of a novel human polypeptide of the
 CC invention.

XX SQ Sequence 782 AA;

Query Match 100.0%; Score 506; DB 8; Length 782;
 Best Local Similarity 100.0%; Pred. No. 3.2e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSGSTYY 60
 DB 637 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSGSTYY 696
 QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
 DB 697 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 734

Search completed: May 12, 2006, 02:27:55
 Job time : 83.5 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 02:25:43 ; Search time 56.5 Seconds
(without alignments)
724.731 Million cell updates/sec

Title: US-09-674-752-52

Perfect score: 506

Sequence: 1 EVQLLEGGGLVPGGSLRL.....LYLQMSLRAEDTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 66

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Listing first 500 summaries

Database :

Published Applications AA_Main:

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*

2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*

3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*

4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*

5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*

6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	506	100.0	98	3	US-09-822-698A-18
2	506	100.0	98	4	US-10-194-975-22
3	506	100.0	98	4	US-10-125-687-19
4	506	100.0	98	4	US-10-010-942B-10
5	506	100.0	98	4	US-10-308-817-62
6	506	100.0	98	4	US-10-032-037B-77
7	506	100.0	98	4	US-10-029-988B-77
8	506	100.0	98	4	US-10-032-423A-77
9	506	100.0	98	4	US-10-453-698-62
10	506	100.0	98	4	US-10-029-926B-77
11	506	100.0	98	4	US-10-038-591-32
12	506	100.0	98	4	US-10-388-389-10
13	506	100.0	98	4	US-10-379-392-23
14	506	100.0	98	4	US-10-703-713-10
15	506	100.0	98	4	US-10-704-070-10
16	506	100.0	98	4	US-10-775-444A-32
17	506	100.0	98	5	US-10-884-830-619
18	506	100.0	98	5	US-10-232-030-10
19	506	100.0	98	5	US-10-869-355-12
20	506	100.0	98	5	US-10-492-668-158
21	506	100.0	98	5	US-10-911-838-20
22	506	100.0	98	5	US-10-996-191-19
23	506	100.0	98	5	US-10-831-459-48
24	506	100.0	109	4	US-10-309-764-17
25	506	100.0	109	4	US-10-779-461-154
26	506	100.0	109	4	US-10-800-197-149
27	506	100.0	109	5	US-10-727-155-279

Sequence 8, Appli
Sequence 8, Appli
Sequence 2, Appli
Sequence 5, Appli
Sequence 104, App
Sequence 262, App
Sequence 59, Appl
Sequence 16, Appl
Sequence 20, Appl
Sequence 124, App
Sequence 77, Appl
Sequence 79, Appl
Sequence 77, Appl
Sequence 79, Appl
Sequence 77, Appl
Sequence 79, Appl
Sequence 184, App
Sequence 487, App
Sequence 64, Appl
Sequence 2, Appli
Sequence 2, Appli
Sequence 2, Appli
Sequence 1, Appli
Sequence 2, Appli
Sequence 147, App
Sequence 48, Appl
Sequence 53, Appl
Sequence 137, App
Sequence 8, Appli
Sequence 12, Appl
Sequence 9, Appli
Sequence 427, App
Sequence 453, App
Sequence 196, App
Sequence 46, Appl
Sequence 46, Appl

ALIGNMENTS

RESULT 1

US-09-822-698A-18

; Sequence 18, Application US/09822698A

; Patent No. US20020146750A1

; GENERAL INFORMATION:

; APPLICANT: Hoogenboom, Hendricus R.J.M.

; APPLICANT: Henderikx, Maria P.G.

; TITLE OF INVENTION: MUCIN-1 Specific Binding Members and Methods of Use Thereof

; FILE REFERENCE: DXX-015.1 US

; CURRENT APPLICATION NUMBER: US/09/822.698A

; PRIOR FILING DATE: 2001-03-30

; PRIOR FILING DATE: 2000-03-30

; NUMBER OF SEQ ID NOS: 112

; SOFTWARE: Microsoft Word

; SEQ ID NO 18

; LENGTH: 98

; TYPE: PRT

; ORGANISM: artificial sequence

; FEATURE:

; OTHER INFORMATION: heavy chain variable region from a DP47 germ line

US-09-822-698A-18

Query Match 100.0%; Score 506; DB 3; Length 98;

Best Local Similarity 100.0%; Pred. No. 1.le-40;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSVRQAPGKLEWVAISGGSTYY 60
|||||

```
Db      1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWWSAISGGSTYY 60
QY      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
      |||
Db      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 2
US-10-194-975-22
; Sequence 22, Application US/10194975
; Publication No. US20030039649A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 22
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-22

      Query Match      100.0%; Score 506; DB 4; Length 98;
      Best Local Similarity 100.0%; Pred. No. 1.1e-40;
      Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWWSAISGGSTYY 60
      |||
Db      1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWWSAISGGSTYY 60
      |||
QY      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
      |||
Db      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 3
US-10-125-687-19
; Sequence 19, Application US/10125687
; Publication No. US20030054407A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Peter
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705
; CURRENT APPLICATION NUMBER: US/10/125,687
; CURRENT FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 19
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-125-687-19

      Query Match      100.0%; Score 506; DB 4; Length 98;
      Best Local Similarity 100.0%; Pred. No. 1.1e-40;
      Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWWSAISGGSTYY 60
      |||
Db      1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWWSAISGGSTYY 60
      |||
QY      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
      |||
Db      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 4
US-10-010-942B-10
; Sequence 10, Application US/10010942B
; Publication No. US20030165496A1
; GENERAL INFORMATION:
; APPLICANT: Baei, Guriq
; APPLICANT: Saldanha, Jose
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
; TITLE OF INVENTION: BETA AMYLOID PEPTIDE
; FILE REFERENCE: ELN-002
; CURRENT APPLICATION NUMBER: US/10/010,942B
; CURRENT FILING DATE: 2002-12-06
; PRIOR APPLICATION NUMBER: US 60/251,892
; PRIOR FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-010-942B-10

      Query Match      100.0%; Score 506; DB 4; Length 98;
      Best Local Similarity 100.0%; Pred. No. 1.1e-40;
      Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWWSAISGGSTYY 60
      |||
Db      1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWWSAISGGSTYY 60
      |||
QY      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
      |||
Db      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 5
US-10-308-817-62
; Sequence 62, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 62
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-308-817-62

      Query Match      100.0%; Score 506; DB 4; Length 98;
      Best Local Similarity 100.0%; Pred. No. 1.1e-40;
      Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWWSAISGGSTYY 60
      |||
Db      1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWWSAISGGSTYY 60
      |||
QY      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
      |||
Db      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 6
US-10-032-037B-77
; Sequence 77, Application US/10032037B
; Publication No. US20040001822A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
```

```
; TITLE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/44
; CURRENT APPLICATION NUMBER: US/10/032.037B
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: Fast-SEQ for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-77

Query Match      100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYCAK 98
   |||||

RESULT 7
US-10-029-988B-77
; Sequence 77, Application US/10029988B
; Publication No. US20040001839A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; TITLE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029,988B
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: Fast-SEQ for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-77

Query Match      100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYCAK 98
   |||||

RESULT 8
US-10-032-423A-77
; Sequence 77, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; TITLE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
```

```
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: Fast-SEQ for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-77

Query Match      100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYCAK 98
   |||||

RESULT 9
US-10-453-698-62
; Sequence 62, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 62
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-453-698-62

Query Match      100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYCAK 98
   |||||

RESULT 10
US-10-029-926B-77
; Sequence 77, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; FILE REFERENCE: 10793/50
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: Fast-SEQ for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-77
```

```
Query Match      100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTTSSYAMSVWROAPGKGLEWVSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTTSSYAMSVWROAPGKGLEWVSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||

RESULT 11
US-10-038-591-32
; Sequence 32, Application US/10038591
; Publication No. US20040086503A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Beebe, Jean
; APPLICANT: Miller, Penelope E.
; APPLICANT: Moyer, James D.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; FILE REFERENCE: ABX-PF2
; CURRENT APPLICATION NUMBER: US/10/038,591
; CURRENT FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,927
; PRIOR FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-038-591-32

Query Match      100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTTSSYAMSVWROAPGKGLEWVSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTTSSYAMSVWROAPGKGLEWVSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||

RESULT 12
US-10-388-389-10
; Sequence 10, Application US/10388389
; Publication No. US2004008777A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Gurig
; APPLICANT: Saldanha, Jose
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
; FILE REFERENCE: ELN-002CP
; CURRENT APPLICATION NUMBER: US/10/388,389
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/010,942
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: US 60/251,892
; PRIOR FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 98
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens
US-10-388-389-10

Query Match      100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTTSSYAMSVWROAPGKGLEWVSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTTSSYAMSVWROAPGKGLEWVSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||

RESULT 13
US-10-379-392-23
; Sequence 23, Application US/10379392
; Publication No. US2004011026A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John Rudolf
; APPLICANT: Marshall, Shannon Alicia
; APPLICANT: Dahiyat, Basil I.
; TITLE OF INVENTION: ANTIBODY OPTIMIZATION
; FILE REFERENCE: A-711386-3 463077-236
; CURRENT APPLICATION NUMBER: US/10/379,392
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/360,843
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 60/384,197
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-379-392-23

Query Match      100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTTSSYAMSVWROAPGKGLEWVSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTTSSYAMSVWROAPGKGLEWVSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||

RESULT 14
US-10-703-713-10
; Sequence 10, Application US/10703713
; Publication No. US20040171815A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Gurig
; APPLICANT: Saldanha, Jose
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
; FILE REFERENCE: ELN-002CP
; CURRENT APPLICATION NUMBER: US/10/703,713
; CURRENT FILING DATE: 2003-11-07
; PRIOR APPLICATION NUMBER: US/10/388,389
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/010,942
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: US 60/251,892
; PRIOR FILING DATE: 2000-12-06
```

; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-703-713-10

Query Match 100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 15

US-10-704-070-10
; Sequence 10, Application US/10704070
; Publication No. US20040171816A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Guriq
; APPLICANT: Saldanha, Jose
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
; TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
; FILE REFERENCE: ELN-002CP
; CURRENT APPLICATION NUMBER: US/10/704,070
; PRIOR FILING DATE: 2003-11-07
; PRIOR APPLICATION NUMBER: 10/388,389
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/010,942
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: US 60/251,892
; PRIOR FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-704-070-10

Query Match 100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 16

US-10-775-444A-32
; Sequence 32, Application US/10775444A
; Publication No. US20040202651A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Bedian, Vahe
; APPLICANT: Obrocea, Mihail
; APPLICANT: Gomez-Navarro, Jesus
; APPLICANT: Cusmano, John D.
; APPLICANT: Wang, Huifen F.
; APPLICANT: Page, Kelly L.

; APPLICANT: Guyot, Deborah J.
; TITLE OF INVENTION: USES OF ANTI-INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; TITLE OF INVENTION: ANTIBODIES
; FILE REFERENCE: PC25232A
; CURRENT APPLICATION NUMBER: US/10/775,444A
; CURRENT FILING DATE: 2004-02-10
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-775-444A-32

Query Match 100.0%; Score 506; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 17

US-10-884-830-619
; Sequence 619, Application US/10884830
; Publication No. US20050004354A1
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/10/884,830
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US/09/534,717
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/126,603
; PRIOR FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 619
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-884-830-619

Query Match 100.0%; Score 506; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVOLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 18

US-10-232-030-10
; Sequence 10, Application US/10232030
; Publication No. US20050009150A1
; GENERAL INFORMATION:
; APPLICANT: Dale Schenk
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
; TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
; FILE REFERENCE: ELN-002CN
; CURRENT APPLICATION NUMBER: US/10/232,030
; CURRENT FILING DATE: 2002-08-30

```
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 09/723,713
; PRIOR FILING DATE: 2000-11-27
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 10/010,942
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: US 60/251,892
; PRIOR FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-232-030-10

Query Match          100.0%; Score 506; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||
Db 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 19
US-10-869-355-12
; Sequence 12, Application US/10869355
; Publication No. US20050048578A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Dongxiao
; TITLE OF INVENTION: METHODS OF SCREENING FOR MONOCLONAL
; FILE REFERENCE: EPIT-007
; CURRENT APPLICATION NUMBER: US/10/869,355
; CURRENT FILING DATE: 2004-06-15
; PRIOR APPLICATION NUMBER: 60/483,391
; PRIOR FILING DATE: 2003-06-26
; PRIOR APPLICATION NUMBER: 60/484,185
; PRIOR FILING DATE: 2003-06-30
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Oryctolagus cuniculus
US-10-869-355-12

Query Match          100.0%; Score 506; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||
Db 1 EVOLLESGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 20
US-10-492-668-158
; Sequence 158, Application US/10492668
; Publication No. US20050054001A1
; GENERAL INFORMATION:
; APPLICANT: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW
```

```
; TITLE OF INVENTION: FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF
; FILE REFERENCE: VIB-030-PCT
; CURRENT APPLICATION NUMBER: US/10/492,668
; CURRENT FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: EP01204037.4
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: JP2002-004184
; PRIOR FILING DATE: 2002-01-11
; PRIOR APPLICATION NUMBER: US60/335,054
; PRIOR FILING DATE: 2001-10-24
; NUMBER OF SEQ ID NOS: 165
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 158
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC FEATURE
; OTHER INFORMATION: DP-47 (a human VH3 germline)
US-10-492-668-158

Query Match          100.0%; Score 506; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
   |||||
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 21
US-10-911-838-20
; Sequence 20, Application US/10911838
; Publication No. US20050069869A1
; GENERAL INFORMATION:
; APPLICANT: AMBROSINO, Donna
; APPLICANT: HERNANDEZ, Hector
; APPLICANT: GREENOUGH, Thomas
; APPLICANT: LUZURIAGA, Katherine
; APPLICANT: SOMASUNDARAN, Mohan
; APPLICANT: BABCOCK, Gregory J.
; APPLICANT: THOMAS, JR., William D.
; APPLICANT: SULLIVAN, John
; TITLE OF INVENTION: SARS NUCLEIC ACIDS, PROTEINS, ANTIBODIES
; FILE REFERENCE: MJ1-002
; CURRENT APPLICATION NUMBER: US/10/911,838
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: US 60/565595
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: US 60/545670
; PRIOR FILING DATE: 2004-02-18
; PRIOR APPLICATION NUMBER: US 60/510251
; PRIOR FILING DATE: 2003-10-09
; PRIOR APPLICATION NUMBER: US 60/492529
; PRIOR FILING DATE: 2003-08-04
; NUMBER OF SEQ ID NOS: 148
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 98
; TYPE: PRT
; ORGANISM: SARS-Associated Coronavirus
US-10-911-838-20

Query Match          100.0%; Score 506; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```


Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWYSAISGGSGSTYY 60
|
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWYSAISGGSGSTYY 60
|
Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
|
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
|

RESULT 22
US-10-996-191-19
; Sequence 19, Application US/10996191
; Publication No. US20050148001A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Peizhi
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705.301
; CURRENT APPLICATION NUMBER: US/10/996,191
; CURRENT FILING DATE: 2004-11-22
; PRIOR APPLICATION NUMBER: US 60/284,407
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: US 10/125,687
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-996-191-19

Query Match 100.0%; Score 506; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWYSAISGGSGSTYY 60
|
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWYSAISGGSGSTYY 60
|
Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
|
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
|

RESULT 23
US-10-831-459-48
; Sequence 48, Application US/10831459
; Publication No. US20050208041A1
; GENERAL INFORMATION:
; APPLICANT: Cardarelli, Josephine
; APPLICANT: Pickford, Lealey
; APPLICANT: Bebbington, Christopher
; APPLICANT: Yarranton, Geoffrey
; APPLICANT: King, David
; APPLICANT: Chen, Tim
; APPLICANT: Poque, Sarah
; TITLE OF INVENTION: Humanized Antibodies to Interferon Alpha Receptor-1 (IFNAR-1)
; FILE REFERENCE: A-7237/GKS/CYO (455675-00260)
; CURRENT APPLICATION NUMBER: US/10/831,459
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: 60/465,058
; PRIOR FILING DATE: 2003-04-23
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 48
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-831-459-48

Query Match 100.0%; Score 506; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWYSAISGGSGSTYY 60
|
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWYSAISGGSGSTYY 60
|
Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
|
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
|

RESULT 24
US-10-309-764-17
; Sequence 17, Application US/10309764
; Publication No. US20030232009A1
; GENERAL INFORMATION:
; APPLICANT: Foltz, Ian
; APPLICANT: Babcock, John
; APPLICANT: Palathumpat, Raju
; APPLICANT: Yang, Xiao-dong
; APPLICANT: King, Chadwick T.
; TITLE OF INVENTION: ANTI-CDR45RB ANTIBODIES FOR USE IN
; TITLE REFERENCE: ABGENIX.029A
; CURRENT APPLICATION NUMBER: US/10/309,764
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337,276
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-764-17

Query Match 100.0%; Score 506; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 1.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWYSAISGGSGSTYY 60
|
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWYSAISGGSGSTYY 60
|
Qy 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
|
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
|

RESULT 25
US-10-779-461-154
; Sequence 154, Application US/10779461
; Publication No. US20040166544A1
; GENERAL INFORMATION:
; APPLICANT: Morton, Philip A
; TITLE OF INVENTION: ANTIBODIES TO c-MET FOR THE TREATMENT OF CANCERS
; FILE REFERENCE: 00980/1
; CURRENT APPLICATION NUMBER: US/10/779,461
; CURRENT FILING DATE: 2004-02-13
; PRIOR APPLICATION NUMBER: 60/447,073
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 161
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 154
; LENGTH: 109
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-779-461-154

Query Match 100.0%; Score 506; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 1.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWYSAISGGSGSTYY 60

```
|||||
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 26
US-10-800-197-149
; Sequence 149, Application US/10800197
; Publication No. US20040202655A1
; GENERAL INFORMATION:
; APPLICANT: Morton, Philip A et al.
; TITLE OF INVENTION: ANTIBODIES TO IGF-I RECEPTOR FOR THE TREATMENT OF CANCERS
; FILE REFERENCE: 01343/1
; CURRENT APPLICATION NUMBER: US/10/800,197
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: 60/455,094
; PRIOR FILING DATE: 2003-03-14
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 149
; LENGTH: 109
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-800-197-149

Query Match 100.0%; Score 506; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 1.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 27
US-10-727-155-279
; Sequence 279, Application US/10727155
; Publication No. US20050049402A1
; GENERAL INFORMATION:
; APPLICANT: John S. Babcock
; APPLICANT: Jaspal S. Kang
; APPLICANT: Orit Foord
; APPLICANT: Larry Green
; APPLICANT: Xiao Feng
; APPLICANT: Scott Klakamp
; APPLICANT: Mary Haak-Frendescho
; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Marchulenchio
; APPLICANT: Raffaella Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; FILE REFERENCE: ABGENIX.073A
; CURRENT APPLICATION NUMBER: US/10/727,155
; PRIOR FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 279
; LENGTH: 109
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens
US-10-727-155-279

Query Match 100.0%; Score 506; DB 5; Length 109;
Best Local Similarity 100.0%; Pred. No. 1.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 28
US-10-877-773-8
; Sequence 8, Application US/10877773
; Publication No. US20050053608A1
; GENERAL INFORMATION:
; APPLICANT: Weber, Richard
; APPLICANT: Feng, Xiao
; APPLICANT: Foord, Orit
; APPLICANT: Green, Larry
; APPLICANT: Gudae, Jean
; APPLICANT: Keyt, Bruce
; APPLICANT: Liu, Ying
; APPLICANT: Rathanaswami, Palani
; APPLICANT: Raya, Robert
; APPLICANT: Yang, Xiao Dong
; APPLICANT: Corvelan, Jose
; APPLICANT: Foitz, Ian
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Kang, Jaspal
; APPLICANT: King, Chadwick T.
; APPLICANT: Klakamp, Scott L.
; APPLICANT: Su, Qiaojuan Jane
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO THE DELETION
; FILE REFERENCE: ABGENIX.087A
; CURRENT APPLICATION NUMBER: US/10/877,773
; CURRENT FILING DATE: 2004-06-25
; PRIOR APPLICATION NUMBER: 60/483,145
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: 60/525,570
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: 60/562,453
; PRIOR FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-877-773-8

Query Match 100.0%; Score 506; DB 5; Length 109;
Best Local Similarity 100.0%; Pred. No. 1.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 29
US-10-877-774-8
; Sequence 8, Application US/10877774
```

Publication No. US20050059087A1
 GENERAL INFORMATION:
 APPLICANT: Weber, Richard
 APPLICANT: Feng, Xiao
 APPLICANT: Feng, Xiao
 APPLICANT: Foord, Orit
 APPLICANT: Green, Larry
 APPLICANT: Gudas, Jean
 APPLICANT: Keyt, Bruce
 APPLICANT: Liu, Ying
 APPLICANT: Rathanaswami, Palani
 APPLICANT: Raya, Robert
 APPLICANT: Yang, Xiao Dong
 APPLICANT: Corvalan, Jose
 APPLICANT: Foltz, Ian
 APPLICANT: Jia, Xiao-Chi
 APPLICANT: Kang, Jaspal
 APPLICANT: King, Chadwick T.
 APPLICANT: Klakamp, Scott L.
 APPLICANT: Su, Qiaojuan Jane
 TITLE OF INVENTION: ANTIBODIES DIRECTED TO THE DELETION
 TITLE OF INVENTION: MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF
 FILE REFERENCE: ARSENIX.087A2
 CURRENT APPLICATION NUMBER: US/10/877,774
 CURRENT FILING DATE: 2004-06-24
 PRIOR APPLICATION NUMBER: 60/483,145
 PRIOR FILING DATE: 2003-06-27
 PRIOR APPLICATION NUMBER: 60/525,570
 PRIOR FILING DATE: 2003-11-26
 PRIOR APPLICATION NUMBER: 60/562,453
 PRIOR FILING DATE: 2004-04-15
 NUMBER OF SEQ ID NOS: 144
 SOFTWARE: FastSeq for Windows Version 4.0
 SEQ ID NO 8
 LENGTH: 109
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-877-774-8

Query Match 100.0%; Score 506; DB 5; Length 109;
 Best Local Similarity 100.0%; Pred. No. 1.3e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 30
 US-10-409-814A-2
 Sequence 2, Application US/10409814A
 Publication No. US20040202995A1
 GENERAL INFORMATION:
 APPLICANT: de Wildt, Rudolf
 TITLE OF INVENTION: NUCLEIC ACIDS, PROTEINS, AND SCREENING METHODS
 FILE REFERENCE: 8039/2032
 CURRENT APPLICATION NUMBER: US/10/409,814A
 CURRENT FILING DATE: 2003-04-09
 NUMBER OF SEQ ID NOS: 42
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 2
 LENGTH: 116
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-409-814A-2

Query Match 100.0%; Score 506; DB 4; Length 116;
 Best Local Similarity 100.0%; Pred. No. 1.3e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 31
 US-10-744-774-5
 Sequence 5, Application US/10744774
 Publication No. US20040219643A1
 GENERAL INFORMATION:
 APPLICANT: Domantis Limited
 APPLICANT: Medical Research Council
 APPLICANT: Ignatovich, Olga
 APPLICANT: Jones, Philip C.
 APPLICANT: Tomlinson, Ian
 APPLICANT: Winter, Greg
 TITLE OF INVENTION: Dual Specific Ligand
 FILE REFERENCE: 8039/2102
 CURRENT APPLICATION NUMBER: US/10/744,774
 CURRENT FILING DATE: 2003-12-23
 PRIOR APPLICATION NUMBER: PCT/GB02/03014
 PRIOR FILING DATE: 2002-06-28
 PRIOR APPLICATION NUMBER: GB 0115841.9
 PRIOR FILING DATE: 2001-06-28
 NUMBER OF SEQ ID NOS: 22
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO 5
 LENGTH: 116
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: VH chain (VH dummy)
 US-10-744-774-5

Query Match 100.0%; Score 506; DB 5; Length 116;
 Best Local Similarity 100.0%; Pred. No. 1.3e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
 Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 32
 US-10-938-353-104
 Sequence 104, Application US/10938353
 Publication No. US20050059113A1
 GENERAL INFORMATION:
 APPLICANT: BEDIAN, VAHE
 APPLICANT: DEVALARAJA, MADHAV NARASIMHA
 APPLICANT: FOLTZ, IAN
 APPLICANT: HAAK-FRENDSCHO, MARY
 APPLICANT: KELLERMANN, SIRID-AIMEE
 APPLICANT: LOW, JOSEPH EDWIN
 APPLICANT: MOBLEY, JAMES LESLIE
 TITLE OF INVENTION: ANTIBODIES TO M-CSF
 FILE REFERENCE: ABX-PF4
 CURRENT APPLICATION NUMBER: US/10/938,353
 CURRENT FILING DATE: 2004-09-09
 PRIOR APPLICATION NUMBER: 60/502,163
 PRIOR FILING DATE: 2003-09-10
 NUMBER OF SEQ ID NOS: 117
 SOFTWARE: PatentIn Ver. 3.2
 SEQ ID NO 104
 LENGTH: 120

```

; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-938-353-104

Query Match      100.0%; Score 506; DB 5; Length 120;
Best Local Similarity 100.0%; Pred. No. 1.4e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 33
US-10-727-155-262
; Sequence 262, Application US/10727155
; Publication No. US20050049402A1
; GENERAL INFORMATION:
; APPLICANT: John S. Babcock
; APPLICANT: Jaapal S. Kang
; APPLICANT: Orit Foord
; APPLICANT: Larry Green
; APPLICANT: Xiao Feng
; APPLICANT: Scott Kiakamp
; APPLICANT: Mary Haak-Frendscho
; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Manchulenchu
; APPLICANT: Raffaella Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; FILE REFERENCE: ABGENIX.073A
; CURRENT APPLICATION NUMBER: US/10/727,155
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 262
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-727-155-262

Query Match      100.0%; Score 506; DB 5; Length 122;
Best Local Similarity 100.0%; Pred. No. 1.4e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 34
US-10-269-805-59
; Sequence 59, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722

```

```

; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 59
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-59

Query Match      100.0%; Score 506; DB 4; Length 123;
Best Local Similarity 100.0%; Pred. No. 1.4e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 35
US-10-040-244-16
; Sequence 16, Application US/10040244
; Publication No. US20030059427A1
; GENERAL INFORMATION:
; APPLICANT: KIRIN BEER KABUSHIKI KAISHA
; APPLICANT: FORCE, WALKER F.
; APPLICANT: TAKAHASHI, NOBUAKI
; APPLICANT: MIKAYAMA, TOSHIFUMI
; TITLE OF INVENTION: ISOLATION AND CHARACTERIZATION OF HIGHLY ACTIVE ANTI-CD40 ANTIBOD
; FILE REFERENCE: 021286/0272501
; CURRENT APPLICATION NUMBER: US/10/040,244
; CURRENT FILING DATE: 2002-06-17
; PRIOR APPLICATION NUMBER: 60/200,601
; PRIOR FILING DATE: 2000-4-28
; PRIOR APPLICATION NUMBER: PCT/US01/13672
; PRIOR FILING DATE: 2001-04-27
; PRIOR APPLICATION NUMBER: 09/844,684
; PRIOR FILING DATE: 2001-04-27
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 3.0
; SEQ ID NO 16
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-040-244-16

Query Match      100.0%; Score 506; DB 4; Length 124;
Best Local Similarity 100.0%; Pred. No. 1.4e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 36
US-10-725-962-20
; Sequence 20, Application US/10725962
; Publication No. US20050013809A1
; GENERAL INFORMATION:
; APPLICANT: Samuel M. Owens
; APPLICANT: Frank I. Carroll
; APPLICANT: Philip Abraham

```

```
; APPLICANT: Melinda G. Gunnell
; APPLICANT: Mary Haak-Frendescho
; APPLICANT: Xiao Feng
; TITLE OF INVENTION: ANTIBODIES AGAINST DRUGS OF ABUSE
; FILE REFERENCE: ABGENIX.071A
; CURRENT APPLICATION NUMBER: US/10/725.962
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430717
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 141
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 126
; TYPE: PRT
; ORGANISM: Mus musculus
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 99, 100, 101, 102, 103, 104, 105
; OTHER INFORMATION: Xaa = Any Amino Acid
; US-10-725-962-20

Query Match          100.0%; Score 506; DB 5; Length 126;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 37
US-10-800-197-124
; Sequence 124, Application US/10800197
; Publication No. US20040202655A1
; GENERAL INFORMATION:
; APPLICANT: Morton, Philip A et al.
; TITLE OF INVENTION: ANTIBODIES TO IGF-I RECEPTOR FOR THE TREATMENT OF CANCERS
; FILE REFERENCE: 01343/1
; CURRENT APPLICATION NUMBER: US/10/800.197
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: 60/455,094
; PRIOR FILING DATE: 2003-03-14
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 124
; LENGTH: 127
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: phage display generated VH or VL region
; US-10-800-197-124

Query Match          100.0%; Score 506; DB 4; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 38
US-09-840-459-77
; Sequence 77, Application US/09840459
; Patent No. US20020150576A1
```

```
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran H.
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840.459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
; US-09-840-459-77

Query Match          100.0%; Score 506; DB 3; Length 128;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 39
US-09-840-459-79
; Sequence 79, Application US/09840459
; Patent No. US20020150576A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840.459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
```

```
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-840-459-79

Query Match      100.0%; Score 506; DB 3; Length 128;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 40
US-10-766-773-77
; Sequence 77, Application US/10766773
; Publication No. US20040126851A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-028
; CURRENT APPLICATION NUMBER: US/10766,773
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-766-773-77

Query Match      100.0%; Score 506; DB 4; Length 128;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 41
US-10-766-773-79
; Sequence 79, Application US/10766773
; Publication No. US20040126851A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-028
; CURRENT APPLICATION NUMBER: US/10766,773
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-766-773-77

Query Match      100.0%; Score 506; DB 4; Length 128;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 42
US-10-766-610-77
; Sequence 77, Application US/10766610
; Publication No. US20040132980A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-029
; CURRENT APPLICATION NUMBER: US/10766,610
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/840,459
; PRIOR FILING DATE: 2001-04-23
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-766-610-77

Query Match      100.0%; Score 506; DB 4; Length 128;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

Query Match      100.0%; Score 506; DB 4; Length 128;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGSGSTYY 60
   |||||
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGSGSTYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
```

```

; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-766-610-77

Query Match      100.0%; Score 506; DB 4; Length 128;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98

RESULT 43
US-10-766-610-79
; Sequence 79, Application US/10766610
; Publication No. US20040132980A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-029
; CURRENT APPLICATION NUMBER: US/10/766,610
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/840,459
; PRIOR FILING DATE: 2001-04-23
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-766-610-79

Query Match      100.0%; Score 506; DB 4; Length 128;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98

RESULT 44
US-10-733-563-77

```

```

; Sequence 77, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; APPLICANT: Ponath, Paul
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-733-563-77

Query Match      100.0%; Score 506; DB 4; Length 128;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 1 EVQLLEGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98

RESULT 45
US-10-733-563-79
; Sequence 79, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; APPLICANT: Ponath, Paul
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-733-563-79

Query Match      100.0%; Score 506; DB 4; Length 128;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98

RESULT 46
US-09-837-306-184
; Sequence 184, Application US/09837306
; Publication No. US20040029113A1
; GENERAL INFORMATION:
; APPLICANT: LADNER, ROBERT C.
; APPLICANT: COHEN, EDWARD H.
; APPLICANT: NASTRI, HORACIO G.
; APPLICANT: ROOKEY, KRISTIN L.
; APPLICANT: HOET, RENE
; TITLE OF INVENTION: NOVEL METHODS OF CONSTRUCTING LIBRARIES OF GENETIC
; TITLE OF INVENTION: PACKAGES THAT COLLECTIVELY DISPLAY THE MEMBERS OF A
; TITLE OF INVENTION: DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS
; FILE REFERENCE: DYAX/002
; CURRENT APPLICATION NUMBER: US/09/837,306
; CURRENT FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: 60/198,069
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 428
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 184
; LENGTH: 136
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: V3-23
US-09-837-306-184

Query Match 100.0%; Score 506; DB 3; Length 136;
Best Local Similarity 100.0%; Pred. No. 1.6e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
Db 7 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 66
Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
Db 67 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 104

RESULT 47
US-10-045-674-487
; Sequence 487, Application US/10045674
; Publication No. US2003023233A1
; GENERAL INFORMATION:
; APPLICANT: LADNER, ROBERT C.
; APPLICANT: COHEN, EDWARD H.
; APPLICANT: NASTRI, HORACIO G.
; APPLICANT: ROOKEY, KRISTIN L.
; APPLICANT: HOET, RENE
; APPLICANT: HOOGENDOORN, HENDRICUS R. J. M.
; TITLE OF INVENTION: NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING
; TITLE OF INVENTION: DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY
; TITLE OF INVENTION: OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL
; TITLE OF INVENTION: LIBRARIES
; FILE REFERENCE: DYAX/002 CIP2
; CURRENT APPLICATION NUMBER: US/10/045,674
; CURRENT FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: 60/198,069
; PRIOR FILING DATE: 2000-04-17
; PRIOR APPLICATION NUMBER: 09/837,306
```

```
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 635
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 487
; LENGTH: 136
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic 3-23
; OTHER INFORMATION: VH protein sequence
US-10-045-674-487

Query Match 100.0%; Score 506; DB 4; Length 136;
Best Local Similarity 100.0%; Pred. No. 1.6e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
Db 7 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 66
Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
Db 67 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 104

RESULT 48
US-10-693-629-64
; Sequence 64, Application US/10693629
; Publication No. US20040120948A1
; GENERAL INFORMATION:
; APPLICANT: KIRIN BEER KABUSHIKI KAISHA
; APPLICANT: MIKAYAMA, Toshifumi
; APPLICANT: YOSHIDA, Hitoshi
; APPLICANT: FORCE, Walker, R.
; APPLICANT: CHEN, Xingjie
; APPLICANT: TAKAHASHI, Nobuaki
; TITLE OF INVENTION: ANTI CD40 MONOCLONAL ANTIBODY
; FILE REFERENCE: 021286-0306473
; CURRENT APPLICATION NUMBER: US/10/693,629
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: PCT/US01/13672
; PRIOR FILING DATE: 2001-04-27
; PRIOR APPLICATION NUMBER: US09/844,684
; PRIOR FILING DATE: 2001-04-27
; PRIOR APPLICATION NUMBER: JP2001/142482
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: JP2001/310535
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: US10/040,244
; PRIOR FILING DATE: 2001-10-26
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 64
; LENGTH: 177
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-693-629-64

Query Match 100.0%; Score 506; DB 4; Length 177;
Best Local Similarity 100.0%; Pred. No. 2.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 60
Db 20 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY 79
Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 117

RESULT 49
US-09-192-854-2
```



```
; Sequence 2, Application US/09192854
; Patent No. US20020068276A1
; GENERAL INFORMATION:
; APPLICANT: Tomlinson, Ian
; APPLICANT: Tomlinson, Greg
; TITLE OF INVENTION: Methods for Selecting Functional Peptides
; FILE REFERENCE: 3789/72916
; CURRENT APPLICATION NUMBER: US/09/192,854
; CURRENT FILING DATE: 1998-11-17
; EARLIER APPLICATION NUMBER: 60/066,729
; EARLIER FILING DATE: 1997-11-21
; NUMBER OF SEQ ID NOS: 212
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-192-854-2

Query Match      100.0%; Score 506; DB 3; Length 240;
Best Local Similarity 100.0%; Pred. No. 2.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||
Db 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||

RESULT 50
US-09-968-561A-2
; Sequence 2, Application US/09968561A
; Patent No. US20020164642A1
; GENERAL INFORMATION:
; APPLICANT: Tomlinson, Ian M
; APPLICANT: Tomlinson, Greg
; TITLE OF INVENTION: Method to Screen Phase Display Libraries with Different Ligands
; FILE REFERENCE: 8039/1073B
; CURRENT APPLICATION NUMBER: US/09/968,561A
; CURRENT FILING DATE: 2001-10-01
; PRIOR FILING DATE: 1997-10-20
; PRIOR FILING DATE: 1997-11-13
; PRIOR FILING DATE: 1997-11-21
; PRIOR FILING DATE: 1998-10-20
; PRIOR FILING DATE: 1998-10-24
; NUMBER OF SEQ ID NOS: 350
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-968-561A-2

Query Match      100.0%; Score 506; DB 3; Length 240;
Best Local Similarity 100.8%; Pred. No. 2.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||
Db 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||

RESULT 51
US-09-968-744A-2
; Sequence 2, Application US/09968744A
; Publication No. US20030148372A1
; GENERAL INFORMATION:
; APPLICANT: Tomlinson, Ian M
; APPLICANT: Winter, Gregory
; TITLE OF INVENTION: Method to Screen Phase Display Libraries with Different Ligands
; FILE REFERENCE: 8039/1073
; CURRENT APPLICATION NUMBER: US/09/968,744A
; CURRENT FILING DATE: 2003-01-13
; PRIOR FILING DATE: 1997-10-20
; PRIOR FILING DATE: 1997-11-21
; PRIOR FILING DATE: 1997-11-13
; PRIOR FILING DATE: 1997-11-21
; PRIOR FILING DATE: 1998-10-20
; PRIOR FILING DATE: 2000-02-24
; NUMBER OF SEQ ID NOS: 350
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-968-744A-2

Query Match      100.0%; Score 506; DB 3; Length 240;
Best Local Similarity 100.0%; Pred. No. 2.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||
Db 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||

RESULT 52
US-09-968-561A-2
; Sequence 2, Application US/09968561A
; Publication No. US20040038291A2
; GENERAL INFORMATION:
; APPLICANT: Tomlinson, Ian M
; APPLICANT: Winter, Gregory
; TITLE OF INVENTION: Method to Screen Phase Display Libraries with Different Ligands
; FILE REFERENCE: 8039/1073B
; CURRENT APPLICATION NUMBER: US/09/968,561A
; CURRENT FILING DATE: 2001-10-01
; PRIOR FILING DATE: 1997-10-20
; PRIOR FILING DATE: 1997-11-13
; PRIOR FILING DATE: 1997-11-21
; PRIOR FILING DATE: 1998-10-20
; PRIOR FILING DATE: 1998-10-24
; NUMBER OF SEQ ID NOS: 350
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-968-561A-2

Query Match      100.0%; Score 506; DB 3; Length 240;
Best Local Similarity 100.8%; Pred. No. 2.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||
Db 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
```

```
RESULT 51
US-09-968-744A-2
; Sequence 2, Application US/09968744A
; Publication No. US20030148372A1
; GENERAL INFORMATION:
; APPLICANT: Tomlinson, Ian M
; APPLICANT: Winter, Gregory
; TITLE OF INVENTION: Method to Screen Phase Display Libraries with Different Ligands
; FILE REFERENCE: 8039/1073
; CURRENT APPLICATION NUMBER: US/09/968,744A
; CURRENT FILING DATE: 2003-01-13
; PRIOR FILING DATE: 1997-10-20
; PRIOR FILING DATE: 1997-11-21
; PRIOR FILING DATE: 1997-11-13
; PRIOR FILING DATE: 1997-11-21
; PRIOR FILING DATE: 1998-10-20
; PRIOR FILING DATE: 2000-02-24
; NUMBER OF SEQ ID NOS: 350
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-968-744A-2

Query Match      100.0%; Score 506; DB 3; Length 240;
Best Local Similarity 100.0%; Pred. No. 2.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||
Db 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||

RESULT 52
US-09-968-561A-2
; Sequence 2, Application US/09968561A
; Publication No. US20040038291A2
; GENERAL INFORMATION:
; APPLICANT: Tomlinson, Ian M
; APPLICANT: Winter, Gregory
; TITLE OF INVENTION: Method to Screen Phase Display Libraries with Different Ligands
; FILE REFERENCE: 8039/1073B
; CURRENT APPLICATION NUMBER: US/09/968,561A
; CURRENT FILING DATE: 2001-10-01
; PRIOR FILING DATE: 1997-10-20
; PRIOR FILING DATE: 1997-11-13
; PRIOR FILING DATE: 1997-11-21
; PRIOR FILING DATE: 1998-10-20
; PRIOR FILING DATE: 1998-10-24
; NUMBER OF SEQ ID NOS: 350
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-968-561A-2

Query Match      100.0%; Score 506; DB 3; Length 240;
Best Local Similarity 100.0%; Pred. No. 2.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||
Db 1 EVQLLEGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWWSAISGGSTYY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
   |||||
```

```
Best Local Similarity 100.0%; Pred. No. 2.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 54
US-10-744-774-1
; Sequence 1, Application US/10744774
; Publication No. US20040219643A1
; GENERAL INFORMATION:
; APPLICANT: Domantis Limited
; APPLICANT: Medical Research Council
; APPLICANT: Ignatovich, Olga
; APPLICANT: Jones, Philip C.
; APPLICANT: Tomlinson, Ian
; APPLICANT: Winter, Greg
; TITLE OF INVENTION: Dual Specific Ligand
; CURRENT APPLICATION NUMBER: US/10/744,774
; CURRENT FILING DATE: 2003-12-23
; PRIOR APPLICATION NUMBER: PCT/GB02/03014
; PRIOR FILING DATE: 2002-06-28
; PRIOR APPLICATION NUMBER: GB 0115841.9
; PRIOR FILING DATE: 2001-06-28
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: VH/HSa
US-10-744-774-1

Query Match 100.0%; Score 506; DB 5; Length 240;
Best Local Similarity 100.0%; Pred. No. 2.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 54
US-11-115-682-2
; Sequence 2, Application US/11115682
; Publication No. US20050202512A1
; GENERAL INFORMATION:
; APPLICANT: Tomlinson, Ian M
; APPLICANT: Winter, Gregory
; TITLE OF INVENTION: Method to Screen Phage Display Libraries with Different Ligands
; FILE REFERENCE: 8039/1073B
; CURRENT APPLICATION NUMBER: US/11/115,682
; CURRENT FILING DATE: 2005-04-27
; PRIOR APPLICATION NUMBER: GB 9722131.1
; PRIOR FILING DATE: 1997-10-20
; PRIOR APPLICATION NUMBER: US 60/065,248
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: US 60/066,729
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: PCT/GB98/03135
; PRIOR FILING DATE: 1998-10-20
```

```
; PRIOR APPLICATION NUMBER: US 09/511,939
; PRIOR FILING DATE: 2000-02-24
; NUMBER OF SEQ ID NOS: 350
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-115-682-2

Query Match 100.0%; Score 506; DB 6; Length 240;
Best Local Similarity 100.0%; Pred. No. 2.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 55
US-11-090-847-147
; Sequence 147, Application US/11090847
; Publication No. US20050215770A1
; GENERAL INFORMATION:
; APPLICANT: Bell, et al.
; TITLE OF INVENTION: Antibodies Against Nogo Receptor
; FILE REFERENCE: PF609
; CURRENT APPLICATION NUMBER: US/11/090,847
; CURRENT FILING DATE: 2003-03-25
; PRIOR APPLICATION NUMBER: US 60/556,386
; PRIOR FILING DATE: 2004-03-26
; NUMBER OF SEQ ID NOS: 249
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 147
; LENGTH: 244
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: scFv protein NKG2123
US-11-090-847-147

Query Match 100.0%; Score 506; DB 6; Length 244;
Best Local Similarity 100.0%; Pred. No. 3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWVSAISGGSTYY 60
Db 1 EVOLLESGGLVQPGGSLRLSCAASGFTFSSYAMSVWRQAPGKLEWVSAISGGSTYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 56
US-11-017-030-48
; Sequence 48, Application US/11017030
; Publication No. US20050158313A1
; GENERAL INFORMATION:
; APPLICANT: Rosen, et al.
; TITLE OF INVENTION: Antibodies that Specifically Bind to Reg IV
; FILE REFERENCE: PF592PCT
; CURRENT APPLICATION NUMBER: US/11/017,030
; CURRENT FILING DATE: 2004-12-21
; PRIOR APPLICATION NUMBER: PCT/US03/19908
; PRIOR FILING DATE: 2003-06-26
; PRIOR APPLICATION NUMBER: 60/392,382
; PRIOR FILING DATE: 2002-07-01
; NUMBER OF SEQ ID NOS: 176
```

```
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 48
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: scFv protein RGD0119
US-11-017-030-48

Query Match      100.0%; Score 506; DB 6; Length 245;
Best Local Similarity 100.0%; Pred. No. 3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
    |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
    |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
    |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
    |||||

RESULT 57
US-11-017-030-53
; Sequence 53, Application US/11017030
; Publication No. US20050158313A1
; GENERAL INFORMATION:
; APPLICANT: Rosen, et al.
; TITLE OF INVENTION: Antibodies that Specifically Bind to Reg IV
; FILE REFERENCE: PF592PCT
; CURRENT APPLICATION NUMBER: US/11/017,030
; CURRENT FILING DATE: 2004-12-21
; PRIOR APPLICATION NUMBER: PCT/US03/19908
; PRIOR FILING DATE: 2003-06-26
; PRIOR APPLICATION NUMBER: 60/392,382
; PRIOR FILING DATE: 2002-07-01
; NUMBER OF SEQ ID NOS: 176
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 53
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: scFv protein RGD0130
US-11-017-030-53

Query Match      100.0%; Score 506; DB 6; Length 245;
Best Local Similarity 100.0%; Pred. No. 3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
    |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
    |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
    |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
    |||||

RESULT 58
US-11-090-847-137
; Sequence 137, Application US/11090847
; Publication No. US20050215770A1
; GENERAL INFORMATION:
; APPLICANT: Bell, et al.
; TITLE OF INVENTION: Antibodies Against Nogo Receptor
; FILE REFERENCE: PF609
; CURRENT APPLICATION NUMBER: US/11/090,847
; CURRENT FILING DATE: 2005-03-25
; PRIOR APPLICATION NUMBER: 2005-03-25
; PRIOR FILING DATE: 2004-03-26
; NUMBER OF SEQ ID NOS: 249
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 137
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: scFv protein NGG2007
US-11-090-847-137

Query Match      100.0%; Score 506; DB 6; Length 245;
Best Local Similarity 100.0%; Pred. No. 3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
    |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
    |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
    |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
    |||||

RESULT 59
US-10-779-461-8
; Sequence 8, Application US/10779461
; Publication No. US20040166544A1
; GENERAL INFORMATION:
; APPLICANT: Morton, Philip A
; TITLE OF INVENTION: ANTIBODIES TO c-MET FOR THE TREATMENT OF CANCERS
; FILE REFERENCE: 00980/1
; CURRENT APPLICATION NUMBER: US/10/779,461
; CURRENT FILING DATE: 2004-02-13
; PRIOR APPLICATION NUMBER: 60/447,073
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 161
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 250
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: phage display generated human antibody
US-10-779-461-8

Query Match      100.0%; Score 506; DB 4; Length 250;
Best Local Similarity 100.0%; Pred. No. 3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
    |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
    |||||

Qy 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
    |||||
Db 61 ADSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCAK 98
    |||||

RESULT 60
US-11-017-030-12
; Sequence 12, Application US/11017030
; Publication No. US20050158313A1
; GENERAL INFORMATION:
; APPLICANT: Rosen, et al.
; TITLE OF INVENTION: Antibodies that Specifically Bind to Reg IV
; FILE REFERENCE: PF592PCT
; CURRENT APPLICATION NUMBER: US/11/017,030
; CURRENT FILING DATE: 2004-12-21
; PRIOR APPLICATION NUMBER: PCT/US03/19908
; PRIOR FILING DATE: 2003-06-26
; PRIOR APPLICATION NUMBER: 60/392,382
; PRIOR FILING DATE: 2002-07-01
; NUMBER OF SEQ ID NOS: 176
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
```

```
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: scfv protein RGB0129
US-11-017-030-12

Query Match      100.0%; Score 506; DB 6; Length 252;
Best Local Similarity 100.0%; Pred. No. 3.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
   |||||

QY 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||

RESULT 61
US-10-800-197-9
; Sequence 9, Application US/10800197
; Publication No. US20040202655A1
; GENERAL INFORMATION:
; APPLICANT: Morton, Philip A et al.
; TITLE OF INVENTION: ANTIBODIES TO IGF-I RECEPTOR FOR THE TREATMENT OF CANCERS
; FILE REFERENCE: 01343/1
; CURRENT APPLICATION NUMBER: US/10/800,197
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: 60/455,094
; PRIOR FILING DATE: 2003-03-14
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 253
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: phage display generated antibody
US-10-800-197-9

Query Match      100.0%; Score 506; DB 4; Length 253;
Best Local Similarity 100.0%; Pred. No. 3.1e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
   |||||
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
   |||||

QY 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||

RESULT 62
US-10-291-265-427
; Sequence 427, Application US/10291265
; Publication No. US20030232054A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; APPLICANT: Tang et al
; TITLE OF INVENTION: No. US20030232054A1el Nucleic Acids and Polypeptides
; FILE REFERENCE: 21272-017 (785)
; CURRENT APPLICATION NUMBER: US/10/291,265
; CURRENT FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 09/491,404
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 09/617,746
; PRIOR FILING DATE: 2000-07-17
; PRIOR APPLICATION NUMBER: 09/631,451
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: 09/633,870

; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 944
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 427
; LENGTH: 313
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-291-265-427

Query Match      100.0%; Score 506; DB 4; Length 313;
Best Local Similarity 100.0%; Pred. No. 3.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
   |||||
Db 61 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 120
   |||||

QY 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 121 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 158
   |||||

RESULT 63
US-10-045-674-453
; Sequence 453, Application US/10045674
; Publication No. US20030232333A1
; GENERAL INFORMATION:
; APPLICANT: LADNER, ROBERT C.
; APPLICANT: COHEN, EDWARD H.
; APPLICANT: NASTRI, HORACIO G.
; APPLICANT: ROOKEY, KRISTIN L.
; APPLICANT: HOET, RENE
; APPLICANT: HOOGENBOOM, HENDRICUS R. J. M.
; TITLE OF INVENTION: NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING
; TITLE OF INVENTION: DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY
; TITLE OF INVENTION: OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL
; TITLE OF INVENTION: LIBRARIES
; FILE REFERENCE: DYAX/002 CIP2
; CURRENT APPLICATION NUMBER: US/10/045,674
; CURRENT FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: 60/198,069
; PRIOR FILING DATE: 2000-04-17
; PRIOR APPLICATION NUMBER: 09/837,306
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 635
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 453
; LENGTH: 367
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: MALIA3 protein
; OTHER INFORMATION: sequence
US-10-045-674-453

Query Match      100.0%; Score 506; DB 4; Length 367;
Best Local Similarity 100.0%; Pred. No. 4.6e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 60
   |||||
Db 23 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVSAISGGSTYY 82
   |||||

QY 61 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
   |||||
Db 83 ADSVKGRTISRDNKNTLYLQWNSLRAEDTAVYYCAK 120
   |||||

RESULT 64
US-09-837-306-196
; Sequence 196, Application US/09837306
; Publication No. US20040029113A1
; GENERAL INFORMATION:
```

; APPLICANT: LADNER, ROBERT C.
; APPLICANT: COHEN, EDWARD H.
; APPLICANT: NASTRI, HORACIO G.
; APPLICANT: ROOKEY, KRISTIN L.
; APPLICANT: HOET, RENE
; TITLE OF INVENTION: NOVEL METHODS OF CONSTRUCTING LIBRARIES OF GENETIC
; TITLE OF INVENTION: PACKAGES THAT COLLECTIVELY DISPLAY THE MEMBERS OF A
; TITLE OF INVENTION: DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS
; FILE REFERENCE: DVAX/002
; CURRENT APPLICATION NUMBER: US/09/837,306
; CURRENT FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: 60/198,069
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 428
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 196
; LENGTH: 368
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: MALIA3
US-09-837-306-196

Query Match 100.0%; Score 506; DB 3; Length 368;
Best Local Similarity 100.0%; Pred. No. 4.6e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 23 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 82

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 83 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 120

RESULT 65
US-10-038-591-46
; Sequence 46, Application US/10038591
; Publication No. US20040086503A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Beebe, Jean
; APPLICANT: Miller, Penelope E.
; APPLICANT: Moyer, James D.
; APPLICANT: Corvaian, Jose R.
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; FILE REFERENCE: ABX-PF2
; CURRENT APPLICATION NUMBER: US/10/038,591
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,927
; PRIOR FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 46
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-038-591-46

Query Match 100.0%; Score 506; DB 4; Length 470;
Best Local Similarity 100.0%; Pred. No. 5.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 20 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 79

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 80 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 117

RESULT 66

US-10-775-444A-46
; Sequence 46, Application US/10775444A
; Publication No. US20040202651A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Bedian, Vahe
; APPLICANT: Obrocea, Mihail
; APPLICANT: Gomez-Navarro, Jesus
; APPLICANT: Cusmano, John D.
; APPLICANT: Wang, Huifen F.
; APPLICANT: Page, Kelly L.
; APPLICANT: Guyot, Deborah J.
; TITLE OF INVENTION: USES OF ANTI-INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; TITLE OF INVENTION: ANTIBODIES
; FILE REFERENCE: PC25232A
; CURRENT APPLICATION NUMBER: US/10/775,444A
; CURRENT FILING DATE: 2004-02-10
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 46
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-775-444A-46

Query Match 100.0%; Score 506; DB 4; Length 470;
Best Local Similarity 100.0%; Pred. No. 5.9e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 60
Db 20 EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKGLEWWSAISGGSTYY 79

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 80 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 117

Search completed: May 12, 2006, 02:29:42
Job time : 58.5 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:58 ; Search time 38.8199 Seconds
(without alignments)
1781.089 Million cell updates/sec

Title: US-09-674-752-52

Perfect score: 506

Sequence: 1 EVQLLESGGGLVPGGSLRL.....LYLQMNSLRAEDTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	502	99.2	117	1 HV3C HUMAN	P01764 homo sapien
2	491	97.0	597	2 Q96B89 HUMAN	Q96bb9 homo sapien
3	465	91.9	121	2 Q9UL71 HUMAN	Q9ul71 homo sapien
4	450	88.9	240	2 Q65ZC9 HUMAN	Q65zc9 homo sapien
5	449	88.7	113	2 Q9UL90 HUMAN	Q9ul90 homo sapien
6	449	88.7	469	2 Q569F4 HUMAN	Q569f4 homo sapien
7	445.5	88.0	116	1 HV05 CARAU	P19181 carassius a
8	445	87.9	613	2 Q8WUK1 HUMAN	Q8wuk1 homo sapien
9	444	87.7	112	2 Q9HCC1 HUMAN	Q9hcc1 homo sapien
10	443.5	87.5	464	2 Q6MZU6 HUMAN	Q6mzu6 homo sapien
11	443	87.5	118	2 Q9UL91 HUMAN	Q9ul91 homo sapien
12	441	87.2	478	2 Q6P181 HUMAN	Q6p181 homo sapien
13	440	87.0	475	2 Q6MZQ6 HUMAN	Q6mzq6 homo sapien
14	439	86.8	116	2 Q9UL93 HUMAN	Q9ul93 homo sapien
15	436	86.2	473	2 Q6MZV7 HUMAN	Q6mzv7 homo sapien
16	436	86.2	605	2 Q6GMV2 HUMAN	Q6gmv2 homo sapien
17	435	86.0	472	2 Q6N089 HUMAN	Q6n089 homo sapien
18	435	86.0	573	2 Q8WU38 HUMAN	Q8wu38 homo sapien
19	433	85.6	470	2 Q6PJAA HUMAN	Q6pja4 homo sapien
20	431	85.0	467	2 Q4VBH1 RAT	Q4vbh1 rattus norv
21	430	85.0	493	2 Q6GMX2 HUMAN	Q6gmx2 homo sapien
22	426	84.2	95	2 Q9ULB6 HUMAN	Q9ulb6 homo sapien
23	424.5	83.9	118	2 Q9UL72 HUMAN	Q9ul72 homo sapien
24	424.5	83.9	120	1 HV3E HUMAN	P01766 homo sapien
25	422.5	83.5	115	1 HV3F HUMAN	P01767 homo sapien
26	422.5	83.5	466	2 Q6IN78 HUMAN	Q6in78 homo sapien
27	422	83.4	114	1 HV3B HUMAN	P01763 homo sapien
28	422	83.4	494	2 Q96K68 HUMAN	Q96k68 homo sapien
29	422	83.4	499	2 Q8NSK4 HUMAN	Q8nsk4 homo sapien
30	421	83.2	122	1 HV3G HUMAN	P01768 homo sapien
31	420	83.0	117	1 HV54_MOUSE	P18525 mus musculus

```

32 418.5 82.7 97 1 HV56_MOUSE
33 418 82.6 117 1 HV55_MOUSE
34 418 82.6 196 2 Q65ZL8_MOUSE
35 418 82.6 479 2 Q5PQK9_RAT
36 417 82.4 465 2 Q6P6C4_HUMAN
37 416 82.2 122 2 Q9UL84_HUMAN
38 416 82.2 147 2 Q9Y509_HUMAN
39 415 82.0 115 1 HV3D_HUMAN
40 415 82.0 475 2 Q6GMW7_HUMAN
41 414 81.8 479 2 Q5BK12_RAT
42 412 81.4 119 2 Q920E7_MOUSE
43 410 81.0 465 2 Q5IOJ0_RAT
44 410 81.0 479 2 Q9IWP5_MOUSE
45 408 80.6 487 2 Q99KA4_MOUSE

```

```

P18527 mus musculus
P18526 mus musculus
Q65ZL8 mus musculus
Q5PQK9 rattus norv
Q6P6C4 homo sapien
Q9UL84 homo sapien
Q9Y509 homo sapien
P01765 homo sapien
Q6GMW7 homo sapien
Q5BK12 rattus norv
Q920E7 mus musculus
Q5IOJ0 rattus norv
Q9IWP5 mus musculus
Q99KA4 mus musculus

```

ALIGNMENTS

RESULT 1

```

HV3C_HUMAN
ID HV3C_HUMAN STANDARD; PRT; 117 AA.
AC P01764;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DE 13-SEP-2005 (Rel. 48, Last annotation update)
DE Ig heavy chain V-III region VH26 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=81101090; PubMed=6450418;
RA Matthysens G., Rabbitts T.H.;
RT "Structure and multiplicity of genes for the human immunoglobulin
RL heavy chain variable region.";
RL Proc. Natl. Acad. Sci. U.S.A. 77:6561-6565(1980).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 20-117.
RX MEDLINE=93209281; PubMed=7681398;
RA Mariette X., Teapis A., Brouet J.C.;
RT "Nucleotide sequence analysis of the variable domains of four human
RT monoclonal IgM with an antibody activity to myelin-associated
RL glycoprotein.";
RL Eur. J. Immunol. 23:846-851(1993).
RN [3]
RP 3D-STRUCTURE MODELING OF 20-117.
RX MEDLINE=86094276; PubMed=3866244;
RA Toyonaga B., Yoshikai Y., Vadasz V., Chin B., Mak T.W.;
RT "Organization and sequences of the diversity, joining, and constant
RT region genes of the human T-cell receptor beta chain.";
RL Proc. Natl. Acad. Sci. U.S.A. 82:8624-8628(1985).
CC -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR EMBL; J00236; AAA53516.1; -; Unassigned DNA.
DR EMBL; M35415; AAA58735.1; -; Genomic_DNA.
DR PIR; A02047; H3HU26.
DR PDB; 1HOU; Model; H=20-117.
DR HGNC; HGNC:5545; IGHV6.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.

```

```

DR PROSITE; PS50835; IG_LIKE; 1.
KW 3D-structure; Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-III region VH26.
FT DOMAIN 20 >117 IG-Like.
FT DON_TER 117 117
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12582 MW; E826733F1A3CB0F1 CRC64;

Query Match 99.2%; Score 502; DB 1; Length 117;
Best Local Similarity 99.0%; Pred. No. 3.5e-45;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVOPGSLRLSCAASGFTFSYAMSVWROAPGKLEWVSAISGSGSTYY 60
Db 20 EVOLLESGGLVOPGSLRLSCAASGFTFSYAMSVWROAPGKLEWVSAISGSGSTYY 79

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
Db 80 GDSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 117

RESULT 2
Q96BB9 HUMAN
ID Q96BB9_HUMAN PRELIMINARY; PRT; 597 AA.
AC Q96BB9
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
GN IGHM
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner K.H., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan B., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Boeak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting M., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalusz D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2500644;
RA Kishimoto T., Okajima H., Okumoto T., Taniguchi M.;
RT "Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-
RT chains of a human monoclonal antibody with broad reactivity to
RT malignant tumor cells."
RL Nucleic Acids Res. 17:4385-0(1989).
DR EMBL; BC015760; AAL15760.1; -; mRNA.

```

```

DR PIR; S05271; S05271.
DR PIR; S24260; S24260.
DR HSSP; P01861; IADQ.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; IG-cl.
DR InterPro; IPR003597; IG-cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.
KW Immunoglobulin domain.
SQ SEQUENCE 597 AA; 65039 MW; 4FCA3AD8ECE263D9 CRC64;

Query Match 97.0%; Score 491; DB 2; Length 597;
Best Local Similarity 95.9%; Pred. No. 3.3e-43;
Matches 94; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVOPGSLRLSCAASGFTFSYAMSVWROAPGKLEWVSAISGSGSTYY 60
Db 20 EVOLLESGGLVOPGSLRLSCAASGFTFSYAMSVWROAPGKLEWVSAISGSGSTYY 79

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 117

RESULT 3
Q9UL71 HUMAN
ID Q9UL71_HUMAN PRELIMINARY; PRT; 121 AA.
AC Q9UL71
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus."
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035043; AAD56279.1; -; mRNA.
DR HSSP; P01852; INF0.
DR SMR; Q9UL71; 1-121.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1 1
FT NON_TER 121 121
SQ SEQUENCE 121 AA; 13154 MW; 2F045CCFA5D50736 CRC64;

Query Match 91.9%; Score 465; DB 2; Length 121;
Best Local Similarity 89.8%; Pred. No. 3e-41;
Matches 88; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 1 EVOLLESGGLVOPGSLRLSCAASGFTFSYAMSVWROAPGKLEWVSAISGSGSTYY 60
Db 1 EVOLLESGGLVOPGSLRLSCAASGFTFSYAMSVWROAPGKLEWVSAISGSGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98

```


Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.

Query Match	88.0%;	Score	445.5;	DB	1;	Length	116;
Best Local Similarity	89.8%;	Pred. No.	3.4e-39;				
Matches	88;	Conservative	3;	Mismatches	6;	Indels	1;
				Gaps	1;		
Qy	1	EVQLVGGGLVDPGGSRLRLSCAASGRTFSYAMSWVRQAPGKGLEWWSAISGGSTYY	60				
Db	20	EVQLVGGGLVDPGGSRLRLSCAASGRTFSYAMSWVRQAPGKGLEWWSVYY	78				
Qy	61	ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK	98				
Db	79	ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAR	116				

RESULT 8

ID	Q8WUK1_HUMAN	PRELIMINARY;	PRT;	613 AA.
AC	Q8WUK1;			
DT	01-MAR-2002	(TrEMBLrel. 20, Created)		
DT	01-MAR-2002	(TrEMBLrel. 20, Last sequence update)		
DT	01-MAR-2004	(TrEMBLrel. 26, Last annotation update)		
DE	IGHM protein.			
GN	Name=IGHM;			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;			
OC	Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	NUCLEOTIDE SEQUENCE.			
RC	TISSUE=Primary B-Cells;			
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;			
RA	Straussberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,			
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,			
RA	Altschul S.F., Zeeberg B., Bustow K.H., Moore T., Max S.I., Wang J., Heide F.,			
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,			
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,			
RA	Stapleton K., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,			
RA	Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,			
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,			
RA	Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,			
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,			
RA	Vallalad D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,			
RA	Fahey J.J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,			
RA	Whiting M., Madan A., Young A.C., Shevchenko V., Bouffard G.G.,			
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,			
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,			
RA	Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,			
RA	Gensch A., Schein J.E., Jones S.J.M., Marra M.A.;			
RT	"Generation and initial analysis of more than 15,000 full-length human			
RT	and mouse cDNA sequences.";			
RP	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).			
RN	[2]			
RP	NUCLEOTIDE SEQUENCE.			
RC	TISSUE=Primary B-Cells;			
RG	NIH MGC Project;			
RP	Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.			
RN	[3]			
RP	NUCLEOTIDE SEQUENCE.			
RX	PubMed=21117273;			
RA	Schroeder H.W. Jr., Wang J.Y.;			
RT	"Preferential utilization of conserved immunoglobulin heavy chain			
RT	variable gene segments during human fetal life.";			
RP	Proc. Natl. Acad. Sci. U.S.A. 87:6146-6150(1990).			
RN	[4]			
RP	NUCLEOTIDE SEQUENCE.			
RX	PubMed=1383695; DOI=10.1016/0161-5890(92)90173-U;			
RA	Quisnier A.M., Fumoux F., Fougereau M., Tonnel C.;			
RT	"IGM kappa/lambda EBV human B cell clone: an early step of			
RT	differentiation of fetal B cells or a distinct B lineage?";			
RP	Mol. Immunol. 29:1363-1373(1992).			
RN	[5]			
RP	NUCLEOTIDE SEQUENCE.			
RX	PubMed=1730252;			
RA	Raaphorst R.M.; Timmers E., Kenter M.J., Van Tol M.J., Vossen J.M.,			
RA	Schuurman F.K.;			
RT	"Restricted utilization of germ-line VH3 genes and short diverse third			
RT	complementarity-determining regions (CDR3) in human fetal B lymphocyte			
RT	immunoglobulin heavy chain rearrangements.";			
RP	Eur. J. Immunol. 22:247-251(1992).			
RN				


```

Matches 85; Conservative 9; Mismatches 4; Indels 1; Gaps 1;
QY 1 EVOLVSGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGSGSTY 59
Db EVOLVSGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGSGSTY 79
QY 60 YADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db YADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAR 118

RESULT 11
Q9UL91_HUMAN
ID Q9UL91_HUMAN PRELIMINARY; PRT; 118 AA.
AC Q9UL91;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528;
RA Hanheimer-Lory A., Katz J.B., Pillinger M., Ghossein C., Smith A.,
RA Diamond B.;
RT "Molecular characteristics of antibodies bearing an anti-DNA-
RT associated idiootype.";
RL J. Exp. Med. 174:1639-1652(1991).
RN [3]
RP PROTEIN SEQUENCE.
RX PubMed=1555592;
RA Makiya R., Stigbrand T.;
RT "Placental alkaline phosphatase has a binding site for the human
RL immunoglobulin-G Fc portion.";
DR Eur. J. Biochem. 205:341-345(1992).
DR ENBL; AF035023; AAD56259.1; -; mRNA.
DR PIR; PH0875; PH0875.
DR PIR; S21205; S21205.
DR PIR; S30531; S30531.
DR HSSP; P01783; IIGC.
DR SMR; Q9UL91; 1-117.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 118
SQ SEQUENCE 118 AA; 12843 MW; D0633949F2AC149D CRC64;

Query Match 87.5%; Score 443; DB 2; Length 118;
Best Local Similarity 86.7%; Pred. No. 6.3e-39;
Matches 85; Conservative 8; Mismatches 5; Indels 0; Gaps 0;
QY 1 EVOLVSGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGSGSTY 60
Db EVOLVSGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGSGSTY 60
QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAR 98

```

```

RESULT 12
Q6PI81_HUMAN
ID Q6PI81_HUMAN PRELIMINARY; PRT; 478 AA.
AC Q6PI81;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHM protein.
GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udgin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Maman A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalish D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX NIH MGC Project;
RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.
DR ENBL; BC041037; AAH41037.1; -; mRNA.
DR HSSP; P01861; IADQ.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_cl.
DR InterPro; IPR003006; Ig_MHC.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGC1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 478 AA; 52667 MW; 17BED38D917970D6 CRC64;

Query Match 87.2%; Score 441; DB 2; Length 478;
Best Local Similarity 85.7%; Pred. No. 5.1e-38;
Matches 84; Conservative 5; Mismatches 9; Indels 0; Gaps 0;
QY 1 EVOLVSGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGSGSTY 60
Db EVOLVSGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVSAISGSGSTY 60
QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAR 117

```

RESULT 13
Q6MZQ6_HUMAN

ID Q6MZQ6 HUMAN PRELIMINARY; PRT; 475 AA.
AC Q6MZQ6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686G1190.
GN Name=DKFZp686G1190;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominoidea;
OC Homo.
OX NCBI_TaxID=9606;
[1]
RN NUCLEOTIDE SEQUENCE.
RP TISSUE=Esoophagus tumor;
RC The German CDNA Consortium;
RG Bahr A., Lauber J., Mewes H.W., Weil B., Amid C., Oanger A., Fobo G.,
RA Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
RE EMBL; BX640947; CAB45972.1; -; mRNA.
DR HSSP; P01861; IADQ.
DR SMR; Q6MZQ6; 20-475.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 3.
DR PROSITE; PS50835; IG_LIKE; 4.
KW Hypothetical protein.
SQ SEQUENCE 475 AA; 52043 MW; B7EAE255A26F4B8E CRC64;

Query Match 87.0%; Score 440; DB 2; Length 475;
Best Local Similarity 86.7%; Pred. No. 6.5e-38;
Matches 85; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

QY 1 EVQLLEGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 EVQLLEGGLVPGGSLRLSCAASGFTFRNAYMNVWRQAPGKLEWWSGISGVNTY 79
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNLYLNLSRAEDTAVTYCAK 98
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 ADSVKGRFTISGDISTNTLYLNLSRAEDTAVTYCAR 117
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 14
Q9UL93_HUMAN

ID Q9UL93 HUMAN PRELIMINARY; PRT; 116 AA.
AC Q9UL93;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
(Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominoidea;
OC Homo.
OX NCBI_TaxID=9606;
[1]
RN NUCLEOTIDE SEQUENCE.
RP MEDLINE=98277139; PubMed=9614934; DOI=10.1006/cclin.1998.4531;
RX Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus."
RT Clin. Immunol. Immunopathol. 87:184-192(1998).

RESULT 13
 Q6MZQ6_HUMAN
 ID Q6MZQ6 HUMAN PRELIMINARY; PRT; 475 AA.
 AC Q6MZQ6;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Hypothetical protein DKFZp686G1190.
 GN Name=DKFZp686G1190;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 [1]
 RN NUCLEOTIDE SEQUENCE.
 RP TISSUE=Esophagus tumor;
 RC The German cDNA Consortium;
 RA Bahr A., Lauber J., Mewes H.W., Weil B., Amid C., Oanger A., Fobo G.,
 RA Han M., Wiemann S.;
 RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
 RE EMBL; BX640947; CAB45972.1; -; mRNA.
 DR HSSP; P01861; IADO.
 DR SMR; Q6MZQ6; 20-475.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig cl.
 DR InterPro; IPR003006; Ig MHC.
 DR InterPro; IPR003596; Ig v.
 DR Pfam; PF07654; Cl-set; 3.
 DR SMART; SM00409; IG; 2.
 DR SMART; SM00407; IGcl; 3.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
 KW Hypothetical protein.
 SQ SEQUENCE 475 AA; 52043 MW; B7EAE255A25F488E CRC64;
 Query Match 87.0%; Score 440; DB 2; Length 475;
 Best Local Similarity 86.7%; Pred. No. 6.5e-38;
 Matches 85; Conservative 6; Mismatches 7; Indels 0; Gaps 0;
 QY 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 60
 Db 20 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWWSAISGGSTYY 79
 QY 61 ADSVKGRFTISRDNKNTLYQMNSLRADPTAVYYCAK 98
 Db 80 ADSVKGRFTISRDNKNTLYQMNSLRADPTAVYYCAR 117
 RESULT 14
 Q9UL93_HUMAN
 ID Q9UL93 HUMAN PRELIMINARY; PRT; 116 AA.
 AC Q9UL93;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
 DE Myosin-reactive immunoglobulin heavy chain variable region
 DE (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 [1]
 RN NUCLEOTIDE SEQUENCE.
 RP MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
 RA Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berney S.M.,
 RA Young D.C.;
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
 RT fetus.";
 RT Clin. Immunol. Immunopathol. 87:184-192(1998).

```
DR PROSITE: PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 473 AA; 52121 MW; 9476AE4C0BFC447 CRC64;
Query Match 86.2%; Score 436; DB 2; Length 473;
Best Local Similarity 81.6%; Pred. No. 1.7e-37;
Matches 80; Conservative 13; Mismatches 5; Indels 0; Gaps 0;
Qy 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVAISGGSTYY 60
Db 20 EIQLVESGGGLVQPGGSLRLSCAASGFTFSSPEMNWVRQAPGKGLEWLSYITRSNTVYY 79
Qy 61 ADSVKGRFTISRDNSTLYLQMNSLRAEDTAVYYCAK 98
Db 80 ADSLQGRFTISRDNARNSTLYLQMNSLRAEDTAVYYCAR 117
Search completed: May 5, 2006, 09:04:20
Job time : 38.8199 secs
```

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:28 ; Search time 48.2142 Seconds
(without alignments)
1111.793 Million cell updates/sec

Title: US-09-674-752-53
Perfect score: 642
Sequence: 1 EVQLVESGGDLVPGGSLRL.....GKYRYGMDVWGQGTTVTVSS 122

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_21.*
1: Geneseqp1980s.*
2: Geneseqp1990s.*
3: Geneseqp2000s.*
4: Geneseqp2001s.*
5: Geneseqp2002s.*
6: Geneseqp2003as.*
7: Geneseqp2003bs.*
8: Geneseqp2004s.*
9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	642	100.0	122	3 AAY50973	Aay50973 Human FVI
2	642	100.0	122	3 AAY50975	Aay50975 Human FVI
3	551.5	85.9	471	9 AEB45861	Aeb45861 Human mon
4	549	85.5	128	4 AAE07014	Aae07014 Human hea
5	549	85.5	128	8 ADQ89299	Adq89299 Human imm
6	549	85.5	128	8 ADQ89301	Adq89301 Human imm
7	549	85.5	128	9 AEB09572	Aeb09572 Human hea
8	549	85.5	128	9 AEB09574	Aeb09574 Human hea
9	547.5	85.3	125	4 AAE07021	Aae07021 Human hea
10	547.5	85.3	125	8 ADQ89306	Adq89306 Human imm
11	547.5	85.3	125	9 AEB09579	Aeb09579 Human hea
12	544.5	84.8	470	5 ABG77158	Abg77158 Germline
13	544.5	84.8	470	8 ADR28580	Adr28580 Human ant
14	539.5	84.0	125	5 ABG77142	Abg77142 Anti-IGF-
15	539.5	84.0	125	8 ADR28550	Adr28550 Human ant
16	539.5	84.0	126	8 ADP46964	Adp46964 Murine he
17	537.5	83.7	118	7 ADP03959	Adp03959 Murine-ex
18	537.5	83.7	384	4 AAM24101	Aam24101 Human EST
19	533.5	83.1	121	9 ADV21389	Adv21389 Human ant
20	533.5	83.1	243	9 ADV21484	Adv21484 Mature fo
21	533.5	83.1	496	9 ADV21523	Adv21523 Mature fo
22	533.5	83.1	496	9 ADV21533	Adv21533 Mature fo
23	533.5	83.1	498	9 ADV21503	Adv21503 Mature fo
24	533.5	83.1	498	9 ADV21513	Adv21513 Mature fo

25	533	83.0	121	9 AEB45962	Aeb45962 Human mon
26	532.5	82.9	288	8 ADR28055	Adr28055 NPB polyp
27	532	82.9	252	8 ADO58062	Ado58062 S2 cell d
28	531.5	82.8	125	4 AAE07013	Aae07013 Human hea
29	531.5	82.8	125	8 ADQ89298	Adq89298 Human imm
30	531.5	82.8	125	9 AEB09571	Aeb09571 Human hea
31	530	82.6	127	8 ADP46950	Adp46950 Murine he
32	528.5	82.3	470	5 ABG77157	Abg77157 Amino aci
33	528.5	82.3	470	8 ADR28579	Adr28579 Human ant
34	526.5	82.0	255	8 ADI58044	Adi58044 Reg IV-ep
35	525	81.8	120	2 AAW27553	Aaw27553 Human Ab
36	525	81.8	120	6 ABJ18675	Abj18675 Antibody
37	525	81.8	281	2 AAW27560	Aaw27560 Consensus
38	524.5	81.7	126	8 ADP46965	Adp46965 Murine he
39	524.5	81.7	249	6 AAE36257	Aae36257 TRAIL rec
40	524.5	81.7	249	8 ADK82202	Adk82202 T1006F07
41	524.5	81.7	249	9 AEA27585	Aea27585 Antibody
42	524.5	81.7	249	9 AEA55201	Aea55201 TRAIL rec
43	524.5	81.7	251	5 ABP45594	Abp45594 Human Bly
44	524.5	81.7	251	7 ADG96421	Adg96421 Single ch
45	524	81.6	124	6 ADA89893	Ada89893 MS-Roche

ALIGNMENTS

RESULT 1
AAY50973
ID AAY50973 standard; protein; 122 AA.

XX	AC	AAY50973;	
XX	DT	23-MAR-2000 (first entry)	
XX	DE	Human FVIII antibody A2 scFv heavy chain protein DP-47 #2.	
XX	KW	Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;	
XX	KW	scFv; A2.	
XX	OS	Homo sapiens.	
XX	PN	WO9958680-A2.	
XX	PD	18-NOV-1999.	
XX	PF	07-MAY-1999; 99WO-NL000285.	
XX	PR	08-MAY-1998; 98EP-00201543.	
XX	PA	(SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.	
XX	PI	Voorberg JJ, Van Den Brink EN, Turenhout EM;	
XX	DR	WPI; 2000-053102/04.	
XX	PT	New polynucleotide, polypeptide and antibody useful for diagnosing the presence of neutralizing antibodies against factor VIII and for treatment of hemophilia A patients with these antibodies.	
XX	PS	Example 9; Fig 11A; 61pp; English.	
XX	CC	This invention describes a novel polynucleotide (I) (and complements and hybridizable polynucleotides) comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity which has hemostatic activity. (I) is useful as a primer or probe for detecting the presence of inhibitory antibodies directed against factor VIII. The polypeptides of the invention and the antibodies generated from them are useful in compositions for neutralizing factor VIII inhibiting antibodies in hemophilia A patients. This sequence represents a human factor VIII antibody A2 specific scFv protein DP-47 which is used in the method of the invention	
XX	SQ	Sequence 122 AA;	

Query Match 100.0%; Score 642; DB 3; Length 122;
 Best Local Similarity 100.0%; Pred. No. 3.1e-52;
 Matches 122; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGDLVOPGSLRLSCAASGFTFSNFMWSVRQAPGKLEWVAAGRSCTTFY 60
 |||||
 DB 1 EVLVESGGDLVOPGSLRLSCAASGFTFSNFMWSVRQAPGKLEWVAAGRSCTTFY 60
 |||||

QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGSGYKYGYGMDVWGQTTTV 120
 |||||
 DB 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGSGYKYGYGMDVWGQTTTV 120
 |||||

QY 121 SS 122
 ||
 DB 121 SS 122

RESULT 2
 AAY50975
 ID AAY50975 standard; protein; 122 AA.
 XX
 AC AAY50975;
 XX
 DT 23-MAR-2000 (first entry)
 XX
 DE Human FVIII heavy chain variable region DP-47 protein fragment.
 XX
 DE Human; heavy chain; antibody; factor VIII; hemostatic; variable region;
 KW hemophilia A.
 KW
 XX Homo sapiens.
 OS
 XX
 PN WO9558680-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 07-MAY-1999; 99WO-NL000285.
 XX
 PR 08-MAY-1998; 98EP-00201543.
 XX
 PA (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
 XX
 PI Voorberg JJ, Van Den Brink EN, Turenhout EM;
 XX
 DR WPI; 2000-053102/04.
 DR N-PSDB; AA243868.
 XX
 PT New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX
 PS Example 9; Fig 11c; 61pp; English.
 XX
 CC This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has
 CC hemostatic activity. (I) is useful a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents a fragment of the
 CC human factor VIII antibody heavy chain variable region protein DP-47
 CC which is used in the method of the invention
 XX
 PS Sequence 122 AA;
 XX

Query Match 100.0%; Score 642; DB 3; Length 122;
 Best Local Similarity 100.0%; Pred. No. 3.1e-52;
 Matches 122; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGDLVOPGSLRLSCAASGFTFSNFMWSVRQAPGKLEWVAAGRSCTTFY 60
 |||||

Db 1 EVLVESGGDLVOPGSLRLSCAASGFTFSNFMWSVRQAPGKLEWVAAGRSCTTFY 60
 QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGSGYKYGYGMDVWGQTTTV 120
 |||||
 Db 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGSGYKYGYGMDVWGQTTTV 120
 |||||

QY 121 SS 122
 ||
 Db 121 SS 122

RESULT 3
 AEB45861
 ID AEB45861 standard; protein; 471 AA.
 XX
 AC AEB45861;
 XX
 DT 06-OCT-2005 (first entry)
 XX
 DE Human monoclonal anti-MaDCAM antibody #13.
 XX
 KW Monoclonal antibody; mucosal addressin cell adhesion molecule; MaDCAM;
 KW inflammation; inflammatory bowel disease; Crohn's disease;
 KW ulcerative colitis; diverticular disease; gastritis; liver disease;
 KW primary biliary cirrhosis; primary sclerosing cholangitis;
 KW insulin dependent diabetes; graft versus host disease; antiinflammatory;
 KW gastrointestinal-gen.; antiulcer; hepatotropic; antidiabetic;
 KW immunosuppressive; antibody.
 XX
 OS Homo sapiens.
 XX
 PN WO2005067620-A2.
 XX
 PD 28-JUL-2005.
 XX
 PF 07-JAN-2005; 2005WO-US000370.
 XX
 PR 09-JAN-2004; 2004US-0535490P.
 XX
 PA (PFIZ) PFIZER INC.
 PA (ABGE-) ABGENIX INC.
 PA (PFIZ) PFIZER LTD.
 XX
 PI Pullen N, Molloy E, Kellermann S, Green LL, Haak-Frendescho M;
 XX
 DR WPI; 2005-554958/56.
 DR N-PSDB; AEB45860.
 XX
 PT New antibody to Mucosal Addressin Cell Adhesion Molecule, useful for
 PT diagnosing and treating an inflammatory disease, e.g. inflammatory bowel
 PT disease, ulcerative colitis, gastritis, insulin-dependent diabetes or
 PT graft versus host disease.
 XX
 PS Claim 8; SEQ ID NO 26; 167pp; English.
 XX
 CC The invention relates to a human monoclonal antibody or its antigen-
 CC binding portion that specifically binds to mucosal addressin cell
 CC adhesion molecule (MaDCAM). The invention also relates to a hybridoma
 CC cell line that produces the human monoclonal antibody, a pharmaceutical
 CC composition comprising an amount of the monoclonal antibody or its
 CC antigen-binding portion and a pharmaceutical carrier, a method of
 CC treating inflammatory disease in a subject, an isolated cell line that
 CC produces the monoclonal antibody or its antigen-binding portion or the
 CC heavy chain or light chain of the antibody or of its portion, an isolated
 CC nucleic acid molecule comprising a nucleotide sequence encoding the heavy
 CC chain or its antigen-binding portion or the light chain or its antigen-
 CC binding portion of an antibody described above, a vector comprising the
 CC nucleic acid molecule, where the vector optionally comprises an
 CC expression control sequence operably linked to the nucleic acid molecule,
 CC a host cell comprising the vector or the nucleic acid molecule above, a
 CC method of producing a human monoclonal antibody or its antigen-binding
 CC portion that specifically binds MaDCAM, a method of isolating an antibody
 CC or its antigen-binding portion that specifically binds to MaDCAM, a

CC method of treating a subject in need of a human antibody or its antigen-
 CC binding portion that specifically binds to MadCAM and inhibits binding to
 CC alpha4beta7, a method of inhibiting alpha4beta7 binding to cells
 CC expressing human MadCAM, a method of inhibiting MadCAM-mediated leukocyte
 CC endothelial cell adhesion, migration and infiltration into tissues, a
 CC method of inhibiting alpha4beta7/MadCAM-dependent cellular adhesion,
 CC inhibiting the MadCAM-mediated recruitment of lymphocytes to
 CC gastrointestinal lymphoid tissue, a method of diagnosing a disorder
 CC characterized by circulating soluble human MadCAM and detecting
 CC inflammation in a subject. The antibody, composition and methods are
 CC useful for diagnosing and treating inflammatory disease, e.g.
 CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
 CC diverticular disease, gastritis, liver disease, primary biliary
 CC cirrhosis, primary sclerosing cholangitis, insulin dependent diabetes and
 CC graft versus host disease. This sequence represents a human monoclonal
 CC anti-MadCAM antibody of the invention.

XX SQ Sequence 471 AA;

Query Match 85.9%; Score 551.5; DB 9; Length 471;
 Best Local Similarity 83.2%; Pred. No. 3.9e-43;
 Matches 104; Conservative 9; Mismatches 9; Indels 3; Gaps 1;

Qy 1 EVQLVESGDLVQPGSLRLSCAASGFTFSNFMVSRQAPGKGLEWVAIGRSGTTFY 60

Db 20 EVQLVESGDLVQPGSLRLSCAASGFTFSYAMNVRQAPGKLEWVSVISGRGGTYY 79

Qy 61 ADSVKGFTISRDNKNTVLEWNSLRADTAIYYCAK---RGGGKYKGMVDMVWGQTT 117

Db 80 ADSVKGFTISRDNKNTLYLQWNSLRADTAIYYCAKIAVAGEGLYYKGMVDMVWGQTT 139

Qy 118 VTVSS 122

Db 140 VTVSS 144

RESULT 4

ID AE07014

XX AA07014 standard; protein; 128 AA.

XX AC AA07014;

XX DT 16-OCT-2001 (first entry)

XX DE Human heavy chain variable (VH) region, 038062.

XX KW Human; humanised antibody; CC-chemokine receptor 2; CCR2; nephrotropic;
 KW neuroprotective; immunosuppressive; human immunodeficiency virus;
 KW HIV infection; cytostatic; vasotropic; leukocyte trafficking; allergy;
 KW inflammatory disorder; autoimmune disorder; rheumatoid arthritis; shock;
 KW multiple sclerosis; atherogenesis; atherosclerosis; restenosis; asthma;
 KW anaphylaxis; malignancy; inflammation; stenosis; allograft rejection;
 KW fibrotic disease; angioplasty; acquired immune deficiency syndrome; AIDS;
 KW inflammatory glomerulopathy; vascular intervention; 1D9 antibody;
 KW neointimal hyperplasia; VH; heavy chain variable region.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers
 FT Region 31..35
 FT /label= CDR1
 FT /note= "Complementarity determining region 1"

FT Region 50..66
 FT /label= CDR2
 FT /note= "Complementarity determining region 2"

FT Region 99..117
 FT /label= CDR3
 FT /note= "Complementarity determining region 3"

FT Misc-difference 109
 FT /label= Unknown

XX FT

XX FT

XX FT

XX FT

XX FT

XX FT

XX FT

PD 09-AUG-2001.

XX PF 02-FEB-2001; 2001WO-US003537.

XX PR 03-FEB-2000; 2000US-00497625.

XX PA (MILL-) MILLENNIUM PHARM INC.

XX PI Larosa GJ, Horvath C, Newman W, Jones ST, O'brien S, O'keefe T;

XX WI; 2001-488898/53.

XX DR WPI; 2001-488898/53.

XX PT Humanized immunoglobulin for treating a CC-chemokine receptor 2-mediated
 disorder in a patient, comprises a binding specificity for CCR2, and a
 non-human antigen binding region and human immunoglobulin.

XX PS Disclosure; Page 168; 183pp; English.

XX CC The patent discloses a humanised antibody or its antigen-binding
 CC fragment, having binding specificity for CC-chemokine receptor 2 (CCR2),
 CC comprising an antigen binding region of non-human origin and at least a
 CC portion of an immunoglobulin of human origin. The humanised antibodies
 CC are useful for inhibiting the interaction of a cell expressing CCR2. They
 CC are useful for inhibiting or treating HIV infection. The proteins of the
 CC invention are useful for inhibiting leukocyte trafficking, for treating
 CC CCR2-mediated disorders such as inflammatory disorder, autoimmune
 CC disorders such as rheumatoid arthritis and multiple sclerosis,
 CC atherogenesis and atherosclerosis, and for inhibiting restenosis. They
 CC are useful in therapy or diagnosis, and in the manufacture of a
 CC medicament for treating CCR2 mediated disease. They are also useful for
 CC treating allergy, anaphylaxis, malignancy, chronic and acute
 CC inflammation, histamine and IgE-mediated allergic reaction, shock,
 CC stenosis, allograft rejection, fibrotic disease, asthma, inflammatory
 CC glomerulopathies, acquired immune deficiency syndrome (AIDS), restenosis
 CC associated with vascular intervention, including angioplasty and/or stent
 CC placement in a mammal. Humanised antibodies are also useful for
 CC inhibiting narrowing of the lumen of a vessel in a mammal, and inhibiting
 CC neointimal hyperplasia of a vessel in a mammal, preferably associated
 CC with vascular intervention. The present sequence is human heavy chain
 CC variable (VH) region, 038062

XX SQ Sequence 128 AA;

Query Match 85.5%; Score 549; DB 4; Length 128;
 Best Local Similarity 82.0%; Pred. No. 1.6e-43;
 Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

Qy 1 EVQLVESGDLVQPGSLRLSCAASGFTFSNFMVSRQAPGKLEWVAIGRSGTTFY 60

Db 1 EVQLVESGDLVQPGSLRLSCAASGFTFSYAMNVRQAPGKLEWVAISGSGSTYY 60

Qy 61 ADSVKGFTISRDNKNTVLEWNSLRADTAIYYCAKGR-----GGKYKGMVDMVWGQ 114

Db 61 ADSVKGFTISRDNKNTLYLQWNSLRADTAIYYCAKRRNYDFWSGXYYKGMVDMVWGQ 120

Qy 115 GTTVTVSS 122

Db 121 GTTVTVSS 128

RESULT 5

ADQ89299

ID ADQ89299 standard; protein; 128 AA.

XX AC ADQ89299;

XX DT 21-OCT-2004 (first entry)

XX DE Human immunoglobulin protein #26.

XX KW Human; immunoglobulin; heavy chain; light chain; CC-chemokine receptor 2;

XX KW CCR2; inflammatory disease; autoimmune disorder; graft rejection;

XX KW HIV infection; atherosclerosis; antinflammatory; immunosuppressive;

```

KW anti-HIV; virucide; antiarteriosclerotic.
XX
OS Homo sapiens.
XX
PN US2004151721-A1.
XX
PD 05-AUG-2004.
XX
PF 10-DEC-2003; 2003US-00733563.
XX
PR 19-OCT-2001; 2001US-0350166P.
XX
PR 26-JUN-2002; 2002US-0392364P.
XX
PR 17-OCT-2002; 2002US-00272899.
XX
XX (OKEE/) O'KEEFE T.
PA (PONA/) PONATH P.
XX
XX O'keefe T, Ponath P;
XX
XX WPI; 2004-580175/56.
XX
XX New humanized immunoglobulin CC-chemokine receptor 2 (CCR2) antagonists,
XX useful for diagnosing and/or treating inflammatory or autoimmune
XX diseases, and HIV infection.
XX
XX Disclosure; SEQ ID NO 77; 128pp; English.
XX
XX The invention relates to humanised immunoglobulin heavy and light chains
XX which have specificity for the CC-chemokine receptor 2 (CCR2) and an
XX immunoglobulin or its antigen binding fragment comprising the chains. The
XX humanised immunoglobulin or its antigen binding fragment preferably
XX comprises two heavy chains and two light chains. The humanised
XX immunoglobulin and its heavy and light chains are useful for the
XX diagnosis, prevention and/or treatment of diseases or conditions
XX associated with aberrant expression or activity of the CCR2 polypeptide.
XX such as inflammatory diseases, autoimmune disorders, graft rejection, HIV
XX infection and atherosclerosis. This sequence represents a human
XX immunoglobulin protein of the invention.
XX
SQ Sequence 128 AA;

Query Match      85.5%; Score 549; DB 8; Length 128;
Best Local Similarity 82.0%; Pred. No. 1.6e-43;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKLEWVAIAIGRSGTTFY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVAISGGSGTYY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKGR-----GGYKYYGMDVWGQ 114
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIYYCAKDRRNYDFWSGXYYIYGMDVWGQ 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 115 GTTIVTSS 122
   |||||:|||||:
Db 121 GTTIVTSS 128
   |||||:|||||:

RESULT 7
AEB09572
ID AEB09572 standard; protein; 128 AA.
XX
AC AEB09572;
XX
XX 08-SEP-2005 (first entry)
XX
XX Human heavy chain variable region SEQ ID NO 77.
XX
XX antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;
XX antibody engineering; therapeutic; diagnosis; inflammation;
XX autoimmune disease; immune disorder; graft rejection; HIV infection;
XX HIV infection; atherosclerosis; antiinflammatory; cardiovascular disease; metabolic disorder;
XX heavy chain variable region.
XX
XX Homo sapiens.
XX

```


PS Disclosure; SEQ ID NO 84; 128pp; English.

XX The invention relates to humanised immunoglobulin heavy and light chains

CC which have specificity for the CC-chemokine receptor 2 (CCR2) and an

CC immunoglobulin or its antigen binding fragment comprising the chains. The

CC humanised immunoglobulin or its antigen binding fragment preferably

CC comprises two heavy chains and two light chains. The humanised

CC immunoglobulin and its heavy and light chains are useful for the

CC diagnosis, prevention and/or treatment of diseases or conditions

CC associated with aberrant expression or activity of the CCR2 polypeptide,

CC such as inflammatory diseases, autoimmune disorders, graft rejection, HIV

CC infection and atherosclerosis. This sequence represents a human

CC immunoglobulin protein of the invention.

XX

SQ Sequence 125 AA;

Query Match 85.3%; Score 547.5; DB 8; Length 125;

Best Local Similarity 84.0%; Pred. No. 2.2e-43;

Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 1;

QY 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKGLEWVAIAIGRSGTTFY 60

DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFTSYAMSVWRQAPGKGLEWVAISGGSGTYY 60

QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---RGRGGYKYTGMDVWVGQTT 117

DB 61 ADSVKGRFTISRDNKNTVLYQMNSLRAEDTAIYYCAKAVVRGVISYYTYGMDVWVGQTT 120

QY 118 VTSS 122

DB 121 VTSS 125

RESULT 11

ABE09579

ID ABE09579 standard; protein; 125 AA.

AC ABE09579;

XX

DT 08-SEP-2005 (first entry)

XX

DE Human heavy chain variable region SEQ ID NO 84.

XX

KW antiinflammatory; immunosuppressive; anti-HIV; antiarteriosclerotic;

KW antibody engineering; therapeutic; diagnosis; inflammation;

KW autoimmune disease; immune disorder; graft rejection; HIV infection;

KW infection; atherosclerosis; cardiovascular disease; metabolic disorder;

KW heavy chain variable region.

XX

OS Homo sapiens.

XX

PN W02005060368-A2.

XX

PD 07-JUL-2005.

XX

PF 10-DEC-2003; 2003WO-US039599.

XX

PR 10-DEC-2003; 2003WO-US039599.

XX

PA (MILL-) MILLENNIUM PHARM INC.

XX

PI Okeefe T, Ponath P;

XX

DR WPI; 2005-488561/49.

XX

XX New humanized immunoglobulin or its antigen binding portion having

PT binding specificity for CC-chemokine receptor 2 and having a heavy chain

PT and light chain, for treating inflammatory diseases, HIV, and autoimmune

PT diseases.

XX

PS Disclosure; SEQ ID NO 84; 192pp; English.

XX

CC The invention describes a humanized immunoglobulin (I) or its antigen

CC binding portion having binding specificity for CC-chemokine receptor 2

CC (CCR2) and having a heavy chain and a light chain, where the heavy chain

CC comprises a fully defined 117 and 330 amino acid (SEQ ID NO: 17 and 110)

CC sequence, given in specification or its portion, and the light chain

CC comprises a fully defined 112 amino acid (SEQ ID NO: 12) sequence given

CC in specification. Also described are: a humanized immunoglobulin heavy

CC chain, or its antigen binding fragment, having binding specificity for

CC CCR2 and comprising the amino acid sequence of (SEQ ID NO: 17) and the

CC amino acid of (SEQ ID NO: 110), or its portion; and a humanized

CC immunoglobulin light chain, or its antigen binding fragment, having

CC binding specificity for CCR2 and comprising the amino acid sequence of

CC (SEQ ID NO: 12) and the fully defined 107 amino acid (SEQ ID NO: 112)

CC sequence, given in specification. The following are disclosed: isolated

CC nucleic acid molecules comprising nucleic acid sequence encoding (I); a

CC construct comprising nucleic acid molecule encoding (I); and host cell

CC comprising the nucleic acid molecule. (I) is useful as a therapeutic

CC agent for controlling lymphocyte homing the mucosal lymphoid tissue thus

CC reducing inflammatory response, for use in the treatment of diseases

CC associated with leukocyte infiltration of tissue, e.g. in the treatment

CC of inflammatory diseases, autoimmune diseases, graft rejection, HIV

CC infection and monocyte-mediated disorders such as atherosclerosis. (I) is

CC useful for detecting and/or measuring the level of CCR2 in a sample (e.g.

CC tissues or body fluids such as inflammatory exudates, blood, serum, bowel

CC fluid), and for modulating binding function and/or leukocyte trafficking

CC modulated by CCR2. This sequence represents a human heavy chain variable

CC region used in a comparison with a murine ID9 antibody heavy chain

CC variable region fragment in the creation of a humanized anti-CCR2-

CC antibody.

XX

SQ Sequence 125 AA;

Query Match 85.3%; Score 547.5; DB 9; Length 125;

Best Local Similarity 84.0%; Pred. No. 2.2e-43;

Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 1;

QY 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKLEWVAIAIGRSGTTFY 60

DB 1 EVQLLESGGGLVQPGGSLRLSCAASGFTFTSYAMSVWRQAPGKLEWVAISGGSGTYY 60

QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---RGRGGYKYTGMDVWVGQTT 117

DB 61 ADSVKGRFTISRDNKNTVLYQMNSLRAEDTAIYYCAKAVVRGVISYYTYGMDVWVGQTT 120

QY 118 VTSS 122

DB 121 VTSS 125

RESULT 12

ABG77158

ID ABG77158 standard; protein; 470 AA.

XX

AC ABG77158;

XX

DT 24-OCT-2002 (first entry)

XX

DE Germline protein sequence of anti-IGF-1R antibody DP-47(3-23)/D6-19/JH6.

XX

KW Insulin-like growth factor I receptor; antibody; human; cytostatic;

KW osteopathic; antiatherosclerotic; antipsoriatic; IGF-1R; tumour;

KW anti-neoplastic; anti-tumour; anti-angiogenic; neuropathy; osteoporosis;

KW acromegaly; gigantism; psoriasis; atherosclerosis.

XX

OS Homo sapiens.

XX

PN W0200253596-A2.

XX

PD 11-JUL-2002.

XX

PF 20-DEC-2001; 2001WO-US051113.

XX

PR 05-JAN-2001; 2001US-0259927P.

XX

KW osteopathic; antiatherosclerotic; antipsoriatic; IGF-IR; tumour;
KW anti-neoplastic; anti-tumour; anti-angiogenic; neuropathy; osteoporosis;
KW acromegaly; gigantism; psoriasis; atherosclerosis.
XX Homo sapiens.
XX WO200253596-A2.
XX 11-JUL-2002.
XX 20-DEC-2001; 2001WO-US051113.
XX 05-JAN-2001; 2001US-0259927P.
XX (PFIZ) PFIZER INC.
XX (ABGE-) ABGENIX INC.
XX Cohen BD, Beebe J, Miller PE, Moyer JD, Corvalan JR, Gallo M;
XX WPI; 2002-575410/61.
XX N-PSDB; ABS62704.
XX Novel humanized, chimeric monoclonal antibody that specifically binds to
PT insulin-like growth factor I (IGF-I) receptor useful for inhibiting
PT binding of IGF-I or IGF-II to receptor and for treating cancer in humans.
XX Claim 13; Page 130; 172pp; English.
XX This invention relates to a novel humanised, chimeric or human monoclonal
CC antibody or its antigen binding portion that specifically binds to
CC insulin-like growth factor I receptor (IGF-IR). The antibodies of the
CC invention can act as an inhibitor of binding of IGF-I or IGF-II with IGF-
CC IR and can inhibit in vivo tumour growth and IGF-IR tyrosine
CC phosphorylation. The antibodies of the invention are useful for
CC diagnosing the presence or location of an IGF-IR-expressing tumour in a
CC subject. The antibody or its antigen-binding portion is also useful for
CC treating cancer in a human. The method for this further involves an anti
CC neoplastic, anti-tumour, anti-angiogenic or chemotherapeutic agent. The
CC antibodies may also be useful for increasing IGF-IR activity and thus
CC restoring IGF-IR activity in a condition characterised by low IGF-IR
CC levels e.g. neuropathy, or osteoporosis. An antibody of the invention is
CC also useful for inducing apoptosis of specific cells in a patient, and to
CC treat non-cancerous states or disease, e.g. acromegaly, gigantism,
CC psoriasis and atherosclerosis. Fully human anti-IGF-IR antibodies
CC minimise the immunogenic and allergic responses intrinsic to mouse or
CC mouse-derived monoclonal antibodies and thus increase the efficacy
CC and safety of the administered antibodies. The present sequence
CC represents an anti-insulin-like growth factor I receptor antibody of the
CC invention
XX
SQ Sequence 125 AA;
Query Match 84.0%; Score 539.5; DB 5; Length 125;
Best Local Similarity 84.0%; Pred. No. 1.2e-42;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 2;
QY 1 EVQLVESGGDLVQPGGSLRLSCAASGFTSFNFMVWROAPGKLEWVAIGRSGTTFY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTSFSSYAMVWROAPGKLEWVAISGGITYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIYYCAK-RGRGG--YKYGMVDVWGQTT 117
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIYYCAKDLGYGDFYYYYGMDVWGQTT 120
QY 118 VTVSS 122
Db 121 VTVSS 125
RESULT 15
ADR28550
ID ADR28550 standard; protein; 125 AA.
XX

AC ADR28550;
XX 18-NOV-2004 (first entry)
XX Human anti-IGF-IR antibody 4.9.2 VH region SEQ ID NO:16.
XX aging; multiple myeloma; liquid tumour; liver cancer; thymus disorder;
KW T-cell-mediated autoimmune disease; endocrinological disorder; ischaemia;
KW neurodegenerative disorder; human;
KW anti-insulin-like growth factor I receptor antibody;
KW anti-IGF-IR antibody; cytostatic; immunosuppressive; endocrine;
KW vasotropic; neuroprotective; nootropic; antithyroid; vaccine;
KW gene therapy.
XX Homo sapiens.
XX WO2004071529-A2.
XX 26-AUG-2004.
XX 03-FEB-2004; 2004WO-IB000366.
XX 13-FEB-2003; 2003US-0447353P.
XX (PFIZ) PFIZER PROD INC.
XX Cohen BD, Bedian V, Wang HF, Obrocea M, Gomez-Navarro J;
XX Cusmano JD, Guyot DJ, Page KL;
XX WPI; 2004-625776/60.
XX N-PSDB; ADR28549.
XX Treating or preventing aging or a disorder (e.g. multiple myeloma,
PT autoimmune disease or neurodegenerative disorder) in humans comprises
PT administering an amount of a human anti-insulin-like growth factor I
XX receptor antibody.
XX Disclosure; SEQ ID NO 16; 105pp; English.
XX The present invention describes a method for treating or preventing aging
CC or a disorder (e.g. multiple myeloma, liquid tumour, liver cancer, thymus
CC disorder, T-cell-mediated autoimmune disease, endocrinological disorder,
CC ischaemia or neurodegenerative disorder) in a mammal. The method
CC comprises administering to the mammal an amount of a human anti-insulin-
CC like growth factor I receptor (IGF-IR) antibody. Also described is a
CC pharmaceutical composition for treating or preventing the above-mentioned
CC disorder in a mammal, comprising an amount of the human anti-IGF-IR
CC antibody and a pharmaceutical carrier. The composition has cytostatic,
CC immunosuppressive, endocrine, vasotropic, neuroprotective, nootropic and
CC antithyroid activities, and can be used in vaccines and in gene therapy.
CC The method and composition are useful for preventing or treating aging or
CC a disorder (e.g. multiple myeloma, liquid tumour, liver cancer, thymus
CC disorder, T-cell-mediated autoimmune disease, endocrinological disorder,
CC ischaemia or neurodegenerative disorder) in mammals, such as humans. The
CC human IGF-IR antibody is used in preparing a composition for the
CC treatment or prevention of the above-mentioned disorders. The present
CC sequence represents a human anti-IGF-IR antibody heavy chain variable
CC region (VH) amino acid sequence, which is used in the exemplification of
CC the present invention.
XX
SQ Sequence 125 AA;
Query Match 84.0%; Score 539.5; DB 8; Length 125;
Best Local Similarity 84.0%; Pred. No. 1.2e-42;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 2;
QY 1 EVQLVESGGDLVQPGGSLRLSCAASGFTSFNFMVWROAPGKLEWVAIGRSGTTFY 60
Db 1 EVQLLESGGGLVQPGGSLRLSCAASGFTSFSSYAMVWROAPGKLEWVAISGGITYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIYYCAK-RGRGG--YKYGMVDVWGQTT 117
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIYYCAKDLGYGDFYYYYGMDVWGQTT 120

Qy 118 VTVSS 122
| | | |
Db 121 VTVSS 125

Search completed: May 5, 2006, 08:57:03
Job time : 50.2142 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:25 ; Search time 14.0813 Seconds
(without alignments)
716.302 Million cell updates/sec

Title: US-09-674-752-53

Perfect score: 642

Sequence: 1 EVOLVESGDLVQPGGSLRL.....GKYKGMVWGQTTVTSS 122

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:*

- 1: /cgn2_6/ptodata/1/iaa/5 COMB.pep.*
- 2: /cgn2_6/ptodata/1/iaa/6 COMB.pep.*
- 3: /cgn2_6/ptodata/1/iaa/H COMB.pep.*
- 4: /cgn2_6/ptodata/1/iaa/PCTUS COMB.pep.*
- 5: /cgn2_6/ptodata/1/iaa/RE COMB.pep.*
- 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	549	85.5	128	2	US-09-840-459-77
2	549	85.5	128	2	US-09-840-459-79
3	549	85.5	128	2	US-09-497-625A-77
4	549	85.5	128	2	US-09-497-625A-79
5	547.5	85.3	125	2	US-09-840-459-84
6	547.5	85.3	125	2	US-09-497-625A-84
7	531.5	82.8	125	2	US-09-840-459-76
8	531.5	82.8	125	2	US-09-497-625A-76
9	525	81.8	120	2	US-09-025-769B-38
10	525	81.8	120	2	US-09-025-769B-63
11	525	81.8	120	2	US-09-490-070A-38
12	525	81.8	120	2	US-09-490-070A-63
13	525	81.8	120	2	US-09-490-153-38
14	525	81.8	120	2	US-09-490-153-63
15	525	81.8	120	2	US-09-490-324-38
16	525	81.8	120	2	US-09-490-324-63
17	525	81.8	281	2	US-09-025-769B-178
18	525	81.8	281	2	US-09-490-070A-178
19	525	81.8	281	2	US-09-490-153-178
20	525	81.8	281	2	US-09-490-324-178
21	521.5	81.2	119	2	US-09-648-067A-15
22	521.5	81.2	119	2	US-09-602-812A-6
23	518	80.7	122	1	US-07-934-373C-21
24	518	80.7	122	2	US-08-437-642B-21
25	518	80.7	122	2	US-08-146-206C-21
26	518	80.7	122	2	US-09-705-686-21
27	518	80.7	122	2	US-09-705-392A-21

Sequence 21, Appl
Sequence 21, Appl
Sequence 81, Appl
Sequence 81, Appl
Sequence 32, Appl
Sequence 78, Appl
Sequence 3, Appl
Sequence 3, Appl
Sequence 6, Appl
Sequence 6, Appl
Sequence 92, Appl
Sequence 92, Appl
Sequence 82, Appl
Sequence 82, Appl
Sequence 89, Appl

28 518 80.7 122 2 US-09-705-398-21
29 518 80.7 122 4 PCT-US93-07832-21
30 517 80.5 124 2 US-09-840-459-81
31 517 80.5 124 2 US-09-497-625A-81
32 513 79.9 140 2 US-08-983-607-32
33 511 79.6 128 2 US-09-840-459-78
34 511 79.6 128 2 US-09-497-625A-78
35 510 79.4 263 2 US-09-069-821-3
36 510 79.4 263 2 US-09-956-086-3
37 510 79.4 263 2 US-09-956-087-3
38 510 79.4 283 2 US-09-420-592A-6
39 510 79.4 283 2 US-09-985-442-6
40 510 79.4 283 2 US-09-983-580-6
41 508.5 79.2 121 2 US-09-840-459-92
42 508.5 79.2 121 2 US-09-497-625A-92
43 508.5 79.2 123 2 US-09-840-459-82
44 508.5 79.2 123 2 US-09-497-625A-82
45 508 79.1 124 2 US-09-840-459-89

ALIGNMENTS

RESULT 1
US-09-840-459-77
; Sequence 77, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT FILING DATE: 2001-02-02
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-840-459-77

Query Match 85.5%; Score 549; DB 2; Length 128;
Best Local Similarity 82.0%; Pred. No. 2e+45;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

Qy 1 EVOLVESGDLVQPGGSLRLSCAASGFTFSNFMAMSVWROAPGKLEWVAIAIGRSQTTFY 60
Db 1 EVOLLESGLVQPGGSLRLSCAASGFTFSNFMAMSVWROAPGKLEWVAIAISGSGSTYY 60

Qy 61 ADSVKGRFTISRDNSKNTVYLENNSLRAEDTAIYYCAKGR-----GGVYKYGMDVMGQ 114
Db 61 ADSVKGRFTISRDNSKNTLYQMNSLRADTAIYYCAKORRNVDFWSGXYYTYGMDVMGQ 120

Qy 115 GTTIVTSS 122
|||||

```
Db      121 GTTWTSS 128

RESULT 2
US-09-840-459-79
; Sequence 79, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-840-459-79

Query Match      85.5%; Score 549; DB 2; Length 128;
Best Local Similarity 82.0%; Pred. No. 2e-45;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY      1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKGLEWVAIGRSGTTFY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 EVQLLESGLGVPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVAISGGSTYY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY      61 ADSVKGRFTISRDNKNTVYLEMNSLRAREDTAIYYCAKGR-----GGKYKYMVDVWGQ 114
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      61 ADSVKGRFTISRDNKNTLYLQNSLRAREDTAIYYCAKRRNYDFWSGXYYIGMDVWGQ 120
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY      115 GTTWTSS 122
      |||:|||||:
Db      121 GTTWTSS 128

RESULT 4
US-09-497-625A-79
; Sequence 79, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-497-625A-79

Query Match      85.5%; Score 549; DB 2; Length 128;
Best Local Similarity 82.0%; Pred. No. 2e-45;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY      1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKGLEWVAIGRSGTTFY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 EVQLLESGLGVPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLEWVAISGGSTYY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY      61 ADSVKGRFTISRDNKNTVYLEMNSLRAREDTAIYYCAKGR-----GGKYKYMVDVWGQ 114
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      61 ADSVKGRFTISRDNKNTLYLQNSLRAREDTAIYYCAKRRNYDFWSGXYYIGMDVWGQ 120
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY      115 GTTWTSS 122
      |||:|||||:
Db      121 GTTWTSS 128

RESULT 3
US-09-497-625A-77
; Sequence 77, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
```

```
Db      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAKRRNYDFWSGYIYYGMDVWGQ 120
      115 GTTVTVSS 122
      121 GTTVTVSS 128

RESULT 5
US-09-840-459-84
; Sequence 84, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR FILING DATE: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR FILING DATE: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR FILING DATE: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 84
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-84

Query Match      85.3%; Score 547.5; DB 2; Length 125;
Best Local Similarity 84.0%; Pred. No. 2.7e-45;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 1;

Qy      1 EVOLVESGGDLVOPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLEWVAIGRSGTTFY 60
      1 EVQLLESGGGLVOPGGSLRLSCAASGFTFTSYAMSWVRQAPGKGLEWVAISGGSGSTYY 60
      61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---RGRGGYKYKGMVWGQGT 117
      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAKAVRVGVISYYIYGMVWGQGT 120

Db      118 VTVSS 122
      121 VTVSS 125

RESULT 6
US-09-497-625A-84
; Sequence 84, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
```

```
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 84
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-497-625A-84

Query Match      85.3%; Score 547.5; DB 2; Length 125;
Best Local Similarity 84.0%; Pred. No. 2.7e-45;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 1;

Qy      1 EVOLVESGGDLVOPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLEWVAIGRSGTTFY 60
      1 EVQLLESGGGLVOPGGSLRLSCAASGFTFTSYAMSWVRQAPGKGLEWVAISGGSGSTYY 60
      61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---RGRGGYKYKGMVWGQGT 117
      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAKAVRVGVISYYIYGMVWGQGT 120

Db      118 VTVSS 122
      121 VTVSS 125

RESULT 7
US-09-840-459-76
; Sequence 76, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR FILING DATE: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR FILING DATE: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR FILING DATE: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 76
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-76

Query Match      82.8%; Score 531.5; DB 2; Length 125;
Best Local Similarity 82.5%; Pred. No. 9.2e-44;
Matches 104; Conservative 8; Mismatches 9; Indels 5; Gaps 2;

Qy      1 EVOLVESGGDLVOPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLEWVAIGRSGTTFY 60
      1 EVOLVESGGGLVOPGGSLRLSCAASGFTFTSYAMSWVRQAPGKGLEWVAISGGSGSTYY 60
      61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---RGRGGYKYKGMVWGQGT 116
      61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAKDIETDAMPFY-YYGMDVWGQGT 119
```



```

;
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 38:
US-09-490-070A-38

Query Match 81.8%; Score 525; DB 2; Length 120;
Best Local Similarity 82.0%; Pred. No. 3,7e-43;
Matches 100; Conservative 10; Mismatches 10; Indels 2; Gaps 1

QY 1 EVOLVSGGDLVPGGSLRLSCAASGFTFNFMWSWVRQAPKGLEWVAATGGRSGTTPY 60
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 1 EVOLVSGGGLVPGGSLRLSCAASGFTSSYAMSWVRQAPKGLEWVAISGGSGSTYY 60
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

QY 61 ADSVKGRFTISRDNKNTVYLENLSRAEDTAIYYCAKRGGRGGYKYYGMDVWGQGTITVTV 120
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 61 ADSVKGRFTISRDNKNTVLYQWNSLRAEDTAVYYCARWGQDG--FYAMDYWGQGTITVTV 118
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

QY 121 SS 122
   ||
Db 119 SS 120

RESULT 12
US-09-490-070A-63
; Sequence 63, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 63:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 63:
US-09-490-070A-63

Query Match 81.8%; Score 525; DB 2; Length 120;

```


Search completed: May 5, 2006, 08:53:47
Job time : 15.0813 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:55:01 ; Search time 38.7516 Seconds
(without alignments)
1315.434 Million cell updates/sec

Title: US-09-674-752-53
Perfect score: 642
Sequence: 1 EVQLVSGDGLVPGGSLRL.....GKYKYGMDVWGQGTITVTVSS 122

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database : Published Applications AA_Main:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	551.5	85.9	471	6	US-11-031-485-26
2	549	85.5	128	3	US-09-840-459-77
3	549	85.5	128	3	US-09-840-459-79
4	549	85.5	128	4	US-10-766-773-77
5	549	85.5	128	4	US-10-766-773-79
6	549	85.5	128	4	US-10-766-610-77
7	549	85.5	128	4	US-10-766-610-79
8	549	85.5	128	4	US-10-733-563-77
9	549	85.5	128	4	US-10-733-563-79
10	547.5	85.3	125	3	US-09-840-459-84
11	547.5	85.3	125	4	US-10-766-773-84
12	547.5	85.3	125	4	US-10-766-610-84
13	547.5	85.3	125	4	US-10-733-563-84
14	544.5	84.8	470	4	US-10-038-591-46
15	544.5	84.8	470	4	US-10-775-444A-46
16	539.5	84.0	125	4	US-10-038-591-16
17	539.5	84.0	125	4	US-10-775-444A-16
18	539.5	84.0	126	5	US-10-725-962-20
19	537.5	83.7	118	4	US-10-309-762-129
20	533	83.0	121	6	US-11-031-485-118
21	531.5	82.8	125	3	US-09-840-459-76
22	531.5	82.8	125	4	US-10-766-773-76
23	531.5	82.8	125	4	US-10-766-610-76
24	531.5	82.8	125	4	US-10-733-563-76
25	530	82.6	127	5	US-10-725-962-6
26	528.5	82.3	470	4	US-10-038-591-45
27	528.5	82.3	470	4	US-10-775-444A-45

28	527	82.1	255	6	US-11-090-847-143	Sequence 143, Appl
29	526.5	82.0	255	6	US-11-017-030-3	Sequence 3, Appli
30	525	81.8	120	4	US-10-125-687-4	Sequence 4, Appli
31	525	81.8	120	5	US-10-996-191-4	Sequence 4, Appli
32	524.5	81.7	126	5	US-10-725-962-21	Sequence 21, Appl
33	524.5	81.7	249	4	US-10-139-785-53	Sequence 53, Appl
34	524.5	81.7	249	5	US-10-986-046-53	Sequence 53, Appl
35	524.5	81.7	249	5	US-10-986-047-53	Sequence 53, Appl
36	524.5	81.7	249	5	US-10-986-349-53	Sequence 53, Appl
37	524.5	81.7	249	5	US-10-986-376-53	Sequence 53, Appl
38	524.5	81.7	221	3	US-09-880-748-1605	Sequence 1605, Ap
39	524.5	81.7	251	4	US-10-293-418-1605	Sequence 1605, Ap
40	524	81.6	124	5	US-10-505-313-8	Sequence 8, Appli
41	523.5	81.5	124	4	US-10-038-591-8	Sequence 8, Appli
42	523.5	81.5	124	4	US-10-775-444A-8	Sequence 8, Appli
43	523.5	81.5	254	6	US-11-017-030-1	Sequence 1, Appli
44	523	81.5	140	5	US-10-783-311-135	Sequence 135, App
45	523	81.5	256	6	US-11-090-847-140	Sequence 140, App

ALIGNMENTS

RESULT 1
US-11-031-485-26
; Sequence 26, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
; APPLICANT: FULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.
; APPLICANT: HAAK-FRENDSCHO, MARY
; TITLE OF INVENTION: ANTIBODIES TO MACCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 26
; LENGTH: 471
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-26

Query Match	85.9%	Score	551.5;	DB	6;	Length	471;
Best Local Similarity	83.2%	Pred. No.	2e-42;				
Matches	104;	Conservative	9;	Mismatches	9;	Indels	3;
Gaps	1;						
Qy	1	EVQLVSGDGLVPGGSLRLSCAASGFTFSNFMNSWVRQAPGKGLVWVAIGRSGTTFY	60				
Db	20	EVQLLESGDGLVPGGSLRLSCAASGFTFSNFMNSWVRQAPGKGLVWVAIGRSGTTFY	79				
Qy	61	ADSVKGRFTISRDNSKNTVLENNLSRAEDTAIYYCAK---RGRGGVKKYGMVDVWGQGT	117				
Db	80	ADSVKGRFTISRDNSKNTVLENNLSRAEDTAIYYCAKIAVAGEGLYYYYYGMVDVWGQGT	139				
Qy	118	VTVSS 122					
Db	140	VTVSS 144					

RESULT 2
US-09-840-459-77
; Sequence 77, Application US/09840459
; Patent No. US20020150576A1
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran

```
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-840-459-77

Query Match      85.5%; Score 549; DB 3; Length 128;
Best Local Similarity 82.0%; Pred. No. 9e-43;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKLEWVAIAIGRSSTTFY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGSGSTYY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKGR-----GGYKYYGMDVWGQ 114
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIYYCAKDRRNYDFWSGXYYYGMDVWGQ 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 115 GTTIVTSS 122
   |||||:|||||:
Db 121 GTTIVTSS 128
   |||||:|||||:

RESULT 4
US-10-766-773-77
; Sequence 77, Application US/10766773
; Publication No. US20040126851A1
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-028
; CURRENT APPLICATION NUMBER: US/10/766,773
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-766-773-77

Query Match      85.5%; Score 549; DB 4; Length 128;
Best Local Similarity 82.0%; Pred. No. 9e-43;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKLEWVAIAIGRSSTTFY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGSGSTYY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKGR-----GGYKYYGMDVWGQ 114
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIYYCAKDRRNYDFWSGXYYYGMDVWGQ 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 115 GTTIVTSS 122
   |||||:|||||:
Db 121 GTTIVTSS 128
   |||||:|||||:

US-09-840-459-77
Query Match      85.5%; Score 549; DB 3; Length 128;
Best Local Similarity 82.0%; Pred. No. 9e-43;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKLEWVAIAIGRSSTTFY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGSGSTYY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKGR-----GGYKYYGMDVWGQ 114
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIYYCAKDRRNYDFWSGXYYYGMDVWGQ 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 115 GTTIVTSS 122
   |||||:|||||:
Db 121 GTTIVTSS 128
   |||||:|||||:

US-09-840-459-79
; Sequence 79, Application US/09840459
; Patent No. US20020150576A1
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
```

```
RESULT 5
US-10-766-773-79
; Sequence 79, Application US/10766773
; Publication No. US20040126851A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-028
; CURRENT APPLICATION NUMBER: US/10/766,773
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-766-773-79

Query Match      85.5%; Score 549; DB 4; Length 128;
Best Local Similarity 82.0%; Pred. No. 9e-43;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMNSWVRQAPGKLEWVAIGRSGTTFY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVAISGGSGSTYY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
QY 61 ADSVKGRFTISRDNKNTVLENNSLRAEDTAIYYCAKGR-----GGYKYGMQVWGQ 114
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAIYYCAKDRRNYDFWSGXYYIGMDVWGQ 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
QY 115 GTTIVTSS 122
   |||||
Db 121 GTTIVTSS 128

RESULT 6
US-10-766-610-77
; Sequence 77, Application US/10766610
; Publication No. US20040132980A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-029
; CURRENT APPLICATION NUMBER: US/10/766,610
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/840,459
; PRIOR FILING DATE: 2001-04-23
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
```

```
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-766-610-77

Query Match      85.5%; Score 549; DB 4; Length 128;
Best Local Similarity 82.0%; Pred. No. 9e-43;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMNSWVRQAPGKLEWVAIGRSGTTFY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVAISGGSGSTYY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
QY 61 ADSVKGRFTISRDNKNTVLENNSLRAEDTAIYYCAKGR-----GGYKYGMQVWGQ 114
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAIYYCAKDRRNYDFWSGXYYIGMDVWGQ 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
QY 115 GTTIVTSS 122
   |||||
Db 121 GTTIVTSS 128

RESULT 7
US-10-766-610-79
; Sequence 79, Application US/10766610
; Publication No. US20040132980A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-029
; CURRENT APPLICATION NUMBER: US/10/766,610
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/840,459
; PRIOR FILING DATE: 2001-04-23
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-766-610-79
```

```

Query Match      85.5%; Score 549; DB 4; Length 128;
Best Local Similarity 82.0%; Pred. No. 9e-43;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY 1 EVOLVESGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKLEWVAAGRSCTTFY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVOLLESGGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKLEWVAISGSGSTYY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNKNTVLEMLNSRAEDTAIYYCAKGR-----GGYKYYGMDVWGQ 114
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTVLEMLNSRAEDTAIYYCAKRRNYDFWSGXYYYGMDVWGQ 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 115 GTTIVTVSS 122
    |||||:|||||:
Db 121 GTTIVTVSS 128
    |||||:|||||:

RESULT 8
US-10-733-563-77
; Sequence 77, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; APPLICANT: Ponath, Paul
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREOF
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 77
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-733-563-77

Query Match      85.5%; Score 549; DB 4; Length 128;
Best Local Similarity 82.0%; Pred. No. 9e-43;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY 1 EVOLVESGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKLEWVAAGRSCTTFY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVOLLESGGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKLEWVAISGSGSTYY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNKNTVLEMLNSRAEDTAIYYCAKGR-----GGYKYYGMDVWGQ 114
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTVLEMLNSRAEDTAIYYCAKRRNYDFWSGXYYYGMDVWGQ 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 115 GTTIVTVSS 122
    |||||:|||||:
Db 121 GTTIVTVSS 128
    |||||:|||||:

RESULT 9
US-10-733-563-79
; Sequence 79, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; APPLICANT: Ponath, Paul
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREOF

```

```

; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 79
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(128)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-733-563-79

Query Match      85.5%; Score 549; DB 4; Length 128;
Best Local Similarity 82.0%; Pred. No. 9e-43;
Matches 105; Conservative 9; Mismatches 8; Indels 6; Gaps 1;

QY 1 EVOLVESGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKLEWVAAGRSCTTFY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVOLLESGGDLVPGGSLRLSCAASGFTFSNFMAMSVWRQAPGKLEWVAISGSGSTYY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNKNTVLEMLNSRAEDTAIYYCAKGR-----GGYKYYGMDVWGQ 114
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTVLEMLNSRAEDTAIYYCAKRRNYDFWSGXYYYGMDVWGQ 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 115 GTTIVTVSS 122
    |||||:|||||:
Db 121 GTTIVTVSS 128
    |||||:|||||:

RESULT 10
US-09-840-459-84
; Sequence 84, Application US/09840459
; Patent No. US20020150576A1
; GENERAL INFORMATION:
; APPLICANT: Lakosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 84
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-84

Query Match      85.3%; Score 547.5; DB 3; Length 125;
Best Local Similarity 84.0%; Pred. No. 1.2e-42;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 1;

```

```
Qy 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLWVAIAIGRSGTTFY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLWVAISGGSGTYY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---RGRGGYKYGMVWGQTT 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAKAVVRGVISYYYGMVWGQTT 120
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 118 VTVSS 122
|||||
Db 121 VTVSS 125
|||||

RESULT 11
US-10-766-773-84
; Sequence 84, Application US/10766773
; Publication No. US20040126851A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran H.
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-028
; CURRENT APPLICATION NUMBER: US/10766,773
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 84
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-766-773-84

Query Match 85.3%; Score 547.5; DB 4; Length 125;
Best Local Similarity 84.0%; Pred. No. 1.2e-42;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 1;

Qy 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLWVAIAIGRSGTTFY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLWVAISGGSGTYY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---RGRGGYKYGMVWGQTT 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAKAVVRGVISYYYGMVWGQTT 120
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 118 VTVSS 122
|||||
Db 121 VTVSS 125
|||||

RESULT 12
US-10-766-610-84
; Sequence 84, Application US/10766610
; Publication No. US20040132980A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran H.
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
```

```
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-029
; CURRENT APPLICATION NUMBER: US/10766,610
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/840,459
; PRIOR FILING DATE: 2001-04-23
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 84
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-766-610-84

Query Match 85.3%; Score 547.5; DB 4; Length 125;
Best Local Similarity 84.0%; Pred. No. 1.2e-42;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 1;

Qy 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLWVAIAIGRSGTTFY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLWVAISGGSGTYY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---RGRGGYKYGMVWGQTT 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAKAVVRGVISYYYGMVWGQTT 120
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 118 VTVSS 122
|||||
Db 121 VTVSS 125
|||||

RESULT 13
US-10-733-563-84
; Sequence 84, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: O'Keefe, Theresa
; APPLICANT: Ponath, Paul
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 84
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-733-563-84

Query Match 85.3%; Score 547.5; DB 4; Length 125;
Best Local Similarity 84.0%; Pred. No. 1.2e-42;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 1;

Qy 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLWVAIAIGRSGTTFY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLWVAISGGSGTYY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---RGRGGYKYGMVWGQTT 117
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAKAVVRGVISYYYGMVWGQTT 120
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 118 VTVSS 122
|||||
Db 121 VTVSS 125
|||||
```


GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:56:13 ; Search time 9.12465 Seconds
(without alignments)
618.844 Million cell updates/sec

Title: US-09-674-752-53

Perfect score: 642

Sequence: 1 EVOLVESGDLVQPGGSLRL.....GKYKGMVWGQTTVTSS 122

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA New:

- 1: /SIDSS5/ptodata/1/pubpaa/US06 NEW PUB.pepi.*
- 2: /SIDSS5/ptodata/1/pubpaa/US06 NEW PUB.pepi.*
- 3: /SIDSS5/ptodata/1/pubpaa/US07 NEW PUB.pepi.*
- 4: /SIDSS5/ptodata/1/pubpaa/US08 NEW PUB.pepi.*
- 5: /SIDSS5/ptodata/1/pubpaa/PCT_NEW PUB.pepi.*
- 6: /SIDSS5/ptodata/1/pubpaa/US09 NEW PUB.pepi.*
- 7: /SIDSS5/ptodata/1/pubpaa/US09 NEW PUB.pepi.*
- 8: /SIDSS5/ptodata/1/pubpaa/US10 NEW PUB.pepi.*
- 9: /SIDSS5/ptodata/1/pubpaa/US10 NEW PUB.pepi.*
- 10: /SIDSS5/ptodata/1/pubpaa/US11 NEW PUB.pepi.*
- 11: /SIDSS5/ptodata/1/pubpaa/US11 NEW PUB.pepi.*
- 12: /SIDSS5/ptodata/1/pubpaa/US60 NEW PUB.pepi.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	544.5	84.8	470	11	US-11-144-248-46 Sequence 46, Appl
2	544.5	84.8	470	11	US-11-144-222-46 Sequence 46, Appl
3	544.5	84.8	470	11	US-11-182-343-46 Sequence 46, Appl
4	539.5	84.0	125	11	US-11-144-248-16 Sequence 16, Appl
5	539.5	84.0	125	11	US-11-144-222-16 Sequence 16, Appl
6	539.5	84.0	125	11	US-11-182-343-16 Sequence 16, Appl
7	528.5	82.3	470	11	US-11-144-248-45 Sequence 45, Appl
8	528.5	82.3	470	11	US-11-144-222-45 Sequence 45, Appl
9	528.5	82.3	470	11	US-11-182-343-45 Sequence 45, Appl
10	525	81.8	120	9	US-10-834-397-38 Sequence 38, Appl
11	525	81.8	120	9	US-10-834-397-63 Sequence 63, Appl
12	525	81.8	281	9	US-10-834-397-178 Sequence 178, Appl
13	524.5	81.7	251	11	US-11-054-515-1605 Sequence 1605, Ap
14	524.5	81.7	251	11	US-11-266-444-1605 Sequence 1605, Ap
15	524	81.6	130	11	US-11-049-536-270 Sequence 270, App
16	524	81.6	130	11	US-11-199-739-270 Sequence 270, App
17	523.5	81.5	124	11	US-11-144-248-8 Sequence 8, Appl
18	523.5	81.5	124	11	US-11-144-222-8 Sequence 8, Appl
19	523.5	81.5	124	11	US-11-182-343-8 Sequence 8, Appl
20	522	81.3	254	11	US-11-054-515-1701 Sequence 1701, Ap
21	522	81.3	254	11	US-11-266-444-1701 Sequence 1701, Ap

22	521.5	81.2	119	10	US-11-254-182-6	Sequence 6, Appl
23	521.5	81.2	119	10	US-11-254-182-30	Sequence 30, Appl
24	521.5	81.2	119	11	US-11-106-820-9	Sequence 9, Appl
25	521.5	81.2	119	11	US-11-154-337-6	Sequence 6, Appl
26	521.5	81.2	119	11	US-11-182-908-6	Sequence 6, Appl
27	521.5	81.2	119	11	US-11-190-364-9	Sequence 9, Appl
28	521.5	81.2	119	11	US-11-102-120-6	Sequence 6, Appl
29	521.5	81.2	119	11	US-11-147-780-9	Sequence 9, Appl
30	521.5	81.2	119	11	US-11-223-361-6	Sequence 6, Appl
31	521.5	81.2	119	11	US-11-222-587-6	Sequence 6, Appl
32	521.5	81.2	119	11	US-11-234-586-6	Sequence 6, Appl
33	520	81.0	248	11	US-11-054-515-1974	Sequence 1974, Ap
34	520	81.0	248	11	US-11-266-444-1974	Sequence 1974, Ap
35	519.5	80.9	313	11	US-11-000-463-427	Sequence 427, App
36	519	80.8	124	11	US-11-049-536-310	Sequence 310, App
37	519	80.8	124	11	US-11-199-739-310	Sequence 310, App
38	518	80.7	126	11	US-11-127-932-5	Sequence 5, Appl
39	518	80.7	126	11	US-11-127-903-5	Sequence 5, Appl
40	515.5	80.3	135	9	US-10-993-543-64	Sequence 989, App
41	515.5	80.3	253	11	US-11-054-515-989	Sequence 989, App
42	515.5	80.3	253	11	US-11-266-444-989	Sequence 989, App
43	515	80.2	248	11	US-11-054-515-1965	Sequence 1965, Ap
44	515	80.2	248	11	US-11-266-444-1965	Sequence 1965, Ap
45	515	80.2	251	11	US-11-054-515-908	Sequence 908, App

ALIGNMENTS

RESULT 1
US-11-144-248-46
; Sequence 46, Application US/11144248
; Publication No. US20050244408A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Beebe, Jean
; APPLICANT: Miller, Penelope E.
; APPLICANT: Moyer, James D.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; FILE REFERENCE: ABX-PF2
; CURRENT APPLICATION NUMBER: US/11/144,248
; CURRENT FILING DATE: 2005-06-02
; PRIOR APPLICATION NUMBER: US/10/038,591
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,927
; PRIOR FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 46
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-144-248-46

Query Match	84.8%	Score 544.5	DB 11	Length 470
Best Local Similarity	83.8%	Pred. No. 2e+36		
Matches 104	Conservative	9	Mismatches	9
			Indels	3
			Gaps	1
QY	1	EVOLVESGDLVQPGGSLRLSCAASGFTFSNFMVSRQAPGKGLVWVAIAIGRSGTTFY	60	
DB	20	EVQLVESGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKGLVWVAISGGSTYY	79	
QY	61	ADSVKGRFTISRDNSKNTLYVLEWNSLRADETATYYCAKRGSG---YKYYGMDVWGQGT	117	
DB	80	ADSVKGRFTISRDNSKNTLYVLEWNSLRADETATYYCAKRGSG---YKYYGMDVWGQGT	139	
QY	118	VTVSS	122	
DB	140	VTVSS	144	

```
RESULT 2
US-11-144-222-46
; Sequence 46, Application US/11144222
; Publication No. US20050281812A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Beebe, Jean
; APPLICANT: Miller, Penelope E.
; APPLICANT: Moyer, James D.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; FILE REFERENCE: ABX-PF2
; CURRENT APPLICATION NUMBER: US/11/144,222
; CURRENT FILING DATE: 2005-06-02
; PRIOR APPLICATION NUMBER: US/10/038,591
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,927
; PRIOR FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 46
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-144-222-46

Query Match      84.8%; Score 544.5; DB 11; Length 470;
Best Local Similarity 83.2%; Pred. No. 2e-36;
Matches 104; Conservative 9; Mismatches 9; Indels 3; Gaps 1;

QY      1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMWVRQAPGKLEWVAIGRSGTTFY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      20 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMWVRQAPGKLEWVAISGGSTYY 79
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY      61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGGRG---YKYYGMDVWGQGT 117
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      80 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGGRG---YKYYGMDVWGQGT 139
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY      118 VTVSS 122
      |||:|||||
Db      140 VTVSS 144
      |||:|||||

RESULT 3
US-11-182-343-46
; Sequence 46, Application US/11182343
; Publication No. US20060018910A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce
; APPLICANT: Gualberto, Antonio
; APPLICANT: Melvin, Carrie
; APPLICANT: Roberts, Luisa M.
; TITLE OF INVENTION: COMBINATION TREATMENT FOR BREAST CANCER
; FILE REFERENCE: PC32226A
; CURRENT APPLICATION NUMBER: US/11/182,343
; CURRENT FILING DATE: 2005-07-15
; PRIOR APPLICATION NUMBER: 60/598,721
; PRIOR FILING DATE: 2004-07-16
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 46
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-182-343-46

Query Match      84.8%; Score 544.5; DB 11; Length 470;
Best Local Similarity 83.2%; Pred. No. 2e-36;
Matches 104; Conservative 9; Mismatches 9; Indels 3; Gaps 1;

QY      1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMWVRQAPGKLEWVAIGRSGTTFY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      20 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMWVRQAPGKLEWVAISGGSTYY 79
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY      61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGGRG---YKYYGMDVWGQGT 117
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      80 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGGRG---YKYYGMDVWGQGT 139
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY      118 VTVSS 122
      |||:|||||
Db      140 VTVSS 144
      |||:|||||

RESULT 4
US-11-144-248-16
; Sequence 16, Application US/11144248
; Publication No. US2005024408A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Beebe, Jean
; APPLICANT: Miller, Penelope E.
; APPLICANT: Moyer, James D.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; FILE REFERENCE: ABX-PF2
; CURRENT APPLICATION NUMBER: US/11/144,248
; CURRENT FILING DATE: 2005-06-02
; PRIOR APPLICATION NUMBER: US/10/038,591
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,927
; PRIOR FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 16
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-144-248-16

Query Match      84.0%; Score 539.5; DB 11; Length 125;
Best Local Similarity 84.0%; Pred. No. 1.6e-36;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 2;

QY      1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMWVRQAPGKLEWVAIGRSGTTFY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFMAMWVRQAPGKLEWVAISGGSTYY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY      61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGGRG---YKYYGMDVWGQGT 117
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGGRG---YKYYGMDVWGQGT 120
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY      118 VTVSS 122
      |||:|||||
Db      121 VTVSS 125
      |||:|||||

RESULT 5
US-11-144-222-16
; Sequence 16, Application US/11144222
; Publication No. US20050281812A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Beebe, Jean
; APPLICANT: Miller, Penelope E.
; APPLICANT: Moyer, James D.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; FILE REFERENCE: ABX-PF2
; CURRENT APPLICATION NUMBER: US/11/144,222
; CURRENT FILING DATE: 2005-06-02
; PRIOR APPLICATION NUMBER: US/10/038,591
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,927
```



```
; PRIOR FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-144-222-16

Query Match      84.0%; Score 539.5; DB 11; Length 125;
Best Local Similarity 84.0%; Pred. No. 1.6e-36;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 2;

Qy 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKGLEWVAIAIGRSCTTFY 60
Db 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKLEWVAISGGGITYY 60

Qy 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK-RGRGG--YKYYGMDVWGQGT 117
Db 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAKDLGYGDFYYYYYGMVWGQGT 120

Qy 118 VTSS 122
Db 121 VTSS 125

RESULT 6
US-11-182-343-16
; Sequence 16, Application US/11182343
; Publication No. US20060018910A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce
; APPLICANT: Gualberto, Antonio
; APPLICANT: Robert, Carrie
; APPLICANT: Robert, Lulea M.
; FILE REFERENCE: PC32226A
; TITLE OF INVENTION: COMBINATION TREATMENT FOR BREAST CANCER
; CURRENT APPLICATION NUMBER: US/11/182,343
; CURRENT FILING DATE: 2005-07-15
; PRIOR APPLICATION NUMBER: 60/588,721
; PRIOR FILING DATE: 2004-07-16
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 16
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-182-343-16

Query Match      84.0%; Score 539.5; DB 11; Length 125;
Best Local Similarity 84.0%; Pred. No. 1.6e-36;
Matches 105; Conservative 8; Mismatches 9; Indels 3; Gaps 2;

Qy 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKLEWVAIAIGRSCTTFY 60
Db 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKLEWVAISGGGITYY 60

Qy 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK-RGRGG--YKYYGMDVWGQGT 117
Db 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAKDLGYGDFYYYYYGMVWGQGT 120

Qy 118 VTSS 122
Db 121 VTSS 125

RESULT 7
US-11-144-248-45
; Sequence 45, Application US/11144248
; Publication No. US2005024408A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Beebe, Jean
; TITLE OF INVENTION: ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; CURRENT APPLICATION NUMBER: US/11/144,248
; CURRENT FILING DATE: 2005-06-02
; PRIOR APPLICATION NUMBER: 60/259,927
; PRIOR FILING DATE: 2002-01-04
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 45
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-144-248-45

Query Match      82.3%; Score 528.5; DB 11; Length 470;
Best Local Similarity 80.8%; Pred. No. 3.8e-35;
Matches 101; Conservative 9; Mismatches 12; Indels 3; Gaps 1;

Qy 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKLEWVAIAIGRSCTTFY 60
Db 20 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKLEWVAISGGGITYY 79

Qy 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---GRGGYKYYGMDVWGQGT 117
Db 80 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAKDLGWSDSYYYYYYGMVWGQGT 139

Qy 118 VTSS 122
Db 140 VTSS 144

RESULT 8
US-11-144-222-45
; Sequence 45, Application US/11144222
; Publication No. US2005028182A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Bruce D.
; APPLICANT: Beebe, Jean
; APPLICANT: Miller, Penelope E.
; APPLICANT: Moyer, James D.
; APPLICANT: Corvalan, Jose R.
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
; CURRENT APPLICATION NUMBER: US/11/144,222
; CURRENT FILING DATE: 2005-06-02
; PRIOR APPLICATION NUMBER: 60/259,927
; PRIOR FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: 60/259,927
; PRIOR FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 45
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-144-222-45

Query Match      82.3%; Score 528.5; DB 11; Length 470;
Best Local Similarity 80.8%; Pred. No. 3.8e-35;
Matches 101; Conservative 9; Mismatches 12; Indels 3; Gaps 1;

Qy 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKLEWVAIAIGRSCTTFY 60
Db 20 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFMAMSWVRQAPGKLEWVAISGGGITYY 79

Qy 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---GRGGYKYYGMDVWGQGT 117
Db 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAK---GRGGYKYYGMDVWGQGT 117
```


APPLICATION NUMBER: US/09/490,324
FILING DATE: 24-Jan-2000
APPLICATION NUMBER: US/09/025,769
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 63:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 63:
US-10-834-397-63

Query Match 81.8%; Score 525; DB 9; Length 120;
Best Local Similarity 82.0%; Pred. No. 2.2e-35;
Matches 100; Conservative 10; Mismatches 10; Indels 2; Gaps 1;

Qy 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAVSWVRQAPGKGLEWVAAGRSSTFF 60
Db 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAVSWVRQAPGKGLEWVAAGRSSTFF 60

Qy 61 ADSVKGRFTISRDNKNTLYLENNSLRAEDTAIYYCAKRGGRGKYKGMVWGQGTITV 120
Db 61 ADSVKGRFTISRDNKNTLYLENNSLRAEDTAIYYCAKRGGRGKYKGMVWGQGTITV 120

Qy 121 SS 122
Db 119 SS 120

RESULT 12
US-10-834-397-178
Sequence 178, Application US/10834397
Publication No. US2006000334A1
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/834,397
FILING DATE: 29-Apr-2004
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/490,324
FILING DATE: 24-Jan-2000
APPLICATION NUMBER: US/09/025,769
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0

FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 178:
SEQUENCE CHARACTERISTICS:
LENGTH: 281 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 178:
US-10-834-397-178

Query Match 81.8%; Score 525; DB 9; Length 281;
Best Local Similarity 82.0%; Pred. No. 4.6e-35;
Matches 100; Conservative 10; Mismatches 10; Indels 2; Gaps 1;

Qy 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAVSWVRQAPGKGLEWVAAGRSSTFF 60
Db 26 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAVSWVRQAPGKGLEWVAAGRSSTFF 85

Qy 61 ADSVKGRFTISRDNKNTLYLENNSLRAEDTAIYYCAKRGGRGKYKGMVWGQGTITV 120
Db 86 ADSVKGRFTISRDNKNTLYLENNSLRAEDTAIYYCAKRGGRGKYKGMVWGQGTITV 143

Qy 121 SS 122
Db 144 SS 145

RESULT 13
US-11-054-515-1605
Sequence 1605, Application US/11054515
Publication No. US2005025532A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523P3
CURRENT APPLICATION NUMBER: US/11/054,515
CURRENT FILING DATE: 2005-02-10
PRIOR APPLICATION NUMBER: 60/543,296
PRIOR FILING DATE: 2004-02-11
PRIOR APPLICATION NUMBER: 60/580,347
PRIOR FILING DATE: 2004-06-18
PRIOR APPLICATION NUMBER: 10/293,418
PRIOR FILING DATE: 2002-11-14
PRIOR APPLICATION NUMBER: 60/331,469
PRIOR FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/340,817
PRIOR FILING DATE: 2001-12-19
PRIOR APPLICATION NUMBER: 09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 3247
SEQ ID NO 1605
LENGTH: 251
TYPE: PRT
ORGANISM: Homo sapiens
US-11-054-515-1605

Query Match 81.7%; Score 524.5; DB 11; Length 251;

```

Best Local Similarity 80.0%; Pred. No. 4.6e-35;
Matches 100; Conservative 11; Mismatches 11; Indels 3; Gaps 1;

QY 1 EVQLVSGGDLVQPGGSLRLSCAASGFTFSNFAVSWVRQAPGKGLEWVAIAIGRSGTTFY 60
Db 1 EVQLVSGGDLVQPGGSLRLSCAASGFTFSNFAVSWVRQAPGKGLEWVAIAIGRSGTTFY 60
QY 61 ADSVKGRFTISRDNKNTVLEWNSLRADTAIYYCAKRG---GYKYYGMDVWGCGTT 117
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIYYCARRSYDILTGYTYYGMDVWGKGTN 120
QY 118 VTVSS 122
Db 121 VTVSS 125

RESULT 14
US-11-266-444-1605
; Sequence 1605, Application US/11266444
; Publication No. US2006002789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1605
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1605

Query Match 81.7%; Score 524.5; DB 11; Length 251;
Best Local Similarity 80.0%; Pred. No. 4.6e-35;
Matches 100; Conservative 11; Mismatches 11; Indels 3; Gaps 1;

QY 1 EVQLVSGGDLVQPGGSLRLSCAASGFTFSNFAVSWVRQAPGKGLEWVAIAIGRSGTTFY 60
Db 1 EVQLVSGGDLVQPGGSLRLSCAASGFTFSNFAVSWVRQAPGKGLEWVAIAIGRSGTTFY 60
QY 61 ADSVKGRFTISRDNKNTVLEWNSLRADTAIYYCAKRG---GYKYYGMDVWGCGTT 117
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIYYCARRSYDILTGYTYYGMDVWGKGTN 120
QY 118 VTVSS 122
Db 121 VTVSS 125

RESULT 15
US-11-049-536-270
; Sequence 270, Application US/11049536
; Publication No. US20060024297A1
; GENERAL INFORMATION:
; APPLICANT: Wood, Clive R.
; APPLICANT: Dransfield, Daniel T.
; APPLICANT: Pieters, Henk
; APPLICANT: Hoet, Rene
; APPLICANT: Hufton, Simon E.

```

```

; TITLE OF INVENTION: TIE COMPLEX BINDING PROTEINS
; FILE REFERENCE: 10280-128001
; CURRENT APPLICATION NUMBER: US/11/049,536
; CURRENT FILING DATE: 2005-02-02
; PRIOR APPLICATION NUMBER: US 10/916,840
; PRIOR FILING DATE: 2004-08-12
; PRIOR APPLICATION NUMBER: US 60/494,713
; PRIOR FILING DATE: 2003-08-12
; NUMBER OF SEQ ID NOS: 721
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 270
; LENGTH: 130
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: Antibody
US-11-049-536-270

Query Match 81.6%; Score 524; DB 11; Length 130;
Best Local Similarity 77.7%; Pred. No. 2.9e-35;
Matches 101; Conservative 8; Mismatches 13; Indels 8; Gaps 1;

QY 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFAVSWVRQAPGKGLEWVAIAIGRSGTTFY 60
Db 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSRYVMGWVRQAPGKGLEWVSSIYPSGGVYY 60
QY 61 ADSVKGRFTISRDNKNTVLEWNSLRADTAIYYCAKRG-----RGYKYYGMDVW 112
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRADTAIYYCAKDSPHCSGSGSCYGGYYGMDVW 120
QY 113 GQGTIVTVSS 122
Db 121 GQGTIVTVSS 130

Search completed: May 5, 2006, 08:57:42
Job time : 9.12465 secs

```


A;Accession: C36005
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-119 <SCH>
A;Cross-references: UNIPARC:UPI0000176C27; GB:M18513
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 79.0%; Score 507.5; DB 2; Length 119;
Best Local Similarity 80.3%; Pred. No. 1.7e-38;
Matches 98; Conservative 9; Mismatches 12; Indels 3; Gaps 1;

Qy 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAMSWVRQAPGKGLEWVAIAIGRSRTTFY 60
Db 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAMSWVRQAPGKGLEWVAISGGSGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLEWNSLRAEDTAIYYCAKRGGRGGYKYYGMDVWGQTTTV 120
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAIYYCAKADAGW---SGFDYWGQGLTV 117

Qy 121 SS 122
Db 118 SS 119

RESULT 7
S31108
Ig heavy chain - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C;Accession: S31108
R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third complement
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31108
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-119 <RA>
A;Cross-references: UNIPARC:UPI0000176DC8; EMBL:X62956
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 78.0%; Score 500.5; DB 2; Length 119;
Best Local Similarity 79.0%; Pred. No. 7.3e-38;
Matches 98; Conservative 10; Mismatches 9; Indels 7; Gaps 2;

Qy 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAMSWVRQAPGKGLEWVAIAIGRSRTTFY 60
Db 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAMSWVRQAPGKGLEWVAISGGSGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLEWNSLRAEDTAIYYCAKRGGR--GGYKYYGMDVWGQTTV 118
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAIYYCAKORLTGTFDY-----WGQGLTV 115

Qy 119 TVSS 122
Db 116 TVSS 119

RESULT 8
S38489
Ig heavy chain - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 23-Jul-1999
C;Accession: S38489
R;Marks, J.D.; Owehand, W.H.; Bye, J.M.; Finnern, R.; Gorick, B.D.; Voak, D.; Thorpe, S
submitted to the EMBL Data Library, June 1993
A;Description: Human antibody fragments specific for human blood group antigens from a p
A;Reference number: S38488

A;Accession: S38489
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-127 <MAR>
A;Cross-references: UNIPARC:UPI0000116547; EMBL:Z23028; NID:9414025; PIDN:CAA80563.1; PI
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 78.0%; Score 500.5; DB 2; Length 127;
Best Local Similarity 74.8%; Pred. No. 7.8e-38;
Matches 99; Conservative 11; Mismatches 14; Indels 7; Gaps 1;

Qy 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAMSWVRQAPGKGLEWVAIAIGRSRTTFY 60
Db 1 QVQLVQSGGGLVPGGSLRLSCAASGFTFSNFAMSWVRQAPGKGLEWVAISGGSGSTYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLEWNSLRAEDTAIYYCAKRG-----RGYKYYGMDVWG 113
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAIYYCAKEGPFPAADYYDSSGYYSFDYWG 120

Qy 114 QGTLTV 120
Db 121 QGTLTV 127

RESULT 9
S31588
Ig heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31588
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31588
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-140 <CUI>
A;Cross-references: UNIPARC:UPI0000116472; EMBL:Z14200; NID:930957; PIDN:CAA78569.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 77.8%; Score 499.5; DB 2; Length 140;
Best Local Similarity 78.9%; Pred. No. 1.1e-37;
Matches 97; Conservative 11; Mismatches 12; Indels 3; Gaps 2;

Qy 1 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAMSWVRQAPGKGLEWVAIAIGRSRTTFY 60
Db 20 EVQLVESGGDLVPGGSLRLSCAASGFTFSNFAMSWVRQAPGKGLEWVAISGGSGSTYY 79

Qy 61 ADSVKGRFTISRDNKNTLYLEWNSLRAEDTAIYYCAK--RGRGGYKYYGMDVWGQTTV 119
Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAIYYCAKHDHYSNYIYF--DYWGQGLTV 137

Qy 120 VSS 122
Db 138 VSS 140

RESULT 10
E36005
Ig heavy chain V region (M72) - human
C;Species: Homo sapiens (man)
C;Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998
C;Accession: E36005
R;Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A;Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A;Reference number: A36005; MUID:90349571; PMID:2117273
A;Accession: E36005

A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-122 <SCH>
A;Cross-references: UNIPARC:UPI0000176C30; GB:M34030
C;Genetics:
A;Gene: GDB:IGH@; IGHDI1
A;Cross-references: GDB:118731; OMIM:146910
A;Map position: 14q32.33-14q32.33
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 77.78; Score 499; DB 2; Length 122;
Best Local Similarity 77.94; Pred. No. 1e-37;
Matches 95; Conservative 9; Mismatches 18; Indels 0; Gaps 0;

QY 1 EVLVESGDLVPGGSLRLSCAASGFTFSNFMAMVWVRQAPGKLEWVAIAIGRSCTTFY 60
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
Db 1 QVQLVESGGGVQPGSLRLSCAASGFTFSYAMHWVRQAPGKLEWVAISYDGSNKYY 60
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGGRGGYKYYGMDVWGQGITTV 120
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
Db 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIYYCARDHRSSWYGYGMDVWGQGITTV 120
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
QY 121 SS 122
||
Db 121 SS 122

RESULT 11
D36005
Ig heavy chain V region (M43) - human
C;Species: Homo sapiens (man)
C;Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998
C;Accession: D36005
R;Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A;Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A;Reference number: A36005; MUID:90349571; PMID:2117273
A;Accession: D36005
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-119 <SCH>
A;Cross-references: UNIPARC:UPI0000176C2A; GB:M34024
C;Genetics:
A;Gene: GDB:IGH@; IGHDI1
A;Cross-references: GDB:118731; OMIM:146910
A;Map position: 14q32.33-14q32.33
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 77.68; Score 498.5; DB 2; Length 119;
Best Local Similarity 78.78; Pred. No. 1.1e-37;
Matches 96; Conservative 11; Mismatches 12; Indels 3; Gaps 1;

QY 1 EVLVESGDLVPGGSLRLSCAASGFTFSNFMAMVWVRQAPGKLEWVAIAIGRSCTTFY 60
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
Db 1 EVQLLESGGVLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVAISGSGSTYY 60
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGGRGGYKYYGMDVWGQGITTV 120
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
Db 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIYYCAK---DWNDFWDPWGQGITTV 117
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
QY 121 SS 122
||
Db 118 SS 119

RESULT 12
S26794
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999

C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 17-Mar-1999
C;Accession: S26794
R;Mortari, F.; Newton, J.A.; Wang, J.Y.; Schroeder Jr., H.W.
Eur. J. Immunol. 22, 241-245, 1992
A;Title: The human cord blood antibody repertoire. Frequent usage of the V(H)7 gene family
A;Reference number: S26786; MUID:92111632; PMID:1730251
A;Accession: S26794
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-123 <MOR>
A;Cross-references: UNIPARC:UPI0000176C2B; EMBL:X61011
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 77.5%; Score 497.5; DB 2; Length 123;
Best Local Similarity 76.8%; Pred. No. 1.4e-37;
Matches 96; Conservative 13; Mismatches 11; Indels 5; Gaps 2;

QY 1 EVLVESGDLVPGGSLRLSCAASGFTFSNFMAMVWVRQAPGKLEWVAIAIGRSCTTFY 60
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
Db 1 EVQLVESGGVLVPGGSLRLSCAASGFTFSYAMWVRQAPGKLEWVAISSSTIYY 60
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAKRGGRGGY---KYGMDVWGQGIT 117
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
Db 61 ADSVKGRFTISRDNKNTLYLQNSLRADTAIYYCARSIK--YYDENYYGMDVWGQGIT 118
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
QY 118 VTSS 122
||||
Db 119 VTSS 123

RESULT 13
S31686
Ig heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31686
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31686
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-140 <CUI>
A;Cross-references: UNIPARC:UPI0000116477; EMBL:Z14205; NID:g30969; PIDN:CAA78574.1; PID:
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 77.0%; Score 494.5; DB 2; Length 140;
Best Local Similarity 78.9%; Pred. No. 3e-37;
Matches 97; Conservative 11; Mismatches 12; Indels 3; Gaps 2;

QY 1 EVLVESGDLVPGGSLRLSCAASGFTFSNFMAMVWVRQAPGKLEWVAIAIGRSCTTFY 60
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
Db 20 EVQLLESGGVLVPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVAISGSGSTYY 79
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
QY 61 ADSVKGRFTISRDNKNTVYLEMNSLRADTAIYYCAK-RGRGGYKYYGMDVWGQGITTV 119
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
Db 80 SDSVKGRFTISRDNKNTLYLQNSLRADTAIYYCAKFPAGGSPSF--DYWGQGITLV 137
:|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :|||||: :
QY 120 VSS 122
|||
Db 138 VSS 140

RESULT 14
S31114
Ig heavy chain - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999

C;Accession: S31114
R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third complement
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31114
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-123 <RAA>
A;Cross-references: UNIPARC:UPI0000176C8A; EMBL:X62963
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 76.9%; Score 493.5; DB 2; Length 123;
Best Local Similarity 78.0%; Pred. No. 3.2e-37;
Matches 96; Conservative 11; Mismatches 15; Indels 1; Gaps 1;
Qy 1 EVQLVESGGDILVQPGGSLRLSCAASGFTFSNFAMSVWRQAPGKGLEWVAIGRSGTTFY 60
Db 1 EVQLVESGGDILVQPGGSLRLSCAASGFTFSNFAMSVWRQAPGKGLEWVAIGRSGTTFY 60
Qy 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAKRGGRG-GYKYYGMDVWGQGTITV 119
Db 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAKRGGRG-GYKYYGMDVWGQGTITV 120
Qy 120 VSS 122
Db 121 VSS 123

RESULT 15
S23624
Ig heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999
C;Accession: S23624
R;Olee, T.; Lu, E.W.; Huang, D.F.; Soto-Gil, R.W.; Defetos, M.; Kozin, F.; Carson, D.A.;
J. Exp. Med. 175, 831-842, 1992
A;Title: Genetic analysis of self-associating immunoglobulin G rheumatoid factors from b
A;Reference number: S23623; MUID:92156804; PMID:1740665
A;Accession: S23624
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-143 <OLE>
A;Cross-references: UNIPARC:UPI0000115F94; EMBL:X59703; NID:G32012; PIDN:CAA42224.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 76.6%; Score 491.5; DB 2; Length 143;
Best Local Similarity 77.0%; Pred. No. 5.6e-37;
Matches 94; Conservative 11; Mismatches 12; Indels 5; Gaps 1;
Qy 1 EVQLVESGGDILVQPGGSLRLSCAASGFTFSNFAMSVWRQAPGKGLEWVAIGRSGTTFY 60
Db 1 EVQLVESGGDILVQPGGSLRLSCAASGFTFSNFAMSVWRQAPGKGLEWVAIGRSGTTFY 60
Qy 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAKRGGRGKYKYYGMDVWGQGTITV 120
Db 61 ADSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAKRGGRGKYKYYGMDVWGQGTITV 115
Qy 121 SS 122
Db 116 SS 117

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:58 ; Search time 48.3269 Seconds
(without alignments)
1781.089 Million cell updates/sec

Title: US-09-674-752-53
Perfect score: 642
Sequence: 1 EVOLVESGDLVQPGSLRL.....GKYKYGMDVWGQGTTVTVSS 122

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Uniprot 05.80.*
1: uniprot_sprot.*
2: uniprot_tremli.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	515	80.2	573	2	Q8WU38_HUMAN
2	503.5	78.4	472	2	O6N089_homo sapien
3	503	78.3	606	2	O6GMV2_HUMAN
4	494	76.9	469	2	O569F4_HUMAN
5	493.5	76.9	537	2	O96BB9_HUMAN
6	481.5	75.0	121	2	O9UL71_HUMAN
7	475.5	74.1	478	2	O6P181_HUMAN
8	467	72.7	136	1	HV16_MOUSE
9	466.5	72.7	464	2	O6MZU6_HUMAN
10	464	72.3	613	2	O8WUK1_HUMAN
11	463	72.1	118	2	O9UL91_HUMAN
12	463	72.1	494	2	O96K68_HUMAN
13	461	71.8	147	2	O9Y509_HUMAN
14	459.5	71.6	113	2	O9UL90_HUMAN
15	459.5	71.6	116	2	O9UL93_HUMAN
16	458.5	71.4	470	2	O6RJA4_HUMAN
17	458.5	71.4	485	2	O6PDB8_MOUSE
18	457.5	71.3	499	2	O8NSK4_HUMAN
19	456	71.0	112	2	O9HCC1_HUMAN
20	455	70.9	475	2	O6GMW7_HUMAN
21	454.5	70.8	240	2	O65ZC9_HUMAN
22	454	70.7	467	2	O4VBH1_RAT
23	453	70.6	117	1	HV3C_HUMAN
24	453	70.6	122	2	O9UL84_HUMAN
25	450	70.1	473	2	O6MZV7_HUMAN
26	448.5	69.9	479	2	O91WP5_MOUSE
27	448	69.8	475	2	O6MZQ6_HUMAN
28	445.5	69.4	115	1	HV3D_HUMAN
29	445.5	69.4	493	2	O6GMX2_HUMAN
30	444.5	69.2	487	2	O80Z17_MOUSE
31	443	69.0	122	1	HV3G_HUMAN

32	440	68.5	465	2	O6P6C4_HUMAN
33	439.5	68.5	115	1	HV3F_HUMAN
34	439	68.4	487	2	O99KA4_MOUSE
35	438.5	68.3	119	2	O920E7_MOUSE
36	437	68.1	116	1	HV3T_HUMAN
37	436.5	68.0	479	2	O5BK12_RAT
38	435	67.8	118	2	O9UL72_HUMAN
39	435	67.8	479	2	O6MZV6_HUMAN
40	434	67.6	119	2	O5F218_MOUSE
41	433.5	67.5	255	2	O6KB05_MOUSE
42	433	67.4	122	1	HV3A_HUMAN
43	433	67.4	126	1	HV3K_HUMAN
44	433	67.4	473	2	O91Z05_MOUSE
45	432.5	67.4	120	1	HV3E_HUMAN

ALIGNMENTS

RESULT 1
ID Q8WU38_HUMAN PRELIMINARY; PRT; 573 AA.
AC Q8WU38_HUMAN
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DE IGHD protein.
DE IGHD protein.
GN Names=IGHD;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinaki M.I., Skalska U., Smalley D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Director MGC Project;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
RN [3]
RP PROTEIN SEQUENCE.
RC PubMed=1555592;
RA Makiya R., Stigbrand T.;
RT "Placental alkaline phosphatase has a binding site for the human
immunoglobulin-G Fc portion";
RL Eur. J. Biochem. 205:341-345(1992).
DR EMBL; BC021276; AAH21276.1; -; mRNA.
DR PIR; S21205; S21205.
DR PIR; S30532; S30532.
DR HSSP; P18529; I18K.

—

```
Qy 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFAVSWVRQAPKGKLEWVAIAIGRSGTTFY 60
Db 20 QVQLVESGGGLVQPGGSLRLSCAASGFTFSNFAVSWVRQAPKGKLEWVAISSTSYTNY 79
Qy 61 ADSVKGRFTISRDNSKNTVYLEWNSLRAEDTAIYYCAKRGK-----GYKYYG 108
Db 80 ADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAIVYCARGGNGIAAGRVVYAEYDYYYG 139
Qy 109 MDVWGQGTITVTVSS 122
Db 140 MDVWGQGTITVTVSS 153

RESULT 4
Q569F4 HUMAN
ID Q569F4 HUMAN PRELIMINARY; PRT; 469 AA.
AC Q569F4;
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Dege J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lymph;
RG NIH MGC Project;
RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL: BC092518; AAH92518.1; -; mRNA.
SQ SEQUENCE 469 AA; 51254 MW; AC13448E3047784F CRC64;

Query Match 76.9%; Score 494; DB 2; Length 469;
Best Local Similarity 77.9%; Pred. No. 4.2e-43;
Matches 95; Conservative 10; Mismatches 15; Indels 2; Gaps 1;

Qy 1 EVQLVESGGDLVQPGGSLRLSCAASGFTFSNFAVSWVRQAPKGKLEWVAIAIGRSGTTFY 60
Db 20 EVQLVESGGVIVQPGGSLRLSCAASGFTFSNFAVSWVRQAPKGKLEWVLSIDWGGSTTY 79
Qy 61 ADSVKGRFTISRDNSKNTVYLEWNSLRAEDTAIYYCAKRGKGYKYGMDVWGQGTITTV 120
Db 80 ADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAIYCAT--RGGYSTAGFDWGGTITTV 137
Qy 121 SS 122
Db ||
```

```
Db 138 SS 139
RESULT 5
Q96BB9 HUMAN
ID Q96BB9 HUMAN PRELIMINARY; PRT; 597 AA.
AC Q96BB9;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Dege J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE.
RC PubMed=2500644;
RA Kishimoto T., Okajima H., Okumoto T., Taniguchi M.;
RT "Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-
RT chains of a human monoclonal antibody with broad reactivity to
RT malignant tumor cells.";
RL Nucleic Acids Res. 17:4385-0 (1989).
DR EMBL: BC015760; AAH15760.1; -; mRNA.
DR PIR: S05271; S05271.
DR PIR: S24260; S24260.
DR HSSP: P01861; 1ADQ.
DR Ensemble; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.
DR Immunoglobulin domain.
SQ SEQUENCE 597 AA; 65039 MW; 4FCA3AD8CE263D9 CRC64;

Query Match 76.9%; Score 493.5; DB 2; Length 597;
Best Local Similarity 76.0%; Pred. No. 6.3e-43;
Matches 95; Conservative 13; Mismatches 14; Indels 3; Gaps 1;
```

```

QY 1 EVOLVESGDLVOPGSLRLSCAASGFTFSNFMVWVRQAPGKGLEWVAIGRSGTTFY 60
DB 20 EVQLLESGLGVOPGSLRLSCAASGFTFSNFMVWVRQAPGKGLEWVAISGGSTY 79
QY 61 ADSVKGRFTISRDNKNTVLEWNSLRAEDTAIYYCAKRG--GYKYYGMDVWGQTT 117
DB 80 ADSVKGRFTISRDNKNTVLEWNSLRAEDTAIYYCAKRGPRGYSASGNTREDYWGQTL 139
QY 118 VTSS 122
DB 140 VTSS 144

RESULT 6
Q9UL71_HUMAN
ID Q9UL71_HUMAN PRELIMINARY; PRT; 121 AA.
AC Q9UL71
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-OCT-2003 (TrEMBLrel. 13, Last sequence update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCB1_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berney S.M.,
RT Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RL fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR ENBL; AF035043; AAD56279.1; -; mRNA.
DR HSP; P01852; INF2.
DR SMR; Q9UL71; 1-121.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1_v.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON TER 121
FT NON TER 121
SQ SEQUENCE 121 AA; 13154 MW; 2F045CCFASD50736 CRC64;

Query Match 75.0%; Score 481.5; DB 2; Length 121;
Best Local Similarity 76.2%; Pred. No. 1.8e-42;
Matches 93; Conservative 11; Mismatches 17; Indels 1; Gaps 1;

QY 1 EVOLVESGDLVOPGSLRLSCAASGFTFSNFMVWVRQAPGKGLEWVAIGRSGTTFY 60
DB 1 EVQLLESGLGVOPGSLRLSCAASGFTFSNFMVWVRQAPGKGLEWVAISGGSTY 60
QY 61 ADSVKGRFTISRDNKNTVLEWNSLRAEDTAIYYCAKRGGYKYYGMDVWGQTTV 120
DB 61 ADSVKGRFTISRDNKNTVLEWNSLRAEDTAIYYCAK--GKVTIYDRFDIWGQTMV 119
QY 121 SS 122
DB 120 SS 121

RESULT 7
Q6PI81_HUMAN
ID Q6PI81_HUMAN PRELIMINARY; PRT; 478 AA.
AC Q6PI81
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHM protein.

```

```

GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCB1_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.P., Zeeberg B., Buetow K.H., Schaefer C.P., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallalal D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.
DR ENBL; BC041037; AAH41037.1; -; mRNA.
DR HSP; P01861; 1ADQ.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 478 AA; 52667 MW; 17BED38D917970D6 CRC64;

Query Match 74.1%; Score 475.5; DB 2; Length 478;
Best Local Similarity 72.1%; Pred. No. 3.8e-41;
Matches 93; Conservative 11; Mismatches 18; Indels 7; Gaps 1;

QY 1 EVOLVESGDLVOPGSLRLSCAASGFTFSNFMVWVRQAPGKGLEWVAIGRSGTTFY 60
DB 20 EVQLLESGLGVOPGSLRLSCAASGFTFSNFMVWVRQAPGKGLEWVAIKDGSSEK 79
QY 61 ADSVKGRFTISRDNKNTVLEWNSLRAEDTAIYYCAK-----GRGKYTYGMDVWG 113
DB 80 ADSVKGRFTISRDNKNTVLEWNSLRAEDTAIYYCAKESFESMTTNTVADYFYFMDVWG 139
QY 114 QGTTVTSS 122
DB 140 KGTVTSS 148

RESULT 8
HV16_MOUSE
ID HV16_MOUSE STANDARD; PRT; 136 AA.
AC P01783;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)

```


Q9Y509_HUMAN	
ID	Q9Y509 HUMAN PRELIMINARY; PRT; 147 AA.
AC	Q9Y509;
DT	01-NOV-1999 (TrEMBLrel. 12, Created)
DT	01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT	01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE	VH3 protein (Fragment).
GN	Name=VH3;
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC	Homo.
OX	NCBI_TaxID=9606;
RN	[1]
RN	NUCLEOTIDE SEQUENCE.
RX	MEDLINE=96071149; PubMed=7475288;
RA	Cao J., Vescio R.A., Rettig M.B., Hong C.H., Kim A., Lee J.C.,
RA	Lichtenstein A.K., Berenson J.R.;
RT	"A CD10-positive subset of malignant cells is identified in multiple
RT	myeloma using PCR with patient-specific immunoglobulin gene primers.";
RL	Leukemia 9:1948-1953(1995).
DR	EMBL; S80860; RAD14339.1; -; mRNA.
DR	HSP; P01842; lAQQ.
DR	Ensembl; ENSG00000130076; Homo sapiens.
DR	GO; GO:0005887; C:integral to plasma membrane; NAS.
DR	GO; GO:0016066; P:cellular defense response (sensu Vertebrata); NAS.
DR	InterPro; IPR007110; IG-like.
DR	InterPro; IPR003596; IG_v.
DR	SMART; SM00406; IGV; 1.
DR	PROSITE; PSS0835; IG_LIKE; 1.
DR	NON TER. 147
SQ	SEQUENCE 147 AA; 15768 MW; 8489FCAAA7BC925C CRC64;
Query Match 71.8%; Score 461; DB 2; Length 147;	
Best Local Similarity 71.4%; Pred. No. 3.2e-40;	
Matches 90; Conservative 9; Mismatches 23; Indels 4; Gaps 1;	
Qy	1 EVLVESGGDLVQPGGSLRLSCAASGFTFSNFMASWVRQAPGKGLEWVAALGGRSGTTFY 60
Db	1 QVHLVSGGVVQPGKSLRLSCAASGFTFSYGNHSWRQAPGKGLDWALLISYDGSTQYY 60
Qy	61 ADSVKGFTISRDNKNTVYLEMNSLRAEDTAIYYCAKGRG---GGYKYYGMDVWGQT 116
Db	61 AGSVKGFTISRDNKNTLYLQMTSLRVEDTAVYYCAKDGNYFDSVGYVYAGIDVWGQT 120
Qy	117 TVTVSS 122
Db	121 LVTVSS 126
RESULT 14	
Q9UL90_HUMAN	
ID	Q9UL90 HUMAN PRELIMINARY; PRT; 113 AA.
AC	Q9UL90;
DT	01-MAY-2000 (TrEMBLrel. 13, Created)
DT	01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT	01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE	Myosin-reactive immunoglobulin heavy chain variable region
DE	(Fragment).
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC	Homo.
OX	NCBI_TaxID=9606;
RN	[1]
RN	NUCLEOTIDE SEQUENCE.
RX	MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA	Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA	Young D.C.;
RT	"Myosin-reactive autoantibodies in rheumatic carditis and normal
RT	fetus.";
RL	Clin. Immunol. Immunopathol. 87:184-192(1998).
RN	[2]

DR EMBL; AF035021; AAD56257.1; -: mRNA.

DR PIR; PH1644; PH1644.

DR FIR; PLO120; PLO120.

DR HSP; P01772; 2FB4.

DR SMR; Q9UL93; 1-116.

DR InterPro; IPR007110; Ig-like.

DR InterPro; IPR003596; Ig_v.

DR SMART; SMO0406; IGV; 1.

DR PROSITE; PS50835; IG_LIKE; 1.

FT NON_TER 1

FT NON_TER 116

SQ SEQUENCE 116 AA; 12434 MW; ODA0348154DD6061 CRC64;

Query Match 71.6%; Score 459.5; DB 2; Length 116;

Best Local Similarity 76.0%; Pred. No. 3.5e-40;

Matches 92; Conservative 8; Mismatches 16; Indels 5; Gaps 2;

Qy 2 VOLVESGGDLVOPGGSLRLSCAASGFTFSNFMWSVVRQAFKGLWVAALGGRSGTTFYA 61

Db 1 VOLVESGGGVVQPGSLRLSCAASGFTFSYAMHWVRQAFKGLWVAISYDGSNKYYA 60

Qy 62 DSVKGRFTISRDNKNTVYLEMNSLRAEDTAIYYCAKRGGRGGYKYGMGVGGTTVTVS 121

Db 61 DSVKGRFTISRDNKNTVYLEMNSLRAEDTAMTYCA--GGGG---LGLGYWGGTTLVTVS 115

Qy 122 S 122

Db 116 S 116

Search completed: May 5, 2006, 09:04:18

Job time : 49.3269 secs

THIS PAGE BLANK (USPTO)

FH Key Location/Qualifiers
 FT Region 31..35
 FT /label= CDR1
 FT Region 50..66
 FT /label= CDR2
 XX WO9508336-A1.
 PN 30-MAR-1995.
 PD
 PF 22-SEP-1994; 94WO-US010756.
 PR 22-SEP-1993; 93US-00124469.
 XX (NICH-) NICHOLS INST DIAGNOSTICS.
 PA Rapoport B, McLachlan SM;
 PI WPI; 1995-139383/18.
 DR N-PSDB; AAQ89327.
 XX Graves' ophthalmopathy-associated monoclonal antibody - produced by
 PT molecular cloning of immunoglobulin genes by PCR.
 PS Disclosure; Page 68; 94pp; English.
 XX L- and H-chain DNA was amplified by PCR from Graves' orbital tissue and
 CC clones encoding autoimmune-associated immunoglobulin fragments were
 CC obtained. 13/15 clones of H chain (IgG1) genes showed homology to the
 CC closest germline genes, Dp10 (AAQ89327) and hv1263 (AAQ89328). The DNA
 CC (AAQ89329) and corresp. amino acid (AAR72070) sequences of the VH region
 CC of a representative clone, OF7H1.2, are provided. (Updated on 25-MAR-2003
 CC to correct PN field.)
 XX Sequence 98 AA;
 SQ

Query Match 100.0%; Score 502; DB 2; Length 98;
 Best Local Similarity 100.0%; Pred. No. 9.5e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFTSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFTSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 QY 61 AOKFQGRVTITADESTSTAYMELSLRSEDVTAVYYCAR 98
 DB 61 AOKFQGRVTITADESTSTAYMELSLRSEDVTAVYYCAR 98

RESULT 2
 ID AAY50970 standard; protein; 98 AA.
 XX
 AC AAY50970;
 XX
 DT 23-MAR-2000 (first entry)
 XX Human FVIII antibody A2 scFv heavy chain protein DP-10 #1.
 DE Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
 KW scFv; A2.
 XX Homo sapiens.
 OS WO958680-A2.
 PN 18-NOV-1999.
 PD 07-MAY-1999; 99WO-NL000285.
 XX 08-MAY-1998; 98EP-00201543.
 XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
 PA

XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 PI WPI; 2000-053102/04.
 DR New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX Example 9; Fig 11A; 61pp; English.
 XX This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has
 CC hemostatic activity. (I) is useful a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents a human factor VIII
 CC antibody A2 specific scFv protein DP-10 which is used in the method of
 CC the invention
 XX Sequence 98 AA;
 SQ

Query Match 100.0%; Score 502; DB 3; Length 98;
 Best Local Similarity 100.0%; Pred. No. 9.5e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFTSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFTSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 QY 61 AOKFQGRVTITADESTSTAYMELSLRSEDVTAVYYCAR 98
 DB 61 AOKFQGRVTITADESTSTAYMELSLRSEDVTAVYYCAR 98

RESULT 3
 ID AAY50949 standard; protein; 98 AA.
 XX
 AC AAY50949;
 XX
 DT 23-MAR-2000 (first entry)
 XX Human anti-factor VIII antibody VH clone DP-10 encoded protein.
 DE Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
 KW VH gene.
 XX Homo sapiens.
 OS WO958680-A2.
 PN 18-NOV-1999.
 PD 07-MAY-1999; 99WO-NL000285.
 XX 08-MAY-1998; 98EP-00201543.
 XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
 PA Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 PI WPI; 2000-053102/04.
 DR New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX Example 4; Fig 4A; 61pp; English.
 XX This invention describes a novel polynucleotide (I) (and complements and

CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
CC coding for a human antibody with factor VIII specificity which has
CC hemostatic activity. (I) is useful a primer or probe for detecting the
CC presence of inhibitory antibodies directed against factor VIII. The
CC polypeptides of the invention and the antibodies generated from them are
CC useful in compositions for neutralizing factor VIII inhibiting antibodies
CC in hemophilia A patients. This sequence represents the human anti-factor
CC VIII antibody clone DP-10 protein which is used in the method of the
CC invention
SQ Sequence 98 AA;

Query Match 100.0%; Score 502; DB 3; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIPIFGTANY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIPIFGTANY 60

QY 61 AQLFQGRVTITADESTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQLFQGRVTITADESTAYMELSSLRSEDTAVYYCAR 98

RESULT 4
ABG78164
ID ABG78164 standard; protein; 98 AA.
XX
AC ABG78164;
XX
DT 15-NOV-2002 (first entry)
XX
DE Human Fv molecule hypervariable region related peptide #39.
XX
XX Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.
XX
OS Homo sapiens.
XX
PN WO200259264-A2.
XX
PD 01-AUG-2002.
XX
PF 31-DEC-2001; 2001WO-US049440.
XX
PR 29-DEC-2000; 2000US-00751181.
XX
PA (BIOT-) BIO-TECHNOLOGY GEN CORP.
XX
PI Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;
PI Plakslin D, Peretz T;
XX
DR WPI; 2002-619166/66.
XX
XX Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
PT or fragment, or construct of fragment with enhanced binding
PT characteristics so as to selectively bind target cell in favor of other
PT cells.
XX
PS Claim 13; Page 165; 232pp; English.
XX
CC The invention relates to a peptide or polypeptide comprising an Fv
CC molecule, a construct or fragments or a construct of a fragment with
CC enhanced binding characteristics which selectively and/or specifically
CC binds to a target cell in favour of other cells, where binding is
CC primarily determined by a first hypervariable region and Fv is a single
CC chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
CC association with or attached, coupled, combined, linked or fused to a
CC pharmaceutical agent, is useful in the manufacture of a medicament, where
CC the medicament has activity against a diseased cell, preferably a cancer
CC cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,

CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
CC composition for use in inhibiting the growth of a diseased or cancer
CC cell. This sequence represents a human Fv molecule hypervariable region
CC related peptide of the invention
XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 502; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIPIFGTANY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIPIFGTANY 60

QY 61 AQLFQGRVTITADESTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQLFQGRVTITADESTAYMELSSLRSEDTAVYYCAR 98

RESULT 5
ABG91855
ID ABG91855 standard; protein; 98 AA.
XX
AC ABG91855;
XX
DT 04-DEC-2002 (first entry)
XX
DE Human antibody fragment #39.
XX
XX Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
KW metastasis; hypervariable region; autoimmune disease; thrombosis;
KW restenosis; leukaemia; inflammatory disease; cardiovascular disease;
KW myocardial infarction; retinopathic disease; abnormal platelet function;
KW sulphated tyrosine-dependent protein-protein interaction.
XX
OS Homo sapiens.
XX
PN WO200253700-A2.
XX
PD 11-JUL-2002.
XX
PF 31-DEC-2001; 2001WO-US049442.
XX
PR 29-DEC-2000; 2000US-00751181.
PR 29-DEC-2000; 2000US-0258948P.
XX
PA (BIOT-) BIO-TECHNOLOGY GEN CORP.
XX
PI Lazarovits J, Hagai Y, Plakslin D, Vogel T, Nimrod A, Mar-Haim H;
PI Szanton E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
XX
DR WPI; 2002-674776/72.
XX
XX Novel isolated epitope present on cancer cells and important in
PT physiological phenomena such as cell rolling, metastasis and
PT inflammation, for treating autoimmune, inflammatory or cardiovascular
PT diseases, and cancer.
XX
PS Disclosure; Page 242-243; Opp; English.
XX
CC The invention relates to an isolated epitope present on cancer cells and
CC important in physiological phenomena such as cell rolling, metastasis and
CC inflammation, where the epitope is capable of being bound by an antibody,
CC its antigen-binding fragment or its complex comprising at least one
CC antibody or its binding fragment having a first hypervariable region. The
CC epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
CC disease, thrombosis, restenosis, metastasis, growth and/or replication of
CC tumour or leukaemia cells, increase in number of tumour or leukaemia
CC cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
CC platelet and/or cell-platelet adhesion or aggregation, for increasing
CC mortality of tumour or leukaemia cells, for increasing the susceptibility

CC of diseased cells to damage by anti-disease, anti-cancer or anti-leukaemia agents, or for decreasing the number of tumour or leukaemia cells in a patient, or in the manufacture of a medicament for the above mentioned purposes. The epitopes are useful for diagnosing and treating diseases such as cancer, leukaemia, autoimmune diseases, inflammatory diseases, cardiovascular diseases such as myocardial infarction, retinopathic diseases and other diseases mediated by abnormal platelet function and diseases caused by sulphated tyrosine-dependent protein-protein interactions. This sequence represents a human antibody fragment of the invention

XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 502; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKPGSSVKVSKCKASGDTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60
DB 1 QVQLVSGAEVKPGSSVKVSKCKASGDTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60

QY 61 AQKFGQRTVITADESTSTAYMELSLRSSEDTAVYYCAR 98
DB 61 AQKFGQRTVITADESTSTAYMELSLRSSEDTAVYYCAR 98

RESULT 6
ABJ18686
ID ABJ18686 standard; protein; 98 AA.
XX
AC ABJ18686;
XX
DT 06-MAR-2003 (first entry)
XX
DE Antibody library related human protein sequence SEQ ID No 15.
KW Library; recombinant antibody; clustering variable region; in silico;
KW immunogenicity; antibody therapeutic; human.
XX Homo sapiens.
XX WO200284277-A1.
XX
PD 24-OCT-2002.
XX
PF 17-APR-2002; 2002WO-US012202.
XX
PR 17-APR-2001; 2001US-0284407P.
XX
PA (ABMA-) ABMAXIS INC.
XX
PI Luo P;
XX
DR WPI; 2003-093043/08.
XX
PT Constructing a library of recombinant antibodies useful as source of
PT antibody candidates for screening antigens comprises clustering variable
PT regions of antibodies having known 3-dimensional structures into
PT structural ensembles.
XX
PS Disclosure; Page 109; 119pp; English.
XX
CC The invention relates to a novel method for the construction of a library
CC of recombinant antibodies. The novel method comprises clustering variable
CC regions of a collection of antibodies having known 3D structures into at
CC least two families of structural ensembles, each comprising at least two
CC different antibody sequences but with substantially identical main chain
CC conformations. The method is useful for constructing a library of
CC artificial antibodies in silico which provides a structurally diverse and
CC yet functionally more relevant source of antibody candidates which can
CC then be screened for binding a wide variety of target molecules,
CC including small molecules, and biomacromolecules such as proteins,
CC peptides and nucleic acids. The libraries constructed are useful as a

CC source of antibody candidates for further screening for novel antibodies
CC with high affinity against a wide range of antigens and having no or
CC minimum immunogenicity to human subjects treated with antibody
CC therapeutics. This sequence represents a human peptide region of an
CC antibody relating to the novel antibody library construction method of
CC the invention
XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 502; DB 6; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKPGSSVKVSKCKASGDTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60
DB 1 QVQLVSGAEVKPGSSVKVSKCKASGDTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60

QY 61 AQKFGQRTVITADESTSTAYMELSLRSSEDTAVYYCAR 98
DB 61 AQKFGQRTVITADESTSTAYMELSLRSSEDTAVYYCAR 98

RESULT 7
ABO27076
ID ABO27076 standard; protein; 98 AA.
XX
AC ABO27076;
XX
DT 10-SEP-2003 (first entry)
XX
DE Human germline heavy chain variable region gene segment #9.
XX
KW Human; heavy chain variable region; VH; humanised antibody;
KW chimeric antibody; complementarity determining region; CDR;
KW canonical CDR structure type.
XX Homo sapiens.
XX US2003039649-A1.
XX
PD 27-FEB-2003.
XX
PF 12-JUL-2002; 2002US-00194975.
XX
PR 12-JUL-2001; 2001US-0305111P.
XX
PA (FOOT/) FOOTE J.
XX
PI Foote J;
XX
DR WPI; 2003-492151/46.
XX
PT Making humanized antibody for converting antibody, by making chimeric
PT antibodies containing complementarity determining region from non-human
PT antibody and appropriate framework sequences of human antibodies.
XX
PS Example 1; Fig 1; 31pp; English.
XX
CC The invention describes a method of making a humanised antibody,
CC comprising making chimeric antibodies containing a complementarity
CC determining region (CDR) from a non-human antibody and appropriate
CC framework sequences (I) of human antibodies. (I) is selected by using
CC canonical CDR structure types of non-human antibody in comparison to
CC germline canonical CDR structure types of human antibodies as the basis
CC for selection, for humanisation. The method is useful for making a
CC humanised antibody or a converted antibody. The method is applicable for
CC converting a subject antibody sequence of any subject species to a less
CC immunogenic form suitable for use in an object species. The method is
CC reliable for identifying suitable human framework sequences to support
CC non-human CDR regions and to provide humanised antibodies that retain
CC high antigen binding with low immunogenicity in humans, without the need
CC for direct comparison of framework sequences, without the need for
CC determining critically important amino acid residues in the framework,

CC and without the need for multiple iteration and construction to obtain
 CC humanised antibodies with suitable therapeutic properties. The antibody
 CC has high affinity and low immunogenicity without need for comparing
 CC framework sequences between non-human and human antibodies. This sequence
 CC represents a human heavy chain variable region gene segment used in the
 CC creation of humanised antibodies
 XX
 SQ Sequence 98 AA;

Query Match 100.0%; Score 502; DB 6; Length 98;
 Best Local Similarity 100.0%; Pred. No. 9.5e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSYVAISWVRQAPGGGLEWMGGIIPIFGTANY 60
 |||||
 DB 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSYVAISWVRQAPGGGLEWMGGIIPIFGTANY 60
 |||||

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
 |||||
 DB 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
 |||||

RESULT 8
 ADF09904
 ID ADF09904 standard; protein; 98 AA.
 XX
 AC ADF09904;
 XX

DT 12-FEB-2004 (first entry)

XX Antibody heavy chain variable region VH_1-69.

DE Antibody; stability; solubility; antigen binding affinity;
 KW variable region; human.
 XX

OS Homo sapiens.

XX WO2003074679-A2.

XX 12-SEP-2003.

XX 03-MAR-2003; 2003WO-US006598.

XX 01-MAR-2002; 2002US-0360843P.

XX 29-MAY-2002; 2002US-0384197P.

XX (XENC-) XENCOR.

XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
 XX WPI; 2003-722066/68.

XX Computer optimization of physicochemical properties of antibodies
 PT comprises analyzing the interactions of amino acids at variable
 PT positions.

XX Disclosure; Fig 2a; 135pp; English.

XX The present invention relates to a method for optimizing at least one
 CC physico-chemical property of an antibody by a computational screening
 CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.

SQ Sequence 98 AA;

Query Match 100.0%; Score 502; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 9.5e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSYVAISWVRQAPGGGLEWMGGIIPIFGTANY 60
 |||||
 DB 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSYVAISWVRQAPGGGLEWMGGIIPIFGTANY 60
 |||||

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
 |||||
 DB 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
 |||||

RESULT 9
 ADF10012
 ID ADF10012 standard; protein; 98 AA.
 XX
 AC ADF10012;
 XX

DT 12-FEB-2004 (first entry)

XX VEGF antibody heavy chain variable region VH_1-69.

DE Antibody; stability; solubility; antigen binding affinity;
 KW variable region; human; VEGF.
 XX

OS Homo sapiens.

XX WO2003074679-A2.

XX 12-SEP-2003.

XX 03-MAR-2003; 2003WO-US006598.

XX 01-MAR-2002; 2002US-0360843P.

XX 29-MAY-2002; 2002US-0384197P.

XX (XENC-) XENCOR.

XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
 XX WPI; 2003-722066/68.

XX Computer optimization of physicochemical properties of antibodies
 PT comprises analyzing the interactions of amino acids at variable
 PT positions.

XX Example 6; Fig 16a; 135pp; English.

XX The present invention relates to a method for optimizing at least one
 CC physico-chemical property of an antibody by a computational screening
 CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.

SQ Sequence 98 AA;

Query Match 100.0%; Score 502; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 9.5e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSYVAISWVRQAPGGGLEWMGGIIPIFGTANY 60
 |||||

Db 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRAPGGGLEMMGGIIPIFGTANY 60
 QY 61 AQKFGQGVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
 Db 61 AQKFGQGVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 10
 ADF10114
 ID ADF10114 standard; protein; 98 AA.
 AC ADF10114;
 DT 12-FEB-2004 (first entry)
 DE Antibody heavy chain variable region VH_1-69.
 KW Antibody; stability; solubility; antigen binding affinity;
 KW variable region; human.
 XX Homo sapiens.
 OS WO2003074679-A2.
 PN 12-SEP-2003.
 PD 03-MAR-2003; 2003WO-US006598.
 XX 01-MAR-2002; 2002US-0360843P.
 PR 29-MAY-2002; 2002US-0384197P.
 XX (XENC-) XENCOR.
 PA Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
 PI WPI; 2003-722066/68.
 DR Computer optimization of physicochemical properties of antibodies
 PT comprises analyzing the interactions of amino acids at variable
 PT positions.
 XX Example 16; Fig 40a; 135pp; English.

XX The present invention relates to a method for optimizing at least one
 CC physico-chemical property of an antibody by a computational screening
 CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.

XX Sequence 98 AA;
 Query Match 100.0%; Score 502; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 9.5e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRAPGGGLEMMGGIIPIFGTANY 60
 Db 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRAPGGGLEMMGGIIPIFGTANY 60
 QY 61 AQKFGQGVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
 Db 61 AQKFGQGVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 11
 ADJ80289
 ID ADJ80289 standard; protein; 98 AA.
 XX ADJ80289;
 AC ADJ80289;
 DT 06-MAY-2004 (first entry)
 DE VH gene locus antibody amino acid sequence #9.
 DE hybrid antibody; antibody; framework region; homology; immunogenicity.
 KW Homo sapiens.
 OS WO2003048321-A2.
 PN 12-JUN-2003.
 PD 03-DEC-2002; 2002WO-US038450.
 XX 03-DEC-2001; 2001US-0336591P.
 PR (ALEX-) ALEXION PHARM INC.
 PA Rother R, Wu D;
 PI WPI; 2003-513753/48.
 DR Producing a hybrid antibody or hybrid antibody fragment by operatively
 PT linking the selected framework sequences to one or more complementarity
 PT determining regions of the initial antibody.
 XX Disclosure; SEQ ID NO 49; 77pp; English.

XX The invention relates to a method of producing a hybrid antibody or
 CC hybrid antibody fragment by: (i) providing an initial antibody having
 CC specificity for a target; (ii) determining the sequence of a variable
 CC region of the initial antibody; (iii) selecting a first component of the
 CC variable region consisting of FR1, FR2, FR3 and FR4; (iv) comparing the
 CC sequence of the first component to sequences contained in a reference
 CC database of antibody sequences or antibody fragment sequences from a
 CC target species; (v) selecting a sequence from an antibody in the database
 CC which demonstrates a high degree of homology to the first component; (vi)
 CC selecting a second component of the variable region which is different
 CC than the first component, the second component selected from the group
 CC consisting of FR1, FR2, FR3 and FR4; (vii) comparing the sequence of the
 CC second component to sequences contained in a reference database of
 CC antibody sequences or antibody fragment sequences from the target species
 CC; (viii) selecting a sequence from the database which demonstrates a high
 CC degree of homology to the second component and which is from a different
 CC antibody than the selected antibody; and (ix) operatively linking the
 CC selected framework sequences to one or more complementarity determining
 CC regions (CDRs) of the initial antibody to produce a hybrid antibody or
 CC hybrid antibody fragment. The method is useful for producing a hybrid
 CC antibody or hybrid antibody fragment (claimed). The antibody and
 CC fragments are useful for therapeutic and diagnostic purposes. The method
 CC uses entire framework regions from a single antibody variable heavy or
 CC variable light chain to receive the CDRs. This produces antibodies that
 CC are highly homologous and exhibit reduced immunogenicity while
 CC maintaining an optimum binding profile. This sequence represents the
 CC amino acid sequence of an antibody from the VH gene locus.

XX Sequence 98 AA;
 Query Match 100.0%; Score 502; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 9.5e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRAPGGGLEMMGGIIPIFGTANY 60
 Db 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRAPGGGLEMMGGIIPIFGTANY 60


```

Best Local Similarity 100.0%; Pred. No. 9.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
   |||||
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
   |||||

RESULT 14
AEB12956
ID AEB12956 standard; protein; 98 AA.
AC AEB12956;
XX
DT 08-SEP-2005 (first entry)
XX
DE Human germline antibody L22582 VH region.
XX
KW Antibody; phage display; protein therapy; antibody engineering;
KW hematopoiesis; immunotherapy; Cardiant; Antidiabetic; Anorectic;
KW cardiac failure; diabetes; obesity; heavy chain variable region.
XX
OS Homo sapiens.
XX
PN WO2005060642-A2.
XX
PD 07-JUL-2005.
XX
PF 15-DEC-2004; 2004WO-US041946.
XX
PR 15-DEC-2003; 2003US-00737290.
XX
PA (ALEX-) ALEXION PHARM INC.
XX
PI Bowdish KS, Frederickson S, Renshaw M, Orenica C;
XX
DR WPI; 2005-479402/48.
XX
PT New immunoglobulin molecule comprising a region where amino acid residues
PT corresponding to at least a portion of a complementarity determining
PT region is replaced with a peptide, for treating congestive heart failure,
PT diabetes or obesity.
XX
XX Example 8; SEQ ID NO 169; 152pp; English.
XX
CC The invention relates to an immunoglobulin (Ig) molecule or its fragment
CC comprising a region where amino acid residues corresponding to at least a
CC portion of a complementarity determining regions (CDR) is replaced with a
CC peptide selected from human brain natriuretic protein (hBNP), hBNP
CC mimetics, glycogen phosphorylase (GLP)-1, GLP-1 mimetics, GLP-2,
CC mimetics, exendin, exendin mimetics, glucagons, glucagon mimetics and
CC PACAP-38. Also included are a nucleic acid encoding the immunoglobulin
CC molecule, an expression vector comprising the nucleic acid, a host cell
CC transformed with the expression vector, producing an immunoglobulin
CC molecule (or its fragment, comprising culturing the host cell under
CC conditions suitable for expression of the immunoglobulin or its
CC fragment), a composition comprising an immunoglobulin (or its fragment)
CC and a pharmaceutically acceptable carrier, treating congestive heart
CC failure (comprising administering to the subject an immunoglobulin
CC molecule or fragment comprising a region where amino acid residues
CC corresponding to at least a portion of a CDR is replaced with a peptide
CC selected from hBNP and hBNP mimetics), treating diabetes or obesity
CC (comprising administering to a subject an immunoglobulin molecule or its
CC fragment comprising a region where amino acid residues corresponding to
CC at least a portion of a CDR is replaced with a peptide selected from GLP-
CC 1, GLP-1 mimetics, GLP-2, GLP-2 mimetics, exendin, exendin mimetics,
CC glucagons, glucagons mimetics and PACAP-38), preserving/improving beta-
CC cell function (comprising administering to a subject an immunoglobulin
CC molecule or fragment comprising a region where amino acid residues

```

```

corresponding to at least a portion of a CDR is replaced with GLP-1),
inducing endothelial-dependent relaxation of precontracted pulmonary
artery rings (comprising administering to a subject an immunoglobulin
molecule or fragment thereof comprising a region where amino acid
residues corresponding to at least a portion of a CDR is replaced with
GLP-1) and administering to a subject an immunoglobulin molecule or its
fragment (comprising a region where amino acid residues corresponding to
at least a portion of a complementarity determining regions (CDR) is
replaced with a thiazolidinedione derivative), regulating adiponectin
expression (comprising administering to a subject an immunoglobulin
molecule or its fragment comprising a region where amino acid residues
corresponding to at least a portion of a CDR is replaced with a
thiazolidinedione derivative). The immunoglobulin is an anti-tetanus
toxoid antibody (TT) where the heavy chain CDR2 and/or CDR3 are fully or
partially replaced with a peptide listed above or (as described in the
examples) a Thrombopoietin (TPO) mimetic, erythropoietin (EPO) mimetic
or ANP (atrial natriuretic peptide). The molecule, composition and
methods are useful for treating congestive heart failure, diabetes or
obesity. The TT antibody was compared to human germline sequences and the
closest relative sequences were cloned for TPO engrafting. The present
sequence represents the germline heavy chain variable region.

XX
SQ Sequence 98 AA;
Query Match 100.0%; Score 502; DB 9; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.5e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
   |||||
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
   |||||

RESULT 15
ABB57559
ID ABB57559 standard; peptide; 115 AA.
XX
AC ABB57559;
XX
DT 18-MAR-2002 (first entry)
XX
DE HLA-DR-specific protein MS-GPCS VH sequence.
XX
KW Immunomodulatory human MHC class II antigen-binding protein; HLA;
KW human leukocyte antigen; immune system; immunosuppression; antibody;
KW major histocompatibility complex; antirheumatic; antiarthritic;
KW neuroprotective; antiinflammatory; antidiabetic; antipsoriatic;
KW immunosuppressive; dermatological; antithyroid; nephrotropic; psoriasis;
KW rheumatoid; hepatotropic; immune response suppressor; narcolepsy;
KW rheumatoid arthritis; juvenile arthritis; multiple sclerosis; insulinitis;
KW Grave's disease; insulin-dependent diabetes; Hashimoto's disease;
KW systemic lupus erythematosus; ankylosing spondylitis; myasthenia gravis;
KW transplant rejection; graft versus host disease; pemphigus vulgaris;
KW glomerulonephritis; thyroiditis; pancreatitis; primary biliary cirrhosis;
KW irritable bowel disease; Sjogren's syndrome.
XX
XX Homo sapiens.
OS Synthetic.
XX
PN WO200187338-A1.
XX
PD 22-NOV-2001.
XX
PF 14-MAY-2001; 2001WO-US015626.
XX
PR 12-MAY-2000; 2000EP-00110063.
PR 06-OCT-2000; 2000US-0238762P.
XX
PA (GPCB-) GPC BIOTECH AG.

```

PA (MORP-) MORPHOSYS AG.
 XX
 PI Nagy Z, Tesar M, Thomassen-Wolf E;
 XX
 XX WPI; 2002-075289/10.
 DR
 XX
 XX Composition for suppressing immune response, treating diseases of immune
 PT system, has polypeptide comprising antibody-based antigen-binding domain
 PT of human composition, which binds antigen expressed on a cell surface.
 XX
 XX Example; Fig 15; 139pp; English.
 PS
 XX
 CC The present invention describes a composition (I), comprising a
 CC polypeptide comprising an antibody-based antigen-binding domain of human
 CC composition with binding specificity for an antigen expressed on the
 CC surface of a cell, where treating cells expressing the antigen with the
 CC polypeptides leads to suppression of an immune response, and the IC50 for
 CC the suppression of immune response is 1 microm or less. (I) has
 CC antineoplastic, antiarthritic, neuroprotective, antiinflammatory,
 CC antidiabetic, antipsoriatic, immunosuppressive, dermatological,
 CC antichyroid, nephrotropic, thyromimetic and hepatotropic activities, and
 CC can be used as a suppressor of immune responses. (I) is useful for
 CC suppressing activation or proliferation of a cell of the immune system,
 CC suppressing IL-2 secretion by a cell, the interaction of a cell of the
 CC immune system with another cell, immunosuppressing a patient and for
 CC killing a cell expressing an antigen, human leukocyte antigen (HLA)-DR on
 CC the surface of the cell, where neither cytotoxic entities nor
 CC immunological mechanisms are needed to cause or lead to the killing. (I)
 CC (optionally linked to cytotoxic or immunogenic agent) is useful for
 CC preparing a pharmaceutical preparation for the treatment of rheumatoid
 CC arthritis, juvenile arthritis, multiple sclerosis, Grave's disease,
 CC insulin-dependent diabetes, narcolepsy, psoriasis, systemic lupus
 CC erythematosus, ankylosing spondylitis, transplant rejection, graft versus
 CC host disease, Hashimoto's disease, myasthenia gravis, pemphigus vulgaris,
 CC glomerulonephritis, thyroiditis, pancreatitis, insulinitis, primary biliary
 CC cirrhosis, irritable bowel disease and Sjogren's syndrome in humans.
 CC ABA92469 to ABA92474 and ABB57457 to ABB57590 represent sequence used in
 CC the exemplification of the present invention
 XX
 SQ Sequence 115 AA;
 Query Match 100.0%; Score 502; DB 5; Length 115;
 Best Local Similarity 100.0%; Pred. No. 1.1e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY 60
 DB 1 QVQLVSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY 60
 QY 61 AQKFGQGVTTTADSTSTAYMELSSLSRSEDYAVYICAR 98
 DB 61 AQKFGQGVTTTADSTSTAYMELSSLSRSEDYAVYICAR 98
 RESULT 16
 AAY99558
 ID AAY99558 standard; protein; 118 AA.
 XX
 AC AAY99558;
 XX
 DT 20-SEP-2000 (first entry)
 XX
 DE Human LH13 monoclonal antibody heavy chain variable region.
 XX
 KW Human; LH13 monoclonal antibody; hybridoma; tumour-specific; cancer;
 KW cytostatic; cytotoxic; heavy chain variable region.
 XX
 OS Homo sapiens.
 XX
 FN WO200032635-A2.
 XX
 PD 08-JUN-2000.
 XX

PF 01-DEC-1999; 99WO-US028485.
 XX
 PR 02-DEC-1998; 98US-00203768.
 XX
 PA (IXSY-) IXSYS INC.
 XX
 XX Watkins JD, Huse WD;
 PI
 XX WPI; 2000-412293/35.
 DR N-PSDB; AAA48411.
 DR
 XX
 PT New tumor-specific human monoclonal antibody, useful for the treatment
 PT and diagnosis of cancer, comprises at least one complementarity
 PT determining region.
 XX
 PS Claim 10; Page 82-83; 84pp; English.
 XX
 CC The present sequence is the heavy chain variable region of a human tumour
 CC -specific monoclonal antibody. Neoplastic cells selectively express
 CC antigens which are not present on normal cells. Thus monoclonal
 CC antibodies can be produced that are specifically directed against tumour-
 CC specific antigens. The antibodies can be conjugated to cytotoxic or
 CC cytostatic agents and used to selectively target cancer cells for the
 CC elimination of tumours. They can also be linked to diagnostic moieties
 CC that allow the imaging of neoplastic cells. Nucleic acids encoding human
 CC tumour-specific monoclonal antibodies can be used to express the
 CC antibodies and can be recombinantly engineered to produce modified
 CC antibodies with higher affinity or higher selectivity for tumour cells.
 CC Tumour-specific antibodies were produced by hybridomas that were
 CC generated by in vitro immunisation of human spleen cell cultures with
 CC breast carcinoma cells. The nucleic acid encoding the monoclonal antibody
 CC was then isolated from the hybridoma by RT-PCR. The present sequence was
 CC produced by LH13 hybridoma cell line
 XX
 SQ Sequence 118 AA;
 Query Match 100.0%; Score 502; DB 3; Length 118;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY 60
 DB 1 QVQLVSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY 60
 QY 61 AQKFGQGVTTTADSTSTAYMELSSLSRSEDYAVYICAR 98
 DB 61 AQKFGQGVTTTADSTSTAYMELSSLSRSEDYAVYICAR 98
 RESULT 17
 ABR42842
 ID ABR42842 standard; protein; 118 AA.
 XX
 AC ABR42842;
 XX
 DT 08-SEP-2003 (first entry)
 XX
 DE Tumour-specific human MAb LH13 VH variant S97N.
 XX
 KW Human; monoclonal antibody; antibody; LH13; breast cancer;
 KW ovarian cancer; lung cancer; antitumour; therapy; diagnosis; mutant;
 KW mutein.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 101
 FT /note= "wild-type Ser substituted by Asn"
 XX
 FN WO20003044036-A1.
 XX
 PD 30-MAY-2003.
 XX

XX PF 19-NOV-2002; 2002WO-US037134.
 XX PR 19-NOV-2001; 2001US-00989901.
 XX PA (MOLE-) APPLIED MOLECULAR EVOLUTION INC.
 XX PI Watkins JD;
 XX DR WPI; 2003-457585/43.
 XX DR N-PSDB; ACC58833.
 XX PT New isolated human monoclonal antibody or its functional fragment
 PT comprising a complementary determining region, useful for reducing
 PT neoplastic cell proliferation, particularly for treating and diagnosing
 PT cancer.
 XX PS Claim 1; Page 124; 151pp; English.
 XX CC This is the protein sequence of the heavy chain variable region (VH) of
 CC tumour-specific human monoclonal antibody (Mab) LH13 variant clone S97N,
 CC in which the Ser residue at position 97 (numbering system of Kabat et al)
 CC of the native LH13 VH is substituted by Asn. A functional variant of LH13
 CC comprises an unmodified VL and the modified VH. Mab LH13 specifically
 CC binds a product produced by breast, lung and ovarian carcinoma cells, as
 CC compared to normal fibroblasts and melanoma cells. The invention provides
 CC tumour-specific human MABs such as LH13 and functional fragments, e.g.
 CC Fv, Fab, Fab' or F(ab')2, of them that comprise a complementarity
 CC determining region selected from a group including the variant VH. These
 CC specifically bind to neoplastic cells compared to normal cells. They are
 CC used in claimed methods of reducing neoplastic cell proliferation and of
 CC detecting a neoplastic cell in a sample, where the neoplastic cell is a
 CC breast cancer, lung cancer or ovarian cancer cell
 XX SQ Sequence 118 AA;
 Query Match 100.0%; Score 502; DB 6; Length 118;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGSSVKVSKASGTFSSYVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 DB 1 QVQLVQSGAEVKKPGSSVKVSKASGTFSSYVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 QY 61 AQKFGQGRVTITADESTSTAYMELSLRSEDYVYYCAR 98
 DB 61 AQKFGQGRVTITADESTSTAYMELSLRSEDYVYYCAR 98
 RESULT 18
 ABR42861
 ID ABR42861 standard; protein; 118 AA.
 AC ABR42861;
 DT 08-SEP-2003 (first entry)
 DE Tumour-specific human monoclonal antibody LH13 VH.
 DE Human; monoclonal antibody; antibody; LH13; breast cancer;
 KW ovarian cancer; lung cancer; antitumour; therapy; diagnosis.
 XX Homo sapiens.
 OS WO2003044036-A1.
 PN 30-MAY-2003.
 PD 19-NOV-2002; 2002WO-US037134.
 XX 19-NOV-2001; 2001US-00989901.
 XX (MOLE-) APPLIED MOLECULAR EVOLUTION INC.

XX PI Watkins JD;
 XX DR WPI; 2003-457585/43.
 XX DR N-PSDB; ACC58852.
 XX PT New isolated human monoclonal antibody or its functional fragment
 PT comprising a complementary determining region, useful for reducing
 PT neoplastic cell proliferation, particularly for treating and diagnosing
 PT cancer.
 XX PS Disclosure; Page 119; 151pp; English.
 XX CC This is the protein sequence of the heavy chain variable region of tumour
 CC -specific human monoclonal antibody (MAB) LH13. The hybridoma producing
 CC this MAB was generated by in vitro immunization of human spleen cells
 CC with breast carcinoma cells, and immortalization of the immunized
 CC lymphocytes by transformation with EBV and fusion with K6H6/B5
 CC heteromyloma cells. Mab LH13 specifically binds a product produced by
 CC breast, lung and ovarian carcinoma cells, as compared to normal
 CC fibroblasts and melanoma cells. The invention provides tumour-specific
 CC human MABs such as LH13 and functional fragments of them. These
 CC specifically bind to neoplastic cells compared to normal cells. They are
 CC used in claimed methods of reducing neoplastic cell proliferation and of
 CC detecting a neoplastic cell in a sample, where the neoplastic cell is a
 CC breast cancer, lung cancer or ovarian cancer cell
 XX SQ Sequence 118 AA;
 Query Match 100.0%; Score 502; DB 6; Length 118;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGSSVKVSKASGTFSSYVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 DB 1 QVQLVQSGAEVKKPGSSVKVSKASGTFSSYVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 QY 61 AQKFGQGRVTITADESTSTAYMELSLRSEDYVYYCAR 98
 DB 61 AQKFGQGRVTITADESTSTAYMELSLRSEDYVYYCAR 98
 RESULT 19
 ABR42840
 ID ABR42840 standard; protein; 118 AA.
 AC ABR42840;
 DT 08-SEP-2003 (first entry)
 DE Tumour-specific human Mab LH13 VH variant S97G.
 DE Human; monoclonal antibody; antibody; LH13; breast cancer;
 KW ovarian cancer; lung cancer; antitumour; therapy; diagnosis; mutant;
 XX mutin.
 OS Homo sapiens.
 OS Synthetic.
 XX Key Location/Qualifiers
 FT Misc-difference 101 /note= "wild-type Ser substituted by Gly"
 FT WO2003044036-A1.
 PN 30-MAY-2003.
 PD 19-NOV-2002; 2002WO-US037134.
 XX 19-NOV-2001; 2001US-00989901.
 XX (MOLE-) APPLIED MOLECULAR EVOLUTION INC.

```

PI Watkins JD;
XX
DR WPI: 2003-457585/43.
DR N-PSDB; ACC58831.
XX
PT New isolated human monoclonal antibody or its functional fragment
PT comprising a complementary determining region, useful for reducing
PT neoplastic cell proliferation, particularly for treating and diagnosing
PT cancer.
XX
PS Claim 1; Page 122; 151pp; English.
XX
CC This is the protein sequence of the heavy chain variable region (VH) of
CC tumour-specific human monoclonal antibody (MAB) LH13 variant clone S97G,
CC in which the Ser residue at position 97 (numbering system of Kabat et al)
CC of the native LH13 VH is substituted by Gly. A functional variant of LH13
CC comprises an unmodified VL and the modified VH. MAB LH13 specifically
CC binds a product produced by breast, lung and ovarian carcinoma cells, as
CC compared to normal fibroblasts and melanoma cells. The invention provides
CC tumour-specific human MABs such as LH13 and functional fragments, e.g.
CC Fv, Fab, Fab' or F(ab')2, of them that comprise a complementarity
CC determining region selected from a group including the variant VH. These
CC specifically bind to neoplastic cells compared to normal cells. They are
CC used in claimed methods of reducing neoplastic cell proliferation and of
CC detecting a neoplastic cell in a sample, where the neoplastic cell is a
CC breast cancer, lung cancer or ovarian cancer cell
XX
SQ Sequence 118 AA;

Query Match 100.0%; Score 502; DB 6; Length 118;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVCASKGTSFSSYAISWVRQAPGQGLEWMGIIPIFGTANY 60
DB 1 QVQLVQSGAEVKKPGSSVKVCASKGTSFSSYAISWVRQAPGQGLEWMGIIPIFGTANY 60
QY 61 AQKFGQGRVITADESTSTAYMELSSLSRSEDYAVYYCAR 98
DB 61 AQKFGQGRVITADESTSTAYMELSSLSRSEDYAVYYCAR 98

RESULT 20
ABW02449
ID ABR42841 standard; protein; 118 AA.
XX
AC ABR42841;
XX
DT 08-SEP-2003 (first entry)
XX
DE Tumour-specific human MAB LH13 VH variant S97T.
XX
KW Human; monoclonal antibody; antibody; LH13; breast cancer;
KW ovarian cancer; lung cancer; antitumour; therapy; diagnosis; mutant;
KW muten.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Misc-difference 101
FT /note= "wild-type Ser substituted by Thr"
FT
PN WO2003044036-A1.
XX
XX 30-MAY-2003.
XX
XX 19-NOV-2002; 2002WO-US037134.
XX
XX 19-NOV-2001; 2001US-00989901.
XX
XX (MOLE-) APPLIED MOLECULAR EVOLUTION INC.
XX

PI Watkins JD;
XX
DR WPI: 2003-457585/43.
DR N-PSDB; ACC58832.
XX
PT New isolated human monoclonal antibody or its functional fragment
PT comprising a complementary determining region, useful for reducing
PT neoplastic cell proliferation, particularly for treating and diagnosing
PT cancer.
XX
PS Claim 1; Page 123; 151pp; English.
XX
CC This is the protein sequence of the heavy chain variable region (VH) of
CC tumour-specific human monoclonal antibody (MAB) LH13 variant clone S97T,
CC in which the Ser residue at position 97 (numbering system of Kabat et al)
CC of the native LH13 VH is substituted by Thr. A functional variant of LH13
CC comprises an unmodified VL and the modified VH. MAB LH13 specifically
CC binds a product produced by breast, lung and ovarian carcinoma cells, as
CC compared to normal fibroblasts and melanoma cells. The invention provides
CC tumour-specific human MABs such as LH13 and functional fragments, e.g.
CC Fv, Fab, Fab' or F(ab')2, of them that comprise a complementarity
CC determining region selected from a group including the variant VH. These
CC specifically bind to neoplastic cells compared to normal cells. They are
CC used in claimed methods of reducing neoplastic cell proliferation and of
CC detecting a neoplastic cell in a sample, where the neoplastic cell is a
CC breast cancer, lung cancer or ovarian cancer cell
XX
SQ Sequence 118 AA;

Query Match 100.0%; Score 502; DB 6; Length 118;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVCASKGTSFSSYAISWVRQAPGQGLEWMGIIPIFGTANY 60
DB 1 QVQLVQSGAEVKKPGSSVKVCASKGTSFSSYAISWVRQAPGQGLEWMGIIPIFGTANY 60
QY 61 AQKFGQGRVITADESTSTAYMELSSLSRSEDYAVYYCAR 98
DB 61 AQKFGQGRVITADESTSTAYMELSSLSRSEDYAVYYCAR 98

RESULT 21
ABW02449
ID ABW02449 standard; protein; 118 AA.
XX
AC ABW02449;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human monoclonal antibody VH variant (S97G) protein from LH13 clone.
XX
KW Human; monoclonal antibody; neoplastic cell proliferation; breast cancer;
KW lung cancer; tumour; ovarian cancer cell; heavy chain variable region;
KW VH; cytostatic; variant.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Misc-difference 101
FT /note= "wild-type Ser substituted with Gly; This position
FT corresponds to position 97 of HCDR3 according to the
FT numbering system of Kabat at al"
FT
PN US2003198638-A1.
XX
XX 23-OCT-2003.
XX
XX 19-NOV-2002; 2002US-00300675.
XX
XX 19-NOV-2001; 2001US-0421146P.
XX

```

```

PA (WATK/) WATKINS J D.
XX
PI Watkins JD;
XX
XX WPI; 2003-852771/79.
DR N-PSDB; AAD64353.
XX
XX New tumor-specific human monoclonal antibodies is useful for detecting
PT neoplastic cells in a biological sample, or for reducing proliferation of
PT neoplastic cells, particularly breast cancer, lung cancer or ovarian
PT cancer cells.
XX
PS Claim 1; SEQ ID NO 10; Opp; English.
XX
CC The present invention relates to novel tumour-specific human monoclonal
CC antibodies or their functional fragments. Sequences of the invention are
CC useful for detecting neoplastic cells in a biological sample or for
CC reducing neoplastic cell proliferation, particularly breast cancer, lung
CC cancer or ovarian cancer cells. The present sequence is human monoclonal
CC antibody heavy chain variable region (VH) variant protein from LH13 clone
XX
SQ Sequence 118 AA;
Query Match 100.0%; Score 502; DB 7; Length 118;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGVITITADESTSTAYMELSLRSEDYVYYCAR 98
Db 61 AQKFGQGVITITADESTSTAYMELSLRSEDYVYYCAR 98
RESULT 22
ABW02451
ID ABW02451 standard; protein; 118 AA.
XX
AC ABW02451;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human monoclonal antibody VH variant (S97N) protein from LH13 clone.
XX
KW Human; monoclonal antibody; neoplastic cell proliferation; breast cancer;
KW lung cancer; tumour; ovarian cancer cell; heavy chain variable region;
KW VH; cytostatic; variant.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 101
FT /note= "Wild-type Ser substituted with Asn; This position
FT corresponds to position 97 of HCDR3 according to the
FT numbering system of Kabat at al"
XX
PN US2003198638-A1.
XX
PD 23-OCT-2003.
XX
XX 19-NOV-2002; 2002US-00300675.
XX
XX (WATK/) WATKINS J D.
PA
XX Watkins JD;
PI
XX WPI; 2003-852771/79.
DR N-PSDB; AAD64355.
XX
XX New tumor-specific human monoclonal antibodies is useful for detecting
PT neoplastic cells in a biological sample, or for reducing proliferation of
PT neoplastic cells, particularly breast cancer, lung cancer or ovarian
PT cancer cells.
XX
PS Claim 1; SEQ ID NO 14; Opp; English.
XX
CC The present invention relates to novel tumour-specific human monoclonal
CC antibodies or their functional fragments. Sequences of the invention are
CC useful for detecting neoplastic cells in a biological sample or for
CC reducing neoplastic cell proliferation, particularly breast cancer, lung
CC cancer or ovarian cancer cells. The present sequence is human monoclonal
CC antibody heavy chain variable region (VH) variant protein from LH13 clone
XX
SQ Sequence 118 AA;
Query Match 100.0%; Score 502; DB 7; Length 118;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGVITITADESTSTAYMELSLRSEDYVYYCAR 98
Db 61 AQKFGQGVITITADESTSTAYMELSLRSEDYVYYCAR 98
RESULT 23
ABW02447
ID ABW02447 standard; protein; 118 AA.
XX
AC ABW02447;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human monoclonal antibody VH protein from LH13 clone.
XX
KW Human; monoclonal antibody; neoplastic cell proliferation; breast cancer;
KW lung cancer; tumour; ovarian cancer cell; heavy chain variable region;
KW VH; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003198638-A1.
XX
PD 23-OCT-2003.
XX
XX 19-NOV-2002; 2002US-00300675.
XX
XX 19-NOV-2001; 2001US-0421146P.
XX
XX (WATK/) WATKINS J D.
PA
XX Watkins JD;
PI
XX WPI; 2003-852771/79.
DR N-PSDB; AAD64351.
XX
XX New tumor-specific human monoclonal antibodies is useful for detecting
PT neoplastic cells in a biological sample, or for reducing proliferation of
PT neoplastic cells, particularly breast cancer, lung cancer or ovarian
PT cancer cells.
XX
PS Disclosure; SEQ ID NO 6; Opp; English.
XX
CC The present invention relates to novel tumour-specific human monoclonal
CC antibodies or their functional fragments. Sequences of the invention are
CC useful for detecting neoplastic cells in a biological sample or for
CC reducing neoplastic cell proliferation, particularly breast cancer, lung
CC cancer or ovarian cancer cells. The present sequence is human monoclonal

```


CC antibody heavy chain variable region (VH) protein from LH13 clone
XX Sequence 118 AA;
SQ

Query Match 100.0%; Score 502; DB 7; Length 118;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSYAISVWRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSYAISVWRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKQGRVTITADESTSTAYMELSSLSRSEDVAVYICAR 98
Db 61 AQKQGRVTITADESTSTAYMELSSLSRSEDVAVYICAR 98

RESULT 24
ABW02450
ID ABW02450 standard; protein; 118 AA.
XX
AC ABW02450;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human monoclonal antibody VH variant (S97T) protein from LH13 clone.
XX
KW Human; monoclonal antibody; neoplastic cell proliferation; breast cancer;
KW lung cancer; tumour; ovarian cancer cell; heavy chain variable region;
KW VH; cytostatic; variant.
XX
OS Homo sapiens.
OS Synthetic.

Key Location/Qualifiers
FT Misc-difference 101
FT /note= "Wild-type Ser substituted with Thr; This position
FT corresponds to position 97 of HCDR3 according to the
FT numbering system of Kabat at al"
XX
XX
PN US2003198638-A1.
XX
PD 23-OCT-2003.
XX
PF 19-NOV-2002; 2002US-00300675.
XX
PR 19-NOV-2001; 2001US-0421146P.
XX
PA (WATK/) WATKINS J D.
XX
PI Watkins JD;
XX
DR WPI; 2003-852771/79.
DR N-PSDB; AAD64354.
XX
XX New tumor-specific human monoclonal antibodies is useful for detecting
XX neoplastic cells in a biological sample, or for reducing proliferation of
XX neoplastic cells, particularly breast cancer, lung cancer or ovarian
XX cancer cells.
XX
PS Claim 1; SEQ ID NO 12; Opp; English.
XX
XX The present invention relates to novel tumour-specific human monoclonal
XX antibodies or their functional fragments. Sequences of the invention are
XX useful for detecting neoplastic cells in a biological sample or for
XX reducing neoplastic cell proliferation, particularly breast cancer, lung
XX cancer or ovarian cancer cells. The present sequence is human monoclonal
XX antibody heavy chain variable region (VH) variant protein from LH13 clone
XX
SQ Sequence 118 AA;
Query Match 100.0%; Score 502; DB 7; Length 118;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSYAISVWRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSYAISVWRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKQGRVTITADESTSTAYMELSSLSRSEDVAVYICAR 98
Db 61 AQKQGRVTITADESTSTAYMELSSLSRSEDVAVYICAR 98

RESULT 25
ADA89118
ID ADA89118 standard; protein; 119 AA.
XX
AC ADA89118;
XX
DT 20-NOV-2003 (first entry)
XX
DE MS-Pro-21-VH amino acid sequence SEQ ID NO:106.
XX
KW antigen binding; antibody; specific binding affinity;
KW receptor protein tyrosine kinase; RPTK;
KW receptor protein tyrosine kinase inhibitor;
KW fibroblast growth factor receptor; FGFR; osteopathic; cytostatic;
KW ophthalmological; bone disorder; cartilage disorder; skeletal disorder;
KW skeletal dysplasia; achondroplasia; thanatophoric dysplasia;
KW hypochondroplasia; craniosynostosis disorder;
KW malignant cell proliferative disease; cancer; tumour; vision disorder;
KW non-neoplastic angiogenic pathologic condition.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2002102973-A2.
XX
PD 27-DEC-2002.
XX
PF 20-JUN-2002; 2002WO-IL000495.
XX
PR 20-JUN-2001; 2001US-0299187P.
XX
PA (PROC-) PROCHON BIOTECH LTD.
XX
PI Yayon A, Rom E;
XX
DR WPI; 2003-175236/17.
XX
XX New antibodies which have specific binding affinity for a receptor
XX protein tyrosine kinase (RPTK) and block constitutive activation of RPTK,
XX useful for treating bone and cartilage disorders, or malignant cell
XX proliferative diseases.
XX
PS Claim 52; Page 18; 122pp; English.
XX
XX The present invention describes a molecule (I) comprising the antigen
XX binding portion of an isolated antibody which has specific binding
XX affinity for a receptor protein tyrosine kinase (RPTK), particularly for
XX a fibroblast growth factor receptor (FGFR), and which blocks constitutive
XX activation of an RPTK. Also described: (1) pharmaceutical compositions
XX comprising (I) as an active ingredient and a pharmaceutical carrier,
XX excipient, or auxiliary agent; (2) a kit comprising (I), at least one
XX reagent for detecting the presence of (I) when bound to the RPTK, and
XX instructions for use; (3) a method for treatment of bone and cartilage
XX related disorders by administering a composition of (1) to the subject;
XX (4) a method for treating or inhibiting a cell proliferative disease or
XX disorder by administering the composition of (1); (5) a method for
XX screening a molecule comprising the composition of (1); (6) a method of an
XX antibody which blocks ligand-dependent activation of RPTK; (6) an
XX isolated nucleic acid molecule encoding a VL-CDR3 DNA region and a VH-
XX CDR3 DNA region; (7) an isolated nucleic acid molecule encoding VL region
XX and a VH region; (8) vectors comprising a nucleic acid molecule of (6) or
XX (7); and (9) host cells transfected with the vector. (I) have

CC osteopathic, cytostatic and ophthalmological activities, and can be used
 CC as a RPTK inhibitor. Compositions comprising (I) are useful for treating
 CC bone and cartilage disorders, including skeletal disorders such as
 CC skeletal dysplasia (achondroplasia, thanatophoric dysplasia,
 CC hypochondroplasia, severe achondroplasia with developmental delay and
 CC acanthosis nigricans dysplasia) or a craniosynostosis disorder (e.g.
 CC Muenke coronal craniosynostosis or Crouzon syndrome with acanthosis
 CC nigricans). The composition may also be used for treating or inhibiting
 CC malignant cell proliferative disease or disorder associated with abnormal
 CC RPTK activity, including a haematopoietic malignancy (e.g. multiple
 CC myeloma), solid tumours (e.g. mammary, colon, cervical, bladder,
 CC colorectal, chondrosarcoma or osteosarcoma), tumour formation, primary
 CC tumours, tumour progression (particularly progression of transitional
 CC cell carcinoma or mammary carcinoma), or tumour metastasis, where the
 CC cell proliferative disorder may be associated with the action of a
 CC constitutively activated RPTK, or with ligand-dependent activation of
 CC RPTK. The compositions may further be used for treating
 CC hyperproliferative diseases and disorders associated with ligand-
 CC dependent FGFR signaling, such as vision disorders (e.g. neovascular
 CC glaucoma, macular degeneration and proliferative retinopathy including
 CC diabetic retinopathy), and non-neoplastic angiogenic pathologic
 CC conditions (e.g. haemangiomas, angiofibromas and psoriasis). The present
 CC sequence is given in the exemplification of the present invention.
 XX
 SQ Sequence 119 AA;
 Query Match 100.0%; Score 502; DB 6; Length 119;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFTSSYVAISWVRQAPGGLEWMGGIPIFGTANY 60
 Db 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFTSSYVAISWVRQAPGGLEWMGGIPIFGTANY 60
 QY 61 AQKFGQVRVITADESTSTAYMELSSLSRSEDYAVYYCAR 98
 Db 61 AQKFGQVRVITADESTSTAYMELSSLSRSEDYAVYYCAR 98
 RESULT 26
 ADA89119
 ID ADA89119 standard; protein; 119 AA.
 AC ADA89119;
 XX
 XX 20-NOV-2003 (first entry)
 DT
 XX MS-Pro-24-VH amino acid sequence SEQ ID NO:107.
 DE
 XX antigen binding; antibody; specific binding affinity;
 KW receptor protein tyrosine kinase; RPTK;
 KW receptor protein tyrosine kinase inhibitor;
 KW fibroblast growth factor receptor; FGFR; osteopathic; cytostatic;
 KW ophthalmological; bone disorder; cartilage disorder; skeletal disorder;
 KW skeletal dysplasia; achondroplasia; thanatophoric dysplasia;
 KW hypochondroplasia; craniosynostosis disorder;
 KW malignant cell proliferative disease; cancer; tumour; vision disorder;
 KW non-neoplastic angiogenic pathologic condition.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX WO2002102973-A2.
 PN
 XX 27-DEC-2002.
 PD
 XX 20-JUN-2002; 2002WO-IL000495.
 PF
 XX 20-JUN-2001; 2001US-0299187P.
 PR
 XX (PROC-) PROCHON BIOTECH LTD.
 PA
 XX Yayon A, Rom E;
 PI

XX
 DR WPI; 2003-175236/17.
 XX
 PT New antibodies which have specific binding affinity for a receptor
 PT protein tyrosine kinase (RPTK) and block constitutive activation of RPTK,
 PT useful for treating bone and cartilage disorders, or malignant cell
 PT proliferative diseases.
 XX
 XX Claim 52; Page 19; 122pp; English.
 PS
 CC The present invention describes a molecule (I) comprising the antigen
 CC binding portion of an isolated antibody which has specific binding
 CC affinity for a receptor protein tyrosine kinase (RPTK), particularly for
 CC a fibroblast growth factor receptor (FGFR), and which blocks constitutive
 CC activation of an RPTK. Also described: (1) pharmaceutical compositions
 CC comprising (I) as an active ingredient; (2) a kit comprising (I), at least one
 CC excipient, or auxiliary agent; (3) a method for treating (I), at least one
 CC reagent for detecting the presence of (I) when bound to the RPTK, and
 CC instructions for use; (3) a method for treatment of bone and cartilage
 CC related disorders by administering a composition of (I) to the subject;
 CC (4) a method for treating or inhibiting a cell proliferative disease or
 CC disorder by administering the composition of (I); (5) a method for
 CC screening a molecule comprising the antigen-binding portion of an
 CC antibody which blocks ligand-dependent activation of RPTK; (6) an
 CC isolated nucleic acid molecule encoding a VI-CDR3 DNA region and a VH-
 CC CDR3 DNA region; (7) an isolated nucleic acid molecule encoding VI region
 CC and a VH region; (8) vectors comprising a nucleic acid molecule of (6) or
 CC (7); and (9) host cells transformed with the vector. (I) have
 CC osteopathic, cytostatic and ophthalmological activities, and can be used
 CC as a RPTK inhibitor. Compositions comprising (I) are useful for treating
 CC bone and cartilage disorders, including skeletal disorders such as
 CC skeletal dysplasia (achondroplasia, thanatophoric dysplasia,
 CC hypochondroplasia, severe achondroplasia with developmental delay and
 CC acanthosis nigricans dysplasia) or a craniosynostosis disorder (e.g.
 CC Muenke coronal craniosynostosis or Crouzon syndrome with acanthosis
 CC nigricans). The composition may also be used for treating or inhibiting
 CC malignant cell proliferative disease or disorder associated with abnormal
 CC RPTK activity, including a haematopoietic malignancy (e.g. multiple
 CC myeloma), solid tumours (e.g. mammary, colon, cervical, bladder,
 CC colorectal, chondrosarcoma or osteosarcoma), tumour formation, primary
 CC tumours, tumour progression (particularly progression of transitional
 CC cell carcinoma or mammary carcinoma), or tumour metastasis, where the
 CC cell proliferative disorder may be associated with the action of a
 CC constitutively activated RPTK, or with ligand-dependent activation of
 CC RPTK. The compositions may further be used for treating
 CC hyperproliferative diseases and disorders associated with ligand-
 CC dependent FGFR signaling, such as vision disorders (e.g. neovascular
 CC glaucoma, macular degeneration and proliferative retinopathy including
 CC diabetic retinopathy), and non-neoplastic angiogenic pathologic
 CC conditions (e.g. haemangiomas, angiofibromas and psoriasis). The present
 CC sequence is given in the exemplification of the present invention.
 XX
 SQ Sequence 119 AA;
 Query Match 100.0%; Score 502; DB 6; Length 119;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFTSSYVAISWVRQAPGGLEWMGGIPIFGTANY 60
 Db 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFTSSYVAISWVRQAPGGLEWMGGIPIFGTANY 60
 QY 61 AQKFGQVRVITADESTSTAYMELSSLSRSEDYAVYYCAR 98
 Db 61 AQKFGQVRVITADESTSTAYMELSSLSRSEDYAVYYCAR 98
 RESULT 27
 ADG74370
 ID ADG74370 standard; protein; 119 AA.
 XX
 XX ADG74370;
 AC
 XX

```
DT 11-MAR-2004 (first entry)
DE MSPRO heavy chain variable region protein, SEQ ID NO 107.
XX
XX
XX antigen binding; receptor protein tyrosine kinase;
XX fibroblast growth factor receptor 3; FGFR3; osteopathic; cytostatic;
XX neurotropic; neuroprotective; ophthalmological; antidiabetic; gene therapy;
XX bone; cartilage; craniosynostosis; skeletal dysplasia;
XX cell proliferative disorder; haematopoietic malignancy;
XX hyperproliferative disorder; neurovascular glaucoma;
XX macular degeneration; proliferative retinopathy; diabetic retinopathy;
XX MSPRO.
XX
XX Unidentified.
XX
XX WO2002102972-A2.
XX
XX 27-DEC-2002.
XX
XX 20-JUN-2002; 2002WO-IL000494.
XX
XX 20-JUN-2001; 2001US-0299187P.
XX
XX (PROC-) PROCHON BIOTECH LTD.
XX (MORP-) MORPHOSYS AG.
XX
XX Yayon A, Rom E, Thomassen-Wolf E, Borges E;
XX WPI; 2003-175235/17.
XX
XX New antigen binding portion of an antibody having a specific binding
XX affinity for a receptor protein tyrosine kinase, useful for treating bone
XX PT and cartilage related disorders, cell proliferative or hyperproliferative
XX PT disorders.
XX
XX Claim 52; SEQ ID NO 107; 122pp; English.
XX
XX The invention relates to a novel molecule comprising the antigen binding
XX portion of an isolated antibody having a specific binding affinity for a
XX receptor protein tyrosine kinase, and which blocks constitutive
XX activation of a receptor protein tyrosine kinase, such as fibroblast
XX growth factor receptor 3 (FGFR3). The novel molecules of the invention
XX have the following activities: osteopathic, cytostatic, neurotropic,
XX neuroprotective, ophthalmological, and antidiabetic. The nucleic acids
XX encoding the novel molecules of the invention can be used in gene therapy
XX to treat disorders. The molecule and nucleic acid molecules are useful
XX for treating bone and cartilage related disorders such as
XX craniosynostosis (e.g. Muenke coronal craniosynostosis or Crouzon
XX syndrome with acanthosis nigricans), or skeletal dysplasia (e.g.
XX achondroplasia, thanatophoric dysplasia (TD), hypochondroplasia, severe
XX achondroplasia with developmental delay and acanthosis nigricans (SADDAN)
XX dysplasia), cell proliferative disorders, haematopoietic malignancy (e.g.
XX multiple myeloma), hyperproliferative disorders, neurovascular glaucoma,
XX macular degeneration or proliferative retinopathy including diabetic
XX retinopathy. This sequence represents an MSPRO antibody heavy chain
XX variable region peptide relating to the invention.
XX
XX Sequence 119 AA;
XX
XX Query Match 100.0%; Score 502; DB 7; Length 119;
XX Best Local Similarity 100.0%; Pred. No. 1.2e-39;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGIIPIFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGIIPIFGTANY 60
QY 61 AQKFGQGVTTITADESTSTAYMELSLRSEDATVYYCAR 98
Db 61 AQKFGQGVTTITADESTSTAYMELSLRSEDATVYYCAR 98
XX
XX RESULT 28
```

```
Db      61  QVQLVQSGAEVKPGSSVKVCKASGTFSSVAISWVRQAPGQGLEWMGIIPIFGTANY 98
      |||
      61  AQKFGQGRVTITADESTSTAYMELSLRSEDSTAVYYCAR 98
      |||
      61  AQKFGQGRVTITADESTSTAYMELSLRSEDSTAVYYCAR 98
      |||

RESULT 29
ADM38825
ID  ADM38825 standard; protein; 119 AA.
XX
AC  ADM38825;
XX
DT  24-MAR-2005 (first entry)
XX
DE  T-cell mediated disease treatment-related VH protein SeqID23.
XX
KW  inflammation; autoimmune disease; FGF3 receptor antagonist;
KW  fibroblast growth factor receptor 3; FGFR3; antiinflammatory;
KW  immunosuppressive; antiarthritic; antirheumatic; neuroprotective;
KW  dermatological; antiporiatic; antidiabetic; antithyroid;
KW  gastrointestinal-gen.; antilucer; rheumatoid arthritis;
KW  multiple sclerosis; systemic lupus erythematosus; psoriasis;
KW  Sjogren's disease; thyroid disease; sarcoidosis; uveitis;
KW  inflammatory bowel disease; Crohns disease; ulcerative colitis;
KW  celiac disease; myasthenia gravis.
XX
OS  Homo sapiens.
XX
PN  WO2004110487-A1.
XX
PD  23-DEC-2004.
XX
PF  17-JUN-2004; 2004WO-IL000528.
XX
PR  17-JUN-2003; 2003IL-00156495.
XX
PR  30-JUL-2003; 2003US-0490961P.
XX
PA  (PROC-) PROCHON BIOTECH LTD.
XX
PI  Yayon A;
XX
DR  WPI; 2005-039989/04.
XX
DR  N-PSDB; ADM38863.
XX
PT  Preventing or treating a T cell mediated inflammatory or autoimmune
PT  disease such as rheumatoid arthritis, comprises administering a
PT  fibroblast growth factor receptor 3 inhibitor.
XX
PS  Claim 9; SEQ ID NO 23; 77pp; English.
XX
CC  This invention relates to a novel method of preventing or treating a T-
CC  cell mediated inflammatory or autoimmune disease, which involves
CC  administering at least one fibroblast growth factor receptor 3 (FGFR3)
CC  inhibitor and a carrier to an individual. The invention antiinflammatory,
CC  immunosuppressive, antiarthritic, antirheumatic, neuroprotective,
CC  dermatological, antiporiatic, antidiabetic, antithyroid,
CC  gastrointestinal-gen. or antilucer activity acting as FGF3 receptor
CC  antagonists. The method is useful for preventing or treating a T-cell
CC  mediated inflammatory or autoimmune disease, chosen from rheumatoid
CC  arthritis, collagen II arthritis, multiple sclerosis, systemic lupus
CC  erythematosus, psoriasis, juvenile onset diabetes, Sjogrens disease,
CC  thyroid disease, sarcoidosis, autoimmune uveitis, inflammatory bowel
CC  disease (Crohns and ulcerative colitis), celiac disease and myasthenia
CC  gravis. The disease treated is especially rheumatoid arthritis. The
CC  present sequence is that of a VH protein which was used in the method of
CC  the invention.
XX
SQ  Sequence 119 AA;

Query Match      100.0%; Score 502; DB 9; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  QVQLVQSGAEVKPGSSVKVCKASGTFSSVAISWVRQAPGQGLEWMGIIPIFGTANY 60
      |||
      1  QVQLVQSGAEVKPGSSVKVCKASGTFSSVAISWVRQAPGQGLEWMGIIPIFGTANY 60
      |||
      1  QVQLVQSGAEVKPGSSVKVCKASGTFSSVAISWVRQAPGQGLEWMGIIPIFGTANY 60
      |||

RESULT 31
ABJ18672
ID  ABJ18672 standard; protein; 120 AA.
XX
AC  ABJ18672;
XX
DT  06-MAR-2003 (first entry)
XX
DE  Antibody library related heavy variable chain protein region SEQ ID No 1.
XX
KW  Library; recombinant antibody; clustering variable region; in silico;

Query Match      100.0%; Score 502; DB 9; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  QVQLVQSGAEVKPGSSVKVCKASGTFSSVAISWVRQAPGQGLEWMGIIPIFGTANY 60
      |||
      1  QVQLVQSGAEVKPGSSVKVCKASGTFSSVAISWVRQAPGQGLEWMGIIPIFGTANY 60
      |||
      1  QVQLVQSGAEVKPGSSVKVCKASGTFSSVAISWVRQAPGQGLEWMGIIPIFGTANY 60
      |||
      61  AQKFGQGRVTITADESTSTAYMELSLRSEDSTAVYYCAR 98
      |||
      61  AQKFGQGRVTITADESTSTAYMELSLRSEDSTAVYYCAR 98
      |||

RESULT 30
AAW27550
ID  AAW27550 standard; protein; 120 AA.
XX
AC  AAW27550;
XX
DT  23-JAN-1998 (first entry)
XX
DE  Human Ab heavy chain variable region VH1A consensus.
XX
KW  Human; antibody; preparation; library; VH1A; variable region;
KW  heavy chain; consensus.
XX
OS  Homo sapiens.
XX
PN  WO9708320-A1.
XX
PD  06-MAR-1997.
XX
PF  19-AUG-1996; 96WO-EP003647.
XX
PR  18-AUG-1995; 95EP-00113021.
XX
PA  (MORP-) MORPHOSYS GES PROTEINOPTIMIERUNG MBH.
XX
PI  Knappik A, Pack P, Ilag V, Ge L, Moroney S, Plueckthun A;
XX
DR  WPI; 1997-179277/16.
XX
DR  N-PSDB; AAT87948.
XX
PT  Preparation of human derived antibody gene library - using synthetic
PT  consensus sequences, and signal consensus antibody gene as universal
PT  framework for highly diverse antibody libraries.
XX
PS  Example 1; Fig 5A; 436pp; English.
XX
CC  The present sequence is the human antibody heavy chain variable region
CC  synthetic sequence VH1A, used in the preparation of a human derived
CC  antibody gene library
XX
SQ  Sequence 120 AA;

Query Match      100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  QVQLVQSGAEVKPGSSVKVCKASGTFSSVAISWVRQAPGQGLEWMGIIPIFGTANY 60
      |||
      1  QVQLVQSGAEVKPGSSVKVCKASGTFSSVAISWVRQAPGQGLEWMGIIPIFGTANY 60
      |||
      1  QVQLVQSGAEVKPGSSVKVCKASGTFSSVAISWVRQAPGQGLEWMGIIPIFGTANY 60
      |||
      61  AQKFGQGRVTITADESTSTAYMELSLRSEDSTAVYYCAR 98
      |||
      61  AQKFGQGRVTITADESTSTAYMELSLRSEDSTAVYYCAR 98
      |||

RESULT 31
ABJ18672
ID  ABJ18672 standard; protein; 120 AA.
XX
AC  ABJ18672;
XX
DT  06-MAR-2003 (first entry)
XX
DE  Antibody library related heavy variable chain protein region SEQ ID No 1.
XX
KW  Library; recombinant antibody; clustering variable region; in silico;
```

immunogenecity; antibody therapeutic.
 Unidentified.
 WO200284277-A1.
 24-OCT-2002.
 17-APR-2002; 2002WO-US012202.
 17-APR-2001; 2001US-0284407P.
 (ABMA-) ABMAXIS INC.
 Luo P;
 WPI; 2003-093043/08.
 Constructing a library of recombinant antibodies useful as source of antibody candidates for screening antigens comprises clustering variable regions of antibodies having known 3-dimensional structures into structural ensembles.
 Disclosure; Page 98-99; 119pp; English.
 The invention relates to a novel method for the construction of a library of recombinant antibodies. The novel method comprises clustering variable regions of a collection of antibodies having known 3D structures into at least two families of structural ensembles, each comprising at least two different antibody sequences but with substantially identical main chain conformations. The method is useful for constructing a library of artificial antibodies in silico which provides a structurally diverse and yet functionally more relevant source of antibody candidates which can then be screened for binding a wide variety of target molecules, including small molecules, and biomacromolecules such as proteins, peptides and nucleic acids. The libraries constructed are useful as a source of antibody candidates for further screening for novel antibodies with high affinity against a wide range of antigens and having no or minimum immunogenicity to human subjects treated with antibody therapeutics. This sequence represents a protein region of an antibody relating to the novel antibody library construction method of the invention

Query Match 100.0%; Score 502; DB 6; Length 120;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGSSVKVSKASGCTFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60
 DB 1 QVOLVSGAEVKKPGSSVKVSKASGCTFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60
 QY 61 AQKFGQRTVITADESTAYMELSSLRSEDTAVYYCAR 98
 DB 61 AQKFGQRTVITADESTAYMELSSLRSEDTAVYYCAR 98

RESULT 32
 ABJ18718
 ID ABJ18718 standard; protein; 120 AA.
 AC ABJ18718;
 XX
 XX 06-MAR-2003 (first entry)
 DT
 XX Antibody library related VH protein region 1DHA.
 DE
 XX Library; recombinant antibody; clustering variable region; in silico;
 KW immunogenecity; antibody therapeutic.
 XX
 OS Unidentified.
 XX

PN WO200284277-A1.
 XX 24-OCT-2002.
 XX 17-APR-2002; 2002WO-US012202.
 PF 17-APR-2001; 2001US-0284407P.
 XX (ABMA-) ABMAXIS INC.
 PA Luo P;
 XX WPI; 2003-093043/08.
 PI Constructing a library of recombinant antibodies useful as source of
 XX antibody candidates for screening antigens comprises clustering variable
 PT regions of antibodies having known 3-dimensional structures into
 PT structural ensembles.
 PT Disclosure; Fig 13B; 119pp; English.
 PS The invention relates to a novel method for the construction of a library
 XX of recombinant antibodies. The novel method comprises clustering variable
 CC regions of a collection of antibodies having known 3D structures into at
 CC least two families of structural ensembles, each comprising at least two
 CC different antibody sequences but with substantially identical main chain
 CC conformations. The method is useful for constructing a library of
 CC artificial antibodies in silico which provides a structurally diverse and
 CC yet functionally more relevant source of antibody candidates which can
 CC then be screened for binding a wide variety of target molecules,
 CC including small molecules, and biomacromolecules such as proteins,
 CC peptides and nucleic acids. The libraries constructed are useful as a
 CC source of antibody candidates for further screening for novel antibodies
 CC with high affinity against a wide range of antigens and having no or
 CC minimum immunogenicity to human subjects treated with antibody
 CC therapeutics. This sequence represents a protein region of an antibody
 CC relating to the novel antibody library construction method of the
 CC invention

Query Match 100.0%; Score 502; DB 6; Length 120;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGSSVKVSKASGCTFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60
 DB 1 QVOLVSGAEVKKPGSSVKVSKASGCTFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60
 QY 61 AQKFGQRTVITADESTAYMELSSLRSEDTAVYYCAR 98
 DB 61 AQKFGQRTVITADESTAYMELSSLRSEDTAVYYCAR 98

RESULT 32
 ADA89182
 ID ADA89182 standard; protein; 122 AA.
 XX
 AC ADA89182;
 XX
 XX 20-NOV-2003 (first entry)
 DT
 XX Human antibody 1D7 heavy chain amino acid sequence SEQ ID NO:26.
 DE
 XX immunoglobulin; Ig; heavy chain variable domain;
 KW light chain variable domain; major histocompatibility complex; MHC;
 KW gp100; MUC1; TAX; hTERT; cytostatic; gene therapy; cancerous disorder;
 XX cancer.
 XX Synthetic.
 OS Homo sapiens.
 XX
 OS
 XX WO2003070752-A2.
 PN

XX	28-AUG-2003.	XX	KW	Ang-2; angiotensin-2; anorectic; cytostatic; antiarteriosclerotic;
PD		XX	KW	gynaecological; antiinflammatory; osteopathic; antipsoriatic; cancer;
XX	20-FEB-2003; 2003WO-US005128.	XX	KW	angiogenesis; antibody.
PF		XX	OS	Homo sapiens.
XX	20-FEB-2002; 2002US-0358994P.	XX	XX	
XX		XX	FH	Key
XX	(DYAX-) DYAX CORP.	XX	FT	Location/Qualifiers
PA	(TECR) TECHNION RES & DEV FOUND LTD.	XX	FT	26..36
XX		XX	FT	/note= "complementarity determining region (CDR) 1"
XX	Hoogenboom HRJM, Reiter Y;	XX	FT	50..66
XX		XX	FT	/note= "complementarity determining region (CDR) 2"
XX	WPI: 2003-663847/62.	XX	FT	96..113
XX	N-PSDB; ADA89181.	XX	FT	/note= "complementarity determining region (CDR) 3"
XX		XX	PN	WO2003030833-A2.
XX	New protein comprising an immunoglobulin heavy chain variable (VH) domain	XX	XX	
XX	and an immunoglobulin light chain variable (VL) domain, useful for	XX	PD	
PT	preparing a composition for treating or preventing a cancerous disorder.	XX	PD	17-APR-2003.
XX		XX	XX	
XX	Disclosure; Fig 5B; 224pp; English.	XX	XX	11-OCT-2002; 2002WO-US032613.
XX		XX	XX	
XX	The present invention describes a protein comprising an immunoglobulin	XX	XX	11-OCT-2001; 2001US-0328604P.
XX	(Ig) heavy chain variable (VH) domain and an Ig light chain variable (VL)	XX	PR	10-OCT-2002; 2002US-00269805.
XX	domain. The protein binds a complex comprising a major histocompatibility	XX	XX	(AMGE-) AMGEN INC.
XX	complex (MHC) and a peptide, does not substantially bind the MHC in the	XX	PA	
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	XX	Oliner JD;
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	PI	
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	XX	WPI; 2003-504963/47.
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	DR	
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	XX	New specific binding agents (i.e. anti-Angiotensin-2 antibodies), useful
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	PT	for inhibiting undesired angiogenesis, or treating e.g. cancers, obesity,
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	PT	hemangioma, arteriosclerosis, atherosclerosis or endometriosis.
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	XX	
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	PS	Claim 1; Page 91; 161pp; English.
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	XX	The invention relates to a specific binding agent, which comprises at
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	least one peptide selected from any of 62 peptides (ABR55769-830) or its
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	fragment. The binding agents are antibodies that recognize and bind to
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	angiotensin-2 (Ang-2). The specific binding agent, particularly the
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	antibody, is useful for inhibiting undesired angiogenesis, treating
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	cancers, inhibiting undesired angiogenesis, modulating or inhibiting Ang-
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	2 activity, modulating vascular permeability or plasma leakage, or
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	treating a disease (e.g. ocular neovascular disease, obesity,
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	haemangioblastoma, haemangioma, arteriosclerosis, inflammatory disease,
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	inflammatory disorders, atherosclerosis, endometriosis, neoplastic
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	disease, bone-related disease, or psoriasis) in a mammal. The present
XX	absence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	sequence represents a heavy chain variable region of an anti-Ang-2
XX	presence of the bound peptide, and does not substantially bind the MHC in the	XX	CC	antibody
XX		XX	XX	
SQ	Sequence 122 AA;	XX	SQ	Sequence 123 AA;
	Query Match 100.0%; Score 502; DB 6; Length 122;			Query Match 100.0%; Score 502; DB 6; Length 123;
	Best Local Similarity 100.0%; Pred. No. 1.2e-39;			Best Local Similarity 100.0%; Pred. No. 1.2e-39;
	Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 QVQLVSGAEVKPGSSVKVSKASGTFSSYAISWVRQAPGQGLEWMGIIPIFTANY 60	QY	1 QVQLVSGAEVKPGSSVKVSKASGTFSSYAISWVRQAPGQGLEWMGIIPIFTANY 60	
DB	1 QVQLVSGAEVKPGSSVKVSKASGTFSSYAISWVRQAPGQGLEWMGIIPIFTANY 60	DB	1 QVQLVSGAEVKPGSSVKVSKASGTFSSYAISWVRQAPGQGLEWMGIIPIFTANY 60	
QY	61 AOKFQGRVTITADESTAYMELSSLRSEDTAVYYCAR 98	QY	61 AOKFQGRVTITADESTAYMELSSLRSEDTAVYYCAR 98	
DB	61 AOKFQGRVTITADESTAYMELSSLRSEDTAVYYCAR 98	DB	61 AOKFQGRVTITADESTAYMELSSLRSEDTAVYYCAR 98	
	RESULT 34			RESULT 35
	ABR55771			ADZ41974
XX	ABR55771 standard; protein; 123 AA.	XX	ID	ADZ41974 standard; peptide; 123 AA.
XX		XX	XX	
XX	ABR55771;	XX	AC	ADZ41974;
XX		XX	XX	
DT	02-SEP-2003 (first entry)	XX	DT	30-JUN-2005 (first entry)
XX		XX	XX	
DE	Heavy chain variable region of anti-Ang-2 antibody 528 HC.	DE	XX	Ig H chain variable region, B-CLL set IV peptide #6.

XX Antibody; antibody engineering; antibody therapy;
 KW light chain variable region; heavy chain variable region;
 KW chronic lymphocytic leukemia; cytostatic; Hodgkins disease; lymphoma;
 KW Burkitts lymphoma; multiple myeloma; systemic lupus erythematosus;
 KW antinflammatory; dermatological; immunosuppressive; myasthenia gravis;
 KW muscular-gen.; neuroprotective; Graves disease; antithyroid;
 KW insulin dependent diabetes; diabetes mellitus; antidiabetic;
 KW autoimmune hemolytic anemia; antianemic.
 XX Homo sapiens.
 XX WO2005034733-A2.
 XX 21-APR-2005.
 XX 08-OCT-2004; 2004WO-US033176.
 XX 08-OCT-2003; 2003US-0509473P.
 XX (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.
 XX Messner BT, Chiorazzi N, Albesiano E;
 XX WPI; 2005-306220/31.
 XX New isolated and purified preparation of light chain and heavy chain
 PT antibody genes, useful for diagnosing, preventing or treating B cell
 PT chronic lymphocytic leukemia, or in screening for agents that may treat
 PT such disease.
 XX Disclosure; Fig 2; 58pp; English.
 XX The new invention relates to combinations of light chain antibody genes
 CC and heavy chain antibody genes, useful for treating B cell chronic
 CC lymphocytic leukemia (B-CLL). B-CLL is a disease of slowly proliferating
 CC CD5+ B lymphocytes. These cells express low levels of surface membrane Ig
 CC that serves as the receptor for antigen (BCR). Analysis of V region gene
 CC cassette usage has shown that distribution of variable region gene
 CC cassettes used by B-CLL clones differs from that in normal cells, with an
 CC increased frequency of VH3-07, VH4-34, and VH1-69 genes. This implies
 CC that the structure of the antibody molecule, and antigen specificity,
 CC play a role in the leukemic transformation of particular B cells. The
 CC present invention discloses that a significant proportion of B-CLL
 CC patients with aggressive disease share the same classes of VH, D, JH, VL
 CC and Jb antibody genes, forming sets of patients with highly homologous B
 CC cell receptors. Alternatively, the patients have a disorder selected from
 CC Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, myeloma or
 CC systemic lupus erythematosus, myasthenia gravis, Grave's disease, type I
 CC diabetes mellitus, autoimmune peripheral neuropathy, and autoimmune
 CC hemolytic anemia. The new members of the antibody genes are: VH4-39/D6-
 CC 13/JH5/VLkappaO12/2/Jkappa1/kappa2 (Set I); VH4-34/D5-
 CC 5/JH6/VLkappaA17/JLkappa1/kappa2 (Set II); VH3-
 CC 21/JH6/VLlambdab3h/JLlambdab3 (Set III); VH1-69/D3-
 CC 16/JH3/VLkappaA27/JLkappa1/kappa4 (Set IV); VH1-69/D3-
 CC 10/JH6/VLlambdab1c/JLlambdab1 (Set V); VH1-02/D6-
 CC 19/JH4/VLkappaO12/2/Jkappa1/kappa2 (Set VIa); VH1-03/D6-
 CC 19/JH4/VLkappaO12/2/Jkappa1/kappa2 (Set VIb); VH1-18/D6-
 CC 19/JH4/VLkappaO12/2/Jkappa1/kappa2 (Set VIc); VH1-46/D6-19/JH4
 CC 51/D6-19/JH4/VLkappaO12/2/JLkappa2 (Set VId); VH5-
 CC 3/JH4/VLkappaA19/JLkappa4 (Set VIe); and VH1-69/D3-
 CC 2/JH6/VLkappaL6/2/JLkappa3 (Set VII). Treating a patient having B-CLL
 CC with the above genes comprises administering an agent that binds to the
 CC antigen-binding region of an antibody encoded by the antibody genes. The
 CC agent is an anti-idiotypic antibody, a peptide antigen, or an aptamer. The
 CC present sequence is an Ig H chain variable region, B-CLL set IV peptide.
 XX Sequence 123 AA;

Query Match 100.0%; Score 502; DB 9; Length 123;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTSSVAISWVRQAPGQGLEWMGGIIPIFGTANY 60
 DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTSSVAISWVRQAPGQGLEWMGGIIPIFGTANY 60
 QY 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
 DB 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
 RESULT 36
 ADA89121
 ID ADA89121 standard; protein; 124 AA.
 XX
 AC ADA89121;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE MS-Pro-28-VH amino acid sequence SEQ ID NO:109.
 XX
 KW antigen binding; antibody; specific binding affinity;
 KW receptor protein tyrosine kinase; RPTK;
 KW receptor protein tyrosine kinase inhibitor;
 KW fibroblast growth factor receptor; FGFR; osteopathic; cytostatic;
 KW ophthalmological; bone disorder; cartilage disorder; skeletal disorder;
 KW skeletal dysplasia; achondroplasia; thanatophoric dysplasia;
 KW hypochondroplasia; craniosynostosis disorder;
 KW malignant cell proliferative disease; cancer; tumour; vision disorder;
 KW non-neoplastic angiogenic pathologic condition.
 XX Synthetic.
 OS Homo sapiens.
 XX WO2002102973-A2.
 XX 27-DEC-2002.
 XX 20-JUN-2002; 2002WO-IL000495.
 XX 20-JUN-2001; 2001US-0299187P.
 XX (PROC-) PROCHON BIOTECH LTD.
 PA Yayon A, Rom E;
 PI WPI; 2003-175236/17.
 DR
 XX New antibodies which have specific binding affinity for a receptor,
 PT protein tyrosine kinase (RPTK) and block constitutive activation of RPTK,
 PT useful for treating bone and cartilage disorders, or malignant cell
 PT proliferative diseases.
 XX Claim 52; Page 19; 122pp; English.
 XX
 CC The present invention describes a molecule (I) comprising the antigen
 CC binding portion of an isolated antibody which has specific binding
 CC affinity for a receptor protein tyrosine kinase (RPTK), particularly for
 CC a fibroblast growth factor receptor (FGFR), and which blocks constitutive
 CC activation of an RPTK. Also described: (1) pharmaceutical compositions
 CC comprising (I) as an active ingredient and a pharmaceutical carrier,
 CC excipient, or auxiliary agent; (2) a kit comprising (I), at least one
 CC reagent for detecting the presence of (I) when bound to the RPTK, and
 CC instructions for use; (3) a method for treatment of bone and cartilage
 CC related disorders by administering a composition of (1) to the subject;
 CC (4) a method for treating or inhibiting a cell proliferative disease or
 CC disorder by administering the composition of (1); (5) a method for
 CC screening a molecule comprising the antigen-binding portion of an
 CC antibody which blocks ligand-dependent activation of RPTK; (6) an
 CC isolated nucleic acid molecule encoding a VL-CDR3 DNA region and a VH-
 CC CDR3 DNA region; (7) an isolated nucleic acid molecule encoding VL region
 CC and a VH region; (8) vectors comprising a nucleic acid molecule of (6) or
 CC (7); and (9) host cells transformed with the vector. (I) have
 CC osteopathic, cytostatic and ophthalmological activities, and can be used
 CC as a RPTK inhibitor. Compositions comprising (I) are useful for treating

XX New antigen binding portion of an antibody having a specific binding
PT affinity for a receptor protein tyrosine kinase, useful for treating bone
PT and cartilage related disorders, cell proliferative or hyperproliferative
PT disorders.
XX
XX Claim 52; SEQ ID NO 109; 122pp; English.
PS
XX The invention relates to a novel molecule comprising the antigen binding
CC portion of an isolated antibody having a specific binding affinity for a
CC receptor protein tyrosine kinase, and which blocks constitutive
CC activation of a receptor protein tyrosine kinase, such as fibroblast
CC growth factor receptor 3 (FGFR3). The novel molecules of the invention
CC have the following activities: osteopathic, cytostatic, neurotropic,
CC neuroprotective, ophthalmological, and antidiabetic. The nucleic acids
CC encoding the novel molecules of the invention can be used in gene therapy
CC to treat disorders. The molecule and nucleic acid molecules are useful
CC for treating bone and cartilage related disorders such as
CC craniosynostosis (e.g. Muenke coronal craniosynostosis or Crouzon
CC syndrome with acanthosis nigricans), or skeletal dysplasia (e.g.
CC achondroplasia, thanatophoric dysplasia (TD), hypochondroplasia, severe
CC achondroplasia with developmental delay and acanthosis nigricans (SADDAN)
CC (dysplasia), cell proliferative disorders, haematopoietic malignancy (e.g.
CC multiple myeloma), hyperproliferative disorders, neurovascular glaucoma,
CC macular degeneration or proliferative retinopathy including diabetic
CC retinopathy. This sequence represents an MSPRO antibody heavy chain
CC variable region peptide relating to the invention.
XX
XX Sequence 124 AA;

Query Match 100.0%; Score 502; DB 7; Length 124;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSYSAISWVRQAPGQGLEWMGGIIPFGTANY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSYSAISWVRQAPGQGLEWMGGIIPFGTANY 60
QY 61 AQKQGRVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKQGRVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 39
AAU02555
ID AAU02555 standard; protein; 125 AA.
XX
AC AAU02555;

XX 29-AUG-2001 (first entry)
XX Anti-adipocyte monoclonal antibody heavy chain, FAT 41.
XX Antibody; adipocyte; heavy chain; light chain; obesity; fat;
XX heart disease; complementarity determining region; CDR.
XX Homo sapiens.

XX WO200127279-A1.
XX 19-APR-2001.
XX 11-OCT-2000; 2000WO-GB003900.
XX 12-OCT-1999; 99US-0158812P.
XX (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Edwards BM, Main SH, Vaughan TJ;
XX WPI; 2001-282031/29.
XX N-PSDB; AAS03455.
XX

PT Panel of specific binding members of antibody molecules which bind to
PT whole adipocytes is used in the treatment of obesity and obesity related
PS diseases.
XX Claim 1; Page 127; 182pp; English.
XX
XX AAU02501-AAU02635, and AAU02641-AAU02748 represent the amino acid
CC sequences of anti-adipocyte monoclonal antibody heavy chain, light chain,
CC and heavy chain complementarity determining regions (CDR) of the
CC invention. The antibodies can be used in the treatment of obesity and
CC obesity related diseases. The antibodies can be used to deliver drugs or
CC pro-drugs directly to the fat mass of an obese patient or the antibody
CC can be used as a therapeutic itself. Antibodies binding specifically to
CC adipocytes can be used to activate the immune system to destroy the cells
CC by complement mediated lysis. The antibodies may be labeled with a
CC detectable label such as radiolabel, fluorescent or chemical group and
CC used in methods of diagnosis in human subjects e.g. to determine the
CC presence of adipocyte antigen on the surface of an adipocyte to detect or
CC determine the presence or level of adipocytes in a cell or tissue sample.
CC The antibodies can be used as an alternative means of treatment for obese
CC patients other than undergoing surgery to remove excess fat. Antibodies
CC for different types of fat deposits can also be produced e.g. intra-
CC abdominal fat associated with heart disease
XX
XX Sequence 125 AA;

Query Match 100.0%; Score 502; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSYSAISWVRQAPGQGLEWMGGIIPFGTANY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSYSAISWVRQAPGQGLEWMGGIIPFGTANY 60
QY 61 AQKQGRVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKQGRVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 40
ABR55803
ID ABR55803 standard; protein; 125 AA.
XX
AC ABR55803;

XX 02-SEP-2003 (first entry)
XX Heavy chain variable region of anti-Ang-2 antibody 565 HC.
XX Ang-2; angiopoietin-2; anorectic; cytostatic; antiarteriosclerotic;
XX gynaecological; antiinflammatory; osteopathic; antipsoriatic; cancer;
XX angiogenesis; antibody.

XX Homo sapiens.
XX Key Location/Qualifiers
XX Region 25..36
XX /note= "complementarity determining region (CDR) 1"
XX Region 50..66
XX /note= "complementarity determining region (CDR) 2"
XX Region 96..115
XX /note= "complementarity determining region (CDR) 3"
XX WO2003030833-A2.
XX 17-APR-2003.
XX 11-OCT-2002; 2002WO-US032613.
XX 11-OCT-2001; 2001US-0328604P.
XX 10-OCT-2002; 2002US-00269805.
XX (AMGE-) AMGEN INC.

```

XX
PI Oliner JD;
XX
DR
XX
DR WPI; 2003-504963/47.
XX
PT New specific binding agents (i.e. anti-Angiopietin-2 antibodies), useful
PT for inhibiting undesired angiogenesis, or treating e.g. cancers, obesity,
PT hemangioma, arteriosclerosis, atherosclerosis or endometriosis.
XX
XX
PS Claim 1; Page 92; 161pp; English.
XX
XX The invention relates to a specific binding agent, which comprises at
XX least one peptide selected from any of 62 peptides (ABR55769-830) or its
XX fragment. The binding agents are antibodies that recognize and bind to
XX angiotensin-2 (Ang-2). The specific binding agent, particularly the
XX antibody, is useful for inhibiting undesired angiogenesis, treating
XX cancers, inhibiting undesired angiogenesis, modulating or inhibiting Ang-
XX 2 activity, modulating vascular permeability or plasma leakage, or
XX treating a disease (e.g. ocular neovascular disease, obesity,
XX haemangioblastoma, haemangioma, arteriosclerosis, inflammatory disease,
XX inflammatory disorders, atherosclerosis, endometriosis, neoplastic
XX disease, bone-related disease, or psoriasis) in a mammal. The present
XX sequence represents a heavy chain variable region of an anti-Ang-2
XX antibody
XX
SQ Sequence 125 AA;
XX
Query Match 100.0%; Score 502; DB 6; Length 125;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGVITTADESTSTAYMELSLRSEDTAVYYCAR 98
DB 61 AQKFGQGVITTADESTSTAYMELSLRSEDTAVYYCAR 98
RESULT 41
ADA90117
XX
AC ADA90117;
XX
XX 20-NOV-2003 (first entry)
XX
DE Anti-Abeta antibody related amino acid sequence SEQ ID NO:232.
XX
XX antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
XX neurotropic; antiparkinsonian; gene therapy; amyloidogenesis;
XX amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
XX Alzheimer's disease; motor neuropathy; Down's syndrome;
XX Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
XX Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
XX neuronal disorder; aging.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO2003070760-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-EP001759.
XX
XX 20-FEB-2002; 2002EP-00003844.
XX
XX (HOFF ) HOFFMANN LA ROCHE & CO AG F.
XX
PA (MORP-) MORPHOSYS AG.
XX
XX Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretschmar T;

```

```

PI Loehning C, Loetscher H, Nordstedt C, Rothe C;
XX
DR WPI; 2003-663848/62.
XX
PT New antibody molecule capable of specifically recognizing two regions of
PT the beta-A4 peptide, useful for diagnosing, preventing or treating
PT diseases associated with amyloidogenesis or amyloid-plaque formation
PT (e.g. dementia).
XX
XX Disclosure; Page 228-229; 312pp; English.
XX
XX The present invention describes an antibody molecule (I) capable of
XX specifically recognising two regions of the beta-A4 peptide/Abeta4. The
XX first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-
XX Ser-Gly-Tyr ADA8986 or its fragment, and the second region comprises the
XX amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
XX Gly ADA8987 or its fragment. Also described: (1) a nucleic acid molecule
XX encoding (1); (2) a vector comprising the nucleic acid of (1); (3) a host
XX cell comprising the vector of (2); (4) preparing (1), comprising
XX culturing the host cell of (3) under conditions that allow synthesis of
XX (1) and recovering (1) from the culture; (5) a composition comprising (1)
XX or an antibody molecule produced by method (4); (6) a kit comprising (1),
XX nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
XX (1); (8) testing the resulting Fab optimisation library by panning
XX against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
XX of selected, optimised clones; (11) preparing a pharmaceutical
XX composition, comprising optimisation of (1), and formulating the
XX optimised antibody/antibody molecule with a carrier; and (12) a
XX pharmaceutical composition prepared by method (8). (1) has
XX used in gene therapy. The antibody molecule (I), nucleic acid molecule,
XX vector or host is useful in preparing a pharmaceutical composition for
XX the prevention and/or treatment of a disease associated with
XX amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
XX may also be used in preparing a diagnostic composition for the detection
XX of the disease mentioned above. The antibody is used for the
XX disintegration of beta-amyloid plaques or for passive immunisation
XX against beta-amyloid plaque formation. In particular, the disease is
XX dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
XX Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
XX amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,
XX amyotrophic lateral sclerosis or neuronal disorders related to aging. The
XX present sequence is used in the exemplification of the present invention.
XX
SQ Sequence 127 AA;
XX
Query Match 100.0%; Score 502; DB 6; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.2e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGVITTADESTSTAYMELSLRSEDTAVYYCAR 98
DB 61 AQKFGQGVITTADESTSTAYMELSLRSEDTAVYYCAR 98
RESULT 42
AAO31082
XX
XX AAO31082 standard; protein; 127 AA.
XX
XX AAO31082;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human antibody VH1A protein.
XX
XX Human; antibody; stem cell factor; mast cell growth factor; asthma; SCF;
XX steel factor; c-kit ligand; gene therapy; heavy chain variable domain;
XX VH.
XX

```

OS Homo sapiens.

XX Key Location/Qualifiers

FT Region 1..25 "Framework region (FR) 1"

FT Region /note= "Encoded by NNN"

FT Region 26..35 "Framework region (FR) 2"

FT Region /note= "Encoded by NNN"

FT Region 36..49 "Framework region (FR) 3"

FT Region /note= "Encoded by NNN"

FT Region 50..66 "Framework region (FR) 4"

FT Region /note= "Encoded by NNN"

FT Region 67..98 "Framework region (FR) 5"

FT Region /note= "Encoded by NNN"

FT Region 99..106 "Framework region (FR) 6"

FT Region /note= "Encoded by NNN"

FT Misc-difference 99 /note= "Encoded by NNN"

FT Misc-difference 100 /note= "Encoded by NNN"

FT Misc-difference 101 /note= "Encoded by NNN"

FT Misc-difference 102 /note= "Encoded by NNN"

FT Misc-difference 103 /note= "Encoded by NNN"

FT Misc-difference 104 /note= "Encoded by NNN"

FT Misc-difference 105 /note= "Encoded by NNN"

FT Misc-difference 106 /note= "Encoded by NNN"

FT Misc-difference 107 /note= "Encoded by NNN"

FT Region 107..127 "Framework region (FR) 4"

FT Misc-difference 107 /note= "Encoded by NNN"

FT Misc-difference 108 /note= "Encoded by NNN"

FT Misc-difference 109 /note= "Encoded by NNN"

FT Misc-difference 110 /note= "Encoded by NNN"

FT Misc-difference 111 /note= "Encoded by NNN"

FT Misc-difference 112 /note= "Encoded by NNN"

FT Misc-difference 113 /note= "Encoded by NNN"

FT Misc-difference 114 /note= "Encoded by NNN"

FT Misc-difference 116 /note= "Encoded by NNN"

XX WO2003051311-A2.

XX 26-JUN-2003.

XX 16-DEC-2002; 2002WO-US040227.

XX 17-DEC-2001; 2001US-0342174P.

XX (FARB) BAYER CORP.

XX Takeuchi T, Tomkinson A, Neben S;

XX WPI; 2003-523500/49.

DR N-PSDB; AAL62598.

XX New purified human antibody that binds to stem cell factor protein,

PT useful for preparing a composition for treating asthma.

PS Example 1; Page 26-28; 94pp; English.

XX The invention provides human antibodies that bind to stem cell factor

CC (SCF) protein. SCF is also known as mast cell growth factor, steel factor or c-kit ligand. Antibodies of the invention are useful for preparing compositions for treating asthma. They are also used in gene therapy. The present sequence is human antibody VH1A (heavy chain variable domain) protein

XX SQ Sequence 127 AA;

Query Match 100.0%; Score 502; DB 6; Length 127;

Best Local Similarity 100.0%; Pred. No. 1.2e-39; Indels 0; Gaps 0;

Matches 98; Conservative 0; Mismatches 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFTSSVAISWVRQAPGQGLEWMGGIIPFGTANY 60

Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFTSSVAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQVRVITADESTSTAYMELSLRSEDVTAVYCAR 98

Db 61 AQKFGQVRVITADESTSTAYMELSLRSEDVTAVYCAR 98

RESULT 43

ADZ41983

ID ADZ41983 standard; peptide; 127 AA.

XX AC ADZ41983;

XX DT 30-JUN-2005 (first entry)

XX DE Ig H chain variable region, B-CLL set V peptide #2.

XX KW Antibody; antibody engineering; antibody therapy;

XX KW light chain variable region; heavy chain variable region;

XX KW chronic lymphocytic leukemia; cytostatic; Hodgkins disease; lymphoma;

XX KW Burkitts lymphoma; multiple myeloma; systemic lupus erythematosus;

XX KW antiinflammatory; dermatological; immunosuppressive; myasthenia gravis;

XX KW muscular-gen.; neuroprotective; Graves disease; antithyroid;

XX KW insulin dependent diabetes; diabetes mellitus; antidiabetic;

XX KW autoimmune hemolytic anemia; antianemic.

XX OS Homo sapiens.

XX WO2005034733-A2.

XX 21-APR-2005.

XX 08-OCT-2004; 2004WO-US033176.

XX 08-OCT-2003; 2003US-0509473P.

XX (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.

XX Messmer BT, Chiorazzi N, Albesiano E;

XX WPI; 2005-306220/31.

XX New isolated and purified preparation of light chain and heavy chain antibody genes, useful for diagnosing, preventing or treating B cell chronic lymphocytic leukemia, or in screening for agents that may treat such disease.

XX Disclosure; Fig 2; 58pp; English.

XX The new invention relates to combinations of light chain antibody genes and heavy chain antibody genes, useful for treating B cell chronic lymphocytic leukemia (B-CLL). B-CLL is a disease of slowly proliferating CD5+ B lymphocytes. These cells express low levels of surface membrane Ig that serves as the receptor for antigen (BCR). Analysis of V region gene cassette usage has shown that distribution of variable region gene cassettes used by B-CLL clones differs from that in normal cells, with an increased frequency of VH3-07, VH4-34, and VH1-69 genes. This implies that the structure of the antibody molecule, and antigen specificity, CC play a role in the leukemic transformation of particular B cells. The

CC present invention discloses that a significant proportion of B-CLL
 CC patients with aggressive disease share the same classes of VH, D, JH, VL
 CC and JH antibody genes, forming sets of patients with highly homologous B
 CC cell receptors. Alternatively, the patients have a disorder selected from
 CC Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, myeloma or
 CC systemic lupus erythematosus, myasthenia gravis, Grave's disease, type I
 CC diabetes mellitus, autoimmune peripheral neuropathy, and autoimmune
 CC hemolytic anemia. The new members of the antibody genes are: VH4-39/D6-
 CC 13/JH6/VLkappaA17/JLkappa1/kappa2 (Set I); VH4-34/D5-
 CC 21/JH6/VLlambdab3h/JLlambdab3 (Set III); VH1-69/D3-
 CC 16/JH3/VLlambdab3h/JLlambdab3 (Set IV); VH1-69/D3-
 CC 10/JH6/VLlambdab3h/JLlambdab3 (Set V); VH1-02/D6-
 CC 19/JH4/VLkappaA17/JLkappa1/kappa2 (Set VIA); VH1-03/D6-
 CC 19/JH4/VLkappaA17/JLkappa1/kappa2 (Set VIB); VH1-18/D6-
 CC 19/JH4/VLkappaA17/JLkappa1/kappa2 (Set VIC); VH1-46/D6-19/JH4
 CC 51/D6-19/JH4/VLkappaA17/JLkappa1 (Set VIE); VH1-69/D3-
 CC 3/JH4/VLkappaA19/JLkappa4 (Set VII); and VH1-69/D2-
 CC 2/JH6/VLkappaA16/JLkappa3 (Set VIII). Treating a patient having B-CLL
 CC with the above genes comprises administering an agent that binds to the
 CC antigen-binding region of an antibody encoded by the antibody genes. The
 CC agent is an anti-idiotypic antibody, a peptide antigen, or an aptamer. The
 CC present sequence is an Ig H chain variable region, B-CLL set V peptide.
 XX Sequence 127 AA;

Query Match 100.0%; Score 502; DB 9; Length 127;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 DB 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 QY 61 AOKFQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98
 DB 61 AOKFQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98

RESULT 44
 AD241988
 ID AD241988 standard; peptide; 127 AA.
 XX AD241988;
 AC AD241988;
 XX 30-JUN-2005 (first entry)
 XX Ig H chain variable region, B-CLL set V peptide #7.
 XX Antibody; antibody engineering; antibody therapy;
 XX light chain variable region; heavy chain variable region;
 XX chronic lymphocytic leukemia; cytostatic; Hodgkins disease; lymphoma;
 XX Burkitts lymphoma; multiple myeloma; systemic lupus erythematosus;
 XX antinflammatory; dermatological; immunosuppressive; myasthenia gravis;
 XX muscular-gen.; neuroprotective; Graves disease; antithyroid;
 XX insulin dependent diabetes; diabetes mellitus; antidiabetic;
 XX autoimmune hemolytic anemia; antianemic.

OS Homo sapiens.
 XX
 XX WO2005034733-A2.
 XX 21-APR-2005.
 XX 08-OCT-2004; 2004WO-US033176.
 XX 08-OCT-2003; 2003US-0509473P.
 XX (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.
 XX Mesemer BT, Chiorazzi N, Albesiano E;
 XX WPI; 2005-306220/31.

XX New isolated and purified preparation of light chain and heavy chain
 PT antibody genes, useful for diagnosing, preventing or treating B cell
 PT chronic lymphocytic leukemia, or in screening for agents that may treat
 PT such disease.

XX Disclosure; Fig 2; 58pp; English.

XX The new invention relates to combinations of light chain antibody genes
 CC and heavy chain antibody genes, useful for treating B cell chronic
 CC lymphocytic leukemia (B-CLL). B-CLL is a disease of slowly proliferating
 CC CD5+ B lymphocytes. These cells express low levels of surface membrane Ig
 CC that serves as the receptor for antigen (BCR). Analysis of V region gene
 CC cassette usage has shown that distribution of variable region gene
 CC increased frequency of VH3-07, VH4-34, and VH1-69 genes. This implies
 CC that the structure of the antibody molecule, and antigen specificity,
 CC play a role in the leukemic transformation of particular B cells. The
 CC present invention discloses that a significant proportion of B-CLL
 CC patients with aggressive disease share the same classes of VH, D, JH, VL
 CC and JH antibody genes, forming sets of patients with highly homologous B
 CC cell receptors. Alternatively, the patients have a disorder selected from
 CC Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, myeloma or
 CC systemic lupus erythematosus, myasthenia gravis, Grave's disease, type I
 CC diabetes mellitus, autoimmune peripheral neuropathy, and autoimmune
 CC hemolytic anemia. The new members of the antibody genes are: VH4-39/D6-
 CC 13/JH5/VLkappaA17/JLkappa1/kappa2 (Set I); VH4-34/D5-
 CC 21/JH6/VLlambdab3h/JLlambdab3 (Set III); VH1-69/D3-
 CC 16/JH3/VLlambdab3h/JLlambdab3 (Set IV); VH1-69/D3-
 CC 10/JH6/VLlambdab3h/JLlambdab3 (Set V); VH1-02/D6-
 CC 19/JH4/VLkappaA17/JLkappa1/kappa2 (Set VIA); VH1-03/D6-
 CC 19/JH4/VLkappaA17/JLkappa1/kappa2 (Set VIB); VH1-18/D6-
 CC 19/JH4/VLkappaA17/JLkappa1/kappa2 (Set VIC); VH1-46/D6-19/JH4
 CC 51/D6-19/JH4/VLkappaA17/JLkappa1 (Set VIE); VH1-69/D3-
 CC 3/JH4/VLkappaA19/JLkappa4 (Set VII); and VH1-69/D2-
 CC 2/JH6/VLkappaA16/JLkappa3 (Set VIII). Treating a patient having B-CLL
 CC with the above genes comprises administering an agent that binds to the
 CC antigen-binding region of an antibody encoded by the antibody genes. The
 CC agent is an anti-idiotypic antibody, a peptide antigen, or an aptamer. The
 CC present sequence is an Ig H chain variable region, B-CLL set V peptide.

XX Sequence 127 AA;

Query Match 100.0%; Score 502; DB 9; Length 127;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 DB 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGQGLEWMGGIPIFGTANY 60
 QY 61 AOKFQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98
 DB 61 AOKFQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98

RESULT 45

AD241987
 ID AD241987 standard; peptide; 127 AA.
 XX AD241987;
 AC AD241987;
 XX 30-JUN-2005 (first entry)
 XX Ig H chain variable region, B-CLL set V peptide #6.

XX Antibody; antibody engineering; antibody therapy;
 KW light chain variable region; heavy chain variable region;
 KW chronic lymphocytic leukemia; cytostatic; Hodgkins disease; lymphoma;
 KW Burkitts lymphoma; multiple myeloma; systemic lupus erythematosus;
 KW antinflammatory; dermatological; immunosuppressive; myasthenia gravis;
 KW muscular-gen.; neuroprotective; Graves disease; antithyroid;

KW insulin dependent diabetes; diabetes mellitus; antidiabetic;
 KW autoimmune hemolytic anemia; antianemic.

OS Homo sapiens.

XX WO2005034733-A2.

XX 21-APR-2005.

XX 08-OCT-2004; 2004WO-US033176.

XX 08-OCT-2003; 2003US-0509473P.

XX (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.

XX Messmer BT, Chiorazzi N, Albesiano E;

XX WPI; 2005-306220/31.

XX New isolated and purified preparation of light chain and heavy chain
 PT antibody genes, useful for diagnosing, preventing or treating B cell
 PT chronic lymphocytic leukemia, or in screening for agents that may treat
 PT such disease.

XX Disclosure; Fig 2; 58pp; English.

XX The new invention relates to combinations of light chain antibody genes
 CC and heavy chain antibody genes, useful for treating B cell chronic
 CC lymphocytic leukemia (B-CLL). B-CLL is a disease of slowly proliferating
 CC CD5+ B lymphocytes. These cells express low levels of surface membrane Ig
 CC that serves as the receptor for antigen (BCR). Analysis of V region gene
 CC cassette usage has shown that distribution of variable region gene
 CC cassettes used by B-CLL clones differs from that in normal cells, with an
 CC increased frequency of VH3-07, VH4-34, and VH1-69 genes. This implies
 CC that the structure of the antibody molecule, and antigen specificity,
 CC play a role in the leukemic transformation of particular B cells. The
 CC present invention discloses that a significant proportion of B-CLL
 CC patients with aggressive disease share the same classes of VH, D, JH, VL
 CC cell receptors. Alternatively, the patients have a disorder selected from
 CC Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, myeloma or
 CC systemic lupus erythematosus, myasthenia gravis, Grave's disease, type I
 CC diabetes mellitus, autoimmune peripheral neuropathy, and autoimmune
 CC hemolytic anemia. The new members of the antibody genes are: VH4-39/D6-

CC 13/JH5/VLkappa012/2/JLkappa1/kappa2 (Set I); VH4-34/D5-
 CC 5/JH6/VLkappaA17/JLkappa1/kappa2 (Set II); VH3-
 CC 21/JH6/VLlambd3h/JLlambd3 (Set III); VH1-69/D3-
 CC 16/JH3/VLkappaA27/JLkappa1/kappa4 (Set IV); VH1-69/D3-
 CC 10/JH6/VLlambdalc/JLlambd1 (Set V); VH1-02/D6-
 CC 19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIa); VH1-03/D6-
 CC 19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIb); VH1-18/D6-
 CC 51/D6-19/JH4/VLkappa012/2/JLkappa2 (Set VIc); VH1-46/D6-19/JH4
 CC 3/JH4/VLkappaA19/JLkappa4 (Set VII); and VH1-69/D2-
 CC 2/JH6/VLkappaL6/2/JLkappa3 (Set VIII). Treating a patient having B-CLL
 CC with the above genes comprises administering an agent that binds to the
 CC antigen-binding region of an antibody encoded by the antibody genes. The
 CC agent is an anti-idiotypic antibody, a peptide antigen, or an aptamer. The
 CC present sequence is an Ig H chain variable region, B-CLL set V peptide.

XX Sequence 127 AA;

Query Match 100.0%; Score 502; DB 9; Length 127;
 Best Local Similarity 100.0%; Pred. No. 1.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSCKASGCTFSSYISAIISWRQAPGGGLEMMGGIIPIFGTANY 60

Db 1 QVQLVQSGAEVKKPGSSVKVSCKASGCTFSSYISAIISWRQAPGGGLEMMGGIIPIFGTANY 60

Qy 61 AQKFGQGVITITADESTSTAYMELSSLRSEDTAVYYCAR 98

Db 61 AQKFGQGVITITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 46

ADZ41980

ID ADZ41980 standard; peptide; 129 AA.

XX ADZ41980;

XX 30-JUN-2005 (first entry)

DE Ig H chain variable region, B-CLL set VIII peptide #4.

XX Antibody; antibody engineering; antibody therapy;

XX light chain variable region; heavy chain variable region;

XX chronic lymphocytic leukemia; cytostatic; Hodgkins disease; lymphoma;

XX Burkitts lymphoma; multiple myeloma; systemic lupus erythematosus;

XX antiinflammatory; dermatological; immunosuppressive; myasthenia gravis;

XX muscular-gen.; neuroprotective; Graves disease; antithyroid;

XX insulin dependent diabetes; diabetes mellitus; antidiabetic;

XX autoimmune hemolytic anemia; antianemic.

OS Homo sapiens.

XX WO2005034733-A2.

XX 21-APR-2005.

XX 08-OCT-2004; 2004WO-US033176.

XX 08-OCT-2003; 2003US-0509473P.

XX (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.

XX Messmer BT, Chiorazzi N, Albesiano E;

XX WPI; 2005-306220/31.

XX New isolated and purified preparation of light chain and heavy chain
 PT antibody genes, useful for diagnosing, preventing or treating B cell
 PT chronic lymphocytic leukemia, or in screening for agents that may treat
 PT such disease.

XX Disclosure; Fig 2; 58pp; English.

XX The new invention relates to combinations of light chain antibody genes
 CC and heavy chain antibody genes, useful for treating B cell chronic
 CC lymphocytic leukemia (B-CLL). B-CLL is a disease of slowly proliferating
 CC CD5+ B lymphocytes. These cells express low levels of surface membrane Ig
 CC that serves as the receptor for antigen (BCR). Analysis of V region gene
 CC cassette usage has shown that distribution of variable region gene
 CC cassettes used by B-CLL clones differs from that in normal cells, with an
 CC increased frequency of VH3-07, VH4-34, and VH1-69 genes. This implies
 CC that the structure of the antibody molecule, and antigen specificity,
 CC play a role in the leukemic transformation of particular B cells. The
 CC present invention discloses that a significant proportion of B-CLL
 CC patients with aggressive disease share the same classes of VH, D, JH, VL
 CC cell receptors. Alternatively, the patients have a disorder selected from
 CC Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, myeloma or
 CC systemic lupus erythematosus, myasthenia gravis, Grave's disease, type I
 CC diabetes mellitus, autoimmune peripheral neuropathy, and autoimmune
 CC hemolytic anemia. The new members of the antibody genes are: VH4-39/D6-

CC 13/JH5/VLkappa012/2/JLkappa1/kappa2 (Set I); VH4-34/D5-
 CC 5/JH6/VLkappaA17/JLkappa1/kappa2 (Set II); VH3-
 CC 21/JH6/VLlambd3h/JLlambd3 (Set III); VH1-69/D3-
 CC 16/JH3/VLkappaA27/JLkappa1/kappa4 (Set IV); VH1-69/D3-
 CC 10/JH6/VLlambdalc/JLlambd1 (Set V); VH1-02/D6-
 CC 19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIa); VH1-03/D6-
 CC 19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIb); VH1-18/D6-
 CC 51/D6-19/JH4/VLkappa012/2/JLkappa2 (Set VIc); VH1-46/D6-19/JH4
 CC 3/JH4/VLkappaA19/JLkappa4 (Set VII); and VH1-69/D2-
 CC 2/JH6/VLkappaL6/2/JLkappa3 (Set VIII). Treating a patient having B-CLL

CC with the above genes comprises administering an agent that binds to the
CC antigen-binding region of an antibody encoded by the antibody genes. The
CC agent is an anti-idiotypic antibody, a peptide antigen, or an aptamer. The
CC present sequence is an Ig H chain variable region, B-CLL set VIII
CC peptide.
XX
SQ Sequence 129 AA;

Query Match 100.0%; Score 502; DB 9; Length 129;
Best Local Similarity 100.0%; Pred. No. 1.3e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSVAISWVRQAPGQGLEWMGGIIPIFGTANY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSVAISWVRQAPGQGLEWMGGIIPIFGTANY 60

QY 61 AQKFGQGRVTITADESTSTAYMELSLRSSEDTAVYYCAR 98
DB 61 AQKFGQGRVTITADESTSTAYMELSLRSSEDTAVYYCAR 98

RESULT 47
AD241979
ID AD241979 standard; peptide; 129 AA.
XX
AC AD241979;
XX
XX 30-JUN-2005 (first entry)
XX
DE Ig H chain variable region, B-CLL set VIII peptide #3.
XX
XX Antibody; antibody engineering; antibody therapy;
KW light chain variable region; heavy chain variable region;
KW chronic lymphocytic leukemia; cytostatic; Hodgkins disease; lymphoma;
KW Burkitts lymphoma; multiple myeloma; systemic lupus erythematosus;
KW antinflammatory; dermatological; immunosuppressive; myasthenia gravis;
KW musclar-gen.; neuroprotective; Graves disease; antithyroid;
KW insulin dependent diabetes; diabetes mellitus; antidiabetic;
KW autoimmune hemolytic anemia; antianemic.
XX
OS Homo sapiens.
XX
XX WO2005034733-A2.
XX
XX 21-APR-2005.
XX
XX 08-OCT-2004; 2004WO-US033176.
XX
XX 08-OCT-2003; 2003US-0509473P.
XX
XX (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.
XX
XX Messmer BT, Chiorazzi N, Albesiano E;
XX
XX WPI; 2005-306220/31.
XX
XX New isolated and purified preparation of light chain and heavy chain
PT antibody genes, useful for diagnosing, preventing or treating B cell
PT chronic lymphocytic leukemia, or in screening for agents that may treat
PT such disease.
XX
XX Disclosure; Fig 2; 58pp; English.
XX
XX The new invention relates to combinations of light chain antibody genes
CC and heavy chain antibody genes, useful for treating B cell chronic
CC lymphocytic leukemia (B-CLL). B-CLL is a disease of slowly proliferating
CC CD5+ B lymphocytes. These cells express low levels of surface membrane Ig
CC that serves as the receptor for antigen (BCR). Analysis of V region gene
CC cassette usage has shown that distribution of variable region gene
CC cassettes used by B-CLL clones differs from that in normal cells, with an
CC increased frequency of VH3-07, VH4-34, and VH1-69 genes. This implies
CC that the structure of the antibody molecule, and antigen specificity,
CC play a role in the leukemic transformation of particular B cells. The

CC present invention discloses that a significant proportion of B-CLL
CC patients with aggressive disease share the same classes of VH, D, JH, VL
CC and JL antibody genes, forming sets of patients with highly homologous B
CC cell receptors. Alternatively, the patients have a disorder selected from
CC Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, myeloma or
CC systemic lupus erythematosus, myasthenia gravis, Grave's disease, type I
CC diabetes mellitus, autoimmune peripheral neuropathy, and autoimmune
CC hemolytic anemia. The new members of the antibody genes are: VH4-39/D6-
CC 13/JH5/VLkappa012/2/JLkappa1/kappa2 (Set I); VH4-34/D5-
CC 5/JH6/VLkappaA17/JLkappa1/kappa2 (Set II); VH3-
CC 21/JH6/VLlambdab3h/JLlambdab3 (Set III); VH1-69/D3-
CC 16/JH3/VLkappaA27/JLkappa1/kappa4 (Set IV); VH1-69/D3-
CC 10/JH6/VLlambdab1c/JLlambdab1 (Set V); VH1-02/D6-
CC 19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIa); VH1-03/D6-
CC 19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIb); VH1-18/D6-
CC 19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIc); VH1-46/D6-19/JH4 (Set Vid); VH5-
CC 51/D6-19/JH4/VLkappa012/2/JLkappa2 (Set Vie); VH1-69/D3-
CC 3/JH4/VLkappaA19/JLkappa4 (Set VII); and VH1-69/D2-
CC 2/JH6/VLkappaA6/2/JLkappa3 (Set VIII). Treating a patient having B-CLL
CC with the above genes comprises administering an agent that binds to the
CC antigen-binding region of an antibody encoded by the antibody genes. The
CC agent is an anti-idiotypic antibody, a peptide antigen, or an aptamer. The
CC present sequence is an Ig H chain variable region, B-CLL set VIII
CC peptide.
XX
SQ Sequence 129 AA;

Query Match 100.0%; Score 502; DB 9; Length 129;
Best Local Similarity 100.0%; Pred. No. 1.3e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSVAISWVRQAPGQGLEWMGGIIPIFGTANY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGGTFSSVAISWVRQAPGQGLEWMGGIIPIFGTANY 60

QY 61 AQKFGQGRVTITADESTSTAYMELSLRSSEDTAVYYCAR 98
DB 61 AQKFGQGRVTITADESTSTAYMELSLRSSEDTAVYYCAR 98

RESULT 48
ABR01523
ID ABR01523 standard; protein; 219 AA.
XX
XX ABR01523;
XX
XX 16-APR-2003 (first entry)
XX
XX Human anti-TIMP-1 antibody heavy chain #21.
XX
XX Human; antibody; tissue inhibitor of metalloprotease-1; TIMP-1; VLCDR3;
KW matrix metalloprotease; MMP; variable heavy chain; VHCDR3; hepatotropic;
KW variable light chain; cytostatic; nephrotropic; cardiant; liver fibrosis;
KW alcoholic liver disease; cardiac fibrosis; acute coronary syndrome;
KW lupus nephritis; glomerulosclerotic renal disease; lung cancer;
KW idiopathic pulmonary fibrosis; benign prostate hypertrophy; colon cancer.
XX
XX Homo sapiens.
XX
XX WO200286085-A2.
XX
XX 31-OCT-2002.
XX
XX 24-APR-2002; 2002WO-US012801.
XX
XX 24-APR-2001; 2001US-0285683P.
XX
XX (FARB) BAYER CORP.
PA (MORP-) MORPHOSYS AG.
XX
XX Pan C, Knorr AM, Schauer M, Hirth-Dietrich C, Kraft S, Krebs B;
XX WPI; 2003-129114/12.
XX
XX

DR N-PSDB; AB274794.
 XX New human anti-TIMP-1 (tissue inhibitor of metalloprotease-1) antibodies,
 PT for diagnosing or ameliorating the symptoms of a disorder in which TIMP-1
 PT is elevated, e.g. liver fibrosis, benign prostate hypertrophy or lung
 PT cancer.
 XX
 PS Claim 20; Page 162; 228pp; English.
 PS
 CC The invention relates to a novel purified preparation of a human
 CC antibody, which binds to a tissue inhibitor of metalloprotease-1 (TIMP-1)
 CC and neutralises a matrix metalloprotease (MMP)-inhibiting activity of TMP
 CC -1. The antibody comprises a variable heavy chain (VHC)DR3 region and a
 CC variable light chain (VLC)DR3 region. An antibody preparation of the
 CC invention has hepatotropic, cytostatic, nephrotropic and cardiant
 CC activity. The human antibody is useful for decreasing an MMP-inhibiting
 CC activity of a TIMP-1. It is especially useful for ameliorating the
 CC symptoms of a disorder in which TIMP-1 is elevated, e.g. liver fibrosis,
 CC alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus
 CC nephritis, glomerulosclerotic renal disease, idiopathic pulmonary
 CC fibrosis, benign prostate hypertrophy, lung cancer or colon cancer. The
 CC antibody is also useful for detecting a TIMP-1 in a test preparation, or
 CC in diagnosing a disorder in which a TIMP-1 level is elevated. The
 CC sequences shown in ABR01502-ABR01545 represent the heavy chain regions of
 CC a human anti-TIMP-1 antibody of the invention
 XX
 XX Sequence 219 AA;
 SQ

Query Match 100.0%; Score 502; DB 6; Length 219;
 Best Local Similarity 100.0%; Pred. No. 2.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKPGSSVKVSKASGCTFSSYVAISWVRQAPGGLEWMGGIIPFGTANY 60
 Db 1 QVQLVSGAEVKPGSSVKVSKASGCTFSSYVAISWVRQAPGGLEWMGGIIPFGTANY 60
 QY 61 AOKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
 Db 61 AOKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 49
 ABR01538
 ID ABR01538 standard; protein; 220 AA.
 XX
 AC ABR01538;
 XX
 DT 16-APR-2003 (first entry)
 DE Human anti-TIMP-1 antibody heavy chain #36.
 XX
 KW Human; antibody; tissue inhibitor of metalloprotease-1; TIMP-1; VLCDR3;
 KW matrix metalloprotease; MMP; variable heavy chain; VHCDR3; hepatotropic;
 KW variable light chain; cytotostatic; nephrotropic; cardiant; liver fibrosis;
 KW alcoholic liver disease; cardiac fibrosis; acute coronary syndrome;
 KW lupus nephritis; glomerulosclerotic renal disease; lung cancer;
 KW idiopathic pulmonary fibrosis; benign prostate hypertrophy; colon cancer.
 XX
 OS Homo sapiens.
 XX
 PN WO200286085-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 24-APR-2002; 2002WO-US012801.
 XX
 PR 24-APR-2001; 2001US-0285683P.
 XX
 PA (FARB) BAYER CORP.
 PA (MORP-) MORPHOSYS AG.
 XX
 PI Pan C, Knorr AM, Schauer M, Hirth-Dietrich C, Kraft S, Krebs B;
 XX

DR WPI; 2003-129114/12.
 DR N-PSDB; AB274809.
 XX New human anti-TIMP-1 (tissue inhibitor of metalloprotease-1) antibodies,
 PT for diagnosing or ameliorating the symptoms of a disorder in which TIMP-1
 PT is elevated, e.g. liver fibrosis, benign prostate hypertrophy or lung
 PT cancer.
 XX
 PS Claim 20; Page 173; 228pp; English.
 PS
 CC The invention relates to a novel purified preparation of a human
 CC antibody, which binds to a tissue inhibitor of metalloprotease-1 (TIMP-1)
 CC and neutralises a matrix metalloprotease (MMP)-inhibiting activity of TMP
 CC -1. The antibody comprises a variable heavy chain (VHC)DR3 region and a
 CC variable light chain (VLC)DR3 region. An antibody preparation of the
 CC invention has hepatotropic, cytostatic, nephrotropic and cardiant
 CC activity. The human antibody is useful for decreasing an MMP-inhibiting
 CC activity of a TIMP-1. It is especially useful for ameliorating the
 CC symptoms of a disorder in which TIMP-1 is elevated, e.g. liver fibrosis,
 CC alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus
 CC nephritis, glomerulosclerotic renal disease, idiopathic pulmonary
 CC fibrosis, benign prostate hypertrophy, lung cancer or colon cancer. The
 CC antibody is also useful for detecting a TIMP-1 in a test preparation, or
 CC in diagnosing a disorder in which a TIMP-1 level is elevated. The
 CC sequences shown in ABR01502-ABR01545 represent the heavy chain regions of
 CC a human anti-TIMP-1 antibody of the invention
 XX
 XX Sequence 220 AA;
 SQ

Query Match 100.0%; Score 502; DB 6; Length 220;
 Best Local Similarity 100.0%; Pred. No. 2.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKPGSSVKVSKASGCTFSSYVAISWVRQAPGGLEWMGGIIPFGTANY 60
 Db 1 QVQLVSGAEVKPGSSVKVSKASGCTFSSYVAISWVRQAPGGLEWMGGIIPFGTANY 60
 QY 61 AOKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
 Db 61 AOKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 50
 ABR01512
 ID ABR01512 standard; protein; 220 AA.
 XX
 AC ABR01512;
 XX
 DT 16-APR-2003 (first entry)
 DE Human anti-TIMP-1 antibody heavy chain #10.
 XX
 KW Human; antibody; tissue inhibitor of metalloprotease-1; TIMP-1; VLCDR3;
 KW matrix metalloprotease; MMP; variable heavy chain; VHCDR3; hepatotropic;
 KW variable light chain; cytotostatic; nephrotropic; cardiant; liver fibrosis;
 KW alcoholic liver disease; cardiac fibrosis; acute coronary syndrome;
 KW lupus nephritis; glomerulosclerotic renal disease; lung cancer;
 KW idiopathic pulmonary fibrosis; benign prostate hypertrophy; colon cancer.
 XX
 OS Homo sapiens.
 XX
 PN WO200286085-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 24-APR-2002; 2002WO-US012801.
 XX
 PR 24-APR-2001; 2001US-0285683P.
 XX
 PA (FARB) BAYER CORP.
 PA (MORP-) MORPHOSYS AG.
 XX
 PI Pan C, Knorr AM, Schauer M, Hirth-Dietrich C, Kraft S, Krebs B;
 XX

XX WPI; 2003-129114/12.
 DR N-PSDB; AB274783.
 XX
 PT New human anti-TIMP-1 (tissue inhibitor of metalloprotease-1) antibodies,
 PT for diagnosing or ameliorating the symptoms of a disorder in which TIMP-1
 PT is elevated, e.g. liver fibrosis, benign prostate hypertrophy or lung
 PT cancer.
 XX
 PS Claim 20; Page 154; 228pp; English.
 XX
 CC The invention relates to a novel purified preparation of a human
 CC antibody, which binds to a tissue inhibitor of metalloprotease-1 (TIMP-1)
 CC and neutralises a matrix metalloprotease (MMP)-inhibiting activity of TMP
 CC -1. The antibody comprises a variable heavy chain (VHC)DR3 region and a
 CC variable light chain (VLC)DR3 region. An antibody preparation of the
 CC invention has hepatotropic, cytostatic, nephrotropic and cardiant
 CC activity. The human antibody is useful for decreasing an MMP-inhibiting
 CC activity of a TIMP-1. It is especially useful for ameliorating the
 CC symptoms of a disorder in which TIMP-1 is elevated, e.g. liver fibrosis,
 CC alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus
 CC nephritis, glomerulosclerotic renal disease, idiopathic pulmonary
 CC fibrosis, benign prostate hypertrophy, lung cancer or colon cancer. The
 CC antibody is also useful for detecting a TIMP-1 in a test preparation, or
 CC in diagnosing a disorder in which a TIMP-1 level is elevated. The
 CC sequences shown in ABR01502-ABR01545 represent the heavy chain regions of
 CC a human anti-TIMP-1 antibody of the invention
 XX
 SQ Sequence 220 AA;
 Query Match 100.0%; Score 502; DB 6; Length 220;
 Best Local Similarity 100.0%; Pred. No. 2.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSVAISWVRQAPQGQLEWMGGIPIFGTANY 60
 DB 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSVAISWVRQAPQGQLEWMGGIPIFGTANY 60
 QY 61 AQKFGQGVTTITADESTSTAYMELSLRSEDSTAVYYCAR 98
 DB 61 AQKFGQGVTTITADESTSTAYMELSLRSEDSTAVYYCAR 98
 RESULT 51
 ABR01531
 ID ABR01531 standard; protein; 222 AA.
 XX
 AC ABR01531;
 XX
 DT 16-APR-2003 (first entry)
 XX
 DE Human anti-TIMP-1 antibody heavy chain #29.
 XX
 KW Human; antibody; tissue inhibitor of metalloprotease-1; TIMP-1; VLCDR3;
 KW matrix metalloprotease; MMP; variable heavy chain; VHCDR3; hepatotropic;
 KW variable light chain; cytosstatic; nephrotropic; cardiant; liver fibrosis;
 KW alcoholic liver disease; cardiac fibrosis; acute coronary syndrome;
 KW lupus nephritis; glomerulosclerotic renal disease; lung cancer;
 KW idiopathic pulmonary fibrosis; benign prostate hypertrophy; colon cancer.
 OS
 XX Homo sapiens.
 XX
 FN WO200286085-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 24-APR-2002; 2002WO-US012801.
 XX
 PR 24-APR-2001; 2001US-0285683P.
 XX
 PA (FARB) BAYER CORP.
 PA (MORP-) MORPHOSYS AG.
 XX

PI Pan C, Knorr AM, Schauer M, Hirth-Dietrich C, Kraft S, Krebs B;
 XX WPI; 2003-129114/12.
 DR N-PSDB; AB274802.
 XX
 PT New human anti-TIMP-1 (tissue inhibitor of metalloprotease-1) antibodies,
 PT for diagnosing or ameliorating the symptoms of a disorder in which TIMP-1
 PT is elevated, e.g. liver fibrosis, benign prostate hypertrophy or lung
 PT cancer.
 XX
 PS Claim 20; Page 168; 228pp; English.
 XX
 CC The invention relates to a novel purified preparation of a human
 CC antibody, which binds to a tissue inhibitor of metalloprotease-1 (TIMP-1)
 CC and neutralises a matrix metalloprotease (MMP)-inhibiting activity of TMP
 CC -1. The antibody comprises a variable heavy chain (VHC)DR3 region and a
 CC variable light chain (VLC)DR3 region. An antibody preparation of the
 CC invention has hepatotropic, cytostatic, nephrotropic and cardiant
 CC activity. The human antibody is useful for decreasing an MMP-inhibiting
 CC activity of a TIMP-1. It is especially useful for ameliorating the
 CC symptoms of a disorder in which TIMP-1 is elevated, e.g. liver fibrosis,
 CC alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus
 CC nephritis, glomerulosclerotic renal disease, idiopathic pulmonary
 CC fibrosis, benign prostate hypertrophy, lung cancer or colon cancer. The
 CC antibody is also useful for detecting a TIMP-1 in a test preparation, or
 CC in diagnosing a disorder in which a TIMP-1 level is elevated. The
 CC sequences shown in ABR01502-ABR01545 represent the heavy chain regions of
 CC a human anti-TIMP-1 antibody of the invention
 XX
 SQ Sequence 222 AA;
 Query Match 100.0%; Score 502; DB 6; Length 222;
 Best Local Similarity 100.0%; Pred. No. 2.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSVAISWVRQAPQGQLEWMGGIPIFGTANY 60
 DB 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSVAISWVRQAPQGQLEWMGGIPIFGTANY 60
 QY 61 AQKFGQGVTTITADESTSTAYMELSLRSEDSTAVYYCAR 98
 DB 61 AQKFGQGVTTITADESTSTAYMELSLRSEDSTAVYYCAR 98
 RESULT 52
 ABR01535
 ID ABR01535 standard; protein; 223 AA.
 XX
 AC ABR01535;
 XX
 DT 16-APR-2003 (first entry)
 XX
 DE Human anti-TIMP-1 antibody heavy chain #33.
 XX
 KW Human; antibody; tissue inhibitor of metalloprotease-1; TIMP-1; VLCDR3;
 KW matrix metalloprotease; MMP; variable heavy chain; VHCDR3; hepatotropic;
 KW variable light chain; cytosstatic; nephrotropic; cardiant; liver fibrosis;
 KW alcoholic liver disease; cardiac fibrosis; acute coronary syndrome;
 KW lupus nephritis; glomerulosclerotic renal disease; lung cancer;
 KW idiopathic pulmonary fibrosis; benign prostate hypertrophy; colon cancer.
 OS
 XX Homo sapiens.
 XX
 FN WO200286085-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 24-APR-2002; 2002WO-US012801.
 XX
 PR 24-APR-2001; 2001US-0285683P.
 XX
 PA (FARB) BAYER CORP.
 PA (MORP-) MORPHOSYS AG.
 XX

XX Pan C, Knorr AM, Schauer M, Hirth-Dietrich C, Kraft S, Krebs B;
 XX MPI; 2003-129114/12.
 DR N-PSDB; ABZ74806.
 XX New human anti-TIMP-1 (tissue inhibitor of metalloprotease-1) antibodies,
 PT for diagnosing or ameliorating the symptoms of a disorder in which TIMP-1
 PT is elevated, e.g. liver fibrosis, benign prostate hypertrophy or lung
 PT cancer.
 XX
 XX Claim 20; Page 170-171; 228pp; English.
 XX The invention relates to a novel purified preparation of a human
 CC antibody, which binds to a tissue inhibitor of metalloprotease-1 (TIMP-1)
 CC and neutralises a matrix metalloprotease (MMP)-inhibiting activity of TMP
 CC -1. The antibody comprises a variable heavy chain (VHC)DR3 region and a
 CC variable light chain (VLC)DR3 region. An antibody preparation of the
 CC invention has hepatotropic, cytostatic, nephrotropic and cardiant
 CC activity. The human antibody is useful for decreasing an MMP-inhibiting
 CC activity of a TIMP-1. It is especially useful for ameliorating the
 CC symptoms of a disorder in which TIMP-1 is elevated, e.g. liver fibrosis,
 CC alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus
 CC nephritis, glomerulosclerotic renal disease, idiopathic pulmonary
 CC fibrosis, benign prostate hypertrophy, lung cancer or colon cancer. The
 CC antibody is also useful for detecting a TIMP-1 in a test preparation, or
 CC in diagnosing a disorder in which a TIMP-1 level is elevated. The
 CC sequences shown in ABR01502-ABR01545 represent the heavy chain regions of
 CC a human anti-TIMP-1 antibody of the invention
 XX
 SQ Sequence 223 AA;
 Query Match 100.0%; Score 502; DB 6; Length 223;
 Best Local Similarity 100.0%; Pred. No. 2.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSYVAISWVRQAPGQGLEWMGGIIPIFGTANY 60
 DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSYVAISWVRQAPGQGLEWMGGIIPIFGTANY 60
 QY 61 AQKFGQVRVITADESTSTAYMELSSLRSEDTAVYYCAR 98
 DB 61 AQKFGQVRVITADESTSTAYMELSSLRSEDTAVYYCAR 98
 RESULT 54
 ABR01510
 ID ABR01510 standard; protein; 225 AA.
 AC ABR01510;
 XX
 XX 16-APR-2003 (first entry)
 DT
 XX Human anti-TIMP-1 antibody heavy chain #8.
 DE
 XX Human; antibody; tissue inhibitor of metalloprotease-1; TIMP-1; VLCDR3;
 KW matrix metalloprotease; MMP; variable heavy chain; VHCDR3; hepatotropic;
 KW variable light chain; cytostatic; nephrotropic; cardiant; liver fibrosis;
 KW alcoholic liver disease; cardiac fibrosis; acute coronary syndrome;
 KW lupus nephritis; glomerulosclerotic renal disease; lung cancer;
 KW idiopathic pulmonary fibrosis; benign prostate hypertrophy; colon cancer.
 XX
 OS Homo sapiens.
 XX
 XX WO200286085-A2.
 XX
 XX 31-OCT-2002.
 PD
 XX 24-APR-2002; 2002WO-US012801.
 PF
 XX 24-APR-2001; 2001US-0285683P.
 XX
 XX (FARB) BAYER CORP.
 PA

(MORP-) MORPHOSYS AG.
 PA Pan C, Knorr AM, Schauer M, Hirth-Dietrich C, Kraft S, Krebs B;
 XX MPI; 2003-129114/12.
 DR N-PSDB; ABZ74781.
 XX New human anti-TIMP-1 (tissue inhibitor of metalloprotease-1) antibodies,
 PT for diagnosing or ameliorating the symptoms of a disorder in which TIMP-1
 PT is elevated, e.g. liver fibrosis, benign prostate hypertrophy or lung
 PT cancer.
 XX
 XX Claim 20; Page 153; 228pp; English.
 XX The invention relates to a novel purified preparation of a human
 CC antibody, which binds to a tissue inhibitor of metalloprotease-1 (TIMP-1)
 CC and neutralises a matrix metalloprotease (MMP)-inhibiting activity of TMP
 CC -1. The antibody comprises a variable heavy chain (VHC)DR3 region and a
 CC variable light chain (VLC)DR3 region. An antibody preparation of the
 CC invention has hepatotropic, cytostatic, nephrotropic and cardiant
 CC activity. The human antibody is useful for decreasing an MMP-inhibiting
 CC activity of a TIMP-1. It is especially useful for ameliorating the
 CC symptoms of a disorder in which TIMP-1 is elevated, e.g. liver fibrosis,
 CC alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus
 CC nephritis, glomerulosclerotic renal disease, idiopathic pulmonary
 CC fibrosis, benign prostate hypertrophy, lung cancer or colon cancer. The
 CC antibody is also useful for detecting a TIMP-1 in a test preparation, or
 CC in diagnosing a disorder in which a TIMP-1 level is elevated. The
 CC sequences shown in ABR01502-ABR01545 represent the heavy chain regions of
 CC a human anti-TIMP-1 antibody of the invention
 XX
 SQ Sequence 225 AA;
 Query Match 100.0%; Score 502; DB 6; Length 225;
 Best Local Similarity 100.0%; Pred. No. 2.2e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSYVAISWVRQAPGQGLEWMGGIIPIFGTANY 60
 DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSYVAISWVRQAPGQGLEWMGGIIPIFGTANY 60
 QY 61 AQKFGQVRVITADESTSTAYMELSSLRSEDTAVYYCAR 98
 DB 61 AQKFGQVRVITADESTSTAYMELSSLRSEDTAVYYCAR 98
 RESULT 54
 ABR01518
 ID ABR01518 standard; protein; 229 AA.
 AC ABR01518;
 XX
 XX 16-APR-2003 (first entry)
 DT
 XX Human anti-TIMP-1 antibody heavy chain #16.
 DE
 XX Human; antibody; tissue inhibitor of metalloprotease-1; TIMP-1; VLCDR3;
 KW matrix metalloprotease; MMP; variable heavy chain; VHCDR3; hepatotropic;
 KW variable light chain; cytostatic; nephrotropic; cardiant; liver fibrosis;
 KW alcoholic liver disease; cardiac fibrosis; acute coronary syndrome;
 KW lupus nephritis; glomerulosclerotic renal disease; lung cancer;
 KW idiopathic pulmonary fibrosis; benign prostate hypertrophy; colon cancer.
 XX
 OS Homo sapiens.
 XX
 XX WO200286085-A2.
 XX
 XX 31-OCT-2002.
 PD
 XX 24-APR-2002; 2002WO-US012801.
 PF
 XX 24-APR-2001; 2001US-0285683P.
 XX
 XX (FARB) BAYER CORP.
 PA

FT Misc-difference 86 /label= VH_FR3
FT FT /note= "Encoded by GTG"
FT Region 99..102
FT FT /label= VH_CDR3
FT Region 103..113
FT FT /label= VH_FR4
FT Region 114..128
FT FT /label= Linker
FT Region 129..150
FT FT /label= VL_FR1
FT Region 151..163
FT FT /label= VL_CDR1
FT Region 164..177
FT FT /label= VL_FR2
FT Region 179..185
FT FT /label= VL_CDR2
FT Region 186..219
FT FT /label= VL_FR3
FT Region 220..227
FT FT /label= VL_CDR3
FT Region 229..238
FT FT /label= VL_FR4
XX
PN WO2003048337-A2.
XX
XX 12-JUN-2003.
XX
XX 04-DEC-2002; 2002WO-US038849.
XX
XX 04-DEC-2001; 2001US-0337294P.
XX (DAND) DANA FARBER CANCER INST INC.
XX
XX Marasco WA, Gennari F;
XX WPI; 2003-482710/45.
DR N-PSDB; ACC84105.
XX
XX Novel antibody to extracellular epitopes of Epstein Barr virus latent
FT membrane protein, useful for prevention and treatment of diseases caused
FT by Epstein-Barr Virus, e.g. malignancies and lymphoproliferative
FT diseases.
XX
XX Disclosure; Page 22; 52pp; English.
XX
XX The present sequence is the protein sequence of anti-Epstein-Barr virus
CC (EBV) latent membrane protein (LMP) scFv FG-47. The scFv was isolated
CC from a human antibody phage display library. It comprises a DP-10/hv1051
CC VH germline and 6a.366F5/V1-22 VL germline. It is an example of
CC antibodies of the invention directed against EBV LMP proteins (LMP1,
CC LMP2A or LMP2B). Claimed methods of generating an immune reaction
CC comprise administering an antibody with specificity for EBV LMP, or an
CC immune cell endowed with antibody specificity for an EBV LMP by
CC transfection, to an individual having an EBV-associated disease such as
CC malignancy, Hodgkin's disease, chronic EBV syndrome or oral hairy cell
CC leukoplakia. The malignancy is especially Burkitt's lymphoma,
CC lymphoproliferative disease, B-lymphoproliferative disease, non-Hodgkin's
CC lymphoma (NHL), T-NHL, NK-NHL, lymphonodopharyngeal carcinoma or gastric
CC carcinoma. Alternatively, the lymphocytes of an individual having an EBV
CC associated malignancy are transformed with a chimeric gene encoding e.g.
XX a single chain antibody as a means of treatment
XX
SQ Sequence 238 AA;

Query Match 100.0%; Score 502; DB 6; Length 238;
Best Local Similarity 100.0%; Pred. No. 2.4e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPQGGLWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPQGGLWMGGIPIFGTANY 60

Qy 61 AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 57
AAB67617
ID AAB67617 standard; protein; 245 AA.
XX
AC AAB67617;
XX
DT 29-MAY-2001 (first entry)
XX Human leukocyte antigen-Cw6 specific scFv fragment from clone Cw6_1.
DE Human leukocyte antigen; HLA; HLA-Cw6; natural killer cell silencing;
KW miscarriage; abortion; psoriasis; antibody; HLA phenotyping; sg.
XX Homo sapiens.
XX OS
XX WO200114558-A1.
XX PN
XX 01-MAR-2001.
XX PD
XX 28-AUG-2000; 2000WO-EP008388.
XX PF
XX 26-AUG-1999; 99EP-00116691.
XX PR
XX (MORP-) MORPHOSYS AG.
XX PA
XX Kretzschmar T, Tesar M, Marget M, Kroenke M;
XX WPI; 2001-218451/22.
XX DR
XX Novel isolated human immunoglobulin or functional immunoglobulin fragment
FT specific for human leukocyte antigen Cw6, useful for treatment of humans
FT and for human leukocyte antigen phenotyping.
XX
XX Claim 3; Fig 1; 23pp; English.
XX
XX AAB67617-23 represent single chain antibody (scFv) fragments which are
CC specific for human leukocyte antigen (HLA)-Cw6. The fragments are derived
CC from a synthetic human combinatorial antibody library based on molecular
CC consensus framework and CDRs randomised with trinucleotides. The
CC specification describes a human immunoglobulin fragments specific for HLA
CC -Cw6. The HLA-Cw6 serotype is considered highly relevant in studies of
CC natural killer cell silencing as well as miscarriages. HLA-Cw6
CC demonstrates a disequilibrium in some recurrent abortions. Psoriasis may
CC also be linked to HLA-Cw6. The anti-HLA-Cw6 immunoglobulin fragments are
CC useful for the preparation of a pharmaceutical for the treatment of
CC humans. They are also useful for HLA phenotyping
XX
SQ Sequence 245 AA;

Query Match 100.0%; Score 502; DB 4; Length 245;
Best Local Similarity 100.0%; Pred. No. 2.5e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPQGGLWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPQGGLWMGGIPIFGTANY 60

Qy 61 AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 58
AAB67618
ID AAB67618 standard; protein; 245 AA.
XX
AC AAB67618;
XX

```

DT 29-MAY-2001 (first entry)
XX
DE Human leukocyte antigen-Cw6 specific scFv fragment from clone Cw6_2.
XX
XX Human leukocyte antigen; HLA; HLA-Cw6; natural killer cell silencing;
KW miscarriage; abortion; psoriasis; antibody; HLA phenotyping; ss.
XX
OS Homo sapiens.
XX
PN WO200114558-A1.
XX
PD 01-MAR-2001.
XX
XX 28-AUG-2000; 2000WO-EP008388.
PF
XX 26-AUG-1999; 99EP-00116691.
XX
XX (MORP-) MORPHOSYS AG.
XX
XX Kretschmar T, Tesar M, Marget M, Kroenke M;
PI WPI; 2001-218451/22.
XX
DR Novel isolated human immunoglobulin or functional immunoglobulin fragment
PT specific for human leukocyte antigen Cw6, useful for treatment of humans
PT and for human leukocyte antigen phenotyping.
XX
XX Claim 3; Fig 1; 23pp; English.
XX
CC AAB67617-23 represent single chain antibody (scFv) fragments which are
CC specific for human leukocyte antigen (HLA)-Cw6. The fragments are derived
CC from a synthetic human combinatorial antibody library based on molecular
CC consensus frameworks and CDRs randomised with trinucleotides. The
CC specification describes a human immunoglobulin fragments specific for HLA
CC -Cw6. The HLA-Cw6 serotype is considered highly relevant in studies of
CC natural killer cell silencing as well as miscarriages. HLA-Cw6
CC demonstrates a disequilibrium in some recurrent abortions. Psoriasis may
CC also be linked to HLA-Cw6. The anti-HLA-Cw6 immunoglobulin fragments are
CC useful for the preparation of a pharmaceutical for the treatment of
CC humans. They are also useful for HLA phenotyping
XX
SQ Sequence 245 AA;
Query Match 100.0%; Score 502; DB 4; Length 245;
Best Local Similarity 100.0%; Pred. No. 2.5e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGSSVKVSKCASKGTFSSYAIISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCASKGTFSSYAIISWVRQAPGQGLEWMGGIPIFGTANY 60
QY 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
RESULT 59
ABP45868
ID ABP45868 standard; protein; 248 AA.
XX
AC ABP45868;
XX
DT 19-AUG-2002 (first entry)
XX
XX Human BlyS binding scFv SEQ ID 1879.
XX
KW BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX

```

```

OS Homo sapiens.
XX
PN WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US019110.
XX
XX 16-JUN-2000; 2000US-0212210P.
PR 17-OCT-2000; 2000US-0240816P.
PR 16-MAR-2001; 2001US-0276248P.
PR 21-MAR-2001; 2001US-0277379P.
PR 25-MAY-2001; 2001US-0293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
PI WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte Stimulating polypeptides, useful for the
PT diagnosis and treatment of cancers and immune disorders.
XX
XX Claim 1; Page 2644-2645; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
CC and so may be used to detect and quantitate the presence of BlyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BlyS. They may also be
CC administered to treat diseases associated with aberrant BlyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP4390-ABP4728 represent
CC the antibodies and fragments of the antibodies described in the method of
CC the invention
XX
SQ Sequence 248 AA;
Query Match 100.0%; Score 502; DB 5; Length 248;
Best Local Similarity 100.0%; Pred. No. 2.5e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGSSVKVSKCASKGTFSSYAIISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCASKGTFSSYAIISWVRQAPGQGLEWMGGIPIFGTANY 60
QY 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
RESULT 60
ABP45707
ID ABP45707 standard; protein; 248 AA.
XX
AC ABP45707;
XX
XX 19-AUG-2002 (first entry)
XX
XX Human BlyS binding scFv SEQ ID 1718.
XX
KW BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX

```

KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US019110.
XX
XX 16-JUN-2000; 2000US-0212210P.
PR 17-OCT-2000; 2000US-0240816P.
PR 16-MAR-2001; 2001US-0276248P.
PR 21-MAR-2001; 2001US-0277379P.
PR 25-MAY-2001; 2001US-0293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
XX diagnosis and treatment of cancers and immune disorders.
XX
XX Claim 1; Page 2452-2453; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method of
CC the invention
XX
XX Sequence 248 AA;
S
Query Match 100.0%; Score 502; DB 5; Length 248;
Best Local Similarity 100.0%; Pred. No. 2.5e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYATISWVRQAPGQGLEWMGGIIPFGTANY 60
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYATISWVRQAPGQGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
RESULT 61
ABP45722
ID ABP45722 standard; protein; 248 AA.
XX
XX ABP45722;
XX
XX 19-AUG-2002 (first entry)
XX
XX Human Blys binding scFv SEQ ID 1733.
XX
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;

KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
OS
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US019110.
XX
XX 16-JUN-2000; 2000US-0212210P.
PR 17-OCT-2000; 2000US-0240816P.
PR 16-MAR-2001; 2001US-0276248P.
PR 21-MAR-2001; 2001US-0277379P.
PR 25-MAY-2001; 2001US-0293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
XX diagnosis and treatment of cancers and immune disorders.
XX
XX Claim 1; Page 2470-2471; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method of
CC the invention
XX
XX Sequence 248 AA;
S
Query Match 100.0%; Score 502; DB 5; Length 248;
Best Local Similarity 100.0%; Pred. No. 2.5e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYATISWVRQAPGQGLEWMGGIIPFGTANY 60
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYATISWVRQAPGQGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
RESULT 62
ABP45723
ID ABP45723 standard; protein; 248 AA.
XX
XX ABP45723;
XX
XX 19-AUG-2002 (first entry)
XX
XX

RESULT 64
ABP45708

```

ID AC XX ABP45708 standard; protein; 248 AA.
XX AC XX ABP45708;
XX DT XX 19-AUG-2002 (first entry)
XX DE XX Human BlyS binding scFv SEQ ID 1719.
XX XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX OS Homo sapiens.
XX PN WO200202641-A1.
XX XX 10-JAN-2002.
XX XX 15-JUN-2001; 2001WO-US019110.
XX PR 16-JUN-2000; 2000US-0212210P.
XX PR 17-OCT-2000; 2000US-0240816P.
XX PR 16-MAR-2001; 2001US-0276248P.
XX PR 21-MAR-2001; 2001US-0277379P.
XX PR 25-MAY-2001; 2001US-0293499P.
XX XX (HUMA-) HUMAN GENOME SCI INC.
XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX DR
XX PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
XX PT diagnosis and treatment of cancers and immune disorders.
XX PS Claim 1; Page 2453-2454; 3148pp; English.
XX CC This invention describes novel antibodies that immunospecifically bind to
XX CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
XX CC tumour necrosis factor (TNF) super family and induces B cell
XX CC proliferation and differentiation. The antibodies of the invention have
XX CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
XX CC and so may be used to detect and quantitate the presence of BlyS in
XX CC biological samples and may be used in this way to diagnose disease
XX CC associated with aberrant expression of BlyS. They may also be
XX CC administered to treat diseases associated with aberrant BlyS expression
XX CC and activity such as cancer, immune, and autoimmune disorders and
XX CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX CC the antibodies and fragments of the antibodies described in the method of
XX CC the invention
XX SQ Sequence 248 AA;
XX Query Match 100.0%; Score 502; DB 5; Length 248;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-39;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAIISWVRAPQGQLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAIISWVRAPQGQLEWMGGIIPFGTANY 60
Oy 61 AQKQGRVTITADESTSTAYMELSSLRSEDTAVYICAR 98
Db 61 AQKQGRVTITADESTSTAYMELSSLRSEDTAVYICAR 98
```

```

RESULT 65
ABP45726
ID ABP45726 standard; protein; 248 AA.
XX AC XX ABP45726;
XX DT XX 19-AUG-2002 (first entry)
XX DE XX Human BlyS binding scFv SEQ ID 1737.
XX XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX OS Homo sapiens.
XX PN WO200202641-A1.
XX XX 10-JAN-2002.
XX XX 15-JUN-2001; 2001WO-US019110.
XX PR 16-JUN-2000; 2000US-0212210P.
XX PR 17-OCT-2000; 2000US-0240816P.
XX PR 16-MAR-2001; 2001US-0276248P.
XX PR 21-MAR-2001; 2001US-0277379P.
XX PR 25-MAY-2001; 2001US-0293499P.
XX XX (HUMA-) HUMAN GENOME SCI INC.
XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX DR
XX PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
XX PT diagnosis and treatment of cancers and immune disorders.
XX PS Claim 1; Page 2475-2476; 3148pp; English.
XX CC This invention describes novel antibodies that immunospecifically bind to
XX CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
XX CC tumour necrosis factor (TNF) super family and induces B cell
XX CC proliferation and differentiation. The antibodies of the invention have
XX CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
XX CC and so may be used to detect and quantitate the presence of BlyS in
XX CC biological samples and may be used in this way to diagnose disease
XX CC associated with aberrant expression of BlyS. They may also be
XX CC administered to treat diseases associated with aberrant BlyS expression
XX CC and activity such as cancer, immune, and autoimmune disorders and
XX CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX CC the antibodies and fragments of the antibodies described in the method of
XX CC the invention
XX SQ Sequence 248 AA;
XX Query Match 100.0%; Score 502; DB 5; Length 248;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-39;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAIISWVRAPQGQLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAIISWVRAPQGQLEWMGGIIPFGTANY 60
Oy 61 AQKQGRVTITADESTSTAYMELSSLRSEDTAVYICAR 98
```

```
Db      |||||||
61 AQPQGRVTITADESTSTAYMELSLRSEDVAVYICAR 98

RESULT 66
ADF18276
ID  ADF18276 standard; protein; 248 AA.
XX  AC  ADF18276;
XX  AC  ADF18276;
XX  DT  12-FEB-2004 (first entry)
XX  DE  Anti-TL5 antibody L003B01 scFv.
XX  XX  Human; TL5; cytostatic; anti-HIV; immunosuppressive; immunostimulant;
KW  vlrucide; dermatological; antiinflammatory; antirheumatic; antiarthritic;
KW  neuroprotective; muscular-gen.; antiasthmatic; antiallergic; scFv;
KW  antibody.
XX  OS  Homo sapiens.
XX  XX  Key      Location/Qualifiers
FH  Domain    1..119
FT           /label= VH
FT  Region    31..35
FT           /label= VH_CDR1
FT  Region    50..66
FT           /label= VH_CDR2
FT  Region    99..111
FT           /label= VH_CDR3
FT  Domain    138..248
FT           /label= VL
FT  Region    160..173
FT           /label= VL_CDR1
FT  Region    189..195
FT           /label= VL_CDR2
FT  Region    228..237
FT           /label= VL_CDR3
XX  XX  WO2003089575-A2.
XX  XX  30-OCT-2003.
XX  XX  10-APR-2003; 2003WO-US010956.
XX  XX  15-APR-2002; 2002US-0372087P.
XX  XX  (HUMA-) HUMAN GENOME SCI INC.
PA  (ROSE/) ROSEN C A.
PA  (RUBE/) RUBEN S M.
XX  XX  Rosen CA, Ruben SM;
XX  XX  WPI; 2003-854097/79.
DR  N-PSDB; ADF18231.
XX  XX  New antibody that specifically bind to TL5, useful for diagnosing,
PT  preventing, treating or ameliorating diseases (e.g. cancer, autoimmune
PT  disease, inflammation or transplant rejection), and in immunophenotyping
PT  or epitope mapping.
XX  XX  Claim 1; SEQ ID NO 6; 195pp; English.
XX  XX  The present sequence is the protein sequence of L003B01, an scFv that
CC  specifically binds to human TL5 ADF18276. The scFv was obtained using
CC  phage display technology. The invention relates to antibodies that
CC  specifically bind to TL5. The antibody may be an scFv or a molecule
CC  comprising or consisting of a fragment or variant of the scFv, including
CC  the heavy chain variable region (VH), VH complementarity determining
CC  regions (CDRs), light chain variable (VL) domains or VL CDRs, which
CC  specifically bind to TL5. Nucleic acids encoding these scFvs or molecules
CC  are also provided, as well as vectors, host cells and methods of
CC  producing the antibodies. Anti-TL5 antibodies are used in the diagnosis,
```

```
CC  prevention or treatment of a disease or disorder such as an autoimmune
CC  disease, rheumatoid arthritis, graft versus host disease, cancer,
CC  lymphadenopathy, transplant rejection, cancer (especially colon cancer,
CC  breast cancer, uterine cancer, pancreatic cancer, lung cancer,
CC  gastrointestinal cancer and Kaposi's sarcoma), an immunodeficiency
CC  syndrome, or an inflammatory disease such as asthma or allergy,
CC  especially in a human.
XX  XX  Sequence 248 AA;
XX  XX  Query Match      100.0%; Score 502; DB 7; Length 248;
XX  XX  Best Local Similarity 100.0%; Pred. No. 2.5e-39;
XX  XX  Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX  XX  QY  1 QVQLVQSGAEVKKPGSSVKVSKASGGTFTSSYAIISWVRQAPGGLEWMGGIIFGTANY 60
XX  XX  DB  1 QVQLVQSGAEVKKPGSSVKVSKASGGTFTSSYAIISWVRQAPGGLEWMGGIIFGTANY 60
XX  XX  QY  61 AQPQGRVTITADESTSTAYMELSLRSEDVAVYICAR 98
XX  XX  DB  61 AQPQGRVTITADESTSTAYMELSLRSEDVAVYICAR 98
XX  XX  RESULT 67
XX  XX  ADG96550
XX  XX  ID  ADG96550 standard; protein; 248 AA.
XX  XX  AC  ADG96550;
XX  XX  DT  11-MAR-2004 (first entry)
XX  XX  DE  Single chain antibody that immunospecifically binds BlyS SeqID 1734.
XX  XX  KW  antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
XX  XX  B cell proliferation; differentiation; scFv; myasthenia gravis;
XX  XX  multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
XX  XX  carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
XX  XX  antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX  XX  OS  Unidentified.
XX  XX  WO2003055979-A2.
XX  XX  10-JUL-2003.
XX  XX  14-NOV-2002; 2002WO-US036496.
XX  XX  16-NOV-2001; 2001US-0331469P.
XX  XX  19-DEC-2001; 2001US-0340817P.
XX  XX  (HUMA-) HUMAN GENOME SCI INC.
XX  XX  Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX  XX  WPI; 2003-505530/47.
XX  XX  Novel antibody that immunospecifically binds to a B lymphocyte stimulator
PT  (BlyS), useful for detecting and treating diseases or disorders e.g.
PT  rheumatoid arthritis, asthma and leukemia.
XX  XX  Example 1; SEQ ID NO 1734; 394pp; English.
XX  XX  This invention relates to novel antibodies that immunospecifically bind
CC  to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
CC  chromosome 13q34 and encodes a protein that is a member of the tumour
CC  necrosis factor superfamily and induces both in vivo and in vitro B cell
CC  proliferation and differentiation. Specifically, it refers to single
CC  chain antibody molecules (scFvs) derived, preferably, from the variable
CC  heavy CDR3 region that immunospecifically bind to a polypeptide, or
CC  fragment thereof, of either human, murine, rat or monkey BlyS. The
CC  present invention refers to the use of such antibodies in various methods
CC  for the detection, diagnosis and prognosis of diseases related to the
CC  aberrant expression or inappropriate function of BlyS or its receptor. As
```


CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds Blys of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
 XX
 SQ Sequence 248 AA;

Query Match 100.0%; Score 502; DB 7; Length 248;
 Best Local Similarity 100.0%; Pred. No. 2.5e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAISWVRQAPGQGLEWMGGIPIFGTANY 60
 |||||
 Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKQGRVTITADESTSTAYMELSLRSEDYAVYYCAR 98
 |||||
 Db 61 AQKQGRVTITADESTSTAYMELSLRSEDYAVYYCAR 98

RESULT 68

ADG96535
 ID ADG96535 standard; protein; 248 AA.

AC ADG96535;

XX 11-MAR-2004 (first entry)

XX Single chain antibody that immunospecifically binds Blys SeqID 1719.

DE antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.

XX Unidentified.

XX WO2003055979-A2.

XX 10-JUL-2003.

XX 14-NOV-2002; 2002WO-US036496.

XX 16-NOV-2001; 2001US-0331469P.

XX 19-DEC-2001; 2001US-0340817P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;

XX WPI; 2003-505530/47.

XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 (Blys), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.

XX Example 1; SEQ ID NO 1719; 394pp; English.

CC This invention relates to novel antibodies that immunospecifically bind
 CC to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour
 CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or

CC fragment thereof, of either human, murine, rat or monkey Blys. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of Blys or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds Blys of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
 XX

SQ Sequence 248 AA;

Query Match 100.0%; Score 502; DB 7; Length 248;
 Best Local Similarity 100.0%; Pred. No. 2.5e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAISWVRQAPGQGLEWMGGIPIFGTANY 60
 |||||
 Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKQGRVTITADESTSTAYMELSLRSEDYAVYYCAR 98
 |||||

Db 61 AQKQGRVTITADESTSTAYMELSLRSEDYAVYYCAR 98

RESULT 69

ADG96549

ID ADG96549 standard; protein; 248 AA.

XX ADG96549;

XX 11-MAR-2004 (first entry)

XX Single chain antibody that immunospecifically binds Blys SeqID 1733.

DE antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.

XX Unidentified.

XX WO2003055979-A2.

XX 10-JUL-2003.

XX 14-NOV-2002; 2002WO-US036496.

XX 16-NOV-2001; 2001US-0331469P.

XX 19-DEC-2001; 2001US-0340817P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;

XX WPI; 2003-505530/47.

XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 (Blys), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.

XX Example 1; SEQ ID NO 1733; 394pp; English.

XX This invention relates to novel antibodies that immunospecifically bind
 CC to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour

CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey BlyS. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of BlyS or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds BlyS of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
 XX Sequence 248 AA;

Query Match 100.0%; Score 502; DB 7; Length 248;
 Best Local Similarity 100.0%; Pred. No. 2.5e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
 Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
 Qy 61 AQKFGQVRVITADESTAYMELSLRSEDYAVYYCAR 98
 Db 61 AQKFGQVRVITADESTAYMELSLRSEDYAVYYCAR 98

RESULT 70
 ADG96553
 ID ADG96553 standard; protein; 248 AA.
 AC ADG96553;

XX 11-MAR-2004 (first entry)

DE Single chain antibody that immunospecifically binds BlyS SeqID 1737.

XX antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.

XX Unidentified.

XX WO2003055979-A2.

XX 10-JUL-2003.

XX 14-NOV-2002; 2002WO-US036496.

XX 16-NOV-2001; 2001US-0331469P.

XX 19-DEC-2001; 2001US-0340817P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;

XX WPI; 2003-505530/47.

XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 PT (BlyS), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.

XX Example 1; SEQ ID NO 1737; 394pp; English.

XX This invention relates to novel antibodies that immunospecifically bind
 CC to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour
 CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey BlyS. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of BlyS or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds BlyS of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
 XX Sequence 248 AA;

Query Match 100.0%; Score 502; DB 7; Length 248;
 Best Local Similarity 100.0%; Pred. No. 2.5e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
 Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQVRVITADESTAYMELSLRSEDYAVYYCAR 98

Db 61 AQKFGQVRVITADESTAYMELSLRSEDYAVYYCAR 98

RESULT 71
 ADG96534
 ID ADG96534 standard; protein; 248 AA.
 AC ADG96534;

XX 11-MAR-2004 (first entry)

DE Single chain antibody that immunospecifically binds BlyS SeqID 1718.

XX antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.

XX Unidentified.

XX WO2003055979-A2.

XX 10-JUL-2003.

XX 14-NOV-2002; 2002WO-US036496.

XX 16-NOV-2001; 2001US-0331469P.

XX 19-DEC-2001; 2001US-0340817P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;

XX WPI; 2003-505530/47.

XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator

PT (Blys), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.

PS Example 1; SEQ ID NO 1718; 394pp; English.

XX This invention relates to novel antibodies that immunospecifically bind
 CC to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour
 CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey Blys. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of Blys or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds Blys of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.

XX Sequence 248 AA;

Query Match 100.0%; Score 502; DB 7; Length 248;
 Best Local Similarity 100.0%; Pred. No. 2.5e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSYATISWVRQAPGQGLEWMGGIPIFGTANY 60
 Db 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSYATISWVRQAPGQGLEWMGGIPIFGTANY 60
 Qy 61 AQKQFGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
 Db 61 AQKQFGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 72
 ADG96695
 ID ADG96695 standard; protein; 248 AA.

XX ADG96695;

XX 11-MAR-2004 (first entry)

XX Single chain antibody that immunospecifically binds Blys SeqID 1879.

XX antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.

XX Unidentified.

XX WO2003055979-A2.

XX 10-JUL-2003.

XX 14-NOV-2002; 2002WO-US036496.

XX 16-NOV-2001; 2001US-0331469P.

XX 19-DEC-2001; 2001US-0340817P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;

XX WPI; 2003-505530/47.

XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 PT (Blys), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.

XX Example 1; SEQ ID NO 1879; 394pp; English.

XX This invention relates to novel antibodies that immunospecifically bind
 CC to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour
 CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey Blys. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of Blys or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds Blys of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.

XX Sequence 248 AA;

Query Match 100.0%; Score 502; DB 7; Length 248;
 Best Local Similarity 100.0%; Pred. No. 2.5e-39;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSYATISWVRQAPGQGLEWMGGIPIFGTANY 60
 Db 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSYATISWVRQAPGQGLEWMGGIPIFGTANY 60
 Qy 61 AQKQFGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
 Db 61 AQKQFGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 73
 ADG96548

ID ADG96548 standard; protein; 248 AA.

XX ADG96548;

XX 11-MAR-2004 (first entry)

XX Single chain antibody that immunospecifically binds Blys SeqID 1732.

XX antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.

XX Unidentified.

XX WO2003055979-A2.

XX 10-JUL-2003.

XX 14-NOV-2002; 2002WO-US036496.

XX 16-NOV-2001; 2001US-0331469P.

XX 19-DEC-2001; 2001US-0340817P.

```
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX
XX WPI; 2003-505530/47.
XX
XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX (Blys), useful for detecting and treating diseases or disorders e.g.
XX rheumatoid arthritis, asthma and leukemia.
XX
XX Example 1; SEQ ID NO 1732; 394pp; English.
XX
XX This invention relates to novel antibodies that immunospecifically bind
XX to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
XX chromosome 13q34 and encodes a protein that is a member of the tumour
XX necrosis factor superfamily and induces both in vivo and in vitro B cell
XX proliferation and differentiation. Specifically, it refers to single
XX chain antibody molecules (scFvs) derived, preferably, from the variable
XX heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX fragment thereof, of either human, murine, rat or monkey Blys. The
XX present invention refers to the use of such antibodies in various methods
XX for the detection, diagnosis and prognosis of diseases related to the
XX aberrant expression or inappropriate function of Blys or its receptor. As
XX such, these compositions are useful for identifying immune disorders
XX including myasthenia gravis and multiple sclerosis, inflammatory
XX disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX as AIDS and proliferative disorders including leukaemia, carcinoma and
XX lymphoma. Accordingly, they can be described as exhibiting various
XX activities such as antirheumatic, antiarthritic, neuroprotective,
XX antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
XX polypeptide sequence is a single chain antibody that binds Blys of the
XX invention. NOTE: The sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX
XX
XX Sequence 248 AA;
XX
XX Query Match 100.0%; Score 502; DB 7; Length 248;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-39;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSYSAISWVRQAPGQGLEWMGGIIPIFGTANY 60
XX Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSYSAISWVRQAPGQGLEWMGGIIPIFGTANY 60
XX
XX QY 61 AQKFGQGRVTTTADSTSTAYMELSSLRSSEDTAVYYCAR 98
XX Db 61 AQKFGQGRVTTTADSTSTAYMELSSLRSSEDTAVYYCAR 98
XX
XX
XX RESULT 74
XX AAB36083
XX ID AAB36083 standard; protein; 249 AA.
XX
XX AC AAB36083;
XX
XX XX 16-FEB-2001 (first entry)
XX
XX DE Recombinant human antibody scFv TN11.
XX
XX KW Human; antibody scFv; TN11; Tenascin-C; TN-C; domain C-containing TNC;
XX CTN-C.
XX
XX OS Homo sapiens.
XX
XX PN W0200063699-A1.
XX
XX XX 26-OCT-2000.
XX
XX PF 19-APR-2000; 2000WO-EP003550.
XX
XX XX 20-APR-1999; 99IT-FI000094.
XX
XX
XX (PHIL-) PHILGEN SRL.
XX
XX Zardi L;
XX
XX WPI; 2000-687225/67.
XX N-PSDB; AAC67868.
XX
XX Ligands used for diagnosis and treatment of human neoplasias, are capable
XX of identifying the tenascin-C isoform containing domain C of tenascin-C.
XX
XX Disclosure; Page 5-6; 31pp; English.
XX
XX The present sequence is a recombinant human antibody scFv. Antibody TN11
XX reacts with the long form of human Tenascin-C (TN-C). The epitope
XX recognised by TN11 is located inside domain C of TN-C. TN11 is therefore
XX only capable of recognising TN-C isoforms containing domain C (CTN-C).
XX TN11 is useful for detecting the presence of TN-C isoforms in vitro or in
XX vivo for diagnosing pathologies expressing the CTN-C isoforms of TN-C. It
XX is useful for the preparation of formulations for the treatment of human
XX neoplasias
XX
XX Sequence 249 AA;
XX
XX Query Match 100.0%; Score 502; DB 3; Length 249;
XX Best Local Similarity 100.0%; Pred. No. 2.5e-39;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSYSAISWVRQAPGQGLEWMGGIIPIFGTANY 60
XX Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSYSAISWVRQAPGQGLEWMGGIIPIFGTANY 60
XX
XX QY 61 AQKFGQGRVTTTADSTSTAYMELSSLRSSEDTAVYYCAR 98
XX Db 61 AQKFGQGRVTTTADSTSTAYMELSSLRSSEDTAVYYCAR 98
XX
XX
XX RESULT 75
XX AAU97198
XX ID AAU97198 standard; protein; 270 AA.
XX
XX AC AAU97198;
XX
XX XX 27-AUG-2002 (first entry)
XX
XX DE Human anti-EGFR single-chain antibody isolated from clone pSEX81-63.
XX
XX KW Human; anti-epidermal growth factor receptor single-chain antibody;
XX anti-EGFR-scFv; IGM; cancer; tumour growth; clone pSEX81-63; cytostatic.
XX
XX OS Homo sapiens.
XX
XX XX W0200230984-A1.
XX
XX PN 18-APR-2002.
XX
XX PD 12-OCT-2001; 2001WO-US031857.
XX
XX PF 13-OCT-2000; 2000US-0240353P.
XX
XX PR (UABR-) UAB RES FOUND.
XX
XX PA Raisch KP, Curriel DT, Bonner JA;
XX
XX PI WPI; 2002-463261/49.
XX
XX DR Novel human anti-epidermal growth factor receptor-single chain antibody
XX PT useful for diagnostic location and assessment of tumor growth, and in
XX PT treating cancer.
XX
XX PS Claim 3; Fig 2; 51pp; English.
XX
XX XX The present invention relates to human anti-epidermal growth factor
```

CC receptor single-chain antibodies (anti-EGFR-scfvs) isolated from a human
CC IGM phage display library using EGFR as antigen. Two isolates with
CC different amino acid sequences were identified. The anti-EGFR-scfvs are
CC useful for treating cancer, and for the diagnostic location and
CC assessment of tumour growth, where the anti-EGFR-scfv is radiolabelled.
CC The present sequence represents human anti-EGFR single-chain antibody
CC isolated from clone pSEX81-63
XX
XX

SQ Sequence 270 AA;

Query Match 100.0%; Score 502; DB 5; Length 270;

Best Local Similarity 100.0%; Pred. No. 2.7e-39;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Db 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98

Db 61 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98

Qy 61 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98

Db 61 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98

RESULT 76

AAR24442

ID AAR24442 standard; protein; 481 AA.

AC AAR24442;

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

DR WPI; 1992-216789/26.

DR N-PSDB; AAQ25443.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Search completed: May 12, 2006, 02:28:00

Job time : 75.5 secs

Query Match 100.0%; Score 502; DB 2; Length 481;

Best Local Similarity 100.0%; Pred. No. 4.9e-39;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Db 25 QVQLVQSGAEVKKPGSSVKVCKASGGTFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 84

Qy 61 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98

Db 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

Qy 85 AQKFQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 122

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:18 ; Search time 50.0631 Seconds
(without alignments)
1140.944 Million cell updates/sec

Title: US-09-674-752-23

Perfect score: 688

Sequence: 1 QVQLVQSGAEAKPGSSVKV.....EPRPDALDWGQGTMTVSS 130

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21.*

1: Geneseq1980s.*

2: Geneseq1990s.*

3: Geneseq2000s.*

4: Geneseq2001s.*

5: Geneseq2002s.*

6: Geneseq2003as.*

7: Geneseq2003bs.*

8: Geneseq2004s.*

9: Geneseq2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	688	100.0	130	3 AAY50948	Aay50948 Human ant
2	511	77.2	122	6 ADA89182	Ada89182 Human ant
3	524.5	76.2	121	6 ABR55787	Abr55787 Heavy cha
4	523	76.0	128	9 ADZ41971	Adz41971 Ig H chai
5	522	75.9	118	6 ABR42842	Abr42842 Tumour-sp
6	522	75.9	118	7 ABW02451	Abw02451 Human mon
7	522	75.9	128	9 ADZ41972	Adz41972 Ig H chai
8	517	75.1	118	3 AAY95558	Aay95558 Human LHL
9	517	75.1	118	6 ABR42861	Abr42861 Tumour-sp
10	517	75.1	118	7 ABW02447	Abw02447 Human mon
11	516	75.0	118	6 ABR42840	Abr42840 Tumour-sp
12	516	75.0	118	6 ABR42841	Abr42841 Tumour-sp
13	516	75.0	118	7 ABW02449	Abw02449 Human mon
14	516	75.0	118	7 ABW02450	Abw02450 Human mon
15	516	75.0	126	9 ADZ41969	Adz41969 Ig H chai
16	514.5	74.8	244	5 ABP45870	Abp45870 Human Bly
17	514.5	74.8	244	7 ADG96697	Adg96697 Single ch
18	514	74.7	128	9 ADG96697	Adg96697 Single ch
19	514	74.7	128	9 ADZ41970	Adz41970 Ig H chai
20	514	74.7	128	9 ADZ41973	Adz41973 Ig H chai
21	513	74.6	124	6 ABR55793	Abr55793 Heavy cha
22	512	74.4	120	2 AAW27550	Aaw27550 Human Ab
23	512	74.4	120	6 ABJ18672	Abj18672 Antibody
24	512	74.4	120	6 ABJ18718	Abj18718 Antibody

ALIGNMENTS

RESULT 1

AAY50948

ID AAY50948 standard; protein; 130 AA.

XX AAY50948;

DT 23-MAR-2000 (first entry)

XX Human anti-factor VIII antibody VH clone EL-14 encoded protein.

XX Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

XX VH gene.

XX Homo sapiens.

XX WO9558680-A2.

XX 18-NOV-1999.

XX 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;

XX WPI; 2000-053102/04.

XX New polynucleotide, polypeptide and antibody useful for diagnosing the

XX presence of neutralizing antibodies against factor VIII and for treatment

XX of hemophilia A patients with these antibodies.

XX Example 4; Fig 4A; 61pp; English.

XX This invention describes a novel polynucleotide (I) (and complements and

XX hybridizable polynucleotides) comprising a contiguous nucleotide sequence

XX coding for a human antibody with factor VIII specificity which has

XX hemostatic activity. (I) is useful a primer or probe for detecting the

XX presence of inhibitory antibodies directed against factor VIII. The

XX polypeptides of the invention and the antibodies generated from them are

XX useful in compositions for neutralizing factor VIII inhibiting antibodies

XX in hemophilia A patients. This sequence represents the human anti-factor

XX VIII antibody clone EL-14 protein which is used in the method of the

XX invention

XX Sequence 130 AA;

SQ

Abro1538 Human ant
Abp45498 Human Bly
Adg96325 Single ch
Adz41975 Ig H chai
Ade97370 Human imm
Ady16877 PRO poly
Abp45869 Human Bly
Adg96696 Single ch
Abp45855 Human Bly
Adg96682 Single ch
Abr55803 Heavy cha
Abr55777 Heavy cha
Ada89121 MS-Pro-28
Adg74372 MSPRO hea
Adn06990 Human EFG
Aau02555 Anti-adip
Aab36083 Recombina
Aau97198 Human ant
Abr62332 Anti-EBV
Abro1518 Human ant
Abp45722 Human Bly

25 512 74.4 220 6 ABR01538
26 511 74.3 253 5 ABP45498
27 511 74.3 253 7 ADG96325
28 510 74.1 128 9 ADZ41975
29 509.5 74.1 627 7 ADE97370
30 509.5 74.1 627 9 ADY16877
31 508.5 73.9 253 5 ABP45869
32 508.5 73.9 253 7 ADG96696
33 508 73.8 254 5 ABP45855
34 508 73.8 254 7 ADG96682
35 507.5 73.8 125 6 ABR55803
36 506.5 73.6 121 6 ABR55777
37 505 73.4 124 6 ADA89121
38 505 73.4 124 7 ADG74372
39 505 73.4 295 8 ADN06990
40 504.5 73.3 125 4 AAU02555
41 504.5 73.3 249 3 AAB36083
42 504 73.3 270 5 AAU97198
43 503 73.1 237 6 ABR62332
44 502.5 73.0 229 6 ABR01518
45 502.5 73.0 248 5 ABP45722

Query Match 100.0%; Score 688; DB 3; Length 130;
 Best Local Similarity 100.0%; Pred. No. 7.8e-58;
 Matches 130; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEAKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGIIPIFGSTKY 60
 DB 1 QVQLVSGAEAKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGIIPIFGSTKY 60
 QY 61 AOKFQGRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGGWYEGPPLLEPRPDALDIW 120
 DB 61 AOKFQGRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGGWYEGPPLLEPRPDALDIW 120
 QY 121 GQGTMVTVSS 130
 DB 121 GQGTMVTVSS 130

RESULT 2
 ADA89182
 ID ADA89182 standard; protein; 122 AA.
 AC ADA89182;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human antibody 1D7 heavy chain amino acid sequence SEQ ID NO:26.
 XX
 KW immunoglobulin; Ig; heavy chain variable domain;
 KW light chain variable domain; major histocompatibility complex; MHC;
 KW gp100; MUC1; TAX; hTERT; cytostatic; gene therapy; cancerous disorder;
 KW Cancer.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 FN WO2003070752-A2.
 XX
 PD 28-AUG-2003.
 XX
 PF 20-FEB-2003; 2003WO-US005128.
 XX
 PR 20-FEB-2002; 2002US-0358994P.
 XX
 PA (DYAX-) DYAX CORP.
 PA (TECR) TECHNION RES & DEV FOUND LTD.
 XX
 PI Hoogenboom HRJM, Reiter Y;
 XX
 DR WPI; 2003-663847/G2.
 DR N-PSDB; ADA89181.
 XX
 PT New protein comprising an immunoglobulin heavy chain variable (VH) domain
 PT and an immunoglobulin light chain variable (VL) domain, useful for
 PT preparing a composition for treating or preventing a cancerous disorder.
 XX
 PS Disclosure; Fig 5B; 224pp; English.
 XX
 CC The present invention describes a protein comprising an immunoglobulin
 CC (Ig) heavy chain variable (VH) domain and an Ig light chain variable (VL)
 CC domain. The protein binds a complex comprising a major histocompatibility
 CC complex (MHC) and a peptide, does not substantially bind the MHC in the
 CC absence of the bound peptide, and does not substantially bind the peptide
 CC in the absence of the MHC. The peptide is a peptide fragment of gp100,
 CC MUC1, TAX or hTERT. Also described: (1) a pharmaceutical composition
 CC comprising the novel protein and a carrier; (2) a cytotoxic T cell
 CC comprising one or more nucleic acids for expressing the Ig that binds a
 CC complex having an MHC and a peptide, does not substantially bind the MHC
 CC in the absence of the bound peptide, and does not substantially bind the
 CC peptide in the absence of the MHC; (3) an isolated nucleic acid
 CC comprising a first segment that encodes the Ig variable domain; (4) a
 CC host cell comprising heterologous nucleic acid sequences that encodes the
 CC novel protein; (5) a transgenic animal whose genome includes heterologous

CC nucleic acid sequences that encode the protein; (6) identifying the
 CC protein that specifically binds the MHC-peptide complex; (7) expressing
 CC an antigen-binding protein; (8) ablating or killing a target cell that
 CC displays a peptide on a surface MHC molecule; (9) treating or preventing
 CC a cancerous disorder in a subject; and (10) detecting an MHC-peptide
 CC complex in a sample. A protein of the invention has cytostatic activity,
 CC and can be used in gene therapy. The protein is useful for preparing a
 CC composition for treating or preventing a cancerous disorder. The present
 CC sequence represents the heavy chain of an antibody which binds to an MHC-
 CC peptide complex where the peptide component in as peptide fragment of
 CC gp100.

XX Sequence 122 AA;

Query Match 77.2%; Score 531; DB 6; Length 122;
 Best Local Similarity 79.2%; Pred. No. 7.4e-43;
 Matches 103; Conservative 7; Mismatches 12; Indels 8; Gaps 1;

QY 1 QVQLVSGAEAKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGIIPIFGSTKY 60
 DB 1 QVQLVSGAEAKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGIIPIFGTANY 60

QY 61 AOKFQGRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGGWYEGPPLLEPRPDALDIW 120
 DB 61 AOKFQGRVTITADESTSTAYMELNSLRSDTAIYYCARDSSGWLX-----DAFDIW 112

QY 121 GQGTMVTVSS 130
 DB 113 GQGTMVTVSS 122

RESULT 3
 ABR55787
 ID ABR55787 standard; protein; 121 AA.
 AC ABR55787;
 XX

DT 02-SEP-2003 (first entry)

DE Heavy chain variable region of anti-Ang-2 antibody 544 HC.

XX Ang-2; angiopoietin-2; anorectic; cytostatic; antiarteriosclerotic;
 KW Gynaecological; antiinflammatory; osteopathic; antipsoriatic; cancer;
 KW angiogenesis; antibody.

XX Homo sapiens.

PH Key Location/Qualifiers

FT Region 26..36 /note= "complementarity determining region (CDR) 1"
 FT Region 50..66 /note= "complementarity determining region (CDR) 2"

FT Region 96..111 /note= "complementarity determining region (CDR) 3"

XX WO2003030833-A2.

XX 17-APR-2003.

XX 11-OCT-2002; 2002WO-US032613.

XX 11-OCT-2001; 2001US-0328604P.

XX 10-OCT-2002; 2002US-00269805.

XX (AMGE-) AMGEN INC.

XX Oliner JD;

XX WPI; 2003-504963/47.

XX New specific binding agents (i.e. anti-Angiopoietin-2 antibodies), useful
 PT for inhibiting undesired angiogenesis, or treating e.g. cancers, obesity,
 PT hemangioma, arteriosclerosis, atherosclerosis or endometriosis.

XX Claim 1; Page 91; 161pp; English.

XX The invention relates to a specific binding agent, which comprises at

CC least one peptide selected from any of 62 peptides (ABR55769-830) or its

CC fragment. The binding agents are antibodies that recognize and bind to

CC angiotensin-2 (Ang-2). The specific binding agent, particularly the

CC antibody, is useful for inhibiting undesired angiogenesis, treating

CC cancers, inhibiting undesired angiogenesis, modulating or inhibiting Ang-

CC 2 activity, modulating vascular permeability or plasma leakage, or

CC treating a disease (e.g. ocular neovascular disease, obesity,

CC haemangioblastoma, haemangio, arteriosclerosis, inflammatory disease,

CC inflammatory disorders, atherosclerosis, endometriosis, neoplastic

CC disease, bone-related disease, or psoriasis) in a mammal. The present

CC sequence represents a heavy chain variable region of an anti-Ang-2

CC antibody

XX Sequence 121 AA;

XX

Query Match 76.2%; Score 524.5; DB 6; Length 121;

Best Local Similarity 78.5%; Pred. No. 3.1e-42;

Matches 102; Conservative 9; Mismatches 10; Indels 9; Gaps 1;

QY 1 QVQLVSGAEAKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMGGIIPFGSTKY 60

DB 1 QVQLVSGAEVKKPGASVKVSKASGDTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AOKFQGRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGGWSGPLEPRPDALDIW 120

DB 61 AOKFQGRVTITADESTSTAYMELNSLRSDTAIYYCARFESGYW-----GDAPDIW 111

QY 121 GQGTMVTVSS 130

DB 112 GQGTMVTVSS 121

RESULT 4

ID ADZ41971

XX ADZ41971;

XX

XX 30-JUN-2005 (first entry)

XX

XX Ig H chain variable region, B-CLL set IV peptide #3.

XX Antibody; antibody engineering; antibody therapy;

XX light chain variable region; heavy chain variable region;

XX chronic lymphocytic leukemia; cytostatic; Hodgkins disease; lymphoma;

XX Burkitts lymphoma; multiple myeloma; systemic lupus erythematosus;

XX antiinflammatory; dermatological; immunosuppressive; myasthenia gravis;

XX muscular-gen.; neuroprotective; Graves disease; antithyroid;

XX insulin dependent diabetes; diabetes mellitus; antidiabetic;

XX autoimmune hemolytic anemia; antianemic.

XX

OS Homo sapiens.

XX

XX WO2005034733-A2.

XX

XX 21-APR-2005.

XX

XX 08-OCT-2004; 2004WO-US033176.

XX

XX 08-OCT-2003; 2003US-0509473P.

XX

XX (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.

XX

XX Messmer BT, Chiorazzi N, Albesiano E;

XX

XX WPI; 2005-306220/31.

XX

XX New isolated and purified preparation of light chain and heavy chain

PT antibody genes, useful for diagnosing, preventing or treating B cell

PT chronic lymphocytic leukemia, or in screening for agents that may treat

XX such disease.

XX

XX Disclosure; Fig 2; 58pp; English.

XX

XX The new invention relates to combinations of light chain antibody genes

CC and heavy chain antibody genes, useful for treating B cell chronic

CC lymphocytic leukemia (B-CLL). B-CLL is a disease of slowly proliferating

CC CD5+ B lymphocytes. These cells express low levels of surface membrane Ig

CC that serves as the receptor for antigen (BCR). Analysis of V region gene

CC cassette usage has shown that distribution of variable region gene

CC cassettes used by B-CLL clones differs from that in normal cells, with an

CC increased frequency of VH3-07, VH4-34, and VH1-69 genes. This implies

CC that the structure of the antibody molecule, and antigen specificity,

CC play a role in the leukemic transformation of particular B cells. The

CC present invention discloses that a significant proportion of B-CLL

CC patients with aggressive disease share the same classes of VH, D, JH, VL

CC and JH antibody genes, forming sets of patients with highly homologous B

CC cell receptors. Alternatively, the patients have a disorder selected from

CC Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, myeloma or

CC systemic lupus erythematosus, myasthenia gravis, Grave's disease, type I

CC diabetes mellitus, autoimmune peripheral neuropathy, and autoimmune

CC hemolytic anemia. The new members of the antibody genes are: VH4-39/D6-

CC 5/JH6/VLkappaA17/JLkappa1/kappa2 (Set I); VH4-34/D5-

CC 21/JH6/VLlambdA3h/JLlambdA3 (Set III); VH1-69/D3-

CC 16/JH3/VLkappaA27/JLkappa1/kappa4 (Set IV); VH1-69/D3-

CC 10/JH6/VLlambdA1c/JLlambdA1 (Set V); VH1-02/D6-

CC 19/JH4/VLkappaA012/2/JLkappa1/kappa2 (Set VIA); VH1-03/D6-

CC 19/JH4/VLkappaA012/2/JLkappa1/kappa2 (Set VIB); VH1-18/D6-

CC 19/JH4/VLkappaA012/2/JLkappa1 (Set VIC); VH1-46/D6-19/JH4 (Set VID); VH5-

CC 15/D6-19/JH4/VLkappaA012/2/JLkappa2 (Set VIE); VH1-69/D3-

CC 3/JH4/VLkappaA19/JLkappa4 (Set VII); and VH1-69/D2-

CC 2/JH6/VLkappaA16/2/JLkappa3 (Set VIII). Treating a patient having B-CLL

CC with the above genes comprises administering an agent that binds to the

CC antigen-binding region of an antibody encoded by the antibody genes. The

CC agent is an anti-idiotype antibody, a peptide antigen, or an aptamer. The

CC present sequence is an Ig H chain variable region, B-CLL set IV peptide.

XX

XX Sequence 128 AA;

XX

Query Match 76.0%; Score 523; DB 9; Length 128;

Best Local Similarity 80.2%; Pred. No. 4.5e-42;

Matches 105; Conservative 8; Mismatches 14; Indels 4; Gaps 2;

QY 1 QVQLVSGAEAKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMGGIIPFGSTKY 60

DB 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AOKFQGRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGGWSGPLEPRP-DALDI 119

DB 61 AOKFQGRVTITADKSTSTAYMELNSLRSDTAIYYCAR---GGIYDVWGSYRPNDAPDV 117

QY 120 WQGQTMVTVSS 130

DB 118 WQGQTMVTVSS 128

RESULT 5

ID ABR42842

XX ABR42842 standard; protein; 118 AA.

XX

XX ABR42842;

XX

XX 08-SEP-2003 (first entry)

XX

XX Tumour-specific human MAb LH13 VH variant S97N.

XX

XX Human; monoclonal antibody; antibody; LH13; breast cancer;

XX ovarian cancer; lung cancer; antitumour; therapy; diagnosis; mutant;

XX

XX Homo sapiens.

OS

KW Burkitts lymphoma; multiple myeloma; systemic lupus erythematosus;
KW antiinflammatory; dermatological; immunosuppressive; myasthenia gravis;
KW muscular-gen.; neuroprotective; Graves disease; antithyroid;
KW insulin dependent diabetes; diabetes mellitus; antidiabetic;
KW autoimmune hemolytic anemia; antianemic.
XX
OS Homo sapiens.
XX
XX WO2005034733-A2.
XX
XX 21-APR-2005.
XX
XX 08-OCT-2004; 2004WO-US033176.
XX
XX 08-OCT-2003; 2003US-0509473P.
XX
XX (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.
XX
XX Messmer BT, Chiorazzi N, Albesiano E;
XX WPI; 2005-306220/31.
XX
XX New isolated and purified preparation of light chain and heavy chain
PT antibody genes, useful for diagnosing, preventing or treating B cell
PT chronic lymphocytic leukemia, or in screening for agents that may treat
PT such disease.
XX
XX Disclosure; Fig 2; 58pp; English.
XX
XX The new invention relates to combinations of light chain antibody genes
CC and heavy chain antibody genes, useful for treating B cell chronic
CC lymphocytic leukemia (B-CLL). B-CLL is a disease of slowly proliferating
CC CD5+ B lymphocytes. These cells express low levels of surface membrane Ig
CC that serves as the receptor for antigen (SCR). Analysis of V region gene
CC cassette usage has shown that distribution of variable region gene
CC cassettes used by B-CLL clones differs from that in normal cells, with an
CC increased frequency of VH3-07, VH4-34, and VH1-69 genes. This implies
CC that the structure of the antibody molecule, and antigen specificity,
CC play a role in the leukemic transformation of particular B cells. The
CC present invention discloses that a significant proportion of B-CLL
CC patients with aggressive disease share the same classes of VH, D, JH, VL
CC and JH antibody genes, forming sets of patients with highly homologous B
CC cell receptors. Alternatively, the patients have a disorder selected from
CC Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, myeloma or
CC systemic lupus erythematosus, myasthenia gravis, Grave's disease, type I
CC diabetes mellitus, autoimmune peripheral neuropathy, and autoimmune
CC hemolytic anemia. The new members of the antibody genes are: VH4-39/D6-
CC 13/JH5/VLkappa012/2/JLkappa1/kappa2 (Set I); VH4-34/D5-
CC 5/JH6/VLkappaA17/JLkappa1/kappa2 (Set II); VH3-
CC 21/JH6/VLlambd3h/JLlambd3 (Set III); VH1-69/D3-
CC 16/JH3/VLkappaA27/JLkappa1/kappa4 (Set IV); VH1-69/D3-
CC 10/JH6/VLlambd4c/JLlambd4i (Set V); VH1-02/D6-
CC 19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIA); VH1-03/D6-
CC 19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIB); VH1-18/D6-
CC 19/JH4/VLkappa012/2/JLkappa1 (Set VIC); VH1-46/D6-19/JH4
CC 51/D6-19/JH4/VLkappa012/2/JLkappa1 (Set VIE); VH1-69/D3-
CC 3/JH4/VLkappaA19/JLkappa4 (Set VII); and VH1-69/D2-
CC 2/JH6/VLkappa6/2/JLkappa3 (Set VIII). Treating a patient having B-CLL
CC with the above genes comprises administering an agent that binds to the
CC antigen-binding region of an antibody encoded by the antibody genes. The
CC agent is an anti-idiotypic antibody, a peptide antigen, or an aptamer. The
CC present sequence is an Ig H chain variable region, B-CLL set IV peptide.
XX
XX Sequence 128 AA;
SQ
Query Match 75.9%; Score 522; DB 9; Length 128;
Best Local Similarity 80.3%; Pred. No. 5.7e-42;
Matches 105; Conservative 8; Mismatches 14; Indels 4; Gaps 2;
QY 1 QVQLVSGAEAKPGSSVKVSKCAGDTFNSPISWVRQAPGQGLEWMGGIIPIFGSTKY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKCAGDTFSSVAISWVRQAPGQGLEWMGGIIPIFGTANY 60
QY 61 AOKFQGRVTMTADGSTSTAYMELNSLRSDTAIYYCARQNGGWYEGPILPRPDALDIW 120

QY 61 AOKFQGRVTMTADGSTSTAYMELNSLRSDTAIYYCARQNGGWYEGPILPRPDALDI 119
DB 61 AOKFQGRVTITADKSTSTAYMELSLRSRSDTAIVYCAR---GQPYDVWGSYRPNDAFDV 117
QY 120 WGGGTMTVTYSS 130
DB 118 WGGGTMTVTYSS 128

RESULT 8
AA999558
ID AA999558 standard; protein; 118 AA.
XX
XX AA999558;
XX
XX 20-SEP-2000 (first entry)
XX
XX Human LH13 monoclonal antibody heavy chain variable region.
DE
XX Human; LH13 monoclonal antibody; hybridoma; tumour-specific; cancer;
KW cytostatic; cytotoxic; heavy chain variable region.
XX
XX Homo sapiens.
OS
XX WO200032635-A2.
PN
XX 08-JUN-2000.
PD
XX
XX 01-DEC-1999; 99WO-US028485.
PF
XX 02-DEC-1998; 98US-00203768.
PR
XX (IXSY-) IXSYS INC.
PA
XX Watkins JD, Huse WD;
PI WPI; 2000-412293/35.
XX
XX N-PSDB; AAA48411.
DR
XX New tumor-specific human monoclonal antibody, useful for the treatment
PT and diagnosis of cancer, comprises at least one complementarity
PT determining region.
XX
XX Claim 10; Page 82-83; 84pp; English.
PS
XX The present sequence is the heavy chain variable region of a human tumour
CC -specific monoclonal antibody. Neoplastic cells selectively express
CC antigens which are not present on normal cells. Thus monoclonal
CC antibodies can be produced that are specifically directed against tumour-
CC specific antigens. The antibodies can be conjugated to cytotoxic or
CC cytostatic agents and used to selectively target cancer cells for the
CC elimination of tumours. They can also be linked to diagnostic moieties
CC that allow the imaging of neoplastic cells. Nucleic acids encoding human
CC tumour-specific monoclonal antibodies can be used to express the
CC antibodies and can be recombinantly engineered to produce modified
CC antibodies with higher affinity or higher selectivity for tumour cells.
CC Tumour-specific antibodies were produced by hybridomas that were
CC generated by in vitro immunisation of human spleen cell cultures with
CC breast carcinoma cells. The nucleic acid encoding the monoclonal antibody
CC was then isolated from the hybridoma by RT-PCR. The present sequence was
CC produced by LH13 hybridoma cell line
XX
XX Sequence 118 AA;
SQ
Query Match 75.1%; Score 517; DB 3; Length 118;
Best Local Similarity 76.2%; Pred. No. 1.6e-41;
Matches 99; Conservative 9; Mismatches 10; Indels 12; Gaps 1;
QY 1 QVQLVSGAEAKPGSSVKVSKCAGDTFNSPISWVRQAPGQGLEWMGGIIPIFGSTKY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKCAGDTFSSVAISWVRQAPGQGLEWMGGIIPIFGTANY 60
QY 61 AOKFQGRVTMTADGSTSTAYMELNSLRSDTAIYYCARQNGGWYEGPILPRPDALDIW 120


```
Db      109 GQGLTVTVSS 118
||||:|||||
RESULT 13
ABW02449
ID ABW02449 standard; protein; 118 AA.
XX
AC ABW02449;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human monoclonal antibody VH variant (S97G) protein from LH13 clone.
XX
KW Human; monoclonal antibody; neoplastic cell proliferation; breast cancer;
lung cancer; tumour; ovarian cancer cell; heavy chain variable region;
XX
KW VH; cytotstatic; variant.
XX
OS Homo sapiens.
XX
XX Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 101
FT /note= "Wild-type Ser substituted with Gly; This position
FT corresponds to position 97 of HCDR3 according to the
FT numbering system of Kabat at al"
FT
FT
XX US2003198638-A1.
XX
XX
XX 23-OCT-2003.
XX
XX 19-NOV-2002; 2002US-00300675.
XX
XX 19-NOV-2001; 2001US-0421146P.
XX
XX (WATK/) WATKINS J D.
XX
XX Watkins JD;
XX
XX WPI; 2003-852771/79.
XX
XX N-PSDB; AAD64353.
XX
XX New tumor-specific human monoclonal antibodies is useful for detecting
PT neoplastic cells in a biological sample, or for reducing proliferation of
PT neoplastic cells, particularly breast cancer, lung cancer or ovarian
PT cancer cells.
XX
PS Claim 1; SEQ ID NO 10; Opp; English.
XX
CC The present invention relates to novel tumour-specific human monoclonal
CC antibodies or their functional fragments. Sequences of the invention are
CC useful for detecting neoplastic cells in a biological sample or for
CC reducing neoplastic cell proliferation, particularly breast cancer, lung
CC cancer or ovarian cancer cells. The present sequence is human monoclonal
CC cancer or ovarian cancer cells. The present sequence is human monoclonal
CC antibody heavy chain variable region (VH) variant protein from LH13 clone
XX
SQ Sequence 118 AA;
Query Match 75.0%; Score 516; DB 7; Length 118;
Best Local Similarity 76.2%; Pred. No. 1.9e-41;
Matches 99; Conservative 8; Mismatches 11; Indels 12; Gaps 1;
QY 1 QVQLVQSGAEAKPGSSVKVSKCASKGDTFNSPISWVRQAPGGLEWMGGIIPFGSTKY 60
||||:|||||:||||:|||||:||||:|||||:||||:|||||:||||:|||||:
Db 1 QVQLVQSGAEVKKPGSSVKVSKCASKGDTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
||||:|||||:||||:|||||:||||:|||||:||||:|||||:||||:|||||:
QY 61 AQKFGQVRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYSGPLLEPRPDALDIW 120
||||:|||||:||||:|||||:||||:|||||:||||:|||||:||||:|||||:
Db 61 AQKFGQVRVTITADESTSTAYMELSLRSEDTAIYYCAREDTSGWYH-----YW 108
||||:|||||
QY 121 GQGLTVTVTVSS 130
||||:|||||
Db 109 GQGLTVTVSS 118
```

```
Db      109 GQGLTVTVSS 118
||||:|||||
RESULT 14
ABW02450
ID ABW02450 standard; protein; 118 AA.
XX
AC ABW02450;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human monoclonal antibody VH variant (S97T) protein from LH13 clone.
XX
KW Human; monoclonal antibody; neoplastic cell proliferation; breast cancer;
lung cancer; tumour; ovarian cancer cell; heavy chain variable region;
XX
KW VH; cytotstatic; variant.
XX
OS Homo sapiens.
XX
XX Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 101
FT /note= "Wild-type Ser substituted with Thr; This position
FT corresponds to position 97 of HCDR3 according to the
FT numbering system of Kabat at al"
FT
FT
XX US2003198638-A1.
XX
XX
XX 23-OCT-2003.
XX
XX 19-NOV-2002; 2002US-00300675.
XX
XX 19-NOV-2001; 2001US-0421146P.
XX
XX (WATK/) WATKINS J D.
XX
XX Watkins JD;
XX
XX WPI; 2003-852771/79.
XX
XX N-PSDB; AAD64354.
XX
XX New tumor-specific human monoclonal antibodies is useful for detecting
PT neoplastic cells in a biological sample, or for reducing proliferation of
PT neoplastic cells, particularly breast cancer, lung cancer or ovarian
PT cancer cells.
XX
PS Claim 1; SEQ ID NO 12; Opp; English.
XX
CC The present invention relates to novel tumour-specific human monoclonal
CC antibodies or their functional fragments. Sequences of the invention are
CC useful for detecting neoplastic cells in a biological sample or for
CC reducing neoplastic cell proliferation, particularly breast cancer, lung
CC cancer or ovarian cancer cells. The present sequence is human monoclonal
CC cancer or ovarian cancer cells. The present sequence is human monoclonal
CC antibody heavy chain variable region (VH) variant protein from LH13 clone
XX
SQ Sequence 118 AA;
Query Match 75.0%; Score 516; DB 7; Length 118;
Best Local Similarity 76.2%; Pred. No. 1.9e-41;
Matches 99; Conservative 8; Mismatches 11; Indels 12; Gaps 1;
QY 1 QVQLVQSGAEAKPGSSVKVSKCASKGDTFNSPISWVRQAPGGLEWMGGIIPFGSTKY 60
||||:|||||:||||:|||||:||||:|||||:||||:|||||:||||:|||||:
Db 1 QVQLVQSGAEVKKPGSSVKVSKCASKGDTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
||||:|||||:||||:|||||:||||:|||||:||||:|||||:||||:|||||:
QY 61 AQKFGQVRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYSGPLLEPRPDALDIW 120
||||:|||||:||||:|||||:||||:|||||:||||:|||||:||||:|||||:
Db 61 AQKFGQVRVTITADESTSTAYMELSLRSEDTAIYYCAREDTSGWYH-----YW 108
||||:|||||
QY 121 GQGLTVTVTVSS 130
||||:|||||
Db 109 GQGLTVTVSS 118
```

RESULT 15
AD241969
ID AD241969 standard; peptide; 126 AA.
XX AC AD241969;
XX AC
XX DT 30-JUN-2005 (first entry)
XX DE Ig H chain variable region, B-CLL set IV peptide #1.
XX KW Antibody; antibody engineering; antibody therapy;
XX KW light chain variable region; heavy chain variable region;
XX KW chronic lymphocytic leukemia; cytostatic; Hodgkins disease; lymphoma;
XX KW Burkitts lymphoma; multiple myeloma; systemic lupus erythematosus;
XX KW antiinflammatory; dermatological; immunosuppressive; myasthenia gravis;
XX KW muscular-gen.; neuroprotective; Graves disease; antithyroid;
XX KW insulin dependent diabetes; diabetes mellitus; antidiabetic;
XX KW autoimmune hemolytic anemia; antianemic.
XX OS Homo sapiens.
XX PN WO2005034733-A2.
XX PD 21-APR-2005.
XX PF 08-OCT-2004; 2004WO-US033176.
XX PR 08-OCT-2003; 2003US-0509473P.
XX PA (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.
XX PI Messmer BT, Chlorazzi N, Albesiano E;
XX DR WPI; 2005-306220/31.
XX PT New isolated and purified preparation of light chain and heavy chain
XX PT antibody genes, useful for diagnosing, preventing or treating B cell
XX PT chronic lymphocytic leukemia, or in screening for agents that may treat
XX PS such disease.
XX PS Disclosure; Fig 2; 58pp; English.

Search completed: May 5, 2006, 09:09:29
Job time : 51.0631 secs

CC agent is an anti-idiotypic antibody, a peptide antigen, or an aptamer. The
CC present sequence is an Ig H chain variable region, B-CLL set IV peptide.
XX
SQ Sequence 126 AA;
Query Match 75.0%; Score 516; DB 9; Length 126;
Best Local Similarity 78.5%; Pred. No. 2.1e-41;
Matches 102; Conservative 9; Mismatches 15; Indels 4; Gaps 1;
Qy 1 QVQLVSGAEAKPGSSVKVSKCKASGDTFNSRPISVVRQAPGOGLEWMGGIPIFGSTKY 60
Db 1 QVQLVSGAEVKKPGSSVKVSKCKASGDTFSSYAISVVRQAPGOGLEWMGGIPIFGTANY 60
Qy 61 AQKFGQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQQNGGWYEGPLLEPRPDALDIW 120
Db 61 AQKFGQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARD---YYDYVMGSGRYDAFDVW 116
Qy 121 GQGTMVTVSS 130
Db 117 GQGTMVTVSS 126

The new invention relates to combinations of light chain antibody genes and heavy chain antibody genes, useful for treating B cell chronic lymphocytic leukemia (B-CLL). B-CLL is a disease of slowly proliferating CD5+ B lymphocytes. These cells express low levels of surface membrane Ig that serves as the receptor for antigen (BCR). Analysis of V region gene cassette usage has shown that distribution of variable region gene cassettes used by B-CLL clones differs from that in normal cells, with an increased frequency of VH3-07, VH4-34, and VH1-69 genes. This implies that the structure of the antibody molecule, and antigen specificity, play a role in the leukemic transformation of particular B cells. The present invention discloses that a significant proportion of B-CLL patients with aggressive disease share the same classes of VH, D, JH, VL and JL antibody genes, forming sets of patients with highly homologous B cell receptors. Alternatively, the patients have a disorder selected from Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, myeloma or systemic lupus erythematosus, myasthenia gravis, Grave's disease, type I diabetes mellitus, autoimmune peripheral neuropathy, and autoimmune hemolytic anemia. The new members of the antibody genes are: VH4-39/D6-13/JH5/VLkappa012/2/JLkappa1/kappa2 (Set I); VH4-34/D5-5/JH6/VLkappaA17/JLkappa1/kappa2 (Set II); VH3-21/JH6/VLlambdadh3/JLlambdadh3 (Set III); VH1-69/D3-16/JH3/VLkappaA27/JLkappa1/kappa4 (Set IV); VH1-69/D3-10/JH6/VLlambdadh3/JLlambdadh3 (Set V); VH1-02/D6-19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIA); VH1-03/D6-19/JH4/VLkappa012/2/JLkappa1/kappa2 (Set VIB); VH1-18/D6-19/JH4/VLkappa012/2/JLkappa1 (Set VIC); VH1-46/D6-19/JH4 (Set VID); VH5-51/D6-19/JH4/VLkappa012/2/JLkappa2 (Set VIE); VH1-69/D3-3/JH4/VLkappaA19/JLkappa4 (Set VII); and VH1-69/D2-2/JH6/VLkappaL6/2/JLkappa3 (Set VIII). Treating a patient having B-CLL with the above genes comprises administering an agent that binds to the antigen-binding region of an antibody encoded by the antibody genes. The

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:53:55 ; Search time 14.2803 Seconds
(without alignments)
752.634 Million cell updates/sec

Title: US-09-674-752-23

Perfect score: 688

Sequence: 1 QVOLVSGAEAKPGSSVKV.....EPRPDALDIWGQGTMTVSS 130

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA:*

- 1: /cgn2_6/prodata/1/iaa/5 COMB.pep.*
- 2: /cgn2_6/prodata/1/iaa/6 COMB.pep.*
- 3: /cgn2_6/prodata/1/iaa/H COMB.pep.*
- 4: /cgn2_6/prodata/1/iaa/PCTUS COMB.pep.*
- 5: /cgn2_6/prodata/1/iaa/RE COMB.pep.*
- 6: /cgn2_6/prodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	517	75.1	118	2	US-09-203-768A-6
2	512	74.4	120	2	US-09-025-769B-35
3	512	74.4	120	2	US-09-025-769B-57
4	512	74.4	120	2	US-09-490-070A-35
5	512	74.4	120	2	US-09-490-070A-57
6	512	74.4	120	2	US-09-490-153-35
7	512	74.4	120	2	US-09-490-153-57
8	512	74.4	120	2	US-09-490-324-35
9	512	74.4	120	2	US-09-490-324-57
10	504	73.3	270	2	US-09-976-118-2
11	496.5	72.2	119	2	US-09-025-769B-21
12	496.5	72.2	119	2	US-09-490-070A-21
13	496.5	72.2	119	2	US-09-490-153-21
14	496.5	72.2	119	2	US-09-490-324-21
15	484.5	70.4	120	1	US-08-428-197-12
16	484.5	70.4	120	4	PCT-US93-10555-12
17	482.5	70.1	121	1	US-08-322-081B-41
18	481.5	70.0	119	2	US-08-983-607-50
19	480.5	69.8	120	1	US-08-428-197-13
20	480.5	69.8	120	4	PCT-US93-10555-13
21	479.5	69.7	123	1	US-08-552-816A-8
22	474.5	69.0	123	1	US-08-652-816A-9
23	471.5	68.5	123	1	US-08-552-816A-9
24	471	68.5	128	1	US-08-202-047-22
25	471	68.5	128	2	US-08-964-690-22
26	471	68.5	147	1	US-08-217-918-4
27	469.5	68.2	123	1	US-08-652-816A-6

28	465.5	67.7	129	1	US-08-561-521-45	Sequence 45, Appl
29	465.5	67.7	129	2	US-08-525-539A-77	Sequence 77, Appl
30	465.5	67.7	129	4	PCT-US95-01219-45	Sequence 45, Appl
31	463.5	67.4	476	1	US-08-378-939-10	Sequence 10, Appl
32	463	67.3	120	2	US-09-025-769B-36	Sequence 36, Appl
33	463	67.3	120	2	US-09-025-769B-59	Sequence 59, Appl
34	463	67.3	120	2	US-09-490-070A-36	Sequence 36, Appl
35	463	67.3	120	2	US-09-490-070A-59	Sequence 59, Appl
36	463	67.3	120	2	US-09-490-153-36	Sequence 36, Appl
37	463	67.3	120	2	US-09-490-153-59	Sequence 59, Appl
38	463	67.3	120	2	US-09-490-324-36	Sequence 36, Appl
39	463	67.3	120	2	US-09-490-324-59	Sequence 59, Appl
40	463	67.3	142	2	US-09-471-276-872	Sequence 872, App
41	462.5	67.2	123	1	US-08-482-882-53	Sequence 53, Appl
42	462.5	67.2	123	1	US-08-483-389-53	Sequence 53, Appl
43	462.5	67.2	123	1	US-08-487-113D-53	Sequence 53, Appl
44	462.5	67.2	123	1	US-08-473-503-53	Sequence 53, Appl
45	462.5	67.2	123	1	US-08-483-932-53	Sequence 53, Appl

ALIGNMENTS

RESULT 1
US-09-203-768A-6
; Sequence 6, Application US/09203768A
; Patent No. 6787638
; GENERAL INFORMATION:
; APPLICANT: Huse, William D.
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Human Monoclonal Antibodies and Methods
; TITLE OF INVENTION: of Use
; FILE REFERENCE: P-IX 2947
; CURRENT APPLICATION NUMBER: US/09/203,768A
; CURRENT FILING DATE: 1998-12-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-203-768A-6

Query Match	75.1%	Score 517;	DB 2;	Length 118;
Best Local Similarity	76.2%	Pred. No. 6.8e-46;		
Matches	99;	Conservative	9;	Mismatches 10; Indels 12; Gaps 1;
Qy	1	QVOLVSGAEAKPGSSVKVSKASGDTFNSPFIWVRQAPGGLEWGGIIFIGSTKY	60	
Db	1	QVOLVSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGGLEWGGIIFIGTANY	60	
Qy	61	AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCARQONGWYEGPLLEPRDLDIW	120	
Db	61	AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCARQONGWYEGPLLEPRDLDIW	120	
Qy	121	GQGTMTVSS 130		
Db	109	GQGTMTVSS 118		

RESULT 2
US-09-025-769B-35
; Sequence 35, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373

CORRESPONDENCE ADDRESS:
 ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
 STREET: 1251 Avenue of the Americas
 CITY: New York
 STATE: New York
 COUNTRY: USA
 ZIP: 10021
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/025,769B
 FILING DATE: 18-FEB-1998
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: EP 95 11 3021.0
 FILING DATE: 18-AUG-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: James F. Haley, Jr., Esq.
 REGISTRATION NUMBER: 27,794
 REFERENCE/DOCKET NUMBER: MORPHO/5
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212)596-9000
 TELEFAX: (212)596-9090
 INFORMATION FOR SEQ ID NO: 35:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 120 amino acids
 TYPE: amino acid
 STRANDEDNESS:
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-09-025-769B-35

[illegible]

```

RESULT 3
US-09-025-769B-57
; Sequence 57, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

```

```

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; UN-09-025-769B-57

Query Match 74.4%; Score 512; DB 2; Length 120;
Best Local Similarity 76.9%; Pred. No. 2.3e-45;
Matches 100; Conservative 9; Mismatches 11; Indels 10;

QY 1 QVLQVSGAEAKPGSSVKVSKASGDTFNSFISWVRQAPCGGLEWVGGIIP
Db 1 QVLQVSGAEVKKPGSSVKVSKASGGTFSSAISWVRQAPCGGLEWVGGIIP
QY 61 AKQFQRVTMTADGSTSTAYMELNSLRSDTAIYTCARQONGWYEGPLLEPRP
Db 61 AKQFQRVTITADESTSTAYMELSLRSEDTAIYTCARQONGWYEGPLLEPRP
QY 121 GQGTWTVTSS 130
Db 111 GQGTWTVSS 120

RESULT 4
US-09-490-070A-35
; Sequence 35, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995

```

```
/
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Colin G. Sandercock, Esq.
/ REGISTRATION NUMBER: 31,298
/ REFERENCE/DOCKET NUMBER: 37629-0005
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (202) 912-2000
/ TELEFAX: (202) 912-2020
/ INFORMATION FOR SEQ ID NO: 35:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 120 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: <Unknown>
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-490-070A-35

Query Match 74.4%; Score 512; DB 2; Length 120;
Best Local Similarity 76.9%; Pred. No. 2.3e-45;
Matches 100; Conservative 9; Mismatches 11; Indels 10; Gaps 1;

QY 1 QVOLVSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGGGLEWMGGIIPFGSTKY 60
Db 1 QVOLVSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAIYYCARWGGDGFY-----AMDYW 110
QY 121 GQGTMTVTSS 130
Db 111 GQGTMTVTSS 120

RESULT 5
US-09-490-070A-57
/ Sequence 57, Application US/09490070A
/ Patent No. 6696248
/ GENERAL INFORMATION:
/ APPLICANT: Knappik, Achim
/ Pack, Peter
/ Ilag, Vic
/ Ge, Liming
/ Moroney, Simon
/ Plueckthun, Andreas
/ TITLE OF INVENTION: Protein/(Poly)peptide libraries
/ NUMBER OF SEQUENCES: 373
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
/ White & McAuliffe
/ STREET: 1666 K Street, N.W., Suite 300
/ CITY: Washington
/ STATE: D.C.
/ COUNTRY: USA
/ ZIP: 20006
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/490,070A
/ FILING DATE: 24-Jan-2000
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: EP 95 11 3021.0
/ FILING DATE: 18-AUG-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Colin G. Sandercock, Esq.
/ REGISTRATION NUMBER: 31,298
/ REFERENCE/DOCKET NUMBER: 37629-0005
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (202) 912-2000
/ TELEFAX: (202) 912-2020

/
/ INFORMATION FOR SEQ ID NO: 57:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 120 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-09-490-070A-57

Query Match 74.4%; Score 512; DB 2; Length 120;
Best Local Similarity 76.9%; Pred. No. 2.3e-45;
Matches 100; Conservative 9; Mismatches 11; Indels 10; Gaps 1;

QY 1 QVOLVSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGGGLEWMGGIIPFGSTKY 60
Db 1 QVOLVSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAIYYCARWGGDGFY-----AMDYW 110
QY 121 GQGTMTVTSS 130
Db 111 GQGTMTVTSS 120

RESULT 6
US-09-490-153-35
/ Sequence 35, Application US/09490153
/ Patent No. 6706484
/ GENERAL INFORMATION:
/ APPLICANT: Knappik, Achim
/ Pack, Peter
/ Ilag, Vic
/ Ge, Liming
/ Moroney, Simon
/ Plueckthun, Andreas
/ TITLE OF INVENTION: Protein/(Poly)peptide libraries
/ NUMBER OF SEQUENCES: 373
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
/ STREET: 1251 Avenue of the Americas
/ CITY: New York
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 10021
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/490,153
/ FILING DATE: 24-Jan-2000
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/09/025,769B
/ FILING DATE: 18-FEB-1998
/ APPLICATION NUMBER: EP 95 11 3021.0
/ FILING DATE: 18-AUG-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: James F. Haley, Jr., Esq.
/ REGISTRATION NUMBER: 27,794
/ REFERENCE/DOCKET NUMBER: MORPHO/5
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212)596-9000
/ TELEFAX: (212)596-9090
/ INFORMATION FOR SEQ ID NO: 35:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 120 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: <Unknown>
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
```

```

;
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-490-153-35
    Query Match          74.4%; Score 512; DB 2; Length 120;
    Best Local Similarity 76.9%; Pred. No. 2.3e-45;
    Matches 100; Conservative 9; Mismatches 11; Indels 10; Gaps 1;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGGLEWMGGIIPFGSTKY 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQVRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQVRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 GQGTMTVTVSS 130
Db |||||:|||||
111 GQGTMTVTVSS 120

RESULT 8
US-09-490-324-35
; Sequence 35, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-490-324-35
    Query Match          74.4%; Score 512; DB 2; Length 120;
    Best Local Similarity 76.9%; Pred. No. 2.3e-45;
    Matches 100; Conservative 9; Mismatches 11; Indels 10; Gaps 1;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGGLEWMGGIIPFGSTKY 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQVRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQVRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 GQGTMTVTVSS 130
Db |||||:|||||
111 GQGTMTVTVSS 120

RESULT 7
US-09-490-153-57
; Sequence 57, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-09-490-153-57
    Query Match          74.4%; Score 512; DB 2; Length 120;
    Best Local Similarity 76.9%; Pred. No. 2.3e-45;
    Matches 100; Conservative 9; Mismatches 11; Indels 10; Gaps 1;

```

```

Db      61 AQKFGQVRVTITADESTSTAYMELSLRSEDYAVYYCARMGGDGFY-----AMDYW 110
QY      121 GQGTMTVTSS 130
      |||||
Db      111 GQGTMTVTSS 120

RESULT 9
US-09-490-324-57
; Sequence 57, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-09-490-324-57

Query Match      74.4%; Score 512; DB 2; Length 120;
Best Local Similarity 76.9%; Pred. No. 2.3e-45;
Matches 100; Conservative 9; Mismatches 11; Indels 10; Gaps 1;

QY      1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMGGIIPFGSTKY 60
      |||||
Db      1 QVQLVSGAEVKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMGGIIPFGTANY 60

QY      61 AQKFGQVRVTITADESTSTAYMELSLRSEDYAVYYCARMQNGWYEGPLLEPRDLDIW 120
      |||||
Db      61 AQKFGQVRVTITADESTSTAYMELSLRSEDYAVYYCARMGGDGFY-----AMDYW 110

QY      121 GQGTMTVTSS 130
      |||||
Db      111 GQGTMTVTSS 120

```

```

RESULT 10
US-09-976-118-2
; Sequence 2, Application US/09976118
; Patent No. 6699473
; GENERAL INFORMATION:
; APPLICANT: Ralsch, Kevin Paul
; APPLICANT: Curiel, David T.
; APPLICANT: Bonner, James Allen
; TITLE OF INVENTION: Human Anti-Epidermal Growth Factor Receptor
; TITLE OF INVENTION: Single-Chain Antibodies
; FILE REFERENCE: D6355
; CURRENT APPLICATION NUMBER: US/09/976,118
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: US 60/240,353
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 270
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: amino acid sequence of anti-EGFR scFV
; OTHER INFORMATION: clone pSEX81-63
US-09-976-118-2

Query Match      73.3%; Score 504; DB 2; Length 270;
Best Local Similarity 74.6%; Pred. No. 4e-44;
Matches 100; Conservative 10; Mismatches 12; Indels 12; Gaps 2;

QY      1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMGGIIPFGSTKY 60
      |||||
Db      1 QVQLVSGAEVKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMGGIIPFGTANY 60

QY      61 AQKFGQVRVTITADESTSTAYMELSLRSEDYAVYYCARQQ-----NGGWYEGPLLEPRDPA 116
      |||||
Db      61 AQKFGQVRVTITADESTSTAYMELSLRSEDYAVYYCARDPDYVYSGSY-----PNW 112

QY      117 LDWVGQGTMTVTSS 130
      |||||
Db      113 FDPWQGTMTVTSS 126

RESULT 11
US-09-025-769B-21
; Sequence 21, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995

```

```

; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-025-769B-21

Query Match 72.2%; Score 496.5; DB 2; Length 119;
Best Local Similarity 76.2%; Pred. No. 8.9e-44;
Matches 99; Conservative 8; Mismatches 12; Indels 11; Gaps 2;

QY 1 QVQLVQSGAEAKPGSSVKVSKASGDTFNSPISWVRQAPQGGLWMGGIIPFGSTKY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPQGGLWMGGIIPFGTANY 60
QY 61 AQKFGQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDTAIYYCARAP--GYCSG-----FDYW 109
QY 121 GQGTMVTVSS 130
Db 110 GQGLTLVTVSS 119

RESULT 12
US-09-490-070A-21
; Sequence 21, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge. Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 376229-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 21:

```

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-09-490-070A-21

Query Match 72.2%; Score 496.5; DB 2; Length 119;
Best Local Similarity 76.2%; Pred. No. 8.9e-44;
Matches 99; Conservative 8; Mismatches 12; Indels 11; Gaps 2;

QY 1 QVQLVQSGAEAKPGSSVKVSKASGDTFNSPISWVRQAPQGGLWMGGIIPFGSTKY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPQGGLWMGGIIPFGTANY 60
QY 61 AQKFGQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDTAIYYCARAP--GYCSG-----FDYW 109
QY 121 GQGTMVTVSS 130
Db 110 GQGLTLVTVSS 119

RESULT 13
US-09-490-153-21
; Sequence 21, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge. Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein

```

SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-09-490-153-21

Query Match 72.2%; Score 496.5; DB 2; Length 119;
Best Local Similarity 76.2%; Pred. No. 8.9e-44;
Matches 99; Conservative 8; Mismatches 12; Indels 11; Gaps 2;

QY 1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGGLEWMGGIIPIFGSTKY 60
Db 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPIFGTANY 60
QY 61 AQKQGRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGWYEGPDLPRDLDIW 120
Db 61 AQKQGRVTTADESTSTAYMELSSLRSDTAIYYCARAP--GYCSG-----FDYW 109
QY 121 GQGTMTVTS 130
Db 110 GQGTMTVTS 119

RESULT 14

US-09-490-324-21
; Sequence 21, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Ge, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-09-490-324-21

Query Match 72.2%; Score 496.5; DB 2; Length 119;
Best Local Similarity 76.2%; Pred. No. 8.9e-44;
Matches 99; Conservative 8; Mismatches 12; Indels 11; Gaps 2;

QY 1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGGLEWMGGIIPIFGSTKY 60
Db 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPIFGTANY 60
QY 61 AQKQGRVTMTADGSTSTAYMELNSLRSDTAIYYCARQONGWYEGPDLPRDLDIW 120
Db 61 AQKQGRVTTADESTSTAYMELSSLRSDTAIYYCARAP--GYCSG-----FDYW 109
QY 121 GQGTMTVTS 130
Db 110 GQGTMTVTS 119

RESULT 15

US-08-428-197-12
; Sequence 12, Application US/08428197
; Patent No. 5891438
; GENERAL INFORMATION:
; APPLICANT: SILVERMAN, GREGG J.
; TITLE OF INVENTION: METHOD FOR STIMULATING PRODUCTION OF
; TITLE OF INVENTION: VARIABLE REGION GENE FAMILY RESTRICTED ANTIBODIES THROUGH
; TITLE OF INVENTION: VACCINATION WITH A B-CELL SUPERANTIGEN AND CONJUGATES
; TITLE OF INVENTION: THEREOF
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Spensley Horn Jubas & Lubitz
; STREET: 1880 Century Park East - Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/428,197
; FILING DATE:

CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/10555
; FILING DATE: 29-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Howells, Stacy L.
; REGISTRATION NUMBER: 34,842
; REFERENCE/DOCKET NUMBER: FD-2630
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 455-5100
; TELEFAX: (619) 455-5110
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; IMMEDIATE SOURCE:
; CLONE: BOR
; FEATURE:
; NAME/KEY: Peptide
; LOCATION: 1..120
US-08-428-197-12

Query Match 70.4%; Score 484.5; DB 1; Length 120;
Best Local Similarity 75.2%; Pred. No. 1.6e-42;
Matches 97; Conservative 9; Mismatches 14; Indels 9; Gaps 2;

QY 2 VOLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGGLEWMGGIIPIFGSTKYA 61
Db 1 VOLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPIFGTNYA 60

```
Qy 62 QKFGRTVTADGSTSTAYMELNSLRSEDTAIYYCARQQNGWYEGPGLLEPRDALDIWG 121
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 QKFGRTVTITDESTAYMEVSSLRSEDTAIYYCAR-----EGRMAINP--FDYWG 111

Qy 122 QGTMTVTSS 130
Db |||:||||
112 QGTMTVTSS 120
```

Search completed: May 5, 2006, 08:56:23
Job time : 14.2803 secs

RESULT 2
US-10-269-805-19
; Sequence 19, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11


```
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Recombinant variant
US-10-300-675-10

Query Match          75.0%; Score 516; DB 4; Length 118;
Best Local Similarity 76.2%; Pred. No. 1.3e-39;
Matches 99; Conservative 8; Mismatches 11; Indels 12; Gaps 1;

QY 1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGGQLEWMGGIIPIFGSTKY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGQLEWMGGIIPIFGTANY 60

QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCARQONGWYEGPGLLEPRPDALDIW 120
DB 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCAREDTSGWYH-----YW 108

QY 121 GQGTMTVTSS 130
DB 109 GQGTMTVTSS 118

RESULT 7
US-10-300-675-12
; Sequence 12, Application US/10300675
; Publication No. US20030198638A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffery D.
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Recombinant variant
US-10-300-675-12

Query Match          75.0%; Score 516; DB 4; Length 118;
Best Local Similarity 76.2%; Pred. No. 1.3e-39;
Matches 99; Conservative 8; Mismatches 11; Indels 12; Gaps 1;

QY 1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGGQLEWMGGIIPIFGSTKY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGQLEWMGGIIPIFGTANY 60

QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCARQONGWYEGPGLLEPRPDALDIW 120
DB 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCAREDTSGWYH-----YW 108

QY 121 GQGTMTVTSS 130
DB 109 GQGTMTVTSS 118

RESULT 8
US-10-300-675-12
; Sequence 12, Application US/10300675
; Publication No. US20030198638A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffery D.
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Recombinant variant
US-10-300-675-12

Query Match          75.0%; Score 516; DB 4; Length 118;
Best Local Similarity 76.2%; Pred. No. 1.3e-39;
Matches 99; Conservative 8; Mismatches 11; Indels 12; Gaps 1;

QY 1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGGQLEWMGGIIPIFGSTKY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGQLEWMGGIIPIFGTANY 60

QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCARQONGWYEGPGLLEPRPDALDIW 120
DB 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCAREDTSGWYH-----YW 108

QY 121 GQGTMTVTSS 130
DB 109 GQGTMTVTSS 118

RESULT 9
US-10-293-418-1881
; Sequence 1881, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1881
; LENGTH: 244

Query Match          74.8%; Score 514.5; DB 3; Length 244;
Best Local Similarity 76.9%; Pred. No. 3.9e-39;
Matches 100; Conservative 9; Mismatches 12; Indels 9; Gaps 1;

QY 1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGGQLEWMGGIIPIFGSTKY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGQLEWMGGIIPIFGTANY 60

QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCARQONGWYEGPGLLEPRPDALDIW 120
DB 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARDGSGYY-----DAPDIW 111

QY 121 GQGTMTVTSS 130
DB 112 GQGTMTVTSS 121
```

```
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1881

Query Match          74.8%; Score 514.5; DB 4; Length 244;
Best Local Similarity 76.9%; Pred. No. 3.e-39;
Matches 100; Conservative 9; Mismatches 12; Indels 9; Gaps 1;

QY 1 QVOLVSGAEAKKPGSSVKVSKASGDTFNSPFIISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVOLVSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AQKFGQGRVTMTADGSTAYMELNSLRSEDTAIYYCARQONGGWYEGPPLLEPRPDALDIW 120
Db 61 AQKFGQGRVTITADKSTAYMELSLRSDDTAVYYCARDGSGYY-----DAFDIW 111

QY 121 GQGTMTVTSS 130
Db 112 GKGTMTVTSS 121

RESULT 10
US-10-269-805-25
; Sequence 25, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-25

Query Match          74.6%; Score 513; DB 4; Length 124;
Best Local Similarity 79.2%; Pred. No. 2.5e-39;
Matches 103; Conservative 9; Mismatches 12; Indels 6; Gaps 2;

QY 1 QVOLVSGAEAKKPGSSVKVSKASGDTFNSPFIISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVOLVSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AQKFGQGRVTMTADGSTAYMELNSLRSEDTAIYYCARQONGGWYEGPPLLEPRPDALDIW 120
Db 61 AQKFGQGRVTITADESTAYMELSLRSDDTAVYYCARGYD--FWSGYSL----DAFDIW 114

QY 121 GQGTMTVTSS 130
Db 115 GQGTMTVTSS 124

RESULT 11
US-10-125-687-1
; Sequence 1, Application US/10125687
; Publication No. US20030054407A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Peter
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705
; CURRENT APPLICATION NUMBER: US/10/125,687
; CURRENT FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-125-687-1

Query Match          74.4%; Score 512; DB 5; Length 120;
Best Local Similarity 76.9%; Pred. No. 3e-39;
Matches 100; Conservative 9; Mismatches 11; Indels 10; Gaps 1;

QY 1 QVOLVSGAEAKKPGSSVKVSKASGDTFNSPFIISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVOLVSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AQKFGQGRVTMTADGSTAYMELNSLRSEDTAIYYCARQONGGWYEGPPLLEPRPDALDIW 120
Db 61 AQKFGQGRVTITADESTAYMELSLRSDDTAVYYCARGWGGDFY-----AMDYW 110

QY 121 GQGTMTVTSS 130
Db 111 GQGTMTVTSS 120

RESULT 12
US-10-996-191-1
; Sequence 1, Application US/10996191
; Publication No. US20050148001A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Peizhi
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705.301
; CURRENT APPLICATION NUMBER: US/10/996,191
; CURRENT FILING DATE: 2004-11-22
; PRIOR APPLICATION NUMBER: US 60/284,407
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: US 10/125,687
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Human consensus antibody heavy chain variable region
US-10-996-191-1

Query Match          74.4%; Score 512; DB 5; Length 120;
Best Local Similarity 76.9%; Pred. No. 3e-39;
Matches 100; Conservative 9; Mismatches 11; Indels 10; Gaps 1;

QY 1 QVOLVSGAEAKKPGSSVKVSKASGDTFNSPFIISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVOLVSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AQKFGQGRVTMTADGSTAYMELNSLRSEDTAIYYCARQONGGWYEGPPLLEPRPDALDIW 120
Db 61 AQKFGQGRVTITADESTAYMELSLRSDDTAVYYCARGWGGDFY-----AMDYW 110

QY 121 GQGTMTVTSS 130
Db 111 GQGTMTVTSS 120

RESULT 13
US-10-128-520-175
; Sequence 175, Application US/10128520
; Publication No. US20040105862A1
; GENERAL INFORMATION:
; APPLICANT: PAN et al.
; TITLE OF INVENTION: Human TIMP-1 Antibodies
; FILE REFERENCE: 02973.00073
; CURRENT APPLICATION NUMBER: US/10/128,520
; CURRENT FILING DATE: 2002-04-24
```


THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:52 ; Search time 9.84848 Seconds
(without alignments)
610.959 Million cell updates/sec

Title: US-09-674-752-23

Perfect score: 688

Sequence: 1 QVOLVSGAEAKPGSSVKV.....EPRDLDIWMQGTMTVTS 130

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Published Applications AA New:
- 1: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
 - 2: /SIDSS5/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
 - 3: /SIDSS5/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
 - 4: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
 - 5: /SIDSS5/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
 - 6: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
 - 7: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
 - 8: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
 - 9: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
 - 10: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
 - 11: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
 - 12: /SIDSS5/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	524.5	76.2	121	9	US-10-982-440-19
2	514.5	74.8	244	11	US-11-054-515-1881
3	514.5	74.8	244	11	US-11-266-444-1881
4	513	74.6	124	9	US-10-982-440-25
5	512	74.4	120	9	US-10-834-397-35
6	512	74.4	120	9	US-10-834-397-57
7	511	74.3	253	11	US-11-054-515-1509
8	511	74.3	253	11	US-11-266-444-1509
9	509.5	74.1	627	9	US-10-493-909-47
10	508.5	73.9	253	11	US-11-054-515-1880
11	508.5	73.9	253	11	US-11-266-444-1880
12	508	73.8	254	11	US-11-054-515-1866
13	508	73.8	254	11	US-11-266-444-1866
14	507.5	73.8	125	9	US-10-982-440-35
15	506.5	73.6	121	9	US-10-982-440-9
16	502.5	73.0	248	11	US-11-054-515-1733
17	502.5	73.0	248	11	US-11-054-515-1734
18	502.5	73.0	248	11	US-11-266-444-1733
19	502.5	73.0	248	11	US-11-266-444-1734
20	501.5	72.9	248	11	US-11-054-515-1718
21	501.5	72.9	248	11	US-11-054-515-1879

22	501.5	72.9	248	11	US-11-266-444-1718	Sequence 1718, Ap
23	501.5	72.9	248	11	US-11-266-444-1879	Sequence 1879, Ap
24	501	72.8	124	11	US-11-040-159-6	Sequence 6, Appl
25	500	72.7	257	11	US-11-054-515-1553	Sequence 1553, Ap
26	500	72.7	257	11	US-11-266-444-1553	Sequence 1553, Ap
27	498.5	72.5	248	11	US-11-054-515-1719	Sequence 1719, Ap
28	498.5	72.5	248	11	US-11-054-515-1732	Sequence 1732, Ap
29	498.5	72.5	248	11	US-11-054-515-1732	Sequence 1732, Ap
30	498.5	72.5	248	11	US-11-266-444-1719	Sequence 1719, Ap
31	498.5	72.5	248	11	US-11-266-444-1732	Sequence 1732, Ap
32	498.5	72.5	248	11	US-11-266-444-1737	Sequence 1737, Ap
33	497.5	72.3	248	11	US-11-054-515-1741	Sequence 1741, Ap
34	497.5	72.3	248	11	US-11-266-444-1741	Sequence 1741, Ap
35	497.5	72.3	250	11	US-11-054-515-2066	Sequence 2066, Ap
36	497.5	72.3	250	11	US-11-266-444-2066	Sequence 2066, Ap
37	497	72.2	254	11	US-11-054-515-1450	Sequence 1450, Ap
38	497	72.2	254	11	US-11-266-444-1450	Sequence 1450, Ap
39	496.5	72.2	119	9	US-10-834-397-21	Sequence 21, Appl
40	495.5	72.0	248	11	US-11-054-515-1727	Sequence 1727, Ap
41	495.5	72.0	248	11	US-11-054-515-1728	Sequence 1728, Ap
42	495.5	72.0	248	11	US-11-266-444-1727	Sequence 1727, Ap
43	495.5	72.0	248	11	US-11-266-444-1728	Sequence 1728, Ap
44	493.5	71.7	251	11	US-11-054-515-1756	Sequence 1756, Ap
45	493.5	71.7	251	11	US-11-266-444-1756	Sequence 1756, Ap

ALIGNMENTS

RESULT 1
US-10-982-440-19
; Sequence 19, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Olinier, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 19
; TYPE: PRT
; LENGTH: 121
; ORGANISM: Homo sapiens
US-10-982-440-19

Query Match	76.2%	Score 524.5;	DB 9;	Length 121;
Best Local Similarity	78.3%	Pred. No. 4.3e-36;		
Matches 102;	Conservative	9;	Mismatches 10;	Indels 9; Gaps 1;
QY	1	QVOLVSGAEAKPGSSVKVSKASGDTFNSFPISWVROAPGQGLEWMGGIIFIGSTKY	60	
Db	1	QVOLVSGAEVKKPGASVKASVSKASGDTFSSVAISVWROAPGQGLEWMGGIIFIGTANY	60	
QY	61	AQKQGRVTMTADGTSSTAYMELNSLRSEDATYYCARQONGWYEGPLLEPRDLDIW	120	
Db	61	AQKQGRVTITADESTSTAYMELSSLRSEDATVYYCARFESGYW-----GDAPDIW	111	
QY	121	GQGTMTVTS 130		
Db	112	GQGTMTVTS 121		

RESULT 2
US-11-054-515-1881
; Sequence 1881, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.

NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/834,397
FILING DATE: 29-Apr-2004
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/490,324
FILING DATE: 24-Jan-2000
APPLICATION NUMBER: US/09/025,769
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-10-834-397-35

Query Match 74.4%; Score 512; DB 9; Length 120;
Best Local Similarity 76.9%; Pred. No. 4.4e-35;
Matches 100; Conservative 9; Mismatches 11; Indels 10; Gaps 1;

Qy 1 QVQLVSGAEAKPGSSVKVSKASGDTFNSFPISWVRQAPGGLEWMGGIIPIFGSTKY 60
Db 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPIFGTANY 60

Qy 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYCARQNGGWYEGPLLEPRPDALDIW 120
Db 61 AQKFGQRTVTITADESTSTAYMELSSLRSEDTAIYCARWGDDGFY-----AMDYW 110

Qy 121 GQGTMTVTVSS 130
Db 111 GQGTMTVTVSS 120

RESULT 6
US-10-834-397-57
Sequence 57, Application US/10834397
Publication No. US2006003334A1
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckhuhn, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas

CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/834,397
FILING DATE: 29-Apr-2004
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/490,324
FILING DATE: 24-Jan-2000
APPLICATION NUMBER: US/09/025,769
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-10-834-397-57

Query Match 74.4%; Score 512; DB 9; Length 120;
Best Local Similarity 76.9%; Pred. No. 4.4e-35;
Matches 100; Conservative 9; Mismatches 11; Indels 10; Gaps 1;

Qy 1 QVQLVSGAEAKPGSSVKVSKASGDTFNSFPISWVRQAPGGLEWMGGIIPIFGSTKY 60
Db 1 QVQLVSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPIFGTANY 60

Qy 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYCARQNGGWYEGPLLEPRPDALDIW 120
Db 61 AQKFGQRTVTITADESTSTAYMELSSLRSEDTAIYCARWGDDGFY-----AMDYW 110

Qy 121 GQGTMTVTVSS 130
Db 111 GQGTMTVTVSS 120

RESULT 7
US-11-054-515-1509
Sequence 1509, Application US/11054515
Publication No. US20050255532A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunoespecifically Bind Blys
FILE REFERENCE: PF523P3
CURRENT APPLICATION NUMBER: US/11/054,515
CURRENT FILING DATE: 2005-02-10
PRIOR APPLICATION NUMBER: 60/543,296
PRIOR FILING DATE: 2004-02-11
PRIOR APPLICATION NUMBER: 60/580,347
PRIOR FILING DATE: 2004-06-18
PRIOR APPLICATION NUMBER: 10/293,418
PRIOR FILING DATE: 2002-11-14
PRIOR APPLICATION NUMBER: 60/331,469
PRIOR FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/340,817
PRIOR FILING DATE: 2001-12-19
PRIOR APPLICATION NUMBER: 09/880,748

```
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1509
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1509

Query Match          74.3%; Score 511; DB 11; Length 253;
Best Local Similarity 72.1%; Pred. No. 1e-34;
Matches 101; Conservative 9; Mismatches 8; Indels 22; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFISWVRQAPGGLEWMGGIIPFGSTKY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQQ-----NGGWYEGPLL 110
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFQGRVTITADKSTSTAYMELSLRSEDTAIYYCAREQGYDILTGYYPEGGWF----- 115
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 111 EPRPDALDIWGQGTMTVSS 130
Db 116 -----DPWKGKGTMTVSS 128

RESULT 8
US-11-266-444-1509
; Sequence 1509, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1509
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1509

Query Match          74.3%; Score 511; DB 11; Length 253;
Best Local Similarity 72.1%; Pred. No. 1e-34;
Matches 101; Conservative 9; Mismatches 8; Indels 22; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFISWVRQAPGGLEWMGGIIPFGSTKY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQQ-----NGGWYEGPLL 110
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFQGRVTITADKSTSTAYMELSLRSEDTAIYYCAREQGYDILTGYYPEGGWF----- 115
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 111 EPRPDALDIWGQGTMTVSS 130
Db 116 -----DPWKGKGTMTVSS 128

RESULT 9
US-10-493-909-47
; Sequence 47, Application US/10493909
; Publication No. US20060015969A1
; GENERAL INFORMATION:
; APPLICANT: LARRICK, JAMES W.
; APPLICANT: WYCOFF, KEITH L.
; TITLE OF INVENTION: NOVEL IMMUNOADHESINS FOR TREATING AND PREVENTING TOXICITY
; TITLE OF INVENTION: AND PATHOGEN-MEDIATED DISEASES
; FILE REFERENCE: 41514-20004.01
; CURRENT APPLICATION NUMBER: US/10/493,909
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: PCT/US01/13932
; PRIOR FILING DATE: 2001-04-28
; PRIOR APPLICATION NUMBER: 60/200,298
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 47
; LENGTH: 627
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-493-909-47

Query Match          74.1%; Score 509.5; DB 9; Length 627;
Best Local Similarity 72.7%; Pred. No. 3.1e-34;
Matches 101; Conservative 10; Mismatches 13; Indels 15; Gaps 3;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFISWVRQAPGGLEWMGGIIPFGSTKY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPFGTANY 79
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCAR-----QQNGGWYEGPLLEPRPD 115
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 AQKFQGRVTITADESTSTAYMELSLRSEDTAIYYCAKTIILGPYSSGWY-----PNSD 133
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 116 ----ALDIWGQGTMTVSS 130
Db 134 YYYGMDVMWGQGTMTVSS 152

RESULT 10
US-11-054-515-1880
; Sequence 1880, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS
; FILE REFERENCE: PFS23P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
```

```

; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1880
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1880

Query Match 73.9%; Score 508.5; DB 11; Length 253;
Best Local Similarity 74.6%; Pred. No. 1.7e-34;
Matches 100; Conservative 11; Mismatches 12; Indels 11; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPIFGSTKY 60
Db 1 QVQLQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY 60

QY 61 AQKFGQVRVTADGSTSTAYMELNSLRSEDTAIYYCARQON-----GGWYEGPLLEPRPDA 116
Db 61 AQKFGQVRVTITADESTSTAYMELSSLRSEDTAIYYCARESHYDILATGYSNP-----S 113

QY 117 LDIWGQGTMTVTSS 130
Db 114 FDIWGRGTMTVTSS 127

RESULT 11
US-11-266-444-1880
; Sequence 1880, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunosepecifically Bind to B Lymphocyte Stimulatc
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1880
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1880

Query Match 73.9%; Score 508.5; DB 11; Length 253;
Best Local Similarity 74.6%; Pred. No. 1.7e-34;
Matches 100; Conservative 11; Mismatches 12; Indels 11; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPIFGSTKY 60
Db 1 QVQLQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY 60

QY 61 AQKFGQVRVTADGSTSTAYMELNSLRSEDTAIYYCARQON-----GGWYEGPLLEPRPDA 116
Db 61 AQKFGQVRVTITADESTSTAYMELSSLRSEDTAIYYCARESHYDILATGYSNP-----S 113
```

```

QY 117 LDIWGQGTMTVTSS 130
Db 114 FDIWGRGTMTVTSS 127

RESULT 12
US-11-054-515-1866
; Sequence 1866, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunosepecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1866
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1866

Query Match 73.8%; Score 508; DB 11; Length 254;
Best Local Similarity 71.4%; Pred. No. 1.8e-34;
Matches 100; Conservative 10; Mismatches 8; Indels 22; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPIFGSTKY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY 60

QY 61 AQKFGQVRVTADGSTSTAYMELNSLRSEDTAIYYCARQO-----NGSWYEGPLL 110
Db 61 AQKFGQVRVTITADKSTSTAYMELSSLRSEDTAIYYCAREQGYDILTGYYPEGGWF----- 115

QY 111 EPRPDALDIWGQGTMTVTSS 130
Db 116 -----DPWKGTLVTVSS 128

RESULT 13
US-11-266-444-1866
; Sequence 1866, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunosepecifically Bind to B Lymphocyte Stimulato;
; FILE REFERENCE: PF523PDI
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
```

```
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1866
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1866

Query Match      73.8%; Score 508; DB 11; Length 254;
Best Local Similarity 71.4%; Pred. No. 1.8e-34;
Matches 100; Conservative 10; Mismatches 8; Indels 22; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGGLEWMGGIIPFGSTKY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQQ-----NGGWYEGPLL 110
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVTITADKSTSTAYMELSSLRSEDTAIYYCAREQGYDILATGYYPEGGWF----- 115
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 111 EPRPDALDITWGQTMVTVSS 130
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 116 -----DPWGKGLTVTVSS 128
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 14
US-10-982-440-35
; Sequence 35, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; PRIOR FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 35
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-35

Query Match      73.8%; Score 507.5; DB 9; Length 125;
Best Local Similarity 78.5%; Pred. No. 1.1e-34;
Matches 102; Conservative 9; Mismatches 14; Indels 5; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGGLEWMGGIIPFGSTKY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPPLLEPRPDALDIW 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAIYYCARSPI--YYD---ILTGIDAFDIW 115
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 GQGTMTVTSS 130
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 116 GQGTMTVTSS 125
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

; RESULT 15
US-10-982-440-9
; Sequence 9, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 9
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-9

Query Match      73.6%; Score 506.5; DB 9; Length 121;
Best Local Similarity 78.5%; Pred. No. 1.3e-34;
Matches 102; Conservative 6; Mismatches 13; Indels 9; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGGLEWMGGIIPFGSTKY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSYAISWVRQAPGGLEWMGGIIPFGTANY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPPLLEPRPDALDIW 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVTITADKSTSTAYMELSSLRSEDTAIYYCAA-----PSPFTE--TDAFDIW 111
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 GQGTMTVTSS 130
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 112 GQGTMTVTSS 121
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Search completed: May 5, 2006, 09:02:43
Job time : 9.84848 secs
```

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:51:41 ; Search time 8.53535 Seconds
(without alignments)
1465.455 Million cell updates/sec

Title: US-09-674-752-23

Perfect score: 688

Sequence: 1 QVOLVQSGAEAKPGSSVKV.....EPRPDALDIWGQGTMTVSS 130

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR 80:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	515	74.9	128	2 PH0952	Ig heavy chain V r
2	509.5	74.1	133	2 C33548	Ig heavy chain V-1
3	509.5	74.1	627	2 S14683	Ig mu chain precu
4	502.5	73.0	135	2 PH0953	Ig heavy chain V r
5	501	72.8	116	2 PH0959	Ig heavy chain V r
6	498	72.4	120	2 PH0962	Ig heavy chain V r
7	498	72.4	122	2 PH0958	Ig heavy chain V r
8	498	72.4	132	2 S46394	Ig heavy chain V r
9	497.5	72.3	119	2 PH0961	Ig heavy chain V r
10	496	72.1	132	2 PH0954	Ig heavy chain V r
11	496	72.1	136	2 PH0960	Ig heavy chain V r
12	494.5	71.9	129	2 A33548	Ig heavy chain V-1
13	490.5	71.3	125	2 PH0957	Ig heavy chain V r
14	488.5	71.0	127	2 PH0955	Ig heavy chain V r
15	486	70.6	126	2 B33548	Ig heavy chain V-1
16	481	69.9	135	2 B32774	Ig heavy chain pre
17	456.5	66.4	113	2 PH1663	Ig heavy chain V r
18	452.5	65.8	121	2 A49590	Ig heavy chain V r
19	452	65.7	108	2 PH1664	Ig heavy chain V r
20	451	65.6	98	2 S26915	Ig heavy chain V r
21	451	65.6	116	2 S31698	Ig heavy chain pre
22	451	65.6	116	2 S36261	Ig heavy chain V r
23	451	65.6	123	2 S44108	Ig heavy chain V-D
24	450	65.4	124	2 S19665	Ig heavy chain V r
25	450	65.4	136	2 S31600	Ig heavy chain V r
26	447.5	65.0	122	2 B49590	Ig heavy chain V r
27	447	65.0	98	2 S24680	Ig heavy chain V1
28	447	65.0	119	2 S44106	Ig heavy chain V-D
29	446.5	64.9	142	2 A32483	Ig heavy chain V r

ALIGNMENTS

RESULT 1

PH0952

Ig heavy chain V region (G6+ CLL-SMI) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996

C;Accession: PH0952

R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kippes, T.J.

J. Exp. Med. 175, 983-991, 1992

A;Title: Evidence for somatic selection of natural autoantibodies.

A;Reference number: PH0952; MUID:92202880; PMID:1552291

A;Accession: PH0952

A;Status: nucleic acid sequence not shown

A;Molecule type: DNA

A;Residues: 1-128 <MAR>

A;Cross-references: UNIPARC:UPI0000176CDC

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin

F;1-30/Region: framework 1

F;15-98/Domain: immunoglobulin homology <IMM>

F;31-35/Region: complementarity-determining 1

F;36-50/Region: framework 2

F;51-67/Region: complementarity-determining 2

F;68-98/Region: framework 3

F;99-116/Region: complementarity-determining 3

Query Match 74.9%; Score 515; DB 2; Length 128;

Best Local Similarity 79.2%; Pred. No. 1.7e-39;

Matches 103; Conservative 7; Mismatches 18; Indels 2; Gaps 1;

QY 1 QVOLVQSGAEAKPGSSVKVSKASGDTFNSFPISVVRQAPGGGLEWGGIIPFGSTKY 60

DB 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSSYAIISVVRQAPGGGLEWGGIIPFGTANY 60

QY 61 AQKQGRVTMTADGSTSTAYMELNSRSEDATYYCARQONGWYEGPLLEPRPDALDIW 120

DB 61 AQKQGRVTMTADGSTSTAYMELNSRSEDATYYCARQONGWYEGPLLEPRPDALDIW 118

QY 121 GQGTMTVTVSS 130

DB 119 GQGTMTVTVSS 128

RESULT 2

C33548

Ig heavy chain V-1 region (783) - human

C;Species: Homo sapiens (man)

C;Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996

C;Accession: C33548

R;Kippes, T.J.; Tomhave, E.; Pratt, L.F.; Duffy, S.; Chen, P.P.; Carson, D.A.

Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989

A;Title: Developmentally restricted immunoglobulin heavy chain variable region gene expr

A;Reference number: A33548; MUID:89345575; PMID:2503826

A:Accession: C33548
A:Status: preliminary; nucleic acid sequence not shown; not compared with conceptual translation
A:Molecule type: DNA
A:Residues: 1-133 <KIP>
A:Cross-references: UNIPARC:UPI0000176D2B
A:Experimental source: the sequence was determined from the differentiated gene
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 74.1%; Score 509.5; DB 2; Length 133;
Best Local Similarity 72.7%; Pred. No. 5.7e-39;
Matches 101; Conservative 10; Mismatches 13; Indels 15; Gaps 3;

QY 1 QVOLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMMGGIIPFGSTKY 60
DB 1 QVOLVSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGQGLEWMMGGIIPFGTANY 60

QY 61 AQKFGQVRVTMTADGSTSTAYMELNSLRSEDTAIYYCAR-----QQNGHWYEGPLLEPRPD 115
DB 61 AQKFGQVRVTITADESTSTAYMELSLRSEDTAIYYCAKTGILGPYSSGWY-----PNSD 114

QY 116 ----ALDIWGQGTMTVTSS 130
DB 115 YYYGMDVWGQGTMTVTSS 133

RESULT 3
S14683
Ig mu chain precursor, membrane-bound (clone 201) - human
C:Species: Homo sapiens (man)
C:Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 23-Jul-1999
C:Accession: S14683; S08047
R:Friedlander, R.M.; Nussenzweig, M.C.; Leder, P.
Nucleic Acids Res. 18, 4278, 1990
A:Title: Complete nucleotide sequence of the membrane form of the human IgM heavy chain.
A:Reference number: S14683; MUID:90332450; PMID:2115996
A:Accession: S14683
A:Molecule type: mRNA
A:Residues: 1-627 <PRI>
A:Cross-references: UNIPARC:UPI000016AB02; EMBL:X17115; NID:G33450; PIDN:CAA34971.1; PID
C:Superfamily: immunoglobulin C region; immunoglobulin homology
C:Keywords: immunoglobulin; membrane protein
F:1-15/Domain: signal sequence #status predicted <SIG>
F:16-627/Product: Ig mu chain #status predicted <MAT>
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match 74.1%; Score 509.5; DB 2; Length 627;
Best Local Similarity 72.7%; Pred. No. 3e-38;
Matches 101; Conservative 10; Mismatches 13; Indels 15; Gaps 3;

QY 1 QVOLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMMGGIIPFGSTKY 60
DB 20 QVOLVSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGQGLEWMMGGIIPFGTANY 79

QY 61 AQKFGQVRVTMTADGSTSTAYMELNSLRSEDTAIYYCAR-----QQNGHWYEGPLLEPRPD 115
DB 80 AQKFGQVRVTITADESTSTAYMELSLRSEDTAIYYCAKTGILGPYSSGWY-----PNSD 133

QY 116 ----ALDIWGQGTMTVTSS 130
DB 134 YYYGMDVWGQGTMTVTSS 152

RESULT 4
PH0953
Ig heavy chain V region (G5+ CLL-SIC) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0953
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.

A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0953
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-135 <MAR>
A:Cross-references: UNIPARC:UPI0000176CDD
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:1-30/Region: framework 1
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-67/Region: complementarity-determining 2
F:88-98/Region: framework 3
F:99-123/Region: complementarity-determining 3

Query Match 73.0%; Score 502.5; DB 2; Length 135;
Best Local Similarity 75.2%; Pred. No. 2.5e-38;
Matches 103; Conservative 8; Mismatches 17; Indels 9; Gaps 2;

QY 1 QVOLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMMGGIIPFGSTKY 60
DB 1 QVOLVSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGQGLEWMMGGIIPFGTANY 60

QY 61 AQKFGQVRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQNG-----GWYEGPLLEPR 113
DB 61 AQKFGQVRVTITADESTSTAYMELSLRSEDTAIYYCAR--NGYCGDGCYSRWELLRFDFS 118

QY 114 PDALDIWGQGTMTVTSS 130
DB 119 EDAFDIWGQGTMTVTSS 135

RESULT 5
PH0959
Ig heavy chain V region (G5+ T-L26) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0959
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-116 <MAR>
A:Cross-references: UNIPARC:UPI0000176CE3
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:1-30/Region: framework 1
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-67/Region: complementarity-determining 2
F:88-98/Region: framework 3
F:99-104/Region: complementarity-determining 3

Query Match 72.8%; Score 501; DB 2; Length 116;
Best Local Similarity 76.2%; Pred. No. 2.9e-38;
Matches 99; Conservative 8; Mismatches 9; Indels 14; Gaps 2;

QY 1 QVOLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMMGGIIPFGSTKY 60
DB 1 QVOLVSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPGQGLEWMMGGIIPFGTANY 60

QY 61 AQKFGQVRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQNGWYEGPLLEPRDLDIW 120
DB 61 AQKFGQVRVTITADESTSTAYMELSLRSEDTAIYYCARGDN--WF-----DPW 106

QY 121 GQGTMTVTSS 130
DB 107 GQGTMTVTSS 116

RESULT 6
PH0962
Ig heavy chain V region (G6+ T-L42) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C;Accession: PH0962
R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0962
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-120 <NAR>
A;Cross-references: UNIPARC:UPI0000176CE6
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-30/Region: framework 1
F;15-98/Domain: immunoglobulin homology <IMM>
F;31-35/Region: complementarity-determining 1
F;36-50/Region: framework 2
F;51-67/Region: complementarity-determining 2
F;51-67/Region: complementarity-determining 3
F;68-98/Region: framework 3
F;99-108/Region: complementarity-determining 3

Query Match 72.4%; Score 498; DB 2; Length 120;
Best Local Similarity 77.9%; Pred. No. 5.6e-38;
Matches 101; Conservative 8; Mismatches 11; Indels 10; Gaps 3;

QY 1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMGGIIPIFGSTKY 60
Db 1 QVQLVSGAEVKKPGSSVKVSKASGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY 60

QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPPLPRDLDIW 120
Db 61 AQKFGQRTITADESTSTAYMELSSLRSEDTAIYYCAR---GG-----VAGRPH-FDYW 110

QY 121 GQGTMTVSS 130
Db 111 GQGTTLTVSS 120

RESULT 7
PH0958
Ig heavy chain V region (G6+ CLL-HUR) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C;Accession: PH0958
R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0958
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-122 <NAR>
A;Cross-references: UNIPARC:UPI0000176CE2
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-30/Region: framework 1
F;15-98/Domain: immunoglobulin homology <IMM>
F;31-35/Region: complementarity-determining 1
F;36-50/Region: framework 2
F;51-67/Region: complementarity-determining 2
F;68-98/Region: framework 3
F;99-110/Region: complementarity-determining 3

Query Match 72.4%; Score 498; DB 2; Length 122;
Best Local Similarity 76.9%; Pred. No. 5.6e-38;
Matches 100; Conservative 8; Mismatches 14; Indels 8; Gaps 2;

QY 1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMGGIIPIFGSTKY 60
Db 1 QVQLVSGAEVKKPGSSVKVSKASGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY 60

QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPPLPRDLDIW 120
Db 61 AQKFGQRTITADESTSTAYMELSSLRSEDTAIYYCARVFN-----PLF--FAVGMDVW 112

QY 121 GQGTMTVSS 130
Db 113 GQGTTLTVSS 122

RESULT 8
S46394
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 27-Jan-1995 #sequence_revision 27-Jan-1995 #text_change 20-Jun-2000
C;Accession: S46394
R;Figini, M.; Marks, J.D.; Winter, G.; Griffiths, A.D.
J. Mol. Biol. 239, 68-78, 1994
A;Title: In vitro assembly of repertoires of antibody chains on the surface of phage;
A;Reference number: S46390; MUID:94254092; PMID:8196048
A;Accession: S46394
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-132 <FIG>
A;Cross-references: UNIPARC:UPI000011663B; EMBL:Z31681; NID:9509788; PIDN:CAA83486.1; PFI
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 72.4%; Score 498; DB 2; Length 132;
Best Local Similarity 75.9%; Pred. No. 6.1e-38;
Matches 101; Conservative 11; Mismatches 17; Indels 4; Gaps 2;

QY 1 QVQLVSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPGQGLEWMGGIIPIFGSTKY 60
Db 1 QVQLVSGAEVKKPGSSVKVSKASGTFSSYAISWVRQAPGQGLEWMGGIIPIGTANH 60

QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPPLPRD---AL 117
Db 61 AQKFGQRTITADESTSTAYMELSSLRSEDTAIYYCARTQLPAADTG-ILEWLPSTVYVM 119

QY 118 DIMGQGTMTVSS 130
Db 120 DVMGKGTMTVSS 132

RESULT 9
PH0961
Ig heavy chain V region (G6+ T-L33) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C;Accession: PH0961
R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0961
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-119 <NAR>
A;Cross-references: UNIPARC:UPI0000176CE5
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-30/Region: framework 1
F;15-98/Domain: immunoglobulin homology <IMM>
F;31-35/Region: complementarity-determining 1
F;36-50/Region: framework 2
F;51-67/Region: complementarity-determining 2
F;68-98/Region: framework 3
F;99-107/Region: complementarity-determining 3

```
Query Match 72.3%; Score 497.5; DB 2; Length 119;
Best Local Similarity 76.2%; Pred. No. 6.1e-38;
Matches 99; Conservative 9; Mismatches 11; Indels 11; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPQGGLWMGGIPIFGSTKY 60
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPQGGLWMGGIPIFGTANY 60
QY 61 AQKFGQRTVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
DB 61 AQKFGQRTVITADESTSTAYMELSSLRSEDTAIYYCARGY--YYG-----MDVM 109

QY 121 GQGTMTVSS 130
DB 110 GQGTMTVSS 119

RESULT 10
PH0954
Ig heavy chain V region (G6+ CLL-HEN) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0954
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0954
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-132 <MAR>
A:Cross-references: UNIPARC:UPI0000176CDE
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:1-30/Region: framework 1
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-67/Region: complementarity-determining 2
F:68-98/Region: framework 3
F:99-120/Region: complementarity-determining 3

Query Match 72.1%; Score 496; DB 2; Length 132;
Best Local Similarity 71.4%; Pred. No. 9.2e-38;
Matches 100; Conservative 10; Mismatches 12; Indels 18; Gaps 3;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPQGGLWMGGIPIFGSTKY 60
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPQGGLWMGGIPIFGTANY 60
QY 61 AQKFGQRTVTMTADGSTSTAYMELNSLRSEDTAIYYCARQON-----GGWYEGPLLEPRP 114
DB 61 AQKFGQRTVITADESTSTAYMELSSLRSEDTAIYYCARPHASIDDPWSGY-----P 112

QY 115 D-----ALDIWGGTMTVSS 130
DB 113 NYYYGMDVWGQGTMTVSS 132

RESULT 11
PH0960
Ig heavy chain V region (G6+ T-L30) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0960
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0960
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
```

```
A:Residues: 1-136 <MAR>
A:Cross-references: UNIPARC:UPI0000176CE4
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:1-30/Region: framework 1
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-67/Region: complementarity-determining 2
F:68-98/Region: framework 3
F:99-124/Region: complementarity-determining 3

Query Match 72.1%; Score 496; DB 2; Length 136;
Best Local Similarity 67.8%; Pred. No. 9.5e-38;
Matches 99; Conservative 10; Mismatches 11; Indels 26; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPQGGLWMGGIPIFGSTKY 60
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPQGGLWMGGIPIFGTANY 60
QY 61 AQKFGQRTVTMTADGSTSTAYMELNSLRSEDTAIYYCARQON-----GGW 104
DB 61 AQKFGQRTVITADKSTSTAYMELSSLRSEDTAIYYCARGTRVSVTLVDSSGYDFSGY 120

QY 105 YEGPLLEPRPDALDIWGGTMTVSS 130
DB 121 Y-----GMDVWGQGTMTVSS 136

RESULT 12
A33548
Ig heavy chain V-1 region (NEI) - human
C:Species: Homo sapiens (man)
C:Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996
C:Accession: A33548; PH0956
R:Kipps, T.J.; Tomhave, E.; Pratt, L.F.; Duffy, S.; Chen, P.P.; Carson, D.A.
Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989
A:Title: Developmentally restricted immunoglobulin heavy chain variable region gene expr
A:Reference number: A33548; MUID:89345575; PMID:2503826
A:Accession: A33548
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-129 <KIP>
A:Cross-references: UNIPARC:UPI0000176CE0
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0956
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-129 <MAR>
A:Cross-references: UNIPARC:UPI0000176CE0
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:1-30/Region: framework 1
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-67/Region: complementarity-determining 2
F:68-98/Region: framework 3
F:99-117/Region: complementarity-determining 3

Query Match 71.9%; Score 494.5; DB 2; Length 129;
Best Local Similarity 73.4%; Pred. No. 1.2e-37;
Matches 102; Conservative 8; Mismatches 10; Indels 19; Gaps 4;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSPISWVRQAPQGGLWMGGIPIFGSTKY 60
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFSSVAISWVRQAPQGGLWMGGIPIFGTANY 60
QY 61 AQKFGQRTVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONG-----WYEGPLLE 111
```



```
Db 61 AQKFGQGVTTTADGSTSTAYMELSLRSEDSTAVYYCAR-----GPRLLADVLLMF-GELSE 115
QY 112 PRPDALDIWGQGTMTVTSS 130
Db 116 -----FDYWGQGTTLVTSS 129

RESULT 13
IG heavy chain V region (G6+ CLL-BRA) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C;Accession: PH0957
R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0957
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-125 <VAR>
A;Cross-references: UNIPARC:UPI0000176CE1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-30/Region: framework 1
F;15-98/Domain: immunoglobulin homology <IMM>
F;31-35/Region: complementarity-determining 1
F;36-50/Region: framework 2
F;51-67/Region: complementarity-determining 2
F;68-98/Region: framework 3
F;99-113/Region: complementarity-determining 3

Query Match 71.3%; Score 490.5; DB 2; Length 125;
Best Local Similarity 71.5%; Pred. No. 2.7e-37;
Matches 98; Conservative 10; Mismatches 10; Indels 19; Gaps 3;

QY 1 QVOLVSGAEAKPGSSVKVSKASGDTFNSPFIWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVOLVSGAEVKKPGSSVKVSKASGDTFSSYAIWVRQAPGQGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGVTTTADGSTSTAYMELSLRSEDSTAVYYCARQ--QNG-----QWYEGPLLEPR 113
Db 61 AQKFGQGVTTTADGSTSTAYMELSLRSEDSTAVYYCARDCGSGGSCYFWGWF----- 112
QY 114 PDALDIWGQGTMTVTSS 130
Db 113 -----DPWGQGTTLVTSS 125

RESULT 14
PH0955
IG heavy chain V region (G6+ CLL-AND) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C;Accession: PH0955
R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0955
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-127 <VAR>
A;Cross-references: UNIPARC:UPI0000176CDF
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-30/Region: framework 1
F;15-98/Domain: immunoglobulin homology <IMM>
F;31-35/Region: complementarity-determining 1
F;36-50/Region: framework 2
F;51-67/Region: complementarity-determining 2
F;68-98/Region: framework 3
F;99-115/Region: complementarity-determining 3
```

```
Query Match 71.0%; Score 488.5; DB 2; Length 127;
Best Local Similarity 71.0%; Pred. No. 4.2e-37;
Matches 98; Conservative 10; Mismatches 11; Indels 19; Gaps 2;

QY 1 QVOLVSGAEAKPGSSVKVSKASGDTFNSPFIWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVOLVSGAEVKKPGSSVKVSKASGDTFSSYAIWVRQAPGQGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGVTTTADGSTSTAYMELSLRSEDSTAVYYCARQONGG-----WYEGPLLEPR 112
Db 61 AQKFGQGVTTTADGSTSTAYMELSLRSEDSTAVYYCARVIFGVQHYVYYY----- 113
QY 113 RPDALDIWGQGTMTVTSS 130
Db 114 ----MDVWGKGTTLVTSS 127

RESULT 15
B33548
IG heavy chain V-1 region (AND) - human
C;Species: Homo sapiens (man)
C;Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996
C;Accession: B33548
R;Kipps, T.J.; Tomhave, E.; Pratt, L.F.; Duffy, S.; Chen, P.P.; Carson, D.A.
Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989
A;Title: Developmentally restricted immunoglobulin heavy chain variable region gene expr
A;Reference number: A3548; MUID:89345575; PMID:2503826
A;Accession: B33548
A;Status: preliminary; nucleic acid sequence not shown; not compared with conceptual tra.
A;Molecule type: DNA
A;Residues: 1-126 <KIP>
A;Cross-references: UNIPARC:UPI0000176D2A
A;Experimental source: the sequence was determined from the differentiated gene
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 70.6%; Score 486; DB 2; Length 126;
Best Local Similarity 71.5%; Pred. No. 7e-37;
Matches 98; Conservative 9; Mismatches 12; Indels 18; Gaps 2;

QY 1 QVOLVSGAEAKPGSSVKVSKASGDTFNSPFIWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVOLVSGAEVKKPGSSVKVSKASGDTFSSYAIWVRQAPGQGLEWMGGIIPFGTANY 60
QY 61 AQKFGQGVTTTADGSTSTAYMELSLRSEDSTAVYYCARQONGG-----WYEGPLLEPR 113
Db 61 AQKFGQGVTTTADGSTSTAYMELSLRSEDSTAVYYCARVIFGVQHYVYYY----- 112
QY 114 PDALDIWGQGTMTVTSS 130
Db 113 ----MDVWGKGTTLVTSS 126

Search completed: May 5, 2006, 08:54:47
Job time : 8.53535 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 09:04:30 ; Search time 48.9141 Seconds
(without alignments)
1875.095 Million cell updates/sec

Title: US-09-674-752-23

Perfect score: 688

Sequence: 1 QVQLVSGAEAKPKGSSVKV.....EPRPDALDIWGQGTMTVTS 130

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Uniprot_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	462	67.2	116	Q9UL89_HUMAN	Q9UL89 homo sapien
2	458.5	66.6	208	O6ZP87_HUMAN	O6ZP87 homo sapien
3	452.5	65.8	125	Q9UL95_HUMAN	Q9UL95 homo sapien
4	447.5	65.0	480	O6PJF1_HUMAN	O6PJF1 homo sapien
5	443	64.4	124	Q9UL92_HUMAN	Q9UL92 homo sapien
6	439	63.8	120	O6NSA4_HUMAN	O6NSA4 homo sapien
7	434	63.1	159	Q96Q80_HUMAN	Q96Q80 homo sapien
8	432.5	62.9	500	O6N091_HUMAN	O6N091 homo sapien
9	430.5	62.6	244	O652C8_HUMAN	O652C8 homo sapien
10	424.5	61.7	150	Q9Y298_HUMAN	Q9Y298 homo sapien
11	421	61.2	498	O6N041_HUMAN	O6N041 homo sapien
12	420.5	61.1	117	HVLA_HUMAN	P01742 homo sapien
13	420.5	61.1	119	Q9UL94_HUMAN	Q9UL94 homo sapien
14	412	59.9	117	HV1B_HUMAN	P01743 homo sapien
15	411	59.7	475	O6N095_HUMAN	O6N095 homo sapien
16	409	59.4	436	Q96DK0_HUMAN	Q96DK0 homo sapien
17	407	59.2	500	Q9BRV0_HUMAN	Q9BRV0 homo sapien
18	406	59.0	469	Q7Z7P5_HUMAN	Q7Z7P5 homo sapien
19	398.5	57.9	519	Q5EBM2_HUMAN	O5ebm2 homo sapien
20	397	57.7	613	Q8VCX7_MOUSE	Q8vcx7 mus musculus
21	394.5	57.3	458	Q5BJZ2_RAT	Q5bjz2 rattus norv
22	394	57.3	518	Q6N030_HUMAN	O6n030 homo sapien
23	392.5	57.0	119	Q9GYZ2_MOUSE	Q9gyz2 mus musculus
24	392	57.0	118	Q9Z1C4_MOUSE	Q9z1c4 mus musculus
25	388.5	56.5	481	Q91WT1_MOUSE	Q91wt1 mus musculus
26	387	56.2	147	HV1C_HUMAN	P01744 homo sapien
27	387	56.2	617	Q4KML5_MOUSE	Q4kml5 mus musculus
28	384.5	55.9	480	Q6P089_HUMAN	Q6p089 homo sapien
29	384	55.8	465	Q6PJB2_MOUSE	O6pjb2 mus musculus
30	383.5	55.7	142	Q924Q1_MOUSE	Q924q1 mus musculus
31	382.5	55.6	157	Q95978_HUMAN	O95978 homo sapien

32	382.5	55.6	168	2	Q8VDC9_MOUSE	Q8vdc9 mus musculus
33	382	55.5	145	2	Q924P7_MOUSE	Q924p7 mus musculus
34	380.5	55.3	497	2	Q8WY24_HUMAN	O8wy24 homo sapien
35	380	55.2	117	1	HV1G_HUMAN	P23083 homo sapien
36	380	55.2	145	2	Q924R1_MOUSE	Q924r1 mus musculus
37	377.5	54.9	473	2	Q9D8L4_MOUSE	Q9d8l4 mus musculus
38	376.5	54.7	468	2	Q569W9_MOUSE	O569w9 mus musculus
39	376	54.7	145	2	Q924Q6_MOUSE	Q924q6 mus musculus
40	376	54.7	145	2	Q924R3_MOUSE	Q924r3 mus musculus
41	375	54.5	143	2	Q924R7_MOUSE	Q924r7 mus musculus
42	375	54.5	482	2	Q8K172_MOUSE	Q8k172 mus musculus
43	374	54.4	590	2	Q4V9V8_MOUSE	Q4v9v8 mus musculus
44	373	54.2	145	2	Q924Q9_MOUSE	Q924q9 mus musculus
45	371.5	54.0	144	2	Q924P5_MOUSE	Q924p5 mus musculus

ALIGNMENTS

RESULT 1
Q9UL89_HUMAN
ID Q9UL89_HUMAN PRELIMINARY; PRT; 116 AA.
AC Q9UL89;
DT 01-MAY-2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
DE
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531; RA Wu X, Liu B., Van der Merwe P.L., Kalis N.N., Bernay S.M., RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus".
RT Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528;
RA Manheimer-Lory A., Katz J.B., Pillinger M., Ghosein C., Smith A., RA Diamond B.;
RT "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype".
RL J. Exp. Med. 174:1639-1652(1991).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=93301610; PubMed=8315388; DOI=10.1084/jem.178.1.331; RA Hillson J.L., Karr N.S., Opplinger I.R., Mannik M., Sasseo E.H.;
RT "The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A".
RL J. Exp. Med. 178:331-336(1993).
DR EMBL, AF035025; AAD56261.1; -, mRNA.
DR PIR; PH0870; PH0870.
DR PIR; PH1671; PH1671.
DR HSSP; P01751; INQB.
DR SMR; Q9UL89; 1-115.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 116 116
SQ SEQUENCE 116 AA; 12605 MW; C8F9131DE13EA898 CRC64;

Query Match 67.2%; Score 462; DB 2; Length 116;
Best Local Similarity 72.4%; Pred. No. 8.9e-39;
Matches 92; Conservative 8; Mismatches 15; Indels 12; Gaps 2;

```
QY 5 VOSGAEEKPGSSVKVSKCASGDTFNSPISWVRQAPGGGLEWMMGGIIPFGSTKYAQKF 64
Db 1 VOSGAEEVKPGSSVKVSKCASGDTFSSYALSWVRQAPGGGLEWMMGGIIPILGIANYAQKF 60
QY 65 QGRVTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGG-WYEGPLLEPRPDALDIWGOG 123
Db 61 QGRVITADKSTSTAYMELSSLRSEDTAIYYCASSNWPVY-----FDLWGRG 109
QY 124 TWMTVSS 130
Db 110 TLTVTSS 116

RESULT 2
Q6ZF87 HUMAN
ID Q6ZF87_HUMAN PRELIMINARY; PRT; 208 AA.
AC Q6ZF87;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein FLJ26266.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC Tissue=dermoid tumor;
RA Ota T., Nakagawa S., Senoh A., Mizuguchi H., Inagaki H., Suzuki Y.,
RA Hata H., Nakagawa K., Mizuno S., Morinaga M., Kawamura M.,
RA Sugiyama T., Irie R., Otsuki T., Sato H., Nishikawa T., Sugiyama A.,
RA Kawakami B., Nagai K., Isogai T., Sugano S.;
RL Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK129777; BAC85233.1; -; mRNA.
DR HSSP; P01857; 1AJ7.
DR SMR; Q6ZF87; 23-152.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
KW Immunoglobulin domain.
SQ SEQUENCE 208 AA; 22226 MW; 2945666F7ABEE3F2C CRC64;

Query Match 66.6%; Score 458.5; DB 2; Length 208;
Best Local Similarity 67.7%; Pred.No. 3.9e-38;
Matches 88; Conservative 13; Mismatches 20; Indels 9; Gaps 1;

QY 1 QVOLVSGAEAKPGSSVKVSKCASGDTFNSPISWVRQAPGGGLEWMMGGIIPFGSTKY 60
Db 20 QVOLAQSGPEVKPGSSVRSVSKSGDTFSNYSALSWVRQARGHGLEWMMGGIIPVFGTNY 79
QY 61 AQKFGQRTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
Db 80 AQKLGQRTVITADSSRTTAYMEVNSLTSEDTAIYYCAREVYGS-----GPNWFDPW 130
QY 121 GGGTMTVSS 130
Db 131 GGGTMTVSS 140

RESULT 3
Q9UL95 HUMAN
ID Q9UL95_HUMAN PRELIMINARY; PRT; 125 AA.
AC Q9UL95;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
```

```
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RL fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035019; AAD56255.1; -; mRNA.
DR HSSP; P01751; 1NQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1 125
FT NON_TER 125 125
SQ SEQUENCE 125 AA; 13516 MW; 0D3CD5C232488EAC CRC64;

Query Match 65.8%; Score 452.5; DB 2; Length 125;
Best Local Similarity 69.2%; Pred.No. 8.8e-38;
Matches 90; Conservative 10; Mismatches 25; Indels 5; Gaps 1;

QY 1 QVOLVSGAEAKPGSSVKVSKCASGDTFNSPISWVRQAPGGGLEWMMGGIIPFGSTKY 60
Db 1 EVOLVESGAEEVKPGASVKVSKASGYTFTGYMHVVRQAPGGGLEWMMGWINPNSGNTY 60
QY 61 AQKFGQRTMTADGSTSTAYMELNSLRSEDTAIYYCARQONGGWYEGPLLEPRPDALDIW 120
Db 61 AQKVGQRTVTRDTRTISTAYMELSLRSDTAYVYCARSQGGG-----RIAAAGDAFDIW 115
QY 121 GGGTMTVSS 130
Db 116 GGGTMTVSS 125

RESULT 4
Q6PJF1 HUMAN
ID Q6PJF1_HUMAN PRELIMINARY; PRT; 480 AA.
AC Q6PJF1;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC Tissue=Lung;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heich F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Prange C.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Abramson R.D.,
RA Raha S.S., Loquellano N.A., Peters K.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
```

RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RL and mouse cDNA sequences.";
 RN Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RP [2].

NUCLEOTIDE SEQUENCE.

RC TISSUE=Lung;
 RA Strausberg R.;
 RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC016381; AAH16381.1; -, mRNA.
 DR HSSP; P01861; IADQ.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig cl.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_v.
 DR Pfam; PF07654; Cl-set; 3.
 DR SMART; SM00409; IG; 2.
 DR SMART; SM00407; IG1; 3.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS0835; IG LIKE; 4.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
 KW Hypothetical protein.
 SQ SEQUENCE 480 AA; 52586 MW; 64DC641AB47CD6C8 CRC64;

Query Match 65.0%; Score 447.5; DB 2; Length 480;
 Best Local Similarity 71.4%; Pred. No. 1.3e-36;
 Matches 95; Conservative 6; Mismatches 27; Indels 5; Gaps 2;

QY 1 QVQLVQSGAEAKPGSSVKVSKASGDTFNSPISWVRQAPGQGLWMGGIIPFGSTKY 60
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
 DB 20 QVQLVQSGAEVKKPGSSVKVSKASGSPFVISWVRQAPGQGLAWMGIIIPAFDITKY 79
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
 QY 61 AQKFGQGRVTMTADGSTSTAYMELNSLRSEDATYIYCARQONGWYE---GPLLEPRDAL 117
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
 DB 80 AQKFGQGRVTISADESDTDTAYMELNSLRSEDATYIYCARDL--ALYELWSGFHTDEKYGL 137
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
 QY 118 DWGQGTMTVTSS 130
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
 DB 138 DWGQGTMTVTSS 150
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 5

Q9UL92 HUMAN
 ID Q9UL92_HUMAN PRELIMINARY; PRT; 124 AA.
 AC Q9UL92;
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
 DE OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1].

NUCLEOTIDE SEQUENCE.

RP MEDLINE=98271139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
 RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Bernsey S.M.,
 RA Young D.C.;
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
 RT fetus.";
 RL Clin. Immunol. Immunopathol. 87:184-192(1998).
 DR EMBL; AF035022; AAD56258.1; -, mRNA.
 DR HSSP; P01751; INQB.
 DR Ensembl; ENSG00000130076; Homo sapiens.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig_v.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS0835; IG LIKE; 1.
 FT NON_TER 1 124
 NON_TER 124 124

Query Match 63.8%; Score 439; DB 2; Length 120;

SQ SEQUENCE 124 AA; 13580 MW; 1BAACBD96ACD2A2 CRC64;
 Query Match 64.4%; Score 443; DB 2; Length 124;
 Best Local Similarity 70.2%; Pred. No. 8e-37;
 Matches 92; Conservative 11; Mismatches 20; Indels 8; Gaps 3;

QY 1 QVQLVQSGAEAKPGSSVKVSKASGDTFNSPISWVRQAPGQGLWMGGIIPFGSTKY 60
 :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
 DB 1 EVQLVESGAEVKKPGASVKVSKASGYTFSSYMHVMVRQAPGQGLWMGIIIPSGGSTSY 60
 :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
 QY 61 AQKFGQGRVTMTADGSTSTAYMELNSLRSEDATYIYCARQONGWYEGPILLEPRP-DALDI 119
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
 DB 61 AQKFGQGRVTMTDSTSTYIMELSSLRSEDATYIYCAR---GLY---VVVPAAPGRFDY 113
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
 QY 120 WGGGTMTVTSS 130
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
 DB 114 WGGGTMTVTSS 124
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 6

Q6NSA4 HUMAN
 ID Q6NSA4_HUMAN PRELIMINARY; PRT; 120 AA.
 AC Q6NSA4;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE IGHV1-69 protein.
 GN NamesIGHV1-69;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1].

NUCLEOTIDE SEQUENCE.

RP TISSUE=Pooled;
 RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Dege J.G.,
 RA Klauener R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Gunaratne P.H.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.J.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smallos D.E.,
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2].

NUCLEOTIDE SEQUENCE.

RP TISSUE=Pooled;
 RC NIH MGC project;
 RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC070333; AAH70333.1; -, mRNA.
 DR HSSP; P01751; IAGW.
 DR SMR; Q6NSA4; 21-116.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig_v.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS0835; IG LIKE; 1.
 KW Immunoglobulin domain.
 SQ SEQUENCE 120 AA; 13035 MW; 64620FAC874585D4 CRC64;


```
Qy 1 QVQLVQSGAEAKPGSSVKVSKASGDTFNSFPISWVRQAPQGQLEWMGGIIPFGSTKY 60
Db 1 QVQLVQSGAEAKPGSDSVKVKASGVTFSFDHYMHVVRQAPQGQLEWMGIDPNNGDTRF 60
Qy 61 AQKFGQVMTADGSTSTAYMELNSLRSEDTAIYYCARQNGGHWYEGFLLEPRDLDIWI 120
Db 61 AQKFGQVMTADGSTSTAYMELNSLRSEDTAIYYCARQNGGHWYEGFLLEPRDLDIWI 120
Qy 121 GQGTMTVTSS 130
Db 112 GQGTMTVTSS 121

RESULT 10
Q9Y298_HUMAN
ID Q9Y298_HUMAN PRELIMINARY; PRT; 150 AA.
AC Q9Y298;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE IGG VH protein precursor (Fragment).
GN Name=IGG VH;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98322155; PubMed=9657749;
RA Jacquemin M.G., Vander Elst L.P.L.;
RT "Mechanism and kinetics of factor VIII inactivation: study with an
RT IGG4 monoclonal antibody derived from a hemophilia A patient with
RT inhibitor.";
RL Blood 92:496-506(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98322155; PubMed=9657749;
RA Vander Elst L.P.;
RL Submitted (FEB-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ224083; CAAL1829.1; -; mRNA.
DR HSSP; P01857; IHZH.
DR SMR; Q9Y298; 20-149.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR GO; GO:0005887; C:integral to plasma membrane; NAS.
DR GO; GO:0016066; P:cellular defense response (sensu Vertebrata); NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Signal.
FT SIGNAL.
FT NON_TER 150 150 Potential.
SQ SEQUENCE 150 AA; 16031 MW; 563D164AB22802D5 CRC64;

Query Match 61.7%; Score 424.5; DB 2; Length 150;
Best Local Similarity 64.6%; Pred. No. 7.4e-35;
Matches 84; Conservative 10; Mismatches 23; Indels 13; Gaps 1;

Qy 1 QVQLVQSGAEAKPGSSVKVSKASGDTFNSFPISWVRQAPQGQLEWMGGIIPFGSTKY 60
Db 20 QVQLVQSGAEAKPGASVKVSKVGYTLTPELVHVVQAPGKGLWVGFDPESGESIY 79
Qy 61 AQKFGQVMTADGSTSTAYMELNSLRSEDTAIYYCARQNGGHWYEGFLLEPRDLDIWI 120
Db 80 AREFGQVMTADGSTSTAYMELNSLRSEDTAIYYCARQNGGHWYEGFLLEPRDLDIWI 126
Qy 121 GQGTMTVTSS 130
Db 127 GQGTMTVTSS 136

RESULT 11
Q6N041_HUMAN
ID Q6N041_HUMAN PRELIMINARY; PRT; 498 AA.
AC Q6N041;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686O16217 (Fragment).
GN Name=DKFZp686O16217;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;
RG The German Human CDNA Consortium;
RA Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA Mewes H.W., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640710; CAE45829.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q6N041; 268-476.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON_TER 1 1
SQ SEQUENCE 498 AA; 54125 MW; 40B3208A84E03B46 CRC64;

Query Match 61.2%; Score 421; DB 2; Length 498;
Best Local Similarity 64.4%; Pred. No. 6.7e-34;
Matches 87; Conservative 12; Mismatches 20; Indels 16; Gaps 2;

Qy 1 QVQLVQSGAEAKPGSSVKVSKASGDTFNSFPISWVRQAPQGQLEWMGGIIPFGSTKY 60
Db 35 QVQLVQSGADVKKPGASVKVSKASGVTFTNYFFHVRQAPGQGPWGMINPRDGSYKY 94
Qy 61 AQKFGQVMTADGSTSTAYMELNSLRSEDTAIYYCARQNGGHWYEGFLLEPRD 115
Db 95 AQKFGQVMTADGSTSTAYMELNSLRSEDTAIYYCARQNGGHWYEGFLLEPRD 144
Qy 116 ALDIWGQGTMTVTSS 130
Db 145 -FDYWGQGTMTVTSS 158

RESULT 12
HVLIA_HUMAN
ID HVLIA_HUMAN STANDARD; PRT; 117 AA.
AC P01742;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region EU.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=71064024; PubMed=5489771;
RA Cunningham B.A., Rutishauser U., Gall W.E., Gottlieb P.D.,
RA Waxdal M.J., Edelman G.M.;
RT "The covalent structure of a human gamma G-immunoglobulin. VII. Amino
```

acid sequence of heavy-chain cyanogen bromide fragments H1-H4." ;
Biochemistry 9:3161-3170 (1970).
[2]
RT DISULFIDE BOND.
RL MEDLINE=71064027; PubMed=4923144;
RN Call W.E., Edelman G.M.;
RP "The covalent structure of a human gamma G-immunoglobulin. X.
RA Intrachain disulfide bonds." ;
RT Biochemistry 9:3168-3196 (1970).
RT -!- MISCELLANEOUS: The sequence of the gamma-1 C region of this
RL myeloma protein has also been determined.
CC
CC -!- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A90563; GIHURU.
DR HSSP; P01751; 1A6W.
DR SMR; P01742; 1-102.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1_v.
DR PROSITE; PS50835; IG_LIKE; 1.
DR myeloma protein has also been determined.
CC
CC -!- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A90563; GIHURU.
DR HSSP; P01751; 1A6W.
DR SMR; P01742; 1-102.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1_v.
DR PROSITE; PS50835; IG_LIKE; 1.
DR Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Pyrrolidone carboxylic acid.
KW DOMAIN 1 112 IG-like.
FT MOD_RES 1 1 Pyrrolidone carboxylic acid.
FT DISULFID 22 96
FT NON_TER 117 117
FT SEQUENCE 117 AA; 12472 MW; 99D60ADAEBD52818 CRC64;

Query Match 61.1%; Score 420.5; DB 1; Length 117;
Best Local Similarity 67.4%; Pred. No. 1.4e-34;
Matches 89; Conservative 11; Mismatches 15; Indels 17; Gaps 4;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIVPMFGPPNY 60
QY 61 AQKFGQRTVMTADGSTSTAYMELNSLRSEDTAIYYCARQONGW--YEGPILLEPRPDALD 118
Db 61 AQKFGQRTVITADESTNTAYMELSLRSEDATFYCA----GGYGIYS-----PEEYN 109
QY 119 IWGQGTMTVSS 130
Db 110 ----GGLVTVSS 117

Query Match 61.1%; Score 420.5; DB 1; Length 117;
Best Local Similarity 67.4%; Pred. No. 1.4e-34;
Matches 89; Conservative 11; Mismatches 15; Indels 17; Gaps 4;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIVPMFGPPNY 60
QY 61 AQKFGQRTVMTADGSTSTAYMELNSLRSEDTAIYYCARQONGW--YEGPILLEPRPDALD 118
Db 61 AQKFGQRTVITADESTNTAYMELSLRSEDATFYCA----GGYGIYS-----PEEYN 109
QY 119 IWGQGTMTVSS 130
Db 110 ----GGLVTVSS 117

Query Match 61.1%; Score 420.5; DB 2; Length 119;
Best Local Similarity 64.9%; Pred. No. 1.4e-34;
Matches 85; Conservative 12; Mismatches 21; Indels 13; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 EVQLVESGAEVKPKGASVKVSKASGVTFTGYMHVVRQAPGQGLEWMGWNENSWTNY 60
QY 61 AQKFGQRTVMTADGSTSTAYMELNSLRSEDTAIYYCARQONGG-WYEGPILLEPRPDALDI 119
Db 61 AQKFGQKVTMTKDTSTISATYMELSRLSRDDTAVYYCARGGGRLWF-----DP 108
QY 120 WGQGTMTVSS 130
Db 109 WGQGTMTVSS 119

RESULT 14
HVLB_HUMAN STANDARD; PRT; 117 AA.
ID HVLB_HUMAN
AC P01743;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region HG3 precursor.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=83144028; PubMed=6298778;
RA Rechavi G., Ram D., Glazer L., Zakut R., Givol D.;
RT "Evolutionary aspects of immunoglobulin heavy chain variable region
RL (VH) gene subgroups." ;
CC Proc. Natl. Acad. Sci. U.S.A. 80:855-859 (1983).
CC -!- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; J00240; AAA52988.1; -; Genomic_DNA.
DR PIR; A02024; HVHUG.
DR HSSP; P01751; 1NOB.
DR SMR; P01743; 20-116.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1_v.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region HG3.

acid sequence of heavy-chain cyanogen bromide fragments H1-H4." ;
Biochemistry 9:3161-3170 (1970).
[2]
RT DISULFIDE BOND.
RL MEDLINE=71064027; PubMed=4923144;
RN Call W.E., Edelman G.M.;
RP "The covalent structure of a human gamma G-immunoglobulin. X.
RA Intrachain disulfide bonds." ;
RT Biochemistry 9:3168-3196 (1970).
RT -!- MISCELLANEOUS: The sequence of the gamma-1 C region of this
RL myeloma protein has also been determined.
CC
CC -!- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A90563; GIHURU.
DR HSSP; P01751; 1A6W.
DR SMR; P01742; 1-102.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1_v.
DR PROSITE; PS50835; IG_LIKE; 1.
DR myeloma protein has also been determined.
CC
CC -!- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A90563; GIHURU.
DR HSSP; P01751; 1A6W.
DR SMR; P01742; 1-102.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1_v.
DR PROSITE; PS50835; IG_LIKE; 1.
DR Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Pyrrolidone carboxylic acid.
KW DOMAIN 1 112 Ig-like.
FT FT MOD_RES 1 1 Pyrrolidone carboxylic acid.
FT DISULFID 22 96
FT NON_TER 117 117
FT SEQUENCE 117 AA; 12472 MW; 99D60ADAEBD52818 CRC64;

Query Match 61.1%; Score 420.5; DB 1; Length 117;
Best Local Similarity 67.4%; Pred. No. 1.4e-34;
Matches 89; Conservative 11; Mismatches 15; Indels 17; Gaps 4;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIVPFGPPNY 60
QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 118
Db 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 118
QY 119 IWGQGTMTVSS 130
Db 110 ----GGLVTVSS 117

Query Match 61.1%; Score 420.5; DB 1; Length 117;
Best Local Similarity 67.4%; Pred. No. 1.4e-34;
Matches 89; Conservative 11; Mismatches 15; Indels 17; Gaps 4;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIVPFGPPNY 60
QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 118
Db 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 118
QY 119 IWGQGTMTVSS 130
Db 110 ----GGLVTVSS 117

Query Match 61.1%; Score 420.5; DB 2; Length 119;
Best Local Similarity 64.9%; Pred. No. 1.4e-34;
Matches 85; Conservative 12; Mismatches 21; Indels 13; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 EVQLVESGAEVKPKGASVKVSKASGDTFTGYTHHWVRQAPGQGLEWMGWNENSWTNY 60
QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
Db 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
QY 120 WGQGTMTVSS 130
Db 109 WGQGTMTVSS 119

Query Match 61.1%; Score 420.5; DB 2; Length 119;
Best Local Similarity 64.9%; Pred. No. 1.4e-34;
Matches 85; Conservative 12; Mismatches 21; Indels 13; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 EVQLVESGAEVKPKGASVKVSKASGDTFTGYTHHWVRQAPGQGLEWMGWNENSWTNY 60
QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
Db 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
QY 120 WGQGTMTVSS 130
Db 109 WGQGTMTVSS 119

Query Match 61.1%; Score 420.5; DB 2; Length 119;
Best Local Similarity 64.9%; Pred. No. 1.4e-34;
Matches 85; Conservative 12; Mismatches 21; Indels 13; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 EVQLVESGAEVKPKGASVKVSKASGDTFTGYTHHWVRQAPGQGLEWMGWNENSWTNY 60
QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
Db 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
QY 120 WGQGTMTVSS 130
Db 109 WGQGTMTVSS 119

Query Match 61.1%; Score 420.5; DB 2; Length 119;
Best Local Similarity 64.9%; Pred. No. 1.4e-34;
Matches 85; Conservative 12; Mismatches 21; Indels 13; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 EVQLVESGAEVKPKGASVKVSKASGDTFTGYTHHWVRQAPGQGLEWMGWNENSWTNY 60
QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
Db 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
QY 120 WGQGTMTVSS 130
Db 109 WGQGTMTVSS 119

Query Match 61.1%; Score 420.5; DB 2; Length 119;
Best Local Similarity 64.9%; Pred. No. 1.4e-34;
Matches 85; Conservative 12; Mismatches 21; Indels 13; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 EVQLVESGAEVKPKGASVKVSKASGDTFTGYTHHWVRQAPGQGLEWMGWNENSWTNY 60
QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
Db 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
QY 120 WGQGTMTVSS 130
Db 109 WGQGTMTVSS 119

Query Match 61.1%; Score 420.5; DB 2; Length 119;
Best Local Similarity 64.9%; Pred. No. 1.4e-34;
Matches 85; Conservative 12; Mismatches 21; Indels 13; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 EVQLVESGAEVKPKGASVKVSKASGDTFTGYTHHWVRQAPGQGLEWMGWNENSWTNY 60
QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
Db 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
QY 120 WGQGTMTVSS 130
Db 109 WGQGTMTVSS 119

Query Match 61.1%; Score 420.5; DB 2; Length 119;
Best Local Similarity 64.9%; Pred. No. 1.4e-34;
Matches 85; Conservative 12; Mismatches 21; Indels 13; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 EVQLVESGAEVKPKGASVKVSKASGDTFTGYTHHWVRQAPGQGLEWMGWNENSWTNY 60
QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
Db 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
QY 120 WGQGTMTVSS 130
Db 109 WGQGTMTVSS 119

Query Match 61.1%; Score 420.5; DB 2; Length 119;
Best Local Similarity 64.9%; Pred. No. 1.4e-34;
Matches 85; Conservative 12; Mismatches 21; Indels 13; Gaps 2;

QY 1 QVQLVQSGAEAKKPGSSVKVSKASGDTFNSFPISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 1 EVQLVESGAEVKPKGASVKVSKASGDTFTGYTHHWVRQAPGQGLEWMGWNENSWTNY 60
QY 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
Db 61 AQKFGQRTVTADGSTSTAYMELNSLRSDTAIYYCARQONGW--YEGPILLEPRPDALD 119
QY 120 WGQGTMTVSS 130
Db 109 WGQGTMTVSS 119

Query Match 61.1%; Score 420.5; DB 2; Length 119;
Best Local Similarity 64

Job time : 48.9141 secs

```

FT DOMAIN      20  >117      Ig-like.
FT NON TER     117      117
SQ SEQUENCE    117 AA; 12946 MW; 2D3F92FC60CD1FE7 CRC64;

Query Match      59.9%; Score 412; DB 1; Length 117;
Best Local Similarity 82.7%; Pred.No. 1e-33;
Matches 81; Conservative 5; Mismatches 12; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEAKPGSSVKVSKASGDTFNSFPIISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 20 QVQLVQSGAEAKPGASVKVSKASGYTFNSYMHVWRQAPGQGLEWMGIIINFGSGTSY 79

Qy 61 AQKFGQGVTTADGSTSTAYMELNSLRSEDTAIYYCAR 98
Db 80 AQKFGQGVTTADGSTSTAYMELNSLRSEDTAVYYCAR 117

RESULT 15
Q6N095_HUMAN
ID Q6N095_HUMAN PRELIMINARY; PRT; 475 AA.
AC Q6N095;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE Hypothetical protein DKFZp686K03196.
GN Name=DKFZp686K03196;
OS Homo sapiens (Human);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Esophagus tumor;
RG The German cDNA Consortium;
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Oeanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640621; CAE45775.1; -; mRNA.
DR HSSP; P01861; IADQ.
DR SMK; Q6N095; 20-475.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 475 AA; 52360 MW; 7BA14104CD2DB8F0 CRC64;

Query Match      59.7%; Score 411; DB 2; Length 475;
Best Local Similarity 63.6%; Pred.No. 6.5e-33;
Matches 84; Conservative 16; Mismatches 24; Indels 8; Gaps 3;

Qy 1 QVQLVQSGAEAKPGSSVKVSKASGDTFNSFPIISWVRQAPGQGLEWMGGIIPFGSTKY 60
Db 20 QVQLVQSGAEAKPGASVTISCRASGYSTFYHWHVWRQAPGORLEWMGIMNPRDSKTY 79

Qy 61 AQKFGQGVTTADGSTSTAYMELNSLRSEDTAIYYCARQQNGG--WYEGPFLPRPDALD 118
Db 80 AQKFGQGVTTADGSTSTAYMELNSLRSEDTAVYYCTRDGRALWFGEL-----DAPD 133

Qy 119 IWGGITWTVYSS 130
Db 134 IWGGITWTVYSS 145

```

Search completed: May 5, 2006, 09:14:32

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:25 ; Search time 11.3112 seconds
(without alignments)
716.302 Million cell updates/sec

Title: US-09-674-752-24

Perfect score: 502

Sequence: 1 QVOLVSGAEVKPKGSSVKV.....AYMELSLRSEDVAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued Patents AA:*
- 1: /cgn2_6/ptodata/1/iaa/5 COMB.pep:*
 - 2: /cgn2_6/ptodata/1/iaa/6 COMB.pep:*
 - 3: /cgn2_6/ptodata/1/iaa/H_COMB.pep:*
 - 4: /cgn2_6/ptodata/1/iaa/PCITUS_COMB.pep:*
 - 5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep:*
 - 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	502	100.0	98	2	US-10-194-975-9
2	502	100.0	118	2	US-09-203-768A-6
3	502	100.0	119	2	US-09-025-769B-21
4	502	100.0	119	2	US-09-490-070A-21
5	502	100.0	119	2	US-09-490-153-21
6	502	100.0	119	2	US-09-490-324-21
7	502	100.0	120	2	US-09-025-769B-35
8	502	100.0	120	2	US-09-025-769B-57
9	502	100.0	120	2	US-09-490-070A-35
10	502	100.0	120	2	US-09-490-070A-57
11	502	100.0	120	2	US-09-490-153-35
12	502	100.0	120	2	US-09-490-153-57
13	502	100.0	120	2	US-09-490-324-35
14	502	100.0	120	2	US-09-490-324-57
15	502	100.0	270	2	US-09-976-118-2
16	498	99.2	98	2	US-10-194-975-10
17	478	95.2	102	1	US-07-834-539A-55
18	478	95.2	102	1	US-08-053-131-63
19	478	95.2	102	1	US-08-645-641-63
20	478	95.2	102	1	US-07-853-408B-63
21	478	95.2	102	1	US-08-096-752-63
22	478	95.2	102	1	US-08-800-353-55
23	478	95.2	102	1	US-08-308-865-63
24	478	95.2	102	4	PCT-US92-06185-55
25	478	95.2	102	4	PCT-US92-10983-63
26	478	95.2	117	2	US-09-042-353-232
27	478	95.2	117	2	US-08-758-417A-80

28	472	94.0	142	2	US-09-471-276-872	Sequence 872, Appl
29	471	93.8	121	1	US-08-232-081B-41	Sequence 41, Appl
30	469	93.4	120	1	US-08-428-197-13	Sequence 13, Appl
31	469	93.4	120	4	PCT-US93-10555-13	Sequence 13, Appl
32	466	92.8	97	2	US-09-627-896B-31	Sequence 31, Appl
33	466	92.8	97	2	US-09-339-596A-44	Sequence 44, Appl
34	464	92.4	123	1	US-08-652-816A-8	Sequence 8, Appl
35	463	92.2	120	1	US-08-428-197-12	Sequence 12, Appl
36	463	92.2	120	4	PCT-US93-10555-12	Sequence 12, Appl
37	462	92.0	119	2	US-08-983-607-50	Sequence 50, Appl
38	459	91.4	123	1	US-08-652-816A-1	Sequence 1, Appl
39	459	91.4	123	1	US-08-652-816A-6	Sequence 6, Appl
40	459	91.4	123	1	US-08-652-816A-7	Sequence 7, Appl
41	459	91.4	123	1	US-08-652-816A-9	Sequence 9, Appl
42	455	90.6	121	2	US-09-513-999C-4130	Sequence 4130, Ap
43	450	89.6	117	1	US-07-634-278-4	Sequence 4, Appl
44	450	89.6	117	1	US-07-634-278-15	Sequence 15, Appl
45	450	89.6	117	1	US-07-634-278-72	Sequence 72, Appl

ALIGNMENTS

RESULT 1
US-10-194-975-9
; Sequence 9, Application US/10194975
; Patent No. 6881557
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-9

Query Match	100.0%	Score 502;	DB 2;	Length 98;
Best Local Similarity	100.0%;	Fred. No. 4.3e-49;	Mismatches 0;	Indels 0; Gaps 0;
Matches 98;	Conservative	0;		
QY	1	QVOLVSGAEVKPKGSSVKVSKASGCTFSSVAISWVRQAPGQGLEWMGGIIPFGTANY	60	
Db	1	QVOLVSGAEVKPKGSSVKVSKASGCTFSSVAISWVRQAPGQGLEWMGGIIPFGTANY	60	
QY	61	AQKFGQRTITADESTSTAYMELSSLRSEDVAVYYCAR	98	
Db	61	AQKFGQRTITADESTSTAYMELSSLRSEDVAVYYCAR	98	

RESULT 2
US-09-203-768A-6
; Sequence 6, Application US/09203768A
; Patent No. 6787638
; GENERAL INFORMATION:
; APPLICANT: Huse, William D.
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Human Monoclonal Antibodies and Methods
; FILE REFERENCE: P-IX 2947
; CURRENT APPLICATION NUMBER: US/09/203,768A
; CURRENT FILING DATE: 1998-12-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 118
; TYPE: PRT

```
; ORGANISM: Homo sapiens
US-09-203-768A-6

Query Match      100.0%; Score 502; DB 2; Length 118;
Best Local Similarity 100.0%; Pred. No. 5.4e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AQKFGQRVITTADESTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQRVITTADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 3
US-09-025-769B-21
; Sequence 21, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-025-769B-21

Query Match      100.0%; Score 502; DB 2; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.4e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AQKFGQRVITTADESTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQRVITTADESTSTAYMELSSLRSEDTAVYYCAR 98

; ORGANISM: Homo sapiens
US-09-203-768A-6

Query Match      100.0%; Score 502; DB 2; Length 118;
Best Local Similarity 100.0%; Pred. No. 5.4e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AQKFGQRVITTADESTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQRVITTADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 4
US-09-490-070A-21
; Sequence 21, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 21:
; US-09-490-070A-21

Query Match      100.0%; Score 502; DB 2; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.4e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
DB 1 QVQLVSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AQKFGQRVITTADESTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQRVITTADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 5
US-09-490-153-21
; Sequence 21, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
```



```
;; PRIOR APPLICATION DATA: EP 95 11 3021.0
;; APPLICATION NUMBER: EP 95 11 3021.0
;; FILING DATE: 18-AUG-1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: James F. Haley, Jr., Esq.
;; REGISTRATION NUMBER: 27,794
;; REFERENCE/DOCKET NUMBER: MORPHO/5
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (212)596-9000
;; TELEFAX: (212)596-9090
;; INFORMATION FOR SEQ ID NO: 35:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 120 amino acids
;; TYPE: amino acid
;; STRANDEDNESS:
;; TOPOLOGY: linear
;; MOLECULE TYPE: protein
US-09-025-7698-35
Query Match 100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.5e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVQSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
DB 1 QVOLVQSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
QY 61 AQKFGQRVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQRVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
RESULT 8
US-09-025-7698-57
; Sequence 57, Application US/090257698
; Patent No. 630064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,7698
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-57
Query Match 100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.5e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVQSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
DB 1 QVOLVQSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
QY 61 AQKFGQRVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQRVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
RESULT 9
US-09-490-070A-35
; Sequence 35, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-490-070A-35
Query Match 100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.5e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVQSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
```

```
;; TYPE: amino acid
;; TOPOLOGY: linear
;; MOLECULE TYPE: protein
US-09-025-769B-57
Query Match 100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.5e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVQSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
DB 1 QVOLVQSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
QY 61 AQKFGQRVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQRVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
RESULT 9
US-09-490-070A-35
; Sequence 35, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-490-070A-35
Query Match 100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.5e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVQSGAEVKKPGSSVKVSKASGCTFSSVAISWVRQAPGGLEWMGGIIPFGTANY 60
```

Db 1 QVOLVSGAEVKKPGSSVKVCKASGGTFSYAISWVRQAPGGGLEWMGGIIPIFGTANY 60
QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
|||||
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 10
US-09-490-070A-57
; Sequence 57, Application US/09490070A
; Patent No. 6696248

GENERAL INFORMATION:

APPLICANT: Knappik, Achim

Pack, Peter

Ilag, Vic

Ge, Liming

Moroney, Simon

Plueckthun, Andreas

TITLE OF INVENTION: Protein/(Poly)peptide libraries

NUMBER OF SEQUENCES: 373

CORRESPONDENCE ADDRESS:

ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman

STREET: 1666 K Street, N.W., Suite 300

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20006

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/490,070A

FILING DATE: 24-Jan-2000

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: EP 95 11 3021.0

FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:

NAME: Colin G. Sandercock, Esq.

REGISTRATION NUMBER: 31,298

REFERENCE/DOCKET NUMBER: 37629-0005

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 912-2000

TELEFAX: (202) 912-2020

INFORMATION FOR SEQ ID NO: 57:

SEQUENCE CHARACTERISTICS:

LENGTH: 120 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

SEQUENCE DESCRIPTION: SEQ ID NO: 57:

US-09-490-070A-57

Query Match 100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.5e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGSSVKVCKASGGTFSYAISWVRQAPGGGLEWMGGIIPIFGTANY 60
|||||
Db 1 QVOLVSGAEVKKPGSSVKVCKASGGTFSYAISWVRQAPGGGLEWMGGIIPIFGTANY 60

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
|||||
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 11
US-09-490-153-35
; Sequence 35, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:

APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/490,153

FILING DATE: 24-Jan-2000

PRIORITY APPLICATION DATA:

APPLICATION NUMBER: US/09/025,769B

FILING DATE: 18-FEB-1998

APPLICATION NUMBER: EP 95 11 3021.0

FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:

NAME: James F. Haley, Jr., Esq.

REGISTRATION NUMBER: 27,794

REFERENCE/DOCKET NUMBER: MORPHO/5

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212)596-9000

TELEFAX: (212)596-9090

INFORMATION FOR SEQ ID NO: 35:

SEQUENCE CHARACTERISTICS:

LENGTH: 120 amino acids

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: protein

SEQUENCE DESCRIPTION: SEQ ID NO: 35:

US-09-490-153-35

Query Match 100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.5e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGSSVKVCKASGGTFSYAISWVRQAPGGGLEWMGGIIPIFGTANY 60
|||||
Db 1 QVOLVSGAEVKKPGSSVKVCKASGGTFSYAISWVRQAPGGGLEWMGGIIPIFGTANY 60

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
|||||
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 12
US-09-490-153-57
; Sequence 57, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas

TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave

```

; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
;
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9090
; TELEFAX: (212)596-9090
;
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 57:
;
US-09-490-153-57

Query Match 100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 5; Se-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0

Qy 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFFSSYATISVWRQAPGQGLEWMGGII
Db 1 QVQLVQSGAEVKKPGSSVKVCKASGGTFFSSYATISVWRQAPGQGLEWMGGII
Qy 61 AQKFGQRTVITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQRTVITADESTSTAYMELSSLSRSEDATVYYCAR 98

RESULT 13
US-09-490-324-35
; Sequence 35, Application US/09490324
; Patent No. 6828422
;
; GENERAL INFORMATION:
; APPLICANT: Knapplik, Achim
; Pack, Peter
; Ilag, Vic
; Ge. Liming
; Moroney, Simon
; Plueckchun, Andreas
;
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSER: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;
; CURRENT APPLICATION DATA:

```



```

; REFERENCE/DOCKET NUMBER: MORPHO/S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-09-490-324-57

Query Match      100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.5e-49;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGGGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGGGLEWMGGIIPFGTANY 60

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 15
US-09-976-118-2
; Sequence 2, Application US/09976118
; Patent No. 6699473
; GENERAL INFORMATION:
; APPLICANT: Raiesch, Kevin Paul
; APPLICANT: Curiel, David T.
; APPLICANT: Bonner, James Allen
; TITLE OF INVENTION: Human Anti-Epidermal Growth Factor Receptor
; TITLE OF INVENTION: Single-Chain Antibodies
; FILE REFERENCE: D6355
; CURRENT APPLICATION NUMBER: US/09/976,118
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: US 60/240,353
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 270
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: amino acid sequence of anti-EGFR scFv
; OTHER INFORMATION: clone pSEX81-63
US-09-976-118-2

Query Match      100.0%; Score 502; DB 2; Length 270;
Best Local Similarity 100.0%; Pred. No. 1.5e-48;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGGGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGGGLEWMGGIIPFGTANY 60

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:56:13 ; Search time 7.32964 Seconds
(without alignments)
618.844 Million cell updates/sec

Title: US-09-674-752-24

Perfect score: 502

Sequence: 1 QVOLVQSGAEVKPGSSVKV.....AYMELSSLRSDETVVYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications AA New:*

- 1: /SID55/ptodata/1/pubpaa/US08_NEW_PUB.pep.1:
- 2: /SID55/ptodata/1/pubpaa/US06_NEW_PUB.pep.1:
- 3: /SID55/ptodata/1/pubpaa/US07_NEW_PUB.pep.1:
- 4: /SID55/ptodata/1/pubpaa/US08_NEW_PUB.pep.1:
- 5: /SID55/ptodata/1/pubpaa/PCT_NEW_PUB.pep.1:
- 6: /SID55/ptodata/1/pubpaa/US09_NEW_PUB.pep.1:
- 7: /SID55/ptodata/1/pubpaa/US09_NEW_PUB.pep.1:
- 8: /SID55/ptodata/1/pubpaa/US10_NEW_PUB.pep.1:
- 9: /SID55/ptodata/1/pubpaa/US10_NEW_PUB.pep.1:
- 10: /SID55/ptodata/1/pubpaa/US11_NEW_PUB.pep.1:
- 11: /SID55/ptodata/1/pubpaa/US11_NEW_PUB.pep.1:
- 12: /SID55/ptodata/1/pubpaa/US60_NEW_PUB.pep.1:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match %	Query Length	DB ID	Description
1	502	100.0	98	10	US-11-221-902-60
2	502	100.0	98	11	US-11-054-669-9
3	502	100.0	98	11	US-11-061-848-19
4	502	100.0	98	11	US-11-004-590-9
5	502	100.0	119	9	US-10-834-397-21
6	502	100.0	120	9	US-10-834-397-35
7	502	100.0	120	9	US-10-834-397-57
8	502	100.0	123	9	US-10-982-440-3
9	502	100.0	124	9	US-10-982-440-25
10	502	100.0	125	9	US-10-982-440-35
11	502	100.0	248	11	US-11-054-515-1718
12	502	100.0	248	11	US-11-054-515-1719
13	502	100.0	248	11	US-11-054-515-1732
14	502	100.0	248	11	US-11-054-515-1733
15	502	100.0	248	11	US-11-054-515-1734
16	502	100.0	248	11	US-11-054-515-1737
17	502	100.0	248	11	US-11-054-515-1879
18	502	100.0	248	11	US-11-266-444-1718
19	502	100.0	248	11	US-11-266-444-1719
20	502	100.0	248	11	US-11-266-444-1732
21	502	100.0	248	11	US-11-266-444-1733

22	502	100.0	248	11	US-11-266-444-1734	Sequence 1734, Ap
23	502	100.0	248	11	US-11-266-444-1737	Sequence 1737, Ap
24	502	100.0	248	11	US-11-266-444-1879	Sequence 1879, Ap
25	499	99.4	121	9	US-10-982-440-19	Sequence 19, Appl
26	499	99.4	124	11	US-11-040-159-6	Sequence 6, Appl
27	499	99.4	188	11	US-11-000-463-866	Sequence 866, App
28	499	99.4	188	11	US-11-000-463-867	Sequence 867, App
29	499	99.4	248	11	US-11-054-515-1728	Sequence 1728, Ap
30	499	99.4	248	11	US-11-266-444-1728	Sequence 1728, Ap
31	499	99.4	589	11	US-11-271-090-3	Sequence 3, Appl
32	499	99.4	627	9	US-10-493-909-47	Sequence 47, Appl
33	498	99.2	98	10	US-11-221-902-61	Sequence 61, Appl
34	498	99.2	98	11	US-11-054-669-10	Sequence 10, Appl
35	498	99.2	98	11	US-11-084-554-22	Sequence 22, Appl
36	498	99.2	98	11	US-11-061-848-22	Sequence 22, Appl
37	498	99.2	98	11	US-11-136-250-22	Sequence 22, Appl
38	498	99.2	253	11	US-11-054-515-1509	Sequence 1509, Ap
39	498	99.2	253	11	US-11-266-444-1509	Sequence 1509, Ap
40	498	99.2	254	11	US-11-054-515-1866	Sequence 1866, Ap
41	498	99.2	254	11	US-11-266-444-1866	Sequence 1866, Ap
42	497	99.0	248	11	US-11-054-515-1741	Sequence 1741, Ap
43	497	99.0	248	11	US-11-266-444-1741	Sequence 1741, Ap
44	496	98.8	248	11	US-11-054-515-1727	Sequence 1727, Ap
45	496	98.8	248	11	US-11-266-444-1727	Sequence 1727, Ap

ALIGNMENTS

RESULT 1

US-11-221-902-60

; Sequence 60, Application US/11221902

; Publication No. US2006008852A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATE

; FILE REFERENCE: 040000-0317285

; CURRENT APPLICATION NUMBER: US/11/221,902

; CURRENT FILING DATE: 2005-09-09

; NUMBER OF SEQ ID NOS: 89

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 60

; LENGTH: 98

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-11-221-902-60

Query Match 100.0%; Score 502; DB 10; Length 98;

Best Local Similarity 100.0%; Pred. No. 1.4e-37;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKPGSSVKVSKASGGTFTSSVAISWVROAPGQGLEMMGGIPIFGTANY 60

Db 1 QVOLVQSGAEVKPGSSVKVSKASGGTFTSSVAISWVROAPGQGLEMMGGIPIFGTANY 60

Qy 61 AOKFQGRVTITADESTSTAYMELSSLRSDETVVYCAR 98

Db 61 AOKFQGRVTITADESTSTAYMELSSLRSDETVVYCAR 98

RESULT 2

US-11-054-669-9

; Sequence 9, Application US/11054669

; Publication No. US20050261480A1

; GENERAL INFORMATION:

; APPLICANT: Foote, Jefferson

; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES

; FILE REFERENCE: 30219/US/3

; CURRENT APPLICATION NUMBER: US/11/054,669

; CURRENT FILING DATE: 2005-02-08

; PRIOR APPLICATION NUMBER: US 10/194,975

; PRIOR FILING DATE: 2002-07-12

; PRIOR APPLICATION NUMBER: US 60/305,111

```
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 9
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-669-9

Query Match      100.0%; Score 502; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKPGSSVKVSKASGCTFSSYVAISWVRQAPGGLEWMGGIIPFGTANY 60
DB 1 QVQLVSGAEVKPGSSVKVSKASGCTFSSYVAISWVRQAPGGLEWMGGIIPFGTANY 60

QY 61 AQKFGSRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98
DB 61 AQKFGSRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98

RESULT 3
US-11-061-848-19
; Sequence 19, Application US/11061848
; Publication No. US20050288491A1
; GENERAL INFORMATION:
; APPLICANT: Wilson, David S.
; APPLICANT: Nock, Steffen
; APPLICANT: Larrick, James W.
; TITLE OF INVENTION: SUPER-HUMANIZED ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS
; FILE REFERENCE: 186280/US
; CURRENT APPLICATION NUMBER: US/11/061,848
; PRIOR FILING DATE: 2005-02-17
; PRIOR APPLICATION NUMBER: US 60/545,011
; PRIOR FILING DATE: 2004-02-17
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 19
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-061-848-19

Query Match      100.0%; Score 502; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKPGSSVKVSKASGCTFSSYVAISWVRQAPGGLEWMGGIIPFGTANY 60
DB 1 QVQLVSGAEVKPGSSVKVSKASGCTFSSYVAISWVRQAPGGLEWMGGIIPFGTANY 60

QY 61 AQKFGSRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98
DB 61 AQKFGSRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98

RESULT 4
US-11-004-590-9
; Sequence 9, Application US/11004590
; Publication No. US2006008883A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hammond, Phillip W.
; TITLE OF INVENTION: METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING
; FILE REFERENCE: 185932/US/5
; CURRENT APPLICATION NUMBER: US/11/004,590
; PRIOR FILING DATE: 2004-12-03
; CURRENT APPLICATION NUMBER: US 60/527,167
; PRIOR FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: US 60/581,613
```

```
; PRIOR FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US 60/601,665
; PRIOR FILING DATE: 2004-08-13
; PRIOR APPLICATION NUMBER: US 60/619,483
; PRIOR FILING DATE: 2004-10-14
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 9
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-004-590-9

Query Match      100.0%; Score 502; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKPGSSVKVSKASGCTFSSYVAISWVRQAPGGLEWMGGIIPFGTANY 60
DB 1 QVQLVSGAEVKPGSSVKVSKASGCTFSSYVAISWVRQAPGGLEWMGGIIPFGTANY 60

QY 61 AQKFGSRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98
DB 61 AQKFGSRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98

RESULT 5
US-10-834-397-21
; Sequence 21, Application US/10834397
; Publication No. US2006000334A1
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION NUMBER: US/10/834,397
; FILING DATE: 29-Apr-2004
; APPLICATION NUMBER: US/09/490,324
; APPLICATION DATA:
; FILING DATE: 24-Jan-2000
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
```

```

;
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-10-834-397-21

Query Match      100.0%; Score 502; DB 9; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.7e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60
Db 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 6
US-10-834-397-35
; Sequence 35, Application US/10834397
; Publication No. US20060003334A1
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/834,397
; FILING DATE: 29-Apr-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-10-834-397-35

Query Match      100.0%; Score 502; DB 9; Length 120;
Best Local Similarity 100.0%; Pred. No. 1.7e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60
Db 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 7
US-10-834-397-57
; Sequence 57, Application US/10834397
; Publication No. US20060003334A1
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/834,397
; FILING DATE: 29-Apr-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-10-834-397-57

Query Match      100.0%; Score 502; DB 9; Length 120;
Best Local Similarity 100.0%; Pred. No. 1.7e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60
Db 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

```

```
RESULT 8
US-10-982-440-3
; Sequence 3, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; PRIOR FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-3

Query Match      100.0%; Score 502; DB 9; Length 123;
Best Local Similarity 100.0%; Pred. No. 1.8e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFTANY 60
Db 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFTANY 60
QY 61 AQKFGQVRVITADESTSTAYMELSLRSEDSTAVYYCAR 98
Db 61 AQKFGQVRVITADESTSTAYMELSLRSEDSTAVYYCAR 98

RESULT 9
US-10-982-440-25
; Sequence 25, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; PRIOR FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 25
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-25

Query Match      100.0%; Score 502; DB 9; Length 124;
Best Local Similarity 100.0%; Pred. No. 1.8e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFTANY 60
Db 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFTANY 60
QY 61 AQKFGQVRVITADESTSTAYMELSLRSEDSTAVYYCAR 98
Db 61 AQKFGQVRVITADESTSTAYMELSLRSEDSTAVYYCAR 98

RESULT 10
US-10-982-440-35
; Sequence 35, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; PRIOR FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 35
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-35

Query Match      100.0%; Score 502; DB 9; Length 125;
Best Local Similarity 100.0%; Pred. No. 1.8e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFTANY 60
Db 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFTANY 60
QY 61 AQKFGQVRVITADESTSTAYMELSLRSEDSTAVYYCAR 98
Db 61 AQKFGQVRVITADESTSTAYMELSLRSEDSTAVYYCAR 98

RESULT 11
US-11-054-515-1718
; Sequence 1718, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS
; FILE REFERENCE: PFS23P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1718
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1718

Query Match      100.0%; Score 502; DB 11; Length 248;
Best Local Similarity 100.0%; Pred. No. 3.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGGLEWMGGIIPFTANY 60
```

```

Db      1 QVQLVQSGAEVKKPGSSVKVSCKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
      61 AQKFGQGRVTITADESTAYMELSLRSEDTAVYYCAR 98
Db      1 AQKFGQGRVTITADESTAYMELSLRSEDTAVYYCAR 98

RESULT 12
US-11-054-515-1719
; Sequence 1719, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523p3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1719
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1719

Query Match      100.0%; Score 502; DB 11; Length 248;
Best Local Similarity 100.0%; Pred. No. 3.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVQSGAEVKKPGSSVKVSCKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
      61 AQKFGQGRVTITADESTAYMELSLRSEDTAVYYCAR 98
Db      1 QVQLVQSGAEVKKPGSSVKVSCKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
      61 AQKFGQGRVTITADESTAYMELSLRSEDTAVYYCAR 98

RESULT 13
US-11-054-515-1732
; Sequence 1732, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523p3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18

```

```

; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1732
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1732

Query Match      100.0%; Score 502; DB 11; Length 248;
Best Local Similarity 100.0%; Pred. No. 3.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVQSGAEVKKPGSSVKVSCKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
      61 AQKFGQGRVTITADESTAYMELSLRSEDTAVYYCAR 98
Db      1 QVQLVQSGAEVKKPGSSVKVSCKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
      61 AQKFGQGRVTITADESTAYMELSLRSEDTAVYYCAR 98

RESULT 14
US-11-054-515-1733
; Sequence 1733, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523p3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1733
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens

```

US-11-054-515-1733

Query Match 100.0%; Score 502; DB 11; Length 248;
Best Local Similarity 100.0%; Pred. No. 3.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVCKASGCTFSSYVAISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVSGAEVKKPGSSVKVCKASGCTFSSYVAISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AOKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AOKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 15

US-11-054-515-1734
; Sequence 1734, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLYs
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1734
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1734

Query Match 100.0%; Score 502; DB 11; Length 248;
Best Local Similarity 100.0%; Pred. No. 3.4e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGSSVKVCKASGCTFSSYVAISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVSGAEVKKPGSSVKVCKASGCTFSSYVAISWVRQAPGQGLEWMGGIIPFGTANY 60

QY 61 AOKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AOKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

Search completed: May 5, 2006, 08:57:45
Job time : 7.32964 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:05 ; Search time 6.24377 seconds
(without alignments)
1510.185 Million cell updates/sec

Title: US-09-674-752-24

Perfect score: 502

Sequence: 1 QVQLVQSGAEVKPKGSSVKV.....AYMELSLRSEDVAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR_80.*

1: pir1.*

2: pir2.*

3: pir3.*

4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	502	100.0	98	2 S26915	Ig heavy chain V r
2	502	100.0	116	2 S31698	Ig heavy chain pre
3	502	100.0	116	2 PH0959	Ig heavy chain V r
4	502	100.0	119	2 PH0961	Ig heavy chain V r
5	502	100.0	120	2 PH0962	Ig heavy chain V r
6	502	100.0	122	2 PH0958	Ig heavy chain V r
7	502	100.0	123	2 S44108	Ig heavy chain V-D
8	502	100.0	126	2 B33488	Ig heavy chain V-1
9	502	100.0	127	2 PH0955	Ig heavy chain V-1
10	502	100.0	129	2 A33548	Ig heavy chain V-1
11	502	100.0	132	2 PH0954	Ig heavy chain V r
12	502	100.0	135	2 PH0953	Ig heavy chain V r
13	499	99.4	133	2 C33488	Ig heavy chain V-1
14	499	99.4	627	2 S14683	Ig mu chain precu
15	498	99.2	98	2 S24680	Ig heavy chain V1
16	498	99.2	128	2 PH0952	Ig heavy chain V r
17	498	99.2	136	2 PH0960	Ig heavy chain V r
18	497	99.0	132	2 S46394	Ig heavy chain V r
19	496	98.8	125	2 PH0957	Ig heavy chain V r
20	493	98.2	116	2 S36261	Ig heavy chain V r
21	493	98.2	119	2 S44106	Ig heavy chain V-D
22	474	94.4	98	2 S46463	Ig heavy chain V1
23	466	92.8	97	2 PH0870	Ig heavy chain V r
24	459	91.4	116	2 S31667	Ig heavy chain V r
25	451	89.8	108	2 PH1664	Ig heavy chain V r
26	451	89.8	113	2 PH1663	Ig heavy chain V r
27	451	89.8	135	2 B32274	Ig heavy chain pre
28	450	89.6	117	1 G1HUEU	Ig heavy chain V-1
29	446	88.8	98	2 A30523	Ig heavy chain V-I

30	444	88.4	121	2 A49590	Ig heavy chain V r
31	436	86.9	109	2 PH1671	Ig heavy chain V r
32	430	85.7	122	2 B49590	Ig heavy chain V r
33	424	84.5	122	2 C49590	Ig heavy chain V r
34	412	82.1	118	2 S36265	Ig heavy chain V r
35	411	81.9	98	2 S26919	Ig heavy chain V r
36	410	81.7	98	2 S26920	Ig heavy chain V r
37	410	81.7	117	1 HVHUGG	Ig heavy chain pre
38	406	80.9	122	2 S36271	Ig heavy chain V r
39	406	80.9	142	2 A32483	Ig heavy chain V r
40	405	80.7	129	2 S36260	Ig heavy chain V r
41	401	79.9	124	2 S19665	Ig heavy chain V r
42	400	79.7	98	2 S26938	Ig heavy chain V r
43	400	79.7	117	2 S31680	Ig heavy chain V r
44	400	79.7	117	2 S18551	Ig heavy chain V r
45	400	79.7	135	2 S49530	anti-Sm antibody V

ALIGNMENTS

RESULT 1

S26915

Ig heavy chain V region (DP-10) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C;Accession: S26915

R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.

J. Mol. Biol. 227, 776-798, 1992

A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V

A;Reference number: S26885; MUID:93021117; PMID:1404388

A;Accession: S26915

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-98 <TOM>

A;Cross-references: UNIPARC:UPI000031F2F; EMBL:Z12312; NID:g32849; PIDN:CAA78182.1; PID

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotrimer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 502; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.3e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	QVQLVQSGAEVKPKGSSVKVSCASGGTSSYAIISVVRQAPGGGLEWMGGIPIFGTANY 60
Db	1	QVQLVQSGAEVKPKGSSVKVSCASGGTSSYAIISVVRQAPGGGLEWMGGIPIFGTANY 60

Qy	61	AQKFGQRTITADESTAYMELSSLRSEDTAVYYCAR 98
Db	61	AQKFGQRTITADESTAYMELSSLRSEDTAVYYCAR 98

RESULT 2

S31698

Ig heavy chain precursor V region - human

C;Species: Homo sapiens (man)

C;Date: 03-Mar-1994 #sequence_revision 03-May-1996 #text_change 23-Jul-1999

C;Accession: S31698

R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.

submitted to the EMBL Data Library, June 1992

A;Description: Mechanisms that generate human immunoglobulin diversity operate from the

A;Reference number: S31585

A;Accession: S31698

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-116 <CUI>

A;Cross-references: UNIPARC:UPI000011647E; EMBL:Z14214; NID:g37797; PIDN:CAA78583.1; PID

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotrimer; immunoglobulin

F;33-116/Domain: immunoglobulin homology <IMM>

F;40-114/Disulfide bonds: #status predicted

```

Query Match      100.0%; Score 502; DB 2; Length 116;
Best Local Similarity 100.0%; Pred. No. 3.9e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60
   |||||
Db 19 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 78
   |||||

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98
   |||||
Db 79 AQKFGQGRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 116
   |||||

RESULT 3
PH0959
Ig heavy chain V region (G6+ T-L26) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0959
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0959
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-116 <MAR>
A:Cross-references: UNIPARC:UPI0000176CE3
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
F:1-30/Region: framework 1
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-57/Region: complementarity-determining 2
F:68-98/Region: framework 3
F:99-104/Region: complementarity-determining 3

Query Match      100.0%; Score 502; DB 2; Length 116;
Best Local Similarity 100.0%; Pred. No. 3.9e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60
   |||||

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98
   |||||
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98
   |||||

RESULT 4
PH0961
Ig heavy chain V region (G6+ T-L33) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0961
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0961
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-119 <MAR>
A:Cross-references: UNIPARC:UPI0000176CE5
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
F:1-30/Region: framework 1
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-57/Region: complementarity-determining 2

```

```

F:68-98/Region: framework 3
F:99-107/Region: complementarity-determining 3

Query Match      100.0%; Score 502; DB 2; Length 119;
Best Local Similarity 100.0%; Pred. No. 4e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60
   |||||

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98
   |||||
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98
   |||||

RESULT 5
PH0962
Ig heavy chain V region (G6+ T-L42) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0962
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0962
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-120 <MAR>
A:Cross-references: UNIPARC:UPI0000176CE6
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
F:1-30/Region: framework 1
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-57/Region: complementarity-determining 2
F:68-98/Region: framework 3
F:99-108/Region: complementarity-determining 3

Query Match      100.0%; Score 502; DB 2; Length 120;
Best Local Similarity 100.0%; Pred. No. 4e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFSSYAISWVRQAPGGLEWMGGIPIFGTANY 60
   |||||

QY 61 AQKFGQGRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98
   |||||
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSSEDTAVYYCAR 98
   |||||

RESULT 6
PH0958
Ig heavy chain V region (G6+ CLL-HUR) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0958
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0958
A:Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-122 <MAR>
A:Cross-references: UNIPARC:UPI0000176CE2
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotrimer; immunoglobulin
F:1-30/Region: framework 1
F:15-98/Domain: immunoglobulin homology <IMM>

```

F;31-35/Region: complementarity-determining 1
 F;36-50/Region: framework 2
 F;51-67/Region: complementarity-determining 2
 F;68-98/Region: framework 3
 F;99-110/Region: complementarity-determining 3

Query Match 100.0%; Score 502; DB 2; Length 122;
 Best Local Similarity 100.0%; Pred. No. 4.1e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGSSVKVSKASGGTSSYSAISVWRQAPGGGLEWMGGIIPIFGTANY 60
 DB 1 QVOLVSGAEVKKPGSSVKVSKASGGTSSYSAISVWRQAPGGGLEWMGGIIPIFGTANY 60
 QY 61 AQKQGRVTITADESTSTAYMELSSLRSEDVAVYYCAR 98
 DB 61 AQKQGRVTITADESTSTAYMELSSLRSEDVAVYYCAR 98

RESULT 7

IG heavy chain V-D-J region - human
 C;Species: Homo sapiens (man)
 C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001
 C;Accession: S44108
 R;Hawkins, R.E.; Zhu, D.; Ovecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.
 submitted to the EMBL Data Library, March 1994
 A;Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable

A;Reference number: S44105
 A;Accession: S44108
 A;Status: preliminary
 A;Molecule type: DNA
 A;Residues: 1-123 <MAR>
 A;Cross-references: UNIPARC:UPI0000116637; EMBL:Z31397; NID:G472962; PIDN:CAA83272.1; PI
 C;Superfamily: immunoglobulin V region; immunoglobulin homology
 C;Keywords: heterotrimer; immunoglobulin
 F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 502; DB 2; Length 123;
 Best Local Similarity 100.0%; Pred. No. 4.1e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGSSVKVSKASGGTSSYSAISVWRQAPGGGLEWMGGIIPIFGTANY 60
 DB 1 QVOLVSGAEVKKPGSSVKVSKASGGTSSYSAISVWRQAPGGGLEWMGGIIPIFGTANY 60
 QY 61 AQKQGRVTITADESTSTAYMELSSLRSEDVAVYYCAR 98
 DB 61 AQKQGRVTITADESTSTAYMELSSLRSEDVAVYYCAR 98

RESULT 8

IG heavy chain V-1 region (AND) - human
 C;Species: Homo sapiens (man)
 C;Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996
 C;Accession: B33548
 R;Kipps, T.J.; Tomhave, E.; Pratt, L.F.; Duffy, S.; Chen, P.P.; Carson, D.A.
 Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989
 A;Title: Developmentally restricted immunoglobulin heavy chain variable region gene exp
 A;Reference number: A33548; MUID:89345575; PMID:2503826
 A;Accession: B33548
 A;Status: preliminary; nucleic acid sequence not shown; not compared with conceptual tra

A;Molecule type: DNA
 A;Residues: 1-126 <KIP>
 A;Cross-references: UNIPARC:UPI0000176D2A
 A;Experimental source: the sequence was determined from the differentiated gene
 C;Superfamily: immunoglobulin V region; immunoglobulin homology
 C;Keywords: heterotrimer; immunoglobulin
 F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 502; DB 2; Length 126;
 Best Local Similarity 100.0%; Pred. No. 4.2e-41;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVOLVSGAEVKKPGSSVKVSKASGGTSSYSAISVWRQAPGGGLEWMGGIIPIFGTANY 60
 DB 1 QVOLVSGAEVKKPGSSVKVSKASGGTSSYSAISVWRQAPGGGLEWMGGIIPIFGTANY 60
 QY 61 AQKQGRVTITADESTSTAYMELSSLRSEDVAVYYCAR 98
 DB 61 AQKQGRVTITADESTSTAYMELSSLRSEDVAVYYCAR 98

RESULT 9

IG heavy chain V region (G6+ CLL-AND) - human (fragment)
 C;Species: Homo sapiens (man)
 C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
 C;Accession: PH0955
 R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
 J. Exp. Med. 175, 983-991, 1992
 A;Title: Evidence for somatic selection of natural autoantibodies.

A;Reference number: PH0952; MUID:92202880; PMID:1552291
 A;Accession: PH0955
 A;Status: nucleic acid sequence not shown
 A;Molecule type: DNA
 A;Residues: 1-127 <MAR>
 A;Cross-references: UNIPARC:UPI0000176CDF
 C;Superfamily: immunoglobulin V region; immunoglobulin homology
 C;Keywords: heterotrimer; immunoglobulin
 F;1-30/Region: framework 1
 F;15-98/Domain: immunoglobulin homology <IMM>
 F;31-35/Region: complementarity-determining 1
 F;36-50/Region: framework 2
 F;51-67/Region: complementarity-determining 2
 F;68-98/Region: framework 3
 F;99-115/Region: complementarity-determining 3

Query Match 100.0%; Score 502; DB 2; Length 127;
 Best Local Similarity 100.0%; Pred. No. 4.2e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGSSVKVSKASGGTSSYSAISVWRQAPGGGLEWMGGIIPIFGTANY 60
 DB 1 QVOLVSGAEVKKPGSSVKVSKASGGTSSYSAISVWRQAPGGGLEWMGGIIPIFGTANY 60
 QY 61 AQKQGRVTITADESTSTAYMELSSLRSEDVAVYYCAR 98
 DB 61 AQKQGRVTITADESTSTAYMELSSLRSEDVAVYYCAR 98

RESULT 10

IG heavy chain V-1 region (NEI) - human
 C;Species: Homo sapiens (man)
 C;Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996
 C;Accession: A33548; PH0956
 R;Kipps, T.J.; Tomhave, E.; Pratt, L.F.; Duffy, S.; Chen, P.P.; Carson, D.A.
 Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989
 A;Title: Developmentally restricted immunoglobulin heavy chain variable region gene exp
 A;Reference number: A33548; MUID:89345575; PMID:2503826
 A;Accession: A33548
 A;Status: preliminary; not compared with conceptual translation

A;Molecule type: mRNA
 A;Residues: 1-129 <KIP>
 A;Cross-references: UNIPARC:UPI0000176CE0
 R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
 J. Exp. Med. 175, 983-991, 1992
 A;Title: Evidence for somatic selection of natural autoantibodies.
 A;Reference number: PH0952; MUID:92202880; PMID:1552291
 A;Accession: PH0956
 A;Status: nucleic acid sequence not shown
 A;Molecule type: DNA
 A;Residues: 1-129 <MAR>
 A;Cross-references: UNIPARC:UPI0000176CE0

```

C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:1-30/Region: framework 1
F:31-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-67/Region: complementarity-determining 2
F:68-98/Region: framework 3
F:99-117/Region: complementarity-determining 3

Query Match      100.0%; Score 502; DB 2; Length 129;
Best Local Similarity 100.0%; Pred. No. 4.4e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSVAISWVRQAPQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSVAISWVRQAPQGLEWMGGIPIFGTANY 60

QY 61 AQKFGRTITADESTSTAYMELSLSRSEDTAVYYCAR 98
Db 61 AQKFGRTITADESTSTAYMELSLSRSEDTAVYYCAR 98

RESULT 11
PH0954
Ig heavy chain V region (G6+ CLL-HEN) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0954
R:Martin, T.; Duffly, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0954
A>Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-132 <MAR>
A:Cross-references: UNIPARC:UPI0000176CDE
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:1-30/Region: framework 1
F:31-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
F:51-67/Region: complementarity-determining 2
F:68-98/Region: framework 3
F:99-120/Region: complementarity-determining 3

Query Match      100.0%; Score 502; DB 2; Length 132;
Best Local Similarity 100.0%; Pred. No. 4.4e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSVAISWVRQAPQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSVAISWVRQAPQGLEWMGGIPIFGTANY 60

QY 61 AQKFGRTITADESTSTAYMELSLSRSEDTAVYYCAR 98
Db 61 AQKFGRTITADESTSTAYMELSLSRSEDTAVYYCAR 98

RESULT 12
PH0953
Ig heavy chain V region (G6+ CLL-SIC) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0953
R:Martin, T.; Duffly, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0953
A>Status: nucleic acid sequence not shown

```

C;Superfamily: immunoglobulin C region; immunoglobulin homology
C;Keywords: immunoglobulin; membrane protein
F;1-15/Domain: signal sequence #status predicted <SIG>
F;16-627/Product: Ig mu chain #status predicted <MAT>
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 99.4%; Score 499; DB 2; Length 627;
Best Local Similarity 99.0%; Pred. No. 4e-40;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGGGLEWMGGIIPFGTANY 60
Db 20 QVQLVQSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGGGLEWMGGIIPFGTANY 79

Qy 61 AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 80 AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAK 117

RESULT 15
S24680
Ig heavy chain V1 region - human
C;Species: Homo sapiens (man)
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 23-Jul-1999
C;Accession: S24680
R;van Es, J.H.
submitted to the EMBL Data Library, July 1992
A;Reference number: S24679
A;Accession: S24680
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-98 <VAN>
A;Cross-references: UNIPARC:UPI000113F84; EMBL:X67905; NID:g33128; PIDN:CAA48103.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 99.2%; Score 498; DB 2; Length 98;
Best Local Similarity 99.0%; Pred. No. 7.9e-41;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGGGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVCKASGCTFSSYAISWVRQAPGGGLEWMGGIIPFGTANY 60

Qy 61 AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

Search completed: May 5, 2006, 08:51:35
Job time : 6.24377 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 02:25:43 ; Search time 56.5 Seconds
(without alignments)
724.731 Million cell updates/sec

Title: US-09-674-752-24

Perfect score: 502

Sequence: 1 QVQLVQSGAEVKKPGSSVKV.....AYMELSLRSEDATVYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 57

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Listing first 500 summaries

Database :

Published Applications_AA_Main:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*

2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*

3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*

4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*

5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*

6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	502	100.0	98	4	US-10-194-975-9
2	502	100.0	98	4	US-10-125-687-15
3	502	100.0	98	4	US-10-308-817-49
4	502	100.0	98	4	US-10-032-017B-39
5	502	100.0	98	4	US-10-029-988B-39
6	502	100.0	98	4	US-10-032-423A-39
7	502	100.0	98	4	US-10-453-698-49
8	502	100.0	98	4	US-10-029-926B-39
9	502	100.0	98	4	US-10-379-392-9
10	502	100.0	98	5	US-10-737-290-169
11	502	100.0	98	5	US-10-996-191-15
12	502	100.0	115	4	US-10-275-046-66
13	502	100.0	118	4	US-10-300-675-6
14	502	100.0	118	4	US-10-300-675-10
15	502	100.0	118	4	US-10-300-675-12
16	502	100.0	118	4	US-10-300-675-14
17	502	100.0	118	5	US-10-910-124-6
18	502	100.0	119	4	US-10-308-817-191
19	502	100.0	119	4	US-10-453-698-191
20	502	100.0	119	5	US-10-734-661A-99
21	502	100.0	119	5	US-10-734-661A-100
22	502	100.0	120	4	US-10-125-687-1
23	502	100.0	120	5	US-10-936-191-1
24	502	100.0	122	4	US-10-371-942-26
25	502	100.0	123	4	US-10-269-805-3
26	502	100.0	124	4	US-10-269-805-25
27	502	100.0	124	5	US-10-734-661A-102

28	502	100.0	125	4	US-10-269-805-35	Sequence 35, Appl
29	502	100.0	127	4	US-10-320-231A-33	Sequence 33, Appl
30	502	100.0	127	5	US-10-867-506-33	Sequence 33, Appl
31	502	100.0	127	5	US-10-505-313-232	Sequence 232, App
32	502	100.0	219	4	US-10-128-520-160	Sequence 160, App
33	502	100.0	220	4	US-10-128-520-149	Sequence 149, App
34	502	100.0	220	4	US-10-128-520-175	Sequence 175, App
35	502	100.0	222	4	US-10-128-520-168	Sequence 168, App
36	502	100.0	223	4	US-10-128-520-172	Sequence 172, App
37	502	100.0	225	4	US-10-128-520-147	Sequence 147, App
38	502	100.0	229	4	US-10-128-520-155	Sequence 155, App
39	502	100.0	231	4	US-10-128-520-161	Sequence 161, App
40	502	100.0	238	5	US-10-496-861-7	Sequence 7, Appl
41	502	100.0	248	3	US-09-880-748-1718	Sequence 1718, Ap
42	502	100.0	248	3	US-09-880-748-1719	Sequence 1719, Ap
43	502	100.0	248	3	US-09-880-748-1732	Sequence 1732, Ap
44	502	100.0	248	3	US-09-880-748-1733	Sequence 1733, Ap
45	502	100.0	248	3	US-09-880-748-1734	Sequence 1734, Ap
46	502	100.0	248	3	US-09-880-748-1737	Sequence 1737, Ap
47	502	100.0	248	3	US-09-880-748-1879	Sequence 1879, Ap
48	502	100.0	248	4	US-10-293-418-1718	Sequence 1718, Ap
49	502	100.0	248	4	US-10-293-418-1719	Sequence 1719, Ap
50	502	100.0	248	4	US-10-293-418-1732	Sequence 1732, Ap
51	502	100.0	248	4	US-10-293-418-1733	Sequence 1733, Ap
52	502	100.0	248	4	US-10-293-418-1734	Sequence 1734, Ap
53	502	100.0	248	4	US-10-293-418-1737	Sequence 1737, Ap
54	502	100.0	248	4	US-10-293-418-1879	Sequence 1879, Ap
55	502	100.0	248	5	US-10-943-197-6	Sequence 6, Appl
56	502	100.0	270	3	US-09-976-118-2	Sequence 2, Appl
57	502	100.0	270	4	US-10-703-277-2	Sequence 2, Appl

ALIGNMENTS

RESULT 1

US-10-194-975-9
; Sequence 9, Application US/10194975
; Publication No. US20030039649A1
; GENERAL INFORMATION:
; APPLICANT: Footce, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-9

Query Match 100.0%; Score 502; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIPIFGTANY 60
Db	1	QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAIISWVRQAPGQGLEWMGGIPIFGTANY 60
Qy	61	AQKFGQRTVTITADESTSTAYMELSLRSEDATVYCAR 98
Db	61	AQKFGQRTVTITADESTSTAYMELSLRSEDATVYCAR 98

RESULT 2

US-10-125-687-15
; Sequence 15, Application US/10125687
; Publication No. US20030054407A1
; GENERAL INFORMATION:

```
; APPLICANT: Luo, Peter
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705
; CURRENT APPLICATION NUMBER: US/10/125,687
; CURRENT FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-125-687-15

Query Match      100.0%; Score 502; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98

RESULT 3
US-10-308-817-49
; Sequence 49, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 49
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-308-817-49

Query Match      100.0%; Score 502; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98

RESULT 4
US-10-032-037B-39
; Sequence 39, Application US/10032037B
; Publication No. US20040001822A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/44
; CURRENT APPLICATION NUMBER: US/10/032,037B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-39
```

```
; SEQ ID NO 39
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-39

Query Match      100.0%; Score 502; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98

RESULT 5
US-10-029-988B-39
; Sequence 39, Application US/10029988B
; Publication No. US20040001839A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029,988B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-39

Query Match      100.0%; Score 502; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYALSWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDVAVYCAR 98

RESULT 6
US-10-032-423A-39
; Sequence 39, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-39
```



```
Query Match      100.0%; Score 502; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIPGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIPGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98

RESULT 7
US-10-453-698-49
; Sequence 49, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-453-698-49

Query Match      100.0%; Score 502; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIPGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIPGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98

RESULT 8
US-10-029-926B-39
; Sequence 39, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; FILE REFERENCE: 10793/50
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 39
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-39

Query Match      100.0%; Score 502; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIPGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIPGTANY 60
```

```
Qy 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98

RESULT 9
US-10-379-392-9
; Sequence 9, Application US/10379392
; Publication No. US20040110226A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Deejarlais, John Rudolf
; APPLICANT: Marshall, Shannon Alicia
; APPLICANT: Dahiyat, Bassil I.
; TITLE OF INVENTION: ANTIBODY OPTIMIZATION
; FILE REFERENCE: A-71386-3 463077-236
; CURRENT APPLICATION NUMBER: US/10/379,392
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/360,843
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 60/384,197
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-379-392-9

Query Match      100.0%; Score 502; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIPGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIPGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYYCAR 98

RESULT 10
US-10-737-290-169
; Sequence 169, Application US/10737290
; Publication No. US20040253242A1
; GENERAL INFORMATION:
; APPLICANT: Bowdish, Katherine S.
; APPLICANT: Frederickson, Shana
; APPLICANT: Renshaw, Mark
; APPLICANT: Orcencia, Cecilia
; TITLE OF INVENTION: RATIONALLY DESIGNED ANTIBODIES
; FILE REFERENCE: 1087-2 CIP III
; CURRENT APPLICATION NUMBER: US/10/737,290
; CURRENT FILING DATE: 2003-12-15
; PRIOR APPLICATION NUMBER: US 10/452,590
; PRIOR FILING DATE: 2003-06-02
; PRIOR APPLICATION NUMBER: US 10/307,724
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 10/006,593
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/251,448
; PRIOR FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/288,889
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/294,068
; PRIOR FILING DATE: 2001-05-29
; NUMBER OF SEQ ID NOS: 193
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 169
; LENGTH: 98
; TYPE: PRT
```

```
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: recombinant Ab VH
US-10-737-290-169

Query Match      100.0%; Score 502; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||

QY 61 AQKQFGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
   |||||
DB 61 AQKQFGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
   |||||

RESULT 11
US-10-996-191-15
; Sequence 15, Application US/10996191
; Publication No. US20050148001A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Peizhi
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705.301
; CURRENT APPLICATION NUMBER: US/10/996,191
; CURRENT FILING DATE: 2004-11-22
; PRIOR APPLICATION NUMBER: US 60/284,407
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: US 10/125,687
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-996-191-15

Query Match      100.0%; Score 502; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||

QY 61 AQKQFGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
   |||||
DB 61 AQKQFGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
   |||||

RESULT 12
US-10-275-046-66
; Sequence 66, Application US/10275046
; Publication No. US20040019187A1
; GENERAL INFORMATION:
; APPLICANT: Nagy et al.
; TITLE OF INVENTION: IMMUNOMODULATORY HUMAN MHC CLASS II ANTIGEN-BINDING POLYPEPTIDES
; FILE REFERENCE: GPCG-P01-260
; CURRENT APPLICATION NUMBER: US/10/275,046
; CURRENT FILING DATE: 2002-10-31
; PRIOR APPLICATION NUMBER: 00110063.5
; PRIOR FILING DATE: 2000-05-12
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 66
; LENGTH: 115
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: MS-GPC5 VH
```

US-10-275-046-66

```
Query Match      100.0%; Score 502; DB 4; Length 115;
Best Local Similarity 100.0%; Pred. No. 5.5e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||

QY 61 AQKQFGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
   |||||
DB 61 AQKQFGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
   |||||
```

RESULT 13

US-10-300-675-6

```
; Sequence 6, Application US/10300675
; Publication No. US20030198638A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-300-675-6
```

```
Query Match      100.0%; Score 502; DB 4; Length 118;
Best Local Similarity 100.0%; Pred. No. 5.7e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
   |||||

QY 61 AQKQFGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
   |||||
DB 61 AQKQFGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
   |||||
```

RESULT 14

US-10-300-675-10

```
; Sequence 10, Application US/10300675
; Publication No. US20030198638A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Recombinant variant
US-10-300-675-10
```

```
Query Match      100.0%; Score 502; DB 4; Length 118;
Best Local Similarity 100.0%; Pred. No. 5.7e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98

RESULT 15
US-10-300-675-12
; Sequence 12, Application US/10300675
; Publication No. US20030198638A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Recombinant variant
US-10-300-675-12

Query Match 100.0%; Score 502; DB 4; Length 118;
Best Local Similarity 100.0%; Pred. No. 5.7e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98

RESULT 16
US-10-300-675-14
; Sequence 14, Application US/10300675
; Publication No. US20030198638A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Monoclonal Antibodies
; FILE REFERENCE: P-IX 5519
; CURRENT APPLICATION NUMBER: US/10/300,675
; CURRENT FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: US 09/989,901
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Recombinant variant
US-10-300-675-14

Query Match 100.0%; Score 502; DB 4; Length 118;
Best Local Similarity 100.0%; Pred. No. 5.7e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
```

```
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98

RESULT 17
US-10-910-124-6
; Sequence 6, Application US/10910124
; Publication No. US20050003469A1
; GENERAL INFORMATION:
; APPLICANT: Huse, William D.
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Tumor Specific Human Monoclonal Antibodies and Methods
; TITLE OF INVENTION: Of Use
; FILE REFERENCE: P-IX 2947
; CURRENT APPLICATION NUMBER: US/10/910,124
; CURRENT FILING DATE: 2004-08-02
; PRIOR APPLICATION NUMBER: US/09/203,768
; PRIOR FILING DATE: 1998-12-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-910-124-6

Query Match 100.0%; Score 502; DB 5; Length 118;
Best Local Similarity 100.0%; Pred. No. 5.7e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98

RESULT 18
US-10-308-817-191
; Sequence 191, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 191
; LENGTH: 119
; TYPE: PRT
; ORGANISM: human
US-10-308-817-191

Query Match 100.0%; Score 502; DB 4; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.8e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYVAISWVRQAPQGQLEWMGGIPIFGTANY 60
Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
```

```
RESULT 19
US-10-453-698-191
; Sequence 191, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 191
; LENGTH: 119
; TYPE: PRT
; ORGANISM: human
US-10-453-698-191

Query Match      100.0%; Score 502; DB 4; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.8e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98

RESULT 20
US-10-734-661A-99
; Sequence 99, Application US/10734661A
; Publication No. US20050147612A1
; GENERAL INFORMATION:
; APPLICANT: ProChon Biotech, Ltd.
; APPLICANT: MorphoSys AG
; APPLICANT: Yavon, Avner
; APPLICANT: Thomassen-Wolf, Elisabeth
; APPLICANT: Rom, Eran
; APPLICANT: Borges, Eric
; TITLE OF INVENTION: ANTIBODIES THAT BLOCK RECEPTOR PROTEIN TYROSINE KINASE ACTIVATION
; FILE REFERENCE: 81408-4400
; CURRENT APPLICATION NUMBER: US/10/734,661A
; CURRENT FILING DATE: 2003-12-15
; PRIOR APPLICATION NUMBER: US 60/299,187
; PRIOR FILING DATE: 2001-06-20
; PRIOR APPLICATION NUMBER: PCT/IL02/00494
; PRIOR FILING DATE: 2002-06-20
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 99
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: polypeptide sequence of a VH domain
US-10-734-661A-99

Query Match      100.0%; Score 502; DB 5; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.8e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98

RESULT 21
US-10-734-661A-100
; Sequence 100, Application US/10734661A
; Publication No. US20050147612A1
; GENERAL INFORMATION:
; APPLICANT: ProChon Biotech, Ltd.
; APPLICANT: MorphoSys AG
; APPLICANT: Yavon, Avner
; APPLICANT: Thomassen-Wolf, Elisabeth
; APPLICANT: Rom, Eran
; APPLICANT: Borges, Eric
; TITLE OF INVENTION: ANTIBODIES THAT BLOCK RECEPTOR PROTEIN TYROSINE KINASE ACTIVATION
; FILE REFERENCE: 81408-4400
; CURRENT APPLICATION NUMBER: US/10/734,661A
; CURRENT FILING DATE: 2003-12-15
; PRIOR APPLICATION NUMBER: US 60/299,187
; PRIOR FILING DATE: 2001-06-20
; PRIOR APPLICATION NUMBER: PCT/IL02/00494
; PRIOR FILING DATE: 2002-06-20
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 100
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: polypeptide sequence of a VH domain
US-10-734-661A-100

Query Match      100.0%; Score 502; DB 5; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.8e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98

RESULT 22
US-10-125-687-1
; Sequence 1, Application US/10125687
; Publication No. US20030054407A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Peter
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705
; CURRENT APPLICATION NUMBER: US/10/125,687
; CURRENT FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Human consensus antibody heavy chain variable region
US-10-125-687-1

Query Match      100.0%; Score 502; DB 4; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.8e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98
```

```
RESULT 21
US-10-734-661A-100
; Sequence 100, Application US/10734661A
; Publication No. US20050147612A1
; GENERAL INFORMATION:
; APPLICANT: ProChon Biotech, Ltd.
; APPLICANT: MorphoSys AG
; APPLICANT: Yavon, Avner
; APPLICANT: Thomassen-Wolf, Elisabeth
; APPLICANT: Rom, Eran
; APPLICANT: Borges, Eric
; TITLE OF INVENTION: ANTIBODIES THAT BLOCK RECEPTOR PROTEIN TYROSINE KINASE ACTIVATION
; FILE REFERENCE: 81408-4400
; CURRENT APPLICATION NUMBER: US/10/734,661A
; CURRENT FILING DATE: 2003-12-15
; PRIOR APPLICATION NUMBER: US 60/299,187
; PRIOR FILING DATE: 2001-06-20
; PRIOR APPLICATION NUMBER: PCT/IL02/00494
; PRIOR FILING DATE: 2002-06-20
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 100
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: polypeptide sequence of a VH domain
US-10-734-661A-100

Query Match      100.0%; Score 502; DB 5; Length 119;
Best Local Similarity 100.0%; Pred. No. 5.8e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98

RESULT 22
US-10-125-687-1
; Sequence 1, Application US/10125687
; Publication No. US20030054407A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Peter
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705
; CURRENT APPLICATION NUMBER: US/10/125,687
; CURRENT FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Human consensus antibody heavy chain variable region
US-10-125-687-1

Query Match      100.0%; Score 502; DB 4; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.8e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYALISWVRQAPGGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDSTAVYYCAR 98
```

```
Db 61 AQKQGRVTITADESTSTAYMELSLRSEDATVYYCAR 98

RESULT 23
US-10-996-191-1
; Sequence 1, Application US/10996191
; Publication No. US20050148001A1
; GENERAL INFORMATION:
; APPLICANT: Luo, Peizhi
; TITLE OF INVENTION: STRUCTURE-BASED CONSTRUCTION OF HUMAN ANTIBODY LIBRARY
; FILE REFERENCE: 26050-705.301
; CURRENT APPLICATION NUMBER: US/10/996,191
; CURRENT FILING DATE: 2004-11-22
; PRIOR APPLICATION NUMBER: US 60/284,407
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: US 10/125,687
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Human consensus antibody heavy chain variable region
US-10-996-191-1

Query Match 100.0%; Score 502; DB 5; Length 120;
Best Local Similarity 100.0%; Pred. No. 5.8e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKQGRVTITADESTSTAYMELSLRSEDATVYYCAR 98
Db 61 AQKQGRVTITADESTSTAYMELSLRSEDATVYYCAR 98

RESULT 24
US-10-371-942-26
; Sequence 26, Application US/10371942
; Publication No. US20030223994A1
; GENERAL INFORMATION:
; APPLICANT: Hoogenboom, Henricus Renerus Jacobus Mattheus
; APPLICANT: Reiter, Yoram
; TITLE OF INVENTION: MHC-PEPTIDE COMPLEX BINDING LIGANDS
; FILE REFERENCE: 10280-034001
; CURRENT APPLICATION NUMBER: US/10/371,942
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,994
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-371-942-26

Query Match 100.0%; Score 502; DB 4; Length 122;
Best Local Similarity 100.0%; Pred. No. 5.9e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKQGRVTITADESTSTAYMELSLRSEDATVYYCAR 98
Db 61 AQKQGRVTITADESTSTAYMELSLRSEDATVYYCAR 98
```

```
RESULT 25
US-10-269-805-3
; Sequence 3, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-3

Query Match 100.0%; Score 502; DB 4; Length 123;
Best Local Similarity 100.0%; Pred. No. 6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKQGRVTITADESTSTAYMELSLRSEDATVYYCAR 98
Db 61 AQKQGRVTITADESTSTAYMELSLRSEDATVYYCAR 98

RESULT 26
US-10-269-805-25
; Sequence 25, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-25

Query Match 100.0%; Score 502; DB 4; Length 124;
Best Local Similarity 100.0%; Pred. No. 6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKQGRVTITADESTSTAYMELSLRSEDATVYYCAR 98
Db 61 AQKQGRVTITADESTSTAYMELSLRSEDATVYYCAR 98

RESULT 27
US-10-734-661A-102
; Sequence 102, Application US/10734661A
; Publication No. US20050147612A1
; GENERAL INFORMATION:
; APPLICANT: ProChon Biotech, Ltd.
```

```
; APPLICANT: MorphoSys AG
; APPLICANT: Yaron, Avner
; APPLICANT: Thomassen-Wolf, Elisabeth
; APPLICANT: Rom, Eran
; APPLICANT: Borges, Eric
; TITLE OF INVENTION: ANTIBODIES THAT BLOCK RECEPTOR PROTEIN TYROSINE KINASE ACTIVATION
; FILE REFERENCE: 81408-4400
; CURRENT APPLICATION NUMBER: US/10/734,661A
; CURRENT FILING DATE: 2003-12-15
; PRIOR APPLICATION NUMBER: US 60/299,187
; PRIOR FILING DATE: 2001-06-20
; PRIOR APPLICATION NUMBER: PCT/IL02/00494
; PRIOR FILING DATE: 2002-06-20
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 102
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: polypeptide sequence of a VH domain
; US-10-734-661A-102

Query Match      100.0%; Score 502; DB 5; Length 124;
Best Local Similarity 100.0%; Pred. No. 6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTTADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTTADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 28
US-10-269-805-35
; Sequence 35, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-269-805-35

Query Match      100.0%; Score 502; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 6.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTTADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTTADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 29
US-10-320-231A-33
; Sequence 33, Application US/10320231A
; Publication No. US20030194405A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Neben, Steven
; APPLICANT: Takeuchi, Toshihiko
; APPLICANT: Tomkinson, Adrian
; TITLE OF INVENTION: Antibody Inhibiting Stem Cell Factor Activity And Use For
; FILE REFERENCE: 7430*163
; CURRENT APPLICATION NUMBER: US/10/320,231A
; CURRENT FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: US 60/342,174
; PRIOR FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic sequence
; NAME/KEY: MISC FEATURE
; LOCATION: (99)..(114)
; OTHER INFORMATION: each occurrence of Xaa is any amino acid
; NAME/KEY: MISC FEATURE
; LOCATION: (116)..(116)
; OTHER INFORMATION: Xaa is any amino acid
; US-10-320-231A-33

Query Match      100.0%; Score 502; DB 4; Length 127;
Best Local Similarity 100.0%; Pred. No. 6.2e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTTADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTTADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 30
US-10-867-506-33
; Sequence 33, Application US/10867506
; Publication No. US20050112698A1
; GENERAL INFORMATION:
; APPLICANT: Neben, Steven
; APPLICANT: Takeuchi, Toshihiko
; APPLICANT: Tomkinson, Adrian
; APPLICANT: Delaria, Kathy
; APPLICANT: Yan, Kelly
; APPLICANT: Wong, Teresa
; APPLICANT: Longphre, Malinda
; TITLE OF INVENTION: Antibody Inhibiting Stem Cell Factor Activity And Use For
; FILE REFERENCE: 11334*10
; CURRENT APPLICATION NUMBER: US/10/867,506
; CURRENT FILING DATE: 2004-06-14
; PRIOR APPLICATION NUMBER: US 10/320,231
; PRIOR FILING DATE: 2002-12-16
; PRIOR APPLICATION NUMBER: US 60/342,174
; PRIOR FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 101
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic sequence
; NAME/KEY: MISC FEATURE
```

```
; LOCATION: (99)..(114)
; OTHER INFORMATION: each occurrence of Xaa is any amino acid
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (116)..(116)
; OTHER INFORMATION: Xaa is any amino acid
US-10-867-506-33

Query Match      100.0%; Score 502; DB 5; Length 127;
Best Local Similarity 100.0%; Pred. No. 6.2e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 31
US-10-505-313-232
; Sequence 232, Application US/10505313
; Publication No. US20050169925A1
; GENERAL INFORMATION:
; APPLICANT: F. Hoffmann-La Roche AG
; APPLICANT: MorphoSys AG
; TITLE OF INVENTION: Anti A-beta antibodies and their use
; FILE REFERENCE: F 2842 PCT
; CURRENT APPLICATION NUMBER: US/10/505,313
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: EP 02003844.4
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 414
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 232
; LENGTH: 127
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct; VH1A
; NAME/KEY: MISC FEATURE
; LOCATION: (99)..(112)
; OTHER INFORMATION: Xaa = any amino acid or a deletion
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (116)..(116)
; OTHER INFORMATION: Xaa = any amino acid out of a mixture of Phe, His, Ile, Leu, Asn,
; OTHER INFORMATION: Pro, Ser, Val, Trp or Tyr
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (114)..(114)
; OTHER INFORMATION: Xaa = any amino acid out of a mixture of Ala, Asp, Glu, Phe, Gly,
; OTHER INFORMATION: Ile, Leu, Met, Pro, Gln, Ser, Thr, Val or Tyr
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (113)..(113)
; OTHER INFORMATION: Xaa = any amino acid
US-10-505-313-232

Query Match      100.0%; Score 502; DB 5; Length 127;
Best Local Similarity 100.0%; Pred. No. 6.2e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
```

```
RESULT 32
US-10-128-520-160
; Sequence 160, Application US/10128520
; Publication No. US20040105862A1
; GENERAL INFORMATION:
; APPLICANT: PAN et al.
; TITLE OF INVENTION: Human TIMP-1 Antibodies
; FILE REFERENCE: 02973.00073
; CURRENT APPLICATION NUMBER: US/10/128,520
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: US 60/285,683
; PRIOR FILING DATE: 2001-04-24
; NUMBER OF SEQ ID NOS: 381
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 160
; LENGTH: 219
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-128-520-160
```

```
Query Match      100.0%; Score 502; DB 4; Length 219;
Best Local Similarity 100.0%; Pred. No. 1.1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
```

```
RESULT 33
US-10-128-520-149
; Sequence 149, Application US/10128520
; Publication No. US20040105862A1
; GENERAL INFORMATION:
; APPLICANT: PAN et al.
; TITLE OF INVENTION: Human TIMP-1 Antibodies
; FILE REFERENCE: 02973.00073
; CURRENT APPLICATION NUMBER: US/10/128,520
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: US 60/285,683
; PRIOR FILING DATE: 2001-04-24
; NUMBER OF SEQ ID NOS: 381
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 149
; LENGTH: 220
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-128-520-149
```

```
Query Match      100.0%; Score 502; DB 4; Length 220;
Best Local Similarity 100.0%; Pred. No. 1.1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
```

```
RESULT 34
US-10-128-520-175
; Sequence 175, Application US/10128520
; Publication No. US20040105862A1
; GENERAL INFORMATION:
```

```
; APPLICANT: PAN et al.
; TITLE OF INVENTION: Human TIMP-1 Antibodies
; FILE REFERENCE: 02973.00073
; CURRENT APPLICATION NUMBER: US/10/128,520
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: US 60/285,683
; PRIOR FILING DATE: 2001-04-24
; NUMBER OF SEQ ID NOS: 381
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 175
; LENGTH: 220
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-128-520-175

Query Match      100.0%; Score 502; DB 4; Length 220;
Best Local Similarity 100.0%; Pred. No. 1.1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDSTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDSTAVYYCAR 98

RESULT 35
US-10-128-520-168
; Sequence 168, Application US/10128520
; Publication No. US20040105862A1
; GENERAL INFORMATION:
; APPLICANT: PAN et al.
; TITLE OF INVENTION: Human TIMP-1 Antibodies
; FILE REFERENCE: 02973.00073
; CURRENT APPLICATION NUMBER: US/10/128,520
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: US 60/285,683
; PRIOR FILING DATE: 2001-04-24
; NUMBER OF SEQ ID NOS: 381
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 168
; LENGTH: 222
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-128-520-168

Query Match      100.0%; Score 502; DB 4; Length 222;
Best Local Similarity 100.0%; Pred. No. 1.1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDSTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDSTAVYYCAR 98

RESULT 36
US-10-128-520-172
; Sequence 172, Application US/10128520
; Publication No. US20040105862A1
; GENERAL INFORMATION:
; APPLICANT: PAN et al.
; TITLE OF INVENTION: Human TIMP-1 Antibodies
; FILE REFERENCE: 02973.00073
; CURRENT APPLICATION NUMBER: US/10/128,520
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: US 60/285,683
; PRIOR FILING DATE: 2001-04-24
```

```
; NUMBER OF SEQ ID NOS: 381
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 172
; LENGTH: 223
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-128-520-172

Query Match      100.0%; Score 502; DB 4; Length 223;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDSTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDSTAVYYCAR 98

RESULT 37
US-10-128-520-147
; Sequence 147, Application US/10128520
; Publication No. US20040105862A1
; GENERAL INFORMATION:
; APPLICANT: PAN et al.
; TITLE OF INVENTION: Human TIMP-1 Antibodies
; FILE REFERENCE: 02973.00073
; CURRENT APPLICATION NUMBER: US/10/128,520
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: US 60/285,683
; PRIOR FILING DATE: 2001-04-24
; NUMBER OF SEQ ID NOS: 381
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 147
; LENGTH: 225
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-128-520-147

Query Match      100.0%; Score 502; DB 4; Length 225;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKCKASGGTFFSSYAISWVRQAPGGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDSTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDSTAVYYCAR 98

RESULT 38
US-10-128-520-155
; Sequence 155, Application US/10128520
; Publication No. US20040105862A1
; GENERAL INFORMATION:
; APPLICANT: PAN et al.
; TITLE OF INVENTION: Human TIMP-1 Antibodies
; FILE REFERENCE: 02973.00073
; CURRENT APPLICATION NUMBER: US/10/128,520
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: US 60/285,683
; PRIOR FILING DATE: 2001-04-24
; NUMBER OF SEQ ID NOS: 381
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 155
; LENGTH: 229
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-128-520-155
```


Query Match 100.0%; Score 502; DB 4; Length 229;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCAR 98

RESULT 39

US-10-128-520-161

; Sequence 161, Application US/10128520

; Publication No. US20040105862A1

; GENERAL INFORMATION:

; APPLICANT: PAN et al.

; TITLE OF INVENTION: Human TIMP-1 Antibodies

; FILE REFERENCE: 02973.00073

; CURRENT APPLICATION NUMBER: US/10/128,520

; CURRENT FILING DATE: 2002-04-24

; PRIOR APPLICATION NUMBER: US 60/285,683

; PRIOR FILING DATE: 2001-04-24

; NUMBER OF SEQ ID NOS: 381

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 161

; LENGTH: 231

; TYPE: PRT

; ORGANISM: Homo sapiens

US-10-128-520-161

Query Match 100.0%; Score 502; DB 4; Length 231;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCAR 98

RESULT 40

US-10-496-861-7

; Sequence 7, Application US/10496861

; Publication No. US20050129701A1

; GENERAL INFORMATION:

; APPLICANT: DANA-FARBER CANCER INSTITUTE, INC.

; TITLE OF INVENTION: ANTIBODY TO LATENT MEMBRANE PROTEINS AND USES THEREOF

; FILE REFERENCE: 52141-PCT

; CURRENT APPLICATION NUMBER: US/10/496,861

; CURRENT FILING DATE: 2004-05-20

; PRIOR APPLICATION NUMBER: PCT/US02/38849

; PRIOR FILING DATE: 2002-12-04

; PRIOR APPLICATION NUMBER: 60/337,294

; PRIOR FILING DATE: 2001-04-12

; NUMBER OF SEQ ID NOS: 8

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 7

; LENGTH: 238

; TYPE: PRT

; ORGANISM: Epstein-Barr virus

US-10-496-861-7

Query Match 100.0%; Score 502; DB 5; Length 238;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Qy 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCAR 98

RESULT 41

US-09-880-748-1718

; Sequence 1718, Application US/09880748

; Publication No. US20030059937A1

; GENERAL INFORMATION:

; APPLICANT: Ruben et al.

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

; FILE REFERENCE: PF523

; CURRENT APPLICATION NUMBER: US/09/880,748

; CURRENT FILING DATE: 2001-06-15

; PRIOR APPLICATION NUMBER: 60/212,210

; PRIOR FILING DATE: 2000-06-15

; PRIOR APPLICATION NUMBER: 60/240,816

; PRIOR FILING DATE: 2000-10-17

; PRIOR APPLICATION NUMBER: 60/276,248

; PRIOR FILING DATE: 2001-03-16

; PRIOR APPLICATION NUMBER: 60/277,379

; PRIOR FILING DATE: 2001-03-21

; PRIOR APPLICATION NUMBER: 60/293,499

; PRIOR FILING DATE: 2001-05-25

; NUMBER OF SEQ ID NOS: 3239

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 1718

; LENGTH: 248

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-880-748-1718

Query Match 100.0%; Score 502; DB 3; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSLRSEDVAVYCAR 98

RESULT 42

US-09-880-748-1719

; Sequence 1719, Application US/09880748

; Publication No. US20030059937A1

; GENERAL INFORMATION:

; APPLICANT: Ruben et al.

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

; FILE REFERENCE: PF523

; CURRENT APPLICATION NUMBER: US/09/880,748

; CURRENT FILING DATE: 2001-06-15

; PRIOR APPLICATION NUMBER: 60/212,210

; PRIOR FILING DATE: 2000-06-15

; PRIOR APPLICATION NUMBER: 60/240,816

; PRIOR FILING DATE: 2000-10-17

; PRIOR APPLICATION NUMBER: 60/276,248

; PRIOR FILING DATE: 2001-03-16

; PRIOR APPLICATION NUMBER: 60/277,379

; PRIOR FILING DATE: 2001-03-21

; PRIOR APPLICATION NUMBER: 60/293,499

; PRIOR FILING DATE: 2001-05-25

; NUMBER OF SEQ ID NOS: 3239

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 1719

```
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-880-748-1719

Query Match      100.0%; Score 502; DB 3; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98

RESULT 43
US-09-880-748-1732
; Sequence 1732, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1732
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-880-748-1732

Query Match      100.0%; Score 502; DB 3; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98

RESULT 44
US-09-880-748-1733
; Sequence 1733, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
```

```
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1733
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-880-748-1733

Query Match      100.0%; Score 502; DB 3; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98

RESULT 45
US-09-880-748-1734
; Sequence 1734, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1734
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-880-748-1734

Query Match      100.0%; Score 502; DB 3; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLSRSEDATVYYCAR 98

RESULT 46
US-09-880-748-1737
; Sequence 1737, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1737
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1737

Query Match      100.0%; Score 502; DB 3; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAISWVRQAPQGQLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAISWVRQAPQGQLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 47
US-09-880-748-1879
; Sequence 1879, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1879
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1879

Query Match      100.0%; Score 502; DB 3; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAISWVRQAPQGQLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAISWVRQAPQGQLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
```

```
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 48
US-10-293-418-1718
; Sequence 1718, Application US/10293418
; Publication No. US2003022396A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1718
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1718

Query Match      100.0%; Score 502; DB 4; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAISWVRQAPQGQLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKPGSSVKVSKASGGTFFSSYAISWVRQAPQGQLEWMGGIPIFGTANY 60

Qy 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTITADESTSTAYMELSSLRSEDTAVYYCAR 98

RESULT 49
US-10-293-418-1719
; Sequence 1719, Application US/10293418
; Publication No. US2003022396A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
```

```
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1719
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-293-418-1719

Query Match      100.0%; Score 502; DB 4; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
   |||||

QY 61 AQLFQGRVTITADESTAYMELSSLSRSEDVAVYYCAR 98
   |||||
Db 61 AQLFQGRVTITADESTAYMELSSLSRSEDVAVYYCAR 98
   |||||

RESULT 50
US-10-293-418-1732
; Sequence 1732, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1732
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-293-418-1732

Query Match      100.0%; Score 502; DB 4; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
   |||||

QY 61 AQLFQGRVTITADESTAYMELSSLSRSEDVAVYYCAR 98
   |||||
Db 61 AQLFQGRVTITADESTAYMELSSLSRSEDVAVYYCAR 98
   |||||

RESULT 51
US-10-293-418-1733
; Sequence 1733, Application US/10293418
; Publication No. US20030223996A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1733
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-293-418-1733

Query Match      100.0%; Score 502; DB 4; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
   |||||
Db 1 QVQLVQSGAEVKKPGSSVKVSKASGCTFSSYAISWVRQAPGQGLEWMGGIIPFGTANY 60
   |||||

QY 61 AQLFQGRVTITADESTAYMELSSLSRSEDVAVYYCAR 98
   |||||
Db 61 AQLFQGRVTITADESTAYMELSSLSRSEDVAVYYCAR 98
   |||||

RESULT 52
US-10-293-418-1734
; Sequence 1734, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1734
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
```


Db 61 AOKFQGRVTITADESTAYMELSSLRSEDYVYYCAR 98

Search completed: May 12, 2006, 02:29:44
Job time : 58.5 secs

```
; Sequence 2, Application US/09976118
; Patent No. US20020058033A1
; GENERAL INFORMATION:
; APPLICANT: Ralsch, Kevin Paul
; APPLICANT: Curiel, David T.
; APPLICANT: Bonner, James Allen
; TITLE OF INVENTION: Human Anti-Epidermal Growth Factor Receptor
; TITLE OF INVENTION: Single-Chain Antibodies
; FILE REFERENCE: D6355
; CURRENT APPLICATION NUMBER: US/09/976,118
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: US 60/240,353
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 270
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: amino acid sequence of anti-EGFR scFV
; OTHER INFORMATION: clone pSEX81-63
US-09-976-118-2

Query Match 100.0%; Score 502; DB 3; Length 270;
Best Local Similarity 100.0%; Pred. No. 1.4e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKYSCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKYSCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AOKFQGRVTITADESTAYMELSSLRSEDYVYYCAR 98
Db 61 AOKFQGRVTITADESTAYMELSSLRSEDYVYYCAR 98

RESULT 57
US-10-703-277-2
; Sequence 2, Application US/10703277
; Publication No. US20040071698A1
; GENERAL INFORMATION:
; APPLICANT: Ralsch, Kevin Paul
; APPLICANT: Curiel, David T.
; APPLICANT: Bonner, James Allen
; TITLE OF INVENTION: Human Anti-Epidermal Growth Factor Receptor
; TITLE OF INVENTION: Single-Chain Antibodies
; FILE REFERENCE: D6355
; CURRENT APPLICATION NUMBER: US/10/703,277
; CURRENT FILING DATE: 2003-11-06
; PRIOR APPLICATION NUMBER: US/09/976,118
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: US 60/240,353
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 270
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: amino acid sequence of anti-EGFR scFV
; OTHER INFORMATION: clone pSEX81-63
US-10-703-277-2

Query Match 100.0%; Score 502; DB 4; Length 270;
Best Local Similarity 100.0%; Pred. No. 1.4e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKYSCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 QVQLVQSGAEVKKPGSSVKYSCKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60

Qy 61 AOKFQGRVTITADESTAYMELSSLRSEDYVYYCAR 98
Db 61 AOKFQGRVTITADESTAYMELSSLRSEDYVYYCAR 98
```

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:58 ; Search time 38.8199 Seconds
(without alignments)
1781.089 Million cell updates/sec

Title: US-09-674-752-24

Perfect score: 502

Sequence: 1 QVQLVQSGAEVKPGSSVKV.....AYMELSSLRSEDYAVYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	490	97.6	120	2	Q6NSA4_HUMAN
2	455	90.6	116	2	Q9UL89_homo sapien
3	450	89.6	117	1	HV1A_HUMAN
4	418	83.3	208	2	Q6ZP87_HUMAN
5	413	82.3	480	2	Q6PJF1_homo sapien
6	410	81.7	117	1	HV1B_HUMAN
7	407	81.1	124	2	Q9UL92_homo sapien
8	393	78.3	117	1	HV1G_HUMAN
9	393	78.3	159	2	Q96Q80_homo sapien
10	390	77.7	119	2	Q9UL94_homo sapien
11	388	77.3	496	2	Q96DK0_homo sapien
12	384	76.5	125	2	Q9UL95_homo sapien
13	380	75.7	500	2	Q6N091_HUMAN
14	376	74.9	244	2	Q65ZC8_homo sapien
15	376	74.9	498	2	Q6N041_HUMAN
16	363	72.3	500	2	Q9RVO0_HUMAN
17	362	72.1	114	1	HV00_MOUSE
18	360	71.7	518	2	Q6N030_HUMAN
19	359	71.5	519	2	Q5EBM2_HUMAN
20	359	71.5	613	2	Q8VCX7_MOUSE
21	358	71.3	119	2	Q9GY22_MOUSE
22	353	70.3	469	2	Q7Z7P5_HUMAN
23	351	69.9	458	2	Q5BJ22_RAT
24	350	69.7	473	2	Q9DBL4_MOUSE
25	348	69.3	150	2	Q9Y298_HUMAN
26	347	69.1	147	1	HV1C_HUMAN
27	347	69.1	480	2	Q6P089_HUMAN
28	346	68.9	497	2	Q8WY24_HUMAN
29	345	68.7	157	2	Q95978_homo sapien
30	344	68.5	168	2	Q8VDC9_MOUSE
31	344	68.5	616	2	Q504M7_MOUSE

32	343	68.3	118	2	Q9Z1C4_MOUSE	Q9Z1C4 mus musculus
33	343	68.3	475	2	Q6N095_HUMAN	Q6N095 homo sapien
34	342	68.1	117	1	HV52_MOUSE	P06327 mus musculus
35	342	68.1	143	2	Q924Q0_MOUSE	Q924Q0 mus musculus
36	341	67.9	617	2	Q4KML5_MOUSE	Q4KML5 mus musculus
37	340	67.7	142	2	Q924Q1_MOUSE	Q924Q1 mus musculus
38	339	67.5	117	1	HV05_MOUSE	P01749 mus musculus
39	339	67.5	117	1	HV06_MOUSE	P01750 mus musculus
40	338	67.3	143	2	Q924P9_MOUSE	Q924P9 mus musculus
41	338	67.3	463	2	Q99LC4_MOUSE	Q99LC4 mus musculus
42	338	67.3	465	2	Q6PJ82_MOUSE	Q6PJ82 mus musculus
43	337	67.1	140	1	HV02_MOUSE	P01746 mus musculus
44	337	67.1	481	2	Q91WT1_MOUSE	Q91WT1 mus musculus
45	337	67.1	590	2	Q4V9V8_MOUSE	Q4V9V8 mus musculus

ALIGNMENTS

RESULT 1
Q6NSA4_HUMAN
ID Q6NSA4_HUMAN PRELIMINARY; PRT; 120 AA.
AC Q6NSA4;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE IGHV1-69 protein.
GN Name=IGHV1-69;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Pooled;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.J., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Brownstein M.J., Uadin T.B., Tohiyuki S., Carninci P., Scheetz T.E.,
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
Bobak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smalhus D.E.,
Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Pooled;
RG NIH MGC Project;
RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC070333; AAH70333.1; -, mRNA.
DR HSSP; P01751; IA6W.
DR SMR; Q6NSA4; 21-116.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 120 AA; 13035 MW; 64620FAC874585D4 CRC64;

Query Match 97.6%; Score 490; DB 2; Length 120;

Best Local Similarity 96.9%; Pred. No. 2e-44; Mismatches 1; Indels 2; Gaps 0;
Matches 95; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
DB 20 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 79
QY 61 AQKFGQRTITADESTSTAYMELSSLRSEDTAVYICAR 98
DB 80 TORFQGRVTITDESTSTAYMELSSLRSEDTAVYICAR 117

RESULT 2

Q9UL89 HUMAN
ID Q9UL89_HUMAN PRELIMINARY; PRT; 116 AA.
AC Q9UL89;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Barney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus.";
RT Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528;
RA Manheimer-Lory A., Katz J.B., Pillinger M., Ghosein C., Smith A.,
RA Diamond B.;
RT "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype.";
RT J. Exp. Med. 174:1639-1652(1991).
RN [3]

RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=93301610; PubMed=8315388; DOI=10.1084/jem.178.1.1331;
RA Hillson J.L., Karr N.S., Opplinger I.R., Mannik M., Sasso E.H.;
RT "The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A.";
RL J. Exp. Med. 178:331-336(1993).
DR EMBL; AF035025; AAD56261.1; -, mRNA.
DR PIR; PH0870; PH0870.
DR PIR; PH1671; PH1671.
DR HSP; P01751; INQB.
DR SMR; Q9UL89; 1-115.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 116
SQ SEQUENCE 116 AA; 12605 MW; C9F9131DE13BA898 CRC64;

Query Match 90.6%; Score 455; DB 2; Length 116;
Best Local Similarity 95.7%; Pred. No. 1.1e-40;
Matches 89; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 5 VQSGAEVKKPGSSVKVSKASGGTFFSSYAIISWVRQAPGQGLEWMGGIIPFGTANYAQKF 64
DB 1 VQSGAEVKKPGSSVKVSKASGGTFFSSYAIISWVRQAPGQGLEWMGGIIPFGTANYAQKF 60
QY 65 QGRVTITADESTSTAYMELSSLRSEDTAVYICAR 97
DB 61 QGRVTITADKSTSTAYMELSSLRSEDTAVYICAR 93

RESULT 3

HVIA_HUMAN
ID HVIA_HUMAN STANDARD; PRT; 117 AA.
AC P01742;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region EU.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=71064024; PubMed=5489771;
RA Cunningham B.A., Rutishauser U., Gall W.E., Gottlieb P.D.,
RA Wexdal M.J., Edelman G.M.;
RT "The covalent structure of a human gamma G-immunoglobulin. VII. Amino acid sequence of heavy-chain cyanogen bromide fragments H1-H4.";
RL Biochemistry 9:3161-3170(1970).
RN [2]
RP DISULFIDE BOND.
RX MEDLINE=71064027; PubMed=4923144;
RA Gall W.E., Edelman G.M.;
RT "The covalent structure of a human gamma G-immunoglobulin. X. Intrachain disulfide bonds.";
RL Biochemistry 9:3188-3196(1970).
CC -1- MISCELLANEOUS: The sequence of the gamma-1 C region of this myeloma protein has also been determined.
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.
CC -----
DR PIR; A90563; GIHURU.
DR HSP; P01751; 1A6W.
DR SMR; P01742; 1-102.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Pyroglutamate carboxylic acid.
FT DOMAIN 1 112
FT MOD_RES 1 112
FT MOD_RES 1 112
FT DISULFID 22 96
FT NON_TER 117
SQ SEQUENCE 117 AA; 12472 MW; 99D60ADAE8D52818 CRC64;

Query Match 89.6%; Score 450; DB 1; Length 117;
Best Local Similarity 89.7%; Pred. No. 3.8e-40;
Matches 87; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
DB 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
QY 61 AQKFGQRTITADESTSTAYMELSSLRSEDTAVYICAR 97
DB 61 AQKFGQRTITADESTNTAYMELSSLRSEDTAFYFCA 97

RESULT 4

Q6ZP87_HUMAN


```

ID Q62P87 HUMAN PRELIMINARY; PRT; 208 AA.
AC Q62P87;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein FLJ26266.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Dermoid tumor;
RA Ota T., Nakagawa S., Senoh A., Mizuguchi H., Inagaki H., Suzuki Y.,
RA Hata H., Nakagawa K., Mizuno S., Morinaga M., Kawamura M.,
RA Kawakami T., Irie R., Otsuki T., Sato H., Nishikawa T., Sugiyama A.,
RA Kawakami B., Nagai K., Isogai T., Sugano S.;
RL Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK129777; BAC85233.1; -; mRNA.
DR HSSP; P01857; 1A7.
DR SMR; Q62P87; 23-192.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00409; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 2.
KW Immunoglobulin domain.
SQ SEQUENCE 208 AA; 22226 MW; 294566F7ABEE3F2C CRC64;

Query Match 83.3%; Score 418; DB 2; Length 208;
Best Local Similarity 79.6%; Pred. No. 1.9e-36;
Matches 78; Conservative 8; Mismatches 12; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEYKPGSSVKVSKASGGTFFSYAISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 20 QVQLAQSGPEVKPGSSVKVSKVSGDTFNSYALSWVRQARGHGLEWMGGIPIVFGTNY 79

Qy 61 AQKQGRVTITADSTSTAYMELSSLRSEDTAVYYCAR 98
Db 80 AQKLQGRVTITADSSRTTVYMEVNSLTSEDTAIYYCAR 117

RESULT 5
Q6PJF1 HUMAN PRELIMINARY; PRT; 480 AA.
AC Q6PJF1;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hong L.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.J.,
RA Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McWen P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
```

```

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krawinski M.I., Skalek U., Smailus D.E.,
RA Butterch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RA Strausberg R.;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC016381; AAH16381.1; -; mRNA.
DR HSSP; P01861; 1ADQ.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG-cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGC1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 480 AA; 52586 MW; 64DC641AE47CD6C8 CRC64;

Query Match 82.3%; Score 413; DB 2; Length 480;
Best Local Similarity 82.7%; Pred. No. 1.6e-35;
Matches 81; Conservative 3; Mismatches 14; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEYKPGSSVKVSKASGGTFFSYAISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 20 QVQLVQSGAEYKPGSSVKVSKASGGSPGFSVSWVRQAPGQGLAWGGIIPADITKY 79

Qy 61 AQKQGRVTITADSTSTAYMELSSLRSEDTAVYYCAR 98
Db 80 AQNFQDRVTISADESDTATMELSLRSEDTAVYYCAR 117

RESULT 6
HV1B HUMAN STANDARD; PRT; 117 AA.
ID HV1B HUMAN STANDARD; PRT; 117 AA.
AC P01743;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region HG3 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA MEDLINE=8314028; PubMed=6298778;
RA Rechavi G., Ram D., Glazer L., Zakut R., Givol D.;
RT "Evolutionary aspects of immunoglobulin heavy chain variable region
RT (VH) gene subgroups."
RL Proc. Natl. Acad. Sci. U.S.A. 80:855-859(1983).
CC -1- SIMILIARTY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC EMBL; J00240; AAA52988.1; -; Genomic_DNA.
DR PIR; A02024; HVHUGH.
DR HSSP; P01751; INQB.
```

```
DR SMR; P01743; 20-116.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG-Like; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region HG3.
FT DOMAIN 20 >117 Ig-like.
FT NON_TER 117
FT SEQUENCE 117 AA; 12946 MW; 2D3F92FC60CD1FE7 CRC64;

Query Match 81.7%; Score 410; DB 1; Length 117;
Best Local Similarity 82.7%; Pred. No. 7.3e-36;
Matches 81; Conservative 6; Mismatches 11; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSCKASGTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 20 QVQLVQSGAEVKKPGASVKVSCKASGYTFNYSYMHVVRQAPGQGLEWMGINPFGSTSY 79

QY 61 AQRFGQGVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
Db 80 AQRFGQGVTTTRDTSTSTVYTMELSSLRSEDTAVYYCAR 117

RESULT 7
Q9UL92_HUMAN
ID Q9UL92_HUMAN PRELIMINARY; PRT; 124 AA.
AC Q9UL92;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.,
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035022; AAD56258.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; IGV.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG-Like; 1.
FT NON_TER 124
FT SEQUENCE 124 AA; 13580 MW; 1BAACBD96ACD2A2 CRC64;

Query Match 81.1%; Score 407; DB 2; Length 124;
Best Local Similarity 81.6%; Pred. No. 1.6e-35;
Matches 80; Conservative 7; Mismatches 11; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGSSVKVSCKASGTFSSYAIISWVRQAPGQGLEWMGGIIPFGTANY 60
Db 1 EVQLVESGAEVKKPGASVKVSCKASGYTFNYSYMHVVRQAPGQGLEWMGINPFGSTSY 60

QY 61 AQRFGQGVTTTADSTSTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQRFGQGVTTTRDTSTSTVYTMELSSLRSEDTAVYYCAR 98
```

```

AC Q96QSO;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Putative matrix cell adhesion molecule-3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Tilson M.D.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY039025; AAK62649.1; -; mRNA.
DR HSSP; P01869; 1AE6.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 159 AA; 17497 MW; 5D29537E881FAF02 CRC64;

Query Match 78.3%; Score 393; DB 2; Length 159;
Best Local Similarity 77.6%; Pred. No. 6.7e-34;
Matches 76; Conservative 11; Mismatches 11; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 20 QVQLVQSGAEVKKPGASVKVSKASGYTFSNYMNVWRQAPGQGPWVGVINPSSGSA 79

Qy 61 AQKFGQGVTTTADSTSTAYMELSLRSEDATVYYCAR 98
Db 80 SQKFGQLTMTDRTSTVYMDLSLRSDDTAVYFCAR 117

RESULT 10
Q9UL94 HUMAN
ID Q9UL94 HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL94;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
FT NON TER 1
FT NON TER 119
SQ SEQUENCE 119 AA; 13205 MW; 13E64F5345FA416E CRC64;

Query Match 77.7%; Score 390; DB 2; Length 119;
Best Local Similarity 77.6%; Pred. No. 1e-33;
Matches 76; Conservative 8; Mismatches 14; Indels 0; Gaps 0;

AC Q96QSO;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Putative matrix cell adhesion molecule-3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Tilson M.D.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY039025; AAK62649.1; -; mRNA.
DR HSSP; P01869; 1AE6.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 159 AA; 17497 MW; 5D29537E881FAF02 CRC64;

Query Match 78.3%; Score 393; DB 2; Length 159;
Best Local Similarity 77.6%; Pred. No. 6.7e-34;
Matches 76; Conservative 11; Mismatches 11; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 20 QVQLVQSGAEVKKPGASVKVSKASGYTFSNYMNVWRQAPGQGPWVGVINPSSGSA 79

Qy 61 AQKFGQGVTTTADSTSTAYMELSLRSEDATVYYCAR 98
Db 80 SQKFGQLTMTDRTSTVYMDLSLRSDDTAVYFCAR 117

RESULT 10
Q9UL94 HUMAN
ID Q9UL94 HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL94;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
FT NON TER 1
FT NON TER 119
SQ SEQUENCE 119 AA; 13205 MW; 13E64F5345FA416E CRC64;

Query Match 77.7%; Score 390; DB 2; Length 119;
Best Local Similarity 77.6%; Pred. No. 1e-33;
Matches 76; Conservative 8; Mismatches 14; Indels 0; Gaps 0;

```

```

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 1 EVQLVESGAEVKKPGASVKVSKASGYTFTGYYMHWRQAPGQGLEWMGWINPNSWTTNY 60

Qy 61 AQKFGQGVTTTADSTSTAYMELSLRSEDATVYYCAR 98
Db 61 AQKFGQGVTTTADSTSTAYMELSLRSEDATVYYCAR 98

RESULT 11
Q96DK0 HUMAN
ID Q96DK0 HUMAN PRELIMINARY; PRT; 496 AA.
AC Q96DK0;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein FLJ25298.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA TISSUE=Stomach mucosa;
RA Ishibashi T., Kanehori K., Yosida M., Watanabe S., Ishida S., Ono Y.,
RA Horita T., Hiraoka S., Murakawa K., Takiguchi S., Kusano J., Chiba Y.,
RA Watanabe M., Fujimori K., Tanai H., Ishida M., Yamashita H., Chiba Y.,
RA Suzuki Y., Hata H., Nakagawa K., Mizuno S., Morinaga M., Kawamura M.,
RA Sugiyama T., Irie R., Otsuki T., Sato H., Nishikawa T., Sugiyama A.,
RA Kawakami B., Nagai K., Isogai T., Sugano S.;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK058027; BAB71633.1; -; mRNA.
DR HSSP; P01876; 1OW0.
DR SMR; Q96DK0; 266-474.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG_c1.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 2.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 496 AA; 53533 MW; C72EE1E247C86FED CRC64;

Query Match 77.3%; Score 388; DB 2; Length 496;
Best Local Similarity 75.5%; Pred. No. 7.8e-33;
Matches 74; Conservative 7; Mismatches 17; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGSSVKVSKASGGTFFSSYALISWVRQAPGQGLEWMGGIPIFGTANY 60
Db 20 QVHLVQSGAEVKMPGSSVKVSKASANMFRSYFTVVRQAPGQGLWVGGINPFGAPNY 79

Qy 61 AQKFGQGVTTTADSTSTAYMELSLRSEDATVYYCAR 98
Db 80 AQNFDQRTVTSADSTTTVTWELTSLTFTATFYCGR 117

RESULT 12
Q9UL95 HUMAN
ID Q9UL95 HUMAN PRELIMINARY; PRT; 125 AA.
AC Q9UL95;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.

```

```
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035019; AAD56255.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 125
SQ SEQUENCE 125 AA; 13516 MW; 0D3CD5C232488EAC CRC64;

Query Match 76.5%; Score 384; DB 2; Length 125;
Best Local Similarity 76.5%; Pred. No. 4.8e-33;
Matches 75; Conservative 8; Mismatches 15; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKPGSSVKVSKASGCTFSSVAISVWRQAPGQGLEWMGGIIPFGTANY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVSGAEVKPGASVKVSKASGYTFGTGYHWHVWRQAPGQGLEWMGWINPNSGNTY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKQGRVTITADESTSTAYMELSLRSRSDTAVYYCAR 98
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKQGRVTITADESTSTAYMELSLRSRSDTAVYYCAR 98
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 13
Q6N091_HUMAN
ID Q6N091_HUMAN PRELIMINARY; PRT; 500 AA.
AC Q6N091;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686C0220;
GN Names=DKFZp686C0220;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;

QY 1 QVOLVSGAEVKPGSSVKVSKASGCTFSSVAISVWRQAPGQGLEWMGGIIPFGTANY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVSGAEVKPGASVKVSKASGYTFGTGYHWHVWRQAPGQGLEWMGWINPNSGNTY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKQGRVTITADESTSTAYMELSLRSRSDTAVYYCAR 98
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKQGRVTITADESTSTAYMELSLRSRSDTAVYYCAR 98
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 14
Q6SZC8_HUMAN
ID Q6SZC8_HUMAN PRELIMINARY; PRT; 244 AA.
AC Q6SZC8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Names=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=921263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR EMBL; Y13057; CAA73500.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PSS0835; IG_LIKE; 2.
FT NON_TER 1
FT NON_TER 244
SQ SEQUENCE 244 AA; 26127 MW; 4B1F17868338F2BF CRC64;

Query Match 74.9%; Score 376; DB 2; Length 244;
Best Local Similarity 75.5%; Pred. No. 7e-32;
Matches 74; Conservative 7; Mismatches 17; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKPGSSVKVSKASGCTFSSVAISVWRQAPGQGLEWMGGIIPFGTANY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVOLVSGAEVKPGASVKVSKASGYTFSDHYHWHVWRQAPGQGLEWMGWDPNNGDTRF 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKQGRVTITADESTSTAYMELSLRSRSDTAVYYCAR 98
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKQGRVTITADESTSTAYMELSLRSRSDTAVYYCAR 98
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 15
Q6N041_HUMAN
ID Q6N041_HUMAN PRELIMINARY; PRT; 498 AA.
AC Q6N041;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686O16217 (Fragment).
GN Names=DKFZp686O16217;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;
```

```
Best Local Similarity 75.5%; Pred. No. 5.6e-32;
Matches 74; Conservative 9; Mismatches 15; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKPGSSVKVSKASGCTFSSVAISVWRQAPGQGLEWMGGIIPFGTANY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 38 QVOLVSGAEVKPGASVKVSKASGYTFSDHSITWLRQAPGQGLEWIGWISAYSGQTY 97
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKQGRVTITADESTSTAYMELSLRSRSDTAVYYCAR 98
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 98 AQNLQGRVTMTTDTSTSTAYMELSLRSRSDTAVYYCAK 135
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 16
Q6SZC8_HUMAN
ID Q6SZC8_HUMAN PRELIMINARY; PRT; 244 AA.
AC Q6SZC8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Names=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=921263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR EMBL; Y13057; CAA73500.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PSS0835; IG_LIKE; 2.
FT NON_TER 1
FT NON_TER 244
SQ SEQUENCE 244 AA; 26127 MW; 4B1F17868338F2BF CRC64;

Query Match 74.9%; Score 376; DB 2; Length 244;
Best Local Similarity 75.5%; Pred. No. 7e-32;
Matches 74; Conservative 9; Mismatches 15; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKPGSSVKVSKASGCTFSSVAISVWRQAPGQGLEWMGGIIPFGTANY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVOLVSGAEVKPGASVKVSKASGYTFSDHYHWHVWRQAPGQGLEWMGWDPNNGDTRF 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKQGRVTITADESTSTAYMELSLRSRSDTAVYYCAR 98
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKQGRVTITADESTSTAYMELSLRSRSDTAVYYCAR 98
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 17
Q6N041_HUMAN
ID Q6N041_HUMAN PRELIMINARY; PRT; 498 AA.
AC Q6N041;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686O16217 (Fragment).
GN Names=DKFZp686O16217;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;
```

Search completed: May 5, 2006, 09:04:21
Job time : 39.8199 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:18 ; Search time 50.8333 Seconds
(without alignments)
1140.944 Million cell updates/sec

Title: US-09-674-752-25

Perfect score: 711

Sequence: 1 QVQLQSATEVKKPGASKMKV.....YPEYAMDVNGQGTTVTSS 132

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21.*

- 1: Geneseqp1980s.*
- 2: Geneseqp1990s.*
- 3: Geneseqp2000s.*
- 4: Geneseqp2001s.*
- 5: Geneseqp2002s.*
- 6: Geneseqp2003as.*
- 7: Geneseqp2003bs.*
- 8: Geneseqp2004s.*
- 9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	711	100.0	132	3	Aay50953 Human ant
2	702	98.7	132	3	Aay50950 Human ant
3	539	75.8	469	9	Aeb45877 Human mon
4	536	75.4	469	9	Aeb45869 Human mon
5	530.5	74.6	125	6	Abr55813 Heavy cha
6	526.5	74.1	127	9	Aeb12761 Antibody
7	525.5	73.9	255	5	Abp45179 Human Bly
8	525.5	73.9	255	7	Adg96006 Single ch
9	524.5	73.8	127	7	Adk18819 Anti-huma
10	524.5	73.8	127	7	Adk18607 Anti-huma
11	524.5	73.8	127	8	Adl25432 Human mAb
12	524.5	73.8	127	8	Adl25432 Human mAb
13	524	73.7	252	5	Abp45663 Human Bly
14	524	73.7	252	7	Adg96490 Single ch
15	523	73.6	121	9	Aeb45964 Human mon
16	523	73.6	251	5	Abp45910 Human Bly
17	523	73.6	251	7	Adg96737 Single ch
18	521.5	73.3	259	5	Abp44962 Human Bly
19	521.5	73.3	259	7	Adg95789 Single ch
20	520	73.1	253	5	Abp45766 Human Bly
21	520	73.1	253	7	Adg96593 Single ch
22	514.5	72.4	248	5	Abp45767 Human Bly
23	514.5	72.4	248	7	Adg96594 Single ch
24	514.5	72.4	257	5	Abp45599 Human Bly

25	514.5	72.4	257	7	Adg96426 Single ch
26	513	72.2	249	5	Abp45414 Human Bly
27	513	72.2	249	7	Adg96241 Single ch
28	512.5	72.1	257	5	Abp45565 Human Bly
29	512.5	72.1	257	7	Adg96392 Single ch
30	510.5	71.8	251	5	Abp45551 Human Bly
31	510.5	71.8	251	7	Adg96378 Single ch
32	510.5	71.8	259	5	Abp45441 Human Bly
33	510.5	71.8	259	7	Adg96268 Single ch
34	508.5	71.5	125	7	Adk18783 Anti-huma
35	508.5	71.5	125	7	Adk18618 Anti-huma
36	508.5	71.5	125	8	Adl25452 Human mAb
37	508.5	71.5	257	5	Abp45343 Human Bly
38	508.5	71.5	257	7	Adg96170 Single ch
39	508	71.4	126	7	Adk18930 Anti-huma
40	508	71.4	254	5	Abp45394 Human Bly
41	508	71.4	254	7	Adg96221 Single ch
42	507.5	71.4	121	4	Aau02549 Anti-adip
43	507.5	71.4	123	9	Aeb12766 Antibody
44	507	71.3	250	5	Abp45584 Human Bly
45	507	71.3	250	7	Adg96411 Single ch

ALIGNMENTS

RESULT 1

AAY50953

ID AAY50953 standard; protein; 132 AA.

XX AAY50953;

DT 23-MAR-2000 (first entry)

DE Human anti-factor VIII antibody VH protein VH IT-2.

XX Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
VH protein.

OS Homo sapiens.

XX WO9958680-A2.

XX 18-NOV-1999.

PF 07-MAY-1999; 99WO-NL000285.

PR 08-MAY-1998; 98EP-00201543.

XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;

XX WPI; 2000-053102/04.

PT New polynucleotide, polypeptide and antibody useful for diagnosing the
presence of neutralizing antibodies against factor VIII and for treatment
of hemophilia A patients with these antibodies.

XX Example 4; Fig 4B; 61pp; English.

CC This invention describes a novel polynucleotide (I) (and complements and
hybridizable polynucleotides) comprising a contiguous nucleotide sequence
coding for a human antibody with factor VIII specificity which has
hemostatic activity. (I) is useful as a primer or probe for detecting the
presence of inhibitory antibodies directed against factor VIII. The
polypeptides of the invention and the antibodies generated from them are
useful in compositions for neutralizing factor VIII inhibiting antibodies
in hemophilia A patients. This sequence represents the human anti-factor
VIII antibody VH IT-2 protein which is used in the method of the
invention

XX Sequence 132 AA;

Query Match 100.0%; Score 711; DB 3; Length 132;
 Best Local Similarity 100.0%; Pred. No. 4.3e-58;
 Matches 132; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPFTSYDTSWVRQAPGGGLEWGWISISYSGNTDY 60
 DB 1 QVQLQSATEVKKPGASMKVSCWASGYPFTSYDTSWVRQAPGGGLEWGWISISYSGNTDY 60

QY 61 AQKFGQRTVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
 DB 61 AQKFGQRTVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120

QY 121 VMGGTTVTVSS 132
 DB 121 VMGGTTVTVSS 132

RESULT 2
 AAY50950
 ID AAY50950 standard; protein; 132 AA.
 AC AAY50950;
 XX
 XX
 DT 23-MAR-2000 (first entry)
 XX Human anti-factor VIII antibody VH clone IT-2 encoded protein.
 XX
 XX Human, heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
 KW VH gene.
 KW
 XX Homo sapiens.
 OS
 XX
 PN WO9958680-A2.
 XX
 PD 18-NOV-1999.
 XX
 XX 07-MAY-1999; 99WO-NL000285.
 PF
 XX 08-MAY-1998; 98EP-00201543.
 PR
 XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
 PA
 XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 PI WPI; 2000-053102/04.
 DR
 XX New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX
 XX Example 4; Fig 4A; 61pp; English.
 PS
 XX This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has
 CC hemostatic activity. (I) is useful a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents the human anti-factor
 CC VIII antibody clone IT-2 protein which is used in the method of the
 CC invention
 XX
 SQ Sequence 132 AA;

Query Match 98.7%; Score 702; DB 3; Length 132;
 Best Local Similarity 99.2%; Pred. No. 3e-57;
 Matches 131; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPFTSYDTSWVRQAPGGGLEWGWISISYSGNTDY 60
 DB 1 QVQLQSATEVKKPGASMKVSCWASGYPFTSYDTSWVRQAPGGGLEWGWISISYSGNTDY 60

QY 61 AQKFGQRTVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
 DB 61 AQKFGQRTVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120

QY 121 VMGGTTVTVSS 132
 DB 121 VMGGTTVTVSS 132

RESULT 3
 AEB45877
 ID AEB45877 standard; protein; 469 AA.
 XX
 AC AEB45877;
 XX
 XX
 DT 06-OCT-2005 (first entry)
 XX
 DE Human monoclonal anti-MADCAM antibody #21.
 XX
 KW Monoclonal antibody; mucosal addressin cell adhesion molecule; MADCAM;
 KW inflammation; inflammatory bowel disease; Crohns disease;
 KW ulcerative colitis; diverticular disease; gastritis; liver disease;
 KW primary biliary cirrhosis; primary sclerosing cholangitis;
 KW insulin dependent diabetes; graft versus host disease; antiinflammatory;
 KW gastrointestinal-gen.; antiulcer; hepatotropic; antidiabetic;
 KW immunosuppressive; antibody.
 XX
 OS Homo sapiens.
 XX
 PN WO2005067620-A2.
 XX
 PD 28-JUL-2005.
 XX
 XX 07-JAN-2005; 2005WO-US000370.
 XX
 XX 09-JAN-2004; 2004US-0535490P.
 PR
 XX (PFIZ) PFIZER INC.
 PA (ABGE-) ABGENIX INC.
 PA (PFIZ) PFIZER LTD.
 XX
 XX Pullen N, Molloy E, Kellermann S, Green LL, Haak-Frendescho M;
 PI WPI; 2005-554958/56.
 XX N-PSDB; AEB45876.
 DR
 XX New antibody to Mucosal Adressin Cell Adhesion Molecule, useful for
 PT diagnosing and treating an inflammatory disease, e.g. inflammatory bowel
 PT disease, ulcerative colitis, gastritis, insulin-dependent diabetes or
 PT graft versus host disease.
 XX
 XX Claim 8; SEQ ID NO 42; 167pp; English.
 PS
 XX The invention relates to a human monoclonal antibody or its antigen-
 CC binding portion that specifically binds to mucosal addressin cell
 CC adhesion molecule (MADCAM). The invention also relates to a hybridoma
 CC cell line that produces the human monoclonal antibody, a pharmaceutical
 CC composition comprising an amount of the monoclonal antibody or its
 CC antigen-binding portion and a pharmaceutical carrier, a method of
 CC treating inflammatory disease in a subject, an isolated cell line that
 CC produces the monoclonal antibody or its antigen-binding portion or the
 CC heavy chain or light chain of the antibody or of its portion, an isolated
 CC nucleic acid molecule comprising a nucleotide sequence encoding the heavy
 CC chain or its antigen-binding portion or the light chain or its antigen-
 CC binding portion of an antibody described above, a vector comprising the
 CC nucleic acid molecule, where the vector optionally comprises an
 CC expression control sequence operably linked to the nucleic acid molecule,
 CC a host cell comprising the vector or the nucleic acid molecule above, a
 CC method of producing a human monoclonal antibody or its antigen-binding
 CC portion that specifically binds MADCAM, a method of isolating an antibody
 CC or its antigen-binding portion that specifically binds to MADCAM, a
 CC method of treating a subject in need of a human antibody or its antigen-

binding portion that specifically binds to MacCAM and inhibits binding to alpha4beta7, a method of inhibiting alpha4beta7 binding to cells expressing human MacCAM, a method of inhibiting MacCAM-mediated leukocyte-endothelial cell adhesion, migration and infiltration into tissues, a method of inhibiting alpha4beta7/MacCAM-dependent cellular adhesion, inhibiting the MacCAM-mediated recruitment of lymphocytes to gastrointestinal lymphoid tissue, a method of diagnosing a disorder characterized by circulating soluble human MacCAM and detecting inflammation in a subject. The antibody, composition and methods are useful for diagnosing and treating inflammatory disease, e.g. inflammatory bowel disease, Crohn's disease, ulcerative colitis, diverticular disease, gastritis, liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, insulin dependent diabetes and graft versus host disease. This sequence represents a human monoclonal anti-MacCAM antibody of the invention.

```

SQ      Sequence 469 AA;
Query Match          75.8%; Score 539; DB 9; Length 469;
Best Local Similarity 78.8%; Pred.No. 1.6e-41;
Matches 104; Conservative 7; Mismatches 13; Indels 8; Gaps 2

Qy      1   QVQLQSATSEVKKPGASMKVSCMASGYPTFTSYDYSWRAQGGLGEMGWGHSIYSGNTDY 60
         |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      20  QVLVSQGAIEVKKPGASKVSKCEASGYTFTSYGIIDWRQAQGGLEMMGWISVYSGNTNY 79
         |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy      61  AQKFGQRTVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGGAYEDVWSGEYPEYYAMD 120
         |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      80  AQKLGRVTMTSDTSTSTAYMELSLRSDDTAVYYCAREGSSS-----SGDY--YYGMD 131
         |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy      121 VWGGGTIVTVSS 132
         |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      132 VWGGGTIVTVSS 143
         |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

```

RESULT 4	
AEB45869	
ID	AEB45869 standard; protein; 469 AA.
XX	
XX	
AC	AEB45869;
XX	
XX	
DT	06-OCT-2005 (first entry)
XX	
XX	
DE	Human monoclonal anti-MaDCAM antibody #17.
XX	
KW	Monoclonal antibody; mucosal addressin cell adhesion molecule; MaDCAM;
KW	inflammation; inflammatory bowel disease; Crohns disease;
KW	ulcerative colitis; diverticular disease; gastritis; liver disease;
KW	primary biliary cirrhosis; primary sclerosing cholangitis;
KW	insulin dependent diabetes; graft versus host disease; antiinflammatory;
KW	gastrointestinal-gen.; antiulcer; hepatotropic; antidiabetic;
KW	immunosuppressive; antibody.

PT diagnosing and treating an inflammatory disease, e.g. inflammatory bowel
PT disease, ulcerative colitis, gastritis, insulin-dependent diabetes or
PT graft versus host disease.

The invention relates to a human monoclonal antibody or its antigen-binding portion that specifically binds to mucosal addressin cell adhesion molecule (MAdCAM). The invention also relates to a hybridoma cell line that produces the human monoclonal antibody, a pharmaceutical composition comprising an amount of the monoclonal antibody or its antigen-binding portion and a pharmaceutical carrier, a method of treating inflammatory disease in a subject, an isolated cell line that produces the monoclonal antibody or its antigen-binding portion or the heavy chain or light chain of the antibody or of its portion, an isolated nucleic acid molecule comprising a nucleotide sequence encoding the heavy chain or its antigen-binding portion or the light chain or its antigen-binding portion of an antibody described above, a vector comprising the nucleic acid molecule, where the vector optionally comprises an expression control sequence operably linked to the nucleic acid molecule, a host cell comprising the vector or the nucleic acid molecule above, a method of producing a human monoclonal antibody or its antigen-binding portion that specifically binds MAdCAM, a method of isolating an antibody or its antigen-binding portion that specifically binds to MAdCAM, a method of treating a subject in need of a human antibody or its antigen-binding portion that specifically binds to MAdCAM and inhibits binding to alpha4beta7, a method of inhibiting alpha4beta7 binding to cells expressing human MAdCAM, a method of inhibiting MAdCAM-mediated leukocyte-endothelial cell adhesion, migration and infiltration into tissues, a method of inhibiting alpha4beta7/MAdCAM-dependent cellular adhesion, inhibiting the MAdCAM-mediated recruitment of lymphocytes to gastrointestinal lymphoid tissue, a method of diagnosing a disorder characterized by circulating soluble human MAdCAM and detecting inflammation in a subject. The antibody, composition and methods are useful for diagnosing and treating inflammatory disease, e.g. inflammatory bowel disease, Crohn's disease, ulcerative colitis, diverticular disease, gastritis, liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, insulin dependent diabetes and graft versus host disease. This sequence represents a human monoclonal anti-MAdCAM antibody of the invention.

```

SQ      Sequence 469 AA;
Query Match       75.4%; Score 536; DB 9; Length 469;
Best Local Similarity 78.0%; Pred. No. 3e-41;
Matches 103; Conservative 8; Mismatches 13; Indels 8; Gaps 2

Qy      1 QVOLLQSATEVKKPGASMKVSCWASGYPFTSYDISWVRQAPGGGLEVMGWISLYSGNTDY 60
        |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:||
Db      20 QVLVSOGAEVKKPGASRVKSCASGYTFTSYGINWVRQAPGGGLEVMGWISLYSGNTNY 79
        |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:||

Qy      61 AOKFQGRVTMTTDTSRRTAYMELRSLRSDDTAVVYCARDDGGGAYEDVWSGEYPEYYAMD 120
        |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:||
Db      80 AQKVQRVTMTADTSSTAYMDLRLSDDTAVVYCAREGSSS-----SGDY--YYGMD 131
        |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:||

Qy      121 VMGGQTTVTIVSS 132
        |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:||
Db      132 VMGGQTTVTIVSS 143
        |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:||

```

RESULT	5
ABRS5813	
ID	ABRS5813 standard; protein; 125 AA.
XX	
AC	ABRS5813;
XX	
DT	02-SEP-2003 (first entry)
XX	
DE	Heavy chain variable region of anti-Ang-2 antibody FJ-G11 HC.
XX	
KW	Ang-2; angiotensin-2; anorectic; cytostatic; antiarteriosclerotic; gynaecological; antiinflammatory; osteopathic; antipsoriatic; cancer; angiogenesis; antibody.
KW	
KW	

```

OS Homo sapiens.
FH Key Location/Qualifiers
FT Region 26..36
FT /note= "complementarity determining region (CDR) 1"
FT Region 50..66
FT /note= "complementarity determining region (CDR) 2"
FT Region 96..115
FT /note= "complementarity determining region (CDR) 3"
XX
XX WO2003030833-A2.
XX
XX 17-APR-2003.
XX
XX 11-OCT-2002; 2002WO-US032613.
XX
XX 11-OCT-2001; 2001US-0328604P.
XX 10-OCT-2002; 2002US-00269805.
XX
XX (AMGE-) AMGEN INC.
XX
XX Oliner JD;
XX
XX WPI; 2003-504963/47.
XX
XX New specific binding agents (i.e. anti-Angiopoietin-2 antibodies), useful
XX for inhibiting undesired angiogenesis, or treating e.g. cancers, obesity,
XX hemangioma, arteriosclerosis, atherosclerosis or endometriosis.
XX
XX Claim 1; Page 92; 16lpp; English.
XX
XX The invention relates to a specific binding agent, which comprises at
XX least one peptide selected from any of 62 peptides (ABR55769-830) or its
XX fragment. The binding agents are antibodies that recognize and bind to
XX angiopoietin-2 (Ang-2). The specific binding agent, particularly the
XX antibody, is useful for inhibiting undesired angiogenesis, treating
XX cancers, inhibiting undesired angiogenesis, modulating or inhibiting Ang-
XX 2 activity, modulating vascular permeability or plasma leakage, or
XX treating a disease (e.g. ocular neovascular disease, obesity,
XX haemangioblastoma, haemangioma, arteriosclerosis, inflammatory disease,
XX inflammatory disorders, atherosclerosis, endometriosis, neoplastic
XX disease, bone-related disease, or psoriasis) in a mammal. The present
XX sequence represents a heavy chain variable region of an anti-Ang-2
XX antibody
XX
XX Sequence 125 AA;
XX
XX Query Match 74.6%; Score 530.5; DB 6; Length 125;
XX Best Local Similarity 77.8%; Pred. No. 2.3e-41;
XX Matches 105; Conservative 4; Mismatches 13; Indels 13; Gaps 2;
XX
XX 1 QVQLVQSGAEVKKPGASVKMSCKASGYPTFTSYDLSWVRQAPGQGLEWMGWSISYSGNTDY 60
XX 1 QVQLVQSGAEVKKPGASVKMSCKASGYPTFTSYDLSWVRQAPGQGLEWMGWSISYSGNTNY 60
XX
XX 61 AQKFGQGRVTMTTDTTSRTTAYMELSLRSDDTAVYYCARDGG---GGAYEDVMSGEYPEY 117
XX 61 AQKLQGRVTMTTDTTSTSTAYMELSLRSDDTAVYYCARDRGIARSAY-----YY 110
XX
XX 118 AMDVWGQGTIVTVSS 132
XX 111 GMDVWGQGTIVTVSS 125
XX
XX RESULT 6
XX AEB12761
XX ID AEB12761 standard; protein; 127 AA.
XX AC AEB12761;
XX XX
XX 08-SEP-2005 (first entry)
XX

```

```

DE Antibody 12E heavy chain variable region SEQ ID NO 9.
XX
XX virucide; respiratory-gen.; vaccine; monoclonal antibody;
XX antibody production; diagnosis; therapeutic;
XX Severe acute respiratory syndrome; sars coronavirus infection; antiviral;
XX respiratory disease; infection; single chain antibody; 12E;
XX heavy chain variable region.
XX
XX Homo sapiens.
XX
XX WO2005060520-A2.
XX
XX 07-JUL-2005.
XX
XX 24-NOV-2004; 2004WO-US039750.
XX
XX 25-NOV-2003; 2003US-0524840P.
XX
XX (DAND ) DANA FARBER CANCER INST INC.
XX
XX Marasco W, Sui J;
XX
XX WPI; 2005-488568/49.
XX
XX Novel monoclonal or scFv antibody capable of binding to epitope on region
XX of spike protein of severe acute respiratory syndrome coronavirus (SARS-
XX Cov) and neutralizing SARS-Cov, useful for treating SARS-Cov infection.
XX
XX Example 2; SEQ ID NO 9; 93pp; English.
XX
XX The invention describes a monoclonal antibody (I) capable of neutralizing
XX SARS-Cov, binding to an epitope on a region of the spike protein of SARS-
XX Cov and neutralizing SARS-Cov, or an scFv antibody (II) capable of
XX neutralizing SARS-Cov, binding to an epitope on a region of the spike
XX protein of SARS-Cov and neutralizing SARS-Cov. Also described are:
XX vaccinating (M1) a patient against SARS-Cov; a composition (III)
XX comprising (I) and a carrier; a kit (IV) comprising (III) in one or more
XX containers; a passive vaccine (V) against SARS-Cov, comprising (III);
XX screening (M2) for compounds that modulate the interaction between SARS-
XX Cov and the SARS-Cov receptor ACE2; and enhancing (M3) the neutralization
XX activity of MAb or scFv 80R. (I) or (II) is useful for preventing a
XX disease or disorder caused by a coronavirus. (I) or (II) is useful for
XX treating a coronavirus-related disease or disorder. (I) is useful for
XX diagnosing a coronavirus-related disease or disorder. The coronavirus-
XX related disease or disorder is SARS. (I) is useful for detecting the
XX presence of a coronavirus in a sample, which involves contacting the
XX sample with (I), and detecting the presence or absence of an antibody-
XX antigen complex, thus detecting the presence of a coronavirus in a
XX sample. (I) is useful for identifying compounds useful to treat a SARS-
XX Cov-related disease or disorder. The at least one SARS-Cov protein is
XX provided as a SARS-Cov molecule. The at least one SARS-Cov protein is
XX provided in a cell infected with the SARS-Cov (M1) is useful for
XX vaccinating a patient against SARS-Cov. This is the amino acid sequence
XX of anti-SARS-Cov spike protein N-terminal single chain (scFv) antibody
XX 12E heavy chain variable region.
XX
XX Sequence 127 AA;
XX
XX Query Match 74.1%; Score 526.5; DB 9; Length 127;
XX Best Local Similarity 79.5%; Pred. No. 5.4e-41;
XX Matches 105; Conservative 5; Mismatches 17; Indels 5; Gaps 3;
XX
XX 1 QVQLQSGATEVKKPGASMKVSCMASGYPTFTSYDLSWVRQAPGQGLEWMGWSISYSGNTDY 60
XX 1 QVQLVQSGAEVKKPGASVKSCASGYPTFTTYGISWVRQAPGQGLEWMGWSISYSGNTNY 60
XX
XX 61 AQKFGQGRVTMTTDTTSRTTAYMELSLRSDDTAVYYCARDGGCGGAYEDVMSGEYPEYAMD 120
XX 61 AQKLQGRVTMTTDTTSTSTAYMELSLRSDDTAVYYCARVGYGDI--AW-GYY--YYGMD 115
XX
XX 121 VMGQGTIVTVSS 132
XX 116 VMGQGTIVTVSS 127
XX

```

```

RESULT 7
ABP45179
ID ABP45179 standard; protein; 255 AA.
XX
XX
AC AC
XX ABP45179;
DT 19-AUG-2002 (first entry)
XX
DE Human BlyS binding scFv SEQ ID 1190.
XX
XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
XX
XX W020202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US019110.
XX
XX 16-JUN-2000; 2000US-0212210P.
XX 17-OCT-2000; 2000US-0240816P.
XX 16-MAR-2001; 2001US-0276248P.
XX 21-MAR-2001; 2001US-0277379P.
XX 25-MAY-2001; 2001US-0293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for the
XX diagnosis and treatment of cancers and immune disorders.
XX
XX Claim 1; Page 1822-1823; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (BlyS) polypeptides. BlyS is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX antirheumatic and antiAIDS activity and can be used in vaccines to
XX inhibit the expression and activity of BlyS. The antibodies bind to BlyS
XX and so may be used to detect and quantitate the presence of BlyS in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of BlyS. They may also be
XX administered to treat diseases associated with aberrant BlyS expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method of
XX the invention
XX
XX Sequence 255 AA;
XX
XX Query Match 73.9%; Score 525.5; DB 5; Length 255;
XX Best Local Similarity 78.0%; Pred. No. 1.4e-40;
XX Matches 103; Conservative 8; Mismatches 18; Indels 3; Gaps 2;
XX
XX 1 QVQLQSGATVKKPGASMKVSCWASGYPTFTSYISWVRQAPGQGLEWMGHSISYGNTRY 60
XX |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
XX 1 QVQLVQSGAEVKKPGASVKVSCKRSGYFTFTSYGISWVRQAPGQGLEWMGHSIYNGNTNY 60
XX |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

61 AQKFGQGRVTMTTDTSRRTAYMELRSLRSDTAVVYCARDGGGGAYEDVWSGEYPEYYAMD 120
||| |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 AQKLQGRVTMTTDTSTAYMELRSLRSDTAVVYCARD--PSPYYDILTGFLPYV-MD 117
||| |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

121 VGGGGTTVTVSS 132
|||:|||||
118 VVGKGTILVTVSS 129
|||:|||||

RESULT 8
ADG96006
ID ADG96006 standard; protein; 255 AA.
XX
XX ADG96006;
AC AC
XX 11-MAR-2004 (first entry)
DT
XX
DE Single chain antibody that immunospecifically binds BlyS SeqID 1190.
XX
XX antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
XX B cell proliferation; differentiation; scFv; myasthenia gravis;
XX multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
XX carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
XX antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX
XX Unidentified.
XX
XX W02003055979-A2.
XX
XX 10-JUL-2003.
XX
XX 14-NOV-2002; 2002WO-US036496.
XX
XX 16-NOV-2001; 2001US-0331469P.
XX 19-DEC-2001; 2001US-0340817P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX WPI; 2003-505530/47.
XX
XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX (BlyS), useful for detecting and treating diseases or disorders e.g.
XX rheumatoid arthritis, asthma and leukemia.
XX
XX Example 1; SEQ ID NO 1190; 394pp; English.
XX
XX This invention relates to novel antibodies that immunospecifically bind
XX to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
XX chromosome 13q34 and encodes a protein that is a member of the tumour
XX necrosis factor superfamily and induces both in vivo and in vitro B cell
XX proliferation and differentiation. Specifically, it refers to single
XX chain antibody molecules (scFvs) derived, preferably, from the variable
XX heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX fragment thereof, of either human, murine, rat or monkey BlyS. The
XX present invention refers to the use of such antibodies in various methods
XX for the detection, diagnosis and prognosis of diseases related to the
XX aberrant expression or inappropriate function of BlyS or its receptor. As
XX such, these compositions are useful for identifying immune disorders
XX including myasthenia gravis and multiple sclerosis, inflammatory
XX disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX as AIDS and proliferative disorders including leukaemia, carcinoma and
XX lymphoma. Accordingly, they can be described as exhibiting various
XX activities such as antirheumatic, antiallergic and neuroprotective,
XX antiinflammatory, antiasthmatic, antiarthritic and cytostatic. This
XX polypeptide sequence is a single chain antibody that binds BlyS of the
XX invention. NOTE: the sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX
XX Sequence 255 AA;

```

Query Match		73.9%;	Score 525.5;	DB 7;	Length 255;
Best Local Similarity		78.0%;	Pred. No. 1.4e-40;		
Matches 103;		Conservative	8;	Mismatches 18;	Indels 3; Gaps 2;
QY	1	QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGGLEWMGWISYSGNTDY	60		
Db	1	QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGGLEWMGWISAYNGNTNY	60		
QY	61	AQKFGQGRVTMTTDSRTAYMELRSRSDDTAVYYCARDGGGAYEDVMSGEY-PEYYAM	120		
Db	61	AQKLGQRVTMTTDTSTSTAYMELRSRSDTAVYYCARD-----HYVD--SSDLYYYGYL	117		
QY	121	VMGGQTTVTVSS 132			
Db	118	VMGKGLTVTVSS 129			
RESULT 9					
ADK18819					
ID	ADK18819	standard; protein; 127 AA.			
XX	ADK18819;				
XX	06-MAY-2004	(first entry)			
DE	Anti-human PDGF-D antibody protein related sequence #45.				
XX	antiinflammatory; immunomodulator; cytostatic; gene therapy.				
OS	Homo sapiens.				
XX	WO2003057857-A2.				
PN	17-JUL-2003.				
XX	06-JAN-2003;	2003WO-US000398.			
XX	07-JAN-2002;	2002US-00041860.			
XX	(ABGE-) ABGENIX INC.				
XX	Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;				
XX	Bezabeh B;				
XX	WPI; 2003-587119/55.				
XX	New human monoclonal antibody that binds to platelet-derived growth factor-D (PDGF-D), useful for treating chronic and recurrent human diseases, such as inflammation, autoimmunity and cancer.				
PS	Disclosure; SEQ ID NO 243; 255pp; English.				
XX	The invention relates to a human monoclonal antibody that binds to platelet-derived growth factor-D (PDGF-D). The antibodies are useful for treating chronic and recurrent human diseases, such as inflammation, autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are useful for modulating collagen formation, and for staging various cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were generated using an active protein fragment of the gene product from the clone 30664188.0.99 arising in the conditioned medium obtained when HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This sequence corresponds to a protein used in the invention.				
XX	Sequence 127 AA;				
Query Match		73.8%;	Score 524.5;	DB 7;	Length 127;
Best Local Similarity		78.9%;	Pred. No. 8.3e-41;		
Matches 105;		Conservative	6;	Mismatches 15;	Indels 7; Gaps 3;
QY	1	QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGGLEWMGWISYSGNTDY	60		
Db	1	QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGGLEWMGWISAYNGNTNY	60		
QY	61	AQKFGQGRVTMTTDSRTAYMELRSRSDDTAVYYCARDGGGAYEDVMSGEY-PEYYAM	119		
Db	61	AQKLGQRVTMTTDTSTSTAYMELRSRSDTAVYYCARD-----HYVD--SSDLYYYGYL	114		
QY	120	DMVGQGTITVTSS 132			
Db	115	DMVGQGTITVTSS 127			

```
RESULT 11
ADK18607
ID ADK18607 standard; protein; 127 AA.
XX
XX
AC ADK18607;
XX
DT 06-MAY-2004 (first entry)
XX
XX
DE Anti-human PDGF-D antibody heavy chain protein sequence.
XX
XX antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
PN WO2003057857-A2.
XX
XX
PD 17-JUL-2003.
XX
XX
PF 06-JAN-2003; 2003WO-US000398.
XX
XX
PR 07-JAN-2002; 2002US-00041860.
XX
XX (ABGE-) ABGENIX INC.
XX
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
XX WPI; 2003-587119/55.
XX
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
XX Disclosure; SEQ ID NO 31; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCSP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
XX Sequence 127 AA;
XX
Query Match 73.8%; Score 524.5; DB 7; Length 127;
Best Local Similarity 78.9%; Pred. No. 8.3e-41;
Matches 105; Conservative 6; Mismatches 15; Indels 7; Gaps 3;
Qy 1 QVQLQSGATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGQGLEWMGWSIYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKSCASGVTTFTSYGISWVRQAPGQGLEWMGWSIYNGNTNY 60
Qy 61 AQKFGQGRVTMTTDSRTATYMWELSLRSDDTATVYTCARDGGGGAYEDVWSGEY-PEYIAM 119
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTATVYTCARD----HYDD--SSDYLIIYYGL 114
Qy 120 DVWGQGTITVTVSS 132
Db 115 DVWGQGTITVTVSS 127
RESULT 12
ADL25432
ID ADL25432 standard; protein; 127 AA.
XX
XX ADL25432;
XX
DT 17-JUN-2004 (first entry)
```

```
XX
DE Human mAb 1.33 heavy chain variable region protein SEQ ID NO:42.
XX
XX antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
XX nephritis; mesangial cell proliferation inhibition;
XX mesangial proliferative glomerulonephritis; nephrotropic;
XX antiinflammatory; dermatological; immunosuppressive; antidiabetic;
XX gene therapy; human; monoclonal antibody; mAb.
XX
OS Homo sapiens.
XX
XX WO2004024098-A2.
XX
XX 25-MAR-2004.
XX
XX 16-SEP-2003; 2003WO-US029414.
XX
XX 16-SEP-2002; 2002US-041137P.
XX
XX (ABGE-) ABGENIX INC.
XX (CURA-) CURAGEN CORP.
XX
PI Floege J, Gazit-Bornstein G, Keyt B, Larochele WJ, Lichenstein H;
XX
XX WPI; 2004-269881/25.
XX N-PSDB; ADL25431.
XX
XX Use of an antibody or its binding fragment that binds platelet derived
PT growth factor-DD (PDGF-DD) for preparing a medicament for treating
PT nephritis.
XX
XX Disclosure; SEQ ID NO 42; 115pp; English.
XX
CC The present invention describes an antibody or its binding fragment that
CC binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
CC useful in preparing a medicament for treating nephritis. Also described:
CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
CC of treating mesangial proliferative glomerulonephritis. The antibody has
CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
CC antidiabetic activities, and can be used in gene therapy. The antibody or
CC its binding fragment, that binds PDGF-DD, can be used in preparing a
CC medicament for treating nephritis and related disorders, e.g., mesangial
CC proliferative glomerulonephritis. The present sequence represents a human
CC monoclonal antibody (mAb) variable region sequence, which is used in the
CC exemplification of the present invention.
XX
XX Sequence 127 AA;
XX
Query Match 73.8%; Score 524.5; DB 8; Length 127;
Best Local Similarity 78.9%; Pred. No. 8.3e-41;
Matches 105; Conservative 6; Mismatches 15; Indels 7; Gaps 3;
Qy 1 QVQLQSGATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGQGLEWMGWSIYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKSCASGVTTFTSYGISWVRQAPGQGLEWMGWSIYNGNTNY 60
Qy 61 AQKFGQGRVTMTTDSRTATYMWELSLRSDDTATVYTCARDGGGGAYEDVWSGEY-PEYIAM 119
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTATVYTCARD----HYDD--SSDYLIIYYGL 114
Qy 120 DVWGQGTITVTVSS 132
Db 115 DVWGQGTITVTVSS 127
RESULT 13
ABP45663
ID ABP45663 standard; protein; 252 AA.
XX
XX ABP45663;
XX
DT 19-AUG-2002 (first entry)
```

```

XX DE Human BlyS binding scFv SEQ ID 1674.
XX AC BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX KW tumour necrosis factor; B cell proliferation; B cell differentiation;
XX KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX OS Homo sapiens.
XX PN WO200202641-A1.
XX PD 10-JAN-2002.
XX PF 15-JUN-2001; 2001WO-US019110.
XX PR 16-JUN-2000; 2000US-0212210P.
XX PR 17-OCT-2000; 2000US-0240816P.
XX PR 16-MAR-2001; 2001US-0276248P.
XX PR 21-MAR-2001; 2001US-0277379P.
XX PR 25-MAY-2001; 2001US-0293499P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX DR WPI; 2002-114799/15.
XX PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
XX PT diagnosis and treatment of cancers and immune disorders.
XX PS Claim 1; Page 2400-2401; 3148pp; English.
XX CC This invention describes novel antibodies that immunospecifically bind to
XX CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
XX CC tumour necrosis factor (TNF) super family and induces B cell
XX CC proliferation and differentiation. The antibodies of the invention have
XX CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
XX CC and so may be used to detect and quantitate the presence of BlyS in
XX CC biological samples and may be used in this way to diagnose disease
XX CC associated with aberrant expression of BlyS. They may also be
XX CC administered to treat diseases associated with aberrant BlyS expression
XX CC and activity such as cancer, immune, and autoimmune disorders and
XX CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX CC the antibodies and fragments of the antibodies described in the method of
XX CC the invention
XX SQ Sequence 252 AA;
XX Query Match 73.7%; Score 524; DB 5; Length 252;
XX Best Local Similarity 78.0%; Pred. No. 1.9e-40;
XX Matches 103; Conservative 7; Mismatches 16; Indels 6; Gaps 2;
QY 1 QVOLLQSATVKKPGASKMKVSCWASGYPTFTSYDISWVRQAPGQGLEWMGHSISYSGNTDY 60
DB 1 QVQLQSGAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHSISYSGNTDY 60
QY 61 AQKFGQRTVMTTDSRRTAYMELRSRSDDTAVYVCARDGGGGAYEDVMSGEYPEYYAMD 120
DB 61 AQKLGQRTVLTSTSTAYMELRSRSDDTAVYVCAR----GAYDILTGYTP--YGMD 114
QY 121 VMGGTFTVTVSS 132
DB 115 VMGGTFTVTVSS 126

```

```

RESULT 14
ADG96490
ID ADG96490 standard; protein; 252 AA.
XX AC ADG96490;
XX DT 11-MAR-2004 (first entry)
XX DE Single chain antibody that immunospecifically binds BlyS SeqID 1674.
XX KW antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
XX KW B cell proliferation; differentiation; scFv; myasthenia gravis;
XX KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
XX KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
XX KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX OS Unidentified.
XX PN WO2003055979-A2.
XX PD 10-JUL-2003.
XX PF 14-NOV-2002; 2002WO-US036496.
XX PR 16-NOV-2001; 2001US-0331469P.
XX PR 19-DEC-2001; 2001US-0340817P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX DR WPI; 2003-505530/47.
XX PT Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX PT (BlyS), useful for detecting and treating diseases or disorders e.g.
XX PT rheumatoid arthritis, asthma and leukemia.
XX PS Example 1; SEQ ID NO 1674; 394pp; English.
XX CC This invention relates to novel antibodies that immunospecifically bind
XX CC to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
XX CC chromosome 13q34 and encodes a protein that is a member of the tumour
XX CC necrosis factor superfamily and induces both in vivo and in vitro B cell
XX CC proliferation and differentiation. Specifically, it refers to single
XX CC chain antibody molecules (scFvs) derived, preferably, from the variable
XX CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX CC fragment thereof, of either human, murine, rat or monkey BlyS. The
XX CC present invention refers to the use of such antibodies in various methods
XX CC for the detection, diagnosis and prognosis of diseases related to the
XX CC aberrant expression or inappropriate function of BlyS or its receptor. As
XX CC such, these compositions are useful for identifying immune disorders
XX CC including myasthenia gravis and multiple sclerosis, inflammatory
XX CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX CC as AIDS and proliferative disorders including leukaemia, carcinoma and
XX CC lymphoma. Accordingly, they can be described as exhibiting various
XX CC activities such as antirheumatic, antiarthritic, neuroprotective,
XX CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
XX CC polypeptide sequence is a single chain antibody that binds BlyS of the
XX CC invention. NOTE: The sequence data for this patent did not form part of
XX CC the printed specification, but was obtained in electronic format
XX CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX SQ Sequence 252 AA;
XX Query Match 73.7%; Score 524; DB 7; Length 252;
XX Best Local Similarity 78.0%; Pred. No. 1.9e-40;
XX Matches 103; Conservative 7; Mismatches 16; Indels 6; Gaps 2;
QY 1 QVOLLQSATVKKPGASKMKVSCWASGYPTFTSYDISWVRQAPGQGLEWMGHSISYSGNTDY 60
DB 1 QVQLQSGAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHSISYSGNTDY 60
QY 61 AQKFGQRTVMTTDSRRTAYMELRSRSDDTAVYVCARDGGGGAYEDVMSGEYPEYYAMD 120

```

Search completed: May 5, 2006, 09:09:31
Job time : 51.8333 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:53:55 ; Search time 14.5 Seconds
(without alignments)
752.634 Million cell updates/sec

Title: US-09-674-752-25

Perfect score: 711

Sequence: 1 QVQLLOSATEVKKPGASKVKYSCMASGYPTFSYDTSWVRQAPGGQLEWGMWISYSGNTDY 60

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

Issued Patents AA:*

1: /cgn2_6/ptodata/1/iaa/5_COMB.pep.*

2: /cgn2_6/ptodata/1/iaa/6_COMB.pep.*

3: /cgn2_6/ptodata/1/iaa/H_COMB.pep.*

4: /cgn2_6/ptodata/1/iaa/PCITUS_COMB.pep.*

5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep.*

6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	503.5	70.8	123	2	US-10-330-613A-21
2	485	68.2	120	2	US-09-025-769B-36
3	485	68.2	120	2	US-09-025-769B-59
4	485	68.2	120	2	US-09-490-070A-36
5	485	68.2	120	2	US-09-490-070A-59
6	485	68.2	120	2	US-09-490-153-36
7	485	68.2	120	2	US-09-490-153-59
8	485	68.2	120	2	US-09-490-324-36
9	485	68.2	120	2	US-09-490-324-59
10	484.5	68.1	117	2	US-09-025-769B-22
11	484.5	68.1	117	2	US-09-490-070A-22
12	484.5	68.1	117	2	US-09-490-153-22
13	484.5	68.1	117	2	US-09-490-324-22
14	478.5	67.3	121	1	US-08-264-093-3
15	476.5	67.0	129	1	US-08-561-521-45
16	476.5	67.0	129	2	US-08-525-539A-77
17	476.5	67.0	129	4	PCT-US95-01219-45
18	476	66.9	128	1	US-08-202-047-22
19	476	66.9	128	2	US-08-964-690-22
20	471.5	66.3	125	2	US-09-199-149-3
21	464.5	65.3	470	1	US-09-859-053-28
22	464	65.3	120	1	US-08-652-816A-19
23	460	64.7	118	2	US-09-726-219A-165
24	460	64.6	118	2	US-09-196-522-165
25	452.5	63.6	139	2	US-08-933-983-21
26	450	63.3	98	2	US-10-194-975-4
27	450	63.3	98	2	US-10-330-613A-53

Sequence 105, App
Sequence 105, App
Sequence 19, Appl
Sequence 19, Appl
Sequence 18, Appl
Sequence 14, Appl
Sequence 13, Appl
Sequence 35, Appl
Sequence 57, Appl
Sequence 35, Appl
Sequence 57, Appl
Sequence 35, Appl
Sequence 57, Appl
Sequence 35, Appl
Sequence 57, Appl
Sequence 35, Appl
Sequence 57, Appl
Sequence 10, Appl
Sequence 10, Appl
Sequence 41, Appl

ALIGNMENTS

RESULT 1

US-10-330-613A-21

; Sequence 21, Application US/10330613A

; Patent No. 6924360

; GENERAL INFORMATION:

; APPLICANT: Gudas, Jean

; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN

; FILE REFERENCE: ABGENIX.022A

; CURRENT APPLICATION NUMBER: US/10/330.613A

; CURRENT FILING DATE: 2002-12-26

; PRIOR APPLICATION NUMBER: 60/346299

; PRIOR FILING DATE: 2001-12-18

; NUMBER OF SEQ ID NOS: 90

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 21

; LENGTH: 123

; TYPE: PRT

; ORGANISM: Homo Sapiens

US-10-330-613A-21

Query March 70.8% Score 503.5; DB 2; Length 123;
Best Local Similarity 75.8%; Pred. No. 4.7e-41;
Matches 100; Conservative 6; Mismatches 17; Indels 9; Gaps 2;

Qy 1 QVQLLOSATEVKKPGASKVKYSCMASGYPTFSYDTSWVRQAPGGQLEWGMWISYSGNTDY 60

Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSGYFSWVRQAPGGQLEWGLWISAYNGNTNY 60

Qy 61 AQKFGQRTVTMTDTTSRTATMELRLSRDSDTAVYICARDGGGGAYEDVWSGEYPEYAMD 120

Db 61 AQKLGQRVTMTDTTSTATMELRLSRDSDTAVYICAR-----ETKVRGVH--YIGMD 111

Qy 121 VMGGGTIVTVSS 132

Db 112 VMGGGTIVTVSS 123

RESULT 2

US-09-025-769B-36

; Sequence 36, Application US/09025769B

; Patent No. 6300064

; GENERAL INFORMATION:

; APPLICANT: Knappick, Achim

; APPLICANT: Pack, Peter

; APPLICANT: Ilag, Vic

; APPLICANT: Ge, Liming

; APPLICANT: Moroney, Simon

; APPLICANT: Plueckthun, Andreas

; TITLE OF INVENTION: Protein/(Poly)peptide libraries

; NUMBER OF SEQUENCES: 373

```
/
/
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
/ STREET: 1251 Avenue of the Americas
/ CITY: New York
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 10021
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: PC-DOS/MS-DOS
/ CURRENT APPLICATION DATA:
/ PATENT APPLICATION NUMBER: US/09/025,769B
/ FILING DATE: 18-FEB-1998
/
/ APPLICATION NUMBER: EP 95 11 3021.0
/ FILING DATE: 18-AUG-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: James F. Haley, Jr., Esq.
/ REGISTRATION NUMBER: 27,794
/ REFERENCE/DOCKET NUMBER: MORPHO/5
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212)596-9090
/ TELEFAX: (212)596-9090
/ INFORMATION FOR SEQ ID NO: 59:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 120 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ US-09-025-769B-59
/
/ Query Match 68.2%; Score 485; DB 2; Length 120;
/ Best Local Similarity 72.7%; Pred. No. 2.8e-39;
/ Matches 96; Conservative 7; Mismatches 17; Indels 12; Gaps 1;
/
/ QY 1 QVQLQATGEVKKPGASMKVSCMASGYPTFTSYDHSWVRQAPGQGLEWMGWISYSGNTDY 60
/ DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQAPGQGLEWMGWINPNSGTTY 60
/
/ QY 61 AQKFGQGVVTTTDSRTTAYMELRLSRDSTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
/ DB 61 AQKFGQGVVTTTDSRTTAYMELRLSRDSTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
/
/ QY 121 VMGGTTLTVSS 132
/ DB 109 YMGQGLTVTVSS 120
/
/ RESULT 4
/ US-09-490-070A-36
/ Sequence 36, Application US/09490070A
/ Patent No. 6696248
/ GENERAL INFORMATION:
/ APPLICANT: Knappik, Achim
/ Pack, Peter
/ Ilag, Vic
/ Ge, Liming
/ Moroney, Simon
/ Plueckthun, Andreas
/ TITLE OF INVENTION: Protein/(Poly)peptide libraries
/ NUMBER OF SEQUENCES: 373
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
/ White & McAuliffe
/ STREET: 1666 K Street, N.W., Suite 300
/ CITY: Washington
/ STATE: D.C.
/ COUNTRY: USA
/ ZIP: 20006
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: PC-DOS/MS-DOS
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/490,070A
/ FILING DATE: 24-Jan-2000
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: EP 95 11 3021.0
/ FILING DATE: 18-AUG-1995
/
/
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
/ STREET: 1251 Avenue of the Americas
/ CITY: New York
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 10021
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: PC-DOS/MS-DOS
/ CURRENT APPLICATION DATA:
/ PATENT APPLICATION NUMBER: US/09025769B
/ FILING DATE: 18-FEB-1998
/
/ APPLICATION NUMBER: EP 95 11 3021.0
/ FILING DATE: 18-AUG-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: James F. Haley, Jr., Esq.
/ REGISTRATION NUMBER: 27,794
/ REFERENCE/DOCKET NUMBER: MORPHO/5
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212)596-9090
/ TELEFAX: (212)596-9090
/ INFORMATION FOR SEQ ID NO: 36:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 120 amino acids
/ TYPE: amino acid
/ STRANDEDNESS:
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ US-09-025-769B-36
/
/ Query Match 68.2%; Score 485; DB 2; Length 120;
/ Best Local Similarity 72.7%; Pred. No. 2.8e-39;
/ Matches 96; Conservative 7; Mismatches 17; Indels 12; Gaps 1;
/
/ QY 1 QVQLQATGEVKKPGASMKVSCMASGYPTFTSYDHSWVRQAPGQGLEWMGWISYSGNTDY 60
/ DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQAPGQGLEWMGWINPNSGTTY 60
/
/ QY 61 AQKFGQGVVTTTDSRTTAYMELRLSRDSTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
/ DB 61 AQKFGQGVVTTTDSRTTAYMELRLSRDSTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
/
/ QY 121 VMGGTTLTVSS 132
/ DB 109 YMGQGLTVTVSS 120
/
/ RESULT 3
/ US-09-025-769B-59
/ Sequence 59, Application US/09025769B
/ Patent No. 6300064
/ GENERAL INFORMATION:
/ APPLICANT: Knappik, Achim
/ Pack, Peter
/ Ilag, Vic
/ Ge, Liming
/ Moroney, Simon
/ Plueckthun, Andreas
/ TITLE OF INVENTION: Protein/(Poly)peptide libraries
/ NUMBER OF SEQUENCES: 373
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
/ STREET: 1251 Avenue of the Americas
/ CITY: New York
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 10021
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
```

```
;
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-09-490-070A-36

Query Match 69.2%; Score 485; DB 2; Length 120;
Best Local Similarity 72.7%; Pred. No. 2.8e-39;
Matches 96; Conservative 7; Mismatches 17; Indels 12; Gaps 1;

QY 1 QVQLQSATEVKKPGASKMKVSCASGYPTFTSYDLSWVRQAPGQGLEWMGHSIYSGNTDY 60
DB 1 QVQLVQSGAEVKKPGASKMKVSCASGYPTFTSYDLSWVRQAPGQGLEWMGHSIYSGNTDY 60
QY 61 AQKFQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
DB 61 AQKFQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
QY 121 VWGGGTTVTVSS 132
DB 109 YWGQGLTVTVSS 120

RESULT 5
US-09-490-070A-59
; Sequence 59, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Pluckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-070A-59

Query Match 68.2%; Score 485; DB 2; Length 120;
Best Local Similarity 72.7%; Pred. No. 2.8e-39;
Matches 96; Conservative 7; Mismatches 17; Indels 12; Gaps 1;

QY 1 QVQLQSATEVKKPGASKMKVSCASGYPTFTSYDLSWVRQAPGQGLEWMGHSIYSGNTDY 60
DB 1 QVQLVQSGAEVKKPGASKMKVSCASGYPTFTSYDLSWVRQAPGQGLEWMGHSIYSGNTDY 60
QY 61 AQKFQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
DB 61 AQKFQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
QY 121 VWGGGTTVTVSS 132
DB 109 YWGQGLTVTVSS 120

RESULT 6
US-09-490-153-36
; Sequence 36, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Pluckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
```

```

; SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-09-490-153-36
Query Match 68.2%; Score 485; DB 2; Length 120;
Best Local Similarity 72.7%; Pred. No. 2.8e-39;
Matches 96; Conservative 7; Mismatches 17; Indels 12; Gaps 1;

QY 1 QVQLQSATEVKKPGASKVSCWASGYPTSYDISWVRQAPGGLEWMGHWISYSGNTDY 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGAEVKKPGASVKSCASGYTFTSYIMHWVRQAPGGLEWMGWINPNSGNTY 60

QY 61 AQKFGQVRVTMTTDSRRRTAYMELSLRSDDTAVYYCARDGGGAYEDVMSGEYPEYYAMD 120
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 AQKFGQVRVTMTTDSRRRTAYMELSLRSDDTAVYYCARDGGGAYEDVMSGEYPEYYAMD 120

QY 121 VMQGQTTVTSS 132
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
109 YMQGGLTIVTSS 120

RESULT 7
US-09-490-153-36
; Sequence 59, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490.153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025.769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-153-39
Query Match 68.2%; Score 485; DB 2; Length 120;
Best Local Similarity 72.7%; Pred. No. 2.8e-39;
Matches 96; Conservative 7; Mismatches 17; Indels 12; Gaps 1;

QY 1 QVQLQSATEVKKPGASKVSCWASGYPTSYDISWVRQAPGGLEWMGHWISYSGNTDY 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGAEVKKPGASVKSCASGYTFTSYIMHWVRQAPGGLEWMGWINPNSGNTY 60

QY 61 AQKFGQVRVTMTTDSRRRTAYMELSLRSDDTAVYYCARDGGGAYEDVMSGEYPEYYAMD 120
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 AQKFGQVRVTMTTDSRRRTAYMELSLRSDDTAVYYCARDGGGAYEDVMSGEYPEYYAMD 120

QY 121 VMQGQTTVTSS 132
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
109 YMQGGLTIVTSS 120

RESULT 8
US-09-490-324-36
; Sequence 36, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490.324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025.769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-09-490-324-36
Query Match 68.2%; Score 485; DB 2; Length 120;
Best Local Similarity 72.7%; Pred. No. 2.8e-39;
Matches 96; Conservative 7; Mismatches 17; Indels 12; Gaps 1;

QY 1 QVQLQSATEVKKPGASKVSCWASGYPTSYDISWVRQAPGGLEWMGHWISYSGNTDY 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGAEVKKPGASVKSCASGYTFTSYIMHWVRQAPGGLEWMGWINPNSGNTY 60

QY 61 AQKFGQVRVTMTTDSRRRTAYMELSLRSDDTAVYYCARDGGGAYEDVMSGEYPEYYAMD 120
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 AQKFGQVRVTMTTDSRRRTAYMELSLRSDDTAVYYCARDGGGAYEDVMSGEYPEYYAMD 120

```

Db 61 AQKQGRVTMTDTSISTAYMELSLRSDTAVYYCARWGGD-----FYAMD 108

Qy 121 VWGQGLTVTVSS 132
| | | | |
Db 109 YWGGTLTVTVSS 120

RESULT 9

US-09-490-324-59
; Sequence 59, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-324-59

Query Match 68.2%; Score 485; DB 2; Length 120;
Best Local Similarity 72.7%; Pred. No. 2.8e-39;
Matches 96; Conservative 7; Mismatches 17; Indels 12; Gaps 1;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTSYDISWVRQAPQGQLEWGMWISYSGNTDY 60
| | | | |
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTSYMHVWRQAPQGQLEWGMWLNPNSGNTNY 60

Qy 61 AQKQGRVTMTDTSRRTAYMELSLRSDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
| | | | |
Db 61 AQKQGRVTMTDTSISTAYMELSLRSDTAVYYCARWGGD-----FYAMD 108

Qy 121 VWGQGLTVTVSS 132
| | | | |
Db 109 YWGGTLTVTVSS 120

RESULT 10

US-09-025-769B-22
; Sequence 22, Application US/09025769B
; Patent No. 630064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-22

Query Match 68.1%; Score 484.5; DB 2; Length 117;
Best Local Similarity 72.7%; Pred. No. 3e-39;
Matches 96; Conservative 5; Mismatches 16; Indels 15; Gaps 1;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTSYDISWVRQAPQGQLEWGMWISYSGNTDY 60
| | | | |
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTSYMHVWRQAPQGQLEWGMWLNPNSGNTNY 60

Qy 61 AQKQGRVTMTDTSRRTAYMELSLRSDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120
| | | | |
Db 61 AQKQGRVTMTDTSISTAYMELSLRSDTAVYYCARDGGG-----FD 105

Qy 121 VWGQGLTVTVSS 132
| | | | |
Db 106 YWGGTLTVTVSS 117

RESULT 11

US-09-490-070A-22
; Sequence 22, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming


```
;
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-490-324-22

Query Match      68.1%; Score 484.5; DB 2; Length 117;
Best Local Similarity 72.7%; Pred. No. 3e-39;
Matches 96; Conservative 5; Mismatches 16; Indels 15; Gaps 1;

Qy 1 QVQLQSATEVKKPGASKVKSCMASGYPTSYDISWVRQAPGQGLEWMGWSIYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYHHWVRQAPGQGLEWMGWINPNSGNTY 60

Qy 61 AQKFGQGRVTMTDTSRTATYMEISSLRSDDTAVYYCARDGGGGAYEDVWSGEYPEYYAMD 120
Db 61 AQKFGQGRVTMTDTSRTATYMEISSLRSDDTAVYYCARDGGGGAYEDVWSGEYPEYYAMD 120

Qy 121 VWGGQTITVTVSS 132
Db 106 YWGGQGLTVTVSS 117

RESULT 14
US-08-264-093-3
; Sequence 3, Application US/08264093
; Patent No. 5639863
; GENERAL INFORMATION:
; APPLICANT: Michael D. Dan
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO
; TITLE OF INVENTION: CELL CYCLE-INDEPENDENT GLIOMA SURFACE
; TITLE OF INVENTION: ANTIGEN
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ridout & Maybee
; STREET: 2300 Richmond-Adelaide Centre
; STREET: 101 Richmond Street West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5H 2J7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.4 Mb storage
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: MS-DOS 6.00
; SOFTWARE: ASCII Editor
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/264,093
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA: No. 5639863 applicable
```

```
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Lake, James R.
; REGISTRATION NUMBER: 31081
; REFERENCE/DOCKET NUMBER: NOVOP/106A/7551
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 868-1482
; TELEFAX: (416) 362-0823
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 121 amino acids
; TYPE: amino acid
; STRANDEDNESS: not applicable
; TOPOLOGY: linear
US-08-264-093-3

Query Match      67.3%; Score 478.5; DB 1; Length 121;
Best Local Similarity 72.0%; Pred. No. 1.2e-38;
Matches 95; Conservative 11; Mismatches 15; Indels 11; Gaps 3;

Qy 1 QVQLQSATEVKKPGASKVKSCMASGYPTSYDISWVRQAPGQGLEWMGWSIYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGLSWVRQAPGQGLEWMGWSIHNNTNS 60

Qy 61 AQKFGQGRVTMTDTSRTATYMEISSLRSDDTAVYYCARDGGGGAYEDVWSGEYPEYYAMD 120
Db 61 AQKFGQGRVTMTDTSRTATYMEISSLRSDDTAVYYCARVG-----VM--DLLNYF--D 109

Qy 121 VWGGQTITVTVSS 132
Db 110 YWGGQGLTVTVSS 121

RESULT 15
US-08-561-521-45
; Sequence 45, Application US/08561521
; Patent No. 5840299
; GENERAL INFORMATION:
; APPLICANT: Bendig, Mary M.
; APPLICANT: Leger, Olivier J.
; APPLICANT: Saldanha, Jose
; APPLICANT: Jones, S. Tarran
; TITLE OF INVENTION: Humanized Antibodies Against Leukocyte
; TITLE OF INVENTION: Adhesion Molecule VLA-4
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/561,521
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/186,269A
; FILING DATE: 25-JAN-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William L.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 15270-14
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-543-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 45:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 129 amino acids
```


GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 09:02:26 ; Search time 40.5 Seconds
(without alignments)
1361.814 Million cell updates/sec

Title: US-09-674-752-25

Perfect score: 711

Sequence: 1 QVQLQSGATEVKKPGASKMKV.....YPEYAMDVWGQGTIVTVSS 132

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

Published Applications_AA_Main:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	539	75.8	469	6	US-11-031-485-42
2	536	75.4	469	6	US-11-031-485-34
3	530.5	74.6	125	4	US-10-269-805-45
4	525.5	73.9	255	3	US-09-880-748-1190
5	525.5	73.9	255	4	US-10-293-418-1190
6	524.5	73.8	127	4	US-10-041-860-31
7	524.5	73.8	127	4	US-10-041-860-243
8	524.5	73.8	127	4	US-10-041-860-325
9	524.5	73.8	127	4	US-10-665-383-42
10	524	73.7	252	3	US-09-880-748-1674
11	524	73.7	252	4	US-10-293-418-1674
12	523	73.6	121	6	US-11-031-485-120
13	523	73.6	251	3	US-09-880-748-1921
14	523	73.6	251	4	US-10-293-418-1921
15	522	73.4	125	6	US-11-031-485-133
16	521.5	73.3	259	3	US-09-880-748-973
17	521.5	73.3	259	4	US-10-293-418-973
18	520	73.1	253	3	US-09-880-748-1777
19	520	73.1	253	4	US-10-293-418-1777
20	514.5	72.4	248	3	US-09-880-748-1778
21	514.5	72.4	248	4	US-10-293-418-1778
22	514.5	72.4	257	3	US-09-880-748-1610
23	514.5	72.4	257	4	US-10-293-418-1610
24	513	72.2	249	3	US-09-880-748-1425
25	513	72.2	249	4	US-10-293-418-1425
26	512.5	72.1	257	3	US-09-880-748-1576
27	512.5	72.1	257	4	US-10-293-418-1576

Sequence 1562, Ap
Sequence 1562, Ap
Sequence 1452, Ap
Sequence 1452, Ap
Sequence 42, Appl
Sequence 207, Appl
Sequence 62, Appl
Sequence 1354, Ap
Sequence 1354, Ap
Sequence 354, App
Sequence 1405, Ap
Sequence 1405, Ap
Sequence 1595, Ap
Sequence 1595, Ap
Sequence 48, Appl
Sequence 200, App
Sequence 237, App
Sequence 372, App

ALIGNMENTS

RESULT 1

US-11-031-485-42
; Sequence 42, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
; APPLICANT: FULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.
; APPLICANT: HAAK-FRENDSCHO, MARY
; TITLE OF INVENTION: ANTIBODIES TO MADCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031.485
; CURRENT FILING DATE: 2005-01-07
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 42
; LENGTH: 469
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-42

Query Match 75.8%; Score 539; DB 6; Length 469;
Best Local Similarity 78.8%; Pred. No. 1.5e-41;
Matches 104; Conservative 7; Mismatches 13; Indels 8; Gaps 2;

Qy 1 QVQLQSGATEVKKPGASKMKVSCWASGYPTFSYDISWTRQAPQGQLEWGMWISYSGNTDY 60

Db 20 QVQLVQSGAEVKKPGASVKVSCEASGYTFTSYGIDWVRQAPQGQLEWGMWISYSGNTNY 79

Qy 61 AQKQGRVTWTTDTSRTAYMELRSLSDDTAVYVCARDGGGAYEDVWSGEYPEYVAMD 120

Db 80 AQKQGRVTWTTDTSRTAYMELRSLSDDTAVYVCARDGGGAYEDVWSGEYPEYVAMD 131

Qy 121 VWGQGTIVTVSS 132

Db 132 VWGQGTIVTVSS 143

RESULT 2

US-11-031-485-34
; Sequence 34, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
; APPLICANT: FULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.

```
; APPLICANT: HAAK-PRENDSCO, MARY
; TITLE OF INVENTION: ANTIBODIES TO MACAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; PRIOR FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 34
; LENGTH: 469
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-34

Query Match 75.4%; Score 536; DB 6; Length 469;
Best Local Similarity 78.0%; Pred. No. 2.8e-41;
Matches 103; Conservative 8; Mismatches 13; Indels 8; Gaps 2;

QY 1 QVQLQSATEVKKPGASKVKSCASGYPTFTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 20 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGINWVRQAPGQGLEWMGWISYSGNTY 79
QY 61 AQKFGQGRVTMTTDSRTATYMELSRLSDDTAVYYCARDGGGGAYEDVWSGEYPEYYAMD 120
Db 80 AQKQGRVTMTTADTSTATYMDLSRLSDDTAVYYCARDGSS-----SGDY--YYGMD 131
QY 121 VWGQGTITVTSS 132
Db 132 VWGQGTITVTSS 143

RESULT 3
US-10-269-805-45
; Sequence 45, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 45
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-45

Query Match 74.6%; Score 530.5; DB 4; Length 125;
Best Local Similarity 77.8%; Pred. No. 2.3e-41;
Matches 105; Conservative 4; Mismatches 13; Indels 13; Gaps 2;

QY 1 QVQLQSATEVKKPGASKVKSCASGYPTFTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISYNGNTNY 60
QY 61 AQKFGQGRVTMTTDSRTATYMELSRLSDDTAVYYCARDGG---GGAYEDVWSGEYPEYY 117
Db 61 AQKQGRVTMTTDTSTATYMELSRLSDDTAVYYCARDGRIAAARSAY-----YY 110
QY 118 AMDVWGQGTITVTSS 132
Db 111 GMDVWGQGTITVTSS 125

RESULT 4
US-09-880-748-1190
; Sequence 1190, Application US/09880748
; Publication No. US20030059937A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1190
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1190

Query Match 73.9%; Score 525.5; DB 3; Length 255;
Best Local Similarity 78.0%; Pred. No. 1.4e-40;
Matches 103; Conservative 8; Mismatches 18; Indels 3; Gaps 2;

QY 1 QVQLQSATEVKKPGASKVKSCASGYPTFTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISYNGNTNY 60
QY 61 AQKFGQGRVTMTTDSRTATYMELSRLSDDTAVYYCARDGGGGAYEDVWSGEYPEYYAMD 120
Db 61 AQKQGRVTMTTDTSTATYMELSRLSDDTAVYYCARD--PSPYYDILTGYFLPYV-MD 117
QY 121 VWGQGTITVTSS 132
Db 118 VWGKGLTITVTSS 129

RESULT 5
US-10-293-418-1190
; Sequence 1190, Application US/10293418
; Publication No. US2003023996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1190
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1190
```

```
Query Match 73.9%; Score 525.5; DB 4; Length 255;
Best Local Similarity 78.0%; Pred. No. 1.4e-40;
Matches 103; Conservative 8; Mismatches 18; Indels 3; Gaps 2;

Qy 1 QVQLQSATEVKKPGASKKVCMSAGYPFTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

Qy 61 AQKFQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEY-PEYYAM 120
Db 61 AQKLQGRVTMTDTSRTAYMELSLRSDDTAVYYCARD---PSYYDILTGFLPYV-MD 117

Qy 121 VMQGQTTVTVSS 132
Db 118 VMKGGLTVTVSS 129

RESULT 6
US-10-041-860-31
; Sequence 31, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 127
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-31

Query Match 73.8%; Score 524.5; DB 4; Length 127;
Best Local Similarity 78.9%; Pred. No. 8.3e-41;
Matches 105; Conservative 6; Mismatches 15; Indels 7; Gaps 3;

Qy 1 QVQLQSATEVKKPGASKKVCMSAGYPFTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

Qy 61 AQKFQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEY-PEYYAM 119
Db 61 AQKLQGRVTMTDTSRTAYMELSLRSDDTAVYYCARD---HYD--SSDYLYYYYGL 114

Qy 120 VMQGQTTVTVSS 132
Db 115 DMVGQTTVTVSS 127

RESULT 7
US-10-041-860-243
; Sequence 243, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
```

```
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 243
; LENGTH: 127
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-243

Query Match 73.8%; Score 524.5; DB 4; Length 127;
Best Local Similarity 78.9%; Pred. No. 8.3e-41;
Matches 105; Conservative 6; Mismatches 15; Indels 7; Gaps 3;

Qy 1 QVQLQSATEVKKPGASKKVCMSAGYPFTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

Qy 61 AQKFQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEY-PEYYAM 119
Db 61 AQKLQGRVTMTDTSRTAYMELSLRSDDTAVYYCARD---HYD--SSDYLYYYYGL 114

Qy 120 VMQGQTTVTVSS 132
Db 115 DMVGQTTVTVSS 127

RESULT 8
US-10-041-860-325
; Sequence 325, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 325
; LENGTH: 127
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-325

Query Match 73.8%; Score 524.5; DB 4; Length 127;
Best Local Similarity 78.9%; Pred. No. 8.3e-41;
Matches 105; Conservative 6; Mismatches 15; Indels 7; Gaps 3;

Qy 1 QVQLQSATEVKKPGASKKVCMSAGYPFTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

Qy 61 AQKFQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEY-PEYYAM 119
Db 61 AQKLQGRVTMTDTSRTAYMELSLRSDDTAVYYCARD---HYD--SSDYLYYYYGL 114

Qy 120 VMQGQTTVTVSS 132
Db 115 DMVGQTTVTVSS 127
```

```

RESULT 9
US-10-665-383-42
; Sequence 42, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: LaRocheHelle, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; TITLE OF INVENTION: USING ANTI-PDGF-DD ANTIBODIES
; FILE REFERENCE: ABGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665,383
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/411,137
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 42
; LENGTH: 127
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-42

Query Match      73.8%; Score 524.5; DB 4; Length 127;
Best Local Similarity 78.9%; Pred. No. 8.3e-41;
Matches 105; Conservative 6; Mismatches 15; Indels 7; Gaps 3;

Qy 1 QVQLQSGATEVKKPGASMKVSCASGYPTFTSYDISWVRQAPGQGLEWMGHSIYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHSIYSGNTNY 60
Qy 61 AQKQFQGRVTMTTDSRRTAYMELSLRSDDTAVYYCARDGGGGAYEDVMSGEYPEYYAM 119
Db 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCARD-----HYD--SSDYLYYYGL 114
Qy 120 DVWGQGTITVTVSS 132
Db 115 DVWGQGTITVTVSS 127

RESULT 10
US-09-880-748-1674
; Sequence 1674, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1674
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1674

Query Match      73.7%; Score 524; DB 4; Length 252;
Best Local Similarity 78.0%; Pred. No. 1.9e-40;
Matches 103; Conservative 7; Mismatches 16; Indels 6; Gaps 2;

Qy 1 QVQLQSGATEVKKPGASMKVSCASGYPTFTSYDISWVRQAPGQGLEWMGHSIYSGNTDY 60
Db 1 QVQLQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHSIYSGNTNY 60
Qy 61 AQKQFQGRVTMTTDSRRTAYMELSLRSDDTAVYYCARDGGGGAYEDVMSGEYPEYYAM 120
Db 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR-----GAYYDILTGYTP--YGM 114
Qy 121 VMGQGTITVTVSS 132
Db 115 VMGQGTITVTVSS 126

RESULT 12
US-11-031-485-120
; Sequence 120, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
; APPLICANT: PULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-NIMEE
```

```
; APPLICANT: GREEN, LARRY L.
; APPLICANT: HAAK-FRENDSCHO, MARY
; TITLE OF INVENTION: ANTIBODIES TO MADCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 120
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-120

Query Match 73.6%; Score 523; DB 6; Length 121;
Best Local Similarity 78.0%; Pred. No. 1.1e-40;
Matches 103; Conservative 4; Mismatches 13; Indels 12; Gaps 2;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPQGGLWGMWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTFTSYGISWVRQAPQGGLWGMWISAYNGNTNY 60

Qy 61 AQKFGQRTVMTDTSRRRTAYMELSLRSDDTAVYYCARDGGGAYEDVMSGEYPEYYAMD 120
Db 61 AQKLGQRTVMTDTSSTAYMELSLRSDDTAVYYCARSSSY--YVGMWD 108

Qy 121 VVGQGTTVTVSS 132
Db 109 VVGQGTTVTVSS 120

RESULT 13
US-09-880-748-1921
; Sequence 1921, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1921
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1921

Query Match 73.6%; Score 523; DB 3; Length 251;
Best Local Similarity 74.6%; Pred. No. 2.3e-40;
Matches 103; Conservative 5; Mismatches 14; Indels 16; Gaps 2;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPQGGLWGMWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTFTSYGISWVRQAPQGGLWGMWISAYNGNTNY 60

Qy 61 AQKFGQRTVMTDTSRRRTAYMELSLRSDDTAVYYCAR-----DGGGAYEDVMSGEYP 114
Db 61 AQKLGQRTVMTDTSSTAYMELSLRSDDTAVYYCARVTSLSYSSSSGGYY----- 111

RESULT 14
US-10-293-418-1921
; Sequence 1921, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1921
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1921

Query Match 73.6%; Score 523; DB 4; Length 251;
Best Local Similarity 74.6%; Pred. No. 2.3e-40;
Matches 103; Conservative 5; Mismatches 14; Indels 16; Gaps 2;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPQGGLWGMWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTFTSYGISWVRQAPQGGLWGMWISAYNGNTNY 60

Qy 61 AQKFGQRTVMTDTSRRRTAYMELSLRSDDTAVYYCAR-----DGGGAYEDVMSGEYP 114
Db 61 AQKLGQRTVMTDTSSTAYMELSLRSDDTAVYYCARVTSLSYSSSSGGYY----- 111

RESULT 15
US-11-031-485-133
; Sequence 133, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
; APPLICANT: PULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.
; APPLICANT: HAAK-FRENDSCHO, MARY
; TITLE OF INVENTION: ANTIBODIES TO MADCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
```

```
; SEQ ID NO 133
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-133

Query Match      73.4%; Score 522; DB 6; Length 125;
Best Local Similarity 76.5%; Pred. No. 1.4e-40;
Matches 101; Conservative 8; Mismatches 15; Indels 8; Gaps 2;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTTSYDISWVRQAPGGGLEWGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCERASGYFTTSYGIDWVRQAPGGGLEWGWISYSGNTNY 60

Qy 61 AQKFQGRVTMTTDSRTAYMELRSLRSDDTAVYYCARDGGGGAYEDVWSGEYPEYYAMD 120
Db 61 AQKLQGRVTMTSTSTSTAFLLRSLRSDDTAVYYCAREGSSS-----SGDY--YIGMD 112

Qy 121 VWGGTTTVTVSS 132
Db 113 VWGGTTTVTVSS 124
```

Search completed: May 5, 2006, 09:07:34
Job time : 41.6429 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:52 ; Search time 10 Seconds
(without alignments)
610.959 Million cell updates/sec

Title: US-09-674-752-25

Perfect score: 711

Sequence: 1 QVQLQSGATEVKKPGASKV.....YPEYYAMDVWGQTTVTVSS 132

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA New:*

- 1: /SIDSS/ptodata/1/pubpaa/US08_NEW_PUB.pep1.*
- 2: /SIDSS/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
- 3: /SIDSS/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
- 4: /SIDSS/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
- 5: /SIDSS/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
- 6: /SIDSS/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
- 7: /SIDSS/ptodata/1/pubpaa/US09_NEW_PUB.pep1.*
- 8: /SIDSS/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
- 9: /SIDSS/ptodata/1/pubpaa/US10_NEW_PUB.pep1.*
- 10: /SIDSS/ptodata/1/pubpaa/US11_NEW_PUB.pep1.*
- 11: /SIDSS/ptodata/1/pubpaa/US11_NEW_PUB.pep1.*
- 12: /SIDSS/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	530.5	74.6	125	9	US-10-982-440-45
2	525.5	73.9	255	11	US-11-054-515-1190
3	525.5	73.9	255	11	US-11-054-515-1190
4	524	73.7	252	11	US-11-054-515-1674
5	524	73.7	252	11	US-11-054-515-1674
6	523	73.6	251	11	US-11-054-515-1921
7	523	73.6	251	11	US-11-054-515-1921
8	521.5	73.3	259	11	US-11-054-515-973
9	521.5	73.3	259	11	US-11-054-515-973
10	520	73.1	253	11	US-11-054-515-1777
11	520	73.1	253	11	US-11-054-515-1777
12	514.5	72.4	248	11	US-11-054-515-1778
13	514.5	72.4	248	11	US-11-054-515-1778
14	514.5	72.4	257	11	US-11-054-515-1610
15	514.5	72.4	257	11	US-11-054-515-1610
16	513	72.2	249	11	US-11-054-515-1425
17	513	72.2	249	11	US-11-054-515-1425
18	512.5	72.1	257	11	US-11-054-515-1576
19	512.5	72.1	257	11	US-11-054-515-1576
20	510.5	71.8	251	11	US-11-054-515-1562
21	510.5	71.8	251	11	US-11-054-515-1562

22	510.5	71.8	259	11	US-11-054-515-1452	Sequence 1452, Ap
23	510.5	71.8	259	11	US-11-054-515-1452	Sequence 1452, Ap
24	508.5	71.5	257	11	US-11-054-515-1354	Sequence 1354, Ap
25	508.5	71.5	257	11	US-11-054-515-1354	Sequence 1354, Ap
26	508	71.4	254	11	US-11-054-515-1405	Sequence 1405, Ap
27	508	71.4	254	11	US-11-054-515-1405	Sequence 1405, Ap
28	507	71.3	250	11	US-11-054-515-1595	Sequence 1595, Ap
29	507	71.3	250	11	US-11-054-515-1595	Sequence 1595, Ap
30	506.5	71.2	257	11	US-11-054-515-1579	Sequence 1579, Ap
31	506.5	71.2	257	11	US-11-054-515-1579	Sequence 1579, Ap
32	505	71.0	247	11	US-11-054-515-1873	Sequence 1873, Ap
33	505	71.0	247	11	US-11-054-515-1873	Sequence 1873, Ap
34	504.5	71.0	248	11	US-11-054-515-1472	Sequence 1472, Ap
35	504.5	71.0	248	11	US-11-054-515-1472	Sequence 1472, Ap
36	504.5	71.0	248	11	US-11-054-515-1116	Sequence 1116, Ap
37	504	70.9	247	11	US-11-054-515-1116	Sequence 1116, Ap
38	504	70.9	247	11	US-11-054-515-1116	Sequence 1116, Ap
39	504	70.9	250	11	US-11-054-515-1560	Sequence 1560, Ap
40	504	70.9	250	11	US-11-054-515-1560	Sequence 1560, Ap
41	503.5	70.8	248	11	US-11-054-515-1446	Sequence 1446, Ap
42	503.5	70.8	248	11	US-11-054-515-1446	Sequence 1446, Ap
43	502	70.6	124	11	US-11-040-159-10	Sequence 10, Appl
44	500.5	70.4	251	11	US-11-054-515-1586	Sequence 1586, Ap
45	500.5	70.4	251	11	US-11-054-515-1872	Sequence 1872, Ap

ALIGNMENTS

RESULT 1

US-10-982-440-45
; Sequence 45, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Olinier, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 45
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-45

Query Match	74.6%	Score	530.5	DB	9	Length	125
Best Local Similarity	77.8%	Pred. No.	3.3e-38				
Matches	105	Conservative	4	Mismatches	13	Indels	13
Gaps	2						
QY	1	QVQLQSGATEVKKPGASKVSCMASGYPFTSYDISWVRQAPCGGLEWGWISYISGNTDY	60				
Db	1	QVQLVQSGAEVKKPGASVKSCKASGFTSYSGISWVRQAPCGGLEWGWISYNGNTNY	60				
QY	61	AQKPGQRTVMTTDTSTRTAYMELSLRSDDTAVYYCARDGG---GGAYEDVWSGEYPEYY	117				
Db	61	AQKLGQRTVMTTDTSTRTAYMELSLRSDDTAVYYCARDGRIARSAY-----YY	110				
QY	118	AMDVWGQTTVTVSS	132				
Db	111	GMDVWGQTTVTVSS	125				

RESULT 2

US-11-054-515-1190
; Sequence 1190, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.

```
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1190
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1190

Query Match 73.9%; Score 525.5; DB 11; Length 255;
Best Local Similarity 78.0%; Pred. No. 1.6e-37;
Matches 103; Conservative 8; Mismatches 18; Indels 3; Gaps 2;

Qy 1 QVQLQSATEVKKPGASKMKVSCMASGYPTFTSYDLSWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

Qy 61 AQKFGQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGGAYEDVWSGEYPEYYAMD 120
Db 61 AQKLQGRVTMTDTSRTAYMELSLRSDDTAVYYCARD--PSPYDILITGYFLPY--MD 117

Qy 121 VWGQGTITVTVSS 132
Db 118 VWGKGLTVTVSS 129

RESULT 3
US-11-266-444-1190
; Sequence 1190, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523PID1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
```

```
; SEQ ID NO 1190
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1190

Query Match 73.9%; Score 525.5; DB 11; Length 255;
Best Local Similarity 78.0%; Pred. No. 1.6e-37;
Matches 103; Conservative 8; Mismatches 18; Indels 3; Gaps 2;

Qy 1 QVQLQSATEVKKPGASKMKVSCMASGYPTFTSYDLSWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

Qy 61 AQKFGQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGGAYEDVWSGEYPEYYAMD 120
Db 61 AQKLQGRVTMTDTSRTAYMELSLRSDDTAVYYCARD--PSPYDILITGYFLPY--MD 117

Qy 121 VWGQGTITVTVSS 132
Db 118 VWGKGLTVTVSS 129

RESULT 4
US-11-054-515-1674
; Sequence 1674, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1674
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1674

Query Match 73.7%; Score 524; DB 11; Length 252;
Best Local Similarity 78.0%; Pred. No. 2.2e-37;
Matches 103; Conservative 7; Mismatches 16; Indels 6; Gaps 2;

Qy 1 QVQLQSATEVKKPGASKMKVSCMASGYPTFTSYDLSWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWISYNDNTNY 60

Qy 61 AQKFGQGRVTMTDTSRRTAYMELSLRSDDTAVYYCARDGGGGAYEDVWSGEYPEYYAMD 120
Db 61 AQKLQGRVTMTDTSRTAYMELSLRSDDTAVYYCAR----GNYYDILITGYYP--YCMD 114
```



```
Qy 121 VMQGTTVTSS 132
Db 115 VMQGTTLTVSS 126

RESULT 5
US-11-266-444-1674
; Sequence 1674, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523PDI
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1674
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1674

Query Match 73.7%; Score 524; DB 11; Length 252;
Best Local Similarity 78.0%; Pred. No. 2.2e-37;
Matches 103; Conservative 7; Mismatches 16; Indels 6; Gaps 2;

Qy 1 QVQLLOSATEVKKPCASMKVSCMASGYPTSYDLSWVRQAPGQGLEWMGWSIYSGNTDY 60
Db 1 QVQLQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSIYSGNTNY 60

Qy 61 AQKFGQRTVMTTDSRRRTAYMELSLRSDDTAVYYCAR----GAYDILTCGYP--YGM 120
Db 61 AQKLGQRTLTDTSTSTAYMELSLRSDDTAVYYCAR---GAYDILTCGYP--YGM 114

Qy 121 VMQGTTVTSS 132
Db 115 VMQGTTLTVSS 126

RESULT 6
US-11-054-515-1921
; Sequence 1921, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
```

```
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1921
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1921

Query Match 73.6%; Score 523; DB 11; Length 251;
Best Local Similarity 74.6%; Pred. No. 2.6e-37;
Matches 103; Conservative 5; Mismatches 14; Indels 16; Gaps 2;

Qy 1 QVQLLOSATEVKKPCASMKVSCMASGYPTSYDLSWVRQAPGQGLEWMGWSIYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSIYSGNTNY 60

Qy 61 AQKFGQRTVMTTDSRRRTAYMELSLRSDDTAVYYCAR-----DGGGAYEDVMSGEYP 114
Db 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCARVTSLSYSSSSGGYY----- 111

Qy 115 EYAMDVMQGTTVTSS 132
Db 112 -YGMQVMDVMGRGTTVTSS 128

RESULT 7
US-11-266-444-1921
; Sequence 1921, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523PDI
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1921
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1921

Query Match 73.6%; Score 523; DB 11; Length 251;
Best Local Similarity 74.6%; Pred. No. 2.6e-37;
Matches 103; Conservative 5; Mismatches 14; Indels 16; Gaps 2;

Qy 1 QVQLLOSATEVKKPCASMKVSCMASGYPTSYDLSWVRQAPGQGLEWMGWSIYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSIYSGNTNY 60

Qy 61 AQKFGQRTVMTTDSRRRTAYMELSLRSDDTAVYYCAR-----DGGGAYEDVMSGEYP 114
Db 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCARVTSLSYSSSSGGYY----- 111

Qy 115 EYAMDVMQGTTVTSS 132
Db 112 -YGMQVMDVMGRGTTVTSS 128
```

```
Db      61 AQLQGRVTMTDTSRTAYMELSLRSDDTAVYICARVTSLSYSSSGGY----- 111
Qy      115 EYAYDMVGQGTMTVSS 132
Db      112 -YMGDMVGRGTTVTVSS 128

RESULT 8
US-11-054-515-973
; Sequence 973, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: 2005-02-10
; PRIOR FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SEQ ID NO 973
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-973

Query Match      73.3%; Score 521.5; DB 11; Length 259;
Best Local Similarity 74.5%; Pred. No. 3.6e-37;
Matches 102; Conservative 8; Mismatches 18; Indels 9; Gaps 2;

Qy      1 QVQLQSATEVKPGASMKVSCMASGYPTTSYDISWVRQAPCGGLEWGMWISYSGNTDY 60
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db      1 QMQLVQSGAEVKMPGASVKVSKASGYTFTSYGISWVRQAPCGGLEWGMWISAYNGNTNY 60
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

Qy      61 AQKFGQRTVMTDTSRTAYMELSLRSDDTAVYICARDGGGGAYEDVMSGEYPEY--- 117
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db      61 AQLQGRVTMTDTSRTAYMELSLRSDDTAVYICARDGGGGAYEDVMSGEYPEY--- 116
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

Qy      118 --AMDVMGQGTMTVTVSS 132
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db      117 SDAFDINGQGTMTVTVSS 133
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

RESULT 10
US-11-054-515-1777
; Sequence 1777, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SEQ ID NO 1777
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-973

Query Match      73.3%; Score 521.5; DB 11; Length 259;
Best Local Similarity 74.5%; Pred. No. 3.6e-37;
Matches 102; Conservative 8; Mismatches 18; Indels 9; Gaps 2;

Qy      1 QVQLQSATEVKPGASMKVSCMASGYPTTSYDISWVRQAPCGGLEWGMWISYSGNTDY 60
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db      1 QMQLVQSGAEVKMPGASVKVSKASGYTFTSYGISWVRQAPCGGLEWGMWISAYNGNTNY 60
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

Qy      61 AQKFGQRTVMTDTSRTAYMELSLRSDDTAVYICARDGGGGAYEDVMSGEYPEY--- 117
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db      61 AQLQGRVTMTDTSRTAYMELSLRSDDTAVYICARDGGGGAYEDVMSGEYPEY--- 116
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

Qy      118 --AMDVMGQGTMTVTVSS 132
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db      117 SDAFDINGQGTMTVTVSS 133
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

RESULT 9
US-11-266-444-973
; Sequence 973, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523P1d1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
```

```
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 973
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-973

Query Match      73.3%; Score 521.5; DB 11; Length 259;
Best Local Similarity 74.5%; Pred. No. 3.6e-37;
Matches 102; Conservative 8; Mismatches 18; Indels 9; Gaps 2;

Qy      1 QVQLQSATEVKPGASMKVSCMASGYPTTSYDISWVRQAPCGGLEWGMWISYSGNTDY 60
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db      1 QMQLVQSGAEVKMPGASVKVSKASGYTFTSYGISWVRQAPCGGLEWGMWISAYNGNTNY 60
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

Qy      61 AQKFGQRTVMTDTSRTAYMELSLRSDDTAVYICARDGGGGAYEDVMSGEYPEY--- 117
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db      61 AQLQGRVTMTDTSRTAYMELSLRSDDTAVYICARDGGGGAYEDVMSGEYPEY--- 116
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

Qy      118 --AMDVMGQGTMTVTVSS 132
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db      117 SDAFDINGQGTMTVTVSS 133
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

RESULT 10
US-11-054-515-1777
; Sequence 1777, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SEQ ID NO 1777
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
```

RESULT 12
US-11-054-515-1778
; Sequence 1778, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that I

```

RESULT 13
US-11-266-444-1778
; Sequence 1778, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulators
; FILE REFERENCE: PFS23PID1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1778

```

```
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1778

Query Match      72.4%; Score 514.5; DB 11; Length 248;
Best Local Similarity 75.8%; Pred. No. 1.4e-36;
Matches 100; Conservative 9; Mismatches 16; Indels 7; Gaps 2;

QY 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGQGLEWMGWISYSGNTDY 60
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1 QVQLQSGAEVKKPGASVKVSKCASKGYTFTSYGISWVRQAPGHGLEWMGWISAYNGNTY 60
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCARDGGGAYEDVMSGEYPEYAMD 120
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 61 AQELQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR-----SYDILTGYP--FGMD 113
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 121 VMGGGTGTTVTSS 132
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 114 VMGGGTGTTVTSS 125
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 14
US-11-054-515-1610
; Sequence 1610, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1610
; LENGTH: 257
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1610

Query Match      72.4%; Score 514.5; DB 11; Length 257;
Best Local Similarity 77.0%; Pred. No. 1.4e-36;
Matches 104; Conservative 6; Mismatches 18; Indels 7; Gaps 3;

QY 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGQGLEWMGWISYSGNTDY 60
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1 QVQLQSGAEVKKPGASVKVSKCASKGYTFTSYGISWVRQAPGGQGLEWMGWISAYNGTKY 60
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCARDGGGAYEDVMSGEYPE---YY 117
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 61 AQELQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCARDTLG---YDILTG-YPPPPYYY 116
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 118 AMDVWGQGTGTTVTSS 132
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 117 DMDVWGRGTLVTSS 131
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

Search completed: May 5, 2006, 09:02:45
Job time : 11 secs

RESULT 15
US-11-266-444-1610
; Sequence 1610, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1610
; LENGTH: 257
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1610

Query Match      72.4%; Score 514.5; DB 11; Length 257;
Best Local Similarity 77.0%; Pred. No. 1.4e-36;
Matches 104; Conservative 6; Mismatches 18; Indels 7; Gaps 3;

QY 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGQGLEWMGWISYSGNTDY 60
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1 QVQLQSGAEVKKPGASVKVSKCASKGYTFTSYGISWVRQAPGGQGLEWMGWISAYNGTKY 60
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCARDGGGAYEDVMSGEYPE---YY 117
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 61 AQELQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCARDTLG---YDILTG-YPPPPYYY 116
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 118 AMDVWGQGTGTTVTSS 132
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 117 DMDVWGRGTLVTSS 131
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

Search completed: May 5, 2006, 09:02:45
Job time : 11 secs
```

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:51:41 ; Search time 8.66667 Seconds
(without alignments)
1465.455 Million cell updates/sec

Title: US-09-674-752-25

Perfect score: 711

Sequence: 1 QVQLQSGATVKKPGASKMKV.....YPEYYAMDVWGQTTVTVSS 132

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR_80.*

1: PIR1.*

2: PIR2.*

3: PIR3.*

4: PIR4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	520.5	73.2	129	2 S36260	Ig heavy chain V r
2	507.5	71.4	122	2 S36271	Ig heavy chain V r
3	486	68.4	124	2 S19655	Ig heavy chain V r
4	481.5	67.7	160	2 P10105	anti-PR2 erythrocy
5	478.5	67.3	129	2 S46393	Ig heavy chain V r
6	474.5	66.7	131	2 S26792	Ig heavy chain V r
7	473	66.5	132	2 PH0954	Ig heavy chain V r
8	463.5	65.2	127	2 S34014	Ig heavy chain V r
9	462.5	65.0	133	2 C33548	Ig heavy chain V-1
10	462.5	65.0	627	2 S14683	Ig mu chain precu
11	460	64.7	136	2 S31600	Ig heavy chain V r
12	454	63.9	114	2 PH1667	Ig heavy chain V r
13	453	63.7	118	2 PH1666	Ig heavy chain V r
14	452.5	63.6	125	2 S68170	Ig heavy chain V r
15	451	63.4	118	2 S36265	Ig heavy chain V r
16	450	63.3	98	2 S26919	Ig heavy chain V r
17	450	63.3	128	2 PH0952	Ig heavy chain V r
18	449.5	63.2	123	2 D33548	Ig heavy chain V-1
19	446	62.7	110	2 PH1670	Ig heavy chain V r
20	445	62.6	131	2 S21944	Ig heavy chain V r
21	443	62.3	135	2 S49530	anti-Sm antibody V
22	443	62.3	136	2 PH0960	Ig heavy chain V r
23	442.5	62.2	119	2 PH0961	Ig heavy chain V r
24	438.5	61.7	127	2 PH0955	Ig heavy chain V r
25	434	61.0	135	2 B32274	Ig heavy chain pre
26	433	60.9	126	2 B33548	Ig heavy chain V-1
27	433	60.9	171	2 S23623	Ig heavy chain V r
28	431.5	60.7	125	2 PH0957	Ig heavy chain V r
29	429.5	60.4	129	2 A33548	Ig heavy chain V-1

RESULT 1

S36260

Ig heavy chain V region (clone alpha-CEA4-8A) - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999

C/Accession: S36260

R/Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.

EMBO J. 12, 725-734, 1993

A/Title: Human anti-self antibodies with high specificity from phage display libraries.

A/Reference number: S36256; MUID:93178448; PMID:7679990

A/Accession: S36260

A/Status: preliminary; nucleic acid sequence not shown

A/Molecule type: mRNA

A/Residues: 1-129 <GRI>

A/Cross-references: UNIPARC:UPI0000118DEB; EMBL:Z18851; NID:g33124; PIDN:CAA79303.1; PID

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotrimer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 73.2%; Score 520.5; DB 2; Length 129;

Best Local Similarity 79.5%; Pred. No. 5.9e-41;

Matches 105; Conservative 4; Mismatches 20; Indels 3; Gaps 2;

Qy 1 QVQLQSGATVKKPGASKMKVSGVPFTSYDLSWVRQAPGGGLWGMWISYSGNTDY 60

Db 1 QVQLQSGAEVKKPGASVKSCASGYFTFTYGISWVRQAPGGGLWGMWISATNGNTNY 60

Qy 61 AQKFQGRVTMTTSTSRRTATYMLRSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYYAMD 120

Db 61 AQKLQGRVTMTTSTSTATYMLRSLRSDDTAVYYCARDSPG--YCSSTSCPY-YYYMD 117

Qy 121 WQGQTTVTVSS 132

Db 118 WVGKTTVTVSS 129

RESULT 2

S36271

Ig heavy chain V region (clone alpha-THY-29) - human (fragment)

C/Species: Homo sapiens (man)

C/Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999

C/Accession: S36271

R/Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.

EMBO J. 12, 725-734, 1993

A/Title: Human anti-self antibodies with high specificity from phage display libraries.

A/Reference number: S36256; MUID:93178448; PMID:7679990

A/Accession: S36271

A/Status: preliminary; nucleic acid sequence not shown

A/Molecule type: mRNA

A/Residues: 1-122 <GRI>

A/Cross-references: UNIPARC:UPI0000118DE3; EMBL:Z18832; NID:g33115; PIDN:CAA79284.1; PID

C/Superfamily: immunoglobulin V region; immunoglobulin homology

RESULT 8

S34014

Ig heavy chain V region - human

C:Species: Homo sapiens (man)

C:Date: 02-Dec-1993 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996

C:Accession: S34014; S30535

R:Mariette, X.; Tsapis, A.; Brouet, J.C.

Eur. J. Immunol. 23, 846-851, 1993

A:Title: Nucleotide sequence analysis of the variable domains of four human monoclonal

A:Reference number: S34001; MUID:93209281; PMID:7681398

A:Accession: S34014

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-127 <MAR>

A:Cross-references: UNIPARC:UPI0000176D31; EMBL:Z18321

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 65.2%; Score 463.5; DB 2; Length 127;

Best Local Similarity 71.2%; Pred. No. 1e-35;

Matches 94; Conservative 12; Mismatches 21; Indels 5; Gaps 2;

Qy 1 QVOLLQATSEVKPGASMKVSCWASGYPTFSYDISWVRQAPGGGLEWGMWISYSGNTDY 60

Db 1 QVQLVSGAEVKPGASVKSCASGTYFTSYDINWVRQATGGGLEWGMWNPSSGNTGY 60

Qy 61 AQKFGQGVTTMTDTSRRATYMWELSLRSDTAVYYCARDCGGGAYEDVWSGEVPEYYAMD 120

Db 61 AQKFGKRVTTWRTNSTSTAYMWELSLRSEDATVYFCARALSIGV--AVIRG---YYVALD 115

Qy 121 VWGGQGTTVTVSS 132

Db 116 VWGGQGTTVSVSS 127

RESULT 9

C33548

Ig heavy chain V-1 region (783) - human

C:Species: Homo sapiens (man)

C:Date: 17-Jan-1990 #sequence_revision 17-Jan-1990 #text_change 16-Aug-1996

C:Accession: C33548

P:Klpps, T.J.; Tomhave, E.; Pratt, L.F.; Duffy, S.; Chen, P.P.; Carson, D.A.

Proc. Natl. Acad. Sci. U.S.A. 86, 5913-5917, 1989

A:Title: Developmentally restricted immunoglobulin heavy chain variable region gene exp

A:Reference number: A33548; MUID:89345575; PMID:2503826

A:Accession: C33548

A:Status: preliminary; nucleic acid sequence not shown; not compared with conceptual tra

A:Molecule type: DNA

A:Residues: 1-133 <KIP>

A:Cross-references: UNIPARC:UPI0000176D2B

A:Experimental source: the sequence was determined from the differentiated gene

C:Superfamily: immunoglobulin V region; immunoglobulin homology

C:Keywords: heterotetramer; immunoglobulin

F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 65.0%; Score 462.5; DB 2; Length 133;

Best Local Similarity 69.1%; Pred. No. 1.3e-35;

Matches 94; Conservative 8; Mismatches 27; Indels 7; Gaps 2;

Qy 1 QVOLLQATSEVKPGASMKVSCWASGYPTFSYDISWVRQAPGGGLEWGMWISYSGNTDY 60

Db 1 QVQLVSGAEVKPGASVKSCASGTYFTSSYAIWVRQAPGGGLEWGMGIPIFGTANY 60

Qy 61 AQKFGQGVTTMTDTSRRATYMWELSLRSDTAVYYCARDCGGGAYEDVWSGEYPE---Y 116

Db 61 AQKFGKRVTTADESTSTAYMWELSLRSEDATVYYCAKTGILGPYSSGW---YPSNDYY 117

Qy 117 YAMDVWGGQGTTVTVSS 132

Db 118 YGMDVWGGQGTTVTVSS 133

RESULT 10
S14683
Ig mu chain precursor, membrane-bound (clone 201) - human
C;Species: Homo sapiens (man)
C;Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 23-Jul-1999
C;Accession: S14683; S08047
R;Friedlander, R.M.; Nussenzweig, M.C.; Leder, P.
Nucleic Acids Res. 18, 4278, 1990
A;Title: Complete nucleotide sequence of the membrane form of the human IgM heavy chain.
A;Reference number: S14683; MUID:90332450; PMID:2115996
A;Accession: S14683
A;Molecule type: mRNA
A;Residues: 1-627 <FRI>
A;Cross-references: UNIPARC:UPI000016AB02; EMBL:X17115; NID:g33450; PIDN:CAA34971.1; PID
C;Superfamily: immunoglobulin C region; immunoglobulin homology
C;Keywords: immunoglobulin; membrane protein
F;1-15/Domain: signal sequence #status predicted <SIG>
F;16-627/Product: Ig mu chain #status predicted <MAT>
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 65.0%; Score 462.5; DB 2; Length 627;
Best Local Similarity 69.1%; Pred. No. 7.2e-35;
Matches 94; Conservative 8; Mismatches 27; Indels 7; Gaps 2;

Qy 1 QVQLQSATVKKPGASMKVSCWASGYPTFTSYDISWVRQAPQGQLEWMGWISYSGNTDY 60
Db 20 QVQLVSGAEVKKPGSSVKVSKASGTFSSYAISWVRQAPQGQLEWMGWISYSGNTDY 79
Qy 61 AQKFGQGVTTTDSRTTAYMELSLRSDTAVYVCARDGGGAYEDVWSGEYPE---Y 116
Db 80 AQKFGQGVTTTADGSTAYMELSLRSDTAVYCAKTGILGPSGGW---YPSDDYY 136
Qy 117 YAMDVWGQGVTTVTVSS 132
Db 137 YGMDVWGQGVTTVTVSS 152

RESULT 11
S31600
Ig heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31600
R;Cuisinier, A.M.; Gauthier, L.; Boulbi, L.; Fougereau, M.; Tonnelle, C.
Submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31600
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-136 <CUI>
A;Cross-references: UNIPARC:UPI0000116453; EMBL:Z14165; NID:g30994; PIDN:CAA78534.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 64.7%; Score 460; DB 2; Length 136;
Best Local Similarity 69.7%; Pred. No. 2.3e-35;
Matches 92; Conservative 8; Mismatches 16; Indels 16; Gaps 2;

Qy 1 QVQLQSATVKKPGASMKVSCWASGYPTFTSYDISWVRQAPQGQLEWMGWISYSGNTDY 60
Db 20 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 79
Qy 61 AQKFGQGVTTTDSRTTAYMELSLRSDTAVYVCARDGGGAYEDVWSGEYPEYYAMD 120
Db 80 AQKFGQGVTTTSTSTAYMELSLRSDTAVYCAR-----WRD-----AFD 123
Qy 121 VWGQGVTTVTVSS 132
Db 124 IWGQGVTTVTVSS 135

RESULT 12
PH1667
Ig heavy chain V region (clone 2H7) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996
C;Accession: PH1667
R;Hillson, J.L.; Karr, N.S.; Opplinger, I.R.; Mannik, M.; Sasso, E.H.
J. Exp. Med. 178, 331-336, 1993
A;Title: The structural basis of germline-encoded VH3 immunoglobulin binding to staphyloc
A;Reference number: PH1642; MUID:93301610; PMID:8315388
A;Accession: PH1667
A;Molecule type: mRNA
A;Residues: 1-114 <HIL>
A;Cross-references: UNIPARC:UPI0000176B88
A;Experimental source: B cell
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;7-90/Domain: immunoglobulin homology <IMM>

Query Match 63.9%; Score 454; DB 2; Length 114;
Best Local Similarity 72.4%; Pred. No. 6.6e-35;
Matches 89; Conservative 7; Mismatches 17; Indels 10; Gaps 2;

Qy 10 EVKPKGASMKVSCWASGYPTFTSYDISWVRQAPQGQLEWMGWISYSGNTDYAQKFGQGV 69
Db 2 EVKPKGASVKVSKASGYTFTSYAMHWVRQAPQGRLEWMGWINAGNNTKYAQKFGQGV 61
Qy 70 MTTDTSRRTAYMELSLRSDTAVYVCARDGGGAYEDVWSGEYPEYYAMDVWGQGV 129
Db 62 ITRDTSASTAYMELSLRSDTAVYCAR-----YVDPSWG-----YYAFDINGQGV 111
Qy 130 VSS 132
Db 112 VSS 114

RESULT 13
PH1666
Ig heavy chain V region (clone 6C9) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996
C;Accession: PH1666
R;Hillson, J.L.; Karr, N.S.; Opplinger, I.R.; Mannik, M.; Sasso, E.H.
J. Exp. Med. 178, 331-336, 1993
A;Title: The structural basis of germline-encoded VH3 immunoglobulin binding to staphyloc
A;Reference number: PH1642; MUID:93301610; PMID:8315388
A;Accession: PH1666
A;Molecule type: mRNA
A;Residues: 1-118 <HIL>
A;Cross-references: UNIPARC:UPI0000176B87
A;Experimental source: B cell
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;7-90/Domain: immunoglobulin homology <IMM>

Query Match 63.7%; Score 453; DB 2; Length 118;
Best Local Similarity 72.2%; Pred. No. 8.5e-35;
Matches 91; Conservative 6; Mismatches 17; Indels 12; Gaps 2;

Qy 10 EVKPKGASMKVSCWASGYPTFTSYDISWVRQAPQGQLEWMGWISYSGNTDYAQKFGQGV 69
Db 2 EVKPKGASVKVSKASGYTFTSYAMHWVRQAPQGRLEWMGWINAGNNTKYAQKFGQGV 61
Qy 70 MTTDTSRRTAYMELSLRSDTAVYVCARDGGGAYEDVWSGEYPEYYAMDVWGQGV 126
Db 62 ITRDTSASTAYMELSLRSDTAVYCARVTLDDGGIKFY-----YYGNDVWGQGV 112
Qy 127 TVTVSS 132
Db 113 TVTVSS 118

Search completed: May 5, 2006, 08:54:49
Job time : 9.66667 secs

```
RESULT 14
S68170
Ig heavy chain V region - human (fragment)
N:Alternate names: anti-cytomegalovirus glycoprotein B antibody
C:Species: Homo sapiens (man)
C>Date: 29-Jul-1997 #sequence_revision 29-Aug-1997 #text_change 21-Jan-2000
C:Accession: S68170
R:Boeldicke, T.; Haase, B.; Boecher, M.; Lindenmaier, W.
Eur. J. Biochem. 234, 397-405, 1995
A:Title: Human monoclonal antibodies to cytomegalovirus. Characterization and recombination
A:Reference number: S68170; MUID:96128166; PMID:8536681
A:Accession: S68170
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-125 <BOE>
A:Cross-references: UNIPARC:UPI0000113987; GB:S80750; NID:g1246061; PIDN:AAB35861.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match      63.6%; Score 452.5; DB 2; Length 125;
Best Local Similarity 66.7%; Pred. No. 1e-34;
Matches 88; Conservative 16; Mismatches 21; Indels 7; Gaps 2;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 EVKLQSGAELKPGASVKVSKTSGYTFSSYNINWVRQAPGQGLEWMGWISVNGKTRY 60

Qy 61 AQKFGQGVTTTDTSRRTAYMELSLRSDDTAVYVCARDGGGAYEDVWSGEYPEYYAMD 120
Db 61 AQKFGQGVTTTDTSRRTAYMELSLRSDDTAVYVCARDGGGAYEDVWSGEYPEYYAMD 120

Qy 121 VWGGTTLTVTVSS 132
Db 114 YWGGTTLTVTVSS 125

RESULT 15
S36265
Ig heavy chain V region (clone alpha-MUC1-1) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C:Accession: S36265
R:Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.
EMBO J. 12, 725-734, 1993
A:Title: Human anti-self antibodies with high specificity from phage display libraries.
A:Reference number: S36256; MUID:93178448; PMID:7679990
A:Accession: S36265
A>Status: preliminary; nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 1-118 <GRI>
A:Cross-references: UNIPARC:UPI0000118DE8; EMBL:Z18846; NID:g33121; PIDN:CAA79298.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match      63.4%; Score 451; DB 2; Length 118;
Best Local Similarity 68.2%; Pred. No. 1.3e-34;
Matches 90; Conservative 8; Mismatches 20; Indels 14; Gaps 1;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKRSGYPTGYMHVWVRQAPGQGLEWMGWINPNSGCTNY 60

Qy 61 AQKFGQGVTTTDTSRRTAYMELSLRSDDTAVYVCARDGGGAYEDVWSGEYPEYYAMD 120
Db 61 AQKFGQGVTTTDTSRRTAYMELSLRSDDTAVYVCARDFELSG-----YLD 106

Qy 121 VWGGTTLTVTVSS 132
Db 107 YWGGTTLTVTVSS 118
```

THIS PAGE BLANK (05/10)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 09:04:30 ; Search time 49.6667 Seconds
(without alignments)
1875.095 Million cell updates/sec

Title: US-09-674-752-25

Perfect score: 711

Sequence: 1 QVQLQSATEVKKPGASKMKV.....YPEYYAMDVNGQGTITVTSS 132

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	456.5	64.2	500	2	Q6N091_HUMAN
2	452.5	63.6	125	2	Q9UL95_HUMAN
3	447	62.9	500	2	Q9BRV0_HUMAN
4	446.5	62.8	119	2	Q9UL94_HUMAN
5	445	62.6	469	2	Q7Z7P5_HUMAN
6	444.5	62.5	244	2	Q65ZC8_HUMAN
7	441	62.0	159	2	Q96Q80_HUMAN
8	434	61.0	518	2	Q6N030_HUMAN
9	427	60.1	147	1	HVLC_HUMAN
10	423	59.5	124	2	Q9UL92_HUMAN
11	417.5	58.7	119	2	Q9GY22_MOUSE
12	415	58.4	498	2	Q6N041_HUMAN
13	407	57.2	475	2	Q6N095_HUMAN
14	406.5	57.2	480	2	Q6PJF1_HUMAN
15	403.5	56.8	480	2	Q6P089_HUMAN
16	403.5	56.8	497	2	Q8WY24_HUMAN
17	394.5	55.5	519	2	Q5EBM2_HUMAN
18	393	55.3	116	2	Q9UL89_HUMAN
19	391.5	55.1	147	2	Q925S3_MOUSE
20	390.5	54.9	481	2	Q91WT1_MOUSE
21	386	54.3	117	1	HV1B_HUMAN
22	385	54.1	606	2	Q6GMV2_HUMAN
23	382.5	53.8	150	2	Q9Y298_HUMAN
24	382	53.7	117	1	HV1G_HUMAN
25	381.5	53.7	458	2	Q5BJZ2_RAT
26	380.5	53.5	208	2	Q6ZP87_HUMAN
27	380	53.4	617	2	Q4KM15_MOUSE
28	379.5	53.4	468	2	Q569W9_MOUSE
29	379	53.3	465	2	Q6PJB2_MOUSE
30	377.5	53.1	170	2	Q925S2_MOUSE
31	376.5	53.0	117	2	Q9QXE9_MOUSE

32	375.5	52.8	142	2	Q924Q1_MOUSE
33	373.5	52.5	458	2	Q5BK05_RAT
34	373	52.5	120	2	Q6NSA4_HUMAN
35	372	52.3	109	2	Q9JL75_MOUSE
36	371	52.2	145	2	Q924R1_MOUSE
37	371	52.2	613	2	Q8VCX7_MOUSE
38	370	52.0	145	2	Q924Q6_MOUSE
39	370	52.0	506	2	Q6N090_HUMAN
40	369	51.9	145	2	Q924R4_MOUSE
41	368.5	51.8	484	2	Q9JLA6_MOUSE
42	368	51.8	143	2	Q924R0_MOUSE
43	368	51.8	482	2	Q8K172_MOUSE
44	368	51.8	590	2	Q4V9V8_MOUSE
45	367.5	51.7	120	1	HV03_MOUSE

ALIGNMENTS

RESULT 1
Q6N091_HUMAN
ID Q6N091_HUMAN PRELIMINARY; PRT; 500 AA.
AC Q6N091;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686C02220 (Fragment).
GN Name=DKFZp686C02220;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;
RG The German Human cDNA Consortium;
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640625; CAB45779.1; -, mRNA.
DR HSP; P01751; 1A6W.
DR SMR; Q6N091; 270-478.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON TER
SQ SEQUENCE 500 AA; 54160 MW; 3C423A17D65A41E4 CRC64;

Query Match 64.2%; Score 456.5; DB 2; Length 500;

Best Local Similarity 68.2%; Pred. No. 1.5e-39;

Matches 90; Conservative 12; Mismatches 21; Indels 9; Gaps 2;

Qy	1	QVQLQSATEVKKPGASKMKV	YPTSYDISVWRQAPGGGLEWGHISISGNTDY	60
Db	38	QVQLVSGAEVKKPGASVKVSKASGYT	FDSDHSITLWRQAPGGGLEWISAYSGQTY	97
Qy	61	AKRFGQRTVT	TTDTSRRRTAYMELRSLRSDDTAVYVCARDGGGAYEDVWSGPEYVAMD	120
Db	98	AQNLQGRVT	TTDTSSTAYMELRSLRSDDTAVYVCARD	148
Qy	121	VWGQGT	TVT	132
Db	149	IWGGT	MT	160

RESULT 2

Q9UL95 HUMAN
ID Q9UL95_HUMAN PRELIMINARY; PRT; 125 AA.
AC Q9UL95;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus."
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035019; AAD56255.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG-LIKE; 1.
FT NON_TER 1
FT NON_TER 125
SQ SEQUENCE 125 AA; 13516 MW; 0D3CD5C232488EAC CRC64;

Query Match 63.6%; Score 452.5; DB 2; Length 125;
Best Local Similarity 68.2%; Pred. No. 7.8e-40;
Matches 90; Conservative 11; Mismatches 24; Indels 7; Gaps 2;
QY 1 QVQLQSATEVKKPGASMKVSCMASGYPTTSYDLSWVRQAPGGGLEWGMWISYSGNTDY 60
Db 1 EVQLVESGAEVKKPGASVKVSKRSGYFTGYTHWVRQAPGGGLEWGMWINSNGTNY 60
QY 61 AQKFGQVRVTMTDTSRRTAYMELSLRSDDTAVYICARDGGGAYEDVWVGSEYPEYAMD 120
Db 61 AQKVGQVRVTMTDTSRRTAYMELSLRSDDTAVYICARDGGGAYEDVWVGSEYPEYAMD 120
QY 121 VMGGQGTVTVSS 132
Db 114 VMGGQGTVTVSS 125

RESULT 3

Q9BRV0 HUMAN
ID Q9BRV0_HUMAN PRELIMINARY; PRT; 500 AA.
AC Q9BRV0;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE MGC27165 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D., Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C., Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A., Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Krzywinaki M.I., Skaleka U., Smailus D.E., Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RA Strausberg R.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC005951; AAH05951.1; -; mRNA.
DR HSSP; P01876; IOWO.
DR SMR; Q9BRV0; 25-300, 270-478.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG-LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 500 AA; 54154 MW; 0A9BF43F2A3CC6D9 CRC64;
Query Match 62.9%; Score 447; DB 2; Length 500;
Best Local Similarity 68.2%; Pred. No. 1.5e-38;
Matches 90; Conservative 10; Mismatches 28; Indels 4; Gaps 2;
QY 1 QVQLQSATEVKKPGASMKVSCMASGYPTTSYDLSWVRQAPGGGLEWGMWISYSGNTDY 60
Db 20 QVHVGSGAEVWSPGASVRSCKTSYGAFHTYSIIWVRQAPGGGLEWGMWISPSNTRF 79
QY 61 AQKFGQVRVTMTDTSRRTAYMELSLRSDDTAVYICARDGGGAYEDVWVGSEYPEYAMD 120
Db 80 AKKFGQVRVTMTDTSRRTAYMELSLRSDDTAVYICAR--RYCSYSSCQNDYY--YYMD 135
QY 121 VMGGQGTVTVSS 132
Db 136 VMGGQGTVTVSS 147
RESULT 4
Q9UL94 HUMAN
ID Q9UL94_HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL94;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., Young D.C.;

```

RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RL fetus.";
DR Clin. Immunol. Immunopathol. 87:184-192 (1998).
DR EMBL; AF035020; AAD56256.1; -, mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG-LIKE; 1.
FT NON TER 1
FT NON TER 119
SQ SEQUENCE 119 AA; 13205 MW; 13E64F5345FA16E CRC64;

Query Match 62.8%; Score 446.5; DB 2; Length 119;
Best Local Similarity 67.4%; Pred. No. 3.2e-39;
Matches 89; Conservative 9; Mismatches 21; Indels 13; Gaps 2;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDTSWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 EVQLVESGAIEVKKPGASVKSCASGYFTFTGYMHVVRQAPGQGLEWMGWINPNSWTTNY 60

Qy 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYAMD 120
Db 61 AQKFGQGRVTMTKDTISITAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYAMD 120

Qy 121 VMGGQTTVTVSS 132
Db 108 VMGGQTLVTVSS 119

RESULT 5
ID Q7Z7P5 HUMAN PRELIMINARY; PRT; 469 AA.
AC Q7Z7P5;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heish F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grinwood J., Schmutz J., Myers R.N.,
RA Butterfield Y.S.N., Krzyzanski M.I., Skalska U., Smallos D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Maira M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
[2]

RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH MGC Project;

Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC051328; AAHS1328.1; -, mRNA.
DR HSSP; P01857; IHZH.
DR SMR; Q7Z7P5; 20-469.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG-LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Immunoglobulin domain.
SQ SEQUENCE 469 AA; 51395 MW; C8D5BE12BAAF795C CRC64;

Query Match 62.6%; Score 445; DB 2; Length 469;
Best Local Similarity 65.2%; Pred. No. 2.3e-38;
Matches 86; Conservative 14; Mismatches 20; Indels 12; Gaps 2;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDTSWVRQAPGQGLEWMGWISYSGNTDY 60
Db 20 QVHLVQSGAEVKKPGASVKLSCKTSGYNFSYDLIWRQAPGQGLEWMGWISAHNGDTKY 79

Qy 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYAMD 120
Db 80 ARKFGQGRVTMTTDSATTSYMEFSLRSDDTALFYCATKSRGQV-----GDF-----D 127

Qy 121 VMGGQTTVTVSS 132
Db 128 VMGGQTLVTVSS 139

RESULT 6
ID Q65ZC8 HUMAN PRELIMINARY; PRT; 244 AA.
AC Q65ZC8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631 (1997).
DR EMBL; Y13057; CAA73500.1; -, mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PS00835; IG-LIKE; 2.
FT NON TER 1
FT NON TER 244
SQ SEQUENCE 244 AA; 26127 MW; 4B1F17868338F2BF CRC64;

Query Match 62.5%; Score 444.5; DB 2; Length 244;
Best Local Similarity 65.9%; Pred. No. 1.2e-38;
Matches 87; Conservative 11; Mismatches 23; Indels 11; Gaps 1;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDTSWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKLSCKTSGYNFSYDLIWRQAPGQGLEWMGWIDPNNGTRF 60

Qy 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYAMD 120
Db 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCARDGGGAYEDVWSGEYPEYAMD 120

```

```

Db      61 AQRFGQVMTWRTDTSISAAAYMEVSLRLSDDTAVYYCAREGTGSA-----IYGMDD 109
Qy      121 VMGGGTTVTVSS 132
        ||||| |||||
Db      110 VMGGGTLVTVSS 121

RESULT 7
Q96Q30 HUMAN
ID Q96Q30 HUMAN PRELIMINARY; PRT; 159 AA.
AC Q96Q30;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Putative matrix cell adhesion molecule-3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Tilson M.D.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY039025; AAK82649.1; -, mRNA.
DR HSSP; P01869; IAE6.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain.
KW IMUNOGLOBULIN DOMAIN.
SQ SEQUENCE 159 AA; 17497 MW; 5D29537B881FAF02 CRC64;

Query Match 62.0%; Score 441; DB 2; Length 159;
Best Local Similarity 67.4%; Pred. No. 1.7e-38;
Matches 91; Conservative 13; Mismatches 23; Indels 8; Gaps 3;

Qy      1 QVQLQSGATEVKKPGASMKVSCWASGYPTFSYDISWVRQAPGQGLEWMGHWISYSGNTDY 60
        ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      20 QVHLVQSGAEVKKPGASVKVSCTASGYPFTNHFNNVROAPGQSLQLEWGMGINTGNGTKY 79
        ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy      61 AQKFGQVMTWTTTDSRTAYMELSLRSDDTAVYYCARD---GGGAYEDVMGSEYPEY 117
        :|||: ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      80 SQKFGQLTWRTDTSVTYMDLSRLSDDTAVYFCAREMEITFGGA---VSKGFY--YY 134
        ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy      118 AMDVMGGGTTVTVSS 132
        ||||| ||||| |||||
Db      135 GMDVMGGGTTVTVSS 149
        ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 8
Q6N030 HUMAN
ID Q6N030 HUMAN PRELIMINARY; PRT; 518 AA.
AC Q6N030;
DT 03-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686I15212.
GN Name=DKFZp686I15212;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Rectum tumor;
RG The German cDNA Consortium;
RA Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA Poustka A., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RA Mewes H.W., 2005) to the EMBL/GenBank/DBJ databases.
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640724; CAB45841.1; -, mRNA.
DR HSSP; P01861; IADQ.

```

```

DR InterPro; IPR000005; HTHARAC.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 3.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0041; HTH ARAC FAMILY_1; UNKNOWN_1.
DR PROSITE; PS50835; IG_LIKE_4.
DR PROSITE; PS00230; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
KW HYPOTHETICAL PROTEIN.
SQ SEQUENCE 518 AA; 57019 MW; 93B5F98613BF6382 CRC64;

Query Match 61.0%; Score 434; DB 2; Length 518;
Best Local Similarity 65.2%; Pred. No. 3.8e-37;
Matches 86; Conservative 13; Mismatches 23; Indels 10; Gaps 2;

Qy      1 QVQLQSGATEVKKPGASMKVSCWASGYPTFSYDISWVRQAPGQGLEWMGHWISYSGNTDY 60
        ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      20 QVHLVQSGAEVKKPGASVKVSCTASGYPFTNHFNNVROAPGQSLQLEWGMGINTGNGTKY 79
        ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy      61 AQKFGQVMTWTTTDSRTAYMELSLRSDDTAVYYCARDGGGAYEDVMGSEYPEYAMD 120
        :|||: ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      80 SQKFGQVMTWTTTDTTAYMDLSRLSDDTAVYWCARDAP-----QGVTTTF--D 129
        ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Qy      121 VMGGGTTVTVSS 132
        ||||| ||||| |||||
Db      130 YMGGGLTVTVSS 141
        ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 9
HV1C HUMAN
ID HV1C HUMAN STANDARD; PRT; 147 AA.
AC P01744;
DT 21-JUL-1986 (Rel. 01, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region ND precursor (Fragments).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=83065234; PubMed=6815656;
RA Kenten J.H., Moigaard H.V., Houghton M., Derbyshire R.B., Viney J.,
RA Bell L.O., Gould H.J.;
RT "Cloning and sequence determination of the gene for the human
RT immunoglobulin epsilon chain expressed in a myeloma cell line.";
RL Proc. Natl. Acad. Sci. U.S.A. 79:6661-6665(1982).
RN [2]
RP PROTEIN SEQUENCE OF 20-147.
RA Bannich H.H., Johansson S.G.O., von Bahr-Lindstrom H.;
RL (In) Bach M.K. (eds.);
RL Immediate hypersensitivity: modern concepts and developments, pp.1-36,
RL Marcel Dekker, New York (1978).
CC -I- MISCELLANEOUS: This epsilon chain was isolated from a myeloma
CC protein.
CC -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC HSSP; P01751; INQB.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.

```

DR GO: 0006955; P: immune response; NAS.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig_v.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PSS0835; IG_LIKE; 1.
 KW Direct protein sequencing; Immunoglobulin domain;
 KW Immunoglobulin V region; Pyrrolidone carboxylic acid; Signal.
 FT SIGNAL 1 19
 FT CHAIN 20 147
 FT DOMAIN 20 131
 FT MOD_RES 20 20
 FT DISULFID 41 115
 FT CONFLICT 21 21
 FT CONFLICT 53 54
 FT CONFLICT 67 68
 FT CONFLICT 125 125
 FT NON_TER 147 147
 SQ SEQUENCE 147 AA; 16496 MW; 948F9F72A5366C20 CRC64;
 Query Match 60.1%; Score 427; DB 1; Length 147;
 Best Local Similarity 62.7%; Pred. No. 4.8e-37;
 Matches 84; Conservative 16; Mismatches 26; Indels 8; Gaps 3;
 QY 1 QVQLQSATEVKKPGASKMKVSCWASGYPTFTSYDISWVRQAPGGGLEWMGWISYSGNTDY 60
 Db 20 QTQLVSGAEVRKPGASVRVSKASGYTFIDSVIHQAPGHLEWVGWNPNSGGTNY 79
 QY 61 AQKFGQVRVTMTTDSRRTAYMELRSRSDTAVYYCARDGGGGAYEDVWSGEYP-EY-YA 118
 Db 80 APFQGRVTMTDRASEFTAYMDLRSRSDSAVFYCAKS-----DPFWSDDYNYFDSY 133
 QY 119 MDVWGQGTITVTVSS 132
 Db 134 LDVWGQGTITVTVSS 147
 RESULT 10
 Q9UL92_HUMAN PRELIMINARY; PRT; 124 AA.
 AC Q9UL92_1
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Myosin-reactive immunoglobulin heavy chain variable region
 DE (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
 RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berny S.M.,
 RA Young D.C.;
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
 RT fetus".
 RL Clin. Immunol. Immunopathol. 87:184-192(1998).
 DR EMBL; AF035022; AAD56258.1; -; mRNA.
 DR HSSP; P01751; INQB.
 DR Ensembl; ENSG00000130076; Homo sapiens.
 DR InterPro; IPR007110; Ig-like.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PSS0835; IG_LIKE; 1.
 FT NON_TER 1 1
 FT NON_TER 124 124
 SQ SEQUENCE 124 AA; 13580 MW; 1BAAACBD96ACD2A2 CRC64;
 Query Match 59.5%; Score 423; DB 2; Length 124;
 Best Local Similarity 65.9%; Pred. No. 1e-36;
 Matches 87; Conservative 11; Mismatches 26; Indels 8; Gaps 2;
 QY 1 QVQLQSATEVKKPGASKMKVSCWASGYPTFTSYDISWVRQAPGGGLEWMGWISYSGNTDY 60
 Db 1 EVQLVESGAERKPGASVKVSKASGYTFSSYMHVVRQAPGGGLEWMGIINPSGGSTSY 60
 QY 61 AQKFGQVRVTMTTDSRRTAYMELRSRSDTAVYYCARDGGGGAYEDVWSGEYP-EY-YA 120
 Db 61 AQKFGQVRVTMTTDSRRTAYMELRSRSDTAVYYCARDGGGGAYEDVWSGEYP-EY-YA 120
 QY 121 VMGQGTITVTVSS 132
 Db 113 YMGQGTITVTVSS 124
 RESULT 11
 Q9GYZ2_MOUSE PRELIMINARY; PRT; 119 AA.
 AC Q9GYZ2_1
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Monoclonal anti-idiotypic Schistosoma japonicum antibody NP30 heavy
 DE chain variable region (Fragment).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RA Song X.T., Feng Z.Q., Guan X.H.;
 RT "Amplification, cloning and sequence analysis of the heavy chain
 RT variable region gene of monoclonal anti-idiotypic antibody NP30 of
 RT Schistosoma japonicum".
 RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF282622; AAG01452.1; -; mRNA.
 DR HSSP; P01751; 1A6W.
 DR SMR; Q9GYZ2; 1-119.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; IG_v.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PSS0835; IG_LIKE; 1.
 FT NON_TER 1 1
 FT NON_TER 119 119
 SQ SEQUENCE 119 AA; 13567 MW; BA893873FDSFAGAB CRC64;
 Query Match 58.7%; Score 417.5; DB 2; Length 119;
 Best Local Similarity 61.4%; Pred. No. 3.9e-36;
 Matches 81; Conservative 17; Mismatches 21; Indels 13; Gaps 1;
 QY 1 QVQLQSATEVKKPGASKMKVSCWASGYPTFTSYDISWVRQAPGGGLEWMGWISYSGNTDY 60
 Db 1 QVQLVESGAERKPGASVRVSKASGYTFGYMNVVRQAPGHLEWIGVINSRGTNY 60
 QY 61 AQKFGQVRVTMTTDSRRTAYMELRSRSDTAVYYCARDGGGGAYEDVWSGEYP-EY-YA 120
 Db 61 NQKFKDRVTMTTDSRRTAYMELRSRSDTAVYYCARDGGGGAYEDVWSGEYP-EY-YA 120
 QY 121 VMGQGTITVTVSS 132
 Db 108 YMGQGTITVTVSS 119
 RESULT 12
 Q6N041_HUMAN PRELIMINARY; PRT; 498 AA.
 AC Q6N041_1
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Hypothetical protein DKFZp686O16217 (Fragment).
 GN Name=DKFZp686O16217;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominoidea; Homomidae;
OC	NCBI_TaxID=9606;
OC	[1]
RP	NUCLEOTIDE SEQUENCE.
RC	TISSUE=Human rectum tumor;
RG	The German Human cDNA Consortium;
RA	Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA	Mewes H.W., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL	Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR	EMBL; BX640710; CAE45829.1; -, mRNA.
DR	HSSP; P01751; 1A6W.
DR	SMR; Q6N041; 268-476.
DR	InterPro; IPR003599; Ig.
DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003597; Ig cl.
DR	InterPro; IPR003006; Ig_MHC.
DR	InterPro; IPR003596; Ig_v.
DR	Pfam; PF07654; C1-set; 2.
DR	SMART; SM00409; IG; 4.
DR	SMART; SM00406; IGV; 1.
DR	SMART; SM00407; IGC1; 3.
DR	PROSITE; PS50835; IG_LIKE; 4.
DR	PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW	Hypothetical protein.
FT	NON TER 1
SQ	SEQUENCE 498 AA; 54125 MW; 40B3208A84E03B46 CRC64;
Query Match 58.4%; Score 415; DB 2; Length 498;	
Best Local Similarity 63.6%; Pred. No. 3.7e-35;	
Matches 84; Conservative 12; Mismatches 28; Indels 8; Gaps 2	
QY	1 QVQLQSATEVKKPGKASMKVSCMASGYPTSYDISMVRQAPGQGLEWVGWISYISGNTDY 60
Db	35 QVQLVQSGADVKKPGASVKVSKASGYFTFTFFHWVRQAPGQGPDEWMINPRDGSTKY 94
QY	61 AQKFGQGRVYMTTDTTSRRRTAYMELRLSRSDTAVYCARDGGGAYEDVMSGEYPPYYAMD 120
Db	95 AQRFGQGRVSMTRDTSITYYMELSLSRSEDIAVFCAKAPG-----YGTASASY-FD 146
QY	121 VWGQGTVTVTSS 132
Db	147 YWGQGTTLVTSS 158
RESULT 13	
Q6N095	HUMAN PRELIMINARY; PRT; 475 AA.
ID	Q6N095_HUMAN PRELIMINARY;
AC	Q6N095;
DT	05-JUL-2004 (TrEMBLrel. 27, Created)
DT	05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT	05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE	Hypothetical protein DKFZP686K03196.
GN	Name=DKFZP686K03196;
OS	Human sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominoidea; Homomidae;
OC	NCBI_TaxID=9606;
OC	[1]
RP	NUCLEOTIDE SEQUENCE.
RC	TISSUE=Esophagus tumor;
RG	The German cDNA Consortium;
RA	Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA	Fobo G., Han M., Wiemann S.;
RL	Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR	EMBL; BX640621; CAE45775.1; -, mRNA.
DR	HSSP; P01861; 1ADQ.
DR	SMR; Q6N095; 20-475.
DR	InterPro; IPR003599; Ig.
DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003597; Ig cl.
DR	InterPro; IPR003006; Ig_MHC.


```
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 480 AA; 52586 MW; 64D6G41AE47CD6C8 CRC64;

Query Match 57.2%; Score 406.5; DB 2; Length 480;
Best Local Similarity 64.2%; Pred. No. 2.9e-34;
Matches 86; Conservative 12; Mismatches 31; Indels 5; Gaps 2;

QY 1 QVQLQSATEVKKPGASKVKVSCWASGYPTSYDISWVRQAPGQGLEWMGHSIYSYSGNTDY 60
DB 20 QVQLVQSGAEVKKPGSSVKVSCASGYSISDNVYHWVRQAPGQGLEMMWIRPQNGTVS 79
QY 61 AQKFGQGRVTMTTDSRTTAYMELRSDDTAVYYCARDGGGGAYEDVMSGEYPE--YYA 118
DB 80 AQNFQDRVTISADESTDTAYMELRSRSEDATYIYCARD---LALYELWSGFHTDEKYYG 136
QY 119 MDVWGQGTITVTVSS 132
DB 137 LDVWGQGTPTVTVSS 150

RESULT 15
Q6P089 HUMAN
ID Q6P089_HUMAN PRELIMINARY; PRT; 480 AA.
AC Q6P089_
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Glandular pool- thyroid;
RX MEDLINE=22388257; PubMed12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Heiton E., Kettaman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
RA Schnerich A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Glandular pool- thyroid;
RA Strausberg R.;
RL Submitted (JAN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC065733; AAH65733.1; -; mRNA.
DR HSSP; P01751; 1A6W.
```

```
DR SMR; Q6P089; 250-458.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 480 AA; 51997 MW; 2E286C57E4F0ED65 CRC64;

Query Match 56.8%; Score 403.5; DB 2; Length 480;
Best Local Similarity 63.6%; Pred. No. 5.9e-34;
Matches 84; Conservative 9; Mismatches 28; Indels 11; Gaps 3;

QY 1 QVQLQSATEVKKPGASKVKVSCWASGYPTSYDISWVRQAPGQGLEWMGHSIYSYSGNTDY 60
DB 20 QVQLVQSGAEVKKPGSSVKVSCASGYSISDNVYHWVRQAPGQGLEMMWIRPQNGTVS 79
QY 61 AQKFGQGRVTMTTDSRTTAYMELRSDDTAVYYCARDGGGGAYEDVMSGEYPEYYAMD 120
DB 80 AEKFGQGRVTITDTSLTAYMELTSLKSDDTALYICAR-----GHSD-WSS-----YYFD 128
QY 121 VWGQGTITVTVSS 132
DB 129 YWGQGTITVTVSS 140

Search completed: May 5, 2006, 09:14:33
Job time : 49.6667 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:53:55 ; Search time 10.7652 Seconds
(without alignments)
752.634 Million cell updates/sec

Title: US-09-674-752-26

Perfect score: 515

Sequence: 1 QVOLVQSGAEVKKPGASVKV.....AYMELRLSRDDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued Patents_AA:*
- 1: /cgn2_6/ptodata/1/iaa/5 COMB.pep:*
 - 2: /cgn2_6/ptodata/1/iaa/6 COMB.pep:*
 - 3: /cgn2_6/ptodata/1/iaa/H_COMB.pep:*
 - 4: /cgn2_6/ptodata/1/iaa/PTUS_COMB.pep:*
 - 5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep:*
 - 6: /cgn2_6/ptodata/1/iaa/backfileesi.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	515	100.0	98	2	US-10-194-975-4
2	515	100.0	98	2	US-10-330-613A-53
3	515	100.0	117	2	US-08-545-809A-105
4	515	100.0	117	2	US-09-515-697-105
5	501	97.3	123	2	US-10-330-613A-21
6	497	96.5	118	2	US-09-726-219A-165
7	497	96.5	118	2	US-09-196-522-165
8	485	94.2	121	1	US-08-264-093-3
9	482	93.6	96	2	US-10-330-613A-54
10	476	92.4	132	2	US-09-513-999C-4112
11	473	91.8	120	2	US-09-513-999C-4111
12	473	91.8	134	2	US-09-471-276-849
13	462.5	89.8	128	1	US-08-202-047-22
14	462.5	89.8	128	2	US-08-964-690-22
15	462.5	89.8	129	1	US-08-561-521-45
16	462.5	89.8	129	2	US-08-525-539A-77
17	462.5	89.8	129	4	PCT-US95-01219-45
18	462	89.7	122	2	US-09-513-999C-7801
19	454	88.2	117	2	US-09-025-769B-22
20	454	88.2	117	2	US-09-490-070A-22
21	454	88.2	117	2	US-09-490-153-22
22	454	88.2	117	2	US-09-490-324-22
23	449.5	87.3	125	2	US-09-199-149-3
24	447.5	86.9	120	1	US-08-652-816A-19
25	444	86.2	120	2	US-09-025-769B-36
26	444	86.2	120	2	US-09-025-769B-59
27	444	86.2	120	2	US-09-490-070A-36

28	444	86.2	120	2	US-09-490-070A-59	Sequence 59, Appl
29	444	86.2	120	2	US-09-490-153-36	Sequence 36, Appl
30	444	86.2	120	2	US-09-490-153-59	Sequence 59, Appl
31	444	86.2	120	2	US-09-490-324-36	Sequence 36, Appl
32	444	86.2	120	2	US-09-490-324-59	Sequence 59, Appl
33	443	86.0	470	2	US-09-859-053-28	Sequence 28, Appl
34	442	85.8	98	2	US-10-194-975-2	Sequence 2, Appl
35	442	85.8	119	1	US-08-561-521-10	Sequence 10, Appl
36	442	85.8	119	2	US-09-438-954-41	Sequence 41, Appl
37	442	85.8	119	4	PCT-US95-01219-10	Sequence 10, Appl
38	439	85.2	98	2	US-10-194-975-1	Sequence 1, Appl
39	439	85.2	117	2	US-08-545-809A-90	Sequence 90, Appl
40	439	85.2	117	2	US-09-515-697-90	Sequence 90, Appl
41	437	84.9	110	2	US-09-899-896-5	Sequence 5, Appl
42	435	84.5	117	2	US-08-545-809A-96	Sequence 96, Appl
43	435	84.5	117	2	US-09-515-697-96	Sequence 96, Appl
44	435	84.5	121	2	US-09-513-999C-4115	Sequence 4115, Ap
45	430	83.5	119	1	US-08-561-521-12	Sequence 12, Appl

ALIGNMENTS

RESULT 1

US-10-194-975-4
; Sequence 4, Application US/10194975
; Patent No. 6881557
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 4
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-4

Query Match 100.0%; Score 515; DB 2; Length 98;
Best Local Similarity 100.0%; Pred No. 1.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGGLEMMGWISAYNGNTNY 60

Db 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGGLEMMGWISAYNGNTNY 60

QY 61 AQKLGQRVTMTTDTSTSTAYMELRLSRDDTAVYYCAR 98

Db 61 AQKLGQRVTMTTDTSTSTAYMELRLSRDDTAVYYCAR 98

RESULT 2

US-10-330-613A-53
; Sequence 53, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudae, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: ABGENIX-022A
; CURRENT APPLICATION NUMBER: US/10/330,613A
; CURRENT FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 53
; LENGTH: 98
; TYPE: PRT

```
; ORGANISM: Homo sapiens
US-10-330-613A-53

Query Match      100.0%; Score 515; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.6e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||
Db 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||

QY 61 AQKLGQRTVMTTDTSTSTAYMELRSRSDDTAVYYCAR 98
   |||||
Db 61 AQKLGQRTVMTTDTSTSTAYMELRSRSDDTAVYYCAR 98
   |||||

RESULT 3
US-08-545-809A-105
; Sequence 105, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: US/08/545,809A
; PRIOR APPLICATION DATA:
; FILING DATE: 10-MAY-1993
; APPLICATION NUMBER: PCT/JP93/00603
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 105:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 105:
US-08-545-809A-105

Query Match      100.0%; Score 515; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 2e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||
Db 20 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 79
   |||||

QY 61 AQKLGQRTVMTTDTSTSTAYMELRSRSDDTAVYYCAR 98
   |||||
Db 80 AQKLGQRTVMTTDTSTSTAYMELRSRSDDTAVYYCAR 117
   |||||

US-08-545-809A-105

Query Match      100.0%; Score 515; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 2e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||
Db 20 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 79
   |||||

QY 61 AQKLGQRTVMTTDTSTSTAYMELRSRSDDTAVYYCAR 98
   |||||
Db 80 AQKLGQRTVMTTDTSTSTAYMELRSRSDDTAVYYCAR 117
   |||||

US-08-545-809A-105

; ORGANISM: Homo sapiens
US-10-330-613A-21

Query Match      100.0%; Score 515; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 2e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||
Db 20 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 79
   |||||

QY 61 AQKLGQRTVMTTDTSTSTAYMELRSRSDDTAVYYCAR 98
   |||||
Db 80 AQKLGQRTVMTTDTSTSTAYMELRSRSDDTAVYYCAR 117
   |||||

US-10-330-613A-21

; Sequence 21, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: ABGENIX.022A
; CURRENT APPLICATION NUMBER: US/10/330,613A
; CURRENT FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo Sapiens
; US-10-330-613A-21

Query Match      97.3%; Score 501; DB 2; Length 123;
Best Local Similarity 96.9%; Pred. No. 5.3e-43;
Matches 95; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGGLEWMGWISAYNGNTNY 60
   |||||
Db 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGGLEWMGWISAYNGNTKY 60
   |||||

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCVR 98
   |||||

RESULT 7
US-09-196-522-165
; Sequence 165, Application US/09196522
; Patent No. 6916605
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Medical Research Council
; APPLICANT: McCafferty, John
; APPLICANT: Pope, Anthony
; APPLICANT: Johnson, Kevin
; APPLICANT: Hoogenboom, Hendricus
; APPLICANT: Griffiths, Andrew
; APPLICANT: Jackson, Ronald
; APPLICANT: Holliger, Kasper
; APPLICANT: Marks, James
; APPLICANT: Clackson, Timothy
; APPLICANT: Chiswell, David
; APPLICANT: Winter, Gregory
; APPLICANT: Bonert, Timothy
; TITLE OF INVENTION: Methods for Producing Members of Specific Binding Pairs
; FILE REFERENCE: 213839-00004
; CURRENT APPLICATION NUMBER: US/09/196,522
; CURRENT FILING DATE: 1998-11-28
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; PRIOR FILING DATE: 1991-03-06
; PRIOR APPLICATION NUMBER: GB 9110549.4
; PRIOR APPLICATION NUMBER: PCT/GB91/01134
; PRIOR FILING DATE: 1991-07-10
; PRIOR APPLICATION NUMBER: US 07/971,857
; PRIOR FILING DATE: 1993-01-08
; PRIOR APPLICATION NUMBER: US 08/484,893
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 272
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 165
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-196-522-165

Query Match      96.5%; Score 497; DB 2; Length 118;
Best Local Similarity 95.9%; Pred. No. 1.3e-42;
Matches 94; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGGLEWMGWISAYNGNTNY 60
   |||||
Db 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGGLEWMGWISAYNGNTKY 60
   |||||

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCVR 98
   |||||

RESULT 6
US-09-726-219A-165
; Sequence 165, Application US/09726219A
; Patent No. 6806079
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Medical Research Council
; APPLICANT: McCafferty, John
; APPLICANT: Pope, Anthony
; APPLICANT: Johnson, Kevin
; APPLICANT: Hoogenboom, Hendricus
; APPLICANT: Griffiths, Andrew
; APPLICANT: Jackson, Ronald
; APPLICANT: Holliger, Kasper
; APPLICANT: Marks, James
; APPLICANT: Clackson, Timothy
; APPLICANT: Chiswell, David
; APPLICANT: Winter, Gregory
; APPLICANT: Bonert, Timothy
; TITLE OF INVENTION: Methods for Producing Members of Specific Binding Pairs
; FILE REFERENCE: 213839-00013
; CURRENT APPLICATION NUMBER: US/09/726,219A
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; PRIOR FILING DATE: 1991-03-06
; PRIOR APPLICATION NUMBER: GB 9110549.4
; PRIOR APPLICATION NUMBER: PCT/GB91/01134
; PRIOR FILING DATE: 1991-07-10
; PRIOR APPLICATION NUMBER: US 07/971,857
; PRIOR FILING DATE: 1993-01-08
; PRIOR APPLICATION NUMBER: US 08/484,893
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 272
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 165
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-726-219A-165

Query Match      96.5%; Score 497; DB 2; Length 118;
Best Local Similarity 95.9%; Pred. No. 1.3e-42;
Matches 94; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
```

RESULT 8
US-08-264-093-3
; Sequence 3, Application US/08264093
; Patent No. 5639863
; GENERAL INFORMATION:
; APPLICANT: Michael D. Dan
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO
; TITLE OF INVENTION: CELL CYCLE-INDEPENDENT GLIOMA SURFACE
; TITLE OF INVENTION: ANTIGEN
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ridout & Maybee
; STREET: 2300 Richmond-Adelaide Centre
; STREET: 101 Richmond Street West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5H 2J7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.4 Mb storage
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: MS-DOS 6.00
; SOFTWARE: ASCII Editor
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/264,093
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA: No. 5639863 applicable
; ATTORNEY/AGENT INFORMATION:
; NAME: Lake, James R.
; REGISTRATION NUMBER: 31081
; REFERENCE/DOCKET NUMBER: NOVOP/106A/7551
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 868-1482
; TELEFAX: (416) 362-0823
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 121 amino acids
; TYPE: amino acid
; STRANDEDNESS: not applicable
; TOPOLOGY: linear
US-08-264-093-3

Query Match 94.2%; Score 485; DB 1; Length 121;
Best Local Similarity 92.9%; Pred. No. 2.1e-41;
Matches 91; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISVWRQAPGGGLEWMMGWISAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGLSVWRQAPGGGLEWMMGWISAHNGNTNS 60

QY 61 AQLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
Db 61 AQLQGRVSMTTDTSTSTAYMEVRSLSRSDDTAVYYCAR 98

RESULT 9
US-10-330-613A-54
; Sequence 54, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudus, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: ABGENIX.022A
; CURRENT APPLICATION NUMBER: US/10/330,613A
; CURRENT FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 54
; LENGTH: 96
; TYPE: PRT

; ORGANISM: Homo sapiens
US-10-330-613A-54

Query Match 93.6%; Score 482; DB 2; Length 96;
Best Local Similarity 96.9%; Pred. No. 3.2e-41;
Matches 95; Conservative 1; Mismatches 0; Indels 2; Gaps 2;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISVWRQAPGGGLEWMMGWISAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTF-SYG-SWVRQAPGGGLEWLGWISAYNGNTNY 58

QY 61 AQLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
Db 59 AQLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 96

RESULT 10
US-09-513-999C-4112
; Sequence 4112, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6783961
; FILE REFERENCE: 59.US2.REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 36681
; SOFTWARE: Patent.pm
; SEQ ID NO 4112
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -19...-1
; OTHER INFORMATION: score 10.8
; OTHER INFORMATION: seq ILFLVAAATGAHS/QV
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 9
; OTHER INFORMATION: Xaa=Ala or Pro
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 31
; OTHER INFORMATION: Xaa=Asn or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 33
; OTHER INFORMATION: Xaa=Asp or Gly
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 35
; OTHER INFORMATION: Xaa=Asn or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 63
; OTHER INFORMATION: Xaa=Asp or Glu or Lys or Asn
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 72
; OTHER INFORMATION: Xaa=Arg or Thr
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 77
; OTHER INFORMATION: Xaa=Lys or Asn or Arg or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 93

```
/ OTHER INFORMATION: Xaa-Ile or Met or Val
/ FEATURE:
/ NAME/KEY: UNSURE
/ LOCATION: 101
/ OTHER INFORMATION: Xaa-Ile or Leu or Val
/ FEATURE:
/ NAME/KEY: UNSURE
/ LOCATION: 103
/ OTHER INFORMATION: Xaa-Ala or Glu or Gly or Val
/ FEATURE:
/ NAME/KEY: UNSURE
/ LOCATION: 104
/ OTHER INFORMATION: Xaa-Leu or Val
US-09-513-999C-4112

Query Match          92.4%; Score 476; DB 2; Length 132;
Best Local Similarity 91.8%; Pred. No. 1.8e-40;
Matches 90; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 20 QVQLVQSGXEVKKPGASVKVSCKASGYTFTYXIXWVRQAPGGQGLEWMGWSAYNGNTNY 79
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

QY 61 AQKLGQRVTMTTDTSTSTAYMELRSRSDDTAVYYCAR 98
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 80 AQKLGQRVTMTXDTSTXTAYMELRSRSDDTAVYYCAR 117
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

RESULT 11
US-09-513-999C-4111
; Sequence 4111, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: 59 US2.REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 36681
; SOFTWARE: Patent.pm
; SEQ ID NO 4111
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -19...-1
; OTHER INFORMATION: score 10.7
; OTHER INFORMATION: seq ILFLVAATGKHS/QV
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: -3
; OTHER INFORMATION: Xaa-Ala or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 9
; OTHER INFORMATION: Xaa-Ala or Pro
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 53
; OTHER INFORMATION: Xaa-Ala or Gly
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 63
; OTHER INFORMATION: Xaa=Glu or Lys
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 64
```

```
/ OTHER INFORMATION: Xaa=Phe or Leu
/ FEATURE:
/ NAME/KEY: UNSURE
/ LOCATION: 72
/ OTHER INFORMATION: Xaa=Arg or Thr
/ FEATURE:
/ NAME/KEY: UNSURE
/ LOCATION: 82
/ OTHER INFORMATION: Xaa=Asp or Glu
/ FEATURE:
/ NAME/KEY: UNSURE
/ LOCATION: 85
/ OTHER INFORMATION: Xaa=Asn or Ser
/ FEATURE:
/ NAME/KEY: UNSURE
/ LOCATION: 98
/ OTHER INFORMATION: Xaa=Lys or Arg
US-09-513-999C-4111

Query Match          91.8%; Score 473; DB 2; Length 120;
Best Local Similarity 91.8%; Pred. No. 3.3e-40;
Matches 89; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 20 QVQLVQSGXEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 79
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

QY 61 AQKLGQRVTMTTDTSTSTAYMELRSRSDDTAVYYCA 97
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 80 AQXXQGRVTMTXDTSTNTAYMXLRLSRSDDTAVYYCA 116
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

RESULT 12
US-09-471-276-849
; Sequence 849, Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A. J.Y.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: GENSET.025CP1
; CURRENT APPLICATION NUMBER: US/09/471,276
; CURRENT FILING DATE: 1999-12-21
; EARLIER APPLICATION NUMBER: 09/057,719
; EARLIER FILING DATE: 1998-04-09
; EARLIER APPLICATION NUMBER: 09/069,047
; EARLIER FILING DATE: 1998-04-28
; EARLIER APPLICATION NUMBER: PCT/IB99/00712
; EARLIER FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 1622
; SOFTWARE: Patent.pm
; SEQ ID NO 849
; LENGTH: 134
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -19...-1
US-09-471-276-849

Query Match          91.8%; Score 473; DB 2; Length 134;
Best Local Similarity 90.8%; Pred. No. 3.7e-40;
Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 20 QVQLVQSGGEVKKPGASVKVSCKASGYTFTRDINWVRQAPGGQGLEWMGWSAXNGNTNY 79
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

QY 61 AQKLGQRVTMTTDTSTSTAYMELRSRSDDTAVYYCAR 98
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
Db 80 AQXVQGRVTMTTDTSTRTAYMELRSRSDDTAVYYCAR 117
   |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
```

```
RESULT 13
US-08-202-047-22
; Sequence 22, Application US/08202047
; Patent No. 5800815
; GENERAL INFORMATION:
; APPLICANT: CHESNUT, Robert W.
; APPLICANT: POLLEY, Margaret J.
; APPLICANT: PAULSON, James C.
; APPLICANT: JONES, S. Tarran
; APPLICANT: SALDANHA, Jose W.
; APPLICANT: BENDIG, Mary M.
; TITLE OF INVENTION: Antibodies to P-Selectin and Their Uses
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESS: Townsend and Townsend Khourie and Crew
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/202,047
; FILING DATE: 25-FEB-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14137-77
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 128 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..128
; OTHER INFORMATION: /label= HUMAN_I
US-08-202-047-22

Query Match      89.8%; Score 462.5; DB 1; Length 128;
Best Local Similarity 89.9%; Pred. No. 4e-39;
Matches 89; Conservative 4; Mismatches 5; Indels 1; Gaps 1;

QY 1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYGISWVRQAPQGGLWGMWISAY-NGNTN 59
Db 1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYAISWVRQAPQGGLWGMWIPYNGNDTN 60

QY 60 YAQKLGQRTVMTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 YAQKFGQRTVITADTSTSTAYMELSLRSDDTAVYYCAR 99

RESULT 14
US-08-964-690-22
; Sequence 22, Application US/08964690
; Patent No. 6033667
; GENERAL INFORMATION:
; APPLICANT: CHESNUT, Robert W.
; APPLICANT: POLLEY, Margaret J.
; APPLICANT: PAULSON, James C.
; APPLICANT: JONES, S. Tarran
```

```
; APPLICANT: SALDANHA, Jose W.
; APPLICANT: BENDIG, Mary M.
; TITLE OF INVENTION: Antibodies to P-Selectin and Their Uses
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESS: Townsend and Townsend Khourie and Crew
; CITY: One Market Plaza, Steuart Tower, Suite 2000
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/964,690
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/202,047
; FILING DATE: 25-FEB-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14137-77
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 128 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..128
; OTHER INFORMATION: /label= HUMAN_I
US-08-964-690-22

Query Match      89.8%; Score 462.5; DB 2; Length 128;
Best Local Similarity 89.9%; Pred. No. 4e-39;
Matches 89; Conservative 4; Mismatches 5; Indels 1; Gaps 1;

QY 1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYGISWVRQAPQGGLWGMWISAY-NGNTN 59
Db 1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYAISWVRQAPQGGLWGMWIPYNGNDTN 60

QY 60 YAQKLGQRTVMTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 YAQKFGQRTVITADTSTSTAYMELSLRSDDTAVYYCAR 99

RESULT 15
US-08-561-521-45
; Sequence 45, Application US/08561521
; Patent No. 5840299
; GENERAL INFORMATION:
; APPLICANT: Bendig, Mary M.
; APPLICANT: Leger, Olivier J.
; APPLICANT: Saldanha, Jose
; APPLICANT: Jones, S. Tarran
; TITLE OF INVENTION: Humanized Antibodies Against Leukocyte
; TITLE OF INVENTION: Adhesion Molecule VLA-4
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESS: Townsend and Townsend Khourie and Crew
; CITY: One Market Plaza, Steuart Tower, Suite 2000
; STATE: California
```



```
;
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/561.521
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/186,269A
; FILING DATE: 25-JAN-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William L.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 15270-14
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-543-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 45:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 129 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-561-521-45

Query Match      89.8%; Score 462.5; DB 1; Length 129;
Best Local Similarity 89.9%; Pred. No. 4.1e-39;
Matches 89; Conservative 4; Mismatches 5; Indels 1; Gaps 1;

Qy      1 QVQLVQSGAEVKKPGASVKSCASGYFTFTSYGISWVRQAPGQGLEWMGHISAY-NGVTN 59
Db      1 QVQLVQSGAEVKKPGASVKSCASGYFTFTSYAISWVRQAPGQGLEWMGHINPYNGDITN 60

Qy      60 YAKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db      61 YAKQFQGRVTITADTSTSTAYMELSLRSEDVAVYYCAR 99
```

Search completed: May 5, 2006, 08:56:25
Job time : 10.7652 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:52 ; Search time 7.42424 Seconds
(without alignments)
610.959 Million cell updates/sec

Title: US-09-674-752-26

Perfect score: 515

Sequence: 1 QVOLVSGAEVKKPGASVKV.....AYMELSLRSDDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications_AA_New*

1: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep:1*
2: /SIDSS5/ptodata/1/pubpaa/US06_NEW_PUB.pep:1*
3: /SIDSS5/ptodata/1/pubpaa/US07_NEW_PUB.pep:1*
4: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep:1*
5: /SIDSS5/ptodata/1/pubpaa/PCT_NEW_PUB.pep:1*
6: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep:1*
7: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep:1*
8: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep:1*
9: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep:1*
10: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep:1*
11: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep:1*
12: /SIDSS5/ptodata/1/pubpaa/US60_NEW_PUB.pep:1*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	515	100.0	98	10	US-11-221-902-55
2	515	100.0	98	11	US-11-054-669-4
3	515	100.0	98	11	US-11-084-554-15
4	515	100.0	98	11	US-11-061-848-17
5	515	100.0	98	11	US-11-004-590-4
6	515	100.0	98	11	US-11-136-250-15
7	515	100.0	125	9	US-10-982-440-45
8	515	100.0	248	11	US-11-054-515-1472
9	515	100.0	248	11	US-11-266-444-1472
10	515	100.0	251	11	US-11-054-515-1562
11	515	100.0	251	11	US-11-054-515-1872
12	515	100.0	251	11	US-11-054-515-1921
13	515	100.0	251	11	US-11-266-444-1562
14	515	100.0	251	11	US-11-266-444-1872
15	515	100.0	251	11	US-11-266-444-1921
16	515	100.0	255	11	US-11-054-515-1190
17	515	100.0	255	11	US-11-266-444-1190
18	515	100.0	259	11	US-11-054-515-1356
19	515	100.0	259	11	US-11-266-444-1356
20	512	99.4	123	9	US-10-982-440-51
21	512	99.4	247	11	US-11-054-515-1873

ALIGNMENTS

RESULT 1

US-11-221-902-55
; Sequence 55, Application US/11221902
; Publication No. US2006008852A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATE
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 55
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-221-902-55

Query Match 100.0%; Score 515; DB 10; Length 98;
Best Local Similarity 100.0%; Pred. No. 7.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
QY 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 2

US-11-054-669-4
; Sequence 4, Application US/11054669
; Publication No. US20050261480A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES
; FILE REFERENCE: 30219/US/3
; CURRENT APPLICATION NUMBER: US/11/054,669
; PRIOR FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: US 10/194,975
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/305,111

Sequence 1873, Ap
Sequence 1425, Ap
Sequence 1425, Ap
Sequence 1878, Ap
Sequence 1878, Ap
Sequence 1871, Ap
Sequence 1871, Ap
Sequence 1586, Ap
Sequence 1870, Ap
Sequence 1586, Ap
Sequence 1870, Ap
Sequence 21, Appl
Sequence 14, Appl
Sequence 1738, Ap
Sequence 1579, Ap
Sequence 1579, Ap
Sequence 1561, Ap
Sequence 1593, Ap
Sequence 1593, Ap
Sequence 1593, Ap
Sequence 1593, Ap
Sequence 1595, Ap
Sequence 1555, Ap

```
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-669-4

Query Match      100.0%; Score 515; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 7.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60

QY 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
DB 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

RESULT 3
US-11-084-554-15
; Sequence 15, Application US/11084554
; Publication No. US20050260679A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A
; CURRENT APPLICATION NUMBER: US/11/084,554
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-084-554-15

Query Match      100.0%; Score 515; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 7.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60

QY 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
DB 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

RESULT 4
US-11-061-848-17
; Sequence 17, Application US/11061848
; Publication No. US20050288491A1
; GENERAL INFORMATION:
; APPLICANT: Wilson, David S.
; APPLICANT: Nock, Steffen
; APPLICANT: Larrick, James W.
; TITLE OF INVENTION: SUPER-HUMANIZED ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS
; FILE REFERENCE: 186280/US
; CURRENT APPLICATION NUMBER: US/11/061,848
; CURRENT FILING DATE: 2005-02-17
; PRIOR APPLICATION NUMBER: US 60/545,011
```

```
; PRIOR FILING DATE: 2004-02-17
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 17
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-061-848-17

Query Match      100.0%; Score 515; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 7.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60

QY 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
DB 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

RESULT 5
US-11-004-590-4
; Sequence 4, Application US/11004590
; Publication No. US20060008883A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hammond, Phillip W.
; TITLE OF INVENTION: METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING
; TITLE OF INVENTION: CONTENT AND COMPOSITIONS THEREOF
; FILE REFERENCE: 185832/US/5
; CURRENT APPLICATION NUMBER: US/11/004,590
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: US 60/527,167
; PRIOR FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: US 60/581,613
; PRIOR FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US 60/601,665
; PRIOR FILING DATE: 2004-08-13
; PRIOR APPLICATION NUMBER: US 60/619,483
; PRIOR FILING DATE: 2004-10-14
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-004-590-4

Query Match      100.0%; Score 515; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 7.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60

QY 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
DB 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

RESULT 6
US-11-136-250-15
; Sequence 15, Application US/11136250
; Publication No. US20060021074A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
```

```

; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A2
; CURRENT APPLICATION NUMBER: US/11/136,250
; CURRENT FILING DATE: 2005-05-23
; PRIOR APPLICATION NUMBER: 11/084,554
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: PCT/US2005/009306
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-136-250-15

```

```

Query Match 100.0%; Score 515; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 7.3e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

```

```

RESULT 7
US-10-982-440-45
; Sequence 45, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 45
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-982-440-45

```

```

Query Match 100.0%; Score 515; DB 9; Length 125;
Best Local Similarity 100.0%; Pred. No. 9.2e-40;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

```

```

RESULT 8
US-11-054-515-1472
; Sequence 1472, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.

```

```

; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1472
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-1472

```

```

Query Match 100.0%; Score 515; DB 11; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

```

```

RESULT 9
US-11-266-444-1472
; Sequence 1472, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1472
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens

```

```

US-11-266-444-1472

Query Match          100.0%; Score 515; DB 11; Length 248;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSKCAGSYTFTSYGISWVRQAPQGQGLEWNGWISAYNGNTNY 60
    |||||
Db 1 QVOLVQSGAEVKKPGASVKVSKCAGSYTFTSYGISWVRQAPQGQGLEWNGWISAYNGNTNY 60
    |||||

Qy 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||

RESULT 10
US-11-054-515-1562
; Sequence 1562, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1562
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1562

Query Match          100.0%; Score 515; DB 11; Length 251;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSKCAGSYTFTSYGISWVRQAPQGQGLEWNGWISAYNGNTNY 60
    |||||
Db 1 QVOLVQSGAEVKKPGASVKVSKCAGSYTFTSYGISWVRQAPQGQGLEWNGWISAYNGNTNY 60
    |||||

Qy 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||

RESULT 11
US-11-054-515-1872
; Sequence 1872, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1562
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1562

Query Match          100.0%; Score 515; DB 11; Length 251;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSKCAGSYTFTSYGISWVRQAPQGQGLEWNGWISAYNGNTNY 60
    |||||
Db 1 QVOLVQSGAEVKKPGASVKVSKCAGSYTFTSYGISWVRQAPQGQGLEWNGWISAYNGNTNY 60
    |||||

Qy 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||

RESULT 11
US-11-054-515-1872
; Sequence 1872, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1562
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1562

Query Match          100.0%; Score 515; DB 11; Length 251;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSKCAGSYTFTSYGISWVRQAPQGQGLEWNGWISAYNGNTNY 60
    |||||
Db 1 QVOLVQSGAEVKKPGASVKVSKCAGSYTFTSYGISWVRQAPQGQGLEWNGWISAYNGNTNY 60
    |||||

Qy 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||

RESULT 11
US-11-054-515-1921
; Sequence 1921, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1562
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1872

Query Match          100.0%; Score 515; DB 11; Length 251;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSKCAGSYTFTSYGISWVRQAPQGQGLEWNGWISAYNGNTNY 60
    |||||
Db 1 QVOLVQSGAEVKKPGASVKVSKCAGSYTFTSYGISWVRQAPQGQGLEWNGWISAYNGNTNY 60
    |||||

Qy 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||

RESULT 12
US-11-054-515-1921
; Sequence 1921, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002
```

```
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1921
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1921

Query Match      100.0%; Score 515; DB 11; Length 251;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

QY 61 AQKLGQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 13
US-11-266-444-1562
; Sequence 1562, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulatc
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1562
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1562

Query Match      100.0%; Score 515; DB 11; Length 251;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

QY 61 AQKLGQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 14
US-11-266-444-1872
; Sequence 1872, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulatc
; FILE REFERENCE: PF523P1D1
```

```
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1872
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1872

Query Match      100.0%; Score 515; DB 11; Length 251;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

QY 61 AQKLGQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 15
US-11-266-444-1921
; Sequence 1921, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1921
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1921

Query Match      100.0%; Score 515; DB 11; Length 251;
Best Local Similarity 100.0%; Pred. No. 1.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
```

Qy 61 AOKLQGRVTMTDTSTSTAYMEIUSIUSDDTAVVYCAR 98
Db 61 AOKLQGRVTMTDTSTSTAYMEIUSIUSDDTAVVYCAR 98

Search completed: May 5, 2006, 09:02:45
Job time : 7.42424 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:51:41 ; Search time 6.43434 Seconds
(without alignments)
1465.455 Million cell updates/sec

Title: US-09-674-752-26

Perfect score: 515

Sequence: 1 QVQLVQSGAEVKKPGASVKV.....AYMELSLRLSDDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR 80.*

1: Piri.*

2: Piri2.*

3: Piri3.*

4: Piri4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	515	100.0	98	2 S26919	Ig heavy chain V r
2	510	99.0	122	2 S36271	Ig heavy chain V r
3	509	98.8	129	2 S36260	Ig heavy chain V r
4	505	98.1	124	2 S19665	Ig heavy chain V r
5	491	95.3	131	2 S21924	Ig heavy chain V r
6	487	94.6	160	2 PL0105	anti-PR2 erythrocy
7	479	93.0	111	2 S21925	Ig heavy chain V r
8	442	85.8	117	2 S18553	Ig heavy chain V r
9	439	85.2	98	2 S26938	Ig heavy chain V r
10	439	85.2	117	2 S31680	Ig heavy chain V r
11	439	85.2	117	2 S18551	Ig heavy chain V r
12	439	85.2	135	2 S49530	anti-Sm antibody V
13	437	84.9	118	2 S36265	Ig heavy chain V r
14	435	84.5	98	2 S26918	Ig heavy chain V r
15	432	83.9	136	2 S31600	Ig heavy chain V r
16	431	83.7	98	2 S26912	Ig heavy chain V r
17	431	83.7	125	2 S68170	Ig heavy chain V r
18	431	83.7	129	2 S46393	Ig heavy chain V r
19	427	82.9	98	2 S26920	Ig heavy chain V r
20	426	82.7	117	2 S18552	Ig heavy chain V r
21	425	82.5	127	2 S34014	Ig heavy chain V r
22	423	82.1	104	2 S69899	Ig heavy chain V r
23	423	82.1	142	2 A32483	Ig heavy chain V r
24	422	81.9	117	1 HVHUG	Ig heavy chain pre
25	421	81.7	116	2 S31667	Ig heavy chain V r
26	420	81.6	123	2 D33548	Ig heavy chain V-1
27	418	81.2	132	2 S31596	Ig heavy chain V r
28	416	80.8	98	2 S24680	Ig heavy chain V1
29	415	80.6	117	1 HVHJ35	Ig heavy chain pre

ALIGNMENTS

RESULT 1

S26919

Ig heavy chain V region (DP-14) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C;Accession: S26919

R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.

J. Mol. Biol. 227, 776-798, 1992

A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of

A;Reference number: S26885; MUID:93021117; PMID:1404388

A;Accession: S26919

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-98 <IOM>

A;Cross-references: UNIPARC:UPI0000031F31; EMBL:Z12316; NID:g32855; PIDN:CAA78186.1; PID

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotrimer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 515; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCASGYTFTSYGISVVRQAPGGQLEWMGWSAYNGNTNY 60

Db 1 QVQLVQSGAEVKKPGASVKVSCASGYTFTSYGISVVRQAPGGQLEWMGWSAYNGNTNY 60

Qy 61 AQKLGQRTVMTTDTSTSTAYMELSLRLSDDTAVYYCAR 98

Db 61 AQKLGQRTVMTTDTSTSTAYMELSLRLSDDTAVYYCAR 98

RESULT 2

S36271

Ig heavy chain V region (clone alpha-THY-29) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999

C;Accession: S36271

R;Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; McCafferty, J.

EMBO J. 12, 725-734, 1993

A;Title: Human anti-self antibodies with high specificity from phage display libraries.

A;Reference number: S36256; MUID:93178448; PMID:7679950

A;Accession: S36271

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-122 <GRI>

A;Cross-references: UNIPARC:UPI0000118DE3; EMBL:Z18832; NID:g33115; PIDN:CAA79284.1; PID

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotrimer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 99.0%; Score 510; DB 2; Length 122;

Best Local Similarity 100.0%; Pred. No. 4.3e-42;
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTKY 60

QY 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA 97
DB 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA 97

RESULT 3
S36260
Ig heavy chain V region (clone alpha-CEA4-8A) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C:Accession: S36260
R:Griffiths, A.D.; Malngqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.
EMBO J. 12, 725-734, 1993
A:Title: Human anti-self antibodies with high specificity from phage display libraries.
A:Reference number: S36256; MUID:93178448; PMID:7679990
A:Accession: S36260
A:Status: preliminary; nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 1-129 <GRI>
A:Cross-references: UNIPARC:UPI0000118DEB; EMBL:Z18851; NID:G33124; PIDN:CAA79303.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.8%; Score 509; DB 2; Length 129;
Best Local Similarity 99.0%; Pred. No. 5.6e-42;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

QY 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA 98
DB 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA 98

RESULT 4
S19665
Ig heavy chain V region (alpha-phOx15) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 28-Oct-1994 #sequence_revision 28-Oct-1994 #text_change 20-Jun-2000
C:Accession: S19665; S24442
R:Marks, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, J. Mol. Biol. 222, 581-597, 1991
A:Title: By-passing immunization. Human antibodies from V-gene libraries displayed on ph
A:Reference number: S19663; MUID:92085276; PMID:1748994
A:Accession: S19665
A:Molecule type: mRNA
A:Residues: 1-124 <MAR>
A:Cross-references: UNIPARC:UPI0000176B80; EMBL:X61647
R:Jones, P.T.
submitted to the EMBL Data Library, October 1991
A:Reference number: S24442
A:Accession: S24442
A:Molecule type: mRNA
A:Residues: 1-40, 'GLSGWDGSAITMTVQSLDK', 61-118, 'T', 120-124 <JON>
A:Cross-references: UNIPARC:UPI0000115FF6; EMBL:X61647; NID:G37667; PIDN:CAA43828.1; PID
A:Note: the difference for residues 41-60 results from misplacement of 10 bases in the s
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.1%; Score 505; DB 2; Length 124;
Best Local Similarity 98.0%; Pred. No. 1.3e-41;
Matches 96; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTKY 60

QY 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA 98
DB 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCVR 98

RESULT 5
S21924
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 23-Jul-1999
C:Accession: S21924; S21923
R:Priedman, D.F.
submitted to the EMBL Data Library, July 1991
A:Reference number: S21923
A:Accession: S21924
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-131 <FRI>
A:Cross-references: UNIPARC:UPI0000115FA2; EMBL:X60505; NID:G33565; PIDN:CAA43025.1; PID:
C:Genetics: 16/1
A:Introns: 16/1
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match 95.3%; Score 491; DB 2; Length 131;
Best Local Similarity 94.9%; Pred. No. 3.1e-40;
Matches 93; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 20 QVOLVPSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSIVTNGDNTY 79

QY 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA 98
DB 80 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA 117

RESULT 6
PL0105
anti-PR2 erythrocyte autoantibody heavy chain precursor - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 31-Mar-1990 #sequence_revision 31-Mar-1990 #text_change 26-Apr-1996
C:Accession: PL0105
R:Silberstein, L.E.; Litwin, S.; Carmack, C.E.
J. Exp. Med. 169, 1631-1643, 1989
A:Title: Relationship of variable region genes expressed by a human B cell lymphoma seque
A:Reference number: PL0106; MUID:89235583; PMID:2541221
A:Accession: PL0105
A:Molecule type: mRNA
A:Residues: 1-160 <SIL>
A:Cross-references: UNIPARC:UPI0000176C7A
A:Note: The authors translated the codon GAC for residues 108 and 109 as Glu
C:Comment: The antibody is one of the cold agglutinins that preferentially bind red blood
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: autoantibody; hemagglutinin
F:1-19/Domain: signal sequence #status predicted <SIG>
F:34-117/Domain: immunoglobulin homology <IMM>
F:49-54/Region: complementarity-determining 1
F:69-84/Region: complementarity-determining 2
F:118-131/Domain: D region <DRG>
F:132-144/Domain: J4 segment <JSG>
F:145-160/Domain: C region <CRG>

Query Match 94.6%; Score 487; DB 2; Length 160;
Best Local Similarity 93.9%; Pred. No. 9.1e-40;
Matches 92; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

```

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGQLEWMGHSAYNGNTNY 60
Db 20 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGQLEWMGHSAYNGNTNY 79

QY 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 80 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 117

RESULT 7
S21925
IG heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 23-Jul-1999
C;Accession: S21925
R;Friedman, D.F.
submitted to the EMBL Data Library, July 1991
A;Reference number: S21923
A;Accession: S21925
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-111 <FRI>
A;Cross-references: UNIPARC:UPI0000115FAL; EMBL:X60503; NID:g33626; PIDN:CAA43023.1; PID
A;Genetics:
A;Introns: 16/1
A;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin

Query Match 93.0%; Score 479; DB 2; Length 111;
Best Local Similarity 100.0%; Pred. No. 3.7e-39;
Matches 92; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGQLEWMGHSAYNGNTNY 60
Db 20 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGQLEWMGHSAYNGNTNY 79

QY 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTA 92
Db 80 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTA 111

RESULT 8
S18553
IG heavy chain V region precursor (VI-3b) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 06-Jun-1997 #text_change 23-Jul-1999
C;Accession: S18553; S24916
R;Shin, E.K.; Matsuda, F.; Nagaoka, H.; Fukita, Y.; Imai, T.; Yokoyama, K.; Soeda, E.; H
EMBO J. 10, 3641-3645, 1991
A;Title: Physical map of the 3' region of the human immunoglobulin heavy chain locus: cl
A;Reference number: S18551; MUID:92037524; PMID:1935893
A;Accession: S18553
A;Status: translation not shown
A;Molecule type: DNA
A;Residues: 1-117 <SHI>
A;Cross-references: UNIPARC:UPI0000176E84; EMBL:X62109
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26916
A;Molecule type: DNA
A;Residues: 20-117 <TOM>
A;Cross-references: UNIPARC:UPI0000116402; EMBL:Z12327; NID:g32871; PIDN:CAA78197.1; PID
C;Genetics:
A;Introns: 16/1
A;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-19/Domain: signal sequence #status predicted <SIG>
F;20-117/Product: Ig heavy chain V region (VI-3b) #status predicted <WAT>
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 85.8%; Score 442; DB 2; Length 117;

```

```

Best Local Similarity 85.7%; Pred. No. 1.4e-35;
Matches 84; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGQLEWMGHSAYNGNTNY 60
Db 20 QVOLVSGAEVKKPGASVKVSKASGYTFTSYAMHWVRQAPGORLEWMGWINAGNGTKY 79

QY 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 80 SQKFQGRVTITRDTSASTAYMELSLRSDDTAVYYCAR 117

RESULT 9
S26938
IG heavy chain V region (DP-75) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 17-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26938
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26938
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-98 <TOM>
A;Cross-references: UNIPARC:UPI000011644A; EMBL:Z14071; NID:g32969; PIDN:CAA78451.1; PID
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, July 1992
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 85.2%; Score 439; DB 2; Length 98;
Best Local Similarity 85.7%; Pred. No. 2.2e-35;
Matches 84; Conservative 3; Mismatches 11; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGQLEWMGHSAYNGNTNY 60
Db 1 QVOLVSGAEVKKPGASVKVSKASGYTFTGYMHWVRQAPGGQLEWMGWINPNSGNTNY 60

QY 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKFGQRVTITRDTSISTAYMELSLRSDDTAVYYCAR 98

RESULT 10
S31680
IG heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31680
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31680
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-117 <CU1>
A;Cross-references: UNIPARC:UPI000011647D; EMBL:Z14213; NID:g37795; PIDN:CAA78582.1; PID
C;Genetics:
A;Introns: 16/1
A;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 85.2%; Score 439; DB 2; Length 117;
Best Local Similarity 85.7%; Pred. No. 2.7e-35;
Matches 84; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGQLEWMGHSAYNGNTNY 60
Db 20 QVOLVSGAEVKKPGASVKVSKASGYTFTSYMHWVRQAPGGQLEWMGWINPNSGNTNY 79

```


Search completed: May 5, 2006, 08:54:49
Job time : 6.43434 sec8

THIS PAGE BLANK (USPTO)

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 02:28:25 ; Search time 77 Seconds
(without alignments)
559.209 Million cell updates/sec

Title: US-09-674-752-26

Perfect score: 515

Sequence: 1 QVQLVSGAEVKKPGASVKV.....AYMELSLRSDDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 52

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 500 summaries

Database :

A_Geneseq_21.*

- 1: Geneseqp1980s.*
- 2: Geneseqp1990s.*
- 3: Geneseqp2000s.*
- 4: Geneseqp2001s.*
- 5: Geneseqp2002s.*
- 6: Geneseqp2003as.*
- 7: Geneseqp2003bs.*
- 8: Geneseqp2004s.*
- 9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	515	100.0	98	3 AAY50952	Aay50952 Human ant
2	515	100.0	98	5 ABG78171	Abg78171 Human Fv
3	515	100.0	98	5 ABG91862	Abg91862 Human ant
4	515	100.0	98	6 ABO27071	Abo27071 Human ger
5	515	100.0	98	7 ADC98824	Adc98824 Germline
6	515	100.0	98	7 ADD05428	Add05428 Anti-MUC1
7	515	100.0	98	7 ADF09899	Adf09899 Antibody
8	515	100.0	98	7 ADF10109	Adf10109 Antibody
9	515	100.0	98	7 ADF10007	Adf10007 VEGF anti
10	515	100.0	98	7 ADF09866	Adf09866 Anti-MUC1
11	515	100.0	98	7 ADK18578	Adk18578 Anti-huma
12	515	100.0	98	7 ADK18932	Adk18932 Anti-huma
13	515	100.0	98	7 ADK18931	Adk18931 Anti-huma
14	515	100.0	98	7 ADK18900	Adk18900 Anti-huma
15	515	100.0	98	7 ADK18902	Adk18902 Anti-huma
16	515	100.0	98	7 ADJ80284	Adj80284 VH gene 1
17	515	100.0	98	9 ADY75289	Ady75289 Protein e
18	515	100.0	98	9 AEA98938	Aea98938 Anti-IFN
19	515	100.0	104	4 ABA40538	Abba40538 Peptide #
20	515	100.0	104	4 ABG55895	Abg55895 Human liv
21	515	100.0	109	8 ADP22378	Adp22378 Human ant
22	515	100.0	109	8 ADP22384	Adp22384 Human ant
23	515	100.0	109	8 ADS12516	Ads12516 Human Vhl
24	515	100.0	117	2 AAR66311	Aar66311 Human imm

25	515	100.0	117	7 ADK18782	Adk18782 Anti-huma
26	515	100.0	118	8 ADJ57857	Adj57857 Heavy var
27	515	100.0	118	8 ADJ57859	Adj57859 Heavy var
28	515	100.0	118	9 ADZ42015	Adz42015 Ig H chai
29	515	100.0	121	9 AEB45964	Aeb45964 Human mon
30	515	100.0	123	9 AEB12766	Aeb12766 Antibody
31	515	100.0	125	6 ABR55813	Abr55813 Heavy cha
32	515	100.0	125	7 ADK18783	Adk18783 Anti-huma
33	515	100.0	125	8 ADK18618	Adk18618 Anti-huma
34	515	100.0	125	8 ADL25452	Adl25452 Human mAb
35	515	100.0	126	7 ADK18930	Adk18930 Anti-huma
36	515	100.0	127	7 ADK18819	Adk18819 Anti-huma
37	515	100.0	127	7 ADK18901	Adk18901 Anti-huma
38	515	100.0	127	7 ADK18607	Adk18607 Anti-huma
39	515	100.0	127	8 ADL25432	Adl25432 Human mAb
40	515	100.0	134	9 ADZ57712	Adz57712 Germline
41	515	100.0	248	5 ABP45461	Abp45461 Human Bly
42	515	100.0	248	7 ADG96288	Adg96288 Single ch
43	515	100.0	251	5 ABP45551	Abp45551 Human Bly
44	515	100.0	251	5 ABP45861	Abp45861 Human Bly
45	515	100.0	251	5 ABP45910	Abp45910 Human Bly
46	515	100.0	251	7 ADG96737	Adg96737 Single ch
47	515	100.0	251	7 ADG96378	Adg96378 Single ch
48	515	100.0	251	7 ADG96688	Adg96688 Single ch
49	515	100.0	255	5 ABP45179	Abp45179 Human Bly
50	515	100.0	255	7 ADG96006	Adg96006 Single ch
51	515	100.0	259	5 ABP45345	Abp45345 Human Bly
52	515	100.0	259	7 ADG96172	Adg96172 Single ch

ALIGNMENTS

RESULT 1

AAY50952
ID AAY50952 standard; protein; 98 AA.

XX AAY50952;

DT 23-MAR-2000 (first entry)

DE Human anti-factor VIII antibody VH clone DP-14 protein #2.

XX Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

KW VH gene.

XX Homo sapiens.

XX WO958680-A2.

PD 18-NOV-1999.

PF 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

PR (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.

PA Voorberg JJ, Van Den Brink EN, Turenhout EAM;

XX WPI; 2000-053102/04.

PT New polynucleotide, polypeptide and antibody useful for diagnosing the presence of neutralizing antibodies against factor VIII and for treatment of hemophilia A patients with these antibodies.

XX Example 4; Fig 4B; 61pp; English.

CC This invention describes a novel polynucleotide (I) (and complements and hybridizable polynucleotides) comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity which has hemostatic activity. (I) is useful a primer or probe for detecting the presence of inhibitory antibodies directed against factor VIII. The

CC polypeptides of the invention and the antibodies generated from them are
CC useful in compositions for neutralizing factor VIII inhibiting antibodies
CC in hemophilia A patients. This sequence represents the human anti-factor
CC VIII antibody clone DP-14 protein which is used in the method of the
CC invention
XX
SQ Sequence 98 AA;
Query Match 100.0%; Score 515; DB 3; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
DB 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
RESULT 2
ABG78171
ID ABG78171 standard; protein; 98 AA.
XX
AC ABG78171;
XX
DT 15-NOV-2002 (first entry)
XX
DE Human Fv molecule hypervariable region related peptide #46.
XX
KW Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.
XX
OS Homo sapiens.
XX
PN WO20025264-A2.
XX
PD 01-AUG-2002.
XX
PF 31-DEC-2001; 2001WO-US049440.
XX
PR 29-DEC-2000; 2000US-00751181.
XX
PA (BIOT-) BIO-TECHNOLOGY GEN CORP.
XX
PI Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;
PI Plaksin D, Peretz T;
XX
DR WPI; 2002-619166/66.
XX
Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
PT or fragment, or construct of fragment with enhanced binding
PT characteristics so as to selectively bind target cell in favor of other
PT cells.
XX
PS Claim 13; Page 169; 232pp; English.
XX
The invention relates to a peptide or polypeptide comprising an Fv
CC molecule, a construct or fragments or a construct of a fragment with
CC enhanced binding characteristics which selectively and/or specifically
CC binds to a target cell in favour of other cells, where binding is
CC primarily determined by a first hypervariable region and Fv is a single
CC chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
CC association with or attached, coupled, combined, linked or fused to a
CC pharmaceutical agent, is useful in the manufacture of a medicament, where
CC the medicament has activity against a diseased cell, preferably a cancer
CC cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
CC composition for use in inhibiting the growth of a diseased or cancer
CC cell. This sequence represents a human Fv molecule hypervariable region

CC related peptide of the invention
XX
SQ Sequence 98 AA;
Query Match 100.0%; Score 515; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
DB 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
RESULT 3
ABG91862
ID ABG91862 standard; protein; 98 AA.
XX
AC ABG91862;
XX
DT 04-DEC-2002 (first entry)
XX
DE Human antibody fragment #46.
XX
KW Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
KW metastasis; hypervariable region; autoimmune disease; thrombosis;
KW restenosis; leukaemia; inflammatory disease; cardiovascular disease;
KW myocardial infarction; retinopathic disease; abnormal platelet function;
KW sulphated tyrosine-dependent protein-protein interaction.
XX
OS Homo sapiens.
XX
PN WO200253700-A2.
XX
PD 11-JUL-2002.
XX
PF 31-DEC-2001; 2001WO-US049442.
XX
PR 29-DEC-2000; 2000US-00751181.
PR 29-DEC-2000; 2000US-0258948P.
XX
PA (BIOT-) BIO-TECHNOLOGY GEN CORP.
XX
PI Lazarovits J, Hagai Y, Plaksin D, Vogel T, Nimrod A, Mar-Haim H;
PI Szanthon E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
XX
DR WPI; 2002-674776/72.
XX
Novel isolated epitope present on cancer cells and important in
PT physiological phenomena such as cell rolling, metastasis and
PT inflammation, for treating autoimmune, inflammatory or cardiovascular
PT diseases, and cancer.
XX
PS Disclosure; Page 246-247; 0pp; English.
XX
The invention relates to an isolated epitope present on cancer cells and
CC important in physiological phenomena such as cell rolling, metastasis and
CC inflammation, where the epitope is capable of being bound by an antibody,
CC its antigen-binding fragment or its complex comprising at least one
CC antibody or its binding fragment having a first hypervariable region. The
CC epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
CC disease, thrombosis, restenosis, metastasis, growth and/or replication of
CC tumour or leukaemia cells, increase in number of tumour or leukaemia
CC cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
CC platelet and/or cell-platelet adhesion or aggregation, for increasing
CC mortality of tumour or leukaemia cells, for increasing the susceptibility
CC of diseased cells to damage by anti-disease, anti-cancer or anti-
CC leukaemia agents, or for decreasing the number of tumour or leukaemia
CC cells in a patient, or in the manufacture of a medicament for the above
CC mentioned purposes. The epitopes are useful for diagnosing and treating


```

Query Match      100.0%; Score 515; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
    |||||
DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
    |||||

QY 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||
DB 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||

RESULT 6
ADD05428
ID ADD05428 standard; protein; 98 AA.
XX
AC ADD05428;
XX
DT 01-JAN-2004 (first entry)
XX
DE Anti-MUC18 antibody heavy chain variable region V1-18 protein, SEQ ID 53.
XX
KW monoclonal antibody; tumour; MUC18; proliferation; cytostatic; vaccine;
KW antigen; tumour metastasis; melanoma; metastatic; human; heavy chain.
XX
OS Unidentified.
XX
PN WO2003057006-A2.
XX
PD 17-JUL-2003.
XX
PF 26-DEC-2002; 2002WO-US041582.
XX
PR 28-DEC-2001; 2001US-0346460P.
XX
PA (ABGE-) ABGENIX INC.
XX
PI Gudas J, Bar-Eli M;
XX
PS WPI; 2003-577496/54.
XX
PT Use of monoclonal antibodies against MUC18 antigen, for diagnosing and
PT treating tumors, inhibiting tumor growth, inhibiting cell invasion
PT associated with melanoma, or increasing survival of an animal having a
PT metastatic tumor.
XX
PS Disclosure; SEQ ID NO 53; 87pp; English.
XX
CC The invention relates to a novel monoclonal antibody used for inhibiting
CC tumour growth in an animal. The tumour inhibition process comprises
CC selecting an animal in need of treatment for a tumour, providing a
CC monoclonal antibody comprising a heavy chain amino acid, where the
CC antibody consists of any one of 10 fully defined sequences of 117-123
CC amino acids given in the specification, and where the monoclonal antibody
CC binds MUC18, and contacting the tumour with the antibody resulting in
CC inhibited proliferation of the cells. The monoclonal antibody has
CC cytostatic and can be used in the production of a vaccine. The monoclonal
CC antibodies against the MUC18 antigen are useful for diagnosing and
CC treating tumors, inhibiting tumour growth (e.g. melanoma, lung tumour or
CC tumour metastasis), inhibiting cell invasion associated with melanoma, or
CC increasing survival of an animal having a metastatic tumour. This
CC sequence represents an anti-MUC18 antibody heavy chain, variable region,
CC protein of the invention.
XX
SQ Sequence 98 AA;

Query Match      100.0%; Score 515; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
    |||||
DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
    |||||

QY 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||
DB 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||

Query Match      100.0%; Score 515; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
    |||||
DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
    |||||

QY 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||
DB 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||

```

```

Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
    |||||
QY 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||
DB 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||

RESULT 7
ADF09899
ID ADF09899 standard; protein; 98 AA.
XX
AC ADF09899;
XX
DT 12-FEB-2004 (first entry)
XX
DE Antibody heavy chain variable region VH_1-18.
XX
KW Antibody; stability; solubility; antigen binding affinity;
KW variable region; human.
XX
OS Homo sapiens.
XX
PN WO2003074679-A2.
XX
PD 12-SEP-2003.
XX
PF 03-MAR-2003; 2003WO-US006598.
XX
PR 01-MAR-2002; 2002US-0360843P.
XX
PR 29-MAY-2002; 2002US-0384197P.
XX
PA (XENC-) XENCOR.
XX
PI Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
XX
PS WPI; 2003-722066/68.
XX
PT Computer optimization of physicochemical properties of antibodies
PT comprises analyzing the interactions of amino acids at variable
PT positions.
XX
PS Disclosure; Fig 2a; 135pp; English.
XX
CC The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC method. The method comprises: receiving a template antibody structure;
CC selecting at least one variable position belonging to the antibody
CC structure; selecting at least one amino acid to be considered at the
CC variable position(s); analyzing the interaction of each selected amino
CC acid at each variable position with at least part of the remainder of the
CC antibody, including the selected amino acids at other variable positions;
CC and identifying a set of at least one antibody sequence with at least one
CC optimized physico-chemical property. The method is useful for optimizing
CC the physico-chemical properties of an antibody, especially the stability,
CC solubility, or antigen binding affinity. The optimized antibody may be
CC useful for treating a patient. The present sequence is an antibody
CC variable region sequence used to illustrate the invention.
XX
SQ Sequence 98 AA;

Query Match      100.0%; Score 515; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
    |||||
DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
    |||||

QY 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||
DB 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
    |||||

```

```

RESULT 8
ADF10109
ID ADF10109 standard; protein; 98 AA.
XX
XX
AC ADF10109;
XX
XX
DT 12-FEB-2004 (first entry)
XX
XX Antibody heavy chain variable region VH_1-18.
DE
XX
XX Antibody; stability; solubility; antigen binding affinity;
KW variable region; human.
XX
XX Homo sapiens.
OS
XX
XX WO2003074679-A2.
PN
XX
XX 12-SEP-2003.
PD
XX
XX 03-MAR-2003; 2003WO-US006598.
PF
XX
XX 01-MAR-2002; 2002US-0360843P.
PR
XX
XX 29-MAY-2002; 2002US-0384197P.
XX
XX (XENC-) XENCOR.
PA
XX
XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
PI
XX WPI; 2003-722066/68.
DR
XX
XX Computer optimization of physicochemical properties of antibodies
PT comprises analyzing the interactions of amino acids at variable
PT positions.
XX
XX Example 16; Fig 40a; 135pp; English.
XX
XX The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC method. The method comprises: receiving a template antibody structure;
CC selecting at least one variable position belonging to the antibody
CC structure; selecting at least one amino acid to be considered at the
CC variable position(s); analyzing the interaction of each selected amino
CC acid at each variable position with at least part of the remainder of the
CC antibody, including the selected amino acids at other variable positions;
CC and identifying a set of at least one antibody sequence with at least one
CC optimized physico-chemical property. The method is useful for optimizing
CC the physico-chemical properties of an antibody, especially the stability,
CC solubility, or antigen binding affinity. The optimized antibody may be
CC useful for treating a patient. The present sequence is an antibody
CC variable region sequence used to illustrate the invention.
XX
XX Sequence 98 AA;
SQ
Query Match 100.0%; Score 515; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

QY 61 AQKLQGRVTMTTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 10
ADF09866
ID ADF09866 standard; protein; 98 AA.
XX
XX ADF09866;
AC
XX
XX 12-FEB-2004 (first entry)
DT
XX
XX Anti-MUC18 monoclonal antibody-related protein #7.
DE
XX
XX cell proliferation inhibition; MUC18 tumour antigen;
KW anti-MUC18 monoclonal antibody; tumour metastasis inhibition; tumour;
KW carcinoma; cancer; malignancy.

```

XX OS Unidentified.
 XX PN WO2003057837-A2.
 XX 17-JUL-2003.
 XX 26-DEC-2002; 2002WO-US041580.
 XX 28-DEC-2001; 2001US-0346414P.
 XX (ABGE-) ABGENIX INC.
 XX PI Gudas J;
 XX DR WPI; 2003-598367/56.
 XX Inhibiting cell proliferation associated with expression of MUC18 tumor
 PT antigen, involves incubating and inhibiting cell by administering anti-
 PT MUC18 monoclonal antibody.
 XX Example 2; SEQ ID NO 53; 83pp; English.
 XX The invention comprises a method for inhibiting cell proliferation
 CC associated with expression of MUC18 tumour antigen. The method involves
 CC administering anti-MUC18 monoclonal antibody. The method of the invention
 CC is useful for inhibiting cell (e.g. melanoma or tumour cell)
 CC proliferation associated with the expression of MUC18 tumour antigen, the
 CC method is preferably useful for inhibiting tumour metastasis. The method
 CC is useful for inhibiting cell proliferation in patients with tumours,
 CC carcinomas, cancer and other malignancies. The present amino acid
 CC sequence is used in an alignment with an MUC18 tumour antigen-specific
 CC monoclonal antibody of the invention.
 XX SQ Sequence 98 AA;
 XX
 Query Match 100.0%; Score 515; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 1.8e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
 DB 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
 QY 61 AQKLGGRVTMTTDTSTSTAYMELRLSRSDDTAVYYCAR 98
 DB 61 AQKLGGRVTMTTDTSTSTAYMELRLSRSDDTAVYYCAR 98
 RESULT 11
 ADK18578
 ID ADK18578 standard; protein; 98 AA.
 AC ADK18578;
 DT 06-MAY-2004 (first entry)
 DE Anti-human PDGF-D antibody Vh 1-18 protein.
 DE antiinflammatory; immunomodulator; cytostatic; gene therapy.
 OS Homo sapiens.
 XX WO2003057857-A2.
 XX 17-JUL-2003.
 XX 06-JAN-2003; 2003WO-US000398.
 XX 07-JAN-2002; 2002US-00041860.
 XX (ABGE-) ABGENIX INC.

PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;
 XX WPI; 2003-587119/55.
 XX New human monoclonal antibody that binds to platelet-derived growth
 PT factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.
 XX Example 7; SEQ ID NO 2; 255pp; English.
 XX The invention relates to a human monoclonal antibody that binds to
 CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 CC treating chronic and recurrent human diseases, such as inflammation,
 CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 CC useful for modulating collagen formation, and for staging various
 CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
 CC sequence corresponds to a protein used in the invention.
 XX SQ Sequence 98 AA;
 XX
 Query Match 100.0%; Score 515; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 1.8e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
 DB 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
 QY 61 AQKLGGRVTMTTDTSTSTAYMELRLSRSDDTAVYYCAR 98
 DB 61 AQKLGGRVTMTTDTSTSTAYMELRLSRSDDTAVYYCAR 98
 RESULT 12
 ADK18932
 ID ADK18932 standard; protein; 98 AA.
 AC ADK18932;
 DT 06-MAY-2004 (first entry)
 DE Anti-human PDGF-D antibody protein related sequence #158.
 DE antiinflammatory; immunomodulator; cytostatic; gene therapy.
 OS Homo sapiens.
 XX WO2003057857-A2.
 XX 17-JUL-2003.
 XX 06-JAN-2003; 2003WO-US000398.
 XX 07-JAN-2002; 2002US-00041860.
 XX (ABGE-) ABGENIX INC.
 XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;
 XX WPI; 2003-587119/55.
 XX New human monoclonal antibody that binds to platelet-derived growth
 PT factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.
 XX Disclosure; SEQ ID NO 356; 255pp; English.
 XX The invention relates to a human monoclonal antibody that binds to


```

RESULT 15
ADK18902
ID ADK18902 standard; protein; 98 AA.
XX
XX ADK18902;
AC
XX
XX 06-MAY-2004 (first entry)
DT
XX
XX Anti-human PDGF-D antibody protein related sequence #128.
DE
XX
XX antinflammatory; immunomodulator; cytostatic; gene therapy.
KW
XX
XX Homo sapiens.
OS
XX
XX WO2003057857-A2.
PN
XX
XX 17-JUL-2003.
PD
XX
XX 06-JAN-2003; 2003WO-US000398.
PF
XX
XX 07-JAN-2002; 2002US-00041860.
PR
XX
XX (ABGE-) ABGENIX INC.
PA
XX
XX Corvalan JRP, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
XX WPI; 2003-587119/55.
DR
XX
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
PT
XX
XX Disclosure; SEQ ID NO 326; 255pp; English.
PS
XX
XX The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
XX Sequence 98 AA;
SQ
Query Match 100.0%; Score 515; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGGLEWGMWISAYNGNTNY 60
Db 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGGLEWGMWISAYNGNTNY 60
QY 61 AQKLGGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
RESULT 16
ADJ80284
ID ADJ80284 standard; protein; 98 AA.
XX
XX ADJ80284;
AC
XX
XX 06-MAY-2004 (first entry)
DT
XX
XX VH gene locus antibody amino acid sequence #4.
DE
XX
XX hybrid antibody; antibody; framework region; homology; immunogenicity.
KW

```

```

XX
OS Homo sapiens.
XX
XX WO2003048321-A2.
PN
XX
XX 12-JUN-2003.
PD
XX
XX 03-DEC-2002; 2002WO-US038450.
PF
XX
XX 03-DEC-2001; 2001US-0336591P.
PR
XX
XX (ALEX-) ALEXION PHARM INC.
PA
XX
XX Rother R, Wu D;
XX
XX WPI; 2003-513753/48.
DR
XX
XX Producing a hybrid antibody or hybrid antibody fragment by operatively
PT linking the selected framework sequences to one or more complementarity
PT determining regions of the initial antibody.
PT
XX
XX Disclosure; SEQ ID NO 44; 77pp; English.
PS
XX
XX The invention relates to a method of producing a hybrid antibody or
CC hybrid antibody fragment by: (i) providing an initial antibody having
CC specificity for a target; (ii) determining the sequence of a variable
CC region of the initial antibody; (iii) selecting a first component of the
CC variable region consisting of FR1, FR2, FR3 and FR4; (iv) comparing the
CC sequence of the first component to sequences contained in a reference
CC database of antibody sequences or antibody fragment sequences from a
CC target species; (v) selecting a sequence from an antibody in the database
CC which demonstrates a high degree of homology to the first component; (vi)
CC selecting a second component of the variable region which is different
CC than the first component, the second component selected from the group
CC consisting of FR1, FR2, FR3 and FR4; (vii) comparing the sequence of the
CC second component to sequences contained in a reference database of
CC antibody sequences or antibody fragment sequences from the target species
CC ; (viii) selecting a sequence from the database which demonstrates a high
CC degree of homology to the second component and which is from a different
CC antibody than the selected antibody; and (ix) operatively linking the
CC selected framework sequences to one or more complementarity determining
CC regions (CDRs) of the initial antibody to produce a hybrid antibody or
CC hybrid antibody fragment. The method is useful for producing a hybrid
CC antibody or hybrid antibody fragment (claimed). The antibody and
CC fragments are useful for therapeutic and diagnostic purposes. The method
CC uses entire framework regions from a single antibody variable heavy or
CC variable light chain to receive the CDRs. This produces antibodies that
CC are highly homologous and exhibit reduced immunogenicity while
CC maintaining an optimum binding profile. This sequence represents the
CC amino acid sequence of an antibody from the VH gene locus.
XX
XX Sequence 98 AA;
SQ
Query Match 100.0%; Score 515; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGGLEWGMWISAYNGNTNY 60
Db 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGGLEWGMWISAYNGNTNY 60
QY 61 AQKLGGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
RESULT 17
ADY75289
ID ADY75289 standard; protein; 98 AA.
XX
XX ADY75289;
AC
XX
XX 02-JUN-2005 (first entry)
DT

```

XX DE Protein encoded by human germline heavy chain V minigene VH1 1-18.
 XX AC
 KW Antibody engineering; antibody; antibody production; gene library;
 KW DNA recombination; gene amplification; primer extension;
 KW heavy chain variable region.
 XX OS
 XX Homo sapiens.
 XX PN WO2005023993-A2.
 XX XX
 XX PD 17-MAR-2005.
 XX XX
 XX PF 09-SEP-2004; 2004WO-US029617.
 XX XX
 XX PR 09-SEP-2003; 2003US-0501073P.
 XX XX
 XX PA (INTE-) INTSGRIGEN INC.
 XX PI Sharma V, Leonard L, Smider V;
 XX XX WPI; 2005-223364/23.
 XX DR
 XX XX
 XX PT Producing polynucleotide encoding human germline antibody V-region for
 PT generating full-length antibody germline V-region genes, by obtaining V
 PT or J minigene and joining V minigene with J minigene, or joining J
 PT minigene with V minigene.
 XX XX
 XX PS Disclosure; Fig 10; 52pp; English.
 XX XX
 CC The present invention relates to producing germline antibody genes by a
 CC completely in vitro approach that mimics the natural process of V(D)J
 CC recombination. The antibody genes are completely human and native in
 CC their sequence, and libraries of such antibody genes can be constructed
 CC which represent an unselected population representing the entire antibody
 CC repertoire. The method uses gene amplification to produce a V minigene,
 CC and a hybrid primer capable of hybridizing to a V minigene and either a D
 CC or V minigene. The hybrid primer facilitates recombination of a V
 CC minigene to a D or J minigene to produce a full length V-region gene.
 CC Also disclosed is a library comprising member polynucleotides encoding
 CC exogenously rearranged human germline antibody V-regions. In producing a
 CC polynucleotide encoding a human germline antibody V-region, a D minigene
 CC is further joined to the 3' end of the V minigene and the 5' end of the J
 CC minigene. The V minigene or the J minigene in is obtained by chemical
 CC synthesis or by amplification from a germline DNA library. Joining the V
 CC minigene with at least one J minigene is performed by primer extension
 CC using at least two or three oligonucleotide primers. The V minigene is
 CC derived from human immunoglobulin kappa locus, human immunoglobulin
 CC lambda locus, or human immunoglobulin heavy chain locus. The V-region
 CC also comprises a serine protease triad. The human germline antibodies can
 CC be used as precursors to more high affinity antibodies, and are useful in
 CC the generation of efficiently pairing libraries of heavy and light
 CC chains. The present sequence is a polypeptide encoded by human germline
 CC heavy chain V minigene, family VH1 locus 1-18.
 XX XX
 SQ Sequence 98 AA;
 Query Match 100.0%; Score 515; DB 9; Length 98;
 Best Local Similarity 100.0%; Pred. NO. 1.8e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
 DB 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
 QY 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
 DB 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
 RESULT 18
 AEA89838
 ID AEA89838 standard; protein; 98 AA.

XX AC AEA89838;
 XX DT 08-SEP-2005 (first entry)
 XX DE Anti-IFN alpha antibody heavy chain variable region 1-18 germline.
 XX XX
 KW interferon alpha; heavy chain variable region; antibody;
 KW systemic lupus erythematosus; multiple sclerosis;
 KW inflammatory bowel disease; insulin-dependent diabetes mellitus;
 KW psoriasis; hashimoto's disease; rheumatoid arthritis; glomerulonephritis;
 KW transplant rejection; graft versus host disease; Dermatological;
 KW immunosuppressive; Antiinflammatory; Neuroprotective;
 KW Gastrointestinal-Gen.; Antipsoriatic; Antidiabetic; Antithyroid;
 KW Antirheumatic; Antiarthritic; Nephrotropic; genitourinary disease;
 KW inflammation; dermatological disease; immune disorder; endocrine disease;
 KW musculoskeletal disease; gastrointestinal disease; metabolic disorder;
 KW neurological disease.
 XX OS Homo sapiens.
 XX PN WO2005059106-A2.
 XX PD 30-JUN-2005.
 XX PF 10-DEC-2004; 2004WO-US041777.
 XX PR 10-DEC-2003; 2003US-0528757P.
 XX XX (MEDA-) MEDAREX INC.
 XX PI Witte A, Williams D, Cardarelli JM, King D, Passmore D;
 XX WPI; 2005-488541/49.
 XX PT Novel isolated anti-interferon alpha monoclonal antibody or its antigen-
 PT binding portion, useful for treating interferon alpha-mediated disease or
 PT disorder e.g. systemic lupus erythematosus.
 XX XX
 PS Example 2; SEQ ID NO 31; 187pp; English.
 XX XX
 CC The invention relates to an isolated anti-interferon alpha monoclonal
 CC antibody (I) or its antigen-binding portion. (I) is useful for inhibiting
 CC the biological activity of interferon alpha. (I) is useful for treating
 CC an interferon alpha-mediated disease or disorder in a subject in need of
 CC treatment. The disease or disorder is systemic lupus erythematosus. The
 CC disease or disorder is chosen from multiple sclerosis, inflammatory bowel
 CC disease, insulin dependent diabetes mellitus, psoriasis, autoimmune
 CC thyroiditis, rheumatoid arthritis and glomerulonephritis. The disease or
 CC disorder is transplant rejection or graft versus host disease. The
 CC present sequence represents the amino acid sequence of the anti-IFN alpha
 CC antibody heavy chain variable region 1-18 germline.
 XX XX
 SQ Sequence 98 AA;
 Query Match 100.0%; Score 515; DB 9; Length 98;
 Best Local Similarity 100.0%; Pred. NO. 1.8e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
 DB 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
 QY 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
 DB 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
 RESULT 19
 ABB40538
 ID ABB40538 standard; peptide; 104 AA.
 XX XX
 AC ABB40538;

```

XX 04-FEB-2002 (first entry)
XX Peptide #8044 encoded by human foetal liver single exon probe.
XX Human; foetal liver; gene expression; single exon nucleic acid probe.
XX Homo sapiens.
XX WO200157277-A2.
XX 09-AUG-2001.
XX 30-JAN-2001; 2001WO-US000669.
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483447/52.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human fetal liver.
XX Claim 27; SEQ ID NO 33173; 639pp + Sequence Listing; English.
XX The invention relates to a single exon nucleic acid probe for measuring
XX human gene expression in a sample derived from human foetal liver. The
XX single exon nucleic acid probes may be used for predicting, measuring and
XX displaying gene expression in samples derived from human fetal liver. The
XX present sequence is a peptide encoded by a single exon nucleic acid probe
XX of the invention. Note: The sequence data for this patent did not form
XX part of the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 104 AA;
XX
Query Match 100.0%; Score 515; DB 4; Length 104;
Best Local Similarity 100.0%; Pred. No. 1.9e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
DB 4 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 63
QY 61 AQKLGGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 64 AQKLGGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 101
RESULT 20
ABG55895
ID ABG55895 standard; peptide; 104 AA.
XX
XX ABG55895;
XX
XX 25-FEB-2003 (first entry)
XX Human liver peptide, SEQ ID No 34543.
XX Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
XX hypercholesterolaemia; coronary heart disease.
XX Homo sapiens.
XX

```

```

PN WO200157273-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488898/53.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human adult liver.
XX Claim 27; SEQ ID NO 34543; 658pp; English.
XX The invention relates to a single exon nucleic acid probe (SENP) (I) for
XX measuring human gene expression in a sample derived from human adult
XX liver, comprising one of 13109 defined nucleotide sequences given in the
XX specification (or complements/ fragments). The probe hybridises at high
XX stringency to a nucleic acid molecule expressed in the human adult liver.
XX (I) may be used for predicting, measuring and displaying gene expression
XX in samples derived from human adult liver. The genes identified may be
XX involved in genetic liver diseases such as cirrhosis,
XX hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX associated with coronary heart disease. ABG47348-ABG59930 represent human
XX liver single exon encoded peptides of the invention. Note: The sequence
XX information for this patent does not appear in the printed specification
XX but was obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX Sequence 104 AA;
XX
Query Match 100.0%; Score 515; DB 4; Length 104;
Best Local Similarity 100.0%; Pred. No. 1.9e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
DB 4 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 63
QY 61 AQKLGGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 64 AQKLGGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 101
RESULT 21
ADP22378
ID ADP22378 standard; protein; 109 AA.
XX
XX ADP22378;
XX
XX 09-SEP-2004 (first entry)
XX Human anti-TNFA antibody heavy chain variable region SEQ ID NO:284.
XX human; monoclonal antibody; tumour necrosis factor-alpha; TNFA;
XX anti-TNFA antibody; anabolic; antiarteriosclerotic; antiarthritic;
XX antibacterial; antiinflammatory; antipsoriatic; antirheumatic;
XX eating-disorder; immunomodulator; immunosuppressive; nephrotropic;
XX neuroprotective; vasotropic; antiapoptotic; TNFA antagonist;
XX TNF induced apoptosis; neoplastic disease; breast cancer; ovarian cancer;
XX bladder cancer; lung cancer; glioblastoma; stomach cancer;
XX endometrial cancer; kidney cancer; colon cancer; pancreatic cancer;

```


KW prostrate cancer; immuno-mediated inflammatory disease;
 KW rheumatoid arthritis; glomerulonephritis; atherosclerosis; psoriasis;
 KW restenosis; autoimmune disease; Crohn's disease; graft-host reaction;
 KW septic shock; cachexia; anorexia; multiple sclerosis.
 XX
 OS Homo sapiens.
 XX
 PN WO2004050683-A2.
 XX
 PD 17-JUN-2004.
 XX
 PF 02-DEC-2003; 2003WO-US038281.
 XX
 PP 02-DEC-2002; 2002US-0430729P.
 XX
 PR (ABGE-) ABGENIX INC.
 XX
 XX Babcock JS, Kang JS, Foord O, Green L, Feng X, Klakamp S;
 PI Haak-Frendscho M, Rathanaswami P, Pigott C, Liang ML, Lee R;
 PI Manchulenchko K, Faggioni R, Senaldi G, Qiaojuan JS;
 XX
 XX WPI; 2004-480601/45.
 DR
 XX New recombinant human monoclonal antibody that specifically binds to
 PT Tumor Necrosis Factor-alpha, useful for treating neoplastic disease such
 PT as cancers, or immuno-mediated inflammatory diseases such as rheumatoid
 PT arthritis.
 XX
 XX Example 10; SEQ ID NO 284; 213pp; English.
 PS
 XX The present invention describes a human monoclonal antibody (I) that
 CC specifically binds to tumour necrosis factor-alpha (TNFa) and comprises:
 CC (a) a heavy chain complementarity determining region 1 (CDR1) having the
 CC two fully defined 5 amino acid sequence (S1, ADP22417) or (S2, ADP22421);
 CC and (b) a light chain CDR1 having the two fully defined 11 amino acid
 CC sequence (S3, ADP22418) or (S4, ADP22424). Also described: (1) assaying
 CC (M1) the level of TNFa in a patient sample, comprising contacting with
 CC (1), and detecting the level of binding between the antibody and TNFa in
 CC the sample; (2) a composition comprising the antibody or its functional
 CC fragment and a carrier; (3) treating (M2) an animal suffering from a
 CC neoplastic, or an immuno-mediated inflammatory disease by selecting an
 CC animal in need of treatment for the disease by administering the human
 CC monoclonal antibody of (I); and (4) inhibiting (M3) TNFa induced
 CC TNFa induced apoptosis by administering the human monoclonal antibody of
 CC (I). (I) has anabolic, antiarteriosclerotic, antiarthritic,
 CC disorders, immunomodulatory, immunosuppressive, nephrotropic,
 CC neuroprotective, vasotropic and antiapoptotic activities, and can be used
 CC as a TNFa antagonist. The antibody (I) is useful in the preparation of
 CC medicament for treating TNF induced apoptosis, neoplastic disease such as
 CC breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma,
 CC stomach cancer, endometrial cancer, kidney cancer, colon cancer,
 CC pancreatic cancer, and prostate cancer; or immuno-mediated inflammatory
 CC diseases such as rheumatoid arthritis, glomerulonephritis,
 CC atherosclerosis, psoriasis, restenosis, autoimmune disease, Crohn's
 CC disease, graft-host reactions, septic shock, cachexia, anorexia, and
 CC multiple sclerosis. The present sequence represents a human anti-TNFA
 CC antibody heavy chain variable region, which is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 109 AA;
 Query Match 100.0%; Score 515; DB 8; Length 109;
 Best Local Similarity 100.0%; Pred. No. 2e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 QVQLVQSGAEVKKPGASVKSCASGYTFTSYGISWVRAPQGQLEWGMHISAYNGNTY 60
 |||||
 Db 1 QVQLVQSGAEVKKPGASVKSCASGYTFTSYGISWVRAPQGQLEWGMHISAYNGNTY 60
 |||||
 Qy 61 AQKLQGRVTWTTDTSTSTAYMELRSLSRDDTAVYCAR 98
 |||||

Db 61 AQKLQGRVTWTTDTSTSTAYMELRSLSRDDTAVYCAR 98
 RESULT 22
 ADP22384
 ID ADP22384 standard; protein; 109 AA.
 XX
 AC ADP22384;
 XX
 DT 09-SEP-2004 (first entry)
 XX
 DE Human anti-TNFA antibody heavy chain variable region SEQ ID NO:290.
 XX
 XX human; monoclonal antibody; tumour necrosis factor-alpha; TNFa;
 KW anti-TNFA antibody; anabolic; antiarteriosclerotic; antiarthritic;
 KW antibacterial; antiinflammatory; antipsoriatic; antirheumatic;
 KW eating-disorder; immunomodulator; immunosuppressive; nephrotropic;
 KW neuroprotective; vasotropic; antiapoptotic; TNFa antagonist;
 KW TNF induced apoptosis; neoplastic disease; breast cancer; ovarian cancer;
 KW bladder cancer; lung cancer; glioblastoma; stomach cancer;
 KW endometrial cancer; kidney cancer; colon cancer; pancreatic cancer;
 KW prostate cancer; immuno-mediated inflammatory disease;
 KW rheumatoid arthritis; glomerulonephritis; atherosclerosis; psoriasis;
 KW restenosis; autoimmune disease; Crohn's disease; graft-host reaction;
 KW septic shock; cachexia; anorexia; multiple sclerosis.
 XX
 OS Homo sapiens.
 XX
 PN WO2004050683-A2.
 XX
 PD 17-JUN-2004.
 XX
 PF 02-DEC-2003; 2003WO-US038281.
 XX
 PR 02-DEC-2002; 2002US-0430729P.
 XX
 XX (ABGE-) ABGENIX INC.
 XX
 XX Babcock JS, Kang JS, Foord O, Green L, Feng X, Klakamp S;
 PI Haak-Frendscho M, Rathanaswami P, Pigott C, Liang ML, Lee R;
 PI Manchulenchko K, Faggioni R, Senaldi G, Qiaojuan JS;
 XX
 XX WPI; 2004-480601/45.
 DR
 XX New recombinant human monoclonal antibody that specifically binds to
 PT Tumor Necrosis Factor-alpha, useful for treating neoplastic disease such
 PT as cancers, or immuno-mediated inflammatory diseases such as rheumatoid
 PT arthritis.
 XX
 XX Example 10; SEQ ID NO 290; 213pp; English.
 PS
 XX The present invention describes a human monoclonal antibody (I) that
 CC specifically binds to tumour necrosis factor-alpha (TNFa) and comprises:
 CC (a) a heavy chain complementarity determining region 1 (CDR1) having the
 CC two fully defined 5 amino acid sequence (S1, ADP22417) or (S2, ADP22421);
 CC and (b) a light chain CDR1 having the two fully defined 11 amino acid
 CC sequence (S3, ADP22418) or (S4, ADP22424). Also described: (1) assaying
 CC (M1) the level of TNFa in a patient sample, comprising contacting with
 CC (1), and detecting the level of binding between the antibody and TNFa in
 CC the sample; (2) a composition comprising the antibody or its functional
 CC fragment and a carrier; (3) treating (M2) an animal suffering from a
 CC neoplastic, or an immuno-mediated inflammatory disease by selecting an
 CC animal in need of treatment for the disease by administering the human
 CC monoclonal antibody of (I); and (4) inhibiting (M3) TNFa induced
 CC TNFa induced apoptosis by administering the human monoclonal antibody of
 CC (I). (I) has anabolic, antiarteriosclerotic, antiarthritic,
 CC disorders, immunomodulatory, immunosuppressive, nephrotropic,
 CC neuroprotective, vasotropic and antiapoptotic activities, and can be used
 CC as a TNFa antagonist. The antibody (I) is useful in the preparation of
 CC medicament for treating TNF induced apoptosis, neoplastic disease such as
 CC breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma,
 CC stomach cancer, endometrial cancer, kidney cancer, colon cancer,
 CC pancreatic cancer, and prostate cancer; or immuno-mediated inflammatory
 CC diseases such as rheumatoid arthritis, glomerulonephritis,
 CC atherosclerosis, psoriasis, restenosis, autoimmune disease, Crohn's
 CC disease, graft-host reactions, septic shock, cachexia, anorexia, and
 CC multiple sclerosis. The present sequence represents a human anti-TNFA
 CC antibody heavy chain variable region, which is used in the
 CC exemplification of the present invention.
 XX

CC stomach cancer, endometrial cancer, kidney cancer, colon cancer,
 CC pancreatic cancer, and prostate cancer; or immuno-mediated inflammatory
 CC diseases such as rheumatoid arthritis, glomerulonephritis,
 CC atherosclerosis, psoriasis, restenosis, autoimmune disease, Crohn's
 CC disease, graft-host reactions, septic shock, cachexia, anorexia, and
 CC multiple sclerosis. The present sequence represents a human anti-TNFA
 CC antibody heavy chain variable region, which is used in the
 CC exemplification of the present invention.

XX
 SQ Sequence 109 AA;

Query Match 100.0%; Score 515; DB 8; Length 109;
 Best Local Similarity 100.0%; Pred. No. 2e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGLEWGMWISAYNGNTNY 60
 DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGLEWGMWISAYNGNTNY 60
 QY 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
 DB 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

RESULT 23
 ADS12516
 ID ADS12516 standard; protein; 109 AA.
 XX
 AC ADS12516;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human Vhl_DP-14_1-18 germline antibody protein Seq 147.
 XX
 KW human; antibody; insulin-like growth factor I receptor; IGF-IR;
 KW somatomedin-C; cancer; inflammation; pathological liver condition;
 KW cytostatic; antiinflammatory; hepatotropic; gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO2004083248-A1.
 XX
 PD 30-SEP-2004.
 XX
 PF 04-MAR-2004; 2004WO-IB000646.
 XX
 PR 14-MAR-2003; 2003US-0455094P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Morton PA, Arbuckle JA, Bailey KJ, Nicastro PJ, Runnels HA;
 XX
 DR WPI; 2004-691024/67.
 XX
 PT New antibody that specifically binds to insulin-like growth factor I
 PT receptor for diagnosing or treating cancer, inflammation or pathological
 PT liver conditions.
 XX
 PS Disclosure; SEQ ID NO 147; 258pp; English.
 XX
 CC This invention relates to a novel antibody or its antigen binding portion
 CC that binds to the insulin-like growth factor I receptor (IGF-IR), also
 CC known as somatomedin-C, in order to inhibit binding of IGF-I and IGF-II
 CC to the receptor (IGF-IR). Specifically, it refers to an IGF-IR antibody
 CC selected from PINT-6A1, PINT-7A2, PINT-7A4, PINT-7A5, PINT-7A6, PINT-8A1,
 CC PINT-9A2, PINT-11A1, PINT-11A2, PINT-11A3, PINT-11A4, PINT-11A5, PINT-
 CC 11A7, PINT-11A12, PINT-12A1, PINT-12A2, PINT-12A3, PINT-12A4, and PINT-
 CC 12A5 or fragments derived thereof. The present invention describes an
 CC isolated cell line (and non-human transgenic animals) useful for
 CC expressing nucleic acid molecules that encode at least one variable light
 CC (VL) and at least one variable heavy (VH) chain antibody regions, as well
 CC as the pharmaceutical compositions derived thereof. Accordingly, it
 CC provides a method of diagnosing the presence or location of an IGF-IR-

CC expressing tissue, a method for treating diseases such as cancer, as well
 CC as diagnosing or treating inflammation and other pathological liver
 CC conditions. As such, these compositions exhibit cytostatic,
 CC antiinflammatory and hepatotropic activities and can be used for gene
 CC therapy purposes. This polypeptide sequence is a human germline IGF-IR
 CC antibody protein of the invention.

XX
 SQ Sequence 109 AA;

Query Match 100.0%; Score 515; DB 8; Length 109;
 Best Local Similarity 100.0%; Pred. No. 2e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGLEWGMWISAYNGNTNY 60
 DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGLEWGMWISAYNGNTNY 60
 QY 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
 DB 61 AQKLGQRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

RESULT 24
 AAR66311
 ID AAR66311 standard; protein; 117 AA.
 XX
 AC AAR66311;
 XX
 DT 25-MAR-2003 (revised)
 DT 03-AUG-1995 (first entry)
 XX
 DE Human immunoglobulin variable heavy chain #17.
 XX
 KW Primer; PCR; amplify; human; immunoglobulin; variable; heavy chain;
 KW cosmid; placenta; vector; pUB81; E.coli; mammalian.
 XX
 OS Homo sapiens.
 XX
 PN WO9426895-A1.
 XX
 PD 24-NOV-1994.
 XX
 PF 10-MAY-1993; 93WO-JP000603.
 XX
 PR 10-MAY-1993; 93WO-JP000603.
 XX
 PA (NIBS) JAPAN TOBACCO INC.
 XX
 PI Honjo T, Matsuda F;
 XX
 DR WPI; 1995-006791/01.
 DR N-PSDB; AAR78956.
 XX
 PT DNA fragment comprising human immunoglobulin Vh genes - for the
 PT production of human immunoglobulin in mammalian hosts.
 XX
 PS Claim 27; Page 54-55; 130pp; Japanese.
 XX
 CC Protein sequences (AAR66295-51) are novel human immunoglobulin heavy
 CC chain sequences encoded by novel isolated genes. The genes (AAR78939-
 CC 79002) were isolated and cloned from a series of cosmid constructions: Y202;
 CC Y103; Y21; Y61;24; 3-31; M84; M18 and M131, by PCR amplification using
 CC primers AAR78917-38. The genes are subdivided into 5 families of Vh
 CC genes. The fragments cover a region of 800 kb. The DNA fragments were
 CC isolated from high molecular weight DNA from human placenta. The DNA was
 CC partially digested with Taqi restriction enzyme. The fragments were
 CC separated by gel electrophoresis and 35-45 kb fractions were collected.
 CC The fragments were ligated with ClaI-digested cosmid vector pUB81. The
 CC ligation products were in vitro packed and infected into E.coli 490A. The
 CC fragments were then subcloned by colony hybridisation. The Vh genes and
 CC the DNA fragments encoding them are useful in producing human
 CC immunoglobulin in mammalian hosts. (Updated on 25-MAR-2003 to correct PN
 CC field.)

XX SQ Sequence 117 AA;

Query Match 100.0%; Score 515; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISVWRQAPGGQLEWMGWISAYNGNTNY 60
Db 20 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISVWRQAPGGQLEWMGWISAYNGNTNY 79

Qy 61 AQKLGQRVTMTDTSTSTAYMELRSLRSDDTAVVYCAR 98
Db 80 AQKLGQRVTMTDTSTSTAYMELRSLRSDDTAVVYCAR 117

RESULT 25
ADK18782
ID ADK18782 standard; protein; 117 AA.
AC ADK18782;
DT 06-MAY-2004 (first entry)
XX Anti-human PDGF-D antibody protein related sequence #8.
XX antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX Homo sapiens.
XX WO2003057857-A2.
XX 17-JUL-2003.
XX 06-JAN-2003; 2003WO-US000398.
XX 07-JAN-2002; 2002US-00041860.
XX (ABGE-) ABGENIX INC.
XX Corvalan JRE, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX WPI; 2003-587119/55.
XX New human monoclonal antibody that binds to platelet-derived growth factor-D (PDGF-D), useful for treating chronic and recurrent human diseases, such as inflammation, autoimmunity and cancer.
XX Disclosure; SEQ ID NO 206; 255pp; English.
XX The invention relates to a human monoclonal antibody that binds to platelet-derived growth factor-D (PDGF-D). The antibodies are useful for treating chronic and recurrent human diseases, such as inflammation, autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are useful for modulating collagen formation, and for staging various cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were generated using an active protein fragment of the gene product from the clone 30664188.0.99 arising in the conditioned medium obtained when HBK293 cells are transfected with the plasmid pCBP4/Sec-30664188. This sequence corresponds to a protein used in the invention.
XX Sequence 117 AA;
Query Match 100.0%; Score 515; DB 7; Length 117;
Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISVWRQAPGGQLEWMGWISAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISVWRQAPGGQLEWMGWISAYNGNTNY 60

Qy 61 AQKLGQRVTMTDTSTSTAYMELRSLRSDDTAVVYCAR 98

Db 61 AQKLGQRVTMTDTSTSTAYMELRSLRSDDTAVVYCAR 98

RESULT 26
ADJ57857
ID ADJ57857 standard; protein; 118 AA.
AC ADJ57857;
DT 06-MAY-2004 (first entry)
XX Heavy variable sequence of K53.
XX Cytostatic; Immunosuppressive; Antibacterial; Virucide; Fungicide; Antiparasitic; auto-immune disease; cancer; neoplastic disorder; leukemia.
XX Synthetic.
XX WO2004009618-A2.
XX 29-JAN-2004.
XX 15-JUL-2003; 2003WO-EP007690.
XX 18-JUL-2002; 2002EP-00077953.
XX 18-JUL-2002; 2002US-0397066P.
XX 27-MAY-2003; 2003WO-EP050201.
XX (CRUC-) CRUCELL HOLLAND BV.
XX Van Berkel PHC, Brus RHP, Bout A, Logtenberg T;
XX WPI; 2004-132914/13.
XX N-PSDB; ADJ57856.
XX Producing mixture of antibodies in recombinant host comprises expressing nucleic acid sequence(s) encoding light chain and three different heavy chains capable of pairing with light chain in recombinant host cell.
XX Disclosure; SEQ ID NO 8; 186pp; English.
XX The present invention relates to producing a mixture of antibodies in a recombinant host comprises expressing in a recombinant host cell a nucleic acid sequence or nucleic acid sequences encoding a light chain and at least three different heavy chains that are capable of pairing with a light chain. The method is useful for producing a mixture of antibodies in a recombinant host, is useful for the preparation of a medicament for use in the treatment or diagnosis of a disease or disorder in a human or animal. The antibodies are useful for treating auto-immune disease and cancer such as solid tumors of the brain, head and neck, breast, prostate, colon, lung, etc., hematologic tumors such as B-cell tumors, neoplastic disorders such as leukemia, lymphoma, sarcoma, carcinoma, neural cell tumors, myelomas, melanomas, neuroblastomas, etc, and are also useful for treating graft-versus-host rejections, infectious diseases due to pathogenic bacteria such as multidrug resistant *Staphylococcus aureus*, fungi such as *Candida albicans*, as prophylaxis against viruses such as rabies virus, for treating or preventing disease caused by adenoviruses, respiratory syncytium virus, and for treating diseases caused by unicellular or multicellular parasites. The method enables exploring many combinations simultaneously, where the combinations include the presence of bispecific antibodies in the produced mixture. The present sequence represents the heavy variable sequence of K53.
XX Sequence 118 AA;
Query Match 100.0%; Score 515; DB 8; Length 118;
Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISVWRQAPGGQLEWMGWISAYNGNTNY 60

```
|||||
Db 1 QVOLVSGAEVKPGASVKSCASGYTFTSYGISWVRQAPGQGLEWMGHSAYNGNTNY 60
QY 61 AQKLGQRVTMTDTSTSTAYMELRSLSDDTAVYYCAR 98
Db 61 AQKLGQRVTMTDTSTSTAYMELRSLSDDTAVYYCAR 98

RESULT 27
ID ADJ57859
XX AC ADJ57859;
XX DT 06-MAY-2004 (first entry)
XX DE Heavy variable sequence of 02-237.
XX KW Cytostatic; Immunosuppressive; Antibacterial; Virucide; Fungicide;
XX KW Antiparasitic; auto-immune disease; cancer; neoplastic disorder;
XX KW leukemia.
XX OS Synthetic.
XX PN WO2004009618-A2.
XX PD 29-JAN-2004.
XX PF 15-JUL-2003; 2003WO-EP007690.
XX PR 18-JUL-2002; 2002EP-00077953.
XX PR 18-JUL-2002; 2002US-0397066P.
XX PR 27-MAY-2003; 2003WO-EP050201.
XX PA (CRUC-) CRUCELL HOLLAND BV.
XX PI Van Berkel PHC, Brus RHP, Bout A, Logtenberg T;
XX WPi; 2004-132914/13.
XX DR N-PSDB; ADJ57858.
XX PT Producing mixture of antibodies in recombinant host comprises expressing
XX PT nucleic acid sequence(s) encoding light chain and three different heavy
XX PT chains capable of pairing with light chain in recombinant host cell.
XX PS Disclosure; SEQ ID NO 10; 186pp; English.
XX CC The present invention relates to producing a mixture of antibodies in a
XX CC recombinant host comprises expressing in a recombinant host cell a
XX CC nucleic acid sequence or nucleic acid sequences encoding a light chain
XX CC and at least three different heavy chains that are capable of pairing
XX CC with a light chain. The method is useful for producing a mixture of
XX CC antibodies in a recombinant host, is useful for the preparation of a
XX CC medicament for use in the treatment or diagnosis of a disease or disorder
XX CC in a human or animal. The antibodies are useful for treating auto-immune
XX CC disease and cancer such as solid tumors of the brain, head and neck,
XX CC breast, prostate, colon, lung, etc., hematologic tumors such as B-cell
XX CC tumors, neoplastic disorders such as leukemia, lymphoma, sarcoma,
XX CC carcinoma, neural cell tumors, myelomas, melanomas, neuroblastomas, etc.
XX CC and are also useful for treating graft-versus-host rejections, infectious
XX CC diseases due to pathogenic bacteria such as multidrug resistant
XX CC Staphylococcus aureus, fungi such as Candida albicans, as prophylaxis
XX CC against viruses such as rabies virus, for treating or preventing disease
XX CC caused by adenoviruses, respiratory syncytium virus, and for treating
XX CC diseases caused by unicellular or multicellular parasites. The method
XX CC enables exploring many combinations simultaneously, where the
XX CC combinations include the presence of bispecific antibodies in the
XX CC produced mixture. The present sequence represents the heavy variable
XX CC sequence 118 AA;
XX SQ Query Match 100.0%; Score 515; DB 8; Length 118;

Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVSGAEVKPGASVKSCASGYTFTSYGISWVRQAPGQGLEWMGHSAYNGNTNY 60
Db 1 QVOLVSGAEVKPGASVKSCASGYTFTSYGISWVRQAPGQGLEWMGHSAYNGNTNY 60
QY 61 AQKLGQRVTMTDTSTSTAYMELRSLSDDTAVYYCAR 98
Db 61 AQKLGQRVTMTDTSTSTAYMELRSLSDDTAVYYCAR 98

RESULT 28
ID ADZ42015 standard; peptide; 118 AA.
XX AC ADZ42015;
XX DT 30-JUN-2005 (first entry)
XX DE Ig H chain variable region, B-CLL set V1c peptide #1.
XX KW Antibody; antibody engineering; antibody therapy;
XX KW light chain variable region; heavy chain variable region;
XX KW chronic lymphocytic leukemia; cytostatic; Hodgkins disease; lymphoma;
XX KW Burkitts lymphoma; multiple myeloma; systemic lupus erythematosus;
XX KW antinflammatory; dermatological; immunosuppressive; myaschenia gravis;
XX KW muscular-gen.; neuroprotective; Graves disease; antithyroid;
XX KW insulin dependent diabetes; diabetes mellitus; antidiabetic;
XX KW autoimmune hemolytic anemia; antianemic.
XX OS Homo sapiens.
XX PN WO2005034733-A2.
XX PD 21-APR-2005.
XX PF 08-OCT-2004; 2004WO-US033176.
XX PR 08-OCT-2003; 2003US-0509473P.
XX PA (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.
XX PI Mesemer BT, Chiorazzi N, Albesiano E;
XX WPi; 2005-306220/31.
XX PT New isolated and purified preparation of light chain and heavy chain
XX PT antibody genes, useful for diagnosing, preventing or treating B cell
XX PT chronic lymphocytic leukemia, or in screening for agents that may treat
XX PT such disease.
XX PS Disclosure; Fig 2; 58pp; English.
XX CC The new invention relates to combinations of light chain antibody genes
XX CC and heavy chain antibody genes, useful for treating B cell chronic
XX CC lymphocytic leukemia (B-CLL). B-CLL is a disease of slowly proliferating
XX CC CD5+ B lymphocytes. These cells express low levels of surface membrane Ig
XX CC that serves as the receptor for antigen (BCR). Analysis of V region gene
XX CC cassette usage has shown that distribution of variable region gene
XX CC increased frequency of VH3-07, VH4-34, and VH1-69 genes. This implies
XX CC that the structure of the antibody molecule, and antigen specificity,
XX CC play a role in the leukemic transformation of particular B cells. The
XX CC present invention discloses that a significant proportion of B-CLL
XX CC patients with aggressive disease share the same classes of VH, D, JH, VL
XX CC and JH antibody genes, forming sets of patients with highly homologous B
XX CC cell receptors. Alternatively, the patients have a disorder selected from
XX CC Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, myeloma or
XX CC systemic lupus erythematosus, myasthenia gravis, Grave's disease, type I
XX CC diabetes mellitus, autoimmune peripheral neuropathy, and autoimmune
XX CC hemolytic anemia. The new members of the antibody genes are: VH4-39/D6-
XX CC 13/JH5/VLkappa012/2/JLkappa1/kappa2 (Set I); VH4-34/D5-
```

```
CC 5/JH6/VLkappaA17/JLkappa1/kappa2 (Set II); VH3-
CC 21/JH6/VLlambdA3h/JLlambdA3 (Set III); VH1-69/D3-
CC 16/JH3/VLkappaA27/JLkappa1/kappa4 (Set IV); VH1-69/D3-
CC 10/JH6/VLlambdA1c/JLlambdA1 (Set V); VH1-02/D6-
CC 19/JH4/VLkappaA012/2/JLkappa1/kappa2 (Set VIa); VH1-03/D6-
CC 19/JH4/VLkappaA012/2/JLkappa1/kappa2 (Set VIb); VH1-18/D6-
CC 19/JH4/VLkappaA012/2/JLkappa1/kappa2 (Set VIc); VH1-46/D6-19/JH4
CC 51/D6-19/JH4/VLkappaA012/2/JLkappa2 (Set VIe); VH1-69/D3-
CC 3/JH4/VLkappaA19/JLkappa4 (Set VII); and VH1-69/D2-
CC 2/JH6/VLkappaA16/2/JLkappa3 (Set VIII). Treating a patient having B-CLL
CC with the above genes comprises administering an agent that binds to the
CC antigen-binding region of an antibody encoded by the antibody genes. The
CC agent is an anti-idiotypic antibody, a peptide antigen, or an aptamer. The
CC present sequence is an Ig H chain variable region, B-CLL set VIC peptide.
XX
SQ Sequence 118 AA;
Query Match 100.0%; Score 515; DB 9; Length 118;
Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Qy 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
RESULT 29
AEB45964
ID AEB45964 standard; protein; 121 AA.
XX AEB45964;
XX
XX 06-OCT-2005 (first entry)
XX Human monoclonal anti-MadCAM antibody related protein #8.
XX Monoclonal antibody; mucosal addressin cell adhesion molecule; MadCAM;
KW inflammation; inflammatory bowel disease; Crohn's disease;
KW ulcerative colitis; diverticular disease; gastritis; liver disease;
KW primary biliary cirrhosis; primary sclerosing cholangitis;
KW insulin dependent diabetes; graft versus host disease; antiinflammatory;
KW gastrointestinal-gen.; antiulcer; hepatototropic; antidiabetic;
KW immunosuppressive; antibody.
XX
XX Homo sapiens.
XX
XX WO2005067620-A2.
XX
XX 28-JUL-2005.
XX
XX 07-JAN-2005; 2005WO-US000370.
XX
XX 09-JAN-2004; 2004US-0535490P.
XX
XX (PFIZ) PFIZER INC.
XX (ABGE-) ABGENIX INC.
XX (PFIZ) PFIZER LTD.
XX
XX Pullen N, Molloy E, Kellermann S, Green LL, Haak-Frendescho M;
XX WPI; 2005-554958/56.
XX
XX New antibody to Mucosal Addressin Cell Adhesion Molecule, useful for
XX diagnosing and treating an inflammatory disease, e.g. inflammatory bowel
XX disease, ulcerative colitis, gastritis, insulin-dependent diabetes or
XX graft versus host disease.
XX
XX Example 5; Fig 1; 167pp; English.
XX
```

```
CC The invention relates to a human monoclonal antibody or its antigen-
CC binding portion that specifically binds to mucosal addressin cell
CC adhesion molecule (MadCAM). The invention also relates to a hybridoma
CC cell line that produces the human monoclonal antibody, a pharmaceutical
CC composition comprising an amount of the monoclonal antibody or its
CC antigen-binding portion and a pharmaceutical carrier, a method of
CC treating inflammatory disease in a subject, an isolated cell line that
CC produces the monoclonal antibody or its antigen-binding portion or the
CC heavy chain or light chain of the antibody or of its portion, an isolated
CC nucleic acid molecule comprising a nucleotide sequence encoding the heavy
CC chain or its antigen-binding portion or the light chain or its antigen-
CC binding portion of an antibody described above, a vector comprising the
CC nucleic acid molecule, where the vector optionally comprises an
CC expression control sequence operably linked to the nucleic acid molecule,
CC a host cell comprising the vector or the nucleic acid molecule above, a
CC method of producing a human monoclonal antibody or its antigen-binding
CC portion that specifically binds MadCAM, a method of isolating an antibody
CC or its antigen-binding portion that specifically binds to MadCAM, a
CC method of treating a subject in need of a human antibody or its antigen-
CC binding portion that specifically binds to MadCAM and inhibits binding to
CC alpha4beta7, a method of inhibiting alpha4beta7 binding to cells
CC expressing human MadCAM, a method of inhibiting MadCAM-mediated leukocyte
CC -endothelial cell adhesion, migration and infiltration into tissues, a
CC method of inhibiting alpha4beta7/MadCAM-dependent cellular adhesion,
CC inhibiting the MadCAM-mediated recruitment of lymphocytes to
CC gastrointestinal lymphoid tissue, a method of diagnosing a disorder
CC characterized by circulating soluble human MadCAM and detecting
CC inflammation in a subject. The antibody, composition and methods are
CC useful for diagnosing and treating inflammatory disease, e.g.
CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC diverticular disease, gastritis, liver disease, primary biliary
CC cirrhosis, primary sclerosing cholangitis, insulin dependent diabetes and
CC graft versus host disease. This sequence represents a human monoclonal
CC anti-MadCAM antibody related protein of the invention.
XX
SQ Sequence 121 AA;
Query Match 100.0%; Score 515; DB 9; Length 121;
Best Local Similarity 100.0%; Pred. No. 2.3e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Qy 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
RESULT 30
AEB12766
ID AEB12766 standard; protein; 123 AA.
XX AEB12766;
XX
XX 08-SEP-2005 (first entry)
XX
XX Antibody 92N heavy chain variable region SEQ ID NO 14.
XX
XX virucide; respiratory-gen.; vaccine; monoclonal antibody;
XX antibody production; diagnosis; therapeutic;
XX Severe acute respiratory syndrome; sars coronavirus infection; antiviral;
XX respiratory disease; infection; single chain antibody; 92N;
XX heavy chain variable region.
XX
XX Homo sapiens.
XX
XX WO2005060520-A2.
XX
XX 07-JUL-2005.
XX
XX 24-NOV-2004; 2004WO-US039750.
XX
```

XX
PR 25-NOV-2003; 2003US-0524840P.
XX
PA (DAND) DANA FARBER CANCER INST INC.
XX
PI Marasco W, Sui J;
XX
DR WPI; 2005-488568/49.
XX
XX Novel monoclonal or scFv antibody capable of binding to epitope on region
PT of spike protein of severe acute respiratory syndrome coronavirus (SARS-
PT Cov) and neutralizing SARS-Cov, useful for treating SARS-Cov infection.
XX
XX
PS Example 2; SEQ ID NO 14; 93pp; English.
XX
CC The invention describes a monoclonal antibody (I) capable of neutralizing
CC SARS-Cov, binding to an epitope on a region of the spike protein of SARS-
CC Cov and neutralizing SARS-Cov, or an scFv antibody (II) capable of
CC neutralizing SARS-Cov, binding to an epitope on a region of the spike
CC protein of SARS-Cov and neutralizing SARS-Cov. Also described are:
CC vaccinating (M1) a patient against SARS-Cov; a composition (III)
CC comprising (I) and a carrier; a kit (IV) comprising (III) in one or more
CC containers; a passive vaccine (V) against SARS-Cov, comprising (III);
CC screening (M2) for compounds that modulate the interaction between SARS-
CC Cov and the SARS-Cov receptor ACE2; and enhancing (M3) the neutralization
CC activity of MAb or scFv 80R. (I) or (II) is useful for preventing a
CC disease or disorder caused by a coronavirus. (I) or (II) is useful for
CC treating a coronavirus-related disease or disorder. (I) is useful for
CC diagnosing a coronavirus-related disease or disorder. The coronavirus-
CC related disease or disorder is SARS. (I) is useful for detecting the
CC presence of a coronavirus in a sample, which involves contacting the
CC sample with (I), and detecting the presence or absence of an antibody-
CC antigen complex, thus detecting the presence of a coronavirus in a
CC sample. (I) is useful for identifying compounds useful to treat a SARS-
CC Cov-related disease or disorder. The at least one SARS-Cov protein is
CC provided as a SARS-Cov molecule. The at least one SARS-Cov protein is
CC provided in a cell infected with the SARS-Cov (M1) is useful for
CC vaccinating a patient against SARS-Cov. This is the amino acid sequence
CC of anti-SARS-Cov spike protein N-terminal single chain (scFv) antibody
CC 92N heavy chain variable region.
XX
XX
SQ Sequence 123 AA;

Query Match 100.0%; Score 515; DB 9; Length 123;
Best Local Similarity 100.0%; Pred. No. 2.3e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
QY 61 AQKLGGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
DB 61 AQKLGGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

RESULT 31
ID ABR55813
XX ABR55813 standard; protein; 125 AA.
XX
AC ABR55813;
XX
XX 02-SEP-2003 (first entry)
DT
XX Heavy chain variable region of anti-Ang-2 antibody FJ-G11 HC.
DE
XX Ang-2; angiotensin-2; anorectic; cytostatic; antiarteriosclerotic;
KW Gynaecological; antiinflammatory; osteopathic; antipsoriatic; cancer;
KW angiogenesis; antibody.
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers

FT Region 26..36
FT /note= "complementarity determining region (CDR) 1"
FT Region 50..66
FT /note= "complementarity determining region (CDR) 2"
FT Region 96..115
FT /note= "complementarity determining region (CDR) 3"
XX
PN WO2003030833-A2.
XX
XX 17-APR-2003.
XX
XX 11-OCT-2002; 2002WO-US032613.
XX
PR 11-OCT-2001; 2001US-0328604P.
PR 10-OCT-2002; 2002US-00289805.
XX
XX (AMGE-) AMGEN INC.
XX
XX Oliner JD;
XX
XX WPI; 2003-504963/47.
XX
XX New specific binding agents (i.e. anti-Angiotensin-2 antibodies), useful
PT for inhibiting undesired angiogenesis, or treating e.g. cancers, obesity,
PT hemangioma, arteriosclerosis, atherosclerosis or endometriosis.
XX
PS Claim 1; Page 92; 161pp; English.
XX
CC The invention relates to a specific binding agent, which comprises at
CC least one peptide selected from any of 62 peptides (ABR55769-830) or its
CC fragment. The binding agents are antibodies that recognize and bind to
CC angiotensin-2 (Ang-2). The specific binding agent, particularly the
CC antibody, is useful for inhibiting undesired angiogenesis, treating
CC cancers, inhibiting undesired angiogenesis, modulating or inhibiting Ang-
CC 2 activity, modulating vascular permeability or plasma leakage, or
CC treating a disease (e.g. ocular neovascular disease, obesity,
CC haemangioblastoma, haemangioma, arteriosclerosis, inflammatory disease,
CC inflammatory disorders, atherosclerosis, endometriosis, neoplastic
CC disease, bone-related disease, or psoriasis) in a mammal. The present
CC sequence represents a heavy chain variable region of an anti-Ang-2
CC antibody
XX
SQ Sequence 125 AA;
Query Match 100.0%; Score 515; DB 6; Length 125;
Best Local Similarity 100.0%; Pred. No. 2.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
QY 61 AQKLGGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
DB 61 AQKLGGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

RESULT 32
ADK18783
ID ADK18783 standard; protein; 125 AA.
XX
AC ADK18783;
XX
XX 06-MAY-2004 (first entry)
DT
XX Anti-human PDGF-D antibody protein related sequence #9.
DE
XX Anti-inflammatory; immunomodulator; cytostatic; gene therapy.
KW
XX Homo sapiens.
OS
XX WO2003057857-A2.
PN
XX

CC The present invention describes an antibody or its binding fragment that
 CC binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
 CC useful in preparing a medicament for treating nephritis. Also described:
 CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
 CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
 CC of treating mesangial proliferative glomerulonephritis. The antibody has
 CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
 CC antidiabetic activities, and can be used in gene therapy. The antibody or
 CC its binding fragment, that binds PDGF-DD, can be used in preparing a
 CC medicament for treating nephritis and related disorders, e.g., mesangial
 CC proliferative glomerulonephritis. The present sequence represents a human
 CC monoclonal antibody (mAb) variable region sequence, which is used in the
 CC exemplification of the present invention.

XX SQ Sequence 125 AA;
 Query Match 100.0%; Score 515; DB 8; Length 125;
 Best Local Similarity 100.0%; Pred. No. 2.4e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
 DB 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
 QY 61 AOKLOGRVMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
 DB 61 AOKLOGRVMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98

RESULT 35
 ADK18930
 ID ADK18930 standard; protein; 126 AA.
 XX
 AC ADK18930;
 DT 06-MAY-2004 (first entry)
 XX
 DE Anti-human PDGF-D antibody protein related sequence #156.
 XX
 KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO2003057857-A2.
 XX
 PD 17-JUL-2003.
 XX
 PF 06-JAN-2003; 2003WO-US000398.
 XX
 PR 07-JAN-2002; 2002US-00041860.
 XX
 PA (ABGE-) ABGENIX INC.
 XX
 PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;
 XX
 DR WPI; 2003-587119/55.
 XX
 PT New human monoclonal antibody that binds to platelet-derived growth
 PT factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.
 XX
 PS Disclosure; SEQ ID NO 354; 255pp; English.

XX The invention relates to a human monoclonal antibody that binds to
 CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 CC treating chronic and recurrent human diseases, such as inflammation,
 CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 CC useful for modulating collagen formation, and for staging various
 CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This

CC sequence corresponds to a protein used in the invention.

XX SQ Sequence 126 AA;
 Query Match 100.0%; Score 515; DB 7; Length 126;
 Best Local Similarity 100.0%; Pred. No. 2.4e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
 DB 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
 QY 61 AOKLOGRVMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
 DB 61 AOKLOGRVMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98

RESULT 36
 ADK18819
 ID ADK18819 standard; protein; 127 AA.
 XX
 AC ADK18819;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Anti-human PDGF-D antibody protein related sequence #45.
 XX
 KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO2003057857-A2.
 XX
 PD 17-JUL-2003.
 XX
 PF 06-JAN-2003; 2003WO-US000398.
 XX
 PR 07-JAN-2002; 2002US-00041860.
 XX
 PA (ABGE-) ABGENIX INC.
 XX
 PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;
 XX
 DR WPI; 2003-587119/55.
 XX
 PT New human monoclonal antibody that binds to platelet-derived growth
 PT factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.
 XX
 PS Disclosure; SEQ ID NO 243; 255pp; English.

XX The invention relates to a human monoclonal antibody that binds to
 CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 CC treating chronic and recurrent human diseases, such as inflammation,
 CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 CC useful for modulating collagen formation, and for staging various
 CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
 CC sequence corresponds to a protein used in the invention.

XX SQ Sequence 127 AA;
 Query Match 100.0%; Score 515; DB 7; Length 127;
 Best Local Similarity 100.0%; Pred. No. 2.4e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
 DB 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

Qy 61 AQLQGRVTWTTDTSTAYMELSLRSDDTAVYYCAR 98
 |||||
 Db 61 AQLQGRVTWTTDTSTAYMELSLRSDDTAVYYCAR 98
 |||||

RESULT 37

ADK18901
 ID ADK18901 standard; protein; 127 AA.

AC ADK18901;
 XX 06-MAY-2004 (first entry)
 DT Anti-human PDGF-D antibody protein related sequence #127.
 DE antiinflammatory; immunomodulator; cytostatic; gene therapy.
 XX Homo sapiens.

OS WO2003057857-A2.

PN 17-JUL-2003.

PD 06-JAN-2003; 2003WO-US000398.

PF 07-JAN-2002; 2002US-00041860.

PR (ABGE-) ABGENIX INC.

XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;

PI WPI; 2003-587119/55.

DR New human monoclonal antibody that binds to platelet-derived growth
 XX factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.

PT Disclosure; SEQ ID NO 325; 255pp; English.

PS The invention relates to a human monoclonal antibody that binds to
 XX platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 CC treating chronic and recurrent human diseases, such as inflammation,
 CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 CC useful for modulating collagen formation, and for staging various
 CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCBP4/Sec-30664188. This
 CC sequence corresponds to a protein used in the invention.

XX Sequence 127 AA;

Query Match 100.0%; Score 515; DB 7; Length 127;
 Best Local Similarity 100.0%; Pred. No. 2.4e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKVSCASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
 |||||
 Db 1 QVQLVQSGAEVKPGASVKVSCASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
 |||||

Qy 61 AQLQGRVTWTTDTSTAYMELSLRSDDTAVYYCAR 98
 |||||
 Db 61 AQLQGRVTWTTDTSTAYMELSLRSDDTAVYYCAR 98
 |||||

RESULT 38

ADK18607

ID ADK18607 standard; protein; 127 AA.

XX ADK18607;

XX 06-MAY-2004 (first entry)

DT Anti-human PDGF-D antibody protein related sequence #127.
 DE antiinflammatory; immunomodulator; cytostatic; gene therapy.
 XX Homo sapiens.

OS WO2003057857-A2.

PN 17-JUL-2003.

PD 06-JAN-2003; 2003WO-US000398.

PF 07-JAN-2002; 2002US-00041860.

PR (ABGE-) ABGENIX INC.

XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;

PI WPI; 2003-587119/55.

DR New human monoclonal antibody that binds to platelet-derived growth
 XX factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.

PT Disclosure; SEQ ID NO 31; 255pp; English.

PS The invention relates to a human monoclonal antibody that binds to
 XX platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 CC treating chronic and recurrent human diseases, such as inflammation,
 CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 CC useful for modulating collagen formation, and for staging various
 CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCBP4/Sec-30664188. This
 CC sequence corresponds to a protein used in the invention.

XX Sequence 127 AA;

Query Match 100.0%; Score 515; DB 7; Length 127;
 Best Local Similarity 100.0%; Pred. No. 2.4e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKVSCASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
 |||||
 Db 1 QVQLVQSGAEVKPGASVKVSCASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
 |||||

Qy 61 AQLQGRVTWTTDTSTAYMELSLRSDDTAVYYCAR 98
 |||||
 Db 61 AQLQGRVTWTTDTSTAYMELSLRSDDTAVYYCAR 98
 |||||

XX Anti-human PDGF-D antibody heavy chain protein sequence.
 DE antiinflammatory; immunomodulator; cytostatic; gene therapy.
 XX Homo sapiens.

OS WO2003057857-A2.

PN 17-JUL-2003.

PD 06-JAN-2003; 2003WO-US000398.

PF 07-JAN-2002; 2002US-00041860.

PR (ABGE-) ABGENIX INC.

XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;

PI WPI; 2003-587119/55.

DR New human monoclonal antibody that binds to platelet-derived growth
 XX factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.

PT Disclosure; SEQ ID NO 31; 255pp; English.

PS The invention relates to a human monoclonal antibody that binds to
 XX platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 CC treating chronic and recurrent human diseases, such as inflammation,
 CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 CC useful for modulating collagen formation, and for staging various
 CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCBP4/Sec-30664188. This
 CC sequence corresponds to a protein used in the invention.

XX Sequence 127 AA;

Query Match 100.0%; Score 515; DB 7; Length 127;
 Best Local Similarity 100.0%; Pred. No. 2.4e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKVSCASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
 |||||
 Db 1 QVQLVQSGAEVKPGASVKVSCASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
 |||||

Qy 61 AQLQGRVTWTTDTSTAYMELSLRSDDTAVYYCAR 98
 |||||
 Db 61 AQLQGRVTWTTDTSTAYMELSLRSDDTAVYYCAR 98
 |||||

RESULT 39

ADL25432

ID ADL25432 standard; protein; 127 AA.

XX ADL25432;

XX 17-JUN-2004 (first entry)

DT Human mAb 1.33 heavy chain variable region protein SEQ ID NO:42.
 DE antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
 KW nephritis; mesangial cell proliferation inhibition;
 KW mesangial proliferative glomerulonephritis; nephrotropic;
 KW antiinflammatory; dermatological; immunosuppressive; antidiabetic;
 KW gene therapy; human; monoclonal antibody; mAb.

XX Homo sapiens.

XX WO2004024098-A2.

```

XX 25-MAR-2004.
PD
XX
XX 16-SEP-2003; 2003WO-US029414.
XX
XX 16-SEP-2002; 2002US-0411137P.
XX
XX (ABGE-) ARGENIX INC.
XX
XX (CURA-) CURAGEN CORP.
PA
PI Floege J, Gazit-Bornatein G, Keyt B, Larochele WJ, Lichenstein H;
PI
XX
XX WPI: 2004-269881/25.
DR
DR N-PSDB; ADI25431.
DR
XX
XX Use of an antibody or its binding fragment that binds platelet derived
PT growth factor-DD (PDGF-DD) for preparing a medicament for treating
PT nephritis.
PT
XX
XX Disclosure; SEQ ID NO 42; 115pp; English.
PS
XX
XX The present invention describes an antibody or its binding fragment that
CC binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
CC useful in preparing a medicament for treating nephritis. Also described:
CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
CC of treating mesangial proliferative glomerulonephritis. The antibody has
CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
CC antidiabetic activities, and can be used in gene therapy. The antibody or
CC its binding fragment, that binds PDGF-DD, can be used in preparing a
CC medicament for treating nephritis and related disorders, e.g., mesangial
CC proliferative glomerulonephritis. The present sequence represents a human
CC monoclonal antibody (mAb) variable region sequence, which is used in the
CC exemplification of the present invention.
XX
XX Sequence 127 AA;
SQ
Query Match 100.0%; Score 515; DB 8; Length 127;
Best Local Similarity 100.0%; Pred. No. 2.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGGLEWMGWSAYNGNTNY 60
Db 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGGLEWMGWSAYNGNTNY 60

QY 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 40
ADZ57712
ID ADZ57712 standard; protein; 134 AA.
XX
XX ADZ57712;
AC
XX
XX 30-JUN-2005 (first entry)
DT
XX
XX Germline antibody Vh1-18,D2-15,Jh4b heavy chain protein.
DE
XX
XX antibody engineering; cystostatic; vulnery; vasotropic; cardiant;
KW monoclonal antibody; heavy chain; light chain; wound healing; skin ulcer;
KW gastrointestinal ulcer; ischemia; transplant rejection;
KW myocardial infarction; reperfusion injury; restenosis; angioplasty;
KW vascular disease; cancer; retinopathy; endometriosis; arthritis;
KW Alzheimers disease; tumor; glioblastoma; sarcoma; carcinoma; diagnosis;
KW antibody.
XX
XX Homo sapiens.
OS
XX GB2404660-A.
XX
XX 09-FEB-2005.
PD

XX 04-AUG-2004; 2004GB-00017384.
XX
XX 04-AUG-2003; 2003US-0492432P.
XX
XX (PFIZ ) PFIZER PROD INC.
XX
XX (ABGE-) ARGENIX INC.
XX
XX Michaud NR, Kajiji S, Borzillo G, Bedian V, Coleman K, Green LL;
PI Jia X;
PI
XX
XX WPI: 2005-145169/16.
DR
XX
XX Human monoclonal antibody or antigen-binding portion that specifically
PT binds to c-Met, useful for treating cancer by inhibiting c-Met or for
PT promoting tissue regeneration and wound healing by activating c-Met.
PT
XX
XX Example 2; SEQ ID NO 21; 128pp; English.
PS
XX
XX The invention relates to a human monoclonal antibody (I) or its antigen-
CC binding portion that specifically binds to c-Met, comprises a heavy chain
CC having a fully defined sequence (S1) of 13.3.2 heavy chain, where X2 is
CC lysine and X4 is threonine, and a light chain having a fully defined
CC sequence (S2) of 13.3.2 light chain, where X8 is threonine, where both
CC chains are without a signal sequence. All the sequences are fully defined
CC in the specification. (I) is useful for the manufacture of a medicament
CC for treating a hyperproliferative disorder in a subject, where the
CC antibody or its portion is a c-Met antagonist. (I) is useful for
CC manufacture of a medicament for promoting wound healing or tissue
CC regeneration in a subject, where the antibody, antigen-binding portion or
CC the composition activates c-Met. (I) which has a c-Met agonist activity
CC is useful in tissue regeneration or wound healing (skin ulcers or gastric
CC ulcers), or treating ischemia associated with kidney transplant
CC rejection, for attenuating toxicity associated with cyclosporin treatment
CC after transplant surgery, for treating myocardial infarction, cardiac
CC ischemia due to reperfusion injury, restenosis after angioplasty or
CC vascular diseases. (I) which has a c-Met antagonist activity is useful
CC for treating cancers of brain, lung, squamous cell, bladder, neck, liver,
CC prostate, etc., proliferative vitreoretinopathy, proliferative diabetic
CC retinopathy, endometriosis, and arthritis, for inhibiting plaque
CC formation in Alzheimer's disease, inhibiting cellular mitogenic
CC responses, or for treating tumor, glioblastoma, sarcomas, or carcinomas.
CC (I) is useful for detecting c-Met in a biological sample in vitro or in
CC vivo, thus useful for diagnosing c-Met-expressing tumor. (I) has
CC selectivity for c-Met that is at least 100 times greater than their
CC selectivity for insulin like growth factor I receptor. This sequence
CC corresponds to the amino acid sequence for a germline antibody heavy
CC chain used in the invention.
XX
XX Sequence 134 AA;
SQ
Query Match 100.0%; Score 515; DB 9; Length 134;
Best Local Similarity 100.0%; Pred. No. 2.5e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGGLEWMGWSAYNGNTNY 60
Db 20 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGGLEWMGWSAYNGNTNY 79

QY 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 80 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 117

RESULT 41
ABP45461
ID ABP45461 standard; protein; 248 AA.
XX
XX ABP45461;
AC
XX
XX 19-AUG-2002 (first entry)
DT
XX
XX Human BlyS binding scFv SEQ ID 1472.
DE

```

XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX Homo sapiens.
 XX
 XX WO200202641-A1.
 XX
 XX 10-JAN-2002.
 XX
 XX 15-JUN-2001; 2001WO-US019110.
 XX
 XX 16-JUN-2000; 2000US-0212210P.
 PR 17-OCT-2000; 2000US-0240816P.
 PR 16-MAR-2001; 2001US-0276248P.
 PR 21-MAR-2001; 2001US-0277379P.
 PR 25-MAY-2001; 2001US-0293499P.
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX
 XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 XX
 XX WPI; 2002-114799/15.
 DR
 XX
 XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 PT diagnosis and treatment of cancers and immune disorders.
 PT
 XX
 XX Claim 1; Page 2159-2160; 3148pp; English.
 PS
 XX This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention
 XX
 SQ Sequence 248 AA;
 Query Match 100.0%; Score 515; DB 5; Length 248;
 Best Local Similarity 100.0%; Pred. No. 4.9e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
 Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
 Qy 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
 Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
 RESULT 42
 ADG96288
 ID ADG96288 standard; protein; 248 AA.
 XX
 AC ADG96288;
 XX

DT 11-MAR-2004 (first entry)
 XX
 DE Single chain antibody that immunospecifically binds Blys SeqID 1472.
 XX
 KW antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
 XX
 OS Unidentified.
 XX
 XX WO2003055979-A2.
 XX
 XX 10-JUL-2003.
 XX
 XX 14-NOV-2002; 2002WO-US036496.
 PF
 XX 16-NOV-2001; 2001US-0331469P.
 PR
 PR 19-DEC-2001; 2001US-0340817P.
 PR
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA
 XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
 XX
 XX WPI; 2003-505530/47.
 DR
 XX
 XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 PT (Blys), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.
 PT
 XX
 PS Example 1; SEQ ID NO 1472; 394pp; English.
 PS
 XX This invention relates to novel antibodies that immunospecifically bind
 CC to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour
 CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey Blys. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of Blys or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiallergic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds Blys of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
 XX
 XX Sequence 248 AA;
 Query Match 100.0%; Score 515; DB 7; Length 248;
 Best Local Similarity 100.0%; Pred. No. 4.9e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
 Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
 Qy 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
 Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
 RESULT 43
 ABP45551

ID ABP45551 standard; protein; 251 AA.
XX ABP45551;
AC
XX
XX
DT 19-AUG-2002 (first entry)
XX
DE Human BlyS binding scFv SEQ ID 1562.
XX
XX
XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
OS
XX
XX WO200202641-A1.
PN
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US019110.
XX
XX 16-JUN-2000; 2000US-0212210P.
PR
XX 17-OCT-2000; 2000US-0240816P.
PR
XX 16-MAR-2001; 2001US-0276248P.
PR
XX 21-MAR-2001; 2001US-0277379P.
PR
XX 25-MAY-2001; 2001US-0293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
PI
XX WPI; 2002-114799/15.
DR
XX
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
PT diagnosis and treatment of cancers and immune disorders.
XX
XX Claim 1; Page 2267-2268; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
CC and so may be used to detect and quantitate the presence of BlyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BlyS. They may also be
CC administered to treat diseases associated with aberrant BlyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method of
CC the invention
XX
XX Sequence 251 AA;
SQ
Query Match 100.0%; Score 515; DB 5; Length 251;
Best Local Similarity 100.0%; Pred. No. 4.9e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60
QY 61 AQKLGQRTVMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
DB 61 AQKLGQRTVMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98

RESULT 44
ABP45861
ID ABP45861 standard; protein; 251 AA.
XX
XX
XX ABP45861;
AC
XX
XX 19-AUG-2002 (first entry)
DT
XX
XX Human BlyS binding scFv SEQ ID 1872.
XX
XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
OS
XX
XX WO200202641-A1.
PN
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US019110.
XX
XX 16-JUN-2000; 2000US-0212210P.
PR
XX 17-OCT-2000; 2000US-0240816P.
PR
XX 16-MAR-2001; 2001US-0276248P.
PR
XX 21-MAR-2001; 2001US-0277379P.
PR
XX 25-MAY-2001; 2001US-0293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
PI
XX WPI; 2002-114799/15.
DR
XX
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
PT diagnosis and treatment of cancers and immune disorders.
XX
XX Claim 1; Page 2635-2636; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
CC and so may be used to detect and quantitate the presence of BlyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BlyS. They may also be
CC administered to treat diseases associated with aberrant BlyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method of
CC the invention
XX
XX Sequence 251 AA;
SQ
Query Match 100.0%; Score 515; DB 5; Length 251;
Best Local Similarity 100.0%; Pred. No. 4.9e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWI SAYNGNTNY 60
QY 61 AQKLGQRTVMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98

```

Db      61 AOKLQGRVTMTDTSTSTAYMELRSLSDDTAVYYCAR 98
|||||
RESULT 45
ABP45910
XX      ID ABP45910 standard; protein; 251 AA.
XX      AC ABP45910;
XX      DT 19-AUG-2002 (first entry)
XX      DE Human BlyS binding scFv SEQ ID 1921.
XX      KW BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX      KW tumour necrosis factor; B cell proliferation; B cell differentiation;
XX      KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX      KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX      KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX      KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX      OS Homo sapiens.
XX      PN WO200202641-A1.
XX      PD 10-JAN-2002.
XX      PF 15-JUN-2001; 2001WO-US019110.
XX      PR 16-JUN-2000; 2000US-0212210P.
XX      PR 17-OCT-2000; 2000US-0240816P.
XX      PR 16-MAR-2001; 2001US-0276248P.
XX      PR 21-MAR-2001; 2001US-0277379P.
XX      PR 25-MAY-2001; 2001US-0293499P.
XX      PA (HUMA-) HUMAN GENOME SCI INC.
XX      PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX      PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX      WPI; 2002-114799/15.
XX      DT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
XX      PT diagnosis and treatment of cancers and immune disorders.
XX      PS Claim 1; Page 2693-2694; 3148pp; English.
XX      CC This invention describes novel antibodies that immunospecifically bind to
XX      CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
XX      CC tumour necrosis factor (TNF) super family and induces B cell
XX      CC proliferation and differentiation. The antibodies of the invention have
XX      CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX      CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX      CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
XX      CC and so may be used to detect and quantitate the presence of BlyS in
XX      CC biological samples and may be used in this way to diagnose disease
XX      CC associated with aberrant expression of BlyS. They may also be
XX      CC administered to treat diseases associated with aberrant BlyS expression
XX      CC and activity such as cancer, immune, and autoimmune disorders and
XX      CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX      CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX      CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX      CC the antibodies and fragments of the antibodies described in the method of
XX      CC the invention
XX      SQ Sequence 251 AA;
Query Match 100.0%; Score 515; DB 5; Length 251;
Best Local Similarity 100.0%; Pred. NO. 4.9e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
|||||
Db      61 AOKLQGRVTMTDTSTSTAYMELRSLSDDTAVYYCAR 98
|||||
RESULT 46
ADG96737
XX      ID ADG96737 standard; protein; 251 AA.
XX      AC ADG96737;
XX      DT 11-MAR-2004 (first entry)
XX      DE Single chain antibody that immunospecifically binds BlyS SeqID 1921.
XX      KW antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
XX      KW B cell proliferation; differentiation; scFv; myasthenia gravis;
XX      KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
XX      KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
XX      KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX      OS Unidentified.
XX      PN WO2003055979-A2.
XX      PD 10-JUL-2003.
XX      PF 14-NOV-2002; 2002WO-US036496.
XX      PR 16-NOV-2001; 2001US-0331469P.
XX      PR 19-DEC-2001; 2001US-0340817P.
XX      PA (HUMA-) HUMAN GENOME SCI INC.
XX      PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX      WPI; 2003-505530/47.
XX      DT Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX      PT (BlyS), useful for detecting and treating diseases or disorders e.g.
XX      PT rheumatoid arthritis, asthma and leukemia.
XX      PS Example 1; SEQ ID NO 1921; 394pp; English.
XX      CC This invention relates to novel antibodies that immunospecifically bind
XX      CC to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
XX      CC chromosome 13q34 and encodes a protein that is a member of the tumour
XX      CC necrosis factor superfamily and induces both in vivo and in vitro B cell
XX      CC proliferation and differentiation. Specifically, it refers to single
XX      CC chain antibody molecules (scFvs) derived, preferably, from the variable
XX      CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX      CC fragment thereof, of either human, murine, rat or monkey BlyS. The
XX      CC present invention refers to the use of such antibodies in various methods
XX      CC for the detection, diagnosis and prognosis of diseases related to the
XX      CC aberrant expression or inappropriate function of BlyS or its receptor. As
XX      CC such, these compositions are useful for identifying immune disorders
XX      CC including myasthenia gravis and multiple sclerosis, inflammatory
XX      CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX      CC as AIDS and proliferative disorders including leukaemia, carcinoma and
XX      CC lymphoma. Accordingly, they can be described as exhibiting various
XX      CC activities such as antirheumatic, antiarthritic, neuroprotective,
XX      CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
XX      CC polypeptide sequence is a single chain antibody that binds BlyS of the
XX      CC invention. NOTE: The sequence data for this patent did not form part of
XX      CC the printed specification, but was obtained in electronic format
XX      CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX      SQ Sequence 251 AA;
Query Match 100.0%; Score 515; DB 7; Length 251;
Best Local Similarity 100.0%; Pred. No. 4.9e-42;

```

	Matches	98;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	1	QVQLVSGAEVKKPGASVKVSKCASKGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY	60							
Db	1	QVQLVSGAEVKKPGASVKVSKCASKGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY	60							
Qy	61	AQKLQRVTMTTDTSTSTAYMELRLSRSDDTAVYYCAR	98							
Db	61	AQKLQRVTMTTDTSTSTAYMELRLSRSDDTAVYYCAR	98							
	RESULT 47									
	ADG96378									
ID	ADG96378	standard; protein; 251 AA.								
XX	AC	ADG96378;								
XX	AC									
DT	11-MAR-2004	(first entry)								
DE		Single chain antibody that immunospecifically binds Blys SeqID 1562.								
KW		antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;								
KW		B cell proliferation; differentiation; scFv; myasthenia gravis;								
KW		multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;								
KW		carcinoma; lymphoma; anti-rheumatic; antiarthritic; neuroprotective;								
KW		anti-inflammatory; antiasthmatic; anti-allergic; cytostatic.								
OS		Unidentified.								
XX										
PN	WO2003055979-A2.									
XX										
PD	10-JUL-2003.									
XX										
XX										
PF	14-NOV-2002; 2002WO-US036496.									
XX										
PR	16-NOV-2001; 2001US-0331469P.									
PR	19-DEC-2001; 2001US-0340817P.									
XX										
PA	(HUMA-) HUMAN GENOME SCI INC.									
PI	Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;									
DR	WPI; 2003-505530/47.									
XX										
PT	Novel antibody that immunospecifically binds to a B lymphocyte stimulator									
PT	(Blys), useful for detecting and treating diseases or disorders e.g.									
PT	rheumatoid arthritis, asthma and leukemia.									
PS	Example 1; SEQ ID NO 1562; 394pp; English.									
CC	This invention relates to novel antibodies that immunospecifically bind									
CC	to B lymphocyte stimulator (Blys). The Blys gene has been mapped to									
CC	chromosome 13q34 and encodes a protein that is a member of the tumour									
CC	necrosis factor superfamily and induces both in vivo and in vitro B cell									
CC	proliferation and differentiation. Specifically, it refers to single									
CC	chain antibody molecules (scFvs) derived, preferably, from the variable									
CC	heavy CDR3 region that immunospecifically bind to a polypeptide, or									
CC	fragment thereof, of either human, murine, rat or monkey Blys. The									
CC	present invention refers to the use of such antibodies in various methods									
CC	for the detection, diagnosis and prognosis of diseases related to the									
CC	aberrant expression or inappropriate function of Blys or its receptor. As									
CC	such, these compositions are useful for identifying immune disorders									
CC	including myasthenia gravis and multiple sclerosis, inflammatory									
CC	disorders e.g. asthma and rheumatoid arthritis, infectious diseases such									
CC	as AIDS and proliferative disorders including leukaemia, carcinoma and									
CC	lymphoma. Accordingly, they can be described as exhibiting various									
CC	activities such as anti-rheumatic, antiarthritic, neuroprotective,									
CC	anti-inflammatory, antiasthmatic, anti-allergic and cytostatic. This									
CC	polypeptide sequence is a single chain antibody that binds Blys of the									
CC	invention. NOTE: the sequence data for this patent did not form part of									
CC	the printed specification, but was obtained in electronic format									
CC	directly from WIPO at ftp.wipo.int/pub/published pct_sequences.									
XX										

SQ	Sequence	251 AA;
	Query Match	100.0%; Score 515; DB 7; Length 251;
	Best Local Similarity	100.0%; Pred. No. 4.9e-42;
	Matches	98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	1	QVOLVSGAEVKKPGASVKVSKCASKGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db	1	Q

CC invention. NOTE: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX
SQ Sequence 251 AA;

Query Match 100.0%; Score 515; DB 7; Length 251;
Best Local Similarity 100.0%; Pred. No. 4.9e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHSAYNGNTNY 60
DB 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHSAYNGNTNY 60
QY 61 AQKLQGRVTMTTDTSTSTAYMELRLSRSDDTAVYYCAR 98
DB 61 AQKLQGRVTMTTDTSTSTAYMELRLSRSDDTAVYYCAR 98

RESULT 49
ABP45179
ID ABP45179 standard; protein; 255 AA.
XX
AC ABP45179;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human BlyS binding scFv SEQ ID 1190.
XX
KW BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
PN WO200202641-A1.
XX
PD 10-JAN-2002.
XX
PF 15-JUN-2001; 2001WO-US019110.
XX
PR 16-JUN-2000; 2000US-0212210P.
PR 17-OCT-2000; 2000US-0240816P.
PR 16-MAR-2001; 2001US-0276248P.
PR 21-MAR-2001; 2001US-0277379P.
PR 25-MAY-2001; 2001US-0293499P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
XX WPI; 2002-114799/15.
XX
DR Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
XX diagnosis and treatment of cancers and immune disorders.
XX
PS Claim 1; Page 1822-1823; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
CC and so may be used to detect and quantitate the presence of BlyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BlyS. They may also be
CC administered to treat diseases associated with aberrant BlyS expression

CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method of
CC the invention
XX
SQ Sequence 255 AA;

Query Match 100.0%; Score 515; DB 5; Length 255;
Best Local Similarity 100.0%; Pred. No. 5e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHSAYNGNTNY 60
DB 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGHSAYNGNTNY 60
QY 61 AQKLQGRVTMTTDTSTSTAYMELRLSRSDDTAVYYCAR 98
DB 61 AQKLQGRVTMTTDTSTSTAYMELRLSRSDDTAVYYCAR 98

RESULT 50
ADG96006
ID ADG96006 standard; protein; 255 AA.
XX
AC ADG96006;
XX
DT 11-MAR-2004 (first entry)
XX
DE Single chain antibody that immunospecifically binds BlyS SeqID 1190.
XX
KW antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
KW B cell proliferation; differentiation; scFv; myasthenia gravis;
KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
KW carcinoma; lymphoma; antirheumatic; antiaarthritis; neuroprotective;
KW antiinflammatory; antiaasthmatic; antiallergic; cytostatic.
XX
OS Unidentified.
XX
PN WO2003055979-A2.
XX
PD 10-JUL-2003.
XX
PF 14-NOV-2002; 2002WO-US036496.
XX
PR 16-NOV-2001; 2001US-0331469P.
PR 19-DEC-2001; 2001US-0340817P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX
XX WPI; 2003-505530/47.
XX
PT Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX (BlyS), useful for detecting and treating diseases or disorders e.g.
XX rheumatoid arthritis, asthma and leukemia.
XX
PS Example 1; SEQ ID NO 1190; 394pp; English.
XX
CC This invention relates to novel antibodies that immunospecifically bind
CC to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
CC chromosome 13q34 and encodes a protein that is a member of the tumour
CC necrosis factor superfamily and induces both in vivo and in vitro B cell
CC proliferation and differentiation. Specifically, it refers to single
CC chain antibody molecules (scFvs) derived, preferably, from the variable
CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
CC fragment thereof, of either human, murine, rat or monkey BlyS. The
CC present invention refers to the use of such antibodies in various methods
CC for the detection, diagnosis and prognosis of diseases related to the
CC aberrant expression or inappropriate function of BlyS or its receptor. As
CC such, these compositions are useful for identifying immune disorders

CC chain antibody molecules (scFvs) derived, preferably, from the variable
CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
CC fragment thereof, of either human, murine, rat or monkey Blys. The
CC present invention refers to the use of such antibodies in various methods
CC for the detection, diagnosis and prognosis of diseases related to the
CC aberrant expression or inappropriate function of Blys or its receptor. As
CC such, these compositions are useful for identifying immune disorders
CC including myasthenia gravis and multiple sclerosis, inflammatory
CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
CC as AIDS and proliferative disorders including leukaemia, carcinoma and
CC lymphoma. Accordingly, they can be described as exhibiting various
CC activities such as antirheumatic, antiarthritic, neuroprotective,
CC antiinflammatory, antiallergic, antiallergic and cytostatic. This
CC polypeptide sequence is a single chain antibody that binds Blys of the
CC invention. NOTE: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.

XX
SQ Sequence 259 AA;

Query Match 100.0%; Score 515; DB 7; Length 259;
Best Local Similarity 100.0%; Pred. No. 5.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVKSCASGYTFTSYGISWVRQAPGGGLEWMGWISAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVKSCASGYTFTSYGISWVRQAPGGGLEWMGWISAYNGNTNY 60
Qy 61 AQKLGKRVTTTDTSTSTAYMELSLRSLRSDDTAVYYCAR 98
Db 61 AQKLGKRVTTTDTSTSTAYMELSLRSLRSDDTAVYYCAR 98

Search completed: May 12, 2006, 02:31:08
Job time : 82 secs

THIS PAGE BLANK (USPTO)


```
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-2

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60

QY 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 3
US-10-041-860-324
; Sequence 324, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Peng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 324
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-324

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60

QY 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 4
US-10-041-860-326
; Sequence 326, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Peng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 326
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-326

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60

QY 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 5
US-10-041-860-355
; Sequence 355, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Peng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 355
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-355

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60

QY 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 6
US-10-041-860-356
; Sequence 356, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
```

```
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 356
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-356

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

Qy 61 AQLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 7
US-10-308-817-44
; Sequence 44, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308.817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 44
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-308-817-44

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

Qy 61 AQLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 8
US-10-032-037B-46
; Sequence 46, Application US/10032037B
; Publication No. US20040001822A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/44
; CURRENT APPLICATION NUMBER: US/10/032.423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; NUMBER OF SEQ ID NOS: 204
```

```
; CURRENT APPLICATION NUMBER: US/10/032.037B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 46
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-46

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

Qy 61 AQLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 9
US-10-029-988B-46
; Sequence 46, Application US/10029988B
; Publication No. US20040001839A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029.988B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 46
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-46

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

Qy 61 AQLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 10
US-10-032-423A-46
; Sequence 46, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032.423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
```

```
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 46
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-46

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVOSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
   |||||
Db 1 QVOLVOSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
   |||||

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||||

RESULT 11
US-10-453-698-44
; Sequence 44, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 44
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-453-698-44

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVOSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
   |||||
Db 1 QVOLVOSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
   |||||

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||||

RESULT 12
US-10-029-926B-46
; Sequence 46, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; FILE REFERENCE: 10793/50
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 46
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-46

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVOSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
   |||||
Db 1 QVOLVOSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
   |||||

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||||

RESULT 13
US-10-379-392-4
; Sequence 4, Application US/10379392
; Publication No. US20040110226A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John Rudolf
; APPLICANT: Marshall, Shannon Alicia
; APPLICANT: Dahiyat, Bassil I.
; TITLE OF INVENTION: ANTIBODY OPTIMIZATION
; FILE REFERENCE: A-71386-3 463077-236
; CURRENT APPLICATION NUMBER: US/10/379,392
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/360,843
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 60/384,197
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 4
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-379-392-4

Query Match      100.0%; Score 515; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 9.1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVOSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
   |||||
Db 1 QVOLVOSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWSAYNGNTNY 60
   |||||

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||||
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||||

RESULT 14
US-09-864-761-47285
; Sequence 47285, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: Aeomica-x-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 47285
; LENGTH: 104
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AB019440.1
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 0.42
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.8
; OTHER INFORMATION: SWISSPROT HIT: P23083, EVALUE 2.00e-39
; OTHER INFORMATION: EST_HUMAN HIT: AW403728.1, EVALUE 4.00e-45
US-09-864-761-47285

Query Match          100.0%; Score 515; DB 3; Length 104;
Best Local Similarity 100.0%; Pred. No. 9,7e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 4 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 63

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 64 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 101

RESULT 15
US-10-800-197-147
; Sequence 147, Application US/10800197
; Publication No. US20040202655A1
; GENERAL INFORMATION:
; APPLICANT: Motson, Philip A et al.
; TITLE OF INVENTION: ANTIBODIES TO IGF-I RECEPTOR FOR THE TREATMENT OF CANCERS
; FILE REFERENCE: 01343/1
; CURRENT APPLICATION NUMBER: US/10/800,197
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: 60/455,094
; PRIOR FILING DATE: 2003-03-14
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 147
; LENGTH: 109
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-800-197-147
```

```
Query Match          100.0%; Score 515; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 16
US-10-727-155-284
; Sequence 284, Application US/10727155
; Publication No. US20050049402A1
; GENERAL INFORMATION:
; APPLICANT: John S. Babcock
; APPLICANT: Jaspal S. Kang
; APPLICANT: Orit Foord
; APPLICANT: Larry Green
; APPLICANT: Xiao Feng
; APPLICANT: Scott Klakamp
; APPLICANT: Mary Haak-Frendscho
; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Manchulenko
; APPLICANT: Raffaella Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; FILE REFERENCE: ABGENIX.073A
; CURRENT APPLICATION NUMBER: US/10/727,155
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 284
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-727-155-284

Query Match          100.0%; Score 515; DB 5; Length 109;
Best Local Similarity 100.0%; Pred. No. 1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60

QY 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 17
US-10-727-155-290
; Sequence 290, Application US/10727155
; Publication No. US20050049402A1
; GENERAL INFORMATION:
; APPLICANT: John S. Babcock
; APPLICANT: Jaspal S. Kang
; APPLICANT: Orit Foord
; APPLICANT: Larry Green
; APPLICANT: Xiao Feng
; APPLICANT: Scott Klakamp
; APPLICANT: Mary Haak-Frendscho
```

```

; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Manchulenchio
; APPLICANT: Raffaela Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; TITLE OF INVENTION: FACTOR AND USES THEREOF
; FILE REFERENCE: ABGENIX.073A
; CURRENT APPLICATION NUMBER: US/10/727,155
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 290
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
; OTHER INFORMATION: VH sequence of K53 (anti-CD46)
US-10-727-155-290

Query Match      100.0%; Score 515; DB 5; Length 109;
Best Local Similarity 100.0%; Pred. No. 1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
QY 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
Db 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98

RESULT 18
US-10-041-860-206
; Sequence 206, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 206
; LENGTH: 117
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-206

Query Match      100.0%; Score 515; DB 4; Length 117;
Best Local Similarity 100.0%; Pred. No. 1.1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
QY 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
Db 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
```

```

RESULT 19
US-11-039-767-8
; Sequence 8, Application US/11039767
; Publication No. US20050170398A1
; GENERAL INFORMATION:
; APPLICANT: CRUCELL HOLLAND B.V.
; TITLE OF INVENTION: Recombinant production of mixtures of antibodies
; FILE REFERENCE: 0079 WO 00 ORD
; CURRENT APPLICATION NUMBER: US/11/039,767
; CURRENT FILING DATE: 2005-01-18
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: VH sequence of K53 (anti-CD46)
US-11-039-767-8

Query Match      100.0%; Score 515; DB 6; Length 118;
Best Local Similarity 100.0%; Pred. No. 1.1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
QY 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
Db 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
```

```

RESULT 20
US-11-039-767-10
; Sequence 10, Application US/11039767
; Publication No. US20050170398A1
; GENERAL INFORMATION:
; APPLICANT: CRUCELL HOLLAND B.V.
; TITLE OF INVENTION: Recombinant production of mixtures of antibodies
; FILE REFERENCE: 0079 WO 00 ORD
; CURRENT APPLICATION NUMBER: US/11/039,767
; CURRENT FILING DATE: 2005-01-18
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: VH sequence of 02-237 (anti-CD46)
US-11-039-767-10

Query Match      100.0%; Score 515; DB 6; Length 118;
Best Local Similarity 100.0%; Pred. No. 1.1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVOLVSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
QY 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
Db 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98

RESULT 21
US-11-031-485-120
; Sequence 120, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
```



```
; APPLICANT: PULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.
; APPLICANT: HAAK-FRENDTSCHO, MARY
; TITLE OF INVENTION: ANTIBODIES TO MADCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 120
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-120

Query Match      100.0%; Score 515; DB 6; Length 121;
Best Local Similarity 100.0%; Pred. No. 1.1e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

Qy 61 AQLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 22
US-10-269-805-45
; Sequence 45, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 45
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-45

Query Match      100.0%; Score 515; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

Qy 61 AQLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 23
US-10-041-860-42
; Sequence 42, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
```

```
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 42
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-42

Query Match      100.0%; Score 515; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

Qy 61 AQLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 24
US-10-041-860-207
; Sequence 207, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 207
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-207

Query Match      100.0%; Score 515; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

Qy 61 AQLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 25
US-10-665-383-62
; Sequence 62, Application US/10665383
```

```
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: LaRoche, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; TITLE OF INVENTION: USING ANTI-PDGF-DD ANTIBODIES
; FILE REFERENCE: ABGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665,383
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/411,137
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 62
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-62

Query Match      100.0%; Score 515; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

QY 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 26
US-10-041-860-354
; Sequence 354, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 354
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-354

Query Match      100.0%; Score 515; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

QY 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 27
US-10-041-860-31
; Sequence 31, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 127
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-31

Query Match      100.0%; Score 515; DB 4; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

QY 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 28
US-10-041-860-243
; Sequence 243, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 243
; LENGTH: 127
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-243

Query Match      100.0%; Score 515; DB 4; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 1 QVOLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWSAYNGNTNY 60

QY 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
```

Qy 61 AQKLGRTVMTTDTSTSTAYMELSLRSDDTAVYCAR 98
|
Db 61 AQKLGRTVMTTDTSTSTAYMELSLRSDDTAVYCAR 98

RESULT 29

US-10-041-860-325
; Sequence 325, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: THEREOF
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 325
; LENGTH: 127
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-325

Query Match 100.0%; Score 515; DB 4; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
|
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
|
Qy 61 AQKLGRTVMTTDTSTSTAYMELSLRSDDTAVYCAR 98
|
Db 61 AQKLGRTVMTTDTSTSTAYMELSLRSDDTAVYCAR 98

RESULT 30

US-10-665-383-42
; Sequence 42, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: Laroche, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; FILE REFERENCE: USING ANTI-PDGF-DD ANTIBODIES
; CURRENT APPLICATION NUMBER: US/10/665,383
; CURRENT FILING DATE: 2003-09-16
; PRIOR FILING DATE: 2003-09-16
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 42
; LENGTH: 127
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-42

Query Match 100.0%; Score 515; DB 4; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
|
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
|
Qy 61 AQKLGRTVMTTDTSTSTAYMELSLRSDDTAVYCAR 98
|
Db 61 AQKLGRTVMTTDTSTSTAYMELSLRSDDTAVYCAR 98

RESULT 31

US-10-910-901-21
; Sequence 21, Application US/10910901
; Publication No. US20050054019A1
; GENERAL INFORMATION:
; APPLICANT: MICHAUD, NEIL R., et al.
; TITLE OF INVENTION: ANTIBODIES TO c-MET
; FILE REFERENCE: ABX-PFS
; CURRENT APPLICATION NUMBER: US/10/910,901
; CURRENT FILING DATE: 2004-08-03
; PRIOR APPLICATION NUMBER: US 60/492,432
; PRIOR FILING DATE: 2003-08-04
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 21
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-910-901-21

Query Match 100.0%; Score 515; DB 5; Length 132;
Best Local Similarity 100.0%; Pred. No. 1.2e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
|
Db 20 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 79
|
Qy 61 AQKLGRTVMTTDTSTSTAYMELSLRSDDTAVYCAR 98
|
Db 80 AQKLGRTVMTTDTSTSTAYMELSLRSDDTAVYCAR 117

RESULT 32

US-09-880-748-1472
; Sequence 1472, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1472
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1472

Query Match 100.0%; Score 515; DB 3; Length 248;
Best Local Similarity 100.0%; Pred. No. 2.4e-43;

FILE REFERENCE: PF523
CURRENT APPLICATION NUMBER: US/09/880,748
CURRENT FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-15
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
NUMBER OF SEQ ID NOS: 3239
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 1921
LENGTH: 251
TYPE: PRT
ORGANISM: Homo sapiens
US-09-880-748-1921

Query Match 100.0%; Score 515; DB 3; Length 251;
Best Local Similarity 100.0%; Pred. No. 2.4e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60

Qy 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 37
US-10-293-418-1562
Sequence 1562, Application US/10293418
Publication No. US20030223996A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523P2
CURRENT APPLICATION NUMBER: US/10/293,418
CURRENT FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: 60/331,469
PRIOR FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/340,817
PRIOR FILING DATE: 2001-12-19
PRIOR APPLICATION NUMBER: 09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-16
NUMBER OF SEQ ID NOS: 3247
SEQ ID NO 1562
LENGTH: 251
TYPE: PRT
ORGANISM: Homo sapiens
US-10-293-418-1562

Query Match 100.0%; Score 515; DB 4; Length 251;
Best Local Similarity 100.0%; Pred. No. 2.4e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60

Qy 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 38
US-10-293-418-1872
Sequence 1872, Application US/10293418
Publication No. US20030223996A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523P2
CURRENT APPLICATION NUMBER: US/10/293,418
CURRENT FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: 60/331,469
PRIOR FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/340,817
PRIOR FILING DATE: 2001-12-19
PRIOR APPLICATION NUMBER: 09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-16
NUMBER OF SEQ ID NOS: 3247
SEQ ID NO 1872
LENGTH: 251
TYPE: PRT
ORGANISM: Homo sapiens
US-10-293-418-1872

Query Match 100.0%; Score 515; DB 4; Length 251;
Best Local Similarity 100.0%; Pred. No. 2.4e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60

Qy 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 39
US-10-293-418-1921
Sequence 1921, Application US/10293418
Publication No. US20030223996A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523P2
CURRENT APPLICATION NUMBER: US/10/293,418
CURRENT FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: 60/331,469
PRIOR FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/340,817
PRIOR FILING DATE: 2001-12-19
PRIOR APPLICATION NUMBER: 09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21

Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60
Qy 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 38
US-10-293-418-1872
Sequence 1872, Application US/10293418
Publication No. US20030223996A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523P2
CURRENT APPLICATION NUMBER: US/10/293,418
CURRENT FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: 60/331,469
PRIOR FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/340,817
PRIOR FILING DATE: 2001-12-19
PRIOR APPLICATION NUMBER: 09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21
PRIOR APPLICATION NUMBER: 60/276,248
PRIOR FILING DATE: 2001-03-16
PRIOR APPLICATION NUMBER: 60/240,816
PRIOR FILING DATE: 2000-10-17
PRIOR APPLICATION NUMBER: 60/212,210
PRIOR FILING DATE: 2000-06-16
NUMBER OF SEQ ID NOS: 3247
SEQ ID NO 1872
LENGTH: 251
TYPE: PRT
ORGANISM: Homo sapiens
US-10-293-418-1872

Query Match 100.0%; Score 515; DB 4; Length 251;
Best Local Similarity 100.0%; Pred. No. 2.4e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWSAYNGNTNY 60

Qy 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 39
US-10-293-418-1921
Sequence 1921, Application US/10293418
Publication No. US20030223996A1
GENERAL INFORMATION:
APPLICANT: Ruben et al.
TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
FILE REFERENCE: PF523P2
CURRENT APPLICATION NUMBER: US/10/293,418
CURRENT FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: 60/331,469
PRIOR FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/340,817
PRIOR FILING DATE: 2001-12-19
PRIOR APPLICATION NUMBER: 09/880,748
PRIOR FILING DATE: 2001-06-15
PRIOR APPLICATION NUMBER: 60/293,499
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: 60/277,379
PRIOR FILING DATE: 2001-03-21

```
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1921
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1921

Query Match      100.0%; Score 515; DB 4; Length 251;
Best Local Similarity 100.0%; Pred. No. 2.4e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||
Db 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||

QY 61 AQKLGQRVTMTTDTSTAYMELRSLRSDDTAVYYCAR 98
   |||||
Db 61 AQKLGQRVTMTTDTSTAYMELRSLRSDDTAVYYCAR 98
   |||||

RESULT 40
US-09-880-748-1190
; Sequence 1190, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1190
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1190

Query Match      100.0%; Score 515; DB 3; Length 255;
Best Local Similarity 100.0%; Pred. No. 2.5e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||
Db 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||

QY 61 AQKLGQRVTMTTDTSTAYMELRSLRSDDTAVYYCAR 98
   |||||
Db 61 AQKLGQRVTMTTDTSTAYMELRSLRSDDTAVYYCAR 98
   |||||

RESULT 41
US-10-293-418-1190
; Sequence 1190, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
```

```
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1190
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1190

Query Match      100.0%; Score 515; DB 4; Length 255;
Best Local Similarity 100.0%; Pred. No. 2.5e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||
Db 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
   |||||

QY 61 AQKLGQRVTMTTDTSTAYMELRSLRSDDTAVYYCAR 98
   |||||
Db 61 AQKLGQRVTMTTDTSTAYMELRSLRSDDTAVYYCAR 98
   |||||

RESULT 42
US-09-880-748-1356
; Sequence 1356, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1356
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1356

Query Match      100.0%; Score 515; DB 3; Length 259;
Best Local Similarity 100.0%; Pred. No. 2.5e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
```

Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGMSAYNGNTNY 60
Qy 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 43

US-10-293-418-1356
; Sequence 1356, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1356
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1356

Query Match 100.0%; Score 515; DB 4; Length 259;
Best Local Similarity 100.0%; Pred. No. 2.5e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGMSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGMSAYNGNTNY 60
Qy 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 44

US-10-269-805-51
; Sequence 51, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 51
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-805-51

Query Match 99.4%; Score 512; DB 4; Length 123;
Best Local Similarity 99.0%; Pred. No. 2.3e-43;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGMSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGMSAYNGNTNY 60
Qy 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 45

US-09-880-748-1873
; Sequence 1873, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1873
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1873

Query Match 99.4%; Score 512; DB 3; Length 247;
Best Local Similarity 99.0%; Pred. No. 4.8e-43;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGMSAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGMSAYNGNTNY 60
Qy 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

Search completed: May 12, 2006, 02:32:16
Job time : 67 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 09:04:30 ; Search time 36.8737 Seconds
(without alignments)
1875.095 Million cell updates/sec

Title: US-09-674-752-26

Perfect score: 515

Sequence: 1 QVQLVSGAEVKKPGASVKV.....AYMELSLRLSDDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt 05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	459	89.1	500	2	Q6N091_HUMAN
2	431	83.7	125	2	Q9UL95_HUMAN
3	428	83.1	469	2	Q7Z7P5_HUMAN
4	422	81.9	117	1	HV1B_HUMAN
5	422	81.9	119	2	Q9UL94_HUMAN
6	417	81.0	124	2	Q9UL92_HUMAN
7	415	80.6	117	1	HV1G_HUMAN
8	414	80.4	500	2	Q9BR70_HUMAN
9	408	79.2	120	2	Q6NSM4_HUMAN
10	408	79.2	244	2	Q6S2C8_HUMAN
11	404	78.4	518	2	Q6N030_HUMAN
12	400	77.7	159	2	Q96Q90_HUMAN
13	396	76.9	498	2	Q6N041_HUMAN
14	389	75.5	119	2	Q9GY22_MOUSE
15	389	75.5	147	1	HV1C_HUMAN
16	384	74.6	116	2	Q9UL89_HUMAN
17	380	73.8	480	2	Q6P089_HUMAN
18	377	73.2	497	2	Q8WY24_HUMAN
19	376	73.0	125	2	Q6P1U0_HUMAN
20	371	72.0	117	1	HV1A_HUMAN
21	370	71.8	519	2	Q5EBE2_HUMAN
22	368	71.5	458	2	Q5BJ22_RAT
23	365	70.9	208	2	Q6ZP87_HUMAN
24	360	69.9	140	1	HV02_MOUSE
25	360	69.9	150	2	Q9Y298_HUMAN
26	358	69.5	120	1	HV03_MOUSE
27	358	69.5	475	2	Q6N095_HUMAN
28	357	69.3	616	2	Q504M7_MOUSE
29	355	68.9	463	2	Q99LC4_MOUSE
30	354	68.7	114	1	HV00_MOUSE
31	354	68.7	117	1	HV52_MOUSE
32	354	68.7	465	2	Q6PJB2_MOUSE
33	354	68.7	613	2	Q8VCK7_MOUSE
34	353	68.5	481	2	Q91WT1_MOUSE
35	351	68.2	143	2	Q924P9_MOUSE
36	351	68.2	480	2	Q6PJF1_HUMAN
37	350	68.0	142	2	Q924Q1_MOUSE
38	350	68.0	473	2	Q9D8L4_MOUSE
39	349	67.8	157	2	Q95978_HUMAN
40	349	67.8	241	2	Q921A6_MOUSE
41	349	67.8	468	2	Q569W9_MOUSE
42	348	67.6	617	2	Q4KML5_MOUSE
43	347	67.4	117	1	HV04_MOUSE
44	347	67.4	117	1	HV14_MOUSE
45	347	67.4	475	2	Q5FVP3_RAT

RESULT 1

Q6N091_HUMAN
ID Q6N091_HUMAN PRELIMINARY; PRT; 500 AA.
AC Q6N091;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE Hypothetical protein DKF2p686C02220 (Fragment).
GN Name=DKF2p686C02220;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;
RG The German Human cDNA Consortium;
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640625; CAB45779.1; -, mRNA.
DR HSP; P01751; 1A6W.
DR SMR; Q6N091; 270-478.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON_TER
SQ SEQUENCE 500 AA; 54160 MW; 3C23A17D65A41E4 CRC64;

Query Match 89.1%; Score 459; DB 2; Length 500;

Best Local Similarity 87.8%; Pred. No. 2.9e-42;

Matches 86; Conservative 7; Mismatches 5; Indels 0; Gaps 0;

Qy 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYGISVWRQAPGGGLEWGHMISAYNGNTNY 60

Db 38 QVQLVSGAEVKKPGASVKVCKASGYTFTSDHSITLWRQAPGGGLEWIGWISYSGQTY 97

Qy 61 AQKLQGRVTMTTDTSTSTAYMELSLRLSDDTAVYYCAR 98

Db 98 AQNLQGRVTMTTDTSTSTAYMELSLRLSDDTAVYYCAK 135

RESULT 2

Q9UL95_HUMAN

```

ID OSUL95 HUMAN PRELIMINARY; PRT; 125 AA.
AC Q9UL95
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berny S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035019; AAD56255.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 1
SQ SEQUENCE 125 AA; 13516 MW; 0D3CD5C23488EAC CRC64;

Query Match 83.7%; Score 431; DB 2; Length 125;
Best Local Similarity 82.7%; Pred. No. 8.1e-40;
Matches 81; Conservative 7; Mismatches 10; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYGTSVWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 1 EVQLVSGAEVKKPGASVKVSCKASGYTFTGYHWVRQAPGQGLEWMGWSAYNGNTNY 60

QY 61 AQKLQGRVTMTDTSTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKVGQRTVTRDTTSTAYMELSLRSDDTAVYYCAR 98

RESULT 3
ID Q7Z7P5 HUMAN PRELIMINARY; PRT; 469 AA.
AC Q7Z7P5
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHL1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Strausberg R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.D., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
```

```

RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,
RA Schnurich A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RG NIH MGC Project;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC051328; AAHS1328.1; -; mRNA.
DR HSSP; P01857; 1HZH.
DR SNR; Q7Z7P5; 20-469.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003066; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Immunoglobulin domain.
SQ SEQUENCE 469 AA; 51395 MW; C8D5BE12BAAF795C CRC64;

Query Match 83.1%; Score 428; DB 2; Length 469;
Best Local Similarity 80.4%; Pred. No. 7.5e-39;
Matches 78; Conservative 10; Mismatches 9; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYGTSVWVRQAPGQGLEWMGWSAYNGNTNY 60
DB 20 QVHLVSGAEVKKPGASVKLSCKTSYGFSSDYLWVRQAPGQGLEWMGWSAHNGDTKY 79

QY 61 AQKLQGRVTMTDTSTAYMELSLRSDDTAVYYCA 97
DB 80 ARKFGQRTVTRDTTSTAYMELSLRSDDTALFYCA 116

RESULT 4
ID HV1B HUMAN STANDARD; PRT; 117 AA.
AC P01743;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region H3 precursor.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=83144028; PubMed=6298778;
RA Rechavi G., Ram D., Glazer L., Zakut R., Givol D.;
RT "Evolutionary aspects of immunoglobulin heavy chain variable region
RT (VH) gene subgroups.";
RL Proc. Natl. Acad. Sci. U.S.A. 80:855-859(1983).
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC EMBL; J00240; AAA52988.1; -; Genomic_DNA.
DR PIR; A02024; HVHUG.
DR HSSP; P01751; INQB.
DR SNR; P01743; 20-116.
```

```

DR GO: 0005576; C:extracellular region; NAS.
DR GO: 0003823; F:antigen binding; NAS.
DR GO: 0006955; P:immune response; NAS.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003596; Ig_v.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS00835; IG-LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region HG3.
FT DOMAIN 20 >117 IG-like.
FT NON_TER 117 117
FT SEQUENCE 117 AA; 12946 MW; 2D3F92FC60CD1FE7 CRC64;

Query Match 81.9%; Score 422; DB 1; Length 117;
Best Local Similarity 83.7%; Pred. No. 7.6e-39;
Matches 82; Conservative 5; Mismatches 11; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKSCASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 20 QVQLVQSGAEVKPGASVKSCASGYTFNSYMHVWRQAPGQGLEWGIINPSGGSTSY 79

Qy 61 AQKLQGRVTMTDTSTAYMELSLRSDDTAVYYCAR 98
Db 80 AQKFGQGRVTMTDTSTSTVYMELSLRSRSDTAVYYCAR 117

RESULT 5
Q9UL94_HUMAN
ID Q9UL94 HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL94;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035022; AAD56258.1; -; mRNA.
DR HSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG-LIKE; 1.
FT NON_TER 1 1
FT NON_TER 119 119
FT SEQUENCE 119 AA; 13205 MW; 13E64F5345FA416E CRC64;

Query Match 81.9%; Score 422; DB 2; Length 119;
Best Local Similarity 81.6%; Pred. No. 7.7e-39;
Matches 80; Conservative 6; Mismatches 12; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKSCASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 1 EVQLVESGAEVKPGASVKSCASGYTFTGYMHVWRQAPGQGLEWGINPSWTNY 60

Qy 61 AQKLQGRVTMTDTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKFGQGRVTMTKDTSTAYMELSLRSDDTAVYYCAR 98

GO: 0005576; C:extracellular region; NAS.
GO: 0003823; F:antigen binding; NAS.
GO: 0006955; P:immune response; NAS.
InterPro: IPR007110; Ig-like.
InterPro: IPR003596; Ig_v.
SMART: SM00406; IGV; 1.
PROSITE: PS00835; IG-LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region HG3.
FT DOMAIN 20 >117 IG-like.
FT NON_TER 117 117
FT SEQUENCE 117 AA; 12946 MW; 2D3F92FC60CD1FE7 CRC64;

Query Match 81.9%; Score 422; DB 1; Length 117;
Best Local Similarity 83.7%; Pred. No. 7.6e-39;
Matches 82; Conservative 5; Mismatches 11; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKSCASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 20 QVQLVQSGAEVKPGASVKSCASGYTFNSYMHVWRQAPGQGLEWGIINPSGGSTSY 79

Qy 61 AQKLQGRVTMTDTSTAYMELSLRSDDTAVYYCAR 98
Db 80 AQKFGQGRVTMTDTSTSTVYMELSLRSRSDTAVYYCAR 117

RESULT 5
Q9UL94_HUMAN
ID Q9UL94 HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL94;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035020; AAD56256.1; -; mRNA.
DR HSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG-LIKE; 1.
FT NON_TER 1 1
FT NON_TER 119 119
FT SEQUENCE 119 AA; 13205 MW; 13E64F5345FA416E CRC64;

Query Match 81.9%; Score 422; DB 2; Length 119;
Best Local Similarity 81.6%; Pred. No. 7.7e-39;
Matches 80; Conservative 6; Mismatches 12; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKSCASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 1 EVQLVESGAEVKPGASVKSCASGYTFTGYMHVWRQAPGQGLEWGINPSWTNY 60

Qy 61 AQKLQGRVTMTDTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKFGQGRVTMTKDTSTAYMELSLRSDDTAVYYCAR 98

```

```

RESULT 6
Q9UL92_HUMAN
ID Q9UL92 HUMAN PRELIMINARY; PRT; 124 AA.
AC Q9UL92;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035022; AAD56258.1; -; mRNA.
DR HSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG-LIKE; 1.
FT NON_TER 1 1
FT NON_TER 124 124
FT SEQUENCE 124 AA; 13580 MW; 1BAACBD96ACD2A2 CRC64;

Query Match 81.0%; Score 417; DB 2; Length 124;
Best Local Similarity 81.8%; Pred. No. 2.9e-38;
Matches 80; Conservative 8; Mismatches 10; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKSCASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 1 EVQLVESGAEVKPGASVKSCASGYTFTSSYMHVWRQAPGQGLEWGIINPSGGSTSY 60

Qy 61 AQKLQGRVTMTDTSTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKFGQGRVTMTDTSTSTVYMELSLRSRSDTAVYYCAR 98

RESULT 7
HVIG_HUMAN
ID HVIG_HUMAN STANDARD; PRT; 117 AA.
AC P23083;
DT 01-NOV-1991 (Rel. 20, Created)
DT 01-NOV-1991 (Rel. 20, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region V35 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=88296408; PubMed=2841108;
RA Matsuda F., Lee K.H., Nakai S., Sato T., Kodaira M., Zong S.Q.,
RA Ohno H., Fukuhara S., Honjo T.;
RT "Dispersed localization of D segments in the human immunoglobulin
RT heavy-chain locus.";
RL EMBO J. 7:1047-1051(1988).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 20-116.
RX PubMed=7681398;
RA Mariette X., Teapais A., Brouet J.C.;
RT "Nucleotide sequence analysis of the variable domains of four human
RT monoclonal IgM with an antibody activity to myelin-associated

```

```

RT glycoprotein.";
RL Eur. J. Immunol. 23:846-851(1993).
CC -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; X07448; -; NOT_ANNOTATED_CDS; Genomic_DNA.
CC PIR; S00476; HVH035.
CC HSSP; P01751; 1NQB.
CC SNR; P23083; 20-117.
CC Ensembl; ENSG00000130076; Homo sapiens.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; Ig-like.
CC InterPro; IPR003596; Ig_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS0835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region V35.
FT DOMAIN 20 >117 Ig-like.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 13009 MW; BE61CE63F8CE97BD CRC64;

Query Match 80.68; Score 415; DB 1; Length 117;
Best Local Similarity 82.74; Pred. No. 4.5e-36;
Matches 81; Conservative 3; Mismatches 14; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKSCASGYTFTSYGISVWRQAPGGGLEWMGWISAYNGNTNY 60
Db 20 QVHLVSGAEVKKPGASVKSCASGYTFTGYVHWWRQAPGGGLEWMGWINPNSGGTNY 79

QY 61 AQKLGQGVTTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 80 AKRFGQGVTTTDTSTSTAYMELSLRSDDTAVYYCAR 117

RESULT 8
Q9BRV0 HUMAN
ID Q9BRV0_HUMAN PRELIMINARY; PRT; 500 AA.
AC Q9BRV0;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE MGC27165 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettaman M., Madan A., Rodríguez S., Sanchez A.,
RA Whiting M., Touchman J.W., Green E.D., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Dickinson M.C.,

```

```

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnarch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RA Strausberg R.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC005951; AAH05951.1; -; mRNA.
DR HSSP; P01876; 1OW0.
DR SNR; Q9BRV0; 25-300, 270-478.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 500 AA; 54154 MW; 0A9BF43F2A3CC6D9 CRC64;

Query Match 80.44; Score 414; DB 2; Length 500;
Best Local Similarity 79.64; Pred. No. 2.9e-37;
Matches 78; Conservative 6; Mismatches 14; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKSCASGYTFTSYGISVWRQAPGGGLEWMGWISAYNGNTNY 60
Db 20 QVHLVSGAEVKKPGASVKSCASGYTFTGYVHWWRQAPGGGLEWMGWISPSDNTRF 79

QY 61 AQKLGQGVTTTDTSTSTAYMELSLRSDDTAVYYCAR 98
Db 80 AKRFGQGVTTTDTSTSTAYMELSLRSDDTAVYYCAR 117

RESULT 9
Q6NSA4 HUMAN
ID Q6NSA4_HUMAN PRELIMINARY; PRT; 120 AA.
AC Q6NSA4;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHV1-69 protein.
GN Name=IGHV1-69;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Pooled;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettaman M., Madan A., Rodríguez S., Sanchez A.,
RA Whiting M., Touchman J.W., Green E.D., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,

```

```
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Maria M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
PL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Pooled;
RG NIH MGC Project;
RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC070333; AAH70333.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q6NSA4; 21-116.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 120 AA; 13035 MW; 64620FAC874585D4 CRC64;

Query Match 79.2%; Score 408; DB 2; Length 120;
Best Local Similarity 81.6%; Pred. No. 2.8e-37;
Matches 80; Conservative 5; Mismatches 13; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 20 QVQLVQSGAEVKKPGSSVKVSCKASGCTFSYALSWVRQAPGQGLEWMGGIPIFGTANY 79

Qy 61 AQKLQGRVTMTDTSTSTAYMELSLRLSDDTAVYYCAR 98
Db 80 TQKFGQRTVITTDSTSTAYMELSLRLSDDTAVYYCAR 117

RESULT 10
Q65ZC8 HUMAN
ID Q65ZC8 HUMAN PRELIMINARY; PRT; 244 AA.
AC Q65ZC8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
SQ SEQUENCE 244 AA; 26127 MW; 4B1F7869338F2BF CRC64;

RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631 (1997).
DR EMBL; Y13057; CAA73500.1; -; mRNA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGv; 2.
DR PROSITE; PS50835; IG_LIKE; 2.
FT NON_TER 244
FT NON_TER 244
SQ SEQUENCE 244 AA; 26127 MW; 4B1F7869338F2BF CRC64;

Query Match 79.2%; Score 408; DB 2; Length 244;
Best Local Similarity 78.6%; Pred. No. 6.1e-37;
Matches 77; Conservative 7; Mismatches 14; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 1 QVQLVQSGAEVKKPGDSVKVSCKASGYTFTSDHYMHVVRQAPGQGLEWMGIDPNNGTFR 60

Qy 61 AQKLQGRVTMTDTSTSTAYMELSLRLSDDTAVYYCAR 98
```

```
Db 61 AORFQGRVTMTDTSISAAAYMEVSLRLSDDTAVYYCAR 98

RESULT 11
Q6N030 HUMAN
ID Q6N030 HUMAN PRELIMINARY; PRT; 518 AA.
AC Q6N030;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKF2p686i15212.
GN Name=DKF2p686i15212;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Rectum tumor;
RG The German CDNA Consortium;
RA Pouscka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA Mewes H.W., Weil B., Anid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640724; CAB45841.1; -; mRNA.
DR HSSP; P01861; 1ADQ.
DR InterPro; IPR000005; HTHArac.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG-cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 3.
DR SMART; SM00407; IG1; 3.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS00041; HTH_ARAC_FAMILY_1; UNKNOWN_1.
DR PROSITE; PS50835; IG_LIKE_4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 518 AA; 57019 MW; 93B5F98613BF6382 CRC64;

Query Match 78.4%; Score 404; DB 2; Length 518;
Best Local Similarity 77.6%; Pred. No. 3.9e-36;
Matches 76; Conservative 10; Mismatches 12; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 20 QVHLVQSGAEVKKPGASVKVSCTASGYPTTFHFINVVRQAPGQGLEWMGINTGNTKY 79

Qy 61 AQKLQGRVTMTDTSTSTAYMELSLRLSDDTAVYYCAR 98
Db 80 SQKFGQRTVITTDITWTITTTAYMDLSLRSDDTAVYYCAR 117

RESULT 12
Q96QS0 HUMAN
ID Q96QS0 HUMAN PRELIMINARY; PRT; 159 AA.
AC Q96QS0;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Putative matrix cell adhesion molecule-3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Tilson M.D.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
```

```

DR EMBL; AY039025; AAK82649.1; -; mRNA.
DR HSSP; P01869; 1AE6.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 159 AA; 17497 MW; 5D29537E881FAF02 CRC64;

Query Match 77.7%; Score 400; DB 2; Length 159;
Best Local Similarity 77.6%; Pred. No. 3e-36;
Matches 76; Conservative 10; Mismatches 12; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKPGASVKVSCKASGYTFTSYGISVWRQAPGGQLEWMGWISAYNGNTNY 60
DB 20 QVQLVSGAEVKPGASVKVSCKASGYTFTSYGISVWRQAPGGQLEWMGWISAYNGNTNY 79
QY 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYICAR 98
DB 80 SQAFQGRLTWTRDTSTSTAYMELSLRSDDTAVYFCAR 117

RESULT 13
Q6N041 HUMAN
ID Q6N041_HUMAN PRELIMINARY; PRT; 498 AA.
AC Q6N041;
DT 03-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE Hypothetical protein DKFp686O16217 (Fragment).
GN Name=DKFp686O16217;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;
RG The German Human cDNA Consortium;
RA Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA Mewes H.W., Weill B., Amid C., Oranger A., Fobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BK640710; CAB45829.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q6N041; 268-476.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON_TER 1
FT NON_TER 1
SQ SEQUENCE 498 AA; 54125 MW; 40B3208A84E03B46 CRC64;

Query Match 76.9%; Score 396; DB 2; Length 498;
Best Local Similarity 76.5%; Pred. No. 2.9e-35;
Matches 75; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKPGASVKVSCKASGYTFTSYGISVWRQAPGGQLEWMGWISAYNGNTNY 60
DB 35 QVQLVSGADVKKPGASVKVSCKASGYTFTSYFHWVRQAPGGQLEWMGWINPRDGSYK 94
QY 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYICAR 98
DB 95 AQRFQGRVSNTRDTSTSTAYMELSLRSDDTAVYFCAR 132

us-09-674-752-26.rup

```

```

RESULT 14
Q9GYZ2_MOUSE
ID Q9GYZ2_MOUSE PRELIMINARY; PRT; 119 AA.
AC Q9GYZ2;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Monoclonal anti-idiotypic Schistosoma japonicum antibody NP30 heavy
DE chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Song X.-T., Feng Z.Q., Guan X.H.;
RT "Amplification, cloning and sequence analysis of the heavy chain
RT variable region gene of monoclonal anti-idiotypic antibody NP30 of
RT Schistosoma japonicum.";
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF282622; AAG01452.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q9GYZ2; 1-119.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 119
FT NON_TER 119
SQ SEQUENCE 119 AA; 13567 MW; BA93873FD5FA6AB CRC64;

Query Match 75.5%; Score 389; DB 2; Length 119;
Best Local Similarity 75.5%; Pred. No. 3.6e-35;
Matches 74; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKPGASVKVSCKASGYTFTSYGISVWRQAPGGQLEWMGWISAYNGNTNY 60
DB 1 QVQLVESGAEVKPGASVKVSCKASGYTFTGYVMVWRQAPGHGIEWIGYINPSRGYTN 60
QY 61 AQKLGQRTVMTTDTSTSTAYMELSLRSDDTAVYICAR 98
DB 61 NQKFKDRVTMTTDTKSFSTAYMDLRLSRLSADSAVYICAR 98

RESULT 15
HV1C_HUMAN
ID HV1C_HUMAN STANDARD; PRT; 147 AA.
AC P01744;
DT 21-JUL-1986 (Rel. 01, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region ND precursor (Fragments).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=83065234; PubMed=6815656;
RA Kenten J.H., Wolgaard H.V., Houghton M., Derbyshire R.B., Viney J.,
RA Bell L.O., Gould H.J.;
RT "Cloning and sequence determination of the gene for the human
RT immunoglobulin epsilon chain expressed in a myeloma cell line.";
RL Proc. Natl. Acad. Sci. U.S.A. 79:6661-6665(1982).
RN [2]
RP PROTEIN SEQUENCE OF 20-147.
RA Bennich H.H., Johansson S.G.O., von Bahr-Lindstrom H.;
RL (in) Bach M.K. (eds.);
RL Immediate hypersensitivity: modern concepts and developments, pp.1-36,
RL Marcel Dekker, New York (1978).

```

```
CC -!- MISCELLANEOUS: This epsilon chain was isolated from a myeloma
CC protein.
CC -!- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR HSP: P01751; INQB.
DR GO: GO:000576; C:extracellular region; NAS.
DR GO: GO:0003823; F:antigen binding; NAS.
DR GO: GO:0006955; P:immune response; NAS.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003596; Ig_v.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS00835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Pyrrolidone carboxylic acid; Signal.
FT SIGNAL 1 19
FT CHAIN 20 147 Ig heavy chain V-I region ND.
FT DOMAIN 20 131 Ig-like.
FT MOD_RES 20 20 Pyrrolidone carboxylic acid.
FT DISULFID 41 115
FT CONFLICT 21 21 T -> V (in Ref. 2).
FT CONFLICT 53 54 IH -> HI (in Ref. 2).
FT CONFLICT 67 68 VG -> GV (in Ref. 2).
FT CONFLICT 125 125 Missing (in Ref. 2).
FT NON_TER 147 147
SQ SEQUENCE 147 AA; 16496 MW; 948F9F72A5366C20 CRC64;

Query Match 75.5%; Score 389; DB 1; Length 147;
Best Local Similarity 73.5%; Pred.No. 4.6e-35;
Matches 72; Conservative 11; Mismatches 15; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY 60
Db 20 QTLVQSGAEVRKPGASVRVSKASGYTFIDSYIHWRQAPGHGLEWVGWVNPNSGCTNY 79

Qy 61 AQKLQGRVTMTDTSTAYMELSLRSDDTAVYYCAR 98
Db 80 APRFQGRVTMTDRDASFSTAYMDLSRLSRSDSDSAVFYCAK 117

Search completed: May 5, 2006, 09:14:34
Job time : 37.8737 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:28 ; Search time 38.7295 Seconds
(without alignments)
1111.793 Million cell updates/sec

Title: US-09-674-752-27

Perfect score: 521

Sequence: 1 QVQLQSATEVKKPGAMKV.....AYMELSLRSDDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21:*

- 1: Geneseq1980s:*
- 2: Geneseq1990s:*
- 3: Geneseq2000s:*
- 4: Geneseq2001s:*
- 5: Geneseq2002s:*
- 6: Geneseq2003as:*
- 7: Geneseq2003bs:*
- 8: Geneseq2004s:*
- 9: Geneseq2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	511	98.1	98	3 AAY50954	Aay50954 Human ant
2	499	95.8	132	3 AAY50953	Aay50953 Human ant
3	490	94.0	132	3 AAY50950	Aay50950 Human ant
4	469	90.0	98	3 AAY50955	Aay50955 Human ant
5	463	88.9	247	5 ABP45105	Abp45105 Human Bly
6	463	88.9	247	7 ADG95932	Adg95932 Single ch
7	463	88.9	250	5 ABP45549	Abp45549 Human Bly
8	463	88.9	250	7 ADG96376	Adg96376 Single ch
9	463	88.9	251	5 ABP45727	Abp45727 Human Bly
10	463	88.9	251	7 ADG96554	Adg96554 Single ch
11	460	88.3	250	5 ABP45584	Abp45584 Human Bly
12	460	88.3	250	7 ADG96411	Adg96411 Single ch
13	456	87.5	98	3 AAY50952	Aay50952 Human ant
14	456	87.5	98	5 ABG78171	Abg78171 Human Fv
15	456	87.5	98	5 ABG91862	Abg91862 Human ant
16	456	87.5	98	6 ABO27071	Abc27071 Human ger
17	456	87.5	98	7 ADC99824	Adc99824 Germline
18	456	87.5	98	7 ADD05428	Add05428 Anti-MUC1
19	456	87.5	98	7 ADF09899	Adf09899 Antibody
20	456	87.5	98	7 ADF10109	Adf10109 Antibody
21	456	87.5	98	7 ADF10007	Adf10007 VEGF anti
22	456	87.5	98	7 ADF09866	Adf09866 Anti-MUC1
23	456	87.5	98	7 ADK18578	Adk18578 Anti-huma
24	456	87.5	98	7 ADK18932	Adk18932 Anti-huma

25	456	87.5	98	7	ADK18931	Adk18931 Anti-huma
26	456	87.5	98	7	ADK18900	Adk18900 Anti-huma
27	456	87.5	98	7	ADK18902	Adk18902 Anti-huma
28	456	87.5	98	7	ADJ80284	Adj80284 VH gene 1
29	456	87.5	98	9	ADY75289	Ady75289 Protein e
30	456	87.5	98	9	AEA89838	Aea89838 Anti-IPN
31	456	87.5	104	4	ABB40538	Abb40538 Peptide #
32	456	87.5	104	4	ABG55895	Abg55895 Human liv
33	456	87.5	109	8	ADP22378	Adp22378 Human ant
34	456	87.5	109	8	ADP22384	Adp22384 Human ant
35	456	87.5	109	8	ADS12516	Ads12516 Human Vh1
36	456	87.5	117	2	AAR66311	Aar66311 Human imm
37	456	87.5	117	7	ADK18782	Adk18782 Anti-huma
38	456	87.5	118	8	ADJ57857	Adj57857 Heavy var
39	456	87.5	118	8	ADJ57859	Adj57859 Heavy var
40	456	87.5	118	9	ADZ42015	Adz42015 Ig H chai
41	456	87.5	121	9	ABE45964	Ab45964 Human mon
42	456	87.5	123	9	ABE12766	Aeb12766 Antibody
43	456	87.5	125	6	ABR55813	AbR55813 Heavy cha
44	456	87.5	125	7	ADK18783	Adk18783 Anti-huma
45	456	87.5	125	7	ADK18618	Adk18618 Anti-huma

ALIGNMENTS

RESULT 1

AAY50954

ID AAY50954 standard; protein; 98 AA.

XX AAY50954;

AC AAY50954;

DT 23-MAR-2000 (first entry)

XX Human anti-factor VIII antibody VH protein VH EL-5.

DE Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

XX Homo sapiens.

OS Homo sapiens.

XX WO9958680-A2.

PN 18-NOV-1999.

XX 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

PD (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;

XX WPI; 2000-053102/04.

XX New polynucleotide, polypeptide and antibody useful for diagnosing the

XX presence of neutralizing antibodies against factor VIII and for treatment

XX of hemophilia A patients with these antibodies.

XX Example 4; Fig 4B; 61pp; English.

XX This invention describes a novel polynucleotide (I) (and complements and

XX hybridizable polynucleotides) comprising a contiguous nucleotide sequence

XX coding for a human antibody with factor VIII specificity which has

XX hemostatic activity. (I) is useful a primer or probe for detecting the

XX presence of inhibitory antibodies directed against factor VIII. The

XX polypeptides of the invention and the antibodies generated from them are

XX useful in compositions for neutralizing factor VIII inhibiting antibodies

XX in hemophilia A patients. This sequence represents the human anti-factor

XX VIII antibody VH EL-5 protein which is used in the method of the

XX invention

XX Sequence 98 AA;

Query Match 98.1%; Score 511; DB 3; Length 98;
 Best Local Similarity 98.0%; Pred. No. 1.3e-44;
 Matches 96; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
 ||||:|||||
 Db 1 QVQLVLSATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
 ||||:|||||

QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
 |||||
 Db 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
 |||||

RESULT 2
 AAY50953
 ID AAY50953 standard; protein; 132 AA.
 AC AAY50953;
 XX
 DT 23-MAR-2000 (first entry)
 XX
 DE Human anti-factor VIII antibody VH protein VH IT-2.
 XX
 KW Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
 KW VH protein.
 XX
 OS Homo sapiens.
 XX
 PN WO9958680-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 07-MAY-1999; 99WO-NL000285.
 XX
 PR 08-MAY-1998; 98EP-00201543.
 XX
 XX (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.
 PA Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 XX WPI; 2000-053102/04.
 XX
 PI New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX
 PS Example 4; Fig 4B; 6lpp; English.
 XX
 CC This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has
 CC hemostatic activity. (I) is useful a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents the human anti-factor
 CC VIII antibody VH IT-2 protein which is used in the method of the
 CC invention
 XX
 SQ Sequence 132 AA;

Query Match 95.8%; Score 499; DB 3; Length 132;
 Best Local Similarity 95.9%; Pred. No. 3e-43;
 Matches 94; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
 |||||
 Db 1 QVQLQSATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
 |||||

QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
 |||||
 Db 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
 |||||

RESULT 4
 AAY50955
 ID AAY50955 standard; protein; 98 AA.
 AC AAY50955;
 XX
 DT 23-MAR-2000 (first entry)
 XX
 DE Human anti-factor VIII antibody VH protein VH EL-25.
 XX

RESULT 3
 AAY50950
 ID AAY50950 standard; protein; 132 AA.
 AC AAY50950;
 XX
 DT 23-MAR-2000 (first entry)
 XX
 DE Human anti-factor VIII antibody VH clone IT-2 encoded protein.
 XX
 KW Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
 KW VH gene.
 XX
 OS Homo sapiens.
 XX
 PN WO9958680-A2.
 XX
 PD 18-NOV-1999.
 XX
 PF 07-MAY-1999; 99WO-NL000285.
 XX
 PR 08-MAY-1998; 98EP-00201543.
 XX
 XX (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.
 PA Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 XX WPI; 2000-053102/04.
 XX
 PI New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX
 PS Example 4; Fig 4A; 6lpp; English.
 XX
 CC This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has
 CC hemostatic activity. (I) is useful a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents the human anti-factor
 CC VIII antibody clone IT-2 protein which is used in the method of the
 CC invention
 XX
 SQ Sequence 132 AA;

Query Match 94.0%; Score 490; DB 3; Length 132;
 Best Local Similarity 94.9%; Pred. No. 2.5e-42;
 Matches 93; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
 |||||
 Db 1 QVQLQSATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
 |||||

QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
 |||||
 Db 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
 |||||

RESULT 4
 AAY50955
 ID AAY50955 standard; protein; 98 AA.
 AC AAY50955;
 XX
 DT 23-MAR-2000 (first entry)
 XX
 DE Human anti-factor VIII antibody VH protein VH EL-25.
 XX

KW Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
 KW VH protein.
 XX
 XX Homo sapiens.
 XX
 XX W09958680-A2.
 XX
 XX 18-NOV-1999.
 XX
 XX 07-MAY-1999; 99WO-NL000285.
 XX
 XX 08-MAY-1998; 98EP-00201543.
 XX
 XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
 XX
 XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 XX WPI; 2000-053102/04.
 XX
 XX New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX
 XX Example 4; Fig 4B; 6lpp; English.
 XX
 XX This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has
 CC hemostatic activity. (I) is useful a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents the human anti-factor
 CC VIII antibody VH EL-25 protein which is used in the method of the
 CC invention
 XX
 XX Sequence 98 AA;
 SQ
 Query Match 90.0%; Score 469; DB 3; Length 98;
 Best Local Similarity 89.8%; Pred. No. 2.6e-40;
 Matches 88; Conservative 4; Mismatches 6; Indels 0; Gaps 0;
 QY 1 QVQLQSATEVKKPGASMKVSCWASGYPFTSYDLSWVRQAPGGGLEWVGWISAYNGNTHY 60
 DB 1 QVQLQSAAEVRKPGASVKVSKASGYPFTSYDLSWVRQAPGGGLEWVGWISYSGNTDY 60
 QY 61 AOKFQGRVTMTTDSRTTAYMELRSLRSDDTAVYYCAR 98
 DB 61 AOKFQGRVTMTTDSRTTAYMELRSLRSDDTAVYYCAR 98
 RESULT 5
 ID ABP45105 standard; protein; 247 AA.
 AC
 AC ABP45105;
 XX
 XX 19-AUG-2002 (first entry)
 DT
 XX Human BLYS binding scFv SEQ ID 1116.
 DE
 XX BLYS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 XX Homo sapiens.
 OS
 XX WO200202641-A1.
 PN
 XX 10-JAN-2002.
 PD

XX 15-JUN-2001; 2001WO-US019110.
 PF
 XX 16-JUN-2000; 2000US-0212210P.
 PR
 PR 17-OCT-2000; 2000US-0240816P.
 PR 16-MAR-2001; 2001US-0276248P.
 PR 21-MAR-2001; 2001US-0277379P.
 PR 25-MAY-2001; 2001US-0293499P.
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 PA
 XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 PI WPI; 2002-114799/15.
 XX
 XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 PT diagnosis and treatment of cancers and immune disorders.
 PT
 XX Claim 1; Page 1734-1735; 3148pp; English.
 PS
 XX This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (BLYS) polypeptides. BLYS is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BLYS. The antibodies bind to BLYS
 CC and so may be used to detect and quantitate the presence of BLYS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BLYS. They may also be
 CC administered to treat diseases associated with aberrant BLYS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention
 XX
 XX Sequence 247 AA;
 SQ
 Query Match 88.9%; Score 463; DB 5; Length 247;
 Best Local Similarity 89.8%; Pred. No. 2.9e-39;
 Matches 98; Conservative 3; Mismatches 7; Indels 0; Gaps 0;
 QY 1 QVQLQSATEVKKPGASMKVSCWASGYPFTSYDLSWVRQAPGGGLEWVGWISAYNGNTHY 60
 DB 1 QVQLQSAAEVRKPGASVKVSKASGYPFTSYDLSWVRQAPGGGLEWVGWISAYNGNTNY 60
 QY 61 AOKFQGRVTMTTDSRTTAYMELRSLRSDDTAVYYCAR 98
 DB 61 AOKLQGRVTMTTDSRTTAYMELRSLRSDDTAVYYCAR 98
 RESULT 6
 ADG95932
 ID ADG95932 standard; protein; 247 AA.
 XX
 XX ADG95932;
 AC
 XX 11-MAR-2004 (first entry)
 DT
 XX Single chain antibody that immunospecifically binds BLYS SeqID 1116.
 DE
 XX antibody; B lymphocyte stimulator; BLYS; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antiaschmatic; antiallergic; cytostatic.
 XX
 XX Unidentified.
 OS
 XX WO2003055979-A2.
 PN

```

XX PD 10-JUL-2003.
XX PF 14-NOV-2002; 2002WO-US036496.
XX PR 16-NOV-2001; 2001US-0331469P.
XX PR 19-DEC-2001; 2001US-0340817P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX DR WPI; 2003-505530/47.
XX PT Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX PT (Blys), useful for detecting and treating diseases or disorders e.g.
XX PT rheumatoid arthritis, asthma and leukemia.
XX PS Example 1; SEQ ID NO 1116; 394pp; English.
XX CC This invention relates to novel antibodies that immunospecifically bind
XX CC to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
XX CC chromosome 13q34 and encodes a protein that is a member of the tumour
XX CC necrosis factor superfamily and induces both in vivo and in vitro B cell
XX CC proliferation and differentiation. Specifically, it refers to single
XX CC chain antibody molecules (scFvs) derived, preferably, from the variable
XX CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX CC fragment thereof, of either human, murine, rat or monkey Blys. The
XX CC present invention refers to the use of such antibodies in various methods
XX CC for the detection, diagnosis and prognosis of diseases related to the
XX CC aberrant expression or inappropriate function of Blys or its receptor. As
XX CC such, these compositions are useful for identifying immune disorders
XX CC including myasthenia gravis and multiple sclerosis, inflammatory
XX CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX CC as AIDS and proliferative disorders including leukaemia, carcinoma and
XX CC lymphoma. Accordingly, they can be described as exhibiting various
XX CC activities such as antirheumatic, antiarthritic, neuroprotective,
XX CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
XX CC polypeptide sequence is a single chain antibody that binds Blys of the
XX CC invention. NOTE: The sequence data for this patent did not form part of
XX CC the printed specification, but was obtained in electronic format
XX CC directly from WIPO at ffp.wipo.int/pub/published pct_sequences.
XX SQ Sequence 247 AA;
Query Match 88.9%; Score 463; DB 7; Length 247;
Best Local Similarity 89.8%; Pred. No. 2.9e-39;
Matches 88; Conservative 3; Mismatches 7; Indels 0; Gaps 0;
QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDLSWVRQAPGGQLEWGVWISAYNGNTHY 60
DB 1 QVQLQSAAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWGMWISAYNGNTHY 60
QY 61 AQKFGQGRVTMTTDSRRTAYMELRSLRSDDTAVYYCAR 98
DB 61 AQKLGQGRVTMTTDSRRTAYMELRSLRSDDTAVYYCAR 98
RESULT 7
ID ABP45549
XX ID ABP45549 standard; protein; 250 AA.
XX AC ABP45549;
XX DT 19-AUG-2002 (first entry)
XX DE Human Blys binding scFv SEQ ID 1560.
XX KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX KW tumour necrosis factor; B cell proliferation; B cell differentiation;
XX KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
XX KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;

```

```

KW XX common variable immunodeficiency; acquired immunodeficiency syndrome.
OS XX Homo sapiens.
PN XX WO200202641-A1.
PD XX 10-JAN-2002.
XX PF 15-JUN-2001; 2001WO-US019110.
XX PR 16-JUN-2000; 2000US-0212210P.
XX PR 17-OCT-2000; 2000US-0240816P.
XX PR 16-MAR-2001; 2001US-0276248P.
XX PR 21-MAR-2001; 2001US-0277379P.
XX PR 25-MAY-2001; 2001US-0293499P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX DR WPI; 2002-114799/15.
XX PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
XX PT diagnosis and treatment of cancers and immune disorders.
XX PS Claim 1; Page 2264-2265; 3148pp; English.
XX CC This invention describes novel antibodies that immunospecifically bind to
XX CC B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the
XX CC tumour necrosis factor (TNF) super family and induces B cell
XX CC proliferation and differentiation. The antibodies of the invention have
XX CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX CC antirheumatic and antiAIDS activity and can be used in vaccines to
XX CC inhibit the expression and activity of Blys. The antibodies bind to Blys
XX CC and so may be used to detect and quantitate the presence of Blys in
XX CC biological samples and may be used in this way to diagnose disease
XX CC associated with aberrant expression of Blys. They may also be
XX CC administered to treat diseases associated with aberrant Blys expression
XX CC and activity such as cancer, immune, and autoimmune disorders and
XX CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX CC the antibodies and fragments of the antibodies described in the method of
XX CC the invention
XX SQ Sequence 250 AA;
Query Match 88.9%; Score 463; DB 5; Length 250;
Best Local Similarity 89.8%; Pred. No. 2.9e-39;
Matches 88; Conservative 3; Mismatches 7; Indels 0; Gaps 0;
QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDLSWVRQAPGGQLEWGVWISAYNGNTHY 60
DB 1 QVQLQSAAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWGMWISAYNGNTHY 60
QY 61 AQKFGQGRVTMTTDSRRTAYMELRSLRSDDTAVYYCAR 98
DB 61 AQKLGQGRVTMTTDSRRTAYMELRSLRSDDTAVYYCAR 98
RESULT 8
ID ADG96376
XX ID ADG96376 standard; protein; 250 AA.
XX AC ADG96376;
XX DT 11-MAR-2004 (first entry)
XX DE Single chain antibody that immunospecifically binds Blys SeqID 1560.
XX KW antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
XX KW B cell proliferation; differentiation; scFv; myasthenia gravis;

```

KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
OS Unidentified.
XX WO2003055979-A2.
XX 10-JUL-2003.
XX 14-NOV-2002; 2002WO-US036496.
XX 16-NOV-2001; 2001US-0331469P.
XX 19-DEC-2001; 2001US-0340817P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX WPI; 2003-505530/47.
XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
PT (Blys), useful for detecting and treating diseases or disorders e.g.
PT rheumatoid arthritis, asthma and leukemia.
XX Example 1; SEQ ID NO 1560; 394pp; English.
XX This invention relates to novel antibodies that immunospecifically bind
CC to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
CC chromosome 13q34 and encodes a protein that is a member of the tumour
CC necrosis factor superfamily and induces both in vivo and in vitro B cell
CC proliferation and differentiation. Specifically, it refers to single
CC chain antibody molecules (scFvs) derived, preferably, from the variable
CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
CC fragment thereof, of either human, murine, rat or monkey Blys. The
CC present invention refers to the use of such antibodies in various methods
CC for the detection, diagnosis and prognosis of diseases related to the
CC aberrant expression or inappropriate function of Blys or its receptor. As
CC such, these compositions are useful for identifying immune disorders
CC including myasthenia gravis and multiple sclerosis, inflammatory
CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
CC as AIDS and proliferative disorders including leukaemia, carcinoma and
CC lymphoma. Accordingly, they can be described as exhibiting various
CC activities such as antirheumatic, antiarthritic, neuroprotective,
CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
CC polypeptide sequence is a single chain antibody that binds Blys of the
CC invention. NOTE: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX SQ Sequence 250 AA;
Query Match 88.9%; Score 463; DB 7; Length 250;
Best Local Similarity 89.8%; Pred. No. 2.9e-39;
Matches 88; Conservative 3; Mismatches 7; Indels 0; Gaps 0;
QY 1 QVQLQSATVKKPGASMKVSCNMGYPFTSYISWVRQAPGQGLEWVGWISAYNGNTHY 60
DB 1 QVQLQSAAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTN 60
QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGRVTMTTDSRTSTAYMELSLRSDDTAVYYCAR 98
RESULT 9
ID ABP45727
XX ABP45727 standard; protein; 251 AA.
XX ABP45727;
XX 19-AUG-2002 (first entry)
XX

DE Human Blys binding scFv SEQ ID 1738.
XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
OS Homo sapiens.
XX WO200202641-A1.
XX 10-JAN-2002.
XX 15-JUN-2001; 2001WO-US019110.
XX 16-JUN-2000; 2000US-0212210P.
XX 17-OCT-2000; 2000US-0240816P.
XX 16-MAR-2001; 2001US-0276248P.
XX 21-MAR-2001; 2001US-0277379P.
XX 25-MAY-2001; 2001US-0293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX Antibodies against B lymphocyte Stimulating polypeptides, useful for the
PT diagnosis and treatment of cancers and immune disorders.
XX Claim 1; Page 2476-2477; 3148pp; English.
XX This invention describes novel antibodies that immunospecifically bind to
CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of Blys. The antibodies bind to Blys
CC and so may be used to detect and quantitate the presence of Blys in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of Blys. They may also be
CC administered to treat diseases associated with aberrant Blys expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method of
CC the invention
XX SQ Sequence 251 AA;
Query Match 88.9%; Score 463; DB 5; Length 251;
Best Local Similarity 88.8%; Pred. No. 3e-39;
Matches 87; Conservative 3; Mismatches 8; Indels 0; Gaps 0;
QY 1 QVQLQSATVKKPGASMKVSCNMGYPFTSYISWVRQAPGQGLEWVGWISAYNGNTHY 60
DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTHY 60
QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGRVTMTTDSRTSTAYMELSLRSDDTAVYYCAR 98
RESULT 10
ID ADG96554
XX ADG96554 standard; protein; 251 AA.
XX AC ADG96554;

```

XX
DT 11-MAR-2004 (first entry)
DE Single chain antibody that immunospecifically binds BlyS SeqID 1738.
DE
XX
XX antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
XX B cell proliferation; differentiation; scFv; myasthenia gravis;
XX multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
XX carcinoma; lymphoma; anti-rheumatic; anti-arthritis; neuroprotective;
XX anti-inflammatory; anti-asthmatic; anti-allergic; cytostatic.
XX
OS Unidentified.
XX
PN WO2003055979-A2.
XX
XX 10-JUL-2003.
XX
XX 14-NOV-2002; 2002WO-US036496.
XX
XX 16-NOV-2001; 2001US-0331469P.
XX 19-DEC-2001; 2001US-0340817P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX WPI; 2003-505530/47.
XX
XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX (BlyS), useful for detecting and treating diseases or disorders e.g.
XX rheumatoid arthritis, asthma and leukemia.
XX
XX Example 1; SEQ ID NO 1738; 394pp; English.
XX
XX This invention relates to novel antibodies that immunospecifically bind
XX to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
XX chromosome 13q34 and encodes a protein that is a member of the tumour
XX necrosis factor superfamily and induces both in vivo and in vitro B cell
XX proliferation and differentiation. Specifically, it refers to single
XX chain antibody molecules (scFvs) derived, preferably, from the variable
XX heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX fragment thereof, of either human, murine, rat or monkey BlyS. The
XX present invention refers to the use of such antibodies in various methods
XX for the detection, diagnosis and prognosis of diseases related to the
XX aberrant expression or inappropriate function of BlyS or its receptor. As
XX such, these compositions are useful for identifying immune disorders
XX including myasthenia gravis and multiple sclerosis, inflammatory
XX disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX as AIDS and proliferative disorders including leukaemia, carcinoma and
XX lymphoma. Accordingly, they can be described as exhibiting various
XX activities such as anti-rheumatic, anti-arthritis, neuroprotective,
XX anti-inflammatory, anti-asthmatic, anti-allergic and cytostatic. This
XX polypeptide sequence is a single chain antibody that binds BlyS of the
XX invention. NOTE: The sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX
SQ Sequence 251 AA;
Query Match 88.9%; Score 463; DB 7; Length 251;
Best Local Similarity 88.8%; Pred. No. 3e-39;
Matches 87; Conservative 3; Mismatches 8; Indels 0; Gaps 0;
QY 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGLEWVGWISAYNGNTHY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGLEWVGWISAYNGNTHY 60
QY 61 AQKFGQGRVTMTTDTTSRRRTAYMELRLSLRSDDTAVYYCAR 98
DB 61 AQKLGQRVTMTTDTSTSTAYMELRLSLRSDDTAVYYCAR 98
RESULT 11

```

```

ABP45584
ID ABP45584 standard; protein; 250 AA.
XX
XX AC ABP45584;
XX
XX 19-AUG-2002 (first entry)
XX
XX Human BlyS binding scFv SEQ ID 1595.
XX
XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; immunomodulatory; anti-rheumatic;
XX anti-AIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
XX Homo sapiens.
XX
XX WO200202641-A1.
XX
XX 10-JAN-2002.
XX
XX 15-JUN-2001; 2001WO-US019110.
XX
XX 16-JUN-2000; 2000US-0212210P.
XX 17-OCT-2000; 2000US-0240816P.
XX 16-MAR-2001; 2001US-0276248P.
XX 21-MAR-2001; 2001US-0277379P.
XX 25-MAY-2001; 2001US-0293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX
XX Antibodies against B lymphocyte stimulating polypeptides, useful for the
XX diagnosis and treatment of cancers and immune disorders.
XX
XX Claim 1; Page 2306-2307; 3148pp; English.
XX
XX This invention describes novel antibodies that immunospecifically bind to
XX B lymphocyte stimulator (BlyS) polypeptides. BlyS is a member of the
XX tumour necrosis factor (TNF) super family and induces B cell
XX proliferation and differentiation. The antibodies of the invention have
XX cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
XX anti-rheumatic and anti-AIDS activity and can be used in vaccines to
XX inhibit the expression and activity of BlyS. The antibodies bind to BlyS
XX and so may be used to detect and quantitate the presence of BlyS in
XX biological samples and may be used in this way to diagnose disease
XX associated with aberrant expression of BlyS. They may also be
XX administered to treat diseases associated with aberrant BlyS expression
XX and activity such as cancer, immune, and autoimmune disorders and
XX diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
XX immunodeficiency (e.g. common variable immunodeficiency (CVID) and
XX acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
XX the antibodies and fragments of the antibodies described in the method of
XX the invention
XX
SQ Sequence 250 AA;
Query Match 88.3%; Score 460; DB 5; Length 250;
Best Local Similarity 88.8%; Pred. No. 6e-39;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;
QY 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGLEWVGWISAYNGNTHY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGLEWVGWISAYNGNTHY 60
QY 61 AQKFGQGRVTMTTDTTSRRRTAYMELRLSLRSDDTAVYYCAR 98
DB 61 AQKLGQRVTMTTDTSTSTAYMELRLSLRSDDTAVYYCAR 98

```

RESULT 12
ADG96411
ID ADG96411 standard; protein; 250 AA.
XX
AC ADG96411;
XX
DT 11-MAR-2004 (first entry)
XX
DE Single chain antibody that immunospecifically binds Blys SeqID 1595.
XX
KW antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
KW B cell proliferation; differentiation; scFv; myasthenia gravis;
KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX
OS Unidentified.
XX
PN WO2003055979-A2.
XX
PD 10-JUL-2003.
XX
PF 14-NOV-2002; 2002WO-US036496.
XX
PR 16-NOV-2001; 2001US-0331469P.
XX
PR 19-DEC-2001; 2001US-0340817P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX
DR WPI; 2003-505530/47.
XX
PT Novel antibody that immunospecifically binds to a B lymphocyte stimulator
PT (Blys), useful for detecting and treating diseases or disorders e.g.
PT rheumatoid arthritis, asthma and leukemia.
XX
PS Example 1; SEQ ID NO 1595; 394pp; English.
XX
CC This invention relates to novel antibodies that immunospecifically bind
CC to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
CC chromosome 13q34 and encodes a protein that is a member of the tumour
CC necrosis factor superfamily and induces both in vivo and in vitro B cell
CC proliferation and differentiation. Specifically, it refers to single
CC chain antibody molecules (scFvs) derived, preferably, from the variable
CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
CC fragment thereof, of either human, murine, rat or monkey Blys. The
CC present invention refers to the use of such antibodies in various methods
CC for the detection, diagnosis and prognosis of diseases related to the
CC aberrant expression or inappropriate function of Blys or its receptor. As
CC such, these compositions are useful for identifying immune disorders
CC including myasthenia gravis and multiple sclerosis, inflammatory
CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
CC as AIDS and proliferative disorders including leukaemia, carcinoma and
CC lymphoma. Accordingly, they can be described as exhibiting various
CC activities such as antirheumatic, antiarthritic, neuroprotective,
CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
CC polypeptide sequence is a single chain antibody that binds Blys of the
CC invention. NOTE: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX
SQ Sequence 250 AA;
Query Match 88.3%; Score 460; DB 7; Length 250;
Best Local Similarity 88.8%; Pred. No. 6e-39;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSGATEVKKPGASMKVSCASGYPTFTSYDISWVRQAPGQGLEWGWISAYNGNTY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWGWISAYNGNTY 60

Qy 61 AQKQFGRVTMTTDTSRRTAYMELRSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

RESULT 13
AAY50952
ID AAY50952 standard; protein; 98 AA.
XX
AC AAY50952;
XX
DT 23-MAR-2000 (first entry)
XX
DE Human anti-factor VIII antibody VH clone DP-14 protein #2.
XX
KW Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
KW VH gene.
XX
OS Homo sapiens.
XX
PN WO9958680-A2.
XX
PD 18-NOV-1999.
XX
PF 07-MAY-1999; 99WO-NL000285.
XX
PR 08-MAY-1998; 98EP-00201543.
XX
PA (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
XX
PI Voorberg JJ, Van Den Brink EN, Turenhout EAM;
XX
DR WPI; 2000-053102/04.
XX
PT New polynucleotide, polypeptide and antibody useful for diagnosing the
PT presence of neutralizing antibodies against factor VIII and for treatment
PT of hemophilia A patients with these antibodies.
XX
PS Example 4; Fig 4B; 61pp; English.
XX
CC This invention describes a novel polynucleotide (I) (and complements and
CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
CC coding for a human antibody with factor VIII specificity which has
CC hemostatic activity. (I) is useful as a primer or probe for detecting the
CC presence of inhibitory antibodies directed against factor VIII. The
CC polypeptides of the invention and the antibodies generated from them are
CC useful in compositions for neutralizing factor VIII inhibiting antibodies
CC in hemophilia A patients. This sequence represents the human anti-factor
CC VIII antibody clone DP-14 protein which is used in the method of the
CC invention
XX
SQ Sequence 98 AA;
Query Match 87.5%; Score 456; DB 3; Length 98;
Best Local Similarity 87.8%; Pred. No. 5.5e-39;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSGATEVKKPGASMKVSCASGYPTFTSYDISWVRQAPGQGLEWGWISAYNGNTY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWGWISAYNGNTY 60

Qy 61 AQKQFGRVTMTTDTSRRTAYMELRSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

RESULT 14
ABG78171
ID ABG78171 standard; protein; 98 AA.
XX
AC ABG78171;
XX

```
DT 15-NOV-2002 (first entry)
XX Human Fv molecule hypervariable region related peptide #46.
DE
XX Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.
XX
OS Homo sapiens.
XX WO200259264-A2.
XX
XX 01-AUG-2002.
XX
XX 31-DEC-2001; 2001WO-US049440.
XX
XX 29-DEC-2000; 2000US-00751181.
XX
XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
XX
XX Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;
XX Plaksin D, Peretz T;
XX
XX WPI; 2002-619166/66.
XX
XX Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
XX or fragment, or construct of fragment with enhanced binding
XX characteristics so as to selectively bind target cell in favor of other
XX cells.
XX
XX Claim 13; Page 169; 232pp; English.
XX
XX The invention relates to a peptide or polypeptide comprising an Fv
XX molecule, a construct or fragments or a construct of a fragment with
XX enhanced binding characteristics which selectively and/or specifically
XX binds to a target cell in favour of other cells, where binding is
XX primarily determined by a first hypervariable region and Fv is a single
XX chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
XX association with or attached, coupled, combined, linked or fused to a
XX pharmaceutical agent, is useful in the manufacture of a medicament, where
XX the medicament has activity against a diseased cell, preferably a cancer
XX cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
XX myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
XX acute myeloid leukaemia cell). The peptide is also useful for preparing a
XX composition for use in inhibiting the growth of a diseased or cancer
XX cell. This sequence represents a human Fv molecule hypervariable region
XX related peptide of the invention
XX
XX Sequence 98 AA;
XX
XX Query Match 87.5%; Score 456; DB 5; Length 98;
XX Best Local Similarity 87.8%; Pred. No. 5.5e-39;
XX Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;
XX
XX 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGQLEWGWISAYNGTHY 60
XX 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGQLEWGMWISAYNGTNY 60
XX
XX 61 AQKFGQGRVTMTTDTTSRRRTAYMELSLRSLRSDDTAVYYCAR 98
XX 61 AQKLQGRVTMTTDTSTSTAYMELSLRSLRSDDTAVYYCAR 98
XX
XX RESULT 15
XX ID ABG91862
XX ABG91862 standard; protein; 98 AA.
XX
XX AC ABG91862;
XX
XX 04-DEC-2002 (first entry)
XX Human antibody fragment #46.
XX
```

```
KW Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
KW metastasis; hypervariable region; autoimmune disease; thrombosis;
KW restenosis; leukaemia; inflammatory disease; cardiovascular disease;
KW myocardial infarction; retinopathic disease; abnormal platelet function;
KW sulphated tyrosine-dependent protein-protein interaction.
XX
OS Homo sapiens.
XX WO200253700-A2.
XX
XX 11-JUL-2002.
XX
XX 31-DEC-2001; 2001WO-US049442.
XX
XX 29-DEC-2000; 2000US-00751181.
XX
XX 29-DEC-2000; 2000US-0258948P.
XX
XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
XX
XX Lazarovits J, Hagai Y, Plaksin D, Vogel T, Nimrod A, Mar-Haim H;
XX Szanthon E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
XX
XX WPI; 2002-674776/72.
XX
XX Novel isolated epitope present on cancer cells and important in
XX physiological phenomena such as cell rolling, metastasis and
XX inflammation, for treating autoimmune, inflammatory or cardiovascular
XX diseases, and cancer.
XX
XX Disclosure; Page 246-247; Opp; English.
XX
XX The invention relates to an isolated epitope present on cancer cells and
XX important in physiological phenomena such as cell rolling, metastasis and
XX inflammation, where the epitope is capable of being bound by an antibody,
XX its antigen-binding fragment or its complex comprising at least one
XX antibody or its binding fragment having a first hypervariable region. The
XX epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
XX disease, thrombosis, restenosis, metastasis, growth and/or replication of
XX tumour or leukaemia cells, increase in number of tumour or leukaemia
XX cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
XX platelet and/or cell-platelet adhesion or aggregation, for increasing
XX mortality of tumour or leukaemia cells, for increasing the susceptibility
XX of diseased cells to damage by anti-disease, anti-cancer or anti-
XX leukaemia agents, or for decreasing the number of tumour or leukaemia
XX cells in a patient, or in the manufacture of a medicament for the above
XX mentioned purposes. The epitopes are useful for diagnosing and treating
XX diseases such as cancer, leukaemia, autoimmune diseases, inflammatory
XX diseases, cardiovascular diseases such as myocardial infarction,
XX retinopathic diseases and other diseases mediated by abnormal platelet
XX function and diseases caused by sulphated tyrosine-dependent protein-
XX protein interactions. This sequence represents a human antibody fragment
XX of the invention
XX
XX Sequence 98 AA;
XX
XX Query Match 87.5%; Score 456; DB 5; Length 98;
XX Best Local Similarity 87.8%; Pred. No. 5.5e-39;
XX Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;
XX
XX 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGQLEWGWISAYNGTHY 60
XX 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGQLEWGMWISAYNGTNY 60
XX
XX 61 AQKFGQGRVTMTTDTTSRRRTAYMELSLRSLRSDDTAVYYCAR 98
XX 61 AQKLQGRVTMTTDTSTSTAYMELSLRSLRSDDTAVYYCAR 98
XX
XX Search completed: May 5, 2006, 08:57:07
XX Job time : 39.7295 secs
```


GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:25 ; Search time 11.3112 Seconds
(without alignments)
716.302 Million cell updates/sec

Title: US-09-674-752-27

Perfect score: 521

Sequence: 1 QVQLLOSATEVYKPGASKMKV.....AYMELSLRSDDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 20000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA.*

- 1: /cgn2_6/ptodata/1/iaa/5_COMB.pep.*
- 2: /cgn2_6/ptodata/1/iaa/6_COMB.pep.*
- 3: /cgn2_6/ptodata/1/iaa/H_COMB.pep.*
- 4: /cgn2_6/ptodata/1/iaa/PCUS_COMB.pep.*
- 5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep.*
- 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	456	87.5	98	2	US-10-194-975-4
2	456	87.5	98	2	US-10-330-613A-53
3	456	87.5	117	2	US-08-545-809A-105
4	456	87.5	117	2	US-09-515-697-105
5	445	85.4	123	2	US-10-330-613A-21
6	444	85.2	118	2	US-09-726-219A-165
7	444	85.2	118	2	US-09-196-522-165
8	443	85.0	134	2	US-09-471-276-849
9	436	83.7	121	1	US-08-264-093-3
10	432	82.9	132	2	US-09-513-999C-4112
11	426	81.8	96	2	US-10-330-613A-54
12	426	81.8	120	2	US-09-513-999C-4111
13	418.5	80.3	128	1	US-08-202-047-22
14	418.5	80.3	128	2	US-08-964-690-22
15	418.5	80.3	129	1	US-08-561-521-45
16	418.5	80.3	129	2	US-08-525-539A-77
17	418.5	80.3	129	4	PCT-US95-01219-45
18	416	79.8	117	2	US-09-025-769B-22
19	416	79.8	117	2	US-09-490-070A-22
20	416	79.8	117	2	US-09-490-153-22
21	416	79.8	117	2	US-09-490-324-22
22	416	79.8	122	2	US-09-513-999C-7801
23	407	78.1	98	2	US-10-194-975-2
24	407	78.1	117	2	US-08-545-809A-96
25	407	78.1	117	2	US-09-515-697-96
26	407	78.1	119	1	US-08-561-521-10
27	407	78.1	119	2	US-09-438-954-41

28	407	78.1	119	4	PCT-US95-01219-10	Sequence 10, Appl
29	406	77.9	120	2	US-09-025-769B-36	Sequence 36, Appl
30	406	77.9	120	2	US-09-025-769B-59	Sequence 59, Appl
31	406	77.9	120	2	US-09-490-070A-36	Sequence 36, Appl
32	406	77.9	120	2	US-09-490-070A-59	Sequence 59, Appl
33	406	77.9	120	2	US-09-490-153-36	Sequence 36, Appl
34	406	77.9	120	2	US-09-490-153-59	Sequence 59, Appl
35	406	77.9	120	2	US-09-490-324-36	Sequence 36, Appl
36	406	77.9	120	2	US-09-490-324-59	Sequence 59, Appl
37	405.5	77.8	120	1	US-08-652-816A-19	Sequence 19, Appl
38	405.5	77.8	125	2	US-09-199-149-3	Sequence 3, Appl
39	405	77.7	470	2	US-09-859-053-28	Sequence 28, Appl
40	404	77.5	121	2	US-09-513-999C-4115	Sequence 4115, Ap
41	401	77.0	98	2	US-10-194-975-1	Sequence 1, Appl
42	401	77.0	116	1	US-08-561-521-41	Sequence 41, Appl
43	401	77.0	116	4	PCT-US95-01219-41	Sequence 41, Appl
44	401	77.0	117	2	US-08-545-809A-90	Sequence 90, Appl
45	401	77.0	117	2	US-09-515-697-90	Sequence 90, Appl

ALIGNMENTS

RESULT 1

US-10-194-975-4
; Sequence 4, Application US/10194975
; Patent No. 6881557
; GENERAL INFORMATION:
; APPLICANT: Footec, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-194-975-4

Query Match 87.5%; Score 456; DB 2; Length 98;
Best Local Similarity 87.8%; Pred. No. 6.5e-42;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLLOSATEVYKPGASKMKVSCMASGYPTSYDISWVRQAPGQGLEWVGMISAYNGNTHY 60

Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWGMISAYNGNTNY 60

Qy 61 AQKFGQHVTTTDTSTRTAYMELSLRSDDTAVYYCAR 98

Db 61 AQKLQGRVTTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 2

US-10-330-613A-53
; Sequence 53, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudae, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: ARGENIX.022A
; CURRENT APPLICATION NUMBER: US/10/330,613A
; CURRENT FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 53
; LENGTH: 98
; TYPE: PRT

```

; ORGANISM: Homo sapiens
US-10-330-613A-53

Query Match      87.5%; Score 456; DB 2; Length 98;
Best Local Similarity 87.8%; Pred. No. 6-5e-42;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGGLEWVGWISAYNGNTHY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSAGAEVKKPGASVKSCASGYTFTSYGISWVRQAPGGGLEWVGWISAYNGNTY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 3
US-08-545-809A-105
; Sequence 105, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA: PCT/JP93/00603
; APPLICATION NUMBER: 29,066
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 105:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 105:
US-08-545-809A-105

Query Match      87.5%; Score 456; DB 2; Length 117;
Best Local Similarity 87.8%; Pred. No. 8e-42;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGGLEWVGWISAYNGNTHY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 QVQLVQSAGAEVKKPGASVKSCASGYTFTSYGISWVRQAPGGGLEWVGWISAYNGNTY 79
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 117
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

US-08-545-809A-105

Query Match      87.5%; Score 456; DB 2; Length 117;
Best Local Similarity 87.8%; Pred. No. 8e-42;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGGLEWVGWISAYNGNTHY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 QVQLVQSAGAEVKKPGASVKSCASGYTFTSYGISWVRQAPGGGLEWVGWISAYNGNTY 79
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 117
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

US-08-545-809A-105

; ORGANISM: Homo sapiens
US-10-330-613A-53

Query Match      87.5%; Score 456; DB 2; Length 98;
Best Local Similarity 87.8%; Pred. No. 6-5e-42;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGGLEWVGWISAYNGNTHY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSAGAEVKKPGASVKSCASGYTFTSYGISWVRQAPGGGLEWVGWISAYNGNTY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 4
US-09-515-697-105
; Sequence 105, Application US/09515697
; Patent No. 6936705
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/515,697
; FILING DATE: 29-Feb-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 105:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 105:
US-09-515-697-105

Query Match      87.5%; Score 456; DB 2; Length 117;
Best Local Similarity 87.8%; Pred. No. 8e-42;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGGLEWVGWISAYNGNTHY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 QVQLVQSAGAEVKKPGASVKSCASGYTFTSYGISWVRQAPGGGLEWVGWISAYNGNTY 79
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 117
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

US-09-515-697-105

; ORGANISM: Homo sapiens
US-10-330-613A-21
; Sequence 21, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: ABGENIX-022A
; CURRENT APPLICATION NUMBER: US/10/330,613A
; CURRENT FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
```

```
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-330-613A-21

Query Match      85.4%; Score 445; DB 2; Length 123;
Best Local Similarity 85.7%; Pred. No. 1.3e-40;
Matches 84; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCMASGYPTFSYDISWVRQAPGQGLEWVGHISAYNGNTHY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWVGHISAYNGNTKY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 AQKIQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCVR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 7
US-09-196-522-165
; Sequence 165, Application US/09196522
; Patent No. 6916605
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Medical Research Council
; APPLICANT: McCafferty, John
; APPLICANT: Pope, Anthony
; APPLICANT: Johnson, Kevin
; APPLICANT: Hoogenboom, Hendricus
; APPLICANT: Griffiths, Andrew
; APPLICANT: Jackson, Ronald
; APPLICANT: Holliger, Kasper
; APPLICANT: Marks, James
; APPLICANT: Clackson, Timothy
; APPLICANT: Chiswell, David
; APPLICANT: Winter, Gregory
; APPLICANT: Bonert, Timothy
; TITLE OF INVENTION: Methods for Producing Members of Specific Binding Pairs
; FILE REFERENCE: 213839-00004
; CURRENT APPLICATION NUMBER: US/09/196,522
; CURRENT FILING DATE: 1998-11-28
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; PRIOR FILING DATE: 1991-03-06
; PRIOR APPLICATION NUMBER: GB 9110549.4
; PRIOR FILING DATE: 1991-05-15
; PRIOR APPLICATION NUMBER: PCT/GB91/01134
; PRIOR FILING DATE: 1991-07-10
; PRIOR APPLICATION NUMBER: US 07/971,857
; PRIOR FILING DATE: 1993-01-08
; PRIOR APPLICATION NUMBER: US 08/484,893
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 272
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 165
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-196-522-165

Query Match      85.2%; Score 444; DB 2; Length 118;
Best Local Similarity 85.7%; Pred. No. 1.6e-40;
Matches 84; Conservative 3; Mismatches 11; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCMASGYPTFSYDISWVRQAPGQGLEWVGHISAYNGNTHY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYGISWVRQAPGQGLEWVGHISAYNGNTKY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 AQKIQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCVR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 6
US-09-726-219A-165
; Sequence 165, Application US/09726219A
; Patent No. 8806079
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Medical Research Council
; APPLICANT: McCafferty, John
; APPLICANT: Pope, Anthony
; APPLICANT: Johnson, Kevin
; APPLICANT: Hoogenboom, Hendricus
; APPLICANT: Griffiths, Andrew
; APPLICANT: Jackson, Ronald
; APPLICANT: Holliger, Kasper
; APPLICANT: Marks, James
; APPLICANT: Clackson, Timothy
; APPLICANT: Chiswell, David
; APPLICANT: Winter, Gregory
; APPLICANT: Bonert, Timothy
; TITLE OF INVENTION: Methods for Producing Members of Specific Binding Pairs
; FILE REFERENCE: 213839-00013
; CURRENT APPLICATION NUMBER: US/09/726,219A
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; PRIOR FILING DATE: 1991-03-06
; PRIOR APPLICATION NUMBER: GB 9110549.4
; PRIOR FILING DATE: 1991-05-15
; PRIOR APPLICATION NUMBER: PCT/GB91/01134
; PRIOR FILING DATE: 1991-07-10
; PRIOR APPLICATION NUMBER: US 07/971,857
; PRIOR FILING DATE: 1993-01-08
; PRIOR APPLICATION NUMBER: US 08/484,893
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 272
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 165
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-726-219A-165

Query Match      85.2%; Score 444; DB 2; Length 118;
Best Local Similarity 85.7%; Pred. No. 1.6e-40;
Matches 84; Conservative 3; Mismatches 11; Indels 0; Gaps 0;
```

```
RESULT 8
US-09-471-276-849
; Sequence 849, Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: GENSER.025CP1
; CURRENT APPLICATION NUMBER: US/09/471,276
; CURRENT FILING DATE: 1999-12-21
; EARLIER APPLICATION NUMBER: 09/057,719
; EARLIER FILING DATE: 1998-04-09
; EARLIER APPLICATION NUMBER: 09/069,047
; EARLIER FILING DATE: 1998-04-28
; EARLIER APPLICATION NUMBER: PCT/IB99/00712
; EARLIER FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 1622
; SOFTWARE: Patent.pm
; SEQ ID NO 849
; LENGTH: 134
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -19..-1
US-09-471-276-849

Query Match      85.0%; Score 443; DB 2; Length 134;
Best Local Similarity 84.7%; Pred. No. 2.4e-40;
Matches 83; Conservative 6; Mismatches 9; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 QVQLVSGGEVKKPGASVKVSCASGYTFTYDINWVRQAPGGQLEWVGWISAXNGNTY 79
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDSRTTAYMELRSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 AQXVQGRVTMTTDTSTRTAYMELRSLRSDDTAVYYCAR 117
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 9
US-08-264-093-3
; Sequence 3, Application US/08264093
; Patent No. 5639863
; GENERAL INFORMATION:
; APPLICANT: Michael D. Dan
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO
; TITLE OF INVENTION: CELL CYCLE-INDEPENDENT GLIOMA SURFACE
; TITLE OF INVENTION: ANTIGEN
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ridout & Maybee
; STREET: 2300 Richmond-Adelaide Centre
; STREET: 101 Richmond Street West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5H 2J7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.4 Mb storage
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: MS-DOS 6.00
; SOFTWARE: ASCII Editor
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/264,093
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA: No. 5639863 applicable
; ATTORNEY/AGENT INFORMATION:
; NAME: Lake, James R.
```

```
; REGISTRATION NUMBER: 31081
; REFERENCE/DOCKET NUMBER: NOVOP/106A/7551
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 868-1482
; TELEFAX: (416) 362-0823
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 121 amino acids
; TYPE: amino acid
; STRANDEDNESS: not applicable
; TOPOLOGY: linear
US-08-264-093-3

Query Match      83.7%; Score 436; DB 1; Length 121;
Best Local Similarity 82.7%; Pred. No. 1.2e-39;
Matches 81; Conservative 9; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVSGGEVKKPGASVKVSCASGYTFTYGLSWVRQAPGGQLEWVGWISAHNGNTNS 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDSRTTAYMELRSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVSMTTDTSTSTAYMEVRSLSRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 10
US-09-513-999C-4112
; Sequence 4112, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6783961
; FILE REFERENCE: 59.US2.REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 36681
; SOFTWARE: Patent.pm
; SEQ ID NO 4112
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -19..-1
; OTHER INFORMATION: score 10.8
; OTHER INFORMATION: seq ILFLVAAATGAHS/QV
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 9
; OTHER INFORMATION: Xaa=Ala or Pro
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 31
; OTHER INFORMATION: Xaa=Asn or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 33
; OTHER INFORMATION: Xaa=Asp or Gly
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 35
; OTHER INFORMATION: Xaa=Asn or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 63
; OTHER INFORMATION: Xaa=Asp or Glu or Lys or Asn
; FEATURE:
```

; NAME/KEY: UNSURE
; LOCATION: 72
; OTHER INFORMATION: Xaa=Arg or Thr
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 77
; OTHER INFORMATION: Xaa=Lys or Asn or Arg or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 93
; OTHER INFORMATION: Xaa=Ile or Met or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 101
; OTHER INFORMATION: Xaa=Ile or Leu or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 103
; OTHER INFORMATION: Xaa=Ala or Glu or Gly or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 104
; OTHER INFORMATION: Xaa=Leu or Val
; US-09-513-999C-4112

Query Match 82.9%; Score 432; DB 2; Length 132;
Best Local Similarity 82.7%; Pred. No. 3.6e-39;
Matches 81; Conservative 4; Mismatches 13; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTSYDTSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 20 QVQLVQSGAEVKKPGASVKVSCKASGYTFYTXIXWVRQAPGQGLEWVGWISAYNGNTHY 79
Qy 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
Db 80 AQXQGRVTMTXDTSTNTAYMELSLRSDDTAVYYCAR 117

RESULT 11

US-10-330-613A-54
; Sequence 54, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: AGENIX.022A
; CURRENT APPLICATION NUMBER: US/10/330.613A
; PRIOR FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 54
; LENGTH: 96
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-330-613A-54

Query Match 81.8%; Score 426; DB 2; Length 96;
Best Local Similarity 85.7%; Pred. No. 1.1e-38;
Matches 84; Conservative 4; Mismatches 8; Indels 2; Gaps 2;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTSYDTSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTF-SYG-SWVRQAPGQGLEWVGWISAYNGNTHY 58
Qy 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
Db 59 AQKQGRVTMTTDTSTNTAYMELSLRSDDTAVYYCAR 96

RESULT 12

US-09-513-999C-4111

; Sequence 4111, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.Y.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: 59.US2.REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 36681
; SOFTWARE: Patent.pm
; SEQ ID NO 4111
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -19..-1
; OTHER INFORMATION: score 10.7
; OTHER INFORMATION: seq ILFLVAAATGXHS/QV
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: -3
; OTHER INFORMATION: Xaa=Ala or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 9
; OTHER INFORMATION: Xaa=Ala or Pro
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 53
; OTHER INFORMATION: Xaa=Ala or Gly
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 63
; OTHER INFORMATION: Xaa=Glu or Lys
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 64
; OTHER INFORMATION: Xaa=Phe or Leu
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 72
; OTHER INFORMATION: Xaa=Arg or Thr
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 82
; OTHER INFORMATION: Xaa=Asp or Glu
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 85
; OTHER INFORMATION: Xaa=Asn or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 98
; OTHER INFORMATION: Xaa=Lys or Arg
; US-09-513-999C-4111

Query Match 81.8%; Score 426; DB 2; Length 120;
Best Local Similarity 82.5%; Pred. No. 1.4e-38;
Matches 80; Conservative 4; Mismatches 13; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTSYDTSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 20 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWVGWISAYNGNTHY 79
Qy 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCA 97
Db 80 AQXQGRVTMTXDTSTNTAYMELSLRSDDTAVYYCA 116

```
RESULT 13
US-08-202-047-22
; Sequence 22, Application US/08202047
; Patent No. 5800815
; GENERAL INFORMATION:
; APPLICANT: CHESNUT, Robert W.
; APPLICANT: POLLEY, Margaret J.
; APPLICANT: PAULSON, James C.
; APPLICANT: JONES, S. Tarran
; APPLICANT: SALDANHA, Jose W.
; APPLICANT: BENDIG, Mary M.
; TITLE OF INVENTION: Antibodies to P-Selectin and Their Uses
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/202,047
; FILING DATE: 25-FEB-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14137-77
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 128 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..128
; OTHER INFORMATION: /label= HUMAN_I
;
US-08-202-047-22

Query Match      80.3%; Score 418.5; DB 1; Length 128;
Best Local Similarity 80.8%; Pred. No. 9.9e-38;
Matches 80; Conservative 8; Mismatches 10; Indels 1; Gaps 1;

QY 1 QVQLQSATEVKKPGASKMKVSCWASGYPTFTSYDISWVRQAPGQGLEWVGWISAY-NGNTH 59
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYAISWVRQAPGQGLEWMGWINPYGNGDTN 60

QY 60 YAKQFGQVRVTMTDTSRRRTAYMELSLRSDDTAVYYCAR 98
Db 61 YAKQFGQVRVTITADTSTSTAYMELSLRSEDATVYYCAR 99

RESULT 14
US-08-964-690-22
; Sequence 22, Application US/08964690
; Patent No. 6033667
; GENERAL INFORMATION:
; APPLICANT: CHESNUT, Robert W.
; APPLICANT: POLLEY, Margaret J.
; APPLICANT: PAULSON, James C.
; APPLICANT: JONES, S. Tarran
```

```
; APPLICANT: SALDANHA, Jose W.
; APPLICANT: BENDIG, Mary M.
; TITLE OF INVENTION: Antibodies to P-Selectin and Their Uses
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/964,690
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/202,047
; FILING DATE: 25-FEB-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14137-77
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 128 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..128
; OTHER INFORMATION: /label= HUMAN_I
;
US-08-964-690-22

Query Match      80.3%; Score 418.5; DB 2; Length 128;
Best Local Similarity 80.8%; Pred. No. 9.9e-38;
Matches 80; Conservative 8; Mismatches 10; Indels 1; Gaps 1;

QY 1 QVQLQSATEVKKPGASKMKVSCWASGYPTFTSYDISWVRQAPGQGLEWVGWISAY-NGNTH 59
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYAISWVRQAPGQGLEWMGWINPYGNGDTN 60

QY 60 YAKQFGQVRVTMTDTSRRRTAYMELSLRSDDTAVYYCAR 98
Db 61 YAKQFGQVRVTITADTSTSTAYMELSLRSEDATVYYCAR 99

RESULT 15
US-08-561-521-45
; Sequence 45, Application US/08561521
; Patent No. 5840299
; GENERAL INFORMATION:
; APPLICANT: Bendig, Mary M.
; APPLICANT: Leger, Olivier J.
; APPLICANT: Saldanha, Jose
; APPLICANT: Jones, S. Tarran
; TITLE OF INVENTION: Humanized Antibodies Against Leukocyte
; TITLE OF INVENTION: Adhesion Molecule VLA-4
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
```

```

; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/561.521
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/186,269A
; FILING DATE: 25-JAN-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William L.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 15270-14
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-543-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 45:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 129 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-561-521-45

```

```

Query Match      80.3%; Score 418.5; DB 1; Length 129;
Best Local Similarity 80.8%; Pred. No. 1e-37;
Matches 80; Conservative 8; Mismatches 10; Indels 1; Gaps 1;

Qy 1 QVQLQSGATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGCGLEWGWISAY-NGNTH 59
Db 1 QVQLVQSGAEYKKPGASVKVSCKASGYTFTSYAISWVRQAPGCGLEWGWINPYNGDITN 60

Qy 60 YAKFQGRVTMTTDTSRRTAYMELSLRSDTAVYYCAR 98
Db 61 YAKFQGRVTITADTSTAYMELSLRSEDVAVYYCAR 99

```

Search completed: May 5, 2006, 08:53:48
Job time : 11.3112 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:55:01 ; Search time 31.1283 Seconds
(without alignments)
1315.434 Million cell updates/sec

Title: US-09-674-752-27

Perfect score: 521

Sequence: 1 QVQLQSGATEVKKPGASMKV.....AYMELSLRSDDTAVYICAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications AA_Main:

- 1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
- 3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
- 4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
- 6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	463	88.9	247	3	US-09-880-748-1116 Sequence 1116, Ap
2	463	88.9	247	4	US-10-293-418-1116 Sequence 1116, Ap
3	463	88.9	250	3	US-09-880-748-1560 Sequence 1560, Ap
4	463	88.9	250	4	US-10-293-418-1560 Sequence 1560, Ap
5	463	88.9	251	3	US-09-880-748-1738 Sequence 1738, Ap
6	463	88.9	251	4	US-10-293-418-1738 Sequence 1738, Ap
7	460	88.3	250	3	US-09-880-748-1595 Sequence 1595, Ap
8	460	88.3	250	4	US-10-293-418-1595 Sequence 1595, Ap
9	456	87.5	98	4	US-10-194-975-4 Sequence 4, Appli
10	456	87.5	98	4	US-10-041-860-2 Sequence 2, Appli
11	456	87.5	98	4	US-10-041-860-324 Sequence 324, App
12	456	87.5	98	4	US-10-041-860-326 Sequence 326, App
13	456	87.5	98	4	US-10-041-860-355 Sequence 355, App
14	456	87.5	98	4	US-10-041-860-356 Sequence 356, App
15	456	87.5	98	4	US-10-308-817-44 Sequence 4, Appli
16	456	87.5	98	4	US-10-032-037B-46 Sequence 46, Appl
17	456	87.5	98	4	US-10-029-988B-46 Sequence 46, Appl
18	456	87.5	98	4	US-10-032-423A-46 Sequence 46, Appl
19	456	87.5	98	4	US-10-453-698-44 Sequence 44, Appl
20	456	87.5	98	4	US-10-029-926B-46 Sequence 46, Appl
21	456	87.5	98	4	US-10-379-392-4 Sequence 4, Appli
22	456	87.5	104	3	US-09-864-761-47285 Sequence 47285, A
23	456	87.5	109	4	US-10-800-197-147 Sequence 147, App
24	456	87.5	109	5	US-10-727-155-284 Sequence 284, App
25	456	87.5	109	5	US-10-727-155-290 Sequence 290, App
26	456	87.5	117	4	US-10-041-860-206 Sequence 206, App
27	456	87.5	118	6	US-11-039-767-8 Sequence 8, Appli

28	456	87.5	118	6	US-11-039-767-10	Sequence 10, Appl
29	456	87.5	121	6	US-11-031-485-120	Sequence 120, App
30	456	87.5	125	4	US-10-269-805-45	Sequence 45, Appl
31	456	87.5	125	4	US-10-041-860-42	Sequence 42, Appl
32	456	87.5	125	4	US-10-041-860-207	Sequence 207, App
33	456	87.5	125	4	US-10-665-383-62	Sequence 62, Appl
34	456	87.5	126	4	US-10-041-860-354	Sequence 354, App
35	456	87.5	127	4	US-10-041-860-31	Sequence 31, Appl
36	456	87.5	127	4	US-10-041-860-243	Sequence 243, App
37	456	87.5	127	4	US-10-041-860-325	Sequence 325, App
38	456	87.5	127	4	US-10-665-383-42	Sequence 42, Appl
39	456	87.5	132	5	US-10-910-901-21	Sequence 21, Appl
40	456	87.5	248	3	US-09-880-748-1472	Sequence 1472, Ap
41	456	87.5	248	4	US-10-293-418-1472	Sequence 1472, Ap
42	456	87.5	251	3	US-09-880-748-1562	Sequence 1562, Ap
43	456	87.5	251	3	US-09-880-748-1872	Sequence 1872, Ap
44	456	87.5	251	3	US-09-880-748-1921	Sequence 1921, Ap
45	456	87.5	251	4	US-10-293-418-1562	Sequence 1562, Ap

ALIGNMENTS

RESULT 1

US-09-880-748-1116
; Sequence 1116, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1116
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1116

Query Match 88.9%; Score 463; DB 3; Length 247;
Best Local Similarity 89.8%; Pred. No. 4.6e-39;
Matches 88; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

Qy	1	QVQLQSGATEVKKPGASMKVSCMASGVPFTSYDTSWRQAPGQGLVGVWISAYNGNTHY 60
Db	1	QVQLQSGAAEKKPGASVKRSKASGTFYISGISWRQAPGQGLVGVWISAYNGNTHY 60
Qy	61	AQKFQGRVTMTTDSRRTAYMELSLRSDDTAVYICAR 98
Db	61	AQKLGQRVTMTTDSRRTAYMELSLRSDDTAVYICAR 98

RESULT 2

US-10-293-418-1116
; Sequence 1116, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418

```

; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1116
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1116

Query Match      88.9%; Score 463; DB 4; Length 247;
Best Local Similarity 89.8%; Pred. No. 4.7e-39;
Matches 88; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCMASGYPFTSYDLSWVRQAPGGGLEWVGWISAYNGNTHY 60
DB 1 QVQLQSAAEVKKPGASVKSCASGYFTSYGISWVRQAPGGGLEWVGWISAYNGNTNY 60

QY 61 AQKFGQGVMTTDTTSRRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 3
US-09-880-748-1560
; Sequence 1560, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1560
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1560

Query Match      88.9%; Score 463; DB 3; Length 250;
Best Local Similarity 89.8%; Pred. No. 4.7e-39;
Matches 88; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCMASGYPFTSYDLSWVRQAPGGGLEWVGWISAYNGNTHY 60
DB 1 QVQLQSAAEVKKPGASVKSCASGYFTSYGISWVRQAPGGGLEWVGWISAYNGNTNY 60

QY 61 AQKFGQGVMTTDTTSRRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 4
US-10-293-418-1560
; Sequence 1560, Application US/10293418
; Publication No. US2003023996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1560
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1560

Query Match      88.9%; Score 463; DB 4; Length 250;
Best Local Similarity 89.8%; Pred. No. 4.7e-39;
Matches 88; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCMASGYPFTSYDLSWVRQAPGGGLEWVGWISAYNGNTHY 60
DB 1 QVQLQSAAEVKKPGASVKSCASGYFTSYGISWVRQAPGGGLEWVGWISAYNGNTNY 60

QY 61 AQKFGQGVMTTDTTSRRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 5
US-09-880-748-1738
; Sequence 1738, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1560
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1738
```

```

QY 61 AQKFGQGVMTTDTTSRRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 4
US-10-293-418-1560
; Sequence 1560, Application US/10293418
; Publication No. US2003023996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1560
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1560

Query Match      88.9%; Score 463; DB 4; Length 250;
Best Local Similarity 89.8%; Pred. No. 4.7e-39;
Matches 88; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCMASGYPFTSYDLSWVRQAPGGGLEWVGWISAYNGNTHY 60
DB 1 QVQLQSAAEVKKPGASVKSCASGYFTSYGISWVRQAPGGGLEWVGWISAYNGNTNY 60

QY 61 AQKFGQGVMTTDTTSRRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGVMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 5
US-09-880-748-1738
; Sequence 1738, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1560
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1738
```

```
; SEQ ID NO 1738
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1738

Query Match      88.9%; Score 463; DB 3; Length 251;
Best Local Similarity 88.8%; Pred. No. 4.7e-39;
Matches 87; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDLSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKSCASGYFTFTSYGISWVRQAPGQGLEWVGWISAYNGNTHY 60
Qy 61 AQKFGQRTVTMTDTSRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQRTVTMTDTSRTAYMELSLRSDDTAVYYCAR 98

RESULT 6
US-10-293-418-1738
; Sequence 1738, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; CURRENT APPLICATION NUMBER: US/10/293,418
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/212,210
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1738
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1738

Query Match      88.9%; Score 463; DB 4; Length 251;
Best Local Similarity 88.8%; Pred. No. 4.7e-39;
Matches 87; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDLSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKSCASGYFTFTSYGISWVRQAPGQGLEWVGWISAYNGNTHY 60
Qy 61 AQKFGQRTVTMTDTSRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLGQRTVTMTDTSRTAYMELSLRSDDTAVYYCAR 98

RESULT 7
US-09-880-748-1595
; Sequence 1595, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
```


Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDTSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWVGWISAYNGNTHY 60
Qy 61 AQKFGQGRVTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 13

US-10-041-860-355
; Sequence 355, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 355
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-355

Query Match 87.5%; Score 456; DB 4; Length 98;
Best Local Similarity 87.8%; Pred. No. 9.1e-39;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDTSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWVGWISAYNGNTHY 60
Qy 61 AQKFGQGRVTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 14

US-10-041-860-356
; Sequence 356, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 356
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens

US-10-041-860-356

Query Match 87.5%; Score 456; DB 4; Length 98;
Best Local Similarity 87.8%; Pred. No. 9.1e-39;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;
Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDTSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWVGWISAYNGNTHY 60
Qy 61 AQKFGQGRVTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 15

US-10-308-817-44
; Sequence 44, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308.817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 44
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-308-817-44

Query Match 87.5%; Score 456; DB 4; Length 98;
Best Local Similarity 87.8%; Pred. No. 9.1e-39;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDTSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWVGWISAYNGNTHY 60
Qy 61 AQKFGQGRVTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTDTSTSTAYMELSLRSDDTAVYYCAR 98

Search completed: May 5, 2006, 09:02:18
Job time : 31.1283 secs

THIS PAGE BLANK (USPTO)


```

; Sequence 1738, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1738
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-1738

Query Match      88.9%; Score 463; DB 11; Length 251;
Best Local Similarity 88.8%; Pred. No. 1.1e-37;
Matches 87; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDSVWRQAPGGGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGGLEWVGWISAYNGNTHY 60
Qy 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 6
US-11-266-444-1738
; Sequence 1738, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0

Query Match      88.9%; Score 463; DB 11; Length 251;
Best Local Similarity 88.8%; Pred. No. 1.1e-37;
Matches 87; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDSVWRQAPGGGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGGLEWVGWISAYNGNTHY 60
Qy 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 6
US-11-266-444-1738
; Sequence 1738, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0

```

```

; SEQ ID NO 1738
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-266-444-1738

Query Match      88.9%; Score 463; DB 11; Length 251;
Best Local Similarity 88.8%; Pred. No. 1.1e-37;
Matches 87; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDSVWRQAPGGGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGGLEWVGWISAYNGNTHY 60
Qy 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 7
US-11-054-515-1595
; Sequence 1595, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1595
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-1595

Query Match      88.3%; Score 460; DB 11; Length 250;
Best Local Similarity 88.8%; Pred. No. 2.1e-37;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDSVWRQAPGGGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSAEAEVKKPGASVKVSKASGYTFTSYGISVWRQAPGGGLEWVGWISAYNGNTHY 60
Qy 61 AQKFGQGRVTMTTDSRTTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 8
US-11-266-444-1595
; Sequence 1595, Application US/11266444

```

```
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523P101
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1595
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1595

Query Match      88.3%; Score 460; DB 11; Length 250;
Best Local Similarity 88.8%; Pred. No. 2.1e-37;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGLEWVGWISAYNGNTHY 60
DB 1 QVQLVQSAAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGLEWVGWISAYNGNTHY 60

QY 61 AQKFGQGVMTTDTTSRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGVMTTDTTSRTAYMELSLRSDDTAVYYCAR 98

RESULT 9
US-11-221-902-55
; Sequence 55, Application US/11221902
; Publication No. US20060088522A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGAT
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 55
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-221-902-55

Query Match      87.5%; Score 456; DB 10; Length 98;
Best Local Similarity 87.8%; Pred. No. 2.1e-37;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGLEWVGWISAYNGNTHY 60
DB 1 QVQLVQSAEAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGLEWVGWISAYNGNTHY 60

QY 61 AQKFGQGVMTTDTTSRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGVMTTDTTSRTAYMELSLRSDDTAVYYCAR 98

RESULT 10
US-11-054-669-4
; Sequence 4, Application US/11054669
; Publication No. US20050261480A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES
; FILE REFERENCE: 30219/US/3
; CURRENT APPLICATION NUMBER: US/11/054,669
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: US 10/194,975
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 4
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-669-4

Query Match      87.5%; Score 456; DB 11; Length 98;
Best Local Similarity 87.8%; Pred. No. 2.1e-37;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGLEWVGWISAYNGNTHY 60
DB 1 QVQLVQSAEAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGLEWVGWISAYNGNTHY 60

QY 61 AQKFGQGVMTTDTTSRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGVMTTDTTSRTAYMELSLRSDDTAVYYCAR 98

RESULT 12
US-11-061-848-17
; Sequence 15, Application US/11084554
; Publication No. US20050260679A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Korver, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A
; CURRENT APPLICATION NUMBER: US/11/084,554
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-084-554-15

Query Match      87.5%; Score 456; DB 11; Length 98;
Best Local Similarity 87.8%; Pred. No. 2.1e-37;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASMKVSCWASGYPTFTSYDISWVRQAPGGLEWVGWISAYNGNTHY 60
DB 1 QVQLVQSAEAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGLEWVGWISAYNGNTHY 60

QY 61 AQKFGQGVMTTDTTSRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQKLGQGVMTTDTTSRTAYMELSLRSDDTAVYYCAR 98

RESULT 12
US-11-061-848-17
```

```

; Sequence 17, Application US/11061848
; Publication No. US20050288491A1
; GENERAL INFORMATION:
; APPLICANT: Wilson, David S.
; APPLICANT: Nock, Steffen
; APPLICANT: Larrick, James W.
; TITLE OF INVENTION: SUPER-HUMANIZED ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS
; FILE REFERENCE: 186280/US
; CURRENT FILING DATE: 2005-02-17
; PRIOR APPLICATION NUMBER: US 60/545,011
; PRIOR FILING DATE: 2004-02-17
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 17
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-061-848-17

Query Match      87.5%; Score 456; DB 11; Length 98;
Best Local Similarity 87.8%; Pred. No. 2.1e-37;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSGATEVKKPGASMKVSCASGYPTFTSYDISWVRQAPGQGLEWVGWISAYNGNTY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWVGWISAYNGNTY 60

Qy 61 AQKQGRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 13
US-11-004-590-4
; Sequence 4, Application US/11004590
; Publication No. US2006008883A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hammond, Phillip W.
; TITLE OF INVENTION: METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING
; FILE REFERENCE: 185832/US/5
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: US 60/527,167
; PRIOR FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: US 60/581,613
; PRIOR FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US 60/601,665
; PRIOR FILING DATE: 2004-08-13
; PRIOR APPLICATION NUMBER: US 60/619,483
; PRIOR FILING DATE: 2004-10-14
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 4
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-004-590-4

Query Match      87.5%; Score 456; DB 11; Length 98;
Best Local Similarity 87.8%; Pred. No. 2.1e-37;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSGATEVKKPGASMKVSCASGYPTFTSYDISWVRQAPGQGLEWVGWISAYNGNTY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWVGWISAYNGNTY 60

Qy 61 AQKQGRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

```

```

RESULT 14
US-11-136-250-15
; Sequence 15, Application US/11136250
; Publication No. US20060021074A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Korver, Wouter
; APPLICANT: Green, Larry L.
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; FILE REFERENCE: ABGENIX.100A2
; CURRENT FILING DATE: 2005-05-23
; PRIOR APPLICATION NUMBER: US/11/136,250
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: PCT/US2005/009306
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-136-250-15

Query Match      87.5%; Score 456; DB 11; Length 98;
Best Local Similarity 87.8%; Pred. No. 2.1e-37;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSGATEVKKPGASMKVSCASGYPTFTSYDISWVRQAPGQGLEWVGWISAYNGNTY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWVGWISAYNGNTY 60

Qy 61 AQKQGRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 15
US-10-982-440-45
; Sequence 45, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiotensin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: US/10/982,440
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 45
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-982-440-45

Query Match      87.5%; Score 456; DB 9; Length 125;
Best Local Similarity 87.8%; Pred. No. 2.6e-37;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSGATEVKKPGASMKVSCASGYPTFTSYDISWVRQAPGQGLEWVGWISAYNGNTY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWVGWISAYNGNTY 60

```


GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:05 ; Search time 6.24377 Seconds
(without alignments)
1510.185 Million cell updates/sec

Title: US-09-674-752-27
Perfect score: 521
Sequence: 1 QVQLLOSATEVKKPGASKMKV.....AYMELSLRSDDTAVYYCAR 98
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	456	87.5	98	2 S26919	Ig heavy chain V r
2	453	86.9	129	2 S36260	Ig heavy chain V r
3	451	86.6	122	2 S36271	Ig heavy chain V r
4	450	86.4	124	2 S19665	Ig heavy chain V r
5	432	82.9	131	2 S21924	Ig heavy chain V r
6	428	82.1	160	2 PL0105	anti-PR2 erythrocy
7	420	80.6	111	2 S21925	Ig heavy chain V r
8	407	78.1	98	2 S26918	Ig heavy chain V r
9	407	78.1	117	2 S18553	Ig heavy chain V r
10	407	78.1	136	2 S31600	Ig heavy chain V r
11	405	77.7	125	2 S68170	Ig heavy chain V r
12	401	77.0	98	2 S26938	Ig heavy chain V r
13	401	77.0	117	2 S31680	Ig heavy chain V r
14	401	77.0	117	2 S18551	Ig heavy chain V r
15	401	77.0	135	2 S49530	anti-Sm antibody V
16	400	76.8	118	2 S36265	Ig heavy chain V r
17	397	76.2	104	2 S69899	Ig heavy chain V r
18	397	76.2	127	2 S34014	Ig heavy chain V r
19	393	75.4	98	2 S26912	Ig heavy chain V r
20	393	75.4	129	2 S46393	Ig heavy chain V r
21	391	75.0	117	2 S18552	Ig heavy chain V r
22	390	74.9	132	2 S31596	Ig heavy chain V r
23	389	74.7	110	2 PH1670	Ig heavy chain V-1
24	389	74.7	123	2 D33548	Ig heavy chain V r
25	388	74.5	98	2 S26920	Ig heavy chain V r
26	387	74.3	117	2 FT0371	Ig Gamma chain pre
27	383	73.5	117	1 HVHUNG	Ig heavy chain V r
28	383	73.5	148	2 S29257	Ig heavy chain V r
29	382	73.3	114	2 PH1667	Ig heavy chain V r

30 382 73.3 118 2 PH1666 Ig heavy chain V r
31 381 73.1 142 2 A32483 Ig heavy chain V r
32 380 72.9 171 2 S23623 Ig heavy chain V r
33 379 72.7 98 2 PH0871 Ig heavy chain V r
34 378 72.6 119 2 JN0295 Ig heavy chain V-D
35 377 72.4 116 2 S31667 Ig heavy chain V r
36 377 72.4 117 1 HVHJ35 Ig heavy chain pre
37 377 72.4 120 2 S31999 Ig heavy chain V r
38 377 72.4 135 2 B32274 Ig heavy chain pre
39 376 72.2 126 2 I41511 Ig heavy chain V r
40 372 71.4 98 2 S24680 Ig heavy chain V1
41 370 71.0 98 2 S26921 Ig heavy chain V r
42 369 70.8 104 2 PH1665 Ig heavy chain V r
43 369 70.8 109 2 PH1668 Ig heavy chain V r
44 367 70.4 98 2 S26915 Ig heavy chain V r
45 367 70.4 116 2 S31698 Ig heavy chain pre

ALIGNMENTS

RESULT 1

S26919
Ig heavy chain V region (DP-14) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C/Accession: S26919
R/Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A/Title: The repertoire of human germline V(H) sequences reveals about fifty groups of
A/Reference number: S26885; MUID:93021117; PMID:1404388
A/Accession: S26919
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-98 <TM>
A/Cross-references: UNIPARC:UPI0000031F31; EMBL:Z12316; NID:g32855; PIDN:CAA78186.1; PID
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 87.5%; Score 456; DB 2; Length 98;
Best Local Similarity 87.8%; Pred. No. 2.9e-39;
Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLLOSATEVKKPGASKMKVSGVPFTSYDLSWVRQAPGGGLEWVGWISAYNGNTHY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|
Db 1 QVQLVSGAEVKKPGASVRVSCASGYTFTSYGLSWVRQAPGGGLEWVGWISAYNGNTNY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|
Qy 61 AQKFQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|
Db 61 AQKLQGRVTMTTDSRTSTAYMELSLRSDDTAVYYCAR 98
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|

RESULT 2

S36260
Ig heavy chain V region (clone alpha-CEA4-8A) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C/Accession: S36260
R/Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; McCafferty, J.
EMBO J. 12, 725-734, 1993
A/Title: Human anti-self antibodies with high specificity from phage display libraries.
A/Reference number: S36256; MUID:93178448; PMID:7679990
A/Accession: S36260
A/Status: preliminary; nucleic acid sequence not shown
A/Molecule type: mRNA
A/Residues: 1-129 <GRI>
A/Cross-references: UNIPARC:UPI0000118DB8; EMBL:Z18851; NID:g33124; PIDN:CAA79303.1; PID
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 86.9%; Score 453; DB 2; Length 129;


```
Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
Db 20 QVQLVASGAENVKPGASVKVSCRASGYTFTSYGISWVRQAPGGQLEWVGWISVYNGDNY 79

Qy 61 AQRFGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 80 AQMLQGRVTMTDTSRTAYMELNRLSRSDDTAVYYCAR 117

RESULT 7
S21925
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 23-Jul-1999
C:Accession: S21925
R:Friedman, D.F.
submitted to the EMBL Data Library, July 1991
A:Reference number: S21923
A:Accession: S21925
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-111 <PRI>
A:Cross-references: UNIPARC:UPI0000115FAI; EMBL:X60503; NID:g33626; PIDN:CAA43023.1; PID
C:Genetics:
A:Introns: 16/1
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

Query Match 80.6%; Score 420; DB 2; Length 111;
Best Local Similarity 87.0%; Pred. No. 1.4e-35;
Matches 80; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
Db 20 QVQLVQSGAEVKKPGASVKVSCRASGYTFTSYGISWVRQAPGGQLEWVGWISAYNGNTY 79

Qy 61 AQRFGQGVTTMTDTSRRTAYMELSLRSDDTA 92
Db 80 AQKLQGRVTMTDTSRTAYMELSLRSDDTA 111

RESULT 8
S26918
Ig heavy chain V region (DP-15) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S26918
R:Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A:Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A:Reference number: S26885; MUID:93021117; PMID:1404388
A:Accession: S26918
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-98 <TON>
A:Cross-references: UNIPARC:UPI000031F36; EMBL:Z12317; NID:g32857; PIDN:CAA78187.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 78.1%; Score 407; DB 2; Length 98;
Best Local Similarity 78.6%; Pred. No. 2.6e-34;
Matches 77; Conservative 9; Mismatches 12; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCRASGYTFTSYDINWVRQATGQGLEWVGWNPNSGNTGY 60

Qy 61 AQRFGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQRFGQGVTTMTDTSRTAYMELSLRSDDTAVYYCAR 98
```

```
RESULT 9
S18553
Ig heavy chain V region precursor (VI-3b) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 06-Jun-1997 #text_change 23-Jul-1999
C:Accession: S18553; S26916
R:Shin, E.K.; Matsuda, F.; Nagaoka, H.; Fukita, Y.; Imai, T.; Yokoyama, K.; Soeda, E.; H.
EMBO J. 10, 3641-3645, 1991
A:Title: Physical map of the 3' region of the human immunoglobulin heavy chain locus: cl
A:Reference number: S18551; MUID:92037524; PMID:1935893
A:Accession: S18553
A:Status: translation not shown
A:Molecule type: DNA
A:Residues: 1-117 <SHI>
A:Cross-references: UNIPARC:UPI0000176E84; EMBL:X62109
R:Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A:Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A:Reference number: S26885; MUID:93021117; PMID:1404388
A:Accession: S26916
A:Molecule type: DNA
A:Residues: 20-117 <TOM>
A:Cross-references: UNIPARC:UPI0000116402; EMBL:Z12327; NID:g32871; PIDN:CAA78197.1; PID
C:Genetics:
A:Introns: 16/1
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:1-19/Domain: signal sequence #status predicted <SIG>
F:20-117/Product: Ig heavy chain V region (VI-3b) #status predicted <MAT>
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match 78.1%; Score 407; DB 2; Length 117;
Best Local Similarity 78.6%; Pred. No. 3.2e-34;
Matches 77; Conservative 8; Mismatches 13; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
Db 20 QVQLVQSGAEVKKPGASVKVSCRASGYTFTSYAMHWVRQAPGORLEWVGWINGNNTKY 79

Qy 61 AQRFGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 80 SQKFGQGVTTITRDTSTASTAYMELSLRSDDTAVYYCAR 117

RESULT 10
S31600
Ig heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31600
R:Quisnier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31600
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-136 <CUI>
A:Cross-references: UNIPARC:UPI0000116453; EMBL:Z14165; NID:g30994; PIDN:CAA78534.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match 78.1%; Score 407; DB 2; Length 136;
Best Local Similarity 78.6%; Pred. No. 3.7e-34;
Matches 77; Conservative 9; Mismatches 12; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASMKVSCMASGYPTFTSYDISWVRQAPGGQLEWVGWISAYNGNTHY 60
Db 20 QVQLVQSGAEVKKPGASVKVSCRASGYTFTSYDINWVRQATGQGLEWVGWNPNSGNTGY 79

Qy 61 AQRFGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQRFGQGVTTITRDTSTASTAYMELSLRSDDTAVYYCAR 117
```



```

RESULT 15
S49530
anti-Sm antibody VH chain (VH1/DK1 or DM1/JH4b) - human
C:Species: Homo sapiens (man)
C>Date: 01-Feb-1995 #sequence_revision 12-May-1995 #text_change 23-Jul-1999
C:Accession: S49530
R:/Mahmoudi, M.; Edwards, J.; Cairns, E.; Bell, D.
submitted to the EMBL Data Library, October 1994.
A:Description: Molecular characterization of natural human anti-Sm autoantibodies.
A:Reference number: S48797
A:Accession: S49530
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-135 <MAH>
A:Cross-references: UNIPARC:UPI00001166FF; EMBL:Z46348; NID:g560839; PIDN:CAA86467.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match      77.0%; Score 401; DB 2; Length 135;
Best Local Similarity 77.6%; Pred. No. 1.5e+33;
Matches          76; Conservative    7; Mismatches 15; Indels    0; Gaps    0;

Qy   1 QVQLQSATVEKKPGASMKVCSWASGYPFTSYDTSVVRQAPGGGLEFWGVCHISAYNGNTYH 60
     |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db   20 QVLVSQGAEVKPGASVKVSKCASGYTFGTYYMHVVRQAPGGGLEWMGWNPNSGGTNY 79
     |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy   61 AQKFQGRVTMTDTSRRTAYMELSLRLSDDTAVYYCAR 98
     |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db   80 AQKFQGRVTMTDTSTISTAYMELSLRLSDDTAVYYCAR 117
     |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Search completed: May 5, 2006, 08:51:34
Job time : 6.24377 secs

```

THIS PAGE BLANK (USPTO)


```

ID Q7Z7P5_HUMAN PRELIMINARY; PRT; 469 AA.
AC Q7Z7P5
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klauener R.D., Collins P.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young J.W., Green E.D., Dickson M.C.,
RA Blakeley R.W., Touchman J.W., Schmutz J., Myers R.M.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH MGC Project;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC051328; AAH51328.1; -; mRNA.
DR HSSP; P01857; IZH.
DR SMR; Q7Z7P5; 20-469.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR Immunoglobulin domain.
KW SEQUENCE 469 AA; 51395 MW; C8D5BE12BAAP795C CRC64;

Query Match 78.5%; Score 409; DB 2; Length 469;
Best Local Similarity 76.3%; Pred. No. 1.1e-38;
Matches 74; Conservative 12; Mismatches 11; Indels 0; Gaps 0;

QY 1 QVOLLQSATVKKPGASMKVSCWASGYPTTSYDISWVRQAPGGGLEWGWISAYNGNTHY 60
DB 20 QVHLVQSGAEVKKPGASVKVSCTGYNFSSYDIIWVRQAPGGGLEWGWISAHNGDTKY 79

QY 61 AQKFGQRTVTMTDTSRTATYMEISSLRSDDTAVYCA 97
DB 80 ARKFGQRTVTMTDTSATTSYMEISSLRSDDTAVYCA 116

RESULT 3
Q6N030_HUMAN
ID Q6N030 HUMAN PRELIMINARY; PRT; 518 AA.
AC Q6N030
DT 05-JUL-2004 (TrEMBLrel. 27, Created)

```

```

DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFP2686115212.
GN Name=DKFP2686115212;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Rectum tumor;
RG The German cDNA Consortium;
RA Pouscka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA Mewes H.W., Weil B., Amid C., Oeinger A., Fobo G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640724; CAE45841.1; -; mRNA.
DR HSSP; P01861; IADQ.
DR InterPro; IPR000005; HTHARAC.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IGV; 3.
DR SMART; SM00407; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00041; HTH ARAC FAMILY_1; UNKNOWN_1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
KW SEQUENCE 518 AA; 57019 MW; 93B5F98613BF6382 CRC64;

Query Match 74.7%; Score 389; DB 2; Length 518;
Best Local Similarity 73.5%; Pred. No. 2.7e-36;
Matches 72; Conservative 12; Mismatches 14; Indels 0; Gaps 0;

QY 1 QVOLLQSATVKKPGASMKVSCWASGYPTTSYDISWVRQAPGGGLEWGWISAYNGNTHY 60
DB 20 QVHLVQSGAEVKKPGASVKVSCTGYNFSSYDIIWVRQAPGGGLEWGWISAHNGDTKY 79

QY 61 AQKFGQRTVTMTDTSRTATYMEISSLRSDDTAVYCA 98
DB 80 SQKFGQRTVTMTDTSRTATYMEISSLRSDDTAVYCA 117

RESULT 4
Q9UL95_HUMAN
ID Q9UL95_HUMAN PRELIMINARY; PRT; 125 AA.
AC Q9UL95;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berny S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192 (1998).
DR EMBL; AF035019; AAD56255.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.

```

```

DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 125
SQ SEQUENCE 125 AA; 13516 MW; 0D3CD5C232488EAC CRC64;

Query Match 73.9%; Score 385; DB 2; Length 125;
Best Local Similarity 73.5%; Pred. No. 1.5e-36;
Matches 72; Conservative 10; Mismatches 16; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASVKSCASGYPTFTSYDLSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 1 EVQLVSGAEVKKPGASVKSCASGYTFTGYMHVVRQAPGQGLEWVGWNPNSGNTY 60

Qy 61 AQKFGQGVMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGVMTTRDTTISTAYMELSLRSLRSDDTAVYYCAR 98

RESULT 5
Q9UL94_HUMAN
ID Q9UL94_HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL94;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clim.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192 (1998).
DR EMBL; AF035020; AAD56256.1; -; mRNA.
DR HSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13205 MW; 13E64F5345F4A16E CRC64;

Query Match 73.7%; Score 384; DB 2; Length 119;
Best Local Similarity 73.5%; Pred. No. 1.9e-36;
Matches 72; Conservative 10; Mismatches 16; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASVKSCASGYPTFTSYDLSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 1 EVQLVSGAEVKKPGASVKSCASGYTFTGYMHVVRQAPGQGLEWVGWNPNSWTNY 60

Qy 61 AQKFGQGVMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGVMTTRDTTISTAYMELSLRSLRSDDTAVYYCAR 98

RESULT 6
HV1B_HUMAN
ID HV1B_HUMAN STANDARD; PRT; 117 AA.
AC P01743;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)

```

```

DE Ig heavy chain V-I region HG3 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=83144028; PubMed=6298778;
RA Rechavi G., Ram D., Glazer L., Zakut R., Givol D.;
RT "Evolutionary aspects of immunoglobulin heavy chain variable region
RT (VH) gene subgroups.";
RL Proc. Natl. Acad. Sci. U.S.A. 80:855-859 (1983).
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; J00240; AAA52988.1; -; Genomic_DNA.
DR PIR; A02024; HVHUNG.
DR HSP; P01751; INQB.
DR SMR; P01743; 20-116.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region HG3.
FT DOMAIN 20 >117 Ig-like.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12946 MW; 2D3F92FC60CD1FE7 CRC64;

Query Match 73.5%; Score 383; DB 1; Length 117;
Best Local Similarity 75.5%; Pred. No. 2.4e-36;
Matches 74; Conservative 7; Mismatches 17; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASVKSCASGYPTFTSYDLSWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 20 QVQLVSGAEVKKPGASVKSCASGYTFTSYMHVVRQAPGQGLEWVGWNPNSGGSTSY 79

Qy 61 AQKFGQGVMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 80 AQKQGVMTTRDTTISTAYMELSLRSLRSDDTAVYYCAR 117

RESULT 7
Q9BRV0_HUMAN
ID Q9BRV0_HUMAN PRELIMINARY; PRT; 500 AA.
AC Q9BRV0;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE MGC27165 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heieh F.,

```

```
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettaman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16999-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RA Strauberg R.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC005951; AAH05951.1; -; mRNA.
DR HSSP; P01876; IOWO.
DR SMR; Q9BRV0; 25-300, 270-478.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig CL.
DR InterPro; IPR003006; Ig_MHC.
DR Pfam; PF07654; C1-set; 2.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 500 AA; 54154 MW; 0A9BF43F2A3CC6D9 CRC64;

Query Match 73.3%; Score 382; DB 2; Length 500;
Best Local Similarity 72.4%; Pred. No. 1.7e-35;
Matches 71; Conservative 9; Mismatches 18; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASKMKVSCMAGYPFTSYDISHVRQAPGQGLEWVGWISAYNGNTHY 60
DB 20 QVHLVQSGAEVMEFGASVRSCKTSGYAFHYTSIIWVRQAPGQGLEWMGWISFSSDNTRF 79

QY 61 AQKFGQGRVTMTDTSRRTAYMELRSLSDDTAVYYCAR 98
DB 80 AKKFGQGRVTLTDTSTSTVTYMELSRLSDDTAVYYCAR 117

RESULT 8
Q9UL92 HUMAN
ID Q9UL92 HUMAN PRELIMINARY; PRT; 124 AA.
AC Q9UL92;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=7681398;
RA Mariette X., Teapais A., Brouet J.C.;
RT "Nucleotide sequence analysis of the variable domains of four human
RT monoclonal IgM with an antibody activity to myelin-associated
RT glycoprotein.";
RL Eur. J. Immunol. 23:846-851(1993).
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; X07448; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR FIR; S00476; HVHUS5.
DR HSSP; P01751; INQB.
DR SMR; P23083; 20-117.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; IGV.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
```

```
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; IGV.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
FT NON_TER 1
FT NON_TER 124
SQ SEQUENCE 124 AA; 13580 MW; 1BAACBD96ACD2A2 CRC64;

Query Match 72.6%; Score 378; DB 2; Length 124;
Best Local Similarity 73.5%; Pred. No. 9.7e-36;
Matches 72; Conservative 10; Mismatches 16; Indels 0; Gaps 0;

QY 1 QVQLQSATEVKKPGASKMKVSCMAGYPFTSYDISHVRQAPGQGLEWVGWISAYNGNTHY 60
DB 1 EVQLVESGAEVKPGASVKSVCKASGYTFSSYMHVVRQAPGQGLEWMGIINPSGGSTSY 60

QY 61 AQKFGQGRVTMTDTSRRTAYMELRSLSDDTAVYYCAR 98
DB 61 AQKFGQGRVTMTDTSTSTVTYMELSRLSDDTAVYYCAR 98

RESULT 9
HVIG_HUMAN
ID HVIG_HUMAN STANDARD; PRT; 117 AA.
AC P23083;
DT 01-NOV-1991 (Rel. 20, Created)
DT 01-NOV-1991 (Rel. 20, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region V35 precursor.
DE Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=7681398;
RA Mariette X., Teapais A., Brouet J.C.;
RT "Nucleotide sequence analysis of the variable domains of four human
RT monoclonal IgM with an antibody activity to myelin-associated
RT glycoprotein.";
RL Eur. J. Immunol. 23:846-851(1993).
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC EMBL; X07448; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR FIR; S00476; HVHUS5.
DR HSSP; P01751; INQB.
DR SMR; P23083; 20-117.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; IGV.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
```

```

FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region V35.
FT DOMAIN 20 >117 Ig-like.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 13009 MW; B861CE63F8CE97BD CRC64;

Query Match 72.4%; Score 377; DB 1; Length 117;
Best Local Similarity 74.5%; Pred. No. 1.2e-35;
Matches 73; Conservative 7; Mismatches 18; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASKVKSCMASGYPTSYDISWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 20 QVQLVQSGAEVKKPGASVKSCAKSGYTFGTGYMHVWRQAPGQGLEWGRINPNSGGTY 79

Qy 61 AQKQFGRVTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 80 AQKQFGRVTSRDTSTISAYMELSLRSDDTAVYYCAR 117

RESULT 10
Q65ZC8 HUMAN
ID Q65ZC8 HUMAN PRELIMINARY; PRT; 244 AA.
AC Q65ZC8
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR EMBL; Y13057; CAA73500.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGv; 2.
DR PROSITE; PS50835; IG_LIKE; 2.
FT NON_TER 1 1
FT NON_TER 244 244
SQ SEQUENCE 244 AA; 26127 MW; 4B1F17868338F2BF CRC64;

Query Match 72.0%; Score 375; DB 2; Length 244;
Best Local Similarity 71.4%; Pred. No. 4.7e-35;
Matches 70; Conservative 10; Mismatches 18; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASKVKSCMASGYPTSYDISWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 1 QVQLVQSGAEVKKPGDSVKVSKASGYTFSDHYMHVWRQAPGQGLEWGWIDPNNGDTRF 60

Qy 61 AQKQFGRVTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQFGRVTMTDTSISAAAYMEVSLRSDDTAVYYCAR 98

RESULT 11
Q6NSA4 HUMAN
ID Q6NSA4 HUMAN PRELIMINARY; PRT; 120 AA.
AC Q6NSA4
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHV1-69 protein.
GN Name=IGHV1-69;
OS Homo sapiens (Human).

```

```

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Pooled;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Straubeberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Colling F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
RA Datchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Tohiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smallos D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Pooled;
RG NIH MGC Project;
RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC070333; AAH70333.1; -; mRNA.
DR HSSP; P01751; Ia6W.
DR SRP; Q6NSA4; 21-116.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGv; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 120 AA; 13035 MW; 64620FAC874585D4 CRC64;

Query Match 69.9%; Score 364; DB 2; Length 120;
Best Local Similarity 72.4%; Pred. No. 4e-34;
Matches 71; Conservative 9; Mismatches 18; Indels 0; Gaps 0;

Qy 1 QVQLQSATEVKKPGASKVKSCMASGYPTSYDISWVRQAPGQGLEWVGWISAYNGNTHY 60
Db 20 QVQLVQSGAEVKKPGSSVKSKASGCTFSSYAISWVRQAPGQGLEWGGIPIFGTANY 79

Qy 61 AQKQFGRVTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 80 TORFQGRVTITTDSTSTAYMKLSLRSDDTAVYYCAR 117

RESULT 12
Q96QSO HUMAN
ID Q96QSO HUMAN PRELIMINARY; PRT; 159 AA.
AC Q96QSO;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Putative matrix cell adhesion molecule-3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Tilson M.D.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.

```

```

DR EMBL; AY039025; AAK82649.1; -; mRNA.
DR HSSP; P01869; 1AE6.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 159 AA; 17497 MW; 5D295378881FAF02 CRC64;

Query Match 69.7%; Score 363; DB 2; Length 159;
Best Local Similarity 69.4%; Pred. No. 7.2e-34;
Matches 68; Conservative 13; Mismatches 17; Indels 0; Gaps 0;

QY 1 QVQLQSATVKKPKGASMKVSCWASGYPTSYDISWVROAPGQGLEWVGWISAYNGNTHY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 QVQLVSGAEVRKPGASVRVSKASGYTFIDSYIHWIRQAPGHLEWVGWISAYNGNTHY 79
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQVRVTMTDTSRRTAYMELRLSRSDDTAVYYCAR 98
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 SQKFGRLTWTDTSTVYMDLSRLSDDTAVYYCAR 117
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 13
HV1C_HUMAN STANDARD; PRT; 147 AA.
AC P01744;
DT 21-JUL-1986 (Rel. 01, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region ND precursor (Fragments).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE
RX MEDLINE=8305234; PubMed=6815656;
RA Kenten J.H., Molgaard H.V., Houghton M., Derbyshire R.B., Viney J.,
RA Bell L.O., Gould H.J.;
RT "Cloning and sequence determination of the gene for the human
   immunoglobulin epsilon chain expressed in a myeloma cell line.";
RL Proc. Natl. Acad. Sci. U.S.A. 79:6661-6665 (1982).
RN [2]
RP PROTEIN SEQUENCE OF 20-147.
RA Bernich H.H., Johansson S.G.O., von Bahr-Lindstrom H.;
RL (in) Bach M.K. (eds.);
RL Immediate hypersensitivity: modern concepts and developments, pp.1-36,
RL Marcel Dekker, New York (1978).
CC -/- MISCELLANEOUS: This epsilon chain was isolated from a myeloma
   protein.
CC -/- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR HSSP; P01751; INQB.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin v region; Pyrrolidone carboxylic acid; Signal.
FT SIGNAL 1 19
FT CHAIN 20 147 Ig heavy chain V-I region ND.
FT DOMAIN 20 131 Ig-like.
FT MOD_RES 20 20 Pyrrolidone carboxylic acid.

```

```

FT DISULFID 41 115
FT CONFLICT 21 21 T -> V (in Ref. 2).
FT CONFLICT 53 54 IH -> HI (in Ref. 2).
FT CONFLICT 67 68 VG -> GV (in Ref. 2).
FT CONFLICT 125 125 Missing (in Ref. 2).
FT NON_TER 147 147
SQ SEQUENCE 147 AA; 16496 MW; 948F9F72A5366C20 CRC64;

Query Match 68.9%; Score 359; DB 1; Length 147;
Best Local Similarity 67.3%; Pred. No. 1.9e-33;
Matches 66; Conservative 13; Mismatches 19; Indels 0; Gaps 0;

QY 1 QVQLQSATVKKPKGASMKVSCWASGYPTSYDISWVROAPGQGLEWVGWISAYNGNTHY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 QVQLVSGAEVRKPGASVRVSKASGYTFIDSYIHWIRQAPGHLEWVGWISAYNGNTHY 79
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQVRVTMTDTSRRTAYMELRLSRSDDTAVYYCAR 98
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 APRFQGRVTMTDTSRRTAYMELRLSRSDDTAVYYCAR 117
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 14
Q9GYZ2_MOUSE PRELIMINARY; PRT; 119 AA.
AC Q9GYZ2;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Monoclonal anti-idiotypic Schistosoma japonicum antibody NP30 heavy
DE chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Song X.T., Peng Z.Q., Guan X.H.;
RT "Amplification, cloning and sequence analysis of the heavy chain
   variable region gene of monoclonal anti-idiotypic antibody NP30 of
   Schistosoma japonicum.";
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF282622; AAG01452.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SNK; Q9GYZ2; 1-119.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1 119
FT NON_TER 119 119
SQ SEQUENCE 119 AA; 13567 MW; BA993873FD5FA6AB CRC64;

Query Match 68.7%; Score 358; DB 2; Length 119;
Best Local Similarity 68.4%; Pred. No. 2e-33;
Matches 67; Conservative 14; Mismatches 17; Indels 0; Gaps 0;

QY 1 QVQLQSATVKKPKGASMKVSCWASGYPTSYDISWVROAPGQGLEWVGWISAYNGNTHY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGAEVRKPGASVRVSKASGYTFITGYMNVVROAPGHLEWIGYINPSRGVTNY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQVRVTMTDTSRRTAYMELRLSRSDDTAVYYCAR 98
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 NQKFKDVRVTMTDTSRRTAYMELRLSRSDTSADSAVYYCAR 98
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 15
Q6N041_HUMAN PRELIMINARY; PRT; 498 AA.
ID Q6N041_HUMAN
AC Q6N041;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)

```



```

DE Hypothetical protein DKFP686016217 (Fragment).
GN Name=DKFP686016217;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;
RG The German Human cDNA Consortium;
RA Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA Mewes H.W., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640710; CAB45829.1; -; mRNA.
DR HSP; P01751; 1A6W.
DR SMR; Q6N041; 268-476.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON_TER
SQ SEQUENCE 498 AA; 54125 MW; 40B3208A84E03B46 CRC64;

Query Match 68.7%; Score 358; DB 2; Length 498;
Best Local Similarity 68.4%; Pred. No. 1e-32;
Matches 67; Conservative 14; Mismatches 17; Indels 0; Gaps 0;

Qy 1 QVQLQSGATEVKPGASMKVSCMASGYPTFTSYDISWVRQAPGQGLEWGWISAYNGNTHY 60
Db 35 QVQLVQSGADVKKPGASVKVSKASGYTFTNYPFHVVRQAPGQGPWWGMINPRDGS TKY 94

Qy 61 AQKFGQRTVTTTDSRTATYMWELSLRSDDTAVYYCAR 98
Db 95 AQRFGQRVSMTRDTSTSTIYMELSLRSDDTAVYYCAR 132

Search completed: May 5, 2006, 09:04:19
Job time : 38.8199 secs

```

THIS PAGE BLANK (USP10)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:18 ; Search time 37.7399 Seconds
(without alignments)
1140.944 Million cell updates/sec

Title: US-09-674-752-28

Perfect score: 516

Sequence: 1 QVQLQSAAEVRKPGASVKV.....AYMELSLRSLRSDDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21.*

1: Geneseqp1980s.*

2: Geneseqp1990s.*

3: Geneseqp2000s.*

4: Geneseqp2001s.*

5: Geneseqp2002s.*

6: Geneseqp2003as.*

7: Geneseqp2003bs.*

8: Geneseqp2004s.*

9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	504	97.7	98	3 AAY50955	Aay50955 Human ant
2	500	96.9	132	3 AAY50953	Aay50953 Human ant
3	491	95.2	132	3 AAY50950	Aay50950 Human ant
4	471	91.3	98	3 AAY50954	Aay50954 Human ant
5	467	90.5	116	9 AEA89842	Aea89842 Anti-IFN
6	467	90.5	116	9 AEA89841	Aea89841 Anti-IFN
7	467	90.5	247	5 ABP45105	Abp45105 Human Bly
8	467	90.5	247	7 ADG95932	Adg95932 Single ch
9	467	90.5	250	5 ABP45549	Abp45549 Human Bly
10	467	90.5	250	7 ADG96376	Adg96376 Single ch
11	464	89.9	250	5 ABP45584	Abp45584 Human Bly
12	464	89.9	250	7 ADG96411	Adg96411 Single ch
13	462	89.5	116	9 AEA89844	Aea89844 Anti-IFN
14	461	89.3	116	9 AEA89843	Aea89843 Anti-IFN
15	460	89.1	98	3 AAY50952	Aay50952 Human ant
16	460	89.1	98	5 ABG78171	Abg78171 Human Fv
17	460	89.1	98	5 ABG91862	Abg91862 Human ant
18	460	89.1	98	6 ABO27071	AbO27071 Human ger
19	460	89.1	98	7 ADC99824	Adc99824 Germline
20	460	89.1	98	7 ADD05428	Add05428 Anti-MUC1
21	460	89.1	98	7 ADF09899	Adf09899 Antibody
22	460	89.1	98	7 ADF10109	Adf10109 Antibody
23	460	89.1	98	7 ADF10007	Adf10007 VEGF anti
24	460	89.1	98	7 ADF09866	Adf09866 Anti-MUC1

ALIGNMENTS

RESULT 1

AAY50955

ID AAY50955 standard; protein; 98 AA.

AC AAY50955;

DT 23-MAR-2000 (first entry)

DS Human anti-factor VIII antibody VH protein VH EL-25.

XX Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

KW VH protein.

OS Homo sapiens.

PN WO9958680-A2.

XX 18-NOV-1999.

XX 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

XX Voorberg JJ, Van Den Brink EN, Turenhout EM;

XX WPI; 2000-053102/04.

XX New polynucleotide, polypeptide and antibody useful for diagnosing the presence of neutralizing antibodies against factor VIII and for treatment of hemophilia A patients with these antibodies.

XX Example 4; Fig 4B; 61pp; English.

XX This invention describes a novel polynucleotide (I) (and complements and hybridizable polynucleotides) comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity which has hemostatic activity. (I) is useful a primer or probe for detecting the presence of inhibitory antibodies directed against factor VIII. The polypeptides of the invention and the antibodies generated from them are useful in competitions for neutralizing factor VIII inhibiting antibodies in hemophilia A patients. This sequence represents the human anti-factor VIII antibody VH EL-25 protein which is used in the method of the invention

XX Sequence 98 AA;

```

Query Match      97.7%; Score 504; DB 3; Length 98;
Best Local Similarity 98.0%; Pred. No. 2.3e-42;
Matches 96; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVCKASGYPTSYDISWVRQAPGGGLEWMGHWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
DB 1 QVQLQSAAEVRKPGASVKVCKASGYPTSYDISWVRQAPGGGLEWMGHWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
DB 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 2
AA50953
ID AAY50953 standard; protein; 132 AA.
AC AAY50953;
XX
XX 23-MAR-2000 (first entry)
XX
XX Human anti-factor VIII antibody VH protein VH IT-2.
XX
XX Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
XX VH protein.
XX
XX Homo sapiens.
XX
XX WO958680-A2.
XX
XX 18-NOV-1999.
XX
XX 07-MAY-1999; 99WO-NL000285.
XX
XX 08-MAY-1998; 98EP-00201543.
XX
XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
XX
XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
XX
XX WPI; 2000-053102/04.
XX
XX New polynucleotide, polypeptide and antibody useful for diagnosing the
XX presence of neutralizing antibodies against factor VIII and for treatment
XX of hemophilia A patients with these antibodies.
XX
XX Example 4; Fig 4B; 61pp; English.
XX
XX This invention describes a novel polynucleotide (I) (and complements and
XX hybridizable polynucleotides) comprising a contiguous nucleotide sequence
XX coding for a human antibody with factor VIII specificity which has
XX hemostatic activity. (I) is useful a primer or probe for detecting the
XX presence of inhibitory antibodies directed against factor VIII. The
XX polypeptides of the invention and the antibodies generated from them are
XX useful in compositions for neutralizing factor VIII inhibiting antibodies
XX in hemophilia A patients. This sequence represents the human anti-factor
XX VIII antibody VH IT-2 protein which is used in the method of the
XX invention
XX
XX Sequence 132 AA;

Query Match      96.9%; Score 500; DB 3; Length 132;
Best Local Similarity 95.9%; Pred. No. 7.9e-42;
Matches 94; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVCKASGYPTSYDISWVRQAPGGGLEWMGHWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
DB 1 QVQLQSAATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGGLEWMGHWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
DB 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Query Match      95.2%; Score 491; DB 3; Length 132;
Best Local Similarity 94.9%; Pred. No. 6.2e-41;
Matches 93; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVCKASGYPTSYDISWVRQAPGGGLEWMGHWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
DB 1 QVQLQSAATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGGLEWMGHWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
DB 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 4
AA50954
ID AAY50954 standard; protein; 98 AA.
XX
XX AAY50954;
XX
XX 23-MAR-2000 (first entry)
XX
XX Human anti-factor VIII antibody VH protein VH EL-5.
XX
XX DE

```

```

RESULT 3
AA50950
ID AAY50950 standard; protein; 132 AA.
XX
XX AAY50950;
XX
XX 23-MAR-2000 (first entry)
XX
XX Human anti-factor VIII antibody VH clone IT-2 encoded protein.
XX
XX Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
XX VH gene.
XX
XX Homo sapiens.
XX
XX WO958680-A2.
XX
XX 18-NOV-1999.
XX
XX 07-MAY-1999; 99WO-NL000285.
XX
XX 08-MAY-1998; 98EP-00201543.
XX
XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
XX
XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
XX
XX WPI; 2000-053102/04.
XX
XX New polynucleotide, polypeptide and antibody useful for diagnosing the
XX presence of neutralizing antibodies against factor VIII and for treatment
XX of hemophilia A patients with these antibodies.
XX
XX Example 4; Fig 4A; 61pp; English.
XX
XX This invention describes a novel polynucleotide (I) (and complements and
XX hybridizable polynucleotides) comprising a contiguous nucleotide sequence
XX coding for a human antibody with factor VIII specificity which has
XX hemostatic activity. (I) is useful a primer or probe for detecting the
XX presence of inhibitory antibodies directed against factor VIII. The
XX polypeptides of the invention and the antibodies generated from them are
XX useful in compositions for neutralizing factor VIII inhibiting antibodies
XX in hemophilia A patients. This sequence represents the human anti-factor
XX VIII antibody clone IT-2 protein which is used in the method of the
XX invention
XX
XX Sequence 132 AA;

Query Match      95.2%; Score 491; DB 3; Length 132;
Best Local Similarity 94.9%; Pred. No. 6.2e-41;
Matches 93; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVCKASGYPTSYDISWVRQAPGGGLEWMGHWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
DB 1 QVQLQSAATEVKKPGASMKVSCWASGYPTSYDISWVRQAPGGGLEWMGHWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
DB 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

RESULT 4
AA50954
ID AAY50954 standard; protein; 98 AA.
XX
XX AAY50954;
XX
XX 23-MAR-2000 (first entry)
XX
XX Human anti-factor VIII antibody VH protein VH EL-5.
XX
XX DE

```

KW Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
 KW VH protein.
 XX
 XX Homo sapiens.
 OS
 XX W09958680-A2.
 PN
 XX 18-NOV-1999.
 PD
 XX
 XX 07-MAY-1999; 99WO-NL000285.
 PF
 XX
 XX 08-MAY-1998; 98EP-00201543.
 PR
 XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
 PA
 XX Voorberg JJ, Van Den Brink EN, Turenhout EM;
 PI WPI; 2000-053102/04.
 XX
 XX New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX
 XX Example 4; Fig 4B; 61pp; English.
 PS
 XX This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has
 CC hemostatic activity. (I) is useful a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents the human anti-factor
 CC VIII antibody VH EL-5 protein which is used in the method of the
 CC invention
 XX
 XX Sequence 98 AA;
 SQ
 Query Match 91.3%; Score 471; DB 3; Length 98;
 Best Local Similarity 89.8%; Pred. No. 4.4e-39;
 Matches 8; Conservative 5; Mismatches 5; Indels 0; Gaps 0;
 QY 1 QVQLQSAAEVRKPGASVKVCKASGYPFTSYDLSWVRQAPGGQLEWMGWISYSGNTDY 60
 DB 1 QVQLVLSATEVKKPGASVKVCKASGYPFTSYDLSWVRQAPGGQLEWMGWISAYNGNTHY 60
 QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
 DB 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
 RESULT 5
 AEA89842
 ID AEA89842 standard; protein; 116 AA.
 XX
 AC AEA89842;
 XX
 DT 08-SEP-2005 (first entry)
 XX
 XX Anti-IFN alpha antibody 13H5 heavy chain variable region N55Q mutant.
 KW interferon alpha; heavy chain variable region; antibody;
 KW systemic lupus erythematosus; multiple sclerosis;
 KW inflammatory bowel disease; insulin-dependent diabetes mellitus;
 KW psoriasis; hashimoto's disease; rheumatoid arthritis; glomerulonephritis;
 KW transplant rejection; graft versus host disease; Dermatological;
 KW immunosuppressive; Antinflammatory; Neuroprotective;
 KW Gastrointestinal-Gen.; Antiporiatic; Antidiabetic; Antithyroid;
 KW Antirheumatic; Antiarthritic; Nephrotropic; genitourinary disease;
 KW inflammation; dermatological disease; immune disorder; endocrine disease;
 KW musculoskeletal disease; gastrointestinal disease; metabolic disorder;
 KW neurological disease; mutein.

OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH Misc-difference 55 /note= "Wild-type Asn substituted by Glu"
 PT
 XX W02005059106-A2.
 PN
 XX 30-JUN-2005.
 PD
 XX
 XX 10-DEC-2004; 2004WO-US041777.
 PF
 XX
 XX 10-DEC-2003; 2003US-0528757P.
 PR
 XX (MEDA-) MEDAREX INC.
 PA
 XX Witte A, Williams D, Cardarelli JM, King D, Pasamore D;
 PI WPI; 2005-488541/49.
 XX
 XX Novel isolated anti-interferon alpha monoclonal antibody or its antigen-
 PT binding portion, useful for treating interferon alpha-mediated disease or
 PT disorder e.g. systemic lupus erythematosus.
 XX
 XX Claim 35; SEQ ID NO 35; 187pp; English.
 PS
 XX The invention relates to an isolated anti-interferon alpha monoclonal
 CC antibody (I) or its antigen-binding portion. (I) is useful for inhibiting
 CC the biological activity of interferon alpha. (I) is useful for treating
 CC an interferon alpha-mediated disease or disorder in a subject in need of
 CC treatment. The disease or disorder is systemic lupus erythematosus. The
 CC disease or disorder is chosen from multiple sclerosis, inflammatory bowel
 CC disease, insulin dependent diabetes mellitus, psoriasis, autoimmune
 CC thyroiditis, rheumatoid arthritis and glomerulonephritis. The disease or
 CC disorder is transplant rejection or graft versus host disease. The
 CC present sequence represents the amino acid sequence of the anti-IFN alpha
 CC antibody 13H5 heavy chain variable region N55Q mutant.
 XX
 XX Sequence 116 AA;
 SQ
 Query Match 90.5%; Score 467; DB 9; Length 116;
 Best Local Similarity 88.8%; Pred. No. 1.3e-38;
 Matches 87; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
 QY 1 QVQLQSAAEVRKPGASVKVCKASGYPFTSYDLSWVRQAPGGQLEWMGWISYSGNTDY 60
 DB 1 QVQLVSGAEVRKPGASVKVCKASGYPFTSYDLSWVRQAPGGQLEWMGWISVYQGTNY 60
 QY 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
 DB 61 AQKFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
 RESULT 6
 AEA89841
 ID AEA89841 standard; protein; 116 AA.
 XX
 AC AEA89841;
 XX
 DT 08-SEP-2005 (first entry)
 XX
 XX Anti-IFN alpha antibody 13H5 heavy chain variable region N55D mutant.
 KW interferon alpha; heavy chain variable region; antibody;
 KW systemic lupus erythematosus; multiple sclerosis;
 KW inflammatory bowel disease; insulin-dependent diabetes mellitus;
 KW psoriasis; hashimoto's disease; rheumatoid arthritis; glomerulonephritis;
 KW transplant rejection; graft versus host disease; Dermatological;
 KW immunosuppressive; Antinflammatory; Neuroprotective;
 KW Gastrointestinal-Gen.; Antiporiatic; Antidiabetic; Antithyroid;
 KW Antirheumatic; Antiarthritic; Nephrotropic; genitourinary disease;
 KW inflammation; dermatological disease; immune disorder; endocrine disease;
 KW musculoskeletal disease; gastrointestinal disease; metabolic disorder;

XX neurological disease; mutein.
XX Homo sapiens.
XX Key Location/Qualifiers
XX Misc-difference 55
XX /note= "Wild-type Aen substituted by Asp"
XX WO2005059106-A2.
XX 30-JUN-2005.
XX 10-DEC-2004; 2004WO-US041777.
XX 10-DEC-2003; 2003US-0528757P.
XX (MEDA-) MEDAREX INC.
XX Witte A, Williams D, Cardarelli JM, King D, Pasemore D;
XX WPI; 2005-488541/49.
XX Novel isolated anti-interferon alpha monoclonal antibody or its antigen-binding portion, useful for treating interferon alpha-mediated disease or disorder e.g. systemic lupus erythematosus.
XX Claim 35; SEQ ID NO 34; 187pp; English.
XX The invention relates to an isolated anti-interferon alpha monoclonal antibody (I) or its antigen-binding portion. (I) is useful for inhibiting the biological activity of interferon alpha. (I) is useful for treating an interferon alpha-mediated disease or disorder in a subject in need of treatment. The disease or disorder is systemic lupus erythematosus. The disease or disorder is chosen from multiple sclerosis, inflammatory bowel disease, insulin dependent diabetes mellitus, psoriasis, autoimmune thyroiditis, rheumatoid arthritis and glomerulonephritis. The disease or disorder is transplant rejection or graft versus host disease. The present sequence represents the amino acid sequence of the anti-IFN alpha antibody 13H5 heavy chain variable region N55D mutant.
XX Sequence 116 AA;
Query Match 90.5%; Score 467; DB 9; Length 116;
Best Local Similarity 88.8%; Pred. No. 1.3e-38;
Matches 87; Conservative 5; Mismatches 6; Indels 0; Gaps 0;
QY 1 QVOLLQSAAEVRKPGASVKVSKASGYPTSYDTSWVRQAPGQGLEWMGWISYSGNTDY 60
DB 1 QVOLLQSGAEVRKPGASVKVSKASGYTFTSYISWVRQAPGQGLEWMGWISYDGNNTY 60
QY 61 AQKFGQGRVTMTTDSRRTAYMELRSRSDDTAVYYCAR 98
DB 61 AQKFGQGRVTMTTDSRRTAYMELRSRSDDTAVYYCAR 98
RESULT 7
ABP45105
ID ABP45105 standard; protein; 247 AA.
XX AC ABP45105;
XX DT 19-AUG-2002 (first entry)
XX DE Human BlyS binding scFv SEQ ID 1116.
XX BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
XX tumour necrosis factor; B cell proliferation; B cell differentiation;
XX immunosuppressive; immunostimulant; autoimmune disorder; antirheumatic;
XX antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
XX systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
XX common variable immunodeficiency; acquired immunodeficiency syndrome.
XX Homo sapiens.
OS

XX WO200202641-A1.
XX 10-JAN-2002.
XX 15-JUN-2001; 2001WO-US019110.
XX 16-JUN-2000; 2000US-0212210P.
XX 17-OCT-2000; 2000US-0240816P.
XX 16-MAR-2001; 2001US-0276248P.
XX 21-MAR-2001; 2001US-0277379P.
XX 25-MAY-2001; 2001US-0293499P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX WPI; 2002-114799/15.
XX Antibodies against B Lymphocyte Stimulating polypeptides, useful for the diagnosis and treatment of cancers and immune disorders.
XX Claim 1; Page 1734-1735; 3148pp; English.
XX This invention describes novel antibodies that immunospecifically bind to B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the tumour necrosis factor (TNF) super family and induces B cell proliferation and differentiation. The antibodies of the invention have cytostatic, immunosuppressive, immunostimulant, immunomodulatory, antirheumatic and antiAIDS activity and can be used in vaccines to inhibit the expression and activity of BlyS. The antibodies bind to BlyS and so may be used to detect and quantitate the presence of BlyS in biological samples and may be used in this way to diagnose disease CC associated with aberrant expression of BlyS. They may also be administered to treat diseases associated with aberrant BlyS expression and activity such as cancer, immune, and autoimmune disorders and diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis, immunodeficiency (e.g. common variable immunodeficiency (CVID) and acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent the antibodies and fragments of the antibodies described in the method of the invention
XX Sequence 247 AA;
Query Match 90.5%; Score 467; DB 5; Length 247;
Best Local Similarity 90.8%; Pred. No. 2.9e-38;
Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;
QY 1 QVOLLQSAAEVRKPGASVKVSKASGYPTSYDTSWVRQAPGQGLEWMGWISYSGNTDY 60
DB 1 QVOLLQSAAEVRKPGASVKVSKASGYTFTSYISWVRQAPGQGLEWMGWISAYNGNTNY 60
QY 61 AQKFGQGRVTMTTDSRRTAYMELRSRSDDTAVYYCAR 98
DB 61 AQKFGQGRVTMTTDSRRTAYMELRSRSDDTAVYYCAR 98
RESULT 8
ADG95932
ID ADG95932 standard; protein; 247 AA.
XX AC ADG95932;
XX DT 11-MAR-2004 (first entry)
XX Single chain antibody that immunospecifically binds BlyS SeqID 1116.
XX antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
XX B cell proliferation; differentiation; scFv; myasthenia gravis;
XX multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
XX carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
XX antiinflammatory; antiasthmatic; antiallergic; cytostatic.

XX OS Unidentified.
 XX OS WO2003055979-A2.
 XX FN 10-JUN-2003.
 XX PD
 XX PF 14-NOV-2002; 2002WO-US036496.
 XX PF 16-NOV-2001; 2001US-0331469P.
 XX PR 19-DEC-2001; 2001US-0340817P.
 XX PR
 XX PA (HUMA-) HUMAN GENOME SCI INC.
 XX PA
 XX PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
 XX PI WPI; 2003-505530/47.
 XX DR
 XX XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 PT (Blys), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.
 XX PT
 XX PS Example 1; SEQ ID NO 1116; 394pp; English.
 XX CC
 XX CC This invention relates to novel antibodies that immunospecifically bind
 CC to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour
 CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scFvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey Blys. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of Blys or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds Blys of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
 XX CC
 XX SQ Sequence 247 AA;
 Query Match 90.5%; Score 467; DB 7; Length 247;
 Best Local Similarity 90.8%; Pred. No. 2.9e-38;
 Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;
 Qy 1 QVQLQSAAEVRKPGASVKVCKASGYPTFTSYISWVRQAPGQGLEWMGWTISYSGNTDY 60
 Db 1 QVQLQSAAEVRKPGASVKVCKASGYPTFTSYISWVRQAPGQGLEWMGWTISYSGNTDY 60
 Qy 61 AQKQGRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
 Db 61 AQKQGRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
 RESULT 9
 ABP45549
 ID ABP45549 standard; protein; 250 AA.
 XX AC
 XX AC ABP45549;
 XX AC
 XX DT 19-AUG-2002 (first entry)
 XX DE Human Blys binding scFv SEQ ID 1560.
 XX DE
 XX KW Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;

KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX
 OS Homo sapiens.
 XX OS
 XX WO200202641-A1.
 XX FN
 XX PD 10-JAN-2002.
 XX PF
 XX PF 15-JUN-2001; 2001WO-US019110.
 XX PR
 XX PR 16-JUN-2000; 2000US-0212210P.
 XX PR 17-OCT-2000; 2000US-0240816P.
 XX PR 16-MAR-2001; 2001US-0276248P.
 XX PR 21-MAR-2001; 2001US-0277379P.
 XX PR 25-MAY-2001; 2001US-0293499P.
 XX PA
 XX PA (HUMA-) HUMAN GENOME SCI INC.
 XX PA (CMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 XX PI WPI; 2002-114799/15.
 XX DR
 XX XX Antibodies against B lymphocyte stimulating polypeptides, useful for the
 PT diagnosis and treatment of cancers and immune disorders.
 XX PT
 XX PS Claim 1; Page 2264-2265; 3148pp; English.
 XX CC
 XX CC This invention describes novel antibodies that immunospecifically bind to
 CC B lymphocyte stimulator (Blys) polypeptides. Blys is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of Blys. The antibodies bind to Blys
 CC and so may be used to detect and quantitate the presence of Blys in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of Blys. They may also be
 CC administered to treat diseases associated with aberrant Blys expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention
 XX CC
 XX SQ Sequence 250 AA;
 Query Match 90.5%; Score 467; DB 5; Length 250;
 Best Local Similarity 90.8%; Pred. No. 2.9e-38;
 Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;
 Qy 1 QVQLQSAAEVRKPGASVKVCKASGYPTFTSYISWVRQAPGQGLEWMGWTISYSGNTDY 60
 Db 1 QVQLQSAAEVRKPGASVKVCKASGYPTFTSYISWVRQAPGQGLEWMGWTISYSGNTDY 60
 Qy 61 AQKQGRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
 Db 61 AQKQGRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
 RESULT 10
 ADG96376
 ID ADG96376 standard; protein; 250 AA.
 XX AC
 XX AC ADG96376;
 XX AC
 XX DT 11-MAR-2004 (first entry)
 XX DE
 XX KW

DE Single chain antibody that immunospecifically binds BlyS SeqID 1560.
 XX antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
 KW B cell proliferation; differentiation; scfv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; anti-rheumatic; anti-arthritis; neuroprotective;
 KW anti-inflammatory; antiasthmatic; antiallergic; cytostatic.
 XX Unidentified.
 OS WO2003055979-A2.
 PN 10-JUL-2003.
 PD 14-NOV-2002; 2002WO-US036496.
 XX 16-NOV-2001; 2001US-0331469P.
 PN 19-DEC-2001; 2001US-0340817P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
 PI WPI; 2003-505530/47.
 DR Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 XX (BlyS), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.
 PT Example 1; SEQ ID NO 1560; 394pp; English.
 PS This invention relates to novel antibodies that immunospecifically bind
 XX to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour
 CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scfvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey BlyS. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of BlyS or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as anti-rheumatic, anti-arthritis, neuroprotective,
 CC anti-inflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds BlyS of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
 XX Sequence 250 AA;
 SQ Query Match 90.5%; Score 467; DB 7; Length 250;
 Best Local Similarity 90.8%; Pred. No. 2.9e-38;
 Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;
 QY 1 QVQLQSAAEVVRKPGASVKVSKASGYPTFTSYISWVRQAPGGLEWMGHWISYSGNTDY 60
 DB 1 QVQLQSAAEVVRKPGASVKVSKASGYPTFTSYISWVRQAPGGLEWMGHWISYSGNTDY 60
 QY 61 AQKFGQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98
 DB 61 AQKFGQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98
 RESULT 11
 ABP45584
 ID ABP45584 standard; protein; 250 AA.
 XX

AC ABP45584;
 XX 19-AUG-2002 (first entry)
 DT Human BlyS binding scFv SEQ ID 1595.
 DE BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
 KW tumour necrosis factor; B cell proliferation; B cell differentiation;
 KW immunosuppressive; immunostimulant; immunomodulatory; anti-rheumatic;
 KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
 KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
 KW common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX Homo sapiens.
 OS WO200202641-A1.
 PN 10-JAN-2002.
 PD 15-JUN-2001; 2001WO-US019110.
 XX 16-JUN-2000; 2000US-0212210P.
 PR 17-OCT-2000; 2000US-0240816P.
 PR 16-MAR-2001; 2001US-0276248P.
 PR 21-MAR-2001; 2001US-0277379P.
 PR 25-MAY-2001; 2001US-0293499P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 PI WPI; 2002-114799/15.
 DR Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
 XX diagnosis and treatment of cancers and immune disorders.
 PT Claim 1; Page 2306-2307; 3148pp; English.
 PS This invention describes novel antibodies that immunospecifically bind to
 CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
 CC tumour necrosis factor (TNF) super family and induces B cell
 CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC anti-rheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
 CC and so may be used to detect and quantitate the presence of BlyS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BlyS. They may also be
 CC administered to treat diseases associated with aberrant BlyS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention
 XX Sequence 250 AA;
 SQ Query Match 89.9%; Score 464; DB 5; Length 250;
 Best Local Similarity 89.8%; Pred. No. 5.8e-38;
 Matches 88; Conservative 4; Mismatches 6; Indels 0; Gaps 0;
 QY 1 QVQLQSAAEVVRKPGASVKVSKASGYPTFTSYISWVRQAPGGLEWMGHWISYSGNTDY 60
 DB 1 QVQLQSAAEVVRKPGASVKVSKASGYPTFTSYISWVRQAPGGLEWMGHWISYSGNTDY 60
 QY 61 AQKFGQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98
 DB 61 AQKFGQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98
 RESULT 12

ADG96411
ID ADG96411 standard; protein; 250 AA.
XX AC ADG96411;
XX
DT 11-MAR-2004 (first entry)
XX
DE Single chain antibody that immunospecifically binds Blys SeqID 1595.
XX
KW antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
KW B cell proliferation; differentiation; scFv; myasthenia gravis;
KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
KW carcinoma; lymphoma; antiinflammatory; antiarthritic; neuroprotective;
KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX
OS Unidentified.
XX
PN W0200305979-A2.
XX
PD 10-JUL-2003.
XX
PF 14-NOV-2002; 2002WO-US036496.
XX
PR 16-NOV-2001; 2001US-0331469P.
PR 19-DEC-2001; 2001US-0340817P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
PI WPI; 2003-505530/47.
XX
XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
XX (Blys), useful for detecting and treating diseases or disorders e.g.
XX rheumatoid arthritis, asthma and leukemia.
XX
XX Example 1; SEQ ID NO 1595; 394pp; English.
XX
XX This invention relates to novel antibodies that immunospecifically bind
XX to B lymphocyte stimulator (Blys). The Blys gene has been mapped to
XX chromosome 13q34 and encodes a protein that is a member of the tumour
XX necrosis factor superfamily and induces both in vivo and in vitro B cell
XX proliferation and differentiation. Specifically, it refers to single
XX chain antibody molecules (scFvs) derived, preferably, from the variable
XX heavy CDR3 region that immunospecifically bind to a polypeptide, or
XX fragment thereof, of either human, murine, rat or monkey Blys. The
XX present invention refers to the use of such antibodies in various methods
XX for the detection, diagnosis and prognosis of diseases related to the
XX aberrant expression or inappropriate function of Blys or its receptor. As
XX such, these compositions are useful for identifying immune disorders
XX including myasthenia gravis and multiple sclerosis, inflammatory
XX disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
XX as AIDS and proliferative disorders including leukaemia, carcinoma and
XX lymphoma. Accordingly, they can be described as exhibiting various
XX activities such as antiinflammatory, antiarthritic, neuroprotective,
XX antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
XX polypeptide sequence is a single chain antibody that binds Blys of the
XX invention. NOTE: The sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX
XX Sequence 250 AA;
XX
Query Match 89.9%; Score 464; DB 7; Length 250;
Best Local Similarity 89.8%; Pred. No. 5.8e-38;
Matches 88; Conservative 4; Mismatches 6; Indels 0; Gaps 0;
QY 1 QVQLQSAAEVKKPKGASVKVSKASGYFTSYDTSVWVQAPQGLLWGWISYSGNTDY 60
Db 1 QVQLVQSAAEVKKPKGASVKVSKASGYFTSYDTSVWVQAPQGLLWGWISYSGNTDY 60
QY 61 AQKQGRVTWTTDTSTSTAYMELRSLRSDDTAVYYCAR 98

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:53:55 ; Search time 10.7652 Seconds
(without alignments)
752.634 Million cell updates/sec

Title: US-09-674-752-28
Perfect score: 516
Sequence: 1 QVQLQSAAEVRKPGASVKV.....AYMELSLRSDDTAVVYCAR 98

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued patents AA:*
1: /cgn2_6/ptodata/1/iaa/5_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/6_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/H_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/PTUS_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	460	89.1	98	2	US-10-194-975-4
2	460	89.1	98	2	US-10-330-613A-53
3	460	89.1	117	2	US-08-545-809A-105
4	460	89.1	117	2	US-09-515-697-105
5	448	86.8	118	2	US-09-726-219A-165
6	448	86.8	118	2	US-09-196-522-165
7	446	86.4	123	2	US-10-330-613A-21
8	445	86.2	134	2	US-09-471-276-849
9	440	85.3	121	1	US-08-264-093-3
10	432	83.7	132	2	US-09-513-999C-4112
11	431	83.5	117	2	US-09-025-769B-22
12	431	83.5	117	2	US-09-490-070A-22
13	431	83.5	117	2	US-09-490-153-22
14	431	83.5	117	2	US-09-490-324-22
15	430	83.3	120	2	US-09-513-999C-4111
16	427	82.8	96	2	US-10-330-613A-54
17	425.5	82.5	128	1	US-08-202-047-22
18	425.5	82.5	128	2	US-08-964-690-22
19	425.5	82.5	129	1	US-08-561-521-45
20	425.5	82.5	129	2	US-08-525-539A-77
21	425.5	82.5	129	4	PCT-US95-01219-45
22	424	82.2	122	2	US-09-513-999C-7801
23	423	82.0	117	2	US-08-545-809A-96
24	423	82.0	117	2	US-09-515-697-96
25	421	81.6	120	2	US-09-025-769B-36
26	421	81.6	120	2	US-09-025-769B-59
27	421	81.6	120	2	US-09-490-070A-36

28	421	81.6	120	2	US-09-490-070A-59	Sequence 59, Appl
29	421	81.6	120	2	US-09-490-153-36	Sequence 36, Appl
30	421	81.6	120	2	US-09-490-153-59	Sequence 59, Appl
31	421	81.6	120	2	US-09-490-324-36	Sequence 36, Appl
32	421	81.6	120	2	US-09-490-324-59	Sequence 59, Appl
33	421	81.6	121	2	US-09-513-999C-4115	Sequence 4115, Ap
34	420	81.4	470	2	US-09-859-053-28	Sequence 28, Appl
35	417.5	80.9	120	1	US-08-652-816A-19	Sequence 19, Appl
36	417.5	80.9	125	2	US-09-199-149-3	Sequence 3, Appl
37	416	80.6	98	2	US-10-194-975-1	Sequence 1, Appl
38	416	80.6	117	2	US-08-545-809A-90	Sequence 90, Appl
39	416	80.6	117	2	US-09-515-697-90	Sequence 90, Appl
40	414	80.2	96	2	US-10-194-975-3	Sequence 3, Appl
41	411	79.7	98	2	US-10-194-975-2	Sequence 2, Appl
42	411	79.7	119	1	US-08-561-521-10	Sequence 10, Appl
43	411	79.7	119	2	US-09-438-954-41	Sequence 41, Appl
44	411	79.7	119	4	PCT-US95-01219-10	Sequence 10, Appl
45	406	78.7	110	2	US-09-899-896-5	Sequence 5, Appl

ALIGNMENTS

RESULT 1
US-10-194-975-4
; Sequence 4, Application US/10194975
; Patent No. 6881557
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-194-975-4

Query Match	89.1%	Score 460;	DB 2;	Length 98;
Best Local Similarity	88.8%	Pred. No. 1.6e-41;		
Matches	87;	Conservative	4;	Mismatches 7; Indels 0; Gaps 0;
Qy	1	QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQGLEWMGWISYISGNTDY	60	
Db	1	QVQLVQSGAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWISAYNGNTNY	60	
Qy	61	AQKFGQGRVTMTTDTSRRTAYMELSLRSDDTAVVYCAR	98	
Db	61	AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVVYCAR	98	

RESULT 2
US-10-330-613A-53
; Sequence 53, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudag, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: ABGENIX.022A
; CURRENT APPLICATION NUMBER: US/10/330,613A
; CURRENT FILING DATE: 2002-12-26
; PRIOR FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 53
; LENGTH: 98
; TYPE: PRT

```

; ORGANISM: Homo sapiens
US-10-330-613A-53

Query Match      89.1%; Score 460; DB 2; Length 98;
Best Local Similarity 88.8%; Pred. No. 1.6e-41;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQLEWMGHSIYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGLISWVRQAPGGQLEWMGHSIYSGNTDY 60

Qy 61 AQKFGQVRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 3
US-08-545-809A-105
; Sequence 105, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: US/08/545,809A
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 105:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 105:
US-08-545-809A-105

Query Match      89.1%; Score 460; DB 2; Length 117;
Best Local Similarity 88.8%; Pred. No. 2e-41;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQLEWMGHSIYSGNTDY 60
Db 20 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGLISWVRQAPGGQLEWMGHSIYSGNTNY 79

Qy 61 AQKFGQVRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 80 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 117

US-08-545-809A-105

Query Match      89.1%; Score 460; DB 2; Length 117;
Best Local Similarity 88.8%; Pred. No. 2e-41;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQLEWMGHSIYSGNTDY 60
Db 20 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGLISWVRQAPGGQLEWMGHSIYSGNTNY 79

Qy 61 AQKFGQVRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 80 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 117

US-08-545-809A-105

; ORGANISM: Homo sapiens
US-10-330-613A-53

Query Match      89.1%; Score 460; DB 2; Length 98;
Best Local Similarity 88.8%; Pred. No. 1.6e-41;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQLEWMGHSIYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGLISWVRQAPGGQLEWMGHSIYSGNTNY 60

Qy 61 AQKFGQVRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 4
US-09-515-697-105
; Sequence 105, Application US/09515697
; Patent No. 6936705
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; FILING DATE: 29-Feb-2000
; APPLICATION NUMBER: US/09/515,697
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 105:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 105:
US-09-515-697-105

Query Match      89.1%; Score 460; DB 2; Length 117;
Best Local Similarity 88.8%; Pred. No. 2e-41;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQLEWMGHSIYSGNTDY 60
Db 20 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGLISWVRQAPGGQLEWMGHSIYSGNTNY 79

Qy 61 AQKFGQVRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 80 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 117

US-09-515-697-105

; ORGANISM: Homo sapiens
US-10-330-613A-53

Query Match      89.1%; Score 460; DB 2; Length 98;
Best Local Similarity 88.8%; Pred. No. 1.6e-41;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQLEWMGHSIYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGLISWVRQAPGGQLEWMGHSIYSGNTNY 60

Qy 61 AQKFGQVRVTMTTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 5
US-09-726-219A-165
; Sequence 165, Application US/09726219A
; Patent No. 6806079
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Medical Research Council
; APPLICANT: McCafferty, John
; APPLICANT: Pope, Anthony
; APPLICANT: Johnson, Kevin
; APPLICANT: Hoogenboom, Hendricus
; APPLICANT: Griffiths, Andrew

```

```
; APPLICANT: Jackson, Ronald
; APPLICANT: Holliger, Kaeper
; APPLICANT: Marks, James
; APPLICANT: Clackson, Timothy
; APPLICANT: Chiswell, David
; APPLICANT: Winter, Gregory
; APPLICANT: Bonert, Timothy
; TITLE OF INVENTION: Methods for Producing Members of Specific Binding Pairs
; FILE REFERENCE: 213839-00013
; CURRENT APPLICATION NUMBER: US/09/726.219A
; CURRENT FILING DATE: 2000-11-28
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1991-03-06
; PRIOR APPLICATION NUMBER: GB 9104744.9
; PRIOR FILING DATE: 1991-05-15
; PRIOR APPLICATION NUMBER: GB 9110549.4
; PRIOR FILING DATE: 1991-07-10
; PRIOR APPLICATION NUMBER: PCT/GB91/01134
; PRIOR FILING DATE: 1993-01-08
; PRIOR APPLICATION NUMBER: US 07/971,857
; PRIOR FILING DATE: 1993-01-08
; PRIOR APPLICATION NUMBER: US 08/484,893
; NUMBER OF SEQ ID NOS: 272
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 165
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-726-219A-165

Query Match      86.8%; Score 448; DB 2; Length 118;
Best Local Similarity 86.7%; Pred. No. 3.7e-40;
Matches 85; Conservative 3; Mismatches 10; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTKY 60

Qy 61 AQKFGQVRVTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKIQGRVTMTDTSRTSTAYMELSLRSDDTAVYYCVR 98

RESULT 6
US-09-196-522-165
; Sequence 165, Application US/09196522
; Patent No. 6916605
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Medical Research Council
; APPLICANT: McCafferty, John
; APPLICANT: Pope, Anthony
; APPLICANT: Johnson, Kevin
; APPLICANT: Hoogenboom, Hendricus
; APPLICANT: Griffiths, Andrew
; APPLICANT: Jackson, Ronald
; APPLICANT: Holliger, Kaeper
; APPLICANT: Marks, James
; APPLICANT: Clackson, Timothy
; APPLICANT: Chiswell, David
; APPLICANT: Winter, Gregory
; APPLICANT: Bonert, Timothy
; TITLE OF INVENTION: Methods for Producing Members of Specific Binding Pairs
; FILE REFERENCE: 213839-00004
; CURRENT APPLICATION NUMBER: US/09/196.522
```

```
; CURRENT FILING DATE: 1998-11-28
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; PRIOR FILING DATE: 1991-03-06
; PRIOR APPLICATION NUMBER: GB 9110549.4
; PRIOR FILING DATE: 1991-05-15
; PRIOR APPLICATION NUMBER: PCT/GB91/01134
; PRIOR FILING DATE: 1991-07-10
; PRIOR APPLICATION NUMBER: US 07/971,857
; PRIOR FILING DATE: 1993-01-08
; PRIOR APPLICATION NUMBER: US 08/484,893
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 272
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 165
; LENGTH: 118
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-196-522-165

Query Match      86.8%; Score 448; DB 2; Length 118;
Best Local Similarity 86.7%; Pred. No. 3.7e-40;
Matches 85; Conservative 3; Mismatches 10; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTKY 60

Qy 61 AQKFGQVRVTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKIQGRVTMTDTSRTSTAYMELSLRSDDTAVYYCVR 98

RESULT 7
US-10-330-613A-21
; Sequence 21, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: ABGENIX.022A
; CURRENT APPLICATION NUMBER: US/10/330,613A
; CURRENT FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo Sapiens
US-10-330-613A-21

Query Match      86.4%; Score 446; DB 2; Length 123;
Best Local Similarity 85.7%; Pred. No. 6.4e-40;
Matches 84; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGFSWVRQAPGQGLEWLGWISAYNGNTNY 60

Qy 61 AQKFGQVRVTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKIQGRVTMTDTSRTSTAYMELSLRSDDTAVYYCAR 98
```

```
RESULT 8
US-09-471-276-849
; Sequence 849, Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: GENSET.025CP1
; CURRENT APPLICATION NUMBER: US/09/471,276
; CURRENT FILING DATE: 1999-12-21
; EARLIER APPLICATION NUMBER: 09/057,719
; EARLIER FILING DATE: 1998-04-09
; EARLIER APPLICATION NUMBER: 09/069,047
; EARLIER FILING DATE: 1998-04-28
; EARLIER APPLICATION NUMBER: PCT/IB99/00712
; EARLIER FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 1622
; SOFTWARE: Patent.pm
; SEQ ID NO 849
; LENGTH: 134
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -19...-1
US-09-471-276-849

Query Match      86.2%; Score 445; DB 2; Length 134;
Best Local Similarity 84.7%; Pred. No. 9e-40;
Matches 83; Conservative 6; Mismatches 9; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTSYDISWVRQAPGQGLEWMGWSIYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 QVQLVSGGEVKPGASVKVSKASGYTFRYDINWVRQAPGQGLEWMGHSAXNGTNY 79
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 AQKFGQGRVTMTTDTSTRRTAYMELRSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 AQXVQGRVTMTTDTSTRRTAYMELRSLRSDDTAVYYCAR 117
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 9
US-08-264-093-3
; Sequence 3, Application US/08264093
; Patent No. 5639863
; GENERAL INFORMATION:
; APPLICANT: Michael D. Dan
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO
; TITLE OF INVENTION: CELL CYCLE-INDEPENDENT GLIOMA SURFACE
; TITLE OF INVENTION: ANTIGEN
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ridout & Maybee
; STREET: 2300 Richmond-Adelaide Centre
; STREET: 101 Richmond Street West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5H 2J7
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.4 Mb storage
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: MS-DOS 6.00
; SOFTWARE: ASCII Editor
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/264,093
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA: No. 5639863 applicable
; ATTORNEY/AGENT INFORMATION:
; NAME: Lake, James R.
```

```
; REGISTRATION NUMBER: 31081
; REFERENCE/DOCKET NUMBER: NOVOP/106A/7551
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 868-1482
; TELEFAX: (416) 362-0823
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 121 amino acids
; TYPE: amino acid
; STRANDEDNESS: not applicable
; TOPOLOGY: linear
US-08-264-093-3

Query Match      85.3%; Score 440; DB 1; Length 121;
Best Local Similarity 83.7%; Pred. No. 2.7e-39;
Matches 82; Conservative 9; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTSYDISWVRQAPGQGLEWMGWSIYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVSGAEVKPGASVKVSKASGYTFTYGLSWVRQAPGQGLEWMGWSIAHNGNTNS 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 AQKFGQGRVTMTTDTSTRRTAYMELRSLRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVSMTTDTSTSTAYMEVRSLSRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 10
US-09-513-999C-4112
; Sequence 4112, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert, A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: 59.US2.REG
; CURRENT APPLICATION NUMBER: US/09/513,999C
; CURRENT FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/122,487
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 16681
; SOFTWARE: Patent.pm
; SEQ ID NO 4112
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -19...-1
; OTHER INFORMATION: score 10.8
; OTHER INFORMATION: seq ILFLVAAATGAHS/QV
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 9
; OTHER INFORMATION: Xaa=Ala or Pro
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 31
; OTHER INFORMATION: Xaa=Asn or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 33
; OTHER INFORMATION: Xaa=Asp or Gly
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 35
; OTHER INFORMATION: Xaa=Asn or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 63
; OTHER INFORMATION: Xaa=Asp or Glu or Lys or Asn
; FEATURE:
```

```
; NAME/KEY: UNSURE
; LOCATION: 72
; OTHER INFORMATION: Xaa=Arg or Thr
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 77
; OTHER INFORMATION: Xaa=Lys or Asn or Arg or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 93
; OTHER INFORMATION: Xaa=Ile or Met or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 101
; OTHER INFORMATION: Xaa=Ile or Leu or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 103
; OTHER INFORMATION: Xaa=Ala or Glu or Gly or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 104
; OTHER INFORMATION: Xaa=Leu or Val
; US-09-513-999C-4112

Query Match      83.7%; Score 432; DB 2; Length 132;
Best Local Similarity 82.7%; Pred. No. 2.1e-38;
Matches 81; Conservative 4; Mismatches 13; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGQGLEWMGWIISYSGNTDY 60
Db 20 QVQLVQSGXEVKPKGASVKVSKASGYTFTTXIXWVRQAPGQGLEWMGWIISYNGNTNY 79

Qy 61 AQKFGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 80 AQDLQGRVTMTXDTSTXTAYMELSLRSDDTAXYYCAR 117

RESULT 11
US-09-025-769B-22
; Sequence 22, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025.769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5

; NAME/KEY: UNSURE
; LOCATION: 72
; OTHER INFORMATION: Xaa=Arg or Thr
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 77
; OTHER INFORMATION: Xaa=Lys or Asn or Arg or Ser
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 93
; OTHER INFORMATION: Xaa=Ile or Met or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 101
; OTHER INFORMATION: Xaa=Ile or Leu or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 103
; OTHER INFORMATION: Xaa=Ala or Glu or Gly or Val
; FEATURE:
; NAME/KEY: UNSURE
; LOCATION: 104
; OTHER INFORMATION: Xaa=Leu or Val
; US-09-025-769B-22

Query Match      83.5%; Score 431; DB 2; Length 117;
Best Local Similarity 84.7%; Pred. No. 2.3e-38;
Matches 83; Conservative 5; Mismatches 10; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGQGLEWMGWIISYSGNTDY 60
Db 1 QVQLVQSGAEVRKPGASVKVSKASGYTFTSYHWHVRQAPGQGLEWMGWINPNSGNTNY 60

Qy 61 AQKFGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKFGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98

RESULT 12
US-09-490-070A-22
; Sequence 22, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490.070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-490-070A-22
```

```

Query Match      83.5%; Score 431; DB 2; Length 117;
Best Local Similarity 84.7%; Pred. No. 2.3e-38;
Matches 83; Conservative 5; Mismatches 10; Indels 0; Gaps 0;

QY      1 QVQLQSAAEVRKPGASVKVSKASGYPFTSYDLSWVRQAPQGLEGWGWGISIYSGNTDY 60
      |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db      1 QVQLVQSGAEVRKPGASVKVSKASGTYFTSYDHWVRQAPQGLEGWGWINPNSGNTY 60
      |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY      61 AQKFGQGVTTMTDTSRRTAYMELSLRSDDDTAVYYCAR 98
      |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db      61 AQKFGQGVTTMTDTSRRTAYMELSLRSDDDTAVYYCAR 98
      |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

RESULT 13
US-09-490-153-22
; Sequence 22, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Pluckethun, Andreas
;
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-490-153-22

Query Match      83.5%; Score 431; DB 2; Length 117;
Best Local Similarity 84.7%; Pred. No. 2.3e-38;
Matches 83; Conservative 5; Mismatches 10; Indels 0; Gaps 0;

QY      1 QVQLQSAAEVRKPGASVKVSKASGYPFTSYDLSWVRQAPQGLEGWGWGISIYSGNTDY 60
      |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db      1 QVQLVQSGAEVRKPGASVKVSKASGTYFTSYDHWVRQAPQGLEGWGWINPNSGNTY 60
      |||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY      61 AQKFGQGVTTMTDTSRRTAYMELSLRSDDDTAVYYCAR 98

```


Page 7

```

1 / APPLICANT: Duclert, A.
2 / APPLICANT: Giordano, J.Y.
3 / TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
4 / Patent No. 6783961
5 / FILE REFERENCE: 59.US2.REG
6 / CURRENT APPLICATION NUMBER: US/09/513,999C
7 / CURRENT FILING DATE: 2000-02-24
8 / PRIOR APPLICATION NUMBER: US 60/122,487
9 / PRIOR FILING DATE: 1999-02-26
10 / NUMBER OF SEQ ID NOS: 36681
11 / SOFTWARE: Patent.pm
12 / SEQ ID NO 4111
13 / LENGTH: 120
14 / TYPE: PRT
15 / ORGANISM: Homo sapiens
16 / FEATURE:
17 / NAME/KEY: SIGNAL
18 / LOCATION: -19..-1
19 / OTHER INFORMATION: score 10.7
20 / OTHER INFORMATION: seq ILFLVAAATGXHS/QV
21 / FEATURE:
22 / NAME/KEY: UNSURE
23 / LOCATION: -3
24 / OTHER INFORMATION: Xaa=Ala or Val
25 / FEATURE:
26 / NAME/KEY: UNSURE
27 / LOCATION: 9
28 / OTHER INFORMATION: Xaa=Ala or Pro
29 / FEATURE:
30 / NAME/KEY: UNSURE
31 / LOCATION: 53
32 / OTHER INFORMATION: Xaa=Ala or Gly
33 / FEATURE:
34 / NAME/KEY: UNSURE
35 / LOCATION: 63
36 / OTHER INFORMATION: Xaa=Glu or Lys
37 / FEATURE:
38 / NAME/KEY: UNSURE
39 / LOCATION: 64
40 / OTHER INFORMATION: Xaa=Phe or Leu
41 / FEATURE:
42 / NAME/KEY: UNSURE
43 / LOCATION: 72
44 / OTHER INFORMATION: Xaa=Arg or Thr
45 / FEATURE:
46 / NAME/KEY: UNSURE
47 / LOCATION: 82
48 / OTHER INFORMATION: Xaa=Asp or Glu
49 / FEATURE:
50 / NAME/KEY: UNSURE
51 / LOCATION: 85
52 / OTHER INFORMATION: Xaa=Asn or Ser
53 / FEATURE:
54 / NAME/KEY: UNSURE
55 / LOCATION: 98
56 / OTHER INFORMATION: Xaa=Lys or Arg
57 / US-09-513-999C-4111

```

```
Query Match      83.3%; Score 430; DB 2; Length 120;
Best Local Similarity 83.5%; Pred. No. 3.1e-38;
Matches 81; Conservative 4; Mismatches 12; Indels 0; Gaps 0;
```

```
Qy   1 QVQLLSAAEVRPGASVKVSCKRSGYPFTSYDTSWVRQAPGQGLEWMGISYSGNTDY 60
      |||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||
Db   20 QVQLVQSXEKKPGASVKVSCKRSGYTFSTYGISWRQAPGQGLEWMGISYXNGNTNY 79
      |||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||

Qy   61 AQKFEGRVTMTTDSRTATAYMELSLRSSDDTAIVYCA 97
      |||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||
Db   80 AQXXQGRVTMTTSDTSTNTATYMXLFLXRSSDDTAIVYCA 116
      |||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||
```

Search completed: May 5, 2006, 08:56:24
Job time : 10.7652 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 09:02:26 ; Search time 30.0682 Seconds
(without alignments)
1361.814 Million cell updates/sec

Title: US-09-674-752-28

Perfect score: 516

Sequence: 1 QVQLQSAAEVRKPGASVKV.....AYMELSLRSDDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA_Main:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	467	90.5	247	3	US-09-880-748-1116 Sequence 1116, Ap
2	467	90.5	247	4	US-10-293-418-1116 Sequence 1116, Ap
3	467	90.5	250	3	US-09-880-748-1560 Sequence 1560, Ap
4	467	90.5	250	4	US-10-293-418-1560 Sequence 1560, Ap
5	464	89.9	250	3	US-09-880-748-1595 Sequence 1595, Ap
6	464	89.9	250	4	US-10-293-418-1595 Sequence 1595, Ap
7	460	89.1	98	4	US-10-194-975-4 Sequence 4, Appli
8	460	89.1	98	4	US-10-041-860-2 Sequence 2, Appli
9	460	89.1	98	4	US-10-041-860-324 Sequence 324, App
10	460	89.1	98	4	US-10-041-860-326 Sequence 326, App
11	460	89.1	98	4	US-10-041-860-355 Sequence 355, App
12	460	89.1	98	4	US-10-041-860-356 Sequence 356, App
13	460	89.1	98	4	US-10-308-817-44 Sequence 44, Appli
14	460	89.1	98	4	US-10-032-037B-46 Sequence 46, Appl
15	460	89.1	98	4	US-10-029-988B-46 Sequence 46, Appl
16	460	89.1	98	4	US-10-032-423A-46 Sequence 46, Appl
17	460	89.1	98	4	US-10-453-698-44 Sequence 44, Appl
18	460	89.1	98	4	US-10-029-326B-46 Sequence 46, Appl
19	460	89.1	98	4	US-10-379-392-4 Sequence 4, Appli
20	460	89.1	104	3	US-09-864-761-47285 Sequence 47285, A
21	460	89.1	109	4	US-10-800-197-147 Sequence 147, App
22	460	89.1	109	5	US-10-727-155-284 Sequence 284, App
23	460	89.1	109	5	US-10-727-155-290 Sequence 290, App
24	460	89.1	117	4	US-10-041-860-206 Sequence 206, App
25	460	89.1	118	6	US-11-039-767-8 Sequence 8, Appli
26	460	89.1	118	6	US-11-039-767-10 Sequence 10, Appl
27	460	89.1	121	6	US-11-031-485-120 Sequence 120, App

28	460	89.1	125	4	US-10-269-805-45 Sequence 45, Appl
29	460	89.1	125	4	US-10-041-860-42 Sequence 42, Appl
30	460	89.1	125	4	US-10-041-860-207 Sequence 207, App
31	460	89.1	125	4	US-10-565-383-62 Sequence 62, Appl
32	460	89.1	126	4	US-10-041-860-354 Sequence 354, App
33	460	89.1	127	4	US-10-041-860-31 Sequence 31, Appl
34	460	89.1	127	4	US-10-041-860-243 Sequence 243, App
35	460	89.1	127	4	US-10-041-860-325 Sequence 325, App
36	460	89.1	127	4	US-10-565-383-42 Sequence 42, Appl
37	460	89.1	132	5	US-10-910-901-21 Sequence 21, Appl
38	460	89.1	248	3	US-09-880-748-1472 Sequence 1472, Ap
39	460	89.1	248	4	US-10-293-418-1472 Sequence 1472, Ap
40	460	89.1	251	3	US-09-880-748-1562 Sequence 1562, Ap
41	460	89.1	251	3	US-09-880-748-1872 Sequence 1872, Ap
42	460	89.1	251	3	US-09-880-748-1921 Sequence 1921, Ap
43	460	89.1	251	4	US-10-293-418-1562 Sequence 1562, Ap
44	460	89.1	251	4	US-10-293-418-1872 Sequence 1872, Ap
45	460	89.1	251	4	US-10-293-418-1921 Sequence 1921, Ap

ALIGNMENTS

RESULT 1
US-09-880-748-1116
; Sequence 1116, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1116
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1116

Query Match 90.5%; Score 467; DB 3; Length 247;
Best Local Similarity 90.8%; Pred. No. 2.7e-38;
Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

Qy	1	QVQLQSAAEVRKPGASVKVSKASGYPFTSYDISHVROAPGQGLEWMGWSISYGNTRY 60
Db	1	QVQLQSAAEVRKPGASVKVSKASGYTTSYGISVWRQAPGQGLEWMGWSISYGNTRY 60
Qy	61	AQKQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98
Db	61	AQKQGRVTMTTDTSTRTAYMELSLRSDDTAVYYCAR 98

RESULT 2
US-10-293-418-1116
; Sequence 1116, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418

```
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1116
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1116

Query Match          90.5%; Score 467; DB 4; Length 247;
Best Local Similarity 90.8%; Pred. No. 2.7e-38;
Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKSCASGYPFTSYDISWVRQAPGGLEWMGWSISYSGNTDY 60
Db 1 QVQLQSAAEVRKPGASVKSCASGYFTSYGISWVRQAPGGLEWMGWSISYNGNTNY 60

QY 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98

RESULT 3
US-09-880-748-1560
; Sequence 1560, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1560
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1560

Query Match          90.5%; Score 467; DB 3; Length 250;
Best Local Similarity 90.8%; Pred. No. 2.7e-38;
Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKSCASGYPFTSYDISWVRQAPGGLEWMGWSISYSGNTDY 60
Db 1 QVQLQSAAEVRKPGASVKSCASGYFTSYGISWVRQAPGGLEWMGWSISYNGNTNY 60

QY 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98

RESULT 4
US-10-293-418-1560
; Sequence 1560, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1560
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1560

Query Match          90.5%; Score 467; DB 4; Length 250;
Best Local Similarity 90.8%; Pred. No. 2.7e-38;
Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKSCASGYPFTSYDISWVRQAPGGLEWMGWSISYSGNTDY 60
Db 1 QVQLQSAAEVRKPGASVKSCASGYFTSYGISWVRQAPGGLEWMGWSISYNGNTNY 60

QY 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98

RESULT 5
US-09-880-748-1595
; Sequence 1595, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1595
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1595

Query Match          90.5%; Score 467; DB 3; Length 250;
Best Local Similarity 90.8%; Pred. No. 2.7e-38;
Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKSCASGYPFTSYDISWVRQAPGGLEWMGWSISYSGNTDY 60
Db 1 QVQLQSAAEVRKPGASVKSCASGYFTSYGISWVRQAPGGLEWMGWSISYNGNTNY 60

QY 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
```

```
QY 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98

RESULT 4
US-10-293-418-1560
; Sequence 1560, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1560
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1560

Query Match          90.5%; Score 467; DB 4; Length 250;
Best Local Similarity 90.8%; Pred. No. 2.7e-38;
Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKSCASGYPFTSYDISWVRQAPGGLEWMGWSISYSGNTDY 60
Db 1 QVQLQSAAEVRKPGASVKSCASGYFTSYGISWVRQAPGGLEWMGWSISYNGNTNY 60

QY 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98

RESULT 5
US-09-880-748-1595
; Sequence 1595, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1595
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1595

Query Match          90.5%; Score 467; DB 3; Length 250;
Best Local Similarity 90.8%; Pred. No. 2.7e-38;
Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKSCASGYPFTSYDISWVRQAPGGLEWMGWSISYSGNTDY 60
Db 1 QVQLQSAAEVRKPGASVKSCASGYFTSYGISWVRQAPGGLEWMGWSISYNGNTNY 60

QY 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
Db 61 AQKQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
```

```
; SEQ ID NO 1595
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1595

Query Match      89.9%; Score 464; DB 3; Length 250;
Best Local Similarity 89.8%; Pred. No. 5.4e-38;
Matches 88; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDLSWVRQAPGGQLEWMGHSISYSGNTDY 60
DB 1 QVQLVQSAAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGHSISYNGNTNY 60

QY 61 AQKFGQGRVTMTTDTSRRTAYMELRSLSRSDDTAVYYCAR 98
DB 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98

RESULT 6
US-10-293-418-1595
; Sequence 1595, Application US/10293418
; Publication No. US2003023996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1595
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1595

Query Match      89.9%; Score 464; DB 4; Length 250;
Best Local Similarity 89.8%; Pred. No. 5.4e-38;
Matches 88; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDLSWVRQAPGGQLEWMGHSISYSGNTDY 60
DB 1 QVQLVQSAAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGHSISYNGNTNY 60

QY 61 AQKFGQGRVTMTTDTSRRTAYMELRSLSRSDDTAVYYCAR 98
DB 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98

RESULT 7
US-10-194-975-4
; Sequence 4, Application US/10194975
; Publication No. US20030039649A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01

; SEQ ID NO 194
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-4

Query Match      89.1%; Score 460; DB 4; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.1e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDLSWVRQAPGGQLEWMGHSISYSGNTDY 60
DB 1 QVQLVQSAAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGHSISYNGNTNY 60

QY 61 AQKFGQGRVTMTTDTSRRTAYMELRSLSRSDDTAVYYCAR 98
DB 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98

RESULT 8
US-10-041-860-2
; Sequence 2, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Peng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gad
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-2

Query Match      89.1%; Score 460; DB 4; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.1e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDLSWVRQAPGGQLEWMGHSISYSGNTDY 60
DB 1 QVQLVQSAAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGHSISYNGNTNY 60

QY 61 AQKFGQGRVTMTTDTSRRTAYMELRSLSRSDDTAVYYCAR 98
DB 61 AQKLGQRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98

RESULT 9
US-10-041-860-324
; Sequence 324, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Peng, Xiao
; APPLICANT: Yang, Xiao-Dong
```

```
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 324
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-324

Query Match      89.1%; Score 460; DB 4; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.1e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTSYDISWVRQAPGQGLEWMGHWISYSGNTDY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTTSRRRTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 10
US-10-041-860-326
; Sequence 326, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 326
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-326

Query Match      89.1%; Score 460; DB 4; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.1e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTSYDISWVRQAPGQGLEWMGHWISYSGNTDY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTTSRRRTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 12
US-10-041-860-356
; Sequence 356, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 356
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-356

Query Match      89.1%; Score 460; DB 4; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.1e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTSYDISWVRQAPGQGLEWMGHWISYSGNTDY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTTSRRRTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 355
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-355

Query Match      89.1%; Score 460; DB 4; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.1e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTSYDISWVRQAPGQGLEWMGHWISYSGNTDY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTTSRRRTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 324
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-324

Query Match      89.1%; Score 460; DB 4; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.1e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTSYDISWVRQAPGQGLEWMGHWISYSGNTDY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGHWISAYNGNTNY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTTSRRRTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 11
US-10-041-860-355
; Sequence 355, Application US/10041860
; Publication No. US20030157109A1
```

```
RESULT 13
US-10-308-817-44
; Sequence 44, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 44
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-308-817-44

Query Match      89.1%; Score 460; DB 4; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.1e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQGLEWMGWISYSGNTDY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWISAYNGNTNY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 AQKFGQGRVTMTTDSRRRTAYMELRSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Search completed: May 5, 2006, 09:07:33
Job time : 30.211 secs

RESULT 14
US-10-032-037B-46
; Sequence 46, Application US/10032037B
; Publication No. US20040001822A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/44
; CURRENT APPLICATION NUMBER: US/10/032,037B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 46
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-46

Query Match      89.1%; Score 460; DB 4; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.1e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQGLEWMGWISYSGNTDY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWISAYNGNTNY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 AQKFGQGRVTMTTDSRRRTAYMELRSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Search completed: May 5, 2006, 09:07:33
Job time : 30.211 secs

RESULT 15
US-10-029-988B-46
; Sequence 46, Application US/10029988B
; Publication No. US20040001839A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
```

```
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029,988B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 46
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-46

Query Match      89.1%; Score 460; DB 4; Length 98;
Best Local Similarity 88.8%; Pred. No. 5.1e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQGLEWMGWISYSGNTDY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQGLEWMGWISAYNGNTNY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 AQKFGQGRVTMTTDSRRRTAYMELRSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 98
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Search completed: May 5, 2006, 09:07:33
Job time : 30.211 secs
```

THIS PAGE BLANK (USPTO)

Query Match 90.5%; Score 467; DB 11; Length 247;
Best Local Similarity 90.8%; Pred. No. 5.4e-36;
Matches 89; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSCKASGYPTFTSYDISWTRQAPGGCGLENGWGIVSIYSGNTDY 60
:
:
:


```
; Sequence 1595, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLyS
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1595
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-1595

Query Match      89.9%; Score 464; DB 11; Length 250;
Best Local Similarity 89.8%; Pred. No. 1e-35;
Matches 88; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYGSIWVRQAPGGGLEWMGMWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSAAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGGGLEWMGMWISAYNGNTNY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTSRRTAYMELRSLSRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLQGRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 6
US-11-266-444-1595
; Sequence 1595, Application US/11266444
; Publication No. US2006062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523P11
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 1595
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-266-444-1595

Query Match      89.9%; Score 464; DB 11; Length 250;
Best Local Similarity 89.8%; Pred. No. 1e-35;
Matches 88; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYGSIWVRQAPGGGLEWMGMWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSAAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGGGLEWMGMWISAYNGNTNY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTSRRTAYMELRSLSRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLQGRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 7
US-11-221-902-55
; Sequence 55, Application US/11221902
; Publication No. US20060088522A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGAT
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 55
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-221-902-55

Query Match      89.1%; Score 460; DB 10; Length 98;
Best Local Similarity 88.8%; Pred. No. 1e-35;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYGSIWVRQAPGGGLEWMGMWISYSGNTDY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSAAEVRKPGASVKVSKASGYTFTSYGISWVRQAPGGGLEWMGMWISAYNGNTNY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFGQGRVTMTTDTSRRTAYMELRSLSRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLQGRVTMTTDTSTSTAYMELRSLSRSDDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 8
US-11-054-669-4
; Sequence 4, Application US/11054669
; Publication No. US20050261480A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES
; FILE REFERENCE: 30219/US/3
; CURRENT APPLICATION NUMBER: US/11/054,669
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: US 10/194,975
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-669-4

Query Match      89.1%; Score 460; DB 11; Length 98;
```



```

; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-136-250-15

Query Match      89.1%; Score 460; DB 11; Length 98;
Best Local Similarity 88.8%; Pred. No. 1e-35;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVOLLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQLEWMGWISYSGNTDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWISAYNGNTNY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 AQKFGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 13
US-10-982-440-45
; Sequence 45, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 45
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-45

Query Match      89.1%; Score 460; DB 9; Length 125;
Best Local Similarity 88.8%; Pred. No. 1.3e-35;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVOLLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQLEWMGWISYSGNTDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWISAYNGNTNY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 AQKFGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 14
US-11-054-515-1472
; Sequence 1472, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14

```

```

; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1472
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1472

Query Match      89.1%; Score 460; DB 11; Length 248;
Best Local Similarity 88.8%; Pred. No. 2.4e-35;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVOLLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQLEWMGWISYSGNTDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWISAYNGNTNY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 AQKFGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKLGQGVTTMTDTSRRTAYMELSLRSDDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 15
US-11-266-444-1472
; Sequence 1472, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1472
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1472

Query Match      89.1%; Score 460; DB 11; Length 248;
Best Local Similarity 88.8%; Pred. No. 2.4e-35;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVOLLQSAAEVRKPGASVKVSKASGYPTFTSYDISWVRQAPGGQLEWMGWISYSGNTDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGGQLEWMGWISAYNGNTNY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

```


GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:51:41 ; Search time 6.43434 Seconds
(without alignments)
1465.455 Million cell updates/sec

Title: US-09-674-752-28
Perfect score: 516
Sequence: 1 QVQLQSAAEVRKPGASVKV.....AYMELSLRSDDTAVYYCAR 98
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	460	89.1	98	2 S26919	Ig heavy chain V r
2	457	88.6	129	2 S36260	Ig heavy chain V r
3	455	88.2	122	2 S36271	Ig heavy chain V r
4	454	88.0	124	2 S19665	Ig heavy chain V r
5	444	86.0	131	2 S21924	Ig heavy chain V r
6	443	85.9	160	2 PL0105	anti-PR2 erythrocy
7	424	82.2	111	2 S21925	Ig heavy chain V r
8	423	82.0	98	2 S26918	Ig heavy chain V r
9	420	81.4	136	2 S31600	Ig heavy chain V r
10	416	80.6	98	2 S26938	Ig heavy chain V r
11	416	80.6	117	2 S31680	Ig heavy chain V r
12	416	80.6	117	2 S18551	Ig heavy chain V r
13	416	80.6	135	2 S49530	anti-Sm antibody V
14	415	80.4	118	2 S36265	Ig heavy chain V r
15	413	80.0	127	2 S34014	Ig heavy chain V r
16	411	79.7	117	2 S18553	Ig heavy chain V r
17	408	79.1	98	2 S26912	Ig heavy chain V r
18	408	79.1	125	2 S68170	Ig heavy chain V r
19	408	79.1	129	2 S46393	Ig heavy chain V r
20	406	78.7	132	2 S31596	Ig heavy chain V r
21	403	78.1	104	2 S69899	Ig heavy chain V r
22	401	77.7	98	2 S26920	Ig heavy chain V r
23	401	77.7	123	2 D33548	Ig heavy chain V-1
24	399	77.3	148	2 S29257	Ig heavy chain V r
25	396	76.7	117	1 HVHUHG	Ig heavy chain pre
26	396	76.7	171	2 S23623	Ig heavy chain V r
27	395	76.6	98	2 PH0871	Ig heavy chain V r
28	395	76.6	117	2 S18552	Ig heavy chain V r
29	394	76.4	110	2 PH1670	Ig heavy chain V r

Ig heavy chain V r
Ig heavy chain pre
Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V1
Ig gamma chain pre
Ig heavy chain V r
Ig heavy chain V-D
Ig heavy chain pre
Ig heavy chain V r
Ig heavy chain pre
Ig heavy chain V r
Ig heavy chain V r
Ig heavy chain V r

ALIGNMENTS

RESULT 1

S26919
Ig heavy chain V region (DP-14) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C/Accession: S26919
R/Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A/Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A/Reference number: S26885; MUID:93021117; PMID:1404388
A/Accession: S26919
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-98 <TOM>
A/Cross-references: UNIPARC:UPI0000031F31; EMBL:Z12316; NID:g32855; PIDN:CAA78186.1; PID
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotrimer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 89.1%; Score 460; DB 2; Length 98;
Best Local Similarity 88.8%; Pred. No. 1.5e-38;
Matches 87; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKSCASGYPTSDISWVRQAPGQGLEWMGHSISYSGNTDY 60
DB 1 QVQLVQSGAEVRKPGASVKSCASGYTFTSGISWVRQAPGQGLEWMGHSISYNGNTNY 60
QY 61 AOKFQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
DB 61 AOKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR 98

RESULT 2

S36260
Ig heavy chain V region (clone alpha-CEA4-8A) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C/Accession: S36260
R/Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.
EMBO J. 12, 725-734, 1993
A/Title: Human anti-self antibodies with high specificity from phage display libraries.
A/Reference number: S36256; MUID:93178448; PMID:7679990
A/Accession: S36260
A/Status: preliminary; nucleic acid sequence not shown
A/Molecule type: mRNA
A/Residues: 1-129 <GRI>
A/Cross-references: UNIPARC:UPI0000118DEB; EMBL:Z18851; NID:g33124; PIDN:CAA79303.1; PID
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotrimer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 88.6%; Score 457; DB 2; Length 129;

	Best Local Similarity	88.8%;	Pred.	No.	3.9e-38;	
	Matches	87; Conservative	3; Mismatches	8; Indels	0; Gaps	0;
Qy	1 QVOLLQSAAEVRKPGASVKSCAKSGYPPFTSYDISWVRQAPGGGLEWMGWISYGNNTDY	60				
Dd	1 QVLQLQGSAEVRRKPGASVKSKCRAGGYTFSTYGIGSWVRQAPGGGLEWMGWISAYNGTNY	60				
Qy	61 AQRFGQGVTTMTDTTSRTATMYELRLSRSDDDTAIVYCARG	98				
Dd	61 AQKLGRVTWTMTDTSRTATMYELRLSLRSDDDTAIVYCARG	98				
RESULT 3						
S36271	Ig heavy chain V region (clone alpha-THY-29) - human (fragment)					
C:	Species: Homo sapiens (man)					
C:	Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999					
C:	Accession: S36271					
R:	Griiffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; McCafferty, J., et al.					
A:	Title: Human anti-self antibodies with high specificity from phage display libraries.					
A:	Reference number: S36256; PMID:7679990					
A:	Accession: S36271					
A:	Status: preliminary; nucleic acid sequence not shown					
A:	Molecule type: mRNA					
A:	Residues: 1-122 <GRI>					
A:	Cross-references: UNIPARC:UPI000011HDE3; EMBL:X61647; NID:g33115; PIDN:CAB43828.1; PFI:					
C:	Superfamily: immunoglobulin v region; immunoglobulin homology					
C:	Keywords: heterotetramer; immunoglobulin					
F:	15-98/Domain: immunoglobulin homology <IMM>					
	Query Match	88.2%;	Score	455; DB 2; Length	122;	
	Best Local Similarity	88.7%;	Pred.	No.	5.8e-38;	
	Matches	86; Conservative	4; Mismatches	7; Indels	0; Gaps	0;
Qy	1 QVOLLQSAAEVRKPGASVKSCAKSGYPPFTSYDISWVRQAPGGGLEWMGWISYGNNTDY	60				
Dd	1 QVLQLQGSAEVRRKPGASVKSKCRAGGYTFSTYGIGSWVRQAPGGGLEWMGWISAYNGTNY	60				
Qy	61 AQRFGQGVTTMTDTTSRTATMYELRLSRSDDDTAIVYCARG	97				
Dd	61 AQKLGRVTWTMTDTSRTATMYELRLSLRSDDDTAIVYCARG	97				
RESULT 4						
S19665	Ig heavy chain V region (alpha-phox15) - human (fragment)					
C:	Species: Homo sapiens (man)					
C:	Date: 28-Oct-1994 #sequence_revision 28-Oct-1994 #text_change 20-Jun-2000					
C:	Accession: S19665; S24442					
R:	Marks, J.D.; Hoogenboom, H.R.; Bonnett, T.P.; McCafferty, J.; Griffiths, A.D.; Winter,					
J.	Mol. Biol.	222, 581-597, 1991				
A:	Title: By-passing immunization. Human antibodies from V-gene libraries displayed on phage					
A:	Reference number: S19663; PMID:92085276; PMID:I1748994					
A:	Accession: S19665					
A:	Molecule type: mRNA					
A:	Residues: 1-124 <MAR>					
A:	Cross-references: UNIPARC:UPI00001176B80; EMBL:X61647					
R:	Jones, P.T.					
A:	Submitted to the EMBL Data Library, October 1991					
A:	Reference number: S24442					
A:	Accession: S24442					
A:	Molecule type: mRNA					
A:	Residues: 1-40, GLSVDGSALTWTQTSLDK' , 61-118, 'T', 120-124 <JON>					
A:	Cross-references: UNIPARC:UPI0000115FE6; EMBL:X61647; NID:g37667; PIDN:CAB43828.1; PFI:					
A:	Note: The difference for residues 41-60 results from misplacement of 10 bases in the					
C:	Superfamily: immunoglobulin v region; immunoglobulin homology					
C:	Keywords: heterotetramer; immunoglobulin					
F:	15-98/Domain: immunoglobulin homology <IMM>					
	Query Match	88.0%;	Score	454; DB 2; Length	124;	
	Best Local Similarity	87.8%;	Pred.	No.	7.4e-38;	
	Matches	86; Conservative	3; Mismatches	9; Indels	0; Gaps	0;


```
Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDLSWVRQAPGGQGLEWMGWISYSGNTDY 60
Db 20 QVQLVASGAENVKPGASVKVSKASGYFTFTSYGISWVRQAPGGQGLEWMGWISVYNGDTNY 79

Qy 61 AOKFQGRVTMTTDSRTATYMWELSLRSDDTAVYYCAR 98
Db 80 AQNLQGRVTMTTDTSTATYMWELSLRSDDTAVYYCAR 117

RESULT 7
S21925
Ig heavy chain V region - human
C/Species: Homo sapiens (man)
C/Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 23-Jul-1999
C/Accession: S21925
R/Friedman, D.F.
submitted to the EMBL Data Library, July 1991
A/Reference number: S21923
A/Accession: S21925
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-111 <PRI>
A/Cross-references: UNIPARC:UPI0000115FAI; EMBL:X60503; NID:g33626; PIDN:CAA43023.1; PID
C/Genetics: 16/1
C/Superspecies: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin

Query Match 82.2%; Score 424; DB 2; Length 111;
Best Local Similarity 88.0%; Pred. No. 6e-35;
Matches 81; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDLSWVRQAPGGQGLEWMGWISYSGNTDY 60
Db 20 QVQLVQSGAEVKKPGASVKVSKASGYFTFTSYGLISWVRQAPGGQGLEWMGWISAYNGTNY 79

Qy 61 AOKFQGRVTMTTDSRTATYMWELSLRSDDTA 92
Db 80 AQKLQGRVTMTTDTSTATYMWELSLRSDDTA 111

RESULT 8
S26918
Ig heavy chain V region (DP-15) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C/Accession: S26918
R/Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A/Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A/Reference number: S26885; MUID:93021117; PMID:1404388
A/Accession: S26918
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-98 <TON>
A/Cross-references: UNIPARC:UPI000031F36; EMBL:Z12317; NID:g32857; PIDN:CAA78187.1; PID
C/Superspecies: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 82.0%; Score 423; DB 2; Length 98;
Best Local Similarity 82.7%; Pred. No. 6.ee-35;
Matches 81; Conservative 7; Mismatches 10; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDLSWVRQAPGGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTFTSYDINWVRQATGQGLEWMGWNPNSGNTGY 60

Qy 61 AOKFQGRVTMTTDSRTATYMWELSLRSDDTAVYYCAR 98
Db 61 AOKFQGRVTMTTSTATYMWELSLRSDDTAVYYCAR 98
```

```
RESULT 9
S31600
Ig heavy chain V region - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C/Accession: S31600
R/Cuisinier, A.M.; Gauthier, L.; Boublil, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A/Description: Mechanisms that generate human immunoglobulin diversity operate from the
A/Reference number: S31585
A/Accession: S31600
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-136 <CUI>
A/Cross-references: UNIPARC:UPI0000116453; EMBL:Z14165; NID:g30994; PIDN:CAA78534.1; PID
C/Superspecies: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 81.4%; Score 420; DB 2; Length 136;
Best Local Similarity 81.6%; Pred. No. 1.8e-34;
Matches 80; Conservative 8; Mismatches 10; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDLSWVRQAPGGQGLEWMGWISYSGNTDY 60
Db 20 QVQLVQSGAEVKKPGASVKVSKASGYFTFTSYDINWVRQATGQGLEWMGWNPNSGNTGY 79

Qy 61 AOKFQGRVTMTTDSRTATYMWELSLRSDDTAVYYCAR 98
Db 80 AOKFQGRVTMTTSTATYMWELSLRSDDTAVYYCAR 117

RESULT 10
S26938
Ig heavy chain V region (DP-75) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 17-Nov-1995 #text_change 23-Jul-1999
C/Accession: S26938
R/Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A/Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A/Reference number: S26885; MUID:93021117; PMID:1404388
A/Accession: S26938
A/Status: preliminary; nucleic acid sequence not shown; translation not shown
A/Molecule type: DNA
A/Residues: 1-98 <TON>
A/Cross-references: UNIPARC:UPI000011644A; EMBL:Z14071; NID:g32869; PIDN:CAA78451.1; PID
C/Superspecies: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 80.6%; Score 416; DB 2; Length 98;
Best Local Similarity 81.6%; Pred. No. 3.2e-34;
Matches 80; Conservative 5; Mismatches 13; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKVSKASGYPTFTSYDLSWVRQAPGGQGLEWMGWISYSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTFTGYIHWVRQAPGGQGLEWMGWNPNSGNTNY 60

Qy 61 AOKFQGRVTMTTDSRTATYMWELSLRSDDTAVYYCAR 98
Db 61 AOKFQGRVTMTTSTATYMWELSLRSDDTAVYYCAR 98

RESULT 11
S31680
Ig heavy chain V region - human
C/Species: Homo sapiens (man)
C/Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C/Accession: S31680
R/Cuisinier, A.M.; Gauthier, L.; Boublil, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
```

```

C;Date: 01-Feb-1995 #sequence_revision 12-May-1995 #text_change 23-Jul-1999
C;Accession: S49530
R;Mahmoudi, M.; Edwards, J.; Cairns, E.; Bell, D.
submitted to the EMBL Data Library, October 1994
A;Description: Molecular characterization of natural human anti-5m autoantibodies.
A;Reference number: S48797
A;Accession: S49530
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-135 <MAH>
A;Cross-references: UNIPARC:UPI00001166FF; EMBL:Z46348; NID:G560839; PIDN:CAA86467.1; PII
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;34-117/Domain: immunoglobulin homology <IMW>

Query Match      80.6%; Score 416; DB 2; Length 135;
Best Local Similarity 81.6%; Pred. No. 4.5e-34;
Matches 80; Conservative 5; Mismatches 13; Indels 0; Gaps 0;

QY 1 QVOLLGSAEVRKPGASVKVSKASGYPTFTSYDYSWVRQAPQGQLEWMGWISYISGNTDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 QVQLVQSGAEVKKPGASVKVSKASGYFTFTGYMHVWRQAPQGQLEWMGWINPNSGGTNY 79
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 AQRFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 AQRFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 117
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 14
S36265
IG heavy chain V region (clone alpha-MUC1-1) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C;Accession: S36265
R;Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.;
EMBO J. 12, 725-734, 1993
A;Title: Human anti-self antibodies with high specificity from phage display libraries.
A;Reference number: S36256; MUID:93178448; PMID:7679990
A;Accession: S36265
A;Status: preliminary; nucleic acid sequence not shown
A;Molecule type: mRNA
A;Residues: 1-118 <GRI>
A;Cross-references: UNIPARC:UPI0000118DE8; EMBL:Z18846; NID:G33121; PIDN:CAA79298.1; PID:
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMW>

Query Match      80.4%; Score 415; DB 2; Length 118;
Best Local Similarity 80.6%; Pred. No. 4.9e-34;
Matches 79; Conservative 7; Mismatches 12; Indels 0; Gaps 0;

QY 1 QVOLLGSAEVRKPGASVKVSKASGYPTFTSYDYSWVRQAPQGQLEWMGWISYISGNTDY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTFTGYMHVWRQAPQGQLEWMGWINPNSGGTNY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 AQRFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQRFGQGRVTMTTDSRRRTAYMELSLRSDDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 15
S34014
IG heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996
C;Accession: S34014; S30535
R;Marette, X.; Tsapis, A.; Brouet, J.C.
Eur. J. Immunol. 23, 846-851, 1993
A;Title: Nucleotide sequence analysis of the variable domains of four human monoclonal
A;Reference number: S34001; MUID:93209281; PMID:7681398
A;Accession: S34014
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-127 <MAR>

```

Query Match 80.0%; Score 413; DB 2; Length 127;
Best Local Similarity 79.6%; Pred. No. 8.4e-34;
Matches 78; Conservative 10; Mismatches 10; Indels 0; Gaps 0;

[illegible]

Search completed: May 5, 2006, 08:54:48
Job time : 6.43434 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 09:04:30 ; Search time 36.8737 Seconds
(without alignments)
1875.095 Million cell updates/sec

Title: US-09-674-752-28

Perfect score: 516

Sequence: 1 QVQLQSAAEVRKPGASVKV.....AYMELSLRSDDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	423	82.0	500	2	Q6N091_HUMAN
2	413	80.0	469	2	Q7Z7P5_HUMAN
3	400	77.5	125	2	Q9UL95_HUMAN
4	399	77.3	119	2	Q9UL94_HUMAN
5	398	77.1	500	2	Q9BRV0_HUMAN
6	396	76.7	117	1	HV1B_HUMAN
7	392	76.0	117	1	HV1G_HUMAN
8	391	75.8	124	2	Q9UL92_HUMAN
9	391	75.8	518	2	Q6N030_HUMAN
10	380	73.6	244	2	Q65ZC8_HUMAN
11	377	73.1	120	2	Q6NSA4_HUMAN
12	375	72.7	497	2	Q8WY24_HUMAN
13	373	72.3	147	1	HV1C_HUMAN
14	373	72.3	159	2	Q96Q50_HUMAN
15	369	71.5	119	2	Q9GYZ2_MOUSE
16	369	71.5	498	2	Q6N041_HUMAN
17	363	70.3	480	2	Q6P089_HUMAN
18	354	68.6	125	2	Q6PIL0_HUMAN
19	353	68.4	116	2	Q9UL89_HUMAN
20	353	68.4	458	2	Q5BJZ2_RAT
21	347	67.2	519	2	Q5EBM2_HUMAN
22	344	66.7	117	1	HV1A_HUMAN
23	343	66.5	117	1	HV52_MOUSE
24	343	66.5	147	2	Q925S3_MOUSE
25	342	66.3	150	2	Q9Y298_HUMAN
26	341	66.1	208	2	Q6ZP87_HUMAN
27	340	65.9	475	2	Q6N095_HUMAN
28	339	65.7	114	1	HV00_MOUSE
29	339	65.7	613	2	Q8VCX7_MOUSE
30	338	65.5	481	2	Q91WT1_MOUSE
31	336	65.1	473	2	Q9D8L4_MOUSE

32	336	65.1	480	2	Q8K0Z4_MOUSE	Q8K0Z4 mus musculus
33	335	64.9	463	2	Q99LC4_MOUSE	Q99LC4 mus musculus
34	335	64.9	591	2	Q4QW0_RAT	Q4QW0 rattus norv
35	333	64.5	465	2	Q6RJB2_MOUSE	Q6RJB2 mus musculus
36	333	64.5	480	2	Q6RJB1_HUMAN	Q6RJB1 homo sapien
37	333	64.5	506	2	Q6N090_HUMAN	Q6N090 homo sapien
38	333	64.5	616	2	Q504M7_MOUSE	Q504M7 mus musculus
39	333	64.5	617	2	Q4KML5_MOUSE	Q4KML5 mus musculus
40	332	64.3	475	2	Q5FVP3_RAT	Q5FVP3 rattus norv
41	331	64.1	157	2	Q95978_HUMAN	Q95978 homo sapien
42	331	64.1	458	2	Q5BK05_RAT	Q5BK05 rattus norv
43	330	64.0	117	1	HV09_MOUSE	P01753 mus musculus
44	330	64.0	468	2	Q569W9_MOUSE	Q569W9 mus musculus
45	329	63.8	120	1	HV03_MOUSE	P01747 mus musculus

ALIGNMENTS

RESULT 1
Q6N091_HUMAN
ID Q6N091_HUMAN PRELIMINARY; PRT; 500 AA.
AC Q6N091_2004 (Tremblrel. 27, Created)
DT 05-JUL-2004 (Tremblrel. 27, Last sequence update)
DE Hypothetical protein DKFZp686C02220 (Fragment).
GN Name=DKFZp686C02220;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC Tissue=Human rectum tumor;
RG The German Human CDNA Consortium;
RA Wambutt R., Heubner D., Newes H.W., Well B., Amid C., Osanger A.,
RA Pobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BK640625; CAE45779.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q6N091; 270-478.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_cl.
DR InterPro; IPR003506; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON_TER 1
SQ SEQUENCE 500 AA; 54160 MW; 3C423A17D65A41E4 CRC64;

Query Match 82.0%; Score 423; DB 2; Length 500;
Best Local Similarity 80.6%; Pred. No. 4.3e-40;
Matches 79; Conservative 8; Mismatches 11; Indels 0; Gaps 0;

Qy	1	QVQLQSAAEVRKPGASVKVSKASGYPTSDISWVRQAPGGGLEWMGWSIYSGNTDY	60
Db	38	QVQLVSGAEVRKPGASVKVSKASGYTSDHSDITWLRQAPGGGLEWIGWISAYSGTYY	97
Qy	61	AQKFQGRVTMTDTSRRTAYMELSLRSDDTAVYYCAR	98
Db	98	AQNLQGRVTMTDTSSTAYMELSLRSDDTAVYYCAK	135

RESULT 2
Q7Z7P5_HUMAN

```

ID Q7Z7P5_HUMAN PRELIMINARY; PRT; 469 AA.
AC Q7Z7P5
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-WAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]_TaxID=9606;
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klauenberg R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.L., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Munz D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettaman M., Madan A.C., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalius D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH MGC Project;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC051328; AAH51328.1; -; mRNA.
DR HSSP; P01857; 1HZH.
DR SMR; Q7Z7P5; 20-469.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Immunoglobulin domain.
SQ SEQUENCE 469 AA; 51395 MW; C8D5BE12BAAF795C CRC64;

Query Match 80.0%; Score 413; DB 2; Length 469;
Best Local Similarity 77.3%; Pred. No. 5.8e-39;
Matches 75; Conservative 12; Mismatches 10; Indels 0; Gaps 0;

QY 1 QVOLLQSAAEVRKPGASVKSCASGYPTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 20 QVHLVQSGAEVRKPGASVKLSCKTSYGFSSYDLIWRQAPGQGLEWMGWISAHNGDTKY 79

QY 61 AQKFGQGRVTMTDTSRRRTAYMELRSLRSDDTAVYYCA 97
Db 80 ARKFGQGRVTMTDTSATTSYMFERSLSRSDDTALFYCA 116

RESULT 3
Q9UL95_HUMAN
ID Q9UL95_HUMAN PRELIMINARY; PRT; 125 AA.
AC Q9UL95;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]_TaxID=9606;
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035020; AAD56256.1; -; mRNA.
DR HSSP; P01751; 1NOB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR NON_TER 1
FT NON_TER 119
FT SEQUENCE 119 AA; 13205 MW; 13B64F5345F4A16E CRC64;

```

```

DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]_TaxID=9606;
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035019; AAD56255.1; -; mRNA.
DR HSSP; P01751; 1NOB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR NON_TER 1
FT NON_TER 125
FT SEQUENCE 125 AA; 13516 MW; 0D3CD5C232488EAC CRC64;

Query Match 77.5%; Score 400; DB 2; Length 125;
Best Local Similarity 77.6%; Pred. No. 4.1e-38;
Matches 76; Conservative 8; Mismatches 14; Indels 0; Gaps 0;

QY 1 QVOLLQSAAEVRKPGASVKSCASGYPTSYDISWVRQAPGQGLEWMGWISYSGNTDY 60
Db 1 EVQLVQSGAEVRKPGASVKSCASGYPTSYDMHVRQAPGQGLEWMGWINPNSGNTY 60

QY 61 AQKFGQGRVTMTDTSRRRTAYMELRSLRSDDTAVYYCAR 98
Db 61 AQKVGQGRVTMTDTSRRRTAYMELRSLRSDDTAVYYCAR 98

RESULT 4
Q9UL94_HUMAN
ID Q9UL94_HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL94;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]_TaxID=9606;
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035020; AAD56256.1; -; mRNA.
DR HSSP; P01751; 1NOB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR NON_TER 1
FT NON_TER 119
FT SEQUENCE 119 AA; 13205 MW; 13B64F5345F4A16E CRC64;

```



```

ID  HV1G HUMAN      STANDARD;          PRT;    117 AA.
AC  P23083;
DT  01-NOV-1991 (Rel. 20, Created)
DT  01-NOV-1991 (Rel. 20, Last sequence update)
DT  01-MAY-2005 (Rel. 47, Last annotation update)
DE  Ig heavy chain V-I region V35 precursor.
OS  Homo sapiens (Human).
OC  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC  Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC  Homo.
OX  NCBI_TaxID=9606;
RN  [1]
RP  NUCLEOTIDE SEQUENCE.
RX  MEDLINE=88296408; PubMed=2841108;
RA  Matsuda F., Lee K.H., Nakai S., Sato T., Kodaira M., Zong S.Q.,
RA  Ohno H., Fukuhara S., Honjo T.;
RT  "Dispersed localization of D segments in the human immunoglobulin
RT  heavy-chain locus.";
RL  EMBO J. 7:1047-1051(1988).
RN  [2]
RP  NUCLEOTIDE SEQUENCE OF 20-116.
RX  PubMed=7681398;
RA  Mariette X., Teaple A., Brouet J.C.;
RT  "Nucleotide sequence analysis of the variable domains of four human
RT  monoclonal IgM with an antibody activity to myelin-associated
RT  glycoprotein.";
RL  Eur. J. Immunol. 23:846-851(1993).
CC  -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC  -----
CC  This Swiss-Prot entry is copyright. It is produced through a collaboration
CC  between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC  the European Bioinformatics Institute. There are no restrictions on its
CC  use as long as its content is in no way modified and this statement is not
CC  removed.
CC  -----
DR  EMBL; X07448; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR  PIR; S00476; HVH25.
DR  HSSP; P01751; INQB.
DR  SMR; P23083; 20-117.
DR  Ensembl; ENSG00000130076; Homo sapiens.
DR  GO; GO:0005576; C:extracellular region; NAS.
DR  GO; GO:0003823; F:antigen binding; NAS.
DR  GO; GO:0006955; P:immune response; NAS.
DR  InterPro; IPR007110; Ig-like.
DR  SMART; SM00406; IGV; 1.
DR  PROSITE; PS50835; IG LIKE; 1.
KW  Immunoglobulin domain; Immunoglobulin V region; Signal.
FT  SIGNAL      1      19
FT  CHAIN       20      117      Ig heavy chain V-I region V35.
FT  DOMAIN      20      >117      Ig-like.
FT  NON_TER     117      117
SQ  SEQUENCE    117 AA; 13009 MW; BE61CE63F8CE97BD CRC64;

Query Match      76.0%; Score 392; DB 1; Length 117;
Best Local Similarity 78.6%; Pred. No. 3.2e-37;
Matches 77; Conservative 5; Mismatches 16; Indels 0; Gaps 0;

QY  1 QVOLLQSAAEVRKPGASVKSCASGYPTFSYDTSWVRQAPGQGLEWMGWISYSGNTDY 60
DQ  20 QVQLVSGAEVKPGASVKSCASGYTFGYTHWVRQAPGQGLEWMGRINPNSGNTY 79
QY  61 AQKFGQGVTTMTDTSRTATYMELSRLSRDSDTAVYYCAR 98
DQ  80 AQKFGQGVTTSDTSISTATYMELSRLSRDSDTAVYYCAR 117

RESULT 8
Q9UL92 HUMAN
ID  Q9UL92 HUMAN PRELIMINARY;          PRT;    124 AA.
AC  Q9UL92;
DT  01-MAY-2000 (TrEMBLrel. 13, Created)
DT  01-MAY-2000 (TrEMBLrel. 13, Last sequence update)

```

```

DT  01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE  Myosin-reactive immunoglobulin heavy chain variable region
DE  (fragment).
OS  Homo sapiens (Human).
OC  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC  Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC  Homo.
OX  NCBI_TaxID=9606;
RN  [1]
RP  NUCLEOTIDE SEQUENCE.
RX  MEDLINE=98277139; PubMed=9614934; DOI=10.1006/cclin.1998.4531;
RA  Wu X., Liu B., Van der Werwe P.L., Kalis N.N., Berney S.M.,
RA  Young D.C.;
RT  "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT  fetus.";
RL  Clin. Immunol. Immunopathol. 87:184-192(1998).
DR  EMBL; AF035022; AAD56258.1; -; mRNA.
DR  HSSP; P01751; INQB.
DR  Ensembl; ENSG00000130076; Homo sapiens.
DR  InterPro; IPR007110; Ig-like.
DR  SMART; SM00406; IGV; 1.
DR  PROSITE; PS50835; IG LIKE; 1.
FT  NON_TER     1      124
FT  NON_TER     124      124
SQ  SEQUENCE    124 AA; 13580 MW; 1BAACBD96ACD2A2 CRC64;

Query Match      75.8%; Score 391; DB 2; Length 124;
Best Local Similarity 76.5%; Pred. No. 4.5e-37;
Matches 75; Conservative 9; Mismatches 14; Indels 0; Gaps 0;

QY  1 QVOLLQSAAEVRKPGASVKSCASGYPTFSYDTSWVRQAPGQGLEWMGWISYSGNTDY 60
DQ  1 EVQLVESGAEVKPGASVKSCASGYTFSSYTHWVRQAPGQGLEWMGIINPNSGNTSY 60
QY  61 AQKFGQGVTTMTDTSRTATYMELSRLSRDSDTAVYYCAR 98
DQ  61 AQKFGQGVTTMTDTSSTVYMELSRLSRDSDTAVYYCAR 98

RESULT 9
Q6N030 HUMAN
ID  Q6N030 HUMAN PRELIMINARY;          PRT;    518 AA.
AC  Q6N030;
DT  05-JUL-2004 (TrEMBLrel. 27, Created)
DT  05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT  05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE  Hypothetical protein DKFZp686I15212.
GN  Name=DKFZp686I15212;
OS  Homo sapiens (Human).
OC  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC  Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC  Homo.
OX  NCBI_TaxID=9606;
RN  [1]
RP  NUCLEOTIDE SEQUENCE.
RC  TISSUE=Rectum tumor;
RG  The German CDNA Consortium;
RA  Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA  Mewes H.W., Weil B., Amid C., Oeinger A., Fobo G., Han M., Wiemann S.;
RL  Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR  EMBL; BX640724; CAE45841.1; -; mRNA.
DR  HSSP; P01861; IADQ.
DR  InterPro; IPR000005; HTHARAC.
DR  InterPro; IPR003599; IG.
DR  InterPro; IPR007110; Ig-like.
DR  InterPro; IPR003597; IG-cl.
DR  InterPro; IPR003006; IG_MHC.
DR  InterPro; IPR003596; IGV.
DR  Pfam; PF07654; C1-set; 3.
DR  SMART; SM00409; IG; 3.
DR  SMART; SM00407; IGcl; 3.
DR  SMART; SM00406; IGV; 1.

```



```
DR PROSITE; PS00041; HTH_ARAC_FAMILY_1; UNKNOWN_1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein_1
SQ SEQUENCE 518 AA; 57019 MW; 93B5F98613BF6382 CRC64;

Query Match 75.8%; Score 391; DB 2; Length 518;
Best Local Similarity 74.5%; Pred. No. 2.3e-36;
Matches 73; Conservative 12; Mismatches 13; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTFSYDISWVRQAPGQGLEWMGHWISYSGNTDY 60
DB 20 QVHLVQSGAEVKKPGASVKVSKASGYPTFSYDISWVRQAPGQGLEWMGHWISYSGNTDY 79
QY 61 AQKFGQGVTTTDTSRRTAYMELSLRSDDTAVYYCAR 98
DB 80 SQKFGQGVTTTDTSRRTAYMELSLRSDDTAVYYCAR 117

RESULT 10
Q6NSA4 HUMAN
ID Q6NSA4 HUMAN PRELIMINARY; PRT; 244 AA.
AC Q6NSA4
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Single-chain Fv (Fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbr0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR ENBL; Y13057; CAA73500.1; -; mRNA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_V.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 2.
FT NON_TER 244 244
FT NON_TER 244 244
SQ SEQUENCE 244 AA; 26127 MW; 4B1F17868338F2BF CRC64;

Query Match 73.68%; Score 380; DB 2; Length 244;
Best Local Similarity 73.5%; Pred. No. 1.8e-35;
Matches 72; Conservative 10; Mismatches 16; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTFSYDISWVRQAPGQGLEWMGHWISYSGNTDY 60
DB 1 QVQLVQSGAEVKKPGDSVKVSKASGYPTFSDHWMVWRQAPGQGLEWMGHWIDPNNGDTRF 60

QY 61 AQKFGQGVTTTDTSRRTAYMELSLRSDDTAVYYCAR 98
DB 61 AQRFGQGVTTTDTSRRTAYMELSLRSDDTAVYYCAR 98

RESULT 11
Q6NSA4 HUMAN
ID Q6NSA4 HUMAN PRELIMINARY; PRT; 120 AA.
AC Q6NSA4
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE IGHV1-69 protein.
GN Name=IGHV1-69;
OS Homo sapiens (Human).
```

```
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan K., Moore T., Max S.I., Wang J., Heish F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Tohiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywineki M.I., Skalska U., Smalus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbr0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR ENBL; Y13057; CAA73500.1; -; mRNA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_V.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 120 AA; 13035 MW; 64620FAC874585D4 CRC64;

Query Match 73.1%; Score 377; DB 2; Length 120;
Best Local Similarity 75.5%; Pred. No. 1.8e-35;
Matches 74; Conservative 8; Mismatches 16; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVRKPGASVKVSKASGYPTFSYDISWVRQAPGQGLEWMGHWISYSGNTDY 60
DB 20 QVQLVQSGAEVKKPGSSVKVSKASGCTFSYAISWVRQAPGQGLEWMGGIPIFGTANY 79

QY 61 AQKFGQGVTTTDTSRRTAYMELSLRSDDTAVYYCAR 98
DB 80 TOKFGQGVTTTDTSRRTAYMELSLRSDDTAVYYCAR 117

RESULT 12
Q8WY24 HUMAN
ID Q8WY24 HUMAN PRELIMINARY; PRT; 497 AA.
AC Q8WY24;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE SNC66 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Zheng S., Shao X., Cao J., Geng L., Fang Y., Dong Q.;
RA Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
RL
```

```

DR EMBL; AF283666; AAL36987.1; -; mRNA.
DR HSSP; P01876; IOWO.
DR SMR; Q8WY24; 267-475.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain.
SQ SEQUENCE 497 AA; 53666 MW; F24D08DFA5A663E5 CRC64;

Query Match 72.7%; Score 375; DB 2; Length 497;
Best Local Similarity 70.4%; Pred. No. 1.6e-34;
Matches 69; Conservative 14; Mismatches 15; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVVRKPGASVKSCASGYPTSYDISHVVRQAPGGLEWMGWHISYSGNTDY 60
Db 20 QEQLQSGAEVTRKPGASVKSCASGYTFYFIDINWVRQAPGGLEWMGWHNPQTGNTGF 79

QY 61 AQKFGQVRVTMTDTSRRRTAYMELSLRSDDTAVYYCAR 98
Db 80 AQKFGQRLTFSDTSINTAYWLSLSTEDSAIFYCAR 117

RESULT 13
HVIC_HUMAN STANDARD; PRT; 147 AA.
AC P01744;
DT 21-JUL-1986 (Rel. 01, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region ND precursor (Fragments).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=83065234; PubMed=6815656;
RA Kenten J.H., Molgaard H.V., Houghton M., Derbyshire R.B., Viney J.,
RA Bell L.O., Gould H.J.;
RT "Cloning and sequence determination of the gene for the human
RT immunoglobulin epsilon chain expressed in a myeloma cell line.";
RL Proc. Natl. Acad. Sci. U.S.A. 79:6661-6665(1982).
RN [2]
RP PROTEIN SEQUENCE OF 20-147.
RA Bennich H.H., Johansson S.G.O., von Bahr-Lindstrom H.;
RL (In) Bach M.K. (eds.);
RL Immediate hypersensitivity: modern concepts and developments, pp.1-36,
RL Marcel Dekker, New York (1978).
CC -1- MISCELLANEOUS: This epsilon chain was isolated from a myeloma
CC protein.
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR HSSP; P01751; INQB.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;

KW Immunoglobulin V region; Pyrrolidone carboxylic acid; Signal.
FT SIGNAL 1 19
FT CHAIN 20 147 Ig heavy chain V-I region ND.
FT DOMAIN 20 131 Ig-like.
FT MOD_RES 20 20 Pyrrolidone carboxylic acid.
FT DISULFID 41 115
FT CONFLICT 21 21 T -> V (in Ref. 2).
FT CONFLICT 53 54 IH -> HI (in Ref. 2).
FT CONFLICT 67 68 VG -> GV (in Ref. 2).
FT CONFLICT 125 125 Missing (in Ref. 2).
FT NON_TER 147 147
SQ SEQUENCE 147 AA; 16496 MW; 948F9F72A5366C20 CRC64;

Query Match 72.3%; Score 373; DB 1; Length 147;
Best Local Similarity 71.4%; Pred. No. 6.7e-35;
Matches 70; Conservative 11; Mismatches 17; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVVRKPGASVKSCASGYPTSYDISHVVRQAPGGLEWMGWHISYSGNTDY 60
Db 20 QVQLVQSGAEVVRKPGASVKSCASGYTFIDSYIHWIRQAPGHLEWGVINPNSGNTY 79

QY 61 AQKFGQVRVTMTDTSRRRTAYMELSLRSDDTAVYYCAR 98
Db 80 ARFQGRVTMTDTSFSTAYMDLSRLSRSDSAVFYCAK 117

RESULT 14
Q96QSO_HUMAN PRELIMINARY; PRT; 159 AA.
AC Q96QSO;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Putative matrix cell adhesion molecule-3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Tilson M.D.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBDJ databases.
DR EMBL; AY039025; AAK82649.1; -; mRNA.
DR HSSP; P01869; IAE6.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 159 AA; 17497 MW; 5D29537E881FAP02 CRC64;

Query Match 72.3%; Score 373; DB 2; Length 159;
Best Local Similarity 72.4%; Pred. No. 7.3e-35;
Matches 71; Conservative 12; Mismatches 15; Indels 0; Gaps 0;

QY 1 QVQLQSAAEVVRKPGASVKSCASGYPTSYDISHVVRQAPGGLEWMGWHISYSGNTDY 60
Db 20 QVQLVQSGAEVVRKPGASVKSCASGYTFSNYVMWVRQAPGGPEWGMVINPSGGSARY 79

QY 61 AQKFGQVRVTMTDTSRRRTAYMELSLRSDDTAVYYCAR 98
Db 80 SQKFGQRLTMTDTSSTVTYMDLSRLSRSDDTAVYYCAR 117

RESULT 15
Q9GYZ2_MOUSE PRELIMINARY; PRT; 119 AA.
AC Q9GYZ2;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Monoclonal anti-idiotypic Schistosoma japonicum antibody NP30 heavy

```

```

DE chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Song X.T., Feng Z.Q., Guan X.H.;
RT "Amplification, cloning and sequence analysis of the heavy chain
RT variable region gene of monoclonal anti-idiotypic antibody NP30 of
RT Schistosoma japonicum.";
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF282622; AAG01452.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q9GYZ2; 1-119.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13567 MW; BA893873FD5FA6AB CRC64;

Query Match 71.5%; Score 369; DB 2; Length 119;
Best Local Similarity 72.4%; Pred. No. 1.5e-34;
Matches 71; Conservative 12; Mismatches 15; Indels 0; Gaps 0;

Qy 1 QVQLQSAAEVRKPGASVKSCASGYPTFTSYDISWVRQAPGQGLEWMGHISYSGNTDY 60
Db 1 QVQLVESGAIEVRKPGASVRVSCASGYTFTGYNMWVRQAPGHGLEWIGYINPSRGYTN 60

Qy 61 AQKFGQRTVTMTDTSRRRTAYMELSLRSLRSDDTAVYYCAR 98
Db 61 NQKPRDRTVTMTDKSFSTATMDLRLSLRSLRSDSAVYYCAR 98

```

Search completed: May 5, 2006, 09:14:33
Job time : 36.8737 secs

THIS PAGE IS BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:25 ; Search time 11.3112 Seconds
(without alignments)
716.302 Million cell updates/sec

Title: US-09-674-752-31

Perfect score: 517

Sequence: 1 QVOLVSGAEVKPGASVKV.....AYMELSSLRSEDVAVYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued Patents AA:*
- 1: /cgn2_6/ptodata/1/iaa/5_COMB.pep.*
- 2: /cgn2_6/ptodata/1/iaa/6_COMB.pep.*
- 3: /cgn2_6/ptodata/1/iaa/H_COMB.pep.*
- 4: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep.*
- 5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep.*
- 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	517	100.0	117	2	US-08-545-809A-96
2	517	100.0	117	2	US-09-515-697-96
3	508	98.3	96	2	US-10-194-975-3
4	476	92.1	117	2	US-09-025-769B-22
5	476	92.1	117	2	US-09-490-070A-22
6	476	92.1	117	2	US-09-490-153-22
7	476	92.1	117	2	US-09-490-324-22
8	473	91.5	120	2	US-09-025-769B-36
9	473	91.5	120	2	US-09-025-769B-59
10	473	91.5	120	2	US-09-490-070A-36
11	473	91.5	120	2	US-09-490-070A-59
12	473	91.5	120	2	US-09-490-153-36
13	473	91.5	120	2	US-09-490-153-59
14	473	91.5	120	2	US-09-490-324-36
15	473	91.5	120	2	US-09-490-324-59
16	461	89.2	98	2	US-10-194-975-1
17	461	89.2	117	2	US-08-545-809A-90
18	461	89.2	117	2	US-09-515-697-90
19	456	88.2	470	2	US-09-859-053-28
20	449	86.8	127	2	US-09-513-999C-4122
21	447	86.5	123	1	US-08-477-877B-94
22	447	86.5	123	1	US-08-472-281A-94
23	447	86.5	123	1	US-08-477-389B-94
24	447	86.5	123	2	US-09-462-140D-102
25	447	86.5	123	2	US-09-462-140D-105
26	443.5	85.8	128	1	US-08-202-047-22
27	443.5	85.8	128	2	US-08-964-690-22

28	443.5	85.8	129	1	US-08-561-521-45	Sequence 45, Appl
29	443.5	85.8	129	2	US-08-525-539A-77	Sequence 77, Appl
30	443.5	85.8	129	4	PCT-US95-01219-45	Sequence 45, Appl
31	442.5	85.6	125	2	US-09-199-149-3	Sequence 3, Appl
32	442	85.5	98	2	US-10-194-975-7	Sequence 7, Appl
33	442	85.5	117	2	US-08-545-809A-128	Sequence 128, App
34	442	85.5	117	2	US-09-515-697-128	Sequence 128, App
35	441	85.3	98	2	US-10-194-975-2	Sequence 2, Appl
36	441	85.3	119	1	US-08-561-521-10	Sequence 10, Appl
37	441	85.3	119	2	US-09-438-954-41	Sequence 41, Appl
38	441	85.3	119	4	PCT-US95-01219-10	Sequence 10, Appl
39	440	85.1	110	2	US-09-899-896-5	Sequence 5, Appl
40	435	84.1	98	2	US-10-194-975-4	Sequence 4, Appl
41	435	84.1	98	2	US-10-330-613A-53	Sequence 53, Appl
42	435	84.1	117	2	US-08-545-809A-105	Sequence 105, App
43	435	84.1	117	2	US-09-515-697-105	Sequence 105, App
44	432	83.6	97	1	US-08-290-592B-16	Sequence 16, Appl
45	432	83.6	97	4	PCT-US96-09448-16	Sequence 16, Appl

ALIGNMENTS

RESULT 1
US-08-545-809A-96
; Sequence 96, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 96:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-545-809A-96

Query Match 100.0%; Score 517; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. NO. 2.8e-48;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVOLVSGAEVKPGASVKVSKASGYTFTSYDINVRQATGQLEWMGNPNSGNTGY 60
|||||

Db 20 QVLVQSGAEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 79

Qy 61 AQKFGQGVMTTRNTSISTAYMELSSLRSEDTAVYYCAR 98
|||||
Db 80 AQKFGQGVMTTRNTSISTAYMELSSLRSEDTAVYYCAR 117
|||||

RESULT 2
US-09-515-697-96
; Sequence 96, Application US/09515697
; Patent No. 6936705
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tazuku
; ; Mateuda, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/515,697
; FILING DATE: 29-Feb-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 96:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 96:
US-09-515-697-96

Query Match 100.0%; Score 517; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 2.8e-48;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVLVQSGAEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
|||||
Db 20 QVLVQSGAEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 79
|||||

Qy 61 AQKFGQGVMTTRNTSISTAYMELSSLRSEDTAVYYCAR 98
|||||
Db 80 AQKFGQGVMTTRNTSISTAYMELSSLRSEDTAVYYCAR 117
|||||

RESULT 3
US-10-194-975-3
; Sequence 3, Application US/10194975
; Patent No. 6881557
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson

; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 96
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-194-975-3

Query Match 98.3%; Score 508; DB 2; Length 96;
Best Local Similarity 100.0%; Pred. No. 2.1e-47;
Matches 96; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 QLVQSGAEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGYAQ 62
|||||
Db 1 QLVQSGAEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGYAQ 60
|||||

Qy 63 KFGQGVMTTRNTSISTAYMELSSLRSEDTAVYYCAR 98
|||||
Db 61 KFGQGVMTTRNTSISTAYMELSSLRSEDTAVYYCAR 96
|||||

RESULT 4
US-09-025-769B-22
; Sequence 22, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-22

```

Query Match          92.1%; Score 476; DB 2; Length 117;
Best Local Similarity 91.8%; Pred. No. 7.4e-44;
Matches 90; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY      1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGCGLEWGMWNPNSGNTGY 60
      |||
Db       1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQAPGQGLEWGMWNPNSGNTNY 60
      |||

QY      61 AQKFGQGVTTWTRNTSISTAYMELSSLSRSEDVAVYYCAR 98
      |||
Db       61 AQKFGQGVTTWTRDTSISTAYMELSSLSRSDDTAVYYCAR 98
      |||

RESULT 5
US-09-490-070A-22
; Sequence 22, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Illag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-490-070A-22

Query Match          92.1%; Score 476; DB 2; Length 117;
Best Local Similarity 91.8%; Pred. No. 7.4e-44;
Matches 90; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY      1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGCGLEWGMWNPNSGNTGY 60
      |||
Db       1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQAPGQGLEWGMWNPNSGNTNY 60
      |||

QY      61 AQKFGQGVTTWTRNTSISTAYMELSSLSRSEDVAVYYCAR 98
      |||
Db       61 AQKFGQGVTTWTRDTSISTAYMELSSLSRSDDTAVYYCAR 98
      |||

```

Db 61 AQRFGQVTTWTRDTSTISAYMELSSLRSDDTAVYYCAR 98

RESULT 6
US-09-490-153-22
; Sequence 22, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Pluckethun, Andreas
; TITLE OF INVENTION: Protein/(poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS: <unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-490-153-22

Query Match 92.1%; Score 476; DB 2; Length 117;
Best Local Similarity 91.8%; Pred. No. 7.4e-44;
Matches 90; Conservative 5; Mismatches 3; Indels 0;

Qy 1 QVQLVQSGAEVKKPGASVKYSCKASGYTFTSYDINWVRQATGCGLEWGMGNP
Db 1 QVQLVQSGAEVKKPGASVKYSCKASGYTFTSYDINWVRQATGCGLEWGMGNP
Qy 61 AQRFGQVTTWTRDTSTISAYMELSSLRSDDTAVYYCAR 98
Db 61 AQRFGQVTTWTRDTSTISAYMELSSLRSDDTAVYYCAR 98

RESULT 7
US-09-490-324-22
; Sequence 22, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter

```

Query Match          92.1%; Score 476; DB 2; Length 117;
Best Local Similarity 91.8%; Pred. No. 7.4e-44;
Matches 90; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy      1  QVQLVQSGAEVKKPGASVKVSCKASGVTFTSYDIINVRQATGQGLEWMGMHPNPSGNTGY 60
         |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db      1  QVQLVQSGAEVKKPGASVKVSCKASGVTFTSYDMHWVRQAPGQGLEWMGMHPNPSGNTNY 60
         |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||

Qy      61  AQRFGQGVTTWTRTSTSTAYMELSSLRSEDVAVVYCAR 98
         |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||
Db      61  AQRFGQGVTTWTRTSTSTAYMELSSLRSDDTAVVYCAR 98
         |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||  |||

RESULT 7
US-09-490-324-22
; Sequence 22, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; pack, Peter

```

```
;
;      Ilag, Vic
;      Ge, Liming
;      Moroney, Simon
;      Plueckthun, Andreas
;
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
;
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
;
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
;
; US-09-490-324-22
;
; Query Match          92.1%; Score 476; DB 2; Length 117;
; Best Local Similarity 91.8%; Pred. No. 7.4e-44;
; Matches 90; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
;
; QY      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
;         |||||
; Db      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYMHVVRQAPGQGLEWMGMNPNSGNTNY 60
;         |||||
;
; QY      61 AQKFGQVRVTMTNTSISTAYMELSSLRSDDTAVYYCAR 98
;         |||||
; Db      61 AQKFGQVRVTMTNTSISTAYMELSSLRSDDTAVYYCAR 98
;         |||||
;
; RESULT 8
; US-09-025-769B-36
; Sequence 36, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
;
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
;
; STATE: New York
; COUNTRY: USA
;
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 36:
;
; US-09-025-769B-36
;
; Query Match          91.5%; Score 473; DB 2; Length 120;
; Best Local Similarity 91.8%; Pred. No. 1.6e-43;
; Matches 90; Conservative 4; Mismatches 4; Indels 0; Gaps 0;
;
; QY      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
;         |||||
; Db      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYMHVVRQAPGQGLEWMGMNPNSGNTNY 60
;         |||||
;
; QY      61 AQKFGQVRVTMTNTSISTAYMELSSLRSDDTAVYYCAR 98
;         |||||
; Db      61 AQKFGQVRVTMTNTSISTAYMELSSLRSDDTAVYYCAR 98
;         |||||
;
; RESULT 9
; US-09-025-769B-59
; Sequence 59, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
;
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
;
; STATE: New York
; COUNTRY: USA
;
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
;
; STATE: New York
; COUNTRY: USA
;
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 36:
;
; US-09-025-769B-36
```



```
;
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-59

Query Match 91.5%; Score 473; DB 2; Length 120;
Best Local Similarity 91.8%; Pred. No. 1.6e-43;
Matches 90; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNNGTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQAPGQGLEWMGNPNNGTNY 60

Qy 61 AQKFGQGVMTTRNTSISTAYMELSSLSRSEDVAVYICAR 98
Db 61 AQKFGQGVMTTRNTSISTAYMELSSLSRSEDVAVYICAR 98

RESULT 10
US-09-490-070A-36
; Sequence 36, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
```

```
;
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-09-490-070A-36

Query Match 91.5%; Score 473; DB 2; Length 120;
Best Local Similarity 91.8%; Pred. No. 1.6e-43;
Matches 90; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNNGTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQAPGQGLEWMGNPNNGTNY 60

Qy 61 AQKFGQGVMTTRNTSISTAYMELSSLSRSEDVAVYICAR 98
Db 61 AQKFGQGVMTTRNTSISTAYMELSSLSRSEDVAVYICAR 98

RESULT 11
US-09-490-070A-59
; Sequence 59, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-070A-59

Query Match 91.5%; Score 473; DB 2; Length 120;
Best Local Similarity 91.8%; Pred. No. 1.6e-43;
Matches 90; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNNGTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQAPGQGLEWMGNPNNGTNY 60
```

QY 61 AOKFQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
Db 61 AOKFQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98

RESULT 12
US-09-490-153-36
; Sequence 36, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-09-490-153-36

Query Match 91.5%; Score 473; DB 2; Length 120;
Best Local Similarity 91.8%; Pred. No. 1.6e-43;
Matches 90; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKPGASVKSCASGYTFTSYDINWVRQATGCGLEWMGMNPNSGNTGY 60
Db 1 QVOLVSGAEVKPGASVKSCASGYTFTSYDINWVRQATGCGLEWMGMNPNSGNTGY 60

QY 61 AOKFQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
Db 61 AOKFQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98

RESULT 13
US-09-490-153-59
; Sequence 59, Application US/09490153
; Patent No. 6706484

; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-153-59

Query Match 91.5%; Score 473; DB 2; Length 120;
Best Local Similarity 91.8%; Pred. No. 1.6e-43;
Matches 90; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVOLVSGAEVKPGASVKSCASGYTFTSYDINWVRQATGCGLEWMGMNPNSGNTGY 60
Db 1 QVOLVSGAEVKPGASVKSCASGYTFTSYDINWVRQATGCGLEWMGMNPNSGNTGY 60

QY 61 AOKFQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
Db 61 AOKFQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98

RESULT 14
US-09-490-324-36
; Sequence 36, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave

STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,324
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-09-490-324-36

Query Match 91.5%; Score 473; DB 2; Length 120;
Best Local Similarity 91.8%; Pred. No. 1.6e-43;
Matches 90; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGCGLEWMGWNPNNSGNTGY 60
DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGCGLEWMGWNPNNSGNTGY 60

QY 61 AQKFGQGRVTMTNRTSISTAYMELSSLSRSEDATVYYCAR 98
DB 61 AQKFGQGRVTMTNRTSISTAYMELSSLSRSEDATVYYCAR 98

RESULT 15
US-09-490-324-59
Sequence 59 Application US/09490324
Patent No. 6828422
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckthun, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,324
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-324-59

Query Match 91.5%; Score 473; DB 2; Length 120;
Best Local Similarity 91.8%; Pred. No. 1.6e-43;
Matches 90; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGCGLEWMGWNPNNSGNTGY 60
DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGCGLEWMGWNPNNSGNTGY 60

QY 61 AQKFGQGRVTMTNRTSISTAYMELSSLSRSEDATVYYCAR 98
DB 61 AQKFGQGRVTMTNRTSISTAYMELSSLSRSEDATVYYCAR 98

Search completed: May 5, 2006, 08:53:49
Job time : 12.3112 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:56:13 ; Search time 7.32964 Seconds
(without alignments)
618.844 Million cell updates/sec

Title: US-09-674-752-31
Perfect score: 517
Sequence: 1 QVQLVQSGAEVKPGASVKV.....AYMELSLRSEDATVYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA New:
1: /SID55/ptodata/1/pubpaa/US08_NEW_PUB.pep1.*
2: /SID55/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
3: /SID55/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
4: /SID55/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
5: /SID55/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
6: /SID55/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
7: /SID55/ptodata/1/pubpaa/US09_NEW_PUB.pep1.*
8: /SID55/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
9: /SID55/ptodata/1/pubpaa/US10_NEW_PUB.pep1.*
10: /SID55/ptodata/1/pubpaa/US11_NEW_PUB.pep1.*
11: /SID55/ptodata/1/pubpaa/US11_NEW_PUB.pep1.*
12: /SID55/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES									
Result No.	Query			DB	ID	Description			
	Score	Match	Length						
1	517	100.0	98	10	US-11-221-902-54	Sequence 54, Appl			
2	517	100.0	98	11	US-11-054-669-3	Sequence 3, Appli			
3	517	100.0	98	11	US-11-004-590-3	Sequence 3, Appli			
4	517	100.0	99	11	US-11-084-554-23	Sequence 23, Appl			
5	517	100.0	99	11	US-11-136-250-23	Sequence 23, Appl			
6	514	99.4	122	9	US-10-982-440-61	Sequence 61, Appl			
7	496	95.9	120	9	US-10-982-440-47	Sequence 47, Appl			
8	494	95.6	247	11	US-11-054-515-927	Sequence 927, App			
9	494	95.6	247	11	US-11-054-515-948	Sequence 948, App			
10	494	95.6	247	11	US-11-266-444-927	Sequence 927, App			
11	494	95.6	247	11	US-11-266-444-948	Sequence 948, App			
12	490	94.8	241	11	US-11-054-515-2031	Sequence 2031, Ap			
13	490	94.8	241	11	US-11-266-444-2031	Sequence 2031, Ap			
14	476	92.1	117	9	US-10-834-397-22	Sequence 22, Appl			
15	474	91.7	253	11	US-11-054-515-3244	Sequence 3244, Ap			
16	473	91.5	120	9	US-10-834-397-36	Sequence 36, Appl			
17	473	91.5	120	9	US-10-834-397-59	Sequence 59, Appl			
18	472	91.3	241	11	US-11-054-515-1948	Sequence 1948, Ap			
19	472	91.3	241	11	US-11-266-444-1948	Sequence 1948, Ap			
20	469	90.7	145	9	US-10-721-763-29	Sequence 29, Appl			
21	468	90.5	249	11	US-11-054-515-919	Sequence 919, App			

22	468	90.5	249	11	US-11-266-444-919	Sequence 919, App
23	465	89.9	238	11	US-11-054-515-1907	Sequence 1907, Ap
24	465	89.9	238	11	US-11-266-444-1907	Sequence 1907, Ap
25	465	89.9	247	11	US-11-054-515-1729	Sequence 1729, Ap
26	465	89.9	247	11	US-11-266-444-1729	Sequence 1729, Ap
27	461	89.2	98	10	US-11-221-902-52	Sequence 52, Appl
28	461	89.2	98	10	US-11-221-902-64	Sequence 64, Appl
29	461	89.2	98	11	US-11-054-669-1	Sequence 1, Appli
30	461	89.2	98	11	US-11-084-554-16	Sequence 16, Appl
31	461	89.2	98	11	US-11-136-250-16	Sequence 16, Appl
32	461	89.2	249	11	US-11-054-515-1635	Sequence 1635, Ap
33	461	89.2	249	11	US-11-266-444-1635	Sequence 1635, Ap
34	458	88.6	256	11	US-11-054-515-1640	Sequence 1640, Ap
35	458	88.6	256	11	US-11-266-444-1640	Sequence 1640, Ap
36	455	88.0	243	11	US-11-054-515-2109	Sequence 2109, Ap
37	455	88.0	243	11	US-11-266-444-2109	Sequence 2109, Ap
38	455	88.0	244	11	US-11-054-515-2037	Sequence 2037, Ap
39	455	88.0	244	11	US-11-266-444-2037	Sequence 2037, Ap
40	455	88.0	245	11	US-11-054-515-2116	Sequence 2116, Ap
41	455	88.0	245	11	US-11-266-444-2116	Sequence 2116, Ap
42	455	88.0	250	11	US-11-054-515-1722	Sequence 1722, Ap
43	455	88.0	250	11	US-11-266-444-1722	Sequence 1722, Ap
44	454	87.8	125	11	US-11-096-074-58	Sequence 58, Appl
45	454	87.8	125	11	US-11-095-822-58	Sequence 58, Appl

ALIGNMENTS

RESULT 1
US-11-221-902-54
; Sequence 54, Application US/11221902
; Publication No. US20060088522A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGAT
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 54
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-221-902-54

Query Match 100.0%; Score 517; DB 10; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	QVQLVQSGAEVKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGNPNSGNTGY	60
Db	1	QVQLVQSGAEVKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGNPNSGNTGY	60
Qy	61	AQKFGQGRVTTRNTSISTAYMELSLRSEDATVYCAR	98
Db	61	AQKFGQGRVTTRNTSISTAYMELSLRSEDATVYCAR	98

RESULT 2
US-11-054-669-3
; Sequence 3, Application US/11054669
; Publication No. US20050261480A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES
; FILE REFERENCE: 30219/US/3
; CURRENT APPLICATION NUMBER: US/11/054,669
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: US 10/194,975
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/305,111

```
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 3
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-669-3

Query Match      100.0%; Score 517; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60

QY 61 AQKFGQGRVTMTNRTNISTAYMELSSLSRSEDVAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTNISTAYMELSSLSRSEDVAVYYCAR 98

RESULT 3
US-11-004-590-3
; Sequence 3, Application US/11004590
; Publication No. US2006008883A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hammond, Phillip W.
; TITLE OF INVENTION: METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING
; FILE REFERENCE: 185832/US/5
; CURRENT APPLICATION NUMBER: US/11/004,590
; PRIOR FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: US 60/527,167
; PRIOR FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: US 60/581,613
; PRIOR FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US 60/601,665
; PRIOR FILING DATE: 2004-08-13
; PRIOR APPLICATION NUMBER: US 60/619,483
; PRIOR FILING DATE: 2004-10-14
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 3
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-004-590-3

Query Match      100.0%; Score 517; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60

QY 61 AQKFGQGRVTMTNRTNISTAYMELSSLSRSEDVAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTNISTAYMELSSLSRSEDVAVYYCAR 98

RESULT 4
US-11-084-554-23
; Sequence 23, Application US/11084554
; Publication No. US20050260679A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
```

```
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A
; CURRENT APPLICATION NUMBER: US/11/084,554
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-084-554-23

Query Match      100.0%; Score 517; DB 11; Length 99;
Best Local Similarity 100.0%; Pred. No. 5.4e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60

QY 61 AQKFGQGRVTMTNRTNISTAYMELSSLSRSEDVAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTNISTAYMELSSLSRSEDVAVYYCAR 98

RESULT 5
US-11-136-250-23
; Sequence 23, Application US/11136250
; Publication No. US20060021074A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; FILE REFERENCE: ABGENIX.100A2
; CURRENT APPLICATION NUMBER: US/11/136,250
; CURRENT FILING DATE: 2005-05-23
; PRIOR APPLICATION NUMBER: 11/084,554
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: PCT/US2005/009306
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-136-250-23

Query Match      100.0%; Score 517; DB 11; Length 99;
Best Local Similarity 100.0%; Pred. No. 5.4e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60

QY 61 AQKFGQGRVTMTNRTNISTAYMELSSLSRSEDVAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTNISTAYMELSSLSRSEDVAVYYCAR 98

RESULT 6
US-10-982-440-61
```

```

; Sequence 61, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 61
; LENGTH: 122
; TYPE: PR1
; ORGANISM: Homo sapiens
; ORGANISM: Homo sapiens
US-10-982-440-61

Query Match          99.4%; Score 514; DB 9; Length 122;
Best Local Similarity 99.0%; Pred. No. 1.2e-38;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNNSGNTGY 60
Db 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNNSGNTGY 60

Qy 61 AQKFGQRTVMTNTSISTAYMELSLRSSEDTAVYYCAR 98
Db 61 AQKFGQRTVMTNTSISTAYMELSLRSSEDTAVYYCAR 98

RESULT 7
US-10-982-440-47
; Sequence 47, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 47
; LENGTH: 120
; TYPE: PR1
; ORGANISM: Homo sapiens
; ORGANISM: Homo sapiens
US-10-982-440-47

Query Match          95.9%; Score 496; DB 9; Length 120;
Best Local Similarity 93.9%; Pred. No. 4.5e-37;
Matches 92; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNNSGNTGY 60
Db 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNNSGNTGY 60

Qy 61 AQKFGQRTVMTNTSISTAYMELSLRSSEDTAVYYCAR 98
Db 61 AQKFGQRTVMTNTSISTAYMELSLRSSEDTAVYYCAR 98

RESULT 8
US-11-054-515-927
; Sequence 927, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys

```

```

; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 927
; LENGTH: 247
; TYPE: PR1
; ORGANISM: Homo sapiens
; ORGANISM: Homo sapiens
US-11-054-515-927

Query Match          95.6%; Score 494; DB 11; Length 247;
Best Local Similarity 95.9%; Pred. No. 1.3e-36;
Matches 94; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNNSGNTGY 60
Db 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNNSGNTGY 60

Qy 61 AQKFGQRTVMTNTSISTAYMELSLRSSEDTAVYYCAR 98
Db 61 AQKFGQRTVMTNTSISTAYMELSLRSSEDTAVYYCAR 98

RESULT 9
US-11-054-515-948
; Sequence 948, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816

```

```
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 948
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: Site
; LOCATION: (227)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-11-054-515-948

Query Match          95.6%; Score 494; DB 11; Length 247;
Best Local Similarity 95.9%; Pred. No. 1.3e-36;
Matches 94; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINNVROATGQGLEWMGMNPNNSGNTGY 60
   |||||
Db 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGMNPNNSGNTGY 60

QY 61 AQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
   |||||
Db 61 AQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 10
US-11-266-444-927
; Sequence 927, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 927
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-927

Query Match          95.6%; Score 494; DB 11; Length 247;
Best Local Similarity 95.9%; Pred. No. 1.3e-36;
Matches 94; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINNVROATGQGLEWMGMNPNNSGNTGY 60
   |||||
Db 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGMNPNNSGNTGY 60

QY 61 AQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
   |||||
Db 61 AQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 11
US-11-266-444-948
; Sequence 948, Application US/11266444
; Publication No. US20060062789A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 948
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: Site
; LOCATION: (227)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-11-266-444-948

Query Match          95.6%; Score 494; DB 11; Length 247;
Best Local Similarity 95.9%; Pred. No. 1.3e-36;
Matches 94; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINNVROATGQGLEWMGMNPNNSGNTGY 60
   |||||
Db 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGMNPNNSGNTGY 60

QY 61 AQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
   |||||
Db 61 AQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 12
US-11-054-515-2031
; Sequence 2031, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
```



```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 2031
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-2031

Query Match          94.8%; Score 490; DB 11; Length 241;
Best Local Similarity 94.9%; Pred. No. 2.8e-36;
Matches 93; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNGTGY 60
Db 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNGTGY 60

Qy 61 AQKFGQGVTTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGVTTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 13
US-11-266-444-2031
; Sequence 2031, Application US/11266444
; Publication No. US2006062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523PDI
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR FILING DATE: 2000-06-16
; PRIOR FILING DATE: 2000-10-17
; PRIOR FILING DATE: 2000-10-17
; PRIOR FILING DATE: 2001-03-16
; PRIOR FILING DATE: 2001-03-21
; PRIOR FILING DATE: 2001-03-21
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2031
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-2031

Query Match          94.8%; Score 490; DB 11; Length 241;
Best Local Similarity 94.9%; Pred. No. 2.8e-36;
Matches 93; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNGTGY 60
Db 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNGTGY 60

Qy 61 AQKFGQGVTTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGVTTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 14
US-10-834-397-22
; Sequence 22, Application US/10834397
; Publication No. US20060003334A1
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
```

```
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
; CURRENT APPLICATION DATA: US/10/834,397
; FILING DATE: 29-Apr-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-834-397-22

Query Match          92.1%; Score 476; DB 9; Length 117;
Best Local Similarity 91.8%; Pred. No. 2.5e-35;
Matches 90; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNGTGY 60
Db 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNGTGY 60

Qy 61 AQKFGQGVTTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGVTTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 15
US-11-054-515-3244
; Sequence 3244, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BlyS
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
```

```
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 3244
; LENGTH: 253
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-3244

Query Match          91.7%; Score 474; DB 11; Length 253;
Best Local Similarity 90.8%; Pred. No. 7.5e-35;
Matches 89; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

Qy 1 QVQLVSGAEVKKPKGASVKYCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
Db 1 QVQLVSGAEVKKPKGASVKYCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60

Qy 61 AQKFQGRVTMTNTSISTAYMELSSLRSSEDTAVVYCAR 98
Db 61 AQNFQGRVTMTNTSISTAYMELSSLKSEDTAVYFCAR 98
```

Search completed: May 5, 2006, 08:57:44
Job time : 8.32964 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:05 ; Search time 6.24377 Seconds
(without alignments)
1510.185 Million cell updates/sec

Title: US-09-674-752-31

Perfect score: 517

Sequence: 1 QVOLVSGAEVKPGASVKV.....AYMELSLRSEDTAIVYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR_80.*

1: pir1.*

2: pir2.*

3: pir3.*

4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	517	100.0	98	2 S26918	Ig heavy chain V r
2	514	99.4	136	2 S31600	Ig heavy chain V r
3	502	97.1	127	2 S34014	Ig heavy chain V r
4	496	95.9	132	2 S31596	Ig heavy chain V r
5	469	90.7	110	2 PH1670	Ig heavy chain V r
6	461	89.2	98	2 S26938	Ig heavy chain V r
7	461	89.2	117	2 S31680	Ig heavy chain V r
8	461	89.2	117	2 S18551	Ig heavy chain V r
9	461	89.2	135	2 S49530	anti-5m antibody V
10	460	89.0	118	2 S36265	Ig heavy chain V r
11	453	87.6	98	2 S26912	Ig heavy chain V r
12	453	87.6	129	2 S46393	Ig heavy chain V r
13	449	86.8	171	2 S23623	Ig heavy chain V r
14	448	86.7	104	2 S69899	Ig heavy chain V r
15	442	85.5	98	2 S26920	Ig heavy chain V r
16	442	85.5	123	2 D33548	Ig heavy chain V-1
17	441	85.3	117	2 S18553	Ig heavy chain V r
18	440	85.1	98	2 PH0871	Ig heavy chain V r
19	437	84.5	117	1 HVHJ35	Ig heavy chain pre
20	437	84.5	117	1 HVHJ35	Ig heavy chain pre
21	435	84.1	98	2 S26919	Ig heavy chain V r
22	433	83.8	142	2 A32483	Ig heavy chain V r
23	430	83.2	122	2 S36271	Ig heavy chain V r
24	429	83.0	117	2 S18552	Ig heavy chain V r
25	429	83.0	124	2 S19665	Ig heavy chain V r
26	429	83.0	129	2 S36260	Ig heavy chain V r
27	424	82.0	98	2 S26910	Ig heavy chain V r
28	418	80.9	126	2 I44151	Ig heavy chain V r
29	415	80.3	116	2 S31667	Ig heavy chain V r

30 415 80.3 117 2 PT0371 Ig gamma chain pre
31 414 80.1 109 2 PH1668 Ig heavy chain V r
32 414 80.1 131 2 S21924 Ig heavy chain V r
33 412 79.7 121 2 S20783 Ig heavy chain V r
34 410 79.3 160 2 PL0105 anti-PR2 erythrocy
35 409 79.1 98 2 S26913 Ig heavy chain V r
36 407 78.7 114 2 PH1667 Ig heavy chain V r
37 407 78.7 118 2 PH1666 Ig heavy chain V r
38 406 78.5 117 2 S18554 Ig heavy chain V r
39 406 78.5 120 2 S31999 Ig heavy chain V r
40 405 78.5 131 2 S26792 Ig heavy chain V r
41 405 78.3 110 2 PH1669 Ig heavy chain V r
42 404 78.1 98 2 S26921 Ig heavy chain V r
43 404 78.1 125 2 S68170 Ig heavy chain V r
44 401 77.6 98 2 A49051 Ig heavy chain V7
45 401 77.6 119 2 JN0295 Ig heavy chain V-D

ALIGNMENTS

RESULT 1

S26918
Ig heavy chain V region (DP-15) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C/Accession: S26918
R/Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A/Title: The repertoire of human germline V(H) sequences reveals about fifty groups of
A/Reference number: S26885; MUID:93021117; PMID:1404388
A/Accession: S26918
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-98 <TM>
A/Cross-references: UNIPARC:UPI000031F36; EMBL:Z12317; NID:g32857; PIDN:CAA78187.1; PID
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 517; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 8.3e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVSGAEVKPGASVKVSKASGVTFTSYDINVRQATGGGLEWGMWNPNSGNTGY 60
Db 1 QVOLVSGAEVKPGASVKVSKASGVTFTSYDINVRQATGGGLEWGMWNPNSGNTGY 60
Qy 61 AQKFGQGRVTMTRNTSISTAYMELSLRSEDTAIVYCAR 98
Db 61 AQKFGQGRVTMTRNTSISTAYMELSLRSEDTAIVYCAR 98

RESULT 2

S31600
Ig heavy chain V region - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C/Accession: S31600
R/Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.
submitted to the EMBL Data Library, June 1992
A/Description: Mechanisms that generate human immunoglobulin diversity operate from the
A/Reference number: S31585
A/Accession: S31600
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-136 <CUI>
A/Cross-references: UNIPARC:UPI0000116453; EMBL:Z14165; NID:g30994; PIDN:CAA78534.1; PID
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotrimer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 99.4%; Score 514; DB 2; Length 136;

```
Best Local Similarity 99.0%; Pred No. 2.3e-42;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

Qy	1	QVQLVQSGAEVKPKGASVKVSKCKASGYTFTSYDINWV	60	QGLLEWMMGMPNSGNTGY
Db	20	QVQLVQSGAEVKPKGASVKVSKCKASGYTFTSYDINWV	79	QGLLEWMMGMPNSGNTGY
Qy	61	AQFQGRVTMTNTSISTAYMELSSLRSEDATVYYCAR	98	
Db	80	AQFQGRVTMTNTSISTAYMELSSLRSEDATVYYCAR	117	

RESULT 3

S34014
Ig heavy chain V region - human
C/Species: Homo sapiens (man)
C/Date: 02-Dec-1993 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996
C/Accession: S34014; S30535
R/Mariette, X.; Teapais, A.; Brouet, J.C.
Eur. J. Immunol. 23, 846-851, 1993
A/Title: Nucleotide sequence analysis of the variable domains of four human monoclonal
A/Reference number: S34001; MUID:93209281; PMID:7681398
A/Accession: S34014
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-127 <MAR>
A/Cross-references: UNIPARC:UPI0000176D31; EMBL:Z18321
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F/15-98/Domain: immunoglobulin homology <FM>

Query Match 97.1%; Score 502; DB 2; Length 127;
Best Local Similarity 95.9%; Pred. No. 3e-41;
Matches 94; Conservative 4; Mismatches 0; Indels

[illegible]

RESIT. T. 4

S31596
Ig heavy chain V region - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C/Accession: S31596
R/Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.
submitted to the EMBL Data Library, June 1992
A/Description: Mechanisms that generate human immunoglobulin diversity operate from the
A/Reference number: S31595
A/Accession: S31596
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-132 <CUI>
A/Cross-references: UNIPARC:UPI0000116454; EMBL:Z14166; NID:G30996; PIDN:CAA78535.1; PIR:
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterotetramer; immunoglobulin
F/34-117/Domain: immunoglobulin homology <IMW>

Query Match 95.9%; Score 496; DB 2; Length 132;
Best Local Similarity 95.9%; Pred. No. 1.2e-40;
Matches 94; Conservative 3; Mismatches 1; Indels

Qy 1 QVQLVSGAEVKKPGASVKVSCKASYTFTSYDINWVRQATGGLEWMGMMNPNSGNTGY 60
| | | | | : | | | | |
Db 20 QVQLVSGAEVKKPGASVKVSCKASYTFTSYDIDWVRQATGGLEWMGMMNPNSGNTGY 79
| | | | | : | | | | |
Qy 61 AQKFQGRVTMTNRTISITAYMELSSLRSEDTAVYFCAR 98
| | | | | : | | | | |

db 80 AOKFOGRVTMTNRTSISTAYMELSSSLRAEDTAVYYLAK 117

RESULT 5
PH1670

I9 heavy chain V region (clone 2A12) - human (fragment)
 C/Species: Homo sapiens (man)
 C/Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996
 C/Accession: PH1670
 R/Hillson, J.L.; Karr, N.S.; Opliger, I.R.; Mannik, M.; Sasso, E.H.
 J. Exp. Med. 178, 331-336, 1993
 A>Title: The structural basis of germline-encoded VH3 immunoglobulin binding
 A/Reference number: PH1642; MUID:93301610; PMID:8315388

A;Accession: PH1670

A;Molecule type: mRNA
A;Residues: 1-110 <HIL>
A;Cross-references: UNIPARC:UPI0000176BEB
A;Experimental source: B cell
C;Superfamily: immunoglobulin V region, immunoglobulin homology
F;Keywords: heterotrimer; immunoglobulin
F;7-90/Domain: immunoglobulin homology <IMW>

Query Match 90.7%; Score 469; DB 2; Length 110
Best Local Similarity 97.8%; Pred. No. 3.8e-38;
Matches 88; Conservative 1; Mismatches 1; Indels

Qy	9	AEVKPGASVKVSCKASGTTFTSYDINVRQATGGGLEWGMGMNPNSGNTGYAQKFGQRV	68
Db	1	AEVKPGASVKVSCKASGTYFTSYDINVRQATGGGLEWGMGMNPNNGTGYAQKFGQRV	60
Qy	69	TWTRNTSISTAYMELSSLSRSEDVAVYYCAR	98
Db	61	TWTRNTSISTAYMELSSLSRSEDVAVYYCAR	90

RESULT 6

IG heavy chain V region (DP-75) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence_revision 17-Nov-1995 #text_change 23-Jul-1999
C:Accession: S26938
R:Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A:Title: The repertoire of human germline V(H) sequences reveals about fifty
A:Reference number: S26885; UID:93021117; PMID:11404388

A;Accession: S28938
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-98 <TM>
A;Cross-references: UNIPARC:UPI000011644A; EMBL:Z14071; NID:g32969; PIDN:CAA7
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, July
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match	89.2%	Score 461;	DB 2;	Length 98;
Best Local Similarity	88.8%	Pred. No. 2e-37;		
Matches 87: Conservative	5;	Mismatches 6;	Indels 0;	Gaps 0

	QY	1 QVQLVOSGAEVKPKPGASVKVSKCKSGSYFTSTVDINVRQAQTGGLEHWGNWNPNSGNTGY	60
		:::::::::::::::::::::	
	Db	1 QVQLVOSGAEVKPKPGASVKVSKCKSGSYFTGTGMHWRVRFAPQGLENMGWINPNSGGTNY	60
	QY	61 AOKFOQRVTMTRTNSTISTAYMELSLRSDTAIVYYCAR	98
		:::::::::::::::::::::	
	Db	61 AOKFOQRVTMTRTNSTISTAYMELSLRSDTAIVYYCAR	98

RESULT 7
531690

S31680
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 03-Mar-1994 #sequence revision 10-Nov-1995 #text change 23-Jul-1999

C;Accession: S31680
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31680
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-117 <UI>
A;Cross-references: UNIPARC:UPI000011647D; EMBL:Z14213; NID:g37795; PIDN:CAA78582.1; PID
C;Genetics:
A;Introns: 16/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMW>

Query Match 89.2%; Score 461; DB 2; Length 117;
Best Local Similarity 88.8%; Pred. No. 2.3e-37;
Matches 87; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
DB 20 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGMNPNNSGNTGY 79

QY 61 AOKFQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
DB 80 AOKFQGRVTMTNTSISTAYMELSLRSDATVYYCAR 117

RESULT 8
S18551
Ig heavy chain V region precursor (VI-2) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 06-Jun-1997 #text_change 23-Jul-1999
C;Accession: S18551; S23625
R;Shin, E.K.; Matsuda, F.; Nagasaka, H.; Fukita, Y.; Imai, T.; Yokoyama, K.; Soeda, E.; H
EMBO J. 10, 3641-3645, 1991
A;Title: Physical map of the 3' region of the human immunoglobulin heavy chain locus: cl
A;Reference number: S18551; MUID:92037524; PMID:1935893
A;Accession: S18551
A;Molecule type: DNA
A;Residues: 1-117 <SHI>
A;Cross-references: UNIPARC:UPI0000115F95; EMBL:X62106; NID:g37831; PIDN:CAA44016.1; PID
R;Olee, T.; Lu, E.W.; Huang, D.F.; Soto-Gil, R.W.; Deftos, M.; Kozin, F.; Carson, D.A.;
J. Exp. Med. 175, 831-842, 1992
A;Title: Genetic analysis of self-associating immunoglobulin G rheumatoid factors from b
A;Reference number: S23623; MUID:92156804; PMID:1740665
A;Accession: S23625
A;Molecule type: DNA
A;Residues: 1-117 <OLE>
A;Cross-references: UNIPARC:UPI0000115F95; EMBL:X59704; NID:g32552; PIDN:CAA42225.1; PID
C;Genetics:
A;Introns: 16/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;1-19/Domain: signal sequence #status predicted <SIG>
F;20-117/Product: Ig heavy chain V region (VI-2) #status predicted <MAT>
F;34-117/Domain: immunoglobulin homology <IMW>

Query Match 89.2%; Score 461; DB 2; Length 117;
Best Local Similarity 88.8%; Pred. No. 2.3e-37;
Matches 87; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
DB 20 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGMNPNNSGNTGY 79

QY 61 AOKFQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
DB 80 AOKFQGRVTMTNTSISTAYMELSLRSDATVYYCAR 117

RESULT 9
S18551
Ig heavy chain V region precursor (VI-2) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 06-Jun-1997 #text_change 23-Jul-1999
C;Accession: S18551; S23625
R;Shin, E.K.; Matsuda, F.; Nagasaka, H.; Fukita, Y.; Imai, T.; Yokoyama, K.; Soeda, E.; H
EMBO J. 10, 3641-3645, 1991
A;Title: Physical map of the 3' region of the human immunoglobulin heavy chain locus: cl
A;Reference number: S18551; MUID:92037524; PMID:1935893
A;Accession: S18551
A;Molecule type: DNA
A;Residues: 1-117 <SHI>
A;Cross-references: UNIPARC:UPI0000115F95; EMBL:X62106; NID:g37831; PIDN:CAA44016.1; PID
R;Olee, T.; Lu, E.W.; Huang, D.F.; Soto-Gil, R.W.; Deftos, M.; Kozin, F.; Carson, D.A.;
J. Exp. Med. 175, 831-842, 1992
A;Title: Genetic analysis of self-associating immunoglobulin G rheumatoid factors from b
A;Reference number: S23623; MUID:92156804; PMID:1740665
A;Accession: S23625
A;Molecule type: DNA
A;Residues: 1-117 <OLE>
A;Cross-references: UNIPARC:UPI0000115F95; EMBL:X59704; NID:g32552; PIDN:CAA42225.1; PID
C;Genetics:
A;Introns: 16/1
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;1-19/Domain: signal sequence #status predicted <SIG>
F;20-117/Product: Ig heavy chain V region (VI-2) #status predicted <MAT>
F;34-117/Domain: immunoglobulin homology <IMW>

S49530
anti-Sm antibody VH chain (VH1/DK1 or DM1/JH4b) - human
C;Species: Homo sapiens (man)
C;Date: 01-Feb-1995 #sequence_revision 12-May-1995 #text_change 23-Jul-1999
C;Accession: S49530
R;Mahmoudi, M.; Edwards, J.; Cairns, E.; Bell, D.
submitted to the EMBL Data Library, October 1994
A;Description: Molecular characterization of natural human anti-Sm autoantibodies.
A;Reference number: S48797
A;Accession: S49530
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-135 <MAH>
A;Cross-references: UNIPARC:UPI00001166FF; EMBL:Z46348; NID:g560839; PIDN:CAA86467.1; PI
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;34-117/Domain: immunoglobulin homology <IMW>

Query Match 89.2%; Score 461; DB 2; Length 135;
Best Local Similarity 88.8%; Pred. No. 2.7e-37;
Matches 87; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
DB 20 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGMNPNNSGNTGY 79

QY 61 AOKFQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
DB 80 AOKFQGRVTMTNTSISTAYMELSLRSDATVYYCAR 117

RESULT 10
S36265
Ig heavy chain V region (clone alpha-MUC1-1) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C;Accession: S36265
R;Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.
EMBO J. 12, 725-734, 1993
A;Title: Human anti-self antibodies with high specificity from phage display libraries.
A;Reference number: S36256; MUID:93178448; PMID:7679950
A;Accession: S36265
A;Status: preliminary; nucleic acid sequence not shown
A;Molecule type: mRNA
A;Residues: 1-118 <GRI>
A;Cross-references: UNIPARC:UPI0000118DB8; EMBL:Z18846; NID:g33121; PIDN:CAA79298.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMW>

Query Match 89.0%; Score 460; DB 2; Length 118;
Best Local Similarity 88.8%; Pred. No. 2.9e-37;
Matches 87; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGMNPNNSGNTGY 60

QY 61 AOKFQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
DB 61 AOKFQGRVTMTNTSISTAYMELSLRSDATVYYCAR 98

RESULT 11
S26912
Ig heavy chain V region (DP-8) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of v
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26912

Search completed: May 5, 2006, 08:51:34
Job time : 6.24377 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 02:15:59 ; Search time 118.333 Seconds
(without alignments)
363.880 Million cell updates/sec

Title: US-09-674-752-31

Perfect score: 517

Sequence: 1 QVOLVSGAEVKKPGASVKV.....AYMELSLRSRSEDFAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21.*

1: Geneseqp1980s.*

2: Geneseqp1990s.*

3: Geneseqp2000s.*

4: Geneseqp2001s.*

5: Geneseqp2002s.*

6: Geneseqp2003as.*

7: Geneseqp2003bs.*

8: Geneseqp2004s.*

9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	517	100.0	98	3 AAY50958	Aay50958 Human FVI
2	517	100.0	98	5 ABG78170	Abg78170 Human Fv
3	517	100.0	98	5 ABG91861	Abg91861 Human ant
4	517	100.0	98	6 ABO27070	Abo27070 Human ger
5	517	100.0	98	7 ADF10108	Adf10108 Antibody
6	517	100.0	98	7 ADF09898	Adf09898 Antibody
7	517	100.0	98	7 ADF10006	Adf10006 VEGF anti
8	517	100.0	98	7 ADK18866	Adk18866 Anti-huma
9	517	100.0	98	7 ADK18920	Adk18920 Anti-huma
10	517	100.0	98	7 ADK18924	Adk18924 Anti-huma
11	517	100.0	98	7 ADK18918	Adk18918 Anti-huma
12	517	100.0	98	7 ADK18937	Adk18937 Anti-huma
13	517	100.0	98	7 ADK18872	Adk18872 Anti-huma
14	517	100.0	98	7 ADK18865	Adk18865 Anti-huma
15	517	100.0	98	7 ADK18871	Adk18871 Anti-huma
16	517	100.0	98	7 ADJ80283	Adj80283 VH gene 1
17	517	100.0	98	9 ADY75288	Ady75288 Protein e
18	517	100.0	99	7 ADK18577	Adk18577 Anti-huma
19	517	100.0	117	2 AAR66302	Aar66302 Human imm
20	517	100.0	125	7 ADK18614	Adk18614 Anti-huma
21	517	100.0	125	7 ADK18779	Adk18779 Anti-huma
22	517	100.0	125	7 ADK18919	Adk18919 Anti-huma
23	517	100.0	125	7 ADK18816	Adk18816 Anti-huma
24	517	100.0	125	8 ADL25444	Adl25444 Human mAb

25	517	100.0	126	7	ADK18864	Adk18864 Anti-huma
26	517	100.0	126	7	ADK18597	Adk18597 Anti-huma
27	517	100.0	126	7	ADK18870	Adk18870 Anti-huma
28	517	100.0	126	7	ADK18595	Adk18595 Anti-huma
29	517	100.0	126	7	ADK18812	Adk18812 Anti-huma
30	517	100.0	126	7	ADK18777	Adk18777 Anti-huma
31	517	100.0	126	7	ADK18775	Adk18775 Anti-huma
32	517	100.0	126	8	ADL25408	Adl25408 Human mAb
33	517	100.0	126	8	ADL25412	Adl25412 Human mAb
34	514	99.4	122	6	ABR55829	AbR55829 Heavy cha
35	513	99.2	98	7	ADK18926	Adk18926 Anti-huma
36	512	99.0	126	7	ADK18778	Adk18778 Anti-huma
37	512	99.0	126	7	ADK18613	Adk18613 Anti-huma
38	512	99.0	126	7	ADK18815	Adk18815 Anti-huma
39	512	99.0	126	8	ADL25464	Adl25464 Human mAb
40	510	98.6	126	7	ADK18925	Adk18925 Anti-huma
41	510	98.6	126	7	ADK18780	Adk18780 Anti-huma
42	510	98.6	126	7	ADK18616	Adk18616 Anti-huma
43	510	98.6	126	7	ADK18817	Adk18817 Anti-huma
44	510	98.6	126	8	ADL25448	Adl25448 Human mAb
45	508	98.3	127	7	ADK18620	Adk18620 Anti-huma

ALIGNMENTS

RESULT 1

AAY50958

ID AAY50958 standard; protein; 98 AA.

XX AAY50958;

AC AAY50958;

XX AAY50958;

DT 23-MAR-2000 (first entry)

DE Human FVIII antibody A3-C1 scFv heavy chain protein DP-15.

XX Human;

KW Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

KW scFv; A3-C1.

XX Homo sapiens.

XX WO9958680-A2.

PN WO9958680-A2.

XX 18-NOV-1999.

PD 07-MAY-1999; 99WO-NL000285.

PF 08-MAY-1998; 98EP-00201543.

XX (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.

XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;

PI WPI; 2000-053102/04.

XX New polynucleotide, polypeptide and antibody useful for diagnosing the

PT presence of neutralizing antibodies against factor VIII and for treatment

PT of hemophilia A patients with these antibodies.

XX Example 8; Fig 9A; 61pp; English.

XX This invention describes a novel polynucleotide (I) (and complements and

CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence

CC coding for a human antibody with factor VIII specificity which has

CC hemostatic activity. (I) is useful a primer or probe for detecting the

CC presence of inhibitory antibodies directed against factor VIII. The

CC polypeptides of the invention and the antibodies generated from them are

CC useful in compositions for neutralizing factor VIII inhibiting antibodies

CC in hemophilia A patients. This sequence represents the human factor VIII

CC antibody A3-C1 specific scFv protein DP-15 which is used in the method of

XX the invention

XX Sequence 98 AA;

Query Match	100.0%; Score 517; DB 3; Length 98;
Best Local Similarity	100.0%; Pred. No. 1.6e-42;
Matches	98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
DB	1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
QY	61 AQRFGQGVTTWTRNTSISTAYMELSSLRSEDVAVYYCAR 98
DB	61 AQRFGQGVTTWTRNTSISTAYMELSSLRSEDVAVYYCAR 98
RESULT 2	
ABG78170	
ID	ABG78170 standard; protein; 98 AA.
XX	
AC	ABG78170;
XX	
DT	15-NOV-2002 (first entry)
XX	
DE	Human Fv molecule hypervariable region related peptide #45.
XX	
KW	Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
KW	disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
KW	lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.
XX	
OS	Homo sapiens.
XX	
XX	
PN	W0200259264-A2.
XX	
PD	01-AUG-2002.
XX	
PF	31-DEC-2001; 2001WO-US049440.
XX	
PR	29-DEC-2000; 2000US-00751181.
XX	
PA	(BIOT-) BIO-TECHNOLOGY GEN CORP.
XX	
PI	Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;
PI	Plaksin D, Peretz T;
XX	
DR	WPI; 2002-619166/66.
XX	
PT	Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
PT	or fragment, or construct of fragment with enhanced binding
PT	characteristics so as to selectively bind target cell in favor of other
XX	cells.
PS	Claim 13; Page 168-169; 232pp; English.
CC	The invention relates to a peptide or polypeptide comprising an Fv
CC	molecule, a construct or fragments or a construct of a fragment with
CC	enhanced binding characteristics which selectively and/or specifically
CC	binds to a target cell in favour of other cells, where binding is
CC	primarily determined by a first hypervariable region and Fv is a single
CC	chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
CC	association with or attached, coupled, combined, linked or fused to a
CC	pharmaceutical agent, is useful in the manufacture of a medicament, where
CC	the medicament has activity against a diseased cell, preferably a cancer
CC	cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
CC	myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
CC	acute myeloid leukaemia cell). The peptide is also useful for preparing a
CC	composition for use in inhibiting the growth of a diseased or cancer
CC	cell. This sequence represents a human Fv molecule hypervariable region
XX	related peptide of the invention
XX	
SQ	Sequence 98 AA;
Query Match	100.0%; Score 517; DB 5; Length 98;
Best Local Similarity	100.0%; Pred. No. 1.6e-42;
Matches	98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```

Db      1 QVQLVQSGAEVKKPGASVKSCAKSGYTFYSYDINNVROATGQGLEWMGMNPNSGNTGY 60
      61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98
      61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 6
ADF09898
ID ADF09898 standard; protein; 98 AA.
XX
AC ADF09898;
XX
DT 12-FEB-2004 (first entry)
XX
DE Antibody heavy chain variable region VH_1-8.
XX
KW Antibody; stability; solubility; antigen binding affinity;
KW variable region; human.
XX
OS Homo sapiens.
XX
PN WO2003074679-A2.
XX
PD 12-SEP-2003.
XX
PF 03-MAR-2003; 2003WO-US0006598.
XX
PR 01-MAR-2002; 2002US-0360843P.
PR 29-MAY-2002; 2002US-0384197P.
XX
PA (XENC-) XENCOR.
PI Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
PI WPI; 2003-722066/68.
XX
PT Computer optimization of physicochemical properties of antibodies
PT comprises analyzing the interactions of amino acids at variable
PT positions.
XX
PS Disclosure; Fig 2a; 135pp; English.
XX
CC The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC method. The method comprises: receiving a template antibody structure;
CC selecting at least one variable position belonging to the antibody
CC structure; selecting at least one amino acid to be considered at the
CC variable position(s); analyzing the interaction of each selected amino
CC acid at each variable position with at least part of the remainder of the
CC antibody, including the selected amino acids at other variable positions;
CC and identifying a set of at least one antibody sequence with at least one
CC optimized physico-chemical property. The method is useful for optimizing
CC the physico-chemical properties of an antibody, especially the stability,
CC solubility, or antigen binding affinity. The optimized antibody may be
CC useful for treating a patient. The present sequence is an antibody
CC variable region sequence used to illustrate the invention.
XX
SQ Sequence 98 AA;
Query Match 100.0%; Score 517; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.6e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVQSGAEVKKPGASVKSCAKSGYTFYSYDINNVROATGQGLEWMGMNPNSGNTGY 60
Db      1 QVQLVQSGAEVKKPGASVKSCAKSGYTFYSYDINNVROATGQGLEWMGMNPNSGNTGY 60
      61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98
      61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 8
ADK18866
ID ADK18866 standard; protein; 98 AA.
XX
AC ADK18866;
XX

```

```

RESULT 7
ADF10006
ID ADF10006 standard; protein; 98 AA.
XX
AC ADF10006;
XX
DT 12-FEB-2004 (first entry)
XX
DE VEGF antibody heavy chain variable region VH_1-8.
XX
KW Antibody; stability; solubility; antigen binding affinity;
KW variable region; human; VEGF.
XX
OS Homo sapiens.
XX
PN WO2003074679-A2.
XX
PD 12-SEP-2003.
XX
PF 03-MAR-2003; 2003WO-US0006598.
XX
PR 01-MAR-2002; 2002US-0360843P.
PR 29-MAY-2002; 2002US-0384197P.
XX
PA (XENC-) XENCOR.
PI Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
PI WPI; 2003-722066/68.
XX
PT Computer optimization of physicochemical properties of antibodies
PT comprises analyzing the interactions of amino acids at variable
PT positions.
XX
PS Example 6; Fig 16a; 135pp; English.
XX
CC The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC method. The method comprises: receiving a template antibody structure;
CC selecting at least one variable position belonging to the antibody
CC structure; selecting at least one amino acid to be considered at the
CC variable position(s); analyzing the interaction of each selected amino
CC acid at each variable position with at least part of the remainder of the
CC antibody, including the selected amino acids at other variable positions;
CC and identifying a set of at least one antibody sequence with at least one
CC optimized physico-chemical property. The method is useful for optimizing
CC the physico-chemical properties of an antibody, especially the stability,
CC solubility, or antigen binding affinity. The optimized antibody may be
CC useful for treating a patient. The present sequence is an antibody
CC variable region sequence used to illustrate the invention.
XX
SQ Sequence 98 AA;
Query Match 100.0%; Score 517; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.6e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVQSGAEVKKPGASVKSCAKSGYTFYSYDINNVROATGQGLEWMGMNPNSGNTGY 60
Db      1 QVQLVQSGAEVKKPGASVKSCAKSGYTFYSYDINNVROATGQGLEWMGMNPNSGNTGY 60
      61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98
      61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 8
ADK18866
ID ADK18866 standard; protein; 98 AA.
XX
AC ADK18866;
XX

```

```
DT 06-MAY-2004 (first entry)
XX
DE Anti-human PDGF-D antibody protein related sequence #92.
XX
KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
PN WO2003057857-A2.
XX
PD 17-JUL-2003.
XX
XX
PF 06-JAN-2003; 2003WO-US000398.
XX
PR 07-JAN-2002; 2002US-00041860.
XX
XX (ABGE-) ABGENIX INC.
XX
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
XX WPI; 2003-587119/55.
XX
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
XX diseases, such as inflammation, autoimmunity and cancer.
XX
XX Disclosure; SEQ ID NO 290; 255pp; English.
XX
XX The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
XX Sequence 98 AA;
XX
XX Query Match 100.0%; Score 517; DB 7; Length 98;
XX Best Local Similarity 100.0%; Pred. No. 1.6e-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
DB 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
QY 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
DB 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
XX
XX Sequence 98 AA;
XX
XX Query Match 100.0%; Score 517; DB 7; Length 98;
XX Best Local Similarity 100.0%; Pred. No. 1.6e-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
DB 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
QY 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
DB 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
XX
XX RESULT 9
XX ADK18920
XX ID ADK18920 standard; protein; 98 AA.
XX
XX AC ADK18920;
XX
XX DT 06-MAY-2004 (first entry)
XX
XX DE Anti-human PDGF-D antibody protein related sequence #146.
XX
XX KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
XX OS Homo sapiens.
XX
XX PN WO2003057857-A2.
XX
XX PD 17-JUL-2003.
XX
```

```
PF 06-JAN-2003; 2003WO-US000398.
XX
PR 07-JAN-2002; 2002US-00041860.
XX
PA (ABGE-) ABGENIX INC.
XX
PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
XX WPI; 2003-587119/55.
XX
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
XX diseases, such as inflammation, autoimmunity and cancer.
XX
XX Disclosure; SEQ ID NO 344; 255pp; English.
XX
XX The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
XX Sequence 98 AA;
XX
XX Query Match 100.0%; Score 517; DB 7; Length 98;
XX Best Local Similarity 100.0%; Pred. No. 1.6e-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
DB 1 QVQLVSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
QY 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
DB 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
XX
XX RESULT 10
XX ADK18924
XX ID ADK18924 standard; protein; 98 AA.
XX
XX AC ADK18924;
XX
XX DT 06-MAY-2004 (first entry)
XX
XX DE Anti-human PDGF-D antibody protein related sequence #150.
XX
XX KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
XX OS Homo sapiens.
XX
XX PN WO2003057857-A2.
XX
XX PD 17-JUL-2003.
XX
XX PF 06-JAN-2003; 2003WO-US000398.
XX
XX PR 07-JAN-2002; 2002US-00041860.
XX
XX (ABGE-) ABGENIX INC.
XX
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
XX WPI; 2003-587119/55.
XX
XX New human monoclonal antibody that binds to platelet-derived growth
PT
```

PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
PS Disclosure; SEQ ID NO 348; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 98 AA;
Query Match 100.0%; Score 517; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.6e-42; Indels 0; Gaps 0;
Matches 98; Conservative 0; Mismatches 0;
QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
QY 61 AQKFGQRTVMTNTSISTAYMELSLRSEDYAVYYCAR 98
Db 61 AQKFGQRTVMTNTSISTAYMELSLRSEDYAVYYCAR 98
RESULT 11
ADK18918
ID ADK18918 standard; protein; 98 AA.
XX
AC ADK18918;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-human PDGF-D antibody protein related sequence #144.
XX
KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
PN WO2003057857-A2.
XX
PD 17-JUL-2003.
XX
PF 06-JAN-2003; 2003WO-US000398.
XX
PR 07-JAN-2002; 2002US-00041860.
XX
PS (ABGE-) ABGENIX INC.
XX
PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
DR WPI; 2003-587119/55.
XX
PT New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
PS Disclosure; SEQ ID NO 342; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the

CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 98 AA;
Query Match 100.0%; Score 517; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.6e-42; Indels 0; Gaps 0;
Matches 98; Conservative 0; Mismatches 0;
QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
QY 61 AQKFGQRTVMTNTSISTAYMELSLRSEDYAVYYCAR 98
Db 61 AQKFGQRTVMTNTSISTAYMELSLRSEDYAVYYCAR 98
RESULT 12
ADK18937
ID ADK18937 standard; protein; 98 AA.
XX
AC ADK18937;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-human PDGF-D antibody protein related sequence #163.
XX
KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
PN WO2003057857-A2.
XX
PD 17-JUL-2003.
XX
PF 06-JAN-2003; 2003WO-US000398.
XX
PR 07-JAN-2002; 2002US-00041860.
XX
PS (ABGE-) ABGENIX INC.
XX
PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
DR WPI; 2003-587119/55.
XX
PT New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
PS Disclosure; SEQ ID NO 361; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 98 AA;
Query Match 100.0%; Score 517; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.6e-42; Indels 0; Gaps 0;
Matches 98; Conservative 0; Mismatches 0;
QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60

```
Db      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
Qy      61 AQKFGQGRVTMTNRTSISTAYMELSLRSEDVAVYYCAR 98
      |||||
Db      61 AQKFGQGRVTMTNRTSISTAYMELSLRSEDVAVYYCAR 98

RESULT 13
ADK18872
ID      ADK18872 standard; protein; 98 AA.
XX
AC      ADK18872;
XX
Dt      06-MAY-2004 (first entry)
XX
DE      Anti-human PDGF-D antibody protein related sequence #98.
XX
KW      antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS      Homo sapiens.
XX
PN      WO2003057857-A2.
XX
PD      17-JUL-2003.
XX
PF      06-JAN-2003; 2003WO-US000398.
XX
PR      07-JAN-2002; 2002US-00041860.
XX
PA      (ABGE-) ABGENIX INC.
XX
PI      Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI      Bezabeh B;
XX
DR      WPI; 2003-587119/55.
XX
PT      New human monoclonal antibody that binds to platelet-derived growth
PT      factor-D (PDGF-D), useful for treating chronic and recurrent human
PT      diseases, such as inflammation, autoimmunity and cancer.
XX
PS      Disclosure; SEQ ID NO 296; 255pp; English.
XX
CC      The invention relates to a human monoclonal antibody that binds to
CC      platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC      treating chronic and recurrent human diseases, such as inflammation,
CC      autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC      useful for modulating collagen formation, and for staging various
CC      cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC      generated using an active protein fragment of the gene product from the
CC      clone 30664188.0.99 arising in the conditioned medium obtained when
CC      HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC      sequence corresponds to a protein used in the invention.
XX
SQ      Sequence 98 AA;

Query Match      100.0%; Score 517; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.6e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
      |||||
Db      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60

Qy      61 AQKFGQGRVTMTNRTSISTAYMELSLRSEDVAVYYCAR 98
      |||||
Db      61 AQKFGQGRVTMTNRTSISTAYMELSLRSEDVAVYYCAR 98

RESULT 14
ADK18865
ID      ADK18865 standard; protein; 98 AA.
XX
AC      ADK18865;

Query Match      100.0%; Score 517; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.6e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
      |||||
Db      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60

Qy      61 AQKFGQGRVTMTNRTSISTAYMELSLRSEDVAVYYCAR 98
      |||||
Db      61 AQKFGQGRVTMTNRTSISTAYMELSLRSEDVAVYYCAR 98

RESULT 15
ADK18871
ID      ADK18871 standard; protein; 98 AA.
XX
AC      ADK18871;
XX
Dt      06-MAY-2004 (first entry)
XX
DE      Anti-human PDGF-D antibody protein related sequence #97.
XX
KW      antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS      Homo sapiens.
XX
PN      WO2003057857-A2.
XX
PD      17-JUL-2003.
XX
```

```
XX      06-MAY-2004 (first entry)
Dt      Anti-human PDGF-D antibody protein related sequence #91.
XX
KW      antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS      Homo sapiens.
XX
PN      WO2003057857-A2.
XX
PD      17-JUL-2003.
XX
PF      06-JAN-2003; 2003WO-US000398.
XX
PR      07-JAN-2002; 2002US-00041860.
XX
PA      (ABGE-) ABGENIX INC.
XX
PI      Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI      Bezabeh B;
XX
DR      WPI; 2003-587119/55.
XX
PT      New human monoclonal antibody that binds to platelet-derived growth
PT      factor-D (PDGF-D), useful for treating chronic and recurrent human
PT      diseases, such as inflammation, autoimmunity and cancer.
XX
PS      Disclosure; SEQ ID NO 289; 255pp; English.
XX
CC      The invention relates to a human monoclonal antibody that binds to
CC      platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC      treating chronic and recurrent human diseases, such as inflammation,
CC      autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC      useful for modulating collagen formation, and for staging various
CC      cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC      generated using an active protein fragment of the gene product from the
CC      clone 30664188.0.99 arising in the conditioned medium obtained when
CC      HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC      sequence corresponds to a protein used in the invention.
XX
SQ      Sequence 98 AA;

Query Match      100.0%; Score 517; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.6e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
      |||||
Db      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60

Qy      61 AQKFGQGRVTMTNRTSISTAYMELSLRSEDVAVYYCAR 98
      |||||
Db      61 AQKFGQGRVTMTNRTSISTAYMELSLRSEDVAVYYCAR 98

RESULT 15
ADK18871
ID      ADK18871 standard; protein; 98 AA.
XX
AC      ADK18871;
XX
Dt      06-MAY-2004 (first entry)
XX
DE      Anti-human PDGF-D antibody protein related sequence #97.
XX
KW      antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS      Homo sapiens.
XX
PN      WO2003057857-A2.
XX
PD      17-JUL-2003.
XX
```

XX 06-JAN-2003; 2003WO-US000398.
 PF
 XX
 PR 07-JAN-2002; 2002US-00041860.
 XX
 XX (ABGE-) ABGENIX INC.
 XX
 XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R,
 PI Bezabeh B;
 XX
 XX WPI; 2003-587119/55.
 DR
 XX New human monoclonal antibody that binds to platelet-derived growth
 PT factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.
 XX
 XX Disclosure; SEQ ID NO 295; 255pp; English.
 XX
 XX The invention relates to a human monoclonal antibody that binds to
 CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 CC treating chronic and recurrent human diseases, such as inflammation,
 CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 CC useful for modulating collagen formation, and for staging various
 CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
 CC sequence corresponds to a protein used in the invention.
 XX
 XX Sequence 98 AA;
 SQ
 Query Match 100.0%; Score 517; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 1.6e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60
 DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60
 QY 61 AQKFGQVRVTMTNTSISTAYMELSSLRSSEDTAVYYCAR 98
 DB 61 AQKFGQVRVTMTNTSISTAYMELSSLRSSEDTAVYYCAR 98
 RESULT 16
 ID ADJ80283
 XX ADJ80283 standard; protein; 98 AA.
 XX
 AC ADJ80283;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 XX VH gene locus amino acid sequence #3.
 DE
 XX hybrid antibody; antibody; framework region; homology; immunogenicity.
 KW
 XX Homo sapiens.
 OS
 XX
 XX WO2003048321-A2.
 PN
 XX
 XX 12-JUN-2003.
 PD
 XX
 XX 03-DEC-2002; 2002WO-US038450.
 PF
 XX
 XX 03-DEC-2001; 2001US-0336591P.
 PR
 XX
 XX (ALEX-) ALEXION PHARM INC.
 PA
 XX
 XX Rother R, Wu D;
 PI
 XX
 XX WPI; 2003-513753/48.
 DR
 XX
 XX Producing a hybrid antibody or hybrid antibody fragment by operatively

PT linking the selected framework sequences to one or more complementarity
 PT determining regions of the initial antibody.
 XX
 PS Disclosure; SEQ ID NO 43; 77pp; English.
 XX
 XX The invention relates to a method of producing a hybrid antibody or
 CC hybrid antibody fragment by: (i) providing an initial antibody having
 CC specificity for a target; (ii) determining the sequence of a variable
 CC region of the initial antibody; (iii) selecting a first component of the
 CC variable region consisting of FR1, FR2, FR3 and FR4; (iv) comparing the
 CC sequence of the first component to sequences contained in a reference
 CC database of antibody sequences or antibody fragment sequences from a
 CC target species; (v) selecting a sequence from an antibody in the database
 CC which demonstrates a high degree of homology to the first component; (vi)
 CC selecting a second component of the variable region which is different
 CC than the first component, the second component selected from the group
 CC consisting of FR1, FR2, FR3 and FR4; (vii) comparing the sequence of the
 CC second component to sequences contained in a reference database of
 CC antibody sequences or antibody fragment sequences from the target species
 CC; (viii) selecting a sequence from the database which demonstrates a high
 CC degree of homology to the second component and which is from a different
 CC antibody than the selected antibody; and (ix) operatively linking the
 CC selected framework sequences to one or more complementarity determining
 CC regions (CDRs) of the initial antibody to produce a hybrid antibody or
 CC hybrid antibody fragment. The method is useful for producing a hybrid
 CC antibody or hybrid antibody fragment (claimed). The antibody and
 CC fragments are useful for therapeutic and diagnostic purposes. The method
 CC uses entire framework regions from a single antibody variable heavy or
 CC variable light chain to receive the CDRs. This produces antibodies that
 CC are highly homologous and exhibit reduced immunogenicity while
 CC maintaining an optimum binding profile. This sequence represents the
 CC amino acid sequence of an antibody from the VH gene locus.
 XX
 XX Sequence 98 AA;
 SQ
 Query Match 100.0%; Score 517; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 1.6e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60
 DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMWNPNSGNTGY 60
 QY 61 AQKFGQVRVTMTNTSISTAYMELSSLRSSEDTAVYYCAR 98
 DB 61 AQKFGQVRVTMTNTSISTAYMELSSLRSSEDTAVYYCAR 98
 RESULT 17
 ADY75288
 ID ADY75288 standard; protein; 98 AA.
 XX
 XX ADY75288;
 AC
 XX
 XX 02-JUN-2005 (first entry)
 DT
 XX
 XX Protein encoded by human germline heavy chain V minigene VH1 1-08.
 DE
 XX
 XX Antibody engineering; antibody; antibody production; gene library;
 KW DNA recombination; gene amplification; primer extension;
 KW heavy chain variable region.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO2005023993-A2.
 PN
 XX
 XX 17-MAR-2005.
 PD
 XX
 XX 09-SEP-2004; 2004WO-US029617.
 PF
 XX
 XX 09-SEP-2003; 2003US-0501073P.
 PR
 XX
 XX (INTE-) INTEGRIGEN INC.
 PA

XX Sharma V, Leonard L, Smider V;
 XX WPI; 2005-223364/23.
 DR Producing polynucleotide encoding human germline antibody V-region for
 XX generating full-length antibody germline V-region genes, by obtaining V
 PT or J minigene and joining V minigene with J minigene, or joining J
 PT minigene with V minigene.
 XX
 XX Disclosure; Fig 10; 52pp; English.
 XX
 CC The present invention relates to producing germline antibody genes by a
 CC completely in vitro approach that mimics the natural process of V(D)J
 CC recombination. The antibody genes are completely human and native in
 CC their sequence, and libraries of such antibody genes can be constructed
 CC which represent an unselected population representing the entire antibody
 CC repertoire. The method uses gene amplification to produce a V minigene,
 CC and a hybrid primer capable of hybridizing to a V minigene and either a D
 CC or V minigene. The hybrid primer facilitates recombination of a V
 CC minigene to a D or J minigene to produce a full length V-region gene.
 CC Also disclosed is a library comprising member polynucleotides encoding a
 CC exogenously rearranged human germline antibody V-regions. In producing a
 CC polynucleotide encoding a human germline antibody V-region, a D minigene
 CC is further joined to the 3' end of the V minigene and the 5' end of the J
 CC minigene. The V minigene or the J minigene in is obtained by chemical
 CC synthesis or by amplification from a germline DNA library. Joining the V
 CC minigene with at least one J minigene is performed by primer extension
 CC using at least two or three oligonucleotide primers. The V minigene is
 CC derived from human immunoglobulin kappa locus, human immunoglobulin
 CC lambda locus, or human immunoglobulin heavy chain locus. The V-region
 CC also comprises a serine protease triad. The human germline antibodies can
 CC be used as precursors to more high affinity antibodies, and are useful in
 CC the generation of efficiently pairing libraries of heavy and light
 CC chains. The present sequence is a polypeptide encoded by human germline
 CC heavy chain V minigene, family VH1 locus 1-08.
 XX
 XX Sequence 98 AA;
 SQ

Query Match 100.0%; Score 517; DB 9; Length 98;
 Best Local Similarity 100.0%; Pred. No. 1.6e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGNPNNGNTGY 60
 DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGNPNNGNTGY 60
 QY 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
 DB 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

RESULT 18
 ADK18577
 ID ADK18577 standard; protein; 99 AA.
 XX
 AC ADK18577;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 DE Anti-human PDGF-D antibody Vh 1-8 protein.
 XX
 XX antiinflammatory; immunomodulator; cytostatic; gene therapy.
 KW
 XX Homo sapiens.
 OS
 XX WO2003057857-A2.
 PN
 XX 17-JUL-2003.
 PD
 XX 06-JAN-2003; 2003WO-US000398.
 XX
 XX 07-JAN-2002; 2002US-00041860.
 PR

XX (ABGE-) ABGENIX INC.
 XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;
 XX WPI; 2003-587119/55.
 DR
 XX New human monoclonal antibody that binds to platelet-derived growth
 PT factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.
 XX
 XX Example 7; SEQ ID NO 1; 255pp; English.
 XX
 CC The invention relates to a human monoclonal antibody that binds to
 CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 CC treating chronic and recurrent human diseases, such as inflammation, for
 CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 CC useful for modulating collagen formation, and for staging various
 CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCBP4/Sec-30664188. This
 CC sequence corresponds to a protein used in the invention.
 XX
 XX Sequence 99 AA;
 SQ

Query Match 100.0%; Score 517; DB 7; Length 99;
 Best Local Similarity 100.0%; Pred. No. 1.7e-42;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGNPNNGNTGY 60
 DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGNPNNGNTGY 60
 QY 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
 DB 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

RESULT 19
 AAR66302
 ID AAR66302 standard; protein; 117 AA.
 XX
 AC AAR66302;
 XX
 XX 25-MAR-2003 (revised)
 DT 02-AUG-1995 (first entry)
 XX
 XX Human immunoglobulin variable heavy chain #8.
 DE
 XX Primer; PCR; amplify; human; immunoglobulin; variable; heavy chain;
 KW cosmid; placenta; vector; pJB81; E.coli; mammalian.
 XX
 XX Homo sapiens.
 OS
 XX WO9426895-A1.
 PN
 XX 24-NOV-1994.
 PD
 XX 10-MAY-1993; 93WO-JP000603.
 PF
 XX 10-MAY-1993; 93WO-JP000603.
 PR
 XX (NIBS) JAPAN TOBACCO INC.
 XX
 XX Honjo T, Matsuda F;
 PI
 XX WPI; 1995-006791/01.
 DR N-PSDB; AAK78946.
 XX
 XX DNA fragment comprising human immunoglobulin Vh genes - for the
 PT production of human immunoglobulin in mammalian hosts.
 PT

XX
PS Claim 17; Page 41-42; 130pp; Japanese.
XX
CC Protein sequences (AAR66295-51) are novel human immunoglobulin heavy
chain sequences encoded by novel isolated genes. The genes (AAQ78939-
79002) were isolated and cloned from a series of cosmid constructs: Y202;
CC Y103; Y21; Y6; Y24; 3-31; M84; M18 and M11, by PCR amplification using
CC primers AAQ78917-38. The genes are subdivided into 5 families of Vh
CC genes. The fragments cover a region of 800 kb. The DNA fragments were
CC isolated from high molecular weight DNA from human placenta. The DNA was
CC partially digested with TaqI restriction enzyme. The fragments were
CC separated by gel electrophoresis and 35-45 kb fractions were collected.
CC The fragments were ligated with ClaI-digested cosmid vector pJB81. The
CC ligation products were in vitro packed and infected into E.coli 490A. The
CC fragments were then subcloned by colony hybridisation. The Vh genes and
CC the DNA fragments encoding them are useful in producing human
CC immunoglobulin in mammalian hosts. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 117 AA;
Query Match 100.0%; Score 517; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
DB 20 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 79
QY 61 AQKFGQVMTTRNTSISTAYMELSSLRSRSDTAVYYCAR 98
DB 80 AQKFGQVMTTRNTSISTAYMELSSLRSRSDTAVYYCAR 117
RESULT 20
ADK18614
ID ADK18614 standard; protein; 125 AA.
XX
AC ADK18614;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-human PDGF-D antibody heavy chain protein sequence.
XX
KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
PN WO2003057857-A2.
XX
PD 17-JUL-2003.
XX
PF 06-JAN-2003; 2003WO-US000398.
XX
PR 07-JAN-2002; 2002US-00041860.
XX
PA (ABGE-) ABGENIX INC.
XX
PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
DR WPI; 2003-587119/55.
XX
PT New human monoclonal antibody that binds to platelet-derived growth
factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
PS Disclosure; SEQ ID NO 38; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are

CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 125 AA;
Query Match 100.0%; Score 517; DB 7; Length 125;
Best Local Similarity 100.0%; Pred. No. 2.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
DB 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
QY 61 AQKFGQVMTTRNTSISTAYMELSSLRSRSDTAVYYCAR 98
DB 61 AQKFGQVMTTRNTSISTAYMELSSLRSRSDTAVYYCAR 98
RESULT 21
ADK18779
ID ADK18779 standard; protein; 125 AA.
XX
AC ADK18779;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-human PDGF-D antibody protein related sequence #5.
XX
KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
PN WO2003057857-A2.
XX
PD 17-JUL-2003.
XX
PF 06-JAN-2003; 2003WO-US000398.
XX
PR 07-JAN-2002; 2002US-00041860.
XX
PA (ABGE-) ABGENIX INC.
XX
PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
DR WPI; 2003-587119/55.
XX
PT New human monoclonal antibody that binds to platelet-derived growth
factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
PS Disclosure; SEQ ID NO 203; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 125 AA;
Query Match 100.0%; Score 517; DB 7; Length 125;
Best Local Similarity 100.0%; Pred. No. 2.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60

Qy 61 AQKFGQGRVTWTRNTSISTAYMELSSLSRSEDVAVYYCAR 98
Db 61 AQKFGQGRVTWTRNTSISTAYMELSSLSRSEDVAVYYCAR 98

RESULT 22
ADK18919
ID ADK18919 standard; protein; 125 AA.
AC
XX
XX ADK18919;
XX
XX 06-MAY-2004 (first entry)
XX
XX Anti-human PDGF-D antibody protein related sequence #145.
XX
XX antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
XX Homo sapiens.
XX
XX WO2003057857-A2.
XX
XX 17-JUL-2003.
XX
XX 06-JAN-2003; 2003WO-US000398.
XX
XX 07-JAN-2002; 2002US-00041860.
XX
XX (ABGE-) ABGENIX INC.
XX
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
XX Bezabeh B;
XX
XX WPI; 2003-587119/55.
XX
XX New human monoclonal antibody that binds to platelet-derived growth
XX factor-D (PDGF-D), useful for treating chronic and recurrent human
XX diseases, such as inflammation, autoimmunity and cancer.
XX
XX Disclosure; SEQ ID NO 343; 255pp; English.
XX
XX The invention relates to a human monoclonal antibody that binds to
XX platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
XX treating chronic and recurrent human diseases, such as inflammation,
XX autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
XX useful for modulating collagen formation, and for staging various
XX cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
XX generated using an active protein fragment of the gene product from the
XX clone 30664188.0.99 arising in the conditioned medium obtained when
XX HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
XX sequence corresponds to a protein used in the invention.
XX
XX Sequence 125 AA;
XX
XX Query Match 100.0%; Score 517; DB 7; Length 125;
XX Best Local Similarity 100.0%; Pred. No. 2.le-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
XX
XX 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
XX
XX 61 AQKFGQGRVTWTRNTSISTAYMELSSLSRSEDVAVYYCAR 98
XX
XX 61 AQKFGQGRVTWTRNTSISTAYMELSSLSRSEDVAVYYCAR 98

RESULT 23
ADK18816
```

```
ID ADK18816 standard; protein; 125 AA.
AC
XX ADK18816;
XX
XX 06-MAY-2004 (first entry)
XX
XX Anti-human PDGF-D antibody protein related sequence #42.
XX
XX antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
XX Homo sapiens.
XX
XX WO2003057857-A2.
XX
XX 17-JUL-2003.
XX
XX 06-JAN-2003; 2003WO-US000398.
XX
XX 07-JAN-2002; 2002US-00041860.
XX
XX (ABGE-) ABGENIX INC.
XX
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
XX Bezabeh B;
XX
XX WPI; 2003-587119/55.
XX
XX New human monoclonal antibody that binds to platelet-derived growth
XX factor-D (PDGF-D), useful for treating chronic and recurrent human
XX diseases, such as inflammation, autoimmunity and cancer.
XX
XX Disclosure; SEQ ID NO 240; 255pp; English.
XX
XX The invention relates to a human monoclonal antibody that binds to
XX platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
XX treating chronic and recurrent human diseases, such as inflammation,
XX autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
XX useful for modulating collagen formation, and for staging various
XX cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
XX generated using an active protein fragment of the gene product from the
XX clone 30664188.0.99 arising in the conditioned medium obtained when
XX HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
XX sequence corresponds to a protein used in the invention.
XX
XX Sequence 125 AA;
XX
XX Query Match 100.0%; Score 517; DB 7; Length 125;
XX Best Local Similarity 100.0%; Pred. No. 2.le-42;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
XX
XX 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
XX
XX 61 AQKFGQGRVTWTRNTSISTAYMELSSLSRSEDVAVYYCAR 98
XX
XX 61 AQKFGQGRVTWTRNTSISTAYMELSSLSRSEDVAVYYCAR 98

RESULT 24
ADL25444
ID ADL25444 standard; protein; 125 AA.
XX
XX ADL25444;
XX
XX 17-JUN-2004 (first entry)
XX
XX Human mAb 1.45 heavy chain variable region protein SEQ ID NO:54.
XX
XX antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
XX nephritis; mesangial cell proliferation inhibition;
XX mesangial proliferative glomerulonephritis; nephrotropic;
XX antiinflammatory; dermatological; immunosuppressive; antidiabetic;
```

KW gene therapy; human; monoclonal antibody; mAb.
XX Homo sapiens.
OS WO2004024098-A2.
XX
PN 25-MAR-2004.
XX
PD
XX
PF 16-SEP-2003; 2003WO-US029414.
XX
XX 16-SEP-2002; 2002US-0411137P.
XX
XX (ABGE-) ABGENIX INC.
PA (CURA-) CURAGEN CORP.
XX
XX Floege J, Gazit-Bornstein G, Keyt B, Larochele WJ, Lichenstein H;
XX WPI; 2004-269881/25.
XX N-PSDB; ADL25443.
DR
XX
XX Use of an antibody or its binding fragment that binds platelet derived
PT growth factor-DD (PDGF-DD) for preparing a medicament for treating
PT nephritis.
XX
XX Disclosure; SEQ ID NO 54; 115pp; English.
PS
XX The present invention describes an antibody or its binding fragment that
CC binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
CC useful in preparing a medicament for treating nephritis. Also described:
CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
CC of treating mesangial proliferative glomerulonephritis. The antibody has
CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
CC antidiabetic activities, and can be used in gene therapy. The antibody or
CC its binding fragment, that binds PDGF-DD, can be used in preparing a
CC medicament for treating nephritis and related disorders, e.g., mesangial
CC proliferative glomerulonephritis. The present sequence represents a human
CC monoclonal antibody (mAb) variable region sequence, which is used in the
CC exemplification of the present invention.
XX
XX Sequence 125 AA;
SQ
Query Match 100.0%; Score 517; DB 8; Length 125;
Best Local Similarity 100.0%; Pred. No. 2.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
DB 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
QY 61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98
RESULT 25
ADK18864
ID ADK18864 standard; protein; 126 AA.
XX
XX ADK18864;
XX
XX 06-MAY-2004 (first entry)
XX
XX Anti-human PDGF-D antibody protein related sequence #90.
XX
XX antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX Homo sapiens.
OS
XX WO2003057857-A2.
XX
XX 17-JUL-2003.
XX

PF 06-JAN-2003; 2003WO-US000398.
XX
XX 07-JAN-2002; 2002US-00041860.
XX
XX (ABGE-) ABGENIX INC.
XX
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
XX WPI; 2003-587119/55.
XX
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
XX Disclosure; SEQ ID NO 288; 255pp; English.
XX
XX The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HBK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
XX Sequence 126 AA;
SQ
Query Match 100.0%; Score 517; DB 7; Length 126;
Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
DB 1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
QY 61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98
DB 61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98
RESULT 26
ADK18597
ID ADK18597 standard; protein; 126 AA.
XX
XX ADK18597;
XX
XX 06-MAY-2004 (first entry)
XX
XX Anti-human PDGF-D antibody heavy chain protein sequence.
XX
XX antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX Homo sapiens.
OS
XX WO2003057857-A2.
XX
XX 17-JUL-2003.
XX
XX 06-JAN-2003; 2003WO-US000398.
XX
XX 07-JAN-2002; 2002US-00041860.
XX
XX (ABGE-) ABGENIX INC.
XX
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
XX WPI; 2003-587119/55.
XX
XX New human monoclonal antibody that binds to platelet-derived growth
PT

PT factor-D (PDGF-D), useful for treating chronic and recurrent human
XX diseases, such as inflammation, autoimmunity and cancer.
PS Disclosure; SEQ ID NO 21; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 126 AA;

Query Match 100.0%; Score 517; DB 7; Length 126;
Best Local Similarity 100.0%; Pred. NO. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60

Qy 61 AQKFGQGRVTWTRNTSISTAYMELSSLRSEDPAVYYCAR 98
Db 61 AQKFGQGRVTWTRNTSISTAYMELSSLRSEDPAVYYCAR 98

RESULT 27
ADK18870
ID ADK18870 standard; protein; 126 AA.
XX
AC ADK18870;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-human PDGF-D antibody protein related sequence #96.
XX
KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
PN W02003057857-A2.
XX
PD 17-JUL-2003.
XX
PF 06-JAN-2003; 2003WO-US000398.
XX
PR 07-JAN-2002; 2002US-00041860.
XX
PS (ABGE-) ABGENIX INC.
XX
PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
DR WPI; 2003-587119/55.
XX
XX New human monoclonal antibody that binds to platelet-derived growth
XX factor-D (PDGF-D), useful for treating chronic and recurrent human
XX diseases, such as inflammation, autoimmunity and cancer.
XX
PS Disclosure; SEQ ID NO 294; 255pp; English.
XX
XX The invention relates to a human monoclonal antibody that binds to
XX platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
XX treating chronic and recurrent human diseases, such as inflammation,
XX autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
XX useful for modulating collagen formation, and for staging various
XX cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
XX generated using an active protein fragment of the gene product from the

CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 126 AA;

Query Match 100.0%; Score 517; DB 7; Length 126;
Best Local Similarity 100.0%; Pred. NO. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60

Qy 61 AQKFGQGRVTWTRNTSISTAYMELSSLRSEDPAVYYCAR 98
Db 61 AQKFGQGRVTWTRNTSISTAYMELSSLRSEDPAVYYCAR 98

RESULT 28
ADK18595
ID ADK18595 standard; protein; 126 AA.
XX
AC ADK18595;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-human PDGF-D antibody heavy chain protein sequence.
XX
KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
PN W02003057857-A2.
XX
PD 17-JUL-2003.
XX
PF 06-JAN-2003; 2003WO-US000398.
XX
PR 07-JAN-2002; 2002US-00041860.
XX
PS (ABGE-) ABGENIX INC.
XX
PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX
DR WPI; 2003-587119/55.
XX
XX New human monoclonal antibody that binds to platelet-derived growth
XX factor-D (PDGF-D), useful for treating chronic and recurrent human
XX diseases, such as inflammation, autoimmunity and cancer.
XX
PS Disclosure; SEQ ID NO 19; 255pp; English.
XX
XX The invention relates to a human monoclonal antibody that binds to
XX platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
XX treating chronic and recurrent human diseases, such as inflammation,
XX autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
XX useful for modulating collagen formation, and for staging various
XX cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
XX generated using an active protein fragment of the gene product from the
XX clone 30664188.0.99 arising in the conditioned medium obtained when
XX HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
XX sequence corresponds to a protein used in the invention.
XX
SQ Sequence 126 AA;

Query Match 100.0%; Score 517; DB 7; Length 126;
Best Local Similarity 100.0%; Pred. NO. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60

```
Db      1 QVOLVSGAEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
QY      61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
      |||
Db      61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
      |||

RESULT 29
ADK18812
ID      ADK18812 standard; protein; 126 AA.
XX
AC      ADK18812;
XX
DT      06-MAY-2004 (first entry)
XX
DE      Anti-human PDGF-D antibody protein related sequence #38.
XX
KW      antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS      Homo sapiens.
XX
PN      WO2003057857-A2.
XX
PD      17-JUL-2003.
XX
PF      06-JAN-2003; 2003WO-US000398.
XX
PR      07-JAN-2002; 2002US-00041860.
XX
PS      (ABGE-) ABGENIX INC.
XX
PI      Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI      Bezabeh B;
XX
DR      WPI; 2003-587119/55.
XX
PT      New human monoclonal antibody that binds to platelet-derived growth
PT      factor-D (PDGF-D), useful for treating chronic and recurrent human
PT      diseases, such as inflammation, autoimmunity and cancer.
XX
PS      Disclosure; SEQ ID NO 236; 255pp; English.
XX
CC      The invention relates to a human monoclonal antibody that binds to
CC      platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC      treating chronic and recurrent human diseases, such as inflammation,
CC      autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC      useful for modulating collagen formation, and for staging various
CC      cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC      generated using an active protein fragment of the gene product from the
CC      clone 30664188.0.99 arising in the conditioned medium obtained when
CC      HBK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC      sequence corresponds to a protein used in the invention.
XX
SQ      Sequence 126 AA;

Query Match      100.0%; Score 517; DB 7; Length 126;
Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVOLVSGAEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
      |||
Db      1 QVOLVSGAEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
      |||

QY      61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
      |||
Db      61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
      |||

RESULT 30
ADK18777
ID      ADK18777 standard; protein; 126 AA.
XX
AC      ADK18777;
XX
```

```
XX      06-MAY-2004 (first entry)
DT
DE      Anti-human PDGF-D antibody protein related sequence #3.
XX
KW      antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS      Homo sapiens.
XX
PN      WO2003057857-A2.
XX
PD      17-JUL-2003.
XX
PF      06-JAN-2003; 2003WO-US000398.
XX
PR      07-JAN-2002; 2002US-00041860.
XX
PS      (ABGE-) ABGENIX INC.
XX
PI      Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI      Bezabeh B;
XX
DR      WPI; 2003-587119/55.
XX
PT      New human monoclonal antibody that binds to platelet-derived growth
PT      factor-D (PDGF-D), useful for treating chronic and recurrent human
PT      diseases, such as inflammation, autoimmunity and cancer.
XX
PS      Disclosure; SEQ ID NO 201; 255pp; English.
XX
CC      The invention relates to a human monoclonal antibody that binds to
CC      platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC      treating chronic and recurrent human diseases, such as inflammation,
CC      autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC      useful for modulating collagen formation, and for staging various
CC      cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC      generated using an active protein fragment of the gene product from the
CC      clone 30664188.0.99 arising in the conditioned medium obtained when
CC      HBK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC      sequence corresponds to a protein used in the invention.
XX
SQ      Sequence 126 AA;

Query Match      100.0%; Score 517; DB 7; Length 126;
Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVOLVSGAEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
      |||
Db      1 QVOLVSGAEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
      |||

QY      61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
      |||
Db      61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
      |||

RESULT 31
ADK18775
ID      ADK18775 standard; protein; 126 AA.
XX
AC      ADK18775;
XX
DT      06-MAY-2004 (first entry)
XX
DE      Anti-human PDGF-D antibody protein related sequence #1.
XX
KW      antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS      Homo sapiens.
XX
PN      WO2003057857-A2.
XX
PD      17-JUL-2003.
```

```
XX 06-JAN-2003; 2003WO-US000398.
XX PF
XX XX
XX 07-JAN-2002; 2002US-00041860.
XX PR
XX XX
XX (ABGE-) ABGENIX INC.
XX PA
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
XX PI Bezabeh B;
XX PI
XX XX
XX WPI; 2003-587119/55.
XX DR
XX XX
XX New human monoclonal antibody that binds to platelet-derived growth
XX PT factor-D (PDGF-D), useful for treating chronic and recurrent human
XX PT diseases, such as inflammation, autoimmunity and cancer.
XX PT
XX XX
XX Disclosure; SEQ ID NO 199; 255pp; English.
XX PS
XX CC The invention relates to a human monoclonal antibody that binds to
XX CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
XX CC treating chronic and recurrent human diseases, such as inflammation,
XX CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
XX CC useful for modulating collagen formation, and for staging various
XX CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
XX CC generated using an active protein fragment of the gene product from the
XX CC clone 30664188.0.99 arising in the conditioned medium obtained when
XX CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
XX CC sequence corresponds to a protein used in the invention.
XX CC
XX SQ Sequence 126 AA;
XX
Query Match 100.0%; Score 517; DB 7; Length 126;
Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
QY 61 AQKFGQVTRMTNTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFGQVTRMTNTSISTAYMELSSLRSSEDTAVYYCAR 98
RESULT 32
ADL25408
ID ADL25408 standard; protein; 126 AA.
XX AC
XX ADL25408;
XX DT
XX 17-JUN-2004 (first entry)
XX XX
XX Human mAb 1.18 heavy chain variable region protein SEQ ID NO:18.
XX DE
XX antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
XX KW nephritis; mesangial cell proliferation inhibition;
XX KW mesangial proliferative glomerulonephritis; nephrotropic;
XX KW antiinflammatory; dermatological; immunosuppressive; antidiabetic;
XX KW gene therapy; human; monoclonal antibody; mAb.
XX OS Homo sapiens.
XX XX
XX WO2004024098-A2.
XX PN
XX 25-MAR-2004.
XX PD
XX 16-SEP-2003; 2003WO-US029414.
XX PF
XX 25-MAR-2004.
XX PR
XX 16-SEP-2003; 2003WO-US029414.
XX PP
XX (ABGE-) ABGENIX INC.
XX PA
XX (CURA-) CURAGEN CORP.
XX XX
XX Floege J, Gazit-Bornstein G, Keyt B, Larochelle WJ, Lichenstein H;
XX PI WPI; 2004-269881/25.
XX DR N-PSDB; ADL25411.
XX DR
```

```
PI Floege J, Gazit-Bornstein G, Keyt B, Larochelle WJ, Lichenstein H;
XX WPI; 2004-269881/25.
XX DR N-PSDB; ADL25407.
XX
XX Use of an antibody or its binding fragment that binds platelet derived
XX PT growth factor-DD (PDGF-DD) for preparing a medicament for treating
XX PT nephritis.
XX PT
XX XX
XX Disclosure; SEQ ID NO 18; 115pp; English.
XX PS
XX CC The present invention describes an antibody or its binding fragment that
XX CC binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
XX CC useful in preparing a medicament for treating nephritis. Also described:
XX CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
XX CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
XX CC of treating mesangial proliferative glomerulonephritis. The antibody has
XX CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
XX CC antidiabetic activities, and can be used in gene therapy. The antibody or
XX CC its binding fragment, that binds PDGF-DD, can be used in preparing a
XX CC medicament for treating nephritis and related disorders, e.g., mesangial
XX CC proliferative glomerulonephritis. The present sequence represents a human
XX CC monoclonal antibody (mAb) variable region sequence, which is used in the
XX CC exemplification of the present invention.
XX CC
XX SQ Sequence 126 AA;
XX
Query Match 100.0%; Score 517; DB 8; Length 126;
Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60
QY 61 AQKFGQVTRMTNTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFGQVTRMTNTSISTAYMELSSLRSSEDTAVYYCAR 98
RESULT 33
ADL25412
ID ADL25412 standard; protein; 126 AA.
XX AC
XX ADL25412;
XX DT
XX 17-JUN-2004 (first entry)
XX XX
XX Human mAb 1.19 heavy chain variable region protein SEQ ID NO:22.
XX DE
XX antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
XX KW nephritis; mesangial cell proliferation inhibition;
XX KW mesangial proliferative glomerulonephritis; nephrotropic;
XX KW antiinflammatory; dermatological; immunosuppressive; antidiabetic;
XX KW gene therapy; human; monoclonal antibody; mAb.
XX OS Homo sapiens.
XX XX
XX WO2004024098-A2.
XX PN
XX 25-MAR-2004.
XX PD
XX 16-SEP-2003; 2003WO-US029414.
XX PF
XX 16-SEP-2002; 2002US-0411137P.
XX PR
XX (ABGE-) ABGENIX INC.
XX PA
XX (CURA-) CURAGEN CORP.
XX XX
XX Floege J, Gazit-Bornstein G, Keyt B, Larochelle WJ, Lichenstein H;
XX PI WPI; 2004-269881/25.
XX DR N-PSDB; ADL25411.
XX DR
```

XX Use of an antibody or its binding fragment that binds platelet derived
PT growth factor-DD (PDGF-DD) for preparing a medicament for treating
PT nephritis.
XX Disclosure; SEQ ID NO 22; 115pp; English.
XX
XX The present invention describes an antibody or its binding fragment that
CC binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
CC useful in preparing a medicament for treating nephritis. Also described:
CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
CC of treating mesangial proliferative glomerulonephritis. The antibody has
CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
CC antidiabetic activities, and can be used in gene therapy. The antibody or
CC its binding fragment, that binds PDGF-DD, can be used in preparing a
CC medicament for treating nephritis and related disorders, e.g., mesangial
CC proliferative glomerulonephritis. The present sequence represents a human
CC monoclonal antibody (mAb) variable region sequence, which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 126 AA;

Query Match 100.0%; Score 517; DB 8; Length 126;
Best Local Similarity 100.0%; Pred. No. 2.2e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
QY 61 AOKFQGRVTMTNTSISTAYMELSSLRSEDATVYYCAR 98
Db 61 AOKFQGRVTMTNTSISTAYMELSSLRSEDATVYYCAR 98

Search completed: May 12, 2006, 02:22:26
Job time : 121.333 secs

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 02:16:41 ; Search time 58 Seconds
(without alignments)
705.987 Million cell updates/sec

Title: US-09-674-752-31

Perfect score: 517

Sequence: 1 QVOLVQSGAEVKKPGASVKV.....AYMELSSLRSEDYAVYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications_AA_Main:*
1: /cgn2_6/prodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/prodata/1/pubpaa/US08_PUBCOMB.pep:*
3: /cgn2_6/prodata/1/pubpaa/US09_PUBCOMB.pep:*
4: /cgn2_6/prodata/1/pubpaa/US10A_PUBCOMB.pep:*
5: /cgn2_6/prodata/1/pubpaa/US10B_PUBCOMB.pep:*
6: /cgn2_6/prodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	517	100.0	98	4	US-10-041-860-289
2	517	100.0	98	4	US-10-041-860-290
3	517	100.0	98	4	US-10-041-860-295
4	517	100.0	98	4	US-10-041-860-296
5	517	100.0	98	4	US-10-041-860-342
6	517	100.0	98	4	US-10-041-860-344
7	517	100.0	98	4	US-10-041-860-348
8	517	100.0	98	4	US-10-041-860-361
9	517	100.0	98	4	US-10-032-037B-45
10	517	100.0	98	4	US-10-029-988B-45
11	517	100.0	98	4	US-10-032-423A-45
12	517	100.0	98	4	US-10-029-926B-45
13	517	100.0	98	4	US-10-379-392-3
14	517	100.0	99	4	US-10-041-860-1
15	517	100.0	125	4	US-10-041-860-38
16	517	100.0	125	4	US-10-041-860-203
17	517	100.0	125	4	US-10-041-860-240
18	517	100.0	125	4	US-10-041-860-343
19	517	100.0	125	4	US-10-041-860-354
20	517	100.0	126	4	US-10-041-860-19
21	517	100.0	126	4	US-10-041-860-21
22	517	100.0	126	4	US-10-041-860-199
23	517	100.0	126	4	US-10-041-860-201
24	517	100.0	126	4	US-10-041-860-236
25	517	100.0	126	4	US-10-041-860-288
26	517	100.0	126	4	US-10-041-860-294
27	517	100.0	126	4	US-10-041-860-294

28	517	100.0	126	4	US-10-665-383-22	Sequence 22, Appl
29	514	99.4	122	4	US-10-269-805-61	Sequence 61, Appl
30	513	99.2	98	4	US-10-041-860-350	Sequence 350, App
31	512	99.0	126	4	US-10-041-860-37	Sequence 37, Appl
32	512	99.0	126	4	US-10-041-860-202	Sequence 202, App
33	512	99.0	126	4	US-10-041-860-239	Sequence 239, App
34	512	99.0	126	4	US-10-665-383-74	Sequence 74, Appl
35	510	98.6	126	4	US-10-041-860-40	Sequence 40, Appl
36	510	98.6	126	4	US-10-041-860-204	Sequence 204, App
37	510	98.6	126	4	US-10-041-860-241	Sequence 241, App
38	510	98.6	126	4	US-10-041-860-349	Sequence 349, App
39	510	98.6	126	4	US-10-665-383-58	Sequence 58, Appl
40	508	98.3	96	4	US-10-194-975-3	Sequence 3, Appl
41	508	98.3	98	4	US-10-308-817-43	Sequence 43, Appl
42	508	98.3	98	4	US-10-453-698-43	Sequence 43, Appl
43	508	98.3	127	4	US-10-041-860-44	Sequence 44, Appl
44	508	98.3	127	4	US-10-041-860-205	Sequence 205, App
45	508	98.3	127	4	US-10-041-860-242	Sequence 242, App

ALIGNMENTS

RESULT 1
US-10-041-860-289
; Sequence 289, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezaheh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 289
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-289

Query Match 100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYDINNVRQATCGGLEWGMGNPNSGNTGY 60
DB 1 QVOLVQSGAEVKKPGASVKVSKASGYTFTSYDINNVRQATCGGLEWGMGNPNSGNTGY 60

QY 61 AQKFGQVRVTMTNTSISTAYMELSSLRSEDYAVYCAR 98
DB 61 AQKFGQVRVTMTNTSISTAYMELSSLRSEDYAVYCAR 98

RESULT 2
US-10-041-860-290
; Sequence 290, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi

```
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 290
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-290

Query Match      100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
Db 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60

Qy 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
Db 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98

RESULT 3
US-10-041-860-295
; Sequence 295, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 295
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-295

Query Match      100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
Db 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60

Qy 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
Db 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98

RESULT 4
US-10-041-860-296
; Sequence 296, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 296
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-296

Query Match      100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
Db 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60

Qy 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
Db 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98

RESULT 5
US-10-041-860-342
; Sequence 342, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 342
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-342

Query Match      100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
Db 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60

Qy 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
Db 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98

RESULT 6
US-10-041-860-296
; Sequence 296, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 296
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-296

Query Match      100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
Db 1 QVOLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60

Qy 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
Db 61 AQKFGQGRVTMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
```

US-10-041-860-344
; Sequence 344, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: AGENIX.051A
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 344
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-344

Query Match 100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60

Qy 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 7
US-10-041-860-348
; Sequence 348, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: AGENIX.051A
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 348
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-348

Query Match 100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60

Qy 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSEDTAVYYCAR 98

Db 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 8
US-10-041-860-361
; Sequence 361, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: AGENIX.051A
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 361
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-361

Query Match 100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60

Qy 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 9
US-10-032-037B-45
; Sequence 45, Application US/10032037B
; Publication No. US20040001822A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/44
; CURRENT APPLICATION NUMBER: US/10/032,037B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 45
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-45

Query Match 100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNGTGY 60

Qy 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSEDTAVYYCAR 98

```
Db      61 AQKQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
|||||
RESULT 10
US-10-029-988B-45
; Sequence 45, Application US/10029988B
; Publication No. US20040001839A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; TITLE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029,988B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 45
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-45

Query Match      100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGGLEWMGMNPNNGNTGY 60
|||||
Db      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGGLEWMGMNPNNGNTGY 60
|||||
QY      61 AQKQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
|||||
Db      61 AQKQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
|||||
RESULT 11
US-10-032-423A-45
; Sequence 45, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; TITLE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 45
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-45

Query Match      100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGGLEWMGMNPNNGNTGY 60
|||||
Db      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGGLEWMGMNPNNGNTGY 60
|||||
QY      61 AQKQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
|||||
Db      61 AQKQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
|||||
RESULT 12
US-10-041-860-1
; Sequence 1, Application US/10041860
```

```
US-10-029-926B-45
; Sequence 45, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; FILE REFERENCE: 10793/50
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 45
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-45

Query Match      100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGGLEWMGMNPNNGNTGY 60
|||||
Db      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGGLEWMGMNPNNGNTGY 60
|||||
QY      61 AQKQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
|||||
Db      61 AQKQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
|||||
RESULT 13
US-10-379-392-3
; Sequence 3, Application US/10379392
; Publication No. US20040110226A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John Rudolf
; APPLICANT: Marshall, Shannon Alicia
; APPLICANT: Dahiyat, Basil I.
; TITLE OF INVENTION: ANTIBODY OPTIMIZATION
; FILE REFERENCE: A-71386-3 463077-236
; CURRENT APPLICATION NUMBER: US/10/379,392
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/360,843
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 60/384,197
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-379-392-3

Query Match      100.0%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGGLEWMGMNPNNGNTGY 60
|||||
Db      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGGLEWMGMNPNNGNTGY 60
|||||
QY      61 AQKQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
|||||
Db      61 AQKQGRVTMTNTSISTAYMELSLRSEDATVYYCAR 98
|||||
RESULT 14
US-10-041-860-1
; Sequence 1, Application US/10041860
```

```
Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 99
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-1

Query Match      100.0%; Score 517; DB 4; Length 99;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60

Qy 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

RESULT 15
US-10-041-860-38
; Sequence 38, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 38
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-38

Query Match      100.0%; Score 517; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 4.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60

Qy 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 99
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-1

Query Match      100.0%; Score 517; DB 4; Length 99;
Best Local Similarity 100.0%; Pred. No. 3.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60

Qy 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

RESULT 16
US-10-041-860-203
; Sequence 203, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 203
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-203

Query Match      100.0%; Score 517; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 4.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60

Qy 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

RESULT 17
US-10-041-860-240
; Sequence 240, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 240
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-240

Query Match      100.0%; Score 517; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 4.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60

Qy 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
```

```
RESULT 16
US-10-041-860-203
; Sequence 203, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 203
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-203

Query Match      100.0%; Score 517; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 4.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60

Qy 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

RESULT 17
US-10-041-860-240
; Sequence 240, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 240
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-240

Query Match      100.0%; Score 517; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 4.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGNPNPNSGNTGY 60

Qy 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
```

```
Db      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
QY      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
      |||
Db      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
      |||

RESULT 18
US-10-041-860-343
; Sequence 54, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 343
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-343

Query Match      100.0%; Score 517; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 4.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
Db      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
      |||

QY      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
Db      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
      |||

RESULT 19
US-10-665-383-54
; Sequence 54, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: Larocheille, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; TITLE OF INVENTION: USING ANTI-PDGF-DD ANTIBODIES
; FILE REFERENCE: ABGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665,383
; CURRENT FILING DATE: 2003-09-16
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 54
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-54

Query Match      100.0%; Score 517; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 4.7e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
Db      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
      |||

QY      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
Db      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
      |||

RESULT 20
US-10-041-860-19
; Sequence 19, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-19

Query Match      100.0%; Score 517; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 4.8e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
Db      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
      |||

QY      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
Db      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
      |||

RESULT 21
US-10-041-860-21
; Sequence 21, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 126
; TYPE: PRT
US-10-041-860-21
```

```
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
      |||
Db      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
      |||

QY      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
Db      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
      |||

RESULT 22
US-10-041-860-19
; Sequence 19, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-19

Query Match      100.0%; Score 517; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 4.8e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
Db      1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNPNSGNTGY 60
      |||

QY      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
Db      61 AQKQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
      |||

RESULT 23
US-10-041-860-21
; Sequence 21, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 126
; TYPE: PRT
US-10-041-860-21
```

```
; ORGANISM: homo sapiens
US-10-041-860-21

Query Match      100.0%; Score 517; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 4.8e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60

Qy 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

RESULT 22
US-10-041-860-199
; Sequence 199, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 199
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-199

Query Match      100.0%; Score 517; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 4.8e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60

Qy 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

RESULT 23
US-10-041-860-201
; Sequence 201, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
```

```
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 201
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-201

Query Match      100.0%; Score 517; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 4.8e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60

Qy 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

RESULT 24
US-10-041-860-236
; Sequence 236, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 236
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-236

Query Match      100.0%; Score 517; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 4.8e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60

Qy 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98
Db 61 AQKFGQGRVTMTNRTSISTAYMELSSLRSSEDTAVYYCAR 98

RESULT 25
US-10-041-860-288
; Sequence 288, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
```

; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 288
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-288

Query Match 100.0%; Score 517; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 4.8e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNSGNTGY 60

Qy 61 AQKFGQRTVMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
Db 61 AQKFGQRTVMTNTSISTAYMELSSLSRSEDYAVYYCAR 98

RESULT 26
US-10-041-860-294
; Sequence 294, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 294
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-294

Query Match 100.0%; Score 517; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 4.8e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNSGNTGY 60

Qy 61 AQKFGQRTVMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
Db 61 AQKFGQRTVMTNTSISTAYMELSSLSRSEDYAVYYCAR 98

RESULT 27
US-10-665-383-18
; Sequence 18, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce

; APPLICANT: LaRochele, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; TITLE OF INVENTION: USING ANTI-PDGF-DD ANTIBODIES
; FILE REFERENCE: ABGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665,383
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/411,137
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-18

Query Match 100.0%; Score 517; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 4.8e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNSGNTGY 60

Qy 61 AQKFGQRTVMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
Db 61 AQKFGQRTVMTNTSISTAYMELSSLSRSEDYAVYYCAR 98

RESULT 28
US-10-665-383-22
; Sequence 22, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: LaRochele, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; TITLE OF INVENTION: USING ANTI-PDGF-DD ANTIBODIES
; FILE REFERENCE: ABGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665,383
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/411,137
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-22

Query Match 100.0%; Score 517; DB 4; Length 126;
Best Local Similarity 100.0%; Pred. No. 4.8e-43;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATGQGLEWMGMNPNNSGNTGY 60

Qy 61 AQKFGQRTVMTNTSISTAYMELSSLSRSEDYAVYYCAR 98
Db 61 AQKFGQRTVMTNTSISTAYMELSSLSRSEDYAVYYCAR 98

RESULT 29
US-10-269-805-61
; Sequence 61, Application US/10269805
; Publication No. US20030124129A1
; GENERAL INFORMATION:


```
; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 61
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-041-860-61

Query Match          99.4%; Score 514; DB 4; Length 122;
Best Local Similarity 99.0%; Pred. No. 9.1e-43;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|

Qy 61 AQKFQGRVTMTNRTSISTAYMELSLRSSEDTAVYYCAR 98
|
Db 61 AQKFQGRVTMTNRTSISTAYMELSLRSSEDTAVYYCAR 98
|

RESULT 30
US-10-041-860-350
; Sequence 350, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ARGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 350
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 55
; OTHER INFORMATION: Xaa = Any Amino Acid
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 55
; OTHER INFORMATION: Xaa = Any Amino Acid
; US-10-041-860-350

Query Match          99.2%; Score 513; DB 4; Length 98;
Best Local Similarity 99.0%; Pred. No. 9.1e-43;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|

Qy 61 AQKFQGRVTMTNRTSISTAYMELSLRSSEDTAVYYCAR 98
|
Db 61 AQKFQGRVTMTNRTSISTAYMELSLRSSEDTAVYYCAR 98
|

; APPLICANT: OLINER, JONATHAN D.
; TITLE OF INVENTION: ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS
; FILE REFERENCE: A-722
; CURRENT APPLICATION NUMBER: US/10/269,805
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/328,604
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 61
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-041-860-61

Query Match          99.4%; Score 514; DB 4; Length 122;
Best Local Similarity 99.0%; Pred. No. 9.1e-43;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|

Qy 61 AQKFQGRVTMTNRTSISTAYMELSLRSSEDTAVYYCAR 98
|
Db 61 AQKFQGRVTMTNRTSISTAYMELSLRSSEDTAVYYCAR 98
|

RESULT 30
US-10-041-860-350
; Sequence 350, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ARGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 350
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 55
; OTHER INFORMATION: Xaa = Any Amino Acid
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 55
; OTHER INFORMATION: Xaa = Any Amino Acid
; US-10-041-860-350

Query Match          99.2%; Score 513; DB 4; Length 98;
Best Local Similarity 99.0%; Pred. No. 9.1e-43;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|

Qy 61 AQKFQGRVTMTNRTSISTAYMELSLRSSEDTAVYYCAR 98
|
Db 61 AQKFQGRVTMTNRTSISTAYMELSLRSSEDTAVYYCAR 98
|
```

```
RESULT 31
US-10-041-860-37
; Sequence 37, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ARGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 37
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
; US-10-041-860-37

Query Match          99.0%; Score 512; DB 4; Length 126;
Best Local Similarity 98.0%; Pred. No. 1.5e-42;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|

Qy 61 AQKFQGRVTMTNRTSISTAYMELSLRSSEDTAVYYCAR 98
|
Db 61 AQKFQGRVTMTNRTSISTAYMELSLRSSEDTAVYYCAR 98
|

RESULT 32
US-10-041-860-202
; Sequence 202, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ARGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 202
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
; US-10-041-860-202

Query Match          99.0%; Score 512; DB 4; Length 126;
Best Local Similarity 98.0%; Pred. No. 1.5e-42;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTSYDINWVRQATGQGLEWMGWNPNPNSGNTGY 60
|
```

Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFITYDINWVRQATGQGLEWMGWMNPNSGNTGY 60

Qy 61 AQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
|||||:|||||

Db 61 AQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
|||||:|||||

RESULT 33

US-10-041-860-239

; Sequence 239, Application US/10041860

; Publication No. US20030157109A1

; GENERAL INFORMATION:

; APPLICANT: Corvalan, Jose R.F.

; APPLICANT: Jia, Xiao-Chi

; APPLICANT: Feng, Xiao

; APPLICANT: Yang, Xiao-Dong

; APPLICANT: Chen, Francine

; APPLICANT: Gazit, Gadi

; APPLICANT: Weber, Richard

; APPLICANT: Bezabeh, Binyam

; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES

; FILE OF INVENTION: THEREOF

; FILE REFERENCE: AGENIX.051A

; CURRENT APPLICATION NUMBER: US/10/041.860

; CURRENT FILING DATE: 2002-01-07

; NUMBER OF SEQ ID NOS: 377

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 239

; LENGTH: 126

; TYPE: PRT

; ORGANISM: homo sapiens

US-10-041-860-239

Query Match 99.0%; Score 512; DB 4; Length 126;

Best Local Similarity 98.0%; Pred. No. 1.5e-42;

Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVCKASGYTFITYDINWVRQATGQGLEWMGWMNPNSGNTGY 60
|||||:|||||

Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFITYDINWVRQATGQGLEWMGWMNPNSGNTGY 60
|||||:|||||

Qy 61 AQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
|||||:|||||

Db 61 AQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
|||||:|||||

Search completed: May 12, 2006, 02:25:17

Job time : 59 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:58 ; Search time 38.8199 Seconds
(without alignments)
1781.089 Million cell updates/sec

Title: US-09-674-752-31
Perfect score: 517
Sequence: 1 QVQLVSGAEVKKPKGASVKV.....AYMELSLRSEDYAVYYCAR 98

Scoring table:
BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_05.80.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	445	86.1	125	Q9UL95_HUMAN	Q9ul95 homo sapien
2	441	85.3	119	Q9UL94_HUMAN	Q9ul94 homo sapien
3	437	84.5	117	HV1B_HUMAN	P01743 homo sapien
4	437	84.5	117	HV1G_HUMAN	P23083 homo sapien
5	432	83.6	124	Q9UL92_HUMAN	Q9ul92 homo sapien
6	422	81.6	244	Q6SZC8_HUMAN	Q6szc8 homo sapien
7	418	80.9	497	Q8WY24_HUMAN	Q8wy24 homo sapien
8	410	79.3	159	Q96Q50_HUMAN	Q96q50 homo sapien
9	408	78.9	498	Q6N041_HUMAN	Q6n041 homo sapien
10	407	78.7	518	Q6N030_HUMAN	Q6n030 homo sapien
11	401	77.6	500	Q6N091_HUMAN	Q6n091 homo sapien
12	397	76.8	147	HVIC_HUMAN	P01744 homo sapien
13	391	75.6	469	Q7Z7P5_HUMAN	Q7z7p5 homo sapien
14	390	75.4	500	Q9BRV0_HUMAN	Q9brv0 homo sapien
15	389	75.2	120	Q6NSA4_HUMAN	Q6nsa4 homo sapien
16	384	74.3	119	Q9GYZ2_HUMAN	Q9gyz2 homo sapien
17	379	73.3	157	Q95978_HUMAN	Q95978 mus musculus
18	376	72.7	480	Q6P089_HUMAN	Q6p089 homo sapien
19	375	72.5	458	Q5BJZ2_RAT	Q5bjz2 rattus norv
20	374	72.3	475	Q6N095_HUMAN	Q6n095 homo sapien
21	371	71.8	519	Q5EBM2_HUMAN	Q5ebm2 homo sapien
22	370	71.6	116	Q9UL89_HUMAN	Q9ul89 homo sapien
23	368	71.2	117	HV52_MOUSE	P06327 mus musculus
24	368	71.2	125	Q6PIL0_HUMAN	Q6pil0 homo sapien
25	363	70.2	150	Q9Y298_HUMAN	Q9y298 homo sapien
26	362	70.0	473	Q9D8L4_MOUSE	Q9d8l4 mus musculus
27	361	69.8	463	Q91LC4_MOUSE	Q91lc4 mus musculus
28	360	69.6	117	HV1A_HUMAN	P01742 homo sapien
29	360	69.6	617	Q4KML5_MOUSE	Q4kml5 mus musculus
30	359	69.4	591	Q4QQW0_RAT	Q4qqw0 rattus norv
31	357	69.1	481	Q91WT1_MOUSE	Q91wt1 mus musculus

32	355	68.7	458	2	Q5BK05_RAT	Q5bk05 rattus norv
33	353	68.3	590	2	Q4V9V8_MOUSE	Q4v9v8 mus musculus
34	353	68.3	613	2	Q8VCX7_MOUSE	Q8vcx7 mus musculus
35	352	68.1	616	2	Q504M7_MOUSE	Q504m7 mus musculus
36	351	67.9	147	2	Q925S3_MOUSE	Q925s3 mus musculus
37	350	67.7	117	1	HV09_MOUSE	P01753 mus musculus
38	350	67.7	117	1	HV14_MOUSE	P01758 mus musculus
39	350	67.7	208	2	Q6ZP87_HUMAN	Q6zpb87 homo sapien
40	350	67.7	470	2	Q7TMK1_MOUSE	Q7tmk1 mus musculus
41	348	67.3	475	2	Q5FVP3_RAT	Q5fvp3 rattus norv
42	347	67.1	134	2	Q65ZK6_MOUSE	Q65zk6 mus musculus
43	347	67.1	142	2	Q924Q1_MOUSE	Q924q1 mus musculus
44	346	66.9	117	1	HV12_MOUSE	P01756 mus musculus
45	346	66.9	117	1	HV13_MOUSE	P01757 mus musculus

ALIGNMENTS

RESULT 1
Q9UL95_HUMAN
ID Q9UL95_HUMAN PRELIMINARY; PRT; 125 AA.
AC Q9UL95_HUMAN
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
DE OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=982771139; PubMed=9614934; DOI=10.1006/clin.1998.4531; Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Barney S.M., Young D.C.;
RA "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus."
RT Clin. Immunol. Immunopathol. 87:184-192(1998).
RL EMBL; AF035019; AAD56255.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IG; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 125
SQ SEQUENCE 125 AA; 13516 MW; 0D3CD5C32488EAC CRC64;

Query Match 86.1%; Score 445; DB 2; Length 125;
Best Local Similarity 84.7%; Pred. No. 8.8e-40;
Matches 83; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

Qy	1	QVQLVSGAEVKKPKGASVKSCASGVFTFTSYDINVRQATGQGLEWMGMPNNSGNTGY	60
Db	1	EVQLVSGAEVKKPKGASVKSCASGVFTFTGYTHHWVRQAPGQGLEWMGMPNNSGNTNY	60
Qy	61	AQKQGRVTMTRTNISTATYMELSLRSEDYAVYYCAR	98
Db	61	AQKQGRVTMTRTNISTATYMELSLRSDYAVYYCAR	98

RESULT 2
Q9UL94_HUMAN
ID Q9UL94_HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL94_HUMAN
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region

```
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]_SEQUENCE
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clim.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Bernay S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035020; AAD56256.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-Like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 119
FT NON_TER 119
SQ SEQUENCE 119 AA; 13205 MW; 13E64F5345F4A16E CRC64;

Query Match 85.3%; Score 441; DB 2; Length 119;
Best Local Similarity 83.7%; Pred. No. 2.2e-39;
Matches 82; Conservative 9; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFSTYDINVRQATGQGLEWMGMNPNSGNTGY 60
DB 1 EVQLVSGAEVKKPGASVKVSCKASGYTFSTYDINVRQATGQGLEWMGMNPNSGNTGY 60

QY 61 AQKFGQRTVMTNTSISTAYMELSLRLSDDTAVYYCAR 98
DB 61 AQKFGQRTVMTNTSISTAYMELSLRLSDDTAVYYCAR 98

RESULT 3
HVLB_HUMAN STANDARD; PRT; 117 AA.
ID P01743;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region HG3 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=83144028; PubMed=6298778;
RA Rechavi G., Ram D., Glazer L., Zakut R., Givol D.;
RT "Evolutionary aspects of immunoglobulin heavy chain variable region
RT (VH) gene subgroups.";
RL Proc. Natl. Acad. Sci. U.S.A. 80:855-859(1983).
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; J00240; AAAS2988.1; -; Genomic_DNA.
DR F1R; A02024; HVHUNG.
DR HSSP; P01751; INQB.
DR SMR; P01743; 20-116.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0009555; P:immune response; NAS.
```

```
DR InterPro; IPR007110; Ig-Like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region HG3.
FT DOMAIN 20 >117 Ig-Like.
FT NON_TER 117
FT NON_TER 117
SQ SEQUENCE 117 AA; 12946 MW; 2D3F92FC60CD1FE7 CRC64;

Query Match 84.5%; Score 437; DB 1; Length 117;
Best Local Similarity 85.7%; Pred. No. 5.9e-39;
Matches 84; Conservative 6; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFSTYDINVRQATGQGLEWMGMNPNSGNTGY 60
DB 20 QVQLVSGAEVKKPGASVKVSCKASGYTFSTYDINVRQATGQGLEWMGMNPNSGNTGY 79

QY 61 AQKFGQRTVMTNTSISTAYMELSLRLSDDTAVYYCAR 98
DB 80 AQKFGQRTVMTNTSISTAYMELSLRLSDDTAVYYCAR 117

RESULT 4
HVLG_HUMAN STANDARD; PRT; 117 AA.
ID P23083;
DT 01-NOV-1991 (Rel. 20, Created)
DT 01-NOV-1991 (Rel. 20, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region V35 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=88296408; PubMed=2841108;
RA Matsuda F., Lee K.H., Nakai S., Sato T., Kodaira M., Zong S.Q.,
RA Ohno H., Fukuhara S., Honjo T.;
RT "Dispersed localization of D segments in the human immunoglobulin
RT heavy-chain locus.";
RL EMBO J. 7:1047-1051(1988).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 20-116.
RX PubMed=7681398;
RA Mariette X., Tsapis A., Brouet J.C.;
RT "Nucleotide sequence analysis of the variable domains of four human
RT monoclonal IgM with an antibody activity to myelin-associated
RT glycoprotein.";
RL Eur. J. Immunol. 23:846-851(1993).
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; X07448; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR F1R; S00476; HVHJ35.
DR HSSP; P01751; INQB.
DR SMR; P23083; 20-117.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0009555; P:immune response; NAS.
DR InterPro; IPR007110; Ig-Like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
```

```

KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region V35.
FT DOMAIN 20 >117 Ig-like.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 13009 MW; BE61CE63F8CE97BD CRC64;

Query Match 84.5%; Score 437; DB 1; Length 117;
Best Local Similarity 85.7%; Pred. No. 5.9e-39;
Matches 84; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGHMNPNSGNTGY 60
Db 20 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGHMNPNSGNTGY 79

QY 61 AQKFQGRVTMTRTSISTAYMELSSLRSEDTAVYYCAR 98
Db 80 AQKFQGRVTMTRTSISTAYMELSSLRSEDTAVYYCAR 117

RESULT 5
Q9UL92_HUMAN
ID Q9UL92_HUMAN PRELIMINARY; PRT; 124 AA.
AC Q9UL92;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1];
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035022; AAD56258.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON_TER 1 1
FT NON_TER 124 124
SQ SEQUENCE 124 AA; 13580 MW; 1BAACBD96ACD2A2 CRC64;

Query Match 83.6%; Score 432; DB 2; Length 124;
Best Local Similarity 83.7%; Pred. No. 2.2e-38;
Matches 82; Conservative 9; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGHMNPNSGNTGY 60
Db 1 EVQLVSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGGGLEWMGIINPSGGSTSY 60

QY 61 AQKFQGRVTMTRTSISTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFQGRVTMTRTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 6
Q652C8_HUMAN
ID Q652C8_HUMAN PRELIMINARY; PRT; 244 AA.
AC Q652C8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)

```

```

DE Single-chain Fv (Fragment).
OS Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1];
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR EMBL; Y13057; CAA73500.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; IGV; 2.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PSS0835; IG_LIKE; 2.
FT NON_TER 1 1
FT NON_TER 244 244
SQ SEQUENCE 244 AA; 26127 MW; 4B1F17868338F2BF CRC64;

Query Match 81.6%; Score 422; DB 2; Length 244;
Best Local Similarity 79.6%; Pred. No. 5.4e-37;
Matches 78; Conservative 13; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGHMNPNSGNTGY 60
Db 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGGGLEWMGIIDPNNGDTRF 60

QY 61 AQKFQGRVTMTRTSISTAYMELSSLRSEDTAVYYCAR 98
Db 61 AQKFQGRVTMTRTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 7
Q8WY24_HUMAN
ID Q8WY24_HUMAN PRELIMINARY; PRT; 497 AA.
AC Q8WY24;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE SNC66 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1];
RP NUCLEOTIDE SEQUENCE.
RA Zheng S., Shao X., Cao J., Geng L., Fang Y., Dong Q.;
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF283666; AAL36987.1; -; mRNA.
DR HSSP; P01876; IOW0.
DR SNR; Q8WY24; 267-475.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 4.
DR PROSITE; PSS0290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain.
SQ SEQUENCE 497 AA; 53666 MW; F24D08DFA5A663E5 CRC64;

Query Match 80.9%; Score 418; DB 2; Length 497;
Best Local Similarity 78.8%; Pred. No. 3.1e-36;
Matches 77; Conservative 11; Mismatches 10; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGHMNPNSGNTGY 60

```

[illegible]


```

RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Malek J.A., Gunaratne P.H.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH NCG Project;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC051328; AAHS1328.1; -; mRNA.
DR HSSP; P01857; 1H2H.
DR SNR; Q727P5; 20-469.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Immunoglobulin domain.
SQ SEQUENCE 469 AA; 51395 MW; C8D5BE12BAAF795C CRC64;

Query Match 75.6%; Score 391; DB 2; Length 469;
Best Local Similarity 73.2%; Pred. No. 2.3e-33;
Matches 71; Conservative 15; Mismatches 11; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMPNSGNTGY 60
DB 20 QVHLVSGAEVKKPGASVKLSCKTSGYNFFSYDLIWRQAPGQGLEWMGMSAHNGDTKY 79
QY 61 AOKFQGRVTMTNTSISTAYMELSLRSRSEDYVYCA 97
DB 80 ARKFGQGRVTMTNTSISTAYMELSLRSRSDDTALFYCA 116

RESULT 14
Q9BRV0_HUMAN
ID Q9BRV0_HUMAN PRELIMINARY; PRT; 500 AA.
AC Q9BRV0;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE MGC27165 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Malek J.A., Gunaratne P.H.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RG NIH NCG Project;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC051328; AAHS1328.1; -; mRNA.
DR HSSP; P01857; 1H2H.
DR SNR; Q727P5; 20-469.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Immunoglobulin domain.
SQ SEQUENCE 469 AA; 51395 MW; C8D5BE12BAAF795C CRC64;

Query Match 75.4%; Score 390; DB 2; Length 500;
Best Local Similarity 74.5%; Pred. No. 3.2e-33;
Matches 73; Conservative 10; Mismatches 15; Indels 0; Gaps 0;

QY 1 QVQLVSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMPNSGNTGY 60
DB 20 QVHLVSGAEVKKPGASVKTSCTGYAFHTTIIWVRQAPGQGLEWMGWSFSSDNTRF 79
QY 61 AOKFQGRVTMTNTSISTAYMELSLRSRSEDYVYCAR 98
DB 80 AKKFGQGRVTMTNTSISTAYMELSLRSRSDDTAVYCAR 117

RESULT 15
Q6NSA4_HUMAN
ID Q6NSA4_HUMAN PRELIMINARY; PRT; 120 AA.
AC Q6NSA4;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHV1-69 protein.
GN Name=IGHV1-69;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Footed;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Malek J.A., Gunaratne P.H.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RG NIH NCG Project;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC005951; AAH05951.1; -; mRNA.
DR HSSP; P01876; 1OW0.
DR SNR; Q9BRV0; 25-300, 270-478.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; PF00047; IGV; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 500 AA; 54154 MW; 0A9BF43F2A3CC6D9 CRC64;
```


RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]

RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Pooled;

RG NIH MGC Project;

RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.

DR EMBL; BC070333; AAH70333.1; -; mRNA.

DR HSP; P01751; IAGW.

DR SMR; Q6NSA4; 21-116.

DR InterPro; IPR007110; Ig-like.

DR InterPro; IPR003596; Ig_v.

DR SMART; SM00406; IGv; 1.

DR PROSITE; PS50835; IG_LIKE; 1.

KW Immunoglobulin domain.

SQ SEQUENCE 120 AA; 13035 MW; 64620FAC874585D4 CRC64;

Query Match

Best Local Similarity 75.2%; Score 389; DB 2; Length 120;

Matches 77; Conservative 7; Mismatches 14; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVKSCAKSGYFTFTSYDINWVRQATGQGLEWMGMNPNNGNTGY 60

Db 20 QVQLVQSGAEVKKPGSSVKVKSCAKSGGTFTSSYAISWVRQAPGQGLEWMGGIPIFGTANY 79

Qy 61 AQKFGQHVMTNRTISTATWELSSLRSEDTAVYYCAR 98

Db 80 TQKFGQVRVTTTDESTATYMKLSSLRSEDTAVYYCAR 117

Search completed: May 5, 2006, 09:04:20

Job time : 39.8199 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:18 ; Search time 46.9823 Seconds
(without alignments)
1140.944 Million cell updates/sec

Title: US-09-674-752-32

Perfect score: 661

Sequence: 1 QVQLQYADVKRPGASVKV.....LLIWFGPAPYNDSWGQGLTV 122

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21.*

- 1: Geneseqp1980s.*
- 2: Geneseqp1990s.*
- 3: Geneseqp2000s.*
- 4: Geneseqp2001s.*
- 5: Geneseqp2002s.*
- 6: Geneseqp2003as.*
- 7: Geneseqp2003bs.*
- 8: Geneseqp2004s.*
- 9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	654	98.9	122	3	AAY50959 Human FVI
2	638	96.5	122	3	AAY50966 Human FVI
3	544	82.3	126	8	ABM79489 Human KM4
4	544	82.3	273	8	ABM79494 Human KM4
5	473	71.6	126	7	ADK18597 Anti-huma
6	473	71.6	126	7	ADK18870 Anti-huma
7	473	71.6	126	7	ADK18812 Anti-huma
8	473	71.6	126	7	ADK18775 Anti-huma
9	473	71.6	126	8	ADL25412 Human mAb
10	467	70.7	126	7	ADK18864 Anti-huma
11	467	70.7	126	7	ADK18595 Anti-huma
12	467	70.7	126	7	ADK18777 Anti-huma
13	467	70.7	126	8	ADL25408 Human mAb
14	465	70.3	126	7	ADK18925 Anti-huma
15	465	70.3	126	7	ADK18778 Anti-huma
16	465	70.3	126	7	ADK18780 Anti-huma
17	465	70.3	126	7	ADK18613 Anti-huma
18	465	70.3	126	7	ADK18616 Anti-huma
19	465	70.3	126	7	ADK18815 Anti-huma
20	465	70.3	126	7	ADK18817 Anti-huma
21	465	70.3	126	8	ADL25448 Human mAb
22	465	70.3	126	8	ADL25464 Human mAb
23	461	69.7	122	6	ABR55829 Heavy cha
24	461	69.7	247	5	ABP44916 Human Bly

25	461	69.7	247	5	ABP44937 Human Bly
26	461	69.7	247	7	ADG95764 Single ch
27	461	69.7	247	7	ADG95743 Single ch
28	460.5	69.7	125	7	ADK18614 Anti-huma
29	460.5	69.7	125	7	ADK18779 Anti-huma
30	460.5	69.7	125	7	ADK18919 Anti-huma
31	460.5	69.7	125	7	ADK18816 Anti-huma
32	460.5	69.7	125	8	ADL25444 Human mAb
33	459	69.4	120	6	ABR55815 Heavy cha
34	459	69.4	146	3	ABR53510 Human col
35	457.5	69.2	125	7	ADK18776 Anti-huma
36	457.5	69.2	125	7	ADK18948 Anti-huma
37	457.5	69.2	125	7	ADK18624 Anti-huma
38	457.5	69.2	125	7	ADK18813 Anti-huma
39	457.5	69.2	125	8	ADL25392 Human mAb
40	456.5	69.1	127	7	ADK18620 Anti-huma
41	456.5	69.1	127	7	ADK18818 Anti-huma
42	456.5	69.1	127	7	ADK18781 Anti-huma
43	456.5	69.1	127	7	ADK18936 Anti-huma
44	456.5	69.1	127	8	ADL25456 Human mAb
45	455	68.8	126	6	ADA89124 MS-Pro-55

ALIGNMENTS

RESULT 1

AAY50959

ID AAY50959 standard; protein; 122 AA.

XX AAY50959;

DT 23-MAR-2000 (first entry)

DE Human FVIII antibody A3-C1 scFv heavy chain protein B38.

KW Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

KW scFv; A3-C1.

XX Homo sapiens.

XX WO9958680-A2.

PD 18-NOV-1999.

XX 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

PI Voorberg JJ, Van Den Brink EN, Turenhout EM;

XX WPI; 2000-053102/04.

PT New polynucleotide, polypeptide and antibody useful for diagnosing the presence of neutralizing antibodies against factor VIII and for treatment of hemophilia A patients with these antibodies.

XX Example 8; Fig 9A; 61pp; English.

CC This invention describes a novel polynucleotide (I) (and complements and hybridizable polynucleotides) comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity which has hemostatic activity. (I) is useful as a primer or probe for detecting the presence of inhibitory antibodies directed against factor VIII. The polypeptides of the invention and the antibodies generated from them are useful in compositions for neutralizing factor VIII inhibiting antibodies in hemophilia A patients. This sequence represents the human factor VIII antibody A3-C1 specific scFv protein B38 which is used in the method of the invention

SQ Sequence 122 AA;

Query Match 98.9%; Score 654; DB 3; Length 122;
 Best Local Similarity 99.2%; Pred. No. 2.8e-52;
 Matches 121; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
 |||||
 DB 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
 |||||

QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTLLIWFPGAPYNDWSGQGT 120
 |||||
 DB 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTLLIWFPGAPYNDWSGQGT 120
 |||||

QY 121 LV 122
 ||
 DB 121 LV 122

RESULT 2
 AAY50966
 ID AAY50966 standard; protein; 122 AA.
 XX AC AAY50966;
 XX DT 23-MAR-2000 (first entry)
 XX DE Human FVIII antibody heavy chain variable region B38 protein fragment.
 XX KW Human; heavy chain; antibody; factor VIII; hemostatic; variable region;
 XX KW hemophilia A.
 XX OS Homo sapiens.
 XX PN WO9958680-A2.
 XX PD 18-NOV-1999.
 XX PF 07-MAY-1999; 99WO-NL000285.
 XX PR 08-MAY-1998; 98EP-00201543.
 XX PA (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
 XX PI Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 DR WPI; 2000-053102/04.
 DR N-PSDB; AAZ43863.
 PT New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX Example 8; Fig 9B; 61pp; English.
 XX This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has
 CC hemostatic activity. (I) is useful a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents a fragment of the
 CC human factor VIII antibody heavy chain variable region protein B38 which
 CC is used in the method of the invention
 XX Sequence 122 AA;
 SQ

Query Match 96.5%; Score 638; DB 3; Length 122;
 Best Local Similarity 97.5%; Pred. No. 8.2e-51;
 Matches 119; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
 |||||
 DB 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
 |||||

Db 1 QVOLLQSAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
 QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTLLIWFPGAPYNDWSGQGT 120
 |||||
 Db 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTLLIWFPGAPYNDWSGQGT 120
 |||||

QY 121 LV 122
 ||
 Db 121 LV 122

RESULT 3
 ABM79489
 ID ABM79489 standard; protein; 126 AA.
 XX AC ABM79489;
 XX DT 22-APR-2004 (first entry)
 XX DE Human KM41 heavy chain.
 XX KW Antibody; human; Factor VIII; LRP; haemostatic; haemophilia A;
 KW low-density lipoprotein receptor-related protein;
 KW blood coagulation disorder.
 XX OS Homo sapiens.
 XX PN WO2003093313-A2.
 XX PD 13-NOV-2003.
 XX PF 28-APR-2003; 2003WO-EP004425.
 XX PR 29-APR-2002; 2002US-0376351P.
 XX PA (BAXT) BAXTER INT INC.
 XX PA (BAXT) BAXTER HEALTHCARE SA.
 XX PA (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
 XX PI Mertens K, Bovenschen AN, Voorberg J, Rieger M, Scheiflinger F;
 XX WPI; 2004-053039/05.
 XX DR N-PSDB; AAZ56420.
 XX Use of peptides derived from and antibodies generated against Factor VIII but
 PT to inhibit Factor VIII interaction with Low Density Lipoprotein Receptor
 PT Protein or to prevent or treat blood coagulation disorders (e.g.
 PT hemophilia A).
 XX Disclosure; Page 53-54; Opp; English.
 XX The present invention relates to peptides derived from Factor VIII but
 CC not having any substantial Factor VIII activity, or an antibody which can
 CC specifically binds to epitopes within the amino acid sequences, which can
 CC be used to inhibit Factor VIII interaction with Low Density Lipoprotein
 CC Receptor Protein (LRP). The peptides or antibody are useful in inhibiting
 CC Factor VIII interaction with LRP, in decreasing Factor VIII degradation
 CC in a biological fluid, in prolonging Factor VIII half-life in blood or in
 CC preparing a medicament for preventing or treating a blood coagulation
 CC disorder (e.g. haemophilia A or von Willebrand's disease) and/or a
 CC temporary impairment of the thrombolytic or fibrinolytic systems. The
 CC present sequence is a polypeptide shown in the exemplification of the
 CC invention
 XX Sequence 126 AA;
 SQ

Query Match 82.3%; Score 544; DB 8; Length 126;
 Best Local Similarity 86.9%; Pred. No. 3.7e-42;
 Matches 106; Conservative 2; Mismatches 14; Indels 0; Gaps 0;

QY 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
 |||||
 Db 1 QVOLLQSAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
 |||||

Qy	61	AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTTLIWFPGAPYNDSWGQGT	120
Db	61	AQKFKGRLTLTRDTSTSTAYMELRRLESEDTAVYYCARSTPHSYSGSLPPTSDSWGQGT	120
Qy	121	LV 122	
Db	121	LV 122	
Qy	121	LV 122	
Db	121	LV 122	
RESULT 4			
ID	ABM79494		
AC	ABM79494 standard; protein; 273 AA.		
XX	ABM79494;		
DT	22-APR-2004 (first entry)		
XX	Human KM41 antibody with linker.		
XX	Antibody; human; Factor VIII; LRP; haemostatic; haemophilia A;		
KW	low-density lipoprotein receptor-related protein;		
KW	blood coagulation disorder.		
XX	Homo sapiens.		
XX	WO2003093313-A2.		
XX	13-NOV-2003.		
XX	28-APR-2003; 2003WO-EP004425.		
XX	29-APR-2002; 2002US-0376351P.		
XX	(BAXT) BAXTER INT INC.		
PA	(BAXT) BAXTER HEALTHCARE SA.		
PA	(SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.		
XX	Mertens K, Bovenschen AN, Voorberg J, Rieger M, Scheiflinger F;		
XX	WPI; 2004-053039/05.		
XX	Use of peptides derived from and antibodies generated against Factor VIII		
PT	to inhibit Factor VIII interaction with Low Density Lipoprotein Receptor		
PT	Protein or to prevent or treat blood coagulation disorders (e.g.		
PT	hemophilia A).		
XX	Claim 20; Page 59-60; Opp; English.		
PS	The present invention relates to peptides derived from Factor VIII but		
CC	not having any substantial Factor VIII activity, or an antibody which		
CC	specifically binds to epitopes within the amino acid sequences, which can		
CC	be used to inhibit Factor VIII interaction with Low Density Lipoprotein		
CC	Receptor Protein (LRP). The peptides or antibody are useful in inhibiting		
CC	Factor VIII interaction with LRP, in decreasing Factor VIII degradation		
CC	in a biological fluid, in prolonging Factor VIII half-life in blood or in		
CC	preparing a medicament for preventing or treating a blood coagulation		
CC	disorder (e.g. haemophilia A or von Willebrand's disease) and/or a		
CC	temporary impairment of the thrombolytic or fibrinolytic systems. The		
CC	present sequence is a polypeptide shown in the exemplification of the		
XX	invention		
XX	Sequence 273 AA;		
Qy	Query Match	82.3%; Score 544; DB 8; Length 273;	
Db	Best Local Similarity	86.9%; Pred. No. 8.3e-42;	
Qy	Matches 106; Conservative	2; Mismatches 14; Indels 0; Gaps 0;	
Qy	1	QVQLQAAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMNPNNGNAGF	60
Db	1	QVQLQAAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMNPNNGNAGF	60
Qy	61	AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTTLIWFPGAPYNDSWGQGT	120

Db	61	AQKFKGRLTLTRDTSTSTAYMELRRLESEDTAVYYCARSTPHSYSGSLPPTSDSWGQGT	120
Qy	121	LV 122	
Db	121	LV 122	
Qy	121	LV 122	
Db	121	LV 122	
RESULT 5			
ID	ADK18597		
XX	ADK18597 standard; protein; 126 AA.		
AC	ADK18597;		
XX	06-MAY-2004 (first entry)		
DT	Anti-human PDGF-D antibody heavy chain protein sequence.		
XX	antiinflammatory; immunomodulator; cytostatic; gene therapy.		
XX	Homo sapiens.		
OS	WO2003057857-A2.		
PN	17-JUL-2003.		
XX	06-JAN-2003; 2003WO-US000398.		
XX	07-JAN-2002; 2002US-00041860.		
XX	(ABGE-) ABGENIX INC.		
XX	Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;		
PI	Bezabeh B;		
XX	WPI; 2003-587119/55.		
DR	New human monoclonal antibody that binds to platelet-derived growth		
PT	factor-D (PDGF-D), useful for treating chronic and recurrent human		
PT	diseases, such as inflammation, autoimmunity and cancer.		
XX	Disclosure; SEQ ID NO 21; 255pp; English.		
XX	The invention relates to a human monoclonal antibody that binds to		
CC	platelet-derived growth factor-D (PDGF-D). The antibodies are useful for		
CC	treating chronic and recurrent human diseases, such as inflammation,		
CC	autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are		
CC	useful for modulating collagen formation, and for staging various		
CC	cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were		
CC	generated using an active protein fragment of the gene product from the		
CC	clone 30664188.0.99 arising in the conditioned medium obtained when		
CC	HEK293 cells are transfected with the plasmid pCBP4/Sec-30664188. This		
CC	sequence corresponds to a protein used in the invention.		
XX	Sequence 126 AA;		
Qy	Query Match	71.6%; Score 473; DB 7; Length 126;	
Db	Best Local Similarity	73.6%; Pred. No. 1.2e-35;	
Qy	Matches 92; Conservative	11; Mismatches 16; Indels 6; Gaps 2;	
Qy	1	QVQLQAAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMNPNNGNAGF	60
Db	1	QVQLVQSGAEVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMNPNNGNAGF	60
Qy	61	AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTTLIWFPGAPYND--DSWG	117
Db	61	AQKFGQGRVTMTNTSISTAYMELSLRSEDTAVYYCAR---DVMITFGGVIVHYGMDVWG	117
Qy	118	QGTILV 122	
Db	118	QGTIV 122	

```
RESULT 6
ADK18870
ID   ADK18870 standard; protein; 126 AA.
XX
XX   AC   ADK18870;
XX
XX   DT   06-MAY-2004 (first entry)
XX
DE   Anti-human PDGF-D antibody protein related sequence #96.
XX
XX   KW   antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
XX   OS   Homo sapiens.
XX
XX   PN   WO2003057857-A2.
XX
XX   PD   17-JUL-2003.
XX
XX   PF   06-JAN-2003; 2003WO-US000398.
XX
XX   PR   07-JAN-2002; 2002US-00041860.
XX
XX   PA   (ABGE-) ABGENIX INC.
XX
XX   PI   Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
XX   PI   Bezabeh B;
XX
XX   DR   WPI; 2003-587119/55.
XX
XX   PT   New human monoclonal antibody that binds to platelet-derived growth
XX   PT   factor-D (PDGF-D), useful for treating chronic and recurrent human
XX   PT   diseases, such as inflammation, autoimmunity and cancer.
XX
XX   PS   Disclosure; SEQ ID NO 294; 255pp; English.
XX
XX   CC   The invention relates to a human monoclonal antibody that binds to
XX   CC   platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
XX   CC   treating chronic and recurrent human diseases, such as inflammation,
XX   CC   autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
XX   CC   useful for modulating collagen formation, and for staging various
XX   CC   cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
XX   CC   generated using an active protein fragment of the gene product from the
XX   CC   clone 30664188.0.99 arising in the conditioned medium obtained when
XX   CC   HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
XX   CC   sequence corresponds to a protein used in the invention.
XX
XX   SQ   Sequence 126 AA;
XX
XX   Query Match      71.6%; Score 473; DB 7; Length 126;
XX   Best Local Similarity 73.6%; Pred. No. 1.2e-35;
XX   Matches 92; Conservative 11; Mismatches 16; Indels 6; Gaps 2;
XX
QY   1 QVQLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
DB   1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
XX
QY   61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTTLTIWFGPAPYN---DSWG 117
DB   61 AQKFGQGRVTMTTRNTSISTAYMELSLRSEDTAVYYCAR---DVNITFGGVIVHYGMDVWG 117
XX
QY   118 QGTLV 122
DB   118 QGTTV 122
XX
RESULT 7
ADK18812
ID   ADK18812 standard; protein; 126 AA.
XX
XX   AC   ADK18812;
XX
XX   DT   06-MAY-2004 (first entry)
XX
XX
XX   DE   Anti-human PDGF-D antibody protein related sequence #1.
XX
XX   KW   antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
XX   OS   Homo sapiens.
XX
XX   PN   WO2003057857-A2.
XX
XX   PD   17-JUL-2003.
XX
XX   PF   06-JAN-2003; 2003WO-US000398.
XX
XX   PR   07-JAN-2002; 2002US-00041860.
XX
XX   PA   (ABGE-) ABGENIX INC.
XX
XX   PI   Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
XX   PI   Bezabeh B;
XX
XX   DR   WPI; 2003-587119/55.
XX
XX   PT   New human monoclonal antibody that binds to platelet-derived growth
XX   PT   factor-D (PDGF-D), useful for treating chronic and recurrent human
XX   PT   diseases, such as inflammation, autoimmunity and cancer.
XX
XX   PS   Disclosure; SEQ ID NO 294; 255pp; English.
XX
XX   CC   The invention relates to a human monoclonal antibody that binds to
XX   CC   platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
XX   CC   treating chronic and recurrent human diseases, such as inflammation,
XX   CC   autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
XX   CC   useful for modulating collagen formation, and for staging various
XX   CC   cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
XX   CC   generated using an active protein fragment of the gene product from the
XX   CC   clone 30664188.0.99 arising in the conditioned medium obtained when
XX   CC   HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
XX   CC   sequence corresponds to a protein used in the invention.
XX
XX   SQ   Sequence 126 AA;
XX
XX   Query Match      71.6%; Score 473; DB 7; Length 126;
XX   Best Local Similarity 73.6%; Pred. No. 1.2e-35;
XX   Matches 92; Conservative 11; Mismatches 16; Indels 6; Gaps 2;
XX
QY   1 QVQLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
DB   1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
XX
QY   61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTTLTIWFGPAPYN---DSWG 117
DB   61 AQKFGQGRVTMTTRNTSISTAYMELSLRSEDTAVYYCAR---DVNITFGGVIVHYGMDVWG 117
XX
QY   118 QGTLV 122
DB   118 QGTTV 122
XX
RESULT 8
ADK18775
ID   ADK18775 standard; protein; 126 AA.
XX
XX   AC   ADK18775;
XX
XX   DT   06-MAY-2004 (first entry)
XX
XX
XX   DE   Anti-human PDGF-D antibody protein related sequence #1.
XX
XX   KW   antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
XX   OS   Homo sapiens.
XX
XX   PN   WO2003057857-A2.
XX
```


PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX WPI; 2003-587119/55.
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
PS Disclosure; SEQ ID NO 288; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 126 AA;
Query Match 70.7%; Score 467; DB 7; Length 126;
Best Local Similarity 72.2%; Pred. No. 4.3e-35;
Matches 91; Conservative 10; Mismatches 17; Indels 8; Gaps 2;
QY 1 QVQLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNSGNAGF 60
DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
QY 61 AQKFKGRLTLTRDTSTAYMELRNLESEDTAVYYCAR----CDTLLIWFGPAPYNDWSW 116
DB 61 AQKFGQRTVTRNTSISTAYMELSSLRSEDTAVYYCAREGIAVAGTYYYYG---MDVW 116
QY 117 GQSTLV 122
DB 117 GQSTTV 122
RESULT 11
ADKL18595
ID ADKL18595 standard; protein; 126 AA.
XX
AC ADK18595;
DT 06-MAY-2004 (first entry)
DE Anti-human PDGF-D antibody heavy chain protein sequence.
XX
KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
OS Homo sapiens.
XX WO2003057857-A2.
XX 17-JUL-2003.
XX 06-JAN-2003; 2003WO-US000398.
XX 07-JAN-2002; 2002US-00041860.
XX (ABGE-) ABGENIX INC.
PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX WPI; 2003-587119/55.
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
PT

XX Disclosure; SEQ ID NO 19; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 126 AA;
Query Match 70.7%; Score 467; DB 7; Length 126;
Best Local Similarity 72.2%; Pred. No. 4.3e-35;
Matches 91; Conservative 10; Mismatches 17; Indels 8; Gaps 2;
QY 1 QVQLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNSGNAGF 60
DB 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNSGNTGY 60
QY 61 AQKFKGRLTLTRDTSTAYMELRNLESEDTAVYYCAR----CDTLLIWFGPAPYNDWSW 116
DB 61 AQKFGQRTVTRNTSISTAYMELSSLRSEDTAVYYCAREGIAVAGTYYYYG---MDVW 116
QY 117 GQSTLV 122
DB 117 GQSTTV 122
RESULT 12
ADKL18777
ID ADKL18777 standard; protein; 126 AA.
XX
AC ADK18777;
DT 06-MAY-2004 (first entry)
XX Anti-human PDGF-D antibody protein related sequence #3.
DE antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
KW Homo sapiens.
XX OS
XX WO2003057857-A2.
XX 17-JUL-2003.
XX 06-JAN-2003; 2003WO-US000398.
XX 07-JAN-2002; 2002US-00041860.
XX (ABGE-) ABGENIX INC.
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX WPI; 2003-587119/55.
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
PS Disclosure; SEQ ID NO 201; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC

CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
 CC sequence corresponds to a protein used in the invention.
 XX
 SQ Sequence 126 AA;

Query Match 70.7%; Score 467; DB 7; Length 126;
 Best Local Similarity 72.2%; Pred. No. 4.3e-35;
 Matches 91; Conservative 10; Mismatches 17; Indels 8; Gaps 2;

Qy 1 QVQLQVAAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWGMWNPNSGNAGF 60
 Db 1 QVQLVQSGAEVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWGMWNPNSGNTGY 60

Qy 61 AQKFQGRLLTTRDTSTAYMELNLSRSEDVAVYVCAR----CDTLLIWFPGAPYNDWSW 116
 Db 61 AQKFQGRVTMTTRNTSISTAYMELSLRSRSEDVAVYVCAREGIAVAGTYYYYYG----MDVW 116

Qy 117 GQGTLLV 122
 Db 117 GQGTIV 122

RESULT 13
 ADL25408
 ID ADL25408 standard; protein; 126 AA.
 XX
 AC ADL25408;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE Human mAb 1.18 heavy chain variable region protein SEQ ID NO:18.
 XX
 KW antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
 KW nephritis; mesangial cell proliferation inhibition;
 KW mesangial proliferative glomerulonephritis; nephrotropic;
 KW antiinflammatory; dermatological; immunosuppressive; antidiabetic;
 KW gene therapy; human; monoclonal antibody; mAb.
 XX
 OS Homo sapiens.
 XX
 PN WO2004024098-A2.
 XX
 PD 25-MAR-2004.
 XX
 PF 16-SEP-2003; 2003WO-US029414.
 XX
 PR 16-SEP-2002; 2002US-0411137P.
 XX
 PA (ABGE-) ABGENIX INC.
 PA (CURA-) CURAGEN CORP.
 XX
 PI Floege J, Gazit-Bornstein G, Keyt B, Larochele WJ, Lichenstein H;
 XX
 DR WPI; 2004-269881/25.
 DR N-PSDB; ADL25407.
 XX
 XX Use of an antibody or its binding fragment that binds platelet derived
 PT growth factor-DD (PDGF-DD) for preparing a medicament for treating
 PT nephritis.
 XX
 PS Disclosure; SEQ ID NO 18; 115pp; English.
 XX
 CC The present invention describes an antibody or its binding fragment that
 CC binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
 CC useful in preparing a medicament for treating nephritis. Also described:
 CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
 CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
 CC of treating mesangial proliferative glomerulonephritis. The antibody has
 CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
 CC antidiabetic activities, and can be used in gene therapy. The antibody or

CC its binding fragment, that binds PDGF-DD, can be used in preparing a
 CC medicament for treating nephritis and related disorders, e.g., mesangial
 CC proliferative glomerulonephritis. The present sequence represents a human
 CC monoclonal antibody (mAb) variable region sequence, which is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 126 AA;

Query Match 70.7%; Score 467; DB 8; Length 126;
 Best Local Similarity 72.2%; Pred. No. 4.3e-35;
 Matches 91; Conservative 10; Mismatches 17; Indels 8; Gaps 2;

Qy 1 QVQLQVAAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWGMWNPNSGNAGF 60
 Db 1 QVQLVQSGAEVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWGMWNPNSGNTGY 60

Qy 61 AQKFQGRLLTTRDTSTAYMELNLSRSEDVAVYVCAR----CDTLLIWFPGAPYNDWSW 116
 Db 61 AQKFQGRVTMTTRNTSISTAYMELSLRSRSEDVAVYVCAREGIAVAGTYYYYYG----MDVW 116

Qy 117 GQGTLLV 122
 Db 117 GQGTIV 122

RESULT 14
 ADK18925
 ID ADK18925 standard; protein; 126 AA.
 XX
 AC ADK18925;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Anti-human PDGF-D antibody protein related sequence #151.
 XX
 KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO2003057857-A2.
 XX
 PD 17-JUL-2003.
 XX
 PF 06-JAN-2003; 2003WO-US000398.
 XX
 PR 07-JAN-2002; 2002US-00041860.
 XX
 PA (ABGE-) ABGENIX INC.
 XX
 PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;
 XX
 DR WPI; 2003-587119/55.
 XX
 XX New human monoclonal antibody that binds to platelet-derived growth
 PT factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.
 XX
 PS Disclosure; SEQ ID NO 349; 255pp; English.
 XX
 CC The invention relates to a human monoclonal antibody that binds to
 CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 CC treating chronic and recurrent human diseases, such as inflammation,
 CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 CC useful for modulating collagen formation, and for staging various
 CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
 CC sequence corresponds to a protein used in the invention.
 XX
 SQ Sequence 126 AA;

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:53:55 ; Search time 13.4015 Seconds
(without alignments)
752.634 Million cell updates/sec

Title: US-09-674-752-32

Perfect score: 661

Sequence: 1 QVQLQYAAADVKKPGASVKY.....LLIWFGPAPYNDSWGQTLV 122

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA:*

- 1: /cgn2_6/ptodata/1/iaa/5_COMB.pep:*
- 2: /cgn2_6/ptodata/1/iaa/6_COMB.pep:*
- 3: /cgn2_6/ptodata/1/iaa/H_COMB.pep:*
- 4: /cgn2_6/ptodata/1/iaa/PCITUS_COMB.pep:*
- 5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep:*
- 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	446	67.5	120	2	US-09-025-769B-36
2	446	67.5	120	2	US-09-025-769B-59
3	446	67.5	120	2	US-09-490-070A-36
4	446	67.5	120	2	US-09-490-070A-59
5	446	67.5	120	2	US-09-490-153-36
6	446	67.5	120	2	US-09-490-153-59
7	446	67.5	120	2	US-09-490-324-36
8	446	67.5	120	2	US-09-490-324-59
9	445	67.3	117	2	US-08-545-809A-96
10	445	67.3	117	2	US-09-515-697-96
11	437.5	66.2	117	2	US-09-025-769B-22
12	437.5	66.2	117	2	US-09-490-070A-22
13	437.5	66.2	117	2	US-09-490-153-22
14	437.5	66.2	117	2	US-09-490-324-22
15	436	66.0	96	2	US-10-194-975-3
16	425	64.3	128	1	US-08-202-047-22
17	425	64.3	128	1	US-08-964-690-22
18	421.5	63.8	470	2	US-08-859-053-28
19	421.5	63.7	236	2	US-09-049-672A-13
20	420.5	63.6	123	1	US-08-477-877B-94
21	420.5	63.6	123	1	US-08-472-281A-94
22	420.5	63.6	123	1	US-08-477-989B-94
23	420.5	63.6	123	2	US-09-462-140D-102
24	420.5	63.6	123	2	US-09-462-140D-105
25	419.5	63.5	121	1	US-08-264-093-3
26	417.5	63.2	129	1	US-08-561-521-45
27	417.5	63.2	129	2	US-08-535-539A-77

28	417.5	63.2	129	4	PCT-US95-01219-45	Sequence 45, Appl
29	413.5	62.6	125	2	US-09-199-149-3	Sequence 3, Appl
30	413	62.5	139	1	US-08-253-877C-19	Sequence 19, Appl
31	413	62.5	139	1	US-08-452-164A-19	Sequence 19, Appl
32	413	62.5	139	2	US-08-603-024-18	Sequence 18, Appl
33	413	62.5	139	2	US-08-450-809-14	Sequence 18, Appl
34	412.5	62.4	119	1	PCT-US95-01219-10	Sequence 10, Appl
35	412.5	62.4	119	4	PCT-US95-01219-10	Sequence 10, Appl
36	410	62.0	118	1	US-08-491-845-14	Sequence 14, Appl
37	410	62.0	137	2	US-08-513-968-38	Sequence 38, Appl
38	409.5	62.0	119	2	US-09-438-954-41	Sequence 41, Appl
39	409.5	62.0	139	2	US-08-933-983-21	Sequence 21, Appl
40	403	61.0	98	2	US-10-194-975-1	Sequence 1, Appl
41	403	61.0	117	2	US-08-545-809A-90	Sequence 90, Appl
42	403	61.0	117	2	US-09-515-697-90	Sequence 90, Appl
43	402.5	60.9	121	1	US-08-202-047-23	Sequence 23, Appl
44	402.5	60.9	121	2	US-08-964-690-23	Sequence 23, Appl
45	401.5	60.7	123	2	US-10-330-613A-21	Sequence 21, Appl

ALIGNMENTS

RESULT 1
US-09-025-769B-36
; Sequence 36, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-36

Query Match 67.5%; Score 446; DB 2; Length 120;
Best Local Similarity 70.7%; Pred. No. 2.3e-40;
Matches 87; Conservative 10; Mismatches 18; Indels 8; Gaps 2;

; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995

; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020

; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:

US-09-490-070A-59
Query Match 67.5%; Score 446; DB 2; Length 120;
Best Local Similarity 70.7%; Pred. No. 2.3e-40;
Matches 87; Conservative 10; Mismatches 18; Indels 8; Gaps 2;

Qy 1 QVQLQYAAADVKKPGASVKVSCASGYFTSYDINWVRQATGQGLEWMGNPNNGNAGF 60
Db 1 QVQLVQSGAEVKKPGASVKVSCASGYFTSYDINWVRQAPGQGLEWMGNPNNGGNTY 60

Qy 61 AQKFGRLLTTRDTSTSTAYMELNLESEDTAVYYCARCDTLLIWFGPAPY-NDSWGQ 119
Db 61 AQKFGRTVTTRDTSTSTAYMELSLSEDTAVYYCAR-----WGDDGFYANDYWGQ 113

Qy 120 TLV 122
Db 114 TLV 116

RESULT 5
US-09-490-153-36
; Sequence 36, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas

; TITLE OF INVENTION: Protein/(poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998

; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995

; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090

; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear

; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 36:

US-09-490-153-36
Query Match 67.5%; Score 446; DB 2; Length 120;
Best Local Similarity 70.7%; Pred. No. 2.3e-40;
Matches 87; Conservative 10; Mismatches 18; Indels 8; Gaps 2;

Qy 1 QVQLQYAAADVKKPGASVKVSCASGYFTSYDINWVRQATGQGLEWMGNPNNGNAGF 60
Db 1 QVQLVQSGAEVKKPGASVKVSCASGYFTSYDINWVRQAPGQGLEWMGNPNNGGNTY 60

Qy 61 AQKFGRLLTTRDTSTSTAYMELNLESEDTAVYYCARCDTLLIWFGPAPY-NDSWGQ 119
Db 61 AQKFGRTVTTRDTSTSTAYMELSLSEDTAVYYCAR-----WGDDGFYANDYWGQ 113

Qy 120 TLV 122
Db 114 TLV 116

RESULT 6
US-09-490-153-59
; Sequence 59, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas

; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York

```
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
;
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
;
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-153-59

Query Match 67.5%; Score 446; DB 2; Length 120;
Best Local Similarity 70.7%; Pred. No. 2.3e-40;
Matches 87; Conservative 10; Mismatches 18; Indels 8; Gaps 2;

QY 1 QVOLLVAAADVKKPGASVKVSCASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
Db 1 QVQLVSGAEVKKPGASVKVSCASGYFTSYHWHVRQAPGQGLEWMGINPNSGGTNY 60
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESDTAVYYCARCDTLLIIFGPPAPY-NDSWGQG 119
Db 61 AQKFGQVMTWTRDTSISTAYMELSLRSEDTAVYYCAR-----WGSDGFYAMDYWGQG 113
QY 120 TLV 122
Db 114 TLV 116

RESULT 7
US-09-490-324-36
; Sequence 36, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
;
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
;
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
;
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-153-59

Query Match 67.5%; Score 446; DB 2; Length 120;
Best Local Similarity 70.7%; Pred. No. 2.3e-40;
Matches 87; Conservative 10; Mismatches 18; Indels 8; Gaps 2;

QY 1 QVOLLVAAADVKKPGASVKVSCASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
Db 1 QVQLVSGAEVKKPGASVKVSCASGYFTSYHWHVRQAPGQGLEWMGINPNSGGTNY 60
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESDTAVYYCARCDTLLIIFGPPAPY-NDSWGQG 119
Db 61 AQKFGQVMTWTRDTSISTAYMELSLRSEDTAVYYCAR-----WGSDGFYAMDYWGQG 113
QY 120 TLV 122
Db 114 TLV 116

RESULT 8
US-09-490-324-59
; Sequence 59, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
;
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
```

```
;
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
;   NAME: James F. Haley, Jr., Esq.
;   REGISTRATION NUMBER: 27,794
;   REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (212)596-9000
;   TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 59:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 120 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-324-59

Query Match          67.5%; Score 446; DB 2; Length 120;
Best Local Similarity 70.7%; Pred. No. 2.3e-40;
Matches 87; Conservative 10; Mismatches 18; Indels 8; Gaps 2;

Qy 1 QVQLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGNPNNSGNAGF 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTFTSYVHWVRQAPGQGLEWMGNINPNSGGTNY 60

Qy 61 AQKFKGRLTLTRDTSTSTAYMELNLESEDTAVYYCAR 119
Db 61 AQKFGKRVTTTRDTSTSTAYMELSLRSEDTAVYYCAR-----WGGDGFYAMDYWGQ 113

Qy 120 TLV 122
Db 114 TLV 116

RESULT 9
US-08-545-809A-96
; Sequence 96, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 29,066
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 96:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 117 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 96:
US-09-515-697-96

Query Match          67.3%; Score 445; DB 2; Length 117;
Best Local Similarity 83.7%; Pred. No. 2.8e-40;
Matches 82; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGNPNNSGNAGF 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTFTSYDINWVRQATGQGLEWMGNPNNSGNTGY 79

Qy 61 AQKFKGRLTLTRDTSTSTAYMELNLESEDTAVYYCAR 98
Db 80 AQKFGKRVTTTRDTSTSTAYMELSLRSEDTAVYYCAR 117

RESULT 10
US-09-515-697-96
; Sequence 96, Application US/09515697
; Patent No. 6936705
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/515,697
; FILING DATE: 29-Feb-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 96:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 117 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 96:
US-09-515-697-96

Query Match          67.3%; Score 445; DB 2; Length 117;
Best Local Similarity 83.7%; Pred. No. 2.8e-40;
Matches 82; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

Qy 1 QVQLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGNPNNSGNAGF 60
Db 1 QVQLVQSGAEVKKPGASVKVSKASGYFTFTSYDINWVRQATGQGLEWMGNPNNSGNTGY 79
```


[illegible]

Search completed: May 5, 2006, 08:56:24
Job time : 14.4015 secs

Result No.	Score	Query		Length	DB	ID	Description
		Match	%				
1	473	71.6	126	4	US-10-041-860-21	Sequence 21, Appl	
2	473	71.6	126	4	US-10-041-860-199	Sequence 199, App	
3	473	71.6	126	4	US-10-041-860-236	Sequence 236, App	
4	473	71.6	126	4	US-10-041-860-294	Sequence 294, App	
5	473	71.6	126	4	US-10-665-383-22	Sequence 22, Appl	
6	467	70.7	126	4	US-10-041-860-19	Sequence 19, Appl	
7	467	70.7	126	4	US-10-041-860-201	Sequence 201, App	
8	467	70.7	126	4	US-10-041-860-288	Sequence 288, App	
9	467	70.7	126	4	US-10-665-383-18	Sequence 18, Appl	
10	465	70.3	126	4	US-10-041-860-37	Sequence 37, Appl	
11	465	70.3	126	4	US-10-041-860-40	Sequence 40, Appl	
12	465	70.3	126	4	US-10-041-860-202	Sequence 202, App	
13	465	70.3	126	4	US-10-041-860-204	Sequence 204, App	
14	465	70.3	126	4	US-10-041-860-239	Sequence 239, App	
15	465	70.3	126	4	US-10-041-860-241	Sequence 241, App	
16	465	70.3	126	4	US-10-041-860-349	Sequence 349, App	
17	465	70.3	126	4	US-10-665-383-58	Sequence 58, Appl	
18	465	70.3	126	4	US-10-665-383-74	Sequence 74, Appl	
19	461	69.7	122	4	US-10-269-805-61	Sequence 61, Appl	
20	461	69.7	127	3	US-09-880-748-927	Sequence 927, App	
21	461	69.7	247	3	US-09-880-748-948	Sequence 948, App	
22	461	69.7	247	4	US-10-293-418-927	Sequence 927, App	
23	461	69.7	247	4	US-10-293-418-948	Sequence 948, App	
24	460.5	69.7	125	4	US-10-041-860-38	Sequence 38, Appl	
25	460.5	69.7	125	4	US-10-041-860-203	Sequence 203, App	
26	460.5	69.7	125	4	US-10-041-860-240	Sequence 240, App	
27	460.5	69.7	125	4	US-10-041-860-343	Sequence 343, App	

; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 199
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-199

Query Match 71.6%; Score 473; DB 4; Length 126;
Best Local Similarity 73.6%; Pred. No. 8e-39;
Matches 92; Conservative 11; Mismatches 16; Indels 6; Gaps 2;
QY 1 QVOLLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
Db 1 QVQLVSGAEVKKPGASVKVCKASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
QY 61 AQKFGKRLTLTRDTSTSTAYMELRNLESDTAVYYCARCDTLLIWFPGPAPYN---DSWG 117
Db 61 AQKFGQVRVTMTRNTSISTAYMELSLRSEDTAVYYCAR---DWMITFGGVIVHYGMDVWG 117
QY 118 QGTLV 122
Db 118 QGTTV 122

RESULT 3
US-10-041-860-236
; Sequence 236, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 236
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-236

Query Match 71.6%; Score 473; DB 4; Length 126;
Best Local Similarity 73.6%; Pred. No. 8e-39;
Matches 92; Conservative 11; Mismatches 16; Indels 6; Gaps 2;
QY 1 QVOLLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
Db 1 QVQLVSGAEVKKPGASVKVCKASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
QY 61 AQKFGKRLTLTRDTSTSTAYMELRNLESDTAVYYCARCDTLLIWFPGPAPYN---DSWG 117
Db 61 AQKFGQVRVTMTRNTSISTAYMELSLRSEDTAVYYCAR---DWMITFGGVIVHYGMDVWG 117

QY 118 QGTLV 122
Db 118 QGTTV 122

RESULT 4
US-10-041-860-294
; Sequence 294, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 294
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-294

Query Match 71.6%; Score 473; DB 4; Length 126;
Best Local Similarity 73.6%; Pred. No. 8e-39;
Matches 92; Conservative 11; Mismatches 16; Indels 6; Gaps 2;
QY 1 QVOLLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
Db 1 QVQLVSGAEVKKPGASVKVCKASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
QY 61 AQKFGKRLTLTRDTSTSTAYMELRNLESDTAVYYCARCDTLLIWFPGPAPYN---DSWG 117
Db 61 AQKFGQVRVTMTRNTSISTAYMELSLRSEDTAVYYCAR---DWMITFGGVIVHYGMDVWG 117
QY 118 QGTLV 122
Db 118 QGTTV 122

RESULT 5
US-10-665-383-22
; Sequence 22, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: LaRochele, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; TITLE OF INVENTION: USING ANTI-PDGF-DD ANTIBODIES
; FILE REFERENCE: ABGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665,383
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/411,137
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-22

```
Query Match      71.6%; Score 473; DB 4; Length 126;
Best Local Similarity 73.6%; Pred. No. 8e-39;
Matches 92; Conservative 11; Mismatches 16; Indels 6; Gaps 2;

QY 1 QVOLLQYAADVKKPGASVKVSCCTASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSCASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESDTAVVYCARCDTLLIWFPGAPYNDW 117
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVTMTRNTSISTAYMELSLRSEDATVYYCAR----DVMITFGGVIVHGDVWG 117
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 118 QGTLV 122
   |||||
Db 118 QGTTV 122
   |||||

RESULT 6
US-10-041-860-19
; Sequence 19, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX 051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-19

Query Match      70.7%; Score 467; DB 4; Length 126;
Best Local Similarity 72.2%; Pred. No. 3.1e-38;
Matches 91; Conservative 10; Mismatches 17; Indels 8; Gaps 2;

QY 1 QVOLLQYAADVKKPGASVKVSCCTASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSCASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESDTAVVYCAR----CDTLLIWFPGAPYNDW 116
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVTMTRNTSISTAYMELSLRSEDATVYYCAR-----MDVW 116
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 117 QGTLV 122
   |||||
Db 117 QGTTV 122
   |||||

RESULT 7
US-10-041-860-201
; Sequence 201, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
```

```
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX 051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 201
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-201

Query Match      70.7%; Score 467; DB 4; Length 126;
Best Local Similarity 72.2%; Pred. No. 3.1e-38;
Matches 91; Conservative 10; Mismatches 17; Indels 8; Gaps 2;

QY 1 QVOLLQYAADVKKPGASVKVSCCTASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSCASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESDTAVVYCAR----CDTLLIWFPGAPYNDW 116
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVTMTRNTSISTAYMELSLRSEDATVYYCAR-----MDVW 116
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 117 QGTLV 122
   |||||
Db 117 QGTTV 122
   |||||

RESULT 8
US-10-041-860-288
; Sequence 288, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX 051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 288
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-288

Query Match      70.7%; Score 467; DB 4; Length 126;
Best Local Similarity 72.2%; Pred. No. 3.1e-38;
Matches 91; Conservative 10; Mismatches 17; Indels 8; Gaps 2;

QY 1 QVOLLQYAADVKKPGASVKVSCCTASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVSCASGYFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESDTAVVYCAR----CDTLLIWFPGAPYNDW 116
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVTMTRNTSISTAYMELSLRSEDATVYYCAR-----MDVW 116
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 117 QGTLV 122
   |||||
Db 117 QGTTV 122
   |||||
```

```

RESULT 9
US-10-665-383-18
; Sequence 18, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: Larochelelle, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; FILE REFERENCE: ABGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665,383
; PRIOR FILING DATE: 2003-09-16
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-18

Query Match      70.7%; Score 467; DB 4; Length 126;
Best Local Similarity 72.2%; Pred. No. 3.1e-38;
Matches 91; Conservative 10; Mismatches 17; Indels 8; Gaps 2;

QY 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINNVROATGQGLEWMGMNPNNSGNAGF 60
Db 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINNVROATGQGLEWMGMNPNNSGNAGF 60
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR-----CDTLLIWFGPAPYND 116
Db 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINNVROATGQGLEWMGMNPNNSGNAGF 60
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR-----CDTLLIWFGPAPYND 116
Db 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR-----CDTLLIWFGPAPYND 116
QY 117 GQGLTV 122
Db 117 GQGLTV 122

RESULT 10
US-10-041-860-37
; Sequence 37, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 37
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-37

Query Match      70.3%; Score 465; DB 4; Length 126;
Best Local Similarity 72.6%; Pred. No. 4.9e-38;
Matches 90; Conservative 12; Mismatches 18; Indels 4; Gaps 2;

QY 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINNVROATGQGLEWMGMNPNNSGNAGF 60
Db 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINNVROATGQGLEWMGMNPNNSGNAGF 60
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR-----WFGPAPYND 115
Db 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR-----WFGPAPYND 115
QY 116 WQGLTV 122
Db 116 WQGLTV 122

RESULT 11
US-10-041-860-40
; Sequence 40, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 40
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-40

Query Match      70.3%; Score 465; DB 4; Length 126;
Best Local Similarity 70.9%; Pred. No. 4.9e-38;
Matches 90; Conservative 14; Mismatches 13; Indels 10; Gaps 3;

QY 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINNVROATGQGLEWMGMNPNNSGNAGF 60
Db 1 QVOLLQYAADVKKPGASVKVCTASGYIFTSYDINNVROATGQGLEWMGMNPNNSGNAGF 60
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR-----WFGPAPYND 115
Db 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR-----WFGPAPYND 115
QY 116 WQGLTV 122
Db 116 WQGLTV 122

RESULT 12
US-10-041-860-202
; Sequence 202, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860

```


GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:52 ; Search time 9.24242 Seconds
(without alignments)
610.959 Million cell updates/sec

Title: US-09-674-752-32

Perfect score: 661

Sequence: 1 QVQLQYAADVKKPGASVKY.....LLIWFGPAPYDWSGGQTLV 122

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Published Applications AA_New:*
- 1: /SIDSS5/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
 - 2: /SIDSS5/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
 - 3: /SIDSS5/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
 - 4: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
 - 5: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
 - 6: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
 - 7: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
 - 8: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
 - 9: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
 - 10: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
 - 11: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
 - 12: /SIDSS5/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	461	69.7	122	9	US-10-982-440-61
2	461	69.7	247	11	US-11-054-515-927
3	461	69.7	247	11	US-11-054-515-948
4	461	69.7	247	11	US-11-266-444-927
5	461	69.7	247	11	US-11-266-444-948
6	459	69.4	120	9	US-10-982-440-47
7	448	67.8	253	11	US-11-054-515-3244
8	446	67.5	120	9	US-10-834-397-36
9	446	67.5	120	9	US-10-834-397-59
10	445.5	67.4	251	11	US-11-054-515-930
11	445.5	67.4	251	11	US-11-266-444-930
12	445	67.3	98	10	US-11-221-902-54
13	445	67.3	98	11	US-11-054-669-3
14	445	67.3	98	11	US-11-004-590-3
15	445	67.3	99	11	US-11-084-554-23
16	445	67.3	99	11	US-11-136-250-23
17	443	67.0	241	11	US-11-054-515-2031
18	443	67.0	241	11	US-11-266-444-2031
19	438	66.3	241	11	US-11-054-515-1948
20	438	66.3	241	11	US-11-266-444-1948
21	437.5	66.2	117	9	US-10-834-397-22

22	436.5	66.0	125	11	US-11-096-074-58	Sequence 58, Appl
23	436.5	66.0	125	11	US-11-095-822-58	Sequence 58, Appl
24	436.5	66.0	248	11	US-11-054-515-1721	Sequence 1721, Ap
25	436.5	66.0	248	11	US-11-266-444-1721	Sequence 1721, Ap
26	436	66.0	251	11	US-11-054-515-1389	Sequence 1389, Ap
27	436	66.0	251	11	US-11-266-444-1389	Sequence 1389, Ap
28	435.5	65.9	251	11	US-11-054-515-1586	Sequence 1586, Ap
29	435.5	65.9	251	11	US-11-266-444-1586	Sequence 1586, Ap
30	434	65.7	249	11	US-11-054-515-919	Sequence 919, App
31	434	65.7	249	11	US-11-266-444-919	Sequence 919, App
32	433.5	65.6	251	11	US-11-054-515-1870	Sequence 1870, Ap
33	433.5	65.6	251	11	US-11-266-444-1870	Sequence 1870, Ap
34	433	65.5	249	11	US-11-054-515-1635	Sequence 1635, Ap
35	433	65.5	249	11	US-11-266-444-1635	Sequence 1635, Ap
36	432.5	65.4	248	11	US-11-054-515-1472	Sequence 1472, Ap
37	432.5	65.4	248	11	US-11-266-444-1472	Sequence 1472, Ap
38	431.5	65.3	248	11	US-11-054-515-893	Sequence 893, App
39	431.5	65.3	248	11	US-11-054-515-1871	Sequence 1871, Ap
40	431.5	65.3	248	11	US-11-266-444-893	Sequence 893, App
41	431.5	65.3	248	11	US-11-266-444-1871	Sequence 1871, App
42	431.5	65.3	251	11	US-11-054-515-1869	Sequence 1869, Ap
43	431.5	65.3	251	11	US-11-266-444-1869	Sequence 1869, Ap
44	430.5	65.1	251	11	US-11-054-515-1738	Sequence 1738, Ap
45	430.5	65.1	251	11	US-11-266-444-1738	Sequence 1738, Ap

ALIGNMENTS

RESULT 1
US-10-982-440-61
; Sequence 61, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 61
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-982-440-61

Query Match	69.7%	Score 461	DB 9	Length 122
Best Local Similarity	73.0%	Pred. No. 2.2e-35		
Matches	89	Conservative	10	Mismatches 19; Indels 4; Gaps 1
Qy	1	QVQLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGGQLEWMGNPNNGAGF	60	
Db	1	QVQLVQSGAEVKKPGASVKVCSKASGYFTSYDINWVRQATGGQLEWMGNPNNGTGY	60	
Qy	61	AQKFGKRLTITRDTSTSTAYMELRNLESEDTAVYVCARCDDTTLLIWFGPAPYDWSGGGT	120	
Db	61	AQKFGKRVTTTRNTSTISTAYMELSLRSEDTAVYVCAKEIATVAGTRYG---MDVWGQGT	116	
Qy	121	LV 122		
Db	117	TV 118		

RESULT 2
US-11-054-515-927
; Sequence 927, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.


```

Db      114 TLV 116

RESULT 9
US-10-834-397-59
; Sequence 59, Application US/10834397
; Publication No. US20060003334A1
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA: US/10/834,397
; FILING DATE: 29-Apr-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-10-834-397-59

Query Match      67.5%; Score 446; DB 9; Length 120;
Best Local Similarity 70.7%; Pred. No. 5.1e-34;
Matches 87; Conservative 10; Mismatches 18; Indels 8; Gaps 2;

Qy 1 QVQLVQAAADVKKPGASVKVCSCTASGYIFTSYDINVVRQATGGGLEWMGMNPNNSGNAGF 60
Db 1 QVQLVQSGAEVKKPGASVKVCSKASGYTFTSYMHVVRQAPCGGLEWMGMNPNNSGTTNY 60
Qy 61 AQKFGRGLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTLLLIWFGPAPY-NDSKGQG 119
Db 61 AQKPGQGRVMTTRDTSTSTAYMELSLRSEDTAVYYCAR-----WGGDGFYAMDYWGQG 113
Qy 120 TLV 122
Db 114 TLV 116

RESULT 10
US-11-054-515-930

```

```

; Sequence 930, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 930
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-930

Query Match      67.4%; Score 445.5; DB 11; Length 251;
Best Local Similarity 70.5%; Pred. No. 1.1e-33;
Matches 86; Conservative 13; Mismatches 22; Indels 1; Gaps 1;

QY 1 QVQLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMPNSGNAGF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSAAEVKKPGASVKVCTASGYFTSYGISWVRQAPGQGLEWMGWSAYNGNTY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFKGRLTLTRDTSTSTAYMELNLESEDTAVYYCARCDTTLIWFPGAPYNDSWGQGT 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQRTVITRDTSTASTAYMELSSLRSEDTAVYYCARGDYDILTGY-YIPLRDYWGQGT 119
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 LV 122
   ||
Db 120 LV 121

RESULT 11
US-11-266-444-930
; Sequence 930, Application US/11266444
; Publication No. US2006062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21

```

```

; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 930
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-266-444-930

Query Match      67.4%; Score 445.5; DB 11; Length 251;
Best Local Similarity 70.5%; Pred. No. 1.1e-33;
Matches 86; Conservative 13; Mismatches 22; Indels 1; Gaps 1;

QY 1 QVQLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMPNSGNAGF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSAAEVKKPGASVKVCTASGYFTSYGISWVRQAPGQGLEWMGWSAYNGNTY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFKGRLTLTRDTSTSTAYMELNLESEDTAVYYCARCDTTLIWFPGAPYNDSWGQGT 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQRTVITRDTSTASTAYMELSSLRSEDTAVYYCARGDYDILTGY-YIPLRDYWGQGT 119
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 LV 122
   ||
Db 120 LV 121

RESULT 12
US-11-221-902-54
; Sequence 54, Application US/11221902
; Publication No. US2006008852A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGAT
; FILE REFERENCE: 040000-0317285
; CURRENT APPLICATION NUMBER: US/11/221,902
; CURRENT FILING DATE: 2005-09-09
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 54
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-221-902-54

Query Match      67.3%; Score 445; DB 10; Length 98;
Best Local Similarity 83.7%; Pred. No. 5.3e-34;
Matches 82; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLQYAADVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMPNSGNAGF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGAEVKKPGASVKVCTASGYFTSYDINWVRQATGQGLEWMGMPNSGNTGY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AQKFKGRLTLTRDTSTSTAYMELNLESEDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQRTVITRNTSISTAYMELSSLRSEDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 13
US-11-054-669-3
; Sequence 3, Application US/11054669
; Publication No. US20050261480A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES
; FILE REFERENCE: 30219/US/3
; CURRENT APPLICATION NUMBER: US/11/054,669
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: US 10/194,975
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 124

```

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-669-3

Query Match      67.3%; Score 445; DB 11; Length 98;
Best Local Similarity 83.7%; Pred. No. 5.3e-34;
Matches 82; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVOLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60

QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 14
US-11-004-590-3
; Sequence 3, Application US/11004590
; Publication No. US2006008883A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hammond, Phillip W.
; TITLE OF INVENTION: METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING
; TITLE OF INVENTION: CONTENT AND COMPOSITIONS THEREOF
; FILE REFERENCE: 185832/US/5
; CURRENT APPLICATION NUMBER: US/11/004,590
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: US 60/527,167
; PRIOR FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: US 60/581,613
; PRIOR FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US 60/601,665
; PRIOR FILING DATE: 2004-08-13
; PRIOR APPLICATION NUMBER: US 60/619,483
; PRIOR FILING DATE: 2004-10-14
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-004-590-3

Query Match      67.3%; Score 445; DB 11; Length 98;
Best Local Similarity 83.7%; Pred. No. 5.3e-34;
Matches 82; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVOLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60

QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98

RESULT 15
US-11-084-554-23
; Sequence 23, Application US/11084554
; Publication No. US20050260679A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A
```

```
; CURRENT APPLICATION NUMBER: US/11/084,554
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-084-554-23

Query Match      67.3%; Score 445; DB 11; Length 99;
Best Local Similarity 83.7%; Pred. No. 5.3e-34;
Matches 82; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVOLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMNPNNSGNAGF 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVOLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWMGMNPNNSGNTGY 60

QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAR 98

Search completed: May 5, 2006, 09:02:43
Job time : 9.24242 secs
```

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:51:41 ; Search time 8.0101 Seconds
(without alignments)
1465.455 Million cell updates/sec

Title: US-09-674-752-32
Perfect score: 661
Sequence: 1 QVQLQYAADVKKPGASVKY.....LLIWFGPAPYNDSWGQTLV 122
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_80.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	468	70.8	136	2 S31600	Ig heavy chain V r
2	456.5	69.1	127	2 S34014	Ig heavy chain V r
3	448	67.8	132	2 S31596	Ig heavy chain V r
4	445	67.3	98	2 S26918	Ig heavy chain V r
5	438	66.3	110	2 PH1670	Ig heavy chain V r
6	435	65.8	118	2 S36265	Ig heavy chain V r
7	431	65.2	135	2 S49530	anti-Sm antibody V
8	428.5	64.8	122	2 S36271	Ig heavy chain V r
9	426	64.4	171	2 S23623	Ig heavy chain V r
10	421.5	63.8	123	2 D33548	Ig heavy chain V-1
11	418.5	63.3	129	2 S36260	Ig heavy chain V r
12	416.5	63.0	129	2 S46393	Ig heavy chain V r
13	414	62.5	124	2 S19665	Ig heavy chain V r
14	411.5	62.3	121	2 S20783	Ig heavy chain V r
15	411.5	62.3	129	2 A33548	Ig heavy chain V-1
16	408.5	61.8	142	2 A32483	Ig heavy chain V r
17	406.5	61.5	142	2 S19245	Ig heavy chain pre
18	404.5	61.2	160	2 PL0105	anti-PR2 erythrocy
19	403.5	61.0	109	2 PH1658	Ig heavy chain V r
20	403	61.0	98	2 S26938	Ig heavy chain V r
21	403	61.0	117	2 S31680	Ig heavy chain V r
22	403	61.0	117	2 S18551	Ig heavy chain V r
23	401	60.7	116	2 PH0959	Ig heavy chain V r
24	399.5	60.4	148	2 S29257	Ig heavy chain V r
25	398	60.2	114	2 PH1667	Ig heavy chain V r
26	395	59.8	98	2 S26912	Ig heavy chain V r
27	395	59.8	98	2 S26919	Ig heavy chain V r
28	393	59.5	132	2 S46394	Ig heavy chain V r
29	392.5	59.4	125	2 PH0957	Ig heavy chain V r

30	392	59.3	128	2 PH0952	Ig heavy chain V r
31	391	59.2	98	2 S26920	Ig heavy chain V r
32	390.5	59.1	125	2 S68170	Ig heavy chain V r
33	390.5	59.1	126	2 I44151	Ig heavy chain V r
34	390	59.0	104	2 S69899	Ig heavy chain V r
35	390	59.0	118	2 PH1666	Ig heavy chain V r
36	390	59.0	120	2 PH0962	Ig heavy chain V r
37	389	58.9	117	2 S18553	Ig heavy chain V r
38	388	58.7	122	2 PH0958	Ig heavy chain V r
39	387	58.5	110	2 PH1669	Ig heavy chain V r
40	386	58.4	117	1 HVH0HG	Ig heavy chain pre
41	385	58.2	104	2 PH1665	Ig heavy chain V r
42	385	58.2	132	2 PH0954	Ig heavy chain V r
43	384	58.1	120	2 S26789	Ig heavy chain V r
44	382.5	57.9	131	2 S26792	Ig heavy chain V r
45	381.5	57.7	127	2 PH0955	Ig heavy chain V r

ALIGNMENTS

RESULT 1
S31600
Ig heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31600
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31600
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-136 <UI>
A;Cross-references: UNIPARC:UPI0000116453; EMBL:Z14165; NID:g30994; PIDN:CAA78534.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMW>

Query Match	70.8%	Score	468;	DB	2;	Length	136;
Best Local Similarity	73.0%	Pred. No.	6.2e-37;				
Matches	89;	Conservative	9;	Mismatches	14;	Indels	10;
Gaps	1;						
Qy	1	QVQLQYAADVKKPGASVKVCTASGVIPTSYDINWVRQATGGGLEWMGMNPNNSGNAGF	60				
Db	20	QVQLVSGAEVKKPGASVKVCSRSGITFTSYDINWVRQATGGGLEWMGMNPNNSGNTGY	79				
Qy	61	AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYVCARCDTLLIWFPGAPYNDSWGOGT	120				
Db	80	AQKFGQRTVTRNTSISTAYMELSLRSEDTAVYVCARWRDAP-----DIMSGGT	129				
Qy	121	LV 122					
Db	130	MV 131					

RESULT 2
S34014
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996
C;Accession: S34014; S30535
R;Mariette, X.; Tsapis, A.; Brouet, J.C.
Eur. J. Immunol. 23, 846-851, 1993
A;Title: Nucleotide sequence analysis of the variable domains of four human monoclonal
A;Reference number: S34001; MUID:93209281; PMID:7681398
A;Accession: S34014
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-127 <MAR>
A;Cross-references: UNIPARC:UPI0000176D31; EMBL:Z18321
C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 69.1%; Score 456.5; DB 2; Length 127;
Best Local Similarity 69.5%; Pred. No. 6.9e-36;
Matches 89; Conservative 11; Mismatches 17; Indels 11; Gaps 2;

QY 1 QVOLLQYADVKKPGASVKVSCASGYFTSYDINVRQATGGLEWGMWNPNSGNAGF 60
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :
Db 1 QVQVQSGAEVKKPGASVKVSCASGYFTSYDINVRQATGGLEWGMWNPNSGNTGY 60
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :

QY 61 AQKFQKGLTLTRDTSTAYMELRNLESEDTAVVYCARCDTLLIWFGPAPYN-----D 114
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :
Db 61 AQKFQGRVTMTNTSISTAYMELSSLRSEDTAVYFCAR-----LSIGVAVIRGYVALD 115
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :

QY 115 SWGQGTIV 122
| | | | |
Db 116 VMGQGTIV 123
| | | | |

RESULT 3
S31596
Ig heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31596
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31596
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-132 <UI>
A;Cross-references: UNIPARC:UPI0000116454; EMBL:Z14166; NID:g30996; PIDN:CAA78535.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 67.8%; Score 448; DB 2; Length 132;
Best Local Similarity 70.5%; Pred. No. 4.5e-35;
Matches 86; Conservative 13; Mismatches 9; Indels 14; Gaps 2;

QY 1 QVOLLQYADVKKPGASVKVSCASGYFTSYDINVRQATGGLEWGMWNPNSGNAGF 60
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :
Db 20 QVQVQSGAEVKKPGASVKVSCASGYFTSYDIDWVRQATGGLEWGMWNPNSGNTGY 79
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :

QY 61 AQKFQKGLTLTRDTSTAYMELRNLESEDTAVVYCARCDTLLIWFGPAPYNDWGQGT 120
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :
Db 80 AQKFQGRVTMTNTSISTAYMELSSLRAEDTAVYILAK-----AP---ANGQGT 125
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :

QY 121 LV 122
| |
Db 126 MV 127
| |

RESULT 4
S26918
Ig heavy chain V region (DP-15) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26918
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26918
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-98 <TOM>
A;Cross-references: UNIPARC:UPI0000031F36; EMBL:Z12317; NID:g32857; PIDN:CAA78187.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 67.3%; Score 445; DB 2; Length 98;
Best Local Similarity 83.7%; Pred. No. 6.3e-35;
Matches 82; Conservative 8; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVOLLQYADVKKPGASVKVSCASGYFTSYDINVRQATGGLEWGMWNPNSGNAGF 60
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :
Db 1 QVQLVQSGAEVKKPGASVKVSCASGYFTSYDINVRQATGGLEWGMWNPNSGNTGY 60
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :

QY 61 AQKFQKGLTLTRDTSTAYMELRNLESEDTAVYYCAR 98
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :
Db 61 AQKFQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR 98
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :

RESULT 5
PH1670
Ig heavy chain V region (clone 2A12) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996
C;Accession: PH1670
R;Hillson, J.L.; Karr, N.S.; Opplinger, I.R.; Mannik, M.; Sasso, E.H.
J. Exp. Med. 178, 331-336, 1993
A;Title: The structural basis of germline-encoded VH3 immunoglobulin binding to staphyloc
A;Reference number: PH1642; MUID:93301610; PMID:8315388
A;Accession: PH1670
A;Molecule type: mRNA
A;Residues: 1-110 <HIL>
A;Cross-references: UNIPARC:UPI0000176BEB
A;Experimental source: B cell
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;7-90/Domain: immunoglobulin homology <IMM>

Query Match 66.3%; Score 438; DB 2; Length 110;
Best Local Similarity 73.7%; Pred. No. 3.2e-34;
Matches 84; Conservative 8; Mismatches 14; Indels 8; Gaps 1;

QY 9 ADVKKPGASVKVSCASGYFTSYDINVRQATGGLEWGMWNPNSGNAGFAQKFKGL 68
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :
Db 1 AEWKPGASVKVSCASGYFTSYDINVRQATGGLEWGMWNPNSGNAGNTGYAQKFGGRV 60
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :

QY 69 TLTRDTSTAYMELRNLESEDTAVVYCARCDTLLIWFGPAPYNDWGQGTIV 122
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :
Db 61 TWRTNTSISTAYMELSSLRSEDTAVYYCAR-----GGKGEFDINGQGTIV 106
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :

RESULT 6
S36265
Ig heavy chain V region (clone alpha-MUC1-1) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C;Accession: S36265
R;Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.;
EMBO J. 12, 725-734, 1993
A;Title: Human anti-self antibodies with high specificity from phage display libraries.
A;Reference number: S36256; MUID:93178448; PMID:7679990
A;Accession: S36265
A;Status: preliminary; nucleic acid sequence not shown
A;Molecule type: mRNA
A;Residues: 1-118 <GRI>
A;Cross-references: UNIPARC:UPI0000118DE8; EMBL:Z18846; NID:g33121; PIDN:CAA79298.1; PID;
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 65.8%; Score 435; DB 2; Length 118;
Best Local Similarity 69.7%; Pred. No. 6.6e-34;
Matches 85; Conservative 11; Mismatches 18; Indels 8; Gaps 2;

QY 1 QVOLLQYADVKKPGASVKVSCASGYFTSYDINVRQATGGLEWGMWNPNSGNAGF 60
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :
Db 1 QVQLVQSGAEVKKPGASVKVSCASGYFTGYMHVVRQAPGQGLEWGMWNPNSGNTNY 60
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | :

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 09:04:30 ; Search time 45.904 Seconds
(without alignments)
1875.095 Million cell updates/sec

Title: US-09-674-752-32
Perfect score: 661
Sequence: 1 QVOLLQYAADVKPGASVKV.....LLIWFPGAPYNDSWGQGLV 122

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_05:80:.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	416.5	63.0	119	2	Q9UL94 HUMAN
2	410	62.0	124	2	Q9UL92 HUMAN
3	407	61.6	518	2	Q6N030 HUMAN
4	406.5	61.5	497	2	Q8WY24 HUMAN
5	405.5	61.3	125	2	Q9UL95 HUMAN
6	405.5	61.3	244	2	Q65ZC8 HUMAN
7	399	60.4	159	2	Q96Q80 HUMAN
8	397	60.1	498	2	Q6N041 HUMAN
9	393	59.5	475	2	Q6N095 HUMAN
10	389	58.9	500	2	Q9BRV0 HUMAN
11	386	58.4	117	1	HV1B HUMAN
12	383.5	58.0	500	2	Q6N091 HUMAN
13	381	57.6	117	1	HV1G HUMAN
14	379	57.3	469	2	Q7Z7P5 HUMAN
15	378	57.2	147	1	HV1C HUMAN
16	371	56.1	116	2	Q9UL89 HUMAN
17	364.5	55.1	147	2	Q925S3 MOUSE
18	364.5	55.1	157	2	Q95978 HUMAN
19	364.5	55.1	480	2	Q6P089 HUMAN
20	363.5	55.0	119	2	Q9GY22 MOUSE
21	363.5	55.0	120	1	HV03 MOUSE
22	360.5	54.5	458	2	Q5BK05 RAT
23	356	53.9	617	2	Q4KML5 MOUSE
24	355.5	53.8	458	2	Q5BJ22 RAT
25	355	53.7	591	2	Q4QW0 RAT
26	354.5	53.6	473	2	Q9D8L4 MOUSE
27	352.5	53.3	140	1	HV02 MOUSE
28	352.5	53.3	519	2	Q5EBM2 HUMAN
29	351.5	53.2	120	2	Q6NSA4 HUMAN
30	351.5	53.2	475	2	Q5FVP3 RAT
31	351.5	53.2	616	2	Q504M7 MOUSE

32	350.5	53.0	120	2	Q920E8 MOUSE
33	350	53.0	139	1	HV07 MOUSE
34	350	53.0	145	2	Q924Q7 MOUSE
35	349.5	52.9	489	2	Q8VCX4 MOUSE
36	349.5	52.9	598	2	Q568Y0 RAT
37	349	52.8	463	2	Q99LC4 MOUSE
38	348	52.6	118	1	HV51 MOUSE
39	348	52.6	241	2	Q921A6 MOUSE
40	347.5	52.6	146	2	Q924Q8 MOUSE
41	346.5	52.4	468	2	Q569W9 MOUSE
42	346.5	52.4	470	2	Q7TMK1 MOUSE
43	346.5	52.4	481	2	Q91WT1 MOUSE
44	346	52.3	590	2	Q4V9V8 MOUSE
45	344.5	52.1	120	2	Q5F211 MOUSE

ALIGNMENTS

RESULT 1
Q9UL94_HUMAN PRELIMINARY; PRT; 119 AA.
AC Q9UL94;2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531; Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035020; AAD56256.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13205 MW; 13E64F5345F4A16E CRC64;

Query Match 63.0%; Score 416.5; DB 2; Length 119;
Best Local Similarity 65.6%; Pred. No. 9.6e-37;
Matches 80; Conservative 14; Mismatches 21; Indels 7; Gaps 2;

Qy	1	QVOLLQYAADVKPGASVKVCTASGYFTSYINVRQATGCGLEWGMWNPNSGNAGF	60
Db	1	EVQLVESGAELKPGASVKSCASGYFTGYVHWVRQAPGQGLEWMGINPNSWTTNY	60
Qy	61	AQKFKGLTLTRDTSTSTAYMELRNLESDTAVVYCARCDTTLILWFGPAPYNDSWGQGT	120
Db	61	AQKFGQVTKTQTSISTAYMELSRLESDDTAVYYCARGGL-WFDP-----WQGGT	113
Qy	121	LV 122	
Db	114	LV 115	

RESULT 2
Q9UL92_HUMAN PRELIMINARY; PRT; 124 AA.
AC Q9UL92;


```
Db      137 GTLV 140
|||||
RESULT 5
Q9UL95_HUMAN PRELIMINARY; PRT; 125 AA.
ID Q9UL95_HUMAN PRELIMINARY; PRT; 125 AA.
AC Q9UL95;
DR InterPro; IPR003599; Ig.
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035019; AAD56255.1; -; mRNA.
DR HSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 125
FT NON_TER 125
SQ SEQUENCE 125 AA; 13516 MW; 0D3CD5C232488EAC CRC64;

Query Match 61.3%; Score 405.5; DB 2; Length 125;
Best Local Similarity 63.9%; Pred. No. 1.6e-35;
Matches 78; Conservative 15; Mismatches 28; Indels 1; Gaps 1;

Qy 1 QVQLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMPNPSGNAGF 60
Db 1 EVQLVESGAEVKKGASVKVCKASGYFTGYVHMVVRQAPGQGLEWMGMPNPSGCTNY 60

Qy 61 AQKFKGLTLTRDTSTSTAYMELRNLESDTAVYYCARCDTLLIWFPGPAPYNDSWQGT 120
Db 61 AQKVGQRTVTRDTTISTAYMELSLRSDPTAVYYCARSGQGGRIAAAGDAF-DIWQGGT 119

Qy 121 LV 122
Db 120 MV 121

RESULT 6
Q65ZC8_HUMAN PRELIMINARY; PRT; 244 AA.
ID Q65ZC8_HUMAN PRELIMINARY; PRT; 244 AA.
AC Q65ZC8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";

Query Match 60.4%; Score 399; DB 2; Length 159;
Best Local Similarity 62.0%; Pred. No. 1e-34;
Matches 80; Conservative 17; Mismatches 22; Indels 10; Gaps 2;

Qy 1 QVQLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMPNPSGNAGF 60
Db 20 QVQLVQSGAEVKKPGASVKVCKASGYFTFSNYVMVVRQAPGQGPWMGVINPSSGSARY 79

Qy 61 AQKFKGLTLTRDTSTSTAYMELRNLESDTAVYYCARCDTLLIWFPGPAPYN----- 113
Db 80 SQKFGQLTMTTRDTSTSTVYMDLSLRSDPTAVYFCAR---EMEITFGGAVSKGFFYYGM 136

Qy 114 DSWGQGTLY 122
Db 137 DVMGQGTIV 145

RESULT 8
Q96QSO_HUMAN PRELIMINARY; PRT; 159 AA.
ID Q96QSO_HUMAN PRELIMINARY; PRT; 159 AA.
AC Q96QSO;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Putative matrix cell adhesion molecule-3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Tilson M.D.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY039025; AAK82649.1; -; mRNA.
DR HSP; P01869; IAE6.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 159 AA; 17497 MW; 5D29537E881PAF02 CRC64;

Query Match 60.4%; Score 399; DB 2; Length 159;
Best Local Similarity 62.0%; Pred. No. 1e-34;
Matches 80; Conservative 17; Mismatches 22; Indels 10; Gaps 2;

Qy 1 QVQLQYAADVKKPGASVKVCTASGYIFTSYDINWVRQATGQGLEWMGMPNPSGNAGF 60
Db 20 QVQLVQSGAEVKKPGASVKVCKASGYFTFSNYVMVVRQAPGQGPWMGVINPSSGSARY 79

Qy 61 AQKFKGLTLTRDTSTSTAYMELRNLESDTAVYYCARCDTLLIWFPGPAPYN----- 113
Db 80 SQKFGQLTMTTRDTSTSTVYMDLSLRSDPTAVYFCAR---EMEITFGGAVSKGFFYYGM 136

Qy 114 DSWGQGTLY 122
Db 137 DVMGQGTIV 145

RESULT 8
```

```
Q6N041_HUMAN
ID Q6N041_HUMAN PRELIMINARY; PRT; 498 AA.
AC Q6N041;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKF2p686O16217 (Fragment).
GN Name=DKF2p686O16217;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP TISSUE=Human rectum tumor;
RC The German Human cDNA Consortium;
RA Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA Mewes H.W., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640710; CAE45829.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q6N041; 268-476.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON TER
SQ SEQUENCE 498 AA; 54125 MW; 40B3208A84E03B46 CRC64;

Query Match 60.1%; Score 397; DB 2; Length 498;
Best Local Similarity 60.9%; Pred. No. 6.2e-34;
Matches 78; Conservative 16; Mismatches 20; Indels 14; Gaps 2;

QY 1 QVQLQYAADVKKPGASVKVCTASGYIFTSYDINWVROATGQLEWMGMNPNNSGNAGF 60
DB 35 QVQLVSGDAELKRPASVTSICRASGYSTFTHHWVRQAGQRLSEWGMIMPRDSKTY 94
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESDTAVYVCARCDTLLIWFPG-----APYND 114
DB 95 AQRFQGVSNTRDTSTSTIYELSSLESDTAMFFCARA-----GPGYGTSAIYFD 146
QY 115 SWGGGTLV 122
DB 147 YWGGGTLV 154

RESULT 9
Q6N095_HUMAN PRELIMINARY; PRT; 475 AA.
ID Q6N095_HUMAN PRELIMINARY;
AC Q6N095;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKF2p686K03196.
GN Name=DKF2p686K03196;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP TISSUE=Esophagus tumor;
RC The German cDNA Consortium;
RA
```

```
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640621; CAE45775.1; -; mRNA.
DR HSSP; P01861; 1ADQ.
DR SMR; Q6N095; 20-475.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 475 AA; 52360 MW; 7BA14104CD2DB8F0 CRC64;

Query Match 59.5%; Score 393; DB 2; Length 475;
Best Local Similarity 60.7%; Pred. No. 1.6e-33;
Matches 74; Conservative 18; Mismatches 30; Indels 0; Gaps 0;

QY 1 QVQLQYAADVKKPGASVKVCTASGYIFTSYDINWVROATGQLEWMGMNPNNSGNAGF 60
DB 20 QVQLVSGDAELKRPASVTSICRASGYSTFTHHWVRQAGQRLSEWGMIMPRDSKTY 79
QY 61 AQKFKGRLTLTRDTSTSTAYMELRNLESDTAVYVCARCDTLLIWFPGAPYNDMSGQGT 120
DB 80 AQTFQGVSNTRDTSTSTIYELSSLESDTAVYVCARCDTLLIWFPGAPYNDMSGQGT 139
QY 121 LV 122
DB 140 KV 141

RESULT 10
Q9BRV0_HUMAN PRELIMINARY; PRT; 500 AA.
ID Q9BRV0_HUMAN PRELIMINARY;
AC Q9BRV0;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE MGC27165 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.W., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heish F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uddin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smalish D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
```



```
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Prostate;
RA Strausberg R.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC005951; AA05951.1; -; mRNA.
DR HSP; P01876; I0W0.
DR SMR; Q9BRV0; 25-300, 270-478.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR Pfam; PF07654; C1-set; 2.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 500 AA; 54154 MW; 0A9BF43F2A3CC6D9 CRC64;

Query Match 58.9%; Score 389; DB 2; Length 500;
Best Local Similarity 58.9%; Pred. No. 4.5e-33;
Matches 76; Conservative 14; Mismatches 27; Indels 12; Gaps 2;

Qy 1 QVQLQYAADVKKGASVKVCTASGYIFTSYDINVRQATGQGLEWMGNPNNSGNAGF 60
Db 20 QVHLVQSGAEVWSPGASVRSCKTSYGAFHYISIIIVRQAPQGQLEWMGWSISSDTRF 79

Qy 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR-----CDTLLIWFGPAPYN 113
Db 80 AKKFGQGRVTLTTRDTSTSTVYMWELSLASDDTAVYYCARRVSSYSCQNDYIY----YM 134

Qy 114 DSWGQGTIV 122
Db 135 DVMGKGTIV 143

RESULT 11
HV1B HUMAN STANDARD; PRT; 117 AA.
AC P01743;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region HG3 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC MEDLINE=83144028; PubMed=6298778;
RA Rechavi G., Ram D., Glazer L., Zakut R., Givol D.;
RT "Evolutionary aspects of immunoglobulin heavy chain variable region
(VH) gene subgroups.";
RL Proc. Natl. Acad. Sci. U.S.A. 80:855-859 (1983).
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR EMBL; J00240; AAA52988.1; -; Genomic_DNA.
DR PIR; A02024; HVHUG.
DR HSP; P01751; INQB.
DR SMR; P01743; 20-116.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.

DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
KW immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region HG3.
FT DOMAIN 20 >117 Ig-like.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12946 MW; 2D3P92FC60CD1FE7 CRC64;

Query Match 58.4%; Score 386; DB 1; Length 117;
Best Local Similarity 73.5%; Pred. No. 1.8e-33;
Matches 72; Conservative 12; Mismatches 14; Indels 0; Gaps 0;

Qy 1 QVQLQYAADVKKGASVKVCTASGYIFTSYDINVRQATGQGLEWMGNPNNSGNAGP 60
Db 20 QVQLVQSGAEVWSPGASVKVSKASGYTFNSYMHVYRQAPQGQLEWMGIINPSGGSTSY 79

Qy 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCAR 98
Db 80 AQKFGQGRVTLTRDTSTSTVYMWELSLRSEDTAVYYCAR 117

RESULT 12
Q6N091 HUMAN
ID Q6N091_HUMAN PRELIMINARY; PRT; 500 AA.
AC Q6N091;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686C02220 (Fragment).
GN Name=DKFZp686C02220;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640625; CAB45779.1; -; mRNA.
DR HSP; P01751; 1A6W.
DR SMR; Q6N091; 270-478.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON_TER 1 1
SQ SEQUENCE 500 AA; 54160 MW; 3C423A17D65A41E4 CRC64;

Query Match 58.0%; Score 383.5; DB 2; Length 500;
Best Local Similarity 60.0%; Pred. No. 1.8e-32;
Matches 75; Conservative 18; Mismatches 23; Indels 9; Gaps 2;

Qy 1 QVQLQYAADVKKGASVKVCTASGYIFTSYDINVRQATGQGLEWMGNPNNSGNAGP 60
Db 38 QVQLVQSGAEVWSPGASVKVSKASGYTFSDHSITLWLRQAPQGQLEWIGWISAYSGTTY 97

Qy 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDTAVYYCARCDTLLIWFGPAPYND---WG 117
```



```
Qy 121 LV 122
Db 134 LV 135

RESULT 15
HV1C HUMAN STANDARD; PRT; 147 AA.
AC P01744;
DT 21-JUL-1986 (Rel. 01, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DE 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region ND precursor (Fragments).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=83065234; PubMed=6815656;
RA Kenten J.H., Molgaard H.V., Houghton M., Derbyshire R.B., Viney J.,
RA Bell L.O., Gould H.J.;
RT "Cloning and sequence determination of the gene for the human
RT immunoglobulin epsilon chain expressed in a myeloma cell line.";
RL Proc. Natl. Acad. Sci. U.S.A. 79:6661-6665(1982).
RN [2]
RP PROTEIN SEQUENCE OF 20-147.
RA Bennich H.H., Johansson S.G.O., von Bahr-Lindstrom H.;
RL (In) Bach M.K. (eds.);
RL Immediate hypersensitivity: modern concepts and developments, pp.1-36,
RL Marcel Dekker, New York (1978).
CC -I- MISCELLANEOUS: This epsilon chain was isolated from a myeloma
CC protein.
CC -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR HSPP; P01751; 1NQB.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; F:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW immunoglobulin V region; Pyrrolidone carboxylic acid; Signal.
FT SIGNAL 1 19
FT CHAIN 20 147 Ig heavy chain V-I region ND.
FT DOMAIN 20 131 IG-like.
FT MOD_RES 20 20 Pyrrolidone carboxylic acid.
FT DISULFID 41 115 T -> V (in Ref. 2).
FT CONFLICT 21 21 IH -> HI (in Ref. 2).
FT CONFLICT 53 54 VG -> GV (in Ref. 2).
FT CONFLICT 67 68 Missing (in Ref. 2).
FT CONFLICT 125 125
FT NON_TER 147 147
SQ SEQUENCE 147 AA; 16496 MW; 948F9F72A5366C20 CRC64;

Query Match
Best Local Similarity 57.2%; Score 378; DB 1; Length 147;
Matches 72; Conservative 19; Mismatches 26; Indels 12; Gaps 2;

Qy 1 QVQLQYAAADVKKPGASVKSCSTASGYIFTSYDINWVRQATGQGLEWGWMPNPSGNAGF 60
Db 20 QTQLVQSGAEVRKPGASVRVSKASGYTFIDSYIHRIWIRQAPGHGLEWGWMPNPSGGTNY 79
Qy 61 AQKFKGRLTLTRDTSTSTAYMELRNLESEDATVYYCARCDTLLIWFPGAPYN----- 113
```

```
Db 80 APRFOGRVTWTRDASFSTAYMDLRLSLRSDDSAVFYCAKSDP-----FMSDYNNFDYSYTL 134
Qy 114 DSWGQGTLV 122
Db 135 DSWGQGTIV 143

Search completed: May 5, 2006, 09:14:32
Job time : 45.904 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:28 ; Search time 39.1247 Seconds
(without alignments)
1111.793 Million cell updates/sec

Title: US-09-674-752-33

Perfect score: 523

Sequence: 1 EVQLVESGGGLVQPGKSLRL.....YMQNSLRABDTALTYCAKD 99

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21.*

- 1: Geneseqp1980s.*
- 2: Geneseqp1990s.*
- 3: Geneseqp2000s.*
- 4: Geneseqp2001s.*
- 5: Geneseqp2002s.*
- 6: Geneseqp2003as.*
- 7: Geneseqp2003bs.*
- 8: Geneseqp2004s.*
- 9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	523	100.0	99	3	AAY50960 Human FVI
2	523	100.0	99	6	ABO27083 Human ger
3	523	100.0	99	7	ADF10018 VEGF anti
4	523	100.0	99	7	ADF09910 Antibody
5	523	100.0	99	7	ADF10120 Antibody
6	523	100.0	99	7	ADJ80296 VH Gene 1
7	523	100.0	99	9	ADJ75301 Protein e
8	523	100.0	123	2	AAR66303 Human imm
9	523	100.0	141	8	ADS88107 Human CD2
10	517	98.9	98	3	AAB40072 Anti-hiL1
11	517	98.9	98	5	ABG78185 Human Fv
12	517	98.9	98	5	ABG91876 Human ant
13	517	98.9	118	4	Aau02593 Anti-adip
14	517	98.9	120	4	AG65553 Amino aci
15	517	98.9	120	5	ABB06276 VH3-4 ami
16	517	98.9	120	7	ADH40225 Human VH3
17	517	98.9	120	8	ADJ57865 Light var
18	513	98.1	252	5	ABP45405 Human Bly
19	513	98.1	252	7	ADG96232 Single ch
20	512	97.9	119	4	AAE07025 Human hea
21	512	97.9	119	8	ADQ89310 Human hea
22	512	97.9	119	9	ABE09583 Human hea
23	511	97.7	120	2	AAY43255 VH domain
24	508	97.1	248	4	AG65559 Anti-NEDR

25	507	96.9	272	8	ADO19054	Ado19054 Human ant
26	506	96.7	120	2	AAU43254	Aay43254 VH Domain
27	506	96.7	131	4	AAU02591	Aau02591 Anti-adip
28	506	96.7	291	8	ADN06989	Adn06989 Human EFG
29	504	96.4	141	8	ADS88053	Ads88053 Human CD2
30	504	96.4	146	6	ABJ36923	Abj36923 Anti-CD40
31	502	96.0	126	4	AAU02623	Aau02623 Anti-adip
32	502	96.0	244	8	ADG34303	Adg34303 Neurokini
33	502	96.0	245	5	ABP45915	Abp45915 Human Bly
34	502	96.0	245	7	ADG96742	Adg96742 Single ch
35	501	95.8	117	9	ABE27732	Aeb27732 prostate
36	501	95.8	241	9	ABE27752	AbE27752 Anti-pros
37	501	95.8	243	8	ADG34310	Adg34310 Neurokini
38	500	95.6	122	9	ABE27730	Aeb27730 prostate
39	500	95.6	227	4	AAU08385	Aau08385 Anti-OPGb
40	500	95.6	245	9	ABE27750	Aeb27750 Anti-pros
41	499	95.4	118	4	AAU02605	Aau02605 Anti-adip
42	499	95.4	127	9	ADY26766	Ady26766 Anti-NGF-
43	498	95.2	124	2	AAW90286	Aaw90286 Human ant
44	498	95.2	141	8	ADS88057	Ads88057 Human CD2
45	498	95.2	149	3	AAY64737	Aay64737 Human 5'

ALIGNMENTS

RESULT 1

AA50960

ID AAY50960 standard; protein; 99 AA.

XX AAY50960;

DT 23-MAR-2000 (first entry)

DE Human FVIII antibody A3-C1 scFv heavy chain protein DP-31.

XX Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

KW scFv; A3-C1.

OS Homo sapiens.

PN WO9958680-A2.

XX 18-NOV-1999.

XX 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

PI Voorberg JJ, Van Den Brink EN, Turenhout EAM;

XX WPI; 2000-053102/04.

PT New polynucleotide, polypeptide and antibody useful for diagnosing the presence of neutralizing antibodies against factor VIII and for treatment of hemophilia A patients with these antibodies.

XX Example 8; Fig 9A; 61pp; English.

CC This invention describes a novel polynucleotide (I) (and complements and hybridizable polynucleotides) comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity which has hemostatic activity. (I) is useful a primer or probe for detecting the presence of inhibitory antibodies directed against factor VIII. The polypeptides of the invention and the antibodies generated from them are useful in compositions for neutralizing factor VIII inhibiting antibodies in hemophilia A patients. This sequence represents the human factor VIII antibody A3-C1 specific scFv protein DP-31 which is used in the method of the invention

XX Sequence 99 AA;

Query Match 100.0%; Score 523; DB 3; Length 99;
 Best Local Similarity 100.0%; Pred. No. 2e-45; Indels 0; Gaps 0;
 Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
 |||||
 Db 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
 |||||

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAKD 99
 |||||
 Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAKD 99
 |||||

RESULT 2
 ABO27083
 ID ABO27083 standard; protein; 99 AA.
 XX
 AC ABO27083;
 XX
 DT 10-SEP-2003 (first entry)
 XX
 DE Human germline heavy chain variable region gene segment #16.
 XX
 KW Human; heavy chain variable region; VH; humanised antibody;
 KW chimeric antibody; complementarity determining region; CDR;
 KW canonical CDR structure type.
 XX
 OS Homo sapiens.
 XX
 PN US2003039649-A1.
 XX
 PD 27-FEB-2003.
 XX
 PF 12-JUL-2002; 2002US-00194975.
 XX
 PR 12-JUL-2001; 2001US-0305111P.
 XX
 PA (FOOT/) FOOTE J.
 XX
 PI Foote J;
 XX
 DR WPI; 2003-492151/46.
 XX
 PT Making humanized antibody for converting antibody, by making chimeric
 PT antibodies containing complementarity determining region from non-human
 PT antibody and appropriate framework sequences of human antibodies.
 XX
 PS Example 1; Fig 1; 31pp; English.
 XX
 CC The invention describes a method of making a humanised antibody,
 CC comprising making chimeric antibodies containing a complementarity
 CC determining region (CDR) from a non-human antibody and appropriate
 CC framework sequences (I) of human antibodies. (I) is selected by using
 CC canonical CDR structure types of non-human antibody in comparison to
 CC germline canonical CDR structure types of human antibodies as the basis
 CC for selection, for humanisation. The method is useful for making a
 CC humanised antibody or a converted antibody. The method is applicable for
 CC converting a subject antibody sequence of any subject species to a less
 CC immunogenic form suitable for use in an object species. The method is
 CC reliable for identifying suitable human framework sequences to support
 CC non-human CDR regions and to provide humanised antibodies that retain
 CC high antigen binding with low immunogenicity in humans, without the need
 CC for direct comparison of framework sequences, without the need for
 CC determining critically important amino acid residues in the framework,
 CC and without the need for multiple iteration and construction to obtain
 CC humanised antibodies with suitable therapeutic properties. The antibody
 CC has high affinity and low immunogenicity without need for comparing
 CC framework sequences between non-human and human antibodies. This sequence
 CC represents a human heavy chain variable region gene segment used in the
 CC creation of humanised antibodies
 XX
 SQ Sequence 99 AA;

Query Match 100.0%; Score 523; DB 6; Length 99;
 Best Local Similarity 100.0%; Pred. No. 2e-45; Indels 0; Gaps 0;
 Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
 |||||
 Db 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
 |||||

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAKD 99
 |||||
 Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAKD 99
 |||||

RESULT 3
 ADF10018
 ID ADF10018 standard; protein; 99 AA.
 XX
 AC ADF10018;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE VEGF antibody heavy chain variable region VH_3-9.
 XX
 KW Antibody; stability; solubility; antigen binding affinity;
 KW variable region; human; VEGF.
 XX
 OS Homo sapiens.
 XX
 PN WO2003074679-A2.
 XX
 PD 12-SEP-2003.
 XX
 PF 03-MAR-2003; 2003WO-US006598.
 XX
 PR 01-MAR-2002; 2002US-0360843P.
 PR 29-MAY-2002; 2002US-0384197P.
 XX
 PA (XENC-) XENCOR.
 XX
 PI Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
 XX WPI; 2003-722066/68.
 DR
 XX
 PT Computer optimization of physicochemical properties of antibodies
 PT comprises analyzing the interactions of amino acids at variable
 PT positions.
 XX
 PS Example 6; Fig 16a; 135pp; English.
 XX
 CC The present invention relates to a method for optimizing at least one
 CC physico-chemical property of an antibody by a computational screening
 CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.
 XX
 SQ Sequence 99 AA;

Query Match 100.0%; Score 523; DB 7; Length 99;
 Best Local Similarity 100.0%; Pred. No. 2e-45; Indels 0; Gaps 0;
 Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
 |||||
 |||||

```
Db      1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Qy      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99
      |||
Db      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99

RESULT 4
ADF09910
ID ADF09910 standard; protein; 99 AA.
XX
AC ADF09910;
XX
DT 12-FEB-2004 (first entry)
XX
DE Antibody heavy chain variable region VH_3-9.
KW Antibody; stability; solubility; antigen binding affinity;
KW variable region; human.
XX
OS Homo sapiens.
XX
PN WO2003074679-A2.
XX
PD 12-SEP-2003.
XX
PF 03-MAR-2003; 2003WO-US006598.
XX
PR 01-MAR-2002; 2002US-0360843P.
XX
PR 29-MAY-2002; 2002US-0384197P.
XX
PA (XENC-) XENCOR.
XX
PI Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
XX
DR WPI; 2003-722066/68.
XX
PT Computer optimization of physicochemical properties of antibodies
PT comprises analyzing the interactions of amino acids at variable
PT positions.
PS Disclosure; Fig 2a; 135pp; English.
XX
CC The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC method. The method comprises: receiving a template antibody structure;
CC selecting at least one variable position belonging to the antibody
CC structure; selecting at least one amino acid to be considered at the
CC variable position(s); analyzing the interaction of each selected amino
CC acid at each variable position with at least part of the remainder of the
CC antibody, including the selected amino acids at other variable positions;
CC and identifying a set of at least one antibody sequence with at least one
CC optimized physico-chemical property. The method is useful for optimizing
CC the physico-chemical properties of an antibody, especially the stability,
CC solubility, or antigen binding affinity. The optimized antibody may be
CC useful for treating a patient. The present sequence is an antibody
CC variable region sequence used to illustrate the invention.
XX
SQ Sequence 99 AA;
      Query Match 100.0%; Score 523; DB 7; Length 99;
      Best Local Similarity 100.0%; Pred. No. 2e-45;
      Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
      |||
Db      1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60

Qy      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99
      |||
Db      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99

RESULT 6
ADJ80296
ID ADJ80296 standard; protein; 99 AA.
XX
AC ADJ80296;
XX
DT 06-MAY-2004 (first entry)
```

```
RESULT 5
ADF10120
ID ADF10120 standard; protein; 99 AA.
XX
AC ADF10120;
XX
DT 12-FEB-2004 (first entry)
XX
DE Antibody heavy chain variable region VH_3-9.
KW Antibody; stability; solubility; antigen binding affinity;
KW variable region; human.
XX
OS Homo sapiens.
XX
PN WO2003074679-A2.
XX
PD 12-SEP-2003.
XX
PF 03-MAR-2003; 2003WO-US006598.
XX
PR 01-MAR-2002; 2002US-0360843P.
XX
PR 29-MAY-2002; 2002US-0384197P.
XX
PA (XENC-) XENCOR.
XX
PI Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
XX
DR WPI; 2003-722066/68.
XX
PT Computer optimization of physicochemical properties of antibodies
PT comprises analyzing the interactions of amino acids at variable
PT positions.
PS Example 16; Fig 40a; 135pp; English.
XX
CC The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC method. The method comprises: receiving a template antibody structure;
CC selecting at least one variable position belonging to the antibody
CC structure; selecting at least one amino acid to be considered at the
CC variable position(s); analyzing the interaction of each selected amino
CC acid at each variable position with at least part of the remainder of the
CC antibody, including the selected amino acids at other variable positions;
CC and identifying a set of at least one antibody sequence with at least one
CC optimized physico-chemical property. The method is useful for optimizing
CC the physico-chemical properties of an antibody, especially the stability,
CC solubility, or antigen binding affinity. The optimized antibody may be
CC useful for treating a patient. The present sequence is an antibody
CC variable region sequence used to illustrate the invention.
XX
SQ Sequence 99 AA;
      Query Match 100.0%; Score 523; DB 7; Length 99;
      Best Local Similarity 100.0%; Pred. No. 2e-45;
      Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
      |||
Db      1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60

Qy      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99
      |||
Db      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99

RESULT 6
ADJ80296
ID ADJ80296 standard; protein; 99 AA.
XX
AC ADJ80296;
XX
DT 06-MAY-2004 (first entry)
```



```

RESULT 8
AAR66303
ID AAR66303 standard; protein; 123 AA.
XX
XX AC AAR66303;
XX
XX 25-MAR-2003 (revised)
DT 02-AUG-1995 (first entry)
XX
XX Human immunoglobulin variable heavy chain #9.
XX
XX Primer; PCR; amplify; human; immunoglobulin; variable; heavy chain;
XX cosmid; placenta; vector; pJB81; E.coli; mammalian.
XX
XX Homo sapiens.
XX
XX WO9426895-A1.
XX
XX 24-NOV-1994.
XX
XX 10-MAY-1993; 93WO-JP000603.
XX
XX 10-MAY-1993; 93WO-JP000603.
XX
XX (NIBS ) JAPAN TOBACCO INC.
XX
XX Honjo T, Matsuda F;
XX
XX WPI; 1995-006791/01.
XX
XX N-PSDB; AAQ78947.
XX
XX DNA fragment comprising human immunoglobulin Vh genes - for the
XX production of human immunoglobulin in mammalian hosts.
XX
XX Claim 18; Page 41-42; 130pp; Japanese.
XX
XX Protein sequences (AAR66295-51) are novel human immunoglobulin heavy
XX chain sequences encoded by novel isolated genes. The genes (AAQ78939-
XX 79002) were isolated and cloned from a series of cosmid constructs: Y202;
XX Y103; Y21; Y6; Y24; 3-31; M84; M18 and M131, by PCR amplification using
XX primers AAQ78917-38. The genes are subdivided into 5 families of Vh
XX genes. The fragments cover a region of 800 kb. The DNA fragments were
XX isolated from high molecular weight DNA from human placenta. The DNA was
XX partially digested with Taqi restriction enzyme. The fragments were
XX separated by gel electrophoresis and 35-45 kb fractions were collected.
XX The fragments were ligated with ClaI-digested cosmid vector pJB81. The
XX ligation products were in vitro packed and infected into E.coli 490A. The
XX fragments were then subcloned by colony hybridisation. The Vh genes and
XX the DNA fragments encoding them are useful in producing human
XX immunoglobulin in mammalian hosts. (Updated on 25-MAR-2003 to correct PN
XX field.)
XX
XX SQ Sequence 123 AA;
XX
XX Query Match 100.0%; Score 523; DB 2; Length 123;
XX Best Local Similarity 100.0%; Pred. No. 2.6e-45;
XX Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
DB 20 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGIGY 79
QY 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAKD 99
DB 80 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAKD 118
XX
XX RESULT 9
XX ADS88107
XX ID ADS88107 standard; protein; 141 AA.
XX
XX AC ADS88107;
XX
XX 18-NOV-2004 (first entry)
XX
XX Human CD20 antibody protein sequence SeqID56.
XX
XX human monoclonal antibody; CD20;
XX human B-lymphocyte-restricted differentiation antigen; Bp35; cytostatic;
XX antipsoriatic; antiinflammatory; neuroprotective; ophthalmological;
XX nephrotropic; antiasthmatic; antiarteriosclerotic; antianaemic;
XX antirheumatic; antiarthritic; antithyroid; anti-HIV; gene therapy;
XX cancer; psoriasis; inflammatory bowel disease; meningitis; uveitis;
XX glomerulonephritis; asthma; atherosclerosis; multiple sclerosis;
XX haemolytic anaemia; myasthenia gravis; rheumatoid arthritis;
XX Graves' disease; HIV; human.
XX
XX Homo sapiens.
XX
XX WO2004035607-A2.
XX
XX 29-APR-2004.
XX
XX 17-OCT-2003; 2003WO-US033057.
XX
XX 17-OCT-2002; 2002US-0419163P.
XX
XX 02-APR-2003; 2003US-0460028P.
XX
XX (GENM-) GENMAB AS.
XX
XX Teeling J, Ruuls S, Glennie M, Van De Winkel JGJ, Parren P;
XX Petersen J, Baadsgaard ODMs, Huang H;
XX
XX WPI; 2004-348434/32.
XX
XX New human monoclonal antibodies against CD20, useful for diagnosing,
XX preventing or treating diseases involving cells expressing CD20, e.g.
XX cancer, psoriasis, HIV, glomerulonephritis, asthma, atherosclerosis or
XX anaemia.
XX
XX Claim 61; SEQ ID NO 56; 201pp; English.
XX
XX This invention relates to a novel isolated human monoclonal antibody
XX which binds to human CD20 (human B-lymphocyte-restricted differentiation
XX antigen or Bp35). The invention may be useful for the production of
XX compositions with a cytostatic, antipsoriatic, antiinflammatory,
XX neuroprotective, ophthalmological, nephrotropic, antiasthmatic,
XX antiarteriosclerotic, antianaemic, antirheumatic, antiarthritic,
XX antithyroid or anti-HIV activity. In addition the invention may be useful
XX for gene therapy. The invention is useful for diagnosing, preventing or
XX treating diseases or disorders involving cells expressing CD20, such as
XX cancer, psoriasis, inflammatory bowel disease, meningitis, uveitis,
XX glomerulonephritis, asthma, atherosclerosis, multiple sclerosis,
XX haemolytic anaemia, myasthenia gravis, rheumatoid arthritis, Graves'
XX disease or HIV. The anti-idiotypic antibody is used for detecting the
XX level of human monoclonal antibody against CD20 in a sample. The present
XX sequence is that of a human CD20 antibody of the invention.
XX
XX SQ Sequence 141 AA;
XX
XX Query Match 100.0%; Score 523; DB 8; Length 141;
XX Best Local Similarity 100.0%; Pred. No. 3e-45;
XX Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
DB 20 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGIGY 79
QY 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAKD 99
DB 80 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAKD 118
XX
XX RESULT 10
XX AAB40072

```

ID AAB40072 standard; protein; 98 AA.
 AC AAB40072;
 XX
 XX
 XX 05-FEB-2001 (first entry)
 DT
 DE Anti-hIL12 antibody H chain V region amino acid sequence SEQ ID 598.
 DE
 XX Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
 KW complementarity determining region; CDR; antirheumatic; antiarthritic;
 KW antileukemic; neuroprotective; antiparasitic; antidiabetic; cardiant;
 KW antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
 KW multiple sclerosis; rheumatoid arthritis.
 XX
 OS Homo sapiens.
 XX
 XX WO200056772-A1.
 PN
 XX 28-SEP-2000.
 XX
 XX 24-MAR-2000; 2000WO-US007946.
 PF
 XX 25-MAR-1999; 99US-0126603P.
 PR
 XX (BADI) BASF AG.
 PA (GEMY) GENETICS INST INC.
 XX
 XX Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DE, White M;
 PI Kaymakalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;
 PI Veldman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
 PI Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL;
 XX
 XX WPI; 2000-638250/61.
 DR
 XX New human antibody specific for human interleukin-12 (IL-12) used to
 PT treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
 PT disease and multiple sclerosis.
 PT
 XX Claim 75; Page 121; 377pp; English.
 PS
 XX This invention relates to a new human antibody specific for human
 CC interleukin-12 (IL-12). The invention also includes antigen binding
 CC portions that bind to IL-12. Sequences AAB39485-B39516 represent human
 CC anti-IL-12 antibody heavy and light chain complementarity determining
 CC region (CDR) amino acid sequences, and also includes variable region
 CC amino acid sequences. Other variable region amino acid sequences are
 CC given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
 CC represent anti-IL-12 CDR3 related amino acid sequences, AAB39772-B40063
 CC represent other CDR sequences. Light chain CDR3 consensus sequences are
 CC given in AAB40064-B40067. Primers used in the identification and
 CC construction of the antibodies of the invention are given in AAC61062-
 CC C61071. The antibody of the invention is a neutralising antibody and has
 CC antirheumatic; antiarthritic; antileukemic; antidiabetic; cardiant;
 CC neuroprotective; antiparasitic; antidiabetic; antiparasitic; antiparasitic;
 CC antibacterial and immunosuppressive activity. The antibodies or antigen-
 CC binding fragments are useful in the treatment of disorders associated
 CC with detrimental release of human IL-12, especially Crohn's disease,
 CC multiple sclerosis and rheumatoid arthritis. They can also be used in the
 CC manufacture of a pharmaceutical composition to treat human IL-12
 CC disorders
 XX
 SQ Sequence 98 AA;
 Query Match 98.9%; Score 517; DB 3; Length 98;
 Best Local Similarity 100.0%; Pred. No. 8.2e-45;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
 DB 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
 QY 61 ADSVKGKFTISRDNKNSLYLQWNSLRADTALYYCAK 98
 DB 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
 QY 61 ADSVKGKFTISRDNKNSLYLQWNSLRADTALYYCAK 98

DB 61 ADSVKGKFTISRDNKNSLYLQWNSLRADTALYYCAK 98
 RESULT 11
 ABG78185
 ID ABG78185 standard; protein; 98 AA.
 XX
 XX ABG78185;
 AC
 XX 15-NOV-2002 (first entry)
 DT
 XX Human Fv molecule hypervariable region related peptide #60.
 DE
 XX Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
 KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
 KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.
 XX
 OS Homo sapiens.
 XX
 XX WO200259264-A2.
 PN
 XX 01-AUG-2002.
 PD
 XX 31-DEC-2001; 2001WO-US049440.
 PF
 XX 29-DEC-2000; 2000US-00751181.
 PR
 XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
 PA
 XX Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;
 PI Plaksin D, Peretz T;
 PI
 XX WPI; 2002-619166/66.
 DR
 XX Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
 PT or fragment, or construct of fragment with enhanced binding
 PT characteristics so as to selectively bind target cell in favor of other
 PT cells.
 PT
 XX Claim 13; Page 177; 232pp; English.
 PS
 XX The invention relates to a peptide or polypeptide comprising an Fv
 CC molecule, a construct or fragments or a construct of a fragment with
 CC enhanced binding characteristics which selectively and/or specifically
 CC binds to a target cell in favour of other cells, where binding is
 CC primarily determined by a first hypervariable region and Fv is a single
 CC chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
 CC association with or attached, coupled, combined, linked or fused to a
 CC pharmaceutical agent, is useful in the manufacture of a medicament, where
 CC the medicament has activity against a diseased cell, preferably a cancer
 CC cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
 CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
 CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
 CC composition for use in inhibiting the growth of a diseased or cancer
 CC cell. This sequence represents a human Fv molecule hypervariable region
 CC related peptide of the invention
 XX
 SQ Sequence 98 AA;
 Query Match 98.9%; Score 517; DB 5; Length 98;
 Best Local Similarity 100.0%; Pred. No. 8.2e-45;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
 DB 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
 QY 61 ADSVKGKFTISRDNKNSLYLQWNSLRADTALYYCAK 98
 DB 61 ADSVKGKFTISRDNKNSLYLQWNSLRADTALYYCAK 98
 RESULT 12

ABG91876
ID ABG91876 standard; protein; 98 AA.
XX AC ABG91876;
XX DT 04-DEC-2002 (first entry)
XX DE Human antibody fragment #60.
XX KW Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
KW metastasis; hypervariable region; autoimmune disease; thrombosis;
KW retinosis; leukaemia; inflammatory disease; cardiovascular disease;
KW myocardial infarction; retinopathic disease; abnormal platelet function;
KW sulphated tyrosine-dependent protein-protein interaction.
XX OS Homo sapiens.
XX PN W0200253700-A2.
XX PD 11-JUL-2002.
XX PF 31-DEC-2001; 2001WO-US049442.
XX PR 29-DEC-2000; 2000US-00751181.
XX PR 29-DEC-2000; 2000US-0258948P.
XX PA (BIOT-) BIO-TECHNOLOGY GEN CORP.
XX PI Lazarovits J, Hagai Y, Plaksin D, Vogel T, Nimrod A, Mar-Haim H;
PI Szanthon E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
XX WPI; 2002-674776/72.
XX Novel isolated epitope present on cancer cells and important in
PT physiological phenomena such as cell rolling, metastasis and
PT inflammation, for treating autoimmune, inflammatory or cardiovascular
PT diseases, and cancer.
XX Disclosure; Page 254; Opp; English.
XX The invention relates to an isolated epitope present on cancer cells and
CC important in physiological phenomena such as cell rolling, metastasis and
CC inflammation, where the epitope is capable of being bound by an antibody,
CC its antigen-binding fragment or its complex comprising at least one
CC antibody or its binding fragment having a first hypervariable region. The
CC epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
CC disease, thrombosis, retinosis, metastasis, growth and/or replication of
CC tumour or leukaemia cells, increase in number of tumour or leukaemia
CC cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
CC platelet and/or cell-platelet adhesion or aggregation, for increasing
CC mortality of tumour or leukaemia cells, for increasing the susceptibility
CC of diseased cells to damage by anti-disease, anti-cancer or anti-
CC leukaemia agents, or for decreasing the number of tumour or leukaemia
CC cells in a patient, or in the manufacture of a medicament for the above
CC mentioned purposes. The epitopes are useful for diagnosing and treating
CC diseases such as cancer, leukaemia, autoimmune diseases, inflammatory
CC diseases, cardiovascular diseases such as myocardial infarction,
CC retinopathic diseases and other diseases mediated by abnormal platelet
CC function and diseases caused by sulphated tyrosine-dependent protein-
CC protein interactions. This sequence represents a human antibody fragment
XX of the invention
XX Sequence 98 AA;
Query Match 98.9%; Score 517; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 8.2e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
QY 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAK 98

|||||
61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAK 98
RESULT 13
AAU02593
ID AAU02593 standard; protein; 118 AA.
XX AC AAU02593;
XX DT 29-AUG-2001 (first entry)
XX DE Anti-adipocyte monoclonal antibody heavy chain, FAT 79.
XX KW Antibody; adipocyte; heavy chain; light chain; obesity; fat;
KW heart disease; complementarity determining region; CDR.
XX OS Homo sapiens.
XX PN W0200127279-A1.
XX PD 19-APR-2001.
XX PF 11-OCT-2000; 2000WO-GB003900.
XX PR 12-OCT-1999; 99US-0158812P.
XX PA (CMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX PI Edwards BM, Main SH, Vaughan TJ;
XX WPI; 2001-282031/29.
XX N-PSDB; AAS03493.
XX Panel of specific binding members of antibody molecules which bind to
PT whole adipocytes is used in the treatment of obesity and obesity related
PT diseases.
XX Claim 1; Page 151; 182pp; English.
XX AAU02501-AAU02635, and AAU02641-AAU02748 represent the amino acid
CC sequences of anti-adipocyte monoclonal antibody heavy chain, light chain,
CC and heavy chain complementarity determining regions (CDR) of the
CC invention. The antibodies can be used in the treatment of obesity and
CC obesity related diseases. The antibodies can be used to deliver drugs or
CC pro-drugs directly to the fat mass of an obese patient or the antibody
CC can be used as a therapeutic itself. Antibodies binding specifically to
CC adipocytes can be used to activate the immune system to destroy the cells
CC by complement mediated lysis. The antibodies may be labeled with a
CC detectable label such as radiolabel, fluorescent or chemical group and
CC used in methods of diagnosis in human subjects e.g. to determine the
CC presence of adipocyte antigen on the surface of an adipocyte to detect or
CC determine the presence or level of adipocytes in a cell or tissue sample.
CC The antibodies can be used as an alternative means of treatment for obese
CC patients other than undergoing surgery to remove excess fat. Antibodies
CC for different types of fat deposits can also be produced e.g. intra-
CC abdominal fat associated with heart disease
XX Sequence 118 AA;
Query Match 98.9%; Score 517; DB 4; Length 118;
Best Local Similarity 98.0%; Pred. No. 1e-44;
Matches 97; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
Db 1 QVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
QY 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAK 99
Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAK 99

```
RESULT 14
AAG65553
ID AAG65553 standard; protein; 120 AA.
XX
AC AAG65553;
XX
DT 30-NOV-2001 (first entry)
XX
DE Amino acid sequence of VH3-4.
XX
KW Gene library; immunoglobulin; antibody library; VH3-4.
XX
OS Homo sapiens.
XX
PN WO200162907-A1.
XX
PD 30-AUG-2001.
XX
PF 22-FEB-2001; 2001WO-JP001298.
XX
PR 22-FEB-2000; 2000JP-00050543.
XX
PA (MEDI-) MEDICAL & BIOLOGICAL LAB CO LTD.
XX
PI Kurosawa Y, Akahori Y, Iba Y, Morino K, Shinohara M, Takahashi M;
PI Okuno Y, Shiraki K;
XX
DR WPI; 2001-565420/63.
XX
PT Producing gene libraries and antibody libraries, involves selecting a
PT light chain that binds to a heavy chain product to produce a functional
PT formation, and producing a gene library of the light chain variable
PT regions.
XX
PS Disclosure; Page 20; 181pp; Japanese.
XX
CC The invention relates to producing gene libraries, comprising
CC immunoglobulin light and heavy variable region. The method involves
CC selecting light chain that binds with the heavy chain product to produce
CC a functional conformation, producing a gene library comprising a
CC collection of these light chain variable genes, and combining with gene
CC library of heavy chain variable genes. The method is used for production
CC of gene and antibody libraries. The present sequence represents the amino
CC acid sequence of VH3-4
XX
SQ Sequence 120 AA;
Query Match 98.9%; Score 517; DB 4; Length 120;
Best Local Similarity 100.0%; Pred. No. 1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTPDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTPDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
RESULT 15
ABB06276
ID ABB06276 standard; protein; 120 AA.
XX
AC ABB06276;
XX
DT 24-MAY-2002 (first entry)
XX
DE VH3-4 amino acid sequence SEQ ID NO:1.
XX
KW Construction; scFv antibody; green fluorescent protein; GFP; immunoassay;
KW fluorescent protein; antigen binding; immunostaining; fusion protein;
KW immunological assay.
```

```
XX Homo sapiens.
OS Synthetic.
XX
PN WO200196401-A1.
XX
PD 20-DEC-2001.
XX
PF 12-JUN-2001; 2001WO-JP004964.
XX
PR 14-JUN-2000; 2000JP-00178880.
XX
PA (MEDI-) MEDICAL & BIOLOGICAL LAB CO LTD.
XX
PI Morino K, Akahori Y, Iba Y, Shinohara M, Ukai Y, Kurosawa Y;
XX
DR WPI; 2002-098058/13.
XX
PT Producing scFv antibody fused to a fluorescent protein, useful for
PT immunoassay and immunostaining, comprises expressing a scFv gene
PT (extracted from selected clones) fused to a fluorescent protein gene.
XX
PS Example; Page 82-83; 105pp; Japanese.
XX
CC The present invention describes a method for producing a scFv antibody
CC fused to a fluorescent protein. The method comprises constructing a scFv
CC antibody library composed of phage clones expressing scFv antibody on
CC their surface, screening this library with an antigen, extracting the
CC gene for scFv antibody from the selected phage clones and inserting it
CC into an expression vector that expresses the gene fused to a fluorescent
CC protein. Also described are: (1) a fusion protein comprising the scFv
CC antibody fused to a fluorescent protein; (2) immunological assays using
CC the fusion protein of (1); (3) an expression vector encoding the fusion
CC protein of (1); and (4) a kit for producing the fusion protein of (1).
CC The fusion protein can be used in immunoassays and immunostaining.
CC Immunological assays using the fusion protein do not require a secondary
CC or tertiary antibody. Direct intracellular and even in vivo assays are
CC possible. ABL49521 to ABL49591 and ABB06268 to ABB06276 represent
CC sequences used in the exemplification of the present invention
XX
SQ Sequence 120 AA;
Query Match 98.9%; Score 517; DB 5; Length 120;
Best Local Similarity 100.0%; Pred. No. 1e-44;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTPDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTPDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
Search completed: May 5, 2006, 08:57:13
Job time : 39.1247 secs
```

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:25 ; Search time 11.4266 Seconds
(without alignments)
716.302 Million cell updates/sec

Title: US-09-674-752-33
Perfect score: 523
Sequence: 1 EVQLVSGGGLVQPGSRSLR.....YIQMNSLRADTALYYCAKD 99

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA.*

- 1: /cgn2_6/ptodata/1/iaa/5_COMB.pep.*
- 2: /cgn2_6/ptodata/1/iaa/6_COMB.pep.*
- 3: /cgn2_6/ptodata/1/iaa/H_COMB.pep.*
- 4: /cgn2_6/ptodata/1/iaa/PCUS_COMB.pep.*
- 5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep.*
- 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	523	100.0	99	2	US-10-194-975-16
2	523	100.0	118	2	US-08-545-809A-97
3	523	100.0	118	2	US-09-515-697-97
4	517	98.9	98	2	US-09-534-717-598
5	512	97.9	119	2	US-09-840-459-88
6	512	97.9	119	2	US-09-497-625A-88
7	511	97.7	120	1	US-08-958-201-10
8	506	96.7	120	1	US-08-958-201-8
9	498	95.2	124	2	US-09-471-276-898
10	498	95.2	149	2	US-09-424-840B-18
11	493	94.3	124	2	US-09-424-840B-123
12	491	93.9	117	1	US-07-942-245-24
13	489	93.5	121	2	US-08-599-226-2
14	489	93.5	121	2	US-09-125-098-2
15	489	93.5	121	2	US-09-540-018-2
16	480	91.8	126	2	US-09-232-290-35
17	472	90.2	116	1	US-08-652-816A-14
18	470	89.9	98	2	US-10-194-975-20
19	470	89.9	98	2	US-09-534-717-599
20	470	89.9	117	2	US-08-545-809A-106
21	470	89.9	117	2	US-09-515-697-106
22	465	88.9	121	2	US-08-599-226-10
23	465	88.9	121	2	US-09-125-098-10
24	465	88.9	121	2	US-09-540-018-10
25	460	88.0	99	2	US-10-194-975-27
26	460	88.0	118	2	US-08-545-809A-125
27	460	88.0	118	2	US-09-515-697-125

28	459	87.8	309	2	US-09-079-029-9	Sequence 9, Appli
29	454	86.8	98	2	US-09-534-717-600	Sequence 600, App
30	454	86.8	98	2	US-08-896-535-75	Sequence 75, Appl
31	450	86.0	483	2	US-09-049-672A-5	Sequence 5, Appli
32	448	85.7	117	2	US-09-025-769B-24	Sequence 24, Appl
33	448	85.7	117	2	US-09-490-070A-24	Sequence 24, Appl
34	448	85.7	117	2	US-09-490-153-24	Sequence 24, Appl
35	448	85.7	117	2	US-09-490-324-24	Sequence 24, Appl
36	444	84.9	116	2	US-09-840-459-80	Sequence 80, Appl
37	444	84.9	116	2	US-09-497-625A-80	Sequence 92, Appl
38	444	84.9	121	2	US-09-840-459-92	Sequence 92, Appl
39	444	84.9	121	2	US-09-497-625A-92	Sequence 92, Appl
40	444	84.9	125	2	US-09-840-459-76	Sequence 76, Appl
41	444	84.9	125	2	US-09-497-625A-76	Sequence 76, Appl
42	444	84.9	127	2	US-09-840-459-87	Sequence 87, Appl
43	444	84.9	127	2	US-09-497-625A-87	Sequence 87, Appl
44	441	84.3	128	2	US-09-840-459-77	Sequence 77, Appl
45	441	84.3	128	2	US-09-840-459-79	Sequence 79, Appl

ALIGNMENTS

RESULT 1
US-10-194-975-16
; Sequence 16, Application US/10194975
; Patent No. 6881557
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; PRIOR FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 16
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-16

Query Match	100.0%	Score 523;	DB 2;	Length 99;
Best Local Similarity	100.0%	Pred. No. 9e-47;		
Matches	99;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	1	EVQLVSGGGLVQPGSRSLRSLSCAASGFTFDYAMHWYRQAPGKGLVWVSGISWNSGSIGY	60	
Db	1	EVQLVSGGGLVQPGSRSLRSLSCAASGFTFDYAMHWYRQAPGKGLVWVSGISWNSGSIGY	60	
Qy	61	ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAKD	99	
Db	61	ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAKD	99	

RESULT 2
US-08-545-809A-97
; Sequence 97, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsumoto, Fumihiko
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804

```
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-545-809A-97

Query Match 100.0%; Score 523; DB 2; Length 118;
Best Local Similarity 100.0%; Pred. No. 1.1e-46;
Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGY 60
DB 20 EVLVESGGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGY 79

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTALYYCAKD 99
DB 80 ADSVKGRFTISRDNKNSLYLQWNSLRADTALYYCAKD 118

RESULT 3
US-09-515-697-97
; Sequence 97, Application US/09515697
; Patent No. 6936705
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/515,697
; FILING DATE: 29-Feb-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; TITLE OF INVENTION: METHODS OF USE THEREFOR
```

```
;
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 118 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 97:
US-09-515-697-97

Query Match 100.0%; Score 523; DB 2; Length 118;
Best Local Similarity 100.0%; Pred. No. 1.1e-46;
Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGY 60
DB 20 EVLVESGGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGY 79

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTALYYCAKD 99
DB 80 ADSVKGRFTISRDNKNSLYLQWNSLRADTALYYCAKD 118

RESULT 4
US-09-534-717-598
; Sequence 598, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 598
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-534-717-598

Query Match 98.9%; Score 517; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.7e-46;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGY 60
DB 1 EVLVESGGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGY 60

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTALYYCAK 98
DB 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTALYYCAK 98

RESULT 5
US-09-840-459-88
; Sequence 88, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: Larosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Sibbhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
```

```
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-88

Query Match          97.9%; Score 512; DB 2; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.5e-45;
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
   |||||
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCA 97
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCA 97
   |||||

RESULT 6
US-09-497-625A-88
; Sequence 88, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-497-625A-88

Query Match          97.9%; Score 512; DB 2; Length 119;
Best Local Similarity 100.0%; Pred. No. 1.5e-45;
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
   |||||
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCA 97
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCA 97
   |||||
```

```
RESULT 7
US-08-958-201-10
; Sequence 10, Application US/08958201
; Patent No. 5977319
; GENERAL INFORMATION:
; APPLICANT: Pope, Anthony R
; APPLICANT: Pritchard, Kevin
; APPLICANT: Williams, Andrew J
; APPLICANT: Johnson, Kevin S
; TITLE OF INVENTION: Specific binding members for estradiol;
; TITLE OF INVENTION: materials and methods
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall O'Toole Gerstein Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/958,201
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/028,897
; FILING DATE: 21-OCT-1996
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: 2Db
US-08-958-201-10

Query Match          97.7%; Score 511; DB 1; Length 120;
Best Local Similarity 98.0%; Pred. No. 1.9e-45;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
   |||||
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
   |||||

RESULT 8
US-08-958-201-8
; Sequence 8, Application US/08958201
; Patent No. 5977319
; GENERAL INFORMATION:
; APPLICANT: Pope, Anthony R
; APPLICANT: Pritchard, Kevin
; APPLICANT: Williams, Andrew J
; APPLICANT: Johnson, Kevin S
; TITLE OF INVENTION: Specific binding members for estradiol;
; TITLE OF INVENTION: materials and methods
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall O'Toole Gerstein Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```

```
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/958,201
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/028,897
; FILING DATE: 21-OCT-1996
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: 2D
US-08-958-201-8

Query Match          96.7%; Score 506; DB 1; Length 120;
Best Local Similarity 97.9%; Pred. No. 6.4e-45;
Matches 95; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY  2 VQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKGLWVSGISWNSGIGYA 61
    |||||
Db   2 VQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKGLWVSGISWNSGIGYA 61
    |||||

QY  62 DSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAK 98
    |||||
Db   62 DSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
    |||||

RESULT 9
US-09-424-840B-18
; Sequence 18, Application US/09424840B
; Patent No. 6790938
; GENERAL INFORMATION:
; APPLICANT: Berchtold, Peter
; APPLICANT: Escher, Robert F. A.
; TITLE OF INVENTION: ANTI-GPIIB/IIIA RECOMBINANT ANTIBODIES
; FILE REFERENCE: 100564-09049
; CURRENT APPLICATION NUMBER: US/09/424,840B
; CURRENT FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: DE 19820663.1
; PRIOR FILING DATE: 1998-05-08
; PRIOR APPLICATION NUMBER: DE 19755227.7
; PRIOR FILING DATE: 1997-12-12
; PRIOR APPLICATION NUMBER: DE 19723904.8
; PRIOR FILING DATE: 1997-06-06
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-424-840B-18

Query Match          95.2%; Score 498; DB 2; Length 124;
Best Local Similarity 92.9%; Pred. No. 4.4e-44;
Matches 92; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY  1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKGLWVSGISWNSGIGY 60
    :|||:
Db   1 QVKLLESGGGLVQPGKSLRLSCAASGFTFDDYALHWVRQAPGKGLWVSGISWDSGTIGY 60
    :|||:

QY  61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAK 99
    |||||
Db   61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCVKD 99
    |||||

RESULT 10
US-09-471-276-898
; Sequence 898, Application US/09471276
; Patent No. 6822072
```

```
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6822072
; FILE REFERENCE: GENSET.025CP1
; CURRENT APPLICATION NUMBER: US/09/471,276
; CURRENT FILING DATE: 1999-12-21
; EARLIER APPLICATION NUMBER: 09/057,719
; EARLIER FILING DATE: 1998-04-09
; EARLIER APPLICATION NUMBER: 09/069,047
; EARLIER FILING DATE: 1998-04-28
; EARLIER APPLICATION NUMBER: PCT/IB99/00712
; EARLIER FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 1622
; SOFTWARE: Patent.pm
; SEQ ID NO 898
; LENGTH: 149
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -19...-1
US-09-471-276-898

Query Match          95.2%; Score 498; DB 2; Length 149;
Best Local Similarity 94.9%; Pred. No. 5.5e-44;
Matches 93; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY  1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKGLWVSGISWNSGIGY 60
    |||||
Db   20 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKGLWVSGITWNSXIGY 79
    |||||

QY  61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAK 98
    |||||
Db   80 ADSVKGRFTISRDNKNSLYLQMNLSRLTEDTAFYCAK 117
    |||||

RESULT 11
US-09-424-840B-123
; Sequence 123, Application US/09424840B
; Patent No. 6790938
; GENERAL INFORMATION:
; APPLICANT: Berchtold, Peter
; APPLICANT: Escher, Robert F. A.
; TITLE OF INVENTION: ANTI-GPIIB/IIIA RECOMBINANT ANTIBODIES
; FILE REFERENCE: 100564-09049
; CURRENT APPLICATION NUMBER: US/09/424,840B
; CURRENT FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: DE 19820663.1
; PRIOR FILING DATE: 1998-05-08
; PRIOR APPLICATION NUMBER: DE 19755227.7
; PRIOR FILING DATE: 1997-12-12
; PRIOR APPLICATION NUMBER: DE 19723904.8
; PRIOR FILING DATE: 1997-06-06
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 123
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-424-840B-123

Query Match          94.3%; Score 493; DB 2; Length 124;
Best Local Similarity 92.9%; Pred. No. 1.5e-43;
Matches 92; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY  1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKGLWVSGISWNSGIGY 60
    :|||:
Db   1 QVKLLESGGGLVQPGKSLRLSCAASGFTFDDYALHWVRQAPGKGLWVSGISWDSIGY 60
    :|||:

QY  61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAK 99
```



```
Db 61 ADSVKGRTISRDNKNSLYLQMNLSRAEDTALYYCVKD 99
|||||
RESULT 12
US-07-942-245-24
; Sequence 24, Application US/07942245
; Patent No. 5639641
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, Jan T.
; APPLICANT: SEARLE, Stephen M.J.
; APPLICANT: REES, Anthony R.
; APPLICANT: ROGUSKA, Michael A.
; APPLICANT: GUILD, Braydon C.
; TITLE OF INVENTION: SURFACE RESIDUE VENEERING OF RODENT
; TITLE OF INVENTION: ANTIBODIES
; NUMBER OF SEQUENCES: 522
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sughrie, Mion, Zinn, Macpeak & Seas
; STREET: 2100 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: United States
; ZIP: 20037-3202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: HP 9000/700 Workstation
; OPERATING SYSTEM: UNIX
; SOFTWARE: In house
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/942,245
; FILING DATE: 09-SEP-1992
; CLASSIFICATION: 530
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 293-7060
; TELEFAX: (202) 293-7860
; TELEX: 6491103
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-07-942-245-24

Query Match 93.9%; Score 491; DB 1; Length 117;
Best Local Similarity 94.9%; Pred. No. 2.2e-43;
Matches 93; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWVRQAPGKGLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWVRQAPGKGLEWVSGISWNSGSIY 60

Qy 61 ADSVKGRTISRDNKNSLYLQMNLSRAEDTALYYCAK 98
|||||
Db 61 ADSVKGRTISRDNKNSLYLQMNLSRAEDTALYYCVK 98
|||||

RESULT 13
US-08-599-226-2
; Sequence 2, Application US/08599226
; Patent No. 6090382
; GENERAL INFORMATION:
; APPLICANT: Salfeld, Jochen G.
; APPLICANT: Allen, Deborah J.
; APPLICANT: Hoogenboom, Hendricus R.J.M.
; APPLICANT: Kaymakalan, Zehra
; APPLICANT: Labkovsky, Boris
; APPLICANT: Mankovich, John A.
; APPLICANT: McGuinness, Brian T.
; APPLICANT: Roberts, Andrew J.
; APPLICANT: Sakorafas, Paul
; APPLICANT: Schoenhaut, David
```

```
; APPLICANT: Vaughan, Tristan J.
; APPLICANT: White, Michael
; APPLICANT: Wilton, Andrew J.
; TITLE OF INVENTION: Human Antibodies that Bind Human TNFa
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 State Street, suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/599,226
; FILING DATE: 08-FEB-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A., Jr.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: BBI-043
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 121 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
US-08-599-226-2

Query Match 93.5%; Score 489; DB 2; Length 121;
Best Local Similarity 93.9%; Pred. No. 3.7e-43;
Matches 92; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWVRQAPGKGLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWVRQAPGKGLEWVSAITWNSCHIDY 60

Qy 61 ADSVKGRTISRDNKNSLYLQMNLSRAEDTALYYCAK 98
|||||
Db 61 ADSVEGRTISRDNKNSLYLQMNLSRAEDTAVYYCAK 98
|||||

RESULT 14
US-09-125-098-2
; Sequence 2, Application US/09125098
; Patent No. 6258562
; GENERAL INFORMATION:
; APPLICANT: Salfeld, Jochen G.
; APPLICANT: Allen, Deborah J.
; APPLICANT: Hoogenboom, Hendricus R.J.M.
; APPLICANT: Kaymakalan, Zehra
; APPLICANT: Labkovsky, Boris
; APPLICANT: Mankovich, John A.
; APPLICANT: McGuinness, Brian T.
; APPLICANT: Roberts, Andrew J.
; APPLICANT: Sakorafas, Paul
; APPLICANT: Schoenhaut, David
; APPLICANT: Vaughan, Tristan J.
; APPLICANT: White, Michael
; APPLICANT: Wilton, Andrew J.
; TITLE OF INVENTION: Human Antibodies that Bind Human TNFa
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 State Street, suite 510
```

;; CITY: Boston
;; STATE: Massachusetts
;; COUNTRY: USA
;; ZIP: 02109-1875
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/125,098
;; FILING DATE:
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/599,226
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: DeConti, Giulio A., Jr.
;; REGISTRATION NUMBER: 31,503
;; REFERENCE/DOCKET NUMBER: BBI-043
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (617)227-7400
;; TELEFAX: (617)227-5941
;; INFORMATION FOR SEQ ID NO: 2:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 121 amino acids
;; TYPE: amino acid
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
;; FRAGMENT TYPE: internal
;; US-09-125-098-2

Query Match 93.5%; Score 489; DB 2; Length 121;
Best Local Similarity 93.9%; Pred. No. 3.7e-43;
Matches 92; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTDDYAMHWVRQAPGKGLVWGSGISWNSGIGY 60
DB 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTDDYAMHWVRQAPGKGLVWGSGISWNSGIGY 60
QY 61 ADSVKGRTISRDNNAKNSLYLQWNSLRADDTALYYCAK 98
DB 61 ADSVEGRFTISRDNNAKNSLYLQWNSLRADDTALYYCAK 98

RESULT 15
US-09-540-018-2
; Sequence 2, Application US/09540018
; Patent No. 6509015
; GENERAL INFORMATION:
; APPLICANT: Salfeld, Jochen G.
; APPLICANT: Allen, Deborah J.
; APPLICANT: Hoogenboom, Hendricus R.J.M.
; APPLICANT: Kaymakalan, Zehra
; APPLICANT: Labkovsky, Boris
; APPLICANT: Mankovich, John A.
; APPLICANT: McGuinness, Brian T.
; APPLICANT: Roberts, Andrew J.
; APPLICANT: Sakorafas, Paul
; APPLICANT: Schoenhaut, David
; APPLICANT: Vaughan, Tristan J.
; APPLICANT: White, Michael
; APPLICANT: Wilton, Andrew J.
; TITLE OF INVENTION: Human Antibodies that Bind Human TNFa
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 State Street, suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:

;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/540,018
;; FILING DATE: 31-MARCH-2000
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/08/599,226
;; FILING DATE: 08-FEB-1996
;; ATTORNEY/AGENT INFORMATION:
;; NAME: DeConti, Giulio A., Jr.
;; REGISTRATION NUMBER: 31,503
;; REFERENCE/DOCKET NUMBER: BBI-043
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (617)227-7400
;; TELEFAX: (617)227-5941
;; INFORMATION FOR SEQ ID NO: 2:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 121 amino acids
;; TYPE: amino acid
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
;; FRAGMENT TYPE: internal
;; US-09-540-018-2

Query Match 93.5%; Score 489; DB 2; Length 121;
Best Local Similarity 93.9%; Pred. No. 3.7e-43;
Matches 92; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTDDYAMHWVRQAPGKGLVWGSGISWNSGIGY 60
DB 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTDDYAMHWVRQAPGKGLVWGSGISWNSGIGY 60
QY 61 ADSVKGRTISRDNNAKNSLYLQWNSLRADDTALYYCAK 98
DB 61 ADSVEGRFTISRDNNAKNSLYLQWNSLRADDTALYYCAK 98

Search completed: May 5, 2006, 08:53:51
Job time : 12.4266 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:55:01 ; Search time 31.446 Seconds
(without alignments)
1315.434 Million cell updates/sec

Title: US-09-674-752-33
Perfect score: 523
Sequence: 1 EVQVSGGLVQGRSLRL.....YLOMNSLRADTALYYCAKD 99

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications_AA_Main:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pap:*

2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pap:*

3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pap:*

4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pap:*

5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pap:*

6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	523	100.0	99	4	US-10-194-975-16
2	523	100.0	99	4	US-10-308-817-56
3	523	100.0	99	4	US-10-453-698-56
4	523	100.0	99	4	US-10-379-392-15
5	523	100.0	132	3	US-09-791-153A-59
6	523	100.0	141	4	US-10-687-799-81
7	517	98.9	98	4	US-10-032-037B-60
8	517	98.9	98	4	US-10-029-988B-60
9	517	98.9	98	4	US-10-032-423A-60
10	517	98.9	98	4	US-10-029-926B-60
11	517	98.9	98	5	US-10-884-830-598
12	517	98.9	120	5	US-10-487-525-1
13	517	98.9	120	6	US-11-039-767-16
14	513	98.1	252	3	US-09-880-748-1416
15	513	98.1	252	4	US-10-293-418-1416
16	512	97.9	119	3	US-09-840-459-88
17	512	97.9	119	4	US-10-766-773-88
18	512	97.9	119	4	US-10-766-610-88
19	512	97.9	119	4	US-10-733-563-88
20	506	96.7	291	4	US-10-406-830-6
21	504	96.4	141	4	US-10-687-799-2
22	504	96.4	146	4	US-10-693-629-32
23	502	96.0	244	5	US-10-981-692-26
24	502	96.0	245	3	US-09-880-748-1926
25	502	96.0	245	4	US-10-293-418-1926
26	501	95.8	117	6	US-11-021-438-4
27	501	95.8	241	6	US-11-021-438-24

28	501	95.8	243	5	US-10-981-692-33	Sequence 33, Appl
29	500	95.6	122	6	US-11-021-438-2	Sequence 2, Appl
30	500	95.6	123	3	US-09-791-153A-66	Sequence 66, Appl
31	500	95.6	227	3	US-09-791-153A-59	Sequence 59, Appl
32	500	95.6	245	6	US-11-021-438-22	Sequence 22, Appl
33	499	95.4	127	5	US-10-891-658-81	Sequence 81, Appl
34	498	95.2	124	4	US-10-844-424-18	Sequence 18, Appl
35	498	95.2	141	4	US-10-687-799-6	Sequence 6, Appl
36	498	95.2	149	5	US-10-926-683-898	Sequence 898, App
37	497	95.0	121	5	US-10-891-658-85	Sequence 85, Appl
38	497	95.0	122	4	US-10-447-331-6	Sequence 6, Appl
39	495	94.6	253	4	US-10-779-461-18	Sequence 16, Appl
40	494	94.5	254	3	US-09-880-748-1427	Sequence 1427, Ap
41	494	94.5	254	4	US-10-293-418-1427	Sequence 1427, Ap
42	493	94.3	124	4	US-10-844-424-123	Sequence 123, App
43	491	93.9	127	5	US-10-891-658-83	Sequence 83, Appl
44	491	93.9	241	2	US-08-779-457-50	Sequence 50, Appl
45	491	93.9	241	5	US-10-921-710-50	Sequence 50, Appl

ALIGNMENTS

RESULT 1
US-10-194-975-16
; Sequence 16, Application US/10194975
; Publication No. US20030039649A1
; GENERAL INFORMATION:
; APPLICANT: Poote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-16

Query Match	100.0%	Score 523;	DB 4;	Length 99;
Best Local Similarity	100.0%	Pred No. 7.9e-47;	Mismatches 0;	Indels 0;
Matches	99;	Conservative	0;	Gaps 0;
Qy	1	EVQVSGGLVQGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLVWVGISWNSGIGY	60	
Db	1	EVQVSGGLVQGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLVWVGISWNSGIGY	60	
Qy	61	ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAKD	99	
Db	61	ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAKD	99	

RESULT 2
US-10-308-817-56
; Sequence 56, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 56
; LENGTH: 99
; TYPE: PRT
; ORGANISM: human


```

; ORGANISM: Homo sapiens
US-10-687-799-56

Query Match      100.0%; Score 523; DB 4; Length 141;
Best Local Similarity 100.0%; Pred. No. 1.2e-46;
Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Db 20 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 79

Qy 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 99
Db 80 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 118

RESULT 7
US-10-032-037B-60
; Sequence 60, Application US/10032037B
; Publication No. US20040001822A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/44
; CURRENT APPLICATION NUMBER: US/10/032,037B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-60

Query Match      98.9%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.3e-46;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60

Qy 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98

RESULT 8
US-10-029-988B-60
; Sequence 60, Application US/10029988B
; Publication No. US20040001839A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029,988B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-60

Query Match      98.9%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.3e-46;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60

Qy 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98

RESULT 9
US-10-032-423A-60
; Sequence 60, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-60

Query Match      98.9%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.3e-46;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60

Qy 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98

RESULT 10
US-10-029-926B-60
; Sequence 60, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; FILE REFERENCE: 10793/50
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-60

Query Match      98.9%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.3e-46;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60

Qy 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98

```

```

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60

Qy 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98

RESULT 9
US-10-032-423A-60
; Sequence 60, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE OF INVENTION: MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-60

Query Match      98.9%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.3e-46;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60

Qy 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98

RESULT 10
US-10-029-926B-60
; Sequence 60, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; FILE REFERENCE: 10793/50
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-60

Query Match      98.9%; Score 517; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.3e-46;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 60

Qy 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDAKNSLYLQMNLSRAEDTALYYCAK 98

```

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
 Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98

RESULT 11
 US-10-884-830-598
 ; Sequence 598, Application US/10884830
 ; Publication No. US20050004354A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Jochen, Salfeld et al.
 ; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
 ; FILE REFERENCE: BBI-093CP
 ; CURRENT APPLICATION NUMBER: US/10/884,830
 ; CURRENT FILING DATE: 2004-07-01
 ; PRIOR APPLICATION NUMBER: US/09/534,717
 ; PRIOR FILING DATE: 2000-03-24
 ; PRIOR APPLICATION NUMBER: 60/126,603
 ; PRIOR FILING DATE: March 25, 1999
 ; NUMBER OF SEQ ID NOS: 675
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 598
 ; LENGTH: 98
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-884-830-598

Query Match 98.9%; Score 517; DB 5; Length 98;
 Best Local Similarity 100.0%; Pred. No. 3.3e-46;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
 Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
 QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
 Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98

RESULT 12
 US-10-487-525-1
 ; Sequence 1, Application US/10487525
 ; Publication No. US20040259153A1
 ; GENERAL INFORMATION:
 ; APPLICANT: INSTITUTE FOR ANTIBODIES CO., LTD.
 ; TITLE OF INVENTION: METHODS FOR SELECTING BINDING MOLECULES
 ; FILE REFERENCE: M3-A0101P
 ; CURRENT APPLICATION NUMBER: US/10/487,525
 ; CURRENT FILING DATE: 2004-02-20
 ; PRIOR APPLICATION NUMBER: JP 2001-252154
 ; PRIOR FILING DATE: 2001-08-22
 ; NUMBER OF SEQ ID NOS: 91
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 1
 ; LENGTH: 120
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-487-525-1

Query Match 98.9%; Score 517; DB 5; Length 120;
 Best Local Similarity 100.0%; Pred. No. 4.1e-46;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
 Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
 QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
 Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98

RESULT 13
 US-11-039-767-16
 ; Sequence 16, Application US/11039767
 ; Publication No. US20050170398A1
 ; GENERAL INFORMATION:
 ; APPLICANT: CRUCCELL HOLLAND B.V.
 ; TITLE OF INVENTION: Recombinant production of mixtures of antibodies
 ; FILE REFERENCE: 0079 WO 00 ORD
 ; CURRENT APPLICATION NUMBER: US/11/039,767
 ; CURRENT FILING DATE: 2005-01-18
 ; NUMBER OF SEQ ID NOS: 18
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 16
 ; LENGTH: 120
 ; TYPE: PRT
 ; ORGANISM: Artificial
 ; FEATURE:
 ; OTHER INFORMATION: VH sequence of clone I-2 (anti-class II phage)
 US-11-039-767-16

Query Match 98.9%; Score 517; DB 6; Length 120;
 Best Local Similarity 98.0%; Pred. No. 4.1e-46;
 Matches 97; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
 Db 3 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGIGY 62
 QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 99
 Db 63 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 101

RESULT 14
 US-09-880-748-1416
 ; Sequence 1416, Application US/09880748
 ; Publication No. US20030059937A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ruben et al.
 ; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
 ; FILE REFERENCE: PF523
 ; CURRENT APPLICATION NUMBER: US/09/880,748
 ; CURRENT FILING DATE: 2001-06-15
 ; PRIOR APPLICATION NUMBER: 60/212,210
 ; PRIOR FILING DATE: 2000-06-15
 ; PRIOR APPLICATION NUMBER: 60/240,816
 ; PRIOR FILING DATE: 2000-10-17
 ; PRIOR APPLICATION NUMBER: 60/276,248
 ; PRIOR FILING DATE: 2001-03-16
 ; PRIOR APPLICATION NUMBER: 60/277,379
 ; PRIOR FILING DATE: 2001-03-21
 ; PRIOR APPLICATION NUMBER: 60/293,499
 ; PRIOR FILING DATE: 2001-05-25
 ; NUMBER OF SEQ ID NOS: 3239
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 1416
 ; LENGTH: 252
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-09-880-748-1416

Query Match 98.1%; Score 513; DB 3; Length 252;
 Best Local Similarity 98.0%; Pred. No. 2.5e-45;
 Matches 97; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
 Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGIGY 60
 QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 99
 Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 99

RESULT 15
US-10-293-418-1416
; Sequence 1416, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLYS
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1416
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1416

Query Match 98.1%; Score 513; DB 4; Length 252;
Best Local Similarity 98.0%; Pred. No. 2.5e-45;
Matches 97; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGSRSLRSCASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSIY 60
Db 1 EVQLVESGGGLVQPGSRSLRSCASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSIY 60
Qy 61 ADSVKGRFTISRDNKNSLYLQWNSLRRAEDTALYYCAKD 99
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRRAEDTALYYCAKD 99

Search completed: May 5, 2006, 09:02:21
Job time : 32.446 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:56:13 ; Search time 7.40443 Seconds
(without alignments)
618.844 Million cell updates/sec

Title: US-09-674-752-33

Perfect score: 523

Sequence: 1 EVQLVESGGGLVQGRSLRL.....YLQNSLRADTALYYCAKD 99

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Published Applications AA New:*
- 1: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep:1*
 - 2: /SIDSS5/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
 - 3: /SIDSS5/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
 - 4: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
 - 5: /SIDSS5/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
 - 6: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
 - 7: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep:1*
 - 8: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
 - 9: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep:1*
 - 10: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep:*
 - 11: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep:1*
 - 12: /SIDSS5/ptodata/1/pubpaa/US60_NEW_PUB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	523	100.0	99	11	US-11-054-669-16
2	523	100.0	99	11	US-11-084-554-48
3	523	100.0	99	11	US-11-004-590-15
4	523	100.0	99	11	US-11-136-250-48
5	513	98.1	252	11	US-11-054-515-1416
6	513	98.1	252	11	US-11-266-444-1416
7	502	96.0	245	11	US-11-054-515-1926
8	502	96.0	245	11	US-11-266-444-1926
9	494	94.5	254	11	US-11-054-515-1427
10	494	94.5	254	11	US-11-266-444-1427
11	489	93.5	120	11	US-11-084-554-13
12	489	93.5	120	11	US-11-136-250-13
13	489	93.5	120	11	US-11-176-525-6
14	489	93.5	121	11	US-11-084-554-2
15	489	93.5	121	11	US-11-104-117-2
16	489	93.5	121	11	US-11-136-250-2
17	489	93.5	121	11	US-11-233-252-2
18	489	93.5	121	11	US-11-245-254-2
19	489	93.5	264	11	US-11-176-525-1
20	479	91.6	121	9	US-10-771-257-16
21	479	91.6	121	11	US-11-127-677-16

22	475	90.8	239	11	US-11-054-515-2015	Sequence 2015, Ap
23	475	90.8	239	11	US-11-266-444-2015	Sequence 2015, Ap
24	475	90.8	251	11	US-11-054-515-1320	Sequence 1320, Ap
25	475	90.8	251	11	US-11-266-444-1320	Sequence 1320, Ap
26	472	90.2	239	11	US-11-054-515-937	Sequence 937, App
27	472	90.2	239	11	US-11-054-515-2038	Sequence 2038, App
28	472	90.2	239	11	US-11-266-444-937	Sequence 937, App
29	472	90.2	239	11	US-11-266-444-2038	Sequence 2038, App
30	472	90.2	251	11	US-11-054-515-922	Sequence 922, App
31	472	90.2	251	11	US-11-266-444-922	Sequence 922, App
32	470	89.9	98	11	US-11-054-669-20	Sequence 20, Appl
33	470	89.9	98	11	US-11-084-554-31	Sequence 31, Appl
34	470	89.9	98	11	US-11-004-590-21	Sequence 21, Appl
35	470	89.9	98	11	US-11-136-250-31	Sequence 31, Appl
36	470	89.9	259	11	US-11-054-515-1664	Sequence 1664, Ap
37	470	89.9	259	11	US-11-266-444-1664	Sequence 1664, Ap
38	465	88.9	121	11	US-11-104-117-10	Sequence 10, Appl
39	465	88.9	121	11	US-11-233-252-10	Sequence 10, Appl
40	465	88.9	121	11	US-11-245-254-10	Sequence 10, Appl
41	465	88.9	244	11	US-11-054-515-82	Sequence 82, Appl
42	465	88.9	244	11	US-11-054-515-164	Sequence 164, App
43	465	88.9	244	11	US-11-054-515-280	Sequence 280, App
44	465	88.9	244	11	US-11-266-444-82	Sequence 82, Appl
45	465	88.9	244	11	US-11-266-444-164	Sequence 164, App

ALIGNMENTS

RESULT 1
US-11-054-669-16
; Sequence 16, Application US/11054669
; Publication No. US20050261480A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES
; FILE REFERENCE: 30219/US/3
; CURRENT APPLICATION NUMBER: US/11/054,669
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: US 10/194,975
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 15
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-669-16

Query Match	100.0%;	Score 523;	DB 11;	Length 99;
Best Local Similarity	100.0%;	Pred. No. 2.7e-42;		
Matches	99;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	1	EVQLVESGGGLVQGRSLRLSCAASGFTFDYAHMWVROAPGKLEWVSGISWNSGSIY	60	
Db	1	EVQLVESGGGLVQGRSLRLSCAASGFTFDYAHMWVROAPGKLEWVSGISWNSGSIY	60	
Qy	61	ADSVKGRFTISRDNKNSLYLQNSLRADTALYYCAKD	99	
Db	61	ADSVKGRFTISRDNKNSLYLQNSLRADTALYYCAKD	99	
RESULT 2				
US-11-084-554-48				
; Sequence 48, Application US/11084554				
; Publication No. US20050260679A1				
; GENERAL INFORMATION:				
; APPLICANT: Kellermann, Sirdid-Ai				
; APPLICANT: Green, Larry L.				
; APPLICANT: Korver, Wouter				
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN				

```
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A
; CURRENT APPLICATION NUMBER: US/11/084,554
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-084-554-48

Query Match      100.0%; Score 523; DB 11; Length 99;
Best Local Similarity 100.0%; Pred. No. 2.7e-42;
Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGGLVQGRSLRLSCAASGFTFDYAMHWVRQAPGKGLVWVSGISWNSGSIY 60
   |||||
Db 1 EVLVESGGGLVQGRSLRLSCAASGFTFDYAMHWVRQAPGKGLVWVSGISWNSGSIY 60
   |||||

QY 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAKD 99
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAKD 99
   |||||

RESULT 3
US-11-004-590-15
; Sequence 15, Application US/11004590
; Publication No. US2006008883A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hammond, Phillip W.
; TITLE OF INVENTION: METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING
; FILE REFERENCE: 185832/US/5
; CURRENT APPLICATION NUMBER: US/11/004,590
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: US 60/527,167
; PRIOR FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: US 60/581,613
; PRIOR FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US 60/601,665
; PRIOR FILING DATE: 2004-08-13
; PRIOR APPLICATION NUMBER: US 60/619,483
; PRIOR FILING DATE: 2004-10-14
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 15
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-004-590-15

Query Match      100.0%; Score 523; DB 11; Length 99;
Best Local Similarity 100.0%; Pred. No. 2.7e-42;
Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGGLVQGRSLRLSCAASGFTFDYAMHWVRQAPGKGLVWVSGISWNSGSIY 60
   |||||
Db 1 EVLVESGGGLVQGRSLRLSCAASGFTFDYAMHWVRQAPGKGLVWVSGISWNSGSIY 60
   |||||

QY 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAKD 99
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAKD 99
   |||||

RESULT 4
US-11-136-250-48
```

```
; Sequence 48, Application US/11136250
; Publication No. US20060021074A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; FILE REFERENCE: ABGENIX.100A2
; CURRENT APPLICATION NUMBER: US/11/136,250
; CURRENT FILING DATE: 2005-05-23
; PRIOR APPLICATION NUMBER: 11/084,554
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: PCT/US2005/009306
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 99
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-136-250-48

Query Match      100.0%; Score 523; DB 11; Length 99;
Best Local Similarity 100.0%; Pred. No. 2.7e-42;
Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGGLVQGRSLRLSCAASGFTFDYAMHWVRQAPGKGLVWVSGISWNSGSIY 60
   |||||
Db 1 EVLVESGGGLVQGRSLRLSCAASGFTFDYAMHWVRQAPGKGLVWVSGISWNSGSIY 60
   |||||

QY 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAKD 99
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCAKD 99
   |||||

RESULT 5
US-11-054-515-1416
; Sequence 1416, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1416
```

```
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1416

Query Match      98.1%; Score 513; DB 11; Length 252;
Best Local Similarity 98.0%; Pred. No. 5.8e-41;
Matches 97; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSIY 60
   |||||
Db 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSIY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99
   |||||

RESULT 6
US-11-266-444-1416
; Sequence 1416, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1416
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1416

Query Match      98.1%; Score 513; DB 11; Length 252;
Best Local Similarity 98.0%; Pred. No. 5.8e-41;
Matches 97; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSIY 60
   |||||
Db 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSIY 60
   |||||

Qy 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99
   |||||

RESULT 7
US-11-054-515-1926
; Sequence 1926, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
```

```
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1926
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1926

Query Match      96.0%; Score 502; DB 11; Length 245;
Best Local Similarity 93.9%; Pred. No. 6e-40;
Matches 93; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSIY 60
   :|||:
Db 1 QVQLVQSGGGLVQPGSRSLRLSCAASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSIY 60
   :|||:

Qy 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTALYYCAKD 99
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTATYYCARE 99
   |||||

RESULT 8
US-11-266-444-1926
; Sequence 1926, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1926
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1926

Query Match      96.0%; Score 502; DB 11; Length 245;
Best Local Similarity 93.9%; Pred. No. 6e-40;
Matches 93; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
```

QY 1 EVOLVESGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
Db 1 QVLVQSGGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 99
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTATYYCARE 99

RESULT 9

US-11-054-515-1427
; Sequence 1427, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1427
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1427

Query Match 94.5%; Score 494; DB 11; Length 254;
Best Local Similarity 92.9%; Pred. No. 3.5e-39;
Matches 91; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 EVOLVESGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
Db 1 EAQLVQSGGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCTR 98

RESULT 10

US-11-266-444-1427
; Sequence 1427, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523P1d1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210

; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1427
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1427

Query Match 94.5%; Score 494; DB 11; Length 254;
Best Local Similarity 92.9%; Pred. No. 3.5e-39;
Matches 91; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1 EVOLVESGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
Db 1 EAQLVQSGGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCTR 98

RESULT 11

US-11-084-554-13
; Sequence 13, Application US/11084554
; Publication No. US20050260679A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A
; CURRENT APPLICATION NUMBER: US/11/084,554
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-084-554-13

Query Match 93.5%; Score 489; DB 11; Length 120;
Best Local Similarity 93.9%; Pred. No. 5e-39;
Matches 92; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 EVOLVESGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
Db 1 EVOLVESGGLVQPGRSRLSLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAK 98

RESULT 12

US-11-136-250-13
; Sequence 13, Application US/11136250
; Publication No. US20060021074A1
; GENERAL INFORMATION:

; APPLICANT: Kellermann, Sirdid-Ai
 ; APPLICANT: Green, Larry L.
 ; APPLICANT: Korver, Wouter
 ; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
 ; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
 ; FILE REFERENCE: ABGENIX.100A2
 ; CURRENT FILING DATE: 2005-05-23
 ; PRIOR FILING DATE: 2005-05-23
 ; PRIOR FILING DATE: 11/084,554
 ; PRIOR FILING DATE: 2005-03-17
 ; PRIOR APPLICATION NUMBER: PCT/US2005/009306
 ; PRIOR FILING DATE: 2005-03-17
 ; PRIOR APPLICATION NUMBER: 60/574,661
 ; PRIOR FILING DATE: 2004-05-24
 ; PRIOR APPLICATION NUMBER: 60/554,372
 ; PRIOR FILING DATE: 2004-03-19
 ; NUMBER OF SEQ ID NOS: 266
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO 13
 ; LENGTH: 120
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-11-136-250-13

Query Match 93.5%; Score 489; DB 11; Length 120;
 Best Local Similarity 93.9%; Pred. No. 5e-39;
 Matches 92; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EVOLVESGGGLVQPGKSLRLSCLASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSGY 60
 Db 1 EVOLVESGGGLVQPGKSLRLSCLASGFTFDDYAMHWVRQAPGKLEWVSAITWNSGHIDY 60
 Qy 61 ADSVKGRTTISRDNKNSLYLQWNSLRRAEDTALYYCAK 98
 Db 61 ADSVEGRFTISRDNKNSLYLQWNSLRRAEDTAVYYCAK 98

RESULT 13
 US-11-176-525-6
 ; Sequence 6, Application US/11176525
 ; Publication No. US20060024308A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Crea, Roberto
 ; APPLICANT: Rajpal, Arvind
 ; APPLICANT: Takeuchi, Toshi
 ; APPLICANT: Cappuccilli, Guido
 ; APPLICANT: Jones, Jennifer
 ; TITLE OF INVENTION: HIGH AFFINITY ANTI-TNF-ALPHA ANTIBODIES AND METHOD
 ; FILE REFERENCE: 43525-8001 US00
 ; CURRENT FILING DATE: 2005-07-06
 ; PRIOR FILING DATE: 2005-07-06
 ; PRIOR APPLICATION NUMBER: US/11/176,525
 ; PRIOR FILING DATE: 2004-07-06
 ; NUMBER OF SEQ ID NOS: 87
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 6
 ; LENGTH: 120
 ; TYPE: PRT
 ; ORGANISM: Artificial sequence
 ; FEATURE:
 ; OTHER INFORMATION: Recombinant D2E7 VH
 US-11-176-525-6

Query Match 93.5%; Score 489; DB 11; Length 120;
 Best Local Similarity 93.9%; Pred. No. 5e-39;
 Matches 92; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EVOLVESGGGLVQPGKSLRLSCLASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSGY 60
 Db 1 EVOLVESGGGLVQPGKSLRLSCLASGFTFDDYAMHWVRQAPGKLEWVSAITWNSGHIDY 60
 Qy 61 ADSVKGRTTISRDNKNSLYLQWNSLRRAEDTALYYCAK 98

Db 61 ADSVEGRFTISRDNKNSLYLQWNSLRRAEDTAVYYCAK 98
 RESULT 14
 US-11-084-554-2
 ; Sequence 2, Application US/11084554
 ; Publication No. US20050260679A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kellermann, Sirdid-Ai
 ; APPLICANT: Green, Larry L.
 ; APPLICANT: Korver, Wouter
 ; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
 ; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
 ; FILE REFERENCE: ABGENIX.100A
 ; CURRENT FILING DATE: 2005-03-17
 ; PRIOR FILING DATE: 2005-03-17
 ; PRIOR APPLICATION NUMBER: 60/554,372
 ; PRIOR FILING DATE: 2004-03-19
 ; PRIOR APPLICATION NUMBER: 60/574,661
 ; PRIOR FILING DATE: 2004-05-24
 ; NUMBER OF SEQ ID NOS: 266
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO 2
 ; LENGTH: 121
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-11-084-554-2

Query Match 93.5%; Score 489; DB 11; Length 121;
 Best Local Similarity 93.9%; Pred. No. 5e-39;
 Matches 92; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EVOLVESGGGLVQPGKSLRLSCLASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSGY 60
 Db 1 EVOLVESGGGLVQPGKSLRLSCLASGFTFDDYAMHWVRQAPGKLEWVSAITWNSGHIDY 60
 Qy 61 ADSVKGRTTISRDNKNSLYLQWNSLRRAEDTALYYCAK 98
 Db 61 ADSVEGRFTISRDNKNSLYLQWNSLRRAEDTAVYYCAK 98

RESULT 15
 US-11-104-117-2
 ; Sequence 2, Application US/11104117
 ; Publication No. US20060009385A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Hoffman, Rebecca
 ; APPLICANT: Taylor, Lori
 ; APPLICANT: Granneman, George
 ; APPLICANT: Yan, Philip
 ; APPLICANT: Chartash, Elliot
 ; TITLE OF INVENTION: Multiple-Variable Dose Regimen For Treating TNFa-Related Disorders
 ; FILE REFERENCE: BBI-210CP
 ; CURRENT FILING DATE: 2005-04-11
 ; PRIOR FILING DATE: 2005-04-11
 ; PRIOR APPLICATION NUMBER: US/11/104,117
 ; PRIOR FILING DATE: 2004-04-09
 ; PRIOR APPLICATION NUMBER: 60/561139
 ; PRIOR FILING DATE: 2004-04-12
 ; PRIOR APPLICATION NUMBER: 60/569100
 ; PRIOR FILING DATE: 2004-05-07
 ; NUMBER OF SEQ ID NOS: 37
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO 2
 ; LENGTH: 121
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: D2E7 heavy chain variable region
 US-11-104-117-2

Query Match 93.5%; Score 489; DB 11; Length 121;
 Best Local Similarity 93.9%; Pred. No. 5e-39;

Matches	92;	Conservative	3;	Mismatches	3;	Indels	0;	Gaps	0;
Qy	1	EVOLVE	CGGLVQ	GRSLRL	SLCAASG	FTFDDY	AMHWVR	QAPGK	GLEWVSGISWNSGSIGY 60
Db	1	EVOLVE	CGGLVQ	GRSLRL	SLCAASG	FTFDDY	AMHWVR	QAPGK	GLEWVSAITWNSGHIDY 60
Qy	61	ADSVKGR	FTISR	DNAKNS	LYLQ	MNSLRA	EDTAL	YVYCAK 98	
Db	61	ADSVKGR	FTISR	DNAKNS	LYLQ	MNSLRA	EDTAV	YVYCAK 98	

Search completed: May 5, 2006, 08:57:46
 Job time : 8.40443 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:05 ; Search time 6.30748 Seconds
(without alignments)
1510.185 Million cell updates/sec

Title: US-09-674-752-33

Perfect score: 523

Sequence: 1 EVQLVESGGGLVQPGKSLRL.....YLQNSLRADTALYYCAKD 99

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_80.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	523	100.0	121	2 S31104	Ig heavy chain (su
2	523	100.0	128	2 S31595	Ig heavy chain v r
3	518	99.0	121	2 S31118	Ig heavy chain - h
4	517	98.9	98	2 S26927	Ig heavy chain v r
5	513	98.1	123	2 S30532	Ig heavy chain v r
6	494	94.5	120	2 S36273	Ig heavy chain v r
7	491	93.9	145	2 S11239	Ig heavy chain v r
8	488	93.3	100	2 S69896	Ig heavy chain v r
9	470	89.9	98	2 S26928	Ig heavy chain v r
10	466	89.1	123	2 PC4281	anti-SS-A/Ro 60K p
11	460	88.0	120	2 S44111	Ig heavy chain V-D
12	454	86.8	98	2 S26929	Ig heavy chain v r
13	454	86.8	98	2 S54856	Ig heavy chain v r
14	444	84.9	119	2 S31107	Ig heavy chain - h
15	441	84.3	114	2 S46390	Ig heavy chain v r
16	441	84.3	119	2 C36005	Ig heavy chain v r
17	441	84.3	119	2 S31108	Ig heavy chain - h
18	441	84.3	120	2 S48798	Ig heavy chain v r
19	438	83.7	118	2 S31121	Ig heavy chain - h
20	438	83.7	119	2 F36005	Ig heavy chain v r
21	438	83.7	121	2 C36005	Ig heavy chain v r
22	438	83.7	122	2 E36005	Ig heavy chain v r
23	437	83.6	112	2 PH1654	Ig heavy chain v r
24	437	83.6	122	2 S31119	Ig heavy chain - h
25	437	83.6	143	2 S23624	Ig heavy chain v r
26	436	83.4	117	2 S21980	Ig heavy chain V-g
27	436	83.4	140	2 S31588	Ig heavy chain v r
28	435	83.2	98	2 S26889	Ig heavy chain v r
29	435	83.2	117	2 A45953	Ig heavy chain pre

RESULT 1

S31104

Ig heavy chain (subclass IgM) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 23-Jul-1999

C;Accession: S31104

R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman, E.; J. Immunol. 22, 247-251, 1992

A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third complement

A;Reference number: S31104; MUID:92111633; PMID:1730252

A;Accession: S31104

A;Status: preliminary; nucleic acid sequence not shown; translation not shown

A;Molecule type: mRNA

A;Residues: 1-121 <RA>

A;Cross-references: UNIPARC:UPI000011600B; EMBL:X63080; NID:G32646; PIDN:CAA44802.1; PID

A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotrimer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 523; DB 2; Length 121;

Best Local Similarity 100.0%; Pred. No. 7.8e-44;

Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTDDYAMHWVRQAPGKLEWVSGISWNSGIGY 60

DB 1 EVQLVESGGGLVQPGKSLRLSCAASGFTDDYAMHWVRQAPGKLEWVSGISWNSGIGY 60

QY 61 ADSVKGRFTISRDNKNSLYLQNSLRADTALYYCAKD 99

DB 61 ADSVKGRFTISRDNKNSLYLQNSLRADTALYYCAKD 99

RESULT 2

S31595

Ig heavy chain V region - human

C;Species: Homo sapiens (man)

C;Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C;Accession: S31595

R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.

submitted to the EMBL Data Library, June 1992

A;Description: Mechanisms that generate human immunoglobulin diversity operate from the

A;Reference number: S31585

A;Accession: S31595

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-128 <CUI>

A;Cross-references: UNIPARC:UPI0000116458; EMBL:Z14171; NID:G31007; PIDN:CAA78540.1; PID

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotrimer; immunoglobulin

F;23-106/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 523; DB 2; Length 128;
 Best Local Similarity 100.0%; Pred. No. 8.3e-44;
 Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGLVQGRSLRLSCAASGFTFDDYAMHWVROAPGKLEWVSGISNSGIGY 60
 |||||
 DB 9 EVOLVESGGLVQGRSLRLSCAASGFTFDDYAMHWVROAPGKLEWVSGISNSGIGY 68
 |||||

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 99
 |||||
 DB 69 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 107
 |||||

RESULT 3
 S31118
 Ig heavy chain - human
 C;Species: Homo sapiens (man)
 C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
 C;Accession: S31118
 R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
 Eur. J. Immunol. 22, 247-251, 1992
 A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
 A;Reference number: S311104; MUID:92111633; PMID:1730252
 A;Accession: S31118
 A;Status: preliminary; nucleic acid sequence not shown; translation not shown
 A;Molecule type: mRNA
 A;Residues: 1-121 <RAA>
 A;Cross-references: UNIPARC:UPI0000176C8B; EMBL:X62969
 A;Title: The nucleotide sequence was submitted to the EMBL Data Library, October 1991
 C;Superfamily: immunoglobulin V region; immunoglobulin homology
 C;Keywords: heterotrimer; immunoglobulin
 F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 99.0%; Score 518; DB 2; Length 121;
 Best Local Similarity 99.0%; Pred. No. 2.4e-43;
 Matches 98; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVOLVESGGLVQGRSLRLSCAASGFTFDDYAMHWVROAPGKLEWVSGISNSGIGY 60
 |||||
 DB 1 EVOLVESGGLVQGRSLRLSCAASGFTFDDYAMHWVROAPGKLEWVSGISNSGIGY 60
 |||||

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 99
 |||||
 DB 61 RDSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 99
 |||||

RESULT 4
 S26927
 Ig heavy chain V region (DP-31) - human (fragment)
 C;Species: Homo sapiens (man)
 C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
 C;Accession: S26927
 R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
 J. Mol. Biol. 227, 776-798, 1992
 A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
 A;Reference number: S26885; MUID:93021117; PMID:1404388
 A;Accession: S26927
 A;Status: preliminary
 A;Molecule type: DNA
 A;Residues: 1-98 <TOM>
 A;Cross-references: UNIPARC:UPI0000116408; EMBL:Z12333; NID:g32885; PIDN:CAA78203.1; PID
 C;Superfamily: immunoglobulin V region; immunoglobulin homology
 C;Keywords: heterotrimer; immunoglobulin
 F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.98%; Score 517; DB 2; Length 98;
 Best Local Similarity 100.0%; Pred. No. 2.4e-43;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGLVQGRSLRLSCAASGFTFDDYAMHWVROAPGKLEWVSGISNSGIGY 60
 |||||
 DB 1 EVOLVESGGLVQGRSLRLSCAASGFTFDDYAMHWVROAPGKLEWVSGISNSGIGY 60
 |||||

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
 |||||
 DB 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
 |||||

RESULT 5
 S30532
 Ig heavy chain V region - human
 C;Species: Homo sapiens (man)
 C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 31-Dec-2004
 C;Accession: S30532
 R;Mariette, X.
 submitted to the EMBL Data Library, October 1992
 A;Reference number: S30520
 A;Accession: S30532
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-123 <MAR>
 A;Cross-references: UNIPROT:Q8WU38; UNIPARC:UPI0000176C38; EMBL:Z18318
 C;Superfamily: immunoglobulin homology
 C;Keywords: heterotrimer; immunoglobulin
 F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.1%; Score 513; DB 2; Length 123;
 Best Local Similarity 97.0%; Pred. No. 7.5e-43;
 Matches 96; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVOLVESGGLVQGRSLRLSCAASGFTFDDYAMHWVROAPGKLEWVSGISNSGIGY 60
 |||||
 DB 1 EVOLVESGGLVQGRSLRLSCAASGFTFDDYAMHWVROAPGKLEWVSGISNSGIGY 60
 |||||

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 99
 |||||
 DB 61 ADSVKGRFAISRDNKNSLYLQWNSLRAEDTALYYCAK 99
 |||||

RESULT 6
 S36273
 Ig heavy chain V region (clone alpha-THY-32) - human (fragment)
 C;Species: Homo sapiens (man)
 C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
 C;Accession: S36273
 R;Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.;
 EMBO J. 12, 725-734, 1993
 A;Title: Human anti-self antibodies with high specificity from phage display libraries.
 A;Reference number: S36256; MUID:93178448; PMID:7679990
 A;Accession: S36273
 A;Status: preliminary; nucleic acid sequence not shown
 A;Molecule type: mRNA
 A;Residues: 1-120 <GRI>
 A;Cross-references: UNIPARC:UPI0000118D84; EMBL:Z18834; NID:g33116; PIDN:CAA79286.1; PID:
 C;Superfamily: immunoglobulin V region; immunoglobulin homology
 C;Keywords: heterotrimer; immunoglobulin
 F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 94.5%; Score 494; DB 2; Length 120;
 Best Local Similarity 95.9%; Pred. No. 5.1e-41;
 Matches 94; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVOLVESGGLVQGRSLRLSCAASGFTFDDYAMHWVROAPGKLEWVSGISNSGIGY 60
 |||||
 DB 1 QVOLVSGGGLVQGRSLRLSCAASGFTFDDYAMHWVROAPGKLEWVSGISNSGIGY 60
 |||||

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAK 98
 |||||
 DB 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTALYYCAR 98
 |||||

RESULT 7
 S11239
 Ig heavy chain V region - human (fragment)
 C;Species: Homo sapiens (man)
 C;Date: 21-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 89.9%; Score 470; DB 2; Length 98;
Best Local Similarity 89.8%; Pred. No. 8.7e-39;
Matches 88; Conservative 5; Mismatches 5; Indels 0; Gaps 0;

Qy 1 EVLVESGGGLVOPGRSLRLSCAASGFTDDYAMHWVRQAPGKLEWVSISWNSGSIGY 60
| | | | | : | | | | | : | | | | | : | | | | | : | | | | |
Db 1 EVLVESGGGVPRPGSLRLSCAASGFTDDYGMSVWRQAPGKLEWVSINWNGSGTGY 60
| | | | | : | | | | | : | | | | | : | | | | | : | | | | |

Qy 61 ADSVKGRFTISRDNNAKNSLYLQWNSLRRAEDTALYYCAK 98
| | | | | : | | | | | : | | | | | : | | | | | : | | | | |
Db 61 ADSVKGRFTISRDNNAKNSLYLQWNSLRRAEDTALYHCAR 98
| | | | | : | | | | | : | | | | | : | | | | | : | | | | |

RESULT 10

PC4281
anti-SS-A/Ro 60K peptide heavy chain E-56 - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 07-Jul-1997 #sequence_revision 29-Aug-1997 #text_change 21-Jan-2000
C;Accession: PC4281
R;Suzuki, H.; Takemura, H.; Suzuki, M.; Sekine, Y.; Kashiwagi, H.
Biochem. Biophys. Res. Commun. 232, 101-106, 1997
A;Title: Molecular cloning of anti-ss-A/Ro 60-kDa peptide fab fragments from infiltrating lymphocytes
A;Reference number: PC4279; MUID:97236289; PMID:9125110
A;Accession: PC4281
A;Molecule type: protein
A;Residues: 1-123 <SUZ>
A;Cross-references: UNIPARC:UPI0000176E91
C;Comment: This antibody is commonly found in systemic autoimmune diseases such as Sjogren's syndrome
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 89.1%; Score 466; DB 2; Length 123;
Best Local Similarity 88.9%; Pred. No. 2.7e-38;
Matches 88; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

Qy 1 EVLVESGGGLVOPGRSLRLSCAASGFTDDYAMHWVRQAPGKLEWVSISWNSGSIGY 60
| | | | | : | | | | | : | | | | | : | | | | | : | | | | |
Db 1 EVLVESGGGLVOPGRSLRLSCVTSFGTTGDVAMSVWRQAPGKLEWVSISWNSGTIGY 60
| | | | | : | | | | | : | | | | | : | | | | | : | | | | |

Qy 61 ADSVKGRFTISRDNNAKNSLYLQWNSLRRAEDTALYYCAKD 99
| | | | | : | | | | | : | | | | | : | | | | | : | | | | |
Db 61 MDSVKGRFTISRDNNAKNSLYLQMSSLRPEDTALYYCAKD 99
| | | | | : | | | | | : | | | | | : | | | | | : | | | | |

RESULT 11

S44111
Ig heavy chain V-D-J region - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 24-May-2001
C;Accession: S44111
R;Hawkins, R.E.; Zhu, D.; Ovecka, M.; Winter, G.; Hamblin, T.J.; Stevenson, F.K.
submitted to the EMBL Data Library, March 1994
A;Description: Idiotypic vaccination against human B-cell lymphoma: rescue of variable regions by transfection of cDNA libraries
A;Reference number: S44105
A;Accession: S44111
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-120 <HAW>
A;Cross-references: UNIPARC:UPI000011662E; EMBL:231387; NID:G472965; PIDN:CAA83262.1; P18722
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 88.0%; Score 460; DB 2; Length 120;
Best Local Similarity 88.9%; Pred. No. 1e-37;
Matches 88; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

Qy 1 EVLVESGGGLVOPGRSLRLSCAASGFTDDYAMHWVRQAPGKLEWVSISWNSGSIGY 60
| | | | | : | | | | | : | | | | | : | | | | | : | | | | |
| | | | | : | | | | | : | | | | | : | | | | | : | | | | |

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:58 ; Search time 39.2161 Seconds
(without alignments)
1781.089 Million cell updates/sec

Title: US-09-674-752-33

Perfect score: 523

Sequence: 1 EVLVESGGGLVQGRSLRL.....YLGQNSLRARDTALYYCAKD 99

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	517	98.9	573	2	Q8WU38_HUMAN
2	509	97.3	472	2	Q6N089_HUMAN
3	470	89.9	112	2	Q9HCC1_HUMAN
4	457	87.4	469	2	Q569F4_HUMAN
5	446	85.3	499	2	Q8N5K4_HUMAN
6	445	85.1	121	2	Q9UL71_HUMAN
7	437	83.6	613	2	Q8WUK1_HUMAN
8	431	82.4	117	1	HV3C_HUMAN
9	431	82.4	597	2	Q96B59_HUMAN
10	429	82.0	116	2	Q9UL93_HUMAN
11	428	81.8	113	2	Q9UL90_HUMAN
12	427	81.6	240	2	Q65ZC9_HUMAN
13	425	81.3	118	2	Q9UL91_HUMAN
14	424	81.1	606	2	Q6GMV2_HUMAN
15	421.5	80.6	464	2	Q6MZU6_HUMAN
16	419	80.1	122	1	HV3G_HUMAN
17	418	79.9	494	2	Q6ZW64_HUMAN
18	416	79.5	104	2	Q9UL87_HUMAN
19	416	79.5	494	2	Q96K68_HUMAN
20	415	79.3	479	2	Q6MZV6_HUMAN
21	413	79.0	467	2	Q4VBH1_RAT
22	413	79.0	478	2	Q6P181_HUMAN
23	412	78.8	120	1	HV3U_HUMAN
24	410	78.4	122	2	Q9UL84_HUMAN
25	409	78.2	116	1	HV3T_HUMAN
26	409	78.2	470	2	Q6PJ4A_HUMAN
27	409	78.2	493	2	Q6GMX2_HUMAN
28	408	78.0	473	2	Q6MZV7_HUMAN
29	402	76.9	473	2	Q91Z05_MOUSE
30	402	76.9	485	2	Q6PDB8_MOUSE
31	400	76.5	121	1	HV3J_HUMAN

32	400	76.5	475	2	Q5BFE5_HUMAN
33	399	76.3	465	2	Q51OJ0_RAT
34	399	75.7	475	2	Q6MZQ6_HUMAN
35	396	75.7	544	2	Q6PJ95_HUMAN
36	395	75.5	479	2	Q5PQK9_RAT
37	394.5	75.4	118	2	Q9UL72_HUMAN
38	394	75.3	95	2	Q9ULB6_HUMAN
39	393.5	75.2	116	1	HV05_CARAU
40	393	75.1	122	1	HV3H_HUMAN
41	393	75.1	126	1	HV3K_HUMAN
42	393	75.1	147	2	Q9Y509_HUMAN
43	393	75.1	461	2	Q5M7V3_RAT
44	392	75.0	119	1	HV3I_HUMAN
45	392	75.0	475	2	Q6GMW7_HUMAN

ALIGNMENTS

RESULT 1
Q8WU38_HUMAN
ID Q8WU38_HUMAN PRELIMINARY; PRT; 573 AA.
AC Q8WU38; 2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHD protein.
GN Name=IGHD;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.D., Feingold E.A., Grouse L.H., Derge J.G.,
RA Strausberg R.L., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalley D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16699-16903(2002).
[2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX PubMed=1555592;
RA Director MGC Project;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
[3]
RP PROTEIN SEQUENCE.
RX PubMed=1555592;
RA Makiya R., Stigbrand T.;
RT "Placental alkaline phosphatase has a binding site for the human
immunoglobulin-G Fc portion";
RL Eur. J. Biochem. 205:341-345(1992).
DR EMBL; BC021276; AAR21276.1; -, mRNA.
DR PIR; S21205; S21205.
DR PIR; S30532; S30532.
DR HSPP; P18529; I18K.

```
DR Ensembl; ENSG00000196122; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 1.
DR Pfam; PF00047; Ig; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 573 AA; 62967 MW; FD072344033AC530 CRC64;

Query Match 98.9%; Score 517; DB 2; Length 573;
Best Local Similarity 100.0%; Pred. No. 3.9e-47;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISNMSGIGY 60
DB 20 EVQLVESGGGLVQPGSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISNMSGIGY 79
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTALYYCAK 98
DB 80 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTALYYCAK 117

RESULT 2
Q6N089 HUMAN
ID Q6N089_HUMAN PRELIMINARY; PRT; 472 AA.
AC Q6N089
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFp686P15220.
GN Name=DKFp686P15220;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Oeanger A.,
RA Fobo G., Han M., Wiemann S.;
RA Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
RL EMBL; BX640627; CA245781.1; -, mRNA.
DR HSSP; P01861; IADQ.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IGV; 2.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 472 AA; 51724 MW; 26CB340D0046D279 CRC64;

Query Match 97.3%; Score 509; DB 2; Length 472;
Best Local Similarity 97.0%; Pred. No. 2.3e-46;
Matches 96; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISNMSGIGY 60
DB 20 EVQLVESGGGLVQPGSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISNMSGIAY 79
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTALYYCAK 99

Query Match 89.9%; Score 470; DB 2; Length 112;
Best Local Similarity 88.8%; Pred. No. 7.4e-43;
Matches 87; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISNMSGIGY 60
DB 1 EVQLVESGGGVVRRPGGSLRISCAASGFTFDYGMVVRQAPGKLEWVSGINNGSGTGY 60
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTALYYCAK 98
DB 61 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTAVYYCAR 98

RESULT 4
Q569F4 HUMAN
ID Q569F4_HUMAN PRELIMINARY; PRT; 469 AA.
AC Q569F4
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lymph;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ussid T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
```

```
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN (2)
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lymph;
RG NIH MGC Project;
RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC092518; AAH32518.1; -, mRNA.
SQ SEQUENCE 469 AA; 51254 MW; AC13448E3047784F CRC64;

Query Match 87.4%; Score 457; DB 2; Length 469;
Best Local Similarity 90.7%; Pred. No. 9.7e-41;
Matches 88; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRSCAASGFTFDYAMHWVRQAPGKGLVWSGINSIGY 60
Db 20 EVQLVESGGGVVQPGGSRSLRSCAASGFTFDYAMHWVRQAPGKGLVWSLISDGGSTYY 79

Qy 61 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTALYYCA 97
Db 80 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTALYYCA 116

RESULT 5
Q8NSK4 HUMAN
ID Q8NSK4 HUMAN PRELIMINARY; PRT; 499 AA.
AC Q8NSK4;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE MGC27165 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN (1)
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Blood;
RX MEDLINE=22386257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heieh F.,
RA Diatchenko L., Narusina K., Farmer A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN (2)
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Blood;
RA Strausberg R.;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
```

```
DR EMBL; BC032249; AAH32249.1; -, mRNA.
DR HSP; Q81876; IOM0.
DR SMR; Q8NSK4; 269-477.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00406; Ig; 1.
DR SMART; SM00406; Ig; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW immunoglobulin domain; Repeat.
SQ SEQUENCE 499 AA; 53376 MW; 93A5C89582054F32 CRC64;

Query Match 85.3%; Score 446; DB 2; Length 499;
Best Local Similarity 84.8%; Pred. No. 1.6e-39;
Matches 84; Conservative 4; Mismatches 11; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRSCAASGFTFDYAMHWVRQAPGKGLVWSGINSIGY 60
Db 20 EVQLVESGGGVVQPGGSRSLRSCATSGFTFDGSGASVVRQAPGKGLVWSINMGGSYNY 79

Qy 61 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTALYYCAKD 99
Db 80 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTALYYCARD 118

RESULT 6
Q9UL71 HUMAN
ID Q9UL71 HUMAN PRELIMINARY; PRT; 121 AA.
AC Q9UL71;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN (1)
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/cclin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035043; AAD56279.1; -, mRNA.
DR HSP; P01852; INF2.
DR SMR; Q9UL71; 1-121.
DR Ensemble; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 121
SQ SEQUENCE 121 AA; 13154 MW; 2F045CCFASD50736 CRC64;

Query Match 85.1%; Score 445; DB 2; Length 121;
Best Local Similarity 88.8%; Pred. No. 4.1e-40;
Matches 87; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRSCAASGFTFDYAMHWVRQAPGKGLVWSGINSIGY 60
Db 1 EVQLVESGGGVVQPGGSRSLRSCAASGFTFDYAMHWVRQAPGKGLVWSLISDGGSTYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTALYYCAK 98
Db 61 ADSVKGRFTISRDNKNSLYLQMSLRRAEDTALYYCAK 98
```

```
RESULT 7
Q8WUK1_HUMAN
ID Q8WUK1_HUMAN PRELIMINARY; PRT; 613 AA.
AC Q8WUK1;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haileh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallalal D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MCC Project;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=21117273;
RA Schroeder H.W. Jr, Wang J.Y.;
RT "Preferential utilization of conserved immunoglobulin heavy chain
RT variable gene segments during human fetal life."
RL Proc. Natl. Acad. Sci. U.S.A. 87:6146-6150(1990).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1383695; DOI=10.1016/0161-5890(92)90173-U;
RA Cuisinier A.M., Fumoux F., Fougereau M., Tonnelie C.;
RT "TGM kappa/lambda BBV human B cell clone: an early step of
RT differentiation of fetal B cells or a distinct B lineage?";
RL Mol. Immunol. 29:1363-1373(1992).
RN [5]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1730252;
RA Raaphorst F.M., Timmers E., Kenter M.J., Van Tol M.J., Vossen J.M.,
RA Schuurman R.K.;
RT "Restricted utilization of germ-line VH3 genes and short diverse third
RT complementarity-determining regions (CDR3) in human fetal B lymphocyte
RT immunoglobulin heavy chain rearrangements."
RL Eur. J. Immunol. 22:247-251(1992).
RN [6]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1904154;
RA Neale G.A., Kitchingman G.R.;
RT "mRNA transcripts initiating within the human immunoglobulin mu heavy
RT chain enhancer region contain a non-translatable exon and are
RT extremely heterogeneous at the 5' end."
RL Nucleic Acids Res. 19:2427-2433(1991).
RN [7]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2840480; DOI=10.1084/jem.168.1.1229;
RA Bird J., Galili N., Link M., Stites D., Sklar J.;
RT "Continuing rearrangement but absence of somatic hypermutation in
RT immunoglobulin genes of human B cell precursor leukemia."
RL J. Exp. Med. 168:229-245(1988).
RN [8]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2538551; DOI=10.1084/jem.169.4.1391;
RA Nickerson K.G., Berman J., Glickman E., Chess L., Alt F.W.;
RT "Early human IgH gene assembly in Epstein-Barr virus-transformed fetal
RT B cell lines. Preferential utilization of the most JH-proximal D
RT segment (DQ52) and two unusual VH-related rearrangements."
RL J. Exp. Med. 169:1391-1403(1989).
RN [9]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=93301610; PubMed=8315388; DOI=10.1084/jem.178.1.331;
RA Hillson J.L., Karr N.S., Oppiger I.R., Mannik M., Sasso E.H.;
RT "The structural basis of germline-encoded VH3 immunoglobulin binding
RT to staphylococcal protein A."
RL J. Exp. Med. 178:331-336(1993).
DR EMBL; BC020240; AAH20240.1; -; mRNA.
DR PIR; F36005; F36005.
DR PIR; G36005; G36005.
DR PIR; PH1642; PH1642.
DR PIR; PH1643; PH1643.
DR PIR; PH1645; PH1645.
DR PIR; PH1646; PH1646.
DR PIR; PL0098; PL0098.
DR PIR; S15590; S15590.
DR PIR; S31116; S31116.
DR PIR; S31119; S31119.
DR PIR; S70442; S70442.
DR HSSP; P01861; IADQ.
DR SNR; Q8WUK1; 20-242.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.
KW Immunoglobulin domain.
SQ SEQUENCE 613 AA; 67296 MW; 60C7F5950671E315 CRC64;
Query Match 83.6%; Score 437; DB 2; Length 613;
Best Local Similarity 82.8%; Pred. No. 1.9e-38;
Matches 82; Conservative 9; Mismatches 8; Indels 0; Gaps 0;
QY 1 EYQLVESGGGLVQPGKSLRLSCAASGFTPDYAMHWVRQAPGKLEWVSGISNWSGIGY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 QYQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSDGSKYY 79
QY 61 ADSVKGRTISRDNKNSLYLQNSLRADTALYYCAKD 99
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 80 ADSVKGRTISRDNKNSKNTLYLQNSLRADTAVYYCAKD 118
RESULT 8
HV3C_HUMAN
ID HV3C_HUMAN STANDARD; PRT; 117 AA.
AC P01764;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 13-SEP-2005 (Rel. 48, Last annotation update)
DE Ig heavy chain V-III region VH26 precursor.
```

```
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=81101090; PubMed=6450418;
RA Matthysens G., Rabbitts T.H.;
RT "Structure and multiplicity of genes for the human immunoglobulin
heavy chain variable region.";
RL Proc. Natl. Acad. Sci. U.S.A. 77:6561-6565 (1980).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 20-117.
RX MEDLINE=93209281; PubMed=7681398;
RA Mariette X., Teapis A., Brouet J.C.;
RT "Nucleotide sequence analysis of the variable domains of four human
monoclonal IgM with an antibody activity to myelin-associated
glycoprotein.";
RL Eur. J. Immunol. 23:846-851 (1993).
RN [3]
RP 3D-STRUCTURE MODELING OF 20-117.
RX MEDLINE=86094276; PubMed=386244;
RA Toyonaga B., Yoshikai Y., Vadasz V., Chin B., Mak T.W.;
RT "Organization and sequences of the diversity, joining, and constant
region genes of the human T-cell receptor beta chain.";
RL Proc. Natl. Acad. Sci. U.S.A. 82:8624-8628 (1985).
CC -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use as long as its content is in no way modified and this statement is not
removed.
CC -----
DR EMBL; J00236; AAA53516.1; -; Unassigned DNA.
DR EMBL; M35415; AAA58735.1; -; Genomic DNA.
DR PIR; A02047; H3HU26.
DR PDB; 1HOU; Model; H=20-117.
DR HGNC; HGNC:5545; IGHV0.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR 3D-structure; Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-III region VH26.
FT DOMAIN 20 >117 Ig-like.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12582 MW; E826733F1A3CB0F1 CRC64;

Query Match 82.4%; Score 431; DB 1; Length 117;
Best Local Similarity 84.7%; Pred. No. 1.3e-39;
Matches 83; Conservative 5; Mismatches 10; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISGSGY 60
DB 20 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGSGSTYY 79

QY 61 ADSVKGRFTISRDNKNSLYLQNNLSRAEDTALYYCAK 98
DB 80 GDSVKGRFTISRDNKNTLYLQNNLSRAEDTAVYYCAK 117

RESULT 9
Q96BB9_HUMAN PRELIMINARY; PRT; 597 AA.
ID Q96BB9 HUMAN
AC Q96BB9
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
```

```
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE IGHM protein.
GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX TISSUE=Primary B-Cells;
MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahney J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX TISSUE=Primary B-Cells;
NH MGC Project;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2500644;
RA Kishimoto T., Okajima H., Okumoto T., Taniguchi M.;
RT "Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-
chains of a human monoclonal antibody with broad reactivity to
malignant tumor cells.";
RL Nucleic Acids Res. 17:4385-0 (1989).
DR EMBL; BC015760; AAH15760.1; -; mRNA.
DR PIR; S05271; S05271.
DR PIR; S24260; S24260.
DR HSSP; P01861; IADQ.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.
KW Immunoglobulin domain.
SQ SEQUENCE 597 AA; 65039 MW; 4FCA3AD8CE263D9 CRC64;

Query Match 82.4%; Score 431; DB 2; Length 597;
Best Local Similarity 82.8%; Pred. No. 8.3e-38;
Matches 82; Conservative 9; Mismatches 8; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISGSGY 60
DB 20 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYAMSVWRQAPGKLEWVAISGSGSTYY 79

QY 61 ADSVKGRFTISRDNKNSLYLQNNLSRAEDTALYYCAK 99
DB 80 ADSVKGRFTISRDNKNTLYLQNNLSRAEDTAVYYCAK 118
```

RESULT 10					
Q9UL93_HUMAN PRELIMINARY;	PRT;	116 AA.			
ID Q9UL93; AC Q9UL93;					
DT 01-MAY-2000 (TrEMBLrel. 13, Created)					
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)					
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)					
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).					
OS Homo sapiens (Human).					
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo.					
NCBI_TaxID=9606;					
[1]					
RN NUCLEOTIDE SEQUENCE.					
RP MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clim.1998.4531;					
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., Young D.C.;					
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus.";					
RL Clin. Immunol. Immunopathol. 87:184-192(1998).					
[2]					
RN NUCLEOTIDE SEQUENCE.					
RP MEDLINE=93301610; PubMed=8315389; DOI=10.1084/jem.178.1.331;					
RA Hallson J.L., Karr N.S., Opliger I.R., Mannik M., Saeso E.H.;					
RT "The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A.";					
RL J. Exp. Med. 178:331-336(1993).					
[3]					
RN NUCLEOTIDE SEQUENCE.					
RP PubMed=2840480;					
RA Bird J., Galili N., Link M., Sites D., Sklar J.;					
RT "Continuing rearrangement but absence of somatic hypermutation in immunoglobulin genes of human B cell precursor leukemia.";					
RL J. Exp. Med. 168:229-245(1988).					
DR ENBL; AF035021; AAC56257.1; -; mRNA.					
PIR; PH1644; PHI644.					
DR PIR; PLO120; PLO120.					
HSSP; P01772; 2FB4.					
SMR; Q9UL93; 1-116.					
DR InterPro; IPR007110; Ig-like.					
DR InterPro; IPR003596; IG_v.					
SMART; SM00406; IG; 1_v.					
DR PROSITE; PSS0835; IG_LIKE; 1.					
FT NON TER 1					
FT NON TER 116					
SQ SEQUENCE 116 AA; 12434 MW; 0DA0348154DD6061 CRC64;					
Query Match 82.0%; Score 429; DB 2; Length 116;					
Best Local Similarity 84.4%; Pred. No. 2.1e-38;					
Matches 81; Conservative 8; Mismatches 7; Indels 0; Gaps 0					
QY 2 VQLVESGGGLVQPGRSLRLSCAASGFTFDHYAMHWVRQAPGKGLEWVGISWNSSIGYA 61					
DB 1 VQLVESGGGVVQPSRLSLSCAASGFTFSFYAMHWVRQAPGKLEWVAIVSYDGSNKYYA 60					
QY 62 DSVKGRTTISRDNKNSLYLQMNSLRADTYLYCA 97					
DB 61 DSVKGRTTISRDNKNTLYLQMNSLRADTYLYCA 96					
RESULT 11					
Q9UL90_HUMAN PRELIMINARY;	PRT;	113 AA.			
ID Q9UL90; AC Q9UL90;					
DT 01-MAY-2000 (TrEMBLrel. 13, Created)					
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)					
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)					
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).					
OS Homo sapiens (Human).					


```
DR PROSITE, PS50835; IG LIKE; 2.
FT NON TER 1
FT NON TER 240 240
SQ SEQUENCE 240 AA; 25569 MW; FDCFD31645F64B373 CRC64;

Query Match 81.6%; Score 427; DB 2; Length 240;
Best Local Similarity 80.8%; Pred. No. 8e-38;
Matches 80; Conservative 10; Mismatches 9; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSGIGY 60
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSYGNHWYRQAPGKGLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAK 99
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAK 99

RESULT 13
Q9UL91_HUMAN PRELIMINARY; PRT; 118 AA.
AC Q9UL91;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528;
RA Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
[2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528;
RA Manheimer-Lory A., Katz J.B., Pillinger M., Ghossein C., Smith A.,
RA Diamond B.;
RT "Molecular characteristics of antibodies bearing an anti-DNA-
RT associated idiotype.";
RL J. Exp. Med. 174:1639-1652(1991).
[3]
RP PROTEIN SEQUENCE.
RX PubMed=155592;
RA Makiya R., Stigbrand T.;
RT "Placental alkaline phosphatase has a binding site for the human
RL immunoglobulin-G Fc portion.";
RL Eur. J. Biochem. 205:341-345(1992).
DR EMBL; AF035023; AAD56259.1; -; mRNA.
DR PIR; PH0875; PH0875.
DR PIR; S21205; S21205.
DR PIR; S30531; S30531.
DR HSP; P01783; IIGC.
DR SMART; Q9UL91; 1-117.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
FT NON TER 1
FT NON TER 118
SQ SEQUENCE 118 AA; 12843 MW; D0633949F2AC149D CRC64;

Query Match 81.3%; Score 425; DB 2; Length 118;
Best Local Similarity 85.7%; Pred. No. 5.8e-38;
Matches 84; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSGIGY 60
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSYGNHWYRQAPGKGLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAK 99
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAK 99

RESULT 14
Q6GMV2_HUMAN PRELIMINARY; PRT; 606 AA.
AC Q6GMV2;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHM protein.
GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=22398257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalls D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[2]
RP NUCLEOTIDE SEQUENCE.
RX NIH WGC Project;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073758; AAH73758.1; -; mRNA.
DR SMR; Q6GMV2; 20-256.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 606 AA; 66185 MW; B6B38B51114E4C55 CRC64;

Query Match 81.1%; Score 424; DB 2; Length 606;
Best Local Similarity 83.7%; Pred. No. 4.8e-37;
Matches 82; Conservative 6; Mismatches 10; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFDYAMHWYRQAPGKGLEWVSGISWNSGSGIGY 60
Db :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYGNHWYRQAPGKGLEWVAVISYIITYY 60
```

Db 20 QVQLVESGGGLVPGGSLRLSCAASGFTFSDDYIMSRQAPGKLEWVSIVSSSSVTNY 79
Qy 61 ADSVKGRFTISRDNKNSLYLQWNSLRRAEDTALYYCAK 98
Db 80 ADSVKGRFTISRDNKNSLYLQWNSLRRAEDTAVYYCAR 117

RESULT 15

Q6MZU6_HUMAN
ID Q6MZU6_HUMAN PRELIMINARY; PRT; 464 AA.
AC Q6MZU6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFZp686C15213.
GN Name=DKFZp686C15213;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Rectum tumor;
RG The German cDNA Consortium;
RA Bloeker H., Boecher M., Brandt P., Mewes H.W., Weil B., Amid C.,
RA Oeinger A., Fobo G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640874; CAB45931.1; -; mRNA.
DR HSSP; P01861; IADQ.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
KW Hypothetical protein_
SQ SEQUENCE 464 AA; 51099 MW; 2FCA72C66E8A0ABC CRC64;

Query Match 80.6%; Score 421.5; DB 2; Length 464;
Best Local Similarity 83.0%; Pred. No. 6.7e-37;
Matches 83; Conservative 6; Mismatches 10; Indels 1; Gaps 1;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSDDYIMSRQAPGKLEWVSIVSSSSVTNY 59
Db 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSDDYIMSRQAPGKLEWVSIVSSSSVTNY 79
Qy 60 YADSVKGRFTISRDNKNSLYLQWNSLRRAEDTALYYCAK 99
Db 80 YADSVKGRFTISRDNKNSLYLQWNSLRRAEDTAVYYCAR 119

Search completed: May 5, 2006, 09:04:21
Job time : 39.2161 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:28 ; Search time 49.795 Seconds
(without alignments)

1111.793 Million cell updates/sec

Title: US-09-674-752-34

Perfect score: 665

Sequence: 1 QVQLVQSGGGLVQPGKSLRL.....REGVAADIMGQGTMTVTSS 126

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21:*

1: Genesecp1980s:*

2: Genesecp1990s:*

3: Genesecp2000s:*

4: Genesecp2001s:*

5: Genesecp2002s:*

6: Genesecp2003as:*

7: Genesecp2003bs:*

8: Genesecp2004s:*

9: Genesecp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	665	100.0	126	3	AAY50967 Human FVI
2	665	100.0	126	3	AAY50961 Human FVI
3	516	77.6	248	2	AAR20059 Recombina
4	516	77.6	475	2	AAR20057 Heavy cha
5	512	77.0	272	8	ADO19054 Human ant
6	511	76.8	124	2	AAR90286 Human ant
7	509	76.5	120	2	AAY43255 VH domain
8	508	76.4	120	2	AAY43254 VH domain
9	508	76.4	120	4	AAG65553 Amino aci
10	508	76.4	120	5	ABB06276 VH3-4 am
11	508	76.4	120	7	ADH40225 Human VH3
12	505.5	76.0	119	4	AAE07025 Human hea
13	505.5	76.0	119	8	ADQ9310 Human imm
14	505.5	76.0	119	9	AEBO9583 Human hea
15	505.5	76.0	241	2	AAW24063 Human WSX
16	505.5	76.0	241	7	ADC08951 Human WSX
17	505.5	76.0	241	9	ADW88159 Human ago
18	505	75.9	122	9	AEB27730 Prostata
19	505	75.9	124	7	ADH40286 Human pro
20	505	75.9	245	9	AEB27750 Anti-pros
21	504	75.8	291	8	ADN06989 Human EFG
22	503.5	75.7	245	5	ABP45915 Human BLY
23	503.5	75.7	245	7	ADG96742 Single ch
24	502.5	75.6	243	8	ADG34310 Neurokini

ALIGNMENTS

RESULT 1

AAY50967

ID AAY50967 standard; protein; 126 AA.

XX AAY50967;

AC AAY50967;

DT 23-MAR-2000 (first entry)

XX Human FVIII antibody heavy chain variable region B18 protein fragment.

DE Human FVIII antibody heavy chain variable region B18 protein fragment.

XX Human; heavy chain; antibody; factor VIII; hemostatic; variable region;

KW hemophilia A.

XX Homo sapiens.

OS Homo sapiens.

XX WO9958680-A2.

PN WO9958680-A2.

XX 18-NOV-1999.

PD 18-NOV-1999.

XX 07-MAY-1999; 99WO-NL000285.

PF 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

PR 08-MAY-1998; 98EP-00201543.

XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

PA Voorberg JJ, Van Den Brink EN, Turenhout EAM;

XX WPI; 2000-053102/04.

DR N-PSDB; AA243864.

XX New polynucleotide, polypeptide and antibody useful for diagnosing the

PT presence of neutralizing antibodies against factor VIII and for treatment

PT of hemophilia A patients with these antibodies.

XX Example 8; Fig 9C; 61pp; English.

PS This invention describes a novel polynucleotide (I) (and complements and

XX hybridizable polynucleotides) comprising a contiguous nucleotide sequence

CC coding for a human antibody with factor VIII specificity which has

CC hemostatic activity. (I) is useful as a primer or probe for detecting the

CC presence of inhibitory antibodies directed against factor VIII. The

CC polypeptides of the invention and the antibodies generated from them are

CC useful in compositions for neutralizing factor VIII inhibiting antibodies

CC in hemophilia A patients. This sequence represents a fragment of the

CC human factor VIII antibody heavy chain variable region protein B18 which

CC is used in the method of the invention

XX

XX

XX

XX

SQ Sequence 126 AA;
 Query Match 100.0%; Score 665; DB 3; Length 126;
 Best Local Similarity 100.0%; Pred. NO. 9.3e-56;
 Matches 126; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGSGLEWVSGVTWSTTIGF 60
 DB 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGSGLEWVSGVTWSTTIGF 60

QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADTALYYCALPYINSNRYRRGVAAFDINGQGT 120
 DB 61 ADSVKGRFTISRDNKNSLYLYMNSLRADTALYYCALPYINSNRYRRGVAAFDINGQGT 120

QY 121 MVTVSS 126
 DB 121 MVTVSS 126

RESULT 2
 AAY50961
 ID AAY50961 standard; protein; 126 AA.
 XX AC AAY50961;
 XX DT 23-MAR-2000 (first entry)
 XX DE Human FVIII antibody A3-C1 scFv heavy chain protein B18.
 XX KW Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
 XX KW scFv; A3-C1.
 XX OS Homo sapiens.
 XX PN WO9558680-A2.
 XX PD 18-NOV-1999.
 XX PF 07-MAY-1999; 99WO-NL000285.
 XX PR 08-MAY-1998; 98EP-00201543.
 XX PA (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
 XX PI Voorberg JJ, Van Den Brink EN, Turenhout EM;
 XX DR WPI; 2000-053102/04.
 XX PT New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX Example 8; Fig 9A; 61pp; English.
 XX This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has
 CC hemostatic activity. (I) is useful a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents the human factor VIII
 CC antibody A3-C1 specific scFv protein B18 which is used in the method of
 CC the invention
 XX SQ Sequence 126 AA;
 Query Match 100.0%; Score 665; DB 3; Length 126;
 Best Local Similarity 100.0%; Pred. NO. 9.3e-56;
 Matches 126; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGSGLEWVSGVTWSTTIGF 60
 DB 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGSGLEWVSGVTWSTTIGF 60

QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADTALYYCALPYINSNRYRRGVAAFDINGQGT 120
 DB 61 ADSVKGRFTISRDNKNSLYLYMNSLRADTALYYCALPYINSNRYRRGVAAFDINGQGT 120

QY 121 MVTVSS 126
 DB 121 MVTVSS 126

RESULT 3
 AAR20059
 ID AAR20059 standard; protein; 248 AA.
 XX AC AAR20059;
 XX DT 25-MAR-1992 (first entry)
 XX DE Recombinant sc3D6 anti-HIV gp160 antibody.
 XX KW Plasmid pUC3D6LC; PUC3D6HC; human immunodeficiency virus; AIDS;
 KW complementarity determining region.
 XX OS Homo sapiens.
 XX FH Key
 FT Region 2..31
 FT /label= Framework_1_heavy_chain
 FT Region 32..36
 FT /label= CDR_1_heavy_chain
 FT Region 37..50
 FT /label= Framework_2_heavy_chain
 FT Region 51..67
 FT /label= CDR_2_heavy_chain
 FT Region 68..99
 FT /label= Framework_3_heavy_chain
 FT Region 100..116
 FT /label= CDR_3_heavy_chain
 FT Region 117..127
 FT /label= Framework_4_heavy_chain
 FT Region 128..142
 FT /label= linker
 FT Region 143..165
 FT /label= Framework_1_light_chain
 FT Region 166..176
 FT /label= CDR_1_light_chain
 FT Region 177..191
 FT /label= Framework_2_light_chain
 FT Region 192..203
 FT /label= CDR_2_light_chain
 FT Region 204..235
 FT /label= Framework_3_light_chain
 FT Region 236..242
 FT /label= CDR_3_light_chain
 FT Region 243..253
 FT /label= Framework_4_light_chain
 XX WO9118983-A.
 XX PN 12-DEC-1991.
 XX PD 29-MAY-1990; 90AT-00001178.
 XX PF 29-MAY-1990; 90AT-00001178.
 XX PR 29-MAY-1990; 90AT-00001178.
 XX (JUNG/) JUNGBAUER A.
 XX Felgenhaue M, Himmel G, Kohl J, Steindl F;
 XX WPI; 1992-007468/01.
 XX DR N-PSDB; AAQ20068.
 XX DR

PT Recombinant protein which binds to complex viral antigen and HIV-1 -
PT contains variable region of antibody derived from 3D6 cell line, used for
PT detecting HIV-1 antigen.
PT

Query Match	77.6%;	Score 516;	DB 2;	Length 248;
Best Local Similarity	77.3%;	Pred. NO. 3.5e-41;		
Matches 99; Conservative	11;	Mismatches 14;	Indels 4;	Gaps 2;

PR 29-MAY-1990; 90AT-00001178.
XX
PA (JUNG/) JUNGBAUER A.

Query Match	77.6%;	Score 516;	DB 2;	Length 475;
Best Local Similarity	77.3%;	Pred. No. 7.1e-41;		
Matches	99:	Conservative	11:	Mismatches
			14:	Indels
				Gaps

XX
PS Claim 21; SEQ ID NO 5; 35pp; English.
XX
CC The invention relates to a non-competitive immunoassay for a small
CC analyte, comprising reacting a sample containing the analyte with a
CC reagent pair comprising a first binding partner that binds to the analyte
CC and a second binding partner that binds to the complex of the analyte and
CC the first binding partner, and determining the binding of the second
CC binding partner, thus indicating the presence of the analyte in the
CC sample. The first and second binding partners are antibody fragments Fab
CC or scFv. The reagent pair is useful in a non-competitive immunoassay for
CC a small analyte, particularly for assaying drugs of abuse e.g., morphine,
CC THC or amphetamine. The immunoassay is useful for detecting environmental
CC hazards, toxic compounds in food and feed, chemicals indicative of
CC ongoing processes (e.g., microbial processes in buildings, metabolic
CC processes of living organisms) and in clinical tests, drug monitoring and
CC pharmacological research. This sequence represents a human antibody K11
CC scFv fragment, used in the method of the invention.
XX
SQ Sequence 272 AA;

Query Match 77.0%; Score 512; DB 8; Length 272;
Best Local Similarity 77.8%; Pred. No. 9.3e-41;
Matches 98; Conservative 10; Mismatches 10; Indels 8; Gaps 1;

QY 1 QVQLVSGGGLVQPGKSLRLSCAASGFTFCDAIHVWRQAPGEGLEWVSGVTWSTTIGF 60
DB 3 QVQLVSGGGLVQPGKSLRLSCAASGFTFCDAIHVWRQAPGEGLEWVSGVTWSTTIGF 62

QY 61 ADSVKGRTISRDNNAKNSLYLNWNSLRADTALYYCALPYINSNRYRRGVAAFDIWQOGT 120
DB 63 ADSVKGRTISRDNNAKNSLYLNWNSLRADTALYYCALPYINSNRYRRGVAAFDIWQOGT 114

QY 121 MVTVSS 126
DB 115 LVTVSS 120

RESULT 6
AAW90286
ID AAW90286 standard; protein; 124 AA.
AC AAW90286;
XX
DT 07-SEP-1999 (first entry)
XX
DE Human anti-GPIIb/IIIa antibody heavy chain protein from phagemid AI-X40.
XX
KW Antibody; GPIIb/IIIa; human; auto-antibody; anti-idiotypic; diagnosis;
KW blood platelet membrane protein; predisposition; prevention; treatment;
KW autoimmune thrombocytopaenic purpura; AITP; fibrinogen binding; thrombi;
KW thrombocyte; cardiac infarction; pulmonary embolism; heavy chain.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Region 1..30
FT /label= FR1
FT /note= "framework region 1"
FT Region 31..35
FT /label= CDR1
FT /note= "complementarity determining region 1"
FT Region 36..49
FT /label= FR2
FT /note= "framework region 2"
FT Region 50..66
FT /label= CDR2
FT /note= "complementarity determining region 2"
FT Region 67..99
FT /label= FR3
FT /note= "framework region 3"
FT Region 100..113
FT /label= CDR3

FT Region /note= "complementarity determining region 3"
FT 114..124
FT /label= FR4
FT /note= "framework region 4"
XX
PN W09855619-A1.
XX
PD 10-DEC-1998.
XX
PF 05-JUN-1998; 98WO-EF003397.
XX
PR 06-JUN-1997; 97DE-01023904.
PR 12-DEC-1997; 97DE-01055227.
PR 08-MAY-1998; 98DE-01020663.
XX
PA (ASAT-) ASAT AG APPLIED SCI & TECHNOLOGY.
XX
PI Berchtold P, Escher RFA;
XX
DR WPI; 1999-105496/09.
DR N-PSDB; AAV72231.
XX
CC Nucleic acid encoding human autoantibodies against platelet glycoprotein
CC Iib/IIIa - used for diagnosis, treatment and prevention of autoimmune
CC thrombocytopaenic purpura and for modulation of fibrinogen binding.
XX
PS Disclosure; Page 58-59; 93pp; German.
XX
CC This invention describes novel nucleic acid fragments that encode human
CC auto-antibodies and anti-idiotypic antibodies against blood platelet
CC membrane protein, GPIIb/IIIa. The products of the invention are used for
CC diagnosis (including monitoring and determining predisposition), (AITP)
CC prevention and treatment of autoimmune thrombocytopaenic purpura
CC and also for modulating binding of fibrinogen to thrombocytes
CC (particularly to dissolve thrombi and/or prevent their formation, e.g. in
CC cases of cardiac infarction or pulmonary embolism). Unlike murine
CC antibodies, human antibodies (hAb) do not induce adverse side effects and
CC persist for longer in vivo than small peptides
XX
SQ Sequence 124 AA;

Query Match 76.8%; Score 511; DB 2; Length 124;
Best Local Similarity 77.3%; Pred. No. 5e-41;
Matches 99; Conservative 11; Mismatches 12; Indels 6; Gaps 2;

QY 1 QVQLVSGGGLVQPGKSLRLSCAASGFTFCDAIHVWRQAPGEGLEWVSGVTWSTTIGF 60
DB 1 QVQLVSGGGLVQPGKSLRLSCAASGFTFCDAIHVWRQAPGEGLEWVSGVTWSTTIGF 60

QY 61 ADSVKGRTISRDNNAKNSLYLNWNSLRADTALYYCALPYINSNRYRRGVAAFDIWQOGT 118
DB 61 ADSVKGRTISRDNNAKNSLYLNWNSLRADTALYYCALPYINSNRYRRGVAAFDIWQOGT 116

QY 119 GTMTVSS 126
DB 117 GTMTVSS 124

RESULT 7
AAV43255
ID AAV43255 standard; protein; 120 AA.
XX
AC AAV43255;
XX
DT 13-JAN-2000 (first entry)
XX
DE VH domain CDR of anti-estradiol antibody.
XX
KW Estradiol; complementarity determining region; CDR; estriol-3-sulphate;
KW antibody antigen binding domain; steroid hormone; estriol; testosterone;
KW dihydrotestosterone; progesterone; estriol 3-beta-di-glucuronide;
KW menstrual cycle; hormone replacement therapy; oestrogen secreting tumour;
KW diagnosis; VH domain.

```

XX OS Homo sapiens.
XX OS US5977319-A.
XX PN
XX XX
XX PD 02-NOV-1999.
XX PF 21-OCT-1997; 97US-00958201.
XX PR 21-OCT-1996; 96US-0028897P.
XX PA (CMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX PI Johnson KS, Pope AR, Pritchard K, Williams AJ;
XX WPI: 1999-619713/53.
XX DR N-PSDB; AAZ31653.
XX PT New specific binding partners for estradiol, used for monitoring
XX PT estradiol levels during the menstrual cycle, in hormone replacement
XX PT therapy and for diagnosing estrogen secreting tumors.
XX PS Claim 1; Col 25-26; 26pp; English.
XX CC This sequence represents a VH domain complementarity determining region
XX CC (CDR) from an antibody specific for estradiol. The invention relates to
XX CC specific binding members (sbp) comprising a polypeptide that comprises an
XX CC antibody antigen binding domain (AABD) which has a dissociation constant
XX CC of less than 1.0x10-8M for estradiol, and a dissociation constant of at
XX CC least 500-fold higher for the steroid hormones selected from estradiol,
XX CC testosterone, dihydrotestosterone, progesterone, estriol-3-sulphate and
XX CC estriol 3-beta-di-glucuronide, where the polypeptide comprises an
XX CC antibody VH domain. The sbps can be used in an immunoassay for
XX CC determining the presence or absence of estradiol in a sample. They can be
XX CC used for monitoring estradiol levels, e.g. during the menstrual cycle, in
XX CC hormone replacement therapy and for diagnosing oestrogen secreting
XX CC tumours. The sbps can provide for discrimination between estradiol and
XX CC other related steroids
XX SQ Sequence 120 AA;

Query Match 76.5%; Score 509; DB 2; Length 120;
Best Local Similarity 76.2%; Pred. No. 7.4e-41;
Matches 96; Conservative 14; Mismatches 10; Indels 6; Gaps 2;

Qy 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWYRQAPGEGLEWVSGTWGTTIGF 60
Db :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWYRQAPGKGLWVSGISWNSGIGY 60

Qy 61 ADSVKGRFTISRDNKNSLYLNMSLRADDTALYYCALPYINSSNYRRGVAAFDIWGGGT 120
Db 61 ADSVKGRFTISRDNKNSLYLNMSLRADDTALYYCARPL-----YPKG-TQYDFWGGGT 114

Qy 121 MVTVSS 126
Db :|||||
115 LVTVSS 120

RESULT 8
AAY43254
ID AAY43254 standard; protein; 120 AA.
XX AC AAY43254;
XX DT 13-JAN-2000 (first entry)
XX DE VH domain CDR of anti-estradiol antibody.
XX KW Estradiol; complementarity determining region; CDR; estriol-3-sulphate;
XX KW antibody antigen binding domain; steroid hormone; estriol; testosterone;
XX KW dihydrotestosterone; progesterone; estriol 3-beta-di-glucuronide;
XX KW menstrual cycle; hormone replacement therapy; oestrogen secreting tumour;
XX KW diagnosis; VH domain.

XX OS Homo sapiens.
XX OS US5977319-A.
XX PN
XX XX
XX PD 02-NOV-1999.
XX PF 21-OCT-1997; 97US-00958201.
XX PR 21-OCT-1996; 96US-0028897P.
XX PA (CMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX PI Johnson KS, Pope AR, Pritchard K, Williams AJ;
XX WPI: 1999-619713/53.
XX DR N-PSDB; AAZ31653.
XX PT New specific binding partners for estradiol, used for monitoring
XX PT estradiol levels during the menstrual cycle, in hormone replacement
XX PT therapy and for diagnosing estrogen secreting tumors.
XX PS Claim 1; Col 23-24; 26pp; English.
XX CC This sequence represents a VH domain complementarity determining region
XX CC (CDR) from an antibody specific for estradiol. The invention relates to
XX CC specific binding members (sbp) comprising a polypeptide that comprises an
XX CC antibody antigen binding domain (AABD) which has a dissociation constant
XX CC of less than 1.0x10-8M for estradiol, and a dissociation constant of at
XX CC least 500-fold higher for the steroid hormones selected from estradiol,
XX CC testosterone, dihydrotestosterone, progesterone, estriol-3-sulphate and
XX CC estriol 3-beta-di-glucuronide, where the polypeptide comprises an
XX CC antibody VH domain. The sbps can be used in an immunoassay for
XX CC determining the presence or absence of estradiol in a sample. They can be
XX CC used for monitoring estradiol levels, e.g. during the menstrual cycle, in
XX CC hormone replacement therapy and for diagnosing oestrogen secreting
XX CC tumours. The sbps can provide for discrimination between estradiol and
XX CC other related steroids
XX SQ Sequence 120 AA;

Query Match 76.4%; Score 508; DB 2; Length 120;
Best Local Similarity 76.2%; Pred. No. 9.3e-41;
Matches 96; Conservative 14; Mismatches 10; Indels 6; Gaps 2;

Qy 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWYRQAPGEGLEWVSGTWGTTIGF 60
Db :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 RVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWYRQAPGKGLWVSGISWNSGIGY 60

Qy 61 ADSVKGRFTISRDNKNSLYLNMSLRADDTALYYCALPYINSSNYRRGVAAFDIWGGGT 120
Db 61 ADSVKGRFTISRDNKNSLYLNMSLRADDTALYYCARPL-----YPKG-TQYDFWGGGT 114

Qy 121 MVTVSS 126
Db :|||||
115 LVTVSS 120

RESULT 9
AAG65553
ID AAG65553 standard; protein; 120 AA.
XX AC AAG65553;
XX DT 30-NOV-2001 (first entry)
XX DE Amino acid sequence of VH3-4.
XX KW Gene library; immunoglobulin; antibody library; VH3-4.
XX OS Homo sapiens.
XX XX
XX PN WO200162907-A1.

```


THIS PAGE BLANK (USPTO)

Result No.	Score	Query		DB	ID	Description
		Match	Length			
1	514	77.3	124	2	US-09-424-840B-123	Sequence 123, Appl
2	511	76.8	124	2	US-09-424-840B-18	Sequence 18, Appl
3	509	76.5	120	1	US-08-958-201-10	Sequence 10, Appl
4	508	76.4	120	1	US-08-958-201-8	Sequence 8, Appl
5	505.5	76.0	119	2	US-09-840-459-88	Sequence 88, Appl
6	505.5	76.0	119	2	US-09-497-625A-88	Sequence 88, Appl
7	505	75.9	126	2	US-09-232-290-35	Sequence 35, Appl
8	492.5	74.1	149	2	US-09-471-276-898	Sequence 898, Appl
9	486.5	73.2	121	2	US-08-599-226-2	Sequence 2, Appl
10	486.5	73.2	121	2	US-09-125-098-2	Sequence 2, Appl
11	486.5	73.2	121	2	US-09-540-018-2	Sequence 2, Appl
12	474	71.3	117	1	US-07-942-245-24	Sequence 24, Appl
13	472.5	71.1	123	1	US-08-665-202-30	Sequence 30, Appl
14	472.5	71.1	123	2	US-09-315-574-30	Sequence 30, Appl
15	471	70.8	116	1	US-08-652-816A-14	Sequence 14, Appl
16	470	70.7	245	2	US-08-918-148-75	Sequence 75, Appl
17	470	70.7	245	2	US-09-138-091A-73	Sequence 73, Appl
18	469	70.5	131	2	US-08-983-607-28	Sequence 28, Appl
19	467.5	70.3	121	2	US-08-599-226-10	Sequence 10, Appl
20	467.5	70.3	121	2	US-09-125-098-10	Sequence 10, Appl
21	467.5	70.3	121	2	US-09-540-018-10	Sequence 10, Appl
22	467.5	70.3	225	2	US-09-456-090A-68	Sequence 68, Appl
23	467.5	70.3	225	2	US-09-453-234-68	Sequence 68, Appl
24	467	70.2	248	2	US-09-315-926A-80	Sequence 80, Appl
25	466.5	70.2	225	2	US-09-456-090A-60	Sequence 60, Appl
26	466.5	70.2	225	2	US-09-456-090A-92	Sequence 92, Appl
27	466.5	70.2	225	2	US-09-456-090A-106	Sequence 106, Appl


```

RESULT 5
US-09-840-459-88
; Sequence 88, Application US/09840459
; Patent No. 696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-88

Query Match          76.0%; Score 505.5; DB 2; Length 119;
Best Local Similarity 77.0%; Pred. No. 5.9e-41;
Matches 97; Conservative 12; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTTFGDIYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTTFDDYAMHWVRQAPGKGLWVSGISMNSSIGY 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNYRGRVAAPFDIWGGT 120
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNYRGRVAAPFDIWGGT 113
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 121 MVTVSS 126
   |||||
Db 114 TTVTVSS 119
   |||||

RESULT 6
US-09-497-625A-88
; Sequence 88, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-497-625A-88

Query Match          76.0%; Score 505.5; DB 2; Length 119;
Best Local Similarity 77.0%; Pred. No. 5.9e-41;
Matches 97; Conservative 12; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTTFGDIYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTTFDDYAMHWVRQAPGKGLWVSGISMNSSIGY 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNYRGRVAAPFDIWGGT 120
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNYRGRVAAPFDIWGGT 113
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 121 MVTVSS 126
   |||||
Db 114 TTVTVSS 119
   |||||

RESULT 7
US-09-232-290-35
; Sequence 35, Application US/09232290A
; Patent No. 6815540
; GENERAL INFORMATION:
; APPLICANT: PLUCKTHUN, ANDREAS
; APPLICANT: NIEBA, LARS
; APPLICANT: HONEGGER, ANNEMARIE
; TITLE OF INVENTION: IMMUNOGLOBULIN SUPER FAMILY DOMAINS AND FRAGMENTS WITH
; TITLE OF INVENTION: INCREASED SOLUBILITY
; FILE REFERENCE: MORPHO/7
; CURRENT APPLICATION NUMBER: US/09/232,290A
; CURRENT FILING DATE: 1999-01-15
; EARLIER APPLICATION NUMBER: PCT/EP96/02230
; EARLIER FILING DATE: 1996-05-23
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 35
; LENGTH: 126
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-232-290-35

Query Match          75.9%; Score 505; DB 2; Length 126;
Best Local Similarity 76.6%; Pred. No. 7e-41;
Matches 98; Conservative 11; Mismatches 15; Indels 4; Gaps 2;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTTFGDIYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTTFNDYAMHWVRQAPGKGLWVSGISMDSSSIGY 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYC--ALPYINSSNYRGRVAAPFDIWGG 118
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYC--ALPYINSSNYRGRVAAPFDIWGG 118
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 119 GTMTVSS 126
   |||||
Db 119 GTMTVSS 126
   |||||

RESULT 8
US-09-471-276-898
; Sequence 898, Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6822072
; FILE REFERENCE: GENSET.025CPI
; CURRENT APPLICATION NUMBER: US/09/471,276

```

```

RESULT 5
US-09-840-459-88
; Sequence 88, Application US/09840459
; Patent No. 696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-88

Query Match          76.0%; Score 505.5; DB 2; Length 119;
Best Local Similarity 77.0%; Pred. No. 5.9e-41;
Matches 97; Conservative 12; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVQSGGGLVQPQKSLRLSCAASGFTTFGDIYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGRSLRLSCAASGFTTFDDYAMHWVRQAPGKGLWVSGTSMNSGSIY 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNYRGRVAAPFDIWGGT 120
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNYRGRVAAPFDIWGGT 113
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 121 MVTVSS 126
   |||||
Db 114 TTVVSS 119
   |||||

RESULT 6
US-09-497-625A-88
; Sequence 88, Application US/09497625A
; Patent No. 6727349
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-004
; CURRENT APPLICATION NUMBER: US/09/497,625A
; CURRENT FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-497-625A-88

Query Match          76.0%; Score 505.5; DB 2; Length 119;
Best Local Similarity 77.0%; Pred. No. 5.9e-41;
Matches 97; Conservative 12; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVQSGGGLVQPQKSLRLSCAASGFTTFGDIYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGRSLRLSCAASGFTTFDDYAMHWVRQAPGKGLWVSGTSMNSGSIY 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNYRGRVAAPFDIWGGT 120
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNYRGRVAAPFDIWGGT 113
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 121 MVTVSS 126
   |||||
Db 114 TTVVSS 119
   |||||

RESULT 7
US-09-232-290-35
; Sequence 35, Application US/09232290A
; Patent No. 6815540
; GENERAL INFORMATION:
; APPLICANT: PLUCKTHUN, ANDREAS
; APPLICANT: NIEBA, LARS
; APPLICANT: HONEGGER, ANNEMARIE
; TITLE OF INVENTION: IMMUNOGLOBULIN SUPER FAMILY DOMAINS AND FRAGMENTS WITH
; TITLE OF INVENTION: INCREASED SOLUBILITY
; FILE REFERENCE: MORPHO/7
; CURRENT APPLICATION NUMBER: US/09/232,290A
; CURRENT FILING DATE: 1999-01-15
; EARLIER APPLICATION NUMBER: PCT/EP96/02230
; EARLIER FILING DATE: 1996-05-23
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 35
; LENGTH: 126
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-232-290-35

Query Match          75.9%; Score 505; DB 2; Length 126;
Best Local Similarity 76.6%; Pred. No. 7e-41;
Matches 98; Conservative 11; Mismatches 15; Indels 4; Gaps 2;

QY 1 QVQLVQSGGGLVQPQKSLRLSCAASGFTTFGDIYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGRSLRLSCAASGFTTFNDYAMHWVRQAPGKGLWVSGTSMDSISY 60
   :|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYC--ALPYINSSNYRGRVAAPFDIWGG 118
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYC--ALPYINSSNYRGRVAAPFDIWGG 118
   |||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 119 GTMTVSS 126
   |||||
Db 119 GTMTVSS 126
   |||||

RESULT 8
US-09-471-276-898
; Sequence 898, Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; FILE REFERENCE: GENSET.025CPI
; CURRENT APPLICATION NUMBER: US/09/471,276
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-471-276-898

```

```

RESULT 5
US-09-840-459-88
; Sequence 88, Application US/09840459
; Patent No. 696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-88

Query Match          76.0%; Score 505.5; DB 2; Length 119;
Best Local Similarity 77.0%; Pred. No. 5.9e-41;
Matches 97; Conservative 12; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTTFGDIYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTTFDDYAMHWVRQAPGKGLWVSGISMNSSIGY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNYRGRVAAPFDIWGQT 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNYRGRVAAPFDIWGQT 113
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 MVTVSS 126
   |||||
Db 114 TTVVSS 119
   |||||

RESULT 7
US-09-232-290-35
; Sequence 35, Application US/09232290A
; Patent No. 6815540
; GENERAL INFORMATION:
; APPLICANT: PLUCKTHUN, ANDREAS
; APPLICANT: NIEBA, LARS
; APPLICANT: HONEGGER, ANNEMARIE
; TITLE OF INVENTION: IMMUNOGLOBULIN SUPER FAMILY DOMAINS AND FRAGMENTS WITH
; TITLE OF INVENTION: INCREASED SOLUBILITY
; FILE REFERENCE: MORPHO/7
; CURRENT APPLICATION NUMBER: US/09/232,290A
; CURRENT FILING DATE: 1999-01-15
; EARLIER APPLICATION NUMBER: PCT/EP96/02230
; EARLIER FILING DATE: 1996-05-23
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 35
; LENGTH: 126
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-232-290-35

Query Match          75.9%; Score 505; DB 2; Length 126;
Best Local Similarity 76.6%; Pred. No. 7e-41;
Matches 98; Conservative 11; Mismatches 15; Indels 4; Gaps 2;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTTFGDIYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTTFNDYAMHWVRQAPGKGLWVSGISMDSSIGY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYC--ALPYINSSNYRGRVAAPFDIWGQ 118
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLYMNSLRADLTALYYC--ALPYINSSNYRGRVAAPFDIWGQ 118
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 119 GTMTVSS 126
   |||||
Db 119 GTMTVSS 126
   |||||

RESULT 8
US-09-471-276-898
; Sequence 98, Application US/09471276
; Patent No. 6822072
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Duclert A.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6822072
; FILE REFERENCE: GENSET.025CPI
; CURRENT APPLICATION NUMBER: US/09/471,276

```

Query Match	74.1%;	Score 492.5;	DB 2;	Length 149;
Best Local Similarity	70.4%;	Pred. No. 1.3e-39;		
Matches	95;	Conservative 11;	Mismatches 12;	Indels 17; Gaps 2;
QY	1	QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWNSGTTIGP	60	
DB	20	EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKGLWVSGITWNSGKIGY	79	
QY	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTALYYCA-----LPYINSSNRYRGVA	111	
DB	80	ADSVKGRFTISRDNKNSLYLNMSLRRTEDTAFYCAKARGLFSDTWPYXH-----Y	131	
QY	112	AFDIMGQGTMTVSS	126	
DB	132	AMDVWGQGTMTVSS	146	

Query Match	73.2%;	Score 486.5;	DB 2;	Length 121;
Best Local Similarity	73.0%;	Pred. No. 3.9e-39;		
Matches	92;	Conservative 14;	Mismatches 15;	Indels 5; Gaps 1;
QY	1	QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWNSGTTIGP	60	
DB	1	EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKGLWVSAITWNSGHIDY	60	
QY	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTALYYCALPYINSSNRYRGVAADFIMGQGT	120	
DB	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTAVYYCA-----KVSYLSTASSLDYWGQGT	115	
QY	121	MVTSS	126	
DB	116	LVTSS	121	

Query Match	73.0%;	Score 486.5;	DB 2;	Length 121;
Best Local Similarity	73.0%; <td>Pred. No. 3.9e-39;</td> <td></td> <td></td>	Pred. No. 3.9e-39;		
Matches	92;	Conservative 14;	Mismatches 15;	Indels 5; Gaps 1;
QY	1	QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWNSGTTIGP	60	
DB	1	EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKGLWVSAITWNSGHIDY	60	
QY	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTALYYCALPYINSSNRYRGVAADFIMGQGT	120	
DB	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTAVYYCA-----KVSYLSTASSLDYWGQGT	115	
QY	121	MVTSS	126	
DB	116	LVTSS	121	

Query Match	73.2%;	Score 486.5;	DB 2;	Length 121;
Best Local Similarity	73.0%;	Pred. No. 3.9e-39;		
Matches	92;	Conservative 14;	Mismatches 15;	Indels 5; Gaps 1;
QY	1	QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWNSGTTIGP	60	
DB	1	EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKGLWVSAITWNSGHIDY	60	
QY	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTALYYCALPYINSSNRYRGVAADFIMGQGT	120	
DB	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTAVYYCA-----KVSYLSTASSLDYWGQGT	115	
QY	121	MVTSS	126	
DB	116	LVTSS	121	

Query Match	73.2%;	Score 486.5;	DB 2;	Length 121;
Best Local Similarity	73.0%;	Pred. No. 3.9e-39;		
Matches	92;	Conservative 14;	Mismatches 15;	Indels 5; Gaps 1;
QY	1	QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWNSGTTIGP	60	
DB	1	EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKGLWVSAITWNSGHIDY	60	
QY	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTALYYCALPYINSSNRYRGVAADFIMGQGT	120	
DB	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTAVYYCA-----KVSYLSTASSLDYWGQGT	115	
QY	121	MVTSS	126	
DB	116	LVTSS	121	

Query Match	73.2%;	Score 486.5;	DB 2;	Length 121;
Best Local Similarity	73.0%;	Pred. No. 3.9e-39;		
Matches	92;	Conservative 14;	Mismatches 15;	Indels 5; Gaps 1;
QY	1	QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWNSGTTIGP	60	
DB	1	EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKGLWVSAITWNSGHIDY	60	
QY	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTALYYCALPYINSSNRYRGVAADFIMGQGT	120	
DB	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTAVYYCA-----KVSYLSTASSLDYWGQGT	115	
QY	121	MVTSS	126	
DB	116	LVTSS	121	

Query Match	73.2%;	Score 486.5;	DB 2;	Length 121;
Best Local Similarity	73.0%;	Pred. No. 3.9e-39;		
Matches	92;	Conservative 14;	Mismatches 15;	Indels 5; Gaps 1;
QY	1	QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWNSGTTIGP	60	
DB	1	EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKGLWVSAITWNSGHIDY	60	
QY	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTALYYCALPYINSSNRYRGVAADFIMGQGT	120	
DB	61	ADSVKGRFTISRDNKNSLYLNMSLRRAEDTAVYYCA-----KVSYLSTASSLDYWGQGT	115	
QY	121	MVTSS	126	


```
; REFERENCE/DOCKET NUMBER: BBI-043
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 121 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
;
US-09-125-098-2
Query Match 73.2%; Score 486.5; DB 2; Length 121;
Best Local Similarity 73.0%; Pred. No. 3.9e-39;
Matches 92; Conservative 14; Mismatches 15; Indels 5; Gaps 1;

QY 1 QVQLVSGGGLVQPGKSLRSLSCAASGFTFGDYAIHWVRQAPGSGLEWVSGVTWGGTTIGF 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGKSLRSLSCAASGFTFGDYAMHWVRQAPGKLEWVSAITWNSGHIDY 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 61 ADSVKGRTISRDNKNSLYLNYSRAEDTALYYCALPYINSNRYRGVAAFDIWGQGT 120
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVEGRFTISRDNKNSLYLNYSRAEDTALYYCALPYINSNRYRGVAAFDIWGQGT 115
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 121 MVTVSS 126
:||||:
Db 116 LVTVSS 121

RESULT 11
US-09-540-018-2
; Sequence 2, Application US/09540018
; Patent No. 6509015
; GENERAL INFORMATION:
; APPLICANT: Saifeld, Jochen G.
; APPLICANT: Allen, Deborah J.
; APPLICANT: Hoogenboom, Hendricus R.J.M.
; APPLICANT: Kaymakalan, Zehra
; APPLICANT: Labkovsky, Boris
; APPLICANT: Mankovich, John A.
; APPLICANT: McGuinness, Brian T.
; APPLICANT: Roberts, Andrew J.
; APPLICANT: Sakorafas, Paul
; APPLICANT: Schoenhaut, David
; APPLICANT: Vaughan, Tristan J.
; APPLICANT: White, Michael
; APPLICANT: Wilton, Andrew J.
; TITLE OF INVENTION: Human Antibodies that Bind Human TNFa
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 State Street, suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/540,018
; FILING DATE: 31-MARCH-2000
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/599,226
; FILING DATE: 08-FEB-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeConti, Giulio A., Jr.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: BBI-043

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 121 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
;
US-09-540-018-2
Query Match 73.2%; Score 486.5; DB 2; Length 121;
Best Local Similarity 73.0%; Pred. No. 3.9e-39;
Matches 92; Conservative 14; Mismatches 15; Indels 5; Gaps 1;

QY 1 QVQLVSGGGLVQPGKSLRSLSCAASGFTFGDYAIHWVRQAPGSGLEWVSGVTWGGTTIGF 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGKSLRSLSCAASGFTFGDYAMHWVRQAPGKLEWVSAITWNSGHIDY 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 61 ADSVKGRTISRDNKNSLYLNYSRAEDTALYYCALPYINSNRYRGVAAFDIWGQGT 120
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVEGRFTISRDNKNSLYLNYSRAEDTALYYCALPYINSNRYRGVAAFDIWGQGT 115
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 121 MVTVSS 126
:||||:
Db 116 LVTVSS 121

RESULT 12
US-07-942-245-24
; Sequence 24, Application US/07942245
; Patent No. 5639641
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, Jan T.
; APPLICANT: SEARLE, Stephen M.J.
; APPLICANT: REES, Anthony R.
; APPLICANT: ROGUSKA, Michael A.
; APPLICANT: GUILD, Braydon C.
; TITLE OF INVENTION: SURFACE RESIDUE VENEERING OF RODENT
; TITLE OF INVENTION: ANTIBODIES
; NUMBER OF SEQUENCES: 522
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sughree, Mion, Zinn, Macpeak & Seas
; STREET: 2100 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: United States
; ZIP: 20037-3202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: HP 9000/700 Workstation
; OPERATING SYSTEM: UNIX
; SOFTWARE: In house
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/942,245
; FILING DATE: 09-SEP-1992
; CLASSIFICATION: 530
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 293-7060
; TELEFAX: (202) 293-7860
; TELEX: 6491103
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
;
US-07-942-245-24
Query Match 71.3%; Score 474; DB 1; Length 117;
Best Local Similarity 75.6%; Pred. No. 5.8e-38;
Matches 90; Conservative 11; Mismatches 14; Indels 4; Gaps 2;
```

[illegible]

RESULT 13
US-08-665-202-30
; Sequence 30, Application US/08665202
; Patent No. 5977322
; GENERAL INFORMATION:
; APPLICANT: Marks, James D.
; APPLICANT: Schier, Robert
; TITLE OF INVENTION: NO. 5977322e1 High Affinity Human Antibodies to
; TITLE OF INVENTION: Tumor Antigens
; NUMBER OF SEQUENCES: 141
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA

Query Match	71.1%;	Score	472.5;	DB 1;	Length	123;	
Best Local Similarity	73.8%;	Pred. No.	8.6e-38;				
Matches	93;	Conservative	11;	Mismatches	19;	Gaps	1;
Qy	1	QVQLVSGGGLVQPQGKSLRLSCAASGTFPDGYATHHWYRQAPGEGLEWNVSVGTWSGTTIGF	60				
		: : : : : : : : : :					
Dd	1	QVLVESGGGLVQPGGSLRLSCAASGTFSSYENMWYRQAPGKLEWVSIVSSSGSTIYY	60				
		: : : : : : : : :					
Qy	61	ADSVKGRFTISRDNAKNSLYLNMSRAEDTALYYCALPYINSSNRRGVAAFDIWGGGT	120				
		: : : : : : : : :					
Dd	61	ADSVKGRFTISRDNAKNSLYLQMSLRADETAVTYCAR---	DLGGYSYGVELDWGGGT 117				
		: : : : : : : : :					
Qy	121	MVTVSS	126				
		:					
Dd	118	LVTVSS	123				
		:					

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

[illegible]

RESULT 15
US-08-652-816A-14
; Sequence 14, Application US/08652816A

```

Db      111 LTVS 115

Search completed: May 5, 2006, 08:53:50
Job time : 14.5429 secs

```

Query Match	70.8%	Score 471;	DB 1;	Length 116;
Best Local Similarity	72.0%;	Pred. No. 1.1e-37;		
Matches	90;	Conservative 12;	Mismatches 13;	Indels 10; Gaps 1;
Qy	1	QVQLVQSGGGLVDPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVVTWSGTTIGF	60	
Db	1	EVQLVESGGGVWRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLWVSGINMNGGSGTGY	60	
Qy	61	ADSVKGRFTISRDNKNSLYLYMNLSRAEDTALYYCALPYINSSNYRRGVAAFDIWGGGT	120	
Db	61	ADSVKGRFTISRDNKNSLYLYMNLSRAEDTAVYYCA-----RRRYALDYWGQGT	110	
Qy	121	MTVTVS	125	
		:		

THIS PAGE BLANK (USP10)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:55:01 ; Search time 40.0222 Seconds
(without alignments)
1315.434 Million cell updates/sec

Title: US-09-674-752-34
Perfect score: 665
Sequence: 1 QVOLVQSGGLVQPKSURL.....RRGVAAFDIWGQGTMTVTSS 126

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA_Main:*
1: /cgn2_6/prodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/prodata/1/pubpaa/US08_PUBCOMB.pep:*
3: /cgn2_6/prodata/1/pubpaa/US09_PUBCOMB.pep:*
4: /cgn2_6/prodata/1/pubpaa/US10A_PUBCOMB.pep:*
5: /cgn2_6/prodata/1/pubpaa/US10B_PUBCOMB.pep:*
6: /cgn2_6/prodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	514	77.3	124	4	US-10-844-424-123 Sequence 123, App
2	512	77.0	132	3	US-09-791-153A-65 Sequence 65, Appl
3	511	76.8	124	4	US-10-844-424-18 Sequence 18, Appl
4	508	76.4	120	5	US-10-487-525-1 Sequence 1, Appli
5	505.5	76.0	119	3	US-09-840-459-88 Sequence 88, Appl
6	505.5	76.0	119	4	US-10-766-773-88 Sequence 88, Appl
7	505.5	76.0	119	4	US-10-766-610-88 Sequence 88, Appl
8	505.5	76.0	119	4	US-10-733-563-88 Sequence 88, Appl
9	505.5	76.0	241	2	US-08-779-457-50 Sequence 50, Appl
10	505.5	76.0	241	5	US-10-921-710-50 Sequence 50, Appl
11	505	75.9	122	6	US-11-021-438-2 Sequence 2, Appli
12	505	75.9	124	5	US-10-487-525-62 Sequence 22, Appl
13	505	75.9	245	6	US-11-021-438-22 Sequence 6, Appli
14	504	75.8	291	4	US-10-406-830-6 Sequence 1926, Ap
15	503.5	75.7	245	3	US-09-880-748-1926 Sequence 1926, Ap
16	503.5	75.7	245	4	US-10-293-418-1926 Sequence 1926, Ap
17	502.5	75.6	243	5	US-10-981-692-33 Sequence 33, Appl
18	500	75.2	141	4	US-10-687-799-56 Sequence 56, Appl
19	499	75.0	253	4	US-10-779-461-18 Sequence 18, Appl
20	498	74.9	120	6	US-11-039-767-16 Sequence 16, Appl
21	497	74.7	141	4	US-10-687-799-6 Sequence 6, Appli
22	496	74.6	141	4	US-10-687-799-2 Sequence 2, Appli
23	494.5	74.4	117	6	US-11-021-438-4 Sequence 4, Appli
24	494.5	74.4	241	6	US-11-021-438-24 Sequence 24, Appl
25	493.5	74.2	121	5	US-10-891-658-85 Sequence 85, Appl
26	492.5	74.1	149	5	US-10-926-683-898 Sequence 898, App
27	491	73.8	244	5	US-10-981-692-26 Sequence 26, Appl

ALIGNMENTS

RESULT 1

US-10-844-424-123 254 3 US-09-880-748-1427 Sequence 1427, Ap
; Sequence 123, Application US/10844424 Sequence 1427, Ap
; Publication No. US20040202659A1 Sequence 81, Appl
; GENERAL INFORMATION: Sequence 6, Appli
; APPLICANT: Berchtold, Peter Sequence 922, App
; APPLICANT: Escher, Robert F. A. Sequence 922, App
; TITLE OF INVENTION: ANTI-GPIIB/IIIA RECOMBINANT ANTIBODIES Sequence 66, Appl
; FILE REFERENCE: 100564-09049 Sequence 59, Appl
; CURRENT APPLICATION NUMBER: US/10/844,424 Sequence 32, Appl
; CURRENT FILING DATE: 2004-05-13 Sequence 1416, Ap
; PRIOR APPLICATION NUMBER: US/09/424,840 Sequence 1416, Ap
; PRIOR FILING DATE: 1993-12-03 Sequence 2, Appli
; PRIOR APPLICATION NUMBER: DE 19820663.1 Sequence 2, Appli
; PRIOR FILING DATE: 1998-05-08 Sequence 2, Appli
; PRIOR APPLICATION NUMBER: DE 19755227.7 Sequence 2, Appli
; PRIOR FILING DATE: 1997-12-12 Sequence 2, Appli
; PRIOR APPLICATION NUMBER: DE 19723904.8 Sequence 2, Appli
; PRIOR FILING DATE: 1997-06-06 Sequence 2, Appli
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 123
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-844-424-123

Query Match 77.3%; Score 514; DB 4; Length 124;
Best Local Similarity 77.3%; Pred. No. 3 Se-41;
Matches 99; Conservative 12; Mismatches 11; Indels 6; Gaps 2;
Qy 1 QVOLVQSGGLVQPKSURLSCAASGFTFGDYAIHWVROAPGEGLEWVGWGTGTIGF 60
Db 1 QVKLESQGLVQPKSURLSCAASGFTFDDYALHWVROAPGKLEWVGISWDSISIGY 60
Qy 61 ADSVGRFTISRDNAKNSLYLNISRLEDYALYCALPYINS--SNYRGGVAAFDIWQ 118
Db 61 ADSVGRFTISRDNAKNSLYLNISRLEDYALYCALPYINS--SNYRGGVAAFDIWQ 116
Qy 119 GTMTVTSS 126
Db 117 GTMTVTSS 124

RESULT 2

US-09-791-153A-65
; Sequence 65, Application US/09791153A
; Publication No. US20030103978A1
; GENERAL INFORMATION:
; APPLICANT: Deshpande, Rajendra

```

; APPLICANT: Hitz, Anna
; APPLICANT: Boyle, William
; APPLICANT: Sullivan, John
; TITLE OF INVENTION: SELECTIVE BINDING AGENTS OF OSTEOCALCIN BINDING PROTEIN
; FILE REFERENCE: A-633A
; CURRENT APPLICATION NUMBER: US/09/791,153A
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/511,139
; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 154
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 65
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-791-153A-65

```

Query Match	77.08;	Score 512;	DB 3;	Length 132;
Best Local Similarity	75.08;	Pred. No. 5.9e-41;		
Matches 99;	Conservative 12;	Mismatches 15;	Indels 6;	Gaps 1;
Qy	1	QVQLVQSGGGLVQPGRSLRLSCAASGFTFGDYATHWRQAPGEGLEWVGWVTSNGTIGF	60	
Db	1	EVQLVESGGGLVQPGRSLRLSCAASGFTFDYAHWRQAPGKLEWVGISWMSSGIGY	60	
Qy	61	ADSVKGRFTISRDNKAKNSLYLQMNSRAEDTALYYCALPYINSNRRGVAA-----FD	114	
Db	61	ADSVKGRFTISRDNKAKNSLYLQMNSRAEDTALYYCAKDGYSYCWYGIAGVQWQLVYFD	120	
Qy	115	IWGQGTMTVYSS	126	
Db	121	YWGGTGLTVYSS	132	

```

RESULT 3
US-10-844-424-18
; Sequence 18, Application US/10844424
; Publication No. US20040202659A1
; GENERAL INFORMATION:
; APPLICANT: Berchtold, Peter
; APPLICANT: Escher, Robert F. A.
; TITLE OF INVENTION: ANTI-GPIIB/IIIA RECOMBINANT ANTIBODIES
; FILE REFERENCE: 100564-09049
; CURRENT APPLICATION NUMBER: US/10/844, 424
; CURRENT FILING DATE: 2004-05-13
; PRIOR APPLICATION NUMBER: US/09/424, 840
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: DE 19820663.1
; PRIOR FILING DATE: 1998-05-08
; PRIOR APPLICATION NUMBER: DE 19755227.7
; PRIOR FILING DATE: 1997-12-12
; PRIOR APPLICATION NUMBER: DE 19723904.8
; PRIOR FILING DATE: 1997-06-06
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-844-424-18

```

Query Match		76.8%	Score 511;	DB 4; Length 124;
Best Local Similarity Matches		77.3%;	Pred. No. 6.8e-41;	
Matches		99; Conservative 11;	Mismatches 12;	Indels 6; Gaps 2;
Qy	1	QVQLVQSGGGLVQPGRSLRLSCAASGFTFGYIAHWVRQAPGEGLEWVS	GVTWSGTIGF	60
	:	: : :	: : :	:
	:	: : :	: : :	:
Dd	1	QVKLGSSGGVLVQPGSRSLRSCAASGTFDDYALHWVRQAPGKGLEWYS	GISWSOGTIGY	60
	:	: : :	: : :	:
Qy	61	ADSVKGRTISRDNAKNSLYLWNLSRAEDTALYYCALPYINS--SNYRRVA	AADFINGQ	118
	:	: : :	: : :	:
Dd	61	ADSVKGRFTISRDNAKNSLYIQNNLSRAEDTALYYCVKMDMGSSVVATYN--	AADFINGQ	116
	:	: : :	: : :	:

```

Qy      119  GTMTVTSS 126
        |||||||
Db      117  GTMTVTSS 124

RESULT 4
US-10-487-525-1
; Sequence 1, Application US/10487525
; Publication No. US20040259153A1
; GENERAL INFORMATION:
; APPLICANT: INSTITUTE FOR ANTIBODIES CO., LTD.
; TITLE OF INVENTION: METHODS FOR SELECTING BINDING MOLECULES
; FILE REFERENCE: M3-A0101P
; CURRENT APPLICATION NUMBER: US/10/487,525
; CURRENT FILING DATE: 2004-02-20
; PRIOR APPLICATION NUMBER: JP 2001-252154
; PRIOR FILING DATE: 2001-08-22
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-487-525-1

```

Query Match	76.4%;	Score 508;	DB 5;	Length 120;
Best Local Similarity	77.8%;	Pred. No. 1.3e-40;		
Matches 98; Conservative 11; Mismatches 11; Indels 6; Gaps 1				
Qy	1	QVQLVQSGLGVLPQGKSLRLSCAASGFTFGDYAIHWVRQAPEGLEWYSGVTWGTTIGF	60	
Dd	1	EVQLVESGGVLVQPGRSURLSCAASGFTFDYAMHWVRQAPEGLEWYSGISWNSGSITGY	60	
Qy	61	ADSVKGRTTISRDNKNSLYLQMNSLRADLTALYCPLPYINSSNRYRGEVAAFDIWGQGT	120	
Dd	61	ADSVKGRTTISRDNKNSLYLQMNSLRADLTALYYCAKGPSGSPD-----AFDIWGQGT	114	
Qy	121	MVTVSS	126	
Dd	115	TVTVSS	120	

```

RESULT 5
US-09-840-459-88
; Sequence 88, Application US/09840459
; Patent No. US20020150576A1
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT APPLICATION NUMBER: US/09/840,459
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: PCT/US01/03537
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-840-459-88

```

```
Query Match      76.0%; Score 505.5; DB 3; Length 119;
Best Local Similarity 77.0%; Pred. No. 2.2e-40;
Matches 97; Conservative 12; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGKLEWVSGVTWGTIGF 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKLEWVSGISWNSG 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNKNSLYLNYSRAEDTALYYCALPYINSSNRRGVAAFDINGQGT 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLNYSRAEDTALYYCATHYY-----YYYGM---DVMGQGT 113
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 MVTVSS 126
   |||||
Db 114 TTVTSS 119

RESULT 6
US-10-766-773-88
; Sequence 88, Application US/10766773
; Publication No. US20040126851A1
; GENERAL INFORMATION:
; APPLICANT: Lakosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 1855.1052-028
; CURRENT APPLICATION NUMBER: US/10/766,773
; CURRENT FILING DATE: 2004-01-27
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 106
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-766-773-88

Query Match      76.0%; Score 505.5; DB 4; Length 119;
Best Local Similarity 77.0%; Pred. No. 2.2e-40;
Matches 97; Conservative 12; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGKLEWVSGVTWGTIGF 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKLEWVSGISWNSG 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNKNSLYLNYSRAEDTALYYCALPYINSSNRRGVAAFDINGQGT 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLNYSRAEDTALYYCATHYY-----YYYGM---DVMGQGT 113
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 MVTVSS 126
   |||||
Db 114 TTVTSS 119

RESULT 7
US-10-766-610-88
; Sequence 88, Application US/10766610
; Publication No. US20040132980A1
; GENERAL INFORMATION:
; APPLICANT: Lakosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter

Query Match      76.0%; Score 505.5; DB 4; Length 119;
Best Local Similarity 77.0%; Pred. No. 2.2e-40;
Matches 97; Conservative 12; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGKLEWVSGVTWGTIGF 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKLEWVSGISWNSG 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFTISRDNKNSLYLNYSRAEDTALYYCALPYINSSNRRGVAAFDINGQGT 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLNYSRAEDTALYYCATHYY-----YYYGM---DVMGQGT 113
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 121 MVTVSS 126
   |||||
Db 114 TTVTSS 119

RESULT 8
US-10-733-563-88
; Sequence 88, Application US/10733563
; Publication No. US20040151721A1
; GENERAL INFORMATION:
; APPLICANT: Ponath, Paul
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; FILE REFERENCE: 10448-213001
; CURRENT APPLICATION NUMBER: US/10/733,563
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US 10/272,899
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/392,364
; PRIOR FILING DATE: 2002-06-26
; PRIOR APPLICATION NUMBER: US 60/350,166
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 88
; LENGTH: 119
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-733-563-88

Query Match      76.0%; Score 505.5; DB 4; Length 119;
Best Local Similarity 77.0%; Pred. No. 2.2e-40;
Matches 97; Conservative 12; Mismatches 10; Indels 7; Gaps 2;
```



```

; GENERAL INFORMATION:
; APPLICANT: LIU, BIN
; APPLICANT: MARKS, JAMES D.
; TITLE OF INVENTION: PROSTATE CANCER SPECIFIC INTERNALIZING HUMAN ANTIBODIES
; FILE REFERENCE: 4077-392710US
; CURRENT APPLICATION NUMBER: US/11/021,438
; CURRENT FILING DATE: 2004-12-21
; PRIOR APPLICATION NUMBER: US 60/532,433
; PRIOR FILING DATE: 2003-12-23
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.3

```

RESULT 15
US-09-880-748-1926
; Sequence 1926, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:

Qy 1 QVOLVQSGGLVQPGKSLRSCAASGTFPGDYAIHWVRQAPGEGLEWVSGVTWSGTTTGF 60

Db 1 QVOLVQSGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
QY 61 ADSVKGRFTISRDNKNSLYLWNSLRADTDALYYCALPYINSSNVRGV---AAFDIWG 117
Db 61 ADSVGRFTISRDNKNSLYLWNSLRADTDATYYCA-----REIGWEGAFDIWG 110
QY 118 QGTMVTVSS 126
Db 111 RGLTVTVSS 119

RESULT 2

US-11-266-444-1926
; Sequence 1926, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-03-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1926
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1926

Query Match 75.7%; Score 503.5; DB 11; Length 245;
Best Local Similarity 75.2%; Pred. No. 2.5e-35;
Matches 97; Conservative 12; Mismatches 7; Indels 13; Gaps 2;
QY 1 QVOLVQSGGLVQPGKSLRLSCAASGFTFDDYAIHWVRQAPGEGLEWVSGVTWSTTIGF 60
Db 1 QVOLVQSGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
QY 61 ADSVKGRFTISRDNKNSLYLWNSLRADTDALYYCALPYINSSNVRGV---AAFDIWG 117
Db 61 ADSVGRFTISRDNKNSLYLWNSLRADTDATYYCA-----REIGWEGAFDIWG 110
QY 118 QGTMVTVSS 126
Db 111 RGLTVTVSS 119

RESULT 3

US-11-054-515-1427
; Sequence 1427, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418

; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1427
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1427

Query Match 73.8%; Score 491; DB 11; Length 254;
Best Local Similarity 71.9%; Pred. No. 2.8e-34;
Matches 92; Conservative 16; Mismatches 18; Indels 2; Gaps 1;
QY 1 QVOLVQSGGLVQPGKSLRLSCAASGFTFDDYAIHWVRQAPGEGLEWVSGVTWSTTIGF 60
Db 1 EAQLVQSGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSGISWNSGSIGY 60
QY 61 ADSVKGRFTISRDNKNSLYLWNSLRADTDALYYC--ALPYINSSNVRGVAAFDINGQ 118
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVVYCTRGYYDILTLGYNELGAFDINGR 120
QY 119 GTMTVTSS 126
Db 121 GTLTVTVS 128

RESULT 4

US-11-266-444-1427
; Sequence 1427, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523PDI
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1427
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1427

Query Match 73.8%; Score 491; DB 11; Length 254;
Best Local Similarity 71.9%; Pred. No. 2.8e-34;
Matches 92; Conservative 16; Mismatches 18; Indels 2; Gaps 1;

```
QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWSTGTTIGF 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EAQLVQSGGGLVQPGKSLRLSCAASGFTPDYAHMWVRQAPGKLEWVSGISWNSGSIY 60

QY 61 ADSVKGRFTISRDNKNSLYLNLSRAEDTALYYC--ALPYINSSNRYRGVAAFDIWGQ 118
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLNLSRAEDTAVYYCTRGVEYDILTGYNELGAFDIWGR 120

QY 119 GTWVTVSS 126
||:|||||
Db 121 GTLVTVP 128

RESULT 5
US-11-054-515-922
; Sequence 922, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 922
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-922

Query Match 73.5%; Score 489; DB 11; Length 251;
Best Local Similarity 67.6%; Pred. No. 4.1e-34;
Matches 94; Conservative 14; Mismatches 7; Indels 24; Gaps 2;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWSTGTTIGF 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTPDYAHMWVRQAPGKLEWVSGISWNSGSIY 60

QY 61 ADSVKGRFTISRDNKNSLYLNLSRAEDTALYYCA-----LPYINSSNRY 107
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AESVKGRFTISRDNKNSLYLNLSRAEDTAVYYCARVSPSYDILTGYLPH----- 113

QY 108 RGVAAFDINGQGTMTVSS 126
||:|||||
Db 114 ----AFDVMGKGLTVTVSS 128

RESULT 6
US-11-054-515-922
; Sequence 922, Application US/11266444
; Publication No. US20060062789A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 922
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-922

Query Match 73.5%; Score 489; DB 11; Length 251;
Best Local Similarity 67.6%; Pred. No. 4.1e-34;
Matches 94; Conservative 14; Mismatches 7; Indels 24; Gaps 2;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWSTGTTIGF 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTPDYAHMWVRQAPGKLEWVSGISWNSGSIY 60

QY 61 ADSVKGRFTISRDNKNSLYLNLSRAEDTALYYCA-----LPYINSSNRY 107
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AESVKGRFTISRDNKNSLYLNLSRAEDTAVYYCARVSPSYDILTGYLPH----- 113

QY 108 RGVAAFDINGQGTMTVTVSS 126
||:|||||
Db 114 ----AFDVMGKGLTVTVSS 128

RESULT 7
US-11-054-515-1416
; Sequence 1416, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 922
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-922

Query Match 73.5%; Score 489; DB 11; Length 251;
Best Local Similarity 67.6%; Pred. No. 4.1e-34;
Matches 94; Conservative 14; Mismatches 7; Indels 24; Gaps 2;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWSTGTTIGF 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTPDYAHMWVRQAPGKLEWVSGISWNSGSIY 60

QY 61 ADSVKGRFTISRDNKNSLYLNLSRAEDTALYYCA-----LPYINSSNRY 107
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AESVKGRFTISRDNKNSLYLNLSRAEDTAVYYCARVSPSYDILTGYLPH----- 113

QY 108 RGVAAFDINGQGTMTVTVSS 126
||:|||||
Db 114 ----AFDVMGKGLTVTVSS 128
```

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1416
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1416

Query Match      73.3%; Score 487.5; DB 11; Length 252;
Best Local Similarity 71.2%; Pred. No. 5.5e-34;
Matches 94; Conservative 14; Mismatches 15; Indels 9; Gaps 2;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDEYAMHWVRQAPGKLEWVSGIWSGSIAY 60
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRTTISRDNNAKNSLYLQWNSLRRAEDTALYYCA-----LPYINSNRYRGGVAAPD 114
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRTTISRDNNAKNSLYLQWNSLRRAEDTALYYCAKDRGVGYDILTGRYYTGM---D 117
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 115 IWQGQTMVTVSS 126
   :||||:|||||:
Db 118 VMGQRTMVTVSS 129

RESULT 8
US-11-266-444-1416
; Sequence 1416, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523PDI1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1416
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1416

Query Match      73.3%; Score 487.5; DB 11; Length 252;
Best Local Similarity 71.2%; Pred. No. 5.5e-34;
Matches 94; Conservative 14; Mismatches 15; Indels 9; Gaps 2;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDEYAMHWVRQAPGKLEWVSGIWSGSIAY 60
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRTTISRDNNAKNSLYLQWNSLRRAEDTALYYCA-----LPYINSNRYRGGVAAPD 114
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRTTISRDNNAKNSLYLQWNSLRRAEDTALYYCAKDRGVGYDILTGRYYTGM---D 117
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 115 IWQGQTMVTVSS 126
   :||||:|||||:
Db 118 VMGQRTMVTVSS 129

RESULT 9
```

```

US-11-084-554-2
; Sequence 2, Application US/11084554
; Publication No. US20050260679A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; FILE REFERENCE: AGENIX.100A
; CURRENT APPLICATION NUMBER: US/11/084,554
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-084-554-2

Query Match      73.2%; Score 486.5; DB 11; Length 121;
Best Local Similarity 73.0%; Pred. No. 3.5e-34;
Matches 92; Conservative 14; Mismatches 15; Indels 5; Gaps 1;

QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWGTIGF 60
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKLEWVSAITWNSGHIDY 60
   :||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRTTISRDNNAKNSLYLQWNSLRRAEDTALYYCALPYINSSNRYRGGVAADFHWGQQT 120
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVEGRTTISRDNNAKNSLYLQWNSLRRAEDTAVYYCA-----KVSYLESTASSLDYWGQQT 115
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 121 MVTVSS 126
   :||||:
Db 116 LVTVSS 121

RESULT 10
US-11-104-117-2
; Sequence 2, Application US/11104117
; Publication No. US20060009385A1
; GENERAL INFORMATION:
; APPLICANT: Hoffman, Rebecca
; APPLICANT: Taylor, Lori
; APPLICANT: Granneman, George
; APPLICANT: Van, Philip
; APPLICANT: Chartash, Elliot
; TITLE OF INVENTION: Multiple-Variable Dose Regimen For Treating TNFa-Related Disorders
; FILE REFERENCE: BBI-210CP
; CURRENT APPLICATION NUMBER: US/11/104,117
; CURRENT FILING DATE: 2005-04-11
; PRIOR APPLICATION NUMBER: 60/561139
; PRIOR FILING DATE: 2004-04-09
; PRIOR APPLICATION NUMBER: 60/561710
; PRIOR FILING DATE: 2004-04-12
; PRIOR APPLICATION NUMBER: 60/569100
; PRIOR FILING DATE: 2004-05-07
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D2E7 heavy chain variable region
US-11-104-117-2

Query Match      73.2%; Score 486.5; DB 11; Length 121;
Best Local Similarity 73.0%; Pred. No. 3.5e-34;
```

```
Matches 92; Conservative 14; Mismatches 15; Indels 5; Gaps 1;
QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWSGTTIGF 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKLEWVSAITWNSGHIDY 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 61 ADSVKGRTISRDNKNSLYLYMNSLRABDTALYYCALPYINSSNYRRGVAAPFDINGQGT 120
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVEGRFTISRDNKNSLYLQWNSLRABDTAVYYCA-----KVSYLSTASSLDYWGQGT 115
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 121 MVTVSS 126
:||||:
Db 116 LVTVSS 121

RESULT 11
US-11-136-250-2
; Sequence 2, Application US/11136250
; Publication No. US20060021074A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; FILE REFERENCE: ABGENIX.100A2
; CURRENT APPLICATION NUMBER: US/11/136,250
; PRIOR FILING DATE: 2005-05-23
; PRIOR APPLICATION NUMBER: 11/084,554
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: PCT/US2005/009306
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-136-250-2

Query Match 73.2%; Score 486.5; DB 11; Length 121;
Best Local Similarity 73.0%; Pred. No. 3.5e-34;
Matches 92; Conservative 14; Mismatches 15; Indels 5; Gaps 1;
QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWSGTTIGF 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKLEWVSAITWNSGHIDY 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 61 ADSVKGRTISRDNKNSLYLYMNSLRABDTALYYCALPYINSSNYRRGVAAPFDINGQGT 120
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVEGRFTISRDNKNSLYLQWNSLRABDTAVYYCA-----KVSYLSTASSLDYWGQGT 115
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 121 MVTVSS 126
:||||:
Db 116 LVTVSS 121

RESULT 12
US-11-233-252-2
; Sequence 2, Application US/11233252
; Publication No. US20060024293A1
; GENERAL INFORMATION:
; APPLICANT: SALFELD, Jochen G.
; APPLICANT: ALLEN, Deborah J.
; APPLICANT: HOOGENBOOM, Hendricus R.J.M.
; APPLICANT: KAYMAKALAN, Zehra
; APPLICANT: LABKOVSKY, Boris
; APPLICANT: MANKOVICH, John A.
; APPLICANT: MCGUINNESS, Brian T.

Query Match 73.2%; Score 486.5; DB 11; Length 121;
Best Local Similarity 73.0%; Pred. No. 3.5e-34;
Matches 92; Conservative 14; Mismatches 15; Indels 5; Gaps 1;
QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWSGTTIGF 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGKSLRLSCAASGFTFGDYAMHWVRQAPGKLEWVSAITWNSGHIDY 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 61 ADSVKGRTISRDNKNSLYLYMNSLRABDTALYYCALPYINSSNYRRGVAAPFDINGQGT 120
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVEGRFTISRDNKNSLYLQWNSLRABDTAVYYCA-----KVSYLSTASSLDYWGQGT 115
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 121 MVTVSS 126
:||||:
Db 116 LVTVSS 121

RESULT 13
US-11-245-254-2
; Sequence 2, Application US/11245254
; Publication No. US20060083741A1
; GENERAL INFORMATION:
; APPLICANT: Hoffman, Rebecca
; APPLICANT: Chartash, Elliot
; APPLICANT: Follack, Paul
; TITLE OF INVENTION: TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION
; FILE REFERENCE: DOCKET NO BBI-219CP
; CURRENT APPLICATION NUMBER: US/11/245,254
; CURRENT FILING DATE: 2005-10-06
; PRIOR APPLICATION NUMBER: 60/617563
; PRIOR FILING DATE: 2004-10-08
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D2E7 heavy chain variable region
US-11-245-254-2

Query Match 73.2%; Score 486.5; DB 11; Length 121;
Best Local Similarity 73.0%; Pred. No. 3.5e-34;
Matches 92; Conservative 14; Mismatches 15; Indels 5; Gaps 1;
QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTWSGTTIGF 60
```


GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:05 ; Search time 8.0277 Seconds
(without alignments)
1510.185 Million cell updates/sec

Title: US-09-674-752-34
Perfect score: 665
Sequence: 1 QVQLVQSGGGLVQPGKSLRL.....RRGVAAPFDIWGGTMTVTSS 126

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	518.5	78.0	123	2 S30532	Ig heavy chain V r
2	516.5	77.7	121	2 S31118	Ig heavy chain - h
3	516	77.6	145	2 S11239	Ig heavy chain V r
4	512	77.0	128	2 S31595	Ig heavy chain V r
5	503.5	75.7	121	2 S31104	Ig heavy chain (su
6	499.5	75.1	120	2 S36273	Ig heavy chain V r
7	477	71.7	118	2 S31105	Ig heavy chain (su
8	475.5	71.5	119	2 F36005	Ig heavy chain V r
9	475	71.4	118	2 S31116	Ig heavy chain - h
10	474	71.3	137	2 S31701	Ig heavy chain V r
11	470.5	70.8	121	2 S19666	Ig heavy chain V r
12	469.5	70.6	123	2 PC4281	anti-SS-A/Ro 60K p
13	466.5	70.2	143	2 S23624	Ig heavy chain V r
14	466	70.1	114	2 S31120	Ig heavy chain - h
15	464	69.8	120	2 S44111	Ig heavy chain V-D
16	463	69.6	128	2 S48797	Ig heavy chain V r
17	463	69.6	140	2 S70442	Ig heavy chain pre
18	462.5	69.5	121	2 S36005	Ig heavy chain V r
19	462	69.5	120	2 S31112	Ig heavy chain - h
20	462	69.5	122	2 E36005	Ig heavy chain V r
21	461.5	69.4	125	2 S30531	Ig heavy chain - h
22	461	69.3	122	2 S31117	Ig heavy chain - h
23	461	69.3	128	2 S26790	Ig heavy chain - h
24	457.5	68.8	137	2 S38489	Ig heavy chain - h
25	456.5	68.6	119	2 S31108	Ig heavy chain - h
26	456.5	68.6	123	2 S26794	Ig heavy chain V r
27	454.5	68.3	138	2 S31666	Ig heavy chain V r
28	454	68.3	98	2 S26927	Ig heavy chain V r
29	454	68.3	128	2 S26786	Ig heavy chain V r

30	453.5	68.2	134	2 S31679	Ig heavy chain V r
31	453.5	68.2	139	2 I37781	Ig variable region
32	453	68.1	124	2 S20782	Ig heavy chain V r
33	452.5	68.0	123	2 S31114	Ig heavy chain - h
34	452.5	68.0	140	2 S31686	Ig heavy chain V r
35	452.5	68.0	160	2 S05271	Ig heavy chain pre
36	452	68.0	136	2 S31587	Ig heavy chain V r
37	451.5	67.9	140	2 S31588	Ig heavy chain V r
38	450.5	67.7	119	2 S31107	Ig heavy chain - h
39	450.5	67.7	135	2 S31598	Ig heavy chain V r
40	449.5	67.6	119	2 C36005	Ig heavy chain V r
41	449	67.5	112	2 PH1654	Ig heavy chain V r
42	449	67.5	139	2 S31674	Ig heavy chain V r
43	448.5	67.4	120	2 S36278	Ig heavy chain V r
44	448.5	67.4	132	2 S31603	Ig heavy chain V r
45	448	67.4	114	2 S46390	Ig heavy chain V r

ALIGNMENTS

RESULT 1
S30532
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 31-Dec-2004
C;Accession: S30532
R;Mariette, X.
submitted to the EMBL Data Library, October 1992
A;Reference number: S30520
A;Accession: S30532
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-123 <MAR>
A;Cross-references: UNIPROT:Q8MU38; UNIPARC:UPI0000176C38; EMBL:Z18318
C;Superfamily: immunoglobulin homology
C;Keywords: heterotrimer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match	78.0%;	Score 518.5;	DB 2;	Length 123;
Best Local Similarity	78.9%;	Pred. No. 8.7e-41;		
Matches 101;	Conservative 11;	Mismatches 9;	Indels 7;	Gaps 3;
QY	1	QVQLVQSGGGLVQPGKSLRLSCAASGFTFQDYAIHWVQRQAPGKGLVQSGTWTIGF	60	
Db	1	EVQLVESGGGLVQPGKSLRLSCAASGFTFDDYAMHWVRQAPGKGLVQSGISNNSGTLYG	60	
QY	61	ADSVKGRFTISRDNAKNSLYLYMNSLRADDTALYYCA--LPYINSSNYRRGVAAFDIWGQ	118	
Db	61	ADSVKGRFAISRDNAKNSLYLQWNSLRADDTALYYCAKDTPY--SSGWSN---AFDIWGQ	115	
QY	119	GTMTVTSS	126	
Db	116	GTMTVTSS	123	

RESULT 2
S31118
Ig heavy chain - human
C;Species: Homo sapiens (man)
C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
Eur. J. Immunol. 22, 247-251, 1992
A;Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A;Reference number: S31104; MUID:92111633; PMID:1730252
A;Accession: S31118
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-121 <RAA>
A;Cross-references: UNIPARC:UPI0000176C8B; EMBL:X62969
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 77.7%; Score 516.5; DB 2; Length 121;
Best Local Similarity 77.8%; Pred. No. 1.3e-40;
Matches 98; Conservative 12; Mismatches 11; Indels 5; Gaps 1;

QY 1 QVQLVQSGGGLVQPGRSLRLSCAASGFTFGDVAIHVVRQAPGEGLEWVSGVTSGTTIGF 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLWVSGISWNSGSIGY 60
:
QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADDTALYYCALPVINSNRYRGGVAAFDIWGQGT 120
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 RDSVKGRFTISRDNKNSLYLQMSLRADDTALYYCAKDILQT-----GPDADIWGQGT 115
:
QY 121 MVTVSS 126
:||||:
Db 116 MVTVSS 121

RESULT 3
S11239
Ig heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 21-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S11239
R:Feigenhauer, M.; Kohl, J.; Rueker, F.
Nucleic Acids Res. 18, 4927, 1990
A:Title: Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-chains of
A:Reference number: S11239; MUID:90370490; PMID:1697678
A:Accession: S11239
A:Status: Preliminary
A:Molecule type: mRNA
A:Residues: 1-145 <FEL>
A:Cross-references: UNIPARC:UPI0000113781; EMBL:X53613; NID:G23865; PIDN:CAA37675.1; PID
A:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:134-117/Domain: immunoglobulin homology <IMM>

Query Match 77.6%; Score 516; DB 2; Length 145;
Best Local Similarity 77.3%; Pred. No. 1.8e-40;
Matches 99; Conservative 11; Mismatches 14; Indels 4; Gaps 2;

QY 1 QVQLVQSGGGLVQPGRSLRLSCAASGFTFGDVAIHVVRQAPGEGLEWVSGVTSGTTIGF 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 20 EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLWVSGISWDSISIGY 79
:
QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADDTALYYC--ALPYINSNRYRGGVAAFDIWGQ 118
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 80 ADSVKGRFTISRDNKNSLYLQMSLRADDMALYYCVKGRDYYDSGGY--FTVAFDIWGQ 137
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 119 GMTVTVSS 126
:||||:
Db 138 GMTVTVSS 145

RESULT 4
S31595
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31595
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelles, C.
submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31595
A:Status: Preliminary
A:Molecule type: mRNA
A:Residues: 1-128 <CUI>
A:Cross-references: UNIPARC:UPI0000116458; EMBL:Z14171; NID:G31007; PIDN:CAA78540.1; PID
A:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

F:23-106/Domain: immunoglobulin homology <IMM>

Query Match 77.0%; Score 512; DB 2; Length 128;
Best Local Similarity 77.8%; Pred. No. 3.6e-40;
Matches 98; Conservative 11; Mismatches 11; Indels 6; Gaps 1;

QY 1 QVQLVQSGGGLVQPGRSLRLSCAASGFTFGDVAIHVVRQAPGEGLEWVSGVTSGTTIGF 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 9 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLWVSGISWNSGSIGY 68
:
QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADDTALYYCALPVINSNRYRGGVAAFDIWGQGT 120
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 69 ADSVKGRFTISRDNKNSLYLQMSLRADDTALYYCAKDAPGDHD-----AFDIWGQGT 122
:
QY 121 MVTVSS 126
:||||:
Db 123 MVTVSS 128

RESULT 5
S31104
Ig heavy chain (subclass IgM) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 23-Jul-1999
C:Accession: S31104
R:Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman,
Eur. J. Immunol. 22, 247-251, 1992
A:Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A:Reference number: S31104; MUID:92111633; PMID:1730252
A:Accession: S31104
A:Status: Preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: mRNA
A:Residues: 1-121 <RAA>
A:Cross-references: UNIPARC:UPI000011600B; EMBL:X63080; NID:G32646; PIDN:CAA44802.1; PID:
A:Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 75.7%; Score 503.5; DB 2; Length 121;
Best Local Similarity 75.4%; Pred. No. 2.1e-39;
Matches 95; Conservative 14; Mismatches 12; Indels 5; Gaps 1;

QY 1 QVQLVQSGGGLVQPGRSLRLSCAASGFTFGDVAIHVVRQAPGEGLEWVSGVTSGTTIGF 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLWVSGISWNSGSIGY 60
:
QY 61 ADSVKGRFTISRDNKNSLYLYMNSLRADDTALYYCALPVINSNRYRGGVAAFDIWGQGT 120
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 ADSVKGRFTISRDNKNSLYLQMSLRADDTALYYCAKDVFWSGW-----YFDLWGRGT 115
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

QY 121 MVTVSS 126
:||||:
Db 116 LVTVSS 121

RESULT 6
S36273
Ig heavy chain V region (clone alpha-THY-32) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C:Accession: S36273
R:Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.;
EMBO J. 12, 725-734, 1993
A:Title: Human anti-self antibodies with high specificity from phage display libraries.
A:Reference number: S36256; MUID:93178448; PMID:7679990
A:Accession: S36273
A:Status: Preliminary; nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 1-120 <GRI>
A:Cross-references: UNIPARC:UPI0000118DE4; EMBL:Z18834; NID:G33116; PIDN:CAA79286.1; PID:
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

A;Gene: GDB:IGH@; IGH DY1

A;Molecule type: mRNA

Search completed: May 5, 2006, 08:51:35
Job time : 8.0277 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:58 ; Search time 49.9114 Seconds
(without alignments)
1781.089 Million cell updates/sec

Title: US-09-674-752-34

Perfect score: 665

Sequence: 1 QVQLVQSGGSLVQPGKSLRL.....RRGVAAPDIWGQGTMTVTVSS 126

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt 05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	502	75.5	573	2 Q8WU38 HUMAN	Q8WU38 homo sapien
2	491.5	73.9	472	2 Q6N089 HUMAN	Q6N089 homo sapien
3	479	72.0	613	2 Q8WU11 HUMAN	Q8WU11 homo sapien
4	471	70.8	469	2 Q569F4 HUMAN	Q569F4 homo sapien
5	459	69.0	118	2 Q9UL91 HUMAN	Q9UL91 homo sapien
6	457.5	68.6	112	2 Q9HCC1 HUMAN	Q9HCC1 homo sapien
7	456	68.6	112	2 Q9HCC1 HUMAN	Q9HCC1 homo sapien
8	448.5	67.4	240	2 Q65ZC9 HUMAN	Q65ZC9 homo sapien
9	446.5	67.1	597	2 Q6BBB9 HUMAN	Q6BBB9 homo sapien
10	446	67.1	606	2 Q6GMT2 HUMAN	Q6GMT2 homo sapien
11	444	66.8	122	1 HV3G HUMAN	Q01768 homo sapien
12	443.5	66.7	116	2 Q9UL93 HUMAN	Q9UL93 homo sapien
13	441.5	66.4	493	2 Q6GXX2 HUMAN	Q6GXX2 homo sapien
14	441	66.3	473	2 Q6MZV7 HUMAN	Q6MZV7 homo sapien
15	440	66.2	479	2 Q6MZV6 HUMAN	Q6MZV6 homo sapien
16	439.5	66.1	499	2 Q8NSK4 HUMAN	Q8NSK4 homo sapien
17	439	66.0	475	2 Q5EFE5 HUMAN	Q5EFE5 homo sapien
18	437.5	65.8	113	2 Q9UL90 HUMAN	Q9UL90 homo sapien
19	437	65.7	120	1 HV3U HUMAN	Q01782 homo sapien
20	431.5	64.9	470	2 Q6PJ44 HUMAN	Q6PJ44 homo sapien
21	431.5	64.9	478	2 Q6PJ81 HUMAN	Q6PJ81 homo sapien
22	427	64.2	147	2 Q9Y509 HUMAN	Q9Y509 homo sapien
23	425.5	64.0	119	1 HV3I HUMAN	Q01770 homo sapien
24	424.5	63.8	479	2 Q5BK12 RAT	Q5BK12 rattus norv
25	424	63.8	116	1 HV3T HUMAN	Q01781 homo sapien
26	423.5	63.7	464	2 Q6MZU6 HUMAN	Q6MZU6 homo sapien
27	423.5	63.7	485	2 Q6PDB8 MOUSE	Q6PDB8 mus musculu
28	422.5	63.5	121	1 HV3J HUMAN	Q01771 homo sapien
29	420	63.2	122	2 Q9UL84 HUMAN	Q9UL84 homo sapien
30	420	63.2	467	2 Q4VBH1 RAT	Q4VBH1 rattus norv
31	420	63.2	494	2 Q6ZW64_HUMAN	Q6ZW64 homo sapien

RESULT 1

ID	Q8WU38_HUMAN	PRELIMINARY;	PRT;	573 AA.
AC	Q8WU38;			
DT	01-MAR-2002	(Tremblrel. 20, Created)		
DT	01-MAR-2002	(Tremblrel. 20, Last sequence update)		
DT	01-MAR-2004	(Tremblrel. 26, Last annotation update)		
DE	IGHD protein.			
GN	Name=IGHD;			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;			
OC	Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	NUCLEOTIDE SEQUENCE.			
RC	TISSUE=Primary B-Cells;			
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.2426038999;			
RA	Strausberg R.L., Fellings F.S., Wagner L., Shenmen C.M., Schuler G.D.,			
RA	Klausner R.D., Collins F.S., Buetow K.H., Schaefer C.P., Bhat N.K.,			
RA	Altschul S.F., Zeeberg B., Moore T., Max S.I., Wang J., Hong L.,			
RA	Hopkins R.F., Jordan H., Marusina K., Farmer A.A., Rubin G.M., Hong L.,			
RA	Diatchenko L., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,			
RA	Stapleton M., Udell T.B., Toshiyuki S., Carninci P., Prange C.,			
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,			
RA	Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,			
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,			
RA	Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,			
RA	Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,			
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,			
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,			
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,			
RA	Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smallos D.E.,			
RA	Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;			
RT	"Generation and initial analysis of more than 15,000 full-length human			
RT	and mouse cDNA sequences."			
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).			
RL	[2]			
RN	NUCLEOTIDE SEQUENCE.			
RP	TISSUE=Primary B-Cells;			
RC	TISSUE=Primary B-Cells;			
RA	Director MGC Project;			
RL	Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.			
RN	[3]			
RP	PROTEIN SEQUENCE.			
RX	PubMed=1555592;			
RA	Makiya R., Stigbrand T.;			
RT	"Placental alkaline phosphatase has a binding site for the human			
RT	immunoglobulin-G Fc portion."			
RL	Eur. J. Biochem. 205:341-345(1992).			
DR	EMBL; BC021276; AAH21276.1; -; mRNA.			
DR	PIR; S21205; S21205.			
DR	PIR; S30532; S30532.			
DR	HSSP; P18529; I18K.			

ALIGNMENTS

```

DR Ensemble; ENSG00000196122; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 1.
DR Pfam; PF00047; ig; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 573 AA; 62967 MW; FD072344033AC530 CRC64;

Query Match 75.5%; Score 502; DB 2; Length 573;
Best Local Similarity 76.2%; Pred. No. 1.1e-42;
Matches 96; Conservative 12; Mismatches 16; Indels 2; Gaps 1;

QY 1 QVQLVSGGGLVQPGKSLRLSCAASGFTFGDYAIHWVRQAPGQGLEWVSGVTVSGTIGF 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 20 EVQLVESGGGLVQPGKSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSGISWNSGSIY 79
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRTISRDNKNSLYLNMNSLRADPTALYYCALPYINSNRRGVAAFDIWGQGT 120
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 ADSVKGRTISRDNKNSLYLQMNLSLRADPTALYYCAKEIGHNFYYGM---DVMGQGT 136
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 121 MVTVSS 126
   :|||:|||||
Db 137 TVTVSS 142
   :|||:|||||

RESULT 3
Q8WUK1 HUMAN
ID Q8WUK1_HUMAN PRELIMINARY; PRT; 613 AA.
AC Q8WUK1;
DT 01-MAR-2002 (TREMBLrel. 20, Created)
DT 01-MAR-2002 (TREMBLrel. 20, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE IGHM protein.
GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., McEwan P.J., McKernan K.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettner M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Maman A.C., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
   and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2117273;
RA Schroeder H.W. Jr., Wang J.Y.;
RT "Preferential utilization of conserved immunoglobulin heavy chain
   variable gene segments during human fetal life";
RL Proc. Natl. Acad. Sci. U.S.A. 87:6146-6150(1990).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1383695; DOI=10.1016/0161-5890(92)90173-U;
RA Cuisinier A.M., Fumoux F., Fougereau M., Tonnel C.;
RT "IGM kappa/lambda EBV human B cell clone: an early step of
   differentiation of fetal B cells or a distinct B lineage?";
RL Mol. Immunol. 29:1363-1373(1992).
RN [5]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1730252;
RA Raaphorst F.M., Timmers E., Kenter M.J., Van Tol M.J., Vossen J.M.,
RA Schuurman R.K.;

```


RT "Restricted utilization of germ-line VH3 genes and short diverse third
RT complementarity-determining regions (CDR3) in human fetal B lymphocyte
RL immunoglobulin heavy chain rearrangements."; Eur. J. Immunol. 22:247-251(1992).

RN [6]

RP NUCLEOTIDE SEQUENCE.

RA PubMed=19041154;

RA Neale G.A., Kitchingman G.R.;

RT "mRNA transcripts initiating within the human immunoglobulin mu heavy
RT chain enhancer region contain a non-translatable exon and are
RT extremely heterogeneous at the 5' end.";

RL Nucleic Acids Res. 19:2427-2433(1991).

RN [7]

RP NUCLEOTIDE SEQUENCE.

RA PubMed=2840480; DOI=10.1084/jem.168.1.229;

RA Bird J., Galli N., Link M., Stites D., Sklar J.;

RT "Continuing rearrangement but absence of somatic hypermutation in

RT immunoglobulin genes of human B cell precursor leukemia.";

RL J. Exp. Med. 168:229-245(1988).

RN [8]

RP NUCLEOTIDE SEQUENCE.

RA PubMed=2538551; DOI=10.1084/jem.169.4.1391;

RA Nickerson K.G., Berman J., Glickman E., Chess L., Alt F.W.;

RT "Early human IgH gene assembly in Epstein-Barr virus-transformed fetal

RT B cell lines. Preferential utilization of the most JH-proximal D

RT segment (DQ52) and two unusual VH-related rearrangements.";

RL J. Exp. Med. 169:1391-1403(1989).

RN [9]

RP NUCLEOTIDE SEQUENCE.

RA MEDLINE=93301610; PubMed=8315388; DOI=10.1084/jem.178.1.331;

RA Hillson J.L., Karr N.S., Opplinger I.R., Mannik M., Sasso E.H.;

RT "The structural basis of germline-encoded VH3 immunoglobulin binding

RT to staphylococcal protein A.";

RL J. Exp. Med. 178:331-336(1993).

DR EMBL; BC020240; AAH20240.1; -; mRNA.

DR PIR; F36005; F36005.

DR PIR; G36005; G36005.

DR PIR; P1642; PH1642.

DR PIR; PH1643; PH1643.

DR PIR; PH1645; PH1645.

DR PIR; PH1646; PH1646.

DR PIR; PLO098; PLO098.

DR PIR; S15590; S15590.

DR PIR; S31116; S31116.

DR PIR; S31119; S31119.

DR PIR; S70442; S70442.

DR HSP; P01861; IADQ.

DR SMR; Q8WUK1; 20-242.

DR Ensembl; ENSG00000130076; Homo sapiens.

DR InterPro; IPR007110; Ig-like.

DR InterPro; IPR003597; Ig-cl.

DR InterPro; IPR003006; Ig_MHC.

DR InterPro; IPR003596; Ig_v.

DR Pfam; PF07654; Cl-Bet; 4.

DR SMART; SM00406; IGV; 1.

DR PROSITE; PS00835; IG LIKE; 5.

DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.

KW immunoglobulin domain.

SQ SEQUENCE 613 AA; 67296 MW; 60C7F5950671E315 CRC64;

Query Match

Best Local Similarity 71.4%; Score 479; DB 2; Length 613;

Matches 90; Conservative 16; Mismatches 14; Indels 6; Gaps 1;

Qy 1 QVQLVQSGGGLVOPGKSLRSLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTSGTTIGF 60

Db 20 QVQLVESGGGVVQPGSRSLRSLSCAASGFTFSSYGHVWRQAPGKLEWVAISYDGSNKY 79

Qy 61 ADSVKGRFTISRDNKNSLYNLSRAEDTALYCALPYINSNRYRGAADFIMQGT 120

Db 80 ADSVKGRFTISRDNKNSLYNLSRAEDTALYCALPYINSNRYRGAADFIMQGT 133

Qy 121 MVTVSS 126

Db 134 MVTVSS 139

RESULT 4

Q569F4 HUMAN

AC Q569F4 HUMAN PRELIMINARY; PRT; 469 AA.

DT 10-MAY-2005 (TrEMBLrel. 30, Created)

DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)

DE 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)

DE IGHG1 protein.

GN Name=IGHG1;

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;

OC Homo.

OX NCBI_TaxID=9606;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Lymph.

RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

RA Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,

RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,

RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fahey J., Heiton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,

RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,

RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,

RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,

RT "Generation and initial analysis of more than 15,000 full-length human

RT and mouse cDNA sequences.";

RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

RN [2]

RP NUCLEOTIDE SEQUENCE.

RC TISSUE=Lymph.

RG NIH MGC Project;

RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.

DR EMBL; BC092518; AAH92518.1; -; mRNA.

SQ SEQUENCE 469 AA; 51254 MW; AC13448E3047784F CRC64;

Query Match

Best Local Similarity 70.8%; Score 471; DB 2; Length 469;

Matches 93; Conservative 11; Mismatches 13; Indels 12; Gaps 2;

Qy 1 QVQLVQSGGGLVOPGKSLRSLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTSGTTIGF 60

Db 20 EVQLVESGGGVVQPGGSLRSLSCAASGFTFDYANHWVRQAPGKLEWVSLISWDGGSTYY 79

Qy 61 ADSVKGRFTISRDNKNSLYNLSRAEDTALYCALPYINSNRYRGAADFIMQ 117

Db 80 ADSVKGRFTISRDNKNSLYNLSRAEDTALYCALPYINSNRYRGAADFIMQ 130

Qy 118 QGTMTVSS 126

Db 131 QGTMTVSS 139

RESULT 5

Q9UL91 HUMAN

ID Q9UL91 HUMAN PRELIMINARY; PRT; 118 AA.

AC Q9UL91;

DT 01-MAY-2000 (TrEMBLrel. 13, Created)

[illegible]

DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
 DE Myosin-reactive immunoglobulin heavy chain variable region
 DE (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
 RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Barney S.M.,
 RA Young D.C.;
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
 RT fetus";
 RL Clin. Immunol. Immunopathol. 87:184-192(1998).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=93301610; PubMed=8315388; DOI=10.1084/jem.178.1.331;
 RA Hillson J.L., Karr N.S., Opplinger I.R., Mannik M., Sasso E.H.;
 RT "The structural basis of germline-encoded VH3 immunoglobulin binding
 RT to staphylococcal protein A";
 RL J. Exp. Med. 178:331-336(1993).
 RN [3]
 RP NUCLEOTIDE SEQUENCE.
 RX PubMed=2840480;
 RA Bird J., Galili N., Link M., Stites D., Sklar J.;
 RT "Continuing rearrangement but absence of somatic hypermutation in
 RT immunoglobulin genes of human B cell precursor leukemia";
 RL J. Exp. Med. 168:229-245(1988).
 DR EMBL; AF035021; AAD56257.1; -; mRNA.
 DR PIR; PH1644; PH1644.
 DR PIR; PLO120; PLO120.
 DR HSP; P01772; 2F84.
 DR SMK; Q9UL93; 1-116.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig_v.
 DR SMART; SM00406; IG; 1.
 DR PROSITE; PS50835; IG_LIKE; 1.
 FT NON_TER 1
 FT TER 116
 SQ SEQUENCE 116 AA; 12434 MW; 0DA0348154DD6061 CRC64;
 Query Match 66.7%; Score 443.5; DB 2; Length 116;
 Best Local Similarity 68.0%; Pred. No. 2e-37;
 Matches 8; Conservative 15; Mismatches 16; Indels 9; Gaps 1;
 QY 2 VQLVSGGGLVQPKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTSQTIGFA 61
 DB 1 VQLVESGGGVQPKSLRLSCAASGFTFSYAMHWVRQAPGKGLWVAIVSDGSKYYA 60
 QY 62 DSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNRYRGVAAFDIWGQGTW 121
 DB 61 DSVKGRFTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNRYRGVAAFDIWGQGT 111
 QY 122 VTVSS 126
 DB 112 VTVSS 116
 RESULT 13
 Q6GMX2_HUMAN
 ID Q6GMX2_HUMAN PRELIMINARY; PRT; 493 AA.
 AC Q6GMX2;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE IGHAI protein.
 GN Name=IGHAI;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.

NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Scapleton M., Soares M.B., Donald M.P., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
 RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton E., Kettelman M., Maman A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Spleen;
 RG NIH MGC Project;
 RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC073771; AAH73771.1; -; mRNA.
 DR SMR; Q6GMX2; 263-471.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig_c1.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_v.
 DR Pfam; PF07654; C1-set; 2.
 DR SMART; SM00409; IG; 4.
 DR SMART; SM00407; IGL1; 2.
 DR SMART; SM00406; IG; 1.
 DR PROSITE; PS50835; IG_LIKE; 4.
 DR PROSITE; PS00290; IG_MHC.
 SQ SEQUENCE 493 AA; 52865 MW; 55B999305B286203 CRC64;
 Query Match 66.4%; Score 441.5; DB 2; Length 493;
 Best Local Similarity 67.5%; Pred. No. 1.6e-36;
 Matches 85; Conservative 14; Mismatches 22; Indels 5; Gaps 1;
 QY 1 QVQLVSGGGLVQPKSLRLSCAASGFTFGDYAIHWVRQAPGEGLEWVSGVTSQTIGF 60
 DB 20 EVQLVESGGGLVQPGGSLRLSCAASGIFPSSYMMHWVRQAPGKGLVWSFINSIGSSTSY 79
 QY 61 ADSVKGRTISRDNKNSLYLYMNSLRADLTALYYCALPYINSSNRYRGVAAFDIWGQGT 120
 DB 80 ADSVKGRTISRDNKNSLYLYMNSLRGDDAAVYVCARGFVSLPR-----STLDIWQGT 134
 QY 121 MVTSS 126
 DB 135 MVTSS 140
 RESULT 14
 Q6MZV7_HUMAN
 ID Q6MZV7_HUMAN PRELIMINARY; PRT; 473 AA.
 AC Q6MZV7;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Hypothetical protein DKF2p686C11235.
 GN Name=DKF2p686C11235;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo
 OX NCBI_TaxID=9606;
 RN [1]
 RC NUCLEOTIDE SEQUENCE.
 RP TISSUE=Small intestine;
 RG The German cDNA Consortium;
 RA Bloecker H., Boecker M., Brandt P., Mewes H.W., Weil B., Amid C.,
 RA Osanger A., Fobo G., Han M., Wiemann S.;
 RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BX640853; CAE45920.1; -; mRNA.
 DR HSSP; P01861; IADQ.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig_c1.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_v.
 DR Pfam; PF07654; C1-set; 3.
 DR SMART; SM00409; IG; 2.
 DR SMART; SM00407; IGc1; 3.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
 KW Hypothetical protein_
 SQ SEQUENCE 473 AA; 52121 MW; 9476EAE4C0BFC447 CRC64;
 Query Match 66.3%; Score 441; DB 2; Length 473;
 Best Local Similarity 67.5%; Pred. No. 1.7e-36;
 Matches 85; Conservative 20; Mismatches 19; Indels 2; Gaps 1;
 QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTPDGYAIHWVROAPGEGLEWVSGVTWSTIGTGF 60
 Db 20 EQQLVESGGGLVQPGGSLRLSCAASGFTFSSPFMNVRQAPGKLEWLSYITRSGNTVY 79
 QY 61 ADSVKGRFTISRDNKNSLYLNNSLRRAEDTALYYCALPYINSNRRGVAAFDI 120
 Db 80 ADSLQGRFTISRDNARNSLYLQNSLRRAEDTAVYYCARQNEHTSPWY--PSFEDYWGQGI 137
 QY 121 MVTVSS 126
 Db 138 LVTVSS 143
 RESULT 15
 Q6MZV6_HUMAN
 ID Q6MZV6_HUMAN PRELIMINARY; PRT; 479 AA.
 AC Q6MZV6;
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
 DE Hypothetical protein DKF2p686L19235;
 GN Names=DKF2p686L19235;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RC NUCLEOTIDE SEQUENCE.
 RP TISSUE=Human small intestine;
 RG The German Human cDNA Consortium;
 RA Bloecker H., Boecker M., Mewes H.W., Weil B., Amid C., Osanger A.,
 RA Fobo G., Han M., Wiemann S.;
 RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BX640854; CAE45921.1; -; mRNA.
 DR HSSP; P01842; 1AOK.
 DR SMR; Q6MZV6; 249-457.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig_c1.
 DR InterPro; IPR003598; Ig_c2.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_v.

DR Pfam; PF07654; C1-set; 2.
 DR SMART; SM00409; IG; 4.
 DR SMART; SM00407; IGc1; 3.
 DR SMART; SM00408; IGC2; 1.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS00835; IG LIKE; 4.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
 KW Hypothetical protein.
 SQ SEQUENCE 479 AA; 51639 MW; 6FA495DF0AA71DD4 CRC64;
 Query Match 66.2%; Score 440; DB 2; Length 479;
 Best Local Similarity 67.7%; Pred. No. 2.2e-36;
 Matches 88; Conservative 11; Mismatches 17; Indels 14; Gaps 2;
 QY 1 QVQLVQSGGGLVQPGKSLRLSCAASGFTPDGYAIHWVROAPGEGLEWVSGVTWSTIGTGF 60
 Db 20 EVQLVESGGGLVQPGGSLRLSCAASGFTVSNYGIHWVROAPGKLEWISFLSYTTDIHY 79
 QY 61 ADSVKGRFTISRDNKNSLYLNNSLRRAEDTALYYCALPYINSNRRGVAAFDI---W 116
 Db 80 ADSVKGRFTISRDNKNSLYLNNSLRDEDTGYYCV-----RSAAGSDIWDVDPW 129
 QY 117 GQGTMTVTSS 126
 Db 130 GQGTMTVTSS 139
 Search completed: May 5, 2006, 09:04:21
 Job time : 49.9114 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:53:55 ; Search time 10.7652 Seconds
(without alignments)
752.634 Million cell updates/sec

Title: US-09-674-752-35

Perfect score: 514

Sequence: 1 QVQLVESGGGVVQPGKSLRL.....LYLQMSLRADTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:*

- 1: /cgn2_6/prodata/1/aaa/5 COMB.pep.*
- 2: /cgn2_6/prodata/1/aaa/6 COMB.pep.*
- 3: /cgn2_6/prodata/1/aaa/H COMB.pep.*
- 4: /cgn2_6/prodata/1/aaa/PCTUS COMB.pep.*
- 5: /cgn2_6/prodata/1/aaa/RE COMB.pep.*
- 6: /cgn2_6/prodata/1/aaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	514	100.0	98	2	US-10-194-975-23
2	514	100.0	98	2	US-10-194-975-25
3	514	100.0	98	2	US-09-534-717-650
4	511	99.4	98	2	US-09-534-717-641
5	511	99.4	98	2	US-09-534-717-642
6	511	99.4	98	2	US-09-534-717-643
7	511	99.4	98	2	US-09-534-717-644
8	511	99.4	98	2	US-09-534-717-646
9	511	99.4	98	2	US-09-534-717-654
10	511	99.4	98	2	US-10-330-613A-61
11	511	99.4	115	2	US-09-726-219A-167
12	511	99.4	115	2	US-09-196-522-167
13	511	99.4	117	2	US-08-545-809A-115
14	511	99.4	117	2	US-09-515-697-115
15	508	98.8	98	2	US-09-534-717-637
16	507	98.6	98	2	US-09-534-717-652
17	505	98.2	98	1	US-08-211-202-118
18	505	98.2	98	2	US-10-194-975-24
19	505	98.2	98	2	US-09-534-717-625
20	505	98.2	98	2	US-09-534-717-627
21	505	98.2	98	2	US-09-534-717-628
22	505	98.2	98	2	US-09-534-717-629
23	505	98.2	98	2	US-09-534-717-630
24	505	98.2	98	2	US-09-534-717-631
25	505	98.2	98	2	US-09-534-717-632
26	505	98.2	98	2	US-09-534-717-636
27	505	98.2	98	2	US-09-534-717-645

28	505	98.2	98	2	US-10-330-613A-62	Sequence 62, Appl
29	505	98.2	115	2	US-09-269-332-89	Sequence 89, Appl
30	505	98.2	120	1	US-07-942-245-35	Sequence 35, Appl
31	505	98.2	120	2	US-10-330-613A-29	Sequence 29, Appl
32	504	98.1	98	2	US-10-194-975-26	Sequence 26, Appl
33	504	98.1	98	2	US-09-534-717-647	Sequence 647, App
34	504	98.1	98	2	US-09-534-717-648	Sequence 648, App
35	504	98.1	98	2	US-09-534-717-651	Sequence 651, App
36	504	98.1	451	2	US-09-472-087-70	Sequence 70, Appl
37	503	97.9	116	1	US-08-211-202-141	Sequence 141, App
38	502	97.7	119	1	US-08-331-398A-46	Sequence 46, Appl
39	502	97.7	119	1	US-08-331-397B-46	Sequence 46, Appl
40	502	97.7	119	1	US-08-759-804A-46	Sequence 46, Appl
41	502	97.7	119	2	US-09-227-693-46	Sequence 80, Appl
42	502	97.7	248	2	US-09-315-926A-80	Sequence 80, Appl
43	501	97.5	98	2	US-09-534-717-624	Sequence 624, App
44	500	97.3	98	2	US-09-534-717-626	Sequence 626, App
45	500	97.3	98	2	US-09-534-717-635	Sequence 635, App

ALIGNMENTS

RESULT 1

US-10-194-975-23
; Sequence 23, Application US/10194975
; Patent No. 6881557
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-23

Query Match 100.0%; Score 514; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.2e-47;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

Db 1 QVQLVESGGGVVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNSKNTLYLQMNSLRADTAVYYCAK 98

Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRADTAVYYCAK 98

RESULT 2

US-10-194-975-25
; Sequence 25, Application US/10194975
; Patent No. 6881557
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 98
; TYPE: PRT

```
; ORGANISM: Homo sapiens
US-10-194-975-25

Query Match      100.0%; Score 514; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.2e-47;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWRQAPGKGLEWVAVISYDGSNKYY 60
Db 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWRQAPGKGLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 3
US-09-534-717-650
; Sequence 650, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 650
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-534-717-650

Query Match      100.0%; Score 514; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.2e-47;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWRQAPGKGLEWVAVISYDGSNKYY 60
Db 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWRQAPGKGLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 4
US-09-534-717-641
; Sequence 641, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 641
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-534-717-641

Query Match      99.4%; Score 511; DB 2; Length 98;
Best Local Similarity 99.0%; Pred. No. 2.6e-47;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWRQAPGKGLEWVAVISYDGSNKYY 60
Db 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWRQAPGKGLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR 98

RESULT 5
US-09-534-717-642
; Sequence 642, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 642
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-534-717-642

Query Match      99.4%; Score 511; DB 2; Length 98;
Best Local Similarity 99.0%; Pred. No. 2.6e-47;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWRQAPGKGLEWVAVISYDGSNKYY 60
Db 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWRQAPGKGLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR 98

RESULT 6
US-09-534-717-643
; Sequence 643, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 643
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-534-717-643

Query Match      99.4%; Score 511; DB 2; Length 98;
Best Local Similarity 99.0%; Pred. No. 2.6e-47;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWRQAPGKGLEWVAVISYDGSNKYY 60
Db 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWRQAPGKGLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR 98
```



```

RESULT 7
US-09-534-717-644
; Sequence 644, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 644
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-534-717-644

Query Match          99.4%; Score 511; DB 2; Length 98;
Best Local Similarity 99.0%; Pred. No. 2.6e-47;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADETAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADETAVYYCAR 98

RESULT 8
US-09-534-717-646
; Sequence 646, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 646
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-534-717-646

Query Match          99.4%; Score 511; DB 2; Length 98;
Best Local Similarity 99.0%; Pred. No. 2.6e-47;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADETAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADETAVYYCAR 98

RESULT 9
US-09-534-717-654
; Sequence 654, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:

```

```

; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 654
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-534-717-654

Query Match          99.4%; Score 511; DB 2; Length 98;
Best Local Similarity 99.0%; Pred. No. 2.6e-47;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADETAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADETAVYYCAR 98

RESULT 10
US-10-330-613A-61
; Sequence 61, Application US/10330613A
; Patent No. 6924360
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; TITLE OF INVENTION: ANTIBODIES AGAINST THE MUC18 ANTIGEN
; FILE REFERENCE: ABGENIX.022A
; CURRENT APPLICATION NUMBER: US/10/330,613A
; CURRENT FILING DATE: 2002-12-26
; PRIOR APPLICATION NUMBER: 60/346299
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 61
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-330-613A-61

Query Match          99.4%; Score 511; DB 2; Length 98;
Best Local Similarity 99.0%; Pred. No. 2.6e-47;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADETAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADETAVYYCAR 98

RESULT 11
US-09-726-219A-167
; Sequence 167, Application US/09726219A
; Patent No. 6806079
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Medical Research Council
; APPLICANT: McCafferty, John
; APPLICANT: Pope, Anthony
; APPLICANT: Johnson, Kevin
; APPLICANT: Hoogenboom, Hendricus

```


TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-542-5070
TELEFAX: 617-542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 115:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-545-809A-115

Query Match 99.4%; Score 511; DB 2; Length 117;
Best Local Similarity 99.0%; Pred. No. 3.2e-47;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 20 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 79
QY 61 ADSVKGRFTISRDNKNTLYLQMSLRADDTAVYYCAK 98
DB 80 ADSVKGRFTISRDNKNTLYLQMSLRADDTAVYYCAR 117

RESULT 14
US-09-515-697-115
Sequence 115, Application US/09515697
Patent No. 6936705
GENERAL INFORMATION:
APPLICANT: Honjo, Tasuku
Matsuda, Fumihiro
TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
NUMBER OF SEQUENCES: 145
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson, P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/515,697
FILING DATE: 29-Feb-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/545,809
FILING DATE: 27-MAR-1996
APPLICATION NUMBER: PCT/JP93/00603
FILING DATE: 10-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Freeman, John W.
REGISTRATION NUMBER: 29,066
REFERENCE/DOCKET NUMBER: 06501/004001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-542-5070
TELEFAX: 617-542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 115:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 115:
US-09-515-697-115

Query Match 99.4%; Score 511; DB 2; Length 117;

Best Local Similarity 99.0%; Pred. No. 3.2e-47;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 20 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 79
QY 61 ADSVKGRFTISRDNKNTLYLQMSLRADDTAVYYCAK 98
DB 80 ADSVKGRFTISRDNKNTLYLQMSLRADDTAVYYCAR 117

RESULT 15
US-09-534-717-637
Sequence 637, Application US/09534717
Patent No. 6914128
GENERAL INFORMATION:
APPLICANT: Jochen, Salfeld et al.
TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
FILE REFERENCE: BBI-093CP
CURRENT APPLICATION NUMBER: US/09/534,717
CURRENT FILING DATE: 2000-03-24
EARLIER APPLICATION NUMBER: 60/126,603
EARLIER FILING DATE: March 25, 1999
NUMBER OF SEQ ID NOS: 675
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 637
LENGTH: 98
TYPE: PRT
ORGANISM: Homo sapiens
US-09-534-717-637

Query Match 98.8%; Score 508; DB 2; Length 98;
Best Local Similarity 99.0%; Pred. No. 5.5e-47;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQMSLRADDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQMSLRADDTAVYYCAR 98

Search completed: May 5, 2006, 08:56:24
Job time : 10.7652 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:57:52 ; Search time 7.42424 Seconds
(without alignments)
610.959 Million cell updates/sec

Title: US-09-674-752-35

Perfect score: 514

Sequence: 1 QVQLVESGGGVQPGKSLRL.....LYLQMSLRAEDTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications_AA_New:*
1: /SIDSS/ptodata/1/pubpaa/US08_NEW_PUB.pep1:*
2: /SIDSS/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
3: /SIDSS/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
4: /SIDSS/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
5: /SIDSS/ptodata/1/pubpaa/PTCT_NEW_PUB.pep:*
6: /SIDSS/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
7: /SIDSS/ptodata/1/pubpaa/US09_NEW_PUB.pep1:*
8: /SIDSS/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
9: /SIDSS/ptodata/1/pubpaa/US10_NEW_PUB.pep1:*
10: /SIDSS/ptodata/1/pubpaa/US11_NEW_PUB.pep:*
11: /SIDSS/ptodata/1/pubpaa/US11_NEW_PUB.pep1:*
12: /SIDSS/ptodata/1/pubpaa/US60_NEW_PUB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	514	100.0	98	11	US-11-054-669-23
2	514	100.0	98	11	US-11-054-669-25
3	511	99.4	98	11	US-11-084-554-34
4	511	99.4	98	11	US-11-136-250-34
5	511	99.4	117	9	US-10-771-257-18
6	511	99.4	117	9	US-10-771-257-89
7	511	99.4	117	9	US-11-127-677-18
8	511	99.4	252	11	US-11-054-515-1731
9	511	99.4	252	11	US-11-266-444-1731
10	510	99.2	249	11	US-11-054-515-512
11	510	99.2	249	11	US-11-266-444-512
12	508	98.8	123	9	US-10-982-440-21
13	508	98.8	247	11	US-11-054-515-1330
14	508	98.8	247	11	US-11-266-444-1330
15	508	98.8	252	11	US-11-054-515-1394
16	508	98.8	252	11	US-11-054-515-1519
17	508	98.8	252	11	US-11-054-515-1627
18	508	98.8	252	11	US-11-266-444-1394
19	508	98.8	252	11	US-11-266-444-1519
20	508	98.8	252	11	US-11-266-444-1627
21	507	98.6	249	11	US-11-054-515-1109

22	507	98.6	249	11	US-11-266-444-1109	Sequence 1109, Ap
23	505	98.2	98	11	US-11-054-669-24	Sequence 24, Appl
24	505	98.2	98	11	US-11-004-590-24	Sequence 24, Appl
25	505	98.2	98	11	US-11-004-590-25	Sequence 25, Appl
26	505	98.2	117	9	US-10-771-257-9	Sequence 9, Appl
27	505	98.2	117	9	US-10-771-257-82	Sequence 82, Appl
28	505	98.2	117	9	US-10-771-257-94	Sequence 94, Appl
29	505	98.2	117	11	US-11-127-677-9	Sequence 9, Appl
30	505	98.2	247	11	US-11-054-515-924	Sequence 924, App
31	505	98.2	247	11	US-11-266-444-924	Sequence 924, App
32	505	98.2	252	11	US-11-054-515-1201	Sequence 1201, Ap
33	505	98.2	252	11	US-11-266-444-1201	Sequence 1201, Ap
34	504	98.1	98	11	US-11-054-669-26	Sequence 26, Appl
35	504	98.1	98	11	US-11-084-554-35	Sequence 35, Appl
36	504	98.1	98	11	US-11-093-274-31	Sequence 31, Appl
37	504	98.1	98	11	US-11-004-590-26	Sequence 26, Appl
38	504	98.1	98	11	US-11-136-250-35	Sequence 35, Appl
39	504	98.1	117	9	US-10-956-008-18	Sequence 18, Appl
40	504	98.1	121	9	US-10-850-635-16	Sequence 16, Appl
41	504	98.1	451	11	US-11-128-900-70	Sequence 70, Appl
42	502	97.7	123	8	US-10-546-594-64	Sequence 64, Appl
43	502	97.7	123	8	US-10-546-594-66	Sequence 66, Appl
44	502	97.7	123	8	US-10-546-594-70	Sequence 70, Appl
45	502	97.7	238	11	US-11-054-515-1931	Sequence 1931, Ap

ALIGNMENTS

RESULT 1
US-11-054-669-23
; Sequence 23, Application US/11054669
; Publication No. US20050261480A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES
; FILE REFERENCE: 30219/US/3
; CURRENT APPLICATION NUMBER: US/11/054,669
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: US 10/194,975
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 23
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-669-23

Query Match 100.0%; Score 514; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.5e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTTSSYGMHWROAPGKGLEWAVISYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTTSSYGMHWROAPGKGLEWAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNSKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNSKNTLYLQMSLRAEDTAVYYCAK 98

RESULT 2
US-11-054-669-25
; Sequence 25, Application US/11054669
; Publication No. US20050261480A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES
; FILE REFERENCE: 30219/US/3
; CURRENT APPLICATION NUMBER: US/11/054,669

```

; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: US 10/194,975
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 25
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-669-25

Query Match          100.0%; Score 514; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 3.5e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGVVQPGSRSLRSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGVVQPGSRSLRSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
DB 61 ADSVKGRTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 3
US-11-084-554-34
; Sequence 34, Application US/11084554
; Publication No. US20050260679A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A
; CURRENT APPLICATION NUMBER: US/11/084,554
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 34
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-084-554-34

Query Match          99.4%; Score 511; DB 11; Length 98;
Best Local Similarity 99.0%; Pred. No. 6.3e-37;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGVVQPGSRSLRSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGVVQPGSRSLRSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
DB 61 ADSVKGRTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 4
US-11-136-250-34
; Sequence 34, Application US/11136250
; Publication No. US20060021074A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A2
; CURRENT APPLICATION NUMBER: US/11/136,250
; CURRENT FILING DATE: 2005-05-23
; PRIOR APPLICATION NUMBER: 11/084,554
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: PCT/US2005/009306
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 34
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-136-250-34

Query Match          99.4%; Score 511; DB 11; Length 98;
Best Local Similarity 99.0%; Pred. No. 6.3e-37;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGVVQPGSRSLRSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGVVQPGSRSLRSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
DB 61 ADSVKGRTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 5
US-10-771-257-18
; Sequence 18, Application US/10771257
; Publication No. US2005028864A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: SISSA - Scuola Superiore Internazionale di Studi Avanzati
; APPLICANT: Cattaneo, Antonino
; APPLICANT: Maritan, Amos
; APPLICANT: Visintin, Michela
; APPLICANT: Rabbitts, Terrence H
; APPLICANT: Settanni, Giovanni
; TITLE OF INVENTION: Intracellular antibodies
; FILE REFERENCE: 18396/2272
; CURRENT APPLICATION NUMBER: US/10/771,257
; CURRENT FILING DATE: 2004-02-03
; PRIOR APPLICATION NUMBER: PCT/GB02/03512
; PRIOR FILING DATE: 2002-08-01
; PRIOR APPLICATION NUMBER: GB 0119004.0
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: GB 0121577.1
; PRIOR FILING DATE: 2001-09-06
; PRIOR APPLICATION NUMBER: GB 0200928.0
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: GB 0203569.9
; PRIOR FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: IT RM2001A000633
; PRIOR FILING DATE: 2001-10-25
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-771-257-18

Query Match          99.4%; Score 511; DB 9; Length 117;
Best Local Similarity 99.0%; Pred. No. 7.3e-37;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 QVQVSEGGVQVQGRSLRLSCAASGFTFSSYGMHVRQAPGKLEWVAVISYDGSNKYY 60
Db 1 QVQVSEGGVQVQGRSLRLSCAASGFTFSSYGMHVRQAPGKLEWVAVISYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVYYCAK 98

RESULT 6

US-10-771-257-89
; Sequence 89, Application US/10771257
; Publication No. US20050288864A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: SISSA - Scuola Superiore Internazionale di Studi Avanzati
; APPLICANT: Cattaneo, Amos
; APPLICANT: Maritan, Amos
; APPLICANT: Visintin, Michela
; APPLICANT: Rabbitts, Terrence H
; APPLICANT: Settanni, Giovanni
; TITLE OF INVENTION: Intracellular antibodies
; FILE REFERENCE: 18396/2272
; CURRENT APPLICATION NUMBER: US/10/771,257
; CURRENT FILING DATE: 2004-02-03
; PRIOR APPLICATION NUMBER: PCT/GB02/03512
; PRIOR FILING DATE: 2002-08-01
; PRIOR APPLICATION NUMBER: GB 0119004.0
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: GB 0121577.1
; PRIOR FILING DATE: 2001-09-06
; PRIOR APPLICATION NUMBER: GB 0200928.0
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: GB 0203569.9
; PRIOR FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: IT RM2001A000633
; PRIOR FILING DATE: 2001-10-25
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 89
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-771-257-89

Query Match 99.4%; Score 511; DB 9; Length 117;
Best Local Similarity 99.0%; Pred. No. 7.3e-37;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQVSEGGVQVQGRSLRLSCAASGFTFSSYGMHVRQAPGKLEWVAVISYDGSNKYY 60
Db 1 QVQVSEGGVQVQGRSLRLSCAASGFTFSSYGMHVRQAPGKLEWVAVISYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVYYCAK 98

RESULT 7

US-11-127-677-18
; Sequence 18, Application US/11127677
; Publication No. US20050272107A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: Rabbitts, Terence H
; APPLICANT: Tanaka, Tomoyuki
; TITLE OF INVENTION: Intracellular antibodies
; FILE REFERENCE: 18396/2462
; CURRENT APPLICATION NUMBER: US/11/127,677
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: PCT/GB03/04942
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: GB 0226729.2

; PRIOR FILING DATE: 2002-11-15
; NUMBER OF SEQ ID NOS: 150
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Derived protein sequence of scFv
US-11-127-677-18

Query Match 99.4%; Score 511; DB 11; Length 117;
Best Local Similarity 99.0%; Pred. No. 7.3e-37;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQVSEGGVQVQGRSLRLSCAASGFTFSSYGMHVRQAPGKLEWVAVISYDGSNKYY 60
Db 1 QVQVSEGGVQVQGRSLRLSCAASGFTFSSYGMHVRQAPGKLEWVAVISYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVYYCAK 98

RESULT 8

US-11-054-515-1731
; Sequence 1731, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1731
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1731

Query Match 99.4%; Score 511; DB 11; Length 252;
Best Local Similarity 99.0%; Pred. No. 1.4e-36;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQVSEGGVQVQGRSLRLSCAASGFTFSSYGMHVRQAPGKLEWVAVISYDGSNKYY 60
Db 1 QVQVSEGGVQVQGRSLRLSCAASGFTFSSYGMHVRQAPGKLEWVAVISYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVYYCAK 98

```
RESULT 9
US-11-266-444-1731
; Sequence 512, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1731
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1731

Query Match          99.4%; Score 511; DB 11; Length 252;
Best Local Similarity 99.0%; Pred. No. 1.4e-36;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGVVQPGKSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGVVQPGKSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 10
US-11-054-515-512
; Sequence 512, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16

Query Match          99.4%; Score 511; DB 11; Length 252;
Best Local Similarity 99.0%; Pred. No. 1.4e-36;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGVVQPGKSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGVVQPGKSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 11
US-11-266-444-512
; Sequence 512, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 512
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-512

Query Match          99.2%; Score 510; DB 11; Length 249;
Best Local Similarity 99.0%; Pred. No. 1.7e-36;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLVESGGVVQPGKSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGVVQPGKSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 12
US-10-982-440-21
; Sequence 21, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
```

```
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 512
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-512

Query Match          99.2%; Score 510; DB 11; Length 249;
Best Local Similarity 99.0%; Pred. No. 1.7e-36;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLVESGGVVQPGKSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGVVQPGKSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 11
US-11-266-444-512
; Sequence 512, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 512
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-512

Query Match          99.2%; Score 510; DB 11; Length 249;
Best Local Similarity 99.0%; Pred. No. 1.7e-36;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLVESGGVVQPGKSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGVVQPGKSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 12
US-10-982-440-21
; Sequence 21, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
```



```
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1394
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1394

Query Match      98.8%; Score 508; DB 11; Length 252;
Best Local Similarity 98.0%; Pred. No. 2.6e-36;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVESGGGVQPGRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60
      :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      1 EVQLVQSGGGVQPGRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60

QY      61 ADSVKGRFTISRDN SKNTLYLQMN SLRAEDTAVYYCAK 98
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      61 ADSVKGRFTISRDN SKNTLYLQMN SLRAEDTAVYYCAK 98

Search completed: May 5, 2006, 09:02:44
Job time : 8.42424 secs
```

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:51:41 ; Search time 6.43434 Seconds
(without alignments)
1465.455 Million cell updates/sec

Title: US-09-674-752-35

Perfect score: 514

Sequence: 1 QVQLVSGGGVQPGKSLRL.....LYLQMSLRAEDTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR_80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	514	100.0	98	2	PL0116
2	514	100.0	122	2	S31119
3	511	99.4	121	2	S19666
4	510	99.2	132	2	S31603
5	509	99.0	118	2	S31116
6	505	98.2	98	2	S29546
7	505	98.2	119	2	F36005
8	505	98.2	121	2	G36005
9	505	98.2	122	2	E36005
10	505	98.2	134	2	S31679
11	505	98.2	139	2	S31674
12	504	98.1	119	2	S31111
13	504	98.1	122	2	S31117
14	504	98.1	128	2	S48797
15	504	98.1	130	2	PL0098
16	503	97.9	120	2	S31112
17	502	97.7	113	2	S38490
18	502	97.7	114	2	S46390
19	497	96.7	98	2	S29543
20	497	96.7	133	2	A49028
21	497	96.7	134	2	S31688
22	497	96.7	135	2	S31598
23	495	96.3	97	2	S44115
24	495	96.3	130	2	S31601
25	495	96.3	137	2	S31701
26	493	95.9	114	2	S46392
27	493	95.9	123	2	S38493
28	491	95.5	140	2	S70442
29	483	94.0	94	2	PL0120

ALIGNMENTS

RESULT 1

PL0116

Ig heavy chain V-III region (AW-Vx) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 07-Jun-1990 #sequence_revision 07-Jun-1990 #text_change 23-Jul-1999

C;Accession: PL0116; S26892

R;Bird, J.; Galli, N.; Link, M.; Stites, D.; Sklar, J.

J. Exp. Med. 168, 229-245, 1988

A;Title: Continuing rearrangement but absence of somatic hypermutation in immunoglobulin

A;Reference number: PL0116; PMID:88286083; PMID:2840480

A;Accession: PL0116

A;Molecule type: mRNA

A;Residues: 1-98 <BIR>

A;Cross-references: UNIPARC:UPI000031P3A

A;Experimental source: B cells from patient AW with acute lymphoblastic leukemia, ALL

A;Note: the sequence shows the V region (AW-Vx) from a nonproductive DNA rearrangement f

R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.

J. Mol. Biol. 227, 776-798, 1992

A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V

A;Reference number: S26895; PMID:93021117; PMID:1404388

A;Accession: S26892

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-98 <TOM>

A;Cross-references: UNIPARC:UPI000031P3A; EMBL:Z12349; NID:G32918; PIDN:CAA78219.1; PID

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: acute lymphoblastic leukemia; heterotetramer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

F;31-35/Region: complementarity-determining 1

F;49-65/Region: complementarity-determining 2

Query Match 100.0%; Score 514; DB 2; Length 98;

Best Local Similarity 100.0%; Pred. No. 2.2e-42;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVSGGGVQPGKSLRLSCAASGFTSSYCMHWVRQAPGKLEWAVISYDGSNKYY 60

Db 1 QVQLVSGGGVQPGKSLRLSCAASGFTSSYCMHWVRQAPGKLEWAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98

Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98

RESULT 2

S31119

Ig heavy chain - human

C;Species: Homo sapiens (man)

C;Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 31-Dec-2004

C;Accession: S31119

R;Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman

Eur. J. Immunol. 22, 247-251, 1992

A>Title: Restricted utilization of germ-line V(H)3 genes and short diverse third complement
A:Reference number: S31104; MUID:92111633; PMID:1730252
A:Accession: S3119
A>Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: mRNA
A:Residues: 1-122 <RAA>
A:Cross-references: UNIPROT:Q8WUK1; UNIPARC:UPI0000176C8F; EMBL:X62970
A>Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C:Superfamily: immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 514; DB 2; Length 122;
Best Local Similarity 100.0%; Pred. No. 2.8e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCAK 98

RESULT 3
S19666
Ig heavy chain V region (VH3DJH4) - human
C:Species: Homo sapiens (man)
C>Date: 22-Jan-1993 #sequence_revision 22-Jan-1993 #text_change 20-Jun-2000
C:Accession: S19666
R:Marka, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, J. Mol. Biol. 222, 581-597, 1991
A>Title: By-passing immunization. Human antibodies from V-gene libraries displayed on phage
A:Reference number: S19663; MUID:92085276; PMID:1748994
A:Accession: S19666
A:Molecule type: mRNA
A:Residues: 1-121 <RAR>
A:Cross-references: UNIPARC:UPI0000115F85; EMBL:X61646; NID:g37688; PIDN:CAA43827.1; PIDN:CAA43827.1; PIDN:CAA43827.1
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 99.4%; Score 511; DB 2; Length 121;
Best Local Similarity 99.0%; Pred. No. 5.3e-42;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCAK 98

RESULT 4
S31603
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 03-Mar-1994 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31603
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelie, C.
submitted to the EMBL Data Library, June 1992
A>Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31603
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-132 <CUI>
A:Cross-references: UNIPARC:UPI0000116455; EMBL:Z14168; NID:g30999; PIDN:CAA78537.1; PIDN:CAA78537.1; PIDN:CAA78537.1
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

F:30-113/Domain: immunoglobulin homology <IMM>

Query Match 99.2%; Score 510; DB 2; Length 132;
Best Local Similarity 99.0%; Pred. No. 7.2e-42;
Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLWVAIVSYDGSNKYY 60
DB 16 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLWVAIVSYDGSNKYY 75

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCAK 98
DB 76 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCAK 113

RESULT 5
S31116
Ig heavy chain - human
C:Species: Homo sapiens (man)
C>Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 31-Dec-2004
C:Accession: S31116
R:Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman, Eur. J. Immunol. 22, 247-251, 1992
A>Title: Restricted utilization of germ-line V(H)3 genes and short diverse third complement
A:Reference number: S31104; MUID:92111633; PMID:1730252
A:Accession: S31116
A>Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: mRNA
A:Residues: 1-118 <RAA>
A:Cross-references: UNIPROT:Q8WUK1; UNIPARC:UPI0000176E37; EMBL:X62966
A>Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C:Superfamily: immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 99.0%; Score 509; DB 2; Length 118;
Best Local Similarity 100.0%; Pred. No. 8.1e-42;
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCA 97
DB 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCA 97

RESULT 6
S29546
Ig heavy chain V region (COS-8 / DP-46) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 07-Jan-1994 #sequence_revision 17-Nov-1995 #text_change 23-Jul-1999
C:Accession: S29546; S26888
R:Tominson, M.; Walter, G.; Cook, G.P.; Winter, G.
submitted to the EMBL Data Library, October 1992
A:Reference number: S29543
A:Accession: S29546
A:Molecule type: DNA
A:Residues: 1-98 <TOM>
A:Cross-references: UNIPARC:UPI000002DD16; EMBL:Z17394; NID:g32843; PIDN:CAA78997.1; PIDN:CAA78997.1; PIDN:CAA78997.1
A>Note: designated COS-8
R:Tominson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A>Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A:Reference number: S26885; MUID:93021117; PMID:1404388
A:Accession: S26888
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-98 <TO2>
A:Cross-references: UNIPARC:UPI000002DD16; EMBL:Z12346; NID:g32912; PIDN:CAA78216.1; PIDN:CAA78216.1; PIDN:CAA78216.1
A>Note: designated DP-46
C:Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.2%; Score 505; DB 2; Length 98;
Best Local Similarity 98.0%; Pred. No. 1.6e-41;
Matches 96; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAR 98

RESULT 7
F36005
IG heavy chain V region (M49) - human
C;Species: Homo sapiens (man)
C;Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 31-Dec-2004
C;Accession: F36005
R;Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A;Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A;Reference number: A36005; MUID:90349571; PMID:2117273
A;Accession: F36005
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-119 <SCH>
A;Cross-references: UNIPROT:Q8WUK1; UNIPARC:UPI0000176C32; GB:M34026
C;Genetics:
A;Gene: GDB:IGH@; IGHDI1
A;Cross-references: GDB:118731; OMIM:146910
A;Map position: 14q32.33-14q32.33
C;Superfamily: immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.2%; Score 505; DB 2; Length 119;
Best Local Similarity 98.0%; Pred. No. 2e-41;
Matches 96; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAR 98

RESULT 8
G36005
IG heavy chain V region (M74) - human
C;Species: Homo sapiens (man)
C;Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 31-Dec-2004
C;Accession: G36005
R;Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A;Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A;Reference number: A36005; MUID:90349571; PMID:2117273
A;Accession: G36005
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-121 <SCH>
A;Cross-references: UNIPROT:Q8WUK1; UNIPARC:UPI0000176C2C; GB:M34031
C;Genetics:
A;Gene: GDB:IGH@; IGHDI1
A;Cross-references: GDB:118731; OMIM:146910
A;Map position: 14q32.33-14q32.33
C;Superfamily: immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.2%; Score 505; DB 2; Length 121;
Best Local Similarity 98.0%; Pred. No. 2e-41;
Matches 96; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAR 98

RESULT 9
E36005
IG heavy chain V region (M72) - human
C;Species: Homo sapiens (man)
C;Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998
C;Accession: E36005
R;Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A;Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A;Reference number: A36005; MUID:90349571; PMID:2117273
A;Accession: E36005
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-122 <SCH>
A;Cross-references: UNIPARC:UPI0000176C30; GB:M34030
C;Genetics:
A;Gene: GDB:IGH@; IGHDI1
A;Cross-references: GDB:118731; OMIM:146910
A;Map position: 14q32.33-14q32.33
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.2%; Score 505; DB 2; Length 122;
Best Local Similarity 98.0%; Pred. No. 2e-41;
Matches 96; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAR 98

RESULT 10
S31679
IG heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S31679
R;Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A;Description: Mechanisms that generate human immunoglobulin diversity operate from the
A;Reference number: S31585
A;Accession: S31679
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-134 <CUI>
A;Cross-references: UNIPARC:UPI000116475; EMBL:Z14203; NID:g30965; PIDN:CAA78572.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;34-117/Domain: immunoglobulin homology <IMM>

Query Match 98.2%; Score 505; DB 2; Length 134;
Best Local Similarity 98.0%; Pred. No. 2.2e-41;
Matches 96; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGSRSLRSLCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
 Db 20 QVQLVESGGGVQPGSRSLRSLCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 79
 QY 61 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAVYYCAK 98
 Db 80 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAVYYCAR 117

RESULT 11

S31674
 Ig heavy chain V region - human (fragment)
 C:Species: Homo sapiens (man)
 C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
 C:Accession: S31674
 R:Cuatrecasas, A.M.; Gauthier, L.; Boublil, L.; Fougereau, M.; Tonnellet, C.
 A:Submitted to the EMBL Data Library, June 1992
 A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
 A:Reference number: S31585
 A:Accession: S31674
 A>Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-139 <CUI>
 A:Cross-references: UNIPARC:UPI0000116476; EMBL:Z14204; NID:G30967; PIDN:CAA78573.1; PID
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:134-117/Domain: immunoglobulin homology <IMM>

Query Match 98.2%; Score 505; DB 2; Length 139;
 Best Local Similarity 99.0%; Pred. No. 2.3e-41;
 Matches 97; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 QVQLVESGGGVQPGSRSLRSLCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
 Db 20 QVQLVESGGGVQPGSRSLRSLCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 79
 QY 61 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAVYYCAK 98
 Db 80 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAVYYCAR 117

RESULT 12

S31111
 Ig heavy chain - human
 C:Species: Homo sapiens (man)
 C>Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
 C:Accession: S31111
 R:Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
 Eur. J. Immunol. 22, 247-251, 1992
 A>Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
 A:Reference number: S31104; MUID:92111633; PMID:1730252
 A:Accession: S31111
 A>Status: preliminary; nucleic acid sequence not shown; translation not shown
 A:Molecule type: mRNA
 A:Residues: 1-119 <RAA>
 A:Cross-references: UNIPARC:UPI0000176DC2; EMBL:X62959
 A>Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.1%; Score 504; DB 2; Length 119;
 Best Local Similarity 98.0%; Pred. No. 2.4e-41;
 Matches 96; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1 QVQLVESGGGVQPGSRSLRSLCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
 Db 1 QVQLVESGGGVQPGSRSLRSLCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAVYYCAR 98

RESULT 13

S31117
 Ig heavy chain - human
 C:Species: Homo sapiens (man)
 C>Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
 C:Accession: S31117
 R:Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman,
 Eur. J. Immunol. 22, 247-251, 1992
 A>Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
 A:Reference number: S31104; MUID:92111633; PMID:1730252
 A:Accession: S31117
 A>Status: preliminary; nucleic acid sequence not shown; translation not shown
 A:Molecule type: mRNA
 A:Residues: 1-122 <RAA>
 A:Cross-references: UNIPARC:UPI0000176C8D; EMBL:X62967
 A>Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.1%; Score 504; DB 2; Length 122;
 Best Local Similarity 98.0%; Pred. No. 2.5e-41;
 Matches 96; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1 QVQLVESGGGVQPGSRSLRSLCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
 Db 1 QVQLVESGGGVQPGSRSLRSLCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAVYYCAR 98

RESULT 14

S48797
 Ig heavy chain V region (anti-Sm, VH3/Dxp4/JH6) - human (fragment)
 C:Species: Homo sapiens (man)
 C>Date: 13-Jan-1995 #sequence_revision 13-Sep-1998 #text_change 23-Jul-1999
 C:Accession: S48797; S26893
 R:Mahmoudi, M.; Edwards, J.; Cairns, E.; Bell, D.
 submitted to the EMBL Data Library, October 1994
 A:Description: Molecular characterization of natural human anti-Sm autoantibodies.
 A:Reference number: S48797
 A:Accession: S48797
 A:Molecule type: mRNA
 A:Residues: 1-128 <MAH>
 A:Cross-references: UNIPARC:UPI00000116700; EMBL:Z46379; NID:G587147; PIDN:CAA86512.1; PII
 R:Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
 J. Mol. Biol. 227, 776-798, 1992
 A>Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
 A:Reference number: S26885; MUID:93021117; PMID:1404388
 A:Accession: S26893
 A:Molecule type: DNA
 A:Residues: 1-98 <TOM>
 A:Cross-references: UNIPARC:UPI0000038183; EMBL:Z12350; NID:G32922; PIDN:CAA78220.1; PID:
 C:Superfamily: immunoglobulin V region; immunoglobulin homology
 C:Keywords: heterotetramer; immunoglobulin
 F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 98.1%; Score 504; DB 2; Length 128;
 Best Local Similarity 98.0%; Pred. No. 2.6e-41;
 Matches 96; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1 QVQLVESGGGVQPGSRSLRSLCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
 Db 1 QVQLVESGGGVQPGSRSLRSLCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAVYYCAK 98
 Db 61 ADSVKGRFTISRDNKNTLYLQNNSLRAEDTAVYYCAR 98

Search completed: May 5, 2006, 08:54:48
Job time : 6.43434 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 02:15:59 ; Search time 118.333 Seconds
(without alignments)
363.880 Million cell updates/sec

Title: US-09-674-752-35

Perfect score: 514

Sequence: 1 QVQLVSGGCVQPGKSLRL.....LYLQMNSLRADTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21.*

- 1: Geneseqp1980s.*
- 2: Geneseqp1990s.*
- 3: Geneseqp2000s.*
- 4: Geneseqp2001s.*
- 5: Geneseqp2002s.*
- 6: Geneseqp2003as.*
- 7: Geneseqp2003bs.*
- 8: Geneseqp2004s.*
- 9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	514	100.0	98	3	AAY50962 Human FVI
2	514	100.0	98	3	Aab40124 Anti-hiL1
3	514	100.0	98	5	ABG78205 Human Fv
4	514	100.0	98	5	ABG91896 Human ant
5	514	100.0	98	6	ABO27090 Human ger
6	514	100.0	98	6	ABO27092 Human ger
7	514	100.0	98	7	ADD28059 Lymphoma
8	514	100.0	98	7	ADJ80305 VH gene 1
9	514	100.0	98	7	ADJ80303 VH gene 1
10	514	100.0	98	9	ADY75310 Protein e
11	514	100.0	98	9	ADY75308 Protein e
12	514	100.0	109	9	ADW96628 Human ger
13	514	100.0	109	9	ADW96625 Human ger
14	514	100.0	109	9	ADW80197 Human ant
15	514	100.0	109	9	ADW80200 Human ant
16	514	100.0	123	2	AAW15534 Anti-TGF
17	514	100.0	223	2	AAW15534 Anti-huma
18	511	99.4	98	3	Aab40116 Anti-hiL1
19	511	99.4	98	3	Aab40118 Anti-hiL1
20	511	99.4	98	3	AAB40115 Anti-hiL1
21	511	99.4	98	3	AAB40120 Anti-hiL1
22	511	99.4	98	3	AAB40117 Anti-hiL1
23	511	99.4	98	3	AAB40128 Anti-hiL1
24	511	99.4	98	7	ADC99832 Germline

25	511	99.4	98	7	ADD05436	Anti-MUC1
26	511	99.4	98	7	ADF09874	Anti-MUC1
27	511	99.4	109	8	ADP22381	Human ant
28	511	99.4	109	8	ADP22364	Human ant
29	511	99.4	115	2	AAR22571	Heavy Cha
30	511	99.4	117	2	AAR66321	Human imm
31	511	99.4	117	8	ADO36354	Intracell
32	511	99.4	119	7	ADL91327	VH chain
33	511	99.4	121	7	ADP03962	Murine-ex
34	511	99.4	122	8	ADP22128	Human ant
35	511	99.4	122	9	AEB45960	Human mon
36	511	99.4	223	8	ADL70773	Anti-TNPa
37	511	99.4	252	5	ABP45720	Human Bly
38	511	99.4	252	7	ADG96547	Single ch
39	511	99.4	583	8	ABM82698	Human dia
40	510	99.2	123	8	ADS84396	Human ant
41	510	99.2	123	8	ADR68538	Anti-EPO-
42	510	99.2	249	5	ABP44501	Human Bly
43	510	99.2	249	7	ADG95328	Single ch
44	508	98.8	98	3	AAB40111	Anti-hiL1
45	508	98.8	120	6	ADA89174	Human ant

ALIGNMENTS

RESULT 1

AAY50962

ID AAY50962 standard; protein; 98 AA.

AC AAY50962;

DT 23-MAR-2000 (first entry)

DE Human FVIII antibody A3-C1 scFv heavy chain protein DP-49.

XX Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

KW scFv; A3-C1.

XX Homo sapiens.

XX WO9958680-A2.

XX 18-NOV-1999.

XX 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

PI Voorberg JJ, Van Den Brink EN, Turenhout EM;

XX WPI; 2000-053102/04.

PT New polynucleotide, polypeptide and antibody useful for diagnosing the presence of neutralizing antibodies against factor VIII and for treatment of hemophilia A patients with these antibodies.

XX Example 8; Fig 9A; 61pp; English.

XX This invention describes a novel polynucleotide (I) (and complements and hybridizable polynucleotides) comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity which has hemostatic activity. (I) is useful as a primer or probe for detecting the presence of inhibitory antibodies directed against factor VIII. The polypeptides of the invention and the antibodies generated from them are useful in competitions for neutralizing factor VIII inhibiting antibodies in hemophilia A patients. This sequence represents the human factor VIII antibody A3-C1 specific scFv protein DP-49 which is used in the method of the invention

SQ Sequence 98 AA;

```

Query Match      100.0%; Score 514; DB 3; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.4e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 98

RESULT 2
AAB40124
ID AAB40124 standard; protein; 98 AA.
AC AAB40124;
XX
DT 05-FEB-2001 (first entry)
DE Anti-hIL12 antibody H chain V region amino acid sequence SEQ ID 650.
XX
KW Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
KW complementarity determining region; CDR; antirheumatic; antiarthritic;
KW antisclerotic; neuroprotective; antiparasitic; antiasthmatic; cardiant;
KW antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
KW multiple sclerosis; rheumatoid arthritis.
XX
OS Homo sapiens.
XX
PN WO200056772-A1.
XX
PD 28-SRP-2000.
XX
PF 24-MAR-2000; 2000WO-US007946.
XX
PR 25-MAR-1999; 99US-0126603P.
XX
PA (BADI ) BASF AG.
XX
PA (GEMY ) GENETICS INST INC.
XX
PI Salfeld JG, Roguska M, Paekind M, Banerjee S, Tracey DE, White M;
PI Kaymakcalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;
PI Veldman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
PI Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL;
XX
DR WPI; 2000-638250/61.
XX
PT New human antibody specific for human interleukin-12 (IL-12) used to
PT treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
PT disease and multiple sclerosis.
XX
PS Claim 75; Page 122; 377pp; English.
XX
CC This invention relates to a new human antibody specific for human
CC interleukin-12 (IL-12). The invention also includes antigen binding
CC portions that bind to IL-12. Sequences AAB39485-B39516 represent human
CC anti-IL-12 antibody heavy and light chain complementarity determining
CC region (CDR) amino acid sequences, and also includes variable region
CC amino acid sequences. Other variable region amino acid sequences are
CC given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
CC represent anti-IL-12 CDR3 related amino acid sequences, AAB39772-B40063
CC represent other CDR sequences. Light chain CDR3 consensus sequences are
CC given in AAB40064-B40067. Primers used in the identification and
CC construction of the antibodies of the invention are given in AAC61062-
CC C61071. The antibody of the invention is a neutralising antibody and has
CC antirheumatic; antiarthritic; antisclerotic; antiinflammatory;
CC neuroprotective; antiparasitic; antiasthmatic; cardiant; antiparasitic;
CC antibacterial and immunosuppressive activity. The antibodies or antigen-
CC binding fragments are useful in the treatment of disorders associated
CC with detrimental release of human IL-12, especially Crohn's disease,
XX
CC multiple sclerosis and rheumatoid arthritis. They can also be used in the
CC manufacture of a pharmaceutical composition to treat human IL-12
CC disorders
XX
SQ Sequence 98 AA;
Query Match      100.0%; Score 514; DB 3; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.4e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 98

RESULT 3
ABG78205
ID ABG78205 standard; protein; 98 AA.
XX
AC ABG78205;
XX
DT 15-NOV-2002 (first entry)
DE Human Fv molecule hypervariable region related peptide #80.
XX
KW Human; Fv molecule; hypervariable region; single chain Fv; cytostatic;
KW disulfide Fv; dsFv; scFv; cancer; carcinoma; sarcoma; leukaemia; adenoma;
KW lymphoma; myeloma; blastoma; seminoma; melanoma; acute myeloid leukaemia.
XX
OS Homo sapiens.
XX
PN WO200259264-A2.
XX
PD 01-AUG-2002.
XX
PF 31-DEC-2001; 2001WO-US049440.
XX
PR 29-DEC-2000; 2000US-00751181.
XX
PA (BIOT-) BIO-TECHNOLOGY GEN CORP.
XX
PI Hagai Y, Lazarovits J, Guy R, Lipschitz O, Szanton E, Levanon A;
PI Plakain D, Peretz T;
XX
DR WPI; 2002-619166/66.
XX
PT Novel peptide/polypeptide for cancer therapy has Fv molecule, construct
PT or fragment, or construct of fragment with enhanced binding
PT characteristics so as to selectively bind target cell in favor of other
PT cells.
XX
PS Claim 13; Page 188-189; 232pp; English.
XX
CC The invention relates to a peptide or polypeptide comprising an Fv
CC molecule, a construct or fragments or a construct of a fragment with
CC enhanced binding characteristics which selectively and/or specifically
CC binds to a target cell in favour of other cells, where binding is
CC primarily determined by a first hypervariable region and Fv is a single
CC chain Fv (scFv) or a disulfide Fv (dsFv). The peptide, optionally in
CC association with or attached, coupled, combined, linked or fused to a
CC pharmaceutical agent, is useful in the manufacture of a medicament, where
CC the medicament has activity against a diseased cell, preferably a cancer
CC cell (selected from carcinoma, sarcoma, leukaemia, adenoma, lymphoma,
CC myeloma, blastoma, seminoma, and melanoma, where the leukaemia cell is an
CC acute myeloid leukaemia cell). The peptide is also useful for preparing a
CC composition for use in inhibiting the growth of a diseased or cancer
CC cell. This sequence represents a human Fv molecule hypervariable region
CC related peptide of the invention
XX

```

SQ Sequence 98 AA;

Query Match 100.0%; Score 514; DB 5; Length 98;
 Best Local Similarity 100.0%; Pred. No. 2.4e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSDGSKYY 60
 DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSDGSKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 4
 ABG91896
 ID ABG91896 standard; protein; 98 AA.
 AC ABG91896;
 XX
 XX
 XX 04-DEC-2002 (first entry)
 XX Human antibody fragment #80.
 XX
 XX Human; antibody; epitope; cancer; tumour; cell rolling; inflammation;
 KW metastasis; hypervariable region; autoimmune disease; thrombosis;
 KW reutenosis; leukaemia; inflammatory disease; cardiovascular disease;
 KW myocardial infarction; retinopathic disease; abnormal platelet function;
 KW sulphated tyrosine-dependent protein-protein interaction.
 XX
 XX Homo sapiens.
 OS
 XX
 XX W0200253700-A2.
 PN
 XX
 XX 11-JUL-2002.
 PD
 XX
 XX 31-DEC-2001; 2001WO-US049442.
 XX
 XX 29-DEC-2000; 2000US-00751181.
 PR 29-DEC-2000; 2000US-0258948P.
 XX
 XX (BIOT-) BIO-TECHNOLOGY GEN CORP.
 PA
 XX
 XX Lazarovits J, Hagai Y, Plaksin D, Vogel T, Nimrod A, Mar-Haim H;
 PI Szanton E, Richter T, Amit B, Kooperman L, Peretz T, Levanon A;
 XX
 XX WPI; 2002-674776/72.
 DR
 XX
 XX Novel isolated epitope present on cancer cells and important in
 PT physiological phenomena such as cell rolling, metastasis and
 PT inflammation, for treating autoimmune, inflammatory or cardiovascular
 PT diseases, and cancer.
 XX
 XX Disclosure; Page 265; Opp; English.

The invention relates to an isolated epitope present on cancer cells and
 important in physiological phenomena such as cell rolling, metastasis and
 inflammation, where the epitope is capable of being bound by an antibody,
 its antigen-binding fragment or its complex comprising at least one
 antibody or its binding fragment having a first hypervariable region. The
 epitopes are useful for inhibiting cell rolling, inflammation, autoimmune
 disease, thrombosis, restenosis, metastasis, growth and/or replication of
 tumour or leukaemia cells, increase in number of tumour or leukaemia
 cells in a patient, cell-cell, cell-matrix, platelet-matrix, platelet-
 platelet and/or cell-platelet adhesion or aggregation, for increasing
 mortality of tumour or leukaemia cells, for increasing the susceptibility
 of diseased cells to damage by anti-disease, anti-cancer or anti-
 leukaemia agents, or for decreasing the number of tumour or leukaemia
 cells in a patient, or in the manufacture of a medicament for the above
 mentioned purposes. The epitopes are useful for diagnosing and treating
 diseases such as cancer, leukaemia, autoimmune diseases, inflammatory
 diseases, cardiovascular diseases such as myocardial infarction,

CC retinopathic diseases and other diseases mediated by abnormal platelet
 CC function and diseases caused by sulphated tyrosine-dependent protein-
 CC protein interactions. This sequence represents a human antibody fragment
 CC of the invention
 XX
 SQ Sequence 98 AA;

Query Match 100.0%; Score 514; DB 5; Length 98;
 Best Local Similarity 100.0%; Pred. No. 2.4e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSDGSKYY 60
 DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSDGSKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 5
 ABO27090
 ID ABO27090 standard; protein; 98 AA.
 XX
 AC ABO27090;
 XX
 XX 10-SEP-2003 (first entry)
 DT
 XX Human germline heavy chain variable region gene segment #23.
 DE
 XX Human; heavy chain variable region; VH; humanised antibody;
 KW chimeric antibody; complementarity determining region; CDR;
 KW canonical CDR structure type.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US2003039649-A1.
 PN
 XX
 XX 27-FEB-2003.
 PD
 XX
 XX 12-JUL-2002; 2002US-00194975.
 PF
 XX
 XX 12-JUL-2001; 2001US-0305111P.
 PR
 XX
 XX (FOOT/) FOOTE J.
 PA
 XX
 XX Foote J;
 PI
 XX
 XX WPI; 2003-492151/46.
 DR
 XX
 XX Making humanized antibody for converting antibody, by making chimeric
 PT antibodies containing complementarity determining region from non-human
 PT antibody and appropriate framework sequences of human antibodies.
 XX
 XX Example 1; Fig 1; 31pp; English.

The invention describes a method of making a humanised antibody,
 comprising making chimeric antibodies containing a complementarity
 determining region (CDR) from a non-human antibody and appropriate
 framework sequences (I) of human antibodies. (I) is selected by using
 canonical CDR structure types of non-human antibody in comparison to
 germline canonical CDR structure types of human antibodies as the basis
 for selection, for humanisation. The method is useful for making a
 humanised antibody or a converted antibody. The method is applicable for
 converting a subject antibody sequence of any subject species to a less
 immunogenic form suitable for use in an object species. The method is
 reliable for identifying suitable human framework sequences to support
 non-human CDR regions and to provide humanised antibodies that retain
 high antigen binding with low immunogenicity in humans, without the need
 for direct comparison of framework sequences, without the need for
 determining critically important amino acid residues in the framework,
 CC and without the need for multiple iteration and construction to obtain
 CC humanised antibodies with suitable therapeutic properties. The antibody

CC has high affinity and low immunogenicity without need for comparing
CC framework sequences between non-human and human antibodies. This sequence
CC represents a human heavy chain variable region gene segment used in the
CC creation of humanised antibodies
XX
XX Sequence 98 AA;
SQ

CC has high affinity and low immunogenicity without need for comparing
CC framework sequences between non-human and human antibodies. This sequence
CC represents a human heavy chain variable region gene segment used in the
CC creation of humanised antibodies
XX
SQ Sequence 98 AA;

CC has high affinity and low immunogenicity without need for comparing
CC framework sequences between non-human and human antibodies. This sequence
CC represents a human heavy chain variable region gene segment used in the
CC creation of humanised antibodies
XX
SQ Sequence 98 AA;

CC medicament for treating non-Hodgkin's lymphoma. The present sequence
CC represents an Ig variable region sequence which is used in the
CC exemplification of the present invention.

XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 514; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.4e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 8
ADJ80305
ID ADJ80305 standard; protein; 98 AA.
XX
AC ADJ80305;
XX
DT 06-MAY-2004 (first entry)
XX
DE VH gene locus amino acid sequence #25.
XX
KW hybrid antibody; antibody; framework region; homology; immunogenicity.
XX
OS Homo sapiens.
XX
PN WO2003048321-A2.
XX
PD 12-JUN-2003.
XX
PF 03-DEC-2002; 2002WO-US038450.
XX
PR 03-DEC-2001; 2001US-0336591P.
XX
PA (ALEX-) ALEXION PHARM INC.
XX
PI Rother R, Wu D;
XX
WP1; 2003-513753/48.
XX
PT Producing a hybrid antibody or hybrid antibody fragment by operatively
PT linking the selected framework sequences to one or more complementarity
PT determining regions of the initial antibody.
XX
PS Disclosure; SEQ ID NO 65; 77pp; English.

XX The invention relates to a method of producing a hybrid antibody or
XX hybrid antibody fragment by: (i) providing an initial antibody having
XX specificity for a target; (ii) determining the sequence of a variable
XX region of the initial antibody; (iii) selecting a first component of the
XX variable region consisting of FR1, FR2, FR3 and FR4; (iv) comparing the
XX sequence of the first component to sequences contained in a reference
XX database of antibody sequences or antibody fragment sequences from a
XX target species; (v) selecting a sequence from an antibody in the database
XX which demonstrates a high degree of homology to the first component; (vi)
XX selecting a second component of the variable region which is different
XX than the first component, the second component selected from the group
XX consisting of FR1, FR2, FR3 and FR4; (vii) comparing the sequence of the
XX second component to sequences contained in a reference database of
XX antibody sequences or antibody fragment sequences from the target species
XX; (viii) selecting a sequence from the database which demonstrates a high
XX degree of homology to the second component and which is from a different
XX antibody than the selected antibody; and (ix) operatively linking the
XX selected framework sequences to one or more complementarity determining
XX regions (CDRs) of the initial antibody to produce a hybrid antibody or
XX hybrid antibody fragment. The method is useful for producing a hybrid

CC antibody or hybrid antibody fragment (claimed). The antibody and
CC fragments are useful for therapeutic and diagnostic purposes. The method
CC uses entire framework regions from a single antibody variable heavy or
CC variable light chain to receive the CDRs. This produces antibodies that
CC are highly homologous and exhibit reduced immunogenicity while
CC maintaining an optimum binding profile. This sequence represents the
CC amino acid sequence of an antibody from the VH gene locus.

XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 514; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.4e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98

RESULT 9
ADJ80303
ID ADJ80303 standard; protein; 98 AA.
XX
AC ADJ80303;
XX
DT 06-MAY-2004 (first entry)
XX
DE VH gene locus amino acid sequence #23.
XX
KW hybrid antibody; antibody; framework region; homology; immunogenicity.
XX
OS Homo sapiens.
XX
PN WO2003048321-A2.
XX
PD 12-JUN-2003.
XX
PF 03-DEC-2002; 2002WO-US038450.
XX
PR 03-DEC-2001; 2001US-0336591P.
XX
PA (ALEX-) ALEXION PHARM INC.
XX
PI Rother R, Wu D;
XX
WP1; 2003-513753/48.

XX Producing a hybrid antibody or hybrid antibody fragment by operatively
XX linking the selected framework sequences to one or more complementarity
XX determining regions of the initial antibody.

XX Disclosure; SEQ ID NO 63; 77pp; English.

XX The invention relates to a method of producing a hybrid antibody or
XX hybrid antibody fragment by: (i) providing an initial antibody having
XX specificity for a target; (ii) determining the sequence of a variable
XX region of the initial antibody; (iii) selecting a first component of the
XX variable region consisting of FR1, FR2, FR3 and FR4; (iv) comparing the
XX sequence of the first component to sequences contained in a reference
XX database of antibody sequences or antibody fragment sequences from a
XX target species; (v) selecting a sequence from an antibody in the database
XX which demonstrates a high degree of homology to the first component; (vi)
XX selecting a second component of the variable region which is different
XX than the first component, the second component selected from the group
XX consisting of FR1, FR2, FR3 and FR4; (vii) comparing the sequence of the
XX second component to sequences contained in a reference database of
XX antibody sequences or antibody fragment sequences from the target species
XX; (viii) selecting a sequence from the database which demonstrates a high
XX degree of homology to the second component and which is from a different

CC antibody than the selected antibody; and (ix) operatively linking the
 CC selected framework sequences to one or more complementarity determining
 CC regions (CDRs) of the initial antibody to produce a hybrid antibody or
 CC hybrid antibody fragment. The method is useful for producing a hybrid
 CC antibody or hybrid antibody fragment (claimed). The antibody and
 CC fragments are useful for therapeutic and diagnostic purposes. The method
 CC uses entire framework regions from a single antibody variable heavy or
 CC variable light chain to receive the CDRs. This produces antibodies that
 CC are highly homologous and exhibit reduced immunogenicity while
 CC maintaining an optimum binding profile. This sequence represents the
 CC amino acid sequence of an antibody from the VH gene locus.

SQ Sequence 98 AA;

Query Match 100.0%; Score 514; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 2.4e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
 DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRTISRDNKNTLYLQWNSLRADDTAVYYCAK 98
 DB 61 ADSVKGRTISRDNKNTLYLQWNSLRADDTAVYYCAK 98

RESULT 10

ID ADY75310
 AC ADY75310; standard; protein; 98 AA.

XX ADY75310;

DT 02-JUN-2005 (first entry)

XX Protein encoded by human germline heavy chain V minigene VH3 3-30.5.
 XX Antibody engineering; antibody; antibody production; gene library;
 KW DNA recombination; gene amplification; primer extension;
 KW heavy chain variable region.

XX Homo sapiens.
 XX WO2005023993-A2.

XX 17-MAR-2005.

XX 09-SEP-2004; 2004WO-US029617.

XX 09-SEP-2003; 2003US-0501073P.

XX (INTE-) INTEGRIGEN INC.

XX Sharma V, Leonard L, Smider V;

XX WPI; 2005-223364/23.

XX Producing polynucleotide encoding human germline antibody V-region for
 PT generating full-length antibody germline V-region genes, by obtaining V
 PT or J minigene and joining V minigene with J minigene, or joining J
 PT minigene with V minigene.

XX Disclosure; Fig 10; 52pp; English.

XX The present invention relates to producing germline antibody genes by a
 CC completely in vitro approach that mimics the natural process of V(D)J
 CC recombination. The antibody genes are completely human and native in
 CC their sequence, and libraries of such antibody genes can be constructed
 CC which represent an unselected population representing the entire antibody
 CC repertoire. The method uses gene amplification to produce a V minigene,
 CC and a hybrid primer capable of hybridizing to a V minigene and either a D
 CC or V minigene. The hybrid primer facilitates recombination of a V
 CC minigene to a D or J minigene to produce a full length V-region gene.

CC Also disclosed is a library comprising member polynucleotides encoding
 CC exogenously rearranged human germline antibody V-regions. In producing a
 CC polynucleotide encoding a human germline antibody V-region, a D minigene
 CC is further joined to the 3' end of the V minigene and the 5' end of the J
 CC minigene. The V minigene or the J minigene in is obtained by chemical
 CC synthesis or by amplification from a germline DNA library. Joining the V
 CC minigene with at least one J minigene is performed by primer extension
 CC using at least two or three oligonucleotide primers. The V minigene is
 CC derived from human immunoglobulin kappa locus, human immunoglobulin
 CC lambda locus, or human immunoglobulin heavy chain locus. The V-region
 CC also comprises a serine protease triad. The human germline antibodies can
 CC be used as precursors to more high affinity antibodies, and are useful in
 CC the generation of efficiently pairing libraries of heavy and light
 CC chains. The present sequence is a polypeptide encoded by human germline
 CC heavy chain V minigene, family VH3 locus 3-30.5.

SQ Sequence 98 AA;

Query Match 100.0%; Score 514; DB 9; Length 98;

Best Local Similarity 100.0%; Pred. No. 2.4e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
 DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRTISRDNKNTLYLQWNSLRADDTAVYYCAK 98

DB 61 ADSVKGRTISRDNKNTLYLQWNSLRADDTAVYYCAK 98

RESULT 11

ID ADY75308
 AC ADY75308; standard; protein; 98 AA.

XX ADY75308;

DT 02-JUN-2005 (first entry)

XX Protein encoded by human germline heavy chain V minigene VH3 3-30.
 XX Antibody engineering; antibody; antibody production; gene library;
 KW DNA recombination; gene amplification; primer extension;
 KW heavy chain variable region.

XX Homo sapiens.

XX WO2005023993-A2.

XX 17-MAR-2005.

XX 09-SEP-2004; 2004WO-US029617.

XX 09-SEP-2003; 2003US-0501073P.

XX (INTE-) INTEGRIGEN INC.

XX Sharma V, Leonard L, Smider V;

XX WPI; 2005-223364/23.

XX Producing polynucleotide encoding human germline antibody V-region for
 PT generating full-length antibody germline V-region genes, by obtaining V
 PT or J minigene and joining V minigene with J minigene, or joining J
 PT minigene with V minigene.

XX Disclosure; Fig 10; 52pp; English.

XX The present invention relates to producing germline antibody genes by a
 CC completely in vitro approach that mimics the natural process of V(D)J
 CC recombination. The antibody genes are completely human and native in
 CC their sequence, and libraries of such antibody genes can be constructed
 CC which represent an unselected population representing the entire antibody

CC repertoire. The method uses gene amplification to produce a V minigene, a D
CC and a hybrid primer capable of hybridizing to a V minigene and either a D
CC or V minigene. The hybrid primer facilitates recombination of a V
CC minigene to a D or J minigene to produce a full length V-region gene.
CC Also disclosed is a library comprising member polynucleotides encoding a
CC exogenously rearranged human germline antibody V-regions. In producing a
CC polynucleotide encoding a human germline antibody V-region, a D minigene
CC is further joined to the 3' end of the V minigene and the 5' end of the J
CC minigene. The V minigene or the J minigene in is obtained by chemical
CC synthesis or by amplification from a germline DNA library. Joining the V
CC minigene with at least one J minigene is performed by primer extension
CC using at least two or three oligonucleotide primers. The V minigene is
CC derived from human immunoglobulin kappa locus, human immunoglobulin
CC lambda locus, or human immunoglobulin heavy chain locus. The V-region
CC also comprises a serine protease triad. The human germline antibodies can
CC be used as precursors to more high affinity antibodies, and are useful in
CC the generation of efficiently pairing libraries of heavy and light
CC chains. The present sequence is a polypeptide encoded by human germline
CC heavy chain V minigene, family VH3 locus 3-30.

XX Sequence 98 AA;

Query Match 100.0%; Score 514; DB 9; Length 98;

Best Local Similarity 100.0%; Pred. No. 2.4e-41;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

DB 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 12

ADW96628

ID ADW96628 standard; protein; 109 AA.

XX

AC ADW96628;

XX

DT 21-APR-2005 (first entry)

XX Human germline antibody VH region #6.

DE

XX Antibody; diagnosis; therapy; cancer; tumor; carcinoma; glioma; neoplasm;

XX Cytostatic; epidermal growth factor receptor.

KW

OS Homo sapiens.

XX

PN W02005012479-A2.

XX

PD 10-FEB-2005.

XX

PF 25-JUN-2004; 2004WO-US020564.

XX

PR 27-JUN-2003; 2003US-0483145P.

XX

PR 26-NOV-2003; 2003US-0525570P.

XX

PR 15-APR-2004; 2004US-0562453P.

XX

XX (ABGE-) ABGENIX INC.

PI Weber R, Feng X, Foord O, Green L, Gudas J, Keyt B, Liu Y;

PI Rathanaswami P, Raya R, Yang XD, Corvalan J, Foltz I, Jia X;

PI Kang J, King CT, Klakamp SL, Su QJ;

XX WPI; 2005-142884/15.

XX

PT New human monoclonal antibodies directed against type III deletion

PT mutants of epidermal growth factor receptor (EGFRvIII), useful for

PT diagnosing, preventing or treating diseases associated with EGFRvIII

PT expression, e.g. cancer.

XX

PS Example 3; SEQ ID NO 14; 207pp; English.

XX The invention relates to an isolated human monoclonal antibody, or its
CC variant, directed against deletion mutants of epidermal growth factor
CC receptor, particularly to the type III deletion mutant (EGFRvIII). Also
CC included are a hybridoma cell line producing the above antibody, a
CC transformed cell comprising a gene encoding the antibody, an inhibiting cell
CC proliferation associated with the expression of EGFRvIII, an isolated
CC polynucleotide molecule comprising a nucleotide sequence encoding a heavy
CC or light chain amino acid sequence (or its fragment), an article of
CC manufacture (comprising a container, a composition contained in the
CC container, and a package insert or label indicating that the composition
CC can be used to treat cancer characterized by the expression of EGFRvIII,
CC where the composition comprises the antibody cited above), an assay kit
CC for the detection of EGFRvIII in mammalian tissues or cells (to screen
CC for lung, colon, gastric, renal, prostate or ovarian carcinomas, the
CC EGFRvIII being an antigen expressed by epithelial cancers, the kit
CC comprising an antibody that binds the antigen protein and means for
CC indicating the reaction of the antibody with the antigen, if present), a
CC purified protein variant of EGFRvIII, selecting variants of antibodies to
CC EGFRvIII, making antibody variants to EGFRvIII and killing a targeted
CC cell. The composition and methods are useful for diagnosing, preventing
CC or treating diseases associated with the expression of EGFRvIII, such as
CC cancer, gliomas, tumors and carcinomas. The present sequence is a human
CC germline antibody heavy chain protein, used to compare to the VH regions
CC of the anti-EGFRvIII antibodies of the invention.

XX Sequence 109 AA;

Query Match 100.0%; Score 514; DB 9; Length 109;

Best Local Similarity 100.0%; Pred. No. 2.7e-41;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

DB 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAK 98

RESULT 13

ADW96625

ID ADW96625 standard; protein; 109 AA.

XX

AC ADW96625;

XX

DT 21-APR-2005 (first entry)

XX Human germline antibody VH region #5.

DE

XX Antibody; diagnosis; therapy; cancer; tumor; carcinoma; glioma; neoplasm;

XX Cytostatic; epidermal growth factor receptor.

KW

OS Homo sapiens.

XX

PN W02005012479-A2.

XX

PD 10-FEB-2005.

XX

PF 25-JUN-2004; 2004WO-US020564.

XX

PR 27-JUN-2003; 2003US-0483145P.

XX

PR 26-NOV-2003; 2003US-0525570P.

XX

PR 15-APR-2004; 2004US-0562453P.

XX

XX (ABGE-) ABGENIX INC.

XX Weber R, Feng X, Foord O, Green L, Gudas J, Keyt B, Liu Y;

PI Rathanaswami P, Raya R, Yang XD, Corvalan J, Foltz I, Jia X;

PI Kang J, King CT, Klakamp SL, Su QJ;

XX

DR WPI; 2005-142884/15.

XX New human monoclonal antibodies directed against type III deletion

PT mutants of epidermal growth factor receptor (EGFRvIII), useful for

PT diagnosing, preventing or treating diseases associated with EGFRvIII

PT expression, e.g. cancer.

XX Example 3; SEQ ID NO 11; 207pp; English.

PS

XX The invention relates to an isolated human monoclonal antibody, or its

CC variant, directed against deletion mutants of epidermal growth factor

CC receptor, particularly to the type III deletion mutant (EGFRvIII). Also

CC included are a hybridoma cell line producing the above antibody, a

CC transformed cell comprising a gene encoding the antibody, inhibiting cell

CC proliferation associated with the expression of EGFRvIII, an isolated

CC polynucleotide molecule comprising a nucleotide sequence encoding a heavy

CC or light chain amino acid sequence (or its fragment), an article of

CC manufacture (comprising a container, a composition contained in the

CC container, and a package insert or label indicating that the composition

CC can be used to treat cancer characterized by the expression of EGFRvIII,

CC where the composition comprises the antibody cited above), an assay kit

CC for the detection of EGFRvIII in mammalian tissues or cells (to screen

CC for lung, colon, gastric, renal, prostate or ovarian carcinomas, the

CC EGFRvIII being an antigen expressed by epithelial cancers, the kit

CC comprising an antibody that binds the antigen protein and means for

CC indicating the reaction of the antibody with the antigen, if present), a

CC purified protein variant of EGFRvIII, selecting variants of antibodies to

CC EGFRvIII, making antibody variants to EGFRvIII and killing a targeted

CC cell. The composition and methods are useful for diagnosing, preventing

CC or treating diseases associated with the expression of EGFRvIII, such as

CC cancer, gliomas, tumors and carcinomas. The present sequence is a human

CC germline antibody heavy chain protein, used to compare to the VH regions

CC of the anti-EGFRvIII antibodies of the invention.

XX

SQ Sequence 109 AA;

Query Match 100.0%; Score 514; DB 9; Length 109;

Best Local Similarity 100.0%; Pred. No. 2.7e-41;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGVVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

Db 1 QVQLVESGGVVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNSLRADDTAVYYCAK 98

Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRADDTAVYYCAK 98

RESULT 14

ADW80197

ID ADW80197 standard; protein; 109 AA.

XX

AC ADW80197;

XX

DT 21-APR-2005 (first entry)

XX

DE Human anti-EGFRvIII antibody 211/124 VH-related germline protein.

XX

KW cell death; antibody; toxin; cytostatic; cancer; neoplasm; lung tumor;

KW colon tumor; stomach tumor; renal tumor; prostatic cancer; breast tumor;

KW ovary tumor; epidermal growth factor receptor; EGFRvIII;

KW heavy chain variable region.

XX

OS Homo sapiens.

XX

PN WO2005010151-A2.

XX

PD 03-FEB-2005.

XX

PF 25-JUN-2004; 2004WO-US020295.

XX

PR 27-JUN-2003; 2003US-0483145P.

PR 26-NOV-2003; 2003US-0525570P.

PR 15-APR-2004; 2004US-0562453P.

XX

PA (ABGE-) AGENIX INC.

XX

PI Weber R, Feng X, Foord O, Green L, Gudas J, Keyt B, Liu Y;

PI Rathanaawami P, Raya R, Yang XD, Corvalan J, Foltz I, Jia X;

PI Kang J, King CT, Klakamp SL, Su QJ;

XX

XX WPI; 2005-123139/13.

XX

XX New isolated antibody that binds to epidermal growth factor receptor type

PT III mutant EGFRvIII and being conjugated to therapeutic agent such as

PT toxin, useful for inhibiting cell proliferation associated with

PT expression of EGFRvIII.

XX

PS Example 3; SEQ ID NO 11; 233pp; English.

XX

CC The invention relates to a novel method for killing a target cell. The

CC method comprises contacting the cell with an isolated antibody or its

CC fragment that binds to epidermal growth factor receptor type III deletion

CC mutant (EGFRvIII), the antibody being conjugated to a therapeutic agent,

CC which is a toxin chosen from AEPF, MVAE, AURISTATIN E, DM-1 and ZAP, and

CC where the antibody comprises a heavy chain amino acid sequence chosen

CC from antibodies 13.1.2, 131, 170, 150, 095, 250. EGFR variants are caused

CC by gene rearrangement accompanied by gene amplification. Eight major

CC variants of EGFR are known. EGFRvIII, which is the most commonly

CC occurring variant of EGFR in human cancers, comprises a 267 aa in-frame

CC deletion in the extracellular domain. The method of the invention

CC demonstrates cytostatic activity and may be useful for inhibiting cell

CC proliferation associated with the expression of EGFRvIII or for

CC inhibiting cell proliferation of cells expressing EGFRvIII. As such the

CC method may be utilized, in vivo, on a mammal e.g. human, suffering from

CC an epithelial cell cancer such as lung, colon, gastric, renal, prostate,

CC breast, glioblastoma or ovarian carcinoma. The current sequence is that

CC of the human anti-EGFRvIII antibody 211/124 VH-related germline protein

CC of the invention.

XX

SQ Sequence 109 AA;

Query Match 100.0%; Score 514; DB 9; Length 109;

Best Local Similarity 100.0%; Pred. No. 2.7e-41;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGVVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

Db 1 QVQLVESGGVVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNSLRADDTAVYYCAK 98

Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRADDTAVYYCAK 98

RESULT 15

ADW80200

ID ADW80200 standard; protein; 109 AA.

XX

AC ADW80200;

XX

DT 21-APR-2005 (first entry)

XX

DE Human anti-EGFRvIII antibody 318/342/333 VH-related germline protein.

XX

KW cell death; antibody; toxin; cytostatic; cancer; neoplasm; lung tumor;

KW colon tumor; stomach tumor; renal tumor; prostatic cancer; breast tumor;

KW ovary tumor; epidermal growth factor receptor; EGFRvIII;

KW heavy chain variable region.

XX

OS Homo sapiens.

XX

PN WO2005010151-A2.

XX

PD 03-FEB-2005.


```
XX 25-JUN-2004; 2004WO-US020295.
XX
XX 27-JUN-2003; 2003US-0483145P.
XX
XX 26-NOV-2003; 2003US-0525570P.
XX
XX 15-APR-2004; 2004US-0562453P.
XX
XX (ABGE-) ABGENIX INC.
XX
XX Weber R, Feng X, Foord O, Green L, Gudas J, Keyt B, Liu Y;
XX Rathanaswami P, Raya R, Yang XD, Corvalan J, Foltz I, Jia X;
XX Kang J, King CT, Klakamp SL, Su QJ;
XX WPI; 2005-123139/13.
XX
XX New isolated antibody that binds to epidermal growth factor receptor type
XX III mutant EGFRvIII and being conjugated to therapeutic agent such as
XX toxin, useful for inhibiting cell proliferation associated with
XX expression of EGFRvIII.
XX
XX Example 3; SEQ ID NO 14; 233pp; English.
XX
XX The invention relates to a novel method for killing a target cell. The
XX method comprises contacting the cell with an isolated antibody or its
XX fragment that binds to epidermal growth factor receptor type III deletion
XX mutant (EGFRvIII), the antibody being conjugated to a therapeutic agent,
XX which is a toxin chosen from AEPF, MMAE, AURISTATIN E, DM-1 and ZAP, and
XX where the antibody comprises a heavy chain amino acid sequence chosen
XX from antibodies 13.1.2, 131, 170, 150, 095, 250. EGFR variants are caused
XX by gene rearrangement accompanied by gene amplification. Eight major
XX variants of EGFR are known. EGFRvIII, which is the most commonly
XX occurring variant of EGFR in human cancers, comprises a 267 aa in-frame
XX deletion in the extracellular domain. The method of the invention cell
XX demonstrates cytostatic activity and may be useful for inhibiting cell
XX proliferation associated with the expression of EGFRvIII or for
XX inhibiting cell proliferation of cells expressing EGFRvIII. As such the
XX method may be utilized, in vivo, on a mammal e.g. human, suffering from
XX an epithelial cell cancer such as lung, colon, gastric, renal, prostate,
XX breast, glioblastoma or ovarian carcinoma. The current sequence is that
XX of the human anti-EGFRvIII antibody 318/342/333 VH-related germline
XX protein of the invention.
XX
XX Sequence 109 AA;
XX
XX Query Match 100.0%; Score 514; DB 9; Length 109;
XX Best Local Similarity 100.0%; Pred. No. 2.7e-41;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 QVQLVESGGGVQPGKSLRLSCAASGFTSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
XX |||||
XX 1 QVQLVESGGGVQPGKSLRLSCAASGFTSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
XX
XX 61 ADSVKGRFTISRDNKNTLYLQMSLRADDTAVYYCAK 98
XX |||||
XX 61 ADSVKGRFTISRDNKNTLYLQMSLRADDTAVYYCAK 98
XX
XX RESULT 16
XX AAW15534
XX ID AAW15534 standard; protein; 123 AA.
XX
XX AC AAW15534;
XX
XX XX
XX 27-NOV-1997 (first entry)
XX
XX Anti-TGF beta-1 scFv antibody 1-B2 VH domain.
XX
XX Transforming growth factor beta-1; TGF-beta-1; human;
XX antibody engineering; scFv; phage display; lung fibrosis;
XX arterial injury; proliferative retinopathy; retinal detachment;
XX adult respiratory distress syndrome; liver cirrhosis;
XX post myocardial infarction; post-angioplasty restenosis; scleroderma;
XX vascular disease; cataract; glaucoma; scarring; glomerulonephritis;
```

```
KW osteoporosis; immune disease; inflammation; rheumatoid arthritis;
KW macrophage deficiency disease; macrophage pathogen infection; therapy.
XX
XX Homo sapiens.
XX
XX GB2305921-A.
XX
XX 23-APR-1997.
XX
XX 07-OCT-1996; 96GB-00020920.
XX
XX 06-OCT-1995; 95GB-00020486.
XX
XX 19-JAN-1996; 96GB-00001081.
XX
XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Thompson JE, Vaughan TJ, Williams AJ, Green JA, Jackson RH;
XX Bacon L, Johnson KS, Wilton AJ, Tempest PR, Pope AR;
XX WPI; 1997-215360/20.
XX N-PSDB; AAT60380.
XX
XX Agent contg. antigen-binding domain of human antibody to transforming
XX growth factor beta 1 or 2 - and nucleic acid encoding it, used to
XX neutralise effects of TGF, e.g. for control of fibrosis, immune and
XX inflammatory disease.
XX
XX Claim 16; Fig 1a(i); 184pp; English.
XX
XX This polypeptide sequence comprises the VH domain of human scFv antibody
XX 1B2 (also known as 7A3), which is specific for transforming growth factor
XX (TGF) beta-1. It is encoded by a gene (AAT60380) isolated from a
XX peripheral blood lymphocyte library. The antigen-binding domains of human
XX antibodies (see AAW15522-40) to TGF beta-1 and/or beta-2 can be used to
XX counter the adverse effects of TGF beta, such as (i) promotion of
XX fibrosis (in dermal, ocular or keloid scarring, lung fibrosis, arterial
XX injury, proliferative retinopathy, retinal detachment, adult respiratory
XX distress syndrome, liver cirrhosis, post myocardial infarction, post-
XX angioplasty restenosis, scleroderma, vascular disorders, cataract,
XX glaucoma, or esp. neural scarring and glomerulonephritis, also (not
XX claimed) osteoporosis), or (ii) immune and inflammatory diseases
XX (rheumatoid arthritis, macrophage deficiency diseases or macrophage
XX pathogen infection). Nucleic acids encoding human antibody VH and VL can
XX be used for prodn. of recombinant antigen-binding domains. These are
XX highly specific, have low dissociation constants (pref. less than 5 nM)
XX and low IC50s for neutralisation
XX
XX Sequence 123 AA;
XX
XX Query Match 100.0%; Score 514; DB 2; Length 123;
XX Best Local Similarity 100.0%; Pred. No. 3.1e-41;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 QVQLVESGGGVQPGKSLRLSCAASGFTSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
XX |||||
XX 1 QVQLVESGGGVQPGKSLRLSCAASGFTSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
XX
XX 61 ADSVKGRFTISRDNKNTLYLQMSLRADDTAVYYCAK 98
XX |||||
XX 61 ADSVKGRFTISRDNKNTLYLQMSLRADDTAVYYCAK 98
XX
XX RESULT 17
XX AAY08598
XX ID AAY08598 standard; protein; 223 AA.
XX
XX AC AAY08598;
XX
XX 05-AUG-1999 (first entry)
XX
XX Anti-human TNF-alpha monoclonal antibody H-chain protein.
XX
XX Monoclonal antibody; H chain; heavy chain; anti-human; TNF-alpha;
```

KW tumour necrosis factor; light chain; L chain.
 XX Homo sapiens.
 OS
 XX JP11127855-A.
 PN
 XX 18-MAY-1999.
 PD
 XX 27-OCT-1997; 97JP-00293994.
 PF
 XX 27-OCT-1997; 97JP-00293994.
 PR
 XX (NIHA) JAPAN ENERGY CORP.
 PA
 XX WPI; 1999-350318/30.
 DR N-PSDB; AAX77407.
 XX
 XX Recombinant anti-human TNF-alpha human monoclonal antibody - produced
 PT stably with a high purity, and in large amounts.
 PT
 XX Claim 3; Page 12-13; 22pp; Japanese.
 PS
 XX This invention describes novel recombinant anti-human TNF-alpha human
 CC monoclonal antibody consisting of a heavy (H) chain and a light (L)
 CC chain. The recombinant anti-human TNF-alpha human monoclonal antibody can
 CC be produced stably in a high purity and in a large amount
 CC
 XX Sequence 223 AA;
 SQ
 Query Match 100.0%; Score 514; DB 2; Length 223;
 Best Local Similarity 100.0%; Pred. No. 5.8e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
 DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
 RESULT 18
 AAB40116
 ID AAB40116 standard; protein; 98 AA.
 AC
 XX AAB40116;
 AC
 XX 05-FEB-2001 (first entry)
 DT
 XX Anti-hIL12 antibody H chain V region amino acid sequence SEQ ID 642.
 DE
 XX Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
 KW complementarity determining region; CDR; antirheumatic; antiarthritic;
 KW antisclerotic; neuroprotective; antipsoriatic; antiasthmatic; cardiant;
 KW antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
 KW multiple sclerosis; rheumatoid arthritis.
 XX
 XX Homo sapiens.
 OS
 XX WO200056772-A1.
 PN
 XX 28-SEP-2000.
 PD
 XX 24-MAR-2000; 2000WO-US0007946.
 PF
 XX 25-MAR-1999; 99US-0126603P.
 PR
 XX (BADI) BASF AG.
 PA (GEM) GENETICS INST INC.
 XX
 XX Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DB, White M;
 PI Kaymakcalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;

PI Veldman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
 PI Derbyshire EJ, Carmen S, Smith S, Hollet TL, Du Fou SL;
 XX
 DR WPI; 2000-638250/61.
 XX
 XX New human antibody specific for human interleukin-12 (IL-12) used to
 PT treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
 PT disease and multiple sclerosis.
 PT
 XX Claim 75; Page 122; 377pp; English.
 PS
 XX This invention relates to a new human antibody specific for human
 CC interleukin-12 (IL-12). The invention also includes antigen binding
 CC portions that bind to IL-12. Sequences AAB39485-B39516 represent human
 CC anti-IL-12 antibody heavy and light chain complementarity determining
 CC region (CDR) amino acid sequences, and also includes variable region
 CC amino acid sequences. Other variable region amino acid sequences are
 CC given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
 CC represent anti-IL-12 CDR3 related amino acid sequences. AAB39772-B40063
 CC represent other CDR sequences. Light chain CDR3 consensus sequences are
 CC given in AAB40064-B40067. Primers used in the identification and
 CC construction of the antibodies of the invention are given in AAC61062-
 CC C61071. The antibody of the invention is a neutralising antibody and has
 CC antirheumatic; antiarthritic; antisclerotic; antiinflammatory;
 CC neuroprotective; antipsoriatic; antiasthmatic; cardiant; antiparasitic;
 CC antibacterial and immunosuppressive activity. The antibodies or antigen-
 CC binding fragments are useful in the treatment of disorders associated
 CC with detrimental release of human IL-12, especially Crohn's disease,
 CC multiple sclerosis and rheumatoid arthritis. They can also be used in the
 CC manufacture of a pharmaceutical composition to treat human IL-12
 CC disorders
 XX
 XX Sequence 98 AA;
 SQ
 Query Match 99.4%; Score 511; DB 3; Length 98;
 Best Local Similarity 99.0%; Pred. No. 4.6e-41;
 Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
 DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
 DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
 RESULT 19
 AAB40118
 ID AAB40118 standard; protein; 98 AA.
 AC
 XX AAB40118;
 AC
 XX 05-FEB-2001 (first entry)
 DT
 XX Anti-hIL12 antibody H chain V region amino acid sequence SEQ ID 644.
 DE
 XX Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
 KW complementarity determining region; CDR; antirheumatic; antiarthritic;
 KW antisclerotic; neuroprotective; antipsoriatic; antiasthmatic; cardiant;
 KW antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
 KW multiple sclerosis; rheumatoid arthritis.
 XX
 XX Homo sapiens.
 OS
 XX WO200056772-A1.
 PN
 XX 28-SEP-2000.
 PD
 XX 24-MAR-2000; 2000WO-US0007946.
 PF
 XX 25-MAR-1999; 99US-0126603P.
 PR
 XX

```

PA (BADI ) BASP AG.
PA (GEMY ) GENETICS INST INC.
XX
XX
PI Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DE, White M;
PI Kaymakalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;
PI Veldman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
PI Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL;
XX
XX WPI; 2000-638250/61.
XX
XX New human antibody specific for human interleukin-12 (IL-12) used to
XX treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
XX disease and multiple sclerosis.
XX
XX Claim 75; Page 122; 377pp; English.
XX
XX This invention relates to a new human antibody specific for human
XX interleukin-12 (IL-12). The invention also includes antigen binding
XX portions that bind to IL-12. Sequences AAB39485-B39516 represent human
XX anti-IL-12 antibody heavy and light chain complementarity determining
XX region (CDR) amino acid sequences, and also includes variable region
XX amino acid sequences. Other variable region amino acid sequences are
XX given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
XX represent anti-IL-12 CDR3 related amino acid sequences, AAB39772-B40063
XX given in AAB40064-B40067. Primers used in the identification and
XX construction of the antibodies of the invention are given in AAC61062-
XX C61071. The antibody of the invention is a neutralising antibody and has
XX antirheumatic; antiarthritic; antisclerotic; antiinflammatory;
XX neuroprotective; antipsoiatric; antiasthmatic; cardiant; antiparasitic;
XX antibacterial and immunosuppressive activity. The antibodies or antigen-
XX binding fragments are useful in the treatment of disorders associated
XX with detrimental release of human IL-12, especially Crohn's disease,
XX multiple sclerosis and rheumatoid arthritis. They can also be used in the
XX manufacture of a pharmaceutical composition to treat human IL-12
XX disorders
XX
XX SQ Sequence 98 AA;
XX
XX Query Match 99.4%; Score 511; DB 3; Length 98;
XX Best Local Similarity 99.0%; Pred. No. 4.6e-41;
XX Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
RESULT 20
AAB40115
ID AAB40115 standard; protein; 98 AA.
XX
XX AAB40115;
XX
XX 05-FEB-2001 (first entry)
XX
XX Anti-hIL12 antibody H chain V region amino acid sequence SEQ ID 641.
XX
XX Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
XX complementarity determining region; CDR; antirheumatic; antiarthritic;
XX antisclerotic; neuroprotective; antipsoiatric; antiasthmatic; cardiant;
XX antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
XX multiple sclerosis; rheumatoid arthritis.
XX
XX Homo sapiens.
XX
XX WO200056772-A1.
XX
XX 28-SEP-2000.
XX

```

```

XX
XX 24-MAR-2000; 2000WO-US007946.
XX
XX 25-MAR-1999; 99US-0126603P.
XX
XX (BADI ) BASP AG.
XX (GEMY ) GENETICS INST INC.
XX
XX Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DE, White M;
XX Kaymakalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;
XX Veldman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
XX Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL;
XX
XX WPI; 2000-638250/61.
XX
XX New human antibody specific for human interleukin-12 (IL-12) used to
XX treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
XX disease and multiple sclerosis.
XX
XX Claim 75; Page 122; 377pp; English.
XX
XX This invention relates to a new human antibody specific for human
XX interleukin-12 (IL-12). The invention also includes antigen binding
XX portions that bind to IL-12. Sequences AAB39485-B39516 represent human
XX anti-IL-12 antibody heavy and light chain complementarity determining
XX region (CDR) amino acid sequences, and also includes variable region
XX amino acid sequences. Other variable region amino acid sequences are
XX given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
XX represent anti-IL-12 CDR3 related amino acid sequences, AAB39772-B40063
XX given in AAB40064-B40067. Primers used in the identification and
XX construction of the antibodies of the invention are given in AAC61062-
XX C61071. The antibody of the invention is a neutralising antibody and has
XX antirheumatic; antiarthritic; antisclerotic; antiinflammatory;
XX neuroprotective; antipsoiatric; antiasthmatic; cardiant; antiparasitic;
XX antibacterial and immunosuppressive activity. The antibodies or antigen-
XX binding fragments are useful in the treatment of disorders associated
XX with detrimental release of human IL-12, especially Crohn's disease,
XX multiple sclerosis and rheumatoid arthritis. They can also be used in the
XX manufacture of a pharmaceutical composition to treat human IL-12
XX disorders
XX
XX SQ Sequence 98 AA;
XX
XX Query Match 99.4%; Score 511; DB 3; Length 98;
XX Best Local Similarity 99.0%; Pred. No. 4.6e-41;
XX Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
RESULT 20
AAB40120
ID AAB40120 standard; protein; 98 AA.
XX
XX AAB40120;
XX
XX 05-FEB-2001 (first entry)
XX
XX Anti-hIL12 antibody H chain V region amino acid sequence SEQ ID 646.
XX
XX Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
XX complementarity determining region; CDR; antirheumatic; antiarthritic;
XX antisclerotic; neuroprotective; antipsoiatric; antiasthmatic; cardiant;
XX antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
XX multiple sclerosis; rheumatoid arthritis.
XX
XX Homo sapiens.
XX
XX WO200056772-A1.
XX
XX 28-SEP-2000.
XX

```

```

OS Homo sapiens.
XX
XX WO200056772-A1.
XX
XX 28-SEP-2000.
XX
XX 24-MAR-2000; 2000WO-US007946.
XX
XX 25-MAR-1999; 99US-0126603P.
XX
XX (BADI ) BASF AG.
XX (GEMY ) GENETICS INST INC.
XX
XX Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DE, White M;
XX Kaymakcalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;
XX Veldman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
XX Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL;
XX
XX WPI; 2000-638250/61.
XX
XX New human antibody specific for human interleukin-12 (IL-12) used to
XX treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
XX disease and multiple sclerosis.
XX
XX Claim 75; Page 122; 377pp; English.
XX
XX This invention relates to a new human antibody specific for human
XX interleukin-12 (IL-12). The invention also includes antigen binding
XX portions that bind to IL-12. Sequences AAB39485-B39516 represent human
XX anti-IL-12 antibody heavy and light chain complementarity determining
XX region (CDR) amino acid sequences, and also includes variable region
XX amino acid sequences. Other variable region amino acid sequences are
XX given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
XX represent anti-IL-12 CDR3 related amino acid sequences, AAB39772-B40063
XX represent other CDR sequences. Light chain CDR3 consensus sequences are
XX given in AAB40064-B40067. Primers used in the identification and
XX construction of the antibodies of the invention are given in AAC61062-
XX C61071. The antibody of the invention is a neutralising antibody and has
XX antirheumatic; antiarthritic; antisclerotic; antiinflammatory;
XX neuroprotective; antipsoriatic; antiasthmatic; cardiant; antiparasitic;
XX antibacterial and immunosuppressive activity. The antibodies or antigen-
XX binding fragments are useful in the treatment of disorders associated
XX with detrimental release of human IL-12, especially Crohn's disease,
XX multiple sclerosis and rheumatoid arthritis. They can also be used in the
XX manufacture of a pharmaceutical composition to treat human IL-12
XX disorders
XX
XX Sequence 98 AA;
XX
XX Query Match 99.4%; Score 511; DB 3; Length 98;
XX Best Local Similarity 99.0%; Pred. No. 4.6e-41;
XX Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 QVQLVESGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
XX DB 1 QVQLVESGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
XX
XX QY 61 ADSVKGRTISRDNKNTLYLQNSLRAEDTAVYYCAK 98
XX DB 61 ADSVKGRTISRDNKNTLYLQNSLRAEDTAVYYCAK 98
XX
XX RESULT 22
XX ID AAB40117
XX AC AAB40117 standard; protein; 98 AA.
XX
XX AAB40117;
XX
XX 05-FEB-2001 (first entry)
XX
XX DE Anti-hIL12 antibody H chain V region amino acid sequence SEQ ID 643.
XX
XX Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
XX

```

```

KW complementarity determining region; CDR; antirheumatic; antiarthritic;
KW antisclerotic; neuroprotective; antipsoriatic; antiasthmatic; cardiant;
KW antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
KW multiple sclerosis; rheumatoid arthritis.
XX
XX Homo sapiens.
XX
XX WO200056772-A1.
XX
XX 28-SEP-2000.
XX
XX 24-MAR-2000; 2000WO-US007946.
XX
XX 25-MAR-1999; 99US-0126603P.
XX
XX (BADI ) BASF AG.
XX (GEMY ) GENETICS INST INC.
XX
XX Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DE, White M;
XX Kaymakcalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;
XX Veldman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
XX Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL;
XX
XX WPI; 2000-638250/61.
XX
XX New human antibody specific for human interleukin-12 (IL-12) used to
XX treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
XX disease and multiple sclerosis.
XX
XX Claim 75; Page 122; 377pp; English.
XX
XX This invention relates to a new human antibody specific for human
XX interleukin-12 (IL-12). The invention also includes antigen binding
XX portions that bind to IL-12. Sequences AAB39485-B39516 represent human
XX anti-IL-12 antibody heavy and light chain complementarity determining
XX region (CDR) amino acid sequences, and also includes variable region
XX amino acid sequences. Other variable region amino acid sequences are
XX given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
XX represent anti-IL-12 CDR3 related amino acid sequences, AAB39772-B40063
XX represent other CDR sequences. Light chain CDR3 consensus sequences are
XX given in AAB40064-B40067. Primers used in the identification and
XX construction of the antibodies of the invention are given in AAC61062-
XX C61071. The antibody of the invention is a neutralising antibody and has
XX antirheumatic; antiarthritic; antisclerotic; antiinflammatory;
XX neuroprotective; antipsoriatic; antiasthmatic; cardiant; antiparasitic;
XX antibacterial and immunosuppressive activity. The antibodies or antigen-
XX binding fragments are useful in the treatment of disorders associated
XX with detrimental release of human IL-12, especially Crohn's disease,
XX multiple sclerosis and rheumatoid arthritis. They can also be used in the
XX manufacture of a pharmaceutical composition to treat human IL-12
XX disorders
XX
XX Sequence 98 AA;
XX
XX Query Match 99.4%; Score 511; DB 3; Length 98;
XX Best Local Similarity 99.0%; Pred. No. 4.6e-41;
XX Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 QVQLVESGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
XX DB 1 QVQLVESGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
XX
XX QY 61 ADSVKGRTISRDNKNTLYLQNSLRAEDTAVYYCAK 98
XX DB 61 ADSVKGRTISRDNKNTLYLQNSLRAEDTAVYYCAK 98
XX
XX RESULT 23
XX ID AAB40128
XX AC AAB40128 standard; protein; 98 AA.
XX
XX AAB40128;
XX

```

```
DT 05-FEB-2001 (first entry)
XX Anti-HIL12 antibody H chain V region amino acid sequence SEQ ID 654.
DE Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
XX complementarity determining region; CDR; antirheumatic; antiarthritic;
KW antisclerotic; neuroprotective; antipsoaritic; antiasthmatic; cardiant;
KW antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
KW multiple sclerosis; rheumatoid arthritis.
XX Homo sapiens.
OS WO200056772-A1.
XX 28-SEP-2000.
XX 24-MAR-2000; 2000WO-US007946.
XX 25-MAR-1999; 99US-0126603P.
XX (BADI ) BASP AG.
PA (GEMY ) GENETICS INST INC.
XX Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DE, White M;
PI Kaymakalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;
PI Veldman GW, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
PI Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL;
XX WPI; 2000-638250/61.
DR New human antibody specific for human interleukin-12 (IL-12) used to
XX treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
PT disease and multiple sclerosis.
XX Claim 75; Page 122; 377pp; English.
XX This invention relates to a new human antibody specific for human
CC interleukin-12 (IL-12). The invention also includes antigen binding
CC portions that bind to IL-12. Sequences AAB39485-B39516 represent human
CC anti-IL-12 antibody heavy and light chain complementarity determining
CC region (CDR) amino acid sequences, and also includes variable region
CC amino acid sequences. Other variable region amino acid sequences are
CC given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
CC represent anti-IL-12 CDR3 related amino acid sequences, AAB39772-B40063
CC represent other CDR sequences. Light chain CDR3 consensus sequences are
CC given in AAB40064-B40067. Primers used in the identification and
CC construction of the antibodies of the invention are given in AAC61062-
CC C61071. The antibody of the invention is a neutralising antibody and has
CC antirheumatic; antiarthritic; antisclerotic; antiinflammatory;
CC neuroprotective; antipsoaritic; antiasthmatic; cardiant; antiparasitic;
CC antibacterial and immunosuppressive activity. The antibodies or antigen-
CC binding fragments are useful in the treatment of disorders associated
CC with detrimental release of human IL-12, especially Crohn's disease,
CC multiple sclerosis and rheumatoid arthritis. They can also be used in the
CC manufacture of a pharmaceutical composition to treat human IL-12
CC disorders
XX
SQ Sequence 98 AA;
Query Match 99.4%; Score 511; DB 3; Length 98;
Best Local Similarity 99.0%; Pred. No. 4.6e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAR 98
RESULT 24
ADD05436
ID ADD05436 standard; protein; 98 AA.
XX ADD05436;
AC ADD05436;
XX 01-JAN-2004 (first entry)
XX Anti-MUC18 antibody heavy chain variable region V3-30 protein, SEQ ID 61.
DE
```

```

XX monoclonal antibody; tumour; MUC18; proliferation; cytostatic; vaccine;
KW antigen; tumour metastasis; melanoma; metastatic; human; heavy chain.
XX Unidentified.
OS
PN WO2003057006-A2.
XX
XX 17-JUL-2003.
XX
XX 26-DEC-2002; 2002WO-US041582.
XX
XX 28-DEC-2001; 2001US-0346460P.
XX
XX (ABGE-) ABGENIX INC.
XX
XX Gudas J, Bar-Eli M;
XX
XX WPI; 2003-577496/54.
XX
XX Use of monoclonal antibodies against MUC18 antigen, for diagnosing and
PT treating tumors, inhibiting tumor growth, inhibiting cell invasion
PT associated with melanoma, or increasing survival of an animal having a
PT metastatic tumor.
XX
XX Disclosure; SEQ ID NO 61; 87pp; English.
XX
XX The invention relates to a novel monoclonal antibody used for inhibiting
CC tumour growth in an animal. The tumour inhibition process comprises
CC selecting an animal in need of treatment for a tumour, providing a
CC monoclonal antibody comprising a heavy chain amino acid, where the
CC antibody consists of any one of 10 fully defined sequences of 117-123
CC amino acids given in the specification, and where the monoclonal antibody
CC binds MUC18, and contacting the tumour with the antibody resulting in
CC inhibited proliferation of the cells. The monoclonal antibody has
CC cytostatic and can be used in the production of a vaccine. The monoclonal
CC antibodies against the MUC18 antigen are useful for diagnosing and
CC treating tumors, inhibiting tumour growth (e.g. melanoma, lung tumour or
CC tumour metastasis), inhibiting cell invasion associated with melanoma, or
CC increasing survival of an animal having a metastatic tumour. This
CC sequence represents an anti-MUC18 antibody heavy chain, variable region,
CC protein of the invention.
XX
XX Sequence 98 AA;
SQ
Query Match 99.4%; Score 511; DB 7; Length 98;
Best Local Similarity 99.0%; Pred. No. 4.6e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAR 98

RESULT 26
ADP09874
ID ADF09874 standard; protein; 98 AA.
XX
XX ADF09874;
AC
XX
XX 12-FEB-2004 (first entry)
DT
XX
XX Anti-MUC18 monoclonal antibody-related protein #11.
DE
XX cell proliferation inhibition; MUC18 tumour antigen;
KW anti-MUC18 monoclonal antibody; tumour metastasis inhibition; tumour;
KW carcinoma; cancer; malignancy.
XX
XX Unidentified.
OS

```

```

XX WO2003057837-A2.
PN
XX 17-JUL-2003.
PD
XX
XX 26-DEC-2002; 2002WO-US041580.
XX
XX 28-DEC-2001; 2001US-0346414P.
XX
XX (ABGE-) ABGENIX INC.
PA
XX
XX Gudas J;
XX
XX WPI; 2003-598367/56.
XX
XX Inhibiting cell proliferation associated with expression of MUC18 tumor
PT antigen, involves incubating and inhibiting cell by administering anti-
PT MUC18 monoclonal antibody.
PT
XX
XX Example 2; SEQ ID NO 61; 83pp; English.
XX
XX The invention comprises a method for inhibiting cell proliferation
CC associated with expression of MUC18 tumour antigen. The method involves
CC administering anti-MUC18 monoclonal antibody. The method of the invention
CC is useful for inhibiting cell (e.g. melanoma or tumour cell)
CC proliferation associated with the expression of MUC18 tumour antigen, the
CC method is preferably useful for inhibiting tumour metastasis. The method
CC is useful for inhibiting cell proliferation in patients with tumours,
CC carcinomas, cancer and other malignancies. The present amino acid
CC sequence is used in an alignment with an MUC18 tumour antigen-specific
CC monoclonal antibody of the invention.
XX
XX Sequence 98 AA;
SQ
Query Match 99.4%; Score 511; DB 7; Length 98;
Best Local Similarity 99.0%; Pred. No. 4.6e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAR 98

RESULT 27
ADP22381
ID ADP22381 standard; protein; 109 AA.
XX
XX ADP22381;
AC
XX
XX 09-SEP-2004 (first entry)
DT
XX
XX Human anti-TNFA antibody heavy chain variable region SEQ ID NO:287.
DE
XX
XX human; monoclonal antibody; tumour necrosis factor-alpha; TNFa;
KW anti-TNFA antibody; anabolic; antiarteriosclerotic; antiarthritic;
KW antibacterial; antiinflammatory; antipsoaric; antirheumatic;
KW eating-disorder; immunomodulator; immunosuppressive; nephrotropic;
KW neuroprotective; vasotropic; antiapoptotic; TNFA antagonist;
KW TNF induced apoptosis; neoplastic disease; breast cancer; ovarian cancer;
KW bladder cancer; lung cancer; glioblastoma; stomach cancer;
KW endometrial cancer; kidney cancer; colon cancer; pancreatic cancer;
KW prostate cancer; immuno-mediated inflammatory disease;
KW rheumatoid arthritis; glomerulonephritis; atherosclerosis; psoriasis;
KW restenosis; autoimmune disease; Crohn's disease; graft-host reaction;
KW septic shock; cachexia; anorexia; multiple sclerosis.
XX
XX Homo sapiens.
OS
XX
XX WO2004050683-A2.
PN

```

XX 17-JUN-2004.
XX 02-DEC-2003; 2003WO-US038281.
XX 02-DEC-2002; 2002US-0430729P.
XX (ABGE-) ABGENIX INC.
XX Babcock JS, Kang JS, Foord O, Green L, Feng X, Klakamp S;
PI Haak-Frendscho M, Rathanaswami P, Pigott C, Liang ML, Lee R;
PI Manchulenchko K, Faggioni R, Senaldi G, Qiaojuan JS;
XX WPI; 2004-480601/45.
XX New recombinant human monoclonal antibody that specifically binds to
PT Tumor Necrosis Factor-alpha, useful for treating neoplastic disease such
PT as cancers, or immuno-mediated inflammatory diseases such as rheumatoid
PT arthritis.
XX
XX Example 10; SEQ ID NO 287; 213pp; English.
XX
XX The present invention describes a human monoclonal antibody (I) that
CC specifically binds to tumour necrosis factor-alpha (TNFa) and comprises:
CC (a) a heavy chain complementarity determining region 1 (CDR1) having the
CC two fully defined 5 amino acid sequence (S1, ADP22417) or (S2, ADP22421);
CC and (b) a light chain CDR1 having the two fully defined 11 amino acid
CC sequence (S3, ADP22418) or (S4, ADP22424). Also described: (1) assaying
CC (M1) the level of TNFa in a patient sample, comprising contacting with
CC the sample; (2) a composition comprising the antibody or its functional
CC fragment and a carrier; (3) treating (M2) an animal suffering from a
CC neoplastic, or an immuno-mediated inflammatory disease by selecting an
CC animal in need of treatment for the disease by administering the human
CC monoclonal antibody of (I); and (4) inhibiting (M3) TNFa induced
CC apoptosis in an animal by selecting an animal in need of treatment for
CC TNFa induced apoptosis by administering the human monoclonal antibody of
CC (I). (I) has anabolic, antiarteriosclerotic, antiarthritic,
CC antibacterial, antiinflammatory, antiapoptotic, antirheumatic, eating-
CC disorders, immunomodulator, immunosuppressive, nephrotropic, and
CC neuroprotective, vasotropic and antiapoptotic activities, and can be used
CC as a TNFa antagonist. The antibody (I) is useful in the preparation of
CC medicament for treating TNF induced apoptosis, neoplastic disease such as
CC breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma,
CC stomach cancer, endometrial cancer, kidney cancer, colon cancer,
CC pancreatic cancer, and prostate cancer; or immuno-mediated inflammatory
CC diseases such as rheumatoid arthritis, glomerulonephritis,
CC atherosclerosis, psoriasis, restenosis, autoimmune disease, Crohn's
CC disease, graft-host reactions, septic shock, cachexia, anorexia, and
CC multiple sclerosis. The present sequence represents a human anti-TNFA
CC antibody heavy chain variable region, which is used in the
CC exemplification of the present invention.
XX
XX Sequence 109 AA;
SQ
Query Match 99.48; Score 511; DB 8; Length 109;
Best Local Similarity 99.08; Pred. No. 5.2e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QVQLVESGGGVQPGRLSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGRLSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Qy 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR 98
RESULT 28
ADP22364
ID ADP22364 standard; protein; 109 AA.
XX
AC ADP22364;

XX 09-SEP-2004 (first entry)
XX Human anti-TNFA antibody heavy chain variable region SEQ ID NO:270.
XX
XX human; monoclonal antibody; tumour necrosis factor-alpha; TNFA;
KW anti-TNFA antibody; anabolic; antiarteriosclerotic; antiarthritic;
KW antibacterial; antiinflammatory; antipaprotic; antirheumatic;
KW eating-disorder; immunomodulator; immunosuppressive; nephrotropic;
KW neuroprotective; vasotropic; antiapoptotic; TNFA antagonist;
KW TNF induced apoptosis; neoplastic disease; breast cancer; ovarian cancer;
KW bladder cancer; lung cancer; glioblastoma; stomach cancer;
KW endometrial cancer; kidney cancer; colon cancer; pancreatic cancer;
KW prostrate cancer; immuno-mediated inflammatory disease;
KW rheumatoid arthritis; glomerulonephritis; atherosclerosis; psoriasis;
KW restenosis; autoimmune disease; Crohn's disease; graft-host reaction;
KW septic shock; cachexia; anorexia; multiple sclerosis.
XX
XX Homo sapiens.
XX
XX WO2004050683-A2.
XX
XX 17-JUN-2004.
XX
XX 02-DEC-2003; 2003WO-US038281.
XX
XX 02-DEC-2002; 2002US-0430729P.
XX (ABGE-) ABGENIX INC.
XX Babcock JS, Kang JS, Foord O, Green L, Feng X, Klakamp S;
PI Haak-Frendscho M, Rathanaswami P, Pigott C, Liang ML, Lee R;
PI Manchulenchko K, Faggioni R, Senaldi G, Qiaojuan JS;
XX WPI; 2004-480601/45.
XX
XX New recombinant human monoclonal antibody that specifically binds to
PT Tumor Necrosis Factor-alpha, useful for treating neoplastic disease such
PT as cancers, or immuno-mediated inflammatory diseases such as rheumatoid
PT arthritis.
XX
XX Example 10; SEQ ID NO 270; 213pp; English.
XX
XX The present invention describes a human monoclonal antibody (I) that
CC specifically binds to tumour necrosis factor-alpha (TNFA) and comprises:
CC (a) a heavy chain complementarity determining region 1 (CDR1) having the
CC two fully defined 5 amino acid sequence (S1, ADP22417) or (S2, ADP22421);
CC and (b) a light chain CDR1 having the two fully defined 11 amino acid
CC sequence (S3, ADP22418) or (S4, ADP22424). Also described: (1) assaying
CC (M1) the level of TNFA in a patient sample, comprising contacting with
CC the sample; (2) a composition comprising the antibody or its functional
CC fragment and a carrier; (3) treating (M2) an animal suffering from a
CC neoplastic, or an immuno-mediated inflammatory disease by selecting an
CC animal in need of treatment for the disease by administering the human
CC monoclonal antibody of (I); and (4) inhibiting (M3) TNFA induced
CC apoptosis in an animal by selecting an animal in need of treatment for
CC TNFA induced apoptosis by administering the human monoclonal antibody of
CC (I). (I) has anabolic, antiarteriosclerotic, antiarthritic,
CC antibacterial, antiinflammatory, antipaprotic, antirheumatic, eating-
CC disorders, immunomodulator, immunosuppressive, nephrotropic, and
CC neuroprotective, vasotropic and antiapoptotic activities, and can be used
CC as a TNFA antagonist. The antibody (I) is useful in the preparation of
CC medicament for treating TNF induced apoptosis, neoplastic disease such as
CC breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma,
CC stomach cancer, endometrial cancer, kidney cancer, colon cancer,
CC pancreatic cancer, and prostate cancer; or immuno-mediated inflammatory
CC diseases such as rheumatoid arthritis, glomerulonephritis,
CC atherosclerosis, psoriasis, restenosis, autoimmune disease, Crohn's
CC disease, graft-host reactions, septic shock, cachexia, anorexia, and
CC multiple sclerosis. The present sequence represents a human anti-TNFA
CC antibody heavy chain variable region, which is used in the
CC exemplification of the present invention.

XX Sequence 109 AA;

SQ Query Match 99.4%; Score 511; DB 8; Length 109;
Best Local Similarity 99.0%; Pred. No. 5.2e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSDGSKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSDGSKYY 60

OY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 29
AAR22571
ID AAR22571 standard; protein; 115 AA.
XX AAR22571;
DT 23-SEP-2004 (revised)
DT 21-MAY-1992 (first entry)
DE Heavy chain VH3.5 from BSA binding scFv fragment.
XX Fd; bacteriophage; gene III; filamentous; phagemid; capsid; coat; pilus;
KW g3p; binding; adsorption; gene VIII; diverse repertoire;
KW specific binding pairs; replicable genetic display package; human.
XX
OS Homo sapiens.
OS Unidentified.
XX WO9201047-A.
XX 23-JAN-1992.
XX 10-JUL-1990; 90GB-00015198.
XX 10-JUL-1990; 90GB-00015198.
PR 19-OCT-1990; 90GB-00022845.
PR 12-NOV-1990; 90GB-00024503.
PR 06-MAR-1991; 91GB-00004744.
PR 15-MAY-1991; 91GB-00010549.
XX (CAMEB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
PA (MEDI-) MED RES COUNCIL.
PA
PI McCafferty J, Pope AR, Johnson KS, Hoogenboom HRJ, Griffiths AD;
PI Jackson RH, Holliger KP, Marks JD;
XX WPI; 1992-056862/07.
XX Producing members of specific binding pairs - by expression in
PT recombinant host cells with a secreting replicable genetic display
PT package.
XX
XX Disclosure; Page ?; 209pp; English.
XX
XX PCR was used to prepare a human scFv library from RNA from white blood
CC cells from an unimmunised donor. Heavy chains from IgG and IgM antibodies
CC were amplified separately. Four separate libraries were generated (IgG-K,
CC IgG-lambda, IgM-K and IgM-lambda). The purified scFv fragments were
CC ligated into the phagemid pHEM1 for expression on the surface of fd
CC bacteriophage as gene III fusions. The clones were then subjected to
CC affinity selection for binding to pHox:BSA by selection on tubes followed
CC by analysis by ELISA. Of 96 clones analysed, 43 showed binding to both
CC pHox:BSA and BSA. These were designated BSA binders. Thirteen of fourteen
CC clones sequenced had the same sequence, the VH derived from a human VH3
CC family gene (shown here) and the VL from a human V lambda 3 family gene
CC (AAR22572). The other was derived from a human VH4 family gene and a
CC human VK1 family gene. One clone bound only to pHox:BSA (oxazolone

CC binder). This sequence revealed a VH derived from a human VH1 family gene
CC (AAR22569) and VL from a human V lambda 1 family gene (AAR22570). See
CC also AAR21260-307, 309-312, AAR22450, AAR22565, AAR22567-81
CC Revised record issued on 23-SEP-2004 : Correction to sequence location
XX Sequence 115 AA;
SQ Query Match 99.4%; Score 511; DB 2; Length 115;
Best Local Similarity 99.0%; Pred. No. 5.5e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSDGSKYY 60
DB 1 QVQLVQSGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSDGSKYY 60

OY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 30
AAR66321
ID AAR66321 standard; protein; 117 AA.
XX AAR66321;
XX 25-MAR-2003 (revised)
DT 03-AUG-1995 (first entry)
XX Human immunoglobulin variable heavy chain #27.
DE
XX Primer; PCR; amplify; human; immunoglobulin; variable; heavy chain;
KW cosmid; placenta; vector; pJ81; E.coli; mammalian.
XX Homo sapiens.
XX WO9426895-A1.
PN 24-NOV-1994.
XX 10-MAY-1993; 93WO-JP000603.
XX 10-MAY-1993; 93WO-JP000603.
PR (NISR) JAPAN TOBACCO INC.
XX Honjo T, Matsuda F;
XX WPI; 1995-006791/01.
DR N-PSDB; AAQ78968.
XX DNA fragment comprising human immunoglobulin Vh genes - for the
PT production of human immunoglobulin in mammalian hosts.
XX Claim 38; Page 69-70; 130pp; Japanese.
XX Protein sequences (AAR66295-51) are novel human immunoglobulin heavy
CC chain sequences encoded by novel isolated genes. The genes (AAQ78939-
CC 79002) were isolated and cloned from a series of cosmid constructs: Y202;
CC Y103; Y21; Y6; Y24; 3-31; M84; M18 and M131, by PCR amplification using
CC primers AAQ78917-38. The genes are subdivided into 5 families of Vh
CC genes. The fragments cover a region of 800 kb. The DNA fragments were
CC isolated from high molecular weight DNA from human placenta. The DNA was
CC partially digested with TagI restriction enzyme. The fragments were
CC separated by gel electrophoresis and 35-45 kb fractions were collected.
CC The fragments were ligated with ClaI-digested cosmid vector pJ81. The
CC ligation products were in vitro packed and infected into E.coli 490A. The
CC fragments were then subcloned by colony hybridisation. The Vh genes and
CC the DNA fragments encoding them are useful in producing human
CC immunoglobulin in mammalian hosts. (Updated on 25-MAR-2003 to correct PN
CC field.)

Seq	Sequence 117 AA;	
Query Match	99.4%; Score 511; DB 2; Length 117;	
Best Local Similarity	99.0%; Pred. No. 5.6e-41;	
Matches	97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
QY	1 QVQLVESGGGVQPGKSLRLISCAASGFTFSYGMHWYRQAPGKLEWVAIVSYDGSNKYY 60	
Db	20 QVQLVESGGGVQPGKSLRLISCAASGFTFSYGMHWYRQAPGKLEWVAIVSYDGSNKYY 79	
QY	61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98	
Db	80 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAR 117	
RESULT 31		
ADO36354		
ID	ADO36354 standard; protein; 117 AA.	
AC	ADO36354;	
XX	26-AUG-2004 (first entry)	
XX	Intracellular interaction-related scFv protein SeqID18.	
DE		
XX	immunoglobulin single domain; intracellular environment;	
KW	intracellular interaction; immunoglobulin domain; scFv;	
KW	single chain variable fragment.	
OS	Unidentified.	
XX		
PN	WO2004046185-A2.	
XX		
PD	03-JUN-2004.	
XX		
XX	14-NOV-2003; 2003WO-GB004942.	
PF		
XX	15-NOV-2002; 2002GB-00026729.	
PR		
XX	(MEDI-) MEDICAL RES COUNCIL.	
XX		
PI	Rabbitts TH, Tanaka T;	
XX		
XX	WPI; 2004-431946/40.	
DR		
XX		
PT	Determining the ability of an immunoglobulin single domain to bind to a	
PT	target in an intracellular environment by assessing the intracellular	
PT	interaction between the immunoglobulin domain and the target by	
PT	monitoring the signal.	
XX		
PS	Disclosure; SEQ ID NO 18; 66pp; English.	
XX		
CC	This invention relates to a novel method of determining the ability of an	
CC	immunoglobulin single domain to bind to a target in an intracellular	
CC	environment comprising assessing the intracellular interaction between	
CC	the immunoglobulin domain and the target by monitoring the signal. The	
CC	method comprises providing a first molecule and a second molecule, where	
CC	stable interaction of the first and second molecules leads to the	
CC	generation of a signal; providing a single intracellular immunoglobulin	
CC	domain which is associated with the first molecule, where the single	
CC	immunoglobulin domain is free of complementary immunoglobulin domains;	
CC	providing an intracellular target which is associated with the second	
CC	molecule, such that association of the immunoglobulin domain and the	
CC	target leads to stable interaction of the first and second molecules and	
CC	generation of the signal; and assessing the intracellular interaction	
CC	between the immunoglobulin domain and the target by monitoring the	
CC	signal. The methods are useful for determining the ability of an	
CC	immunoglobulin single domain to bind to a target in an intracellular	
CC	environment. The present sequence is that of a single chain variable	
CC	fragment (scFv) protein which was used to illustrate the method of the	
CC	invention.	
XX		
SQ	Sequence 117 AA;	
SQ		

Query Match	99.4%; Score 511; DB 8; Length 117;
Best Local Similarity	99.0%; Pred. No. 5.6e-41;
Matches	97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY	1 QVQLVESGGGVQPGSRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60
DB	1 QVQLVESGGGVQPGSRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60
QY	61 ADSVKGRFTISRDNRSKNTLYLQMSLRADTVVYCAK 98
DB	61 ADSVKGRFTISRDNRSKNTLYLQMSLRADTVVYCAK 98
RESULT 32	
ADL91327	ID ADL91327 standard; protein; 119 AA.
XX	XX ADL91327;
XX	XX 20-MAY-2004 (first entry)
XX	XX VH chain clone A20 of an intracellularly binding immunoglobulin SeqID 18.
XX	XX antibody; variable chain; cytotstatic; cytoplasmic degradation;
KW	KW intracellular relocation; specific antigen positive cancer; leukaemia;
KW	KW lymphoma; intracellularly binding immunoglobulin; BCR-ABL.
XX	XX Unidentified.
OS	OS WO2003077945-A1.
PN	PN 25-SEP-2003.
XX	XX 14-MAR-2003; 2003WO-GB001077.
XX	XX 14-MAR-2002; 2002GB-00006043.
PR	PR 15-NOV-2002; 2002GB-00026723.
PR	PR 15-NOV-2002; 2002GB-00026727.
XX	XX (MEDI-) MEDICAL RES COUNCIL.
PA	PA Lobato-Caballero MN, Rabbits TH;
XX	XX WPI; 2003-779088/73.
XX	XX Use of an intracellularly binding immunoglobulin comprising at least one
PT	PT antibody variable chain, in preparing a medicament for degrading one or
PT	PT more specific antigens, or for treating specific antigen positive cancer,
PT	PT e.g. leukemia.
XX	XX Example 1; SEQ ID NO 18; 86pp; English.
PS	PS This invention relates to novel immunoglobulin molecules that comprise at
XX	XX least one antibody variable chain VH or VL framework region and are
CC	CC capable of binding to a specific antigens within an intracellular
CC	CC environment. Specifically, it refers to antibodies that can form an
CC	CC insoluble complex with a cognate antigen, such that it can then be target
CC	CC for degradation via the lysosome or proteosome systems. The present
CC	CC invention describes the specific target antigen as the oncogenic fusion
CC	CC protein BCR-ABL or the RAS antigen, such that this method can be used to
CC	CC prepare a cytotstatic medicament for the cytoplasmic degradation or
CC	CC intracellular relocation of such an antigen or for the treatment of the
CC	CC specific antigen positive cancer i.e. leukaemia or lymphoma. Furthermore,
CC	CC the immunoglobulins may also be used for therapeutic, prophylactic or
CC	CC diagnostic applications both in vitro and in vivo, as well as for assay
CC	CC and reagent applications or in functional genomics. This polypeptide
CC	CC sequence is a variable heavy chain (VH) framework region of an
CC	CC intracellularly binding anti-ABL antibody of the invention.
XX	XX Sequence 119 AA;
SQ	SQ

Best Local Similarity 99.0%; Pred. No. 5.7e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60
DB 3 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVSVISYDGSNKYY 62
QY 61 ADSVKGRFTISRDN SKNTLYLQWNSLRAEDTAVYYCAK 98
DB 63 ADSVKGRFTISRDN SKNTLYLQWNSLRAEDTAVYYCAK 100

RESULT 33
ADP03962
ID ADP03962 standard; protein; 121 AA.
XX
AC ADP03962;
XX
DT 29-JUL-2004 (first entry)
XX
DE Murine-expressed anti-human CA IX monoclonal antibody VH protein SEQ 132.
XX
KW monoclonal antibody; carbonic anhydrase IX; CA IX tumour antigen;
KW cytotatic; colorectal neoplasm; renal cell carcinoma;
KW cervical intraepithelial squamous neoplasia;
KW cervical intraepithelial glandular neoplasia; oesophageal; breast cancer;
KW gene therapy; murine; mouse; human; heavy chain variable domain.
XX
OS Unidentified.
XX
PN WO2003048328-A2.
XX
PD 12-JUN-2003.
XX
PF 02-DEC-2002; 2002WO-US038550.
XX
PR 03-DEC-2001; 2001US-0337275P.
XX
PA (ABGE-) ABGENIX INC.
XX
PI Gudas J, Foltz I, Handa M, Gallo M;
XX WPI; 2003-523295/49.
XX
PT New anti-CA IX monoclonal antibody, useful for treating a tumor e.g.,
PT colorectal neoplasms, colorectal tumors, cervical carcinoma, cervical
PT intraepithelial squamous and glandular neoplasia or esophageal tumors.
XX
PS Example 2; SEQ ID NO 132; 89pp; English.
XX

CC The invention relates to a novel isolated monoclonal antibody (mAb)
CC comprising a heavy chain polypeptide and light chain polypeptide having a
CC sequence chosen from one of 53 fully defined amino acid sequences given
CC in the specification, where the antibody specifically binds carbonic
CC anhydrase IX (CA IX) tumour antigen. The antibody of the invention
CC demonstrates cytostatic activity and may be useful for treating a tumour,
CC such as colorectal neoplasm, renal cell carcinoma, cervical carcinoma,
CC cervical intraepithelial squamous and glandular neoplasia, oesophageal
CC tumour or breast cancer, possibly via gene therapy. The current sequence
CC is that of a murine-expressed anti-human CA IX monoclonal antibody VH
CC (heavy chain variable domain) protein of the invention. The protein was
CC generated via the introduction of the human CA IX protein into a
CC transgenic mouse strain.
XX
SQ Sequence 121 AA;

Query Match 99.4%; Score 511; DB 7; Length 121;
Best Local Similarity 99.0%; Pred. No. 5.8e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVSVISYDGSNKYY 60

QY 61 ADSVKGRFTISRDN SKNTLYLQWNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRFTISRDN SKNTLYLQWNSLRAEDTAVYYCAR 98
Search completed: May 12, 2006, 02:22:23
Job time : 127.333 secs

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 02:16:41 ; Search time 58 Seconds
(without alignments)
705.987 Million cell updates/sec

Title: US-09-674-752-35

Perfect score: 514

Sequence: 1 QVQLVSGGGVQGRSLRL.....LYLQMNLSRAEDTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications AA_Main:

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	514	100.0	98	4	US-10-194-975-23
2	514	100.0	98	4	US-10-194-975-25
3	514	100.0	98	4	US-10-308-817-63
4	514	100.0	98	4	US-10-308-817-65
5	514	100.0	98	4	US-10-032-037B-80
6	514	100.0	98	4	US-10-029-988B-80
7	514	100.0	98	4	US-10-032-423A-80
8	514	100.0	98	4	US-10-453-698-63
9	514	100.0	98	4	US-10-453-698-65
10	514	100.0	98	4	US-10-029-926B-80
11	514	100.0	98	5	US-10-884-830-650
12	514	100.0	109	5	US-10-877-773-11
13	514	100.0	109	5	US-10-877-773-14
14	514	100.0	109	5	US-10-877-774-11
15	514	100.0	109	5	US-10-877-774-14
16	514	100.0	113	3	US-09-791-153A-63
17	514	100.0	123	5	US-10-625-307A-8
18	511	99.4	98	5	US-10-884-830-641
19	511	99.4	98	5	US-10-884-830-642
20	511	99.4	98	5	US-10-884-830-643
21	511	99.4	98	5	US-10-884-830-644
22	511	99.4	98	5	US-10-884-830-646
23	511	99.4	109	5	US-10-884-830-654
24	511	99.4	109	5	US-10-727-155-270
25	511	99.4	109	5	US-10-727-155-287
26	511	99.4	115	4	US-10-803-622-167
27	511	99.4	115	4	US-10-803-653-167

Sequence 132, App
Sequence 114, App
Sequence 34, App
Sequence 116, App
Sequence 115, App
Sequence 107, App
Sequence 106, App
Sequence 107, App
Sequence 144, App
Sequence 87, App
Sequence 1731, App
Sequence 1731, App
Sequence 43, App
Sequence 35, App
Sequence 512, App
Sequence 512, App
Sequence 637, App
Sequence 18, App

28 511 99.4 121 4 US-10-309-762-132
29 511 99.4 122 4 US-10-292-088-114
30 511 99.4 122 5 US-10-727-155-34
31 511 99.4 122 6 US-11-031-485-116
32 511 99.4 123 4 US-10-292-088-115
33 511 99.4 123 4 US-10-292-088-116
34 511 99.4 124 4 US-10-292-088-106
35 511 99.4 125 4 US-10-292-088-107
36 511 99.4 138 4 US-10-325-694-144
37 511 99.4 250 6 US-11-090-847-87
38 511 99.4 252 3 US-09-880-748-1731
39 511 99.4 252 4 US-10-293-418-1731
40 510 99.2 123 4 US-10-269-711-43
41 510 99.2 123 4 US-10-684-109-35
42 510 99.2 249 3 US-09-880-748-512
43 510 99.2 249 4 US-10-293-418-512
44 508 98.8 98 5 US-10-884-830-637
45 508 98.8 120 4 US-10-371-942-18

ALIGNMENTS

RESULT 1

US-10-194-975-23

; Sequence 23, Application US/10194975

; Publication No. US20030039649A1

; GENERAL INFORMATION:

; APPLICANT: Foote, Jefferson

; TITLE OF INVENTION: Super Humanized Antibodies

; FILE REFERENCE: 501231.01

; CURRENT APPLICATION NUMBER: US/10/194,975

; CURRENT FILING DATE: 2002-10-10

; PRIOR APPLICATION NUMBER: US 60/305,111

; PRIOR FILING DATE: 2001-07-12

; NUMBER OF SEQ ID NOS: 122

; SOFTWARE: Patent in version 3.1

; SEQ ID NO 23

; LENGTH: 98

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-10-194-975-23

Query Match 100.0%; Score 514; DB 4; Length 98;

Best Local Similarity 100.0%; Pred. No. 5.4e-42;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVSGGGVQGRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

Db 1 QVQLVSGGGVQGRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 2

US-10-194-975-25

; Sequence 25, Application US/10194975

; Publication No. US20030039649A1

; GENERAL INFORMATION:

; APPLICANT: Foote, Jefferson

; TITLE OF INVENTION: Super Humanized Antibodies

; FILE REFERENCE: 501231.01

; CURRENT APPLICATION NUMBER: US/10/194,975

; CURRENT FILING DATE: 2002-10-10

; PRIOR APPLICATION NUMBER: US 60/305,111

; PRIOR FILING DATE: 2001-07-12

; NUMBER OF SEQ ID NOS: 122

; SOFTWARE: Patent in version 3.1

; SEQ ID NO 25

; LENGTH: 98

; TYPE: PRT

```
; ORGANISM: Homo sapiens
US-10-194-975-25

Query Match      100.0%; Score 514; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||

RESULT 5
US-10-032-037B-80
; Sequence 80, Application US/10032037B
; Publication No. US20040001822A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/44
; CURRENT APPLICATION NUMBER: US/10/032,037B
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 80
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-037B-80

Query Match      100.0%; Score 514; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||

RESULT 6
US-10-029-988B-80
; Sequence 80, Application US/10029988B
; Publication No. US20040001839A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; FILE REFERENCE: 10793/46
; CURRENT APPLICATION NUMBER: US/10/029,988B
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 2000-12-29
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 80
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-988B-80

Query Match      100.0%; Score 514; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||

; ORGANISM: Homo sapiens
US-10-194-975-25

Query Match      100.0%; Score 514; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||

RESULT 3
US-10-308-817-63
; Sequence 63, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 63
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-308-817-63

Query Match      100.0%; Score 514; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||

RESULT 4
US-10-308-817-65
; Sequence 65, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 65
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-308-817-65

Query Match      100.0%; Score 514; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCAK 98
   |||||
```

```
RESULT 7
US-10-032-423A-80
; Sequence 80, Application US/10032423A
; Publication No. US20040002450A1
; GENERAL INFORMATION:
; APPLICANT: Bio-Technology General Corp.
; TITLE OF INVENTION: Y17-ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED
; TITLE OF INVENTION: MOJETTES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF
; FILE REFERENCE: 10793/45
; CURRENT APPLICATION NUMBER: US/10/032,423A
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 80
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-032-423A-80

Query Match      100.0%; Score 514; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 8
US-10-453-698-63
; Sequence 63, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 63
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-453-698-63

Query Match      100.0%; Score 514; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 9
US-10-453-698-65
; Sequence 65, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
```

```
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 65
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-453-698-65

Query Match      100.0%; Score 514; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 10
US-10-029-926B-80
; Sequence 80, Application US/10029926B
; Publication No. US20040073011A1
; GENERAL INFORMATION:
; APPLICANT: HAGAY, et al.
; TITLE OF INVENTION: SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
; FILE REFERENCE: 10793/50
; CURRENT APPLICATION NUMBER: US/10/029,926B
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/258,948
; PRIOR FILING DATE: 12/29/2000
; NUMBER OF SEQ ID NOS: 203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 80
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-029-926B-80

Query Match      100.0%; Score 514; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
DB 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 11
US-10-884-830-650
; Sequence 650, Application US/10884830
; Publication No. US20050004354A1
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/10/884,830
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US/09/534,717
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/126,603
; PRIOR FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
```

```
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 650
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-884-830-650

Query Match      100.0%; Score 514; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 5.4e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYSGHWVRQAPGKGLEWVAIVSYDGSNKYY 60
   |||||
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYSGHWVRQAPGKGLEWVAIVSYDGSNKYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYQMNSLRADTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYQMNSLRADTAVYYCAK 98
   |||||

RESULT 12
US-10-877-773-11
; Sequence 11, Application US/10877773
; Publication No. US20050053608A1
; GENERAL INFORMATION:
; APPLICANT: Weber, Richard
; APPLICANT: Feng, Xiao
; APPLICANT: Foord, Orit
; APPLICANT: Green, Larry
; APPLICANT: Gudas, Jean
; APPLICANT: Keyt, Bruce
; APPLICANT: Liu, Ying
; APPLICANT: Rathanaasami, Palani
; APPLICANT: Raya, Robert
; APPLICANT: Yang, Xiao Dong
; APPLICANT: Corvalan, Jose
; APPLICANT: Foltz, Ian
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Kang, Jaepal
; APPLICANT: King, Chadwick T.
; APPLICANT: Klakamp, Scott L.
; APPLICANT: Su, Qiaojuan Jane
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO THE DELETION
; FILE REFERENCE: ABGENIX.087A
; CURRENT APPLICATION NUMBER: US/10/877,773
; CURRENT FILING DATE: 2004-06-25
; PRIOR APPLICATION NUMBER: 60/483,145
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: 60/525,570
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: 60/562,453
; PRIOR FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-877-773-14

Query Match      100.0%; Score 514; DB 5; Length 109;
Best Local Similarity 100.0%; Pred. No. 6.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYSGHWVRQAPGKGLEWVAIVSYDGSNKYY 60
   |||||
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYSGHWVRQAPGKGLEWVAIVSYDGSNKYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYQMNSLRADTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYQMNSLRADTAVYYCAK 98
   |||||

RESULT 13
US-10-877-773-14
; Sequence 14, Application US/10877773
; Publication No. US20050053608A1
; GENERAL INFORMATION:
; APPLICANT: Weber, Richard
; APPLICANT: Feng, Xiao
; APPLICANT: Foord, Orit
; APPLICANT: Green, Larry
; APPLICANT: Gudas, Jean
; APPLICANT: Keyt, Bruce
; APPLICANT: Liu, Ying
; APPLICANT: Rathanaasami, Palani
; APPLICANT: Raya, Robert
; APPLICANT: Yang, Xiao Dong
; APPLICANT: Corvalan, Jose
; APPLICANT: Foltz, Ian
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Kang, Jaepal
; APPLICANT: King, Chadwick T.
; APPLICANT: Klakamp, Scott L.
; APPLICANT: Su, Qiaojuan Jane
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO THE DELETION
; FILE REFERENCE: ABGENIX.087A
; CURRENT APPLICATION NUMBER: US/10/877,773
; CURRENT FILING DATE: 2004-06-25
; PRIOR APPLICATION NUMBER: 60/483,145
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: 60/525,570
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: 60/562,453
; PRIOR FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-877-773-14

Query Match      100.0%; Score 514; DB 5; Length 109;
Best Local Similarity 100.0%; Pred. No. 6.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYSGHWVRQAPGKGLEWVAIVSYDGSNKYY 60
   |||||
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYSGHWVRQAPGKGLEWVAIVSYDGSNKYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNTLYQMNSLRADTAVYYCAK 98
   |||||
Db 61 ADSVKGRFTISRDNKNTLYQMNSLRADTAVYYCAK 98
   |||||

RESULT 14
US-10-877-774-11
; Sequence 11, Application US/10877774
; Publication No. US20050059087A1
; GENERAL INFORMATION:
; APPLICANT: Weber, Richard
; APPLICANT: Feng, Xiao
; APPLICANT: Foord, Orit
; APPLICANT: Green, Larry
; APPLICANT: Gudas, Jean
; APPLICANT: Keyt, Bruce
; APPLICANT: Liu, Ying
; APPLICANT: Rathanaasami, Palani
; APPLICANT: Raya, Robert
; APPLICANT: Yang, Xiao Dong
; APPLICANT: Corvalan, Jose
; APPLICANT: Foltz, Ian
; APPLICANT: Jia, Xiao-Chi
```

```
; APPLICANT: Kang, Jaspal
; APPLICANT: King, Chadwick T.
; APPLICANT: Klakamp, Scott L.
; APPLICANT: Su, Qiaojuan Jane
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO THE DELETION
; TITLE OF INVENTION: MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF
; FILE REFERENCE: ABGENIX.087A2
; CURRENT APPLICATION NUMBER: US/10/877,774
; CURRENT FILING DATE: 2004-06-24
; PRIOR FILING DATE: 2003-06-27
; PRIOR FILING DATE: 2003-06-27
; PRIOR FILING DATE: 2003-11-26
; PRIOR FILING DATE: 2004-04-15
; PRIOR FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-877-774-11

Query Match      100.0%; Score 514; DB 5; Length 109;
Best Local Similarity 100.0%; Pred. No. 6.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 16
US-09-791-153A-63
; Sequence 63, Application US/09791153A
; Publication No. US20030103978A1
; GENERAL INFORMATION:
; APPLICANT: Deshpande, Rajendra
; APPLICANT: Hitz, Anna
; APPLICANT: Boyle, William
; APPLICANT: Sullivan, John
; TITLE OF INVENTION: SELECTIVE BINDING AGENTS OF OSTEOPROTEGERIN BINDING PROTEIN
; FILE REFERENCE: A-633A
; CURRENT APPLICATION NUMBER: US/09/791,153A
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/511,139
; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 154
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 63
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-791-153A-63

Query Match      100.0%; Score 514; DB 3; Length 113;
Best Local Similarity 100.0%; Pred. No. 6.3e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 17
US-10-625-307A-8
; Sequence 8, Application US/10625307A
; Publication No. US20050049403A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Julia E.
; APPLICANT: Vaughan, Tristan J.
; APPLICANT: Williams, Andrew J.
; APPLICANT: Green, Jonathan A.
; APPLICANT: Jackson, Ronald H.
; APPLICANT: Bacon, Louise
; APPLICANT: Johnson, Kevin S.
; APPLICANT: Wilton, Alison J.
; APPLICANT: Tempest, Philip R.
; APPLICANT: Pope, Anthony R.
; TITLE OF INVENTION: Specific Binding Members for Human Transforming Growth Factor Beta
; TITLE OF INVENTION: Materials and Methods
; FILE REFERENCE: 213839-00031
; CURRENT APPLICATION NUMBER: US/10/625,307A
; CURRENT FILING DATE: 2003-07-23
```

```
; APPLICANT: Kang, Jaspal
; APPLICANT: King, Chadwick T.
; APPLICANT: Klakamp, Scott L.
; APPLICANT: Su, Qiaojuan Jane
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO THE DELETION
; TITLE OF INVENTION: MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF
; FILE REFERENCE: ABGENIX.087A2
; CURRENT APPLICATION NUMBER: US/10/877,774
; CURRENT FILING DATE: 2004-06-24
; PRIOR FILING DATE: 2003-06-27
; PRIOR FILING DATE: 2003-06-27
; PRIOR FILING DATE: 2003-11-26
; PRIOR FILING DATE: 2004-04-15
; PRIOR FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-877-774-11

Query Match      100.0%; Score 514; DB 5; Length 109;
Best Local Similarity 100.0%; Pred. No. 6.1e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98

RESULT 15
US-10-877-774-14
; Sequence 14, Application US/1087774
; Publication No. US20050059087A1
; GENERAL INFORMATION:
; APPLICANT: Weber, Richard
; APPLICANT: Feng, Xiao
; APPLICANT: Ford, Orit
; APPLICANT: Green, Larry
; APPLICANT: Gudas, Jean
; APPLICANT: Keyt, Bruce
; APPLICANT: Liu, Ying
; APPLICANT: Rathanaswami, Palani
; APPLICANT: Rava, Robert
; APPLICANT: Yang, Xiao Dong
; APPLICANT: Corvalan, Jose
; APPLICANT: Foltz, Ian
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Kang, Jaspal
; APPLICANT: King, Chadwick T.
; APPLICANT: Klakamp, Scott L.
; APPLICANT: Su, Qiaojuan Jane
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO THE DELETION
; TITLE OF INVENTION: MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF
; FILE REFERENCE: ABGENIX.087A2
; CURRENT APPLICATION NUMBER: US/10/877,774
; CURRENT FILING DATE: 2004-06-24
; PRIOR APPLICATION NUMBER: 60/483,145
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: 60/525,570
; PRIOR FILING DATE: 2003-11-26
; PRIOR FILING DATE: 2004-04-15
; PRIOR FILING DATE: 2004-04-15
; NUMBER OF SEQ ID NOS: 144
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 109
```

; PRIOR APPLICATION NUMBER: 09/054,847
; PRIOR FILING DATE: 1998-04-03
; PRIOR APPLICATION NUMBER: 08/571,755
; PRIOR FILING DATE: 1995-12-13
; NUMBER OF SEQ ID NOS: 125
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Human
US-10-625-307A-8

Query Match 100.0%; Score 514; DB 5; Length 123;
Best Local Similarity 100.0%; Pred. No. 6.9e-42;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
QY 61 ADSVGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98
DB 61 ADSVGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98

RESULT 18
US-10-884-830-641
; Sequence 641, Application US/10884830
; Publication No. US20050004354A1
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/10/884,830
; PRIOR FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US/09/534,717
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/126,603
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 641
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-884-830-641

Query Match 99.4%; Score 511; DB 5; Length 98;
Best Local Similarity 99.0%; Pred. No. 1.1e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
QY 61 ADSVGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98
DB 61 ADSVGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98

RESULT 19
US-10-884-830-642
; Sequence 642, Application US/10884830
; Publication No. US20050004354A1
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/10/884,830
; PRIOR FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US/09/534,717
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/126,603

; PRIOR FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 642
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-884-830-642

Query Match 99.4%; Score 511; DB 5; Length 98;
Best Local Similarity 99.0%; Pred. No. 1.1e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
QY 61 ADSVGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98
DB 61 ADSVGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98

RESULT 20
US-10-884-830-643
; Sequence 643, Application US/10884830
; Publication No. US20050004354A1
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/10/884,830
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US/09/534,717
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/126,603
; PRIOR FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 643
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-884-830-643

Query Match 99.4%; Score 511; DB 5; Length 98;
Best Local Similarity 99.0%; Pred. No. 1.1e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
DB 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
QY 61 ADSVGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98
DB 61 ADSVGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98

RESULT 21
US-10-884-830-644
; Sequence 644, Application US/10884830
; Publication No. US20050004354A1
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/10/884,830
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US/09/534,717
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/126,603
; PRIOR FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0


```
; SEQ ID NO 644
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-884-830-644

Query Match          99.4%; Score 511; DB 5; Length 98;
Best Local Similarity 99.0%; Pred. No. 1.1e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAR 98

RESULT 22
US-10-884-830-646
; Sequence 646, Application US/10884830
; Publication No. US20050004354A1
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BB1-093CP
; CURRENT APPLICATION NUMBER: US/10/884,830
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US/09/534,717
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/126,603
; PRIOR FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 646
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-884-830-646

Query Match          99.4%; Score 511; DB 5; Length 98;
Best Local Similarity 99.0%; Pred. No. 1.1e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAR 98

RESULT 23
US-10-884-830-654
; Sequence 654, Application US/10884830
; Publication No. US20050004354A1
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BB1-093CP
; CURRENT APPLICATION NUMBER: US/10/884,830
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US/09/534,717
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/126,603
; PRIOR FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 654
; LENGTH: 98
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens
US-10-884-830-654

Query Match          99.4%; Score 511; DB 5; Length 98;
Best Local Similarity 99.0%; Pred. No. 1.1e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAR 98

RESULT 24
US-10-727-155-270
; Sequence 270, Application US/10727155
; Publication No. US20050049402A1
; GENERAL INFORMATION:
; APPLICANT: John S. Babcock
; APPLICANT: Jaespal S. Kang
; APPLICANT: Orit Foord
; APPLICANT: Larry Green
; APPLICANT: Xiao Feng
; APPLICANT: Scott Klakamp
; APPLICANT: Mary Haak-Frendscho
; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Manchulenko
; APPLICANT: Raffaella Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; FILE REFERENCE: ABGENIX 073A
; CURRENT APPLICATION NUMBER: US/10/727,155
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 270
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-727-155-270

Query Match          99.4%; Score 511; DB 5; Length 109;
Best Local Similarity 99.0%; Pred. No. 1.2e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAVISYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRAEDTAVYYCAR 98

RESULT 25
US-10-727-155-287
; Sequence 287, Application US/10727155
; Publication No. US20050049402A1
; GENERAL INFORMATION:
; APPLICANT: John S. Babcock
; APPLICANT: Jaespal S. Kang
; APPLICANT: Orit Foord
; APPLICANT: Larry Green
```

```
; APPLICANT: Xiao Feng
; APPLICANT: Scott Klakamp
; APPLICANT: Mary Haak-Frendocho
; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Manchulenchio
; APPLICANT: Raffaella Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; FILE REFERENCE: ABGENIX-073A
; CURRENT APPLICATION NUMBER: US/10/727,155
; PRIOR FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 287
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-727-155-287

Query Match          99.4%; Score 511; DB 5; Length 109;
Best Local Similarity 99.0%; Pred. No. 1.2e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

Qy 61 ADSVKGRTISRDNKNTLYLQWNSLRADDTAVYYCAK 98
Db 61 ADSVKGRTISRDNKNTLYLQWNSLRADDTAVYYCAK 98

RESULT 26
US-10-803-622-167
; Sequence 167, Application US/10803622
; Publication No. US20040157214A1
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Medical Research Council
; APPLICANT: McCafferty, John
; APPLICANT: Pope, Anthony
; APPLICANT: Johnson, Kevin
; APPLICANT: Hoogenboom, Hendricus
; APPLICANT: Griffiths, Andrew
; APPLICANT: Jackson, Ronald
; APPLICANT: Holliger, Kasper
; APPLICANT: Marks, James
; APPLICANT: Clackson, Timothy
; APPLICANT: Chiswell, David
; APPLICANT: Winter, Gregory
; APPLICANT: Bonert, Timothy
; TITLE OF INVENTION: Methods for Producing Members of Specific Binding Pairs
; FILE REFERENCE: 13839-00013
; CURRENT APPLICATION NUMBER: US/10/803,622
; CURRENT FILING DATE: 2004-03-18
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; CURRENT APPLICATION NUMBER: US/10/803,622
; CURRENT FILING DATE: 2004-03-18
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; PRIOR FILING DATE: 1991-03-06
; SOFTWARE: PatentIn version 3.1

; APPLICANT: Xiao Feng
; APPLICANT: Scott Klakamp
; APPLICANT: Mary Haak-Frendocho
; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Manchulenchio
; APPLICANT: Raffaella Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; FILE REFERENCE: ABGENIX-073A
; CURRENT APPLICATION NUMBER: US/10/727,155
; PRIOR FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 287
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-727-155-287

Query Match          99.4%; Score 511; DB 5; Length 109;
Best Local Similarity 99.0%; Pred. No. 1.2e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

Qy 61 ADSVKGRTISRDNKNTLYLQWNSLRADDTAVYYCAK 98
Db 61 ADSVKGRTISRDNKNTLYLQWNSLRADDTAVYYCAK 98

RESULT 27
US-10-803-653-167
; Sequence 167, Application US/10803653
; Publication No. US20040157215A1
; GENERAL INFORMATION:
; APPLICANT: Cambridge Antibody Technology
; APPLICANT: Cambridge Antibody Technology Limited
; APPLICANT: Medical Research Council
; APPLICANT: McCafferty, John
; APPLICANT: Pope, Anthony
; APPLICANT: Johnson, Kevin
; APPLICANT: Hoogenboom, Hendricus
; APPLICANT: Griffiths, Andrew
; APPLICANT: Jackson, Ronald
; APPLICANT: Holliger, Kasper
; APPLICANT: Marks, James
; APPLICANT: Clackson, Timothy
; APPLICANT: Chiswell, David
; APPLICANT: Winter, Gregory
; APPLICANT: Bonert, Timothy
; TITLE OF INVENTION: Methods for Producing Members of Specific Binding Pairs
; FILE REFERENCE: 13839-00013
; CURRENT APPLICATION NUMBER: US/10/803,653
; CURRENT FILING DATE: 2004-03-18
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; CURRENT APPLICATION NUMBER: US/10/803,653
; CURRENT FILING DATE: 2004-03-18
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; CURRENT APPLICATION NUMBER: US/10/803,653
; CURRENT FILING DATE: 2004-03-18
; PRIOR FILING DATE: 1990-07-10
; PRIOR APPLICATION NUMBER: GB 9015198.6
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9022845.3
; PRIOR FILING DATE: 1990-10-19
; PRIOR APPLICATION NUMBER: GB 9024503.6
; PRIOR FILING DATE: 1990-11-12
; PRIOR APPLICATION NUMBER: GB 9104744.9
; PRIOR FILING DATE: 1991-03-06
; SOFTWARE: PatentIn version 3.1
```

```
; SEQ ID NO 167
; LENGTH: 115
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-803-653-167

Query Match          99.4%; Score 511; DB 4; Length 115;
Best Local Similarity 99.0%; Pred. No. 1.3e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVQSGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98

RESULT 28
US-10-309-762-132
; Sequence 132, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: AGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/337275
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: Fast-SEQ for Windows Version 4.0
; SEQ ID NO 132
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-132

Query Match          99.4%; Score 511; DB 4; Length 121;
Best Local Similarity 99.0%; Pred. No. 1.3e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98

RESULT 29
US-10-292-088-114
; Sequence 114, Application US/10292088
; Publication No. US2003021100A1
; GENERAL INFORMATION:
; APPLICANT: BEDIAN, VAHE
; APPLICANT: GLADUE, RONALD P.
; APPLICANT: CORVALAN, JOSE
; APPLICANT: JIA, XIAO-CHI
; APPLICANT: FENG, XIAO
; TITLE OF INVENTION: ANTIBODIES TO CD40
; FILE REFERENCE: ABX-PF/3 US
; CURRENT APPLICATION NUMBER: US/10/292,088
; CURRENT FILING DATE: 2003-03-14
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 114
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-292-088-114

Query Match          99.4%; Score 511; DB 4; Length 122;
Best Local Similarity 99.0%; Pred. No. 1.3e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98

RESULT 30
US-10-727-155-34
; Sequence 34, Application US/10727155
; Publication No. US20050049402A1
; GENERAL INFORMATION:
; APPLICANT: John S. Babcock
; APPLICANT: Jaapal S. Kang
; APPLICANT: Ozit Foord
; APPLICANT: Larry Green
; APPLICANT: Xiao Feng
; APPLICANT: Scott Klakamp
; APPLICANT: Mary Haak-Frendscho
; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Manchulenko
; APPLICANT: Raffaella Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; FILE REFERENCE: AGENIX.073A
; CURRENT APPLICATION NUMBER: US/10/727,155
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 34
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-727-155-34

Query Match          99.4%; Score 511; DB 5; Length 122;
Best Local Similarity 99.0%; Pred. No. 1.3e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRRAEDTAVYYCAK 98

RESULT 31
US-11-031-485-116
; Sequence 116, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
```

```
; APPLICANT: PULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.
; APPLICANT: HAAK-FRENDSCHO, MARY
; TITLE OF INVENTION: ANTIBODIES TO MADCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 116
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-116

Query Match          99.4%; Score 511; DB 6; Length 122;
Best Local Similarity 99.0%; Pred. No. 1.3e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 32
US-10-292-088-115
; Sequence 115, Application US/10292088
; Publication No. US2003021100A1
; GENERAL INFORMATION:
; APPLICANT: BEDIAN, VAHE
; APPLICANT: GLADUE, RONALD P.
; APPLICANT: CORVALAN, JOSE
; APPLICANT: JIA, XIAO-CHI
; APPLICANT: FENG, XIAO
; TITLE OF INVENTION: ANTIBODIES TO CD40
; FILE REFERENCE: ABX-PF/3 US
; CURRENT APPLICATION NUMBER: US/10/292,088
; CURRENT FILING DATE: 2003-03-14
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 115
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-292-088-115

Query Match          99.4%; Score 511; DB 4; Length 123;
Best Local Similarity 99.0%; Pred. No. 1.3e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

RESULT 33
US-10-292-088-116
; Sequence 116, Application US/10292088
; Publication No. US2003021100A1
```

```
; GENERAL INFORMATION:
; APPLICANT: BEDIAN, VAHE
; APPLICANT: GLADUE, RONALD P.
; APPLICANT: CORVALAN, JOSE
; APPLICANT: JIA, XIAO-CHI
; APPLICANT: FENG, XIAO
; TITLE OF INVENTION: ANTIBODIES TO CD40
; FILE REFERENCE: ABX-PF/3 US
; CURRENT APPLICATION NUMBER: US/10/292,088
; CURRENT FILING DATE: 2003-03-14
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 116
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-292-088-116

Query Match          99.4%; Score 511; DB 4; Length 123;
Best Local Similarity 99.0%; Pred. No. 1.3e-41;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAK 98

Search completed: May 12, 2006, 02:25:16
Job time : 60 secs
```

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 09:04:30 ; Search time 36.8737 Seconds
(without alignments)
1875.095 Million cell updates/sec

Title: US-09-674-752-35

Perfect score: 514

Sequence: 1 QVLVSGGQVQGRSLRL.....LYLQMNLSRAEDTAVYYCAK 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	514	100.0	613	2	Q8WUK1_HUMAN
2	498	96.9	240	2	Q65ZC9_HUMAN
3	495	96.3	116	2	Q9UL93_HUMAN
4	494	96.1	113	2	Q9UL90_HUMAN
5	473	92.0	122	1	HV3G_HUMAN
6	459	89.3	122	2	Q9UL84_HUMAN
7	457	88.9	544	2	Q6PJ95_HUMAN
8	456	88.7	147	2	Q9Y509_HUMAN
9	451	87.7	121	1	HV3J_HUMAN
10	449	87.4	119	1	HV3I_HUMAN
11	446	86.8	121	2	Q9UL71_HUMAN
12	445	86.6	478	2	Q6PJ81_HUMAN
13	443	86.2	122	1	HV3H_HUMAN
14	443	86.2	469	2	Q569F4_HUMAN
15	441	85.8	117	1	HV3C_HUMAN
16	437	85.0	470	2	Q6PJ44_HUMAN
17	435	84.6	597	2	Q96BB9_HUMAN
18	434	84.4	475	2	Q5EF5_HUMAN
19	433	84.2	126	1	HV3K_HUMAN
20	431	83.9	95	2	Q9UL86_HUMAN
21	431	83.9	472	2	Q6N089_HUMAN
22	431	83.9	573	2	Q8WU38_HUMAN
23	425	82.7	461	2	Q5M7V3_RAT
24	425	82.7	465	2	Q510J0_RAT
25	425	82.7	467	2	Q4VBH1_RAT
26	424	82.5	118	2	Q9UL91_HUMAN
27	423	82.3	112	2	Q9HCC1_HUMAN
28	423	82.3	493	2	Q6GMX2_HUMAN
29	421	81.9	519	2	Q6N092_HUMAN
30	419.5	81.6	116	1	HV05_CARAU
31	417.5	81.2	464	2	Q6MZU6_HUMAN

32	417	81.1	119	1	HV3L_HUMAN
33	416	80.9	473	2	Q6MZV7_HUMAN
34	415	80.7	606	2	Q6GMY2_HUMAN
35	414	80.5	479	2	Q5BK12_RAT
36	413.5	80.4	466	2	Q6IN78_HUMAN
37	411	80.0	493	2	Q8NCL6_HUMAN
38	409	79.6	479	2	Q6MZV6_HUMAN
39	407	79.2	475	2	Q6MZQ6_HUMAN
40	406.5	79.1	118	2	Q9UL72_HUMAN
41	406	79.0	116	1	HV3T_HUMAN
42	406	79.0	136	1	HV16_MOUSE
43	404	78.6	114	1	HV3B_HUMAN
44	404	78.6	473	2	Q91Z05_MOUSE
45	404	78.6	479	2	Q5PQK9_RAT

ALIGNMENTS

RESULT 1

ID	Q8WUK1_HUMAN	PRELIMINARY;	PRT;	613	AA.
AC	Q8WUK1				
DT	01-MAR-2002	(TrEMBLrel. 20, Created)			
DT	01-MAR-2002	(TrEMBLrel. 20, Last sequence update)			
DT	01-MAR-2004	(TrEMBLrel. 26, Last annotation update)			
DE	IGHM protein.				
GN	Name=IGHM;				
OS	Homo sapiens (Human).				
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;				
OC	Homo.				
OX	NCBI_TaxID=9606;				
RP	[1]				
RN	NUCLEOTIDE SEQUENCE.				
RC	TISSUE=Primary B-Cells;				
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;				
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,				
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,				
RA	Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,				
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,				
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,				
RA	Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,				
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,				
RA	Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,				
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,				
RA	Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,				
RA	Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,				
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,				
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,				
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,				
RA	Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,				
RA	Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;				
RT	"Generation and initial analysis of more than 15,000 full-length human				
RT	and mouse cDNA sequences."				
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).				
RN	[2]				
RP	NUCLEOTIDE SEQUENCE.				
RC	TISSUE=Primary B-Cells;				
RG	NIH MGC Project;				
RL	Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.				
RN	[3]				
RP	NUCLEOTIDE SEQUENCE.				
RX	PubMed=2117273;				
RA	Schroeder H.W. Jr, Wang J.Y.;				
RT	"Preferential utilization of conserved immunoglobulin heavy chain				
RT	variable gene segments during human fetal life."				
RL	Proc. Natl. Acad. Sci. U.S.A. 87:6146-6150(1990).				
RN	[4]				
RP	NUCLEOTIDE SEQUENCE.				
RX	PubMed=1383695; DOI=10.1016/0161-5890(92)90173-U;				
RA	Cuisinier A.M., Fumoux F., Fougereau M., Tonnelle C.;				

RT "IGM kappa/lambda EBV human B cell clone: an early step of
 RT differentiation of fetal B cells or a distinct B lineage?";
 RL Mol. Immunol. 29:1363-1373(1992).
 RN [5]
 RP NUCLEOTIDE SEQUENCE.
 RX PubMed=1730252;
 RA Raaphorst F.M., Timmers E., Kenter M.J., Van Tol M.J., Vossen J.M.,
 RA Schuurman R.K.;
 RT "Restricted utilization of germ-line VH3 genes and short diverse third
 RT complementarity-determining regions (CDR3) in human fetal B lymphocyte
 RT immunoglobulin heavy chain rearrangements.";
 RL Eur. J. Immunol. 22:247-251(1992).
 RN [6]
 RP NUCLEOTIDE SEQUENCE.
 RX PubMed=1904154;
 RA Neale G.A., Kitchingman G.R.;
 RT "mRNA transcripts initiating within the human immunoglobulin mu heavy
 RT chain enhancer region contain a non-translatable exon and are
 RT extremely heterogeneous at the 5' end.";
 RL Nucleic Acids Res. 19:2427-2433(1991).
 RN [7]
 RP NUCLEOTIDE SEQUENCE.
 RX PubMed=2840480; DOI=10.1084/jem.168.1.229;
 RA Bird J., Galili N., Link M., Stites D., Sklar J.;
 RT "Continuing rearrangement but absence of somatic hypermutation in
 RT immunoglobulin genes of human B cell precursor leukemia.";
 RL J. Exp. Med. 168:229-245(1988).
 RN [8]
 RP NUCLEOTIDE SEQUENCE.
 RX PubMed=2538551; DOI=10.1084/jem.169.4.1391;
 RA Nickerson K.G., Berman J., Glickman E., Chess L., Alt F.W.;
 RT "Early human IgH gene assembly in Epstein-Barr virus-transformed fetal
 RT B cell lines. Preferential utilization of the most JH-proximal D
 RT segment (DQ52) and two unusual VH-related rearrangements.";
 RL J. Exp. Med. 169:1391-1403(1989).
 RN [9]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=93301610; PubMed=8315388; DOI=10.1084/jem.178.1.331;
 RA Hillson J.L., Karr N.S., Opplinger I.R., Mannik M., Sasso E.H.;
 RT "The structural basis of germline-encoded VH3 immunoglobulin binding
 RT to staphylococcal protein A.";
 RL J. Exp. Med. 178:331-336(1993).
 DR EMBL; BC020240; AAH20240.1; -; mRNA.
 DR PIR; F36005; F36005.
 DR PIR; G36005; G36005.
 DR PIR; PH1642; PH1642.
 DR PIR; PH1643; PH1643.
 DR PIR; PH1645; PH1645.
 DR PIR; PH1646; PH1646.
 DR PIR; PL0098; PL0098.
 DR PIR; PL0120; PL0120.
 DR PIR; S15590; S15590.
 DR PIR; S31116; S31116.
 DR PIR; S31119; S31119.
 DR PIR; S70442; S70442.
 DR HSSP; P01861; 1ADQ.
 DR SMR; Q8WUK1; 20-242.
 DR Ensembl; ENSG00000130076; Homo sapiens.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003597; Ig_c1.
 DR InterPro; IPR003006; Ig_MHC.
 DR InterPro; IPR003596; Ig_v.
 DR Pfam; PF07654; C1-set; 4.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; PS50835; IG LIKE; 5.
 DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.
 KW Immunoglobulin domain.
 SQ SEQUENCE 613 AA; 67296 MW; 60CF7F5950671E315 CRC64;

Query Match 100.0%; Score 514; DB 2; Length 613;
 Best Local Similarity 100.0%; Pred. No. 9,3e-48;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWAVISYDGSNKYY 60
 DB |||||
 QY 20 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWAVISYDGSNKYY 79
 DB |||||
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 98
 DB |||||
 QY 80 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 117
 DB |||||
 RESULT 2
 Q65ZC9 HUMAN PRELIMINARY; PRT; 240 AA.
 AC Q65ZC9;
 DT 25-OCT-2004 (Tremblrel. 28, Created)
 DT 25-OCT-2004 (Tremblrel. 28, Last sequence update)
 DT 25-OCT-2004 (Tremblrel. 28, Last annotation update)
 DE Single-chain Fv (Fragment).
 GN Names=scFv;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC STRAIN=Clq/7;
 RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
 RA Kontermann R.E., Wing M.G., Winter G.;
 RT "Complement recruitment using bispecific diabodies.";
 RL Nat. Biotechnol. 15:629-631(1997).
 DR EMBL; Y13056; CAA73499.1; -; mRNA.
 DR InterPro; IPR003599; Ig.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig_v.
 DR SMART; SM00409; IGV; 2.
 DR SMART; SM00406; IGV; 2.
 DR PROSITE; PS50835; IG LIKE; 2.
 DR NON_TER 1
 FT NON_TER 240
 FT NON_TER 240
 SQ SEQUENCE 240 AA; 25569 MW; FDCFD3645F64B373 CRC64;
 Query Match 96.9%; Score 498; DB 2; Length 240;
 Best Local Similarity 95.9%; Pred. No. 1.8e-46;
 Matches 94; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWAVISYDGSNKYY 60
 DB |||||
 QY 1 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSYGMHWVRQAPGKLEWAVISYDGSNKYY 60
 DB |||||
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAK 98
 DB |||||
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAR 98
 DB |||||
 RESULT 3
 Q9UL93 HUMAN PRELIMINARY; PRT; 116 AA.
 AC Q9UL93;
 DT 01-MAY-2000 (Tremblrel. 13, Created)
 DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
 DT 01-MAY-2000 (Tremblrel. 26, Last annotation update)
 DE Myosin-reactive immunoglobulin heavy chain variable region
 DE (Fragment).
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC MEDLINE=9827139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
 RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
 RA Young D.C.;

```

RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RT Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE
RX MEDLINE=93301610; PubMed=8315388; DOI=10.1084/jem.178.1.331;
RA Hillson J.L., Karr N.S., Opplinger I.R., Mannik M., Sasso E.H.;
RT "The structural basis of germline-encoded VH3 immunoglobulin binding
RT to staphylococcal protein A.";
RL J. Exp. Med. 178:331-336(1993).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2840480;
RA Bird J., Galili N., Link M., Stites D., Sklar J.;
RT "Continuing rearrangement but absence of somatic hypermutation in
RT immunoglobulin genes of human B cell precursor leukemia.";
RL J. Exp. Med. 168:229-245(1988).
DR EMBL; AF035021; AAD56257.1; -; mRNA.
DR PIR; PH1644; PH1644.
DR PIR; PLO120; PLO120.
DR HSSP; P01772; 2FB4.
DR SNR; Q9UL93; 1-116.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 116
FT NON_TER 116
SQ SEQUENCE 116 AA; 12434 MW; 0DA0348154DD6061 CRC64;

Query Match 96.3%; Score 495; DB 2; Length 116;
Best Local Similarity 97.9%; Pred. No. 1.6e-46;
Matches 94; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 VQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLVWVAVISYDGSNKYYA 61
Db 1 VQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLVWVAVISYDGSNKYYA 60

Qy 62 DSVKGRFTISRDNKNTLYLQMSLRRAEDTAVYYCA 97
Db 61 DSVKGRFTISRDNKNTLYLQMSLRRAEDTAVYYCA 96

RESULT 4
Q9UL90_HUMAN PRELIMINARY; PRT; 113 AA.
AC Q9UL90;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1730252;
RA Raaphorst F.M., Timmers E., Kenter M.J., Van Tol M.J., Vossen J.M.,
RA Schuurman R.K.;
RT "Restricted utilization of germ-line VH3 genes and short diverse third
RT complementarity-determining regions (CDR3) in human fetal B lymphocyte
RT immunoglobulin heavy chain rearrangements.";
```

```

RL Eur. J. Immunol. 22:247-251(1992).
DR EMBL; AF035024; AAD56260.1; -; mRNA.
DR PIR; S78486; S78486.
DR HSSP; P01772; 2FB4.
DR SNR; Q9UL90; 1-113.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 113
FT NON_TER 113
SQ SEQUENCE 113 AA; 12437 MW; ED57FDD19086D07F CRC64;

Query Match 96.1%; Score 494; DB 2; Length 113;
Best Local Similarity 95.9%; Pred. No. 2e-46;
Matches 94; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLVWVAVISYDGSNKYY 60
Db 1 EVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLVWVAVIRYDGSNKYY 60

Qy 61 ADSVKGRFTISRDNKNTLYLQMSLRRAEDTAVYYCAK 98
Db 61 ADSVKGRFTISRDNKNTLYLQMSLRRAEDTAVYYCAK 98

RESULT 5
HV3G_HUMAN STANDARD; PRT; 122 AA.
AC P01768;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-III region CAM.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=81013859; PubMed=6774332;
RA Lehman D.W., Putnam F.W.;
RT "Amino acid sequence of the variable region of a human mu chain:
RT location of a possible JH segment.";
RL Proc. Natl. Acad. Sci. U.S.A. 77:3239-3243(1980).
CC -I- MISCELLANEOUS: This mu chain was isolated from the plasma of a
CC patient with macroglobulinemia.
CC -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR PIR; A02051; M3HUM.
DR HSSP; P01772; 2FB4.
DR SNR; P01768; 2-122.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Pyridoxone carboxylic acid.
FT DOMAIN 1 112 Ig-like.
FT MOD_RES 1 1 Pyridoxone carboxylic acid.
FT NON_TER 122 122
SQ SEQUENCE 122 AA; 13668 MW; A42D0F17D252F1C2 CRC64;
```

```
Query Match      92.0%; Score 473; DB 1; Length 122;
Best Local Similarity 86.7%; Pred. No. 4.6e-44;
Matches 85; Conservative 10; Mismatches 3; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFPSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 QVELVESGGGVQPGKSLRLSCAASGFTFPSSYAMHWVRQPPGKLEWVAIVSYGBBKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADETAVYYCAK 98
DB 61 ABSVKGRTISRDNKNTLYLQNSLRADETAVYYCAR 98

RESULT 6
Q9UL84 HUMAN PRELIMINARY; PRT; 122 AA.
AC Q9UL84;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
NCBI_TaxID=9606;
[1]
RN NUCLEOTIDE SEQUENCE.
RP TISSUE=Primary B-Cells;
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berny S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035030; AAD56266.1; -; mRNA.
DR HSSP; P01772; 2FB4.
DR SMR; Q9UL84; 1-122.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 122
SQ SEQUENCE 122 AA; 13579 MW; 36054D41366545B8 CRC64;

Query Match      89.3%; Score 459; DB 2; Length 122;
Best Local Similarity 89.8%; Pred. No. 1.6e-42;
Matches 88; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFPSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 1 EVQLVESGGGVQPGKSLRLSCAASRFTFSNYGMHWVRQAPGKLEWVAIVSYDGSNKFY 60

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADETAVYYCAK 98
DB 61 ADSVKGRTIFRDNKNTLYLQNSLRADETAVYYCAK 98

RESULT 7
Q6PU95 HUMAN PRELIMINARY; PRT; 544 AA.
AC Q6PU95;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IgHGI protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
```

```
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Dege J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Lottoliano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butcherfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBSJ databases.
DR EMBL; BC019046; RAH19046.1; -; mRNA.
DR HSSP; P01861; 1ADQ.
DR SMR; Q6PU95; 20-473.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_C1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGC1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC;
SQ SEQUENCE 544 AA; 60102 MW; 1895814B2297C668 CRC64;

Query Match      88.9%; Score 457; DB 2; Length 544;
Best Local Similarity 89.8%; Pred. No. 1.5e-41;
Matches 88; Conservative 2; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFPSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
DB 20 QAQLVESGGGVQPGKSLRLSCAASGFRFSNYGMHWVRQAPGKLEWVAIVSYDSKYY 79

QY 61 ADSVKGRFTISRDNKNTLYLQNSLRADETAVYYCAK 98
DB 80 AASVKGRTISRDNKNTLYLQNSLRADETAVYYCAK 117

RESULT 8
Q9Y509 HUMAN PRELIMINARY; PRT; 147 AA.
AC Q9Y509;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE VH3 protein (Fragment).
GN Name=VH3;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
NCBI_TaxID=9606;
```



```

NN NUCLEOTIDE SEQUENCE.
RX MEDLINE=960711149; PubMed=7475288;
RA Cao J., Vescio R.A., Rettig M.B., Hong C.H., Kim A., Lee J.C.,
RA Lichtenstein A.K., Berenson J.R.;
RT "A CD10-positive subset of malignant cells is identified in multiple
RT myeloma using PCR with patient-specific immunoglobulin gene primers.";
RL Leukemia 9:1948-1953(1995).
DR EMBL; S80860; AAD14339.1; -; mRNA.
DR HSP; P01842; IAKQ.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR GO; GO:0005887; C:integral to plasma membrane; NAS.
DR GO; GO:0016066; P:cellular defense response (sensu Vertebrata); NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 147
SQ SEQUENCE 147 AA; 15768 MW; 8489FCAA7BC925C CRC64;

Query Match 88.7%; Score 456; DB 2; Length 147;
Best Local Similarity 87.8%; Pred. No. 4.3e-42;
Matches 86; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVISYDGSNKYY 60
DB 1 QVHLVSGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLDWVAIVISYDGSQYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
DB 61 AGSVKGRFTISRDNKNTLYLQWNSLRVEDTAVYYCAK 98

RESULT 9
HV3J HUMAN
ID HV3J_HUMAN STANDARD; PRT; 121 AA.
AC P01771;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-III region HIL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=79124695; PubMed=420800;
RA Chiu Y.-Y.H., Lopez de Castro J.A., Poljak R.J.;
RT "Amino acid sequence of the VH region of human myeloma
RT cryoimmunoglobulin IgG Hil.";
RL Biochemistry 18:553-560(1979).
CC -1- MISCELLANEOUS: This chain was isolated from an IgG1 myeloma
CC protein.
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A02054; GIHULH.
CC HSP; P01772; 2FB4.
CC SMR; P01771; 2-121.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; Ig-like.
CC InterPro; IPR003596; Ig_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS50835; IG_LIKE; 1.

```

```

KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Pyrrolidone carboxylic acid.
FT DOMAIN 1 112
FT MOD_RES 121 1 Pyrrolidone carboxylic acid.
FT NON_TER 121
SQ SEQUENCE 121 AA; 13566 MW; 480FCS3610EF5DAB CRC64;

Query Match 87.7%; Score 451; DB 1; Length 121;
Best Local Similarity 84.7%; Pred. No. 1.2e-41;
Matches 83; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVISYDGSNKYY 60
DB 1 QVHLVSGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVYNGSRYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAVYYCAK 98
DB 61 GDSVKGRFTISRDNKRTLYMNSLRTEDTAVYYCAR 98

RESULT 10
HV3I HUMAN
ID HV3I_HUMAN STANDARD; PRT; 119 AA.
AC P01770;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-III region NIE.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=77070269; PubMed=826475;
RA Ponstingl H., Hilschmann N.;
RT "The rule of antibody structure. The primary structure of a monoclonal
RT IgG1 immunoglobulin (myeloma protein NIE). III. The chymotryptic
RT peptides of the H-chain, alignment of the tryptic peptides and
RT discussion of the complete structure.";
RL Hoppe-Seyler's Z. Physiol. Chem. 357:1571-1604(1976).
RN [2]
RP DISULFIDE BOND.
RX MEDLINE=77070267; PubMed=1002129;
RA Dreker L., Schwarz J., Reichel W., Hilschmann N.;
RT "Rule of antibody structure. The primary structure of a monoclonal
RT IgG1 immunoglobulin (myeloma protein NIE). I: purification and
RT characterization of the protein, the L- and H-chains, the cyanogen
RT bromide cleavage products, and the disulfide bridges.";
RL Hoppe-Seyler's Z. Physiol. Chem. 357:1515-1540(1976).
CC -1- MISCELLANEOUS: This chain was isolated from an IgG1 myeloma
CC protein.
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A91668; GIHUNT.
CC HSP; P01772; 2FB4.
CC SMR; P01770; 1-119.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; Ig-like.
CC InterPro; IPR003596; Ig_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS50835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Pyrrolidone carboxylic acid.

```

```

FT DOMAIN          1 112 Ig-like.
FT MOD_RES         1 1 Pyroliidone carboxylic acid.
FT DISULFID        22 96
FT NON_TER         119 119
SQ SEQUENCE        119 AA; 13243 MW; C96935A6E5E165B CRC64;

Query Match
Best Local Similarity 84.7%; Pred. No. 2e-41; Length 119;
Matches 83; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 QVQLVQSGGSGVQPGKSLRLSCAASGFTFSRYTIHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVNGRFTISRDNKNTLYLQWNSLRPEDTAVYYCAR 98

RESULT 11
Q9UL71_HUMAN
ID Q9UL71_HUMAN PRELIMINARY; PRT; 121 AA.
AC Q9UL71;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RL fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192 (1998).
DR EMBL; AF035043; AAD56279.1; -; mRNA.
DR HSSP; P01852; INF0.
DR SMR; Q9UL71; 1-121.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
FT NON_TER 1 121
FT NON_TER 121 121
SQ SEQUENCE 121 AA; 13154 MW; 2F045CCFASD50736 CRC64;

Query Match
Best Local Similarity 86.8%; Score 446; DB 2; Length 121;
Matches 84; Conservative 6; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 1 EVQLVESGGGVQPGGSLRLFCAASGFTFDGYAMHWVRQAPGKLEWVSLISDGGSTYY 60

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 61 ADSVNGRFTISRDNKNTLYLQWNSLRPEDTAVYYCAR 98

RESULT 12
Q6P181_HUMAN
ID Q6P181_HUMAN PRELIMINARY; PRT; 478 AA.
AC Q6P181;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)

```

```

DE IGHM protein.
GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.D., Colling F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zesberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Dickson M.C.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smallos D.E.,
RA Schnerf A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC041037; AAH41037.1; -; mRNA.
DR HSSP; P01861; 1A0Q.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_C1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGC1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 478 AA; 52667 MW; 17BED38D917970D6 CRC64;

Query Match
Best Local Similarity 86.6%; Score 445; DB 2; Length 478;
Matches 85; Conservative 5; Mismatches 8; Indels 0; Gaps 0;

QY 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
Db 20 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 79

QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK 98
Db 80 VDSVNGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAR 117

RESULT 13
HV3H_HUMAN
ID HV3H_HUMAN STANDARD; PRT; 122 AA.
AC P01769;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-III region GA.
OS Homo sapiens (Human).

```

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC NCBI_TaxID=9606;
 RN [1]
 RP PROTEIN SEQUENCE.
 RX MEDLINE=74175307; PubMed=4208843;
 RA Florent G., Lehman D., Putnam F.W.;
 RT "The switch point in mu heavy chains of human Igm immunoglobulins.";
 RL Biochemistry 13:2482-2498(1974).
 CC -I- MISCELLANEOUS: This chain was isolated from a Waldenström's
 CC macroglobulin.
 CC -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC -----
 DR PIR: A02052; M3HUGA.
 DR HSP: P01772; 2FB4.
 DR SNR: P01769; 5-122.
 DR GO: GO:0005576; C:extracellular region; NAS.
 DR GO: GO:0003823; F:antigen binding; NAS.
 DR GO: GO:0006955; P:immune response; NAS.
 DR InterPro: IPR007110; Ig-like.
 DR InterPro: IPR003596; Ig-v.
 DR SMART: SM00406; IGV; 1.
 DR PROSITE; PSS0835; IG_LIKE; 1.
 KW Direct protein sequencing; Immunoglobulin domain;
 KW Immunoglobulin V region; Pyrrolidone carboxylic acid.
 FT DOMAIN 1 112
 FT MOD_RES 1 112
 FT NON_TER 122 122
 FT PYRROLIDONE CARBOXYLIC ACID.
 FT SEQUENCE 122 AA; 131.67 MW; 74ESB6959E84100A CRC64;
 Query Match 86.2%; Score 443; DB 1; Length 122;
 Best Local Similarity 77.6%; Pred. No. 9.4e-41;
 Matches 76; Conservative 18; Mismatches 4; Indels 0; Gaps 0;
 QY 1 QVQLVSGGAVPQGRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGNKYY 60
 Db 1 QVQLVSGGAVPQGRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGNKYY 60
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCA 98
 Db 61 AASVKGRFTISRDNKNTLYLQWNSLRADTAIVYCA 98
 RESULT 14
 QS69F4 HUMAN
 ID QS69F4_HUMAN PRELIMINARY; PRT; 469 AA.
 AC QS69F4;
 DT 10-MAY-2005 (TrEMBLrel. 30, Created)
 DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
 DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
 DE IGHG1 protein.
 GN Name=IGHG1;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OC NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Lymph;
 RX MEDLINE=22398257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner K.H., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smailus D.E.,
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Lymph;
 RG NIH MGC Project;
 RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
 DR EMBL: BC092518; AAH92518.1; -; mRNA.
 SQ SEQUENCE 469 AA; 51254 MW; AC13448E3047784F CRC64;
 Query Match 86.2%; Score 443; DB 2; Length 469;
 Best Local Similarity 85.6%; Pred. No. 4.5e-40;
 Matches 83; Conservative 7; Mismatches 7; Indels 0; Gaps 0;
 QY 1 QVQLVSGGAVPQGRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGNKYY 60
 Db 20 EVQLVESGGVVPQGGSLRLSCAASGFTFDYAMHWVRQAPGKLEWVSLISWDGGSTYY 79
 QY 61 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCA 97
 Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRADTAIVYCA 116
 RESULT 15
 HV3C HUMAN
 ID HV3C_HUMAN STANDARD; PRT; 117 AA.
 AC P01764;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 13-SEP-2005 (Rel. 48, Last annotation update)
 DE Ig heavy chain V-III region VH26 precursor.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OC NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=8101090; PubMed=6450418;
 RA Matthysens G., Rabbitts T.H.;
 RT "Structure and multiplicity of genes for the human immunoglobulin
 RT heavy chain variable region.";
 RL Proc. Natl. Acad. Sci. U.S.A. 77:6561-6565(1980).
 RN [2]
 RP NUCLEOTIDE SEQUENCE OF 20-117.
 RX MEDLINE=93209281; PubMed=7681398;
 RA Mariette X., Teapais A., Broutet J.C.;
 RT "Nucleotide sequence analysis of the variable domains of four human
 RT monoclonal IgM with an antibody activity to myelin-associated
 RT glycoprotein.";
 RL Eur. J. Immunol. 23:846-851(1993).
 RN [3]
 RP 3D-STRUCTURE MODELING OF 20-117.
 RX MEDLINE=86094276; PubMed=3866244;
 RA Toyonaga B., Yoshikai Y., Vadaez V., Chin B., Mak T.W.;
 RT "Organization and sequences of the diversity, joining, and constant
 RT region genes of the human T-cell receptor beta chain.";
 RL Proc. Natl. Acad. Sci. U.S.A. 82:8624-8628(1985).
 CC -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
 CC -----

CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.

 CC
 DR EMBL; J00236; AA53516.1; -; Unassigned DNA.
 DR EMBL; M35415; AA58735.1; -; Genomic DNA.
 DR PIR; A02047; H3HU26.
 DR FDB; IHOU; Model; H=20-117.
 DR HGNC; HGNC:5545; IGHV@.
 DR GO; GO:0005576; C:extracellular region; NAS.
 DR GO; GO:003823; F:antigen binding; NAS.
 DR GO; GO:0006955; P:immune response; NAS.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003596; Ig_v.
 DR SMART; SM00406; IGV; 1.
 DR PROSITE; P850835; IG LIKE; 1.
 KW 3D-structure; Immunoglobulin domain; Immunoglobulin V region; Signal.
 FT SIGNAL 1 19
 FT CHAIN 20 117 Ig heavy chain V-III region VH26.
 FT DOMAIN 20 >117 Ig-like.
 FT NON_TER 117 117
 SQ SEQUENCE 117 AA; 12582 MW; E826733F1A3CB0F1 CRC64;

Query Match 85.8%; Score 441; DB 1; Length 117;
 Best Local Similarity 85.7%; Pred. No. 1.5e-40;
 Matches 84; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY	1	QVQLVESGGGVQPGGSLRLSCAASGFTFSYSGMHWVRQAPGKLEWVAIVSYDGSNKYY	60
Db	20	EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVSAISGGSTYY	79
QY	61	ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK	98
Db	80	GDSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAK	117

Search completed: May 5, 2006, 09:14:33
 Job time : 37.8737 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:28 ; Search time 47.4238 Seconds
(without alignments)

1111.793 Million cell updates/sec

Title: US-09-674-752-36

Perfect score: 622

Sequence: 1 EVQLVESGGGLVQPGKSLRL.....IESNIAELWGQGLTVTVSS 120

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21.*

1: Geneseqp1980s.*

2: Geneseqp1990s.*

3: Geneseqp2000s.*

4: Geneseqp2001s.*

5: Geneseqp2002s.*

6: Geneseqp2003as.*

7: Geneseqp2003bs.*

8: Geneseqp2004s.*

9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	622	100.0	120	3	AA50968 Human FVI
2	622	100.0	120	3	AA50963 Human FVI
3	615	98.9	120	8	ABM79491 Human KM3
4	615	98.9	266	8	ABM79495 Human KM3
5	514	82.6	223	2	AA508598 Anti-huma
6	511	82.2	223	8	ADL70773 Anti-TNFA
7	503.5	80.9	124	8	ADS16557 Human ant
8	503	80.9	120	6	ADA89174 Human ant
9	502	80.7	583	8	ABM82698 Human dia
10	501.5	80.6	121	6	ADA89210 Human ant
11	501.5	80.6	121	6	ADA89218 Human ant
12	501.5	80.6	123	8	ADS84368 Human ant
13	501.5	80.6	123	8	ADR68510 Anti-EPO-
14	501	80.5	227	7	ADJ32122 Human int
15	501	80.5	241	7	ADG30467 Human GMB
16	501	80.5	243	8	ADI58047 Reg IV-sp
17	500.5	80.5	123	8	ADS84396 Human ant
18	500.5	80.5	123	8	ADR68538 Anti-EPO-
19	499.5	80.3	121	9	ADP70212 Human mon
20	499	80.2	121	8	ADP47221 Human ant
21	499	80.2	122	8	ADP22128 Human ant
22	498.5	80.1	118	8	ADS82561 Anti-IL-2
23	498.5	80.1	123	6	ABR55789 Heavy cha
24	498.5	80.1	242	8	ADS82563 Anti-IL-2

25	498.5	80.1	252	5	ABP45720 Human Bly
26	498.5	80.1	252	7	ADG96547 Single ch
27	497.5	80.0	117	7	ADO36354 Intracell
28	497.5	80.0	119	5	ABB07186 sHgm22 h
29	497.5	80.0	119	7	ADL91327 VH chain
30	497.5	80.0	123	6	ADA89270 Human ant
31	497.5	80.0	123	8	ADS84372 Human ant
32	497.5	80.0	123	8	ADR68514 Anti-EPO-
33	497	79.9	119	8	ADP47106 Human pho
34	496.5	79.8	109	9	ADW96628 Human ger
35	496.5	79.8	109	9	ADW96625 Human ger
36	496.5	79.8	109	9	ADW80197 Human ant
37	496.5	79.8	109	9	ADW80200 Human ant
38	496.5	79.8	115	2	AAW15522 Anti-TGF
39	496.5	79.8	121	7	ADP03962 Murine-ex
40	496.5	79.8	127	2	AAV17954 Human D4
41	496.5	79.8	138	2	AAW80815 Amino aci
42	496.5	79.8	457	9	AEC16143 Human ant
43	496.5	79.8	523	3	AAAY44994 HD708cFv-
44	496.5	79.8	524	3	AAAY44995 HD708cFv-
45	496	79.7	121	8	ADP47227 Human pho

ALIGNMENTS

RESULT 1

AA50968

ID AA50968 standard; protein; 120 AA.

XX AA50968;

DT 23-MAR-2000 (first entry)

XX Human FVIII antibody heavy chain variable region B35 protein fragment.

XX Human; heavy chain; antibody; factor VIII; hemostatic; variable region; hemophilia A.

XX Homo sapiens.

XX WO9958680-A2.

XX 18-NOV-1999.

PF 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;

XX WPI; 2000-053102/04.

XX N-PSDB; AAZ43865.

XX New polynucleotide, polypeptide and antibody useful for diagnosing the presence of neutralizing antibodies against factor VIII and for treatment of hemophilia A patients with these antibodies.

XX Example 8; Fig 9D; 61pp; English.

XX This invention describes a novel polynucleotide (I) (and complements and hybridizable polynucleotides) comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity which has hemostatic activity. (I) is useful as a primer or probe for detecting the presence of inhibitory antibodies directed against factor VIII. The polypeptides of the invention and the antibodies generated from them are useful in compositions for neutralizing factor VIII inhibiting antibodies in hemophilia A patients. This sequence represents a fragment of the human factor VIII antibody heavy chain variable region protein B35 which is used in the method of the invention

```

SQ Sequence 120 AA;
Query Match 100.0%; Score 622; DB 3; Length 120;
Best Local Similarity 100.0%; Pred. No. 2.9e-51;
Matches 120; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
DB 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGTFLTVSS 120
DB 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGTFLTVSS 120

RESULT 2
ID AAY50963
AC AAY50963;
XX 23-MAR-2000 (first entry)
XX Human FVIII antibody A3-C1 scFv heavy chain protein B35.
DE Human, heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
KW scFv; A3-C1.
XX Homo sapiens.
XX WO958680-A2.
XX 18-NOV-1999.
XX 07-MAY-1999; 99WO-NL000285.
XX 08-MAY-1998; 98EP-00201543.
XX (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.
XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
XX WPI; 2000-053102/04.
XX New polynucleotide, polypeptide and antibody useful for diagnosing the
XX presence of neutralizing antibodies against factor VIII and for treatment
XX of hemophilia A patients with these antibodies.
XX Example 8; Fig 9A; 61pp; English.
XX This invention describes a novel polynucleotide (I) (and complements and
XX hybridizable polynucleotides) comprising a contiguous nucleotide sequence
XX coding for a human antibody with factor VIII specificity which has
XX hemostatic activity. (I) is useful a primer or probe for detecting the
XX presence of inhibitory antibodies directed against factor VIII. The
XX polypeptides of the invention and the antibodies generated from them are
XX useful in compositions for neutralizing factor VIII inhibiting antibodies
XX in hemophilia A patients. This sequence represents the human factor VIII
XX antibody A3-C1 specific scFv protein B35 which is used in the method of
XX the invention
XX Sequence 120 AA;
Query Match 100.0%; Score 622; DB 3; Length 120;
Best Local Similarity 100.0%; Pred. No. 2.9e-51;
Matches 120; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
DB 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGTFLTVSS 120
DB 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGTFLTVSS 120

SQ Sequence 120 AA;
Query Match 98.9%; Score 615; DB 8; Length 120;
Best Local Similarity 98.3%; Pred. No. 1.4e-50;
Matches 118; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
DB 1 EVQLVESGGGVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGTFLTVSS 120
DB 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGTFLTVSS 120

RESULT 4
ABM79495
ID ABM79491
AC ABM79491;
XX 22-APR-2004 (first entry)
XX Human KW33 heavy chain.
DE Antibody; human; Factor VIII; LRP; haemostatic; haemophilia A;
KW low-density lipoprotein receptor-related protein;
KW blood coagulation disorder.
XX Homo sapiens.
XX WO2003093313-A2.
XX 13-NOV-2003.
XX 28-APR-2003; 2003WO-EP004425.
XX 29-APR-2002; 2002US-0376351P.
XX (BAXT ) BAXTER INT INC.
XX (BAXT ) BAXTER HEALTHCARE SA.
XX (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.
XX Mertens K, Bovenschen AN, Voorberg J, Rieger M, Scheiflinger F;
XX WPI; 2004-053039/05.
XX N-PSDB; AAL56422.
XX Use of peptides derived from and antibodies generated against Factor VIII
XX to inhibit Factor VIII interaction with Low Density Lipoprotein Receptor
XX Protein or to prevent or treat blood coagulation disorders (e.g.
XX hemophilia A).
XX Disclosure; Page 56-57; Opp; English.
XX The present invention relates to peptides derived from Factor VIII but
XX not having any substantial Factor VIII activity, or an antibody which
XX specifically binds to epitopes within the amino acid sequences, which can
XX be used to inhibit Factor VIII interaction with Low Density Lipoprotein
XX Receptor Protein (LRP). The peptides or antibody are useful in inhibiting
XX Factor VIII interaction with LRP, in decreasing Factor VIII degradation
XX in a biological fluid, in prolonging Factor VIII half-life in blood or in
XX preparing a medicament for preventing or treating a blood coagulation
XX disorder (e.g. haemophilia A or von Willebrand's disease) and/or a
XX temporary impairment of the thrombolytic or fibrinolytic systems. The
XX present sequence is a polypeptide shown in the exemplification of the
XX invention
XX Sequence 120 AA;
Query Match 98.9%; Score 615; DB 8; Length 120;
Best Local Similarity 98.3%; Pred. No. 1.4e-50;
Matches 118; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
DB 1 EVQLVESGGGVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGTFLTVSS 120
DB 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGTFLTVSS 120

RESULT 4
ABM79495

```

```
ID  ABM79495 standard; protein; 266 AA.
XX
AC  ABM79495;
XX
DT  22-APR-2004 (first entry)
XX
DE  Human KM33 antibody with linker.
XX
KW  Antibody; human; Factor VIII; LRP; haemostatic; haemophilia A;
KW  low-density lipoprotein receptor-related protein;
KW  blood coagulation disorder.
XX
OS  Homo sapiens.
XX
PN  WO2003093313-A2.
XX
PD  13-NOV-2003.
XX
PF  28-APR-2003; 2003WO-EP004425.
XX
PR  29-APR-2002; 2002US-0376351P.
XX
PA  (BAXT ) BAXTER INT INC.
PA  (BAXT ) BAXTER HEALTHCARE SA.
XX
XX  (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
XX
PI  Mertens K, Bovenschen AN, Voorberg J, Rieger M, Scheiflinger F;
XX  WPI; 2004-053039/05.
XX
XX  Use of peptides derived from and antibodies generated against Factor VIII
PT  to inhibit Factor VIII interaction with Low Density Lipoprotein Receptor
PT  Protein or to prevent or treat blood coagulation disorders (e.g.
PT  hemophilia A).
XX
XX  Claim 20; Page 60-61; Opp; English.
XX
XX  The present invention relates to peptides derived from Factor VIII but
CC  not having any substantial Factor VIII activity, or an antibody which
CC  specifically binds to epitopes within the amino acid sequences, which can
CC  be used to inhibit Factor VIII interaction with low density lipoprotein
CC  Receptor Protein (LRP). The peptides or antibody are useful in inhibiting
CC  Factor VIII interaction with LRP, in decreasing Factor VIII degradation
CC  in a biological fluid, in prolonging Factor VIII half-life in blood or in
CC  preparing a medicament for preventing or treating a blood coagulation
CC  disorder (e.g. haemophilia A or von Willebrand's disease) and/or a
CC  temporary impairment of the thrombolytic or fibrinolytic systems. The
CC  present sequence is a polypeptide shown in the exemplification of the
CC  invention
XX
SQ  Sequence 266 AA;
XX
Query Match 98.9%; Score 615; DB 8; Length 266;
Best Local Similarity 98.3%; Pred. No. 3.4e-50;
Matches 118; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY  1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
DB  1 EVQLVESGGGVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
QY  61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDLESNIAEALWGQGLTVTVSS 120
DB  61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDLESNIAEALWGQGLTVTVSS 120
RESULT 5
AAY08598
ID  AAY08598 standard; protein; 223 AA.
XX
AC  AAY08598;
XX
DT  05-AUG-1999 (first entry)
XX
DE  Anti-human TNF-alpha monoclonal antibody H-chain protein.
XX
KW  Monoclonal antibody; H chain; heavy chain; anti-human; TNF-alpha;
KW  tumour necrosis factor; light chain; L chain.
XX
OS  Homo sapiens.
XX
PN  JP11127855-A.
XX
PD  18-MAY-1999.
XX
PF  27-OCT-1997; 97JP-00293994.
XX
PR  27-OCT-1997; 97JP-00293994.
XX
PA  (NIHA ) JAPAN ENERGY CORP.
XX
XX  WPI; 1999-350318/30.
XX  N-PSDB; AAX77407.
XX
XX  Recombinant anti-human TNF-alpha human monoclonal antibody - produced
PT  stably with a high purity, and in large amounts.
XX
XX  Claim 3; Page 12-13; 22pp; Japanese.
XX
XX  This invention describes novel recombinant anti-human TNF-alpha human
CC  monoclonal antibody consisting of a heavy (H) chain and a light (L)
CC  chain. The recombinant anti-human TNF-alpha human monoclonal antibody can
CC  be produced stably in a high purity and in a large amount
XX
SQ  Sequence 223 AA;
XX
Query Match 82.6%; Score 514; DB 2; Length 223;
Best Local Similarity 81.7%; Pred. No. 1.1e-40;
Matches 98; Conservative 9; Mismatches 11; Indels 2; Gaps 1;
QY  1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
DB  1 QVQLVESGGGVQPGSRSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
QY  61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDLESNIAEALWGQGLTVTVSS 120
DB  61 ADSVKGRFTISRDNKNTLYLQWNSLTIEDTAVYYCAKD--SGDLAPDINGQGTMVTVSS 118
RESULT 6
ADL70773
ID  ADL70773 standard; protein; 223 AA.
XX
AC  ADL70773;
XX
DT  03-JUN-2004 (first entry)
XX
DE  Anti-TNFalpha antibody VH region, SEQ ID 46.
XX
XX  Immunosuppressive; Haemostatic; Antiallergic; Antiaesthetic;
KW  Dermatological; Antiinflammatory; Antibacterial; Vasotropic;
KW  Nephrotropic; Neuroprotective; Cytostatic; Cerebroprotective; Vulnerary;
KW  Antiparkinsonian; Nootropic; Cardiant; Antianemic; Antithrombotic;
KW  Thrombolytic; Anticoagulant; Gastrointestinal; Respiratory; transferrin;
KW  Tf; transferrin fusion protein; Tf fusion protein; anti-TNFalpha;
KW  antibody; VH region.
XX
XX  Unidentified.
XX
XX  WO2004020588-A2.
XX
XX  11-MAR-2004.
XX
XX  28-AUG-2003; 2003WO-US026779.
XX
XX  30-AUG-2002; 2002US-0406977P.
XX
XX  10-MAR-2003; 2003US-00384060.
XX
```


CC host cell comprising heterologous nucleic acid sequences that encodes the
CC novel protein; (5) a transgenic animal whose genome identifies heterologous
CC nucleic acid sequences that encode the protein; (6) identifying the
CC protein that specifically binds the MHC-peptide complex; (7) expressing
CC an antigen-binding protein; (8) ablating or killing a target cell that
CC displays a peptide on a surface MHC molecule; (9) treating or preventing
CC a cancerous disorder in a subject; and (10) detecting an MHC-peptide
CC complex in a sample. A protein of the invention has cytostatic activity,
CC and can be used in gene therapy. The protein is useful for preparing a
CC composition for treating or preventing a cancerous disorder. The present
CC sequence represents the heavy chain of an antibody which binds to an MHC-
CC peptide complex where the peptide component in as peptide fragment of
CC gp100.

[illegible]

RESULT	12	
ADS84368		
ID	ADS84368	standard; protein; 123 AA.
XX		
XX		
AC	ADS84368;	
XX		
XX		
DT	18-NOV-2004	(first entry)
XX		
DE	Human anti-EPO-R antibody heavy chain variable region	SEQ ID NO:7.

human; erythropoietin receptor; EPO receptor;
erythropoietin receptor binding antibody; EPO
antianemic; neuroprotective; vulnery; gene therapy; anaemia;
wound healing; neural cell damage protection;
neural tissue damage protection; brain injury;
stroke; anti-erythropoietin receptor antibody; anti-EPO-R antibody.

XX	Homo sapiens.	
OS		
XX		
PN	WO2004035603-A2.	
XX		
PD	29-APR-2004.	
XX		
PF	14-OCT-2003; 2003WO-US032243.	
XX		
PR	14-OCT-2002; 2002US-00269711.	
PR	10-OCT-2003; 2003US-00684109.	
XX		
PA	(ABBO) ABBOTT LAB.	
XX		
PI	Devries PJ, Green LL, Ostrow DH, Reilly EB, Wieler J;	
XX		
DR	WPI; 2004-348433/32.	
DR	N-PSDS; ADS84367.	
XX		
PT	New antibodies that bind to or activate an endogenous human	
PT	erythropoietin receptor, useful for diagnosing, preventing or treating	
PT	disorders associated with dysfunctional erythropoietin receptor, e.g.	
PT	anemia.	
XX		

Claim 6; SEQ ID NO 7; 192pp; English.

The present invention describes an antibody or its fragment that binds to or activates an endogenous activity of a human erythropoietin (EPO) receptor in a mammal, but does not interact with a peptide having a sequence of 30 amino acids (SPO ID NO:1, ADS843562). Also described: (1) methods of modulating or activating an endogenous activity of a human EPO receptor in a mammal, comprising administering to the mammal a therapeutic amount of the above antibody or its fragment to modulate or activate the receptor; (2) a method of treating a mammal suffering from aplasia, comprising administering to the mammal a therapeutic amount of the above antibody or its fragment to modulate or activate the receptor; (3) a pharmaceutical composition comprising a therapeutic amount of the above antibody or antibody fragment, and a pharmaceutical excipient; (4) an isolated and purified polynucleotide sequence, and their fragments, complements and degenerate codon equivalents; and (5) an isolated and purified amino acid sequence, and their fragments. The EPO receptor binding antibody has antanaemic, neuroprotective and vulnerable activities, and can be used in gene therapy. The compositions and methods from the present invention can be used for modulating an endogenous activity of a human EPO receptor or for treating mammals suffering from aplasia or anaemia. They may also be used for identifying mammals having a dysfunctional EPO receptor. The composition may also be used in promoting wound healing or in protecting against neural cell and/or tissue damage resulting from brain/spinal cord injury, stroke and the like. The present sequence represents a human anti-EPO-R antibody heavy chain variable region, which is given in the exemplification of the present invention.

Sequence 123 AA;

Query Match 80.6%; Score 501.5; DB 8; Length 123;
Best Local Similarity 78.9%; Pred. No. 8.6e-40;
Matches 97: Conservative 9: Mismatches 14: Indels 3

Qy	1 EVQLVESGGGLVQPGRSLRLSCVDLSLTFSYGMHWYRQAPGAGLEWAVISYDGNKYY 60 : :
pb	1 QVQLVESGGGWOPGRSLRLSCVASSTFSYGMHWYRQAPGKGLEWAVISYDGSNKYY 60 : :

Qy	61	ADSVKGRFAISRDNAKNTLYLYLQNNLSLTIEDTAVYYCAKD---	LIESNIAEALWGQGTFLV	117
Dp	61	ADSVKGRFTISRDNSKNTLYLYLQNNLSRVEDTAVYCARDHGRGVYV	DYDGMVDWGQGTFTV	120

Qy	118	VSS	120
Dp	121	VSS	123

RESULT 13

RESO 13
ADR68510
ID ADR68510 standard: protein: 123 AA.

AC ADR68510:

02-DEC-2004 (first entry)

DE Anti-EPO-R-antibody heavy chain variable region seqid 7.

KW antianaemic; respiratory; vulnery; gene therapy; vaccine;
KW erythropoietin receptor; EPO-R; anti-EPO-R-antibody; aplasia; anaemia;
KW hypoxaemia; chronic tissue hypoxia; blood circulation; blood flow;
KW wound healing; neural cell damage; tissue damage; brain injury;
KW spinal cord injury; stroke; anti-EPO-R-antibody; heavy chain;
KW variable region.

OS Homo sapiens.

US2004175379-A1.

09-SEP-2004.

AA
PF 10-OCT-2003; 2003US-00684109.

KW single chain antibody; antidiabetic; type II diabetes; human; GMB683.
XX Homo sapiens.
OS
XX WO2003085093-A2.
PN
XX
XX
XX 16-OCT-2003.
PD
XX
XX 28-MAR-2003; 2003WO-US009625.
PF
XX
XX 01-APR-2002; 2002US-0368813P.
PR
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA
XX
XX Baker KP, Albert VR, Chowdhury P;
PI
XX
XX WPI; 2003-804305/75.
DR
XX N-PSDB; ADG30564.
DR
XX
XX New antibody that specifically binds to GMAD polypeptide, useful for
PT diagnosing, monitoring, treating, preventing or ameliorating type II
PT diabetes.
PT
XX
XX Claim 2; SEQ ID NO 100; 410pp; English.
PS
XX
XX The invention relates to a novel antibody that specifically binds to a
CC GMAD polypeptide comprising a first amino acid sequence that is at least
CC 95% identical to a second amino acid sequence of a VH CDR
CC (complementarity determining region) or VL CDR of an scFv (single chain
CC antibody molecule). The antibody of the invention demonstrates
CC antidiabetic activity and may be useful for diagnosing, monitoring,
CC treating, preventing or ameliorating type II diabetes. The current
CC sequence is that of the human scFv protein of the invention.
CC
XX
SQ Sequence 241 AA;

Query Match 80.5%; Score 501; DB 7; Length 241;
Best Local Similarity 81.7%; Pred. No. 2.1e-39;
Matches 98; Conservative 4; Mismatches 16; Indels 2; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSTSGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
DB 1 EVQLVESGGGLVQPGSRSLRLSCAASGFTFSSTSGMHWVRQAPGKLEWVAIVSYDGSNKYY 60
QY 61 ADSVKGRFAISRDNKNTLYLQNNLSLTIEDTAVYYCAKDLIESNIAEALWGQGLTVTVSS 120
DB 61 ADSVKGRFTISRDNKNTLYLQNNLSRAEDTAVYYCAKRAAAGTL--DYWGQGLTVTVSS 118

Search completed: May 5, 2006, 08:57:10
Job time : 48.4238 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:25 ; Search time 13.8504 Seconds
(without alignments)
716.302 Million cell updates/sec

Title: US-09-674-752-36

Perfect score: 622

Sequence: 1 EVOLVESGGGLVQGRSLRL.....IESNIAELWGQGLTVTVSS 120

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued Patents AA:*
- 1: /cgn2_6/ptodata/1/iaa/5 COMB.pap.*
 - 2: /cgn2_6/ptodata/1/iaa/6 COMB.pap.*
 - 3: /cgn2_6/ptodata/1/iaa/H COMB.pap.*
 - 4: /cgn2_6/ptodata/1/iaa/PCTUS COMB.pap.*
 - 5: /cgn2_6/ptodata/1/iaa/RE_COMB.pap.*
 - 6: /cgn2_6/ptodata/1/iaa/backfiles1.pap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	495	79.6	248	2	US-09-315-926A-80
2	490.5	78.9	120	1	US-07-942-245-35
3	489.5	78.7	115	2	US-09-269-332-89
4	488.5	78.5	451	2	US-09-472-087-70
5	486.5	78.2	119	1	US-08-331-398A-46
6	486.5	78.2	119	1	US-08-331-397B-46
7	486.5	78.2	119	1	US-08-759-804A-46
8	486.5	78.2	119	2	US-09-227-693-46
9	485.5	78.1	123	2	US-09-560-198A-2
10	484.5	77.9	117	2	US-09-025-769B-24
11	484.5	77.9	117	2	US-09-490-070A-24
12	484.5	77.9	117	2	US-09-490-153-24
13	484.5	77.9	117	2	US-09-490-324-24
14	483	77.7	118	2	US-09-798-058-2
15	484	77.7	124	2	US-09-424-840B-16
16	482.5	77.6	225	2	US-09-456-090A-60
17	482.5	77.6	225	2	US-09-456-090A-92
18	482.5	77.6	225	2	US-09-453-234-60
19	482.5	77.6	225	2	US-09-453-234-92
20	482	77.5	120	2	US-10-330-613A-29
21	480.5	77.3	115	2	US-09-534-717-31
22	480.5	77.3	115	2	US-09-534-717-49
23	480.5	77.3	115	2	US-09-534-717-67
24	480.5	77.3	115	2	US-09-534-717-69
25	479.5	77.1	123	2	US-09-424-840B-22
26	479.5	77.1	225	2	US-09-456-090A-56
27	479.5	77.1	225	2	US-09-456-090A-108

28	479.5	77.1	225	2	US-09-453-234-56	Sequence 56, Appl
29	479.5	77.1	225	2	US-09-453-234-108	Sequence 108, Appl
30	478.5	76.9	115	2	US-09-534-717-35	Sequence 35, Appl
31	478.5	76.9	123	2	US-09-560-198A-4	Sequence 4, Appl1
32	478	76.8	463	2	US-09-472-087-1	Sequence 1, Appl1
33	478	76.8	463	2	US-09-472-087-63	Sequence 63, Appl
34	478	76.8	463	2	US-09-472-087-64	Sequence 64, Appl
35	477.5	76.8	123	2	US-09-560-198A-10	Sequence 10, Appl
36	477.5	76.8	125	2	US-09-240-274-8	Sequence 8, Appl1
37	477.5	76.8	125	2	US-09-240-274-20	Sequence 20, Appl
38	477.5	76.8	125	2	US-09-240-274-21	Sequence 21, Appl
39	477.5	76.8	125	2	US-09-240-274-22	Sequence 22, Appl
40	477.5	76.8	125	2	US-09-848-798-8	Sequence 8, Appl1
41	477.5	76.8	125	2	US-09-848-798-20	Sequence 20, Appl
42	477.5	76.8	125	2	US-09-848-798-21	Sequence 21, Appl
43	477.5	76.8	125	2	US-09-848-798-22	Sequence 22, Appl
44	476.5	76.6	225	2	US-09-456-090A-106	Sequence 106, Appl
45	476.5	76.6	225	2	US-09-453-234-106	Sequence 106, Appl

ALIGNMENTS

RESULT 1
US-09-315-926A-80
; Sequence 80, Application US/09315926A
; Patent No. 6498027
; GENERAL INFORMATION:
; APPLICANT: Es van, Helmut
; APPLICANT: Havenga, Menzo
; APPLICANT: Verlinden, Stefan
; TITLE OF INVENTION: TARGETED DELIVERY THROUGH A CATIONIC AMINO ACID TRANSPORTER
; FILE REFERENCE: 2183-4080US
; CURRENT APPLICATION NUMBER: US/09/315,926A
; PRIOR FILING DATE: 1999-05-20
; PRIOR APPLICATION NUMBER: EP 99201593.3
; PRIOR FILING DATE: 1999-05-20
; PRIOR APPLICATION NUMBER: EP 98201693.3
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 80
; TYPE: PRT
; LENGTH: 248
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Description of Artificial Sequence: phage
; NAME/KEY: PEPTIDE
; LOCATION: (1)..(248)
; OTHER INFORMATION: /note="hCAT1 amino acid sequence"
US-09-315-926A-80

Query Match	79.6%	Score 495;	DB 2;	Length 248;
Best Local Similarity	78.3%	Pred. No. 1.8e-41;		
Matches	94;	Mismatches	17;	Indels 0;
Gaps	0;			
QY	1	EVOLVESGGGLVQGRSLRLSCVDSGLTFTSSVGMHWVRQAPGAGLEWVAIVSDGNDKYY	60	
Db	23	QVQLVQSGGVLVQGRSLRLSCAASGFTFSYAMHWVRQAPGKGLWVAIVSDGSNKYY	82	
QY	61	ADSVKGRFAISRDNKNTLYLQNSLTIEDTAVYVCAKDLIESNIAELWGQGLTVTVSS	120	
Db	83	ADSVKGRFTISRDNKNTLYLQNSLRADETAVYVCAKDLIESNIAELWGQGLTVTVSS	142	

RESULT 2
US-07-942-245-35
; Sequence 35, Application US/07942245
; Patent No. 5639641
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, Jan T.
; APPLICANT: SEARLE, Stephen M.J.

```
; APPLICANT: REES, Anthony R.
; APPLICANT: ROGUSKA, Michael A.
; APPLICANT: GUILD, Braydon C.
; TITLE OF INVENTION: SURFACE RESIDUE VENEERING OF RODENT
; TITLE OF INVENTION: ANTIBODIES
; NUMBER OF SEQUENCES: 522
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Sughrue, Mion, Zinn, Macpeak & Seas
; STREET: 2100 Pennsylvania Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: United States
; ZIP: 20037-3202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: HP 9000/700 Workstation
; OPERATING SYSTEM: UNIX
; SOFTWARE: In house
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/942,245
; FILING DATE: 09-SEP-1992
; CLASSIFICATION: 530
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 293-7060
; TELEFAX: (202) 293-7860
; TELEX: 6491103
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-07-942-245-35

Query Match 78.9%; Score 490.5; DB 1; Length 120;
Best Local Similarity 79.5%; Pred. No. 2.2e-41;
Matches 97; Conservative 7; Mismatches 13; Indels 5; Gaps 2;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFAISRDNAKNTLYLQMSLTIEDTAVYYCAKDLIESNIAEALWGQGLT 117
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMSLTIEDTAVYYCARD--RKDWGWFALFDYWGQGLT 118
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 118 VS 119
||
Db 119 VS 120

RESULT 3
US-09-269-332-89
; Sequence 89, Application US/09269332
; Patent No. 6903194
; GENERAL INFORMATION:
; APPLICANT: SATO, KOH
; APPLICANT: WAKAHARA, YUJI
; APPLICANT: YABUTA, NAOHITO
; TITLE OF INVENTION: ANTIBODY AGAINST HUMAN PARATHORMONE RELATED PEPTIDES
; FILE REFERENCE: 04853-0033
; CURRENT APPLICATION NUMBER: US/09/269,332
; CURRENT FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: PCT/JP97/03382
; PRIOR FILING DATE: 1997-09-24
; PRIOR APPLICATION NUMBER: JP 255196/1996
; PRIOR FILING DATE: 1996-09-26
; PRIOR APPLICATION NUMBER: JP 214168/1997
; PRIOR FILING DATE: 1997-07-24
; NUMBER OF SEQ ID NOS: 113
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 89
; LENGTH: 115

; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-269-332-89

Query Match 78.7%; Score 489.5; DB 2; Length 115;
Best Local Similarity 79.2%; Pred. No. 2.6e-41;
Matches 95; Conservative 7; Mismatches 13; Indels 5; Gaps 1;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFAISRDNAKNTLYLQMSLTIEDTAVYYCAKDLIESNIAEALWGQGLT 120
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMSLTIEDTAVYYCARD-----SRGDYWGQGLT 115
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 4
US-09-472-087-70
; Sequence 70, Application US/09472087
; Patent No. 6682736
; GENERAL INFORMATION:
; APPLICANT: HANSON, DOUGLAS C.
; APPLICANT: NEVEU, MARK J.
; APPLICANT: MUELLER, ELLEN E.
; APPLICANT: HANKE, JEFFREY H.
; APPLICANT: GILMAN, STEVEN C.
; APPLICANT: DAVIS, C. GEOFFREY
; APPLICANT: CORVALAN, JOSE R.
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES TO CTLA-4
; FILE REFERENCE: ABX-PFI
; CURRENT APPLICATION NUMBER: US/09/472,087
; CURRENT FILING DATE: 1999-12-23
; PRIOR APPLICATION NUMBER: 60/113,647
; PRIOR FILING DATE: 1998-12-23
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 70
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-472-087-70

Query Match 78.5%; Score 488.5; DB 2; Length 451;
Best Local Similarity 76.8%; Pred. No. 1.6e-40;
Matches 96; Conservative 7; Mismatches 17; Indels 5; Gaps 1;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFAISRDNAKNTLYLQMSLTIEDTAVYYCAKD-----LIESNIAEALWGQGLT 115
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMSLTIEDTAVYYCARDPRGATLYYYVYGVMDVWGQGLT 120
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 116 VTVSS 120
|||||
Db 121 VTVSS 125

RESULT 5
US-08-331-398A-46
; Sequence 46, Application US/08331398A
; Patent No. 5608039
; GENERAL INFORMATION:
; APPLICANT: Pastan, Ira
; APPLICANT: Willingham, Mark
; APPLICANT: Fitzgerald, David
; APPLICANT: Brinkmann, Ulrich
; APPLICANT: Pai, Lee
; TITLE OF INVENTION: Single Chain B3 Antibody Fusion Proteins
; TITLE OF INVENTION: and Their Uses (as amended)
; NUMBER OF SEQUENCES: 68
```



```
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/759,804A
; FILING DATE: 03-DEC-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/331,396
; FILING DATE:
; APPLICATION DATA:
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 015280-126140US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..119
; OTHER INFORMATION: /note= "Human fetal immunoglobulin
; chain (V-H)"
;
; US-08-759-804A-46
Query Match 78.2%; Score 486.5; DB 1; Length 119;
Best Local Similarity 78.3%; Pred. No. 5.3e-41;
Matches 94; Conservative 9; Mismatches 16; Indels 1; Gaps 1;
Qy 1 EVQLVESGGGLVQPGRSLRLSCVDLSLTSSYGMHWRAPAGLEWVAIVSYDGNKYY 60
Db 1 QVELVESGGGVQPGRSLRSCASGFTFSYAHMWVRQAPGKGLEWVAIVSYDGSNKKY 60
Qy 61 ADSVKGRFAISRDNNAKTLYLQMNSLTIEDTAVYYCAKDLESIAEALWGQGTLVTVS 120
Db 61 ADSVKGRFTISRDNSNTLYLQMNSLRADETAVYYCARRSARTTYFD-YWGQGTILTVSS 119
RESULT 8
US-09-227-693-46
Sequence 46 Application US/09227693
Patent No. 6287562
GENERAL INFORMATION:
APPLICANT: PASTAN, Ira
APPLICANT: BENHAR, Itai
APPLICANT: PADLAN, Eduardo A.
APPLICANT: JUNG, Sun-Hee
APPLICANT: LEE, Byungkook
TITLE OF INVENTION: HUMANIZED TUMOR-SPECIFIC ANTIBODY
FRAGMENTS, AND USES THEREOF
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: Stewart Street Tower, One Market Plaza
CITY: San Francisco
STATE: California
COUNTRY: US
ZIP: 94105-1493
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/759,804A
; FILING DATE: 03-DEC-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/331,396
; FILING DATE: 08-OCT-1994
; APPLICATION NUMBER: US 07/767,331
; FILING DATE: 30-SEP-1991
; APPLICATION NUMBER: US 07/596,289
; FILING DATE: 12-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen L.
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 015280-126140US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 119 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..119
; OTHER INFORMATION: /note= "Human fetal immunoglobulin
; chain (V-H)"
; US-08-759-804A-46

Query Match 78.2%; Score 486.5; DB 1; Length 119;
Best Local Similarity 78.3%; Pred. No. 5.3e-41;
Matches 94; Conservative 9; Mismatches 16; Indels 1; Gaps 1;

Qy 1 EVQLVESGGGLVQPGRSLRLSCVDSGLTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 QVELVESGGGVQPGSRSLRSCAASGFTFSYAHMWVRQAPGKGLEWVAIVSYDGSNNKY 60
Qy 61 ADSVKGRFAISRDNNAKNTLYLQNSLTIEDTAVYYCAKDLESIAEALWGQGLTVTVSS 120
Db 61 ADSVKGRFTISRDNSKNTLYLQNSLRRAEDTAVYYCARRSARTTYFD-YWGQGTLTVTVSS 119

RESULT 8
US-09-227-693-46
Sequence 46 Application US/09227693
Patent No. 6287562
GENERAL INFORMATION:
APPLICANT: PASTAN, Ira
APPLICANT: BENHAR, Itai
APPLICANT: PADLAN, Eduardo A.
APPLICANT: JUNG, Sun-Hee
APPLICANT: LEE, Byungkook
TITLE OF INVENTION: HUMANIZED TUMOR-SPECIFIC ANTIBODY
TITLE OF INVENTION: FRAGMENTS, FUSION PROTEINS, AND USES THEREOF
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: Stewart Street Tower, One Market Plaza
CITY: San Francisco
STATE: California
COUNTRY: US
ZIP: 94105-1493
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
```

Query Match 78.1%; Score 485.5; DB 2; Length 123;
Best Local Similarity 78.0%; Pred. No. 6.9e-41;
Matches 96; Conservative 7; Mismatches 17; Indels 3; Gaps 1;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSYSGHHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 QVQLVQSGGGLVQPGSRSLRLSCVDSGLTFSYSGHHWVRQAPGAGLEWVAIVSYDGSIKYY 60
Qy 61 ADSVKGRFAISRDNKNTLYLQMNSLTIETAVYYCAKDLIESNIAEALWGQGLTVT 117
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARDGGSG---DYMGGGLTVTVSS 117
Qy 118 VSS 120
Db 121 VSS 123

RESULT 10

US-09-025-769B-24
; Sequence 24, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769B
FILING DATE: 18-FEB-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: linear
MOLECULE TYPE: protein
US-09-025-769B-24

Query Match 77.9%; Score 484.5; DB 2; Length 117;
Best Local Similarity 80.0%; Pred. No. 8.2e-41;
Matches 96; Conservative 4; Mismatches 17; Indels 3; Gaps 1;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSYSGHHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYAMHWVRQAPGKLEWVSVSYDGGNTYY 60

Qy 61 ADSVKGRFAISRDNKNTLYLQMNSLTIETAVYYCAKDLIESNIAEALWGQGLTVTVSS 120
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARDGGSG---DYMGGGLTVTVSS 117

RESULT 11

US-09-490-070A-24
; Sequence 24, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAuliffe
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,070A
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: Colin G. Sandercock, Esq.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 37629-0005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 912-2000
TELEFAX: (202) 912-2020
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 117 amino acids
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 24:
US-09-490-070A-24

Query Match 77.9%; Score 484.5; DB 2; Length 117;
Best Local Similarity 80.0%; Pred. No. 8.2e-41;
Matches 96; Conservative 4; Mismatches 17; Indels 3; Gaps 1;

Qy 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSYSGHHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYAMHWVRQAPGKLEWVSVSYDGGNTYY 60
Qy 61 ADSVKGRFAISRDNKNTLYLQMNSLTIETAVYYCAKDLIESNIAEALWGQGLTVTVSS 120
Db 61 ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARDGGSG---DYMGGGLTVTVSS 117

RESULT 12

US-09-490-153-24
; Sequence 24, Application US/09490153
; Patent No. 6706484
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim

;
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090

INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 24:

US-09-490-153-24

Query Match 77.9%; Score 484.5; DB 2; Length 117;
Best Local Similarity 80.0%; Pred. No. 8.2e-41;
Matches 96; Conservative 4; Mismatches 17; Indels 3; Gaps 1;

Qy 1 EVQLVESGGGLVQPGSRSLRSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 EVQLVESGGGLVQPGSRSLRSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Qy 61 ADSVKGRFAISRDNKNTLYLQNNLSLTIEDTAVYYCAKDLIESNAEALWGQGTILTVSS 120
Db 61 ADSVKGRFTISRDNKNTLYLQNNLSLAEDTAVYYCARDRGSG---DYWGQGTILTVSS 117

RESULT 13

US-09-490-324-24
; Sequence 24, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim

; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas

; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas

; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995

ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090

INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 24:

US-09-490-324-24

Query Match 77.9%; Score 484.5; DB 2; Length 117;
Best Local Similarity 80.0%; Pred. No. 8.2e-41;
Matches 96; Conservative 4; Mismatches 17; Indels 3; Gaps 1;

Qy 1 EVQLVESGGGLVQPGSRSLRSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 EVQLVESGGGLVQPGSRSLRSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Qy 61 ADSVKGRFAISRDNKNTLYLQNNLSLTIEDTAVYYCAKDLIESNAEALWGQGTILTVSS 120
Db 61 ADSVKGRFTISRDNKNTLYLQNNLSLAEDTAVYYCARDRGSG---DYWGQGTILTVSS 117

RESULT 14

US-09-798-058-2
; Sequence 2, Application US/09798058
; Patent No. 6946546
; GENERAL INFORMATION:

; APPLICANT: Vaughan, Tristan John
; APPLICANT: Wilton, Alison Jane
; APPLICANT: Smith, Stephen
; APPLICANT: Main, Sarah Helen
; TITLE OF INVENTION: Human antibodies against eotaxin and their use
; FILE REFERENCE: 84632-000100
; CURRENT APPLICATION NUMBER: US/09/798,058
; CURRENT FILING DATE: 2001-08-29
; PRIOR APPLICATION NUMBER: US 60/187,246
; PRIOR FILING DATE: 2000-03-03
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 2

; LENGTH: 118

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-798-058-2

Query Match 77.8%; Score 484; DB 2; Length 118;
Best Local Similarity 78.3%; Pred. No. 9.3e-41;
Matches 94; Conservative 9; Mismatches 15; Indels 2; Gaps 1;

[illegible]

RESULT 15

```

US-09-424-840B-16
; Sequence 16, Application US/09424840B
; Patent No. 6790938
; GENERAL INFORMATION:
; APPLICANT: Berchtold, Peter A.
; APPLICANT: Escher, Robert F. A.
; TITLE OF INVENTION: ANTI-GPIIB/IIIA RECOMBINANT ANTIBODIES
; FILE REFERENCE: 100564-09049
; CURRENT APPLICATION NUMBER: US/09/424,840B
; CURRENT FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: DE 19820663.1
; PRIOR FILING DATE: 1998-05-08
; PRIOR APPLICATION NUMBER: DE 19755227.7
; PRIOR FILING DATE: 1997-12-12
; PRIOR APPLICATION NUMBER: DE 19723904.8
; PRIOR FILING DATE: 1997-06-06
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-424-840B-16

```

Query Match	77.7%	Score 483;	DB 2;	Length 124;
Best Local Similarity	75.8%	Pred. No. 1.2e-40;		
Matches 94;	Conservative 10;	Mismatches 16;	Indels 4;	Gaps 1;

[illegible]

Search completed: May 5, 2006, 08:53:49
Job time : 13.8504 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:55:01 ; Search time 38.1163 Seconds
(without alignments)
1315.434 Million cell updates/sec

Title: US-09-674-752-36

Perfect score: 622

Sequence: 1 EVOLVSGGGLVQGRSLRL.....IESNIAELWQGQGLTVTVSS 120

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications AA_Main:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pgp:*

2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pgp:*

3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pgp:*

4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pgp:*

5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pgp:*

6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pgp:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	503	80.9	120	4	US-10-371-942-18
2	501.5	80.6	121	4	US-10-371-942-54
3	501.5	80.6	121	4	US-10-371-942-62
4	501.5	80.6	123	4	US-10-269-711-7
5	501.5	80.6	123	4	US-10-684-109-7
6	501	80.5	122	4	US-10-292-088-114
7	501	80.5	227	3	US-09-972-656-76
8	501	80.5	241	5	US-10-935-290-100
9	501	80.5	243	6	US-11-017-030-6
10	501	80.5	261	4	US-10-642-120-6
11	501	80.5	261	4	US-10-642-060-6
12	501	80.5	261	4	US-10-642-122-6
13	501	80.5	261	4	US-10-642-059-6
14	501	80.5	261	4	US-10-642-124-6
15	501	80.5	261	4	US-10-621-269-6
16	501	80.5	261	4	US-10-620-850-6
17	501	80.5	261	4	US-10-642-118-6
18	501	80.5	261	4	US-10-642-119-6
19	501	80.5	261	4	US-10-642-117-6
20	501	80.5	261	5	US-10-642-099-6
21	501	80.5	261	5	US-10-642-064-6
22	501	80.5	261	5	US-10-642-116-6
23	501	80.5	261	5	US-10-642-100-6
24	501	80.5	261	5	US-10-642-058-6
25	501	80.5	261	5	US-10-642-121-6
26	501	80.5	261	5	US-10-642-065-6
27	501	80.5	261	5	US-10-642-071-6

28	500.5	80.5	123	4	US-10-269-711-43	Sequence 43, Appl
29	500.5	80.5	123	4	US-10-684-109-35	Sequence 35, Appl
30	500.5	80.5	124	5	US-10-805-177-54	Sequence 54, Appl
31	499.5	80.3	138	4	US-10-325-694-144	Sequence 144, App
32	499	80.2	121	5	US-10-726-332-136	Sequence 136, App
33	499	80.2	122	5	US-10-727-155-34	Sequence 34, Appl
34	498.5	80.1	118	5	US-10-798-380-19	Sequence 19, Appl
35	498.5	80.1	123	4	US-10-269-805-21	Sequence 21, Appl
36	498.5	80.1	242	5	US-10-798-380-21	Sequence 21, Appl
37	498.5	80.1	252	3	US-09-880-748-1731	Sequence 1731, Ap
38	498.5	80.1	252	4	US-10-293-418-1731	Sequence 1731, Ap
39	497.5	80.0	113	3	US-09-791-153A-63	Sequence 63, Appl
40	497.5	80.0	123	4	US-10-371-942-114	Sequence 114, App
41	497.5	80.0	123	4	US-10-269-711-11	Sequence 11, Appl
42	497.5	80.0	123	4	US-10-269-711-23	Sequence 23, Appl
43	497.5	80.0	123	4	US-10-269-711-27	Sequence 27, Appl
44	497.5	80.0	123	4	US-10-269-711-31	Sequence 31, Appl
45	497.5	80.0	123	4	US-10-269-711-35	Sequence 35, Appl

ALIGNMENTS

RESULT 1

US-10-371-942-18
; Sequence 18, Application US/10371942
; Publication No. US20030223994A1
; GENERAL INFORMATION:
; APPLICANT: Hoogenboom, Henricus Renerus Jacobus Mattheus
; APPLICANT: Reiter, Yoram
; TITLE OF INVENTION: MHC-PEPTIDE COMPLEX BINDING LIGANDS
; FILE REFERENCE: 10280-034001
; CURRENT APPLICATION NUMBER: US/10/371,942
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,994
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-371-942-18

Query Match 80.9%; Score 503; DB 4; Length 120;
Best Local Similarity 80.0%; Pred.No. 1.5e-41;
Matches 96; Conservative 7; Mismatches 17; Indels 0; Gaps 0;

QY 1 EVOLVSGGGLVQGRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAVISYDGNKKY 60

Db 1 QVOLVSGGGVQVQGRSLRLSCAASGFTTSSYGMHWVRQAPGAGLEWVAVISYDGSNKY 60

QY 61 ADSVKGRFAISRDNKNTLYLQNSLTIEDTAVYYCAKLIESNIAELWQGQGLTVTVSS 120

Db 61 ADSVKGRFATSRDNSKNTLYLQNSLRABDTAVYYCARDYGYDYLIDYNGQGGLTVTVSS 120

RESULT 2

US-10-371-942-54
; Sequence 54, Application US/10371942
; Publication No. US20030223994A1
; GENERAL INFORMATION:
; APPLICANT: Hoogenboom, Henricus Renerus Jacobus Mattheus
; APPLICANT: Reiter, Yoram
; TITLE OF INVENTION: MHC-PEPTIDE COMPLEX BINDING LIGANDS
; FILE REFERENCE: 10280-034001
; CURRENT APPLICATION NUMBER: US/10/371,942
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,994
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 54

```
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-371-942-54

Query Match      80.6%; Score 501.5; DB 4; Length 121;
Best Local Similarity 81.0%; Pred. No. 2.1e-41;
Matches 98; Conservative 7; Mismatches 15; Indels 1; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGGVSVPGRSLRLSCAASGFTFSYGMHWVRQAPGKGLWVAIFISYDGSKNF 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFAISRDNAKNTLYLQMNLSLTIEDTAVYYCAKLIENIA-EALWGQGLTVTS 119
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAKDSYDNSAFQADWGQGLTVTS 120
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 120 S 120
Db 121 S 121

RESULT 3
US-10-371-942-62
; Sequence 62, Application US/10371942
; Publication No. US20030223994A1
; GENERAL INFORMATION:
; APPLICANT: Hoogenboom, Henricus Renerus Jacobus Mattheus
; APPLICANT: Reiter, Yoram
; TITLE OF INVENTION: MHC-PEPTIDE COMPLEX BINDING LIGANDS
; FILE REFERENCE: 10280-034001
; CURRENT APPLICATION NUMBER: US/10/371,942
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,994
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 62
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-371-942-62

Query Match      80.6%; Score 501.5; DB 4; Length 121;
Best Local Similarity 81.0%; Pred. No. 2.1e-41;
Matches 98; Conservative 7; Mismatches 15; Indels 1; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGGVSVPGRSLRLSCAASGFTFSYGMHWVRQAPGKGLWVAIFISYDGSKNF 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFAISRDNAKNTLYLQMNLSLTIEDTAVYYCAKLIENIA-EALWGQGLTVTS 119
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAKDSYDNSAFQADWGQGLTVTS 120
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 120 S 120
Db 121 S 121

RESULT 4
US-10-269-711-7
; Sequence 7, Application US/10269711
; Publication No. US20040071694A1
; GENERAL INFORMATION:
; APPLICANT: Abbott Laboratories
; APPLICANT: Devries, Peter J.
; APPLICANT: Reilly, Edward B.
; APPLICANT: Ostrow, Dave
; APPLICANT: Weiler, James
; APPLICANT: Green, Larry
; TITLE OF INVENTION: ERYTHROPOIETIN RECEPTOR BINDING
; TITLE OF INVENTION: ANTIBODIES

; FILE REFERENCE: 6989.US.O1
; CURRENT APPLICATION NUMBER: US/10/269,711
; PRIOR APPLICATION NUMBER: 10/269,711
; PRIOR FILING DATE: 2002-10-14
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-269-711-7

Query Match      80.6%; Score 501.5; DB 4; Length 123;
Best Local Similarity 78.9%; Pred. No. 2.1e-41;
Matches 97; Conservative 9; Mismatches 14; Indels 3; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGVSVPGRSLRLSCVSGFTFSYGMHWVRQAPGKGLWVAIVSYDGSNKYY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFAISRDNAKNTLYLQMNLSLTIEDTAVYYCAKD---LIESNIAEALWGQGLTVT 117
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRVEDTAVYYCARDHGGRYVYDGMVWGQGLTVT 120
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 118 VSS 120
Db 121 VSS 123

RESULT 5
US-10-684-109-7
; Sequence 7, Application US/10684109
; Publication No. US20040175379A1
; GENERAL INFORMATION:
; APPLICANT: Devries, Peter J.
; APPLICANT: Green, Larry L.
; APPLICANT: Ostrow, David H.
; APPLICANT: Reilly, Edward B.
; APPLICANT: Wieler, James
; TITLE OF INVENTION: Erythropoietin Receptor Binding
; TITLE OF INVENTION: Antibodies
; FILE REFERENCE: 6989.US.O2
; CURRENT APPLICATION NUMBER: US/10/684,109
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: 10/269,711
; PRIOR FILING DATE: 2002-10-14
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-684-109-7

Query Match      80.6%; Score 501.5; DB 4; Length 123;
Best Local Similarity 78.9%; Pred. No. 2.1e-41;
Matches 97; Conservative 9; Mismatches 14; Indels 3; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGVSVPGRSLRLSCVSGFTFSYGMHWVRQAPGKGLWVAIVSYDGSNKYY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFAISRDNAKNTLYLQMNLSLTIEDTAVYYCAKD---LIESNIAEALWGQGLTVT 117
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQMNLSRVEDTAVYYCARDHGGRYVYDGMVWGQGLTVT 120
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 118 VSS 120
Db 121 VSS 123

RESULT 6
US-10-292-088-114
; Sequence 114, Application US/10292088
```



```
Publication No. US20030211100A1
GENERAL INFORMATION:
APPLICANT: BEDIA, VAHE
APPLICANT: GLADUE, RONALD P.
APPLICANT: CORVALAN, JOSE
APPLICANT: JIA, XIAO-CHI
APPLICANT: FENG, XIAO
TITLE OF INVENTION: ANTIBODIES TO CD40
FILE REFERENCE: ABX-PF/3 US
CURRENT APPLICATION NUMBER: US/10/292,088
CURRENT FILING DATE: 2003-03-14
PRIOR APPLICATION NUMBER: 60/348,980
PRIOR FILING DATE: 2001-11-09
NUMBER OF SEQ ID NOS: 147
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 114
LENGTH: 122
TYPE: PRT
ORGANISM: Homo sapiens
US-10-292-088-114

Query Match      80.5%; Score 501; DB 4; Length 122;
Best Local Similarity 80.6%; Pred. No. 2.3e-41;
Matches 100; Conservative 6; Mismatches 12; Indels 6; Gaps 2;

QY 1 EVOLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFAISRDNKNTLYLQNSLTIEDTAVYYCAK-----DLIESNIAEALWGQGLTV 116
Db 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCARYCGGDCY--GIAVAGWGQGLTV 118

QY 117 TVSS 120
Db 119 TVSS 122

RESULT 7
US-09-972-656-76
Sequence 76, Application US/09972656
Publication No. US20030099647A1
GENERAL INFORMATION:
APPLICANT: Deshpande, Rajendra
APPLICANT: Teai, Mei-Mei
TITLE OF INVENTION: Fully Human Antibody Fab Fragments with Human Interferon-Gamma
FILE REFERENCE: Neutralizing Activity
CURRENT APPLICATION NUMBER: US/09/972,656
CURRENT FILING DATE: 2001-10-05
NUMBER OF SEQ ID NOS: 135
SOFTWARE: Patentin version 3.0
SEQ ID NO 76
LENGTH: 227
TYPE: PRT
ORGANISM: Homo sapiens
US-09-972-656-76

Query Match      80.5%; Score 501; DB 3; Length 227;
Best Local Similarity 77.4%; Pred. No. 4.7e-41;
Matches 96; Conservative 9; Mismatches 15; Indels 4; Gaps 1;

QY 1 EVOLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 QVQLVETGGGVQPGKSLRLSCAASGFTFSYAMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFAISRDNKNTLYLQNSLTIEDTAVYYCAKDLI-----ESNIAEALWGQGLTV 116
Db 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCASDLVLTMTSRAAFDIWGQGTWV 120

QY 117 TVSS 120
Db 121 TVSS 124
```

```
RESULT 8
US-10-935-290-100
Sequence 100, Application US/10935290
Publication No. US20050069542A1
GENERAL INFORMATION:
APPLICANT: Baker et al.
TITLE OF INVENTION: Antibodies that Specifically Bind to GMAD
FILE REFERENCE: PF584P1
CURRENT APPLICATION NUMBER: US/10/935,290
CURRENT FILING DATE: 2004-09-08
PRIOR APPLICATION NUMBER: PCT/US03/09625
PRIOR FILING DATE: 2003-03-28
PRIOR APPLICATION NUMBER: 60/368,813
PRIOR FILING DATE: 2002-04-01
NUMBER OF SEQ ID NOS: 234
SEQ ID NO 100
LENGTH: 241
TYPE: PRT
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: scFv protein GMBc683
US-10-935-290-100

Query Match      80.5%; Score 501; DB 5; Length 241;
Best Local Similarity 81.7%; Pred. No. 5e-41;
Matches 98; Conservative 4; Mismatches 16; Indels 2; Gaps 1;

QY 1 EVOLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 EVOLVESGGGLVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFAISRDNKNTLYLQNSLTIEDTAVYYCAKDLIESNIAEALWGQGLTVTVSS 120
Db 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCAKRAAAGTL--DYWGQGTTVTVSS 118

RESULT 9
US-11-017-030-6
Sequence 6, Application US/11017030
Publication No. US20050158313A1
GENERAL INFORMATION:
APPLICANT: Rosen, et al.
TITLE OF INVENTION: Antibodies that Specifically Bind to Reg IV
FILE REFERENCE: PF592PCT
CURRENT APPLICATION NUMBER: US/11/017,030
CURRENT FILING DATE: 2004-12-21
PRIOR APPLICATION NUMBER: PCT/US03/19908
PRIOR FILING DATE: 2003-06-26
PRIOR APPLICATION NUMBER: 60/392,382
PRIOR FILING DATE: 2002-07-01
NUMBER OF SEQ ID NOS: 176
SOFTWARE: Patentin version 3.1
SEQ ID NO 6
LENGTH: 243
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: scFv protein RGB0110
US-11-017-030-6

Query Match      80.5%; Score 501; DB 6; Length 243;
Best Local Similarity 80.0%; Pred. No. 5.1e-41;
Matches 96; Conservative 8; Mismatches 16; Indels 0; Gaps 0;

QY 1 EVOLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 EVQLVQSGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFAISRDNKNTLYLQNSLTIEDTAVYYCAKDLIESNIAEALWGQGLTVTVSS 120
Db 61 ADSVKGRFTISRDNKNTLYLQNSLRAEDTAVYYCAKASTYYDFWFDWGQGTWTVSS 120
```

```
RESULT 10
US-10-642-120-6
; Sequence 6, Application US/10642120
; Publication No. US20040131610A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: Soares, M. Melina
; APPLICANT: Ran, Sophia
; TITLE OF INVENTION: Methods for Treating Viral Infections Using Antibodies to
; FILE REFERENCE: 4001.002900
; CURRENT APPLICATION NUMBER: US/10/642,120
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: US 10/621,269
; PRIOR FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: 60/396,263
; PRIOR FILING DATE: 2002-07-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 261
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: POLYPEPTIDE
US-10-642-120-6

Query Match      80.5%; Score 501; DB 4; Length 261;
Best Local Similarity 80.8%; Pred. No. 5.5e-41;
Matches 97; Conservative 6; Mismatches 11; Indels 6; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRSLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 7 EVQLVESGGGVQPGSRSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 66

QY 61 ADSVKGRFAISRDNAKNTLYLQMNLSLTIEDTAVYYCAKDLIESNTIAEALWGQGLTVTVSS 120
Db 67 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAR-----LHAQTWGQGLTVTVSS 120

RESULT 11
US-10-642-060-6
; Sequence 6, Application US/10642060
; Publication No. US20040131621A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: Soares, M. Melina
; APPLICANT: Ran, Sophia
; TITLE OF INVENTION: Combinations and Kits for Treating Viral Infections Using Antibod
; FILE REFERENCE: 4001.002982
; CURRENT APPLICATION NUMBER: US/10/642,060
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: US 10/621,269
; PRIOR FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: 60/396,263
; PRIOR FILING DATE: 2002-07-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 261
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: POLYPEPTIDE
US-10-642-060-6

Query Match      80.5%; Score 501; DB 4; Length 261;
Best Local Similarity 80.8%; Pred. No. 5.5e-41;
Matches 97; Conservative 6; Mismatches 11; Indels 6; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRSLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 7 EVQLVESGGGVQPGSRSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 66

QY 61 ADSVKGRFAISRDNAKNTLYLQMNLSLTIEDTAVYYCAKDLIESNTIAEALWGQGLTVTVSS 120
Db 67 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAR-----LHAQTWGQGLTVTVSS 120

RESULT 12
US-10-642-122-6
; Sequence 6, Application US/10642122
; Publication No. US20040131622A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: Soares, M. Melina
; APPLICANT: Ran, Sophia
; TITLE OF INVENTION: Combinations and Kits for Treating Viral Infections Using
; FILE REFERENCE: 3999.002985
; CURRENT APPLICATION NUMBER: US/10/642,122
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: US 10/621,269
; PRIOR FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: 60/396,263
; PRIOR FILING DATE: 2002-07-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 261
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: POLYPEPTIDE
US-10-642-122-6

Query Match      80.5%; Score 501; DB 4; Length 261;
Best Local Similarity 80.8%; Pred. No. 5.5e-41;
Matches 97; Conservative 6; Mismatches 11; Indels 6; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRSLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 7 EVQLVESGGGVQPGSRSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 66

QY 61 ADSVKGRFAISRDNAKNTLYLQMNLSLTIEDTAVYYCAKDLIESNTIAEALWGQGLTVTVSS 120
Db 67 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAR-----LHAQTWGQGLTVTVSS 120

RESULT 13
US-10-642-059-6
; Sequence 6, Application US/10642059
; Publication No. US20040147440A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: He, Jin
; TITLE OF INVENTION: Compositions Comprising Cell-Impermeant Duramycin Derivatives
; FILE REFERENCE: 4001.003100
; CURRENT APPLICATION NUMBER: US/10/642,059
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: US 10/621,269
; PRIOR FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: 60/396,263
; PRIOR FILING DATE: 2002-07-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 261
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: POLYPEPTIDE
US-10-642-059-6
```

```
QY 1 EVQLVESGGGLVQPGSRSLRSLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 7 EVQLVESGGGVQPGSRSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 66

QY 61 ADSVKGRFAISRDNAKNTLYLQMNLSLTIEDTAVYYCAKDLIESNTIAEALWGQGLTVTVSS 120
Db 67 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAR-----LHAQTWGQGLTVTVSS 120

RESULT 12
US-10-642-122-6
; Sequence 6, Application US/10642122
; Publication No. US20040131622A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: Soares, M. Melina
; APPLICANT: Ran, Sophia
; TITLE OF INVENTION: Combinations and Kits for Treating Viral Infections Using
; FILE REFERENCE: 3999.002985
; CURRENT APPLICATION NUMBER: US/10/642,122
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: US 10/621,269
; PRIOR FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: 60/396,263
; PRIOR FILING DATE: 2002-07-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 261
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: POLYPEPTIDE
US-10-642-122-6

Query Match      80.5%; Score 501; DB 4; Length 261;
Best Local Similarity 80.8%; Pred. No. 5.5e-41;
Matches 97; Conservative 6; Mismatches 11; Indels 6; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRSLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 7 EVQLVESGGGVQPGSRSLRSLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 66

QY 61 ADSVKGRFAISRDNAKNTLYLQMNLSLTIEDTAVYYCAKDLIESNTIAEALWGQGLTVTVSS 120
Db 67 ADSVKGRFTISRDNKNTLYLQMNLSRAEDTAVYYCAR-----LHAQTWGQGLTVTVSS 120

RESULT 13
US-10-642-059-6
; Sequence 6, Application US/10642059
; Publication No. US20040147440A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: He, Jin
; TITLE OF INVENTION: Compositions Comprising Cell-Impermeant Duramycin Derivatives
; FILE REFERENCE: 4001.003100
; CURRENT APPLICATION NUMBER: US/10/642,059
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: US 10/621,269
; PRIOR FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: 60/396,263
; PRIOR FILING DATE: 2002-07-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 261
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: POLYPEPTIDE
US-10-642-059-6
```

Query Match 80.5%; Score 501; DB 4; Length 261;
Best Local Similarity 80.8%; Pred. No. 5.5e-41;
Matches 97; Conservative 6; Mismatches 11; Indels 6; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
DB 7 EVQLVESGGGVQPGSRSLRLSCAASGFTFTSSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 66

QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDLESNIAEALWGQGLTVTVSS 120
DB 67 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAR-----LHAQTWGGQGLTVTVSS 120

RESULT 14
US-10-642-124-6
; Sequence 6, Application US/10642124
; Publication No. US20040161429A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: Soares, M. Melina
; APPLICANT: Ran, Sophia
; TITLE OF INVENTION: Compositions for Treating Viral Infections Using Immunoconjugates
; TITLE OF INVENTION: Aminophospholipids
; FILE REFERENCE: 3999.002984
; CURRENT APPLICATION NUMBER: US/10/642,124
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: US 10/621,269
; PRIOR FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: 60/396,263
; PRIOR FILING DATE: 2002-07-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 261
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: POLYPEPTIDE
US-10-642-124-6

Query Match 80.5%; Score 501; DB 4; Length 261;
Best Local Similarity 80.8%; Pred. No. 5.5e-41;
Matches 97; Conservative 6; Mismatches 11; Indels 6; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
DB 7 EVQLVESGGGVQPGSRSLRLSCAASGFTFTSSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 66

QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDLESNIAEALWGQGLTVTVSS 120
DB 67 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAR-----LHAQTWGGQGLTVTVSS 120

RESULT 15
US-10-621-269-6
; Sequence 6, Application US/10621269
; Publication No. US20040170620A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: Ran, Sophia
; TITLE OF INVENTION: Selected Antibody Compositions for Binding to Aminophospholipids
; FILE REFERENCE: 4001.003000
; CURRENT APPLICATION NUMBER: US/10/621,269
; CURRENT FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: 60/396,263
; PRIOR FILING DATE: 2002-07-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 261
; TYPE: PRT
; ORGANISM: ARTIFICIAL SEQUENCE

; FEATURE:
; OTHER INFORMATION: POLYPEPTIDE
US-10-621-269-6

Query Match 80.5%; Score 501; DB 4; Length 261;
Best Local Similarity 80.8%; Pred. No. 5.5e-41;
Matches 97; Conservative 6; Mismatches 11; Indels 6; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
DB 7 EVQLVESGGGVQPGSRSLRLSCAASGFTFTSSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 66

QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDLESNIAEALWGQGLTVTVSS 120
DB 67 ADSVKGRFTISRDNKNTLYLQWNSLRADDTAVYYCAR-----LHAQTWGGQGLTVTVSS 120

Search completed: May 5, 2006, 09:02:19
Job time : 38.1163 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:56:13 ; Search time 8.97507 Seconds
(without alignments)
618.844 Million cell updates/sec

Title: US-09-674-752-36

Perfect score: 622

Sequence: 1 EVQLVSGGGLVQGRSLRL.....IESNIAELWGQGLTVTVSS 120

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA New:*
1: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
2: /SIDSS5/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
3: /SIDSS5/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
4: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
5: /SIDSS5/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
6: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
7: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
8: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
9: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
10: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
11: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
12: /SIDSS5/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	520.5	83.7	117	9	US-10-771-257-89
2	509.5	81.9	117	9	US-10-771-257-82
3	509.5	81.9	117	9	US-10-771-257-94
4	501.5	80.6	117	9	US-10-771-257-96
5	499.5	80.3	117	9	US-10-771-257-85
6	499.5	80.3	117	9	US-10-771-257-93
7	499.5	80.3	121	9	US-10-850-635-16
8	498.5	80.1	252	11	US-11-054-515-1731
9	498.5	80.1	252	11	US-11-266-444-1731
10	498.5	80.1	117	9	US-10-771-257-18
11	497.5	80.0	117	11	US-11-127-677-18
12	497.5	80.0	117	11	US-11-093-274-19
13	496.5	79.8	117	11	US-11-956-008-18
14	495.5	79.7	123	8	US-10-546-594-64
15	495.5	79.7	123	8	US-10-546-594-70
16	495.5	79.7	123	11	US-11-054-515-1394
17	495.5	79.7	252	11	US-11-266-444-1394
18	495.5	79.7	472	8	US-10-546-594-130
19	495.5	79.7	472	8	US-10-546-594-130
20	495	79.6	249	11	US-11-054-515-512
21	495	79.6	249	11	US-11-266-444-512

22	494.5	79.5	117	9	US-10-771-257-97	Sequence 97, Appl
23	494	79.4	249	11	US-11-054-515-1109	Sequence 1109, Ap
24	494	79.4	249	11	US-11-266-444-1109	Sequence 1109, Ap
25	493.5	79.3	240	11	US-11-054-515-1912	Sequence 1912, Ap
26	493.5	79.3	240	11	US-11-266-444-1912	Sequence 1912, Ap
27	493	79.3	248	11	US-11-054-515-1890	Sequence 1890, Ap
28	493	79.3	248	11	US-11-266-444-1890	Sequence 1890, Ap
29	492.5	79.2	117	9	US-10-771-257-81	Sequence 81, Appl
30	492.5	79.2	117	9	US-10-771-257-83	Sequence 83, Appl
31	492.5	79.2	117	9	US-10-771-257-87	Sequence 87, Appl
32	492.5	79.2	117	9	US-10-771-257-92	Sequence 92, Appl
33	491.5	79.0	123	9	US-10-982-440-1	Sequence 1, Appl
34	491	78.9	120	9	US-10-771-257-12	Sequence 12, Appl
35	491	78.9	120	11	US-11-127-677-12	Sequence 12, Appl
36	491	78.9	122	9	US-10-982-440-39	Sequence 39, Appl
37	490	78.8	241	11	US-11-054-515-1887	Sequence 1887, Ap
38	490	78.8	241	11	US-11-054-515-1901	Sequence 1901, Ap
39	490	78.8	241	11	US-11-266-444-1887	Sequence 1887, Ap
40	490	78.8	241	11	US-11-266-444-1901	Sequence 1901, Ap
41	490	78.8	247	11	US-11-054-515-1330	Sequence 1330, Ap
42	490	78.8	247	11	US-11-266-444-1330	Sequence 1330, Ap
43	490	78.8	249	11	US-11-054-515-397	Sequence 397, App
44	490	78.8	249	11	US-11-054-515-1102	Sequence 1102, Ap
45	490	78.8	249	11	US-11-054-515-1115	Sequence 1115, Ap

ALIGNMENTS

RESULT 1
US-10-771-257-89
; Sequence 89, Application US/10771257
; Publication No. US2005028864A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: SISSA - Scuola Superiore Internazionale di Studi Avanzati
; APPLICANT: Cattaneo, Antonino
; APPLICANT: Maritan, Amos
; APPLICANT: Visintin, Michela
; APPLICANT: Rabbitts, Terrence H
; APPLICANT: Settanni, Giovanni
; TITLE OF INVENTION: Intracellular antibodies
; FILE REFERENCE: 18396/2272
; CURRENT APPLICATION NUMBER: US/10/771,257
; CURRENT FILING DATE: 2004-02-03
; PRIOR APPLICATION NUMBER: PCT/GB02/03512
; PRIOR FILING DATE: 2002-08-01
; PRIOR APPLICATION NUMBER: GB 0119004.0
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: GB 0121577.1
; PRIOR FILING DATE: 2001-09-06
; PRIOR APPLICATION NUMBER: GB 0200928.0
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: GB 0203569.9
; PRIOR FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: IT RM2001A000633
; PRIOR FILING DATE: 2001-10-25
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 89
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-771-257-89

Query Match 83.7%; Score 520.5; DB 9; Length 117;

Best Local Similarity 83.3%; Pred. No. 4e-39;

Matches 100; Conservative 10; Mismatches 10; Indels 3; Gaps 1;

Qy 1 EVQLVSGGGLVQGRSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWAVISVDGNDKYY 60

Db 1 QVQLVSGGGLVQGRSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWAVISVDGNDKYY 60


```
QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGLTVTVSS 120
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAKDLV---AKGNWGQGLTVTVSS 117

RESULT 5
US-10-771-257-85
; Sequence 85, Application US/10771257
; Publication No. US20050288864A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: SISSA - Scuola Superiore Internazionale di Studi Avanzati
; APPLICANT: Cattaneo, Antonino
; APPLICANT: Maritan, Amos
; APPLICANT: Visintin, Michela
; APPLICANT: Rabbitts, Terrence H
; APPLICANT: Settanni, Giovanni
; TITLE OF INVENTION: Intracellular antibodies
; FILE REFERENCE: 18396/2272
; CURRENT APPLICATION NUMBER: US/10/771,257
; CURRENT FILING DATE: 2004-02-03
; PRIOR APPLICATION NUMBER: PCT/GB02/03512
; PRIOR FILING DATE: 2002-08-01
; PRIOR APPLICATION NUMBER: GB 0119004.0
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: GB 0121577.1
; PRIOR FILING DATE: 2001-09-06
; PRIOR APPLICATION NUMBER: GB 0200928.0
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: GB 0203569.9
; PRIOR FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: IT RM2001A000633
; PRIOR FILING DATE: 2001-10-25
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 85
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-771-257-85

Query Match 80.3%; Score 499.5; DB 9; Length 117;
Best Local Similarity 80.8%; Pred. No. 2.8e-37;
Matches 97; Conservative 7; Mismatches 13; Indels 3; Gaps 1;

QY 1 EVLVESGGGLVQPGRSRLSLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAVISYDGNKKY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGGSGVQPGRSRLSLSCAASGFTFSSYGMHWVRQAPGKLEWVAISYDGSNKY 60

QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGLTVTVSS 120
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAKDLV---RGALDYWGQGLTVTVSS 117

RESULT 6
US-10-771-257-93
; Sequence 93, Application US/10771257
; Publication No. US20050288864A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: SISSA - Scuola Superiore Internazionale di Studi Avanzati
; APPLICANT: Cattaneo, Antonino
; APPLICANT: Maritan, Amos
; APPLICANT: Visintin, Michela
; APPLICANT: Rabbitts, Terrence H
; APPLICANT: Settanni, Giovanni
; TITLE OF INVENTION: Intracellular antibodies
; FILE REFERENCE: 18396/2272
; CURRENT APPLICATION NUMBER: US/10/771,257
; CURRENT FILING DATE: 2004-02-03
; PRIOR APPLICATION NUMBER: PCT/GB02/03512
; PRIOR FILING DATE: 2002-08-01
```

```
; PRIOR APPLICATION NUMBER: GB 0119004.0
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: GB 0121577.1
; PRIOR FILING DATE: 2001-09-06
; PRIOR APPLICATION NUMBER: GB 0200928.0
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: GB 0203569.9
; PRIOR FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: IT RM2001A000633
; PRIOR FILING DATE: 2001-10-25
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 93
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-771-257-93

Query Match 80.3%; Score 499.5; DB 9; Length 117;
Best Local Similarity 80.0%; Pred. No. 2.8e-37;
Matches 96; Conservative 8; Mismatches 13; Indels 3; Gaps 1;

QY 1 EVLVESGGGLVQPGRSRLSLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAISYDGNKKY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGGSGVQPGRSRLSLSCAASGFTFSSYGMHWVRQAPGKLEWVAISYDGSNKY 60

QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGLTVTVSS 120
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAKDLV---AKGNWQGLTVTVSS 117

RESULT 7
US-10-850-635-16
; Sequence 16, Application US/10850635
; Publication No. US20050287149A1
; GENERAL INFORMATION:
; APPLICANT: Keller, Tibor
; APPLICANT: Lowy, Israel
; APPLICANT: Vitale, Laura
; APPLICANT: Bianset, Diane
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES AGAINST
; FILE REFERENCE: MXI-305
; CURRENT APPLICATION NUMBER: US/10/850,635
; CURRENT FILING DATE: 2004-05-21
; PRIOR APPLICATION NUMBER: 60/472636
; PRIOR FILING DATE: 2003-05-21
; PRIOR APPLICATION NUMBER: 60/512336
; PRIOR FILING DATE: 2003-10-16
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-850-635-16

Query Match 80.3%; Score 499.5; DB 9; Length 121;
Best Local Similarity 81.0%; Pred. No. 2.9e-37;
Matches 98; Conservative 8; Mismatches 14; Indels 1; Gaps 1;

QY 1 EVLVESGGGLVQPGRSRLSLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAISYDGNKKY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGGSGVQPGRSRLSLSCAASGFTFSSYGMHWVRQAPGKLEWVAIWYDGSNKY 60

QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDLIESNIAEALWGQGLTVTVSS 119
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRAEDTAVYYCAREGNSHYIPFATWGQGLTVTVSS 120

QY 120 S 120
Db 121 S 121
```

```
RESULT 8
US-10-982-440-21
; Sequence 21, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 21
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-21

Query Match      80.1%; Score 498.5; DB 9; Length 123;
Best Local Similarity 79.7%; Pred. No. 3.6e-37;
Matches 98; Conservative 6; Mismatches 16; Indels 3; Gaps 1;

QY 1 EVLVESGGGLVOPGRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFAISRDNNAKNTLYLQNNSLTIEDTAVYYCAK---DLIESIAEALWGQGTFLV 117
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNNAKNTLYLQNNSLRAEDTAVYYCAKGPVDFDYGDAIDYWGGTFLVT 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 118 VSS 120
   |||
Db 121 VSS 123

RESULT 9
US-11-054-515-1731
; Sequence 1731, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1731
; LENGTH: 252
```

```
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1731

Query Match      80.1%; Score 498.5; DB 11; Length 252;
Best Local Similarity 75.2%; Pred. No. 7.1e-37;
Matches 97; Conservative 9; Mismatches 14; Indels 9; Gaps 1;

QY 1 EVLVESGGGLVOPGRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFAISRDNNAKNTLYLQNNSLTIEDTAVYYCAKDLIE-----SNIAEALWG 111
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNNAKNTLYLQNNSLRAEDTAVYYCARDRLYYDILTCYYYYYYGMVDWG 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 112 QGTLVTVSS 120
   :|||||:|||||
Db 121 RGTLTVSS 129

RESULT 10
US-11-266-444-1731
; Sequence 1731, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-08-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1731
; LENGTH: 252
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1731

Query Match      80.1%; Score 498.5; DB 11; Length 252;
Best Local Similarity 75.2%; Pred. No. 7.1e-37;
Matches 97; Conservative 9; Mismatches 14; Indels 9; Gaps 1;

QY 1 EVLVESGGGLVOPGRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVVQPGRSRLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIVSYDGSNKYY 60
   :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 ADSVKGRFAISRDNNAKNTLYLQNNSLTIEDTAVYYCAKDLIE-----SNIAEALWG 111
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNNAKNTLYLQNNSLRAEDTAVYYCARDRLYYDILTCYYYYYYGMVDWG 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 112 QGTLVTVSS 120
   :|||||:|||||
Db 121 RGTLTVSS 129

RESULT 11
US-10-771-257-18
; Sequence 18, Application US/10771257
; Publication No. US2005028864A1
; GENERAL INFORMATION:
```



```

QY 1 EVLVESGGGLVQGRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAVISYDGNKYY 60
Db 1 QVLVESGGGVQVQGRSLRLSLSAASGFTSSYGMHWVRQAPGKGLDWAVAVISYDGSNKFY 60
QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKD---LIESNIAEALWGQGTTLVT 117
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLTIEDTAVYYCAKDHWELLD-----YWGQGTTLVT 114
QY 118 VSS 120
Db 115 VSS 117

```

```

RESULT 15
US-10-546-594-64
; Sequence 64, Application US/10546594
; Publication No. US20060088538A1
; GENERAL INFORMATION:
; APPLICANT: HOSOKAWA, Saiko
; APPLICANT: AOKI, Masahiko
; APPLICANT: HIRAKAWA, Yoko
; APPLICANT: ITAMI, Seima
; APPLICANT: UMEKI, Hiroe
; APPLICANT: SAIKAWA, Yoshiro
; APPLICANT: KUMAI, Koichiro
; APPLICANT: FUKUDA, Kazumasa
; TITLE OF INVENTION: MONOCLONAL ANTIBODY AND GENE ENCODING THE SAME, HYBRIDOMA, PHARMA
; FILE OF INVENTION: COMPOSITION, AND DIAGNOSTIC REAGENT
; FILE REFERENCE: 238067
; CURRENT APPLICATION NUMBER: US/10/546,594
; CURRENT FILING DATE: 2005-08-19
; PRIOR APPLICATION NUMBER: JP 2003/54670
; PRIOR FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: JP 2003/194643
; PRIOR FILING DATE: 2003-07-09
; NUMBER OF SEQ ID NOS: 132
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 64
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-546-594-64

```

```

Query Match      79.7%; Score 495.5; DB 8; Length 123;
Best Local Similarity 78.9%; Pred. No. 6.6e-37;
Matches 97; Conservative 6; Mismatches 17; Indels 3; Gaps 1;

QY 1 EVLVESGGGLVQGRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAVISYDGNKYY 60
Db 1 QVLVESGGGVQVQGRSLRLSLSAASGFTSSYGMHWVRQAPGKGLDWAVAVISYDGSNKYY 60
QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVYYCAKDIESNIAE---LWGQGTTLVT 117
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLTIEDTAVYYCARDHRSYDFWSGSLDYWGQGTTLVT 120
QY 118 VSS 120
Db 121 VSS 123

```

Search completed: May 5, 2006, 08:57:45
Job time : 9.97507 secs

F; 15-58/Donnell: Immunology & Immunopathology

```
Query Match      80.7%; Score 502; DB 2; Length 118;
Best Local Similarity 80.8%; Pred. No. 2.9e-40;
Matches 97; Conservative 7; Mismatches 14; Indels 2; Gaps 1;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYAMHWVRQAPGKGLEWVAIVSYDGSNKY 60

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAIVSYDGSNKY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQMNSLTIEDTAVYYCAKDLIESNTAEALWGQGLTVTVSS 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATD--GGKAAFDIWGQGTMTVTVSS 118

RESULT 3
Ig heavy chain V region (M49) - human
C:Species: Homo sapiens (man)
C>Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 31-Dec-2004
C:Accession: F36005
R:Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A:Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A:Reference number: A36005; MUID:90349571; PMID:2117273
A:Accession: F36005
A:Status: Preliminary
A:Molecule type: mRNA
A:Residues: 1-119 <SCH>
A:Cross-references: UNIPROT:Q8WUK1; UNIPARC:UPI0000176C32; GB:M34026
C:Genetics:
A:Gene: GDB:IGH@; IGHDY1
A:Cross-references: GDB:118731; OMIM:146910
A:Map position: 14q32.33-14q32.33
C:Superfamily: immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match      80.6%; Score 501.5; DB 2; Length 119;
Best Local Similarity 80.8%; Pred. No. 3.2e-40;
Matches 97; Conservative 9; Mismatches 13; Indels 1; Gaps 1;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYAMHWVRQAPGKGLEWVAIVSYDGSNKY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQMNSLTIEDTAVYYCAKDLIESNTAEALWGQGLTVTVSS 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDKASD-AFDIWGQGTMTVTVSS 119

RESULT 4
Ig heavy chain - human
C:Species: Homo sapiens (man)
C>Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C:Accession: S3112
R:Raaphorst, F.W.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman
Eur. J. Immunol. 22, 247-251, 1992
A:Title: Restricted utilization of germ-line V(H)3 genes and short diverse third complement
A:Reference number: S31104; MUID:92111633; PMID:1730252
A:Accession: S31112
A:Status: Preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: mRNA
A:Residues: 1-120 <RAA>
A:Cross-references: UNIPARC:UPI0000176C8C; EMBL:X62961
A:Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match      80.4%; Score 500; DB 2; Length 120;
Best Local Similarity 80.0%; Pred. No. 4.5e-40;
Matches 96; Conservative 7; Mismatches 17; Indels 0; Gaps 0;
```

```
QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYAMHWVRQAPGKGLEWVAIVSYDGSNKY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQMNSLTIEDTAVYYCAKDLIESNTAEALWGQGLTVTVSS 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATGVVVVAAATDYGQGLTVTVSS 120

RESULT 5
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 27-Jan-1995 #sequence_revision 27-Jan-1995 #text_change 20-Jun-2000
C:Accession: S46390
R:Figini, M.; Marke, J.D.; Winter, G.; Griffiths, A.D.
J. Mol. Biol. 239, 68-78, 1994
A:Title: In vitro assembly of repertoires of antibody chains on the surface of phage by
A:Reference number: S46390; MUID:94254092; PMID:8196048
A:Accession: S46390
A:Status: Preliminary
A:Molecule type: DNA
A:Residues: 1-114 <FIG>
A:Cross-references: UNIPARC:UPI000011663F; EMBL:Z31686; NID:9509782; PIDN:CAA83491.1; PII
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match      80.2%; Score 499; DB 2; Length 114;
Best Local Similarity 80.8%; Pred. No. 5.3e-40;
Matches 97; Conservative 6; Mismatches 11; Indels 6; Gaps 1;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGVQPGKSLRLSCAASGFTFSYAMHWVRQAPGKGLEWVAIVSYDGSNKY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQMNSLTIEDTAVYYCAKDLIESNTAEALWGQGLTVTVSS 120
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDWGD-----YWGQGLTVTVSS 114

RESULT 6
Ig heavy chain V region (M74) - human
C:Species: Homo sapiens (man)
C>Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 31-Dec-2004
C:Accession: G36005
R:Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A:Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A:Reference number: A36005; MUID:90349571; PMID:2117273
A:Accession: G36005
A:Status: Preliminary
A:Molecule type: mRNA
A:Residues: 1-121 <SCH>
A:Cross-references: UNIPROT:Q8WUK1; UNIPARC:UPI0000176C2C; GB:M34031
C:Genetics:
A:Gene: GDB:IGH@; IGHDY1
A:Cross-references: GDB:118731; OMIM:146910
A:Map position: 14q32.33-14q32.33
C:Superfamily: immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match      79.5%; Score 494.5; DB 2; Length 121;
Best Local Similarity 79.7%; Pred. No. 1.5e-39;
Matches 98; Conservative 7; Mismatches 13; Indels 5; Gaps 2;

QY 1 EVQLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
   :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGVQPGKSLRLSCAASGFTFSYAMHWVRQAPGKGLEWVAIVSYDGSNKY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQMNSLTIEDTAVYYCAKDLIESNTAEAL--WGQGLTVT 117
```

```

||||| 61 ADSVKGRFTISRDNSKNTLYLQWNSLRRAEDTAVYYCARD--RKDMGWFADYWGQGLTVT 118
Db 118 VSS 120
|||
Db 119 VSS 121

RESULT 7
E36005
IG heavy chain V region (M72) - human
C:Species: Homo sapiens (man)
C>Date: 21-Dec-1990 #sequence_revision 21-Dec-1990 #text_change 16-Dec-1998
C:Accession: E36005
R:Schroeder Jr., H.W.; Wang, J.Y.
Proc. Natl. Acad. Sci. U.S.A. 87, 6146-6150, 1990
A:Title: Preferential utilization of conserved immunoglobulin heavy chain variable gene
A:Reference number: A36005; MUID:90349571; PMID:2117273
A:Accession: E36005
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-122 <SCH>
A:Cross-references: UNIPARC:UPI0000176C30; GB:M34030
C:Genetics:
A:Gene: GDB:IGH@; IGHDI1
A:Cross-references: GDB:118731; OMIM:146910
A:Map position: 14q32.33-14q32.33
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 79.4%; Score 494; DB 2; Length 122;
Best Local Similarity 78.7%; Pred. No. 1.7e-39;
Matches 96; Conservative 8; Mismatches 16; Indels 2; Gaps 1;

QY 1 EVLVESGGGLVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 QVQLVSGGGVQVPGKSLRLSCAASGFTTSSYAMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLIESN--IAEALWGQGLTVTV 118
Db 61 ADSVKGRFTISRDNSKNTLYLQWNSLRRAEDTAVYYCARDRHSSWYYGMDVWGQGLTVTV 120

QY 119 SS 120
Db 121 SS 122

RESULT 8
S19666
IG heavy chain V region (VH3DJH4) - human
C:Species: Homo sapiens (man)
C>Date: 22-Jan-1993 #sequence_revision 22-Jan-1993 #text_change 20-Jun-2000
C:Accession: S19666
R:Marks, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.; Winter,
J. Mol. Biol. 222, 581-597, 1991
A:Title: By-passing immunization. Human antibodies from V-gene libraries displayed on phage
A:Reference number: S19663; MUID:92085276; PMID:1748994
A:Accession: S19666
A:Molecule type: mRNA
A:Residues: 1-121 <MAR>
A:Cross-references: UNIPARC:UPI0000115PF5; EMBL:X61646; NID:g37688; PIDN:CAA43827.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 79.3%; Score 493.5; DB 2; Length 121;
Best Local Similarity 80.2%; Pred. No. 1.9e-39;
Matches 97; Conservative 6; Mismatches 17; Indels 1; Gaps 1;

QY 1 EVLVESGGGLVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 QVQLVSGGGVQVPGKSLRLSCAASGFTTSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

```

```

QY 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLIESNAB-ALWGQGLTVTVS 119
Db 61 ADSVKGRFTISRDNSKNTLYLQWNSLRRAEDTAVYYCAKGYSGWGYFDYWGQGLTVTVS 120

QY 120 S 120
Db 121 S 121

RESULT 9
S31117
IG heavy chain - human
C:Species: Homo sapiens (man)
C>Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C:Accession: S31117
R:Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman,
Eur. J. Immunol. 22, 247-251, 1992
A:Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A:Reference number: S31104; MUID:92111633; PMID:1730252
A:Accession: S31117
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: mRNA
A:Residues: 1-122 <RAA>
A:Cross-references: UNIPARC:UPI0000176C8D; EMBL:X62967
A>Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 78.9%; Score 491; DB 2; Length 122;
Best Local Similarity 79.5%; Pred. No. 3.2e-39;
Matches 97; Conservative 7; Mismatches 16; Indels 2; Gaps 2;

QY 1 EVLVESGGGLVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 QVQLVSGGGVQVPGKSLRLSCAASGFTTSSYGMHWVRQAPGKLEWVAIVSYDGSNKYY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQWNSLTIEDTAVYYCAKDLI-ESNIAE-ALWGQGLTVTV 118
Db 61 ADSVKGRFTISRDNSKNTLYLQWNSLRRAEDTAVYYCARDFFAPPNWSHFDDYWGQGLTVTV 120

QY 119 SS 120
Db 121 SS 122

RESULT 10
S31679
IG heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31679
R:Cuisinier, A.M.; Gauthier, L.; Boulbi, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31679
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-134 <CUI>
A:Cross-references: UNIPARC:UPI0000116475; EMBL:Z14203; NID:g30965; PIDN:CAA78572.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match 78.7%; Score 489.5; DB 2; Length 134;
Best Local Similarity 79.2%; Pred. No. 4.9e-39;
Matches 95; Conservative 7; Mismatches 13; Indels 5; Gaps 1;

QY 1 EVLVESGGGLVQPGKSLRLSCVDSGLTFTSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 20 QVQLVSGGGVQVPGKSLRLSCAASGFTTSSYAMHWVRQAPGKLEWVAIVSYDGSNKYY 79

```

```
QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVVYCAKDLIESNTAEALWGQTLTVSS 120
Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVVYCARE-----SRGDYWGQTLTVSS 134

RESULT 11
S70442
Ig heavy chain precursor V region (mu) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 24-Jul-1998 #sequence_revision 24-Jul-1998 #text_change 31-Dec-2004
C:Accession: S70442
R:Cuisinier, A.M.; Fumoux, F.; Fougereau, M.; Tonnelle, C.
Mol. Immunol. 29, 1363-1373, 1992
A:Title: IGM kappa/lambdA EBV human B cell clone: an early step of differentiation of fe
A:Reference number: S70442; MUID:93024508; PMID:1383695
A:Accession: S70442
A:Status: not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-140 <CUI>
A:Cross-references: UNIPROT:Q8WUK1; UNIPARC:UPI0000176EB7
C:Superfamily: immunoglobulin homology
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match 78.5%; Score 488; DB 2; Length 140;
Best Local Similarity 78.3%; Pred. No. 7.2e-39;
Matches 94; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 20 QVQLVESGGGVQPGGSLRLSCAASGFTFSNGYGMHWVRQAPGKLEWVAIFRDYDSNKYY 79

QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVVYCAKDLIESNTAEALWGQTLTVSS 120
Db 80 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVVYCAKDLIESNTAEALWGQTLTVSS 139

RESULT 12
A49028
Ig heavy chain V-III region - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 21-Jan-1994 #sequence_revision 18-Nov-1994 #text_change 23-Jul-1999
C:Accession: A49028
R:Timmers, E.; Kenter, M.; Thompson, A.; Kraakman, M.E.; Berman, J.E.; Alt, F.W.; Schuur
Eur. J. Immunol. 21, 2355-2363, 1991
A:Title: Diversity of immunoglobulin heavy chain gene segment rearrangement in B lymphob
A:Reference number: A49028; MUID:92008140; PMID:1915549
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-133 <TIM>
A:Cross-references: UNIPARC:UPI0000113P2C; GB:S64471; NID:G236904; PIDN:AAB20011.1; PID:
A:Experimental source: X-linked agammaglobulinemia patients, B lymphoblastoid cell lines
A:Note: sequence extracted from NCBI backbone (NCBIN:64471, NCBIIP:64470)
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 78.1%; Score 485.5; DB 2; Length 133;
Best Local Similarity 78.2%; Pred. No. 1.2e-38;
Matches 97; Conservative 6; Mismatches 16; Indels 5; Gaps 2;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 QVQLVESGGVVQPGSRSLRLSCAASGFTFSYGMHWVLRQAPGKLEWVAIVYDGSNKYY 60

QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVVYCAKDLIESNTAEALWGQTLV 116
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVVYCARDRL-RLTAAAGNFYWGQTLA 119

QY 117 TVSS 120
Db 120 TVSS 123
```

```
RESULT 13
S48797
Ig heavy chain V region (anti-Sm, VH3/Dxp4/JH6) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Sep-1998 #text_change 23-Jul-1999
C:Accession: S48797; S26893
R:Mahmoudi, M.; Edwards, J.; Cairns, E.; Bell, D.
submitted to the EMBL Data Library, October 1994
A:Description: Molecular characterization of natural human anti-Sm autoantibodies.
A:Reference number: S48797
A:Accession: S48797
A:Molecule type: mRNA
A:Residues: 1-128 <MAH>
A:Cross-references: UNIPARC:UPI0000116700; EMBL:Z46379; NID:G587147; PIDN:CAA86512.1; PII
R:Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A:Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A:Reference number: S26895; MUID:93021117; PMID:1404388
A:Accession: S26893
A:Molecule type: DNA
A:Residues: 1-98 <TOM>
A:Cross-references: UNIPARC:UPI0000038183; EMBL:Z12350; NID:G32922; PIDN:CAA78220.1; PID:
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 78.0%; Score 485; DB 2; Length 128;
Best Local Similarity 75.0%; Pred. No. 1.2e-38;
Matches 96; Conservative 9; Mismatches 15; Indels 8; Gaps 2;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 1 QVQLVESGGVVQPGSRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVYDGSNKYY 60

QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVVYCAKDLIESNTAEALWGQ 112
Db 61 ADSVKGRFTISRDNKNTLYLQWNSLRABDTAVVYCARDNYDSSGYYVYGGMDVWGQ 120

QY 113 GTLTVSS 120
Db 121 GTTTVSS 128

RESULT 14
S31701
Ig heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31701
R:Cuisinier, A.M.; Gauthier, L.; Boublil, L.; Fougereau, M.; Tonnelle, C.
submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the t
A:Reference number: S31585
A:Accession: S31701
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-137 <CUI>
A:Cross-references: UNIPARC:UPI000011645D; EMBL:Z14177; NID:G31020; PIDN:CAA78546.1; PID:
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match 77.8%; Score 484; DB 2; Length 137;
Best Local Similarity 78.3%; Pred. No. 1.7e-38;
Matches 94; Conservative 8; Mismatches 16; Indels 2; Gaps 1;

QY 1 EVQLVESGGGLVQPGSRSLRLSCVDSGLTFSSYGMHWVRQAPGAGLEWVAIVSYDGNKYY 60
Db 20 QVQLVESGGVVQPGSRSLRLSCAASGFTFSYGMHWVRQAPGKLEWVAIVYDGSNKYY 79

QY 61 ADSVKGRFAISRDNKNTLYLQWNSLTIEDTAVVYCAKDLIESNTAEALWGQTLTVSS 120
```


THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:58 ; Search time 47.5346 Seconds
(without alignments)
1781.089 Million cell updates/sec

Title: US-09-674-752-36

Perfect score: 622

Sequence: 1 EVLVESGGGLVQGRSLRL.....IESNIAELMGQGLTVTVSS 120

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt_05_80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	513	82.5	613	2	Q8WU1_HUMAN
2	496.5	79.8	113	2	Q9UL90_HUMAN
3	490.5	78.9	240	2	Q65ZC9_HUMAN
4	484.5	77.9	116	2	Q9UL93_HUMAN
5	477	76.7	122	1	HV3G_HUMAN
6	461	74.1	147	2	Q9Y509_HUMAN
7	455	73.2	544	2	Q6PU95_HUMAN
8	454.5	73.1	470	2	Q6PUA4_HUMAN
9	453.5	72.9	119	1	HV3I_HUMAN
10	452.5	72.7	121	1	HV3J_HUMAN
11	452	72.7	122	2	Q9UL84_HUMAN
12	450.5	72.4	478	2	Q6P181_HUMAN
13	444.5	71.5	121	2	Q9UL71_HUMAN
14	444.5	71.5	597	2	Q96BB9_HUMAN
15	443	71.2	469	2	Q569F4_HUMAN
16	441	70.9	122	1	HV3H_HUMAN
17	440.5	70.8	472	2	Q6N089_HUMAN
18	439	70.6	465	2	Q5I070_RAT
19	439	70.6	467	2	Q4VBH1_RAT
20	438	70.4	118	2	Q9UL91_HUMAN
21	437	70.3	479	2	Q6MZV6_HUMAN
22	436	70.1	494	2	Q96K68_HUMAN
23	436	70.1	573	2	Q8WU38_HUMAN
24	434	69.8	475	2	Q5EFES_HUMAN
25	433	69.6	126	1	HV3K_HUMAN
26	432.5	69.5	464	2	Q6MZU6_HUMAN
27	432.5	69.5	493	2	Q6GMX2_HUMAN
28	431.5	69.4	466	2	Q6IN78_HUMAN
29	428.5	68.9	519	2	Q6N092_HUMAN
30	426	68.5	483	2	Q6MZK9_HUMAN
31	420	67.5	461	2	Q5M7V3_RAT

32	420	67.5	465	2	Q6P6C4_HUMAN	Q6p6c4 homo sapien
33	418	67.2	118	2	Q9UL72_HUMAN	Q9ul72 homo sapien
34	417.5	67.1	479	2	Q5PQK9_RAT	Q5pqk9 rattus norv
35	417	67.0	116	1	HV3T_HUMAN	P01781 homo sapien
36	417	67.0	473	2	Q6MZV7_HUMAN	Q6mzv7 homo sapien
37	416.5	67.0	119	1	HV3L_HUMAN	P01773 homo sapien
38	416	66.9	473	2	Q91205_MOUSE	Q91205 mus musculu
39	415.5	66.8	119	2	Q920E7_MOUSE	Q920e7 mus musculu
40	415.5	66.8	485	2	Q6PDB8_MOUSE	Q6pdb8 mus musculu
41	414.5	66.6	493	2	Q8NCL6_HUMAN	Q8nc16 homo sapien
42	413	66.4	120	1	HV3U_HUMAN	P01782 homo sapien
43	412.5	66.3	479	2	Q5BK12_RAT	Q5bk12 rattus norv
44	412	66.2	112	2	Q9HCC1_HUMAN	Q9hcc1 homo sapien
45	412	66.2	478	2	Q5FVQ3_RAT	Q5fvq3 rattus norv

ALIGNMENTS

RESULT 1
Q8WU1_HUMAN
ID Q8WU1_HUMAN PRELIMINARY; PRT; 613 AA.
AC Q8WU1;
DT 01-MAR-2002 (Tremblrel. 20, Created)
DT 01-MAR-2002 (Tremblrel. 20, Last sequence update)
DE 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE IGHM protein.
GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.2426030899;
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Brownstein M.J., Bonaldi M.F., Casavant T.L., Scheetz T.E.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywiniski M.I., Skalek U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2117273;
RA Schroeder H.W. Jr, Wang J.Y.;
RT "Preferential utilization of conserved immunoglobulin heavy chain
variable gene segments during human fetal life.";
RL Proc. Natl. Acad. Sci. U.S.A. 87:6146-6150(1990).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1383695; DOI=10.1016/0161-5890(92)90173-U;
RA Cuisinier A.M., Fumoux F., Fougereau M., Tonnelle C.;


```
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C1q/7;
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR EMBL; Y13056; CAA73499.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PS00835; IG_LIKE; 2.
FT NON_TER 1
FT NON_TER 240
FT NON_TER 240
SQ SEQUENCE 240 AA; 25569 MW; FDCPD3645F64B373 CRC64;

Query Match 78.9%; Score 490.5; DB 2; Length 240;
Best Local Similarity 78.7%; Pred. No. 1.8e-43;
Matches 96; Conservative 9; Mismatches 10; Indels 7; Gaps 2;

QY 1 EVQLVESGGGLVQPGGSLRLSCVDSGLTFTSSYGHWVRQAPGAGLEWVAIVSDGNDKYY 60
DB 1 QVQLVQSGGGLVQPGGSLRLSCAASGFTSSYGHWVRQAPGKLEWVAIVSDGSKYY 60

QY 61 ADSVKGRFAISRDNKNTLYLQNSLTIEDTAVYVYCAKDLIESNIAEAL--WGQGLTIVT 118
DB 61 ADSVKGRFTISRDNSKNTLYLQNSLRAEDTAVYICARW-----GSDLPWGKGLTIVT 115

QY 119 SS 120
DB 116 SS 117

RESULT 4
ID Q9UL93 HUMAN PRELIMINARY; PRT; 116 AA.
AC Q9UL93
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berny S.M., Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=93301610; PubMed=8315388; DOI=10.1084/jem.178.1.331;
RA Hillson J.L., Karr N.S., Opplinger I.R., Mannik M., Sasso E.H.;
RT "The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A.";
RL J. Exp. Med. 178:331-336(1993).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2840480;
```

```
RA Bird J., Galili N., Link M., Stites D., Sklar J.;
RT "Continuing rearrangement but absence of somatic hypermutation in immunoglobulin genes of human B cell precursor leukemia.";
RL J. Exp. Med. 168:229-245(1988).
DR EMBL; AF035021; AAD56257.1; -; mRNA.
DR PIR; PH1644; PH1644.
DR PIR; P0120; P0120.
DR HSSP; P01772; 2FB4.
DR SMR; Q9UL93; 1-116.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 116
FT NON_TER 116
SQ SEQUENCE 116 AA; 12434 MW; ODA0348154DD6061 CRC64;

Query Match 77.9%; Score 484.5; DB 2; Length 116;
Best Local Similarity 79.0%; Pred. No. 3.1e-43;
Matches 94; Conservative 6; Mismatches 16; Indels 3; Gaps 1;

QY 2 VOLVESGGGLVQPGGSLRLSCVDSGLTFTSSYGHWVRQAPGAGLEWVAIVSDGNDKYYA 61
DB 1 VQLVESGGGVQPGGSLRLSCAASGFTSSYGHWVRQAPGKLEWVAIVSDGSKYYA 60

QY 62 DSVKGRFAISRDNKNTLYLQNSLTIEDTAVYVYCAKDLIESNIAEALWGQGLTIVTSS 120
DB 61 DSVKGRFTISRDNSKNTLYLQNSLRAEDTAVYICAGG---GGGLGNGQGLTIVTSS 116

RESULT 5
ID HV3G HUMAN STANDARD; PRT; 122 AA.
AC P01768;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-III region CAM.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=81013859; PubMed=6774332;
RA Lehman D.W., Putnam F.W.;
RT "Amino acid sequence of the variable region of a human mu chain: location of a possible JH segment.";
RL Proc. Natl. Acad. Sci. U.S.A. 77:3239-3243(1980).
CC -I- MISCELLANEOUS: This mu chain was isolated from the plasma of a patient with macroglobulinemia.
CC -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.
CC -----
CC PIR; A02051; M3HUAM.
CC HSSP; P01772; 2FB4.
CC SMR; P01768; 2-122.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; Ig-like.
CC InterPro; IPR003596; Ig_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS00835; IG_LIKE; 1.
CC Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Pyroglutamate carboxylic acid.
FT DOMAIN 1 112 Ig-like.
```

```

FT MOD_RES      1      1      Pyrrrolidone carboxylic acid.
PT NON_TER      122    122
SQ SEQUENCE      122 AA; 13668 MW; A42D0F17D5252F1C2 CRC64;

Query Match      76.7%; Score 477; DB 1; Length 122;
Best Local Similarity 73.0%; Pred. No. 2.1e-42;
Matches 89; Conservative 14; Mismatches 17; Indels 2; Gaps 1;

QY 1 EVOLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVROAPGAGLEWVAIVSYDGNKYY 60
DB 1 QVELVESGGVVPGRSLRLSCAASGFTFSNVAHMHVROPPGKGLEWVAIVSYBGBKYY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQMSLTIEDTAVYYCAKD--LIESNIAEALWCGTLVTV 118
DB 61 ABSVKGRFTISRDNKNTLYLQMSLTIEDTAVYYCARDRLPYGVRNFRNFGQGLTVTV 120

QY 119 SS 120
DB 121 SS 122

RESULT 6
QY509 HUMAN
ID QY509_HUMAN PRELIMINARY; PRT; 147 AA.
AC QY509;
DT 01-NOV-1999 (TREMBLrel. 12, Created)
DT 01-NOV-1999 (TREMBLrel. 12, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE VH3 protein (Fragment).
GN Name=VH3;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=96071149; PubMed=7475288;
RA Cao J., Vesicio R.A., Rettig M.B., Hong C.H., Kim A., Lee J.C.,
RA Lichtenstein A.K., Berenson J.R.;
RT "A CD10-positive subset of malignant cells is identified in multiple
RT myeloma using PCR with patient-specific immunoglobulin gene primers.";
RL Leukemia 9:1948-1953(1995).
DR EMBL; S80860; AAD14339.1; -, mRNA.
DR HSSP; P01842; IAQK.
DR Ensemble; ENSG00000130076; Homo sapiens.
DR GO; GO:005887; C:integral to plasma membrane; NAS.
DR GO; GO:0016066; P:cellular defense response (sensu Vertebrata); NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER      147    147
SQ SEQUENCE      147 AA; 15768 MW; 8489FCAAA7BC925C CRC64;

Query Match      74.1%; Score 461; DB 2; Length 147;
Best Local Similarity 69.8%; Pred. No. 1.3e-40;
Matches 90; Conservative 13; Mismatches 14; Indels 12; Gaps 2;

QY 1 EVOLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVROAPGAGLEWVAIVSYDGNKYY 60
DB 1 QVHLVESGGVVPQKSLRLSCAASGFTFSYGMHWVROAPGKGLDWVALISYDGTQYY 60

QY 61 ADSVKGRFAISRDNAKNTLYLQMSLTIEDTAVYYCAKDIESNIAEAL-----WG 111
DB 61 AGSVKGRFTISRDNKNTLYLQMSLTIEDTAVYYCAKD--GNYPDSVGYYYAGIDYWG 117

QY 112 QGTLTVSS 120
DB 118 QGTLTVSS 126

RESULT 7

```

```

Q6PJ95 HUMAN
ID Q6PJ95_HUMAN PRELIMINARY; PRT; 544 AA.
AC Q6PJ95;
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J.M., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Smailus D.E.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalick U.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX NIH MGC Project;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC019046; AAH19046.1; -, mRNA.
DR HSSP; P01861; IAQK.
DR SMR; Q6PJ95; 20-473.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 544 AA; 60102 MW; 1895814B2297C668 CRC64;

Query Match      73.2%; Score 455; DB 2; Length 544;
Best Local Similarity 71.1%; Pred. No. 2.8e-39;
Matches 91; Conservative 8; Mismatches 19; Indels 10; Gaps 2;

QY 1 EVOLVESGGGLVQPGKSLRLSCVDSGLTFSSYGMHWVROAPGAGLEWVAIVSYDGNKYY 60
DB 20 QAQLVESGGVVPQGSRLRLSCAASGFRFSNYGMHWVROAPGKGLEWVAIVSYDSKYY 79

QY 61 ADSVKGRFAISRDNAKNTLYLQMSLTIEDTAVYYCAKD-----LIESNIAEALWQ 112
DB 80 AASVKGRFTISRDNKNTLYLQMSLTIEDTAVYYCAKDQKPWNSWFLTNFDS--WGR 137

QY 113 GTLTVSS 120
DB 138 GTLTVSS 145

```

```

RESULT 8
Q6PJA4 HUMAN
ID Q6PJA4_HUMAN PRELIMINARY; PRT; 470 AA.
AC Q6PJA4;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
R1 NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner K.H., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Uadin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullay S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Touchman J.W., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Grimwood J., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U.,
RA Schnurch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[2]
RN NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC018747; AAH18747.1; -, mRNA.
DR HSSP; P01861; 1ADQ.
DR SMR; Q6PJA4; 20-470.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 470 AA; 51716 MW; 7B49556A11FD7D99 CRC64;

Query Match 73.1%; Score 454.5; DB 2; Length 470;
Best Local Similarity 73.2%; Pred. No. 2.6e-39;
Matches 93; Conservative 5; Mismatches 16; Indels 13; Gaps 2;

QY 1 EVLVESGGGLVQPGKSLRLSCVDSGLTFSYGMHWVRQAPGAGLEWVAIVSDGNDKYY 60
DB |||||
20 EVLVESGGGLVQPGKSLRLSCVDSGLTFSYGMHWVRQAPGAGLEWVAIVSDGNDKYY 79
QY 61 ADSVKGRFAISRDNKNTLYLQNMSLTIEDTAVYYCAKDLIESNIAEALWGQGLTVSS 113
DB |||||
80 VDSVKGRFTISRDNKNTLYLQNMSLRAEDTAVYYCARD-----GSSWYRDWFDPMWQG 133

us-09-674-752-36.rup
114 TLTVSS 120
134 TLTVSS 140

RESULT 9
HV3I HUMAN
ID HV3I_HUMAN STANDARD; PRT; 119 AA.
AC P01770;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-II region NIE.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
R1 PROTEIN SEQUENCE.
RX MEDLINE=77070269; PubMed=826475;
RA Ponstingl H., Hilschmann N.;
RT "The rule of antibody structure. The primary structure of a monoclonal
RT IgG1 immunoglobulin (myeloma protein NIE). III. The chymotryptic
RT peptides of the H-chain, alignment of the tryptic peptides and
RT discussion of the complete structure.";
RL Hoppe-Seyler's Z. Physiol. Chem. 357:1571-1604(1976).
[2]
RN DISULFIDE BOND.
RX MEDLINE=77070267; PubMed=1002129;
RA Dreker L., Schwarz J., Reichel W., Hilschmann N.;
RT "Rule of antibody structure. The primary structure of a monoclonal
RT IgG1 immunoglobulin (myeloma protein NIE). I: purification and
RT characterization of the protein, the L- and H-chains, the cyanogen
RT bromide cleavage products, and the disulfide bridges.";
RL Hoppe-Seyler's Z. Physiol. Chem. 357:1515-1540(1976).
CC -I- MISCELLANEOUS: This chain was isolated from an IgG1 myeloma
protein.
CC -I- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A91668; GIHUNI.
CC HSSP; P01772; 2FB4.
CC SMR; P01770; 1-119.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; Ig-like.
CC InterPro; IPR003596; Ig_v.
CC SMART; SM00406; IG; 1.
CC PROSITE; PS50835; IG_LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region; Pyrrolidone carboxylic acid.
FT DOMAIN 1 112
FT MOD_RES 1 1 Pyrrolidone carboxylic acid.
FT DISULFID 22 96
FT NON_TER 119 119
SQ SEQUENCE 119 AA; 13243 MW; C96935A6S5E165B CRC64;

Query Match 72.9%; Score 453.5; DB 1; Length 119;
Best Local Similarity 71.7%; Pred. No. 6.2e-40;
Matches 86; Conservative 17; Mismatches 16; Indels 1; Gaps 1;

QY 1 EVLVESGGGLVQPGKSLRLSCVDSGLTFSYGMHWVRQAPGAGLEWVAIVSDGNDKYY 60
DB |||||
1 QVLVQSGGGVQPGKSLRLSCAASGFTFSRYTIHWVRQAPGKLEWVAIVSYGBBKHY 60
QY 61 ADSVKGRFAISRDNKNTLYLQNMSLTIEDTAVYYCAKDLIESNIAEALWGQGLTVSS 120
```


RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA	Villation D.K., Muzny D.M., Sodergren E.U., Lu X., Gibbs R.A.,
RA	Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA	Rodriguez A.C., Grilwood J., Schmutz J., Myers R.M.,
RA	Butterfield Y.S.N., Krywinski M.I., Skalska U., Smalus D.E.,
RA	Schuerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT	"Generation and initial analysis of more than 15,000 full-length human
RT	and mouse cDNA sequences.";
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RL	[2]
RP	NUCLEOTIDE SEQUENCE.
RC	TISSUE=Primary B-Cells;
RG	NIH MGC Project;
RG	Submitted (DBC-2002) to the EMBL/GenBank/DBJ databases.
RL	EMBL: BC041037; AAH41037.1; -, mRNA.
DR	HSSP: P01861; 1ADQ.
DR	InterPro: IPR003599; IG.
DR	InterPro: IPR007110; IG-like.
DR	InterPro: IPR003597; IG cl.
DR	InterPro: IPR003006; IG MHC.
DR	InterPro: IPR003596; IG v.
DR	Pfam: PF07654; Cl-set; 3.
DR	SMART: SM00409; IG; 2.
DR	SMART: SM00407; IGcl; 3.
DR	SMART: SM00406; IGV; 1.
DR	PROSITE: PS0835; IG LIKE; 4.
DR	PROSITE: PS00290; IG MHC; UNKNOWN 2.
SQ	SEQUENCE 478 AA; 52667 MW; 17BED38D917970D6 CRC64;

Query Match	72.4%;	Score 450.5;	DB 2;	Length 478;
Best Local Similarity	70.0%;	Pred. No. 7.1e-39;		
Matches	91;	Conservative	8;	Mismatches 20;
				Indels 11;
				Gaps 2;

Qy	1	EVQLVESGGGLVQPGSRRLRLSCVDSGLTFSSYGHHWVRQAPGAGLEWVAIVSYDGNKY	60
Db	20	EVQLVESGGGLVQPGGSRRLRLSCAASGTFSSYWNWSVRQAPGKLEWVANIKQDSEKY	79
Qy	61	ADSVKGRFATSRDNKNTLYLQMNLSLTEDTAVTYCAKDLIESNIAEA-----LW	110
Db	80	VDSVKGRFTSRDNKNSLYLQMNLSRAEDTAVTYCARE-FESTTNTVADYFYFYMDVW	138
Qy	111	GGQTLTVTVSS 120	
Db	139	GKGTTTVTVSS 148	

RESULT 13

ID	Q9UL71	HUMAN
AC	Q9UL71;	
AC	Q9UL71;	PRT; 121 AA.
DT	01-MAY-2000	(TREMBLrel. 13, Created)
DT	01-MAY-2000	(TREMBLrel. 13, Last sequence update)
DT	01-OCT-2003	(TREMBLrel. 25, Last annotation update)
DE	Myosin-reactive immunoglobulin heavy chain variable region	
DE	(Fragment).	
OS	Homo sapiens (Human)	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;	
OC	Homo.	
OX	NCBI_TaxID=9606;	
OX	(1)	
RP	NUCLEOTIDE SEQUENCE.	
RX	MEDLINE=96271139; PubMed=9614934; DOI=10.1006/clin.1998.4531;	
RA	Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berney S.M.,	
RA	Young D.C.;	
RT	"Myosin-reactive autoantibodies in rheumatic carditis and normal	
RT	fetus";	
RL	Clin. Immunol. Immunopathol. 87:184-192 (1998).	
DR	EMBL: AF035043; AAU56279.1; -, mRNA.	
DR	HSSP: P01852; 1NFD.	
DR	SMR: Q9UL71; 1-121.	

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:25 ; Search time 11.3112 Seconds
(without alignments)
716.302 Million cell updates/sec

Title: US-09-674-752-37

Perfect score: 503

Sequence: 1 EVQLVESGGGLVPGGSLRL.....LYLQMNSLRAEDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA:*
1: /cgn2_6/ptodata/1/iaa/5 COMB.pep.*
2: /cgn2_6/ptodata/1/iaa/6 COMB.pep.*
3: /cgn2_6/ptodata/1/iaa/H COMB.pep.*
4: /cgn2_6/ptodata/1/iaa/PCTUS COMB.pep.*
5: /cgn2_6/ptodata/1/iaa/RE COMB.pep.*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	503	100.0	98	2	US-10-194-975-21
2	503	100.0	98	2	US-09-534-717-657
3	503	100.0	98	2	US-09-534-717-659
4	503	100.0	117	2	US-08-545-809A-107
5	503	100.0	117	2	US-09-515-697-107
6	492	97.8	245	2	US-08-918-148-78
7	492	97.8	245	2	US-09-138-091A-76
8	488.5	97.1	97	2	US-09-534-717-658
9	488.5	97.1	109	1	US-08-379-057-32
10	484	96.2	98	2	US-09-534-717-660
11	484	96.2	117	2	US-08-545-809A-130
12	484	96.2	117	2	US-09-515-697-130
13	483	96.0	127	2	US-09-240-274-27
14	483	96.0	127	2	US-09-848-798-27
15	481	95.6	111	1	US-08-211-202-134
16	478	95.0	98	1	US-08-211-202-116
17	478	95.0	98	2	US-10-194-975-28
18	478	95.0	98	2	US-09-534-717-656
19	476	94.6	98	1	US-08-665-202-31
20	476	94.6	98	2	US-09-315-574-31
21	476	94.6	98	2	US-08-534-717-639
22	473	94.0	123	1	US-08-665-202-30
23	473	94.0	123	2	US-09-315-574-30
24	466	92.6	112	1	US-08-211-202-133
25	465	92.4	98	2	US-10-194-975-17
26	465	92.4	98	2	US-09-534-717-601
27	465	92.4	117	2	US-08-545-809A-99

28 465 92.4 117 2 US-09-515-697-99 Sequence 99, Appl
29 463 92.0 131 2 US-09-240-274-28 Sequence 28, Appl
30 463 92.0 131 2 US-09-848-798-28 Sequence 28, Appl
31 461 91.7 98 2 US-09-534-717-602 Sequence 602, App
32 459 91.3 245 2 US-08-918-148-75 Sequence 75, Appl
33 459 91.3 245 2 US-09-138-091A-73 Sequence 73, Appl
34 458 91.1 110 1 US-08-211-202-117 Sequence 117, App
35 456 90.7 120 2 US-09-025-769B-38 Sequence 38, Appl
36 456 90.7 120 2 US-09-025-769B-63 Sequence 63, Appl
37 456 90.7 120 2 US-09-490-070A-38 Sequence 38, Appl
38 456 90.7 120 2 US-09-490-070A-63 Sequence 63, Appl
39 456 90.7 120 2 US-09-490-153-38 Sequence 38, Appl
40 456 90.7 120 2 US-09-490-153-63 Sequence 63, Appl
41 456 90.7 120 2 US-09-490-324-38 Sequence 38, Appl
42 456 90.7 120 2 US-09-490-324-63 Sequence 63, Appl
43 456 90.7 281 2 US-09-025-769B-178 Sequence 178, App
44 456 90.7 281 2 US-09-490-070A-178 Sequence 178, App
45 456 90.7 281 2 US-09-490-153-178 Sequence 178, App

ALIGNMENTS

RESULT 1
US-10-194-975-21
; Sequence 21, Application US/10194975
; Patent No. 6881557
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 21
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-194-975-21

Query Match 100.0%; Score 503; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.7e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTTSSYSMMWVRQAPGKGLVWSSISSSSYIYY 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTTSSYSMMWVRQAPGKGLVWSSISSSSYIYY 60
Qy 61 ADSVKGRTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98

RESULT 2
US-09-534-717-657
; Sequence 657, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 657
; LENGTH: 98
; TYPE: PRT

```
; ORGANISM: Homo sapiens
US-09-534-717-657

Query Match      100.0%; Score 503; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.7e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 60
   |||||
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNSLYLQNSLRADTAVYYCAR 98
   |||||
DB 61 ADSVKGRFTISRDNKNSLYLQNSLRADTAVYYCAR 98

RESULT 3
US-09-534-717-659
; Sequence 659, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 659
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-534-717-659

Query Match      100.0%; Score 503; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.7e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 60
   |||||
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNSLYLQNSLRADTAVYYCAR 98
   |||||
DB 61 ADSVKGRFTISRDNKNSLYLQNSLRADTAVYYCAR 98

RESULT 4
US-08-545-809A-107
; Sequence 107, Application US/08545809A
; Patent No. 6096878
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiro
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809A

; ORGANISM: Homo sapiens
US-09-534-717-657

Query Match      100.0%; Score 503; DB 2; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.7e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 60
   |||||
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNSLYLQNSLRADTAVYYCAR 98
   |||||
DB 61 ADSVKGRFTISRDNKNSLYLQNSLRADTAVYYCAR 98

RESULT 5
US-09-515-697-107
; Sequence 107, Application US/09515697
; Patent No. 6936785
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiro
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/515,697
; FILING DATE: 29-Feb-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 107:
; SEQUENCE CHARACTERISTICS:
```

```
; FILING DATE: 27-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 107:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-545-809A-107

Query Match      100.0%; Score 503; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 2.1e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 60
   |||||
DB 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 79
   |||||

QY 61 ADSVKGRFTISRDNKNSLYLQNSLRADTAVYYCAR 98
   |||||
DB 80 ADSVKGRFTISRDNKNSLYLQNSLRADTAVYYCAR 117

RESULT 5
US-09-515-697-107
; Sequence 107, Application US/09515697
; Patent No. 6936785
; GENERAL INFORMATION:
; APPLICANT: Honjo, Tasuku
; APPLICANT: Matsuda, Fumihiro
; TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE
; TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME
; NUMBER OF SEQUENCES: 145
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/515,697
; FILING DATE: 29-Feb-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/545,809
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: PCT/JP93/00603
; FILING DATE: 10-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 06501/004001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 107:
; SEQUENCE CHARACTERISTICS:
```

```
;
; LENGTH: 117 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 107:
US-09-515-697-107

Query Match      100.0%; Score 503; DB 2; Length 117;
Best Local Similarity 100.0%; Pred. No. 2.1e-45;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLWVSSISSSSYIYY 60
Db 20 EVLVESGGGLVKPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLWVSSISSSSYIYY 79
QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
Db 80 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 117

RESULT 6
US-08-918-148-78
; Sequence 78, Application US/08918148A
; Patent No. 6342220
; GENERAL INFORMATION:
; APPLICANT: Adams, Camellia
; APPLICANT: W.
; APPLICANT: Carter, Paul J.
; APPLICANT: Fendly, Brian M.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Agonist Antibodies
; FILE REFERENCE: P0979
; CURRENT APPLICATION NUMBER: US/08/918,148A
; CURRENT FILING DATE: 1997-08-25
; NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 78
; LENGTH: 245
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; NAME/KEY: unknown
; LOCATION: 208
; OTHER INFORMATION: unknown amino acid
US-08-918-148-78

Query Match      97.8%; Score 492; DB 2; Length 245;
Best Local Similarity 96.9%; Pred. No. 7.1e-44;
Matches 95; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLWVSSISSSSYIYY 60
Db 3 QVLVESGGGLVKPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLWVSSISSSSYIYY 62
QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
Db 63 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 100

RESULT 7
US-09-138-091A-76
; Sequence 76, Application US/09138091A
; Patent No. 6737249
; GENERAL INFORMATION:
; APPLICANT: Adams, Camellia W.
; APPLICANT: Carter, Paul J.
; APPLICANT: Fendly, Brian M.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Agonist Antibodies
; FILE REFERENCE: 9491-013-27
; CURRENT APPLICATION NUMBER: US/09/138,091A
; CURRENT FILING DATE: 1998-08-21
; PRIOR APPLICATION NUMBER: US 60/056,736
; PRIOR FILING DATE: 1997-08-22
```

```
;
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 76
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: single chain antibody (scFv) fragments
; NAME/KEY: VARIANT
; LOCATION: 208
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-138-091A-76

Query Match      97.8%; Score 492; DB 2; Length 245;
Best Local Similarity 96.9%; Pred. No. 7.1e-44;
Matches 95; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLWVSSISSSSYIYY 60
Db 3 QVLVESGGGLVKPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLWVSSISSSSYIYY 62
QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
Db 63 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 100

RESULT 8
US-09-534-717-658
; Sequence 658, Application US/09534717
; Patent No. 6914128
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/09/534,717
; CURRENT FILING DATE: 2000-03-24
; EARLIER APPLICATION NUMBER: 60/126,603
; EARLIER FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 658
; LENGTH: 97
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-534-717-658

Query Match      97.1%; Score 488.5; DB 2; Length 97;
Best Local Similarity 99.0%; Pred. No. 5.5e-44;
Matches 97; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLWVSSISSSSYIYY 60
Db 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLWVSSI-SSSSYIYY 59
QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
Db 60 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 97

RESULT 9
US-08-179-057-32
; Sequence 32, Application US/08379057
; Patent No. 5876950
; GENERAL INFORMATION:
; APPLICANT: Siadak, Anthony W.
; APPLICANT: Hollenbaugh, Diane L.
; APPLICANT: Gilliland, Lisa K.
; APPLICANT: Gordon, Marcia L.
; APPLICANT: Bajorath, Jurgen
; APPLICANT: Aruffo, Alejandro A.
; TITLE OF INVENTION: Monoclonal Antibodies Specific For
; TITLE OF INVENTION: Different Epitopes of Human gp39 and Methods For Their Use
```

;	TITLE OF INVENTION: In Diagnosis and Therapy	
;	NUMBER OF SEQUENCES: 57	
;	CORRESPONDENCE ADDRESS:	
;	ADDRESSEE: Bristol-Myers Squibb Company	
;	STREET: 3005 First Avenue	
;	CITY: Seattle	
;	STATE: Washington	
;	COUNTRY: USA	
;	ZIP: 98121	
;	COMPUTER READABLE FORM:	
;	MEDIUM TYPE: Floppy disk	
;	COMPUTER: IBM PC compatible	
;	OPERATING SYSTEM: PC-DOS/MS-DOS	
;	SOFTWARE: Patent In Release #1.0, Version #1.25	
;	CURRENT APPLICATION DATA:	
;	APPLICATION NUMBER: US/08/379,057	
;	FILING DATE: 26-JAN-1995	
;	CLASSIFICATION: 435	
;	ATTORNEY/AGENT INFORMATION:	
;	NAME: Poor, Brian W.	
;	REGISTRATION NUMBER: 32,928	
;	REFERENCE/DOCKET NUMBER: ON0133-	
;	TELECOMMUNICATION INFORMATION:	
;	TELEPHONE: (206) 727-3670	
;	TELEFAX: (206) 727-3601	
;	INFORMATION FOR SEQ ID NO: 32:	
;	SEQUENCE CHARACTERISTICS:	
;	LENGTH: 109 amino acids	
;	TYPE: amino acid	
;	TOPOLOGY: linear	
;	MOLECULE TYPE: protein	
;	FRAGMENT TYPE: internal	
;	US-08-379-057-32	
	Query Match	97.1%; Score 488.5; DB 1; Length 109;
	Best Local Similarity	99.0%; Pred. No. 6.4e-44;
	Matches	97; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
Qy	1	EVQLVESGGGLVQPGGSLRLS
Db	1	EVQLVESGGGLVQPGGSLRLS
Qy	61	ADSVKGRFTISRDNKNSLYLQ
Db	60	ADSVKGRFTISRDNKNSLYLQ
	RESULT 10	
	US-09-534-717-660	
	Sequence 660, Application US/09534717	
	Patent No. 6914128	
	GENERAL INFORMATION:	
	APPLICANT: Jochen, Salfeld et al.	
	TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing	
	FILE REFERENCE: BBI-093CP	
	CURRENT APPLICATION NUMBER: US/09/534,717	
	CURRENT FILING DATE: 2000-03-24	
	EARLIER APPLICATION NUMBER: 60/126,603	
	EARLIER FILING DATE: March 25, 1999	
	NUMBER OF SEQ ID NOS: 675	
	SOFTWARE: Patent In Ver. 2.0	
	SEQ ID NO 660	
	LENGTH: 98	
	TYPE: PR	
	ORGANISM: Homo sapiens	
	US-09-534-717-660	
	Query Match	96.2%; Score 484; DB 2; Length 98;
	Best Local Similarity	96.9%; Pred. No. 1.7e-43;
	Matches	95; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy	1	EVQLVESGGGLVQPGGSLRLS

Db	1	EVQLVESGGGLVQPGGSLRLS
Qy	61	ADSVKGRFTISRDNKNSLYLQ
Db	61	ADSVKGRFTISRDNKNSLYLQ
	RESULT 11	
	US-08-545-809A-130	
	Sequence 130, Application US/08545809A	
	Patent No. 6096878	
	GENERAL INFORMATION:	
	APPLICANT: Honjo, Tasuku	
	APPLICANT: Matsuda, Fumihiko	
	TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE	
	TITLE OF INVENTION: SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME	
	NUMBER OF SEQUENCES: 145	
	CORRESPONDENCE ADDRESS:	
	ADDRESSEE: Fish & Richardson, P.C.	
	STREET: 225 Franklin Street	
	CITY: Boston	
	STATE: MA	
	COUNTRY: US	
	ZIP: 02110-2804	
	COMPUTER READABLE FORM:	
	MEDIUM TYPE: Diskette	
	COMPUTER: IBM Compatible	
	OPERATING SYSTEM: Windows95	
	SOFTWARE: FastSeq for Windows Version 2.0	
	CURRENT APPLICATION DATA:	
	APPLICATION NUMBER: US/08/545,809A	
	FILING DATE: 27-MAR-1996	
	PRIOR APPLICATION DATA:	
	APPLICATION NUMBER: PCT/JP93/00603	
	FILING DATE: 10-MAY-1993	
	ATTORNEY/AGENT INFORMATION:	
	NAME: Freeman, John W.	
	REGISTRATION NUMBER: 29,066	
	REFERENCE/DOCKET NUMBER: 06501/004001	
	TELECOMMUNICATION INFORMATION:	
	TELEPHONE: 617-542-5070	
	TELEFAX: 617-542-8906	
	TELEX: 200154	
	INFORMATION FOR SEQ ID NO: 130:	
	SEQUENCE CHARACTERISTICS:	
	LENGTH: 117 amino acids	
	TYPE: amino acid	
	TOPOLOGY: linear	
	MOLECULE TYPE: protein	
	US-08-545-809A-130	
	Query Match	96.2%; Score 484; DB 2; Length 117;
	Best Local Similarity	96.9%; Pred. No. 2e-43;
	Matches	95; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy	1	EVQLVESGGGLVQPGGSLRLS
Db	20	EVQLVESGGGLVQPGGSLRLS
Qy	61	ADSVKGRFTISRDNKNSLYLQ
Db	80	ADSVKGRFTISRDNKNSLYLQ
	RESULT 12	
	US-09-515-697-130	
	Sequence 130, Application US/09515697	
	Patent No. 6916705	
	GENERAL INFORMATION:	
	APPLICANT: Honjo, Tasuku	
	APPLICANT: Matsuda, Fumihiko	
	TITLE OF INVENTION: HUMAN IMMUNOGLOBULIN VH GENE	
	SEGMENTS AND DNA FRAGMENTS CONTAINING THE SAME	

```

; OTHER INFORMATION: anti-Rh(D) chain E01ie
US-09-240-274-27

Query Match          96.0%; Score 483; DB 2; Length 127;
Best Local Similarity 93.9%; Pred. No. 2.9e-43;
Matches 92; Conservative 6; Mismatches 0; Indels 0; Gaps 0

Qy 1 EVOLVSGGGLVKPGGSLRLSCAASGFTFSSYSNMVVRQAPGKLEWVSSISSTSIYY 60
Db 1 EVOLLESGGGLVKPGGSLRLSCAASGFTFSSYSNMVVRQAPGKLEWVSSISSTSIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYICAR 98
Db 61 ADAVKGRFTISRDNKNSLYLQNSLRAEDTAVYICAR 98

RESULT 14
US-09-848-798-27
; Sequence 27, Application US/09848798
; Patent No. 6858719
; GENERAL INFORMATION:
; APPLICANT: Siegel, Donald L.
; TITLE OF INVENTION: Rh(D)-BINDING PROTEINS AND MAGNETICALLY ACTIVATED CELL
; TITLE OF INVENTION: SORTING METHOD FOR PRODUCTION THEREOF
; FILE REFERENCE: 09596-4202
; CURRENT APPLICATION NUMBER: US/09/848,798
; CURRENT FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/240,274
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/028,550
; PRIOR FILING DATE: EARLIER FILING DATE: 1996-10-11
; NUMBER OF SEQ ID NOS: 224
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 27
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: anti-Rh(D) chain E01ie
US-09-848-798-27

Query Match          96.0%; Score 483; DB 2; Length 127;
Best Local Similarity 93.9%; Pred. No. 2.9e-43;
Matches 92; Conservative 6; Mismatches 0; Indels 0; Gaps 0

Qy 1 EVOLVSGGGLVKPGGSLRLSCAASGFTFSSYSNMVVRQAPGKLEWVSSISSTSIYY 60
Db 1 EVOLLESGGGLVKPGGSLRLSCAASGFTFSSYSNMVVRQAPGKLEWVSSISSTSIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYICAR 98
Db 61 ADAVKGRFTISRDNKNSLYLQNSLRAEDTAVYICAR 98

RESULT 15
US-08-211-202-134
; Sequence 134, Application US/08211202
; Patent No. 5565332
; GENERAL INFORMATION:
; APPLICANT: HOOGENBOOM, Hendricus Renerus Jacobus Matteus
; APPLICANT: BAIER, Michael
; APPLICANT: JESPERS, Laurent Stephane Anne Therese
; APPLICANT: WINTER, Gregory Paul
; TITLE OF INVENTION: Production of chimeric antibodies - a
; TITLE OF INVENTION: combinatorial approach
; NUMBER OF SEQUENCES: 144
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David W. Clough, Marshall O'Toole Gerstein Murray &
; ADDRESSEE: Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA

```

```

; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/211,202
; FILING DATE: 23-SEP-1992
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9120252.3
; FILING DATE: 23-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9120377.8
; FILING DATE: 25-SEP-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9206318.9
; FILING DATE: 24-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9206372.6
; FILING DATE: 24-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB92/00883
; FILING DATE: 15-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: David W. Clough
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 28111/31960
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; TELEFAX: 312-474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 134:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 111 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-211-202-134

```

```

Query Match      95.6%; Score 481; DB 1; Length 111;
Best Local Similarity 95.9%; Pred. No. 4e-43;
Matches 94; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 EVLVESGGGLVKPGSLRLSCAASGFTFSYSMNVVRQAPGKLEWVSSISSSYIYY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 EVQLVQSGGGLVQPGSLRLSCAASGFTFSYSMNVVRQAPGKLEWVSSISSSYIYY 60
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

```

Search completed: May 5, 2006, 08:53:48
Job time : 12.3112 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:56:13 ; Search time 7.32964 Seconds
(without alignments)
618.844 Million cell updates/sec

Title: US-09-674-752-37

Perfect score: 503

Sequence: 1 EVOLVSGGLVKPGSLRL.....LYLQNMNSLRADTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 235405 seqs, 46284737 residues

Total number of hits satisfying chosen parameters: 235405

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Published Applications AA New:*
- 1: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
 - 2: /SIDSS5/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
 - 3: /SIDSS5/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
 - 4: /SIDSS5/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
 - 5: /SIDSS5/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
 - 6: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
 - 7: /SIDSS5/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
 - 8: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
 - 9: /SIDSS5/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
 - 10: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
 - 11: /SIDSS5/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
 - 12: /SIDSS5/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	503	100.0	98	11	US-11-054-669-21
2	503	100.0	98	11	US-11-084-554-32
3	503	100.0	98	11	US-11-004-590-22
4	503	100.0	98	11	US-11-136-250-32
5	500	99.4	256	11	US-11-054-515-1318
6	500	99.4	256	11	US-11-266-444-1318
7	499	99.2	249	11	US-11-054-515-1856
8	499	99.2	249	11	US-11-266-444-1856
9	497	98.8	247	11	US-11-054-515-1764
10	497	98.8	247	11	US-11-266-444-1764
11	495	98.4	244	11	US-11-054-515-1991
12	495	98.4	244	11	US-11-266-444-1991
13	495	98.4	247	11	US-11-054-515-1703
14	495	98.4	247	11	US-11-266-444-1703
15	491	97.6	120	9	US-10-771-257-46
16	491	97.6	120	11	US-11-127-677-44
17	489	97.2	252	11	US-11-054-515-1362
18	489	97.2	252	11	US-11-266-444-1362
19	487	96.8	119	9	US-10-771-257-14
20	487	96.8	119	11	US-11-127-677-14
21	487	96.8	241	11	US-11-054-515-1937

22	487	96.8	241	11	US-11-266-444-1937	Sequence 1937, Ap
23	484	96.2	98	11	US-11-004-590-30	Sequence 30, Appl
24	484	96.2	123	9	US-10-771-257-86	Sequence 86, Appl
25	483	96.0	127	11	US-11-064-174-27	Sequence 27, Appl
26	481	95.6	243	11	US-11-054-515-2102	Sequence 2102, Ap
27	481	95.6	243	11	US-11-266-444-2102	Sequence 2102, Ap
28	481	95.6	255	11	US-11-054-515-1608	Sequence 1608, Ap
29	481	95.6	255	11	US-11-266-444-1608	Sequence 1608, Ap
30	479	95.2	250	11	US-11-054-515-1613	Sequence 1613, Ap
31	479	95.2	250	11	US-11-266-444-1613	Sequence 1613, Ap
32	479	95.2	262	11	US-11-054-515-2081	Sequence 2081, Ap
33	479	95.2	262	11	US-11-266-444-2081	Sequence 2081, Ap
34	478	95.0	98	11	US-11-054-669-28	Sequence 28, Appl
35	478	95.0	98	11	US-11-084-554-39	Sequence 39, Appl
36	478	95.0	98	11	US-11-136-250-39	Sequence 913, App
37	478	95.0	248	11	US-11-054-515-913	Sequence 913, App
38	478	95.0	248	11	US-11-266-444-913	Sequence 913, App
39	474	94.2	249	11	US-11-054-515-974	Sequence 974, App
40	474	94.2	249	11	US-11-266-444-974	Sequence 974, App
41	473	94.0	237	11	US-11-054-515-2020	Sequence 2020, Ap
42	473	94.0	237	11	US-11-266-444-2020	Sequence 2020, Ap
43	473	94.0	248	11	US-11-054-515-1974	Sequence 1974, Ap
44	473	94.0	248	11	US-11-266-444-1974	Sequence 1974, Ap
45	472	93.8	444	11	US-11-172-320-6	Sequence 6, Appl

ALIGNMENTS

RESULT 1

- US-11-054-669-21
- ; Sequence 21, Application US/11054669
 - ; Publication No. US20050261480A1
 - ; GENERAL INFORMATION:
 - ; APPLICANT: Foote, Jefferson
 - ; TITLE OF INVENTION: SUPER HUMANIZED ANTIBODIES
 - ; FILE REFERENCE: 30219/US/3
 - ; CURRENT APPLICATION NUMBER: US/11/054,669
 - ; CURRENT FILING DATE: 2005-02-08
 - ; PRIOR APPLICATION NUMBER: US 10/194,975
 - ; PRIOR FILING DATE: 2002-07-12
 - ; PRIOR APPLICATION NUMBER: US 60/305,111
 - ; PRIOR FILING DATE: 2001-07-12
 - ; NUMBER OF SEQ ID NOS: 124
 - ; SOFTWARE: PatentIn version 3.3
 - ; SEQ ID NO 21
 - ; LENGTH: 98
 - ; TYPE: PRT
 - ; ORGANISM: Homo sapiens
- US-11-054-669-21

Query Match 100.0%; Score 503; DB 11; Length 98;

Best Local Similarity 100.0%; Pred. No. 1.5e-37;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVOLVSGGLVKPGSLRLSCAASGFTFSYSMNVRQAPGKLEWSSISSSSIYY 60

Db 1 EVOLVSGGLVKPGSLRLSCAASGFTFSYSMNVRQAPGKLEWSSISSSSIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQNMNSLRADTAVYYCAR 98

Db 61 ADSVKGRFTISRDNKNSLYLQNMNSLRADTAVYYCAR 98

RESULT 2

- US-11-084-554-32
- ; Sequence 32, Application US/11084554
 - ; Publication No. US20050260679A1
 - ; GENERAL INFORMATION:
 - ; APPLICANT: Kellermann, Sirdid-Ai
 - ; APPLICANT: Green, Larry L.
 - ; APPLICANT: Korver, Wouter
 - ; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN

; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A
; CURRENT APPLICATION NUMBER: US/11/084,554
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 32
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-084-554-32

Query Match 100.0%; Score 503; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.5e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSNMWVRQAPGKGLWVSSISSSSYIYY 60
|||
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSNMWVRQAPGKGLWVSSISSSSYIYY 60
|||

QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
|||
DB 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
|||

RESULT 3

US-11-004-590-22
; Sequence 22, Application US/11004590
; Publication No. US2006008883A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John R.
; APPLICANT: Hammond, Phillip W.
; TITLE OF INVENTION: METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING
; TITLE OF INVENTION: CONTENT AND COMPOSITIONS THEREOF
; FILE REFERENCE: 185832/US/5
; CURRENT APPLICATION NUMBER: US/11/004,590
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: US 60/527,167
; PRIOR FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: US 60/581,613
; PRIOR FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US 60/601,665
; PRIOR FILING DATE: 2004-08-13
; PRIOR APPLICATION NUMBER: US 60/619,483
; PRIOR FILING DATE: 2004-10-14
; NUMBER OF SEQ ID NOS: 458
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-004-590-22

Query Match 100.0%; Score 503; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.5e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSNMWVRQAPGKGLWVSSISSSSYIYY 60
|||
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSNMWVRQAPGKGLWVSSISSSSYIYY 60
|||

QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
|||
DB 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
|||

RESULT 4

US-11-136-250-32

; Sequence 32, Application US/11136250
; Publication No. US20060021074A1
; GENERAL INFORMATION:
; APPLICANT: Kellermann, Sirid-Ai
; APPLICANT: Green, Larry L.
; APPLICANT: Korver, Wouter
; TITLE OF INVENTION: REDUCING THE RISK OF HUMAN ANTI-HUMAN
; TITLE OF INVENTION: ANTIBODIES THROUGH V GENE MANIPULATION
; FILE REFERENCE: ABGENIX.100A2
; CURRENT APPLICATION NUMBER: US/11/136,250
; CURRENT FILING DATE: 2005-05-23
; PRIOR APPLICATION NUMBER: 11/084,554
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: PCT/US2005/009306
; PRIOR FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: 60/574,661
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/554,372
; PRIOR FILING DATE: 2004-03-19
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 32
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-136-250-32

Query Match 100.0%; Score 503; DB 11; Length 98;
Best Local Similarity 100.0%; Pred. No. 1.5e-37;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSNMWVRQAPGKGLWVSSISSSSYIYY 60
|||
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSNMWVRQAPGKGLWVSSISSSSYIYY 60
|||

QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
|||
DB 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
|||

RESULT 5

US-11-054-515-1318
; Sequence 1318, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunoespecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1318


```
; LENGTH: 256
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1318

Query Match          99.4%; Score 500; DB 11; Length 256;
Best Local Similarity 99.0%; Pred. No. 6.6e-37;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVLVESGGGLVPGGSLRLSCAASGFTFSYNNMVRQAPGKLEWVSSISSSSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVLVQSGGGLVPGGSLRLSCAASGFTFSYNNMVRQAPGKLEWVSSISSSSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 6
US-11-266-444-1318
; Sequence 1318, Application US/11266444
; Publication No. US2006062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1318
; LENGTH: 256
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1318

Query Match          99.4%; Score 500; DB 11; Length 256;
Best Local Similarity 99.0%; Pred. No. 6.6e-37;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVLVESGGGLVPGGSLRLSCAASGFTFSYNNMVRQAPGKLEWVSSISSSSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVLVQSGGGLVPGGSLRLSCAASGFTFSYNNMVRQAPGKLEWVSSISSSSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 7
US-11-054-515-1856
; Sequence 1856, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
```

```
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1856
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1856

Query Match          99.2%; Score 499; DB 11; Length 249;
Best Local Similarity 99.0%; Pred. No. 7.9e-37;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVLVESGGGLVPGGSLRLSCAASGFTFSYNNMVRQAPGKLEWVSSISSSSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVLVQSGGGLVPGGSLRLSCAASGFTFSYNNMVRQAPGKLEWVSSISSSSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

Qy 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 8
US-11-266-444-1856
; Sequence 1856, Application US/11266444
; Publication No. US2006062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1856
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1856

Query Match          99.2%; Score 499; DB 11; Length 249;
Best Local Similarity 99.0%; Pred. No. 7.9e-37;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMNVRQAPGKGLWVSSISSSSIYY 60
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMNVRQAPGKGLWVSSISSSSIYY 60
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNSLYLQNNSLRAEDTAVYYCAR 98
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLQNNSLRAEDTAVYYCAR 98
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

```

```

RESULT 9
US-11-054-515-1764
; Sequence 1764, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunosepecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1764
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1764

```

```

Query Match 98.8%; Score 497; DB 11; Length 247;
Best Local Similarity 98.0%; Pred. No. 1.2e-36;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMNVRQAPGKGLWVSSISSSSIYY 60
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGGGLVPGGSLRLSCAASGFTFSYSSMMNVRQAPGKGLWVSSISSSSIYY 60
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNSLYLQNNSLRAEDTAVYYCAR 98
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLQNNSLRAEDTAVYYCAR 98
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

```

```

RESULT 10
US-11-266-444-1764
; Sequence 1764, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunosepecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523PDI1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210

```

```

; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1764
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1764

Query Match 98.8%; Score 497; DB 11; Length 247;
Best Local Similarity 98.0%; Pred. No. 1.2e-36;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMNVRQAPGKGLWVSSISSSSIYY 60
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVQSGGGLVPGGSLRLSCAASGFTFSYSSMMNVRQAPGKGLWVSSISSSSIYY 60
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNSLYLQNNSLRAEDTAVYYCAR 98
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLQNNSLRAEDTAVYYCAR 98
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

```

```

RESULT 11
US-11-054-515-1991
; Sequence 1991, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunosepecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1991
; LENGTH: 244
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1991

```

```

Query Match 98.4%; Score 495; DB 11; Length 244;
Best Local Similarity 98.0%; Pred. No. 1.7e-36;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMNVRQAPGKGLWVSSISSSSIYY 60

```

Db 1 EVQLVSGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSHIYY 60
61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98

RESULT 12
US-11-266-444-1991
; Sequence 1991, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; PRIOR FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1991
; LENGTH: 244
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1991

Query Match 98.4%; Score 495; DB 11; Length 244;
Best Local Similarity 98.0%; Pred. No. 1.7e-36;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLVSGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSHIYY 60
Db 1 EVQLVSGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSHIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98

RESULT 13
US-11-054-515-1703
; Sequence 1703, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15

; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1703
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-1703

Query Match 98.4%; Score 495; DB 11; Length 247;
Best Local Similarity 99.0%; Pred. No. 1.7e-36;
Matches 96; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLVSGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSHIYY 60
Db 1 QVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSHIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCA 97
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCA 97

RESULT 14
US-11-266-444-1703
; Sequence 1703, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulato
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1703
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1703

Query Match 98.4%; Score 495; DB 11; Length 247;
Best Local Similarity 99.0%; Pred. No. 1.7e-36;
Matches 96; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVQLVSGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSHIYY 60
Db 1 QVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSHIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCA 97
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCA 97

RESULT 15

US-10-771-257-46
; Sequence 46, Application US/10771257
; Publication No. US20050288864A1
; GENERAL INFORMATION:
; APPLICANT: Medical Research Council
; APPLICANT: SISSA - Scuola Superiore Internazionale di Studi Avanzati
; APPLICANT: Cattaneo, Antonino
; APPLICANT: Maritan, Amos
; APPLICANT: Visintin, Michela
; APPLICANT: Rabbitts, Terrence H
; APPLICANT: Settanni, Giovanni
; TITLE OF INVENTION: Intracellular antibodies
; FILE REFERENCE: 18396/2272
; CURRENT APPLICATION NUMBER: US/10/771,257
; CURRENT FILING DATE: 2004-02-03
; PRIOR APPLICATION NUMBER: PCT/GB02/03512
; PRIOR FILING DATE: 2002-08-01
; PRIOR APPLICATION NUMBER: GB 0119004.0
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: GB 0121577.1
; PRIOR FILING DATE: 2001-09-06
; PRIOR APPLICATION NUMBER: GB 0200928.0
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: GB 0203569.9
; PRIOR FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: IT RM2001A000633
; PRIOR FILING DATE: 2001-10-25
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 46
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-771-257-46

Query Match 97.6%; Score 491; DB 9; Length 120;
Best Local Similarity 96.9%; Pred. No. 2e-36;
Matches 95; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKGLEWVSISSSSYIYY 60
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 3 QVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNWVRQAPGKGLEWVSISSSSYIYY 62
QY 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 63 ADSVKGRFTISRDNKNSLYLQMNSLRDEDTAVYYCAR 100

Search completed: May 5, 2006, 08:57:43
Job time : 7.32964 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:05 ; Search time 6.24377 Seconds
(without alignments)
1510.185 Million cell updates/sec

Title: US-09-674-752-37

Perfect score: 503

Sequence: 1 EVQLVESGGGLVPGGSLRL.....LYLQMNLSRAEDTAVYICAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR_80.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	503	100.0	98	2 S26940	Ig heavy chain V r
2	503	100.0	141	2 S31669	Ig heavy chain V r
3	498	99.0	116	2 S21979	Ig heavy chain V-g
4	488.5	97.1	116	2 S17080	Ig heavy chain V-g
5	484	96.2	117	2 S21980	Ig heavy chain V-g
6	483	96.0	125	2 S30531	Ig heavy chain V r
7	481	95.6	143	2 S23624	Ig heavy chain V r
8	478	95.0	98	2 S26894	Ig heavy chain V r
9	478	95.0	123	2 S26794	Ig heavy chain V r
10	476	94.6	98	2 S26891	Ig heavy chain V r
11	472.5	93.9	117	2 S34012	Ig heavy chain V r
12	465	92.4	98	2 S26930	Ig heavy chain V r
13	465	92.4	128	2 S26790	Ig heavy chain V r
14	464	92.2	128	2 S26786	Ig heavy chain V r
15	460	91.5	114	2 S31120	Ig heavy chain - h
16	460	91.5	118	2 S31105	Ig heavy chain (su
17	459	91.3	127	2 S19878	Ig heavy chain V r
18	458	91.1	97	2 PH0875	Ig heavy chain V r
19	453	90.1	118	2 S31121	Ig heavy chain - h
20	453	90.1	119	2 S31107	Ig heavy chain - h
21	451	89.7	124	2 S20782	Ig heavy chain V r
22	450	89.5	98	2 S26889	Ig heavy chain V r
23	450	89.5	98	2 PH0874	Ig heavy chain V r
24	450	89.5	117	2 A45953	Ig heavy chain pre
25	450	89.5	119	2 D36005	Ig heavy chain V r
26	450	89.5	119	2 D36005	Ig heavy chain V r
27	450	89.5	119	2 S31108	Ig heavy chain - h
28	450	89.5	120	2 S48798	Ig heavy chain V r
29	450	89.5	123	2 S31114	Ig heavy chain - h

30	450	89.5	138	2 S31666	Ig heavy chain V r
31	448	89.1	121	2 S31113	Ig heavy chain - h
32	447	88.9	140	2 S31686	Ig heavy chain V r
33	447	88.9	160	2 S05271	Ig heavy chain pre
34	446	88.7	117	1 H3HU26	Ig heavy chain pre
35	446	88.7	117	2 S78486	Ig heavy chain V r
36	445	88.5	98	2 PL0123	Ig heavy chain V-I
37	445	88.5	117	2 S17079	Ig heavy chain V-g
38	445	88.5	136	2 S31587	Ig heavy chain V r
39	445	88.5	140	2 S31588	Ig heavy chain V r
40	444	88.3	110	2 S36282	Ig heavy chain V r
41	444	88.3	117	2 A34364	Ig heavy chain pre
42	444	88.3	127	2 S38489	Ig heavy chain - h
43	442	87.9	97	2 PH0872	Ig heavy chain V r
44	442	87.9	134	2 S31699	Ig heavy chain V r
45	440	87.5	121	2 I55673	Ig heavy chain - h

ALIGNMENTS

RESULT 1

S26940

Ig heavy chain V region (DP-77) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 22-Nov-1993 #sequence_revision 17-Nov-1995 #text_change 23-Jul-1999

C;Accession: S26940

R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.

J. Mol. Biol. 227, 776-798, 1992

A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of

A;Reference number: S26885; MUID:93021117; PMID:1404388

A;Accession: S26940

A;Status: preliminary; nucleic acid sequence not shown; translation not shown

A;Molecule type: DNA

A;Residues: 1-98 <TOM>

A;Cross-references: UNIPARC:UPI000031F3C; EMBL:Z14073; NID:g32973; PIDN:CAA78453.1; PID

A;Note: the nucleotide sequence was submitted to the EMBL Data Library, July 1992

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 100.0%; Score 503; DB 2; Length 98;

Best Local Similarity 100.0%; Pred. No. 7.2e-40;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKLEWVSSISSSSSIYY 60

Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKLEWVSSISSSSSIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYICAR 98

Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYICAR 98

RESULT 2

S31669

Ig heavy chain V region - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999

C;Accession: S31669

R;Cuisinier, A.M.; Gauthier, L.; Boublil, L.; Fougereau, M.; Tonnelle, C.

submitted to the EMBL Data Library, June 1992

A;Description: Mechanisms that generate human immunoglobulin diversity operate from the

A;Reference number: S31585

A;Accession: S31669

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-141 <CUI>

A;Cross-references: UNIPARC:UPI000011647C; EMBL:Z14212; NID:g30959; PIDN:CAA78581.1; PID

C;Superfamily: immunoglobulin V region; immunoglobulin homology

C;Keywords: heterotetramer; immunoglobulin

F;34-117/Domain: immunoglobulin homology <IMM>

```
Query Match      100.0%; Score 503; DB 2; Length 141;
Best Local Similarity 100.0%; Pred. No. 1e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNMVVRQAPGKLEWVSISSSSSIYY 60
DB 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNMVVRQAPGKLEWVSISSSSSIYY 79

QY 61 ADSVKGRFTISRDNKNSLYLQMSLRADTAVYYCAR 98
DB 80 ADSVKGRFTISRDNKNSLYLQMSLRADTAVYYCAR 117

RESULT 3
S21979
Ig heavy chain V-gene (clone WHG16) - human
C:Species: Homo sapiens (man)
C>Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 23-Jul-1999
C:Accession: S60298; S21979
R:Kueppers, R.; Fischer, U.; Rajewsky, K.; Gause, A.
Immunol. Lett. 34, 57-62, 1992
A:Title: Immunoglobulin heavy and light chain gene sequences of a human CD5 positive imm
A:Reference number: S60295; MUID:93122853; PMID:1282498
A:Accession: S60298
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-116 <KU2>
A:Cross-references: UNIPARC:UPI0000115FF3; EMBL:X62127; NID:g38338; PIDN:CAA44058.1; PID
A>Note: submitted to the EMBL Data Library, September 1991
C:Keywords: the authors did not translate the codons for residues 6, 32, 69, and 76
C:Genetics:
A:Introns: 16/1
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin

Query Match      99.0%; Score 498; DB 2; Length 116;
Best Local Similarity 100.0%; Pred. No. 2.5e-39;
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNMVVRQAPGKLEWVSISSSSSIYY 60
DB 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNMVVRQAPGKLEWVSISSSSSIYY 79

QY 61 ADSVKGRFTISRDNKNSLYLQMSLRADTAVYYCA 97
DB 80 ADSVKGRFTISRDNKNSLYLQMSLRADTAVYYCA 116

RESULT 4
S17080
Ig heavy chain V-gene (clone HHG4) - human
C:Species: Homo sapiens (man)
C>Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 23-Jul-1999
C:Accession: S60300; S17080
R:Kueppers, R.; Fischer, U.; Rajewsky, K.; Gause, A.
Immunol. Lett. 34, 57-62, 1992
A:Title: Immunoglobulin heavy and light chain gene sequences of a human CD5 positive imm
A:Reference number: S60300; MUID:93122853; PMID:1282498
A:Accession: S60300
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-116 <KU2>
A:Cross-references: UNIPARC:UPI0000115FF5; EMBL:X62129; NID:g38342; PIDN:CAA44060.1; PID
A>Note: submitted to the EMBL Data Library, September 1991
C:Keywords: the authors did not translate the codons for residues 6, 32, 69, and 75
C:Genetics:
A:Introns: 16/1
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:34-116/Domain: immunoglobulin homology <IMM>

Query Match      97.1%; Score 488.5; DB 2; Length 116;
Best Local Similarity 99.0%; Pred. No. 1.9e-38;
```

```
Matches 97; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNMVVRQAPGKLEWVSISSSSSIYY 60
DB 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNMVVRQAPGKLEWVSISSSSSIYY 78

QY 61 ADSVKGRFTISRDNKNSLYLQMSLRADTAVYYCAR 98
DB 79 ADSVKGRFTISRDNKNSLYLQMSLRADTAVYYCAR 116

RESULT 5
S21980
Ig heavy chain V-gene (clone WHG26) precursor - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 20-Feb-1995 #sequence_revision 25-Oct-1996 #text_change 23-Jul-1999
C:Accession: S60295; S21980
R:Kueppers, R.; Fischer, U.; Rajewsky, K.; Gause, A.
Immunol. Lett. 34, 57-62, 1992
A:Title: Immunoglobulin heavy and light chain gene sequences of a human CD5 positive imm
A:Reference number: S60295; MUID:93122853; PMID:1282498
A:Accession: S60295
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-117 <KU2>
A:Cross-references: UNIPARC:UPI0000115FF6; EMBL:X62130; NID:g38344; PIDN:CAA44061.1; PID:
C:Genetics:
A:Introns: 16/1
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match      96.2%; Score 484; DB 2; Length 117;
Best Local Similarity 96.9%; Pred. No. 4.9e-38;
Matches 95; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNMVVRQAPGKLEWVSISSSSSIYY 60
DB 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNMVVRQAPGKLEWVSISSSSSIYY 79

QY 61 ADSVKGRFTISRDNKNSLYLQMSLRADTAVYYCAR 98
DB 80 ADSVKGRFTISRDNKNSLYLQMSLRADTAVYYCAR 117

RESULT 6
S30531
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 31-Dec-2004
C:Accession: S30531
R:Marlette, X.
submitted to the EMBL Data Library, October 1992
A:Reference number: S30520
A:Accession: S30531
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-125 <MAR>
A:Cross-references: UNIPROT:Q9UL91; UNIPARC:UPI0000176C10; EMBL:Z18317
C:Superfamily: immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match      96.0%; Score 483; DB 2; Length 125;
Best Local Similarity 95.9%; Pred. No. 6.5e-38;
Matches 94; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNMVVRQAPGKLEWVSISSSSSIYY 60
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSMNMVVRQAPGKLEWVSISSSSSIYY 60

QY 61 ADSVKGRFTISRDNKNSLYLQMSLRADTAVYYCAR 98
```

Db 61 ADSVKGRFTISRDNNAKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 7
S23624
Ig heavy chain V region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1999
C;Accession: S23624
R;Olee, T.; Lu, E.W.; Huang, D.F.; Soto-Gil, R.W.; Deftos, M.; Kozin, F.; Carson, D.A.;
J. Exp. Med. 175, 831-842, 1992
A;Title: Genetic analysis of self-associating immunoglobulin G rheumatoid factors from
A;Reference number: S23623; MUID:92156804; PMID:1740665
A;Accession: S23624
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-143 <OLE>
A;Cross-references: UNIPARC:UPI0000115F94; EMBL:X59703; NID:g32012; PIDN:CAA42224.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 95.6%; Score 481; DB 2; Length 143;
Best Local Similarity 95.9%; Pred. No. 1.2e-37;
Matches 94; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLVWVSISSSSSIYY 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLVWVSISSSSSIYY 60

Qy 61 ADSVKGRFTISRDNNAKNSLYLQMNLSRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNNAKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 8
S26894
Ig heavy chain V region (DP-51) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26894
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26894
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-98 <TOM>
A;Cross-references: UNIPARC:UPI00002DD14; EMBL:Z12351; NID:g32924; PIDN:CAA78221.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 95.0%; Score 478; DB 2; Length 98;
Best Local Similarity 95.9%; Pred. No. 1.5e-37;
Matches 94; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLVWVSISSSSSIYY 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLVWVSISSSSSIYY 60

Qy 61 ADSVKGRFTISRDNNAKNSLYLQMNLSRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNNAKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 9
S26794
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 17-Mar-1999
C;Accession: S26794

R;Mortari, F.; Newton, J.A.; Wang, J.Y.; Schroeder Jr., H.W.
Eur. J. Immunol. 22, 241-245, 1992
A;Title: The human cord blood antibody repertoire. Frequent usage of the V(H)7 gene fami
A;Reference number: S26786; MUID:92111632; PMID:1730251
A;Accession: S26794
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-123 <MOR>
A;Cross-references: UNIPARC:UPI0000176C2B; EMBL:X61011
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 95.0%; Score 478; DB 2; Length 123;
Best Local Similarity 95.9%; Pred. No. 1.9e-37;
Matches 94; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLVWVSISSSSSIYY 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLVWVSISSSSSIYY 60

Qy 61 ADSVKGRFTISRDNNAKNSLYLQMNLSRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNNAKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 10
S26891
Ig heavy chain V region (DP-58) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C;Accession: S26891
R;Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewelyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A;Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A;Reference number: S26885; MUID:93021117; PMID:1404388
A;Accession: S26891
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-98 <TOM>
A;Cross-references: UNIPARC:UPI0000116414; EMBL:Z12358; NID:g32935; PIDN:CAA78228.1; PID
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 94.6%; Score 476; DB 2; Length 98;
Best Local Similarity 94.9%; Pred. No. 2.3e-37;
Matches 93; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLVWVSISSSSSIYY 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMVVRQAPGKGLVWVSISSSGSIYY 60

Qy 61 ADSVKGRFTISRDNNAKNSLYLQMNLSRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNNAKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 11
S34012
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996
C;Accession: S34012; S30538
R;Marette, X.; Tsapis, A.; Brouet, J.C.
Eur. J. Immunol. 23, 846-851, 1993
A;Title: Nucleotide sequence analysis of the variable domains of four human monoclonal
A;Reference number: S34001; MUID:93209281; PMID:7681398
A;Accession: S34012
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-117 <MAR>
A;Cross-references: UNIPARC:UPI0000176D30; EMBL:Z18324

C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 93.9%; Score 472.5; DB 2; Length 117;
Best Local Similarity 94.9%; Pred. No. 5.7e-37;
Matches 93; Conservative 2; Mismatches 0; Indels 3; Gaps 1;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKGLWVSSISSSSYIYY 60
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKGLWV---SSSSSYIFY 57
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRADDTAVYYCAR 98
DB 58 ADSVKGRFTISRDNKNSLYLQMSLRADDTAVYYCAR 95

RESULT 12
S26930
Ig heavy chain V region (DP-35) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S26930
R:Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992
A:Title: The repertoire of human germline V(H) sequences reveals about fifty groups of V
A:Reference number: S26885; MUID:93021117; PMID:1404388
A:Accession: S26930
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-98 <TOM>
C:Cross-references: UNIPARC:UPI000004CF7F; EMBL:Z12337; NID:g32892; PIDN:CAA78207.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 92.4%; Score 465; DB 2; Length 98;
Best Local Similarity 91.8%; Pred. No. 2.4e-36;
Matches 90; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKGLWVSSISSSSYIYY 60
DB 1 QVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKGLWVSYISSSGSTIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRADDTAVYYCAR 98
DB 61 ADSVKGRFTISRDNKNSLYLQMSLRADDTAVYYCAR 98

RESULT 13
S26790
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C:Accession: S26790
R:Morcari, F.; Newton, J.A.; Wang, J.Y.; Schroeder Jr., H.W.
Eur. J. Immunol. 22, 241-245, 1992
A:Title: The human cord blood antibody repertoire. Frequent usage of the V(H) gene fami
A:Reference number: S26786; MUID:92111632; PMID:1730251
A:Accession: S26790
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-128 <MOR>
C:Cross-references: UNIPARC:UPI0000115FC4; EMBL:X61013; NID:g32798; PIDN:CAA43347.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 92.4%; Score 465; DB 2; Length 128;
Best Local Similarity 91.8%; Pred. No. 3.1e-36;
Matches 90; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKGLWVSSISSSSYIYY 60

DB 1 QVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKGLWVSYISSSGSTIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRADDTAVYYCAR 98
DB 61 ADSVKGRFTISRDNKNSLYLQMSLRADDTAVYYCAR 98

RESULT 14
S26786
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C:Accession: S26786
R:Morcari, F.; Newton, J.A.; Wang, J.Y.; Schroeder Jr., H.W.
Eur. J. Immunol. 22, 241-245, 1992
A:Title: The human cord blood antibody repertoire. Frequent usage of the V(H) gene fami
A:Reference number: S26786; MUID:92111632; PMID:1730251
A:Accession: S26786
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-128 <MOR>
C:Cross-references: UNIPARC:UPI0000115FC5; EMBL:X61014; NID:g32800; PIDN:CAA43348.1; PID
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 92.2%; Score 464; DB 2; Length 128;
Best Local Similarity 91.8%; Pred. No. 3.9e-36;
Matches 90; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKGLWVSSISSSSYIYY 60
DB 1 QVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKGLWVSYISSSGSTIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRADDTAVYYCAR 98
DB 61 ADSVKGRFTISRDNKNSLYLQMSLRADDTAVYYCAR 98

RESULT 15
S31120
Ig heavy chain - human
C:Species: Homo sapiens (man)
C:Date: 02-Dec-1993 #sequence_revision 26-May-1995 #text_change 17-Mar-1999
C:Accession: S31120
R:Raaphorst, F.M.; Timmers, E.; Kenter, M.J.H.; van Tol, M.J.D.; Vossen, J.M.; Schuurman,
Eur. J. Immunol. 22, 247-251, 1992
A:Title: Restricted utilization of germ-line V(H)3 genes and short diverse third comple
A:Reference number: S31104; MUID:92111633; PMID:1730252
A:Accession: S31120
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: mRNA
A:Residues: 1-114 <RAA>
C:Cross-references: UNIPARC:UPI0000176DC9; EMBL:X62972
A:Note: the nucleotide sequence was submitted to the EMBL Data Library, October 1991
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 91.5%; Score 460; DB 2; Length 114;
Best Local Similarity 91.8%; Pred. No. 8e-36;
Matches 89; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKGLWVSSISSSSYIYY 60
DB 1 QVQLVESGGGLVPGGSLRLSCAASGFTFSYSSMMVVRQAPGKGLWVSYISSSGSTIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRADDTAVYYCA 97
DB 61 ADSVKGRFTISRDNKNSLYLQMSLRADDTAVYYCA 97

Search completed: May 5, 2006, 08:51:34
Job time : 7.24377 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 02:15:59 ; Search time 118.333 Seconds
(without alignments)
363.880 Million cell updates/sec

Title: US-09-674-752-37

Perfect score: 503

Sequence: 1 EVQLVESGGGLVPGGSLRL.....LYLQMNSLRADTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq 21:*

- 1: Geneseq1980s:*
- 2: Geneseq1990s:*
- 3: Geneseq2000s:*
- 4: Geneseq2001s:*
- 5: Geneseq2002s:*
- 6: Geneseq2003as:*
- 7: Geneseq2003bs:*
- 8: Geneseq2004s:*
- 9: Geneseq2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	503	100.0	98	3	AAV50964 Human FVI
2	503	100.0	98	3	AB40131 Anti-HLL1
3	503	100.0	98	3	AB40133 Anti-HLL1
4	503	100.0	98	6	ABO27088 Human ger
5	503	100.0	98	7	ADD28051 Lymphoma
6	503	100.0	98	7	ADF10025 VEGF anti
7	503	100.0	98	7	ADF10127 Antibody
8	503	100.0	98	7	ADF09917 Antibody
9	503	100.0	98	7	ADK18579 Anti-huma
10	503	100.0	98	7	ADK18847 Anti-huma
11	503	100.0	98	7	ADK18847 Anti-huma
12	503	100.0	98	9	ADY75306 Protein e
13	503	100.0	103	4	ABG55992 Human liv
14	503	100.0	103	5	ABG44145 Human pep
15	503	100.0	109	7	ADP03936 Murine-ex
16	503	100.0	109	8	ADSI12519 Human vhm
17	503	100.0	117	2	AAR66313 Human imm
18	503	100.0	123	8	ADI22093 Anti-plat
19	503	100.0	123	8	ADP22252 Human ant
20	503	100.0	125	9	ABE45963 Human mon
21	503	100.0	471	9	ABE45899 Human mon
22	503	100.0	472	9	ABE45865 Human mon
23	503	100.0	475	7	ADM47075 Mouse ant
24	500	99.4	116	5	AAE28870 Human KDR

25	500	99.4	116	6	ABJ26763	Abj26763 VEGF bind
26	500	99.4	116	7	ADD24417	Add24417 Human hea
27	500	99.4	116	7	ADD80794	Add80794 Human clo
28	500	99.4	116	8	ADK18270	Adk18270 KDR bindi
29	500	99.4	137	8	ADI13464	Adi13464 Human var
30	500	99.4	256	5	ABP45307	Abp45307 Human Bly
31	500	99.4	256	7	ADG96134	Adg96134 Single ch
32	499	99.2	249	5	ABP45845	Abp45845 Human Bly
33	499	99.2	249	7	ADG96672	Adg96672 Single ch
34	498	99.0	109	8	ADP22374	Adp22374 Human ant
35	498	99.0	125	8	ADP46961	Adp46961 Murine he
36	497	98.8	247	5	ABP45753	Abp45753 Human Bly
37	497	98.8	247	7	ADG96580	Adg96580 Single ch
38	495	98.4	116	5	AAE28873	Aae28873 Human KDR
39	495	98.4	116	6	ABJ26766	Abj26766 VEGF bind
40	495	98.4	116	7	ADD24424	Add24424 Human hea
41	495	98.4	116	7	ADD80801	Add80801 Human clo
42	495	98.4	116	8	ADK18277	Adk18277 KDR bindi
43	495	98.4	125	8	ADP46962	Adp46962 Murine he
44	495	98.4	152	4	AAE99111	Aae99111 Human pro
45	495	98.4	244	5	ABP45980	Abp45980 Human Bly

ALIGNMENTS

RESULT 1

AAV50964

ID AAV50964 standard; protein; 98 AA.

XX AAV50964;

AC AAV50964;

DT 23-MAR-2000 (first entry)

XX Human FVIII antibody A3-C1 scFv heavy chain protein DP-77.

DE Human FVIII antibody A3-C1 scFv heavy chain protein DP-77.

XX Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

KW scFv; A3-C1.

XX Homo sapiens.

OS Homo sapiens.

XX WO9958680-A2.

PN WO9958680-A2.

XX 18-NOV-1999.

PD 18-NOV-1999.

XX 07-MAY-1999; 99WO-NL000285.

PF 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

PR 08-MAY-1998; 98EP-00201543.

XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;

PI Voorberg JJ, Van Den Brink EN, Turenhout EAM;

XX WPI; 2000-053102/04.

DR WPI; 2000-053102/04.

XX New polynucleotide, polypeptide and antibody useful for diagnosing the

PT Presence of neutralizing antibodies against factor VIII and for treatment

PT Presence of neutralizing antibodies against factor VIII and for treatment

XX of hemophilia A patients with these antibodies.

XX Example 8; Fig 9A; 61pp; English.

PS This invention describes a novel polynucleotide (I) (and complements and

XX hybridizable polynucleotides) comprising a contiguous nucleotide sequence

CC coding for a human antibody with factor VIII specificity which has

CC hemostatic activity. (I) is useful as a primer or probe for detecting the

CC presence of inhibitory antibodies directed against factor VIII. The

CC polypeptides of the invention and the antibodies generated from them are

CC useful in compositions for neutralizing factor VIII inhibiting antibodies

CC in hemophilia A patients. This sequence represents the human factor VIII

CC antibody A3-C1 specific scFv protein DP-77 which is used in the method of

XX the invention

XX Sequence 98 AA;

```

Query Match      100.0%; Score 503; DB 3; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.3e-41;
Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMNVVRQAPGKLEWVSSISSSSYIYY 60
   |||||
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMNVVRQAPGKLEWVSSISSSSYIYY 60
   |||||
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98
   |||||

RESULT 2
AAB40131
ID AAB40131 standard; protein; 98 AA.
XX
AC AAB40131;
XX
DT 05-FEB-2001 (first entry)
XX
DE Anti-hIL12 antibody H chain V region amino acid sequence SEQ ID 657.
XX
KW Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
KW complementarity determining region; CDR; antirheumatic; antiarthritic;
KW antisclerotic; neuroprotective; antipsoriatic; antiasthmatic; cardiant;
KW antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
KW multiple sclerosis; rheumatoid arthritis.
XX
OS Homo sapiens.
XX
PN WO200056772-A1.
XX
PD 28-SEP-2000.
XX
PF 24-MAR-2000; 2000WO-US007946.
XX
PR 25-MAR-1999; 99US-0126603P.
XX
PA (BADI ) BASF AG.
PA (GEMY ) GENETICS INST INC.
XX
PI Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DE, White M;
PI Kaymakalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;
PI Veldman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
PI Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL;
XX
DR WPI; 2000-638250/61.
XX
PT New human antibody specific for human interleukin-12 (IL-12) used to
PT treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
PT disease and multiple sclerosis.
XX
PS Claim 75; Page 122; 377pp; English.
XX
CC This invention relates to a new human antibody specific for human
CC interleukin-12 (IL-12). The invention also includes antigen binding
CC portions that bind to IL-12. Sequences AAB39485-B39516 represent human
CC anti-IL-12 antibody heavy and light chain complementarity determining
CC region (CDR) amino acid sequences, and also includes variable region
CC amino acid sequences. Other variable region amino acid sequences are
CC given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
CC represent anti-IL-12 CDR3 related amino acid sequences, AAB39772-B40063
CC represent other CDR sequences. Light chain CDR3 consensus sequences are
CC given in AAB40064-B40067. Primers used in the identification and
CC construction of the antibodies of the invention are given in AAC61062-
CC C61071. The antibody of the invention is a neutralising antibody and has
CC antirheumatic; antiarthritic; antisclerotic; antiinflammatory;
CC neuroprotective; antipsoriatic; antiasthmatic; cardiant; antiparasitic;
CC antibacterial and immunosuppressive activity. The antibodies or antigen-
CC binding fragments are useful in the treatment of disorders associated
CC with detrimental release of human IL-12, especially Crohn's disease,

```

```

CC multiple sclerosis and rheumatoid arthritis. They can also be used in the
CC manufacture of a pharmaceutical composition to treat human IL-12
CC disorders
XX
SQ Sequence 98 AA;
Query Match      100.0%; Score 503; DB 3; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.3e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMNVVRQAPGKLEWVSSISSSSYIYY 60
   |||||
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMNVVRQAPGKLEWVSSISSSSYIYY 60
   |||||
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98
   |||||
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98
   |||||

RESULT 3
AAB40133
ID AAB40133 standard; protein; 98 AA.
XX
AC AAB40133;
XX
DT 05-FEB-2001 (first entry)
XX
DE Anti-hIL12 antibody H chain V region amino acid sequence SEQ ID 659.
XX
KW Human; neutralising antibody; interleukin-12; IL-12; antiinflammatory;
KW complementarity determining region; CDR; antirheumatic; antiarthritic;
KW antisclerotic; neuroprotective; antipsoriatic; antiasthmatic; cardiant;
KW antiparasitic; antibacterial; immunosuppressive; Crohn's disease;
KW multiple sclerosis; rheumatoid arthritis.
XX
OS Homo sapiens.
XX
PN WO200056772-A1.
XX
PD 28-SEP-2000.
XX
PF 24-MAR-2000; 2000WO-US007946.
XX
PR 25-MAR-1999; 99US-0126603P.
XX
PA (BADI ) BASF AG.
PA (GEMY ) GENETICS INST INC.
XX
PI Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DE, White M;
PI Kaymakalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles A;
PI Veldman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR;
PI Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL;
XX
DR WPI; 2000-638250/61.
XX
PT New human antibody specific for human interleukin-12 (IL-12) used to
PT treat disorders characterized by aberrant IL-12 expression e.g. Crohn's
PT disease and multiple sclerosis.
XX
PS Claim 75; Page 122; 377pp; English.
XX
CC This invention relates to a new human antibody specific for human
CC interleukin-12 (IL-12). The invention also includes antigen binding
CC portions that bind to IL-12. Sequences AAB39485-B39516 represent human
CC anti-IL-12 antibody heavy and light chain complementarity determining
CC region (CDR) amino acid sequences, and also includes variable region
CC amino acid sequences. Other variable region amino acid sequences are
CC given in AAB39517-B39560 and AAB40068-B40149. Sequences AAB39561-B39771
CC represent anti-IL-12 CDR3 related amino acid sequences, AAB39772-B40063
CC represent other CDR sequences. Light chain CDR3 consensus sequences are
CC given in AAB40064-B40067. Primers used in the identification and
CC construction of the antibodies of the invention are given in AAC61062-
CC C61071. The antibody of the invention is a neutralising antibody and has

```

CC antiarthritic; antiarthritic; antisclerotic; antiinflammatory;
CC neuroprotective; antiparasitic; antiparasitic; antiparasitic;
CC antibacterial and immunosuppressive activity. The antibodies or antigen-
CC binding fragments are useful in the treatment of disorders associated
CC with detrimental release of human IL-12, especially Crohn's disease,
CC multiple sclerosis and rheumatoid arthritis. They can also be used in the
CC manufacture of a pharmaceutical composition to treat human IL-12
CC disorders
XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 503; DB 3; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.3e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWRQAPGKLEWVSSISSSSYIYY 60
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWRQAPGKLEWVSSISSSSYIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
DB 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 4
ABO27088
ID ABO27088 standard; protein; 98 AA.
XX
AC ABO27088;
XX
DT 10-SEP-2003 (first entry)
XX
DE Human germline heavy chain variable region gene segment #21.
XX
KW Human; heavy chain variable region; VH; humanised antibody;
KW chimeric antibody; complementarity determining region; CDR;
KW canonical CDR structure type.
XX
OS Homo sapiens.

XX US200309649-A1.
XX 27-FEB-2003.
XX
XX 12-JUL-2002; 2002US-00194975.
XX
XX 12-JUL-2001; 2001US-0305111P.
XX (FOOT/) FOOTE J.
XX
XX Foote J;
XX
XX WPI; 2003-492151/46.
XX
XX Making humanized antibody for converting antibody by making chimeric
XX antibodies containing complementarity determining region from non-human
XX antibody and appropriate framework sequences of human antibodies.
XX
XX Example 1; Fig 1; 31pp; English.

XX The invention describes a method of making a humanised antibody,
XX comprising making chimeric antibodies containing a complementarity
XX determining region (CDR) from a non-human antibody and appropriate
XX framework sequences (I) of human antibodies. (I) is selected by using
XX canonical CDR structure types of non-human antibody in comparison to
XX germline canonical CDR structure types of human antibodies as the basis
XX for selection, for humanisation. The method is useful for making a
XX humanised antibody or a converted antibody. The method is applicable for
XX converting a subject antibody sequence of any subject species to a less
XX immunogenic form suitable for use in an object species. The method is
XX reliable for identifying suitable human framework sequences to support
XX non-human CDR regions and to provide humanised antibodies that retain
XX high antigen binding with low immunogenicity in humans, without the need

CC for direct comparison of framework sequences, without the need for
CC determining critically important amino acid residues in the framework,
CC and without the need for multiple iteration and construction to obtain
CC humanised antibodies with suitable therapeutic properties. The antibody
CC has high affinity and low immunogenicity without need for comparing
CC framework sequences between non-human and human antibodies. This sequence
CC represents a human heavy chain variable region gene segment used in the
CC creation of humanised antibodies
XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 503; DB 6; Length 98;
Best Local Similarity 100.0%; Pred. No. 4.3e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWRQAPGKLEWVSSISSSSYIYY 60
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWRQAPGKLEWVSSISSSSYIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
DB 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 5
ADD28051
ID ADD28051 standard; protein; 98 AA.
XX
AC ADD28051;
XX
DT 15-JAN-2004 (first entry)
XX
DE Lymphoma related immunoglobulin variable region V3-12.
XX
KW B-cell; malignant; immunoglobulin; immunoglobulin variable region;
KW Ig variable region; glycosylation site; lymphoma; B cell receptor;
KW cytostatic; gene therapy; glycosylation inhibitor;
KW non-Hodgkin's lymphoma.
XX
OS Synthetic.
OS Homo sapiens.

XX WO2003074059-A2.
XX 12-SEP-2003.
XX
XX 24-FEB-2003; 2003WO-GB000783.
XX
XX 07-MAR-2002; 2002GB-00005395.
XX (CANC-) CANCER RES TECHNOLOGY LTD.
XX
XX Zhu D, Stevenson F;
XX
XX WPI; 2003-902720/82.
XX
XX Classifying a B-cell as malignant or normal by isolating a sequence
XX representing an Ig variable region from the B cell, detecting the
XX presence of a glycosylation site and classifying the cell as malignant or
XX normal.

XX Disclosure; Fig 3; 61pp; English.
XX
XX The present invention describes a method for classifying a B-cell as
XX malignant or normal comprising: (a) isolating a sequence representing an
XX immunoglobulin (Ig) variable region from the B cell; (b) detecting the
XX presence of a glycosylation site; and (c) classifying the cell as
XX malignant or normal on the basis of the presence or absence of a
XX glycosylation site. Also described: (1) treating a patient suffering from
XX or at risk of having lymphoma; (2) screening for substances capable of
XX inhibiting glycosylation of the Ig variable region of the B cell receptor
XX ; and (3) screening for substances (s) capable of inhibiting the
XX interaction between lectins of the type found in the germinal centre and

CC N-glycans found on the surface of Ig of lymphoma cells. (S) has
 CC cytostatic activity, and can be used in gene therapy, and as a
 CC glycosylation inhibitor. The method is useful in classifying a B-cell as
 CC malignant or normal. The glycosylation inhibitor is useful in preparing a
 CC medicament for treating non-Hodgkin's lymphoma. The present sequence
 CC represents an Ig variable region sequence which is used in the
 CC exemplification of the present invention.

XX Sequence 98 AA;

Query Match 100.0%; Score 503; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 4.3e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGGLVKPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSISSSSYY 60
 |||
 DB 1 EVOLVESGGGLVKPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSISSSSYY 60
 |||
 QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRRAEDTAVYYCAR 98
 |||
 DB 61 ADSVKGRFTISRDNKNSLYLQWNSLRRAEDTAVYYCAR 98
 |||

RESULT 6

ADF10025
 ID ADF10025 standard; protein; 98 AA.

XX ADF10025;

DT 12-FEB-2004 (first entry)

DE VEGF antibody heavy chain variable region VH_3-21.

XX Antibody; stability; solubility; antigen binding affinity;
 KW variable region; human; VEGF.

XX Homo sapiens.

XX WO2003074679-A2.

XX 12-SEP-2003.

XX 03-MAR-2003; 2003WO-US006598.

XX 01-MAR-2002; 2002US-0360843P.

XX 29-MAY-2002; 2002US-0384197P.

XX (XENC-) XENCOR.

XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;

XX WPI; 2003-722066/68.

XX Computer optimization of physicochemical properties of antibodies
 PT comprises analyzing the interactions of amino acids at variable
 PT positions.

PS Example 6; Fig 16a; 135pp; English.

XX The present invention relates to a method for optimizing at least one
 CC physico-chemical property of an antibody by a computational screening
 CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.

XX Sequence 98 AA;

Query Match 100.0%; Score 503; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 4.3e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGGLVKPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSISSSSYY 60
 |||
 DB 1 EVOLVESGGGLVKPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSISSSSYY 60
 |||
 QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRRAEDTAVYYCAR 98
 |||
 DB 61 ADSVKGRFTISRDNKNSLYLQWNSLRRAEDTAVYYCAR 98
 |||

RESULT 7

ADF10127
 ID ADF10127 standard; protein; 98 AA.

XX ADF10127;

DT 12-FEB-2004 (first entry)

DE Antibody heavy chain variable region VH_3-21.

XX Antibody; stability; solubility; antigen binding affinity;
 KW variable region; human.

XX Homo sapiens.

XX WO2003074679-A2.

XX 12-SEP-2003.

XX 03-MAR-2003; 2003WO-US006598.

XX 01-MAR-2002; 2002US-0360843P.

XX 29-MAY-2002; 2002US-0384197P.

XX (XENC-) XENCOR.

XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;

XX WPI; 2003-722066/68.

XX Computer optimization of physicochemical properties of antibodies
 PT comprises analyzing the interactions of amino acids at variable
 PT positions.

PS Example 16; Fig 40a; 135pp; English.

XX The present invention relates to a method for optimizing at least one
 CC physico-chemical property of an antibody by a computational screening
 CC method. The method comprises: receiving a template antibody structure;
 CC selecting at least one variable position belonging to the antibody
 CC structure; selecting at least one amino acid to be considered at the
 CC variable position(s); analyzing the interaction of each selected amino
 CC acid at each variable position with at least part of the remainder of the
 CC antibody, including the selected amino acids at other variable positions;
 CC and identifying a set of at least one antibody sequence with at least one
 CC optimized physico-chemical property. The method is useful for optimizing
 CC the physico-chemical properties of an antibody, especially the stability,
 CC solubility, or antigen binding affinity. The optimized antibody may be
 CC useful for treating a patient. The present sequence is an antibody
 CC variable region sequence used to illustrate the invention.

XX Sequence 98 AA;

Query Match 100.0%; Score 503; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 4.3e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLCSAASGFTFSYSSNNVVRQAPGKGLEWVSSISSSSSYY 60
Db 1 EVQLVESGGGLVPGGSLRLCSAASGFTFSYSSNNVVRQAPGKGLEWVSSISSSSSYY 60
Qy 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98

RESULT 8
ID ADF09917 standard; protein; 98 AA.
XX ADF09917;
AC ADF09917;
DT 12-FEB-2004 (first entry)
XX Antibody heavy chain variable region VH_3-21.
DE Antibody; stability; solubility; antigen binding affinity;
KW variable region; human.
KW Homo sapiens.
OS Homo sapiens.
PN WO2003074679-A2.
XX 12-SEP-2003.
XX 03-MAR-2003; 2003WO-US006598.
XX 01-MAR-2002; 2002US-0360843P.
PR 29-MAY-2002; 2002US-0384197P.
XX (XENC-) XENCOR.
XX Lazar GA, Desjarlais JR, Marshall SA, Dahiyat B;
PI WPI; 2003-722066/68.
XX Computer optimization of physicochemical properties of antibodies
PT comprises analyzing the interactions of amino acids at variable
PT positions.
XX Disclosure; Fig 2a; 135pp; English.

XX The present invention relates to a method for optimizing at least one
CC physico-chemical property of an antibody by a computational screening
CC method. The method comprises: receiving a template antibody structure;
CC selecting at least one variable position belonging to the antibody
CC structure; selecting at least one amino acid to be considered at the
CC variable position(s); analyzing the interaction of each selected amino
CC acid at each variable position with at least part of the remainder of the
CC antibody, including the selected amino acids at other variable positions;
CC and identifying a set of at least one antibody sequence with at least one
CC optimized physico-chemical property. The method is useful for optimizing
CC the physico-chemical properties of an antibody, especially the stability,
CC solubility, or antigen binding affinity. The optimized antibody may be
CC useful for treating a patient. The present sequence is an antibody
CC variable region sequence used to illustrate the invention.
XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 503; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. NO. 4.3e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLCSAASGFTFSYSSNNVVRQAPGKGLEWVSSISSSSSYY 60
Db 1 EVQLVESGGGLVPGGSLRLCSAASGFTFSYSSNNVVRQAPGKGLEWVSSISSSSSYY 60
Qy 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98

RESULT 9
ADK18579
ID ADK18579 standard; protein; 98 AA.
XX ADK18579;
AC ADK18579;
DT 06-MAY-2004 (first entry)
XX Anti-human PDGF-D antibody Vh 3-21 protein.
DE antiinflammatory; immunomodulator; cytostatic; gene therapy.
KW Homo sapiens.
OS Homo sapiens.
PN WO2003057857-A2.
XX 17-JUL-2003.
XX 06-JAN-2003; 2003WO-US000398.
PF 07-JAN-2002; 2002US-00041860.
PR (ABGE-) ABGENIX INC.
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
PI WPI; 2003-587119/55.
DR New human monoclonal antibody that binds to platelet-derived growth
XX factor-D (PDGF-D), useful for treating chronic and recurrent human
XX diseases, such as inflammation, autoimmunity and cancer.

XX Example 7; SEQ ID NO 3; 255pp; English.
XX The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC Clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCBP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 98 AA;

Query Match 100.0%; Score 503; DB 7; Length 98;
Best Local Similarity 100.0%; Pred. NO. 4.3e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLCSAASGFTFSYSSNNVVRQAPGKGLEWVSSISSSSSYY 60
Db 1 EVQLVESGGGLVPGGSLRLCSAASGFTFSYSSNNVVRQAPGKGLEWVSSISSSSSYY 60
Qy 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98

RESULT 10
ADK18847
ID ADK18847 standard; protein; 98 AA.
XX ADK18847;
AC ADK18847;
DT 06-MAY-2004 (first entry)
XX Anti-human PDGF-D antibody protein related sequence #73.
DE
XX

KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
 XX Homo sapiens.
 OS
 PN WO2003057857-A2.
 XX
 PD 17-JUL-2003.
 XX
 PF 06-JAN-2003; 2003WO-US000398.
 XX
 PR 07-JAN-2002; 2002US-00041860.
 XX
 PA (ABGE-) ABGENIX INC.
 XX
 XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;
 DR WPI; 2003-587119/55.
 XX
 PT New human monoclonal antibody that binds to platelet-derived growth
 factor-D (PDGF-D), useful for treating chronic and recurrent human
 PT diseases, such as inflammation, autoimmunity and cancer.
 XX
 PS Disclosure; SEQ ID NO 271; 255pp; English.
 XX
 CC The invention relates to a human monoclonal antibody that binds to
 CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 CC treating chronic and recurrent human diseases, such as inflammation,
 CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 CC useful for modulating collagen formation, and for staging various
 CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 CC generated using an active protein fragment of the gene product from the
 CC clone 30664188.0.99 arising in the conditioned medium obtained when
 CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
 CC sequence corresponds to a protein used in the invention.
 XX
 XX Sequence 98 AA;
 SQ
 Query Match 100.0%; Score 503; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 4.3e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSIYY 60
 DB 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSIYY 60
 QY 61 ADSVKGRTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
 DB 61 ADSVKGRTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
 RESULT 11
 ID ADJ80301
 XX ADJ80301 standard; protein; 98 AA.
 AC ADJ80301;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX VH gene locus amino acid sequence #21.
 DE
 XX hybrid antibody; antibody; framework region; homology; immunogenicity.
 KW
 OS Homo sapiens.
 XX
 PN WO2003048321-A2.
 XX
 PD 12-JUN-2003.
 XX
 PF 03-DEC-2002; 2002WO-US038450.
 XX
 PR 03-DEC-2001; 2001US-0336591P.
 XX

PA (ALEX-) ALEXION PHARM INC.
 XX
 PI Rother R, Wu D;
 XX
 DR WPI; 2003-513753/48.
 XX
 PT Producing a hybrid antibody or hybrid antibody fragment by operatively
 PT linking the selected framework sequences to one or more complementarity
 PT determining regions of the initial antibody.
 XX
 PS Disclosure; SEQ ID NO 61; 77pp; English.
 XX
 CC The invention relates to a method of producing a hybrid antibody or
 CC hybrid antibody fragment by: (i) providing an initial antibody having
 CC specificity for a target; (ii) determining the sequence of a variable
 CC region of the initial antibody; (iii) selecting a first component of the
 CC variable region consisting of FR1, FR2, FR3 and FR4; (iv) comparing the
 CC sequence of the first component to sequences contained in a reference
 CC database of antibody sequences or antibody fragment sequences from a
 CC target species; (v) selecting a sequence from an antibody in the database
 CC which demonstrates a high degree of homology to the first component; (vi)
 CC selecting a second component of the variable region which is different
 CC than the first component, the second component selected from the group
 CC consisting of FR1, FR2, FR3 and FR4; (vii) comparing the sequence of the
 CC second component to sequences contained in a reference database of
 CC antibody sequences or antibody fragment sequences from the target species
 CC; (viii) selecting a sequence from the database which demonstrates a high
 CC degree of homology to the second component and which is from a different
 CC antibody than the selected antibody; and (ix) operatively linking the
 CC selected framework sequences to one or more complementarity determining
 CC regions (CDRs) of the initial antibody to produce a hybrid antibody or
 CC hybrid antibody fragment. The method is useful for producing a hybrid
 CC antibody or hybrid antibody fragment (claimed). The antibody and
 CC fragments are useful for therapeutic and diagnostic purposes. The method
 CC uses entire framework regions from a single antibody variable heavy or
 CC variable light chain to receive the CDRs. This produces antibodies that
 CC are highly homologous and exhibit reduced immunogenicity while
 CC maintaining an optimum binding profile. This sequence represents the
 CC amino acid sequence of an antibody from the VH gene locus.
 XX
 XX Sequence 98 AA;
 SQ
 Query Match 100.0%; Score 503; DB 7; Length 98;
 Best Local Similarity 100.0%; Pred. No. 4.3e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSIYY 60
 DB 1 EVLVESGGGLVKPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSIYY 60
 QY 61 ADSVKGRTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
 DB 61 ADSVKGRTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
 RESULT 12
 ID ADJ75306
 XX ADJ75306 standard; protein; 98 AA.
 AC ADJ75306;
 XX
 XX 02-JUN-2005 (first entry)
 DT
 XX Protein encoded by human germline heavy chain V minigene VH3 3-21.
 DE
 XX Antibody engineering; antibody; antibody production; gene library;
 KW DNA recombination; gene amplification; primer extension;
 KW heavy chain variable region.
 XX
 OS Homo sapiens.
 XX
 PN WO2005023993-A2.
 XX


```
PD 17-MAR-2005.
XX
XX 09-SEP-2004; 2004WO-US029617.
XX
XX 09-SEP-2003; 2003US-0501073P.
XX
XX (INTE-) INTEGRIGEN INC.
XX
XX Sharma V, Leonard L, Smider V;
XX
XX WPI; 2005-223364/23.
XX
XX Producing polynucleotide encoding human germline antibody V-region for
XX generating full-length antibody germline V-region genes, by obtaining V
XX or J minigene and joining V minigene with J minigene, or joining J
XX minigene with V minigene.
XX
XX Disclosure; Fig 10; 52pp; English.
XX
XX The present invention relates to producing germline antibody genes by a
XX completely in vitro approach that mimics the natural process of V(D)J
XX recombination. The antibody genes are completely human and native in
XX their sequence, and libraries of such antibody genes can be constructed
XX which represent an unselected population representing the entire antibody
XX repertoire. The method uses gene amplification to produce a V minigene,
XX and a hybrid primer capable of hybridizing to a V minigene and either a D
XX or V minigene. The hybrid primer facilitates recombination of a V
XX minigene to a D or J minigene to produce a full length V-region gene.
XX Also disclosed is a library comprising member polynucleotides encoding
XX exogenously rearranged human germline antibody V-regions. In producing a
XX polynucleotide encoding a human germline antibody V-region, a D minigene
XX is further joined to the 3' end of the V minigene and the 5' end of the J
XX minigene. The V minigene or the J minigene in is obtained by chemical
XX synthesis or by amplification from a germline DNA library. Joining the V
XX minigene with at least one J minigene is performed by primer extension
XX using at least two or three oligonucleotide primers. The V minigene is
XX derived from human immunoglobulin kappa locus, human immunoglobulin
XX lambda locus, or human immunoglobulin heavy chain locus. The V-region
XX also comprises a serine protease triad. The human germline antibodies can
XX be used as precursors to more high affinity antibodies, and are useful in
XX the generation of efficiently pairing libraries of heavy and light
XX chains. The present sequence is a polypeptide encoded by human germline
XX heavy chain V minigene, family VH3 locus 3-21.
XX
XX Sequence 98 AA;
XX
XX Query Match 100.0%; Score 503; DB 9; Length 98;
XX Best Local Similarity 100.0%; Pred. No. 4.3e-41;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSIYY 60
XX | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
XX Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSIYY 60
XX | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
XX
XX QY 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYICAR 98
XX | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
XX Db 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYICAR 98
XX | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
XX
XX RESULT 13
XX ABG55992
XX ID ABG55992 standard; peptide; 103 AA.
XX
XX AC ABG55992;
XX
XX XX 25-FEB-2003 (first entry)
XX
XX DE Human liver peptide, SEQ ID No 34640.
XX
XX DE Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
XX KW hypercholesterolaemia; coronary heart disease.
XX
XX KW Homo sapiens.
XX
XX OS
```

```
XX WO200157273-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234887P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2001-488898/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
XX gene expression in human adult liver.
XX
XX Claim 27; SEQ ID NO 34640; 658pp; English.
XX
XX The invention relates to a single exon nucleic acid probe (SENP) (I) for
XX measuring human gene expression in a sample derived from human adult
XX liver, comprising one of 13109 defined nucleotide sequences given in the
XX specification (or complements/ fragments). The probe hybridises at high
XX stringency to a nucleic acid molecule expressed in the human adult liver.
XX (I) may be used for predicting, measuring and displaying gene expression
XX in samples derived from human adult liver. The genes identified may be
XX involved in genetic liver diseases such as cirrhosis,
XX hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX associated with coronary heart disease. ABG47348-ABG59930 represent human
XX liver single exon encoded peptides of the invention. Note: The sequence
XX information for this patent does not appear in the printed specification
XX but was obtained in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 103 AA;
XX
XX Query Match 100.0%; Score 503; DB 4; Length 103;
XX Best Local Similarity 100.0%; Pred. No. 4.5e-41;
XX Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSIYY 60
XX | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
XX Db 4 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSIYY 63
XX | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
XX
XX QY 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYICAR 98
XX | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
XX Db 64 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYICAR 101
XX | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
XX
XX RESULT 14
XX ABG44145
XX ID ABG44145 standard; peptide; 103 AA.
XX
XX AC ABG44145;
XX
XX XX 19-AUG-2002 (first entry)
XX
XX DE Human peptide encoded by genome-derived single exon probe SEQ ID 33810.
XX
XX KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
XX KW chronic obstructive pulmonary disease; interstitial lung disease;
XX KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
XX KW tuberosus sclerosis; Gaucher's disease; Niemann-Pick disease;
XX KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
XX KW pulmonary histiocytosis; lymphangioleiomyomatosis; Karagenar syndrome;
XX KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
```

KW primary ciliary dyskinesia; pulmonary hypertension;
 KW hyaline membrane disease.

XX Homo sapiens.

XX WO200186003-A2.

XX 15-NOV-2001.

XX 30-JAN-2001; 2001WO-US000665.

XX 04-FEB-2000; 2000US-0180312P.

XX 26-MAY-2000; 2000US-0207456P.

XX 30-JUN-2000; 2000US-00608408.

XX 03-AUG-2000; 2000US-00632366.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2002-114183/15.

XX Spatially-addressable set of single exon nucleic acid probes, used to

XX measure gene expression in human lung samples.

XX Claim 27; SEQ ID NO 33810; 634pp; English.

XX The invention relates to a spatially-addressable set of single exon
 CC nucleic acid probes for measuring gene expression in a sample derived
 CC from human lung comprising single exon nucleic acid probes having one of
 CC 12614 nucleic acid sequences mentioned in the specification, or their
 CC complements or the 12387 open reading frames derived from the 12614
 CC probes. Also included are a microarray comprising the novel set of probes
 CC in the novel set of probes which hybridize at high stringency to a nucleic
 CC acid expressed in the human lung; measuring gene expression in a sample
 CC derived from human lung, comprising (a) contacting the array with a
 CC collection of detectably labeled nucleic acids derived from human lung
 CC mRNA, and (b) measuring the label detectably bound to each probe of the
 CC array; identifying exons in a eukaryotic genome, comprising (a)
 CC algorithmically predicting at least one exon from genomic sequences of
 CC the eukaryote; and (b) detecting specific hybridisation of detectably
 CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
 CC having a fragment identical to the predicted exon, the probe is included
 CC in the above mentioned microarray; assigning exons to a single gene,
 CC comprising (a) identifying exons from genomic sequence by the method
 CC above and (b) measuring the expression of each of the exons in several
 CC tissues and/or cell types using hybridisation to a single exon
 CC microarrays having a probe with the exon, where a common pattern of
 CC expression of the exons in the tissues and/or cell types indicates that
 CC the exons should be assigned to a single gene; a peptide comprising one
 CC of 12011 sequences, mentioned in the specification, or encoded by the
 CC probes/open reading frames (ORF). The probes are used for gene expression
 CC analysis, and for identifying exons in a gene, particularly using human
 CC lung derived mRNA and for the study of lung diseases such as asthma, lung
 CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
 CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
 CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
 CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
 CC histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,
 CC Karsenger syndrome, fibrocystic pulmonary dysplasia, primary ciliary
 CC dyskinesia, pulmonary hypertension and hyaline membrane disease. The
 CC present sequence is a peptide/protein encoded by a single exon probe of
 CC the invention. Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic format
 CC directly from WFO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 103 AA;

Query Match 100.0%; Score 503; DB 5; Length 103;
 Best Local Similarity 100.0%; Pred. No. 4.5e-41;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVKPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSISSSSYIYY 60

DB 4 EVQLVESGGGLVKPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSISSSSYIYY 63

QY 61 ADSVKGRTISRDNKNSLYLOWNSLRADTAVYYCAR 98

DB 64 ADSVKGRTISRDNKNSLYLOWNSLRADTAVYYCAR 101

RESULT 15

ADP03936

ID ADP03936 standard; protein; 109 AA.

XX ADP03936;

XX 29-JUL-2004 (first entry)

XX Murine-expressed anti-human CA IX monoclonal antibody VH protein -SEQ 76.

XX monoclonal antibody; carbonic anhydrase IX; CA IX tumour antigen;

KW cytostatic; colorectal neoplasm; renal cell carcinoma;

KW cervical intraepithelial squamous neoplasia;

KW cervical intraepithelial glandular neoplasia; oesophageal; breast cancer;

KW gene therapy; murine; mouse; human; heavy chain variable domain.

XX Unidentified.

XX WO2003048328-A2.

XX 12-JUN-2003.

XX 02-DEC-2002; 2002WO-US039550.

XX 03-DEC-2001; 2001US-0337275P.

XX (ABGE-) ABGENIX INC.

XX Gudas J, Foltz I, Handa M, Gallo M;

XX WPI; 2003-523295/49.

XX New anti-CA IX monoclonal antibody, useful for treating a tumor e.g.,

XX colorectal neoplasms, colorectal tumors, cervical carcinoma, cervical

XX intraepithelial squamous and glandular neoplasia or esophageal tumors.

XX Example 2; SEQ ID NO 76; 89pp; English.

XX The invention relates to a novel isolated monoclonal antibody (mAb)
 CC comprising a heavy chain polypeptide and light chain polypeptide having a
 CC sequence chosen from one of 53 fully defined amino acid sequences given
 CC in the specification, where the antibody specifically binds carbonic
 CC anhydrase IX (CA IX) tumour antigen. The antibody of the invention
 CC demonstrates cytostatic activity and may be useful for treating a tumour,
 CC such as colorectal neoplasm, renal cell carcinoma, cervical carcinoma,
 CC cervical intraepithelial squamous and glandular neoplasia, oesophageal
 CC tumour or breast cancer, possibly via gene therapy. The current sequence
 CC is that of a murine-expressed anti-human CA IX monoclonal antibody VH
 CC (heavy chain variable domain) protein of the invention. The protein was
 CC generated via the introduction of the human CA IX protein into a
 CC transgenic mouse strain.

XX Sequence 109 AA;

Query Match 100.0%; Score 503; DB 7; Length 109;

Best Local Similarity 100.0%; Pred. No. 4.8e-41;

Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVKPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSISSSSYIYY 60

DB 1 EVQLVESGGGLVKPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSISSSSYIYY 60

XX AC ADI22093;
XX DT 22-APR-2004 (first entry)
XX DE Anti-platelet autoantibody related heavy chain amino acid H29 SEQ:56.
XX KW anti-platelet autoantibody; autoantibody; blood clotting inhibition;
XX KW thrombus; platelet adhesion inhibition;
XX KW thrombotic thrombocytopenic purpura; platelet aggregation inhibition;
XX KW idiopathic thrombocytopenic purpura; haemostatic; anticoagulant;
XX KW thrombolytic; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004005890-A2.
XX PD 15-JAN-2004.
XX PF 03-JUL-2003; 2003WO-US021304.
XX PR 03-JUL-2002; 2002US-0394352P.
XX PR 18-SEP-2002; 2002US-0411594P.
XX PA (UYPE-) UNIV PENNSYLVANIA.
XX PI Siegel DL;
XX DR WPI: 2004-142998/14.
XX DR N-PSDB; ADI22040.
XX PS Claim 12; SEQ ID NO 56; 232pp; English.
XX CC The present invention describes a method (M1) for identifying an anti-platelet autoantibody (I) in a mammal. The autoantibody is detected by producing an antibody phage display library from B-lymphocytes obtained from the mammal, and screening the library to detect a phage that specifically binds with a platelet component, where the screening comprises panning the phage on intact platelets using competitive cell-surface panning. Also described: (1) an autoantibody identified by (M1); (2) an isolated nucleic acid encoding an anti-platelet autoantibody; (3) inhibiting (M2) blood clotting in a mammal having a thrombus or at risk of thrombus formation; (4) reversibly (M3) inhibiting blood clotting in a mammal having a thrombus or at risk of thrombus formation; (5) inhibiting (M4) binding of an anti-platelet autoantibody with a platelet component; (6) inhibiting (M5) platelet adhesion in a mammal; (7) treating (M6) thrombotic thrombocytopenic purpura in a mammal; (8) inhibiting (M7) platelet aggregation; (9) inhibiting (M8) platelet activation; (10) inhibiting (M9) platelet function; (11) inhibiting (M10) binding of an anti-platelet autoantibody, or its biologically active fragment with a platelet; (12) identifying (M11) a peptide that inhibits binding of an anti-platelet autoantibody with a platelet; (13) a peptide identified by the method of (12); (14) a peptide that specifically binds with an anti-platelet autoantibody; (15) treating (M12) idiopathic thrombocytopenic purpura (ITP) in a mammal; and (16) a kit for reversibly inhibiting blood clotting, inhibiting platelet aggregation, inhibiting platelet function or inhibiting platelet activation comprising an amount of an anti-platelet autoantibody, or its biologically active fragment that specifically binds with glycoprotein IIb/IIIa, where the autoantibody, or its fragment comprises an antigen binding region derived from an H44U4 anti-platelet autoantibody, the kit further comprising a peptide inhibitor of the binding with glycoprotein IIb/IIIa, and an applicator and an instructions for use. (I) has haemostatic, anticoagulant and thrombolytic activities. The autoantibodies (I) are useful for diagnosing and for developing therapeutics for diseases mediated by autoantibody binding with platelet antigens. (M6) and (M12) are useful for treating thrombotic thrombocytopenic purpura and idiopathic thrombocytopenic purpura, respectively. (M2) and (M3) are useful for inhibiting blood clotting. The present sequence is used in the exemplification of the present invention.
XX CC Sequence 123 AA;
XX CC

Query Match 100.0%; Score 503; DB 8; Length 123;
Best Local Similarity 100.0%; Pred. No. 5.5e-41;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVOLVSGGGLVKPGGSLRLSCAASGFTFSYSSMMVVRQAPGKLEWVSSISSSYIYY 60
DB 1 EVOLVSGGGLVKPGGSLRLSCAASGFTFSYSSMMVVRQAPGKLEWVSSISSSYIYY 60
QY 61 ADSVKGRTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
DB 61 ADSVKGRTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
RESULT 19
ADP22252
ID ADP22252 standard; protein; 123 AA.
XX AC ADP22252;
XX DT 09-SEP-2004 (first entry)
XX DE Human anti-TNFa antibody heavy chain variable region SEQ ID NO:158.
XX DE human; monoclonal antibody; tumour necrosis factor-alpha; TNFa;
XX KW anti-TNFa antibody; anabolic; antiarteriosclerotic; antiarthritic;
XX KW antibacterial; antiinflammatory; antipsoriasis; antirheumatic;
XX KW eating-disorder; immunomodulator; immunosuppressive; nephrotropic;
XX KW neuroprotective; vasotropic; antiapoptotic; TNFa antagonist;
XX KW TNF induced apoptosis; neoplastic disease; breast cancer; ovarian cancer;
XX KW bladder cancer; lung cancer; glioblastoma; stomach cancer;
XX KW endometrial cancer; kidney cancer; colon cancer; pancreatic cancer;
XX KW prostate cancer; immuno-mediated inflammatory disease;
XX KW rheumatoid arthritis; glomerulonephritis; atherosclerosis; psoriasis;
XX KW restenosis; autoimmune disease; Crohn's disease; graft-host reaction;
XX KW septic shock; cachexia; anorexia; multiple sclerosis.
XX OS Homo sapiens.
XX PN WO2004050683-A2.
XX PD 17-JUN-2004.
XX PF 02-DEC-2003; 2003WO-US039281.
XX PR 02-DEC-2002; 2002US-0430729P.
XX PA (ABGE-) ABGENIX INC.
XX PI Babcock JS, Kang JS, Foord O, Green L, Feng X, Klakamp S;
XX PI Haak-Frendscho M, Rathanaswami P, Pigott C, Liang ML, Lee R;
XX PI Manchulenchko K, Faggioni R, Senaldi G, Qiaojuan JS;
XX WPI: 2004-480601/45.
XX DR N-PSDB; ADP22251.
XX CC New recombinant human monoclonal antibody that specifically binds to Tumor Necrosis Factor-alpha, useful for treating neoplastic disease such as cancers, or immuno-mediated inflammatory diseases such as rheumatoid arthritis.
XX PS Example 10; SEQ ID NO 158; 213pp; English.
XX CC The present invention describes a human monoclonal antibody (I) that specifically binds to tumour necrosis factor-alpha (TNFa) and comprises: (a) a heavy chain complementarity determining region 1 (CDR1) having the two fully defined 5 amino acid sequence (S1, ADP22417) or (S2, ADP22421); and (b) a light chain CDR1 having the two fully defined 11 amino acid sequence (S3, ADP22418) or (S4, ADP22424). Also described: (1) assaying (M1) the level of TNFa in a patient sample, comprising contacting with (I), and detecting the level of binding between the antibody and TNFa in the sample; (2) a composition comprising the antibody or its functional fragment and a carrier; (3) treating (M2) an animal suffering from a

neoplastic, or an immuno-mediated inflammatory disease by selecting an animal in need of treatment for the disease by administering the human monoclonal antibody of (1); and (4) inhibiting (M3) TNFa induced apoptosis in an animal by selecting an animal in need of treatment for TNFa induced apoptosis by administering the human monoclonal antibody of (1). (1) has anabolic, antiarteriosclerotic, antiarthritic, antibacterial, antiinflammatory, antipapillary, antirheumatic, eating-disorders, immunomodulatory, immunosuppressive, nephrotropic, neuroprotective, vasotropic and antiapoptotic activities, and can be used as a TNFa antagonist. The antibody (1) is useful in the preparation of a medicament for treating TNF induced apoptosis, neoplastic disease such as breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, stomach cancer, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, and prostate cancer; or immuno-mediated inflammatory diseases such as rheumatoid arthritis, glomerulonephritis, atherosclerosis, psoriasis, restenosis, autoimmune disease, Crohn's disease, graft-host reactions, septic shock, cachexia, anorexia, and multiple sclerosis. The present sequence represents a human anti-TNFa antibody heavy chain variable region, which is used in the exemplification of the present invention.

XX Sequence 123 AA;

Query Match 100.0%; Score 503; DB 8; Length 123;
 Best Local Similarity 100.0%; Pred. No. 5.5e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVRQAPGKLEWVSSISSSSIYY 60
 Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVRQAPGKLEWVSSISSSSIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98
 Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98

RESULT 20

AEBA5963
 ID AEB45963 standard; protein; 125 AA.

XX AEB45963;

XX 06-OCT-2005 (first entry)

XX Human monoclonal anti-MadCAM antibody related protein #7.

XX Monoclonal antibody; mucosal addressin cell adhesion molecule; MadCAM;
 inflammation; inflammatory bowel disease; Crohn's disease;
 ulcerative colitis; diverticular disease; gastritis; liver disease;
 primary biliary cirrhosis; primary sclerosing cholangitis;
 insulin dependent diabetes; graft versus host disease; antiinflammatory;
 gastrointestinal-gen.; antiulcer; hepatotropic; antidiabetic;
 immunosuppressive; antibody.

XX Homo sapiens.

XX WO2005067620-A2.

XX 28-JUL-2005.

XX 07-JAN-2005; 2005WO-US000370.

XX 09-JAN-2004; 2004US-0535490P.

XX (PFIZ) PFIZER INC.

XX (ABGE-) ABGENIX INC.

XX (PFIZ) PFIZER LTD.

XX Pullen N, Molloy E, Kellermann S, Green LL, Haak-Frendscho M;

XX WPI; 2005-554958/56.

XX New antibody to Mucosal Addressin Cell Adhesion Molecule, useful for

PT diagnosing and treating an inflammatory disease, e.g. inflammatory bowel
 PT disease, ulcerative colitis, gastritis, insulin-dependent diabetes or
 PT graft versus host disease.

XX Example 5; Fig 1; 167pp; English.

XX The invention relates to a human monoclonal antibody or its antigen-
 CC binding portion that specifically binds to mucosal addressin cell
 CC adhesion molecule (MADCAM). The invention also relates to a hybridoma
 CC cell line that produces the human monoclonal antibody, a pharmaceutical
 CC composition comprising an amount of the monoclonal antibody or its
 CC antigen-binding portion and a pharmaceutical carrier, a method of
 CC treating inflammatory disease in a subject, an isolated cell line that
 CC produces the monoclonal antibody or its antigen-binding portion or the
 CC heavy chain or light chain of the antibody or of its portion, an isolated
 CC nucleic acid molecule comprising a nucleotide sequence encoding the heavy
 CC chain or its antigen-binding portion or the light chain or its antigen-
 CC binding portion of an antibody described above, a vector comprising the
 CC nucleic acid molecule, where the vector optionally comprises an
 CC expression control sequence operably linked to the nucleic acid molecule,
 CC a host cell comprising the vector or the nucleic acid molecule above, a
 CC method of producing a human monoclonal antibody or its antigen-binding
 CC portion that specifically binds MADCAM, a method of isolating an antibody
 CC or its antigen-binding portion that specifically binds to MadCAM, a
 CC method of treating a subject in need of a human antibody or its antigen-
 CC binding portion that specifically binds to MadCAM and inhibits binding to
 CC alpha4beta7, a method of inhibiting alpha4beta7 binding to cells
 CC expressing human MadCAM, a method of inhibiting MadCAM-mediated leukocyte
 CC endothelial cell adhesion, migration and infiltration into tissues, a
 CC method of inhibiting alpha4beta7/MadCAM-dependent cellular adhesion,
 CC inhibiting the MadCAM-mediated recruitment of lymphocytes to
 CC gastrointestinal lymphoid tissue, a method of diagnosing a disorder
 CC characterized by circulating soluble human MadCAM and detecting
 CC inflammation in a subject. The antibody, composition and methods are
 CC useful for diagnosing and treating inflammatory disease, e.g.
 CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
 CC diverticular disease, gastritis, liver disease, primary biliary
 CC cirrhosis, primary sclerosing cholangitis, insulin dependent diabetes and
 CC graft versus host disease. This sequence represents a human monoclonal
 CC anti-MadCAM antibody related protein of the invention.

XX Sequence 125 AA;

Query Match 100.0%; Score 503; DB 9; Length 125;
 Best Local Similarity 100.0%; Pred. No. 5.6e-41;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVRQAPGKLEWVSSISSSSIYY 60

Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVRQAPGKLEWVSSISSSSIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98

Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98

RESULT 21

AEBA5899

ID AEB45899 standard; protein; 471 AA.

XX AEB45899;

XX 06-OCT-2005 (first entry)

XX Human monoclonal anti-MadCAM antibody #31.

XX Monoclonal antibody; mucosal addressin cell adhesion molecule; MadCAM;
 inflammation; inflammatory bowel disease; Crohn's disease;
 ulcerative colitis; diverticular disease; gastritis; liver disease;
 primary biliary cirrhosis; primary sclerosing cholangitis;
 insulin dependent diabetes; graft versus host disease; antiinflammatory;
 gastrointestinal-gen.; antiulcer; hepatotropic; antidiabetic;
 immunosuppressive; antibody.

XX OS Homo sapiens.
 XX PN WO2005067620-A2.
 XX PD 28-JUL-2005.
 XX PF 07-JAN-2005; 2005WO-US000370.
 XX PR 09-JAN-2004; 2004US-0535490P.
 XX PA (PFIZ) PFIZER INC.
 XX PA (ABGE-) ABGENIX INC.
 XX PA (PFIZ) PFIZER LTD.
 XX PI Pullen N, Molloy E, Kellermann S, Green LL, Haak-Frendscho M;
 XX DR WPI; 2005-554958/56.
 XX DR N-PSDB; AEB45898.
 XX PT New antibody to Mucosal Adressin Cell Adhesion Molecule, useful for
 PT diagnosing and treating an inflammatory disease, e.g. inflammatory bowel
 PT disease, ulcerative colitis, gastritis, insulin-dependent diabetes or
 PT graft versus host disease.
 XX PS Claim 8; SEQ ID NO 64; 167pp; English.
 XX CC The invention relates to a human monoclonal antibody or its antigen-
 CC binding portion that specifically binds to mucosal adressin cell
 CC adhesion molecule (MADCAM). The invention also relates to a hybridoma
 CC cell line that produces the human monoclonal antibody, a pharmaceutical
 CC composition comprising an amount of the monoclonal antibody or its
 CC antigen-binding portion and a pharmaceutical carrier, a method of
 CC treating inflammatory disease in a subject, an isolated cell line that
 CC produces the monoclonal antibody or its antigen-binding portion or the
 CC heavy chain or light chain of the antibody or of its portion, an isolated
 CC nucleic acid molecule comprising a nucleotide sequence encoding the heavy
 CC chain or its antigen-binding portion or the light chain or its antigen-
 CC binding portion of an antibody described above, a vector comprising the
 CC nucleic acid molecule, where the vector optionally comprises an
 CC expression control sequence operably linked to the nucleic acid molecule,
 CC a host cell comprising the vector or the nucleic acid molecule above, a
 CC method of producing a human monoclonal antibody or its antigen-binding
 CC portion that specifically binds MADCAM, a method of isolating an antibody
 CC or its antigen-binding portion that specifically binds to MADCAM, a
 CC method of treating a subject in need of a human antibody or its antigen-
 CC binding portion that specifically binds to MADCAM and inhibits binding to
 CC alpha4beta7, a method of inhibiting alpha4beta7 binding to cells
 CC expressing human MADCAM, a method of inhibiting MADCAM-mediated leukocyte
 CC -endothelial cell adhesion, migration and infiltration into tissues, a
 CC method of inhibiting alpha4beta7/MADCAM-dependent cellular adhesion,
 CC inhibiting the MADCAM-mediated recruitment of lymphocytes to
 CC gastrointestinal lymphoid tissue, a method of diagnosing a disorder
 CC characterized by circulating soluble human MADCAM and detecting
 CC inflammation in a subject. The antibody, composition and methods are
 CC useful for diagnosing and treating inflammatory disease, e.g.
 CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
 CC diverticular disease, gastritis, liver disease, primary biliary
 CC cirrhosis, primary sclerosing cholangitis, insulin dependent diabetes and
 CC graft versus host disease. This sequence represents a human monoclonal
 CC anti-MADCAM antibody of the invention.
 XX SQ Sequence 471 AA;
 Query Match 100.0%; Score 503; DB 9; Length 471;
 Best Local Similarity 100.0%; Pred. No. 2.4e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVLVESGGGLVPGGSLRLSCAASGFTFSYNNWVRQAPGKLEWVSSISSSYIYY 60
 Db 20 EVLVESGGGLVPGGSLRLSCAASGFTFSYNNWVRQAPGKLEWVSSISSSYIYY 79
 QY 61 ADSVKGRTTISRDNKNSLYLQWNSLRADTAVYYCAR 98

Db 80 ADSVKGRTTISRDNKNSLYLQWNSLRADTAVYYCAR 117
 RESULT 22
 AEB45865
 ID AEB45865 standard; protein; 472 AA.
 XX AC AEB45865;
 XX DT 06-OCT-2005 (first entry)
 XX DE Human monoclonal anti-MadCAM antibody #15.
 XX KW Monoclonal antibody; mucosal adressin cell adhesion molecule; MadCAM;
 KW inflammation; inflammatory bowel disease; Crohns disease;
 KW ulcerative colitis; diverticular disease; gastritis; liver disease;
 KW primary biliary cirrhosis; primary sclerosing cholangitis;
 KW insulin dependent diabetes; graft versus host disease; antiinflammatory;
 KW gastrointestinal-gen.; antiulcer; hepatotropic; antidiabetic;
 KW immunosuppressive; antibody.
 XX OS Homo sapiens.
 XX PN WO2005067620-A2.
 XX PD 28-JUL-2005.
 XX PF 07-JAN-2005; 2005WO-US000370.
 XX PR 09-JAN-2004; 2004US-0535490P.
 XX PA (PFIZ) PFIZER INC.
 XX PA (ABGE-) ABGENIX INC.
 XX PA (PFIZ) PFIZER LTD.
 XX PI Pullen N, Molloy E, Kellermann S, Green LL, Haak-Frendscho M;
 XX DR WPI; 2005-554958/56.
 XX DR N-PSDB; AEB45864.
 XX PT New antibody to Mucosal Adressin Cell Adhesion Molecule, useful for
 PT diagnosing and treating an inflammatory disease, e.g. inflammatory bowel
 PT disease, ulcerative colitis, gastritis, insulin-dependent diabetes or
 PT graft versus host disease.
 XX PS Claim 8; SEQ ID NO 30; 167pp; English.
 XX CC The invention relates to a human monoclonal antibody or its antigen-
 CC binding portion that specifically binds to mucosal adressin cell
 CC adhesion molecule (MADCAM). The invention also relates to a hybridoma
 CC cell line that produces the human monoclonal antibody, a pharmaceutical
 CC composition comprising an amount of the monoclonal antibody or its
 CC antigen-binding portion and a pharmaceutical carrier, a method of
 CC treating inflammatory disease in a subject, an isolated cell line that
 CC produces the monoclonal antibody or its antigen-binding portion or the
 CC heavy chain or light chain of the antibody or of its portion, an isolated
 CC nucleic acid molecule comprising a nucleotide sequence encoding the heavy
 CC chain or its antigen-binding portion or the light chain or its antigen-
 CC binding portion of an antibody described above, a vector comprising the
 CC nucleic acid molecule, where the vector optionally comprises an
 CC expression control sequence operably linked to the nucleic acid molecule,
 CC a host cell comprising the vector or the nucleic acid molecule above, a
 CC method of producing a human monoclonal antibody or its antigen-binding
 CC portion that specifically binds MADCAM, a method of isolating an antibody
 CC or its antigen-binding portion that specifically binds to MADCAM, a
 CC method of treating a subject in need of a human antibody or its antigen-
 CC binding portion that specifically binds to MADCAM and inhibits binding to
 CC alpha4beta7, a method of inhibiting alpha4beta7 binding to cells
 CC expressing human MADCAM, a method of inhibiting MADCAM-mediated leukocyte
 CC -endothelial cell adhesion, migration and infiltration into tissues, a
 CC method of inhibiting alpha4beta7/MADCAM-dependent cellular adhesion,
 CC inhibiting the MADCAM-mediated recruitment of lymphocytes to
 CC gastrointestinal lymphoid tissue, a method of diagnosing a disorder
 CC characterized by circulating soluble human MADCAM and detecting
 CC inflammation in a subject. The antibody, composition and methods are
 CC useful for diagnosing and treating inflammatory disease, e.g.
 CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
 CC diverticular disease, gastritis, liver disease, primary biliary
 CC cirrhosis, primary sclerosing cholangitis, insulin dependent diabetes and
 CC graft versus host disease. This sequence represents a human monoclonal
 CC anti-MADCAM antibody of the invention.

CC gastrointestinal lymphoid tissue, a method of diagnosing a disorder
 CC characterized by circulating soluble human MADCAM and detecting
 CC inflammation in a subject. The antibody, composition and methods are
 CC useful for diagnosing and treating inflammatory disease, e.g.
 CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
 CC diverticular disease, gastritis, liver disease, primary biliary
 CC cirrhosis, primary sclerosing cholangitis, insulin dependent diabetes and
 CC graft versus host disease. This sequence represents a human monoclonal
 CC anti-MADCAM antibody of the invention.

XX Sequence 472 AA;

Query Match 100.0%; Score 503; DB 9; Length 472;
 Best Local Similarity 100.0%; Pred. No. 2.4e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVRQAPGKLEWVSSISSSSIYY 60
 Db 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVRQAPGKLEWVSSISSSSIYY 79
 Qy 61 ADSVKGRTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
 Db 80 ADSVKGRTISRDNKNSLYLQMNLSRAEDTAVYYCAR 117

RESULT 23

ID ADM47075 standard; protein; 475 AA.

XX ADM47075;

XX 03-JUN-2004 (first entry)

XX Mouse anti-human G-CSF antibody heavy chain protein.

XX methylothroph yeast; mammalian sugar chain; OCH1; alpha-1;
 KW 6-mannosyl transferase; alpha-1; 2-mannosidase;
 KW orotidin-5'-phosphate decarboxylase; URA3;
 KW phosphoribosyl-amino-imidazole succinocarboxamide synthase; ADE1;
 KW imidazole-glycerol-phosphate dehydratase; HIS3;
 KW 3-isopropyl malate dehydrogenase; LEU2; proteinase A; proteinase B; PRB1;
 KW PEP4; YPS1; KTR1; MN9; AOX; GAPDH; mannosyl transferase;
 KW glyceraldehyde 3-phosphate dehydrogenase; mannose glycoprotein.

XX Mus sp.

OS WO2003091431-A1.

XX 06-NOV-2003.

XX 28-APR-2003; 2003WO-JP005464.

XX 26-APR-2002; 2002JP-00127677.

XX (KIRI) KIRIN BEER KK.

XX (NAAAD-) NAT INST ADVANCED IND SCI & TECHNOLOGY.

XX Kobayashi K, Kitagawa Y, Komeda T, Kawashima N, Jigami Y;

XX Chiba Y;

XX WPI; 2003-854401/79.

XX Producing methylothroph yeast that expresses mammalian sugar chains by
 PT disrupting the OCH1 gene and inserting an alpha-1,2-mannosidase gene.

XX Example 28; SEQ ID NO 94; 247pp; Japanese.

XX The invention relates to the production of a methylothroph yeast that
 CC produces mammalian sugar chains, comprising disrupting the OCH1 gene in
 CC the yeast that encodes for alpha-1,6-mannosyl transferase and inserting
 CC and expressing the alpha-1,2-mannosidase gene. The specification also
 CC includes DNA sequences encoding: (a) orotidin-5'-phosphate decarboxylase
 CC (URA3); (b) phosphoribosyl-amino-imidazole succinocarboxamide synthase

CC (ADE1); (c) imidazole-glycerol-phosphate dehydratase (HIS3); (d) 3-
 CC isopropyl malate dehydrogenase (LEU2); (e) alpha-1,6-mannosyl transferase
 CC (OCH1); (f) proteinase A (PEP4); (g) proteinase B (PRB1); and (h)
 CC aspartic protease (YPS1), mannosyl transferase (KTR1 or MN9), alcohol
 CC oxidase (AOX) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene
 CC sequences. The yeast is used for the production of human and mammalian
 CC high mannose glycoproteins with high yield and purity. The method is also
 CC useful for producing hybrid or complex sugar chains containing mammalian
 CC type chains. This sequence represents a mouse anti-human G-CSF antibody
 CC heavy chain used in the invention.

XX Sequence 475 AA;

Query Match 100.0%; Score 503; DB 7; Length 475;
 Best Local Similarity 100.0%; Pred. No. 2.4e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVRQAPGKLEWVSSISSSSIYY 60
 Db 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVRQAPGKLEWVSSISSSSIYY 79
 Qy 61 ADSVKGRTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
 Db 80 ADSVKGRTISRDNKNSLYLQMNLSRAEDTAVYYCAR 117

RESULT 24

AAE28870

ID AAE28870 standard; protein; 116 AA.

XX AAE28870;

XX 27-DEC-2002 (first entry)

XX Human KDR (VEGFR-2) Fab heavy chain protein from D2C6 and DiH4 clone.

XX Human; tumour; vascular endothelial growth factor receptor; metastasis;
 KW epidermal growth factor receptor; non-small cell lung carcinoma; NSCLC;
 KW breast; VEGFR; heart; EGFR; therapy; invasiveness; heavy chain; VH.

XX Homo sapiens.

XX WO200270008-A1.

XX 12-SEP-2002.

XX 04-MAR-2002; 2002WO-US006762.

XX 02-MAR-2001; 2001US-00798689.

XX (IMCL-) IMCLONE SYSTEMS INC.

XX (ROCK/) ROCKWELL P.

XX (GOLD/) GOLDSTEIN N I.

XX WPI; 2002-691738/74.

XX N-PSDB; AAD46290, AAD46292.

XX Inhibiting tumor growth in humans involves administering vascular
 PT endothelial growth factor receptor antagonists in combination with
 PT radiation, chemotherapeutic agents, or epidermal growth factor receptor
 PT antagonists.

XX Example 9; Page 123; 151pp; English.

XX The invention relates to a method of inhibiting tumour growth which
 CC involves administering, vascular endothelial growth factor receptor
 CC (VEGFR) antagonists in combination with radiation, chemotherapeutic
 CC agent, or epidermal growth factor receptor (EGFR) antagonist. The method
 CC is useful for inhibiting tumour growth in a human, where the tumour (e.g.
 CC tumour of the breast, heart, lung, small intestine, colon, spleen, bone,
 CC kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin,
 CC bone marrow, blood, thymus, uterus, testicles, cervix or liver) over
 CC expresses VEGFR. It is also useful for inhibiting growth of colon tumour

CC or non-small cell lung carcinoma (NSCLC) and tumour overexpressing EGFR.
 CC It is preferably useful for treating subjects with both solid tumours,
 CC preferably high vascular tumours and non-solid tumours. The inhibition or
 CC reduction of tumour growth includes prevention or inhibition of the
 CC progression of tumour, including cancerous and non-cancerous tumours,
 CC where the progression of tumours includes the invasiveness, metastasis,
 CC recurrence and increase in size of the tumour. The present sequence is
 CC human KDR (VEGFR-2) Fab antibody heavy chain protein
 XX
 SQ Sequence 116 AA;
 Query Match 99.4%; Score 500; DB 5; Length 116;
 Best Local Similarity 99.0%; Pred. No. 1e-40;
 Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVOLVESGGGLVKPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSSISSSSIYY 60
 Db 1 EVQLVQSGGGLVKPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSSISSSSIYY 60
 QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98
 Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98
 RESULT 25
 ABJ26763
 ID ABJ26763 standard; protein; 116 AA.
 XX
 AC ABJ26763;
 XX
 DT 01-MAY-2003 (first entry)
 XX
 DE VEGF binding related protein SEQ ID No 76.
 XX
 KW Cytostatic; antibody; antigen binding site; VEGF receptor; mitogenesis;
 KW leukaemia cell; vascular endothelial growth factor; tumour;
 KW bispecific antigen-binding protein; human.
 XX
 OS Homo sapiens.
 XX
 PN WO2003002144-A1.
 XX
 XX 09-JAN-2003.
 PD
 XX 26-JUN-2002; 2002WO-US020332.
 PF
 XX 26-JUN-2001; 2001US-0301299P.
 PR
 XX (IMCL-) IMCLONE SYSTEMS INC.
 PA
 XX Zhu Z;
 PI
 XX WPI; 2003-201468/19.
 DR N-PSDB; ABT23325.
 DR
 XX New bispecific antibodies having antigen-binding sites specific for a
 PT first vascular endothelial growth factor (VEGF) receptor and for a second
 PT VEGF receptor, useful for inhibiting migration of leukemia cells, or for
 PT treating tumors.
 PT
 XX Claim 15; Page 70-71; 98pp; English.
 PS
 XX The invention relates to a novel antibody having a first antigen binding
 CC site specific for a first vascular endothelial growth factor (VEGF)
 CC receptor and a second antigen-binding site specific for a second VEGF
 CC receptor. The bispecific antigen-binding proteins block activation of the
 CC VEGF receptor and are useful for reducing or inhibiting VEGF-induced
 CC cellular functions such as mitogenesis of vascular endothelial cells and
 CC migration of leukaemia cells. The antibodies are useful for treating
 CC tumours and for in vivo or in vitro for investigative and diagnostic
 CC methods. This sequence represents a human protein relating to the
 CC bispecific antibodies that bind to the VEGF receptors of the invention
 XX

SQ Sequence 116 AA;
 Query Match 99.4%; Score 500; DB 6; Length 116;
 Best Local Similarity 99.0%; Pred. No. 1e-40;
 Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVOLVESGGGLVKPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSSISSSSIYY 60
 Db 1 EVQLVQSGGGLVKPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSSISSSSIYY 60
 QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98
 Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRADTAVYYCAR 98
 RESULT 26
 ADD24417
 ID ADD24417 standard; protein; 116 AA.
 XX
 AC ADD24417;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human heavy chain variable region #2.
 XX
 KW tumour; vascular endothelial growth factor receptor; VEGFR;
 KW epidermal growth factor receptor; EGFR; cancer; human.
 XX
 OS Homo sapiens.
 XX
 PN US2003108545-A1.
 XX
 PD 12-JUN-2003.
 XX
 PF 04-MAR-2002; 2002US-00091300.
 XX
 PR 10-FEB-1994; 94US-00196041.
 PR 20-OCT-1994; 94US-00326552.
 PR 07-JUN-1995; 95US-00476533.
 PR 03-SEP-1996; 96US-00706804.
 PR 07-JAN-1997; 97US-00779450.
 PR 10-NOV-1997; 97US-00967113.
 PR 22-SEP-1999; 99US-00401163.
 PR 02-MAR-2001; 2001US-00798689.
 XX
 PA (ROCK/) ROCKWELL P.
 PA (GOLD/) GOLDSTEIN N I.
 XX
 PI Rockwell P, Goldstein NI;
 XX
 DR WPI; 2003-801265/75.
 DR N-PSDB; ADD24416, ADD24420.
 XX
 PT Inhibiting tumor growth by administering to a human a vascular
 PT endothelial growth factor receptor (VEGFR) antagonist and epidermal
 PT growth factor receptor (EGFR) antagonist.
 XX
 XX Example 12; SEQ ID NO 24; 90pp; English.
 PS
 CC The invention relates to a method of inhibiting tumour growth comprising
 CC administering to a human a vascular endothelial growth factor receptor
 CC (VEGFR) antagonist and epidermal growth factor receptor (EGFR)
 CC antagonist. The method is useful for inhibiting tumour growth. The
 CC present sequence is used in the exemplification of the invention.
 XX
 SQ Sequence 116 AA;
 Query Match 99.4%; Score 500; DB 7; Length 116;
 Best Local Similarity 99.0%; Pred. No. 1e-40;
 Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1 EVOLVESGGGLVKPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSSISSSSIYY 60
 Db 1 EVQLVQSGGGLVKPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSSISSSSIYY 60


```

Db      1 EVQLVQSGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIY 60
Qy      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98

RESULT 27
ADD80794
ID      ADD80794 standard; protein; 116 AA.
XX
AC      ADD80794;
XX
DT      29-JAN-2004 (first entry)
XX
DE      Human clone D2C6/D1H4 KDR-binding Fab variable heavy chain SEQ ID NO:24.
XX
KW      human; antibody; KDR; cytostatic; gene therapy; anti-KDR antibody;
KW      tumour; angiogenesis.
XX
OS      Homo sapiens.
XX
PN      WO2003075840-A2.
XX
PD      18-SEP-2003.
XX
PF      04-MAR-2003; 2003WO-US006459.
XX
PR      04-MAR-2002; 2002US-0361783P.
XX
PA      (IMCL-) IMCLONE SYSTEMS INC.
XX
PI      Zhu Z;
XX
WI      WPI; 2003-779032/73.
DR      N-PSDB; ADD80793, ADD80797.
XX
New human anti-KDR antibody, useful for preparing a composition for
PT      reducing tumor growth and inhibiting angiogenesis.
XX
Claim 5; SEQ ID NO 24; 49pp; English.
XX
The invention relates to a novel isolated human antibody or its fragment
CC      binds selectively to KDR. An antibody of the invention has cytostatic
CC      activity, and may have a use in gene therapy. The antibody is anti-KDR
CC      antibody. The antibody is useful for preparing a composition for reducing
CC      tumour growth and inhibiting angiogenesis. The present sequence is used
CC      in the exemplification of the invention.
XX
SQ      Sequence 116 AA;

Query Match      99.4%; Score 500; DB 7; Length 116;
Best Local Similarity 99.0%; Pred. No. 1e-40;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLVSGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIY 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      1 EVQLVQSGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIY 60

Qy      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98

RESULT 28
ADK18270
ID      ADK18270 standard; protein; 116 AA.
XX
AC      ADK18270;
XX
DT      06-MAY-2004 (first entry)
XX
DE      KDR binding human Fabs D2C6/D1H4 clone variable heavy chain protein.

```

```

XX      antibody; antigen binding site; vascular endothelial growth factor;
KW      VEGF receptor; immunoglobulin; tumour; angiogenesis; cytostatic;
KW      immunostimulant; vaccine; kinase insert domain-containing receptor; KDR;
KW      human; CDR; complementarity determining region.
XX
OS      Homo sapiens.
XX
PN      WO2004003211-A1.
XX
PD      08-JAN-2004.
XX
PF      24-DEC-2002; 2002WO-US041372.
XX
PR      26-JUN-2002; 2002WO-US020332.
XX
PA      (IMCL-) IMCLONE SYSTEMS INC.
XX
PI      Zhu Z;
XX
WI      WPI; 2004-083065/08.
DR      N-PSDB; ADK18269.
XX
New antibody having a first and second binding sites specific for a first
PT      and second vascular endothelial growth factor (VEGF) receptor, useful for
PT      reducing tumor growth in a mammal and for inhibiting angiogenesis.
XX
Claim 15; SEQ ID NO 76; 99pp; English.
XX
The invention relates to a novel antibody having a first antigen binding
CC      site specific for a first vascular endothelial growth factor (VEGF)
CC      receptor and a second antigen specific for a second VEGF receptor. The
CC      invention further relates to: an antibody that specifically binds to an
CC      extracellular domain of a first VEGF receptor and an extracellular domain
CC      of a second VEGF receptor, where binding of the antibody to the first and
CC      second VEGF receptor neutralizes activation of that VEGF receptor; a
CC      method for making the antibody by co-expressing in a host cell a
CC      recombinant DNA construct encoding a first polypeptide having the first
CC      immunoglobulin heavy chain domain located to the N-terminus of the second
CC      immunoglobulin light chain variable domain; a recombinant DNA construct
CC      encoding a second polypeptide having the second immunoglobulin heavy
CC      chain variable domain located to the N-terminus of the first
CC      immunoglobulin light chain variable domain, for time and in a manner
CC      sufficient to allow expression of the polypeptides and formation of the
CC      antibody; a method for neutralizing activation of a first VEGF receptor
CC      and the second VEGF receptor in a cell by treating a cell with the
CC      antibody cited above; a method for reducing tumour growth in a mammal by
CC      treating the mammal with the antibody cited above; and a method for
CC      inhibiting angiogenesis in a mammal by treating the mammal with the
CC      antibody cited above. The antibody has cytostatic and immunostimulant
CC      activities. The VEGF receptor antigen can be used to create a vaccine.
CC      The antibody is useful for reducing tumor growth in a mammal and for
CC      inhibiting angiogenesis. This sequence represents a human kinase insert
CC      domain-containing receptor binding Fabs complementarity determining
CC      region (CDR) protein of the invention.
XX
SQ      Sequence 116 AA;

Query Match      99.4%; Score 500; DB 8; Length 116;
Best Local Similarity 99.0%; Pred. No. 1e-40;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIY 60
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      1 EVQLVQSGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIY 60

Qy      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98

RESULT 29
AD113464

```

ID ADI13464 standard; protein; 137 AA.
XX
AC ADI13464;
XX
DT 22-APR-2004 (first entry)
XX
DE Human variable region of mu-chain 2G9 monoclonal antibody protein.
XX
KW mu-chain; human; IgM monoclonal antibody; human immunodeficiency virus;
KW HIV; apoptosis; anti-HIV; HAART; highly active anti-retroviral therapy;
KW 2G9.
XX
OS Homo sapiens.
XX
PN W02004003021-A1.
XX
PD 08-JAN-2004.
XX
PF 30-JUN-2003; 2003WO-JP008305.
XX
PR 01-JUL-2002; 2002JP-00227953.
PR 18-MAR-2003; 2003JP-00074316.
XX
XX (OKAD/) OKADA H.
PA (OKAD/) OKADA N.
XX
PI Okada H, Okada N;
XX
DR WPI; 2004-083023/08.
DR N-PSDB; ADI13462.
XX
PT Human IgM monoclonal antibody specific for human immunodeficiency virus
PT (HIV) infected cells but not for tumor or normal cells, useful for
PT treatment of HIV infection and for preventing its development into AIDS.
XX
PS Disclosure; Page 8-11; 34pp; Japanese.
XX
CC This invention relates to a novel human IgM monoclonal antibody that
CC recognises an antigen expressed specifically by human immunodeficiency
CC virus (HIV) infected cells but not by tumorigenic or normal cells. The
CC antibody, identified as 2G9, is intended to provide a treatment for HIV
CC infection by inducing cell death (apoptosis) of HIV infected cells. The
CC present invention describes the use of this human monoclonal 2G9 antibody
CC as exhibiting anti-HIV activity, and accordingly it can be used in HAART
CC (highly active anti-retroviral therapy). This polypeptide sequence is the
CC variable region of the human mu-chain of the 2G9 monoclonal antibody
CC protein of the invention.
XX
SQ Sequence 137 AA;

Query Match 99.4%; Score 500; DB 8; Length 137;
Best Local Similarity 99.0%; Pred. No. 1.2e-40;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVKGPGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 60
DB 20 EVQLVESGGGLVKGPGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 79
QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
DB 80 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 117

RESULT 30
ID ABP45307
XX ABP45307 standard; protein; 256 AA.
XX
AC ABP45307;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human BlyS binding scFv SEQ ID 1318.
XX

KW BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS Homo sapiens.
XX
PN W0200202641-A1.
XX
PD 10-JAN-2002.
XX
PF 15-JUN-2001; 2001WO-US019110.
XX
PR 16-JUN-2000; 2000US-0212210P.
PR 17-OCT-2000; 2000US-0240816P.
PR 16-MAR-2001; 2001US-0276248P.
PR 21-MAR-2001; 2001US-0277379P.
PR 25-MAY-2001; 2001US-0293499P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
XX Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
XX WPI; 2002-1147999/15.
XX
DR Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
DR diagnosis and treatment of cancers and immune disorders.
XX
XX Claim 1; Page 1975-1976; 3148pp; English.
XX
CC This invention describes novel antibodies that immunospecifically bind to
CC B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
CC tumour necrosis factor (TNF) super family and induces B cell
CC proliferation and differentiation. The antibodies of the invention have
CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC antirheumatic and antiAIDS activity and can be used in vaccines to
CC inhibit the expression and activity of BlyS. The antibodies bind to BlyS
CC and so may be used to detect and quantitate the presence of BlyS in
CC biological samples and may be used in this way to diagnose disease
CC associated with aberrant expression of BlyS. They may also be
CC administered to treat diseases associated with aberrant BlyS expression
CC and activity such as cancer, immune, and autoimmune disorders and
CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC the antibodies and fragments of the antibodies described in the method of
CC the invention
XX
SQ Sequence 256 AA;

Query Match 99.4%; Score 500; DB 5; Length 256;
Best Local Similarity 99.0%; Pred. No. 2.4e-40;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVKGPGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 60
DB 1 EVQLVESGGGLVKGPGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSISSSSYIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
DB 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98

RESULT 31
ID ADG96134
XX ADG96134 standard; protein; 256 AA.
XX
AC ADG96134;
XX
DT 11-MAR-2004 (first entry)
XX


```
RESULT 33
ID  ADG96672 standard; protein; 249 AA.
XX
AC  ADG96672;
XX
DT  11-MAR-2004 (first entry)
XX
DE  Single chain antibody that immunospecifically binds BlyS SeqID 1856.
XX
KW  antibody; B lymphocyte stimulator; BlyS; tumour necrosis factor;
KW  B cell proliferation; differentiation; scFv; myasthenia gravis;
KW  multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
KW  carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
KW  antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX
OS  Unidentified.
XX
PN  WO2003055979-A2.
XX
PD  10-JUL-2003.
XX
PF  14-NOV-2002; 2002WO-US036496.
XX
PR  16-NOV-2001; 2001US-0331469P.
PR  19-DEC-2001; 2001US-0340817P.
XX
PA  (HUMA-) HUMAN GENOME SCI INC.
XX
PI  Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX  WPI; 2003-505530/47.
XX
PT  Novel antibody that immunospecifically binds to a B lymphocyte stimulator
PT  (BlyS), useful for detecting and treating diseases or disorders e.g.
PT  rheumatoid arthritis, asthma and leukemia.
XX
PS  Example 1; SEQ ID NO 1856; 394pp; English.
XX
CC  This invention relates to novel antibodies that immunospecifically bind
CC  to B lymphocyte stimulator (BlyS). The BlyS gene has been mapped to
CC  chromosome 13q34 and encodes a protein that is a member of the tumour
CC  necrosis factor superfamily and induces both in vivo and in vitro B cell
CC  proliferation and differentiation. Specifically, it refers to single
CC  chain antibody molecules (scFvs) derived, preferably, from the variable
CC  heavy CDR3 region that immunospecifically bind to a polypeptide, or
CC  fragment thereof, of either human, murine, rat or monkey BlyS. The
CC  present invention refers to the use of such antibodies in various methods
CC  for the detection, diagnosis and prognosis of diseases related to the
CC  aberrant expression or inappropriate function of BlyS or its receptor. As
CC  such, these compositions are useful for identifying immune disorders
CC  including myasthenia gravis and multiple sclerosis, inflammatory
CC  disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
CC  as AIDS and proliferative disorders including leukaemia, carcinoma and
CC  lymphoma. Accordingly, they can be described as exhibiting various
CC  activities such as antirheumatic, antiallergic, neuroprotective,
CC  antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
CC  polypeptide sequence is a single chain antibody that binds BlyS of the
CC  invention. NOTE: The sequence data for this patent did not form part of
CC  the printed specification, but was obtained in electronic format
CC  directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
XX
SQ  Sequence 249 AA;

Query Match          99.2%; Score 499; DB 7; Length 249;
Best Local Similarity 99.0%; Pred. No. 2.9e-40;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY  1 EVQLVDSGGGLVPGGSLRLSCAASGFTFSYSNMNVVRQAPGKLEWVSISSSYIYY 60
Db  1 EVQLVDSGGGLVPGGSLRLSCAASGFTFSYSNMNVVRQAPGKLEWVSISSSYIYY 60
QY  61 ADSVKGRFTISRDNAKNSLYLQWNSLRAEDTAVYYCAR 98
```

```
Db 61 ADSVKGRFTISRDNAKNSLYLQWNSLRAEDTAVYYCAR 98

Search completed: May 12, 2006, 02:22:34
Job time : 126.333 secs
```

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 02:16:41 ; Search time 58 Seconds
(without alignments)
705.987 Million cell updates/sec

Title: US-09-674-752-37

Perfect score: 503

Sequence: 1 EVLVESGGGLVPGGSLRL.....LYLQMNLSRAEDTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications_AA_Main:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*

2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*

3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*

4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*

5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*

6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	503	100.0	98	4	US-10-194-975-21
2	503	100.0	98	4	US-10-041-860-3
3	503	100.0	98	4	US-10-041-860-3
4	503	100.0	98	4	US-10-308-817-61
5	503	100.0	98	4	US-10-453-698-61
6	503	100.0	98	4	US-10-379-392-22
7	503	100.0	98	5	US-10-884-830-657
8	503	100.0	98	5	US-10-884-830-659
9	503	100.0	103	3	US-09-864-761-47355
10	503	100.0	109	4	US-10-309-762-76
11	503	100.0	109	4	US-10-800-197-150
12	503	100.0	123	5	US-10-727-155-158
13	503	100.0	123	6	US-11-021-715-56
14	503	100.0	125	6	US-11-031-485-119
15	503	100.0	471	6	US-11-031-485-64
16	503	100.0	472	6	US-11-031-485-30
17	500	99.4	116	4	US-10-091-300-24
18	500	99.4	116	5	US-10-482-630-76
19	500	99.4	116	5	US-10-506-997-24
20	500	99.4	256	3	US-09-880-748-1318
21	500	99.4	256	4	US-10-293-418-1318
22	499	99.2	249	3	US-09-880-748-1856
23	499	99.2	249	4	US-10-293-418-1856
24	498	99.0	109	5	US-10-727-155-280
25	498	99.0	125	5	US-10-725-962-17
26	497	98.8	247	3	US-09-880-748-1764
27	497	98.8	247	4	US-10-293-418-1764

Sequence 31, Appl
Sequence 83, Appl
Sequence 31, Appl
Sequence 18, Appl
Sequence 1991, Ap
Sequence 1991, Ap
Sequence 1703, Ap
Sequence 9, Appl1
Sequence 7, Appl1
Sequence 75, Appl
Sequence 1362, Ap
Sequence 1362, Ap
Sequence 658, App
Sequence 1937, Ap
Sequence 1937, Ap
Sequence 31, Appl
Sequence 660, App

495 98.4 116 4 US-10-091-300-31
495 98.4 116 5 US-10-482-630-83
495 98.4 116 5 US-10-506-997-31
495 98.4 125 5 US-10-725-962-18
495 98.4 244 3 US-09-880-748-1991
495 98.4 244 4 US-10-293-418-1991
495 98.4 247 3 US-09-880-748-1703
495 98.4 247 4 US-10-293-418-1703
495 98.4 240 4 US-10-062-188-9
495 98.4 257 4 US-10-062-188-7
495 98.4 257 5 US-10-778-394-76
495 98.4 252 3 US-09-880-748-1362
495 98.4 252 4 US-10-293-418-1362
488.5 97.1 97 5 US-10-884-830-658
42 487 96.8 241 3 US-09-880-748-1937
43 487 96.8 241 4 US-10-293-418-1937
44 484 96.2 98 4 US-10-379-392-31
45 484 96.2 98 5 US-10-884-830-660

ALIGNMENTS

RESULT 1

US-10-194-975-21
; Sequence 21, Application US/10194975
; Publication No. US20030039649A1
; GENERAL INFORMATION:
; APPLICANT: Foote, Jefferson
; TITLE OF INVENTION: Super Humanized Antibodies
; FILE REFERENCE: 501231.01
; CURRENT APPLICATION NUMBER: US/10/194,975
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/305,111
; PRIOR FILING DATE: 2001-07-12
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 21
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-194-975-21

Query Match 100.0%; Score 503; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVLVESGGGLVPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSISSSSYY 60
Db 1 EVLVESGGGLVPGGSLRLSCAASGFTFSYSMNVRQAPGKLEWVSISSSSYY 60
Qy 61 ADSVKGRTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
Db 61 ADSVKGRTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 2

US-10-041-860-3
; Sequence 3, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R. F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860

```
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-3

Query Match      100.0%; Score 503; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSYSMNVWVROAPGKGLWVSSISSSSYIYY 60
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSYSMNVWVROAPGKGLWVSSISSSSYIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98

RESULT 3
US-10-041-860-271
; Sequence 271, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 271
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-271

Query Match      100.0%; Score 503; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSYSMNVWVROAPGKGLWVSSISSSSYIYY 60
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSYSMNVWVROAPGKGLWVSSISSSSYIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98

RESULT 4
US-10-308-817-61
; Sequence 61, Application US/10308817
; Publication No. US20030219861A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; APPLICANT: Wu, Dayang
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 1087-37
; CURRENT APPLICATION NUMBER: US/10/308,817
; CURRENT FILING DATE: 2002-12-03
; NUMBER OF SEQ ID NOS: 195

; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 98
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-3

Query Match      100.0%; Score 503; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSYSMNVWVROAPGKGLWVSSISSSSYIYY 60
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSYSMNVWVROAPGKGLWVSSISSSSYIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98

RESULT 5
US-10-453-698-61
; Sequence 61, Application US/10453698
; Publication No. US20040038308A1
; GENERAL INFORMATION:
; APPLICANT: Rother, Russell
; TITLE OF INVENTION: HYBRID ANTIBODIES
; FILE REFERENCE: 82 CIP (1087-37 CIP)
; CURRENT APPLICATION NUMBER: US/10/453,698
; CURRENT FILING DATE: 2003-06-03
; NUMBER OF SEQ ID NOS: 196
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 61
; LENGTH: 98
; TYPE: PRT
; ORGANISM: human
US-10-453-698-61

Query Match      100.0%; Score 503; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSYSMNVWVROAPGKGLWVSSISSSSYIYY 60
Db 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSYSMNVWVROAPGKGLWVSSISSSSYIYY 60
QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98

RESULT 6
US-10-379-392-22
; Sequence 22, Application US/10379392
; Publication No. US20040110226A1
; GENERAL INFORMATION:
; APPLICANT: Lazar, Gregory Alan
; APPLICANT: Desjarlais, John Rudolf
; APPLICANT: Marshall, Shannon Alicia
; APPLICANT: Dahiyat, Basill I.
; TITLE OF INVENTION: ANTIBODY OPTIMIZATION
; FILE REFERENCE: A-71386-3 463077-236
; CURRENT APPLICATION NUMBER: US/10/379,392
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/360,843
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 60/384,197
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22
; LENGTH: 98
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens
US-10-379-392-22

Query Match      100.0%; Score 503; DB 4; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIYY 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQNMNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQNMNSLRAEDTAVYYCAR 98

RESULT 7
US-10-884-830-657
; Sequence 657, Application US/10884830
; Publication No. US20050004354A1
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/10/884,830
; PRIOR FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US/09/534,717
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/126,603
; PRIOR FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 657
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-884-830-657

Query Match      100.0%; Score 503; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIYY 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQNMNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQNMNSLRAEDTAVYYCAR 98

RESULT 8
US-10-884-830-659
; Sequence 659, Application US/10884830
; Publication No. US20050004354A1
; GENERAL INFORMATION:
; APPLICANT: Jochen, Salfeld et al.
; TITLE OF INVENTION: Human Antibodies That Bind Human IL-12 And Methods For Producing
; FILE REFERENCE: BBI-093CP
; CURRENT APPLICATION NUMBER: US/10/884,830
; PRIOR FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US/09/534,717
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 60/126,603
; PRIOR FILING DATE: March 25, 1999
; NUMBER OF SEQ ID NOS: 675
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 659
; LENGTH: 98
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-884-830-659
```

```
Query Match      100.0%; Score 503; DB 5; Length 98;
Best Local Similarity 100.0%; Pred. No. 2.7e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIYY 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLEWVSSISSSSYIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQNMNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQNMNSLRAEDTAVYYCAR 98

RESULT 9
US-09-864-761-47355
; Sequence 47355, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: Aeomica-X-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Annonax Sequence Listing Engine vers. 1.1
; SEQ ID NO 47355
; LENGTH: 103
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AB019439.1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.42
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 0.51
```

```
; OTHER INFORMATION: EST HUMAN HIT: AW408304.1, EVALUE 7.00e-45
; OTHER INFORMATION: SWISSPROT HIT: P01764, EVALUE 3.00e-43
US-09-864-761-47355

Query Match      100.0%; Score 503; DB 3; Length 103;
Best Local Similarity 100.0%; Pred. No. 2.8e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 60
   |||
Db 4 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 63
   |||
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98
   |||
Db 64 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 101

RESULT 10
US-10-309-762-76
; Sequence 76, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; PRIOR FILING DATE: 2002-12-02
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 76
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-76

Query Match      100.0%; Score 503; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 60
   |||
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 60
   |||
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98
   |||
Db 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98

RESULT 11
US-10-800-197-150
; Sequence 150, Application US/10800197
; Publication No. US20040202655A1
; GENERAL INFORMATION:
; APPLICANT: Moston, Philip A et al.
; TITLE OF INVENTION: ANTIBODIES TO IGF-I RECEPTOR FOR THE TREATMENT OF CANCERS
; FILE REFERENCE: 01343/1
; CURRENT APPLICATION NUMBER: US/10/800,197
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: 60/455,094
; PRIOR FILING DATE: 2003-03-14
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 150
; LENGTH: 109
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-800-197-150

; OTHER INFORMATION: EST HUMAN HIT: AW408304.1, EVALUE 7.00e-45
; OTHER INFORMATION: SWISSPROT HIT: P01764, EVALUE 3.00e-43
US-09-864-761-47355

Query Match      100.0%; Score 503; DB 3; Length 103;
Best Local Similarity 100.0%; Pred. No. 2.8e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 60
   |||
Db 4 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 63
   |||
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98
   |||
Db 64 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 101

RESULT 10
US-10-309-762-76
; Sequence 76, Application US/10309762
; Publication No. US20040018198A1
; GENERAL INFORMATION:
; APPLICANT: Gudas, Jean
; APPLICANT: Foltz, Ian
; APPLICANT: Handa, Masahisa
; APPLICANT: Gallo, Michael
; TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
; FILE REFERENCE: ABGENIX.027A
; CURRENT APPLICATION NUMBER: US/10/309,762
; PRIOR FILING DATE: 2002-12-02
; PRIOR FILING DATE: 2001-12-03
; NUMBER OF SEQ ID NOS: 246
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 76
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-309-762-76

Query Match      100.0%; Score 503; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 60
   |||
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 60
   |||
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98
   |||
Db 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98

RESULT 11
US-10-800-197-150
; Sequence 150, Application US/10800197
; Publication No. US20040202655A1
; GENERAL INFORMATION:
; APPLICANT: Moston, Philip A et al.
; TITLE OF INVENTION: ANTIBODIES TO IGF-I RECEPTOR FOR THE TREATMENT OF CANCERS
; FILE REFERENCE: 01343/1
; CURRENT APPLICATION NUMBER: US/10/800,197
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: 60/455,094
; PRIOR FILING DATE: 2003-03-14
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 150
; LENGTH: 109
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-800-197-150

; OTHER INFORMATION: EST HUMAN HIT: AW408304.1, EVALUE 7.00e-45
; OTHER INFORMATION: SWISSPROT HIT: P01764, EVALUE 3.00e-43
US-09-864-761-47355

Query Match      100.0%; Score 503; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 60
   |||
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 60
   |||
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98
   |||
Db 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98

RESULT 12
US-10-727-155-158
; Sequence 158, Application US/10727155
; Publication No. US20050049402A1
; GENERAL INFORMATION:
; APPLICANT: John S. Babcock
; APPLICANT: Jaspal S. Kang
; APPLICANT: Orit Foord
; APPLICANT: Larry Green
; APPLICANT: Xiao Feng
; APPLICANT: Scott Klakamp
; APPLICANT: Mary Haak-Frendescho
; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Manchulenko
; APPLICANT: Raffaella Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; FILE REFERENCE: ABGENIX.073A
; CURRENT APPLICATION NUMBER: US/10/727,155
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 158
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-727-155-158

Query Match      100.0%; Score 503; DB 5; Length 123;
Best Local Similarity 100.0%; Pred. No. 3.4e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 60
   |||
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSSYSMMWVRQAPGKGLWVSSISSSSIYY 60
   |||
QY 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98
   |||
Db 61 ADSVKGRFTISRDNKNSLYLQMSLRAEDTAVYYCAR 98

RESULT 13
US-11-021-715-56
; Sequence 56, Application US/11021715
; Publication No. US20050208596A1
; GENERAL INFORMATION:
; APPLICANT: Siegel, Donald L.
; TITLE OF INVENTION: COMPOSITIONS, METHODS AND KITS RELATING TO ANTI-PLATELET
; TITLE OF INVENTION: AUTOANTIBODIES AND INHIBITORS THEREOF
; FILE REFERENCE: 053893-5050
; CURRENT APPLICATION NUMBER: US/11/021,715
; CURRENT FILING DATE: 2004-12-23
```



```
; PRIOR APPLICATION NUMBER: PCT/US03/21304
; PRIOR FILING DATE: 2003-07-03
; PRIOR APPLICATION NUMBER: 60/394,352
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: 60/411,694
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 153
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 123
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-021-715-56

Query Match      100.0%; Score 503; DB 6; Length 123;
Best Local Similarity 100.0%; Pred. No. 3.4e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSYIY 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSYIY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 14
US-11-031-485-119
; Sequence 119, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
; APPLICANT: PULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.
; APPLICANT: HAAK-FRENDSCHO, MARY
; TITLE OF INVENTION: ANTIBODIES TO MADCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 119
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-119

Query Match      100.0%; Score 503; DB 6; Length 125;
Best Local Similarity 100.0%; Pred. No. 3.4e-39;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSYIY 60
Db 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSYIY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 15
US-11-031-485-64
; Sequence 64, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
; APPLICANT: PULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.
```

```
; APPLICANT: HAAK-FRENDSCHO, MARY
; TITLE OF INVENTION: ANTIBODIES TO MADCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 64
; LENGTH: 471
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-64

Query Match      100.0%; Score 503; DB 6; Length 471;
Best Local Similarity 100.0%; Pred. No. 1.4e-38;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSYIY 60
Db 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSYIY 79

Qy 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
Db 80 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 117

RESULT 16
US-11-031-485-30
; Sequence 30, Application US/11031485
; Publication No. US20050232917A1
; GENERAL INFORMATION:
; APPLICANT: PULLEN, NICHOLAS
; APPLICANT: MOLLOY, ELIZABETH
; APPLICANT: KELLERMANN, SIRID-AIMEE
; APPLICANT: GREEN, LARRY L.
; APPLICANT: HAAK-FRENDSCHO, MARY
; TITLE OF INVENTION: ANTIBODIES TO MADCAM
; FILE REFERENCE: ABX-PF6
; CURRENT APPLICATION NUMBER: US/11/031,485
; CURRENT FILING DATE: 2005-01-07
; PRIOR APPLICATION NUMBER: 60/535,490
; PRIOR FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 30
; LENGTH: 472
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-031-485-30

Query Match      100.0%; Score 503; DB 6; Length 472;
Best Local Similarity 100.0%; Pred. No. 1.4e-38;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSYIY 60
Db 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMWVRQAPGKLEWVSSISSSSYIY 79

Qy 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
Db 80 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 117

RESULT 17
US-10-091-300-24
; Sequence 24, Application US/10091300
; Publication No. US20030108545A1
; GENERAL INFORMATION:
; APPLICANT: Rockwell, Patricia
; APPLICANT: Goldstein, Neil I.
; TITLE OF INVENTION: Combination Methods of Inhibiting Tumor Growth with a Vascular
```



```

; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1318
; LENGTH: 256
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1318

Query Match          99.4%; Score 500; DB 4; Length 256;
Best Local Similarity 99.0%; Pred. No. 1.4e-38;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYSSNMNVRQAPGKGLEWVSSISSSSYIYY 60
Db 1 EVQLVQSGGGLVQPGGSLRLSCAASGFTFSYSSNMNVRQAPGKGLEWVSSISSSSYIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 22
US-09-880-748-1856
; Sequence 1856, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1856
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1856

Query Match          99.2%; Score 499; DB 3; Length 249;
Best Local Similarity 99.0%; Pred. No. 1.7e-38;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYSSNMNVRQAPGKGLEWVSSISSSSYIYY 60
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYSSNMNVRQAPGKGLEWVSSISSSSYIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98

```

```

Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 23
US-10-293-418-1856
; Sequence 1856, Application US/10293418
; Publication No. US2003022396A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1856
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1856

Query Match          99.2%; Score 499; DB 4; Length 249;
Best Local Similarity 99.0%; Pred. No. 1.7e-38;
Matches 97; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYSSNMNVRQAPGKGLEWVSSISSSSYIYY 60
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYSSNMNVRQAPGKGLEWVSSISSSSYIYY 60

Qy 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYYCAR 98

RESULT 24
US-10-727-155-280
; Sequence 280, Application US/10727155
; Publication No. US20050049402A1
; GENERAL INFORMATION:
; APPLICANT: John S. Babcock
; APPLICANT: Jaespal S. Kang
; APPLICANT: Orit Foord
; APPLICANT: Larry Green
; APPLICANT: Xiao Feng
; APPLICANT: Scott Klakamp
; APPLICANT: Mary Haak-Frendescho
; APPLICANT: Palaniswami Rathanaswami
; APPLICANT: Craig Pigott
; APPLICANT: Meina Liang
; APPLICANT: Rozanne Lee
; APPLICANT: Kathy Manchulenchio
; APPLICANT: Raffaella Faggioni
; APPLICANT: Giorgio Senaldi
; APPLICANT: Qiaojuan Jane Su
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO TUMOR NECROSIS
; TITLE OF INVENTION: FACTOR AND USES THEREOF
; FILE REFERENCE: ABGENIX.073A

```

```
; CURRENT APPLICATION NUMBER: US/10/727,155
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430729
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 280
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 98
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-727-155-280

Query Match          99.0%; Score 498; DB 5; Length 109;
Best Local Similarity 100.0%; Pred. No. 8.7e-19;
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMNVRQAPGKLEWVSSISSSSYIYY 60
   |||||
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMNVRQAPGKLEWVSSISSSSYIYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCA 97
   |||||
DB 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCA 97

RESULT 25
US-10-725-962-17
; Sequence 17, Application US/10725962
; Publication No. US20050013809A1
; GENERAL INFORMATION:
; APPLICANT: Samuel M. Owens
; APPLICANT: Frank I. Carroll
; APPLICANT: Philip Abraham
; APPLICANT: Melinda G. Gunnell
; APPLICANT: Mary Haak-Frendscho
; APPLICANT: Xiao Feng
; TITLE OF INVENTION: ANTIBODIES AGAINST DRUGS OF ABUSE
; FILE REFERENCE: ABGENIX 071A
; CURRENT APPLICATION NUMBER: US/10/725,962
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430717
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 141
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Mus musculus
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 98, 99, 100, 101, 102, 104, 105
; OTHER INFORMATION: Xaa = Any Amino Acid
US-10-725-962-17

Query Match          99.0%; Score 498; DB 5; Length 125;
Best Local Similarity 100.0%; Pred. No. 1e-38;
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMNVRQAPGKLEWVSSISSSSYIYY 60
   |||||
DB 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMNVRQAPGKLEWVSSISSSSYIYY 60
   |||||

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCA 97
   |||||
DB 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCA 97

RESULT 26
US-09-880-748-1764
```

```
; Sequence 1764, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1764
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1764

Query Match          98.8%; Score 497; DB 3; Length 247;
Best Local Similarity 98.0%; Pred. No. 2.5e-38;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSSNMNVRQAPGKLEWVSSISSSSYIYY 60
   :|||:|||||
DB 1 QVQLVQGGGLVKPGGSLRLSCAASGFTFSYSSNMNVRQAPGKLEWVSSISSSSYIYY 60
   :|||:|||||

QY 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
   |||||
DB 61 ADSVKGRFTISRDNKNSLYLQWNSLRAEDTAVYYCAR 98
   |||||

RESULT 27
US-10-293-418-1764
; Sequence 1764, Application US/10293418
; Publication No. US2003023996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1764
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1764

Query Match          98.8%; Score 497; DB 4; Length 247;
```



```

Matches 96; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVOLVESGGGLVPGGSLRLSCLCAASGFTFSSYSNMVVRQAPGKLEWVSSISSSSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVOLVESGGGLVPGGSLRLSCLCAASGFTFSSYSNMVVRQAPGKLEWVSSISSSSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYICAR 97
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYICAR 97
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

```

```

RESULT 32
US-09-880-748-1991
; Sequence 1991, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1991
; LENGTH: 244
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1991

```

```

Query Match 98.4%; Score 495; DB 3; Length 244;
Best Local Similarity 98.0%; Pred. No. 3.8e-38;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVOLVESGGGLVPGGSLRLSCLCAASGFTFSSYSNMVVRQAPGKLEWVSSISSSSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVOLVESGGGLVPGGSLRLSCLCAASGFTFSSYSNMVVRQAPGKLEWVSSISSSSHIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYICAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYICAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

```

```

RESULT 33
US-10-293-418-1991
; Sequence 1991, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248

```

```

; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1991
; LENGTH: 244
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1991

```

```

Query Match 98.4%; Score 495; DB 4; Length 244;
Best Local Similarity 98.0%; Pred. No. 3.8e-38;
Matches 96; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 EVOLVESGGGLVPGGSLRLSCLCAASGFTFSSYSNMVVRQAPGKLEWVSSISSSSYIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVOLVESGGGLVPGGSLRLSCLCAASGFTFSSYSNMVVRQAPGKLEWVSSISSSSHIY 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYICAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYICAR 98
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

```

Search completed: May 12, 2006, 02:25:18
Job time : 59 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:58 ; Search time 38.8199 Seconds
(without alignments)
1781.089 Million cell updates/sec

Title: US-09-674-752-37

Perfect score: 503

Sequence: 1 EVQLVDSGGGLVKGPSRL.....LYLQMSLRADTAVYYCAR 98

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	469	93.2	118	2	Q9UL91_HUMAN
2	468.5	93.1	464	2	Q6MZU6_homo sapien
3	466	92.6	494	2	Q96K68_homo sapien
4	464	92.2	606	2	Q6GMV2_HUMAN
5	446	88.7	117	1	HV3C_HUMAN
6	446	88.7	473	2	Q6MZV7_HUMAN
7	445	88.5	478	2	Q6PI81_HUMAN
8	443	88.1	597	2	Q96BB9_HUMAN
9	439	87.3	240	2	Q65ZC9_HUMAN
10	437	86.9	470	2	Q6PUA4_HUMAN
11	434	86.3	113	2	Q9UL90_HUMAN
12	432	85.9	573	2	Q8WU38_HUMAN
13	429	85.3	112	2	Q9HCC1_HUMAN
14	429	85.3	121	2	Q9UL71_HUMAN
15	429	85.3	472	2	Q6N089_HUMAN
16	428	85.1	114	1	HV3B_HUMAN
17	428	85.1	613	2	Q8WUK1_HUMAN
18	425	84.5	95	2	Q9ULB6_HUMAN
19	424	84.3	119	2	Q920E7_MOUSE
20	424	84.3	196	2	Q65ZL8_MOUSE
21	423	84.1	473	2	Q91Z05_MOUSE
22	423	84.1	493	2	Q6GMX2_HUMAN
23	422	83.9	116	2	Q9UL93_HUMAN
24	421	83.7	469	2	Q569F4_HUMAN
25	421	83.7	475	2	Q6MZQ6_homo sapien
26	419	83.3	487	2	Q99K44_MOUSE
27	418	83.1	479	2	Q6MZV6_homo sapien
28	417.5	83.0	116	1	HV05_CARAU
29	417	82.9	98	1	HV57_MOUSE
30	417	82.9	485	2	Q6PDB8_MOUSE
31	413.5	82.2	120	1	HV3E_HUMAN

32	412	81.9	455	2	Q6P6C4_HUMAN	Q6P6C4_homo sapien
33	410	81.5	136	1	HV16_MOUSE	Q01783_mus musculus
34	410	81.5	499	2	Q8N5K4_HUMAN	Q8N5K4_homo sapien
35	409.5	81.4	97	1	HV56_MOUSE	P18527_mus musculus
36	408	81.1	467	2	Q4VBH1_RAT	Q4VBH1_tattus norv
37	407	80.9	236	2	Q6ZP85_HUMAN	Q6ZP85_homo sapien
38	406	80.7	117	1	HV55_MOUSE	P18526_mus musculus
39	406	80.7	122	1	HV3G_HUMAN	P01768_homo sapien
40	406	80.7	255	2	Q6KB05_MOUSE	Q6KB05_mus musculus
41	406	80.7	487	2	Q6ZVK0_HUMAN	Q6ZVK0_homo sapien
42	405	80.5	117	1	HV59_MOUSE	P18530_mus musculus
43	404.5	80.4	118	2	Q9UL72_HUMAN	Q9UL72_homo sapien
44	404	80.3	475	2	Q6GMW7_HUMAN	Q6GMW7_homo sapien
45	403	80.1	119	2	Q5F2I8_MOUSE	Q5F2I8_mus musculus

ALIGNMENTS

RESULT 1
Q9UL91_HUMAN
ID Q9UL91_HUMAN PRELIMINARY; PRT; 118 AA.
AC Q9UL91; 2000 (Tremblrel. 13, Created)
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
DE OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531; Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M., Young D.C.;
RA "Myosin-reactive autoantibodies in rheumatic carditis and normal fetus."
RT Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1660528; Manheimer-Lory A., Katz J.B., Pillinger M., Ghousein C., Smith A., Diamond B.;
RA P01764_homo sapien
RT "Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype."
RL J. Exp. Med. 174:1639-1652(1991).
RN [3]
RP PROTEIN SEQUENCE.
RX PubMed=1555592; Makiya R., Stigbrand T.;
RA "Placental alkaline phosphatase has a binding site for the human immunoglobulin-G Fc portion."
RL Eur. J. Biochem. 205:341-345(1992).
DR EMBL; AF035023; AAD56259.1; -; mRNA.
DR PIR; PH0875; PH0875.
DR PIR; S21205; S21205.
DR PIR; S30531; S30531.
DR HSSP; P01783; IIGC.
DR SMR; Q9UL91; 1-117.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 118
SQ SEQUENCE 118 AA; 12843 MW; D0633949F2AC149D CRC64;

Query Match 93.2%; Score 469; DB 2; Length 118;
Best Local Similarity 93.9%; Pred. No. 5.3e-41;
Matches 92; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

```

QY 1 EVOLVESGGLVKPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLWVSSISSSSIYY 60
Db 1 EVOLVESGGLVKPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLWVSSISSTIYY 60

QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
Db 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98

RESULT 2
Q6MZU6_HUMAN
ID Q6MZU6_HUMAN PRELIMINARY; PRT; 464 AA.
AC Q6MZU6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein DKFp686C15213.
GN Name=DKFp686C15213;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC Tissue=Rectum tumor;
RG The German cDNA Consortium;
RA Bloeker H., Boecher M., Brandt P., Mewes H.W., Weil B., Amid C.,
RA Oanger A., Fobco G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640874; CAB45931.1; -; mRNA.
DR HSSP; P01861; 1ADQ.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
DR Hypothetical protein.
KW Hypothetical protein.
SQ SEQUENCE 464 AA; 51099 MW; 2FCA72C66E9A0ABC CRC64;

Query Match 93.1%; Score 468.5; DB 2; Length 464;
Best Local Similarity 93.9%; Pred. No. 2.8e-40;
Matches 93; Conservative 1; Mismatches 4; Indels 1; Gaps 1;

QY 1 EVOLVESGGLVKPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLWVSSISSSSIYY 59
Db 20 EVOLVESGGLVKPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLWVSSFSRGSY 79

QY 60 YADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
Db 80 YADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 118

RESULT 3
Q96K68_HUMAN
ID Q96K68_HUMAN PRELIMINARY; PRT; 494 AA.
AC Q96K68;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein FLJ14473.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;

```

```

RN RP NUCLEOTIDE SEQUENCE.
RC Tissue=Mammary gland;
RX PubMed=14702039; DOI=10.1038/ngl1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J.-I., Saito K., Kawai Y., Isono Y., Nakamura Y.,
RA Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H.,
RA Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E.,
RA Omura Y., Abe K., Kamiyama K., Katsuta N., Sato K., Tanikawa M.,
RA Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K.,
RA Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoa K., Chiba Y.,
RA Ishida S., Ono Y., Takiguchi S., Watanabe S., Yoshida M., Hota T.,
RA Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O.,
RA Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M.,
RA Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA Toghiani H., Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA Okumura K., Negase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RL cDNAs."
RL Nat. Genet. 36:40-45(2004).
RN [2]
RP PROTEIN SEQUENCE.
RX PubMed=1555592;
RA Makiya R., Stigbrand T.;
RT "Placental alkaline phosphatase has a binding site for the human
RL immunoglobulin-G Fc portion."
RL Eur. J. Biochem. 205:341-345(1992).
DR EMBL; AK027379; BAB55072.1; -; mRNA.
DR PIR; S21205; S21205.
DR HSSP; P01876; 1OW0.
DR SMR; Q96K68; 264-472.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain.
SQ SEQUENCE 494 AA; 53088 MW; 9A1D7AB5AE4C0E CRC64;

Query Match 92.6%; Score 466; DB 2; Length 494;
Best Local Similarity 90.8%; Pred. No. 5.4e-40;
Matches 89; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

QY 1 EVOLVESGGLVKPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLWVSSISSSSIYY 60
Db 20 EVOLVESGGLVKPGGSLRLSCAASGFTFSYSNMWVRQAPGKGLWVSSISRSIYY 79

QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
Db 80 RDSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 117

RESULT 4
Q6GMY2_HUMAN
ID Q6GMY2_HUMAN PRELIMINARY; PRT; 606 AA.

```


AC Q6GM2; 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE IGHM protein.
GN Name=IGHM;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22386257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalls D.E.,
RA Schnerch A., Schein J.B., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC NIH MGC Project;
RG NTH MGC Project;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073758; AAH73758.1; -; mRNA.
DR SMR; Q6GM2; 20-256.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 4.
DR SMART; SM00409; Ig; 2.
DR SMART; SM00406; Ig; 1.
DR SMART; SM00407; Igcl; 4.
DR PROSITE; PSS0835; IG_LIKE; 5.
DR PROSITE; PSS0290; IG_MHC; UNKNOWN 3.
SQ SEQUENCE 606 AA; 66185 MW; B6B38B51114B4C55 CRC64;

Query Match 92.28; Score 464; DB 2; Length 606;
Best Local Similarity 91.88; Pred. No. 1.1e-39;
Matches 90; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVVRQAPGKLEWVSISSTSYIY 60
Db 20 QVQLVESGGGLVPGGSLRLSCAASGFTFSYMSWIRQAPGKLEWVSISSTSYIY 79

Qy 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYCAR 98
Db 80 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYCAR 117

RESULT 5
HV3C HUMAN
ID HV3C HUMAN STANDARD; PRT; 117 AA.
AC P01764;
DT 21-JUL-1986 (Rel. 01, Created)

DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 13-SEP-2005 (Rel. 48, Last annotation update)
DE Ig heavy chain V-III region VH26 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=81101090; PubMed=6450418;
RA Matthyssens G., Rabbitts T.H.;
RT "Structure and multiplicity of genes for the human immunoglobulin
heavy chain variable region.";
RL Proc. Natl. Acad. Sci. U.S.A. 77:6561-6565(1980).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 20-117.
RX MEDLINE=93209281; PubMed=7681398;
RA Mariette X., Tsapis A., Brouet J.C.;
RT "Nucleotide sequence analysis of the variable domains of four human
monoclonal IgM with an antibody activity to myelin-associated
glycoprotein.";
RL Eur. J. Immunol. 23:846-851(1993).
RN [3]
RP 3D-STRUCTURE MODELING OF 20-117.
RX MEDLINE=86094276; PubMed=3866244;
RA Toyonaga B., Yoshikai Y., Vadasz V., Chin B., Mak T.W.;
RT "Organization and sequences of the diversity, joining, and constant
region genes of the human T-cell receptor beta chain.";
RL Proc. Natl. Acad. Sci. U.S.A. 82:8624-8628(1985).
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use as long as its content is in no way modified and this statement is not
removed.
CC -----
DR EMBL; J00236; AAAS3516.1; -; Unassigned DNA.
DR EMBL; M35415; AAAS58735.1; -; Genomic DNA.
DR PIR; A02047; H3HU26.
DR PDB; 1HOU; Model; H=20-117.
DR HGNC; HGNC:5545; IGHV0.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IG; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
KW 3D-structure; Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-III region VH26.
FT DOMAIN 20 >117 Ig-like.
FT NON TER 117 117
SQ SEQUENCE 117 AA; 12582 MW; E826733F1A3CB0F1 CRC64;

Query Match 88.7%; Score 446; DB 1; Length 117;
Best Local Similarity 85.7%; Pred. No. 1.3e-38;
Matches 84; Conservative 8; Mismatches 6; Indels 0; Gaps 0;

Qy 1 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVVRQAPGKLEWVSISSTSYIY 60
Db 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYSNMVVRQAPGKLEWVSISSTSYIY 79

Qy 61 ADSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYCAR 98
Db 80 GDSVKGRFTISRDNKNSLYLQMNLSRAEDTAVYCAR 117

RESULT 6
Q6MZV7 HUMAN
ID Q6MZV7_HUMAN PRELIMINARY; PRT; 473 AA.

RA	Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA	Vallalon D.K., Munzy D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA	Fahy M., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA	Whiting J., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA	Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smillius D.E.,
RA	Schnorch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT	"Generation and initial analysis of more than 15,000 full-length human
RT	and mouse cDNA sequences.";
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN	[2]
RN	NUCLEOTIDE SEQUENCE.
RP	TISSUE=Primary B-Cells;
RC	NIH MGC Project;
RG	Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.
DR	EMBL; BC041037; AH41037.1; -, mRNA.
DR	HSP; P01861; IADQ.
DR	InterPro; IPR003599; Ig.
DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003597; Ig cl.
DR	InterPro; IPR003006; Ig_MHC.
DR	InterPro; IPR003596; Ig_V.
DR	Pfam; PF07654; Cl-set; 3.
DR	SMART; SM00409; IG; 2.
DR	SMART; SM00407; IGcl; 3.
DR	SMART; SM00406; IGV; 1.
DR	PROSITE; PS50835; IG LIKE; 4.
DR	PROSITE; PS00290; IG_MHC; UNKNOWN 2.
DR	SEQUENCE 478 AA; 52667 MW; 17BED38D917970D6 CRC64;
QY	Query Match 88.5%; Score 445; DB 2; Length 478;
Db	Best Local Similarity 87.8%; Pred. No. 8.1e-38;
Db	Matches 86; Conservative 4; Mismatches 8; Indels 0; Gaps 0;
QY	1 EVLVESGGGLVPGGSLRLSCAASGFTSSYSMMWVRQAPGKLEWSSISSSSYIYY 60
Db	20 EVLVESGGGLVPGGSLRLSCAASGFTSSYSMMWVRQAPGKLEWSSISSSSYIYY 79
QY	61 ADSVKGRFTISRDNANKSLYLQNLSRAEDTAVYYCAR 98
Db	80 VDSVKGRFTISRDNANKSLYLQNLSRAEDTAVYYCAR 117
RESULT 8	
Q96BE9_HUMAN	
ID	Q96BB9 HUMAN PRELIMINARY; PRT; 597 AA.
AC	Q96BB9;
DT	01-DEC-2001 (TrEMBLrel. 19, Created)
DT	01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT	01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE	IGHM protein.
GN	Name=IGHM;
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae;
OC	HOMO.
OX	NCBI_TaxID=9606;
RN	[1]
RN	NUCLEOTIDE SEQUENCE.
RP	TISSUE=Primary B-Cells;
RC	MEDLINE=22398257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA	Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heif F.,
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA	Scapleton M., Soares M.B., Bonaldi M.P., Casavant T.L., Scheetz T.E.,
RA	Brownstein M.J., Udén T.B., Toshikiyo S., Carninci P., Prange C.,
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA	Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalley D.E.,
RA Schnurch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RN NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (Oct-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RN NUCLEOTIDE SEQUENCE.
RX PubMed=2500644;
RA Kishimoto T., Okajima H., Okumoto T., Taniguchi M.;
RT "Nucleotide sequences of the cDNAs encoding the V-regions of H- and L-
RT chains of a human monoclonal antibody with broad reactivity to
RT malignant tumor cells.";
RL Nucleic Acids Res. 17:4385-0(1989).
DR EMBL; BC015760; AAH15760.1; -; mRNA.
DR PIR; S05271; S05271.
DR PIR; S24260; S24260.
DR HSP; P01861; IADQ.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 4.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_LIKE; 5.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_3.
KW Immunoglobulin domain.
SQ SEQUENCE 597 AA; 65039 MW; 4FCA3AD8CE263D9 CRC64;

Query Match 88.1%; Score 443; DB 2; Length 597;
Best Local Similarity 84.7%; Pred. No. 1.7e-37;
Matches 83; Conservative 10; Mismatches 5; Indels 0; Gaps 0;
QY 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSYMMVVRQAPGKGLVWSSISSSSIYY 60
DB 20 EVQLVESGGGLVPGGSLRLSCAASGFTFSYMMVVRQAPGKGLVWSSISGSGSTYY 79
QY 61 ADSVKGRTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
DB 80 ADSVKGRTISRDNKNSLYLQNSLRAEDTAVYYCAR 117
RESULT 9
Q65ZC9 HUMAN
ID Q65ZC9 HUMAN PRELIMINARY; PRT; 240 AA.
AC Q65ZC9
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RN NUCLEOTIDE SEQUENCE.
RC STRAIN=C1q/7;
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).

DR EMBL; Y13056; CAA73499.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PS00835; IG_LIKE; 2.
FT NON_TER 1 1
FT NON_TER 240 240
SQ SEQUENCE 240 AA; 25569 MW; FDCFD3645F64B373 CRC64;
Query Match 87.3%; Score 439; DB 2; Length 240;
Best Local Similarity 85.7%; Pred. No. 1.6e-37;
Matches 84; Conservative 7; Mismatches 7; Indels 0; Gaps 0;
QY 1 EVOLVESGGGLVPGGSLRLSCAASGFTFSYMMVVRQAPGKGLVWSSISSSSIYY 60
DB 1 QVQLVQSGGGLVPGGSLRLSCAASGFTFSYMMVVRQAPGKGLVWSSISGSKYY 60
QY 61 ADSVKGRTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
DB 61 ADSVKGRTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
RESULT 10
Q6PJA4 HUMAN
ID Q6PJA4 HUMAN PRELIMINARY; PRT; 470 AA.
AC Q6PJA4
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE IGHG1 protein.
GN Name=IGHG1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RN NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.D., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalley D.E.,
RA Schnurch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RN NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RG NIH MGC Project;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC018747; AAH18747.1; -; mRNA.
DR HSP; P01861; IADQ.
DR SMR; Q6PJA4; 20-470.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig-cl.

```
DR InterPro: IPR0031006; Ig_MHC.
DR InterPro: IPR003196; Ig_v.
DR Pfam: PF07654; C1-set; 3.
DR SMART: SM00409; IG; 2.
DR SMART: SM00407; IG1; 3.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS50835; IG_LIKE; 4.
DR PROSITE: PS00290; IG_MHC; UNKNOWN 2.
SQ SEQUENCE 470 AA; 51716 MW; 7B49556A11FD7D99 CRC64;

Query Match      86.9%; Score 437; DB 2; Length 470;
Best Local Similarity 85.7%; Pred. No. 5.4e-37;
Matches 84; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

QY 1 EVQLVESGGGLVPGGSLRLCSAASGFTFSYSNWVRQAPGKGLEWVSSISSSSIYY 60
DB 20 EVQLVESGGGLVPGGSLRLCSVVGFTFSYMSWVRQAPGKLEWVANIKDQSEKYY 79
QY 61 ADSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 98
DB 80 VDSVKGRFTISRDNKNSLYLQNSLRAEDTAVYYCAR 117

RESULT 11
Q9UL90 HUMAN
ID Q9UL90_HUMAN PRELIMINARY; PRT; 113 AA.
AC Q9UL90;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RC NUCLEOTIDE SEQUENCE.
RP TISSUE=Primary B-Cells;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Dege J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ussid T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Murty D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Primary B-Cells;
RA Director MGC Project;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
RN [3]
RP PROTEIN SEQUENCE.
RX PubMed=1555592;
RA Makiya R., Stigbrand T.;
RT "Placental alkaline phosphatase has a binding site for the human
RT immunoglobulin-G Fc portion."
RL Eur. J. Biochem. 205:341-345(1992).
DR EMBL: BC021276; AAH21276.1; -; mRNA.
DR PIR: S21205; S21205.
DR PIR: S30532; S30532.
DR HSSP: P18529; 118K.
DR Ensembl: ENSG00000196122; Homo sapiens.
DR InterPro: IPR007110; Ig-like.
DR InterPro: IPR003597; Ig_c1.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_v.
DR Pfam: PF07654; C1-set; 1.
DR SMART: SM00407; ig; 2.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS50835; IG_LIKE; 4.
DR PROSITE: PS00290; IG_MHC; UNKNOWN 2.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 573 AA; 62967 MW; FD072344033AC530 CRC64;
```

```

Query Match      85.9%; Score 432; DB 2; Length 573;
Best Local Similarity 85.7%; Pred.No. 2.3e-36;
Matches 84; Conservative 6; Mismatches 8; Indels 0; Gaps 0;

Qy      1 EVQLVESGGGLVKPGGSLRLSCAASGFTFSYSNNVWRQAPGKLEWVSSISSSSYIY 60
Db      20 EVQLVESGGGLVQPSRLSRLSCAASGFTDDYAMHWWRQAPGKLEWVSGISWNSGSIGY 79

Qy      61 ADSVKGRFTISRDNKAKNSLYLQNNLSRAEDTAVYYCAR 98
Db      80 ADSVKGRFTISRDNKAKNSLYLQNNLSRAEDTALYYCAK 117

RESULT 13
Q9HCC1_HUMAN
ID Q9HCC1_HUMAN PRELIMINARY; PRT; 112 AA.
AC Q9HCC1;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Single chain Fv (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Kikuchi M., Takeda C., Tsujimoto Y., Asada S., Nagata K.;
RL Submitted (OCT-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB049915; BAB16829.1; -, mRNA.
DR HSP; P01783; 1IGC.
DR SMK; Q9HCC1; 1-112.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGv; 1_.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 112
SQ SEQUENCE 112 AA; 12243 MW; 24F1A45EC3B84788 CRC64;

```

Query Match	85.3%	Score 429;	DB 2;	Length 112;
Best Local Similarity	83.7%	Pred. No. 7.5e-37;		
Matches	82;	Conservative	6;	Mismatches 10; Indels 0; Gaps 0;
QY	1	EVQLVESGGGAVKPGGSLRLSCAASGFTFSYSMNWVRQAPGKLEWVSSTISSSSVIYY	60	
Db	1	EVQLVESGGGVRRPGGSLRLSCAASGFTFDYGMWVRQAPGKLEWVSIGINWNGSTGY	60	
QY	61	ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR	98	
Db	61	ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR	98	

RESULT 14
Q9UL71 HUMAN
ID Q9UL71 HUMAN PRELIMINARY; PRT; 121 AA.
AC Q9UL71; AC
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region (Fragment).
DE DE
OS Homo sapiens (Human).
OC Eukaryota; Metazoa;
OC Mammalia; Eutheria;
OC Homo.
NCBI_TaxID=9606;
[1]
FN NUCLEOTIDE SEQUENCE.
RP MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.

RA	Young D.C.;
RT	"Myosin-reactive autoantibodies in rheumatic carditis and normal fetus.";
RL	Clin. Immunol. Immunopathol. 87:184-192(1998).
DR	EMBL; AF035043; AAD56279.1; -; mRNA.
DR	HSSP; P01852; INFD.
DR	SMR; Q9UL71; 1-121.
DR	Ensembl; ENSG00000130076; Homo sapiens.
DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003596; Ig_v.
DR	SMART; SM00406; IGv_1.
DR	PROSITE; PS50835; IG_LIKE; 1.
FT	NON_TER 1
FT	NON_TER 121
SQ	SEQUENCE 121 AA; 13154 MW; 2F045CCFA5D50736 CRC64;
Query Match 85.3%; Score 429; DB 2; Length 121;	
Best Local Similarity 82.7%; Pred. No. g.le-37;	
Matches 83; Conservative 7; Mismatches 10; Indels 0; Gaps 0;	
Qy	1 EVQLVESGGGLVPGGSLRLSCAASGTFPSYSNMNVRQAPGKLEWVSISISSSYIY 60 : : : : : : : : : : :
Dd	1 EVQLVESGGGVQVPGGSLRLFCFAASGTFPDGYAMHWVRQAPGKLEWVSLISGDGSITY 60 : : : : : : : : : : :
Qy	61 ADSVKGRFTISRDNAKNSLYLQMNLSRAEDTAVYYCAR 98 : : : : : : : : : : :
Dd	61 ADSVKGRFTISRDNKSNSLYLQMNLSRAEDTALYYCAK 98 : : : : : : : : : : :
RESULT 15	
ID	Q6N089 HUMAN PRELIMINARY; PRT; 472 AA.
KD	Q6N089;
AC	Q6N089;
DT	05-JUL-2004 (TrEMBLrel. 27, Created)
DT	05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE	05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE	Hypothetical protein DKFZp686P15220.
OS	Name=DKFZp686P15220;
GN	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homidae;
OC	Homo.
OX	NCBI_TaxID=9606;
RX	[1]
RF	NUCLEOTIDE SEQUENCE.
RC	TISSUE=Rectum tumor;
RG	The German cDNA Consortium;
RA	Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
FA	Fodo G., Han M., Wlemann S.;
RL	Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR	EMBL; BX640627; CAB45781.1; -; mRNA.
DR	HSSP; P01861; IADO.
DR	InterPro; IPR003599; Ig.
DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003597; Ig_c1.
DR	InterPro; IPR003006; Ig_MHC.
DR	InterPro; IPR003596; Ig_v.
DR	Pfam; PF07654; Cl-set; 3.
DR	SMART; SM00409; IG; 2.
DR	SMART; SM00407; IGC1; 3.
DR	SMART; SM00406; IGv; 1.
DR	PROSITE; PS50835; IG_LIKE; 4.
DR	PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW	Hypothetical protein
SQ	SEQUENCE 472 AA; 51724 MW; 26CB340D0046D279 CRC64;
Query Match 85.3%; Score 429; DB 2; Length 472;	
Best Local Similarity 84.7%; Pred. No. 3.7e-36;	
Matches 83; Conservative 6; Mismatches 9; Indels 0; Gaps 0;	
Qy	1 EVQLVESGGGLVPGGSLRLSCAASGTFPSYSNMNVRQAPGKLEWVSISISSSYIY 60 : : : : : : : : : : :
Dd	20 EVQLVESGGGLVDPGRSLRLSCAASGTFPDGYAMHWVRQAPGKLEWVSGISWNSGIAY 79 : : : : : : : : : : :

Qy 61 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR 98
| | | | | | | | | | | | | | | | | | | | | | : | | | | |
Db 80 ADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCAK 117

Search completed: May 5, 2006, 09:04:19
Job time : 39.8199 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:49:28 ; Search time 49.795 Seconds
(without alignments)
1111.793 Million cell updates/sec

Title: US-09-674-752-38

Perfect score: 664

Sequence: 1 EVQLVKSGLVPGGSLRL.....ATWRAFDWGRGTMTVTSSG 126

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_21:*

1: Geneseqp1980s:*

2: Geneseqp1990s:*

3: Geneseqp2000s:*

4: Geneseqp2001s:*

5: Geneseqp2002s:*

6: Geneseqp2003as:*

7: Geneseqp2003bs:*

8: Geneseqp2004s:*

9: Geneseqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	664	100.0	126	3	AAY50965 Human FVI
2	658	99.1	125	3	AAY50969 Human FVI
3	483.5	72.8	252	5	ABP45351 Human Bly
4	483.5	72.8	252	7	ADG96178 Single ch
5	483	72.7	240	7	ADD31770 Anti-beta
6	483	72.7	257	7	ADD31768 Anti-beta
7	478	72.0	248	5	ABP44902 Human Bly
8	478	72.0	248	7	ADG95729 Single ch
9	477.5	71.9	185	8	ADU81110 MAB G15B4
10	476.5	71.8	471	9	ABE45899 Human mon
11	476.5	71.8	472	9	ABE45899 Human mon
12	475.5	71.6	116	5	AAE28870 Human KDR
13	475.5	71.6	116	6	ABJ26763 VEGF bind
14	475.5	71.6	116	7	ADD24417 Human hea
15	475.5	71.6	116	7	ADD80794 Human clo
16	475.5	71.6	116	8	ADK18270 KDR bindi
17	474.5	71.5	250	5	ABP44872 Human Bly
18	474.5	71.5	250	7	ADG95699 Single ch
19	474.5	71.5	256	5	ABP45307 Human Bly
20	474.5	71.5	256	7	ADG96134 Single ch
21	474	71.4	119	8	ADO36350 Intracell
22	474	71.4	121	7	ADL91323 VH chain
23	473.5	71.3	245	2	AAY06717 Antibody
24	473.5	71.3	245	8	ADO39736 Human C-m

25	473.5	71.3	247	5	ABP45753 Human Bly
26	473.5	71.3	247	7	ADG96580 Single ch
27	472.5	71.2	114	6	AAE34873 BIWA8 ant
28	472.5	71.2	240	4	AAB46007 Human MUC
29	472.5	71.2	444	6	AAE35327 Humanized
30	472.5	71.2	444	6	AAE34876 Humanized
31	472.5	71.2	444	8	ADL15443 Humanized
32	472.5	71.2	444	8	ADO00851 Humanized
33	472.5	71.2	444	9	ABE29789 Humanized
34	472.5	71.2	444	9	ABE29780 Humanized
35	471.5	71.0	125	8	ADP46962 Murine he
36	471.5	71.0	126	7	ADK18784 Anti-huma
37	471.5	71.0	126	7	ADK18589 Anti-huma
38	471.5	71.0	126	8	ADL25396 Human mAb
39	471.5	71.0	129	9	ADY50076 Endotheli
40	471	70.9	250	5	ABP45168 Human Bly
41	471	70.9	250	7	ADG95995 Single ch
42	470.5	70.9	116	5	AAE28873 Human KDR
43	470.5	70.9	116	6	ABJ26766 VEGF bind
44	470.5	70.9	116	7	ADD24424 Human hea
45	470.5	70.9	116	7	ADD80801 Human clo

ALIGNMENTS

RESULT 1

AAY50965

ID AAY50965 standard; protein; 126 AA.

XX AAY50965;

DT 23-MAR-2000 (first entry)

DE Human FVIII antibody A3-C1 scFv heavy chain protein B04.

XX Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;

KW scFv; A3-C1.

OS Homo sapiens.

XX WO9958680-A2.

PD 18-NOV-1999.

XX 07-MAY-1999; 99WO-NL000285.

XX 08-MAY-1998; 98EP-00201543.

XX (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.

XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;

XX WPI; 2000-053102/04.

PT New polynucleotide, polypeptide and antibody useful for diagnosing the presence of neutralizing antibodies against factor VIII and for treatment of hemophilia A patients with these antibodies.

XX Example 8; Fig 9A; 61pp; English.

CC This invention describes a novel polynucleotide (I) (and complements and hybridizable polynucleotides) comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity which has hemostatic activity. (I) is useful as a primer or probe for detecting the presence of inhibitory antibodies directed against factor VIII. The polypeptides of the invention and the antibodies generated from them are useful in compositions for neutralizing factor VIII inhibiting antibodies in hemophilia A patients. This sequence represents the human factor VIII antibody A3-C1 specific scFv protein B04 which is used in the method of the invention

XX Sequence 126 AA;

```
Query Match      100.0%; Score 664; DB 3; Length 126;
Best Local Similarity 100.0%; Pred. No. 2.4e-53;
Matches 126; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EVQLVKGSGGLVPGGSLRLSCAASGFTFRYYDIHWVROTPGKGLEWVSSISSGGNYIDY 60
      |||
      1 EVQLVKGSGGLVPGGSLRLSCAASGFTFRYYDIHWVROTPGKGLEWVSSISSGGNYIDY 60
      |||
QY      61 ADSVKGRTISRDNANNVYLVQNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
      |||
      61 ADSVKGRTISRDNANNVYLVQNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
      |||
QY      121 VTVSSG 126
      |||
      121 VTVSSG 126
      |||

RESULT 2
AAV50969
ID  AAV50969 standard; protein; 125 AA.
XX
AC  AAV50969;
XX
DT  23-MAR-2000 (first entry)
XX
DE  Human FVIII antibody heavy chain variable region B04 protein fragment.
XX
KW  Human; heavy chain; antibody; factor VIII; hemostatic; variable region;
KW  hemophilia A.
XX
OS  Homo sapiens.
XX
PN  WO9558680-A2.
XX
PD  18-NOV-1999.
XX
PF  07-MAY-1999; 99WO-NL000285.
XX
PR  08-MAY-1998; 98EP-00201543.
XX
PA  (SANQ-) STICHTING SANQUIN BLOEDVOORZIENING.
XX
PI  Voorberg JJ, Van Den Brink EN, Turenhout EAM;
XX
DR  WPI; 2000-053102/04.
XX
DR  N-PSDB; AA243866.
XX
PT  New polynucleotide, polypeptide and antibody useful for diagnosing the
PT  presence of neutralizing antibodies against factor VIII and for treatment
PT  of hemophilia A patients with these antibodies.
XX
PS  Example 8; Fig 9E; 61pp; English.
XX
CC  This invention describes a novel polynucleotide (I) (and complements and
CC  hybridizable polynucleotides) comprising a contiguous nucleotide sequence
CC  coding for a human antibody with factor VIII specificity which has
CC  hemostatic activity. (I) is useful a primer or probe for detecting the
CC  presence of inhibitory antibodies directed against factor VIII. The
CC  polypeptides of the invention and the antibodies generated from them are
CC  useful in compositions for neutralizing factor VIII inhibiting antibodies
CC  in hemophilia A patients. This sequence represents a fragment of the
CC  human factor VIII antibody heavy chain variable region protein B04 which
CC  is used in the method of the invention
XX
SQ  Sequence 125 AA;

Query Match      99.1%; Score 658; DB 3; Length 125;
Best Local Similarity 100.0%; Pred. No. 8.4e-53;
Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 EVQLVKGSGGLVPGGSLRLSCAASGFTFRYYDIHWVROTPGKGLEWVSSISSGGNYIDY 60
      |||
```

```
Db      1 EVQLVKGSGGLVPGGSLRLSCAASGFTFRYYDIHWVROTPGKGLEWVSSISSGGNYIDY 60
QY      61 ADSVKGRTISRDNANNVYLVQNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
      |||
      61 ADSVKGRTISRDNANNVYLVQNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
      |||
QY      121 VTVSS 125
      |||
      121 VTVSS 125
      |||

RESULT 3
ABP45351
ID  ABP45351 standard; protein; 252 AA.
XX
AC  ABP45351;
XX
DT  19-AUG-2002 (first entry)
XX
DE  Human BlyS binding scFv SEQ ID 1362.
XX
KW  BlyS; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW  tumour necrosis factor; B cell proliferation; B cell differentiation;
KW  immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW  antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW  systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW  common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS  Homo sapiens.
XX
PN  WO200202641-A1.
XX
PD  10-JAN-2002.
XX
PF  15-JUN-2001; 2001WO-US019110.
XX
PR  16-JUN-2000; 2000US-0212210P.
PR  17-OCT-2000; 2000US-0240816P.
PR  16-MAR-2001; 2001US-0276248P.
PR  21-MAR-2001; 2001US-0277379P.
PR  25-MAY-2001; 2001US-0293499P.
XX
PA  (HUMA-) HUMAN GENOME SCI INC.
PA  (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
PI  Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
XX
DR  WPI; 2002-114799/15.
XX
PT  Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
PT  diagnosis and treatment of cancers and immune disorders.
XX
PS  Claim 1; Page 2028-2029; 3148pp; English.
XX
CC  This invention describes novel antibodies that immunospecifically bind to
CC  B Lymphocyte Stimulator (BlyS) polypeptides. BlyS is a member of the
CC  tumour necrosis factor (TNF) super family and induces B cell
CC  proliferation and differentiation. The antibodies of the invention have
CC  cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC  antirheumatic and antiAIDS activity and can be used in vaccines to
CC  inhibit the expression and activity of BlyS. The antibodies bind to BlyS
CC  and so may be used to detect and quantitate the presence of BlyS in
CC  biological samples and may be used in this way to diagnose disease
CC  associated with aberrant expression of BlyS. They may also be
CC  administered to treat diseases associated with aberrant BlyS expression
CC  and activity such as cancer, immune, and autoimmune disorders and
CC  diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC  immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC  acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC  the antibodies and fragments of the antibodies described in the method of
CC  the invention
XX
SQ  Sequence 252 AA;
```


Query Match 72.8%; Score 483.5; DB 5; Length 252;
 Best Local Similarity 74.2%; Pred. No. 2.1e-36;
 Matches 98; Conservative 6; Mismatches 15; Indels 13; Gaps 2;

QY 1 EVQLVKGEGLVKPGGSLRLSCAASGFTFRYDIHWVRQTPGKLEWVSSISGNNIDY 60
 DB 1 EVQLVESGGGLVKPGGSLRLSCAASGFTFNPYTMNVRQAPGKLEWVSSISNNIYY 60

QY 61 ADSVKGRFTISRDNANNVYLOMNSLRADTMVYFCAR-----DGIIFGSAATWRAFDI 114
 DB 61 ADSVKGRFTISRDNANKNSLYLOMNSLRADTMVYFCARGHYDILTGYFFG-----FDY 113

QY 115 WGRGTMVTSSG 126
 DB 114 WGRGTLVTSSG 125

RESULT 4
 ADG96178
 ID ADG96178 standard; protein; 252 AA.
 AC ADG96178;
 DT 11-MAR-2004 (first entry)
 DE Single chain antibody that immunospecifically binds Blys SeqID 1362.
 KW antibody; B lymphocyte stimulator; Blys; tumour necrosis factor;
 KW B cell proliferation; differentiation; scFv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antiarthritic; antiarthritic; neuroprotective;
 KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
 OS Unidentified.
 XX
 XX WO2003055979-A2.
 XX
 XX 10-JUL-2003.
 XX
 XX 14-NOV-2002; 2002WO-US036496.
 XX
 XX 16-NOV-2001; 2001US-0331469P.
 XX
 XX 19-DEC-2001; 2001US-0340817P.
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX
 XX Ruben SM, Baraah SC, Choi GH, Vaughan TU, Hilbert D;
 XX WPI; 2003-505530/47.
 XX
 XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 (Blys), useful for detecting and treating diseases or disorders e.g.
 rheumatoid arthritis, asthma and leukemia.
 XX
 XX Example 1; SEQ ID NO 1362; 394pp; English.

This invention relates to novel antibodies that immunospecifically bind to B lymphocyte stimulator (Blys). The Blys gene has been mapped to chromosome 13q34 and encodes a protein that is a member of the tumour necrosis factor superfamily and induces both in vivo and in vitro B cell proliferation and differentiation. Specifically, it refers to single chain antibody molecules (scFvs) derived, preferably, from the variable heavy CDR3 region that immunospecifically bind to a polypeptide, or fragment thereof, of either human, murine, rat or monkey Blys. The present invention refers to the use of such antibodies in various methods for the detection, diagnosis and prognosis of diseases related to the aberrant expression or inappropriate function of Blys or its receptor. As such, these compositions are useful for identifying immune disorders including myasthenia gravis and multiple sclerosis, inflammatory disorders e.g. asthma and rheumatoid arthritis, infectious diseases such as AIDS and proliferative disorders including leukaemia, carcinoma and lymphoma. Accordingly, they can be described as exhibiting various

CC activities such as antirheumatic, antiarthritic, neuroprotective,
 CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds Blys of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.
 XX
 SQ Sequence 252 AA;

Query Match 72.8%; Score 483.5; DB 7; Length 252;
 Best Local Similarity 74.2%; Pred. No. 2.1e-36;
 Matches 98; Conservative 6; Mismatches 15; Indels 13; Gaps 2;

QY 1 EVQLVKGEGLVKPGGSLRLSCAASGFTFRYDIHWVRQTPGKLEWVSSISGNNIDY 60
 DB 1 EVQLVESGGGLVKPGGSLRLSCAASGFTFNPYTMNVRQAPGKLEWVSSISNNIYY 60

QY 61 ADSVKGRFTISRDNANNVYLOMNSLRADTMVYFCAR-----DGIIFGSAATWRAFDI 114
 DB 61 ADSVKGRFTISRDNANKNSLYLOMNSLRADTMVYFCARGHYDILTGYFFG-----FDY 113

QY 115 WGRGTMVTSSG 126
 DB 114 WGRGTLVTSSG 125

RESULT 5
 ADD31770
 ID ADD31770 standard; protein; 240 AA.
 AC ADD31770;
 DT 15-JAN-2004 (first entry)
 DE Anti-beta-galactosidase ScFv antibody truncated protein SEQ ID NO:9.
 XX
 XX recombination product; synthetic gene technology;
 KW anti-beta-galactosidase ScFv antibody.
 XX
 XX Synthetic.
 OS
 XX WO2003064611-A2.
 XX
 XX 07-AUG-2003.
 XX
 XX 29-JAN-2003; 2003WO-US002612.
 XX
 XX 30-JAN-2002; 2002US-00062188.
 XX
 XX (EGEA-) EGEA BIOSCIENCES INC.
 XX
 XX Evans GA;
 XX WPI; 2003-663477/62.
 XX
 XX Creating recombination products between two distinct nucleotide
 sequences, useful in the field of synthetic gene technology, and in
 PT assembling a library, or a population or a collection of polypeptide
 PT variants.
 XX
 XX Example 2; SEQ ID NO 9; 132pp; English.

The present invention describes a method for creating a collection of recombination products between two nucleotide sequences. The method comprises combining an initial set of oligonucleotides corresponding to a first nucleotide sequence with a subsequent set of oligonucleotides corresponding to a distinct nucleotide sequence and further combining the initial and subsequent sets of combination oligonucleotides having a sequence region corresponding to the initial nucleotide sequence and a sequence region corresponding to the second oligonucleotide sequence. Also described is a method of creating a collection of recombination products between two genes. The methods and compositions of the present invention are useful in the field of synthetic gene technology, and more

CC proliferation and differentiation. The antibodies of the invention have
 CC cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
 CC antirheumatic and antiAIDS activity and can be used in vaccines to
 CC inhibit the expression and activity of BLYS. The antibodies bind to BLYS
 CC and so may be used to detect and quantitate the presence of BLYS in
 CC biological samples and may be used in this way to diagnose disease
 CC associated with aberrant expression of BLYS. They may also be
 CC administered to treat diseases associated with aberrant BLYS expression
 CC and activity such as cancer, immune, and autoimmune disorders and
 CC diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
 CC immunodeficiency (e.g. common variable immunodeficiency (CVID) and
 CC acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
 CC the antibodies and fragments of the antibodies described in the method of
 CC the invention
 CC
 CC SQ Sequence 248 AA;

Query Match 72.0%; Score 478; DB 5; Length 248;
 Best Local Similarity 72.2%; Pred. No. 6.6e-36;
 Matches 91; Conservative 14; Mismatches 21; Indels 0; Gaps 0;

QY 1 EVQLVKGSGGLVPGGSLRLSCAASGFTFRFDYDTHWVQTPGKGLEWVSSISGSGNYIDY 60

Db 1 EVQLVESGGGLVQPGGSLRLSCAAGFTFTSSYSNMWVRQAPGKGLEWVSSISNRGSYIY 60

QY 61 ADSVKGRFTISRDNANNVYVYLNQNSLRADNMAVYFCARDGTIFGSAATWRAFDWGRGTM 120

Db 61 ADSVKGRFTISRDNANNVYVYLNQNSLRADNMAVYFCAREGRDITGVYYGLDVGQGTLL 120

QY 121 VTVSSG 126

Db 121 VTVSSG 126

RESULT 8

ADG95729

ID ADG95729 standard; protein; 248 AA.

AC ADG95729;

DT 11-MAR-2004 (first entry)

DE Single chain antibody that immunospecifically binds BLYS SeqID 913.

XX antibody; B lymphocyte stimulator; BLYS; tumour necrosis factor;
 KW B cell proliferation; differentiation; scfv; myasthenia gravis;
 KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
 KW carcinoma; lymphoma; antirheumatic; antiallergic; neuroprotective;
 KW antiinflammatory; antiaesthetic; antiallergic; cytostatic.

OS Unidentified.

XX WO2003055979-A2.

XX 10-JUL-2003.

XX 14-NOV-2002; 2002WO-US036496.

XX 16-NOV-2001; 2001US-0331469P.

XX 19-DEC-2001; 2001US-0340817P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Barash SC, Choi GH, Vaughan TU, Hilbert D;

XX WPI; 2003-505530/47.

XX Novel antibody that immunospecifically binds to a B lymphocyte stimulator
 PT (Blys), useful for detecting and treating diseases or disorders e.g.
 PT rheumatoid arthritis, asthma and leukemia.

PS Example 1; SEQ ID NO 913; 394pp; English.

CC This invention relates to novel antibodies that immunospecifically bind
 CC to B lymphocyte stimulator (BLYS). The BLYS gene has been mapped to
 CC chromosome 13q34 and encodes a protein that is a member of the tumour
 CC necrosis factor superfamily and induces both in vivo and in vitro B cell
 CC proliferation and differentiation. Specifically, it refers to single
 CC chain antibody molecules (scfvs) derived, preferably, from the variable
 CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
 CC fragment thereof, of either human, murine, rat or monkey BLYS. The
 CC present invention refers to the use of such antibodies in various methods
 CC for the detection, diagnosis and prognosis of diseases related to the
 CC aberrant expression or inappropriate function of BLYS or its receptor. As
 CC such, these compositions are useful for identifying immune disorders
 CC including myasthenia gravis and multiple sclerosis, inflammatory
 CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
 CC as AIDS and proliferative disorders including leukaemia, carcinoma and
 CC lymphoma. Accordingly, they can be described as exhibiting various
 CC activities such as antirheumatic, antiallergic, neuroprotective,
 CC antiinflammatory, antiaesthetic, antiallergic and cytostatic. This
 CC polypeptide sequence is a single chain antibody that binds BLYS of the
 CC invention. NOTE: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp.wipo.int/pub/published pct_sequences.

XX SQ Sequence 248 AA;

Query Match 72.0%; Score 478; DB 7; Length 248;
 Best Local Similarity 72.2%; Pred. No. 6.6e-36;
 Matches 91; Conservative 14; Mismatches 21; Indels 0; Gaps 0;

QY 1 EVQLVKSSEGLVPGGSLRLSCAASGFTFRFDYDTHWVQTPGKGLEWVSSISGSGNYIDY 60

Db 1 EVQLVESGGGLVQPGGSLRLSCAAGFTFTSSYSNMWVRQAPGKGLEWVSSISNRGSYIY 60

QY 61 ADSVKGRFTISRDNANNVYVYLNQNSLRADNMAVYFCARDGTIFGSAATWRAFDWGRGTM 120

Db 61 ADSVKGRFTISRDNANNVYVYLNQNSLRADNMAVYFCAREGRDITGVYYGLDVGQGTLL 120

QY 121 VTVSSG 126

Db 121 VTVSSG 126

RESULT 9

ADU81110

ID ADU81110 standard; protein; 185 AA.

AC ADU81110;

DT 10-FEB-2005 (first entry)

DE Mab G15B4G5 heavy chain.

XX antibody; G14F7B5; G15B4G5; G19B9G7; variable; constant; region;
 KW complementarity determining region; CDR; Mab; monoclonal;
 KW capsular polysaccharide; glucuronoxylomannan; GXM;
 KW Cryptococcus neoformans; VH 3-64; VH-6-1; Vk A27; infection.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT Peptide 1..14 /label= Leader sequence

FT Peptide 40..49 /label= CDR1

FT Peptide 64..80 /label= CDR2

FT Peptide 113..125 /label= CDR3

XX WO2004099251-A2.

XX 18-NOV-2004.

PD

```

XX PF 06-MAY-2004; 2004WO-US014276.
XX PR 06-MAY-2003; 2003US-0468475P.
XX PR 30-MAY-2003; 2003US-0474530P.
XX PR 23-MAR-2004; 2004US-0555540P.
XX PA (YESH ) UNIV YESHIVA EINSTEIN COLLEGE MEDICINE.
XX PI Pirofski L, Maitta RW;
XX DR WPI; 2004-814048/80.
XX DR N-PSDB; ADU81098.
XX PT New human monoclonal antibody specifically binding the capsular
PT polysaccharide glucuronoxylomannan (GXM) of Cryptococcus neoformans,
PT useful for treating or diagnosing cryptococcal infections.
XX PS Example 4; Page 40; 56pp; English.
XX CC This sequence represents the monoclonal antibody (Mab) G15B4G5 heavy
CC chain. This sequence was used in the generation of the Mab of the
CC invention. The Mab of the invention or its antigen-binding portion
CC specifically binds the capsular polysaccharide glucuronoxylomannan (GXM)
CC of Cryptococcus neoformans and comprises a heavy and/or light chain amino
CC acid sequence having CDR1, CDR2 and CDR3 amino sequences of a human VH 3-
CC 64 or VH-6-1 gene, or human VK A27 gene, respectively, with or without a
CC signal sequence, where the sequence have up to 6 mutations from the
CC germline gene sequence. The Mab of the invention may be used for
CC detection, prevention and/or treatment of C. neoformans infection.
XX SQ Sequence 185 AA;

Query Match 71.9%; Score 477.5; DB 8; Length 185;
Best Local Similarity 74.6%; Pred. No. 5.4e-36;
Matches 94; Conservative 10; Mismatches 19; Indels 3; Gaps 1;

QY 1 EVQLVKSGLVPGGSLRLSCAASGFTPRFDYIHVWRTQPGKLEWVSSISGGNYIDY 60
DB 15 EVQLVESGEGLVPGGSLRLSCAASGFTFSYAMHWVRQAPGKLEYVSAISSNGGSTY 74
QY 61 ADSVKGRFTISRDNANNVYVLOMNSLRADDMVAVFCARDGTIFGSAATWRAFDIWRGTM 120
DB 75 ADSVKGRFTISRDNKNTLYLQMSLRADDMVAVYCARDHTIFGLVP---PLDYWGQGTLL 131
QY 121 VTVSSG 126
DB 132 VTVSSG 137

RESULT 10
AEB45899
ID AEB45899 standard; protein; 471 AA.
XX AC AEB45899;
XX DT
XX DT 06-OCT-2005 (first entry)
XX DE Human monoclonal anti-MadCAM antibody #31.
XX KW Monoclonal antibody; mucosal addressin cell adhesion molecule; MadCAM;
KW inflammation; inflammatory bowel disease; Crohn's disease;
KW ulcerative colitis; diverticular disease; gastritis; liver disease;
KW primary biliary cirrhosis; primary sclerosing cholangitis;
KW insulin dependent diabetes; graft versus host disease; antiinflammatory;
KW gastrointestinal-gen.; anticulcer; hepatotropic; antidiabetic;
XX OS immunosuppressive; antibody.
XX OS Homo sapiens.
XX PN WO2005067620-A2.
XX PN
XX XX 28-JUL-2005.
XX PD

XX PF 07-JAN-2005; 2005WO-US000370.
XX PR 08-JAN-2004; 2004US-0535490P.
XX PA (PFIZ ) PFIZER INC.
XX PA (ABGE-) ABGENIX INC.
XX PA (PFIZ ) PFIZER LTD.
XX PI Pullen N, Molloy E, Kellermann S, Green LL, Haak-Frendscho M;
XX DR WPI; 2005-554958/56.
XX DR N-PSDB; AEB45898.
XX PT New antibody to Mucosal Addressin Cell Adhesion Molecule, useful for
PT diagnosing and treating an inflammatory disease, e.g. inflammatory bowel
PT disease, ulcerative colitis, gastritis, insulin-dependent diabetes or
PT graft versus host disease.
XX PS Claim 8; SEQ ID NO 64; 167pp; English.
XX CC The invention relates to a human monoclonal antibody or its antigen-
CC binding portion that specifically binds to mucosal addressin cell
CC adhesion molecule (MadCAM). The invention also relates to a hybridoma
CC cell line that produces the human monoclonal antibody, a pharmaceutical
CC composition comprising an amount of the monoclonal antibody or its
CC antigen-binding portion and a pharmaceutical carrier, a method of
CC treating inflammatory disease in a subject, an isolated cell line that
CC produces the monoclonal antibody or its antigen-binding portion or the
CC heavy chain or light chain of the antibody or of its portion, an isolated
CC nucleic acid molecule comprising a nucleotide sequence encoding the heavy
CC chain or its antigen-binding portion or the light chain or its antigen-
CC binding portion of an antibody described above, a vector comprising the
CC nucleic acid molecule, where the vector optionally comprises an
CC expression control sequence operably linked to the nucleic acid molecule,
CC a host cell comprising the vector or the nucleic acid molecule above, a
CC method of producing a human monoclonal antibody or its antigen-binding
CC portion that specifically binds MadCAM, a method of isolating an antibody
CC or its antigen-binding portion that specifically binds to MadCAM, a
CC method of treating a subject in need of a human antibody or its antigen-
CC binding portion that specifically binds to MadCAM and inhibits binding to
CC alpha4beta7, a method of inhibiting alpha4beta7 binding to cells
CC expressing human MadCAM, a method of inhibiting MadCAM-mediated leukocyte
CC -endothelial cell adhesion, migration and infiltration into tissues, a
CC method of inhibiting alpha4beta7/MadCAM-dependent cellular adhesion,
CC inhibiting the MadCAM-mediated recruitment of lymphocytes to
CC gastrointestinal lymphoid tissue, a method of diagnosing a disorder
CC characterized by circulating soluble human MadCAM and detecting
CC inflammation in a subject. The antibody, composition and methods are
CC useful for diagnosing and treating inflammatory disease, e.g.
CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC diverticular disease, gastritis, liver disease, primary biliary
CC cirrhosis, primary sclerosing cholangitis, insulin dependent diabetes and
CC graft versus host disease. This sequence represents a human monoclonal
XX anti-MadCAM antibody of the invention.
XX SQ Sequence 471 AA;

Query Match 71.8%; Score 476.5; DB 9; Length 471;
Best Local Similarity 75.4%; Pred. No. 1.8e-35;
Matches 95; Conservative 9; Mismatches 21; Indels 1; Gaps 1;

QY 1 EVQLVKSGLVPGGSLRLSCAASGFTPRFDYIHVWRTQPGKLEWVSSISGGNYIDY 60
DB 20 EVQLVESGGLVPGGSLRLSCAASGFTPSYSMMNVRQAPGKLEWVSSISSSSYIYY 79
QY 61 ADSVKGRFTISRDNANNVYVLOMNSLRADDMVAVFCARDGTIFGSAATWRAFDIWRGTM 119
DB 80 ADSVKGRFTISRDNKNTLYLQMSLRADDMVAVYCARDGTIFGSAATWRAFDIWRGTM 139
QY 120 MTVSS 125
DB 140 TTVSS 145

```

CC	inflammation in a subject. The antibody, composition and methods are
CC	useful for diagnosing and treating inflammatory disease, e.g.
CC	inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC	diverticular disease, gastritis, liver disease, primary biliary
CC	cirrhosis, primary sclerosing cholangitis, insulin dependent diabetes and
CC	graft versus host disease. This sequence represents a human monoclonal
CC	anti-MAGCAM antibody of the invention.
XX	
XX	
SQ	Sequence 472 AA;
	Query Match 71.8%; Score 476.5; DB 9; Length 472;
	Best Local Similarity 75.4%; Pred. No. 1.8e-35;
	Matches 95; Conservative 9; Mismatches 21; Indels 1; Gaps 1
QY	1 EVLVKSGGLVKPGGSLRLSCAASGFTPRRYDIHWVROTPTGKLEWVSSISGGNYIDY 60
DB	20 EVLVESGGGLVKPGGSLRLSCAASGFTFSSYMNWVRQAPGKLEWVSSISSSSYIYY 79
QY	61 ADSVKGRTISRDNANNVYLNLSRAEDMAYFCARDGTIFG-SAATWRAPDIWGRGT 119
DB	80 ADSVKGRTISRDNAKNSLYLNLSRAEDTAVYYCARDGYSGWSSYYIYYGMDVMGGQT 139
QY	120 MVTVSS 125
DB	140 TTVTVSS 145
RESULT 12	
AAE28870	
ID	AAE28870 standard; protein; 116 AA.
XX	
AC	AAE28870;
XX	
DT	27-DEC-2002 (first entry)
XX	
DE	Human KDR (VEGFR-2) Fab heavy chain protein from D2C6 and DIH4 clone.
XX	
KW	Human; tumour; vascular endothelial growth factor receptor; metastasis;
KW	epidermal growth factor receptor; non-small cell lung carcinoma; NSCLC;
KW	breast; VEGFR; heart; EGFR; therapy; invasiveness; heavy chain; VH.
XX	
OS	Homo sapiens.
XX	
PN	WO200270008-A1.
XX	
PD	12-SEP-2002.
XX	
PF	04-MAR-2002; 2002WO-US006762.
XX	
PR	02-MAR-2001; 2001US-00798689.
XX	
XX	(IMCL-) IMCLONE SYSTEMS INC.
PA	(ROCK/) ROCKWELL P.
PA	(GOLD/) GOLDSTEIN N I.
XX	
DR	WPI; 2002-691738/74.
XX	
DR	N-PSDB; AAD46290, AAD46292.
XX	
PT	Inhibiting tumor growth in humans involves administering vascular
PT	endothelial growth factor receptor antagonists in combination with
PT	radiation, chemotherapeutic agents, or epidermal growth factor receptor
PT	antagonists.
XX	
PS	Example 9; Page 123; 151pp; English.
XX	
CC	The invention relates to a method of inhibiting tumour growth which
CC	involves administering, vascular endothelial growth factor receptor
CC	(VEGFR) antagonists in combination with radiation, chemotherapeutic
CC	agent, or epidermal growth factor receptor (EGFR) antagonist. The method
CC	is useful for inhibiting tumour growth in a human, where the tumour (e.g.
CC	tumour of the breast, heart, lung, small intestine, colon, spleen, bone,
CC	kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin,
CC	bone marrow, blood, thymus, uterus, testicles, cervix or liver) over


```

XX SQ Sequence 116 AA;
Query Match 71.6%; Score 475.5; DB 7; Length 116;
Best Local Similarity 76.0%; Pred. No. 4.9e-36;
Matches 95; Conservative 7; Mismatches 14; Indels 9; Gaps 1;

Qy 1 EVQLVKGEGLVKPGGSLRLSCAASGFTFRYDIHWVQTPGKGLEWVSSISGSGNYIDY 60
Db 1 EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSNMVVRQAPGKGLEWVSSISSSSYIYY 60

Qy 61 ADSVKGRFTISRDNANNVYLQNNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
Db 61 ADSVKGRFTISRDNAKNSLYLQNNSLRAEDTAVYVCAR-----VTDAFDIWGGQTM 111

Qy 121 VTVSS 125
Db 112 VTVSS 116

Search completed: May 5, 2006, 08:57:05
Job time : 51.795 secs

RESULT 15
ADD80794
ID ADD80794 standard; protein; 116 AA.
XX
AC ADD80794;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human clone D2C6/D1H4 KDR-binding Fab variable heavy chain SEQ ID NO:24.
XX
KW human; antibody; KDR; cytostatic; gene therapy; anti-KDR antibody;
KW tumour; angiogenesis.
XX
OS Homo sapiens.
XX
PN WO2003075840-A2.
XX
PD 18-SEP-2003.
XX
PP 04-MAR-2003; 2003WO-US006459.
XX
PR 04-MAR-2002; 2002US-0361783P.
XX
PA (IMCL-) IMCLONE SYSTEMS INC.
XX
PI Zhu Z;
XX
DR WPI; 2003-779032/73.
DR N-PSDB; ADD80793, ADD80797.
XX
PT New human anti-KDR antibody, useful for preparing a composition for
PT reducing tumor growth and inhibiting angiogenesis.
XX
PS Claim 5; SEQ ID NO 24; 49pp; English.
XX
CC The invention relates to a novel isolated human antibody or its fragment
CC binds selectively to KDR. An antibody of the invention has cytostatic
CC activity, and may have a use in gene therapy. The antibody is anti-KDR
CC antibody. The antibody is useful for preparing a composition for reducing
CC tumour growth and inhibiting angiogenesis. The present sequence is used
CC in the exemplification of the invention.
XX
XX SQ Sequence 116 AA;
Query Match 71.6%; Score 475.5; DB 7; Length 116;
Best Local Similarity 76.0%; Pred. No. 4.9e-36;
Matches 95; Conservative 7; Mismatches 14; Indels 9; Gaps 1;

Qy 1 EVQLVKGEGLVKPGGSLRLSCAASGFTFRYDIHWVQTPGKGLEWVSSISGSGNYIDY 60
Db 1 EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSNMVVRQAPGKGLEWVSSISSSSYIYY 60

Qy 61 ADSVKGRFTISRDNANNVYLQNNSLRAEDMAVYFCARDGTIFGSAATWRAFDIWRGTM 120
Db 61 ADSVKGRFTISRDNAKNSLYLQNNSLRAEDTAVYVCAR-----VTDAFDIWGGQTM 111

Qy 121 VTVSS 125
Db 112 VTVSS 116
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 5, 2006, 08:50:25 ; Search time 14.5429 Seconds
(without alignments)
716.302 Million cell updates/sec

Title: US-09-674-752-38

Perfect score: 664

Sequence: 1 EVOLVKSGLVPGGSLRL.....ATWRAFDIMGRGTMVTSSG 126

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA:*

- 1: /cgn2_6/ptodata/1/iaa/5_COMB.pep.*
- 2: /cgn2_6/ptodata/1/iaa/6_COMB.pep.*
- 3: /cgn2_6/ptodata/1/iaa/H_COMB.pep.*
- 4: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep.*
- 5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep.*
- 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	473.5	71.3	245	2	US-08-918-148-78
2	473.5	71.3	245	2	US-09-138-091A-76
3	466.5	70.3	245	2	US-08-918-148-75
4	466.5	70.3	245	2	US-09-138-091A-73
5	460	69.3	127	2	US-09-240-274-27
6	460	69.3	127	2	US-09-848-798-27
7	456	68.7	123	1	US-08-665-202-30
8	456	68.7	123	1	US-09-315-574-30
9	455	68.5	127	2	US-09-840-459-87
10	455	68.5	127	2	US-09-457-625A-87
11	451.5	68.0	124	2	US-09-424-840B-18
12	451.5	68.0	124	2	US-09-424-840B-123
13	450.5	67.8	268	2	US-09-976-118-1
14	448	67.5	121	2	US-09-202-181-4
15	447.5	67.4	126	2	US-09-240-274-10
16	447.5	67.4	126	2	US-09-240-274-144
17	447.5	67.4	126	2	US-09-240-274-150
18	447.5	67.4	126	2	US-09-848-798-10
19	447.5	67.4	126	2	US-09-848-798-144
20	447.5	67.4	126	2	US-09-848-798-150
21	447.5	67.4	240	2	US-09-192-854-2
22	447.5	67.4	240	2	US-09-511-939-2
23	446.5	67.2	140	2	US-08-983-607-32
24	445.5	67.1	245	2	US-08-918-148-76
25	445.5	67.1	245	2	US-09-138-091A-74
26	445	67.0	125	1	US-08-428-197-1
27	445	67.0	125	4	PCT-US93-10555-1

28	444.5	66.9	109	1	US-08-379-057-32	Sequence 32, Appl
29	443.5	66.8	120	1	US-07-934-373C-4	Sequence 4, Appl
30	443.5	66.8	120	1	US-08-437-642B-4	Sequence 4, Appl
31	443.5	66.8	120	2	US-08-146-206C-4	Sequence 4, Appl
32	443.5	66.8	120	2	US-09-705-686-4	Sequence 4, Appl
33	443.5	66.8	120	2	US-09-705-392A-4	Sequence 4, Appl
34	443.5	66.8	120	2	US-09-705-398-4	Sequence 10, Appl
35	443.5	66.8	120	2	US-09-079-029-10	Sequence 10, Appl
36	442.5	66.6	135	2	US-08-579-378A-20	Sequence 20, Appl
37	442.5	66.6	443	4	PCT-US96-13152-4	Sequence 4, Appl
38	442	66.6	117	2	US-09-025-769B-24	Sequence 24, Appl
39	442	66.6	117	2	US-09-490-070A-24	Sequence 24, Appl
40	442	66.6	117	2	US-09-490-153-24	Sequence 24, Appl
41	442	66.6	117	2	US-09-490-324-24	Sequence 24, Appl
42	442	66.6	120	1	US-07-942-245-35	Sequence 35, Appl
43	442	66.6	125	2	US-09-240-274-24	Sequence 24, Appl
44	442	66.6	125	2	US-09-848-798-24	Sequence 24, Appl
45	442	66.6	131	2	US-09-240-274-28	Sequence 28, Appl

ALIGNMENTS

RESULT 1
US-08-918-148-78
; Sequence 78, Application US/08918148A
; Patent No. 6342220
; GENERAL INFORMATION:
; APPLICANT: Adams, Camellia
; APPLICANT: W.
; APPLICANT: Carter, Paul J.
; APPLICANT: Fendly, Brian M.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Agonist Antibodies
; FILE REFERENCE: P0979
; CURRENT APPLICATION NUMBER: US/08/918,148A
; CURRENT FILING DATE: 1997-08-25
; NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 78
; LENGTH: 245
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; NAME/KEY: unknown
; LOCATION: 208
; OTHER INFORMATION: unknown amino acid
US-08-918-148-78

Query Match	71.3%	Score 473.5;	DB 2;	Length 245;
Best Local Similarity	74.6%	Pred. No. 1.4e-39;		
Matches	94;	Conservative	11;	Mismatches 14;
				Indels 7;
				Gaps 2;
Qy	1	EVOLVKSGLVPGGSLRLSCAASGFTFRYDIHWVQTPFGKGLVWSSISGGNVIDY	60	
Db	3	QVQLVSGGGLVPGGSLRLSCAASGFTSSHNWVROAPGKGLVWSSISGSSSIYY	62	
Qy	61	ADSVKGRFTISRDNANVYVQNLSRAEDMAYVFCARDGTIFGSAATWRAFDIWRGSTM	120	
Db	63	ADSVKGRFTISRDNANVYVQNLSRAEDTAVYYCARDR---GST---GMDVWGRGTL	115	
Qy	121	VTVSSG	126	
Db	116	VTVSSG	121	

RESULT 2
US-09-138-091A-76
; Sequence 76, Application US/09138091A
; Patent No. 6737249
; GENERAL INFORMATION:
; APPLICANT: Adams, Camellia W.
; APPLICANT: Carter, Paul J.
; APPLICANT: Fendly, Brian M.

```

; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Agonist Antibodies
; FILE REFERENCE: 9491-013-27
; CURRENT APPLICATION NUMBER: US/09/138,091A
; CURRENT FILING DATE: 1998-08-21
; PRIOR APPLICATION NUMBER: US 60/056,736
; PRIOR FILING DATE: 1997-08-22
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 76
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: single chain antibody (scFv) fragments
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: 208
; OTHER INFORMATION: Xaa = Any Amino Acid
; US-09-138-091A-76

Query Match          71.3%; Score 473.5; DB 2; Length 245;
Best Local Similarity 74.6%; Pred. No. 1.4e-39;
Matches 94; Conservative 11; Mismatches 14; Indels 7; Gaps 2;

Qy 1 EVLVKSGEGLVKPGGSLRLSCAASGFTFRYYDIHWVRQTPGKGLEWVSSISGGNYIDY 60
   :|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||
Db 3 QVQLVSGGGLVKPGGSLRLSCAASGFTTFSHNMMWVRQAPGKGLEWVSSISSSSIYY 62

Qy 61 ADSVKGRFTISRDNANNVVYLQNNLSRAEDNAVVFCA RDGTIFGSAATWRAFDIWRGRTM 120
   :|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||
Db 63 ADSVKGRFTISRDNANNSLYLQNNLSRAEDTAVYYCARDR---GST-----GMDVWGRGTL 115

Qy 121 VTVSSG 126
Db 116 VTVSSG 121

RESULT 3
US-08-918-148-75
; Sequence 75, Application US/08918148A
; Patent No. 6342220
; GENERAL INFORMATION:
; APPLICANT: Adams, Camellia
; APPLICANT: W.
; APPLICANT: Carter, Paul J.
; APPLICANT: Fendly, Brian M.
; APPLICANT: Gurney, Austin L.
; TITLE OF INVENTION: Agonist Antibodies
; FILE REFERENCE: P0979
; CURRENT APPLICATION NUMBER: US/08/918,148A
; CURRENT FILING DATE: 1997-08-25
; NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 75
; LENGTH: 245
; TYPE: PRT
; ORGANISM: artificial
; US-08-918-148-75

Query Match          70.3%; Score 466.5; DB 2; Length 245;
Best Local Similarity 72.9%; Pred. No. 7.1e-39;
Matches 94; Conservative 8; Mismatches 14; Indels 13; Gaps 2;

Qy 1 EVLVKSGEGLVKPGGSLRLSCAASGFTFRYYDIHWVRQTPGKGLEWVSSISGGNYIDY 60
Db 3 EVQLVQGGGLVKPGGSLRLSCAASGFTFSDYIMSWIRQAPGKGLEWVSYISSSGSTIYY 62

Qy 61 ADSVKGRFTISRDNANNVVYLQNNLSRAEDNAVVFCA RDGTIFGSAATW---AFDIWGR 117
Db 63 ADSVKGRFTISRDNKNLTLYLQNNLSRAEDTAVYYCAR-----WSGEDAFDIWQG 112

Qy 118 GTVTVSSG 126

```

```
Qy 1 EVQLVKGEGLVKPGGSLRLSCAASGFTFRYDIHWVRQTPGKGLEWVSSISGNYIDY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLLESGGGLVPGGSLRLSCAASGFTFSYSHHWVRQAPGKGLEWVSSISNTYIY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 61 ADSVKGRFTISRDNANNVYLNQNSLRADDMVYFCARDGTIFGSAATW---RAFDIWR 117
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADAVKGRFTISRDNAKNSLYLQNSLRADMTAVVYCARDSR-YSNFLRWVRS DGMVWGQ 119
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 118 GTWTVSS 125
|||:|||||
Db 120 GTTVVSS 127
|||:|||||

RESULT 6
US-09-848-798-27
; Sequence 27, Application US/09848798
; Patent No. 6858719
; GENERAL INFORMATION:
; APPLICANT: Siegel, Donald L.
; TITLE OF INVENTION: Rh(D)-BINDING PROTEINS AND MAGNETICALLY ACTIVATED CELL
; FILE REFERENCE: 09596-42U2
; CURRENT APPLICATION NUMBER: US/09/848,798
; CURRENT FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/240,274
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/028,550
; PRIOR FILING DATE: EARLIER FILING DATE: 1996-10-11
; NUMBER OF SEQ ID NOS: 224
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 27
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: anti-Rh(D) chain E01is
US-09-848-798-27

Query Match 69.3%; Score 460; DB 2; Length 127;
Best Local Similarity 70.3%; Pred. No. 1.4e-38;
Matches 90; Conservative 11; Mismatches 23; Indels 4; Gaps 2;

Qy 1 EVQLVKGEGLVKPGGSLRLSCAASGFTFRYDIHWVRQTPGKGLEWVSSISGNYIDY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 EVQLLESGGGLVKPGGSLRLSCAASGFTFSYSHHWVRQAPGKGLEWVSSISNTYIY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 61 ADSVKGRFTISRDNANNVYLNQNSLRADDMVYFCARDGTIFGSAATW---RAFDIWR 117
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADAVKGRFTISRDNAKNSLYLQNSLRADMTAVVYCARDSR-YSNFLRWVRS DGMVWGQ 119
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 118 GTWTVSS 125
|||:|||||
Db 120 GTTVVSS 127
|||:|||||

RESULT 7
US-08-665-202-30
; Sequence 30, Application US/08665202
; Patent No. 5977322
; GENERAL INFORMATION:
; APPLICANT: Marks, James D.
; APPLICANT: Schier, Robert
; TITLE OF INVENTION: No. 5977322el High Affinity Human Antibodies to
; NUMBER OF SEQUENCES: 141
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
```

```
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/08/665,202
; APPLICATION NUMBER: US/08/665,202
; FILING DATE: 13-JUN-1996
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/000,238
; FILING DATE: 14-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/000,250
; FILING DATE: 15-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunter, Tom
; REGISTRATION NUMBER: 38,498
; REFERENCE/DOCKET NUMBER: 02307E-061410
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-665-202-30

Query Match 68.7%; Score 456; DB 1; Length 123;
Best Local Similarity 72.0%; Pred. No. 3.5e-38;
Matches 90; Conservative 14; Mismatches 19; Indels 2; Gaps 1;

Qy 1 EVQLVKGEGLVKPGGSLRLSCAASGFTFRYDIHWVRQTPGKGLEWVSSISGNYIDY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 QVQLVESGGGLVQPGGSLRLSCAASGFTFSYEMNWRQAPGKGLEWVSYISSGSIY 60
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 61 ADSVKGRFTISRDNANNVYLNQNSLRADDMVYFCARDGTIFGSAATWRAFDIWRGTM 120
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 ADSVKGRFTISRDNAKNSLYLQNSLRADMTAVVYCARD--LGGYSYGYVGLDYGQGT 118
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 121 VTSS 125
|||:|||||
Db 119 VTSS 123
|||:|||||

RESULT 8
US-09-315-574-30
; Sequence 30, Application US/09315574
; Patent No. 6512097
; GENERAL INFORMATION:
; APPLICANT: Marks, James D.
; APPLICANT: Schier, Robert
; TITLE OF INVENTION: No. 6512097el High Affinity Human Antibodies to
; NUMBER OF SEQUENCES: 141
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Majestic, Parsons, Siebert & Haue P.C.
; STREET: Four Embarcadero Center, Suite 1100
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4106
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/315,574
; FILING DATE: 20-MAY-99
```

```

; CLASSIFICATION: 530
; PRIOR APPLICATION DATA: US 60/000,238
; FILING DATE: 14-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/000,250
; FILING DATE: 15-JUN-1995
; PRIOR APPLICATION DATA: US 08/665,202
; FILING DATE: 13-JUN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunter, Tom
; REGISTRATION NUMBER: 38,498
; REFERENCE/DOCKET NUMBER: 02307E-061411
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-09-315-574-30

Query Match 68.7%; Score 456; DB 2; Length 123;
Best Local Similarity 72.0%; Pred. No. 3.5e-38;
Matches 90; Conservative 14; Mismatches 19; Indels 2; Gaps 1;

QY 1 EVOLVSGGLVPGGSLRLSCAASGFTPRRYDIHWVQTTPGKLEWVSSISGGNYIDY 60
Db 1 QVQLVESGGGLVQPGGSLRLSCAASGFTSSYEMVMVRQAPGKLEWVSISSGSTIYY 60
QY 61 ADSVKGRFTISRDNANNVYLVQNSLRADMTAVYFCARDGTIFGSAAT--WRAFDIWRG 120
Db 61 ADSVKGRFTISRDNANNVYLVQNSLRADMTAVYFCARDGTIFGSAAT--WRAFDIWRG 120
QY 121 VTSS 125
Db 119 VTSS 123

RESULT 9
US-09-840-459-87
; Sequence 87, Application US/09840459
; Patent No. 6696550
; GENERAL INFORMATION:
; APPLICANT: LaRosa, Gregory J.
; APPLICANT: Horvath, Christopher
; APPLICANT: Newman, Walter
; APPLICANT: Jones, S. Tarran
; APPLICANT: O'Brien, Siobhan H.
; APPLICANT: O'Keefe, Theresa
; TITLE OF INVENTION: HUMANIZED ANTI-CCR2 ANTIBODIES AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: 1855.1052-012
; CURRENT FILING DATE: 2001-02-02
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: 09/497,625
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/359,193
; PRIOR FILING DATE: 1999-07-22
; PRIOR APPLICATION NUMBER: 09/121,781
; PRIOR FILING DATE: 1998-07-23
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 87
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-840-459-87

Query Match 68.5%; Score 455; DB 2; Length 127;
Best Local Similarity 72.4%; Pred. No. 4.5e-38;
Matches 92; Conservative 9; Mismatches 24; Indels 2; Gaps 1;

QY 1 EVOLVSGGLVPGGSLRLSCAASGFTPRRYDIHWVQTTPGKLEWVSSISGGNYIDY 60
Db 1 EVOLVESGGGLVQPGGSLRLSCAASGFTSSYAMSVVRQAPGKLEWVSAISGDSGTYY 60
QY 61 ADSVKGRFTISRDNANNVYLVQNSLRADMTAVYFCARDGTIFGSAAT--WRAFDIWRG 118
Db 61 ADSVKGRFTISRDNANNVYLVQNSLRADMTAVYFCARDGTIFGSAAT--WRAFDIWRG 118
QY 119 TMVTSS 125
Db 121 TMVTSS 127

RESULT 11
US-09-424-840B-18
; Sequence 18, Application US/09424840B
; Patent No. 6790938
; GENERAL INFORMATION:
; APPLICANT: Berchtold, Peter
; APPLICANT: Escher, Robert F. A.
; TITLE OF INVENTION: ANTI-GPIIb/IIIa RECOMBINANT ANTIBODIES
; FILE REFERENCE: 100564-09049
```


Db 1 QVQLVESGGGVQPGGSLRLSCAPSGFVFRSYGMHWVRQTPGKGLEWVSLIWHDGSNRFY 60
QY 61 ADSVKGRFTISRDNANNVYLQWNSLRAEDMAYVFCARDGTIFGSAATWRAFDIWRGTM 120
Db 117 VTSS 121
QY 121 VTSS 125
Db 117 VTSS 121

RESULT 15
US-09-240-274-10
; Sequence 10, Application US/09240274
; Patent No. 6255455
; GENERAL INFORMATION:
; APPLICANT: Siegel, Donald L.
; TITLE OF INVENTION: Rh(D)-BINDING PROTEINS AND MAGNETICALLY ACTIVATED CELL
; TITLE OF INVENTION: SORTING METHOD FOR PRODUCTION THEREOF
; FILE REFERENCE: 09596-42U2
; CURRENT APPLICATION NUMBER: US/09/240,274
; EARLIER FILING DATE: 1999-01-29
; EARLIER APPLICATION NUMBER: 60/081,380
; EARLIER FILING DATE: 1998-04-10
; EARLIER APPLICATION NUMBER: 60/028,550
; EARLIER FILING DATE: 1996-10-11
; NUMBER OF SEQ ID NOS: 224
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
; LENGTH: 126
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: anti-Rh(D) chain D04
US-09-240-274-10

Query Match 67.4%; Score 447.5; DB 2; Length 126;
Best Local Similarity 68.3%; Pred. No. 2.5e-37;
Matches 86; Conservative 15; Mismatches 24; Indels 1; Gaps 1;
QY 1 EVQLVESGGGVQPGGSLRLSCAASGFTPRRYDIHWVRQTPGKGLEWVSSISSGGNYIDY 60
Db 1 EVQLVESGGGVQPGGSLRLSCVAGSFLRSYGMHWVRQAPGKLEWVADIWFDGSKDY 60
QY 61 ADSVKGRFTISRDNANNVYLQWNSLRAEDMAYVFCARDGTIFGSAATW-RAFDIWRGT 119
Db 61 ADSVKGRFTISRDNANKNTLYLQWNSLRAEDTAVVYCARDWRVRAFSGMLSAFDIWRGQT 120
QY 120 MVTSS 125
Db 121 MVTSS 126

Search completed: May 5, 2006, 08:53:47
Job time : 14.5429 secs

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.
OM protein - protein search, using sw model
Run on: May 12, 2006, 02:23:11 ; Search time 70.5 Seconds
(without alignments)
610.768 Million cell updates/sec

Title: US-09-674-752-24
Perfect score: 502
Sequence: 1 QVQVQSGAEVKKPGSSVKV.....AYNELSLRSEDYAVYCAR 98
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 2443163 seqs, 439378781 residues
Total number of hits satisfying chosen parameters: 76
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 500 summaries

Database : A_Geneseq_21.*
1: Geneseq1980s.*
2: Geneseq1990s.*
3: Geneseq2000s.*
4: Geneseq2001s.*
5: Geneseq2002s.*
6: Geneseq2003as.*
7: Geneseq2003bs.*
8: Geneseq2004s.*
9: Geneseq2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES			
Result No.	Score	Query Match Length	Description
1	502	100.0	Aar72068 DP10 VH r
2	502	100.0	Aay50970 Human FVI
3	502	100.0	Aay50949 Human ant
4	502	100.0	Abg78164 Human Fv
5	502	100.0	Abg91855 Human ant
6	502	100.0	Abj18686 Antibody
7	502	100.0	Abc27076 Human ger
8	502	100.0	Adf05904 Antibody
9	502	100.0	Adf10012 VEGF anti
10	502	100.0	Adf10114 Antibody
11	502	100.0	Adj80289 VH gene 1
12	502	100.0	Adv44475 Human L22
13	502	100.0	Ady75294 Protein e
14	502	100.0	Aeb12956 Human ger
15	502	100.0	Abbs7559 HLA-DR-sp
16	502	100.0	Aay99558 Human LH1
17	502	100.0	Ab42842 Tumour-sp
18	502	100.0	Ab42861 Tumour-sp
19	502	100.0	Ab42840 Tumour-sp
20	502	100.0	Ab42841 Tumour-sp
21	502	100.0	Abw02449 Human mon
22	502	100.0	Abw02451 Human mon
23	502	100.0	Abw02447 Human mon
24	502	100.0	Abw02450 Human mon

ALIGNMENTS			
RESULT 1	ID	AA	Sequence
AAR72068	AAR72068	AA	MS-Pro-21
XX	AD89118	6	MS-Pro-21
AC	AD89118	119	MS-Pro-21
XX	AD89118	119	MS-Pro-21
DT	AD89118	119	MS-Pro-21
DT	AD89118	119	MS-Pro-21
XX	AD89118	119	MS-Pro-21
DE	AD89118	119	MS-Pro-21
XX	AD89118	119	MS-Pro-21
KW	AD89118	119	MS-Pro-21
XX	AD89118	119	MS-Pro-21
OS	AD89118	119	MS-Pro-21
XX	AD89118	119	MS-Pro-21

FH Key Location/Qualifiers
 FT Region 31..35
 FT /label= CDR1
 FT Region 50..66
 FT /label= CDR2
 XX W09508336-A1.
 PN 30-MAR-1995.
 XX 22-SEP-1994; 94WO-US010756.
 XX 22-SEP-1993; 93US-00124469.
 XX (NICH-) NICHOLS INST DIAGNOSTICS.
 XX Rapoport B, McLachlan SM;
 XX WPI; 1995-139383/18.
 DR N-PSDB; AAQ89327.
 XX Graves' ophthalmopathy-associated monoclonal antibody - produced by
 PT molecular cloning of immunoglobulin genes by PCR.
 XX Disclosure; Page 68; 94pp; English.
 XX L- and H-chain DNA was amplified by PCR from Graves' orbital tissue and
 CC clones encoding autoimmune-associated immunoglobulin fragments were
 CC obtained. 13/15 clones of H chain (IgG1) genes showed homology to the
 CC closest germline genes, DP10 (AAQ89327) and hv1263 (AAQ89328). The DNA
 CC (AAQ89329) and corresp. amino acid (AAQ89329) sequences of the VH region
 CC of a representative clone, O7H1.2, are provided. (Updated on 25-MAR-2003
 CC to correct PN field.)
 XX Sequence 98 AA;
 SQ
 Query Match 100.0%; Score 502; DB 2; Length 98;
 Best Local Similarity 100.0%; Pred. No. 9.5e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVSGAEVKKPGSSVKVCKASGCTFSSYALSWVRQAPGQGLEWMGGIIPFGTANY 60
 DB 1 QVQLVSGAEVKKPGSSVKVCKASGCTFSSYALSWVRQAPGQGLEWMGGIIPFGTANY 60
 QY 61 AOKFQGRVITADESTSTAYMELSLRSEDTAVYYCAR 98
 DB 61 AOKFQGRVITADESTSTAYMELSLRSEDTAVYYCAR 98
 RESULT 2
 AAY50970
 ID AAY50970 standard; protein; 98 AA.
 AC AAY50970;
 XX 23-MAR-2000 (first entry)
 DT Human FVIII antibody A2 scFv heavy chain protein DP-10 #1.
 DE Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
 KW scFv; A2.
 XX Homo sapiens.
 OS W09558680-A2.
 PN 18-NOV-1999.
 XX 07-MAY-1999; 99WO-NL000285.
 PF 08-MAY-1998; 98EP-00201543.
 XX (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.
 XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 WPI; 2000-053102/04.
 XX New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX Example 4; Fig 4A; 61pp; English.
 CC This invention describes a novel polynucleotide (I) (and complements and

XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 WPI; 2000-053102/04.
 XX New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX Example 9; Fig 11A; 61pp; English.
 XX This invention describes a novel polynucleotide (I) (and complements and
 CC hybridizable polynucleotides) comprising a contiguous nucleotide sequence
 CC coding for a human antibody with factor VIII specificity which has the
 CC hemostatic activity. (I) is useful as a primer or probe for detecting the
 CC presence of inhibitory antibodies directed against factor VIII. The
 CC polypeptides of the invention and the antibodies generated from them are
 CC useful in compositions for neutralizing factor VIII inhibiting antibodies
 CC in hemophilia A patients. This sequence represents a human factor VIII
 CC antibody A2 specific scFv protein DP-10 which is used in the method of
 CC the invention
 XX Sequence 98 AA;
 SQ
 Query Match 100.0%; Score 502; DB 3; Length 98;
 Best Local Similarity 100.0%; Pred. No. 9.5e-40;
 Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 QVQLVSGAEVKKPGSSVKVCKASGCTFSSYALSWVRQAPGQGLEWMGGIIPFGTANY 60
 DB 1 QVQLVSGAEVKKPGSSVKVCKASGCTFSSYALSWVRQAPGQGLEWMGGIIPFGTANY 60
 QY 61 AOKFQGRVITADESTSTAYMELSLRSEDTAVYYCAR 98
 DB 61 AOKFQGRVITADESTSTAYMELSLRSEDTAVYYCAR 98
 RESULT 3
 AAY50949
 ID AAY50949 standard; protein; 98 AA.
 AC AAY50949;
 XX 23-MAR-2000 (first entry)
 DT Human anti-factor VIII antibody VH clone DP-10 encoded protein.
 DE Human; heavy chain; antibody; factor VIII; hemostatic; hemophilia A;
 KW VH gene.
 XX Homo sapiens.
 OS W09558680-A2.
 PN 18-NOV-1999.
 XX 07-MAY-1999; 99WO-NL000285.
 PF 08-MAY-1998; 98EP-00201543.
 XX (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.
 XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
 WPI; 2000-053102/04.
 XX New polynucleotide, polypeptide and antibody useful for diagnosing the
 PT presence of neutralizing antibodies against factor VIII and for treatment
 PT of hemophilia A patients with these antibodies.
 XX Example 4; Fig 4A; 61pp; English.
 CC This invention describes a novel polynucleotide (I) (and complements and